
@article{crenshaw823,
	title = {Extracorporeal gastric stapling reduces the incidence of gastric conduit failure after minimally invasive esophagectomy},
	volume = {76},
	issn = {0003-1348 (Print) 0003-1348 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20726411},
	number = {8},
	journal = {Am Surg},
	author = {Crenshaw, G. D. and Shankar, S. S. and Brown, R. E. and Abbas, A. E. and Bolton, J. S.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {823--8},
}

@article{craig1381,
	title = {International physical activity questionnaire: 12-country reliability and validity},
	volume = {35},
	issn = {0195-9131 (Print) 0195-9131 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12900694},
	doi = {10.1249/01.MSS.0000078924.61453.FB},
	number = {8},
	journal = {Med Sci Sports Exerc},
	author = {Craig, C. L. and Marshall, A. L. and Sjostrom, M. and Bauman, A. E. and Booth, M. L. and Ainsworth, B. E. and Pratt, M. and Ekelund, U. and Yngve, A. and Sallis, J. F. and Oja, P.},
	year = {2003},
	note = {Type: Journal Article},
	pages = {1381--95},
}

@article{coughlin,
	title = {Use of consumer wearable devices to promote physical activity among breast, prostate, and colorectal cancer survivors: a review of health intervention studies},
	issn = {1932-2267 (Electronic) 1932-2259 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31933148},
	doi = {10.1007/s11764-020-00855-1},
	journal = {J Cancer Surviv},
	author = {Coughlin, S. S. and Caplan, L. S. and Stone, R.},
	year = {2020},
	note = {Type: Journal Article},
}

@article{correa-de-araujo591,
	title = {Skeletal muscle function deficit: a new terminology to embrace the evolving concepts of sarcopenia and age-related muscle dysfunction},
	volume = {69},
	issn = {1758-535X (Electronic) 1079-5006 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24737562},
	doi = {10.1093/gerona/glt208},
	number = {5},
	journal = {J Gerontol A Biol Sci Med Sci},
	author = {Correa-de-Araujo, R. and Hadley, E.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {591--4},
}

@article{chen5246,
	title = {Post-discharge complications after esophagectomy account for high readmission rates},
	volume = {22},
	issn = {2219-2840 (Electronic) 1007-9327 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27298567},
	doi = {10.3748/wjg.v22.i22.5246},
	number = {22},
	journal = {World J Gastroenterol},
	author = {Chen, S. Y. and Molena, D. and Stem, M. and Mungo, B. and Lidor, A. O.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {5246--53},
}

@article{chen106,
	title = {The effect of ultrasound-guided intercostal nerve block, single-injection erector spinae plane block and multiple-injection paravertebral block on postoperative analgesia in thoracoscopic surgery: {A} randomized, double-blinded, clinical trial},
	volume = {59},
	issn = {1873-4529 (Electronic) 0952-8180 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31330457},
	doi = {10.1016/j.jclinane.2019.07.002},
	journal = {J Clin Anesth},
	author = {Chen, N. and Qiao, Q. and Chen, R. and Xu, Q. and Zhang, Y. and Tian, Y.},
	year = {2020},
	note = {Type: Journal Article},
	pages = {106--111},
}

@article{chen98,
	title = {Hand-grip strength is a simple and effective outcome predictor in esophageal cancer following esophagectomy with reconstruction: a prospective study},
	volume = {6},
	issn = {1749-8090 (Electronic) 1749-8090 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21843340},
	doi = {10.1186/1749-8090-6-98},
	journal = {J Cardiothorac Surg},
	author = {Chen, C. H. and Ho, Chang and Huang, Y. Z. and Hung, T. T.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {98},
	file = {Chen et al. - 2011 - Hand-grip strength is a simple and effective outco.pdf:/Users/jcsal/Zotero/storage/TTQXQ9W9/Chen et al. - 2011 - Hand-grip strength is a simple and effective outco.pdf:application/pdf},
}

@article{cerfolio1187,
	title = {Fast tracking after {Ivor} {Lewis} esophagogastrectomy},
	volume = {126},
	issn = {0012-3692 (Print) 0012-3692 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15486381},
	doi = {10.1378/chest.126.4.1187},
	number = {4},
	journal = {Chest},
	author = {Cerfolio, R. J. and Bryant, A. S. and Bass, C. S. and Alexander, J. R. and Bartolucci, A. A.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {1187--94},
}

@article{charlote128,
	title = {Patient {Activation} {Mediates} {Health} {Literacy} {Associated} with {Hospital} {Utilization} among {Whites}},
	volume = {1},
	issn = {2474-8307 (Print)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29806046},
	doi = {10.3928/24748307-20170621-01},
	number = {3},
	journal = {Health Lit Res Pract},
	author = {Charlot, M. and Winter, M. R. and Cabral, H. and Wolf, M. S. and Curtis, L. M. and Hanchate, A. and Paasche-Orlow, M.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {e128--e135},
}

@article{cella1179,
	title = {The {Patient}-{Reported} {Outcomes} {Measurement} {Information} {System} ({PROMIS}) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008},
	volume = {63},
	issn = {1878-5921 (Electronic) 0895-4356 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20685078},
	doi = {10.1016/j.jclinepi.2010.04.011},
	number = {11},
	journal = {J Clin Epidemiol},
	author = {Cella, D. and Riley, W. and Stone, A. and Rothrock, N. and Reeve, B. and Yount, S. and Amtmann, D. and Bode, R. and Buysse, D. and Choi, S. and Cook, K. and Devellis, R. and DeWalt, D. and Fries, J. F. and Gershon, R. and Hahn, E. A. and Lai, J. S. and Pilkonis, P. and Revicki, D. and Rose, M. and Weinfurt, K. and Hays, R. and Group, Promis Cooperative},
	year = {2010},
	note = {Type: Journal Article},
	pages = {1179--94},
}

@article{cella570,
	title = {The {Functional} {Assessment} of {Cancer} {Therapy} scale: development and validation of the general measure},
	volume = {11},
	issn = {0732-183X (Print) 0732-183X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8445433},
	doi = {10.1200/JCO.1993.11.3.570},
	number = {3},
	journal = {J Clin Oncol},
	author = {Cella, D. F. and Tulsky, D. S. and Gray, G. and Sarafian, B. and Linn, E. and Bonomi, A. and Silberman, M. and Yellen, S. B. and Winicour, P. and Brannon, J. and al, et},
	year = {1993},
	note = {Type: Journal Article},
	pages = {570--9},
}

@article{casson205,
	title = {What is the optimal distal resection margin for esophageal carcinoma?},
	volume = {69},
	issn = {0003-4975 (Print) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10654514},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Casson, A. G. and Darnton, S. J. and Subramanian, S. and Hiller, L.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {205--9},
}

@article{campbell806,
	title = {Conduit {Vascular} {Evaluation} is {Associated} with {Reduction} in {Anastomotic} {Leak} {After} {Esophagectomy}},
	volume = {19},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25791907},
	doi = {10.1007/s11605-015-2794-3},
	number = {5},
	journal = {J Gastrointest Surg},
	author = {Campbell, C. and Reames, M. K. and Robinson, M. and Symanowski, J. and Salo, J. C.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {806--12},
}

@article{bray394,
	title = {Global cancer statistics 2018: {GLOBOCAN} estimates of incidence and mortality worldwide for 36 cancers in 185 countries},
	volume = {68},
	issn = {1542-4863 (Electronic) 0007-9235 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30207593},
	doi = {10.3322/caac.21492},
	number = {6},
	journal = {CA Cancer J Clin},
	author = {Bray, F. and Ferlay, J. and Soerjomataram, I. and Siegel, R. L. and Torre, L. A. and Jemal, A.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {394--424},
}

@article{botsen955,
	title = {Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients},
	volume = {18},
	issn = {1471-2407 (Electronic) 1471-2407 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30286724},
	doi = {10.1186/s12885-018-4860-1},
	number = {1},
	journal = {BMC Cancer},
	author = {Botsen, D. and Ordan, M. A. and Barbe, C. and Mazza, C. and Perrier, M. and Moreau, J. and Brasseur, M. and Renard, Y. and Tailliere, B. and Slimano, F. and Bertin, E. and Bouche, O.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {955},
	file = {Botsen et al_2018_Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in.pdf:/Users/jcsal/Zotero/storage/KQB55RJE/Botsen et al_2018_Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in.pdf:application/pdf},
}

@article{bonilha77,
	title = {Radiation exposure time during {MBSS}: influence of swallowing impairment severity, medical diagnosis, clinician experience, and standardized protocol use},
	volume = {28},
	issn = {1432-0460 (Electronic) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22692431},
	doi = {10.1007/s00455-012-9415-z},
	number = {1},
	journal = {Dysphagia},
	author = {Bonilha, H. S. and Humphries, K. and Blair, J. and Hill, E. G. and McGrattan, K. and Carnes, B. and Huda, W. and Martin-Harris, B.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {77--85},
}

@article{bonilha922,
	title = {Radiation {Risks} to {Adult} {Patients} {Undergoing} {Modified} {Barium} {Swallow} {Studies}},
	volume = {34},
	issn = {1432-0460 (Electronic) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30830303},
	doi = {10.1007/s00455-019-09993-w},
	number = {6},
	journal = {Dysphagia},
	author = {Bonilha, H. S. and Huda, W. and Wilmskoetter, J. and Martin-Harris, B. and Tipnis, S. V.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {922--929},
}

@article{blumenthal2451,
	title = {The {Affordable} {Care} {Act} at 5 {Years}},
	volume = {372},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25946142},
	doi = {10.1056/NEJMhpr1503614},
	number = {25},
	journal = {N Engl J Med},
	author = {Blumenthal, D. and Abrams, M. and Nuzum, R.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {2451--8},
}

@article{blencowe658,
	title = {Reporting of short-term clinical outcomes after esophagectomy: a systematic review},
	volume = {255},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22395090},
	doi = {10.1097/SLA.0b013e3182480a6a},
	number = {4},
	journal = {Ann Surg},
	author = {Blencowe, N. S. and Strong, S. and McNair, A. G. and Brookes, S. T. and Crosby, T. and Griffin, S. M. and Blazeby, J. M.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {658--66},
}

@article{blazeby1912,
	title = {Development of an {EORTC} questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. {The} {EORTC} {Quality} of {Life} {Study} {Group}},
	volume = {32A},
	issn = {0959-8049 (Print) 0959-8049 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8943674},
	number = {11},
	journal = {Eur J Cancer},
	author = {Blazeby, J. M. and Alderson, D. and Winstone, K. and Steyn, R. and Hammerlid, E. and Arraras, J. and Farndon, J. R.},
	year = {1996},
	note = {Type: Journal Article},
	pages = {1912--7},
}

@article{bizekis402,
	title = {Initial experience with minimally invasive {Ivor} {Lewis} esophagectomy},
	volume = {82},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16863737},
	doi = {10.1016/j.athoracsur.2006.02.052},
	number = {2},
	journal = {Ann Thorac Surg},
	author = {Bizekis, C. and Kent, M. S. and Luketich, J. D. and Buenaventura, P. O. and Landreneau, R. J. and Schuchert, M. J. and Alvelo-Rivera, M.},
	year = {2006},
	note = {Type: Journal Article},
	pages = {402--6; discussion 406--7},
}

@article{blazeby1384,
	title = {Clinical and psychometric validation of an {EORTC} questionnaire module, the {EORTC} {QLQ}-{OES18}, to assess quality of life in patients with oesophageal cancer},
	volume = {39},
	issn = {0959-8049 (Print) 0959-8049 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12826041},
	number = {10},
	journal = {Eur J Cancer},
	author = {Blazeby, J. M. and Conroy, T. and Hammerlid, E. and Fayers, P. and Sezer, O. and Koller, M. and Arraras, J. and Bottomley, A. and Vickery, C. W. and Etienne, P. L. and Alderson, D. and European Organisation for, Research and Treatement of Cancer, Gastrointestinal and Quality of Life, Groups},
	year = {2003},
	note = {Type: Journal Article},
	pages = {1384--94},
}

@article{birkmeyer1128,
	title = {Hospital volume and surgical mortality in the {United} {States}},
	volume = {346},
	issn = {1533-4406 (Electronic) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11948273},
	doi = {10.1056/NEJMsa012337},
	number = {15},
	journal = {N Engl J Med},
	author = {Birkmeyer, J. D. and Siewers, A. E. and Finlayson, E. V. and Stukel, T. A. and Lucas, F. L. and Batista, I. and Welch, H. G. and Wennberg, D. E.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {1128--37},
}

@article{biere1887,
	title = {Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial},
	volume = {379},
	issn = {1474-547X (Electronic) 0140-6736 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22552194},
	doi = {10.1016/S0140-6736(12)60516-9},
	number = {9829},
	journal = {Lancet},
	author = {Biere, S. S. and van Berge Henegouwen, M. I. and Maas, K. W. and Bonavina, L. and Rosman, C. and Garcia, J. R. and Gisbertz, S. S. and Klinkenbijl, J. H. and Hollmann, M. W. and de Lange, E. S. and Bonjer, H. J. and van der Peet, D. L. and Cuesta, M. A.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {1887--92},
}

@article{berry1266,
	title = {A comprehensive evaluation for aspiration after esophagectomy reduces the incidence of postoperative pneumonia},
	volume = {140},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20884018},
	doi = {10.1016/j.jtcvs.2010.08.038},
	number = {6},
	journal = {J Thorac Cardiovasc Surg},
	author = {Berry, M. F. and Atkins, B. Z. and Tong, B. C. and Harpole, D. H. and D'Amico, T. A. and Onaitis, M. W.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {1266--71},
}

@article{bergman635,
	title = {The {EORTC} {QLQ}-{LC13}: a modular supplement to the {EORTC} {Core} {Quality} of {Life} {Questionnaire} ({QLQ}-{C30}) for use in lung cancer clinical trials. {EORTC} {Study} {Group} on {Quality} of {Life}},
	volume = {30A},
	issn = {0959-8049 (Print) 0959-8049 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8080679},
	number = {5},
	journal = {Eur J Cancer},
	author = {Bergman, B. and Aaronson, N. K. and Ahmedzai, S. and Kaasa, S. and Sullivan, M.},
	year = {1994},
	note = {Type: Journal Article},
	pages = {635--42},
}

@article{bergese107,
	title = {Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia},
	volume = {5},
	issn = {1178-7090 (Electronic) 1178-7090 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22570563},
	doi = {10.2147/JPR.S30861},
	journal = {J Pain Res},
	author = {Bergese, S. D. and Ramamoorthy, S. and Patou, G. and Bramlett, K. and Gorfine, S. R. and Candiotti, K. A.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {107--16},
}

@article{ben-david1748,
	title = {Prospective {Comprehensive} {Swallowing} {Evaluation} of {Minimally} {Invasive} {Esophagectomies} with {Cervical} {Anastomosis}: {Silent} {Versus} {Vocal} {Aspiration}},
	volume = {19},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26202151},
	doi = {10.1007/s11605-015-2889-x},
	number = {10},
	journal = {J Gastrointest Surg},
	author = {Ben-David, K. and Fullerton, A. and Rossidis, G. and Michel, M. and Thomas, R. and Sarosi, G. and White, J. and Giordano, C. and Hochwald, S.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1748--52},
}

@article{baracos527,
	title = {Psoas as a sentinel muscle for sarcopenia: a flawed premise},
	volume = {8},
	issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28675689},
	doi = {10.1002/jcsm.12221},
	number = {4},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Baracos, V. E.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {527--528},
	file = {Baracos_2017_Psoas as a sentinel muscle for sarcopenia.pdf:/Users/jcsal/Zotero/storage/ISMMY3L7/Baracos_2017_Psoas as a sentinel muscle for sarcopenia.pdf:application/pdf},
}

@article{basch557,
	title = {Symptom {Monitoring} {With} {Patient}-{Reported} {Outcomes} {During} {Routine} {Cancer} {Treatment}: {A} {Randomized} {Controlled} {Trial}},
	volume = {34},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26644527},
	doi = {10.1200/JCO.2015.63.0830},
	number = {6},
	journal = {J Clin Oncol},
	author = {Basch, E. and Deal, A. M. and Kris, M. G. and Scher, H. I. and Hudis, C. A. and Sabbatini, P. and Rogak, L. and Bennett, A. V. and Dueck, A. C. and Atkinson, T. M. and Chou, J. F. and Dulko, D. and Sit, L. and Barz, A. and Novotny, P. and Fruscione, M. and Sloan, J. A. and Schrag, D.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {557--65},
}

@article{baker181,
	title = {Drain amylase aids detection of anastomotic leak after esophagectomy},
	volume = {7},
	issn = {2078-6891 (Print) 2078-6891 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27034784},
	doi = {10.3978/j.issn.2078-6891.2015.074},
	number = {2},
	journal = {J Gastrointest Oncol},
	author = {Baker, E. H. and Hill, J. S. and Reames, M. K. and Symanowski, J. and Hurley, S. C. and Salo, J. C.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {181--8},
}

@article{azab,
	title = {Impact of {Chemoradiation}-to-{Surgery} {Interval} on {Pathological} {Complete} {Response} and {Short}- and {Long}-{Term} {Overall} {Survival} in {Esophageal} {Cancer} {Patients}},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30311162},
	doi = {10.1245/s10434-018-6897-4},
	journal = {Ann Surg Oncol},
	author = {Azab, B. and Amundson, J. R. and Picado, O. and Ripat, C. and Macedo, F. I. and Franceschi, D. and Livingstone, A. S. and Yakoub, D.},
	year = {2018},
	note = {Type: Journal Article},
}

@incollection{zotero-39,
	address = {Silver Spring (MD)},
	title = {{BEST} ({Biomarkers}, {EndpointS}, and other {Tools}) {Resource} {Glossary}},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27010052},
	booktitle = {{BEST} ({Biomarkers}, {EndpointS}, and other {Tools}) {Resource}},
	year = {2016},
	note = {Type: Book Section},
}

@article{aaronson365,
	title = {The {European} {Organization} for {Research} and {Treatment} of {Cancer} {QLQ}-{C30}: a quality-of-life instrument for use in international clinical trials in oncology},
	volume = {85},
	issn = {0027-8874 (Print) 0027-8874 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8433390},
	number = {5},
	journal = {J Natl Cancer Inst},
	author = {Aaronson, N. K. and Ahmedzai, S. and Bergman, B. and Bullinger, M. and Cull, A. and Duez, N. J. and Filiberti, A. and Flechtner, H. and Fleishman, S. B. and de Haes, J. C. and al, et},
	year = {1993},
	note = {Type: Journal Article},
	pages = {365--76},
}

@article{macdonald342,
	title = {The advantages and limitations of cross-sectional body composition analysis},
	volume = {5},
	issn = {1751-4266},
	doi = {10.1097/SPC.0b013e32834c49eb},
	abstract = {PURPOSE OF REVIEW: Cross-sectional (C-S) imaging is now commonly used to measure body composition in clinical studies. This review highlights the advantages, limitations and suggested future directions for this technique.
RECENT FINDINGS: Current understanding of C-S imaging reproducibility, tissue identification and segmentation methods, comparison between imaging techniques and estimates of whole body composition using a single image are described.
SUMMARY: C-S imaging can reliably measure muscle and fat distribution and uniquely discriminate between intra-abdominal organ and muscle component of fat-free mass. It precisely tracks changes within an individual, but is less able to distinguish true differences in whole body estimates between individuals.},
	language = {eng},
	number = {4},
	journal = {Current Opinion in Supportive and Palliative Care},
	author = {MacDonald, Alisdair J. and Greig, Carolyn A. and Baracos, Vickie},
	month = dec,
	year = {2011},
	pmid = {21986910},
	keywords = {Abdomen, Adipose Tissue, Adiposity, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Tomography, X-Ray Computed},
	pages = {342--349},
}

@article{awad74,
	title = {Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer},
	volume = {31},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2011.08.008},
	abstract = {BACKGROUND \& AIMS: Patients with sarcopenia [reduced fat free mass (FFM)] have a higher incidence of chemotherapy-related toxicity and decreased survival. As there are no such data in patients with oesophagogastric cancer (OGC), this study investigated changes in body composition in OGC patients receiving neoadjuvant chemotherapy (NAC).
METHODS: OGC patients who had CT scans before and after NAC were studied. CT images at the L3 vertebral level were analysed using SliceOmatic(®) software to derive estimates of FFM and fat mass (FM). Comparisons were made between pre- and post-NAC CT images. Data are reported as mean ± SD.
RESULTS: Forty-seven patients (34 male) aged 63 ± 12 years were studied and 79\% completed their course of NAC. The interval between CT scans was 107 ± 27 days. The proportion of patients with sarcopenia increased from 57\% pre-NAC to 79\% post-NAC (p = 0.046). During NAC there were significant reductions in estimated FFM and FM (2.9 ± 4.7 kg, p {\textless} 0.0001 and 1.3 ± 3.2 kg, p = 0.007, respectively). No association was demonstrated between loss of FFM and non-completion of NAC, increased hospital stay or mortality.
CONCLUSIONS: In patients with OGC commencing NAC, sarcopenia was present in 57\%. NAC was associated with further reductions in FFM and an increase in the proportion of patients becoming sarcopenic.},
	language = {eng},
	number = {1},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Awad, Sherif and Tan, Benjamin H. and Cui, Helen and Bhalla, Ashish and Fearon, Kenneth C. H. and Parsons, Simon L. and Catton, James A. and Lobo, Dileep N.},
	month = feb,
	year = {2012},
	pmid = {21875767},
	keywords = {Body Composition, Humans, Aged, Female, Gastrointestinal Neoplasms, Hospitalization, Length of Stay, Male, Middle Aged, Neoadjuvant Therapy, Obesity, Pilot Projects, Postoperative Care, Prevalence, Sarcopenia, Treatment Outcome},
	pages = {74--77},
	file = {Awad et al. - 2012 - Marked changes in body composition following neoad.pdf:/Users/jcsal/Zotero/storage/EH3CXYBG/Awad et al. - 2012 - Marked changes in body composition following neoad.pdf:application/pdf},
}

@article{caan1008,
	title = {Explaining the {Obesity} {Paradox}: {The} {Association} between {Body} {Composition} and {Colorectal} {Cancer} {Survival} ({C}-{SCANS} {Study})},
	volume = {26},
	issn = {1538-7755},
	shorttitle = {Explaining the {Obesity} {Paradox}},
	doi = {10.1158/1055-9965.EPI-17-0200},
	abstract = {Background: Body composition may partially explain the U-shaped association between body mass index (BMI) and colorectal cancer survival.Methods: Muscle and adiposity at colorectal cancer diagnosis and survival were examined in a retrospective cohort using Kaplan-Meier curves, multivariable Cox regression, and restricted cubic splines in 3,262 early-stage (I-III) male (50\%) and female (50\%) patients. Sarcopenia was defined using optimal stratification and sex- and BMI-specific cut points. High adiposity was defined as the highest tertile of sex-specific total adipose tissue (TAT). Primary outcomes were overall mortality and colorectal cancer-specific mortality (CRCsM).Results: Slightly over 42\% patients were sarcopenic. During 5.8 years of follow-up, 788 deaths occurred, including 433 from colorectal cancer. Sarcopenic patients had a 27\% [HR, 1.27; 95\% confidence interval (CI), 1.09-1.48] higher risk of overall mortality than those who were not sarcopenic. Females with both low muscle and high adiposity had a 64\% higher risk of overall mortality (HR, 1.64; 95\% CI, 1.05-2.57) than females with adequate muscle and lower adiposity. The lowest risk of overall mortality was seen in patients with a BMI between 25 and {\textless}30 kg/m2, a range associated with the greatest number of patients (58.6\%) who were not at increased risk of overall mortality due to either low muscle or high adiposity.Conclusions: Sarcopenia is prevalent among patients with non-metastatic colorectal cancer, and should, along with adiposity be a standard oncological marker.Impact: Our findings suggest a biologic explanation for the obesity paradox in colorectal cancer and refute the notion that the association between overweight and lower mortality is due solely to methodologic biases. Cancer Epidemiol Biomarkers Prev; 26(7); 1008-15. ©2017 AACR.},
	language = {eng},
	number = {7},
	journal = {Cancer Epidemiology, Biomarkers \& Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology},
	author = {Caan, Bette J. and Meyerhardt, Jeffrey A. and Kroenke, Candyce H. and Alexeeff, Stacey and Xiao, Jingjie and Weltzien, Erin and Feliciano, Elizabeth Cespedes and Castillo, Adrienne L. and Quesenberry, Charles P. and Kwan, Marilyn L. and Prado, Carla M.},
	month = jul,
	year = {2017},
	pmid = {28506965},
	pmcid = {PMC5647152},
	keywords = {Adiposity, Humans, Aged, Female, Male, Middle Aged, Obesity, Prevalence, Sarcopenia, Body Mass Index, Cause of Death, Colorectal Neoplasms, Follow-Up Studies, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Risk Factors, Sex Factors},
	pages = {1008--1015},
	annote = {Restricted cubic splines
},
	file = {Caan et al. - Explaining the Obesity Paradox The Association be.pdf:/Users/jcsal/Zotero/storage/REEYF855/Caan et al. - Explaining the Obesity Paradox The Association be.pdf:application/pdf},
}

@article{blauwhoff-buskermolen1339,
	title = {Loss of {Muscle} {Mass} {During} {Chemotherapy} {Is} {Predictive} for {Poor} {Survival} of {Patients} {With} {Metastatic} {Colorectal} {Cancer}},
	volume = {34},
	issn = {1527-7755},
	doi = {10.1200/JCO.2015.63.6043},
	abstract = {PURPOSE: Low muscle mass is present in approximately 40\% of patients with metastatic colorectal cancer (mCRC) and may be associated with poor outcome. We studied change in skeletal muscle during palliative chemotherapy in patients with mCRC and its association with treatment modifications and overall survival.
PATIENTS AND METHODS: In 67 patients with mCRC (mean age ± standard deviation, 66.4 ± 10.6 years; 63\% male), muscle area (square centimeters) was assessed using computed tomography scans of the third lumbar vertebra before and during palliative chemotherapy. Treatment modifications resulting from toxicity were evaluated, including delay, dose reduction, or termination of chemotherapy. Multiple regression analyses were performed for the association between change in muscle area and treatment modification and secondly overall survival.
RESULTS: Muscle area of patients with mCRC decreased significantly during 3 months of chemotherapy by 6.1\% (95\% CI, -8.4 to -3.8; P {\textless} .001). Change in muscle area was not associated with treatment modifications. However, patients with muscle loss during treatment of 9\% or more (lowest tertile) had significantly lower survival rates than patients with muscle loss of less than 9\% (at 6 months, 33\% v 69\% of patients alive; at 1 year, 17\% v 49\% of patients alive; log-rank P = .001). Muscle loss of 9\% or more remained independently associated with survival when adjusted for sex, age, baseline lactate dehydrogenase concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progression at first evaluation by computed tomography scan (hazard ratio, 4.47; 95\% CI, 2.21 to 9.05; P {\textless} .001).
CONCLUSION: Muscle area decreased significantly during chemotherapy and was independently associated with survival in patients with mCRC. Further clinical evaluation is required to determine whether nutritional interventions and exercise training may preserve muscle area and thereby improve outcome.},
	language = {eng},
	number = {12},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Blauwhoff-Buskermolen, Susanne and Versteeg, Kathelijn S. and de van der Schueren, Marian A. E. and den Braver, Nicole R. and Berkhof, Johannes and Langius, Jacqueline A. E. and Verheul, Henk M. W.},
	month = apr,
	year = {2016},
	pmid = {26903572},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Kaplan-Meier Estimate, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Body Weight, Cachexia, Disease Progression, Health Status, Muscular Atrophy, Neoplasm Metastasis, Palliative Care, Proportional Hazards Models, Prospective Studies, Radiography, Risk Assessment, Time Factors},
	pages = {1339--1344},
	file = {Blauwhoff-Buskermolen and Versteeg - Loss of Muscle Mass During Chemotherapy Is Predict.pdf:/Users/jcsal/Zotero/storage/VDU3ZQQI/Blauwhoff-Buskermolen and Versteeg - Loss of Muscle Mass During Chemotherapy Is Predict.pdf:application/pdf},
}

@article{prado1012,
	title = {Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?},
	volume = {98},
	issn = {1938-3207},
	shorttitle = {Central tenet of cancer cachexia therapy},
	doi = {10.3945/ajcn.113.060228},
	abstract = {BACKGROUND: Skeletal muscle wasting is considered the central feature of cachexia, but the potential for skeletal muscle anabolism in patients with advanced cancer is unproven.
OBJECTIVE: We investigated the clinical course of skeletal muscle wasting in advanced cancer and the window of possible muscle anabolism.
DESIGN: We conducted a quantitative analysis of computed tomography (CT) images for the loss and gain of muscle in population-based cohorts of advanced cancer patients (lung, colorectal, and pancreas cancer and cholangiocarcinoma) in a longitudinal observational study.
RESULTS: Advanced-cancer patients (n = 368; median survival: 196 d) had a total of 1279 CT images over the course of their disease. With consideration of all time points, muscle loss occurred in 39\% of intervals between any 2 scans. However, the overall frequency of muscle gain was 15.4\%, and muscle was stable in 45.6\% of intervals between any 2 scans, which made the maintenance or gain of muscle the predominant behavior. Multinomial logistic regression revealed that being within 90 d (compared with {\textgreater}90 d) from death was the principal risk factor for muscle loss (OR: 2.67; 95\% CI: 1.45, 4.94; P = 0.002), and muscle gain was correspondingly less likely (OR: 0.37; 95\% CI: 0.20, 0.69; P = 0.002) at this time. Sex, age, BMI, and tumor group were not significant predictors of muscle loss or gain.
CONCLUSIONS: A window of anabolic potential exists at defined early phases of the disease trajectory ({\textgreater}90 d survival), creating an opportunity for nutritional intervention to stop or reverse cachexia. Cancer patients within 90 d of death have a low likelihood of anabolic potential.},
	language = {eng},
	number = {4},
	journal = {The American Journal of Clinical Nutrition},
	author = {Prado, Carla M. and Sawyer, Michael B. and Ghosh, Sunita and Lieffers, Jessica R. and Esfandiari, Nina and Antoun, Sami and Baracos, Vickie E.},
	month = oct,
	year = {2013},
	pmid = {23966429},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Neoplasm Staging, Cachexia, Muscular Atrophy, Cholangiocarcinoma, Longitudinal Studies, Lung Neoplasms, Metabolism, Neoplasms, Pancreatic Neoplasms, Survival Rate},
	pages = {1012--1019},
	file = {prado1012.pdf:/Users/jcsal/Zotero/storage/ZMS2TIEE/prado1012.pdf:application/pdf},
}

@article{prado269,
	title = {The emerging role of computerized tomography in assessing cancer cachexia},
	volume = {3},
	issn = {1751-4266},
	doi = {10.1097/SPC.0b013e328331124a},
	abstract = {PURPOSE OF REVIEW: The present review represents an overview of the potential opportunistic use of computerized tomography (CT) to enhance our understanding of abnormal body composition, specifically lean and adipose tissue changes in cancer cachexia.
RECENT FINDINGS: One of the characteristics of cancer cachexia is the depletion of muscle with or without adipose tissue loss. Therefore, a body composition tool that specifically distinguishes between these tissues is essential in assessing this syndrome. Cancer patients are routinely evaluated by high resolution imaging such as CT for the purpose of diagnosis and follow-up. Recent work exploiting CT images for body composition analysis has revealed the natural history of cancer cachexia, including progressive alterations in skeletal muscle, adipose tissue, organs, and tumor mass. CT-based quantification of skeletal muscle has permitted identification of individuals with sarcopenia, and links between sarcopenia and functional status, chemotherapy toxicity, time to tumor progression, and mortality.
SUMMARY: CT images routinely acquired from health records of cancer patients can be used to quantify specific lean and adipose tissues, to interpret body composition in population-based studies, and to evaluate individual patients in a clinical and therapeutic decision-making setting.},
	language = {eng},
	number = {4},
	journal = {Current Opinion in Supportive and Palliative Care},
	author = {Prado, Carla M. M. and Birdsell, Laura A. and Baracos, Vickie E.},
	month = dec,
	year = {2009},
	pmid = {19667996},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Cachexia, Disease Progression, Neoplasms, Thinness},
	pages = {269--275},
}

@article{baracos1133S,
	title = {Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis},
	volume = {91},
	issn = {1938-3207},
	shorttitle = {Body composition in patients with non-small cell lung cancer},
	doi = {10.3945/ajcn.2010.28608C},
	abstract = {BACKGROUND: The prominent clinical feature of cachexia has traditionally been understood to be weight loss; however, in recognition of the potential for divergent behavior of muscle and adipose tissue, cachexia was recently defined as loss of muscle with or without loss of fat mass. Detailed assessments are required to verify body composition in patients with cancer cachexia.
DESIGN: We adopted a population-based approach to study body composition in patients with cancer, with the use of diagnostic computed tomography images acquired for cancer diagnosis and follow-up. A prospective cohort of 441 patients with non-small cell lung cancer, who were referred consecutively to a regional medical oncology service in Alberta, Canada, was evaluated.
RESULTS: At referral (median time to death: 265 d), mean body mass index (BMI; in kg/m(2)) was 24.9, with 47.4\% of patients being overweight or obese. Only 7.5\% overall were underweight as conventionally understood (BMI {\textless} 18.5). Analysis of computed tomography images showed extremely high heterogeneity of muscle mass within all strata of BMI. The overall prevalence of severe muscle depletion (sarcopenia) was 46.8\% and was present in patients in all BMI categories. A much higher proportion of men (61\%) than women (31\%) met the criteria for sarcopenia.
CONCLUSIONS: Wasting of skeletal muscle is a prominent feature of patients with lung cancer, despite normal or heavy body weights. The significance of muscle wasting in normal-weight, overweight, and obese patients as a nutritional risk factor, as a prognostic factor, and as a predictor of cancer treatment toxicity is discussed in this article.},
	language = {eng},
	number = {4},
	journal = {The American Journal of Clinical Nutrition},
	author = {Baracos, Vickie E. and Reiman, Tony and Mourtzakis, Marina and Gioulbasanis, Ioannis and Antoun, Sami},
	month = apr,
	year = {2010},
	pmid = {20164322},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Body Mass Index, Risk Factors, Sex Factors, Body Weight, Cachexia, Muscular Atrophy, Prospective Studies, Lung Neoplasms, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Prognosis},
	pages = {1133S--1137S},
}

@article{tan6973,
	title = {Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer},
	volume = {15},
	issn = {1557-3265},
	doi = {10.1158/1078-0432.CCR-09-1525},
	abstract = {PURPOSE: The average weight-losing pancreatic cancer patient undergoing palliative therapy is frequently overweight rather than underweight, and this can confound conventional measures used for risk stratification. The aim of this study was to evaluate if weight and body composition, specifically sarcopenia, assessed from diagnostic computed tomography (CT) scans, is of prognostic value in patients with pancreatic cancer. The nature and extent of tissue loss over subsequent months was also evaluated.
EXPERIMENTAL DESIGN: A total of 111 patients entering a palliative therapy program, who had CT images and had undergone nutritional screening, were studied. In patients for whom follow-up scans were available (n = 44), longitudinal changes in body composition were studied at a mean of 230 +/- 62 and 95 +/- 60 days prior to demise.
RESULTS: Sixty-two patients (55.9\%) were sarcopenic, 44 (39.6\%) were overweight/obese, and 18 (16.2\%) were both. Age {\textgreater} or =59 years (hazard ratio, 1.71; 95\% confidence interval, 1.10-2.66; P = 0.018), and overweight/obese sarcopenia (hazard ratio, 2.07; 95\% confidence interval, 1.23-3.50; P = 0.006) were identified as independent predictors of survival on multivariate analysis. Longitudinal analysis revealed that total fat-free mass index decreased from 15.5 +/- 2.5 kg/m(2) to 14.5 +/- 2.0 kg/m2 (P = 0.002), and total fat mass index decreased from 7.5 +/- 2.0kg/m2 to 6.0 +/- 1.5kg/m2 (P {\textless} 0.0001) over 135 days.
CONCLUSIONS: Sarcopenia in overweight/obese patients with advanced pancreatic cancer is an occult condition but can be identified using CT scans. This condition is an independent adverse prognostic indicator that should be considered for stratification of patients' entering clinical trials, systemic therapy, or support care programs.},
	language = {eng},
	number = {22},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Tan, Benjamin H. L. and Birdsell, Laura A. and Martin, Lisa and Baracos, Vickie E. and Fearon, Kenneth C. H.},
	month = nov,
	year = {2009},
	pmid = {19887488},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Obesity, Sarcopenia, Treatment Outcome, Body Weight, Pancreatic Neoplasms, Prognosis, Overweight, Risk, Pancreatic},
	pages = {6973--6979},
	file = {Tan et al. - 2009 - Sarcopenia in an Overweight or Obese Patient Is an.pdf:/Users/jcsal/Zotero/storage/S7WDW42K/Tan et al. - 2009 - Sarcopenia in an Overweight or Obese Patient Is an.pdf:application/pdf},
}

@article{lieffers1173,
	title = {A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands},
	volume = {89},
	issn = {1938-3207},
	shorttitle = {A viscerally driven cachexia syndrome in patients with advanced colorectal cancer},
	doi = {10.3945/ajcn.2008.27273},
	abstract = {BACKGROUND: Cancer cachexia-associated weight loss is poorly understood; energetically demanding tissues (eg, organ and tumor mass) and resting energy expenditure (REE) are reported to increase with advanced cancer.
OBJECTIVE: The objective was to quantify the potential contribution of increasing masses of energetically demanding tissues to REE with colorectal cancer cachexia progression.
DESIGN: A longitudinal computed tomography (CT) image review was performed to quantify organ size (liver, including metastases, and spleen) and peripheral tissues (skeletal muscle and adipose tissue) during colorectal cancer cachexia progression (n = 34). Body composition was prospectively evaluated by CT and dual-energy X-ray absorptiometry, and REE was determined by indirect calorimetry in advanced colorectal cancer patients (n = 18).
RESULTS: Eleven months from death, the liver (2.3 +/- 0.7 kg) and spleen (0.32 +/- 0.2 kg) were larger than reference values. One month from death, liver weight increased to 3.0 +/- 1.5 kg (P = 0.010), spleen showed a trend to increase (P = 0.077), and concurrent losses of muscle (4.2 kg) and fat (3.5 kg) (P {\textless} 0.05) were observed. The estimated percentage of fat-free mass (FFM) occupied by the liver increased from 4.5\% to 7.0\% (P {\textless} 0.001). The most rapid loss of peripheral tissues and liver and metastases gain occurred within 3 mo of death. A positive linear relation existed between liver mass and measured whole-body REE (r(2) = 0.35, P = 0.010); because liver accounted for a larger percentage of FFM, measured REE . kg FFM(-1) . d(-1) increased (r(2) = 0.35, P = 0.010).
CONCLUSIONS: Increases in mass and in the proportion of high metabolic rate tissues, including liver and tumor, represented a cumulative incremental REE of approximately 17,700 kcal during the last 3 mo of life and may contribute substantially to cachexia-associated weight loss.},
	language = {eng},
	number = {4},
	journal = {The American Journal of Clinical Nutrition},
	author = {Lieffers, Jessica R. and Mourtzakis, Marina and Hall, Kevin D. and McCargar, Linda J. and Prado, Carla M. M. and Baracos, Vickie E.},
	month = apr,
	year = {2009},
	pmid = {19244378},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Male, Middle Aged, Colorectal Neoplasms, Retrospective Studies, Cachexia, Disease Progression, Neoplasm Metastasis, Prospective Studies, Longitudinal Studies, Absorptiometry, Photon, Basal Metabolism, Calorimetry, Indirect, Cohort Studies, CRC, Liver, Organ Size, Spleen, Weight Loss},
	pages = {1173--1179},
	file = {Lieffers et al_2009_A viscerally driven cachexia syndrome in patients with advanced colorectal.pdf:/Users/jcsal/Zotero/storage/RWRGXGW8/Lieffers et al_2009_A viscerally driven cachexia syndrome in patients with advanced colorectal.pdf:application/pdf},
}

@article{frontera1038,
	title = {Strength conditioning in older men: skeletal muscle hypertrophy and improved function},
	volume = {64},
	issn = {8750-7587},
	shorttitle = {Strength conditioning in older men},
	doi = {10.1152/jappl.1988.64.3.1038},
	abstract = {The effects of strength conditioning on skeletal muscle function and mass were determined in older men. Twelve healthy untrained volunteers (age range 60-72 yr) participated in a 12-wk strength training program (8 repetitions/set; 3 sets/day; 3 days/wk) at 80\% of the one repetition maximum (1 RM) for extensors and flexors of both knee joints. They were evaluated before the program and after 6 and 12 wk of training. Weekly measurements of 1 RM showed a progressive increase in strength in extensors and flexors. By 12 wk extensor and flexor strength had increased 107.4 (P less than 0.0001) and 226.7\% (P less than 0.0001), respectively. Isokinetic peak torque of extensors and flexors measured on a Cybex II dynamometer increased 10.0 and 18.5\% (P less than 0.05) at 60 degrees/s and 16.7 and 14.7\% (P less than 0.05) at 240 degrees/s. The torque-velocity relationship showed an upward displacement of the curve at the end of training, mainly in the slow-velocity high-torque region. Midthigh composition from computerized tomographic scans showed an increase (P less than 0.01) in total thigh area (4.8\%), total muscle area (11.4\%), and quadriceps area (9.3\%). Biopsies of the vastus lateralis muscle revealed similar increases (P less than 0.001) in type I fiber area (33.5\%) and type II fiber area (27.6\%). Daily excretion of urinary 3-methyl-L-histidine increased with training (P less than 0.05) by an average 40.8\%. Strength gains in older men were associated with significant muscle hypertrophy and an increase in myofibrillar protein turnover.},
	language = {eng},
	number = {3},
	journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
	author = {Frontera, W. R. and Meredith, C. N. and O'Reilly, K. P. and Knuttgen, H. G. and Evans, W. J.},
	month = mar,
	year = {1988},
	pmid = {3366726},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Male, Middle Aged, Body Weight, Organ Size, Creatinine, Exercise Therapy, Hypertrophy, Methylhistidines, Muscles},
	pages = {1038--1044},
}

@article{mitsiopoulos115,
	title = {Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography},
	volume = {85},
	issn = {8750-7587},
	doi = {10.1152/jappl.1998.85.1.115},
	abstract = {Magnetic resonance imaging (MRI) and computerized tomography (CT) are promising reference methods for quantifying whole body and regional skeletal muscle mass. Earlier MRI and CT validation studies used data-acquisition techniques and data-analysis procedures now outdated, evaluated anatomic rather than adipose tissue-free skeletal muscle (ATFSM), studied only the relatively large thigh, or found unduly large estimation errors. The aim of the present study was to compare arm and leg ATFSM cross-sectional area estimates (cm2) by using standard MRI and CT acquisition and image-analysis methods with corresponding cadaver estimates. A second objective was to validate MRI and CT measurements of adipose tissue embedded within muscle (interstitial adipose tissue) and surrounding muscle (subcutaneous adipose tissue). ATFSM area (n = 119) by MRI [38.9 +/- 22.3 (SD) cm2], CT (39.7 +/- 22.8 cm2), and cadaver (39.5 +/- 23.0 cm2) were not different (P {\textgreater} 0.001), and both MRI and CT estimates of ATFSM were highly correlated with corresponding cadaver values [MRI: r = 0.99, SE of estimate (SEE) 3.9 cm2, P {\textless} 0.001; and CT: r = 0.99, SEE = 3.8 cm2, P {\textless} 0.001]. Similarly good results were observed between MRI- and CT-measured vs. cadaver-measured interstitial and subcutaneous adipose tissue. For MRI-ATFSM the intraobserver correlation for duplicate measurements in vivo was 0. 99 [SEE = 8.7 cm2 (2.9\%), P {\textless} 0.001]. These findings strongly support the use of MRI and CT as reference methods for appendicular skeletal muscle, interstitial and subcutaneous adipose tissue measurement in vivo.},
	language = {eng},
	number = {1},
	journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
	author = {Mitsiopoulos, N. and Baumgartner, R. N. and Heymsfield, S. B. and Lyons, W. and Gallagher, D. and Ross, R.},
	month = jul,
	year = {1998},
	pmid = {9655763},
	keywords = {Adipose Tissue, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Middle Aged, Obesity, Image Processing, Computer-Assisted, L3, Aged, 80 and over, Cadaver, Leg, Reproducibility of Results},
	pages = {115--122},
}

@article{shen2333,
	title = {Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image},
	volume = {97},
	issn = {8750-7587},
	shorttitle = {Total body skeletal muscle and adipose tissue volumes},
	doi = {10.1152/japplphysiol.00744.2004},
	abstract = {A single abdominal cross-sectional computerized axial tomography and magnetic resonance image is often obtained in studies examining adipose tissue (AT) distribution. An abdominal image might also provide additional useful information on total body skeletal muscle (SM) and AT volumes with related physiological insights. We therefore investigated the relationships between abdominal SM and AT areas from single images and total body component volumes in a large and diverse sample of healthy adult subjects. Total body SM and AT volumes were derived by whole body multislice magnetic resonance imaging in 123 men [age (mean +/- SD) of 41.6 +/- 15.8 yr; body mass index of 25.9 +/- 3.4 kg/m(2)] and 205 women (age of 47.8 +/- 18.7 yr; body mass index of 26.7 +/- 5.6 kg/m(2)). Single abdominal SM and AT slice areas were highly correlated with total body SM (r = 0.71-0.92; r = 0.90 at L(4)-L(5) intervertebral space) and AT (r = 0.84-0.96; r = 0.94 at L(4)-L(5) intervertebral space) volumes, respectively. R(2) increased by only 5.7-6.1\% for SM and 2.7-4.4\% for AT with the inclusion of subject sex, age, ethnicity, scanning position, body mass index, and waist circumference in the model. The developed SM and AT models were validated in an additional 49 subjects. To achieve equivalent power to a study measuring total body SM or AT volumes, a study using a single abdominal image would require 17-24\% more subjects for SM and 6-12\% more subjects for AT. Measurement of a single abdominal image can thus provide estimates of total body SM and AT for group studies of healthy adults.},
	language = {eng},
	number = {6},
	journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
	author = {Shen, Wei and Punyanitya, Mark and Wang, ZiMian and Gallagher, Dympna and St-Onge, Marie-Pierre and Albu, Jeanine and Heymsfield, Steven B. and Heshka, Stanley},
	month = dec,
	year = {2004},
	pmid = {15310748},
	keywords = {Abdomen, Adipose Tissue, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Reproducibility of Results, Adult, Predictive Value of Tests},
	pages = {2333--2338},
}

@article{kurk1033,
	title = {Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: {Secondary} analysis of the phase 3 {CAIRO3} trial},
	volume = {9},
	issn = {2045-7634},
	shorttitle = {Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer},
	doi = {10.1002/cam4.2787},
	abstract = {BACKGROUND: Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown.
METHODS: This is a retrospective analysis of the phase 3 CAIRO3 study. The CAIRO3 study randomized 557 patients between maintenance capecitabine + bevacizumab (CAP-B) or observation, after six cycles capecitabine + oxaliplatin + bevacizumab (CAPOX-B). Upon first disease progression (PD1), CAPOX-B was reintroduced until second progression (PD2). SMI was assessed by computed tomography (CT) (total 1355 scans). SMI and body mass index (BMI) changes were analyzed for three time-periods; p1: during initial CAPOX-B, p2: randomization to PD1, and p3: PD1 to PD2. The association between absolute and change in SMI and BMI (both per 1 standard deviation) during p1-p3, with PD1, PD2, and survival was studied by Cox regression models.
RESULTS: This analysis included 450 of the 557 patients randomized in the CAIRO3 study. Mean SMI decreased during p1: mean -0.6 SMI units [95\% CI -1.07;-0.26] and p3: -2.2 units [-2.7;-1.8], whereas during p2, SMI increased + 1.2 units [0.8-1.6]. BMI changes did not reflect changes in SMI. SMI loss during p2 and p3 was significantly associated with shorter survival (HR 1.19 [1.09-1.35]; 1.54 [1.31-1.79], respectively). Sarcopenia at PD1 was significantly associated with early PD2 (HR 1.40 [1.10-1.70]). BMI loss independent of SMI loss was only associated with shorter overall survival during p3 (HR 1.35 [1.14-1.63]).
CONCLUSIONS: In mCRC patients, SMI loss during palliative systemic treatment was related with early disease progression and reduced survival. BMI did not reflect changes in SMI and could not identify patients at risk of poor outcome during early treatment lines.},
	language = {eng},
	number = {3},
	journal = {Cancer Medicine},
	author = {Kurk, Sophie A. and Peeters, Petra H. M. and Dorresteijn, Bram and de Jong, Pim A. and Jourdan, Marion and Creemers, Geert-Jan M. and Erdkamp, Frans L. G. and de Jongh, Felix E. and Kint, Peter A. M. and Poppema, Boelo J. and Radema, Sandra A. and Simkens, Lieke H. J. and Tanis, Bea C. and Tjin-A-Ton, Manuel L. R. and Van Der Velden, Ankie and Punt, Cornelis J. A. and Koopman, Miriam and May, Anne M.},
	month = feb,
	year = {2020},
	pmid = {31850687},
	pmcid = {PMC6997070},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Colorectal Neoplasms, Retrospective Studies, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Palliative Care, Time Factors, Longitudinal Studies, Prognosis, sarcopenia, Body composition, body mass index, chemo, chemotherapy, Clinical Trials, Phase III as Topic, crc, Maintenance Chemotherapy, metastatic colorectal cancer, Progression-Free Survival, Randomized Controlled Trials as Topic, skeletal muscle mass, survival},
	pages = {1033--1043},
}

@article{bozzetti2107,
	title = {Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy},
	volume = {28},
	issn = {1569-8041},
	shorttitle = {Forcing the vicious circle},
	doi = {10.1093/annonc/mdx271},
	abstract = {Sarcopenia has recently emerged as a new condition that, independently from malnutrition, may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to define the prevalence of sarcopenia in different primaries, its role in leading to chemotherapy toxicity and decreased compliance with the oncological therapy and the effect of some drugs on the onset of sarcopenia. Finally, the review aims to describe the current approaches to restore the muscle mass through nutrition, exercise and anti-inflammatory agents or multimodal programmes with a special emphasis on the results of randomized controlled trials. The examination of the computed tomography scan at the level of the third lumbar vertebra-a common procedure for staging many tumours-has allowed the oncologist to evaluate the muscle mass and to collect many retrospective data on the prevalence of sarcopenia and its clinical consequences. Sarcopenia is a condition affecting a high percentage of patients with a range depending on type of primary tumour and stage of disease. It is noteworthy that patients may be sarcopenic even if their nutritional status is apparently maintained or they are obese. Sarcopenic patients exhibited higher chemotherapy toxicity and poorer compliance with oncological treatments. Furthermore, several antineoplastic drugs appeared to worsen the sarcopenic status. Therapeutic approaches are several and this review will focus on those validated by randomized controlled trials. They include the use of ω-3-enriched oral nutritional supplements and orexigenic agents, the administration of adequate high-protein regimens delivered enterally or parenterally, and programmes of physical exercise. Better results are expected combining different procedures in a multimodal approach. In conclusion, there are several premises to prevent/treat sarcopenia. The oncologist should coordinate this multimodal approach by selecting priorities and sequences of treatments and then involving a nutrition health care professional or a physical therapist depending on the condition of the single patient.},
	language = {eng},
	number = {9},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Bozzetti, F.},
	month = sep,
	year = {2017},
	pmid = {28911059},
	keywords = {Humans, Tomography, X-Ray Computed, Prevalence, Sarcopenia, Neoplasms, Antineoplastic Agents, Prognosis, sarcopenia, chemo, Randomized Controlled Trials as Topic, cancer and sarcopenia, sarcopenia and chemotherapy, sarcopenia and prognosis, sarcopenia and toxicity, sarcopenia therapy},
	pages = {2107--2118},
}

@article{kurk803,
	title = {Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients},
	volume = {10},
	issn = {2190-6009},
	doi = {10.1002/jcsm.12436},
	abstract = {BACKGROUND: Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI loss was related with shorter time to disease progression and overall survival during first-line maintenance treatment with capecitabine + bevacizumab (CAP-B) or observation and during more intensive capecitabine + oxaliplatin + bevacizumab (CAPOX-B) reintroduction treatment. As a potential risk factor for reduced survival, we explored whether sarcopenia and SMI loss were associated with dose-limiting toxicities (DLTs) during CAP-B and CAPOX-B.
METHODS: Sarcopenia status and SMI loss were assessed by using consecutive computed tomography scans. DLTs were defined as any dose delay/reduction/discontinuation of systemic treatment because of reported CTCAE (version 3.0) toxicities at the start or during treatment. Poisson regression models were used to study whether sarcopenia and body mass index (BMI) at the start of treatment and SMI and BMI loss during treatment were associated with DLTs.
RESULTS: One hundred eighty-two patients (mean age 63.0 ± 8.8 years, 37\% female) received CAP-B, and 232 patients (mean age 63.0 ± 9.0 years, 34\% female) received CAPOX-B. At the start of CAP-B and CAPOX-B, 54\% and 46\% of patients were sarcopenic, respectively. Mean BMI was lower in sarcopenic patients, although patients were on average still overweight (sarcopenic vs. non-sarcopenic at the start of CAP-B 25.0 ± 3.9 vs. 26.7 ± 4.1 and CAPOX-B 25.8 ± 3.8 vs. 27.1 ± 3.8 kg/m2 ). Sarcopenia at the start of CAP-B was not associated with DLTs [relative risk 0.87 (95\% confidence interval 0.64-1.19)], whereas patients with {\textgreater}2\% SMI loss had a significantly higher risk of DLTs [1.29 (1.01-1.66)]. At the start of subsequent CAPOX-B, 25\% of patients received a dose reduction, and the risk of dose reduction was significantly higher for patients with preceding SMI loss [1.78 (1.06-3.01)] or sarcopenia [1.75 (1.08-2.86)]. After the received dose reductions, sarcopenia or SMI loss was not significantly associated with a higher risk of DLTs during CAPOX-B [sarcopenia vs. non-sarcopenic: 0.86 (0.69-1.08) and SMI loss vs. stable/gain: 0.83 (0.65-1.07)]. In contrast, BMI (loss) at the start or during either treatment was not associated with an increased risk of DLTs.
CONCLUSIONS: In this large longitudinal study in metastatic colorectal cancer patients during palliative systemic treatment, sarcopenia and/or muscle loss was associated with an increased risk of DLTs. BMI was not associated with DLTs and could not detect sarcopenia or SMI loss. Prospective (randomized) studies should reveal whether normalizing chemotherapeutic doses to muscle mass or muscle mass preservation (by exercise and nutritional interventions) increases chemotherapeutic tolerance and improves survival.},
	language = {eng},
	number = {4},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Kurk, Sophie and Peeters, Petra and Stellato, Rebecca and Dorresteijn, B. and de Jong, Pim and Jourdan, Marion and Creemers, Geert-Jan and Erdkamp, Frans and de Jongh, Felix and Kint, Peter and Simkens, Lieke and Tanis, Bea and Tjin-A-Ton, Manuel and Van Der Velden, Ankie and Punt, Cornelis and Koopman, Miriam and May, Anne},
	month = aug,
	year = {2019},
	pmid = {31094083},
	pmcid = {PMC6711417},
	keywords = {Humans, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Longitudinal Studies, Body composition, chemo, crc, Chemotherapy, Dose-limiting toxicity, Dose-Response Relationship, Drug, Metastatic colorectal cancer, Skeletal muscle mass},
	pages = {803--813},
	file = {Kurk et al. - Skeletal muscle mass loss and dose-limiting toxici.pdf:/Users/jcsal/Zotero/storage/L5PMBGBE/Kurk et al. - Skeletal muscle mass loss and dose-limiting toxici.pdf:application/pdf},
}

@article{ali607,
	title = {Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with {FOLFOX} regimens},
	volume = {5},
	issn = {2045-7634},
	doi = {10.1002/cam4.621},
	abstract = {Evidence suggests that lean body mass (LBM) may be useful to normalize chemotherapy doses. Data from one prospective and one retrospective study were used to determine if the highest doses of oxaliplatin/kg LBM within FOLFOX regimens would be associated with dose-limiting toxicity (DLT) in colon cancer patients. Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD). Muscle tissue was measured by computerized tomography (CT) and used to evaluate the LBM compartment of the whole body. In prospective randomized clinical trials conducted in France (n = 58), for patients given FOLFOX-based regimens according to body surface area, values of oxaliplatin/kg LBM were highly variable, ranging from 2.55 to 6.6 mg/kg LBM. A cut point of 3.09 mg oxaliplatin/kg LBM for developing toxicity was determined by Receiver Operating Characteristic (ROC) analysis, below this value 0/17 (0.0\%) of patients experienced DLT; in contrast above this value 18/41 (44.0\%) of patients were dose reduced or had treatment terminated owing to toxicity (≥Grade 3 or neuropathy ≥Grade 2); for 9/41 the DLT was sensory neuropathy. These findings were validated in an independent cohort of colon cancer patients (n = 80) receiving FOLFOX regimens as part of standard care, in Canada. Low LBM is a significant predictor of toxicity and neuropathy in patients administered FOLFOX-based regimens using conventional body surface area (BSA) dosing.},
	language = {eng},
	number = {4},
	journal = {Cancer Medicine},
	author = {Ali, Raafi and Baracos, Vickie E. and Sawyer, Michael B. and Bianchi, Laurent and Roberts, Sarah and Assenat, Eric and Mollevi, Caroline and Senesse, Pierre},
	month = apr,
	year = {2016},
	pmid = {26814378},
	pmcid = {PMC4831278},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Body composition, chemo, crc, Canada, colon cancer, Colonic Neoplasms, Fluorouracil, Leucovorin, Organoplatinum Compounds, Body Surface Area, chemotherapy toxicity, Drug-Related Side Effects and Adverse Reactions, France, irinotecan, lean body mass, Nervous System Diseases, neuropathy, oxaliplatin, Population Surveillance},
	pages = {607--616},
	file = {Ali et al_2016_Lean body mass as an independent determinant of dose-limiting toxicity and.pdf:/Users/jcsal/Zotero/storage/UD5W9E2R/Ali et al_2016_Lean body mass as an independent determinant of dose-limiting toxicity and.pdf:application/pdf},
}

@article{prado3264,
	title = {Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity},
	volume = {13},
	issn = {1078-0432},
	doi = {10.1158/1078-0432.CCR-06-3067},
	abstract = {PURPOSE: Evidence suggests that lean body mass (LBM) may be useful to normalize doses of chemotherapy. Data from a prospective study were used to determine if the highest doses of 5-fluorouracil (5-FU) per kilogram LBM would be associated with dose-limiting toxicity in stage II/III colon cancer patients treated with 5-FU and leucovorin.
EXPERIMENTAL DESIGN: Toxicity after cycle 1 was graded according to National Cancer Institute Common Toxicity Criteria, version 2.0. Muscle tissue was measured by computerized tomography. An extrapolation to the LBM compartment of the whole body was employed.
RESULTS: Mean values of 5-FU/LBM of the entire population were different in terms of presence or absence of toxicity (P = 0.036). A cut point of 20 mg 5-FU/kg LBM seemed to be a threshold for developing toxicity (P = 0.005). This observation was pertinent to women (odds ratio, 16.73; P = 0.021). Women in this study had a relatively low proportion of LBM relative to their body surface area.
CONCLUSION: Our study shows that low LBM is a significant predictor of toxicity in female patients administered 5-FU using the convention of dosing per unit of body surface area. We conclude that variation in toxicity between females and males may be partially explained by this feature of body composition.},
	language = {eng},
	number = {11},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Prado, Carla M. M. and Baracos, Vickie E. and McCargar, Linda J. and Mourtzakis, Marina and Mulder, Karen E. and Reiman, Tony and Butts, Charles A. and Scarfe, Andrew G. and Sawyer, Michael B.},
	month = jun,
	year = {2007},
	pmid = {17545532},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Sex Factors, Prospective Studies, Antineoplastic Agents, Adult, chemo, crc, Dose-Response Relationship, Drug, Fluorouracil, Leucovorin, Body Surface Area},
	pages = {3264--3268},
}

@article{park17683,
	title = {Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer},
	volume = {10},
	issn = {2045-2322},
	doi = {10.1038/s41598-020-74765-8},
	abstract = {Cancer causes muscle mass loss, which is associated with a poor prognosis. Chemotherapy may also reduce muscle mass. We investigated skeletal muscle mass change during palliative chemotherapy for advanced gastric cancer (AGC) and its association with treatment outcomes. We retrospectively reviewed 111 consecutive AGC patients who underwent first-line palliative chemotherapy. Skeletal muscle area was measured before and after chemotherapy at the third lumbar vertebra level using computed tomography scans. We compared skeletal muscle index (SMI), body mass index (BMI), and body weight changes to chemotherapy response and survival. The 80 male and 31 female patients' median age was 65 (range 31-87) years, and 46.8\% had sarcopenia at baseline. Median pre-chemotherapy to post-chemotherapy SMI, BMI, and body weight decreases were - 4.5 cm2/m2 (- 11.3\%) (P {\textless} 0.001); - 0.7 kg/m2 (- 3.2\%) (P {\textless} 0.001); and - 2.0 kg (- 3.5\%) (P {\textless} 0.001), respectively. Median SMI decreases for patients with objective response, stable disease, and disease progression were - 4.0 cm2/m2 (range - 20.1 {\textasciitilde} 9.5); - 4.5 cm2/m2 (range - 19.8 {\textasciitilde} 0.8); and - 3.8 cm2/m2 (range: - 17.6 {\textasciitilde} 0.1), respectively. Response to chemotherapy was not associated with SMI decrease (P = 0.463). In multivariable analysis, sarcopenia at baseline (HR 1.681; 95\% CI 1.083-2.609, P = 0.021), decreased SMI (HR 1.620; 95\% CI 1.041-2.520; P = 0.032) were significant poor prognostic factors for survival. Skeletal muscle mass decreased significantly during chemotherapy in AGC patients, but was not associated with chemotherapy response. Decreased SMI was a poor prognostic factor in AGC patients during first-line palliative chemotherapy.},
	language = {eng},
	number = {1},
	journal = {Scientific Reports},
	author = {Park, Song Ee and Choi, Jin Hwa and Park, Jae Yong and Kim, Beom Jin and Kim, Jae Gyu and Kim, Jong Won and Park, Joong-Min and Chi, Kyong-Choun and Hwang, In Gyu},
	month = oct,
	year = {2020},
	pmid = {33077864},
	pmcid = {PMC7573603},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Palliative Care, Antineoplastic Agents, Prognosis, Organ Size, Aged, 80 and over, Adult, chemo, gastric, Stomach Neoplasms},
	pages = {17683},
	file = {Park - 2020 - Loss of skeletal muscle mass during palliative che.pdf:/Users/jcsal/Zotero/storage/GPQ3897L/Park - 2020 - Loss of skeletal muscle mass during palliative che.pdf:application/pdf},
}

@article{wang751,
	title = {Muscle {Density}, but {Not} {Size}, {Correlates} {Well} {With} {Muscle} {Strength} and {Physical} {Performance}},
	volume = {22},
	issn = {1525-8610},
	url = {https://www.sciencedirect.com/science/article/pii/S1525861020305740},
	doi = {10.1016/j.jamda.2020.06.052},
	abstract = {Objectives
There is increasing evidence that muscle volume and mass are poor predictors of muscle strength and physical performance. Other assessments of muscle quality such as skeletal muscle density measured by computed tomography (CT) may be more important. The aim of this study was to explore associations of muscle size and density with handgrip strength (HGS) and the Timed Up and Go test (TUG). We also hypothesized that the strength of these associations would depend on the specific muscle of muscle group, namely trunk, hip, and mid-thigh muscles.
Design
Cross-sectional study.
Setting and Participants
University hospital; 316 volunteers aged 59 to 85 years.
Methods
HGS, TUG, and quantitative CT imaging of the lumber, hip, and mid-thigh were performed in volunteers. From the CT images, cross-sectional area and attenuation were determined for the gluteus muscle, trunk muscle at vertebrae L2 level, and mid-thigh muscle.
Results
In men and women, associations of muscle area with TUG were insignificant after adjustment for age, height, and weight. Associations with HGS were only significant in men for the gluteus maximus and the mid-thigh but slopes were rather low (β {\textless} 0.20). Associations between muscle density and TUG/HGS were more pronounced, in particular for HGS. After adjustment, associations with TUG were significant in women for the gluteus maximus and trunk muscle even (β −0.06, P .001 and β −0.07, P .031, respectively).
Conclusions and Implications
Muscle density is more strongly associated with muscle strength than muscle size andin women muscle density was also more strongly associated than muscle size with physical performance. Therefore, muscle density may represent a more clinically meaningful surrogate of muscle performance than muscle size. Muscle density measurements of trunk and gluteus muscles can be easily obtained from routine CT scan and, therefore, may become an important measurement to diagnose and screen for sarcopenia.},
	language = {en},
	number = {4},
	urldate = {2021-06-17},
	journal = {Journal of the American Medical Directors Association},
	author = {Wang, Ling and Yin, Lu and Zhao, Yue and Su, Yongbin and Sun, Wei and Chen, Shuo and Liu, Yandong and Yang, Minghui and Yu, Aihong and Guglielmi, Giuseppe and Blake, Glen M. and Cheng, Xiaoguang and Wu, Xinbao and Veldhuis-Vlug, Annegreet G. and Engelke, Klaus},
	month = apr,
	year = {2021},
	keywords = {sarcopenia, computed tomography, grip strength, Muscle density, muscle size, Myosteatosis, Timed Up and Go test},
	pages = {751--759.e2},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/7PKCKLE7/S1525861020305740.html:text/html},
}

@article{rinninella2045,
	title = {Muscle mass, assessed at diagnosis by {L3}-{CT} scan as a prognostic marker of clinical outcomes in patients with gastric cancer: {A} systematic review and meta-analysis},
	volume = {39},
	issn = {0261-5614},
	shorttitle = {Muscle mass, assessed at diagnosis by {L3}-{CT} scan as a prognostic marker of clinical outcomes in patients with gastric cancer},
	url = {https://www.sciencedirect.com/science/article/pii/S0261561419331085},
	doi = {10.1016/j.clnu.2019.10.021},
	abstract = {Background \& aims
Computed tomographic (CT) imaging at third lumbar vertebra (L3), routinely used by oncologists, represents a reliable tool to quantify muscle mass. A systematic review and meta-analysis was performed to assess the efficacy of CT scan to define muscle mass as a prognostic marker in gastric cancer (GC) patients undergoing gastrectomy and/or chemotherapy. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS) and the secondary outcomes included postoperative length of hospital stay (P-LOS), total and severe complications in GC patients undergoing gastrectomy.
Methods
Three electronic bibliographic databases — MEDLINE, Web of Science and Cochrane Central Register of Controlled Trials - were used to conduct a systematic literature search based on fixed inclusion and exclusion criteria, until April 2019. The adjusted and unadjusted hazard ratio (HR), odds ratio (OR) and mean difference (MD) with 95\% confidence interval (CI) were used to analyse the dichotomous variables (OS, RFS, total and severe complications) and continuous variables (P-LOS). Random- and fixed effects models were used according to the heterogeneity.
Results
A total of 5610 GC patients from 20 studies were identified. Low muscle mass at diagnosis was found in 32.7\% of GC patients and was significantly associated with poorer OS (HR 2.02, 95\% CI 1.71–2.38, p {\textless} 0.00001, I2 = 47\%) and worse RFS (HR 1.97, 95\% CI 1.71–2.26, p {\textless} 0.00001, I2 = 0\%). Meta-analysis of adjusted HR from multivariable analyses confirmed the association between OS and low muscle mass (HR 1.89, 95\% CI 1.68–2.12, p {\textless} 0.00001, I2 = 36\%). Furthermore, low muscle mass and poorer OS were significantly associated in metastatic GC patients exclusively undergoing chemotherapy (HR 1.61, 95\% CI 1.23–2.11, p {\textless} 0.0006, I2 = 18\%). Moreover, preoperative low muscle mass was significantly associated with longer P-LOS (MD 1.19, 95\% CI 0.68–1.71, p {\textless} 0.00001, I2 = 0\%), higher risk of postoperative complications (OR 1.76, 95\% CI 1.17–2.66, p = 0.007, I2 = 77\%) and severe complications (OR 1.54, 95\% CI 1.03–2.29, p = 0.04, I2 = 49\%) in GC patients undergoing gastrectomy.
Conclusions
Low muscle mass, assessed by L3 CT-scan, affects almost 1/3 of GC patients at diagnosis and acts as a negative prognostic marker on many clinical outcomes. Therefore, identifying GC patients with low muscle mass at diagnosis or at follow-up visit should be recommendable. Clinical nutritionists should be part of tumor boards meetings to screen low muscle mass in order to prompt personalized nutritional support.},
	language = {en},
	number = {7},
	urldate = {2021-06-17},
	journal = {Clinical Nutrition},
	author = {Rinninella, Emanuele and Cintoni, Marco and Raoul, Pauline and Pozzo, Carmelo and Strippoli, Antonia and Bria, Emilio and Tortora, Giampaolo and Gasbarrini, Antonio and Mele, Maria Cristina},
	month = jul,
	year = {2020},
	keywords = {Sarcopenia, Disease-related malnutrition, Gastric cancer, Muscle mass, Personalised medicine, Tumor boards},
	pages = {2045--2054},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/IUBJ3T6B/S0261561419331085.html:text/html},
}

@article{sugiyama5859,
	title = {Baseline {Sarcopenia} and {Skeletal} {Muscle} {Loss} {During} {Chemotherapy} {Affect} {Survival} {Outcomes} in {Metastatic} {Gastric} {Cancer}},
	volume = {38},
	copyright = {Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved},
	issn = {0250-7005, 1791-7530},
	url = {https://ar.iiarjournals.org/content/38/10/5859},
	doi = {10.21873/anticanres.12928},
	abstract = {{\textless}p{\textgreater}Aim: To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy. Patients and Methods: Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a ≥10\% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS). Results: Of 118 patients, 89\% had baseline sarcopenia and 31\% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities. Conclusion: Muscle loss during chemotherapy negatively affected survival among patients with mGC.{\textless}/p{\textgreater}},
	language = {en},
	number = {10},
	urldate = {2021-06-17},
	journal = {Anticancer Research},
	author = {Sugiyama, Keiji and Narita, Yukiya and Mitani, Seiichiro and Honda, Kazunori and Masuishi, Toshiki and Taniguchi, Hiroya and Kadowaki, Shigenori and Ura, Takashi and Ando, Masashi and Tajika, Masahiro and Muro, Kei},
	month = oct,
	year = {2018},
	pmid = {30275211},
	note = {Publisher: International Institute of Anticancer Research
Section: Clinical Studies},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Follow-Up Studies, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Prognosis, Aged, 80 and over, Adult, sarcopenia, chemo, Chemotherapy, gastric, Stomach Neoplasms, Adenocarcinoma, Case-Control Studies, gastric cancer, Liver Neoplasms, Peritoneal Neoplasms, prognostic factor, skeletal muscle loss, Stage4},
	pages = {5859--5866},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/DFP429QJ/Sugiyama et al. - 2018 - Baseline Sarcopenia and Skeletal Muscle Loss Durin.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/3KU4EEAZ/5859.html:text/html},
}

@article{narita52,
	title = {Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients},
	volume = {9},
	issn = {2078-6891},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848026/},
	doi = {10.21037/jgo.2017.11.08},
	abstract = {Background
It remains unclear whether human epidermal growth factor receptor 2 (HER2) status is an outcome-associated biomarker independent of known prognostic factors for metastatic gastric cancer. Moreover, there are few reports about nomograms in inoperable locally advanced or metastatic gastric cancer (AGC), although several studies have been reported regarding other cancer types. This retrospective study aimed to develop nomograms that combine HER2 status and other prognostic factors to predict the survival outcomes of AGC patients starting first-line treatment.

Methods
In this study, 838 consecutive AGC patients starting first-line chemotherapy at the Aichi Cancer Center Hospital (ACC) were included to establish the nomograms that calculated the predicted probability of survival at different time points, 6 months and 1 and 2 years for overall survival (OS) and 3 and 6 months, and 1 year for progression free survival (PFS). Nomograms were independently validated with 269 consecutive AGC patients at the Cancer Center Hospital (SCC) who underwent first-line chemotherapy. The discriminatory ability and accuracy of the models were assessed using Harrell’s c-index. IHC3+ or IHC2+/ISH+ tumors were defined as HER2 positive.

Results
At a median follow-up of 12.3 (ACC) and 11.6 (SCC) months, the median OS was 12.5 and 12.4 months (P=1.00), and the median PFS was 4.8 and 5.8 months (P=0.03), respectively. The nomograms showed good C-index values: OS was respectively 0.688 and 0.576 and PFS was respectively for 0.643 and 0.544.

Conclusions
The nomograms including HER2 status as covariate are crucial determinants of clinical care.},
	number = {1},
	urldate = {2021-06-17},
	journal = {Journal of Gastrointestinal Oncology},
	author = {Narita, Yukiya and Kadowaki, Shigenori and Oze, Isao and Kito, Yosuke and Kawakami, Takeshi and Machida, Nozomu and Taniguchi, Hiroya and Ura, Takashi and Ando, Masashi and Ito, Seiji and Tajika, Masahiro and Yatabe, Yasushi and Yasui, Hirofumi and Muro, Kei},
	month = feb,
	year = {2018},
	pmid = {29564171},
	pmcid = {PMC5848026},
	keywords = {Stage4},
	pages = {52--63},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/4HMEJ8Y2/Narita et al. - 2018 - Establishment and validation of prognostic nomogra.pdf:application/pdf},
}

@article{custodio1526,
	title = {Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab},
	volume = {116},
	copyright = {2017 The Author(s)},
	issn = {1532-1827},
	shorttitle = {Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy},
	url = {https://www.nature.com/articles/bjc2017122},
	doi = {10.1038/bjc.2017.122},
	abstract = {To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy.},
	language = {en},
	number = {12},
	urldate = {2021-06-17},
	journal = {British Journal of Cancer},
	author = {Custodio, A. and Carmona-Bayonas, A. and Jiménez-Fonseca, P. and Sánchez, M. L. and Viudez, A. and Hernández, R. and Cano, J. M. and Echavarria, I. and Pericay, C. and Mangas, M. and Visa, L. and Buxo, E. and García, T. and Rodríguez Palomo, A. and Álvarez Manceñido, F. and Lacalle, A. and Macias, I. and Azkarate, A. and Ramchandani, A. and Fernández Montes, A. and López, C. and Longo, F. and Sánchez Bayona, R. and Limón, M. L. and Díaz-Serrano, A. and Hurtado, A. and Madero, R. and Gómez, C. and Gallego, J.},
	month = jun,
	year = {2017},
	note = {Number: 12
Publisher: Nature Publishing Group},
	keywords = {Stage4},
	pages = {1526--1535},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/KZAXNPF9/Custodio et al. - 2017 - Nomogram-based prediction of survival in patients .pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/I9RXBV8K/bjc2017122.html:text/html},
}

@article{takahari358,
	title = {Determination of {Prognostic} {Factors} in {Japanese} {Patients} {With} {Advanced} {Gastric} {Cancer} {Using} the {Data} {From} a {Randomized} {Controlled} {Trial}, {Japan} {Clinical} {Oncology} {Group} 9912},
	volume = {19},
	issn = {1083-7159},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983816/},
	doi = {10.1634/theoncologist.2013-0306},
	abstract = {In this study, the authors explored baseline prognostic factors in Japanese advanced gastric cancer (AGC) patients. They propose a new prognostic index for patients with AGC. This can be used for more appropriate patient stratification in future clinical trials.},
	number = {4},
	urldate = {2021-06-17},
	journal = {The Oncologist},
	author = {Takahari, Daisuke and Boku, Narikazu and Mizusawa, Junki and Takashima, Atsuo and Yamada, Yasuhide and Yoshino, Takayuki and Yamazaki, Kentaro and Koizumi, Wasaburo and Fukase, Kazutoshi and Yamaguchi, Kensei and Goto, Masahiro and Nishina, Tomohiro and Tamura, Takao and Tsuji, Akihito and Ohtsu, Atsushi},
	month = apr,
	year = {2014},
	pmid = {24668328},
	pmcid = {PMC3983816},
	keywords = {Stage4},
	pages = {358--366},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/GF4USAIG/Takahari et al. - 2014 - Determination of Prognostic Factors in Japanese Pa.pdf:application/pdf},
}

@article{koo913,
	title = {A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models},
	volume = {68},
	issn = {1432-0843},
	shorttitle = {A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer},
	url = {https://doi.org/10.1007/s00280-011-1561-8},
	doi = {10.1007/s00280-011-1561-8},
	abstract = {To make up for the limitations of previous prognostic models, we developed and validated a model in patients with metastatic or recurrent gastric adenocarcinoma (AGC), and to compare with previous models.},
	language = {en},
	number = {4},
	urldate = {2021-06-17},
	journal = {Cancer Chemotherapy and Pharmacology},
	author = {Koo, Dong Hoe and Ryoo, Baek-Yeol and Kim, Hwa Jung and Ryu, Min-Hee and Lee, Sung-Sook and Moon, Jung-Hwa and Chang, Heung-Moon and Lee, Jae-Lyun and Kim, Tae Won and Kang, Yoon-Koo},
	month = oct,
	year = {2011},
	keywords = {Stage4},
	pages = {913--921},
}

@article{yagi71,
	title = {Prognostic factors in stage {IV} gastric cancer: univariate and multivariate analyses},
	volume = {3},
	issn = {1436-3291},
	shorttitle = {Prognostic factors in stage {IV} gastric cancer},
	url = {https://doi.org/10.1007/PL00011699},
	doi = {10.1007/PL00011699},
	language = {en},
	number = {2},
	urldate = {2021-06-16},
	journal = {Gastric Cancer},
	author = {Yagi, Yoshinori and Seshimo, Akiyoshi and Kameoka, Shingo},
	month = sep,
	year = {2000},
	keywords = {Stage4},
	pages = {71--80},
	file = {Springer Full Text PDF:/Users/jcsal/Zotero/storage/8LNHURYR/Yagi et al. - 2000 - Prognostic factors in stage IV gastric cancer uni.pdf:application/pdf},
}

@article{castoro1375,
	title = {Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?},
	volume = {17},
	issn = {1873-4626},
	shorttitle = {Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus},
	doi = {10.1007/s11605-013-2269-3},
	abstract = {BACKGROUND: Neoadjuvant chemoradiotherapy (CT-RT) before oesophagectomy is standard management for squamous cell carcinoma(SCC) of the thoracic oesophagus. The aim of this study was to compare the outcome of patients who had clinical complete response(CR) with neoadjuvant CT-RT + oesophagectomy with the survival of patients who had clinical CR and were not operated on.
PATIENTS AND METHODS: Seventy-seven consecutive patients with SCC of the thoracic oesophagus with CR with neoadjuvant CT-RT presenting at the Regional Center of Esophageal Diseases from 1992 to 2008 were included in this retrospective study on a prospectively collected database. Thirty-nine patients underwent oesophagectomy (CT-RT + oesophagectomy), while 38(CT-RT) were not operated on because they were considered unfit for surgery or refused the operation. Patients’ outcome and survival were compared.
RESULTS: In the CT-RT + oesophagectomy group, clinical CR was confirmed after histological examination of the surgical specimen in 27/39 (69.2 \%) patients. Five-year overall survival rates were 50.0 \% in the CT-RT + oesophagectomy group and 57.0 \% in the CT-RT group (p=0.99); 5-year disease-free survival rates were 55.5\%in the CT-RT + oesophagectomy group and 34.6\%in the CTRT group (p=0.15). Even after adjusting for propensity score, age, ASA and clinical stage, the treatment regimen did not show a statistically significant effect on overall survival (adjusted p=0.65) nor on disease-free survival (adjusted p=0.15).
CONCLUSION: In our group of patients with clinical CR after neoadjuvant CT-RT for SCC of the thoracic oesophagus, waiting for recurrence and then using salvage surgery did not negatively impact their survival compared to patients treated with surgery. More accurate restaging protocols are warranted to improve decision making after CR with neoadjuvant CT-RT.},
	language = {eng},
	number = {8},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Castoro, Carlo and Scarpa, Marco and Cagol, Matteo and Alfieri, Rita and Ruol, Alberto and Cavallin, Francesco and Michieletto, Silvia and Zanchettin, Giampietro and Chiarion-Sileni, Vanna and Corti, Luigi and Ancona, Ermanno},
	month = aug,
	year = {2013},
	pmid = {23797888},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Fluorouracil, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Cisplatin, Disease-Free Survival, Dose Fractionation, Radiation, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local},
	pages = {1375--1381},
}

@article{noordman142,
	title = {Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial},
	volume = {18},
	issn = {1471-2407},
	shorttitle = {Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer},
	doi = {10.1186/s12885-018-4034-1},
	abstract = {BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment for locally advanced oesophageal cancer. With this treatment, 29\% of patients have a pathologically complete response in the resection specimen. This provides the rationale for investigating an active surveillance approach. The aim of this study is to assess the (cost-)effectiveness of active surveillance vs. standard oesophagectomy after nCRT for oesophageal cancer.
METHODS: This is a phase-III multi-centre, stepped-wedge cluster randomised controlled trial. A total of 300 patients with clinically complete response (cCR, i.e. no local or disseminated disease proven by histology) after nCRT will be randomised to show non-inferiority of active surveillance to standard oesophagectomy (non-inferiority margin 15\%, intra-correlation coefficient 0.02, power 80\%, 2-sided α 0.05, 12\% drop-out). Patients will undergo a first clinical response evaluation (CRE-I) 4-6 weeks after nCRT, consisting of endoscopy with bite-on-bite biopsies of the primary tumour site and other suspected lesions. Clinically complete responders will undergo a second CRE (CRE-II), 6-8 weeks after CRE-I. CRE-II will include 18F-FDG-PET-CT, followed by endoscopy with bite-on-bite biopsies and ultra-endosonography plus fine needle aspiration of suspected lymph nodes and/or PET- positive lesions. Patients with cCR at CRE-II will be assigned to oesophagectomy (first phase) or active surveillance (second phase of the study). The duration of the first phase is determined randomly over the 12 centres, i.e., stepped-wedge cluster design. Patients in the active surveillance arm will undergo diagnostic evaluations similar to CRE-II at 6/9/12/16/20/24/30/36/48 and 60 months after nCRT. In this arm, oesophagectomy will be offered only to patients in whom locoregional regrowth is highly suspected or proven, without distant dissemination. The main study parameter is overall survival; secondary endpoints include percentage of patients who do not undergo surgery, quality of life, clinical irresectability (cT4b) rate, radical resection rate, postoperative complications, progression-free survival, distant dissemination rate, and cost-effectiveness. We hypothesise that active surveillance leads to non-inferior survival, improved quality of life and a reduction in costs, compared to standard oesophagectomy.
DISCUSSION: If active surveillance and surgery as needed after nCRT leads to non-inferior survival compared to standard oesophagectomy, this organ-sparing approach can be implemented as a standard of care.},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Noordman, Bo Jan and Wijnhoven, Bas P. L. and Lagarde, Sjoerd M. and Boonstra, Jurjen J. and Coene, Peter Paul L. O. and Dekker, Jan Willem T. and Doukas, Michael and van der Gaast, Ate and Heisterkamp, Joos and Kouwenhoven, Ewout A. and Nieuwenhuijzen, Grard A. P. and Pierie, Jean-Pierre E. N. and Rosman, Camiel and van Sandick, Johanna W. and van der Sangen, Maurice J. C. and Sosef, Meindert N. and Spaander, Manon C. W. and Valkema, Roelf and van der Zaag, Edwin S. and Steyerberg, Ewout W. and van Lanschot, J. Jan B. and {SANO-study group}},
	month = feb,
	year = {2018},
	pmid = {29409469},
	pmcid = {PMC5801846},
	keywords = {Humans, Neoadjuvant Therapy, Outcome Assessment, Health Care, Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Active surveillance, Chemoradiotherapy, Cost-Benefit Analysis, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Multicenter Studies as Topic, Neoadjuvant chemoradiotherapy, Oesophageal cancer, Positron Emission Tomography Computed Tomography, Research Design, Standard oesophagectomy},
	pages = {142},
	file = {Full Text:/Users/jcsal/Zotero/storage/JPM8RE68/Noordman et al. - 2018 - Neoadjuvant chemoradiotherapy plus surgery versus .pdf:application/pdf},
}

@article{vanderwilk462,
	title = {Towards an {Organ}-{Sparing} {Approach} for {Locally} {Advanced} {Esophageal} {Cancer}},
	volume = {36},
	issn = {1421-9883},
	doi = {10.1159/000493435},
	abstract = {BACKGROUND: Active surveillance after neoadjuvant therapies has emerged among several malignancies. During active surveillance, frequent assessments are performed to detect residual disease and surgery is only reserved for those patients in whom residual disease is proven or highly suspected without distant metastases. After neoadjuvant chemoradiotherapy (nCRT), nearly one-third of esophageal cancer patients achieve a pathologically complete response (pCR). Both patients that achieve a pCR and patients that harbor subclinical disseminated disease after nCRT could benefit from an active surveillance strategy.
SUMMARY: Esophagectomy is still the cornerstone of treatment in patients with esophageal cancer. Non-surgical treatment via definitive chemoradiotherapy (dCRT) is currently reserved only for patients not eligible for esophagectomy. Since salvage esophagectomy after dCRT (50-60 Gy) results in increased complications, morbidity and mortality compared to surgery after nCRT (41.4 Gy), the latter seems preferable in the setting of active surveillance. Clinical response evaluations can detect substantial (i.e., tumor regression grade [TRG] 3-4) tumors after nCRT with a sensitivity of 90\%, minimizing the risk of development of non-resectable recurrences. Current scarce and retrospective literature suggests that active surveillance following nCRT might not jeopardize overall survival and postponed surgery could be performed safely. Key Message: Before an active surveillance approach could be considered standard treatment, results of phase III randomized trials should be awaited.},
	language = {eng},
	number = {6},
	journal = {Digestive Surgery},
	author = {van der Wilk, Berend Jan and Eyck, Ben M. and Spaander, Manon C. W. and Valkema, Roelf and Lagarde, Sjoerd M. and Wijnhoven, Bas P. L. and van Lanschot, J. Jan B.},
	year = {2019},
	pmid = {30227434},
	pmcid = {PMC6878756},
	keywords = {Humans, Neoadjuvant Therapy, Esophageal Neoplasms, Esophagectomy, Active surveillance, Chemoradiotherapy, Neoadjuvant chemoradiotherapy, Esophageal cancer, Organ Sparing Treatments, Organ-sparing treatment, Watchful Waiting},
	pages = {462--469},
	file = {Full Text:/Users/jcsal/Zotero/storage/VNUPTADR/van der Wilk et al. - 2019 - Towards an Organ-Sparing Approach for Locally Adva.pdf:application/pdf},
}

@article{domachevskye13412,
	title = {Baseline {18F}-{FDG} {PET}/{CT} as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: {A} retrospective study},
	volume = {97},
	issn = {1536-5964},
	shorttitle = {Baseline {18F}-{FDG} {PET}/{CT} as predictor of the pathological response to neoadjuvant therapy in esophageal cancer},
	doi = {10.1097/MD.0000000000013412},
	abstract = {The type of pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer predicts overall survival (OS).We aimed to assess early 18F-FDG positron emission tomography/computed tomography parameters in predicting the pathological response to neoadjuvant treatment.The cohort included consecutive patients with locally advanced esophageal cancer who underwent baseline 18F-FDG positron emission tomography/computed tomography between September 2006 and February 2015. Positron emission tomography variables of maximum and average standardized uptake values (SUVmax, SUVaverage), metabolic tumor volume (MTV), and total lesion glycolysis were recorded in addition to computed tomography volume. MTV was calculated using cut-off values of 42\%, 50\% and 60\% (MTV 0.42, 0.5, and 0.6) of the tumoral SUVmax. Receiver operating characteristic (ROC) analysis was used to determine sensitivity and specificity.Sixty-one patients (44 male, 17 female) fulfilled the inclusion criteria. Only MTV values of 13.6 mL (MTV 0.42) and 7.4 mL (MTV 0.5) remained significant on ROC analysis, with an area under the curve of 0.690 (confidence interval 0.557-0.823, p = .02] and 0.664 (confidence interval 0.527-0.802, P = .048), respectively in differentiating patients with a complete (n = 44) or incomplete (n = 17) pathological response.MTV at presentation is associated with the pathological response to neoadjuvant chemoradiation in patients with locally advanced esophageal cancer.},
	language = {eng},
	number = {49},
	journal = {Medicine},
	author = {Domachevsky, Liran and Kashtan, Hanoch and Brenner, Baruch and Nidam, Meital and Morgenstern, Sara and Kundel, Yulia and Groshar, David and Bernstine, Hanna},
	month = dec,
	year = {2018},
	pmid = {30544419},
	pmcid = {PMC6310504},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Prognosis, Esophageal Neoplasms, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Radiopharmaceuticals},
	pages = {e13412},
	file = {Full Text:/Users/jcsal/Zotero/storage/QFQQS3RT/Domachevsky et al. - 2018 - Baseline 18F-FDG PETCT as predictor of the pathol.pdf:application/pdf},
}

@article{huange0210055,
	title = {Post-chemoradiotherapy {FDG} {PET} with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma},
	volume = {14},
	issn = {1932-6203},
	doi = {10.1371/journal.pone.0210055},
	abstract = {OBJECTIVES: Post-chemoradiotherapy (CRT) FDG PET is a useful prognosticator of esophageal cancer. However, debate on the diverse criteria of previous publications preclude worldwide multicenter comparisons, and even a universal practice guide. We aimed to validate a simple qualitative interpretation criterion of post-CRT FDG PET for outcome stratification and compare it with other criteria.
METHODS: The post-CRT FDG PET of 114 patients with esophageal squamous cell carcinoma (ESCC) were independently interpreted using a qualitative 4-point scale (Qual4PS) that identified focal esophageal FDG uptake greater than liver uptake as residual tumor. Cohen's κ coefficient (κ) was used to measure interobserver agreement of Qual4PS. The Kaplan-Meier method and Cox proportional hazards regression analyses were used for survival analysis. Other criteria included a different qualitative approach (QualBK), maximal standardized uptake values (SUVmax3.4, SUVmax2.5), relative change of SUVmax between pre- and post-CRT FDG PET (ΔSUVmax), mean standardized uptake values (SUVmean), metabolic volume (MV) and total lesion glycolysis (TLG).
RESULTS: Overall interobserver agreement on the Qual4PS criterion was excellent (κ: 0.95). Except the QualBK, SUVmax2.5, and TLG, all the other criteria were significant predictors for overall survival (OS). Multivariable analysis showed only Qual4PS (HR: 15.41; P = 0.005) and AJCC stage (HR: 2.47; P = 0.007) were significant independent variables. The 2-year OS rates of Qual4PS(‒) patients undergoing CRT alone (68.4\%) and patients undergoing trimodality therapy (62.5\%) were not significant different, but the 2-year OS rates of Qual4PS(+) patients undergoing CRT alone (10.0\%) were significantly lower than in patients undergoing trimodality therapy (42.1\%).
CONCLUSIONS: The Qual4PS criterion is reproducible for assessing the response of ESCC to CRT, and valuable for predicting survival. It may add value to response-adapted treatment for ESCC patients, and help to decide whether surgery is warranted after CRT.},
	language = {eng},
	number = {1},
	journal = {PloS One},
	author = {Huang, Yung-Cheng and Li, Shau-Hsuan and Lu, Hung-I. and Hsu, Chien-Chin and Wang, Yu-Ming and Lin, Wei-Che and Chen, Chao-Jung and Ho, Kuo-Wei and Chiu, Nan-Tsing},
	year = {2019},
	pmid = {30615636},
	pmcid = {PMC6322736},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Retrospective Studies, Proportional Hazards Models, Aged, 80 and over, Adult, Outcome Assessment, Health Care, Carcinoma, Squamous Cell, Esophageal Neoplasms, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18},
	pages = {e0210055},
	file = {Full Text:/Users/jcsal/Zotero/storage/6CMDDZQS/Huang et al. - 2019 - Post-chemoradiotherapy FDG PET with qualitative in.pdf:application/pdf},
}

@article{faiz986,
	title = {Impact of {Age} and {Comorbidity} on {Choice} and {Outcome} of {Two} {Different} {Treatment} {Options} for {Patients} with {Potentially} {Curable} {Esophageal} {Cancer}},
	volume = {26},
	issn = {1534-4681},
	doi = {10.1245/s10434-019-07181-6},
	abstract = {PURPOSE: This study was designed to assess the impact of age and comorbidity on choice and outcome of definitive chemoradiotherapy (dCRT) or neoadjuvant chemoradiotherapy plus surgery.
METHODS: In this population-based study, all patients with potentially curable EC (cT1N+/cT2-3, TX, any cN, cM0) diagnosed in the South East of the Netherlands between 2004 and 2014 were included. Kaplan-Meier method with log-rank tests and multivariable Cox regression analysis were used to compare overall survival (OS).
RESULTS: A total of 702 patients was included. Age ≥ 75 years and multiple comorbidities were associated with a higher probability for dCRT (odds ratio [OR] 8.58; 95\% confidence interval [CI] 4.72-15.58; and OR 3.09; 95\% CI 1.93-4.93). The strongest associations were found for the combination of hypertension plus diabetes (OR 3.80; 95\% CI 1.97-7.32) and the combination of cardiovascular with pulmonary comorbidity (OR 3.18; 95\% CI 1.57-6.46). Patients with EC who underwent dCRT had a poorer prognosis than those who underwent nCRT plus surgery, irrespective of age, number, and type of comorbidities. In contrast, for patients with squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, OS was comparable between both groups (hazard ratio [HR] 1.52; 95\% CI 0.78-2.97; and HR 0.73; 95\% CI 0.13-4.14).
CONCLUSIONS: Histological tumor type should be acknowledged in treatment choices for patients with esophageal cancer. Neoadjuvant chemoradiotherapy plus surgery should basically be advised as treatment of choice for operable esophageal adenocarcinoma patients. For patients with esophageal squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, dCRT may be the preferred strategy.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgical Oncology},
	author = {Faiz, Z. and van Putten, M. and Verhoeven, R. H. A. and van Sandick, J. W. and Nieuwenhuijzen, G. a. P. and van der Sangen, M. J. C. and Lemmens, V. E. P. P. and Wijnhoven, B. P. L. and Plukker, J. T. M.},
	month = apr,
	year = {2019},
	pmid = {30719634},
	pmcid = {PMC6399439},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Age Factors, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, Comorbidity, Netherlands, SCCA},
	pages = {986--995},
	file = {Full Text:/Users/jcsal/Zotero/storage/MPJFEZPR/Faiz et al. - 2019 - Impact of Age and Comorbidity on Choice and Outcom.pdf:application/pdf},
}

@article{stahl183,
	title = {Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction ({POET}): {Long}-term results of a controlled randomised trial},
	volume = {81},
	issn = {1879-0852},
	shorttitle = {Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction ({POET})},
	doi = {10.1016/j.ejca.2017.04.027},
	abstract = {BACKGROUND: Results of the PreOperative therapy in Esophagogastric adenocarcinoma Trial (POET) showed some benefits when including radiotherapy into the preoperative treatment. This article is reporting long-term results of this phase III study.
PATIENTS AND METHODS: Patients with locally advanced adenocarcinomas of the oesophagogastric junction (Siewert types I-III) were eligible. Randomisation was done to chemotherapy (group A) or induction chemotherapy and chemoradiotherapy (CRT; group B) followed by surgery.
RESULTS: The primary end-point of the study was overall survival at 3 years. The study was closed early after 119 patients having been randomised and were eligible. Local progression-free survival after tumour resection was significantly improved by CRT (hazard ratio [HR] 0.37; 0.16-0.85, p = value 0.01) and 20 versus 12 patients were free of local tumour progression at 5 years (p = 0.03). Although the rate of postoperative in-hospital mortality was somewhat higher with CRT (10.2\% versus 3.8\%, p = 0.26), more patients were alive at 3 and 5 years after CRT (46.7\% and 39.5\%) compared with chemotherapy (26.1\% and 24.4\%). Thus, overall survival showed a trend in favour of preoperative CRT (HR 0.65, 95\% confidence interval [CI] 0.42-1.01, p = 0.055).
CONCLUSION: Although the primary end-point overall survival of the study was not met, our long-term follow-up data suggest a benefit in local progression-free survival when radiotherapy was added to preoperative chemotherapy in patients with locally advanced adenocarcinoma of the oesophagogastric junction.},
	language = {eng},
	journal = {European Journal of Cancer (Oxford, England: 1990)},
	author = {Stahl, Michael and Walz, Martin K. and Riera-Knorrenschild, Jorge and Stuschke, Martin and Sandermann, Andreas and Bitzer, Michael and Wilke, Hansjochen and Budach, Wilfried},
	month = aug,
	year = {2017},
	pmid = {28628843},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adult, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Chemoradiotherapy, Esophagogastric Junction, Germany, Oesophagogastric adenocarcinoma, Phase III trial, Preoperative chemoradiotherapy, Preoperative chemotherapy},
	pages = {183--190},
}

@article{degraaf988,
	title = {The role of staging laparoscopy in oesophagogastric cancers},
	volume = {33},
	issn = {0748-7983},
	doi = {10.1016/j.ejso.2007.01.007},
	abstract = {AIMS: Selection of patients for treatment of oesophagogastric cancers rests on accurate staging. Laparoscopy has become a safe and effective staging tool in upper gastrointestinal cancers because of its ability to detect small peritoneal and liver metastases missed by imaging techniques. The aim of this study was to evaluate the role of staging laparoscopy (SL) in determining resectability of oesophagogastric cancers.
METHODS: A review of 511 patients with oesophagogastric cancers referred to our centre during a 7-year period was performed. Four hundred and sixteen of them assessed to have resectable tumours after preoperative staging with CT and/or ultrasound underwent SL. The main outcome measure was the number of patients in whom laparoscopy changed treatment decision.
RESULTS: Staging laparoscopy changed treatment decision in 84 cases (20.2\%): locally advanced disease in 17, extensive lymph node disease in four and distant metastases (liver and peritoneum) in 63 cases. The sensitivity of laparoscopy for resectability was 88\%. Eighty-one percent of patients who had combined CT scan and EUS were resectable at surgery compared with 65\% of those who had CT scan alone (statistically significant with P-value{\textless}0.05). Of those patients deemed resectable by SL 8.1\% were found to be unresectable at laparotomy, 16 with locally advanced disease and 11 with metastases.
CONCLUSION: Staging laparoscopy avoided unnecessary laparotomy in 20.2\% of our patients and was most useful in adenocarcinoma, distal oesophageal, GOJ and gastric cancers and probably not necessary in lesions of the upper two-third of the oesophagus.},
	language = {eng},
	number = {8},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {de Graaf, G. W. and Ayantunde, A. A. and Parsons, S. L. and Duffy, J. P. and Welch, N. T.},
	month = oct,
	year = {2007},
	pmid = {17344017},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Adult, Predictive Value of Tests, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Evaluation Studies as Topic, Laparoscopy, Sensitivity and Specificity, Ultrasonography},
	pages = {988--992},
}

@article{messager318,
	title = {Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid ({FOLFOX}) for resectable esophageal and junctional cancer: the {PROTECT}-1402, randomized phase 2 trial},
	volume = {16},
	issn = {1471-2407},
	shorttitle = {Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid ({FOLFOX}) for resectable esophageal and junctional cancer},
	doi = {10.1186/s12885-016-2335-9},
	abstract = {BACKGROUND: Often curative treatment for locally advanced resectable esophageal or gastro-esophageal junctional cancer consists of concurrent neoadjuvant radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy regimens in this setting is a combination of a fluoropyrimidin and of a platinum analogue. Due to the promising results of the recent CROSS trial, another regimen combining paclitaxel and carboplatin is also widely used by European and American centers. No clinical study has shown the superiority of one treatment over the other. The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments. Our aim is to evaluate, in operable esophageal and gastro-esophageal junctional cancer, the complete resection rate and severe postoperative morbidity rate associated with these two neoadjuvant chemotherapeutic regimens (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid) when each is combined with the radiation regime utilized in the CROSS trial.
METHODS/DESIGN: PROTECT is a prospective, randomized, multicenter, open arms, phase II trial. Eligible patients will have a histologically confirmed adenocarcinoma or squamous cell carcinoma and be treated with neoadjuvant radiochemotherapy followed by surgery for stage IIB or stage III resectable esophageal cancer. A total of 106 patients will be randomized to receive either 3 cycles of FOLFOX combined to concurrent radiotherapy (41.4 Grays) or carboplatin and paclitaxel with the same radiation regimen, using a 1:1 allocation ratio.
DISCUSSION: This ongoing trial offers the unique opportunity to compare two standards of chemotherapy delivered with a common regimen of preoperative radiation, in the setting of operable locally advanced esophageal or gastro-esophageal junctional tumors.
TRIAL REGISTRATION: NCT02359968 (ClinicalTrials.gov) (registration date: 9 FEB 2015), EudraCT: 2014-000649-62 (registration date: 10 FEB 2014).},
	language = {eng},
	journal = {BMC cancer},
	author = {Messager, Mathieu and Mirabel, Xavier and Tresch, Emmanuelle and Paumier, Amaury and Vendrely, Véronique and Dahan, Laetitia and Glehen, Olivier and Vasseur, Frederique and Lacornerie, Thomas and Piessen, Guillaume and El Hajbi, Farid and Robb, William B. and Clisant, Stéphanie and Kramar, Andrew and Mariette, Christophe and Adenis, Antoine},
	month = may,
	year = {2016},
	pmid = {27194176},
	pmcid = {PMC4872363},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adult, Fluorouracil, Leucovorin, Organoplatinum Compounds, Survival Analysis, Young Adult, Carcinoma, Squamous Cell, Cisplatin, Dose Fractionation, Radiation, Esophageal Neoplasms, Chemoradiotherapy, Esophageal cancer, FOLFOX, Paclitaxel, Paclitaxel-carboplatin, Randomized trial},
	pages = {318},
	file = {Full Text:/Users/jcsal/Zotero/storage/2H5DG8SX/Messager et al. - 2016 - Preoperative chemoradiation with paclitaxel-carbop.pdf:application/pdf},
}

@article{zhaoe0202185,
	title = {Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: {A} meta-analysis based on clinical trials},
	volume = {13},
	issn = {1932-6203},
	shorttitle = {Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction},
	doi = {10.1371/journal.pone.0202185},
	abstract = {BACKGROUND: The benefit of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for treating cancer of the esophagus or the gastroesophageal junction remains controversial. In the present study, we conducted a comprehensive meta-analysis to examine the efficacy of these two management strategies.
METHODS: The MEDLINE (PubMed), SinoMed, Embase, and Cochrane Library databases were searched for eligible studies. We searched for the most relevant studies published until the end of September 2017. Data were extracted independently and were analyzed using RevMan statistical software version 5.3 (Cochrane Collaboration, http://tech.cochrane.org/revman/download). Weighted mean differences, risk ratios (RRs), and 95\% confidence intervals (CIs) were calculated. Cochrane Collaboration's risk of bias tool was used to assess the risk of bias. In this comprehensive meta-analysis, we examined the efficiency of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for the treatment of cancer of the esophagus or the gastroesophageal junction as reported in qualified clinical trials.
RESULTS: Six qualified articles that included a total of 866 patients were identified. The meta-analysis showed that for 3-year and 5-year survival rates in primary outcomes, the results favored neoadjuvant chemoradiotherapy strategies compared with neoadjuvant chemotherapy (RR = 0.78, 95\% CI = 0.62-0.98, P = 0.03; RR = 0.69, 95\% CI = 0.50-0.96, P = 0.03, respectively). In terms of secondary outcomes, neoadjuvant chemoradiotherapy significantly increased the rate of R0 resection and pathological complete response as well (RR = 0.87, 95\% CI = 0.81-0.92, P {\textless} 0.0001; RR = 0.16, 95\% CI = 0.09-0.28, P {\textless} 0.00001, respectively). However, there were no significant differences in postoperative mortality between the two groups (RR = 1.85, 95\% CI = 0.93-3.65, P = 0.08). For the results of postoperative complications, revealed that there was a statistically significant difference between the two groups in the incidence of postoperative complications such as pulmonary, anastomotic leak and cardiovascular complications. The subgroup analysis of patients with esophageal adenocarcinoma or squamous cell carcinoma showed that both esophageal adenocarcinoma and squamous cell carcinoma patients achieved a high rate of R0 resection (RR = 0.85, 95\% CI = 0.77-0.93, P = 0.0006; RR = 0.88, 95\% CI = 0.81-0.96, P = 0.005, respectively) and pathological complete response benefit of neoadjuvant chemoradiotherapy (RR = 0.23, 95\% CI = 0.09-0.57, P = 0.001; RR = 0.18, 95\% CI = 0.03-0.96, P = 0.05, respectively).
CONCLUSION: Our findings suggested that compared with neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy should be recommended with a significant long-term survival benefit in patients with cancer of the esophagus or the gastroesophageal junction. In view of the clinical heterogeneity, whether these conclusions are broadly applicable should be further determined.},
	language = {eng},
	number = {8},
	journal = {PloS One},
	author = {Zhao, Xin and Ren, Yiming and Hu, Yong and Cui, Naiqiang and Wang, Ximo and Cui, Yunfeng},
	year = {2018},
	pmid = {30138325},
	pmcid = {PMC6107145},
	keywords = {Humans, Neoadjuvant Therapy, Randomized Controlled Trials as Topic, Stomach Neoplasms, Esophageal Neoplasms, Chemoradiotherapy, Esophagogastric Junction},
	pages = {e0202185},
	file = {Full Text:/Users/jcsal/Zotero/storage/AITR5E6P/Zhao et al. - 2018 - Neoadjuvant chemotherapy versus neoadjuvant chemor.pdf:application/pdf},
}

@article{yang2796,
	title = {Neoadjuvant {Chemoradiotherapy} {Followed} by {Surgery} {Versus} {Surgery} {Alone} for {Locally} {Advanced} {Squamous} {Cell} {Carcinoma} of the {Esophagus} ({NEOCRTEC5010}): {A} {Phase} {III} {Multicenter}, {Randomized}, {Open}-{Label} {Clinical} {Trial}},
	volume = {36},
	issn = {1527-7755},
	shorttitle = {Neoadjuvant {Chemoradiotherapy} {Followed} by {Surgery} {Versus} {Surgery} {Alone} for {Locally} {Advanced} {Squamous} {Cell} {Carcinoma} of the {Esophagus} ({NEOCRTEC5010})},
	doi = {10.1200/JCO.2018.79.1483},
	abstract = {Purpose The efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. In this trial, we compared the survival and safety of NCRT plus surgery with surgery alone in patients with locally advanced ESCC. Patients and Methods From June 2007 to December 2014, 451 patients with potentially resectable thoracic ESCC, clinically staged as T1-4N1M0/T4N0M0, were randomly allocated to NCRT plus surgery (group CRT; n = 224) and surgery alone (group S; n = 227). In group CRT, patients received vinorelbine 25 mg/m2 intravenously (IV) on days 1 and 8 and cisplatin 75 mg/m2 IV day 1, or 25 mg/m2 IV on days 1 to 4 every 3 weeks for two cycles, with a total concurrent radiation dose of 40.0 Gy administered in 20 fractions of 2.0 Gy on 5 days per week. In both groups, patients underwent McKeown or Ivor Lewis esophagectomy. The primary end point was overall survival. Results The pathologic complete response rate was 43.2\% in group CRT. Compared with group S, group CRT had a higher R0 resection rate (98.4\% v 91.2\%; P = .002), a better median overall survival (100.1 months v 66.5 months; hazard ratio, 0.71; 95\% CI, 0.53 to 0.96; P = .025), and a prolonged disease-free survival (100.1 months v 41.7 months; hazard ratio, 0.58; 95\% CI, 0.43 to 0.78; P {\textless} .001). Leukopenia (48.9\%) and neutropenia (45.7\%) were the most common grade 3 or 4 adverse events during chemoradiotherapy. Incidences of postoperative complications were similar between groups, with the exception of arrhythmia (group CRT: 13\% v group S: 4.0\%; P = .001). Peritreatment mortality was 2.2\% in group CRT versus 0.4\% in group S ( P = .212). Conclusion This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.},
	language = {eng},
	number = {27},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Yang, Hong and Liu, Hui and Chen, Yuping and Zhu, Chengchu and Fang, Wentao and Yu, Zhentao and Mao, Weimin and Xiang, Jiaqing and Han, Yongtao and Chen, Zhijian and Yang, Haihua and Wang, Jiaming and Pang, Qingsong and Zheng, Xiao and Yang, Huanjun and Li, Tao and Lordick, Florian and D'Journo, Xavier Benoit and Cerfolio, Robert J. and Korst, Robert J. and Novoa, Nuria M. and Swanson, Scott J. and Brunelli, Alessandro and Ismail, Mahmoud and Fernando, Hiran C. and Zhang, Xu and Li, Qun and Wang, Geng and Chen, Baofu and Mao, Teng and Kong, Min and Guo, Xufeng and Lin, Ting and Liu, Mengzhong and Fu, Jianhua and {AME Thoracic Surgery Collaborative Group}},
	month = sep,
	year = {2018},
	pmid = {30089078},
	pmcid = {PMC6145832},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemoradiotherapy, Adjuvant, Cisplatin, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophageal Squamous Cell Carcinoma, Incidence, Postoperative Complications, Vinorelbine},
	pages = {2796--2803},
	file = {Full Text:/Users/jcsal/Zotero/storage/6NCLMHG8/Yang et al. - 2018 - Neoadjuvant Chemoradiotherapy Followed by Surgery .pdf:application/pdf},
}

@article{soetikno4490,
	title = {Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract},
	volume = {23},
	issn = {0732-183X},
	doi = {10.1200/JCO.2005.19.935},
	abstract = {The purpose of this literature review is to examine recent advances in technique and technology of endoscopic mucosal resection of superficial early cancers of the upper gastrointestinal tract. Endoscopic mucosal resection (EMR) of superficial early cancers of the upper gastrointestinal tract is standard technique in Japan and is increasingly used in Western countries. Newer techniques of EMR allow removal of larger lesions en-bloc. These minimally invasive techniques, when applied correctly, allow safe and efficacious treatment in situations that would otherwise require major surgery. Through the establishment of long-term outcomes data, standardization of endoscopic and pathologic reporting, and newer EMR technology and techniques, the future treatment of early cancers in the upper gastrointestinal tract may be achieved primarily through the endoscope.},
	language = {eng},
	number = {20},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Soetikno, Roy and Kaltenbach, Tonya and Yeh, Ronald and Gotoda, Takuji},
	month = jul,
	year = {2005},
	pmid = {16002839},
	keywords = {Humans, Stomach Neoplasms, Esophageal Neoplasms, Endoscopy, Gastrointestinal, Intestinal Mucosa, Lymphatic Metastasis},
	pages = {4490--4498},
}

@article{rusch444,
	title = {Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?},
	volume = {31},
	issn = {0093-7754},
	doi = {10.1053/j.seminoncol.2004.04.023},
	abstract = {Recent epidemiological shifts have led to controversy about the etiology and treatment of gastroesophageal (GE) junction adenocarcinomas. The Siewert classification conveniently describes the anatomical location of these tumors relative to the GE junction. However, available data suggest that there may be epidemiological, clinical, and molecular differences among GE junction adenocarcinomas, depending on whether they are predominantly esophageal or gastric in location. Much more investigation is required to confirm or refute these apparent differences, which can affect clinical treatment.},
	language = {eng},
	number = {4},
	journal = {Seminars in Oncology},
	author = {Rusch, Valerie W.},
	month = aug,
	year = {2004},
	pmid = {15297937},
	keywords = {Humans, Neoplasm Staging, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Cardia, Terminology as Topic},
	pages = {444--449},
}

@article{repici715,
	title = {Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective {Western} series},
	volume = {71},
	issn = {1097-6779},
	shorttitle = {Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma},
	doi = {10.1016/j.gie.2009.11.020},
	abstract = {BACKGROUND: Although endoscopic submucosal dissection (ESD) is becoming accepted as an established treatment for superficial esophageal squamous cell neoplasia, the majority of data on this endoscopic modality has been provided by Japanese series.
OBJECTIVE: To assess the efficacy and safety of ESD for esophageal squamous cell neoplasia in a consecutive series of patients treated in a Western setting.
DESIGN AND SETTING: Single-center, prospective observational study.
PATIENTS AND INTERVENTION: From January 2005 to July 2008, 20 patients with superficial esophageal squamous cell neoplasia were treated by ESD.
MAIN OUTCOME MEASUREMENTS: Rates of en bloc resection, complete resection, and complications were evaluated as short-term outcomes. Overall survival, local or distant recurrence, and postoperative stricture rates were evaluated as long-term outcomes.
RESULTS: ESD was performed in 20 patients (mean age 64 years, range 46-81 years; 16 men). The mean size of the lesion was 32 mm (range 15-60 mm); it was 30 mm or larger in 14 patients (70\%). The mean time of ESD was 89 minutes (range 58-180 minutes). En bloc resection with resection-free margins was achieved in 18 patients (90\%), whereas 2 patients presented with incomplete or indeterminate resection. Two cases (10\%) of mediastinal emphysema without overt perforation and 1 case (5\%) of post-ESD symptomatic stricture were reported. No local or distant post-ESD recurrence occurred in those with resection-free margins at a median follow-up of 18 months.
LIMITATIONS: Small number of patients and limited follow-up.
CONCLUSION: This Western series study confirms that ESD is a potentially curative treatment for superficial esophageal squamous cell neoplasia. Early and late complication rates were comparable to those of Japanese series. ESD should be probably considered as the treatment of choice in all large lesions amenable to endoscopic treatment.},
	language = {eng},
	number = {4},
	journal = {Gastrointestinal Endoscopy},
	author = {Repici, Alessandro and Hassan, Cesare and Carlino, Alessandra and Pagano, Nico and Zullo, Angelo and Rando, Giacomo and Strangio, Giuseppe and Romeo, Fabio and Nicita, Rinaldo and Rosati, Riccardo and Malesci, Alberto},
	month = apr,
	year = {2010},
	pmid = {20363414},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Prospective Studies, Aged, 80 and over, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Postoperative Complications, Animals, Esophagoscopy, Esophagus},
	pages = {715--721},
}

@article{orringer363,
	title = {Two thousand transhiatal esophagectomies: changing trends, lessons learned},
	volume = {246},
	issn = {0003-4932},
	shorttitle = {Two thousand transhiatal esophagectomies},
	doi = {10.1097/SLA.0b013e31814697f2},
	abstract = {OBJECTIVE: "Rediscovered" in 1976, transhiatal esophagectomy (THE) has been applicable in most situations requiring esophageal resection and reconstruction. The objective of this study was to review the authors' 30-year experience with THE and changing trends in its use.
METHODS: Using the authors' prospective Esophagectomy Database, this single institution experience with THE was analyzed retrospectively.
RESULTS: Two thousand and seven THEs were performed-1063 (previously reported) between 1976 and 1998 (group I) and 944 from 1998 to 2006 (group II), 24\% for benign disease, 76\%, cancer. THE was possible in 98\%. Stomach was the esophageal substitute in 97\%. Comparing outcomes between group I and group II, statistically significant differences (P {\textless} 0.001) were observed in hospital mortality (4\% vs. 1\%); adenocarcinoma histology (69\% vs. 86\%); use of neoadjuvant chemoradiation (28\% vs. 52\%); mean blood loss (677 vs. 368 mL); anastomotic leak (14\% vs. 9\%); and discharge within 10 days (52\% vs. 78\%). Major complications remain infrequent: wound infection/dehiscence, 3\%, atelectasis/pneumonia, 2\%, intrathoracic hemorrhage, recurrent laryngeal nerve paralysis, chylothorax, and tracheal laceration, {\textless}1\% each. Late functional results have been good or excellent in 73\%. Aggressive preoperative conditioning, avoiding the ICU, improved pain management, and early ambulation reduce length of stay, with 50\% in group II discharged within 1 week.
CONCLUSION: THE refinements have reduced the historic morbidity and mortality of esophageal resection. This largest reported THE experience reinforces the value of consistent technique and a clinical pathway in managing these high acuity esophageal patients.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgery},
	author = {Orringer, Mark B. and Marshall, Becky and Chang, Andrew C. and Lee, Julia and Pickens, Allan and Lau, Christine L.},
	month = sep,
	year = {2007},
	pmid = {17717440},
	pmcid = {PMC1959358},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Proportional Hazards Models, Survival Rate, Chi-Square Distribution, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Early Ambulation, Esophageal Diseases, Logistic Models, Stomach},
	pages = {363--372; discussion 372--374},
	file = {Full Text:/Users/jcsal/Zotero/storage/6NS7F4WJ/Orringer et al. - 2007 - Two thousand transhiatal esophagectomies changing.pdf:application/pdf},
}

@article{noh1389,
	title = {Adjuvant capecitabine plus oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC}): 5-year follow-up of an open-label, randomised phase 3 trial},
	volume = {15},
	issn = {1474-5488},
	shorttitle = {Adjuvant capecitabine plus oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC})},
	doi = {10.1016/S1470-2045(14)70473-5},
	abstract = {BACKGROUND: The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The planned interim analysis of CLASSIC (median follow-up 34 months) showed that adjuvant capecitabine plus oxaliplatin significantly improved disease-free survival, the primary endpoint, compared with observation after D2 gastrectomy. We report the 5-year follow-up data from the trial.
METHODS: CLASSIC was a phase 3, randomised, open-label study done at 35 cancer centres, medical centres, and hospitals in China, South Korea, and Taiwan. Patients with stage II-IIIB gastric cancer who underwent curative D2 gastrectomy were randomly assigned (1:1) after surgery to receive adjuvant chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m(2) twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m(2) on day 1) for 6 months or observation alone. Randomisation was stratified by country and disease stage with a permuted block (size four) design. Neither patients nor investigators were masked to treatment assignment. The primary outcome was 3-year disease-free survival in the intention-to-treat population. This analysis presents the final preplanned assessment of outcomes after 5 years. The study is registered with ClinicalTrials.gov, NCT00411229.
FINDINGS: We enrolled 1035 patients: 520 were randomly assigned to adjuvant capecitabine and oxaliplatin, and 515 to observation. Median follow-up for this analysis in the intention-to-treat population was 62·4 months (IQR 54-70). 139 (27\%) patients had disease-free survival events in the adjuvant capecitabine and oxaliplatin group versus 203 (39\%) patients in the observation group (stratified hazard ratio [HR] 0·58, 95\% CI 0·47-0·72; p{\textless}0·0001). Estimated 5-year disease-free survival was 68\% (95\% CI 63-73) in the adjuvant capecitabine and oxaliplatin group versus 53\% (47-58) in the observation alone group. By the clinical cutoff date, 103 patients (20\%) had died in the adjuvant capecitabine and oxaliplatin group versus 141 patients (27\%) in the observation group (stratified HR 0·66, 95\% CI 0·51-0·85; p=0·0015). Estimated 5-year overall survival was 78\% (95\% CI 74-82) in the adjuvant capecitabine and oxaliplatin group versus 69\% (64-73) in the observation group. Adverse event data were not collected after the primary analysis.
INTERPRETATION: Adjuvant treatment with capecitabine plus oxaliplatin after D2 gastrectomy should be considered for patients with operable stage II or III gastric cancer.
FUNDING: F Hoffmann La-Roche and Sanofi.},
	language = {eng},
	number = {12},
	journal = {The Lancet. Oncology},
	author = {Noh, Sung Hoon and Park, Sook Ryun and Yang, Han-Kwang and Chung, Hyun Cheol and Chung, Ik-Joo and Kim, Sang-Woon and Kim, Hyung-Ho and Choi, Jin-Hyuk and Kim, Hoon-Kyo and Yu, Wansik and Lee, Jong Inn and Shin, Dong Bok and Ji, Jiafu and Chen, Jen-Shi and Lim, Yunni and Ha, Stella and Bang, Yung-Jue and {CLASSIC trial investigators}},
	month = nov,
	year = {2014},
	pmid = {25439693},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Fluorouracil, Organoplatinum Compounds, Drug-Related Side Effects and Adverse Reactions, Stomach Neoplasms, Disease-Free Survival, Capecitabine, Deoxycytidine, Gastrectomy, Oxaliplatin},
	pages = {1389--1396},
}

@article{maish1777,
	title = {Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma},
	volume = {78},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2004.04.064},
	abstract = {BACKGROUND: Endoscopic ablation and vagal-sparing esophagectomy offer the potential for reduced morbidity in patients with high-grade dysplasia or early esophageal adenocarcinoma, but neither includes a lymphadenectomy. Although adequate for intramucosal tumors, both are potentially inadequate for patients with submucosal tumor invasion given the high prevalence of nodal metastases with these lesions. Currently there is no test including endoscopic ultrasound that can accurately determine whether a small tumor is confined to the mucosa or has penetrated into the submucosa. The aim of this study was to compare the pathologic depth of invasion by endoscopic mucosal resection with findings and outcome after surgical resection to assess the accuracy and reliability of endoscopic mucosal resection for staging early esophageal adenocarcinoma.
METHODS: From 2001 to 2003, 7 patients presented with small, endoscopically visible adenocarcinomas. All underwent endoscopic mucosal resection followed by surgical resection.
RESULTS: Analysis of the resected specimens confirmed that the endoscopic mucosal resection had accurately determined the depth of tumor invasion in all patients, and had completely excised the lesion in all but 1 patient (86\%). Lymph node dissection was included as part of the resection in 2 patients with submucosal invasion by endoscopic mucosal resection, and a vagal-sparing esophagectomy was used in the 5 patients with only intramucosal tumors. All patients are alive and disease-free at a median follow-up of 7 months.
CONCLUSIONS: Endoscopic mucosal resection accurately determines the depth of tumor invasion, and should be used as a staging procedure in patients with early esophageal cancer when therapies that do not include a lymphadenectomy are considered.},
	language = {eng},
	number = {5},
	journal = {The Annals of Thoracic Surgery},
	author = {Maish, Mary S. and DeMeester, Steven R.},
	month = nov,
	year = {2004},
	pmid = {15511474},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Neoplasm Invasiveness, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophagoscopy, Gastrectomy, Lymph Node Excision, Mucous Membrane, Remission Induction, Vagus Nerve},
	pages = {1777--1782},
}

@article{leichman4555,
	title = {S0356: a phase {II} clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma},
	volume = {29},
	issn = {1527-7755},
	shorttitle = {S0356},
	doi = {10.1200/JCO.2011.36.7490},
	abstract = {PURPOSE: Pathologic complete response (pCR) after neoadjuvant therapy for locally advanced esophageal adenocarcinoma is associated with improved survival. The Southwest Oncology Group designed a trimodality, phase II, single-arm trial with objectives of achieving a pCR rate of 40\% with prospective exploratory analyses of intratumoral molecular markers postulated to affect response and survival.
PATIENTS AND METHODS: Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions; surgery was performed 28 to 42 days after neoadjuvant therapy. Chemotherapy was planned after surgery. Tumors were analyzed for mRNA expression and polymorphisms in genes involved in drug metabolism and DNA repair.
RESULTS: Ninety-three patients were evaluable. Two deaths (2.2\%) were attributable to preoperative therapy, and two deaths (2.2\%) were attributable to surgery. Grade 3 and 4 toxicities were recorded for 47.3\% and 19.4\% of patients, respectively. Seventy-nine patients (84.9\%) underwent surgery; 67.7\% of patients had R0 resections. Twenty-six patients (28.0\%) had confirmed pCR (95\% CI, 19.1\% to 38.2\%). At a median follow-up of 39.2 months, estimates of median and 3-year overall survival (OS) were 28.3 months and 45.1\%, respectively. Intratumoral ERCC-1 gene expression was inversely related to progression-free survival and OS.
CONCLUSION: Neoadjuvant oxaliplatin, PI-FU, and EBRT for esophageal adenocarcinoma is active and tolerable. Because the regimen failed to meet the primary end point, it does not define a new standard. However, future trials can be built on this platform to validate the role of ERCC-1 in determining the best systemic regimen for individual patients.},
	language = {eng},
	number = {34},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Leichman, Lawrence P. and Goldman, Bryan H. and Bohanes, Pierre O. and Lenz, Heinz J. and Thomas, Charles R. and Billingsley, Kevin G. and Corless, Christopher L. and Iqbal, Syma and Gold, Philip J. and Benedetti, Jacqueline K. and Danenberg, Kathleen D. and Blanke, Charles D.},
	month = dec,
	year = {2011},
	pmid = {22025151},
	pmcid = {PMC3236655},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Drug Administration Schedule, Fluorouracil, Organoplatinum Compounds, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Oxaliplatin, Radiotherapy, Adjuvant},
	pages = {4555--4560},
	file = {Full Text:/Users/jcsal/Zotero/storage/UZJAFIUX/Leichman et al. - 2011 - S0356 a phase II clinical and prospective molecul.pdf:application/pdf},
}

@article{kofoed26,
	title = {Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction},
	volume = {101},
	issn = {1799-7267},
	doi = {10.1177/145749691210100106},
	abstract = {BACKGROUND AND AIMS: Longterm survival after curative resection for adenocarcinoma at the gastro-esophageal junction (GEJ) range between 18\% and 50\%. In the pivotal Intergroup-0116 Phase III trial by Macdonald et all, adjuvant chemoradiotherapy improved both disease-free and overall survival in curatively resected patients with mainly gastric adenocarcinoma. We compared survival data for curatively resected patients with adeno-carcinoma solely at the gastro-esophageal junction (GEJ), treated with surgery alone or surgery and adjuvant chemoradio-therapy.
METHODS: From 2003 to 2009, 211 patients underwent curative resection. Surgery alone was performed in 95 pa-tients and 116 patients received adjuvant therapy after resection. All patients underwent Lewis-Tanner operation with D1 node resection including coliac nodes (D1+). Informations about recurrence and death were collected from the Danish Cancer Register and the Central Death Register. Patients who died after experiencing severe complications after surgery were excluded from the survival analysis. Patients with T0N0 or T1N0 were also excluded because patients of this category were not given adjuvant therapy according to the Macdonald protocol.
RESULTS: Patients with positive node status in the resected specimen, the 3-year disease-free survival after adjuvant chemoradiotherapy (n = 91) or surgery alone (n = 43) was 24\% and 37\%, respectively. Median time of survival was prolonged by 10 month in favour of those who received chemoradiotherapy. However, after controlling for the confounding effect of age and node status, only positive node status in the resected specimen had significant partial effect on survival.
CONCLUSION: Chemoradiotherapy according to the Intergroup-0116 protocol might still be a reasonable option after curative resection in patients with GEJ adenocarcinomas and positive lymph node status, who did not receive neoadjuvant chemotherapy.},
	language = {eng},
	number = {1},
	journal = {Scandinavian journal of surgery: SJS: official organ for the Finnish Surgical Society and the Scandinavian Surgical Society},
	author = {Kofoed, S. C. and Muhic, A. and Baeksgaard, L. and Jendresen, M. and Gustafsen, J. and Holm, J. and Bardram, L. and Brandt, B. and Brenø, J. and Svendsen, L. B.},
	year = {2012},
	pmid = {22414465},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Stomach Neoplasms, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophagogastric Junction, Lymphatic Metastasis, Radiotherapy Dosage},
	pages = {26--31},
}

@article{ganz35,
	title = {Circumferential ablation of {Barrett}'s esophagus that contains high-grade dysplasia: a {U}.{S}. {Multicenter} {Registry}},
	volume = {68},
	issn = {1097-6779},
	shorttitle = {Circumferential ablation of {Barrett}'s esophagus that contains high-grade dysplasia},
	doi = {10.1016/j.gie.2007.12.015},
	abstract = {BACKGROUND: The management strategies for Barrett's esophagus (BE) that contains high-grade dysplasia (HGD) include intensive endoscopic surveillance, photodynamic therapy, thermal ablation, EMR, and esophagectomy.
OBJECTIVE: To assess the safety and effectiveness of endoscopic circumferential balloon-based ablation by using radiofrequency energy for treating BE HGD.
DESIGN: Multicenter U.S. registry.
SETTING: Sixteen academic and community centers; treatment period from September 2004 to March 2007.
PATIENTS: Patients with histologic evidence of intestinal metaplasia (IM) that contained HGD confirmed by at least 2 expert pathologists. A prior EMR was permitted, provided that residual HGD remained in the BE region for ablation.
INTERVENTION: Endoscopic circumferential ablation with follow-up esophageal biopsies to assess the histologic response to treatment.
OUTCOMES: Histologic complete response (CR) end points: (1) all biopsy specimen fragments obtained at the last biopsy session were negative for HGD (CR-HGD), (2) all biopsy specimens were negative for any dysplasia (CR-D), and (3) all biopsy specimens were negative for IM (CR-IM).
RESULTS: A total of 142 patients (median age 66 years, interquartile range [IQR] 59-75 years) who had BE HGD (median length 6 cm, IQR 3-8 cm) underwent circumferential ablation (median 1 session, IQR 1-2). No serious adverse events were reported. There was 1 asymptomatic stricture and no buried glands. Ninety-two patients had at least 1 follow-up biopsy session (median follow-up 12 months, IQR 8-15 months). A CR-HGD was achieved in 90.2\% of patients, CR-D in 80.4\%, and CR-IM in 54.3\%.
LIMITATIONS: A nonrandomized study design, without a control arm, a lack of centralized pathology review, ablation and biopsy technique not standardized, and a relatively short-term follow-up.
CONCLUSIONS: Endoscopic circumferential ablation is a promising modality for the treatment of BE that contains HGD. In this multicenter registry, the intervention safely achieved a CR for HGD in 90.2\% of patients at a median of 12 months of follow-up.},
	language = {eng},
	number = {1},
	journal = {Gastrointestinal Endoscopy},
	author = {Ganz, Robert A. and Overholt, Bergein F. and Sharma, Virender K. and Fleischer, David E. and Shaheen, Nicholas J. and Lightdale, Charles J. and Freeman, Stephen R. and Pruitt, Ronald E. and Urayama, Shiro M. and Gress, Frank and Pavey, Darren A. and Branch, M. Stanley and Savides, Thomas J. and Chang, Kenneth J. and Muthusamy, V. Raman and Bohorfoush, Anthony G. and Pace, Samuel C. and DeMeester, Steven R. and Eysselein, Viktor E. and Panjehpour, Masoud and Triadafilopoulos, George and {U.S. Multicenter Registry}},
	month = jul,
	year = {2008},
	pmid = {18355819},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Risk Assessment, United States, Esophageal Neoplasms, Sensitivity and Specificity, Esophagoscopy, Barrett Esophagus, Biopsy, Needle, Catheter Ablation, Education, Medical, Continuing, Immunohistochemistry, Precancerous Conditions, Registries},
	pages = {35--40},
}

@article{swisher175,
	title = {Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy},
	volume = {123},
	issn = {0022-5223},
	doi = {10.1067/mtc.2002.119070},
	abstract = {OBJECTIVES: Some patients and oncologists choose to treat localized esophageal cancer with definitive chemotherapy and radiation therapy rather than surgery. A subset of these patients have local relapse without distant metastases and therefore have no other curative intent treatment option but salvage esophagectomy.
METHODS: We reviewed our experience with salvage esophagectomy from 1987 to 2000 at M.D. Anderson Cancer Center (n = 13, salvage after chemotherapy and radiotherapy group) and compared the data with those of patients receiving esophagectomy in a planned fashion 4 to 6 weeks after preoperative chemotherapy and radiation therapy (n = 99, preoperative chemotherapy and radiotherapy group).
RESULTS: Increases in morbidity were seen after resection in the salvage after chemotherapy and radiotherapy group relative to the preoperative chemotherapy and radiotherapy group: mechanical ventilation (9.0 days vs 3.3 days, P =.08), intensive care unit stay (11.2 days vs 5.1 days, P =.07), hospital stay (29.4 days vs 18.4 days, P =.03), and anastomotic leak rates (5/13 [39\%] vs 7/99 [7\%], P =.005). Operative mortality (within 30 days) also tended to be increased statistically nonsignificantly (2/13 [15\%] vs 6/99 [6\%], P =.2). Salvage esophagectomy resulted in long-term survival (25\% 5-year survival) in a subset of patients. Improved survival after salvage esophagectomy was associated with early pathologic stage (T1 N0, T2 N0), prolonged time to relapse, and R0 surgical resection.
CONCLUSION: Patients who undergo salvage esophagectomy for relapse of tumor after definitive chemoradiation therapy have increased morbidity, mortality, and hospital use relative to patients undergoing planned esophagectomy after preoperative chemoradiation. Nevertheless, long-term survival can be achieved in this group, and such treatment should be considered for carefully selected patients at an experienced center.},
	language = {eng},
	number = {1},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Swisher, Stephen G. and Wynn, Paula and Putnam, Joe B. and Mosheim, Melinda B. and Correa, Arlene M. and Komaki, Ritsuko R. and Ajani, Jaffer A. and Smythe, W. Roy and Vaporciyan, Ara A. and Roth, Jack A. and Walsh, Garrett L.},
	month = jan,
	year = {2002},
	pmid = {11782772},
	keywords = {Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Esophageal Neoplasms, Esophagectomy, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Salvage Therapy, Survival Rate},
	pages = {175--183},
}

@article{ouattara1088,
	title = {Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer},
	volume = {41},
	issn = {1873-734X},
	doi = {10.1093/ejcts/ezr182},
	abstract = {OBJECTIVE: Malnutrition is common after oesophageal cancer surgery. This study aims to investigate body mass index (BMI) kinetics and the risk factors of malnutrition among 1-year disease-free survivors after radical transthoracic oesophagectomy for cancer.
METHODS: From a prospective single-institution database, 118 1-year disease-free survivors having undergone a R0 transthoracic oesophagectomy with gastric tubulization between 2000 and 2008 were identified retrospectively. BMI values were collected at the onset of the disease (pre-treatment BMI), at the time of surgery (preoperative BMI), at postoperative 6 months and 1 year after oesophagectomy (1-year BMI). Logistic regression was performed with adjustment for confounders to estimate odds ratios of the factors associated with a 1-year weight loss (WL) of at least 15\% of the pre-treatment body weight (BW).
RESULTS: At the onset of the disease, 5 patients (4\%) were underweighted (BMI {\textless} 8.5 kg/m\&sup2;), 65 (55\%) were normal (BMI = 18.5-24.9 kg/m\&sup2;), 36 (31\%) were overweighted (BMI {\textgreater} 25 kg/m\&sup2;) and 12 (10\%) were obese (BMI {\textgreater} 30 kg/m\&sup2;). Mean pre-treatment, preoperative, postoperative 6-month and 1-year BMI values were 24.64 ± 4 kg/m\&sup2;, 23.55 ± 3.8 kg/m\&sup2;, 21.7 ± 3 kg/m\&sup2; and 21.97 ± 4 kg/m\&sup2;, respectively. One-year WL ≥ 15\% of the pre-treatment BW was present in 29 patients (25\%): 18 among the 48 patients (37\%) with a pre-treatment BMI ≥ 25 and 11 among the 70 patients (15\%) with pre-treatment BMI {\textless} 25 (P = 0.006). On logistic regression, initial overweighting was the sole independent prognosticator of 1-year postoperative WL of at least 15\% of the pre-treatment BW (P = 0.039; OR: 2.96, [1.06-8.32]).
CONCLUSIONS: Postoperative malnutrition remains a severe problem after oesophageal cancer resection, even in long-term disease-free survivors. Overweight and obese patients are the segment population most exposed to this postoperative malnutrition, suggesting that such surgery could have substantial bariatric effect. A special vigilance programme on the nutritional status of this sub-group of patients should be the rule.},
	language = {eng},
	number = {5},
	journal = {European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery},
	author = {Ouattara, Moussa and D'Journo, Xavier Benoit and Loundou, Anderson and Trousse, Delphine and Dahan, Laetitia and Doddoli, Christophe and Seitz, Jean Francois and Thomas, Pascal-Alexandre},
	month = may,
	year = {2012},
	pmid = {22334635},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Body Mass Index, Neoplasm Staging, Retrospective Studies, Risk Factors, Sex Factors, Overweight, Weight Loss, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Malnutrition, Weight Loss; GE},
	pages = {1088--1093},
	file = {Full Text:/Users/jcsal/Zotero/storage/T8SMT8EF/Ouattara et al. - 2012 - Body mass index kinetics and risk factors of malnu.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/2QH3LMTC/Ouattara et al. - 2012 - Body mass index kinetics and risk factors of malnu.pdf:application/pdf},
}

@article{worrell484,
	title = {Accuracy of {Clinical} {Staging} and {Outcome} {With} {Primary} {Resection} for {Local}-{Regionally} {Limited} {Esophageal} {Adenocarcinoma}},
	volume = {267},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000002139},
	abstract = {OBJECTIVE: The aim of this study was to determine the accuracy of clinical staging, to assess survival with surgical resection alone, and to determine factors associated with understaging in patients with esophageal adenocarcinoma thought to have limited local-regional disease.
BACKGROUND: Primary surgical resection is the preferred treatment in patients with esophageal adenocarcinoma clinically staged to have limited nodal disease. This approach requires reliable clinical staging.
METHODS: A retrospective chart review was performed of all patients who had primary esophagectomy for clinical stage T1-3 N0-1 adenocarcinoma (seventh edition AJCC) from January 2002 to May 2013. Clinical and pathologic stages were compared and overall survival was analyzed.
RESULTS: There were 88 patients who met inclusion criteria. Final pathology confirmed appropriate clinical staging (≤T3N1) in 76\% of patients (67/88). There were 21 patients who were understaged ({\textgreater}T3N1), and in all cases, understaging was based on the presence of advanced nodal (N2 or N3) disease. Factors independently associated with understaging were the presence of dysphagia, tumor length {\textgreater}3 cm, and poor differentiation. At a median follow-up of 35 months, 63\% of all patients (55/88) remain alive. The 5-year survival in correctly staged patients was 67\%, compared with 33\% for those who were understaged (P {\textless} 0.0001).
CONCLUSIONS: Modern clinical staging will accurately identify the majority of patients with esophageal adenocarcinoma and limited local-regional disease (≤pT3N1). Survival with surgery alone in correctly staged patients was excellent and unlikely to be improved with neoadjuvant therapy. A combination of dysphagia, poor differentiation, and tumor length {\textgreater}3 cm was associated with understaging in 92\% of patients. Patients with these factors are likely to have more advanced disease than clinically suspected and may benefit from neoadjuvant therapy before resection.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgery},
	author = {Worrell, Stephanie G. and Alicuben, Evan T. and Oh, Daniel S. and Hagen, Jeffrey A. and DeMeester, Steven R.},
	month = mar,
	year = {2018},
	pmid = {28151801},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Risk Factors, Survival Rate, Aged, 80 and over, Adult, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Lymphatic Metastasis},
	pages = {484--488},
}

@article{taketa1139,
	title = {Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma},
	volume = {12},
	issn = {1540-1413},
	doi = {10.6004/jnccn.2014.0111},
	abstract = {Current algorithms for surveillance of patients with esophageal adenocarcinoma (EAC) after chemoradiation and surgery (trimodality therapy [TMT]) remain empiric. The authors hypothesized that the frequency, type, and timing of relapses after TMT would be highly associated with surgical pathology stage (SPS), and therefore SPS could be used to individualize the surveillance strategy. Between 2000 and 2010, 518 patients with EAC were identified who underwent TMT at The University of Texas MD Anderson Cancer Center and were frequently surveyed. Frequency, type, and timing of the first relapse (locoregional and/or distant) were tabulated according to SPS. Standard statistical approaches were used. The median follow-up time after esophageal surgery was 55.4 months (range, 1.0-149.2 months). Disease relapse occurred in 215 patients (41.5\%). Higher SPS was associated with a higher rate of relapse (0/I vs II/III, P≤.001; 0/I vs II, P=.002; SPS 0/I vs III, P≤.001; and SPS II vs III, P=.005) and with shorter time to relapse (P{\textless}.001). Irrespective of the SPS, approximately 95\% of all relapses occurred within 36 months of surgery. The 3- and 5-year overall survival rates were shorter for patients with a higher SPS than those with a lower SPS (0/I vs II/III, P≤.001; 0/I vs II, P≤.001; 0/I vs III, P≤.001; and II vs III, P=.014). The compelling data show an excellent association between SPS and frequency/type/timing of relapses after TMT in patients with EAC. Thus, the surveillance strategy can potentially be customized based on SPS. These data can inform a future evidence-based surveillance strategy that can be efficient and cost-effective.},
	language = {eng},
	number = {8},
	journal = {Journal of the National Comprehensive Cancer Network: JNCCN},
	author = {Taketa, Takashi and Sudo, Kazuki and Correa, Arlene M. and Wadhwa, Roopma and Shiozaki, Hironori and Elimova, Elena and Campagna, Maria-Claudia and Blum, Mariela A. and Skinner, Heath D. and Komaki, Ritsuko U. and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian R. and Rice, David C. and Swisher, Stephen G. and Maru, Dipen M. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
	month = aug,
	year = {2014},
	pmid = {25099446},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Adult, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Combined Modality Therapy},
	pages = {1139--1144},
	file = {Full Text:/Users/jcsal/Zotero/storage/GQA733Q2/Taketa et al. - 2014 - Post-chemoradiation surgical pathology stage can c.pdf:application/pdf},
}

@article{sudo4306,
	title = {Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies},
	volume = {31},
	issn = {1527-7755},
	doi = {10.1200/JCO.2013.51.7250},
	abstract = {PURPOSE: The primary purpose of surveillance of patients with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local therapy (eg, chemoradiotherapy followed by surgery or trimodality therapy [TMT]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality caused by locoregional failure (LRF). However, the benefits of surveillance are not well understood. We report on LRFs and salvage strategies in a large cohort.
PATIENTS AND METHODS: Between 2000 and 2010, 518 patients with EAC who completed TMT were analyzed for the frequency of LRF over time and salvage therapy outcomes. Standard statistical techniques were used.
RESULTS: For 518 patients, the median follow-up time was 29.3 months (range, 1 to 149 months). Distant metastases (with or without LRF) occurred in 188 patients (36\%), and LRF only occurred in 27 patients (5\%). Eleven of 27 patients had lumen-only LRF. Most LRFs (89\%) occurred within 36 months of surgery. Twelve patients had salvage chemoradiotherapy, but only five survived more than 2 years. Four patients needed salvage surgery, and three who survived more than 2 years developed distant metastases. The median overall survival of 27 patients with LRF was 17 months, and 10 patients (37\%) survived more than 2 years. Thus, only 2\% of all 518 patients benefited from surveillance/salvage strategies.
CONCLUSION: Our surveillance strategy, which is representative of many others currently being used, raises doubts about its effectiveness and benefits (along with concerns regarding types and times of studies and costs implications) to patients with EAC who have LRF only after TMT. Fortunately, LRFs are rare after TMT, but the salvage strategies are not highly beneficial. Our data can help develop an evidence-based surveillance strategy.},
	language = {eng},
	number = {34},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Sudo, Kazuki and Taketa, Takashi and Correa, Arlene M. and Campagna, Maria-Claudia and Wadhwa, Roopma and Blum, Mariela A. and Komaki, Ritsuko and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian and Skinner, Heath D. and Maru, Dipen M. and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
	month = dec,
	year = {2013},
	pmid = {24145339},
	pmcid = {PMC3837091},
	keywords = {Adenocarcinoma, Adult, Aged, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Proportional Hazards Models, Reoperation, Retrospective Studies, Risk Factors, Salvage Therapy, Time Factors, Treatment Failure, Young Adult},
	pages = {4306--4310},
	file = {Full Text:/Users/jcsal/Zotero/storage/7CNQWK75/Sudo et al. - 2013 - Locoregional failure rate after preoperative chemo.pdf:application/pdf},
}

@article{terheggen783,
	title = {A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early {Barrett}'s neoplasia},
	volume = {66},
	issn = {1468-3288},
	doi = {10.1136/gutjnl-2015-310126},
	abstract = {BACKGROUND: For endoscopic resection of early GI neoplasia, endoscopic submucosal dissection (ESD) achieves higher rates of complete resection (R0) than endoscopic mucosal resection (EMR). However, ESD is technically more difficult and evidence from randomised trial is missing.
OBJECTIVE: We compared the efficacy and safety of ESD and EMR in patients with neoplastic Barrett's oesophagus (BO).
DESIGN: BO patients with a focal lesion of high-grade intraepithelial neoplasia (HGIN) or early adenocarcinoma (EAC) ≤3 cm were randomised to either ESD or EMR. Primary outcome was R0 resection; secondary outcomes were complete remission from neoplasia, recurrences and adverse events (AEs).
RESULTS: There were no significant differences in patient and lesion characteristics between the groups randomised to ESD (n=20) or EMR (n=20). Histology of the resected specimen showed HGIN or EAC in all but six cases. Although R0 resection defined as margins free of HGIN/EAC was achieved more frequently with ESD (10/17 vs 2/17, p=0.01), there was no difference in complete remission from neoplasia at 3 months (ESD 15/16 vs EMR 16/17, p=1.0). During a mean follow-up period of 23.1±6.4 months, recurrent EAC was observed in one case in the ESD group. Elective surgery was performed in four and three cases after ESD and EMR, respectively (p=1.0). Two severe AEs were recorded for ESD and none for EMR (p=0.49).
CONCLUSIONS: In terms of need for surgery, neoplasia remission and recurrence, ESD and EMR are both highly effective for endoscopic resection of early BO neoplasia. ESD achieves a higher R0 resection rate, but for most BO patients this bears little clinical relevance. ESD is, however, more time consuming and may cause severe AE.
TRIAL REGISTRATION NUMBER: NCT1871636.},
	language = {eng},
	number = {5},
	journal = {Gut},
	author = {Terheggen, Grischa and Horn, Eva Maria and Vieth, Michael and Gabbert, Helmut and Enderle, Markus and Neugebauer, Alexander and Schumacher, Brigitte and Neuhaus, Horst},
	month = may,
	year = {2017},
	pmid = {26801885},
	pmcid = {PMC5531224},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Prospective Studies, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Barrett Esophagus, Carcinoma in Situ, Reoperation, BARRETT’S OESOPHAGUS, Endoscopic Mucosal Resection, ENDOSCOPIC PROCEDURES, ENDOSCOPY, Margins of Excision, Neoplasm, Residual},
	pages = {783--793},
	file = {baldwin.pdf:/Users/jcsal/Zotero/storage/XZZ6HHIX/baldwin.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/M5KNJB2X/Terheggen et al. - 2017 - A randomised trial of endoscopic submucosal dissec.pdf:application/pdf},
}

@article{vakil1791,
	title = {A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction},
	volume = {96},
	issn = {0002-9270},
	doi = {10.1111/j.1572-0241.2001.03923.x},
	abstract = {OBJECTIVE: Palliation of malignant esophageal obstruction is an important clinical problem. Expandable metal stents are a major advance in therapy, but many stents become obstructed because of tumor ingrowth. The aim of this study was to compare a new, membrane-covered expandable metal stent to conventional prostheses in a randomized controlled trial.
METHODS: Sixty-two patients with malignant inoperable esophageal obstruction at the gastroesophageal junction participated in the study. Patients were randomly assigned to covered or uncovered stents. The principal outcome measure was the need for reintervention because of recurrent dysphagia or migration. Secondary endpoints were relief of dysphagia measured by a dysphagia score (grade 0 = no dysphagia, grade 1 = able to eat solid food, grade 2 = semisolids only, grade 3 = liquids only, grade 4 = complete dysphagia) and the rate of complications and functional status. All patients were observed at monthly intervals until death or for 6 months.
RESULTS: One week after stenting the dysphagia score improved significantly in both the uncovered (n = 32, 3 +/- 0.1 to 1 +/- 0.1 [means +/- SEMs], p {\textless} 0.001) and covered (n = 30, 3 +/- 0.1 to 1 +/- 0.2 [means +/- SEMs], p {\textless} 0.001) stents. Obstructing tumor ingrowth was significantly more likely in the uncovered stent group (9/30) than in the covered group (1/32) (p = 0.005). Significant stent migration occurred in 2/30 patients with uncovered stents, as compared with 4/32 patients in the covered group (p = 0.44). Reinterventions for tumor ingrowth were significantly greater in the uncovered stent group (27\%), as compared with 0\% in the covered group (p = 0.002). Life table analysis showed similar survival in both groups.
CONCLUSION: Membrane-covered stents have significantly better palliation than conventional bare metal stents because of decreased rates of tumor ingrowth that necessitate endoscopic reintervention for dysphagia.},
	language = {eng},
	number = {6},
	journal = {The American Journal of Gastroenterology},
	author = {Vakil, N. and Morris, A. I. and Marcon, N. and Segalin, A. and Peracchia, A. and Bethge, N. and Zuccaro, G. and Bosco, J. J. and Jones, W. F.},
	month = jun,
	year = {2001},
	pmid = {11419831},
	keywords = {Humans, Aged, Treatment Outcome, Palliative Care, Survival Rate, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Deglutition Disorders, Intestinal Obstruction, Karnofsky Performance Status, Stents},
	pages = {1791--1796},
}

@article{beukema85,
	title = {Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?},
	volume = {114},
	issn = {1879-0887},
	doi = {10.1016/j.radonc.2014.11.037},
	abstract = {PURPOSE: In recent years several papers have been published on radiation-induced cardiac toxicity, especially in breast cancer patients. However, in esophageal cancer patients the radiation dose to the heart is usually markedly higher. To determine whether radiation-induced cardiac toxicity is also a relevant issue for this group, we conducted a review of the current literature.
METHODS: A literature search was performed in Medline for papers concerning cardiac toxicity in esophageal cancer patients treated with radiotherapy with or without chemotherapy.
RESULTS: The overall crude incidence of symptomatic cardiac toxicity was as high as 10.8\%. Toxicities corresponded with several dose-volume parameters of the heart. The most frequently reported complications were pericardial effusion, ischemic heart disease and heart failure.
CONCLUSION: Cardiac toxicity is a relevant issue in the treatment of esophageal cancer. However, valid Normal Tissue Complication Probability models for esophageal cancer are not available at present.},
	language = {eng},
	number = {1},
	journal = {Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology},
	author = {Beukema, Jannet C. and van Luijk, Peter and Widder, Joachim and Langendijk, Johannes A. and Muijs, Christina T.},
	month = jan,
	year = {2015},
	pmid = {25554226},
	keywords = {Humans, Female, Male, Esophageal Neoplasms, Esophageal cancer, Incidence, Radiotherapy Dosage, Cardiac toxicity, Cardiotoxicity, Heart, Heart Diseases, Radiation Dosage, Radiation Injuries, Radiotherapy},
	pages = {85--90},
}

@article{sts1661,
	title = {The {Society} of {Thoracic} {Surgeons} {Composite} {Score} for {Evaluating} {Esophagectomy} for {Esophageal} {Cancer}},
	volume = {103},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28385375},
	doi = {10.1016/j.athoracsur.2016.10.027},
	number = {5},
	journal = {Ann Thorac Surg},
	author = {STS, Force},
	year = {2017},
	note = {Type: Journal Article},
	pages = {1661--1667},
}

@article{sudo3400,
	title = {Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer},
	volume = {32},
	issn = {1527-7755},
	doi = {10.1200/JCO.2014.56.7156},
	abstract = {PURPOSE: Patients with esophageal carcinoma (EC) who are treated with definitive chemoradiotherapy (bimodality therapy [BMT]) experience frequent relapses. In a large cohort, we assessed the timing, frequency, and types of relapses during an aggressive surveillance program and the value of the salvage strategies.
PATIENTS AND METHODS: Patients with EC (N = 276) who received BMT were analyzed. Patients who had surgery within 6 months of chemoradiotherapy were excluded to reduce bias. We focused on local relapse (LR) and distant metastases (DM) and the salvage treatment of patients with LR only. Standard statistical methods were applied.
RESULTS: The median follow-up time was 54.3 months (95\% CI, 48.4 to 62.4). First relapses included LR only in 23.2\% (n = 64), DM with or without LR in 43.5\% (n = 120), and no relapses in 33.3\% (n = 92) of patients. Final relapses included no relapses in 33.3\%, LR only in 14.5\%, DM only in 15.9\%, and DM plus LR in 36.2\% of patients. Ninety-one percent of LRs occurred within 2 years and 98\% occurred within 3 years of BMT. Twenty-three (36\%) of 64 patients with LR only underwent salvage surgery, and their median overall survival was 58.6 months (95\% CI, 28.8 to not reached) compared with those patients with LR only who were unable to undergo surgery (9.5 months; 95\% CI, 7.8 to 13.3).
CONCLUSION: Unlike in patients undergoing trimodality therapy, for whom surveillance/salvage treatment plays a lesser role,(1) in the BMT population, approximately 8\% of all patients (or 36\% of patients with LR only) with LRs occurring more than 6 months after chemoradiotherapy can undergo salvage treatment, and their survival is excellent. Our data support vigilant surveillance, at least in the first 24 months after chemotherapy, in these patients.},
	language = {eng},
	number = {30},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Sudo, Kazuki and Xiao, Lianchun and Wadhwa, Roopma and Shiozaki, Hironori and Elimova, Elena and Taketa, Takashi and Blum, Mariela A. and Lee, Jeffrey H. and Bhutani, Manoop S. and Weston, Brian and Ross, William A. and Komaki, Ritsuko and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Maru, Dipen M. and Skinner, Heath D. and Ajani, Jaffer A.},
	month = oct,
	year = {2014},
	pmid = {25225435},
	pmcid = {PMC4195852},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Aged, 80 and over, Adult, Esophageal Neoplasms, Chemoradiotherapy, Salvage Therapy},
	pages = {3400--3405},
	file = {Sudo et al. - 2014 - Importance of surveillance and success of salvage .pdf:/Users/jcsal/Zotero/storage/IFSMZGKM/Sudo et al. - 2014 - Importance of surveillance and success of salvage .pdf:application/pdf},
}

@article{smalley2327,
	title = {Updated analysis of {SWOG}-directed intergroup study 0116: a phase {III} trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection},
	volume = {30},
	issn = {1527-7755},
	shorttitle = {Updated analysis of {SWOG}-directed intergroup study 0116},
	doi = {10.1200/JCO.2011.36.7136},
	abstract = {PURPOSE: Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures. We performed a randomized phase III trial of postoperative radiochemotherapy in those at moderate risk of locoregional failure (LRF) following surgery. We originally reported results with 4-year median follow-up. This update, with a more than 10-year median follow-up, presents data on failure patterns and second malignancies and explores selected subset analyses.
PATIENTS AND METHODS: In all, 559 patients with primaries ≥ T3 and/or node-positive gastric cancer were randomly assigned to observation versus radiochemotherapy after R0 resection. Fluorouracil and leucovorin were administered before, during, and after radiotherapy. Radiotherapy was given to all LRF sites to a dose of 45 Gy.
RESULTS: Overall survival (OS) and relapse-free survival (RFS) data demonstrate continued strong benefit from postoperative radiochemotherapy. The hazard ratio (HR) for OS is 1.32 (95\% CI, 1.10 to 1.60; P = .0046). The HR for RFS is 1.51 (95\% CI, 1.25 to 1.83; P {\textless} .001). Adjuvant radiochemotherapy produced substantial reduction in both overall relapse and locoregional relapse. Second malignancies were observed in 21 patients with radiotherapy versus eight with observation (P = .21). Subset analyses show robust treatment benefit in most subsets, with the exception of patients with diffuse histology who exhibited minimal nonsignificant treatment effect.
CONCLUSION: Intergroup 0116 (INT-0116) demonstrates strong persistent benefit from adjuvant radiochemotherapy. Toxicities, including second malignancies, appear acceptable, given the magnitude of RFS and OS improvement. LRF reduction may account for the majority of overall relapse reduction. Adjuvant radiochemotherapy remains a rational standard therapy for curatively resected gastric cancer with primaries T3 or greater and/or positive nodes.},
	language = {eng},
	number = {19},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Smalley, Stephen R. and Benedetti, Jacqueline K. and Haller, Daniel G. and Hundahl, Scott A. and Estes, Norman C. and Ajani, Jaffer A. and Gunderson, Leonard L. and Goldman, Bryan and Martenson, James A. and Jessup, J. Milburn and Stemmermann, Grant N. and Blanke, Charles D. and Macdonald, John S.},
	month = jul,
	year = {2012},
	pmid = {22585691},
	pmcid = {PMC4517071},
	keywords = {Humans, Female, Male, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Leucovorin, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Gastrectomy},
	pages = {2327--2333},
	file = {Full Text:/Users/jcsal/Zotero/storage/G4JPLSTN/Smalley et al. - 2012 - Updated analysis of SWOG-directed intergroup study.pdf:application/pdf},
}

@article{shaheen30,
	title = {{ACG} {Clinical} {Guideline}: {Diagnosis} and {Management} of {Barrett}'s {Esophagus}},
	volume = {111},
	issn = {1572-0241},
	shorttitle = {{ACG} {Clinical} {Guideline}},
	doi = {10.1038/ajg.2015.322},
	abstract = {Barrett's esophagus (BE) is among the most common conditions encountered by the gastroenterologist. In this document, the American College of Gastroenterology updates its guidance for the best practices in caring for these patients. These guidelines continue to endorse screening of high-risk patients for BE; however, routine screening is limited to men with reflux symptoms and multiple other risk factors. Acknowledging recent data on the low risk of malignant progression in patients with nondysplastic BE, endoscopic surveillance intervals are attenuated in this population; patients with nondysplastic BE should undergo endoscopic surveillance no more frequently than every 3-5 years. Neither routine use of biomarker panels nor advanced endoscopic imaging techniques (beyond high-definition endoscopy) is recommended at this time. Endoscopic ablative therapy is recommended for patients with BE and high-grade dysplasia, as well as T1a esophageal adenocarcinoma. Based on recent level 1 evidence, endoscopic ablative therapy is also recommended for patients with BE and low-grade dysplasia, although endoscopic surveillance continues to be an acceptable alternative. Given the relatively common recurrence of BE after ablation, we suggest postablation endoscopic surveillance intervals. Although many of the recommendations provided are based on weak evidence or expert opinion, this document provides a pragmatic framework for the care of the patient with BE.},
	language = {eng},
	number = {1},
	journal = {The American Journal of Gastroenterology},
	author = {Shaheen, Nicholas J. and Falk, Gary W. and Iyer, Prasad G. and Gerson, Lauren B. and {American College of Gastroenterology}},
	month = jan,
	year = {2016},
	pmid = {26526079},
	keywords = {Humans, Risk Factors, Barrett Esophagus, Decision Trees},
	pages = {30--50; quiz 51},
}

@article{cotton681,
	title = {Late {Recurrence} of {Barrett}'s {Esophagus} {After} {Complete} {Eradication} of {Intestinal} {Metaplasia} is {Rare}: {Final} {Report} {From} {Ablation} in {Intestinal} {Metaplasia} {Containing} {Dysplasia} {Trial}},
	volume = {153},
	issn = {1528-0012},
	shorttitle = {Late {Recurrence} of {Barrett}'s {Esophagus} {After} {Complete} {Eradication} of {Intestinal} {Metaplasia} is {Rare}},
	doi = {10.1053/j.gastro.2017.05.044},
	abstract = {BACKGROUND \& AIMS: The goal of treatment for Barrett's esophagus (BE) with dysplasia is complete eradication of intestinal metaplasia (CEIM). The long-term durability of CEIM has not been well characterized, so the frequency and duration of surveillance are unclear. We report results from a 5-year follow-up analysis of patients with BE and dysplasia treated by radiofrequency ablation (RFA) in the randomized controlled Ablation of Intestinal Metaplasia Containing Dysplasia (AIM) trial.
METHODS: Participants for the AIM Dysplasia trial (18-80 years old) were recruited from 19 sites in the United States and had endoscopic evidence of non-nodular dysplastic BE ≤8 cm in length. Subjects (n = 127) were randomly assigned (2:1 ratio) to receive either RFA (entire BE segment ablated circumferentially) or a sham endoscopic procedure; patients in the sham group were offered RFA treatment 1 year later, and all patients were followed for 5 years. We collected data on BE recurrence (defined as intestinal metaplasia in the tubular esophagus) and dysplastic BE recurrence among patients who achieved CEIM. We constructed Kaplan-Meier estimates and applied parametric survival analysis to examine proportions of patients without any recurrence and without dysplastic recurrence.
RESULTS: Of 127 patients in the AIM Dysplasia trial, 119 received RFA and met inclusion criteria. Of those 119, 110 (92\%) achieved CEIM. Over 401 person-years of follow-up (mean, 3.6 years per patient; range, 0.2-5.8 years), 35 of 110 (32\%) patients had recurrence of BE or dysplasia, and 19 (17\%) had dysplasia recurrence. The incidence rate of BE recurrence was 10.8 per 100 person-years overall (95\% CI, 7.8-15.0); 8.3 per 100 person-years among patients with baseline low-grade dysplasia (95\% CI, 4.9-14.0), and 13.5 per 100 person-years among patients with baseline high-grade dysplasia (95\% CI 8.8-20.7). The incidence rate of dysplasia recurrence was 5.2 per 100 person-years overall (95\% CI 3.3-8.2); 3.3 per 100 person-years among patients with baseline low-grade dysplasia (95\% CI 1.5-7.2), and 7.3 per 100 person-years among patients with baseline high-grade dysplasia (95\% CI 4.2-12.5). Neither BE nor dysplasia recurred at a constant rate. There was a greater probability of recurrence in the first year following CEIM than in the following 4 years combined.
CONCLUSIONS: In this analysis of prospective cohort data from the AIM Dysplasia trial, we found BE to recur after CEIM by RFA in almost one third of patients with baseline dysplastic disease; most recurrences occurred during the first year after CEIM. However, patients who achieved CEIM and remained BE free at 1 year after RFA had a low risk of BE recurrence. Studies are needed to determine when surveillance can be decreased or discontinued; our study did not identify any BE or dysplasia recurrence after 4 years of surveillance.},
	language = {eng},
	number = {3},
	journal = {Gastroenterology},
	author = {Cotton, Cary C. and Wolf, W. Asher and Overholt, Bergein F. and Li, Nan and Lightdale, Charles J. and Wolfsen, Herbert C. and Pasricha, Sarina and Wang, Kenneth K. and Shaheen, Nicholas J. and {AIM Dysplasia Trial Group}},
	month = sep,
	year = {2017},
	pmid = {28579538},
	pmcid = {PMC5581683},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Kaplan-Meier Estimate, Disease Progression, Prospective Studies, Time Factors, Population Surveillance, Incidence, Esophagus, Mucous Membrane, Barrett Esophagus, Catheter Ablation, HGD, High Grade Dysplasia, LGD, Long-term Outcome, Low Grade Dysplasia, Metaplasia, Prognostic Factor, Recurrence},
	pages = {681--688.e2},
	file = {Full Text:/Users/jcsal/Zotero/storage/AXWXYKRT/Cotton et al. - 2017 - Late Recurrence of Barrett's Esophagus After Compl.pdf:application/pdf},
}

@article{sharma258,
	title = {Role of esophageal stents in benign and malignant diseases},
	volume = {105},
	issn = {1572-0241},
	doi = {10.1038/ajg.2009.684},
	abstract = {These recommendations provide an evidence-based approach to the role of esophageal stents in the management of benign and malignant diseases. These guidelines have been developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the Board of Trustees. The following guidelines are based on a critical review of the available scientific literature on the topic identified in Medline and PubMed (January 1992-December 2008) using search terms that included stents, self-expandable metal stents, self-expandable plastic stents, esophageal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, esophageal stricture, perforations, anastomotic leaks, tracheoesophageal fistula, and achalasia. These guidelines are intended for use by health-care providers and apply to adult, but not pediatric, patients. As with other practice guidelines, these guidelines are not intended to replace clinical judgment but rather to provide general guidelines applicable to the majority of patients. Clinicians need to integrate recommendations with their own clinical judgment, and with individual patient circumstances, values, and preferences. They are intended to be flexible, in contrast to standards of care, which are inflexible policies designed to be followed in every case. Specific recommendations are based on relevant published information. The quality of evidence and strength of recommendations have been assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, which is a system that has been adopted by multiple national and international societies. The GRADE system is based on a sequential assessment of quality of evidence, followed by assessment of the balance between benefits vs. downsides (harms, burden, and costs) and subsequent judgment regarding the strength of recommendation.},
	language = {eng},
	number = {2},
	journal = {The American Journal of Gastroenterology},
	author = {Sharma, Prateek and Kozarek, Richard and {Practice Parameters Committee of American College of Gastroenterology}},
	month = feb,
	year = {2010},
	pmid = {20029413},
	keywords = {Humans, Treatment Outcome, Adult, United States, Esophageal Diseases, Stents, Endoscopy, Equipment Design, Equipment Failure, Severity of Illness Index},
	pages = {258--273; quiz 274},
}

@article{thomas1609,
	title = {Trimodal imaging-assisted endoscopic mucosal resection of early {Barrett}'s neoplasia},
	volume = {23},
	issn = {1432-2218},
	doi = {10.1007/s00464-009-0429-z},
	abstract = {BACKGROUND: Chromoendoscopy is traditionally used to identify inconspicuous Barrett's neoplasia and mark the boundaries before endoscopic mucosal resection (EMR). Trimodal imaging endoscopy is useful in identifying early neoplasia in Barrett's esophagus. The purpose of this study was to determine the efficacy (lateral and deep margin clearance) of trimodal imaging endoscopy-assisted EMR in early Barrett's neoplasia in a tertiary referral setting.
METHODS: The entire Barrett's segment was visualized by high-resolution endoscopy followed by autofluorescence imaging, and suspicious areas were identified. Narrow band imaging and magnification was used to confirm the suspicious areas. The outer boundary of the lesion was then marked using the tip of a snare diathermy and EMR was performed using multiband mucosectomy technique by a single operator (KR).
RESULTS: Sixteen patients were included: 13 patients had high-grade intraepithelial neoplasia (HGIN); 3 patients had intramucosal carcinoma (IMC); (8 males, median age, 69.5 (range, 50-77) years with Barrett's esophagus (interquartile range (IQR), 2-5 cm; median length, 3 cm). All lesions were successfully identified, using trimodal imaging endoscopy. Overall EMR was complete in 14 of 16 (81.2\%) patients with early Barrett's neoplasia. Four of 16 patients (18\%; all with pre-EMR HGIN) were considered to have incomplete EMR (deep margins involved), but operative histology showed only Barrett's metaplasia in 2 (histological false positive) and IMC in 1. Thus, overall 14 of 16 (87.5\%) patients had complete EMR of the original lesions. In patients who did not undergo esophagectomy, there was no disease recurrence on endoscopic biopsies at a mean follow-up of 8 (IQR, 6-12) months. Three of the 16 patients (18.75\%) with post-EMR bleeding were successfully treated with APC/hemoclips.
CONCLUSIONS: Trimodal imaging endoscopy is a feasible alternative to chromoendoscopy to identify inconspicuous neoplasia and assist EMR of early neoplasia in Barrett's esophagus.},
	language = {eng},
	number = {7},
	journal = {Surgical Endoscopy},
	author = {Thomas, T. and Singh, R. and Ragunath, K.},
	month = jul,
	year = {2009},
	pmid = {19296171},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Disease Progression, Aged, 80 and over, Adenocarcinoma, Esophageal Neoplasms, Esophagoscopy, Mucous Membrane, Barrett Esophagus, Carcinoma in Situ, Diathermy, Fluorometry, Gastroscopes, Hemostasis, Surgical, Postoperative Hemorrhage, Video-Assisted Surgery},
	pages = {1609--1613},
}

@article{nurkin1090,
	title = {Outcomes of endoscopic resection for high-grade dysplasia  and esophageal cancer},
	volume = {28},
	issn = {1432-2218},
	doi = {10.1007/s00464-013-3270-3},
	abstract = {BACKGROUND: Endoscopic resection (ER) is an important advance in the management of esophageal tumors. It has been used successfully for superficial esophageal cancer and high-grade dysplasia (HGD) arising out of Barrett epithelium.
METHODS: From a single institution within the Department of Surgery, patients who underwent ER for esophageal tumors between December 2001 and January 2012 were evaluated. Demographic, clinical, and pathologic variables were collected and reviewed.
RESULTS: We identified 81 patients who underwent ER for esophageal lesions. Median patient age was 69 years, and the median follow-up was 3.25 years. In patients with HGD, at the time of last endoscopy, the complete eradication rate of HGD was 84 \% and cancer-specific survival was 100 \%. During surveillance, one patient developed an invasive carcinoma that required endoscopic therapy. Patients with T1a and negative deep margins on ER had a recurrence-free and cancer-specific survival of 100 \%. There were seven patients with T1b and negative margins on ER. Three patients underwent esophagectomy; final pathology revealed no residual malignancy or lymph node metastasis. Two patients had definitive chemoradiation, and two patients were observed. To date, there has been no cancer recurrence. In all patients who underwent ER, there was one episode of bleeding that required endoscopic treatment and admission for observation.
CONCLUSIONS: ER can be performed safely and can adequately stage and often treat patients with HGD and superficial cancers. Patients with HGD and T1a disease with negative margins are cured with ER alone. Observation and surveillance may be an option for select patients with low-risk, early submucosal disease (T1b) and negative margins.},
	language = {eng},
	number = {4},
	journal = {Surgical Endoscopy},
	author = {Nurkin, Steven J. and Nava, Hector R. and Yendamuri, Sai and LeVea, Charles M. and Nwogu, Chumy E. and Groman, Adrienne and Wilding, Gregory and Bain, Andrew J. and Hochwald, Steven N. and Khushalani, Nikhil I.},
	month = apr,
	year = {2014},
	pmid = {24232046},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Risk Assessment, Time Factors, Survival Rate, Aged, 80 and over, Adult, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Incidence, Endoscopy, Gastrointestinal, Lymphatic Metastasis, Barrett Esophagus, New York},
	pages = {1090--1095},
}

@article{martin1308,
	title = {Long-term weight change after oesophageal cancer surgery},
	volume = {96},
	issn = {1365-2168},
	doi = {10.1002/bjs.6723},
	abstract = {BACKGROUND: Malnutrition is common after oesophageal cancer surgery. This study investigated weight changes and the risk of malnutrition among long-term survivors.
METHODS: A nationwide cohort study was conducted in Sweden in 2001-2004, with follow-up to 2008. Weight was assessed before oesophagectomy, after 6 months and at 3 years. Logistic regression was performed with adjustment for confounders. Odds ratios (ORs) for postoperative weight loss of at least 15 per cent were estimated.
RESULTS: Some 203 patients survived at least 3 years after oesophagectomy. Continuous weight loss occurred for up to 3 years. Women and men had a similar risk of malnutrition after 3 years (OR 0.85 (95 per cent confidence interval 0.24 to 2.98)). In overweight patients (preoperative body mass index at least 25 kg/m(2)) the risk of malnutrition was increased almost fivefold at 6 months (OR 4.90 (2.27 to 10.59)) and 3 years (OR 4.60 (1.80 to 11.78)). There was no difference in weight loss at 6 months between survivors and those who died between 6 months and 3 years after surgery (OR 1.11 (0.64 to 1.94)).
CONCLUSION: Weight loss can be long lasting after oesophagectomy; overweight patients are at particularly increased risk of malnutrition.},
	language = {eng},
	number = {11},
	journal = {The British Journal of Surgery},
	author = {Martin, L. and Lagergren, P.},
	month = nov,
	year = {2009},
	pmid = {19847871},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Weight Loss, Adult, Stomach Neoplasms, Esophageal Neoplasms, Postoperative Complications, Malnutrition, Epidemiologic Methods, Survivors, Survivorship, Weight Loss;GE},
	pages = {1308--1314},
}

@article{lee268,
	title = {Phase {III} trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with {D2} lymph node dissection: the {ARTIST} trial},
	volume = {30},
	issn = {1527-7755},
	shorttitle = {Phase {III} trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with {D2} lymph node dissection},
	doi = {10.1200/JCO.2011.39.1953},
	abstract = {PURPOSE: The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge to investigate the role of postoperative chemoradiotherapy therapy in patients with curatively resected gastric cancer with D2 lymph node dissection. This trial was designed to compare postoperative treatment with capecitabine plus cisplatin (XP) versus XP plus radiotherapy with capecitabine (XP/XRT/XP).
PATIENTS AND METHODS: The XP arm received six cycles of XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks) chemotherapy. The XP/XRT/XP arm received two cycles of XP followed by 45-Gy XRT (capecitabine 1,650 mg/m2 per day for 5 weeks) and two cycles of XP.
RESULTS: Of 458 patients, 228 were randomly assigned to the XP arm and 230 to the XP/XRT/XP arm. Treatment was completed as planned by 75.4\% of patients (172 of 228) in the XP arm and 81.7\% (188 of 230) in the XP/XRT/XP arm. Overall, the addition of XRT to XP chemotherapy did not significantly prolong disease-free survival (DFS; P = .0862). However, in the subgroup of patients with pathologic lymph node metastasis at the time of surgery (n = 396), patients randomly assigned to the XP/XRT/XP arm experienced superior DFS when compared with those who received XP alone (P = .0365), and the statistical significance was retained at multivariate analysis (estimated hazard ratio, 0.6865; 95\% CI, 0.4735 to 0.9952; P = .0471). CONCLUSION The addition of XRT to XP chemotherapy did not significantly reduce recurrence after curative resection and D2 lymph node dissection in gastric cancer. A subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned.},
	language = {eng},
	number = {3},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Lee, Jeeyun and Lim, Do Hoon and Kim, Sung and Park, Se Hoon and Park, Joon Oh and Park, Young Suk and Lim, Ho Yeong and Choi, Min Gew and Sohn, Tae Sung and Noh, Jae Hyung and Bae, Jae Moon and Ahn, Yong Chan and Sohn, Insuk and Jung, Sin Ho and Park, Cheol Keun and Kim, Kyoung-Mee and Kang, Won Ki},
	month = jan,
	year = {2012},
	pmid = {22184384},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Young Adult, Stomach Neoplasms, Chemoradiotherapy, Adjuvant, Cisplatin, Disease-Free Survival, Neoplasm Recurrence, Local, Capecitabine, Deoxycytidine, Lymph Node Excision},
	pages = {268--273},
}

@article{gharzaie0158916,
	title = {Radiation {Therapy} and {Cardiac} {Death} in {Long}-{Term} {Survivors} of {Esophageal} {Cancer}: {An} {Analysis} of the {Surveillance}, {Epidemiology}, and {End} {Result} {Database}},
	volume = {11},
	issn = {1932-6203},
	shorttitle = {Radiation {Therapy} and {Cardiac} {Death} in {Long}-{Term} {Survivors} of {Esophageal} {Cancer}},
	doi = {10.1371/journal.pone.0158916},
	abstract = {OBJECTIVE: Radiation therapy (RT) for esophageal cancer often results in unintended radiation doses delivered to the heart owing to anatomic proximity. Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined late cardiac death in survivors of esophageal cancer that had or had not received RT.
METHODS: 5,630 patients were identified that were diagnosed with esophageal squamous cell carcinoma (SCC) or adenocarcinoma (AC) from 1973-2012, who were followed for at least 5 years after therapy. Examined risk factors for cardiac death included age (≤55/56-65/66-75/{\textgreater}75), gender, race (white/non-white), stage (local/regional/distant), histology (SCC/AC), esophageal location ({\textless}18cm/18-24cm/25-32cm/33-40cm from incisors), diagnosis year (1973-1992/1993-2002/2003-2012), and receipt of surgery and/or RT. Time to cardiac death was evaluated using the Kaplan-Meier method. A Cox model was used to evaluate risk factors for cardiac death in propensity score matched data.
RESULTS: Patients who received RT were younger, diagnosed more recently, had more advanced disease, SCC histology, and no surgery. The RT group had higher risk of cardiac death than the no-RT group (log-rank p{\textless}0.0001). The median time to cardiac death in the RT group was 289 months (95\% CI, 255-367) and was not reached in the no-RT group. The probability of cardiac death increased with age and decreased with diagnosis year, and this trend was more pronounced in the RT group. Multivariate analysis found RT to be associated with higher probability of cardiac death (OR 1.23, 95\% CI 1.03-1.47, HR 1.961, 95\% CI 1.466-2.624). Lower esophageal subsite (33-40 cm) was also associated with a higher risk of cardiac death. Other variables were not associated with cardiac death.
CONCLUSIONS: Recognizing the limitations of a SEER analysis including lack of comorbidity accountability, these data should prompt more definitive study as to whether a possible associative effect of RT on cardiac death could potentially be a causative effect.},
	language = {eng},
	number = {7},
	journal = {PloS One},
	author = {Gharzai, Laila and Verma, Vivek and Denniston, Kyle A. and Bhirud, Abhijeet R. and Bennion, Nathan R. and Lin, Chi},
	year = {2016},
	pmid = {27428362},
	pmcid = {PMC4948887},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Kaplan-Meier Estimate, Proportional Hazards Models, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Esophagus, Survivors, Death},
	pages = {e0158916},
	file = {Full Text:/Users/jcsal/Zotero/storage/FCIURAFT/Gharzai et al. - 2016 - Radiation Therapy and Cardiac Death in Long-Term S.pdf:application/pdf},
}

@article{frandsen516,
	title = {Increased risk of death due to heart disease after radiotherapy for esophageal cancer},
	volume = {6},
	issn = {2078-6891},
	doi = {10.3978/j.issn.2078-6891.2015.040},
	abstract = {OBJECTIVE: To evaluate the risk of heart disease related death (HDRD) following radiation therapy (RT) for esophageal cancer (EC).
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, two cohorts of patients with EC were created: (I) patients who received RT with their initial therapy; and (II) those who did not. Heart disease specific survival (HDSS) was analyzed using Kaplan-Meier methods. Cox proportional-hazards regression methods were used for univariate and multivariate analyses.
RESULTS: We identified 40,778 patients with EC. A total of 26,377 patients received RT and 14,401 did not. HDSS analysis revealed increased risk of HDRD in those receiving RT (P{\textless}0.05), with an absolute risk of HDRD of 2.8\%, 5.3\% and 9.4\% at 5-, 10- and 20-year, respectively. Log rank test of HDSS revealed the risk of HDRD became significant at 8 months (P{\textless}0.05). The following were associated with HDRD: RT, age, race, stage at presentation, time period of diagnosis, and known comorbid condition keeping one from esophagectomy. On multivariate analysis, RT remained predictive of HDRD [hazard ratio (HR) 1.46, P{\textless}0.05]. When considering only candidates for definitive therapy, RT remained predictive of HDRD on univariate (HR 1.53, P{\textless}0.0001) and multivariate (HR 1.62, P{\textless}0.0001) analyses.
CONCLUSIONS: The use of RT leads to increased risk of HDRD that is detectable as early as eight months from diagnosis. More research is needed to define optimal dose volume parameters to prevent cardiac death. Consideration should be given to this risk in relation to prognosis and the expected benefits of RT.},
	language = {eng},
	number = {5},
	journal = {Journal of Gastrointestinal Oncology},
	author = {Frandsen, Jonathan and Boothe, Dustin and Gaffney, David K. and Wilson, Brent D. and Lloyd, Shane},
	month = oct,
	year = {2015},
	pmid = {26487946},
	pmcid = {PMC4570919},
	keywords = {Esophageal cancer (EC), heart disease, radiation therapy (RT)},
	pages = {516--523},
}

@article{dunbar850,
	title = {The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in {Barrett}'s esophagus: a systematic review},
	volume = {107},
	issn = {1572-0241},
	shorttitle = {The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in {Barrett}'s esophagus},
	doi = {10.1038/ajg.2012.78},
	abstract = {OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The risk of such metastases has been proposed as a reason to consider esophagectomy rather than endoscopic therapy for esophageal mucosal neoplasia. The objective of our study was to determine the frequency of lymph-node metastases in patients with high-grade dysplasia (HGD) and intramucosal carcinoma in Barrett's esophagus.
METHODS: We performed a systematic review using the PRISMA guidelines to identify studies that included patients who had esophagectomy for HGD or intramucosal carcinoma in Barrett's esophagus, and that reported final pathology results after examination of esophagectomy specimens.
RESULTS: We identified 70 relevant reports that included 1,874 patients who had esophagectomy performed for HGD or intramucosal carcinoma in Barrett's esophagus. Lymph-node metastases were found in 26 patients (1.39 \% , 95 \% CI 0.86 – 1.92). No metastases were found in the 524 patients who had a final pathology diagnosis of HGD, whereas 26 (1.93 \% , 95 \% CI 1.19 – 2.66 \%) of the 1,350 patients with a final pathology diagnosis of intramucosal carcinoma had positive lymph nodes.
CONCLUSIONS: The risk of unexpected lymph-node metastases for patients with mucosal neoplasms in Barrett's esophagus is in the range of 1 – 2 \%. Esophagectomy has a mortality rate that often exceeds 2 \%, with substantial morbidity and no guarantee of curing metastatic disease. Therefore, the risk of lymph node metastases alone does not warrant the choice of esophagectomy over endoscopic therapy for HGD and intramucosal carcinoma in Barrett's esophagus.},
	language = {eng},
	number = {6},
	journal = {The American Journal of Gastroenterology},
	author = {Dunbar, Kerry B. and Spechler, Stuart Jon},
	month = jun,
	year = {2012},
	pmid = {22488081},
	pmcid = {PMC3578695},
	keywords = {Humans, Risk Factors, Risk Assessment, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Incidence, Lymphatic Metastasis, Esophagoscopy, Mucous Membrane, Barrett Esophagus, Lymph Nodes, Carcinoma, Neoplasm Grading},
	pages = {850--862; quiz 863},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/LL3AHQRI/Dunbar and Spechler - 2012 - The risk of lymph-node metastases in patients with.pdf:application/pdf},
}

@article{dorth2099,
	title = {Patterns of recurrence after trimodality therapy for esophageal cancer},
	volume = {120},
	issn = {1097-0142},
	doi = {10.1002/cncr.28703},
	abstract = {BACKGROUND: Patterns of failure after neoadjuvant chemoradiotherapy and surgery for esophageal cancer are poorly defined.
METHODS: All patients in the current study were treated with trimodality therapy for nonmetastatic esophageal cancer from 1995 to 2009. Locoregional failure included lymph node failure (NF), anastomotic failure, or both. Abdominal paraaortic failure (PAF) was defined as disease recurrence at or below the superior mesenteric artery.
RESULTS: Among 155 patients, the primary tumor location was the upper/middle esophagus in 18\%, the lower esophagus in 32\%, and the gastroesophageal junction in 50\% (adenocarcinoma in 79\% and squamous cell carcinoma in 21\%) of patients. Staging methods included endoscopic ultrasound (73\%), computed tomography (46\%), and positron emission tomography/computed tomography (54\%). Approximately 40\% of patients had American Joint Committee on Cancer stage II disease and 60\% had stage III disease. The median follow-up was 1.3 years. The 2-year locoregional control, event-free survival, and overall survival rates were 86\%, 36\%, and 48\%, respectively. The 2-year NF rate was 14\%, the isolated NF rate was 3\%, and the anastomotic failure rate was 6\%. The 2-year PAF rate was 9\% and the isolated PAF rate was 5\%. PAF was found to be increased among patients with gastroesophageal junction tumors (12\% vs 6\%), especially for the subset with ≥ 2 clinically involved lymph nodes at the time of diagnosis (19\% vs 4\%).
CONCLUSIONS: Few patients experience isolated NF or PAF as their first disease recurrence. Therefore, it is unlikely that targeting additional regional lymph node basins with radiotherapy would significantly improve clinical outcomes.},
	language = {eng},
	number = {14},
	journal = {Cancer},
	author = {Dorth, Jennifer A. and Pura, John A. and Palta, Manisha and Willett, Christopher G. and Uronis, Hope E. and D'Amico, Thomas A. and Czito, Brian G.},
	month = jul,
	year = {2014},
	pmid = {24711267},
	pmcid = {PMC4519032},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Adult, Fluorouracil, United States, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Lymphatic Metastasis, Radiotherapy Dosage, Treatment Failure, Anastomotic Leak, esophageal cancer, esophagectomy, lymphatic irradiation, lymphatic metastasis, Platinum Compounds, Positron-Emission Tomography, Taxoids},
	pages = {2099--2105},
	file = {Full Text:/Users/jcsal/Zotero/storage/99SP9W84/Dorth et al. - 2014 - Patterns of recurrence after trimodality therapy f.pdf:application/pdf},
}

@article{bergeron765,
	title = {Endoscopic ultrasound is inadequate to determine which {T1}/{T2} esophageal tumors are candidates for endoluminal therapies},
	volume = {147},
	issn = {1097-685X},
	doi = {10.1016/j.jtcvs.2013.10.003},
	abstract = {OBJECTIVES: Esophageal endoscopic ultrasound is now regarded as essential in the staging of esophageal carcinoma. There is an increasing trend toward endoluminal therapies (ie, endoscopic mucosal resection and radiofrequency ablation) for pre-cancer or early-stage cancers because of concerns of high morbidity associated with esophagectomy. This study reviews our institutional experience with preoperative endoscopic ultrasound staging of early esophageal cancers in patients who underwent an esophagectomy to evaluate the accuracy of staging by endoscopic ultrasound and how this affects treatment recommendations.
METHODS: A prospective esophagectomy database of all patients undergoing an esophagectomy for esophageal cancer at a single high-volume institution was retrospectively reviewed for patients with early-stage esophageal cancer. This study analyzed patients with clinical Tis to T1 disease, as predicted by preoperative endoscopic ultrasound, and correlated this with the pathologic stages after esophagectomy. The surgical outcomes were evaluated to assess the safety of esophagectomy as a treatment modality.
RESULTS: From 2005 to 2011, 107 patients (93 male, 14 female) with a mean age of 66 years (range, 39-91 years) were staged by preoperative endoscopic ultrasound to have esophageal high-grade dysplasia, carcinoma in situ, or T1 cancer and underwent an esophagectomy. Tumor depth was correctly staged by endoscopic ultrasound in only 39\% (23/59) of pT1a tumors (invading into the lamina propria or muscularis mucosa) and 51\% (18/35) of pT1b tumors (submucosal). Of the endoscopic ultrasound-staged cT1a-lpN0 lesions, there were positive lymph nodes in 15\% of pathologic specimens (2/13). Patients with pT1a-mm lesions had a 9\% rate of pathologic lymph node involvement (1/11), and those with pT1b tumors had a 17\% rate of lymph node spread (6/35). Esophagectomy was performed in all 107 patients with a 30-day mortality rate of less than 1\% (1/107).
CONCLUSIONS: The sensitivity and specificity of endoscopic ultrasound for determining true pathologic staging are poor for early-stage esophageal cancers. Lesions thought to be cT1a-lpN0 by endoscopic ultrasound have at least pN1 disease in 15\% of cases. Endoluminal therapy of these lesions based on endoscopic ultrasound undertreats a significant number of patients. Esophagectomy is still the standard therapy for early-stage esophageal cancers in the majority of patients.},
	language = {eng},
	number = {2},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Bergeron, Edward J. and Lin, Jules and Chang, Andrew C. and Orringer, Mark B. and Reddy, Rishindra M.},
	month = feb,
	year = {2014},
	pmid = {24314788},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Risk Factors, Time Factors, Aged, 80 and over, Adult, Predictive Value of Tests, Neoplasm Invasiveness, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Lymphatic Metastasis, Catheter Ablation, Carcinoma, 7, 8.1, 8.4, 8.7, Barrett’s esophagus, BE, Decision Support Techniques, EAC, EMR, endomucosal resection, endoscopic ultrasound, Endosonography, esophageal adenocarcinoma, EUS, Hospital Mortality, Hospitals, High-Volume, Michigan, negative predictive value, NPV, Patient Selection, PDT, PET, photodynamic therapy, positive predictive value, positron emission tomography, PPV, radiofrequency ablation, RFA, THE, transhiatal esophagectomy},
	pages = {765--771: Discussion 771--773},
	file = {Full Text:/Users/jcsal/Zotero/storage/ZK6NMRZU/Bergeron et al. - 2014 - Endoscopic ultrasound is inadequate to determine w.pdf:application/pdf},
}

@article{siewert260,
	title = {Adenocarcinoma of the esophago-gastric junction},
	volume = {95},
	issn = {1457-4969},
	doi = {10.1177/145749690609500409},
	abstract = {BACKGROUND: The border between the esophagus and stomach gives rise to many discrepancies in the current literature regarding the etiology, classification and surgical treatment of adenocarcinoma arising at the esophago-gastric junction. We have consequently used the AEG-criteria (adenocarcinoma of the esophago-gastric junction) for classification and have based the selection of the surgical approach on the anatomic topographic subclassification.
METHODS: In the following we report an analysis of a large and homogeneously classified population of 1602 consecutive patients with adenocarcinoma of the esophago-gastric junction, with an emphasis on the surgical approach, the pattern of lymphatic spread, the outcome after surgical treatment and the prognostic factors. Demographic data, morphologic and histopathologic tumor characteristics, and long-term survival rates were compared among the three tumor subclassifiations.
RESULTS: The study confirms the marked differences in sex distribution, associated specialized intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, lymphatic spread, and stage between the three tumor entities. The degree of resection and lymph node status were the dominating independent prognostic factors by multivariate analysis. The data show no significant differences of long-term survival after abdomino-thoracic esophagectomy and extended total gastrectomy in these patients.
CONCLUSION: The classification of adenocarcinomas of the esophago-gastric junction in three types, AEG type I, type II and type III shows marked differences between the tumor entities and is recommended for selection of a proper surgical approach. Complete tumor resection and adequate lymphadenectomy are associated with good long-term prognosis. Better surgical management and standardized procedures will improve the outcome also of patients who need to undergo more radical surgery, i.e. abdomino-thoracic esophagectomy.},
	language = {eng},
	number = {4},
	journal = {Scandinavian journal of surgery: SJS: official organ for the Finnish Surgical Society and the Scandinavian Surgical Society},
	author = {Siewert, J. R. and Stein, H. J. and Feith, M.},
	year = {2006},
	pmid = {17249275},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Prognosis, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Lymphatic Metastasis, Sex Distribution},
	pages = {260--269},
}

@article{haidry87,
	title = {Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the {UK} {National} {Halo} {RFA} {Registry}},
	volume = {145},
	issn = {1528-0012},
	shorttitle = {Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma},
	doi = {10.1053/j.gastro.2013.03.045},
	abstract = {BACKGROUND \& AIMS: Patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) or early neoplasia increasingly receive endoscopic mucosal resection and radiofrequency ablation (RFA) therapy. We analyzed data from a UK registry that follows the outcomes of patients with BE who have undergone RFA for neoplasia.
METHODS: We collected data on 335 patients with BE and neoplasia (72\% with HGD, 24\% with intramucosal cancer, 4\% with low-grade dysplasia [mean age, 69 years; 81\% male]), treated at 19 centers in the United Kingdom from July 2008 through August 2012. Mean length of BE segments was 5.8 cm (range, 1-20 cm). Patients' nodules were removed by endoscopic mucosal resection, and the patients then underwent RFA every 3 months until all areas of BE were ablated or cancer developed. Biopsies were collected 12 months after the first RFA; clearance of HGD, dysplasia, and BE were assessed.
RESULTS: HGD was cleared from 86\% of patients, all dysplasia from 81\%, and BE from 62\% at the 12-month time point, after a mean of 2.5 (range, 2-6) RFA procedures. Complete reversal dysplasia was 15\% less likely for every 1-cm increment in BE length (odds ratio = 1.156; SE = 0.048; 95\% confidence interval: 1.07-1.26; P {\textless} .001). Endoscopic mucosal resection before RFA did not provide any benefit. Invasive cancer developed in 10 patients (3\%) by the 12-month time point and disease had progressed in 17 patients (5.1\%) after a median follow-up time of 19 months. Symptomatic strictures developed in 9\% of patients and were treated by endoscopic dilatation. Nineteen months after therapy began, 94\% of patients remained clear of dysplasia.
CONCLUSIONS: We analyzed data from a large series of patients in the United Kingdom who underwent RFA for BE-related neoplasia and found that by 12 months after treatment, dysplasia was cleared from 81\%. Shorter segments of BE respond better to RFA; http://www.controlled-trials.com, number ISRCTN93069556.},
	language = {eng},
	number = {1},
	journal = {Gastroenterology},
	author = {Haidry, Rehan J. and Dunn, Jason M. and Butt, Mohammed A. and Burnell, Matthew G. and Gupta, Abhinav and Green, Sarah and Miah, Haroon and Smart, Howard L. and Bhandari, Pradeep and Smith, Lesley Ann and Willert, Robert and Fullarton, Grant and Morris, John and Di Pietro, Massimo and Gordon, Charles and Penman, Ian and Barr, Hugh and Patel, Praful and Boger, Philip and Kapoor, Neel and Mahon, Brinder and Hoare, Jonathon and Narayanasamy, Ravi and O'Toole, Dermot and Cheong, Edward and Direkze, Natalie C. and Ang, Yeng and Novelli, Marco and Banks, Matthew R. and Lovat, Laurence Bruce},
	month = jul,
	year = {2013},
	pmid = {23542069},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Disease Progression, Aged, 80 and over, Adult, Adenocarcinoma, Esophageal Neoplasms, Esophagoscopy, Mucous Membrane, Barrett Esophagus, Catheter Ablation, Registries},
	pages = {87--95},
}

@article{kato921,
	title = {Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma},
	volume = {94},
	issn = {0008-543X},
	abstract = {BACKGROUND: The role and potential value of positron emission tomography (PET) scanning in certain tumors has been widely investigated in recent years. The authors retrospectively assessed the performance of 18-F-fluorodeoxyglucose (FDG)-PET in the assessment of esophageal squamous cell carcinoma (SCC).
METHODS: The results using PET were compared with those using computed tomography (CT), and these were correlated with the pathologic findings. The authors studied 32 patients with thoracic esophageal SCC who had undergone radical esophagectomy.
RESULTS: Uptake of FDG in the primary tumor was found in 25 of the 32 (78.1\%) cases. Comparison of the FDG uptake and the clinicopathologic findings showed that there was a significant association between the FDG uptake and each of the depth of tumor invasion (P {\textless} 0.05), occurrence of lymph node metastasis (P {\textless} 0.01), and lymphatic invasion (P {\textless} 0.01). The survival rate in cases with high FDG uptake (standardized uptake value [SUV], {\textgreater}3) was significantly lower than that in cases with low FDG uptake (SUV, {\textless} 3; P {\textless} 0.05). In the evaluation of lymph node staging by the detection of lymph node metastasis, FDG-PET showed 77.8\% sensitivity, 92.9\% specificity, and 84.4\% accuracy, and CT scanning showed 61.1\% sensitivity, 71.4\% specificity, and 65.6\% accuracy. Positron emission tomography scanning showed a high degree of accuracy in the neck, upper thoracic, and abdominal regions. However, in the mid- and lower thoracic regions, the sensitivity was very low. The smallest lymph node metastasis that was detected by FDG-PET imaging was 6 mm. The average size of lymph node metastasis that was undetected by FDG-PET scanning was 7.3 mm (range, 1-17 mm).
CONCLUSIONS: In conclusion, FDG-PET may be used as a noninvasive diagnostic technique in assessing the aggressiveness of the tumor and the prognosis in patients with esophageal SCC. During the preoperative diagnostic procedures, the sensitivity, specificity, and accuracy of lymph node staging is higher with FDG-PET than with CT imaging. In view of the high specificity of FDG-PET, it also gives useful information to guide the choice of treatment of esophageal carcinoma.},
	language = {eng},
	number = {4},
	journal = {Cancer},
	author = {Kato, Hiroyuki and Kuwano, Hiroyuki and Nakajima, Masanobu and Miyazaki, Tatsuya and Yoshikawa, Minako and Ojima, Hitoshi and Tsukada, Katsuhiko and Oriuchi, Noboru and Inoue, Tomio and Endo, Keigo},
	month = feb,
	year = {2002},
	pmid = {11920459},
	note = {tex.ids: kato921a},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Prognosis, Reproducibility of Results, Adult, Esophageal Neoplasms, Fluorodeoxyglucose F18, Radiopharmaceuticals, Sensitivity and Specificity, Lymphatic Metastasis, Carcinoma, Tomography, Emission-Computed},
	pages = {921--928},
}

@article{minsky1167,
	title = {{INT} 0123 ({Radiation} {Therapy} {Oncology} {Group} 94-05) phase {III} trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy},
	volume = {20},
	issn = {0732-183X},
	shorttitle = {{INT} 0123 ({Radiation} {Therapy} {Oncology} {Group} 94-05) phase {III} trial of combined-modality therapy for esophageal cancer},
	doi = {10.1200/JCO.2002.20.5.1167},
	abstract = {PURPOSE: To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer.
PATIENTS AND METHODS: A total of 236 patients with clinical stage T1 to T4, N0/1, M0 squamous cell carcinoma or adenocarcinoma selected for a nonsurgical approach, after stratification by weight loss, primary tumor size, and histology, were randomized to receive combined-modality therapy consisting of four monthly cycles of fluorouracil (5-FU) (1,000 mg/m(2)/24 hours for 4 days) and cisplatin (75 mg/m(2) bolus day 1) with concurrent 64.8 Gy versus the same chemotherapy schedule but with concurrent 50.4 Gy. The trial was stopped after an interim analysis. The median follow-up was 16.4 months for all patients and 29.5 months for patients still alive.
RESULTS: For the 218 eligible patients, there was no significant difference in median survival (13.0 v 18.1 months), 2-year survival (31\% v 40\%), or local/regional failure and local/regional persistence of disease (56\% v 52\%) between the high-dose and standard-dose arms. Although 11 treatment-related deaths occurred in the high-dose arm compared with two in the standard-dose arm, seven of the 11 deaths occurred in patients who had received 50.4 Gy or less.
CONCLUSION: The higher radiation dose did not increase survival or local/regional control. Although there was a higher treatment-related mortality rate in the patients assigned to the high-dose radiation arm, it did not seem to be related to the higher radiation dose. The standard radiation dose for patients treated with concurrent 5-FU and cisplatin chemotherapy is 50.4 Gy.},
	language = {eng},
	number = {5},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Minsky, Bruce D. and Pajak, Thomas F. and Ginsberg, Robert J. and Pisansky, Thomas M. and Martenson, James and Komaki, Ritsuko and Okawara, Gordon and Rosenthal, Seth A. and Kelsen, David P.},
	month = mar,
	year = {2002},
	pmid = {11870157},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Recurrence, Local, Combined Modality Therapy, Radiotherapy Dosage, Radiotherapy},
	pages = {1167--1174},
}

@article{ajani3953,
	title = {Phase {II} trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma ({RTOG} 9904): quality of combined modality therapy and pathologic response},
	volume = {24},
	issn = {1527-7755},
	shorttitle = {Phase {II} trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma ({RTOG} 9904)},
	doi = {10.1200/JCO.2006.06.4840},
	abstract = {PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal. We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20\% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points.
PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible. A negative laparoscopic evaluation was required. Patients received two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiation and chemotherapy (infusional fluorouracil and weekly paclitaxel). Resection was attempted 5 to 6 weeks after chemoradiotherapy was completed. Quality of therapy was assessed with other end points.
RESULTS: Twenty institutions participated. Forty-nine patients were entered and 43 were assessable (12\% stage IB; 37\% stage II; and 52\% stage III). The pathCR and R0 resection rates were 26\% and 77\%, respectively. At 1 year, more patients with pathCR (82\%) are living than those with less than pathCR (69\%). Grade 4 toxicity occurred in 21\% of patients. Chemotherapy, radiotherapy, and surgery per protocol (including acceptable variations) occurred in 98\%, 44\%, and 63\% of patients, respectively. A D2 dissection was performed in 50\% of patients. Of 18 major radiotherapy variations, 17 were due to the lack of inclusion of the L3-4 vertebral interphase as prespecified.
CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20\% in a cooperative group setting. The quality of surgery improved (50\% with D2 dissection) possibly because surgery was part of this trial. With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.},
	language = {eng},
	number = {24},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Ajani, Jaffer A. and Winter, Kathryn and Okawara, Gordon S. and Donohue, John H. and Pisters, Peter W. T. and Crane, Christopher H. and Greskovich, John F. and Anne, P. Rani and Bradley, Jeffrey D. and Willett, Christopher and Rich, Tyvin A.},
	month = aug,
	year = {2006},
	pmid = {16921048},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Disease-Free Survival, Gastrectomy, Radiotherapy, Adjuvant},
	pages = {3953--3958},
}

@article{hoeppner503,
	title = {{ESOPEC}: prospective randomized controlled multicenter phase {III} trial comparing perioperative chemotherapy ({FLOT} protocol) to neoadjuvant chemoradiation ({CROSS} protocol) in patients with adenocarcinoma of the esophagus ({NCT02509286})},
	volume = {16},
	issn = {1471-2407},
	shorttitle = {{ESOPEC}},
	doi = {10.1186/s12885-016-2564-y},
	abstract = {BACKGROUND: Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for combined modality treatment of patients with localized esophageal adenocarcinoma. However, head-to-head comparisons of neoadjuvant chemoradiation and perioperative chemotherapy applying contemporary treatment protocols are lacking. The present trial was initiated to obtain valid information whether neoadjuvant chemoradiation or perioperative chemotherapy yields better survival in the treatment of localized esophageal adenocarcinoma.
METHODS/DESIGN: The ESOPEC trial is an investigator-initiated multicenter prospective randomized controlled two-arm trial, comparing the efficacy of neoadjuvant chemoradiation (CROSS protocol: 41.4Gy plus carboplatin/paclitaxel) followed by surgery versus perioperative chemotherapy and surgery (FLOT protocol: 5-FU/leucovorin/oxaliplatin/docetaxel) for the curative treatment of localized esophageal adenocarcinoma. Patients with cT1cN + cM0 and cT2-4acNxcM0 esophageal and junctional adenocarcinoma are eligible. The trial aims to include 438 participants who are centrally randomized to one of the two treatment groups in a 1:1 ratio stratified by N-stage and study site. The primary endpoint of the trial is overall survival assessed with a minimum follow-up of 36 months. Secondary objectives are progression-free survival, recurrence-free survival, site of failure, postoperative morbidity and mortality, duration of hospitalization as well as quality of life.
DISCUSSION: The ESOPEC trial compares perioperative chemotherapy according to the FLOT protocol to neoadjuvant chemoradiation according to the CROSS protocol in multimodal treatment of non-metastasized recectable adenocarcinoma of the esophagus and the gastroesophageal junction. The goal of the trial is identify the superior protocol with regard to patient survival, treatment morbidity and quality of life.
TRIAL REGISTRATION: NCT02509286 (July 22, 2015).},
	language = {eng},
	journal = {BMC cancer},
	author = {Hoeppner, Jens and Lordick, Florian and Brunner, Thomas and Glatz, Torben and Bronsert, Peter and Röthling, Nadine and Schmoor, Claudia and Lorenz, Dietmar and Ell, Christian and Hopt, Ulrich T. and Siewert, J. Rüdiger},
	month = jul,
	year = {2016},
	pmid = {27435280},
	pmcid = {PMC4952147},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adult, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Neoplasm Recurrence, Local, Chemoradiotherapy, Esophageal cancer, Esophagus, Radiotherapy, Quality of Life, Drug Therapy, Neoadjuvant chemoradiation, Perioperative chemotherapy},
	pages = {503},
	file = {Full Text:/Users/jcsal/Zotero/storage/WEA45JGV/Hoeppner et al. - 2016 - ESOPEC prospective randomized controlled multicen.pdf:application/pdf},
}

@article{al-batran1948,
	title = {Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma ({FLOT4}): a randomised, phase 2/3 trial},
	volume = {393},
	issn = {1474-547X},
	shorttitle = {Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma ({FLOT4})},
	doi = {10.1016/S0140-6736(18)32557-1},
	abstract = {BACKGROUND: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours.
METHODS: In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and three postoperative 3-week cycles of 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 plus either 200 mg/m2 fluorouracil as continuous intravenous infusion or 1250 mg/m2 capecitabine orally on days 1 to 21 (ECF/ECX; control group) or four preoperative and four postoperative 2-week cycles of 50 mg/m2 docetaxel, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin and 2600 mg/m2 fluorouracil as 24-h infusion on day 1 (FLOT; experimental group). The primary outcome of the trial was overall survival (superiority) analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01216644.
FINDINGS: Between Aug 8, 2010, and Feb 10, 2015, 716 patients were randomly assigned to treatment in 38 German hospitals or with practice-based oncologists. 360 patients were assigned to ECF/ECX and 356 patients to FLOT. Overall survival was increased in the FLOT group compared with the ECF/ECX group (hazard ratio [HR] 0·77; 95\% confidence interval [CI; 0.63 to 0·94]; median overall survival, 50 months [38·33 to not reached] vs 35 months [27·35 to 46·26]). The number of patients with related serious adverse events (including those occurring during hospital stay for surgery) was similar in the two groups (96 [27\%] in the ECF/ECX group vs 97 [27\%] in the FLOT group), as was the number of toxic deaths (two [{\textless}1\%] in both groups). Hospitalisation for toxicity occurred in 94 patients (26\%) in the ECF/ECX group and 89 patients (25\%) in the FLOT group.
INTERPRETATION: In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX.
FUNDING: The German Cancer Aid (Deutsche Krebshilfe), Sanofi-Aventis, Chugai, and Stiftung Leben mit Krebs Foundation.},
	language = {eng},
	number = {10184},
	journal = {Lancet (London, England)},
	author = {Al-Batran, Salah-Eddin and Homann, Nils and Pauligk, Claudia and Goetze, Thorsten O. and Meiler, Johannes and Kasper, Stefan and Kopp, Hans-Georg and Mayer, Frank and Haag, Georg Martin and Luley, Kim and Lindig, Udo and Schmiegel, Wolff and Pohl, Michael and Stoehlmacher, Jan and Folprecht, Gunnar and Probst, Stephan and Prasnikar, Nicole and Fischbach, Wolfgang and Mahlberg, Rolf and Trojan, Jörg and Koenigsmann, Michael and Martens, Uwe M. and Thuss-Patience, Peter and Egger, Matthias and Block, Andreas and Heinemann, Volker and Illerhaus, Gerald and Moehler, Markus and Schenk, Michael and Kullmann, Frank and Behringer, Dirk M. and Heike, Michael and Pink, Daniel and Teschendorf, Christian and Löhr, Carmen and Bernhard, Helga and Schuch, Gunter and Rethwisch, Volker and von Weikersthal, Ludwig Fischer and Hartmann, Jörg T. and Kneba, Michael and Daum, Severin and Schulmann, Karsten and Weniger, Jörg and Belle, Sebastian and Gaiser, Timo and Oduncu, Fuat S. and Güntner, Martina and Hozaeel, Wael and Reichart, Alexander and Jäger, Elke and Kraus, Thomas and Mönig, Stefan and Bechstein, Wolf O. and Schuler, Martin and Schmalenberg, Harald and Hofheinz, Ralf D. and {FLOT4-AIO Investigators}},
	month = may,
	year = {2019},
	pmid = {30982686},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Fluorouracil, Leucovorin, Stomach Neoplasms, Adenocarcinoma, Cisplatin, Disease-Free Survival, Esophagogastric Junction, Capecitabine, Oxaliplatin, Administration, Oral, Digestive System Surgical Procedures, Docetaxel},
	pages = {1948--1957},
	file = {Al-Batran et al_2019_Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and.pdf:/Users/jcsal/Zotero/storage/IHAJSYZ3/Al-Batran et al_2019_Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and.pdf:application/pdf},
}

@article{macdonald725,
	title = {Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction},
	volume = {345},
	issn = {0028-4793},
	doi = {10.1056/NEJMoa010187},
	abstract = {BACKGROUND: Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases. We investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.
METHODS: A total of 556 patients with resected adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to surgery plus postoperative chemoradiotherapy or surgery alone. The adjuvant treatment consisted of 425 mg of fluorouracil per square meter of body-surface area per day, plus 20 mg of leucovorin per square meter per day, for five days, followed by 4500 cGy of radiation at 180 cGy per day, given five days per week for five weeks, with modified doses of fluorouracil and leucovorin on the first four and the last three days of radiotherapy. One month after the completion of radiotherapy, two five-day cycles of fluorouracil (425 mg per square meter per day) plus leucovorin (20 mg per square meter per day) were given one month apart.
RESULTS: The median overall survival in the surgery-only group was 27 months, as compared with 36 months in the chemoradiotherapy group; the hazard ratio for death was 1.35 (95 percent confidence interval, 1.09 to 1.66; P=0.005). The hazard ratio for relapse was 1.52 (95 percent confidence interval, 1.23 to 1.86; P{\textless}0.001). Three patients (1 percent) died from toxic effects of the chemoradiotherapy; grade 3 toxic effects occurred in 41 percent of the patients in the chemoradiotherapy group, and grade 4 toxic effects occurred in 32 percent.
CONCLUSIONS: Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection.},
	language = {eng},
	number = {10},
	journal = {The New England Journal of Medicine},
	author = {Macdonald, J. S. and Smalley, S. R. and Benedetti, J. and Hundahl, S. A. and Estes, N. C. and Stemmermann, G. N. and Haller, D. G. and Ajani, J. A. and Gunderson, L. L. and Jessup, J. M. and Martenson, J. A.},
	month = sep,
	year = {2001},
	pmid = {11547741},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Survival Rate, Aged, 80 and over, Adult, Fluorouracil, Leucovorin, Stomach Neoplasms, Adenocarcinoma, Disease-Free Survival, Combined Modality Therapy, Esophagogastric Junction, Gastrectomy, Lymph Node Excision, Radiation Dosage, Antimetabolites, Antineoplastic},
	pages = {725--730},
}

@article{stahl2310,
	title = {Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus},
	volume = {23},
	issn = {0732-183X},
	doi = {10.1200/JCO.2005.00.034},
	abstract = {PURPOSE: Combined chemoradiotherapy with and without surgery are widely accepted alternatives for the curative treatment of patients with locally advanced esophageal cancer. The value of adding surgery to chemotherapy and radiotherapy is unknown.
PATIENTS AND METHODS: Patients with locally advanced squamous cell carcinoma (SCC) of the esophagus were randomly allocated to either induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A), or the same induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B). Primary outcome was overall survival time.
RESULTS: The median observation time was 6 years. The analysis of 172 eligible, randomized patients (86 patients per arm) showed overall survival to be equivalent between the two treatment groups (log-rank test for equivalence, P {\textless} .05). Local progression-free survival was better in the surgery group (2-year progression-free survival, 64.3\%; 95\% CI, 52.1\% to 76.5\%) than in the chemoradiotherapy group (2-year progression-free survival, 40.7\%; 95\% CI, 28.9\% to 52.5\%; hazard ratio [HR] for arm B v arm A, 2.1; 95\% CI, 1.3 to 3.5; P = .003). Treatment-related mortality was significantly increased in the surgery group than in the chemoradiotherapy group (12.8\% v 3.5\%, respectively; P = .03). Cox regression analysis revealed clinical tumor response to induction chemotherapy to be the single independent prognostic factor for overall survival (HR, 0.30; 95\% CI, 0.19 to 0.47; P {\textless} .0001).
CONCLUSION: Adding surgery to chemoradiotherapy improves local tumor control but does not increase survival of patients with locally advanced esophageal SCC. Tumor response to induction chemotherapy identifies a favorable prognostic group within these high-risk patients, regardless of the treatment group.},
	language = {eng},
	number = {10},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Stahl, Michael and Stuschke, Martin and Lehmann, Nils and Meyer, Hans-Joachim and Walz, Martin K. and Seeber, Siegfried and Klump, Bodo and Budach, Wilfried and Teichmann, Reinhard and Schmitt, Marcus and Schmitt, Gerd and Franke, Claus and Wilke, Hansjochen},
	month = apr,
	year = {2005},
	pmid = {15800321},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Leucovorin, Survival Analysis, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Combined Modality Therapy, ChemoRT\_Surgery, Etoposide},
	pages = {2310--2317},
	file = {Submitted Version:/Users/jcsal/Zotero/storage/A89BCRRC/Stahl et al. - 2005 - Chemoradiation with and without surgery in patient.pdf:application/pdf},
}

@article{birkmeyer2117,
	title = {Surgeon volume and operative mortality in the {United} {States}},
	volume = {349},
	issn = {1533-4406},
	doi = {10.1056/NEJMsa035205},
	abstract = {BACKGROUND: Although the relation between hospital volume and surgical mortality is well established, for most procedures, the relative importance of the experience of the operating surgeon is uncertain.
METHODS: Using information from the national Medicare claims data base for 1998 through 1999, we examined mortality among all 474,108 patients who underwent one of eight cardiovascular procedures or cancer resections. Using nested regression models, we examined the relations between operative mortality and surgeon volume and hospital volume (each in terms of total procedures performed per year), with adjustment for characteristics of the patients and other characteristics of the providers.
RESULTS: Surgeon volume was inversely related to operative mortality for all eight procedures (P=0.003 for lung resection, P{\textless}0.001 for all other procedures). The adjusted odds ratio for operative death (for patients with a low-volume surgeon vs. those with a high-volume surgeon) varied widely according to the procedure--from 1.24 for lung resection to 3.61 for pancreatic resection. Surgeon volume accounted for a large proportion of the apparent effect of the hospital volume, to an extent that varied according to the procedure: it accounted for 100 percent of the effect for aortic-valve replacement, 57 percent for elective repair of an abdominal aortic aneurysm, 55 percent for pancreatic resection, 49 percent for coronary-artery bypass grafting, 46 percent for esophagectomy, 39 percent for cystectomy, and 24 percent for lung resection. For most procedures, the mortality rate was higher among patients of low-volume surgeons than among those of high-volume surgeons, regardless of the surgical volume of the hospital in which they practiced.
CONCLUSIONS: For many procedures, the observed associations between hospital volume and operative mortality are largely mediated by surgeon volume. Patients can often improve their chances of survival substantially, even at high-volume hospitals, by selecting surgeons who perform the operations frequently.},
	language = {eng},
	number = {22},
	journal = {The New England Journal of Medicine},
	author = {Birkmeyer, John D. and Stukel, Therese A. and Siewers, Andrea E. and Goodney, Philip P. and Wennberg, David E. and Lucas, F. Lee},
	month = nov,
	year = {2003},
	pmid = {14645640},
	keywords = {Humans, Aged, Female, Male, Neoplasms, Outcome Assessment, Health Care, Databases, Factual, United States, Logistic Models, Cardiovascular Surgical Procedures, General Surgery, Hospitals, Medicare, Surgical Procedures, Operative},
	pages = {2117--2127},
	file = {Submitted Version:/Users/jcsal/Zotero/storage/6CFPE35V/Birkmeyer et al. - 2003 - Surgeon volume and operative mortality in the Unit.pdf:application/pdf},
}

@article{markar922,
	title = {Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis},
	volume = {21},
	issn = {1534-4681},
	shorttitle = {Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy},
	doi = {10.1245/s10434-013-3364-0},
	abstract = {BACKGROUND: Combined chemoradiotherapy is increasingly being used as definitive treatment for locoregional esophageal malignancy. Patients with residual or recurrent localized cancer are often selectively considered for salvage esophagectomy (SALV). The aim of this pooled analysis was to compare short-term clinical outcomes from SALV following definitive chemoradiotherapy with those from planned esophagectomy following neoadjuvant chemoradiotherapy (NCRS).
METHODS: MEDLINE, EMBASE, Cochrane, trial registries, conference proceedings and reference lists were searched for relevant comparative studies. Primary outcome measures were in-hospital mortality, anastomotic leak and pulmonary complications. Secondary outcomes were length of hospital stay, negative (R0) resection margin, and estimated blood loss.
RESULTS: Eight studies comprising 954 patients; 242 (SALV) and 712 (NCRS) were included. SALV was associated with a significantly increased incidence of post-operative mortality (9.50 vs. 4.07 \%; pooled odds ratio [POR] = 3.02; p {\textless} 0.001), anastomotic leak (23.97 vs. 14.47 \%; POR = 1.99; p = 0.005), pulmonary complications (29.75 vs. 16.99 \%; POR = 2.12; p {\textless} 0.001), and an increased length of hospital stay (weighted mean difference = 8.29 days; 95 \% CI 7.08-9.5; p {\textless} 0.001). There were no significant differences between the groups in the incidence of negative resection margins or estimated blood loss.
CONCLUSIONS: SALV has poorer short-term outcomes when compared with planned esophagectomy following neoadjuvant chemoradiotherapy. Patients and multidisciplinary tumor boards should be made aware of these differences in outcomes and SALV should be reserved for practice in high-volume institutions.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgical Oncology},
	author = {Markar, Sheraz R. and Karthikesalingam, Alan and Penna, Marta and Low, Donald E.},
	month = mar,
	year = {2014},
	pmid = {24212722},
	keywords = {Esophageal Neoplasms, Esophagectomy, Humans, Prognosis, Salvage Therapy, Survival Rate},
	pages = {922--931},
}

@article{orringer282,
	title = {Transhiatal esophagectomy without thoracotomy for carcinoma of the thoracic esophagus},
	volume = {200},
	issn = {0003-4932},
	doi = {10.1097/00000658-198409000-00005},
	abstract = {Transhiatal esophagectomy (THE) without thoracotomy was performed in 100 patients with carcinoma of the thoracic esophagus (7 upper, 45 mid, and 48 lower third). The esophagus was replaced with stomach (96) or colon (4). Intraoperative complications included pneumothorax requiring a chest tube(s) (63) and membranous tracheal tear (2). Blood loss averaged 880 ml. Postoperative complications included transient recurrent laryngeal nerve paresis (31), anastomotic leak (5), and chylothorax (2). There were no intraoperative deaths or re-explorations for postoperative bleeding. Six hospital deaths resulted from aspiration pneumonia (2), retroperitoneal or mediastinal abscess (2), pulmonary embolus (1), and respiratory insufficiency (1). Postoperative hospitalization averaged 14 days. Actuarial survival among the 94 operative survivors is 82\% at 6 months, 52\% at 12 months, 32\% at 24 months, 22\% at 36 months, and 17\% at 48 months. Of the operative survivors, 15\% have lived 2 years or more and 10\% are clinically disease free. THE is safe, associated with a low morbidity, and achieves excellent palliation and survival at least as good as that reported in many series of transthoracic esophagectomies for esophageal carcinoma.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgery},
	author = {Orringer, M. B.},
	month = sep,
	year = {1984},
	pmid = {6465981},
	pmcid = {PMC1250471},
	keywords = {Humans, Follow-Up Studies, Prognosis, Esophageal Neoplasms, Postoperative Complications, Chylothorax, Intraoperative Complications, Ligation, Methods, Thoracic Duct, Trachea, Vocal Cord Paralysis},
	pages = {282--288},
	file = {Full Text:/Users/jcsal/Zotero/storage/J4R2GSJ3/Orringer - 1984 - Transhiatal esophagectomy without thoracotomy for .pdf:application/pdf},
}

@article{zhang429,
	title = {Neoadjuvant chemoradiation therapy is beneficial for clinical stage {T2} {N0} esophageal cancer patients due to inaccurate preoperative staging},
	volume = {93},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22269708},
	doi = {10.1016/j.athoracsur.2011.10.061},
	number = {2},
	journal = {Ann Thorac Surg},
	author = {Zhang, J. Q. and Hooker, C. M. and Brock, M. V. and Shin, J. and Lee, S. and How, R. and Franco, N. and Prevas, H. and Hulbert, A. and Yang, S. C.},
	year = {2012},
	pmcid = {PMC4365971},
	pmid = {22269708},
	note = {tex.ids: zhang429a
type: Journal Article},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Proportional Hazards Models, Fluorouracil, Neoplasm Invasiveness, Organoplatinum Compounds, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Postoperative Complications, Lymphatic Metastasis, Radiotherapy Dosage, Diagnostic Errors, Induction Chemotherapy, Preoperative Care},
	pages = {429--35; discussion 436--7},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/SJIWBSXX/Zhang et al. - 2012 - Neoadjuvant chemoradiation therapy is beneficial f.pdf:application/pdf},
}

@article{speicher1195,
	title = {Induction therapy does not improve survival for clinical stage {T2N0} esophageal cancer},
	volume = {9},
	issn = {1556-1380},
	doi = {10.1097/JTO.0000000000000228},
	abstract = {INTRODUCTION: This study compared survival after initial treatment with esophagectomy as primary therapy to induction therapy followed by esophagectomy for patients with clinical T2N0 (cT2N0) esophageal cancer in the National Cancer Database (NCDB).
METHODS: Predictors of therapy selection for patients with cT2N0 esophageal cancer in the NCDB from 1998 to 2011 were identified with multivariable logistic regression. Survival was evaluated using Kaplan-Meier and Cox proportional hazards methods.
RESULTS: Surgery was used in 42.9\% (2057 of 4799) of cT2N0 patients. Of 1599 esophagectomy patients for whom treatment timing was recorded, induction therapy was used in 44.1\% (688). Pretreatment staging was proven accurate in only 26.7\% of patients (210 of 786) who underwent initial surgery without induction treatment and had complete pathologic data available: 41.6\% (n = 327) were upstaged and 31.7\% (n = 249) were downstaged. Adjuvant therapy (chemotherapy or radiation therapy) was given to 50.2\% of patients treated initially with surgery who were found after resection to have nodal disease. There was no significant difference in long-term survival between strategies of primary surgery and induction therapy followed by surgery (median 41.1 versus 41.9 months, p = 0.51). In multivariable analysis, induction therapy was not independently associated with risk of death (hazard ratio [HR], 1.16, p = 0.32).
CONCLUSIONS: Current clinical staging for early-stage esophageal cancer is highly inaccurate, with only a quarter of surgically resected cT2N0 patients found to have had accurate pretreatment staging. Induction therapy for patients with cT2N0 esophageal cancer in the NCDB is not associated with improved survival.},
	language = {eng},
	number = {8},
	journal = {Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer},
	author = {Speicher, Paul J. and Ganapathi, Asvin M. and Englum, Brian R. and Hartwig, Matthew G. and Onaitis, Mark W. and D'Amico, Thomas A. and Berry, Mark F.},
	month = aug,
	year = {2014},
	pmcid = {PMC4145610},
	pmid = {25157773},
	note = {tex.ids: speicher1195a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Retrospective Studies, Survival Rate, Chemotherapy, Adjuvant, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagectomy, Radiotherapy, Adjuvant},
	pages = {1195--1201},
	file = {Full Text:/Users/jcsal/Zotero/storage/QJQEDGSE/Speicher et al. - 2014 - Induction therapy does not improve survival for cl.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/S53GQMPN/Speicher et al. - 2014 - Induction therapy does not improve survival for cl.pdf:application/pdf},
}

@article{shaheen2277,
	title = {Radiofrequency ablation in {Barrett}'s esophagus with dysplasia},
	volume = {360},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa0808145},
	abstract = {BACKGROUND: Barrett's esophagus, a condition of intestinal metaplasia of the esophagus, is associated with an increased risk of esophageal adenocarcinoma. We assessed whether endoscopic radiofrequency ablation could eradicate dysplastic Barrett's esophagus and decrease the rate of neoplastic progression.
METHODS: In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus in a 2:1 ratio to receive either radiofrequency ablation (ablation group) or a sham procedure (control group). Randomization was stratified according to the grade of dysplasia and the length of Barrett's esophagus. Primary outcomes at 12 months included the complete eradication of dysplasia and intestinal metaplasia.
RESULTS: In the intention-to-treat analyses, among patients with low-grade dysplasia, complete eradication of dysplasia occurred in 90.5\% of those in the ablation group, as compared with 22.7\% of those in the control group (P{\textless}0.001). Among patients with high-grade dysplasia, complete eradication occurred in 81.0\% of those in the ablation group, as compared with 19.0\% of those in the control group (P{\textless}0.001). Overall, 77.4\% of patients in the ablation group had complete eradication of intestinal metaplasia, as compared with 2.3\% of those in the control group (P{\textless}0.001). Patients in the ablation group had less disease progression (3.6\% vs. 16.3\%, P=0.03) and fewer cancers (1.2\% vs. 9.3\%, P=0.045). Patients reported having more chest pain after the ablation procedure than after the sham procedure. In the ablation group, one patient had upper gastrointestinal hemorrhage, and five patients (6.0\%) had esophageal stricture.
CONCLUSIONS: In patients with dysplastic Barrett's esophagus, radiofrequency ablation was associated with a high rate of complete eradication of both dysplasia and intestinal metaplasia and a reduced risk of disease progression. (ClinicalTrials.gov number, NCT00282672.)},
	language = {eng},
	number = {22},
	journal = {The New England Journal of Medicine},
	author = {Shaheen, Nicholas J. and Sharma, Prateek and Overholt, Bergein F. and Wolfsen, Herbert C. and Sampliner, Richard E. and Wang, Kenneth K. and Galanko, Joseph A. and Bronner, Mary P. and Goldblum, John R. and Bennett, Ana E. and Jobe, Blair A. and Eisen, Glenn M. and Fennerty, M. Brian and Hunter, John G. and Fleischer, David E. and Sharma, Virender K. and Hawes, Robert H. and Hoffman, Brenda J. and Rothstein, Richard I. and Gordon, Stuart R. and Mashimo, Hiroshi and Chang, Kenneth J. and Muthusamy, V. Raman and Edmundowicz, Steven A. and Spechler, Stuart J. and Siddiqui, Ali A. and Souza, Rhonda F. and Infantolino, Anthony and Falk, Gary W. and Kimmey, Michael B. and Madanick, Ryan D. and Chak, Amitabh and Lightdale, Charles J.},
	month = may,
	year = {2009},
	pmid = {19474425},
	note = {tex.ids: shaheen2277a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Disease Progression, Aged, 80 and over, Esophagus, Logistic Models, Barrett Esophagus, Catheter Ablation, Metaplasia},
	pages = {2277--2288},
	file = {Submitted Version:/Users/jcsal/Zotero/storage/XSBVNK7Y/Shaheen et al. - 2009 - Radiofrequency ablation in Barrett's esophagus wit.pdf:application/pdf;Submitted Version:/Users/jcsal/Zotero/storage/K5YB5ZII/Shaheen et al. - 2009 - Radiofrequency ablation in Barrett's esophagus wit.pdf:application/pdf},
}

@article{phoa1209,
	title = {Radiofrequency ablation vs endoscopic surveillance for patients with {Barrett} esophagus and low-grade dysplasia: a randomized clinical trial},
	volume = {311},
	issn = {1538-3598},
	shorttitle = {Radiofrequency ablation vs endoscopic surveillance for patients with {Barrett} esophagus and low-grade dysplasia},
	doi = {10.1001/jama.2014.2511},
	abstract = {IMPORTANCE: Barrett esophagus containing low-grade dysplasia is associated with an increased risk of developing esophageal adenocarcinoma, a cancer with a rapidly increasing incidence in the western world.
OBJECTIVE: To investigate whether endoscopic radiofrequency ablation could decrease the rate of neoplastic progression.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial that enrolled 136 patients with a confirmed diagnosis of Barrett esophagus containing low-grade dysplasia at 9 European sites between June 2007 and June 2011. Patient follow-up ended May 2013.
INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to either endoscopic treatment with radiofrequency ablation (ablation) or endoscopic surveillance (control). Ablation was performed with the balloon device for circumferential ablation of the esophagus or the focal device for targeted ablation, with a maximum of 5 sessions allowed.
MAIN OUTCOMES AND MEASURES: The primary outcome was neoplastic progression to high-grade dysplasia or adenocarcinoma during a 3-year follow-up since randomization. Secondary outcomes were complete eradication of dysplasia and intestinal metaplasia and adverse events.
RESULTS: Sixty-eight patients were randomized to receive ablation and 68 to receive control. Ablation reduced the risk of progression to high-grade dysplasia or adenocarcinoma by 25.0\% (1.5\% for ablation vs 26.5\% for control; 95\% CI, 14.1\%-35.9\%; P {\textless} .001) and the risk of progression to adenocarcinoma by 7.4\% (1.5\% for ablation vs 8.8\% for control; 95\% CI, 0\%-14.7\%; P = .03). Among patients in the ablation group, complete eradication occurred in 92.6\% for dysplasia and 88.2\% for intestinal metaplasia compared with 27.9\% for dysplasia and 0.0\% for intestinal metaplasia among patients in the control group (P {\textless} .001). Treatment-related adverse events occurred in 19.1\% of patients receiving ablation (P {\textless} .001). The most common adverse event was stricture, occurring in 8 patients receiving ablation (11.8\%), all resolved by endoscopic dilation (median, 1 session). The data and safety monitoring board recommended early termination of the trial due to superiority of ablation for the primary outcome and the potential for patient safety issues if the trial continued.
CONCLUSIONS AND RELEVANCE: In this randomized trial of patients with Barrett esophagus and a confirmed diagnosis of low-grade dysplasia, radiofrequency ablation resulted in a reduced risk of neoplastic progression over 3 years of follow-up.
TRIAL REGISTRATION: trialregister.nl Identifier: NTR1198.},
	language = {eng},
	number = {12},
	journal = {JAMA},
	author = {Phoa, K. Nadine and van Vilsteren, Frederike G. I. and Weusten, Bas L. A. M. and Bisschops, Raf and Schoon, Erik J. and Ragunath, Krish and Fullarton, Grant and Di Pietro, Massimiliano and Ravi, Narayanasamy and Visser, Mike and Offerhaus, G. Johan and Seldenrijk, Cees A. and Meijer, Sybren L. and ten Kate, Fiebo J. W. and Tijssen, Jan G. P. and Bergman, Jacques J. G. H. M.},
	month = mar,
	year = {2014},
	pmid = {24668102},
	note = {tex.ids: phoa1209a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Disease Progression, Adenocarcinoma, Esophageal Neoplasms, Watchful Waiting, Esophagoscopy, Esophagus, Barrett Esophagus, Catheter Ablation},
	pages = {1209--1217},
	file = {Full Text:/Users/jcsal/Zotero/storage/2MJ8Z3LW/Phoa et al. - 2014 - Radiofrequency ablation vs endoscopic surveillance.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/XK5ED99S/Phoa et al. - 2014 - Radiofrequency ablation vs endoscopic surveillance.pdf:application/pdf},
}

@article{pech652,
	title = {Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus},
	volume = {146},
	issn = {1528-0012},
	doi = {10.1053/j.gastro.2013.11.006},
	abstract = {BACKGROUND \& AIMS: Barrett's esophagus-associated high-grade dysplasia is commonly treated by endoscopy. However, most guidelines offer no recommendations for endoscopic treatment of mucosal adenocarcinoma of the esophagus (mAC). We investigated the efficacy and safety of endoscopic resection in a large series of patients with mAC.
METHODS: We collected data from 1000 consecutive patients (mean age, 69.1 ± 10.7 years; 861 men) with mAC (481 with short-segment and 519 with long-segment Barrett's esophagus) who presented at a tertiary care center from October 1996 to September 2010. Patients with low-grade and high-grade dysplasia and submucosal or more advanced cancer were excluded. All patients underwent endoscopic resection of mACs. Patients found to have submucosal cancer at their first endoscopy examination were excluded from the analysis.
RESULTS: After a mean follow-up period of 56.6 ± 33.4 months, 963 patients (96.3\%) had achieved a complete response; surgery was necessary in 12 patients (3.7\%) after endoscopic therapy failed. Metachronous lesions or recurrence of cancer developed during the follow-up period in 140 patients (14.5\%) but endoscopic re-treatment was successful in 115, resulting in a long-term complete remission rate of 93.8\%; 111 died of concomitant disease and 2 of Barrett's esophagus-associated cancer. The calculated 10-year survival rate of patients who underwent endoscopic resection of mACs was 75\%. Major complications developed in 15 patients (1.5\%) but could be managed conservatively.
CONCLUSIONS: Endoscopic therapy is highly effective and safe for patients with mAC, with excellent long-term results. In an almost 5-year follow-up of 1000 patients treated with endoscopic resection, there was no mortality and less than 2\% had major complications. Endoscopic therapy should become the standard of care for patients with mAC.},
	language = {eng},
	number = {3},
	journal = {Gastroenterology},
	author = {Pech, Oliver and May, Andrea and Manner, Hendrik and Behrens, Angelika and Pohl, Jürgen and Weferling, Maren and Hartmann, Urs and Manner, Nicola and Huijsmans, Josephus and Gossner, Liebwin and Rabenstein, Thomas and Vieth, Michael and Stolte, Manfred and Ell, Christian},
	month = mar,
	year = {2014},
	pmid = {24269290},
	note = {tex.ids: pechLongtermEfficacySafety2014},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Retrospective Studies, Prospective Studies, Survival Rate, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Incidence, Esophagus, Mucous Membrane, Endoscopic Mucosal Resection, Endoscopy, Barrett’s Esophagus, Esophageal Cancer, Local, Neoplasm Recurrence, T1},
	pages = {652--660.e1},
}

@article{penniment114,
	title = {Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial ({TROG} 03.01)},
	volume = {3},
	issn = {2468-1253},
	shorttitle = {Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer},
	doi = {10.1016/S2468-1253(17)30363-1},
	abstract = {BACKGROUND: A short course of radiotherapy is commonly prescribed for palliative relief of malignant dysphagia in patients with incurable oesophageal cancer. We compared chemoradiotherapy with radiotherapy alone for dysphagia relief in the palliative setting.
METHODS: This multicentre randomised controlled trial included patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) through a computer-generated adaptive biased coin design to either palliative chemoradiotherapy or radiotherapy alone for treatment of malignant dysphagia at 22 hospitals in Australia, Canada, New Zealand, and the UK. Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative treatment, symptomatic dysphagia, Eastern Cooperative Oncology Group performance status 0-2, and adequate haematological and renal function. Patients were stratified by hospital, dysphagia score (Mellow scale 1-4), and presence of metastases. The radiotherapy dose was 35 Gy in 15 fractions over 3 weeks for patients in Australia and New Zealand and 30 Gy in ten fractions over 2 weeks for patients in Canada and the UK. Chemotherapy consisted of one cycle of intravenous cisplatin (either 80 mg/m2 on day 1 or 20 mg/m2 per day on days 1-4 of radiotherapy at clinician's discretion) and intravenous fluorouracil 800 mg/m2 per day on days 1-4 of radiotherapy in week 1. Patients were assessed weekly during treatment. The primary endpoint was dysphagia relief (defined as ≥1 point reduction on the Mellow scale at 9 weeks and maintained 4 weeks later), and key secondary endpoints were dysphagia progression-free survival (defined as a worsening of at least 1 point on the Mellow scale from baseline or best response) and overall survival. These endpoints were analysed in the intention-to-treat population. This study is registered at ClinicalTrials.gov, number NCT00193882. This trial is closed.
FINDINGS: Between July 7, 2003, and March 21, 2012, 111 patients were randomly assigned to chemoradiotherapy and 109 patients to radiotherapy. One patient in the chemoradiotherapy group was omitted from analysis because of ineligibility. 50 (45\%, 95\% CI 36-55) patients in the chemoradiotherapy group and 38 (35\%, 26-44) in the radiotherapy group obtained dysphagia relief (difference 10·6\%, 95\% CI -2 to 23; p=0·13). Median dysphagia progression-free survival was 4·1 months (95\% CI 3·5-4·8) versus 3·4 months (3·1-4·3) in the chemoradiotherapy and radiotherapy groups, respectively (p=0·58), and median overall survival was 6·9 months (95\% CI 5·1-8·3) versus 6·7 months (4·9-8·0), respectively (p=0·88). Of the 211 patients who commenced radiotherapy, grade 3-4 acute toxicity occurred in 38 (36\%) patients in the chemoradiotherapy group and in 17 (16\%) patients in the radiotherapy group (p=0·0017). Anaemia, thrombocytopenia, neutropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly worse in patients who had chemoradiotherapy than in patients who had radiotherapy.
INTERPRETATION: Palliative chemoradiotherapy showed a modest, but not statistically significant, increase in dysphagia relief compared with radiotherapy alone, with minimal improvement in dysphagia progression-free survival and overall survival with chemoradiotherapy but at a cost of increased toxicity. A short course of radiotherapy alone should be considered a safe and well tolerated treatment for malignant dysphagia in the palliative setting.
FUNDING: National Health and Medical Research Council, Canadian Cancer Society Research Institute, Canadian Cancer Trials Group, Trans Tasman Radiation Oncology Group, and Cancer Australia.},
	language = {eng},
	number = {2},
	journal = {The Lancet. Gastroenterology \& Hepatology},
	author = {Penniment, Michael G. and De Ieso, Paolo B. and Harvey, Jennifer A. and Stephens, Sonya and Au, Heather-Jane and O'Callaghan, Christopher J. and Kneebone, Andrew and Ngan, Samuel Y. and Ward, Iain G. and Roy, Rajarshi and Smith, Jennifer G. and Nijjar, Tirath and Biagi, James J. and Mulroy, Liam A. and Wong, Rebecca and {TROG 03.01/CCTG ES.2 group}},
	month = feb,
	year = {2018},
	pmid = {29248399},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Metastasis, Palliative Care, Antineoplastic Agents, Aged, 80 and over, Fluorouracil, Survival Analysis, Cisplatin, Esophageal Neoplasms, Chemoradiotherapy, Deglutition Disorders, Radiotherapy, Intention to Treat Analysis},
	pages = {114--124},
}

@article{zhoue0132889,
	title = {Superiority of {Minimally} {Invasive} {Oesophagectomy} in {Reducing} {In}-{Hospital} {Mortality} of {Patients} with {Resectable} {Oesophageal} {Cancer}: {A} {Meta}-{Analysis}},
	volume = {10},
	issn = {1932-6203},
	shorttitle = {Superiority of {Minimally} {Invasive} {Oesophagectomy} in {Reducing} {In}-{Hospital} {Mortality} of {Patients} with {Resectable} {Oesophageal} {Cancer}},
	doi = {10.1371/journal.pone.0132889},
	abstract = {BACKGROUND: Compared with open oesophagectomy (OE), minimally invasive oesophagectomy (MIO) proves to have benefits in reducing the risk of pulmonary complications for patients with resectable oesophageal cancer. However, it is unknown whether MIO has superiority in reducing the occurrence of in-hospital mortality (IHM).
OBJECTIVE: The objective of this meta-analysis was to explore the effect of MIO vs. OE on the occurrence of in-hospital mortality (IHM).
DATA SOURCES: Sources such as Medline (through December 31, 2014), Embase (through December 31, 2014), Wiley Online Library (through December 31, 2014), and the Cochrane Library (through December 31, 2014) were searched.
STUDY SELECTION: Data of randomized and non-randomized clinical trials related to MIO versus OE were included.
INTERVENTIONS: Eligible studies were those that reported patients who underwent MIO procedure. The control group included patients undergoing conventional OE.
STUDY APPRAISAL AND SYNTHESIS METHODS: Fixed or random -effects models were used to calculate summary odds ratios (ORs) or relative risks (RRs) for quantification of associations. Heterogeneity among studies was evaluated by using Cochran's Q and I2 statistics.
RESULTS: A total of 48 studies involving 14,311 cases of resectable oesophageal cancer were included in the meta-analysis. Compared to patients undergoing OE, patients undergoing MIO had statistically reduced occurrence of IHM (OR=0.69, 95\%CI =0.55 -0.86). Patients undergoing MIO also had significantly reduced incidence of pulmonary complications (PCs) (RR=0.73, 95\%CI = 0.63-0.86), pulmonary embolism (PE) (OR=0.71, 95\%CI= 0.51-0.99) and arrhythmia (OR=0.79, 95\%CI = 0.68-0.92). Non-significant reductions were observed among the included studies in the occurrence of anastomotic leak (AL) (OR=0.93, 95\%CI =0.78-1.11), or Gastric Tip Necrosis (GTN) (OR=0.89, 95\%CI =0.54-1.49).
LIMITATION: Most of the included studies were non-randomized case-control studies, with a diversity of study designs, demographics of participants and surgical intervention.
CONCLUSIONS: Minimally invasive oesophagectomy (MIO) has superiority over open oesophagectomy (OE) in terms of the occurrence of in-hospital mortality (IHM) and should be the first-choice surgical procedure in esophageal surgery.},
	language = {eng},
	number = {7},
	journal = {PloS One},
	author = {Zhou, Can and Zhang, Li and Wang, Hua and Ma, Xiaoxia and Shi, Bohui and Chen, Wuke and He, Jianjun and Wang, Ke and Liu, Peijun and Ren, Yu},
	year = {2015},
	pmcid = {PMC4509855},
	pmid = {26196135},
	note = {tex.ids= zhoue0132889a},
	keywords = {Humans, Treatment Outcome, Risk, Esophageal Neoplasms, Esophagectomy, Esophagus, Anastomotic Leak, Hospital Mortality, Arrhythmias, Cardiac, Clinical Trials as Topic, Minimally Invasive Surgical Procedures, Necrosis, Odds Ratio},
	pages = {e0132889},
	file = {Full Text:/Users/jcsal/Zotero/storage/NN3TAP3B/Zhou et al. - 2015 - Superiority of Minimally Invasive Oesophagectomy i.pdf:application/pdf},
}

@article{ychou1715,
	title = {Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an {FNCLCC} and {FFCD} multicenter phase {III} trial},
	volume = {29},
	issn = {1527-7755},
	shorttitle = {Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma},
	doi = {10.1200/JCO.2010.33.0597},
	abstract = {PURPOSE: After curative resection, the prognosis of gastroesophageal adenocarcinoma is poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma.
PATIENTS AND METHODS: Overall, 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction (GEJ), or stomach were randomly assigned to either perioperative chemotherapy and surgery (CS group; n = 113) or surgery alone (S group; n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous cisplatin (100 mg/m(2)) on day 1, and a continuous intravenous infusion of fluorouracil (800 mg/m(2)/d) for 5 consecutive days (days 1 to 5) every 28 days and three or four postoperative cycles of the same regimen. The primary end point was OS.
RESULTS: Compared with the S group, the CS group had a better OS (5-year rate 38\% v 24\%; hazard ratio [HR] for death: 0.69; 95\% CI, 0.50 to 0.95; P = .02); and a better disease-free survival (5-year rate: 34\% v 19\%; HR, 0.65; 95\% CI, 0.48 to 0.89; P = .003). In the multivariable analysis, the favorable prognostic factors for survival were perioperative chemotherapy (P = .01) and stomach tumor localization (P {\textless} .01). Perioperative chemotherapy significantly improved the curative resection rate (84\% v 73\%; P = .04). Grade 3 to 4 toxicity occurred in 38\% of CS patients (mainly neutropenia) but postoperative morbidity was similar in the two groups.
CONCLUSION: In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.},
	language = {eng},
	number = {13},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Ychou, Marc and Boige, Valérie and Pignon, Jean-Pierre and Conroy, Thierry and Bouché, Olivier and Lebreton, Gilles and Ducourtieux, Muriel and Bedenne, Laurent and Fabre, Jean-Michel and Saint-Aubert, Bernard and Genève, Jean and Lasser, Philippe and Rougier, Philippe},
	month = may,
	year = {2011},
	pmid = {21444866},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemotherapy, Adjuvant, Drug Administration Schedule, Fluorouracil, Stomach Neoplasms, Cisplatin, Disease-Free Survival, Esophageal Neoplasms, Combined Modality Therapy, Esophagogastric Junction, Perioperative Period},
	pages = {1715--1721},
}

@article{visbal1803,
	title = {Ivor {Lewis} esophagogastrectomy for esophageal cancer},
	volume = {71},
	issn = {0003-4975},
	doi = {10.1016/s0003-4975(01)02601-7},
	abstract = {BACKGROUND: To examine the efficacy of the Ivor Lewis esophagogastrectomy for esophageal carcinoma prior to the widespread use of preoperative chemotherapy and irradiation, we reviewed our experience.
METHODS: We reexamined the cases of 220 consecutive patients who underwent an Ivor Lewis esophagogastrectomy for esophageal cancer from January 1992 through December 1995.
RESULTS: There were 196 men (89.1\%) and 24 women. Median age was 65 years (range, 29 to 85 years). The results of pathological study showed adenocarcinoma in 188 patients (85.5\%), squamous cell carcinoma in 31 (14.1\%), and leiomyosarcoma in 1 patient (0.5\%). Postsurgical staging was as follows: stage 0 in 10 patients, stage I in 19, stage IIa in 38, stage IIb in 28, stage III in 111, and stage IV in 14. The operative mortality rate was 1.4\% (3 patients), and complications occurred in 83 patients (37.7\%). Follow-up was 98.6\% complete. Median survival for operative survivors was 1.9 years (range, 32 days to 8.7 years). The overall 5-year survival rate was 25.2\%; it was 80\% for patients in stage 0, 94.4\% for those in stage I, 36.0\% for those in stage IIa, 14.3\% for patients in stage IIb, 10\% for those in stage III and 0\% for patients in stage IV.
CONCLUSIONS: Ivor Lewis esophagogastrectomy for esophageal cancer is a safe operation. Long-term survival is stage dependent. The low survival associated with advanced cancers should stimulate the search for effective neoadjuvant therapy.},
	language = {eng},
	number = {6},
	journal = {The Annals of Thoracic Surgery},
	author = {Visbal, A. L. and Allen, M. S. and Miller, D. L. and Deschamps, C. and Trastek, V. F. and Pairolero, P. C.},
	month = jun,
	year = {2001},
	pmid = {11426751},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Survival Rate, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Gastrectomy},
	pages = {1803--1808},
}

@article{sjoquist681,
	title = {Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis},
	volume = {12},
	issn = {1474-5488},
	shorttitle = {Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma},
	doi = {10.1016/S1470-2045(11)70142-5},
	abstract = {BACKGROUND: In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. We updated this meta-analysis with results from new or updated randomised trials presented in the past 3 years. We also compared the benefits of preoperative neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy.
METHODS: To identify additional studies and published abstracts from major scientific meetings, we searched Medline, Embase, and Central (Cochrane clinical trials database) for studies published since January, 2006, and also manually searched for abstracts from major conferences from the same period. Only randomised studies analysed by intention to treat were included, and searches were restricted to those databases citing articles in English. We used published hazard ratios (HRs) if available or estimates from other survival data. We also investigated treatment effects by tumour histology and relations between risk (survival after surgery alone) and effect size.
FINDINGS: We included all 17 trials from the previous meta-analysis and seven further studies. 12 were randomised comparisons of neoadjuvant chemoradiotherapy versus surgery alone (n=1854), nine were randomised comparisons of neoadjuvant chemotherapy versus surgery alone (n=1981), and two compared neoadjuvant chemoradiotherapy with neoadjuvant chemotherapy (n=194) in patients with resectable oesophageal carcinoma; one factorial trial included two comparisons and was included in analyses of both neoadjuvant chemoradiotherapy (n=78) and neoadjuvant chemotherapy (n=81). The updated analysis contained 4188 patients whereas the previous publication included 2933 patients. This updated meta-analysis contains about 3500 events compared with about 2230 in the previous meta-analysis (estimated 57\% increase). The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95\% CI 0.70-0.88; p{\textless}0.0001); the HR for squamous-cell carcinoma only was 0.80 (0.68-0.93; p=0.004) and for adenocarcinoma only was 0.75 (0.59-0.95; p=0.02). The HR for all-cause mortality for neoadjuvant chemotherapy was 0.87 (0.79-0.96; p=0.005); the HR for squamous-cell carcinoma only was 0.92 (0.81-1.04; p=0.18) and for adenocarcinoma only was 0.83 (0.71-0.95; p=0.01). The HR for the overall indirect comparison of all-cause mortality for neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy was 0.88 (0.76-1.01; p=0.07).
INTERPRETATION: This updated meta-analysis provides strong evidence for a survival benefit of neoadjuvant chemoradiotherapy or chemotherapy over surgery alone in patients with oesophageal carcinoma. A clear advantage of neoadjuvant chemoradiotherapy over neoadjuvant chemotherapy has not been established. These results should help inform decisions about patient management and design of future trials.
FUNDING: Cancer Australia and the NSW Cancer Institute.},
	language = {eng},
	number = {7},
	journal = {The Lancet. Oncology},
	author = {Sjoquist, Katrin M. and Burmeister, Bryan H. and Smithers, B. Mark and Zalcberg, John R. and Simes, R. John and Barbour, Andrew and Gebski, Val and {Australasian Gastro-Intestinal Trials Group}},
	month = jul,
	year = {2011},
	pmid = {21684205},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Follow-Up Studies, Antineoplastic Agents, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Radiotherapy, Adjuvant, Australia, Databases as Topic},
	pages = {681--692},
}

@article{pasquali481,
	title = {Survival {After} {Neoadjuvant} and {Adjuvant} {Treatments} {Compared} to {Surgery} {Alone} for {Resectable} {Esophageal} {Carcinoma}: {A} {Network} {Meta}-analysis},
	volume = {265},
	issn = {1528-1140},
	shorttitle = {Survival {After} {Neoadjuvant} and {Adjuvant} {Treatments} {Compared} to {Surgery} {Alone} for {Resectable} {Esophageal} {Carcinoma}},
	doi = {10.1097/SLA.0000000000001905},
	abstract = {OBJECTIVE: This network meta-analysis compared overall survival after neoadjuvant or adjuvant chemotherapy (CT), radiotherapy (RT), or combinations of both (chemoradiotherapy, CRT) or surgery alone to identify the most effective approach.
SUMMARY BACKGROUND DATA: The optimal treatment for resectable esophageal cancer is unknown.
METHODS: A search for randomized controlled trials reporting on neoadjuvant and adjuvant therapies was conducted. Using a network meta-analysis, treatments were ranked based on their effectiveness for improving survival.
RESULTS: In 33 eligible randomized controlled trials, 6072 patients were randomized to receive either surgery alone (N = 2459) or neoadjuvant CT (N = 1332), RT (N = 58), and CRT (N = 1196) followed by surgery or surgery followed by adjuvant CT (N = 542), RT (N = 383), and CRT (N = 102). Twenty-one comparisons were generated. Neoadjuvant CRT followed by surgery compared with surgery alone was the only treatment to significantly improve survival [hazard ratio (HR) = 0.77, 95\% confidence interval (CI): 0.68-0.87]. When trials were grouped considering neoadjuvant and adjuvant therapies and surgery alone, neoadjuvant therapies combined with surgery compared with surgery alone showed a survival advantage (HR = 0.83, 95\% CI 0.76-0.90), whereas surgery along with adjuvant therapies showed no significant survival advantage (HR = 0.87, 95\% CI 0.67-1.14). A subgroup analysis of neoadjuvant therapies showed a superior effectiveness of neoadjuvant CRT and surgery compared with surgery alone (HR = 0.77, 95\% CI 0.68-0.87).
CONCLUSIONS: This network meta-analysis showed neoadjuvant CRT followed by surgery to be the most effective strategy in improving survival of resectable esophageal cancer. Resources should be focused on developing the most effective neoadjuvant CRT regimens for both adenocarcinomas and squamous cell carcinomas of the esophagus.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgery},
	author = {Pasquali, Sandro and Yim, Guang and Vohra, Ravinder S. and Mocellin, Simone and Nyanhongo, Donald and Marriott, Paul and Geh, Ju Ian and Griffiths, Ewen A.},
	month = mar,
	year = {2017},
	pmid = {27429017},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Risk Assessment, Prognosis, Randomized Controlled Trials as Topic, Chemotherapy, Adjuvant, Survival Analysis, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Radiotherapy, Adjuvant, Network Meta-Analysis},
	pages = {481--491},
}

@article{orringer643,
	title = {Esophagectomy without thoracotomy},
	volume = {76},
	issn = {0022-5223},
	abstract = {Blunt esophagectomy without thoracotomy has been performed in 26 patients: four with benign disease and 22 with carcinomas involving various levels of the esophagus (10 cervicothoracic, one upper third, five middle third, and six distal third). Continuity of the alimentary tract was restored by anastomosing the pharynx or cervical esophagus either to stomach (19 patients) or to a colonic graft (seven patients). Esophageal resection and reconstruction were performed in a single stage in 25 patients, and the esophageal substitute was positioned in the posterior mediastinum in the original esophageal bed in 24 patients. There were no deaths directly related to the technique of blunt esophagectomy. Average intraoperative blood loss was 1,350 ml. for the entire group, 1,650 ml. for those requiring concomitant laryngectomy and 1,050 ml. for those undergoing esophagectomy without laryngectomy. Complications in these patients included pneumothorax (eight), transient hoarseness (five), pleural effusion (five), anastomotic leak (four), subphrenic abscess (one), and cerebrovascular accident (one). The five deaths were due to pheumonia (two), innominate artery rupture (two), and pulmonary embolus (one). Blunt esophagectomy without thoracotomy is safe and is far better tolerated physiologically than the combined transthoracic and abdominal operations more traditionally used for exophageal resection and reconstruction.},
	language = {eng},
	number = {5},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Orringer, M. B. and Sloan, H.},
	month = nov,
	year = {1978},
	pmid = {703369},
	keywords = {Humans, Follow-Up Studies, Adenocarcinoma, Esophageal Neoplasms, Postoperative Complications, Esophagus, Esophageal Diseases, Methods, Esophagoplasty},
	pages = {643--654},
}

@article{oppedijk385,
	title = {Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the {CROSS} trials},
	volume = {32},
	issn = {1527-7755},
	doi = {10.1200/JCO.2013.51.2186},
	abstract = {PURPOSE: To analyze recurrence patterns in patients with cancer of the esophagus or gastroesophageal junction treated with either preoperative chemoradiotherapy (CRT) plus surgery or surgery alone.
PATIENTS AND METHODS: Recurrence pattern was analyzed in patients from the previously published CROSS I and II trials in relation to radiation target volumes. CRT consisted of five weekly courses of paclitaxel and carboplatin combined with a concurrent radiation dose of 41.4 Gy in 1.8-Gy fractions to the tumor and pathologic lymph nodes with margin.
RESULTS: Of the 422 patients included from 2001 to 2008, 418 were available for analysis. Histology was mostly adenocarcinoma (75\%). Of the 374 patients who underwent resection, 86\% were allocated to surgery and 92\% to CRT plus surgery. On January 1, 2011, after a minimum follow-up of 24 months (median, 45 months), the overall recurrence rate in the surgery arm was 58\% versus 35\% in the CRT plus surgery arm. Preoperative CRT reduced locoregional recurrence (LRR) from 34\% to 14\% (P {\textless} .001) and peritoneal carcinomatosis from 14\% to 4\% (P {\textless} .001). There was a small but significant effect on hematogenous dissemination in favor of the CRT group (35\% v 29\%; P = .025). LRR occurred in 5\% within the target volume, in 2\% in the margins, and in 6\% outside the radiation target volume. In 1\%, the exact site in relation to the target volume was unclear. Only 1\% had an isolated infield recurrence after CRT plus surgery.
CONCLUSION: Preoperative CRT in patients with esophageal cancer reduced LRR and peritoneal carcinomatosis. Recurrence within the radiation target volume occurred in only 5\%, mostly combined with outfield failures.},
	language = {eng},
	number = {5},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Oppedijk, Vera and van der Gaast, Ate and van Lanschot, Jan J. B. and van Hagen, Pieter and van Os, Rob and van Rij, Caroline M. and van der Sangen, Maurice J. and Beukema, Jannet C. and Rütten, Heidi and Spruit, Patty H. and Reinders, Janny G. and Richel, Dick J. and van Berge Henegouwen, Mark I. and Hulshof, Maarten C. C. M.},
	month = feb,
	year = {2014},
	pmid = {24419108},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Kaplan-Meier Estimate, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, Time Factors, Adult, Chemotherapy, Adjuvant, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Dose Fractionation, Radiation, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Esophagogastric Junction, Paclitaxel, Gastrectomy, Multivariate Analysis, Carboplatin},
	pages = {385--391},
	file = {Submitted Version:/Users/jcsal/Zotero/storage/M4JZC4RT/Oppedijk et al. - 2014 - Patterns of recurrence after surgery alone versus .pdf:application/pdf},
}

@article{omloo992,
	title = {Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial},
	volume = {246},
	issn = {0003-4932},
	shorttitle = {Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus},
	doi = {10.1097/SLA.0b013e31815c4037},
	abstract = {OBJECTIVE: To determine whether extended transthoracic esophagectomy for adenocarcinoma of the mid/distal esophagus improves long-term survival.
BACKGROUND: A randomized trial was performed to compare surgical techniques. Complete 5-year survival data are now available.
METHODS: A total of 220 patients with adenocarcinoma of the distal esophagus (type I) or gastric cardia involving the distal esophagus (type II) were randomly assigned to limited transhiatal esophagectomy or to extended transthoracic esophagectomy with en bloc lymphadenectomy. Patients with peroperatively irresectable/incurable cancer were excluded from this analysis (n = 15). A total of 95 patients underwent transhiatal esophagectomy and 110 patients underwent transthoracic esophagectomy.
RESULTS: After transhiatal and transthoracic resection, 5-year survival was 34\% and 36\%, respectively (P = 0.71, per protocol analysis). In a subgroup analysis, based on the location of the primary tumor according to the resection specimen, no overall survival benefit for either surgical approach was seen in 115 patients with a type II tumor (P = 0.81). In 90 patients with a type I tumor, a survival benefit of 14\% was seen with the transthoracic approach (51\% vs. 37\%, P = 0.33). There was evidence that the treatment effect differed depending on the number of positive lymph nodes in the resection specimen (test for interaction P = 0.06). In patients (n = 55) without positive nodes locoregional disease-free survival after transhiatal esophagectomy was comparable to that after transthoracic esophagectomy (86\% and 89\%, respectively). The same was true for patients (n = 46) with more than 8 positive nodes (0\% in both groups). Patients (n = 104) with 1 to 8 positive lymph nodes in the resection specimen showed a 5-year locoregional disease-free survival advantage if operated via the transthoracic route (23\% vs. 64\%, P = 0.02).
CONCLUSION: There is no significant overall survival benefit for either approach. However, compared with limited transhiatal resection extended transthoracic esophagectomy for type I esophageal adenocarcinoma shows an ongoing trend towards better 5-year survival. Moreover, patients with a limited number of positive lymph nodes in the resection specimen seem to benefit from an extended transthoracic esophagectomy.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Omloo, Jikke M. T. and Lagarde, Sjoerd M. and Hulscher, Jan B. F. and Reitsma, Johannes B. and Fockens, Paul and van Dekken, Herman and Ten Kate, Fiebo J. W. and Obertop, Huug and Tilanus, Hugo W. and van Lanschot, J. Jan B.},
	month = dec,
	year = {2007},
	pmid = {18043101},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Time Factors, Survival Rate, Adult, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Laparotomy, Thoracotomy},
	pages = {992--1000; discussion 1000--1001},
}

@article{mckeown259,
	title = {Total three-stage oesophagectomy for cancer of the oesophagus},
	volume = {63},
	issn = {0007-1323},
	doi = {10.1002/bjs.1800630403},
	abstract = {The technique of total three-stage oesophagectomy is described fully. Points of detail in the procedure of the abdominal, thoracic and cervical phases are emphasized. A brief note is made regarding the management of the respiratory situation at the end of the operation.},
	language = {eng},
	number = {4},
	journal = {The British Journal of Surgery},
	author = {McKeown, K. C.},
	month = apr,
	year = {1976},
	pmid = {1276657},
	keywords = {Humans, Esophageal Neoplasms, Esophagus, Stomach, Methods},
	pages = {259--262},
}

@article{mackenzie88,
	title = {National proficiency-gain curves for minimally invasive gastrointestinal cancer surgery},
	volume = {103},
	issn = {1365-2168},
	doi = {10.1002/bjs.9963},
	abstract = {BACKGROUND: Minimal access surgery for gastrointestinal cancer has short-term benefits but is associated with a proficiency-gain curve. The aim of this study was to define national proficiency-gain curves for minimal access colorectal and oesophagogastric surgery, and to determine the impact on clinical outcomes.
METHODS: All adult patients undergoing minimal access oesophageal, colonic and rectal surgery between 2002 and 2012 were identified from the Hospital Episode Statistics database. Proficiency-gain curves were created using risk-adjusted cumulative sum analysis. Change points were identified, and bootstrapping was performed with 1000 iterations to identify a confidence level. The primary outcome was 30-day mortality; secondary outcomes were 90-day mortality, reintervention, conversion and length of hospital stay.
RESULTS: Some 1696, 15 008 and 16 701 minimal access oesophageal, rectal and colonic cancer resections were performed during the study period. The change point in the proficiency-gain curve for 30-day mortality for oesophageal, rectal and colonic surgery was 19 (confidence level 98·4 per cent), 20 (99·2 per cent) and three (99·5 per cent) procedures; the mortality rate fell from 4·0 to 2·0 per cent (relative risk reduction (RRR) 0·50, P = 0·033), from 2·1 to 1·2 per cent (RRR 0·43, P {\textless} 0·001) and from 2·4 to 1·8 per cent (RRR 0·25, P = 0·058) respectively. The change point in the proficiency-gain curve for reintervention in oesophageal, rectal and colonic resection was 19 (98·1 per cent), 32 (99·5 per cent) and 26 (99·2 per cent) procedures respectively. There were also significant proficiency-gain curves for 90-day mortality, conversion and length of stay.
CONCLUSION: The introduction of minimal access gastrointestinal cancer surgery has been associated with a proficiency-gain curve for mortality and major morbidity at a national level. Unnecessary patient harm should be avoided by appropriate training and monitoring of new surgical techniques.},
	language = {eng},
	number = {1},
	journal = {The British Journal of Surgery},
	author = {Mackenzie, H. and Markar, S. R. and Askari, A. and Ni, M. and Faiz, O. and Hanna, G. B.},
	month = jan,
	year = {2016},
	pmid = {26578089},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Length of Stay, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Adult, Colectomy, Esophagectomy, Gastrectomy, Learning Curve, Digestive System Surgical Procedures, Minimally Invasive Surgical Procedures, Clinical Competence, Conversion to Open Surgery, Rectum, United Kingdom},
	pages = {88--96},
}

@article{hollis1114,
	title = {Prognostic significance of tumor length in patients receiving esophagectomy for esophageal cancer},
	volume = {116},
	issn = {1096-9098},
	doi = {10.1002/jso.24789},
	abstract = {AIMS: We investigated the prognostic value of tumor length measurements acquired both from pre-operative imaging and post-operative pathology in esophageal cancer.
METHODS: Tumor lengths were examined retrospectively for 389 esophagectomy patients with respect to Endoscopy, EUS (Endoscopic Ultrasound), CT and PET-CT, and pathology. Correlations between the measurements on the different approaches were assessed, and associations between tumor length and survival were analyzed.
RESULTS: Only the tumor lengths assessed on pathology were found to be significantly associated with overall (P = 0.001) and recurrence free (P {\textless} 0.001) survival on univariable analysis. The median overall survival was 47.1 months in those patients with tumor lengths {\textless}3.0 cm, falling to 19.6 and 18.0 months in those with 3.0-4.4 and 4.5+ cm tumors, respectively, demonstrating a reduction in patient survival at a tumor length of around 3 cm. Tumor length on pathology was significantly correlated with tumor differentiation and both T- and N-categories. After accounting for these factors, tumor length on pathology was a significant independent predictor of recurrence-free (P = 0.016), but not overall (P = 0.128) survival.
CONCLUSIONS: Tumor lengths on pathology were found to be the most predictive of patient outcome. However, after accounting for other tumor-related factors, tumor length only resulted in a marginal improvement in predictive accuracy.},
	language = {eng},
	number = {8},
	journal = {Journal of Surgical Oncology},
	author = {Hollis, Alexander C. and Quinn, Lauren M. and Hodson, James and Evans, Emily and Plowright, James and Begum, Ruksana and Mitchell, Harriet and Hallissey, Mike T. and Whiting, John L. and Griffiths, Ewen A.},
	month = dec,
	year = {2017},
	pmid = {28767142},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Prognosis, survival, Esophageal Neoplasms, Esophagectomy, esophageal cancer, esophagectomy, Endosonography, recurrence, tumor length},
	pages = {1114--1122},
}

@article{cunningham11,
	title = {Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer},
	volume = {355},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa055531},
	abstract = {BACKGROUND: A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer.
METHODS: We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin (50 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (200 mg per square meter per day) for 21 days. The primary end point was overall survival.
RESULTS: ECF-related adverse effects were similar to those previously reported among patients with advanced gastric cancer. Rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. The resected tumors were significantly smaller and less advanced in the perioperative-chemotherapy group. With a median follow-up of four years, 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died. As compared with the surgery group, the perioperative-chemotherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 95 percent confidence interval, 0.60 to 0.93; P=0.009; five-year survival rate, 36 percent vs. 23 percent) and of progression-free survival (hazard ratio for progression, 0.66; 95 percent confidence interval, 0.53 to 0.81; P{\textless}0.001).
CONCLUSIONS: In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).},
	language = {eng},
	number = {1},
	journal = {The New England Journal of Medicine},
	author = {Cunningham, David and Allum, William H. and Stenning, Sally P. and Thompson, Jeremy N. and Van de Velde, Cornelis J. H. and Nicolson, Marianne and Scarffe, J. Howard and Lofts, Fiona J. and Falk, Stephen J. and Iveson, Timothy J. and Smith, David B. and Langley, Ruth E. and Verma, Monica and Weeden, Simon and Chua, Yu Jo and MAGIC Trial Participants, null},
	month = jul,
	year = {2006},
	pmid = {16822992},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Fluorouracil, Stomach Neoplasms, Adenocarcinoma, Cisplatin, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Gastrectomy, Epirubicin, Perioperative Care},
	pages = {11--20},
	file = {Submitted Version:/Users/jcsal/Zotero/storage/QRE45YL7/Cunningham et al. - 2006 - Perioperative chemotherapy versus surgery alone fo.pdf:application/pdf},
}

@article{hulscher1662,
	title = {Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus},
	volume = {347},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa022343},
	abstract = {BACKGROUND: Controversy exists about the best surgical treatment for esophageal carcinoma.
METHODS: We randomly assigned 220 patients with adenocarcinoma of the mid-to-distal esophagus or adenocarcinoma of the gastric cardia involving the distal esophagus either to transhiatal esophagectomy or to transthoracic esophagectomy with extended en bloc lymphadenectomy. Principal end points were overall survival and disease-free survival. Early morbidity and mortality, the number of quality-adjusted life-years gained, and cost effectiveness were also determined.
RESULTS: A total of 106 patients were assigned to undergo transhiatal esophagectomy, and 114 to undergo transthoracic esophagectomy. Demographic characteristics and characteristics of the tumor were similar in the two groups. Perioperative morbidity was higher after transthoracic esophagectomy, but there was no significant difference in in-hospital mortality (P=0.45). After a median follow-up of 4.7 years, 142 patients had died--74 (70 percent) after transhiatal resection and 68 (60 percent) after transthoracic resection (P=0.12). Although the difference in survival was not statistically significant, there was a trend toward a survival benefit with the extended approach at five years: disease-free survival was 27 percent in the transhiatal-esophagectomy group, as compared with 39 percent in the transthoracic-esophagectomy group (95 percent confidence interval for the difference, -1 to 24 percent [the negative value indicates better survival with transhiatal resection]), whereas overall survival was 29 percent as compared with 39 percent (95 percent confidence interval for the difference, -3 to 23 percent).
CONCLUSIONS: Transhiatal esophagectomy was associated with lower morbidity than transthoracic esophagectomy with extended en bloc lymphadenectomy. Although median overall, disease-free, and quality-adjusted survival did not differ statistically between the groups, there was a trend toward improved long-term survival at five years with the extended transthoracic approach.},
	language = {eng},
	number = {21},
	journal = {The New England Journal of Medicine},
	author = {Hulscher, Jan B. F. and van Sandick, Johanna W. and de Boer, Angela G. E. M. and Wijnhoven, Bas P. L. and Tijssen, Jan G. P. and Fockens, Paul and Stalmeier, Peep F. M. and ten Kate, Fiebo J. W. and van Dekken, Herman and Obertop, Huug and Tilanus, Hugo W. and van Lanschot, J. Jan B.},
	month = nov,
	year = {2002},
	pmid = {12444180},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Adult, Survival Analysis, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Cost-Benefit Analysis, Health Care Costs, Quality-Adjusted Life Years},
	pages = {1662--1669},
	file = {Full Text:/Users/jcsal/Zotero/storage/MBHERUZX/Hulscher et al. - 2002 - Extended transthoracic resection compared with lim.pdf:application/pdf},
}

@article{cao751,
	title = {Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract},
	volume = {41},
	issn = {1438-8812},
	doi = {10.1055/s-0029-1215053},
	abstract = {BACKGROUND AND STUDY AIMS: Endoscopic submucosal dissection (ESD) has been developed to overcome the limitations of endoscopic mucosal resection (EMR). We aimed to compare the outcomes of these two methods.
METHODS: Databases, including Pubmed, EMBASE, and The Cochrane Library, were searched to identify studies comparing ESD with EMR for premalignant and malignant lesions of the gastrointestinal tract. In a meta-analysis, primary end points were the en bloc resection rate and the curative resection rate; secondary end points were operation time, and rates of bleeding, perforation, and local recurrence.
RESULTS: 15 nonrandomized studies (seven full-text and eight abstracts) were identified. Meta-analysis showed higher en bloc and curative resection rates (odds ratio [OR] 13.87, 95 \%CI 10.12 - 18.99; OR 3.53, 95 \%CI 2.57 - 4.84) irrespective of lesion size. Subgroup analysis showed higher en bloc and curative resection rates with ESD for esophageal, gastric, and colorectal neoplasms, and for lesions of size {\textless} 10 mm, 10 mm {\textless} 20 mm, and {\textgreater} 20 mm. Local recurrence was lower with ESD (OR 0.09, 95 \%CI 0.04 - 0.18). But ESD was more time-consuming than EMR (weighted mean difference [WMD] 1.76; 95 \%CI 0.60 - 2.92), and showed high procedure-related bleeding and perforation rates (OR 2.20, 95 \%CI 1.58 - 3.07; OR 4.09, 95 \%CI 2.47 - 6.80).
CONCLUSIONS: ESD showed better en bloc and curative resection rates and local recurrence compared with EMR, but was more time-consuming and had higher rates of bleeding and perforation complications. These results need to be confirmed by high quality trials and further studies in the west.},
	language = {eng},
	number = {9},
	journal = {Endoscopy},
	author = {Cao, Y. and Liao, C. and Tan, A. and Gao, Y. and Mo, Z. and Gao, F.},
	month = sep,
	year = {2009},
	pmid = {19693750},
	keywords = {Humans, Gastrointestinal Neoplasms, Treatment Outcome, Adenocarcinoma, Neoplasm Recurrence, Local, Endoscopy, Gastrointestinal, Dissection, Electrocoagulation, Gastric Mucosa},
	pages = {751--757},
}

@article{bedenne1160,
	title = {Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: {FFCD} 9102},
	volume = {25},
	issn = {1527-7755},
	shorttitle = {Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus},
	doi = {10.1200/JCO.2005.04.7118},
	abstract = {PURPOSE: Uncontrolled studies suggest that chemoradiation has similar efficacy as surgery for esophageal cancer. Therefore, a randomized trial was carried out to compare, in responders only, chemoradiation alone with chemoradiation followed by surgery in patients with locally advanced tumors.
PATIENTS AND METHODS: Eligible patients had operable T3N0-1M0 thoracic esophageal cancer. Patients received two cycles of fluorouracil (FU) and cisplatin (days 1 to 5 and 22 to 26) and either conventional (46 Gy in 4.5 weeks) or split-course (15 Gy, days 1 to 5 and 22 to 26) concomitant radiotherapy. Patients with response and no contraindication to either treatment were randomly assigned to surgery (arm A) or continuation of chemoradiation (arm B; three cycles of FU/cisplatin and either conventional [20 Gy] or split-course [15 Gy] radiotherapy). Chemoradiation was considered equivalent to surgery if the difference in 2-year survival rate was less than 10\%.
RESULTS: Of 444 eligible patients, 259 were randomly assigned; 230 patients (88.8\%) had epidermoid cancer, and 29 (11.2\%) had glandular carcinoma. Two-year survival rate was 34\% in arm A versus 40\% in arm B (hazard ratio for arm B v arm A = 0.90; adjusted P = .44). Median survival time was 17.7 months in arm A compared with 19.3 months in arm B. Two-year local control rate was 66.4\% in arm A compared with 57.0\% in arm B, and stents were less required in the surgery arm (5\% in arm A v 32\% in arm B; P {\textless} .001). The 3-month mortality rate was 9.3\% in arm A compared with 0.8\% in arm B (P = .002). Cumulative hospital stay was 68 days in arm A compared with 52 days in arm B (P = .02).
CONCLUSION: Our data suggest that, in patients with locally advanced thoracic esophageal cancers, especially epidermoid, who respond to chemoradiation, there is no benefit for the addition of surgery after chemoradiation compared with the continuation of additional chemoradiation.},
	language = {eng},
	number = {10},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Bedenne, Laurent and Michel, Pierre and Bouché, Olivier and Milan, Chantal and Mariette, Christophe and Conroy, Thierry and Pezet, Denis and Roullet, Bernard and Seitz, Jean-François and Herr, Jean-Philippe and Paillot, Bernard and Arveux, Patrick and Bonnetain, Franck and Binquet, Christine},
	month = apr,
	year = {2007},
	pmid = {17401004},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Esophageal Neoplasms, Combined Modality Therapy, Radiotherapy Dosage, Radiotherapy, Positron-Emission Tomography, Quality of Life},
	pages = {1160--1168},
	file = {Submitted Version:/Users/jcsal/Zotero/storage/4U2Z558T/Bedenne et al. - 2007 - Chemoradiation followed by surgery compared with c.pdf:application/pdf},
}

@article{bang315,
	title = {Adjuvant capecitabine and oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC}): a phase 3 open-label, randomised controlled trial},
	volume = {379},
	issn = {1474-547X},
	shorttitle = {Adjuvant capecitabine and oxaliplatin for gastric cancer after {D2} gastrectomy ({CLASSIC})},
	doi = {10.1016/S0140-6736(11)61873-4},
	abstract = {BACKGROUND: D2 gastrectomy is recommended in US and European guidelines, and is preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy improves patient outcomes after surgery, but the benefits after a D2 resection have not been extensively investigated in large-scale trials. We investigated the effect on disease-free survival of adjuvant chemotherapy with capecitabine plus oxaliplatin after D2 gastrectomy compared with D2 gastrectomy only in patients with stage II-IIIB gastric cancer.
METHODS: The capecitabine and oxaliplatin adjuvant study in stomach cancer (CLASSIC) study was an open-label, parallel-group, phase 3, randomised controlled trial undertaken in 37 centres in South Korea, China, and Taiwan. Patients with stage II-IIIB gastric cancer who had had curative D2 gastrectomy were randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of oral capecitabine (1000 mg/m(2) twice daily on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m(2) on day 1 of each cycle) for 6 months or surgery only. Block randomisation was done by a central interactive computerised system, stratified by country and disease stage. Patients, and investigators giving interventions, assessing outcomes, and analysing data were not masked. The primary endpoint was 3 year disease-free survival, analysed by intention to treat. This study reports a prespecified interim efficacy analysis, after which the trial was stopped after a recommendation by the data monitoring committee. The trial is registered at ClinicalTrials.gov (NCT00411229).
FINDINGS: 1035 patients were randomised (520 to receive chemotherapy and surgery, 515 surgery only). Median follow-up was 34·2 months (25·4-41·7) in the chemotherapy and surgery group and 34·3 months (25·6-41·9) in the surgery only group. 3 year disease-free survival was 74\% (95\% CI 69-79) in the chemotherapy and surgery group and 59\% (53-64) in the surgery only group (hazard ratio 0·56, 95\% CI 0·44-0·72; p{\textless}0·0001). Grade 3 or 4 adverse events were reported in 279 of 496 patients (56\%) in the chemotherapy and surgery group and in 30 of 478 patients (6\%) in the surgery only group. The most common adverse events in the intervention group were nausea (n=326), neutropenia (n=300), and decreased appetite (n=294).
INTERPRETATION: Adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy should be considered as a treatment option for patients with operable gastric cancer.
FUNDING: F Hoffmann-La Roche and Sanofi-Aventis.},
	language = {eng},
	number = {9813},
	journal = {Lancet (London, England)},
	author = {Bang, Yung-Jue and Kim, Young-Woo and Yang, Han-Kwang and Chung, Hyun Cheol and Park, Young-Kyu and Lee, Kyung Hee and Lee, Keun-Wook and Kim, Yong Ho and Noh, Sang-Ik and Cho, Jae Yong and Mok, Young Jae and Kim, Yeul Hong and Ji, Jiafu and Yeh, Ta-Sen and Button, Peter and Sirzén, Florin and Noh, Sung Hoon and {CLASSIC trial investigators}},
	month = jan,
	year = {2012},
	pmid = {22226517},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Chemotherapy, Adjuvant, Fluorouracil, Organoplatinum Compounds, Stomach Neoplasms, Adenocarcinoma, Disease-Free Survival, Capecitabine, Deoxycytidine, Gastrectomy, Oxaliplatin},
	pages = {315--321},
}

@article{guttmann1131,
	title = {Improved {Overall} {Survival} with {Aggressive} {Primary} {Tumor} {Radiotherapy} for {Patients} with {Metastatic} {Esophageal} {Cancer}},
	volume = {12},
	issn = {1556-1380},
	doi = {10.1016/j.jtho.2017.03.026},
	abstract = {OBJECTIVES: The aim of this study was to characterize utilization and survival outcomes associated with primary tumor-directed radiotherapy (PTDRT) in patients with newly diagnosed metastatic esophageal cancer.
METHODS: We conducted an observational cohort study using the National Cancer Data Base to evaluate patients with newly diagnosed metastatic esophageal cancer between 2004 and 2012. Overall survival outcomes after treatment with chemotherapy plus conventional palliative dose radiotherapy ({\textless}5040 cGy), chemotherapy plus definitive dose radiotherapy (≥5040 cGy), or chemotherapy alone were compared by using Cox proportional hazards models with inverse probability of treatment weighting using the propensity score. Potential unmeasured confounding was assessed through sensitivity analyses.
RESULTS: The final cohort consisted of 12,683 patients: 57\% were treated with chemotherapy alone, 24\% were treated with chemotherapy plus palliative dose radiotherapy, and 19\% were treated with chemotherapy plus definitive dose radiotherapy. Compared with chemotherapy alone, chemotherapy plus definitive dose radiotherapy was associated with improved survival (median overall survival of 8.3 versus 11.3 months [hazard ratio = 0.72, 95\% confidence interval: 0.70-0.74, p ≤ 0.001]), whereas chemotherapy plus palliative dose radiotherapy was associated with slightly inferior outcomes (median overall survival of 8.3 months versus 7.5 months (hazard ratio = 1.10, 95\% confidence interval 1.07-1.13, p ≤ 0.001). These findings were robust to potential unmeasured confounding in sensitivity analyses. Additionally, landmark analyses confirmed these findings in patients surviving 12 months or longer.
CONCLUSIONS: Definitive dose, but not conventional palliative dose, PTDRT is associated with improved overall survival in metastatic esophageal cancer, suggesting that local control may be important to prognosis. These findings support integrating PTDRT into future clinical trials aimed at refining personalized treatment for patients with metastatic esophageal cancer.},
	language = {eng},
	number = {7},
	journal = {Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer},
	author = {Guttmann, David M. and Mitra, Nandita and Bekelman, Justin and Metz, James M. and Plastaras, John and Feng, Weiwei and Swisher-McClure, Samuel},
	month = jul,
	year = {2017},
	pmid = {28461255},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Metastasis, Cohort Studies, Aged, 80 and over, Survival Analysis, Esophageal Neoplasms, Radiotherapy, Esophageal neoplasms, Neoplasm metastasis, Palliative care, Radiation},
	pages = {1131--1142},
	file = {Full Text:/Users/jcsal/Zotero/storage/GJ9E6HED/Guttmann et al. - 2017 - Improved Overall Survival with Aggressive Primary .pdf:application/pdf},
}

@article{stahl851,
	title = {Phase {III} comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction},
	volume = {27},
	issn = {1527-7755},
	doi = {10.1200/JCO.2008.17.0506},
	abstract = {PURPOSE: Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma. Adding radiation therapy to preoperative chemotherapy appears promising, but its definitive value remains unknown.
PATIENTS AND METHODS: Patients with locally advanced (uT3-4NXM0) adenocarcinoma of the lower esophagus or gastric cardia were randomly allocated to one of two treatment groups: induction chemotherapy (15 weeks) followed by surgery (arm A); or chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B). Primary outcome was overall survival time. A total of 354 patients were needed to detect a 10\% increase in 3-year survival from 25\% to 35\% by addition of radiation therapy. The study was prematurely closed due to low accrual.
RESULTS: The median observation time was 46 months. A total of 126 patients were randomly assigned and 119 eligible patients were evaluated. The number of patients undergoing complete tumor resection was not different between treatment groups (69.5\% v 71.5\%). Patients in arm B had a significant higher probability of showing pathologic complete response (15.6\% v 2.0\%) or tumor-free lymph nodes (64.4\% v 37.7\%) at resection. Preoperative radiation therapy improved 3-year survival rate from 27.7\% to 47.4\% (log-rank P = .07, hazard ratio adjusted for randomization strata variables 0.67, 95\% CI, 0.41 to 1.07). Postoperative mortality was nonsignificantly increased in the chemoradiotherapy group (10.2\% v 3.8\%; P = .26).
CONCLUSION: Although the study was closed early and statistical significance was not achieved, results point to a survival advantage for preoperative chemoradiotherapy compared with preoperative chemotherapy in adenocarcinomas of the esophagogastric junction.},
	language = {eng},
	number = {6},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Stahl, Michael and Walz, Martin K. and Stuschke, Martin and Lehmann, Nils and Meyer, Hans-Joachim and Riera-Knorrenschild, Jorge and Langer, Peter and Engenhart-Cabillic, Rita and Bitzer, Michael and Königsrainer, Alfred and Budach, Wilfried and Wilke, Hansjochen},
	month = feb,
	year = {2009},
	pmid = {19139439},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Prospective Studies, Antineoplastic Agents, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Combined Modality Therapy, Esophagogastric Junction, Radiotherapy},
	pages = {851--856},
	file = {Submitted Version:/Users/jcsal/Zotero/storage/LY6ZPTBQ/Stahl et al. - 2009 - Phase III comparison of preoperative chemotherapy .pdf:application/pdf},
}

@article{kim403,
	title = {Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy},
	volume = {29},
	issn = {1527-1323},
	shorttitle = {Multimodality assessment of esophageal cancer},
	doi = {10.1148/rg.292085106},
	abstract = {Esophageal cancer is a leading cause of cancer mortality worldwide. Complete resection of esophageal cancer and adjacent malignant lymph nodes is the only potentially curative treatment. Accurate preoperative staging and assessment of therapeutic response after neoadjuvant therapy are crucial in determining the most suitable therapy and avoiding inappropriate attempts at curative surgery. Computed tomography (CT) is recommended for initial imaging following confirmation of malignancy at pathologic analysis, primarily to rule out unresectable or distant metastatic disease. With the advent of multidetector CT, use of thin sections and multiplanar reformation allows more accurate staging of esophageal cancer. Endoscopic ultrasonography (US) is the best modality for determining the depth of tumor invasion and presence of regional lymph node involvement. Combined use of fine-needle aspiration and endoscopic US can improve assessment of lymph node involvement. Positron emission tomography (PET) is useful for assessment of distant metastases but is not appropriate for detecting and staging primary tumors. PET may also be helpful in restaging after neoadjuvant therapy, since it allows identification of early response to treatment and detection of interval distant metastases. Each imaging modality has its advantages and disadvantages; therefore, CT, endoscopic US, and PET should be considered complementary modalities for preoperative staging and therapeutic monitoring of patients with esophageal cancer.},
	language = {eng},
	number = {2},
	journal = {Radiographics: A Review Publication of the Radiological Society of North America, Inc},
	author = {Kim, Tae Jung and Kim, Hyae Young and Lee, Kyung Won and Kim, Moon Soo},
	month = apr,
	year = {2009},
	pmid = {19325056},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Prognosis, Outcome Assessment, Health Care, Esophageal Neoplasms, Positron-Emission Tomography, Endosonography, Preoperative Care},
	pages = {403--421},
	file = {Full Text:/Users/jcsal/Zotero/storage/BQSG8IXG/Kim et al. - 2009 - Multimodality assessment of esophageal cancer pre.pdf:application/pdf},
}

@article{chatterton354,
	title = {Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study},
	volume = {36},
	issn = {1619-7089},
	shorttitle = {Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer},
	doi = {10.1007/s00259-008-0959-y},
	abstract = {OBJECTIVES: The aims of this study were (1) to determine the incremental information provided by (18)F-FDG positron emission tomography (PET) in staging patients with oesophageal cancer, and (2) to determine the impact of PET staging on post-PET clinical management of oesophageal cancer, and on prognosis.
METHODS: In a multicentre, single-arm open study, patients with proved oesophageal cancer without definite distant metastases and regarded as suitable for potentially curative treatment were examined by PET. Clinicians were requested to supply a management plan before and another plan after being supplied with the PET scan results. Patients were followed for at least 1 year for outcome analysis.
RESULTS: A total of 129 patients (104 men, mean age 67 y) were recruited. PET detected additional sites of disease in 53 patients (41\%). Significant changes in management (high or medium impact) were observed in 38\% of patients, primarily as a result of identifying additional sites of disease and/or confirming previously equivocal regional and distant metastases. Progression-free survival was significantly shorter in patients found to have additional lesions on PET (p {\textless} 0.05), but was not related to SUV(max).
CONCLUSION: These findings demonstrate the significant impact of PET on the clinical management of patients with newly diagnosed oesophageal carcinoma, and on prognostic stratification of these patients.},
	language = {eng},
	number = {3},
	journal = {European Journal of Nuclear Medicine and Molecular Imaging},
	author = {Chatterton, B. E. and Ho Shon, I. and Baldey, A. and Lenzo, N. and Patrikeos, A. and Kelley, B. and Wong, D. and Ramshaw, J. E. and Scott, A. M.},
	month = mar,
	year = {2009},
	pmid = {18931839},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Neoplasm Staging, Prospective Studies, Prognosis, Disease-Free Survival, Esophageal Neoplasms, Fluorodeoxyglucose F18, Radiopharmaceuticals, Positron-Emission Tomography, Fluorine Radioisotopes},
	pages = {354--361},
}

@article{vanvliet547,
	title = {Staging investigations for oesophageal cancer: a meta-analysis},
	volume = {98},
	issn = {0007-0920},
	shorttitle = {Staging investigations for oesophageal cancer},
	doi = {10.1038/sj.bjc.6604200},
	abstract = {The aim of the study was to compare the diagnostic performance of endoscopic ultrasonography (EUS), computed tomography (CT), and 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in staging of oesophageal cancer. PubMed was searched to identify English-language articles published before January 2006 and reporting on diagnostic performance of EUS, CT, and/or FDG-PET in oesophageal cancer patients. Articles were included if absolute numbers of true-positive, false-negative, false-positive, and true-negative test results were available or derivable for regional, celiac, and abdominal lymph node metastases and/or distant metastases. Sensitivities and specificities were pooled using a random effects model. Summary receiver operating characteristic analysis was performed to study potential effects of study and patient characteristics. Random effects pooled sensitivities of EUS, CT, and FDG-PET for regional lymph node metastases were 0.80 (95\% confidence interval 0.75-0.84), 0.50 (0.41-0.60), and 0.57 (0.43-0.70), respectively, and specificities were 0.70 (0.65-0.75), 0.83 (0.77-0.89), and 0.85 (0.76-0.95), respectively. Diagnostic performance did not differ significantly across these tests. For detection of celiac lymph node metastases by EUS, sensitivity and specificity were 0.85 (0.72-0.99) and 0.96 (0.92-1.00), respectively. For abdominal lymph node metastases by CT, these values were 0.42 (0.29-0.54) and 0.93 (0.86-1.00), respectively. For distant metastases, sensitivity and specificity were 0.71 (0.62-0.79) and 0.93 (0.89-0.97) for FDG-PET and 0.52 (0.33-0.71) and 0.91 (0.86-0.96) for CT, respectively. Diagnostic performance of FDG-PET for distant metastases was significantly higher than that of CT, which was not significantly affected by study and patient characteristics. The results suggest that EUS, CT, and FDG-PET each play a distinctive role in the detection of metastases in oesophageal cancer patients. For the detection of regional lymph node metastases, EUS is most sensitive, whereas CT and FDG-PET are more specific tests. For the evaluation of distant metastases, FDG-PET has probably a higher sensitivity than CT. Its combined use could however be of clinical value, with FDG-PET detecting possible metastases and CT confirming or excluding their presence and precisely determining the location(s).},
	language = {eng},
	number = {3},
	journal = {British Journal of Cancer},
	author = {van Vliet, E. P. M. and Heijenbrok-Kal, M. H. and Hunink, M. G. M. and Kuipers, E. J. and Siersema, P. D.},
	month = feb,
	year = {2008},
	pmid = {18212745},
	pmcid = {PMC2243147},
	keywords = {Humans, Tomography, X-Ray Computed, Neoplasm Staging, Neoplasm Metastasis, Esophageal Neoplasms, Fluorodeoxyglucose F18, Sensitivity and Specificity, Lymphatic Metastasis, Positron-Emission Tomography, Endosonography},
	pages = {547--557},
	file = {Full Text:/Users/jcsal/Zotero/storage/S2GH3SWG/van Vliet et al. - 2008 - Staging investigations for oesophageal cancer a m.pdf:application/pdf},
}

@article{markar1528,
	title = {Surgical {Proficiency} {Gain} and {Survival} {After} {Esophagectomy} for {Cancer}},
	volume = {34},
	issn = {1527-7755},
	doi = {10.1200/JCO.2015.65.2875},
	abstract = {PURPOSE: We aimed to identify the presence and length of esophagectomy proficiency gain curves in terms of short- and long-term mortality for esophageal cancer.
PATIENTS AND METHODS: Patients who underwent esophagectomy for esophageal cancer between 1987 and 2010 with follow-up until 2014 were identified from a well-established, population-based, nationwide Swedish cohort study. Proficiency gain curves were created by using risk-adjusted cumulative sum analysis for 30-day, 90-day, 1-year, 3-year, and 5-year all-cause and disease-specific mortality measures. Similarly, the proficiency gain curves for lymph node harvest, resection margin status, and reoperation incidence were assessed as performance-contributing factors to the observed changes in long-term survival.
RESULTS: Esophagectomies in 1,821 patients with esophageal cancer were conducted by 139 surgeons. The change-point in proficiency gain curve for all-cause 30-day mortality was early, at 15 cases, when mortality decreased from 7.9\% to 3.1\% (P {\textless} .001). Later change-points, which ranged from 35 to 59 cases, were observed for 1-, 3- and 5-year mortality rates, for which all-cause mortality decreased from 34.9\% to 27.7\% (P = .011), from 47.4\% to 41.5\% (P = .049), and from 31.4\% to 19.1\% (P = .009), respectively. Similar change-points were observed in disease-specific mortality at 1 and 3 years. There was a continuous increase in lymph node harvest, which did not plateau. Also, change-points were observed for resection margin with tumor involvement at 17 cases, with a reduction from 20.9\% to 15.2\% (P = .004), and for reoperation rate at 55 cases, with a reduction from 12.6\% to 5.0\% (P {\textless} .001).
CONCLUSION: The gain of proficiency in esophagectomy for cancer is associated with measurable changes in short- and long-term mortality results. These findings indicate a need for structured national training and mentorship programs for esophageal cancer surgery.},
	language = {eng},
	number = {13},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Markar, Sheraz R. and Mackenzie, Hugh and Lagergren, Pernilla and Hanna, George B. and Lagergren, Jesper},
	month = may,
	year = {2016},
	pmid = {26951311},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Cohort Studies, Aged, 80 and over, Adult, Young Adult, Esophageal Neoplasms, Esophagectomy, Registries, Adolescent, Sweden},
	pages = {1528--1536},
	file = {Full Text:/Users/jcsal/Zotero/storage/8BPPVD93/Markar et al. - 2016 - Surgical Proficiency Gain and Survival After Esoph.pdf:application/pdf},
}

@article{bennettCD007334,
	title = {Surgery versus radical endotherapies for early cancer and high-grade dysplasia in {Barrett}'s oesophagus},
	volume = {5},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD007334.pub5},
	abstract = {BACKGROUND: Barrett's oesophagus is one of the most common pre-malignant lesions in the world. Currently the mainstay of therapy is surgical management of advanced cancer but this has improved the five-year survival very little since the 1980s. As a consequence, improved survival relies on early detection through endoscopic surveillance programmes. Success of this strategy relies on the fact that late-stage pre-malignant lesions or very early cancers can be cured by intervention. Currently there is considerable controversy over which method is best: that is conventional open surgery or endotherapy (techniques involving endoscopy).
OBJECTIVES: We used data from randomised controlled trials (RCTs) to examine the effectiveness of endotherapies compared with surgery in people with Barrett's oesophagus, those with early neoplasias (defined as high-grade dysplasia (HGD) and those with early cancer (defined as carcinoma in-situ, superficially invasive, early cancer or superficial cancer T-1m (T1-a) and T-1sm (T1-b)).
SEARCH METHODS: We used the Cochrane highly sensitive search strategy to identify RCTs in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), ISI Web of Science, EBMR, Controlled Trials mRCT and ISRCTN, and LILACS, in July and August 2008. The searches were updated in 2009 and again in April 2012.
SELECTION CRITERIA: Types of studies: RCTs comparing endotherapies with surgery in the treatment of high-grade dysplasia or early cancer. All cellular types of cancer were included (i.e. adenocarcinomas, squamous cell carcinomas and more unusual types) but will be discussed separately.
TYPES OF PARTICIPANTS: patients of any age and either gender with a histologically confirmed diagnosis of early neoplasia (HGD and early cancer) in Barrett's or squamous lined oesophagus. Types of interventions; endotherapies (the intervention) compared with surgery (the control), all with curative intent.
DATA COLLECTION AND ANALYSIS: Reports of studies that meet the inclusion criteria for this review would have been analysed using the methods detailed in Appendix 9.
MAIN RESULTS: We did not identify any studies that met the inclusion criteria. In total we excluded 13 studies that were not RCTs but that compared surgery and endotherapies.
AUTHORS' CONCLUSIONS: This Cochrane review has indicated that there are no RCTs to compare management options in this vital area, therefore trials should be undertaken as a matter of urgency. The problems with such randomised methods are standardising surgery and endotherapies in all sites, standardising histopathology in all centres, assessing which patients are fit or unfit for surgery and making sure there are relevant outcomes for the study (i.e. long-term survival (over five or more years)) and no progression of HGD.},
	language = {eng},
	journal = {The Cochrane Database of Systematic Reviews},
	author = {Bennett, Cathy and Green, Susi and DeCaestecker, John and Almond, Max and Barr, Hugh and Bhandari, Pradeep and Ragunath, Krish and Singh, Rajvinder and Jankowski, Janusz},
	month = may,
	year = {2020},
	pmid = {32442322},
	pmcid = {PMC7390331},
	keywords = {Humans, Esophageal Neoplasms, Esophagoscopy, Barrett Esophagus, Precancerous Conditions},
	pages = {CD007334},
}

@article{pech1200,
	title = {Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in {Barrett}'s oesophagus},
	volume = {57},
	issn = {1468-3288},
	doi = {10.1136/gut.2007.142539},
	abstract = {OBJECTIVE: Endoscopic therapy is increasingly being used in the treatment of high-grade intraepithelial neoplasia (HGIN) and mucosal adenocarcinoma (BC) in patients with Barrett's oesophagus. This report provides 5 year follow-up data from a large prospective study investigating the efficacy and safety of endoscopic treatment in these patients and analysing risk factors for recurrence.
DESIGN: Prospective case series.
SETTING: Academic tertiary care centre.
PATIENTS: Between October 1996 and September 2002, 61 patients with HGIN and 288 with BC were included (173 with short-segment and 176 with long-segment Barrett's oesophagus) from a total of 486 patients presenting with Barrett's neoplasia. Patients with submucosal or more advanced cancer were excluded.
INTERVENTIONS: Endoscopic therapy.
MAIN OUTCOME MEASURES: Rate of complete remission and recurrence rate, tumour-associated death.
RESULTS: Endoscopic resection was performed in 279 patients, photodynamic therapy in 55, and both procedures in 13; two patients received argon plasma coagulation. The mean follow-up period was 63.6 (SD 23.1) months. Complete response (CR) was achieved in 337 patients (96.6\%); surgery was necessary in 13 (3.7\%) after endoscopic therapy failed. Metachronous lesions developed during the follow-up in 74 patients (21.5\%); 56 died of concomitant disease, but none died of BC. The calculated 5 year survival rate was 84\%. The risk factors most frequently associated with recurrence were piecemeal resection, long-segment Barrett's oesophagus, no ablative therapy of Barrett's oesophagus after CR, time until CR achieved {\textgreater}10 months and multifocal neoplasia.
CONCLUSIONS: This study showed that endoscopic therapy was highly effective and safe, with an excellent long-term survival rate. The risk factors identified may help stratify patients who are at risk for recurrence and those requiring more intensified follow-up.},
	language = {eng},
	number = {9},
	journal = {Gut},
	author = {Pech, O. and Behrens, A. and May, A. and Nachbar, L. and Gossner, L. and Rabenstein, T. and Manner, H. and Guenter, E. and Huijsmans, J. and Vieth, M. and Stolte, M. and Ell, C.},
	month = sep,
	year = {2008},
	pmid = {18460553},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Aged, 80 and over, Adult, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophagoscopy, Barrett Esophagus, Precancerous Conditions, Carcinoma in Situ, Epidemiologic Methods},
	pages = {1200--1206},
}

@article{crabtree1509,
	title = {Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival},
	volume = {91},
	issn = {1552-6259},
	shorttitle = {Endoscopic ultrasound for early stage esophageal adenocarcinoma},
	doi = {10.1016/j.athoracsur.2011.01.063},
	abstract = {BACKGROUND: Patients often receive induction therapy based on endoscopic ultrasound (EUS)-identified nodal spread (N1) or deep tumor invasion (T3), although controversy exists regarding the role of induction therapy for early stage disease. We aim to evaluate the reliability of EUS in identifying early stage disease and the subsequent impact on treatment and outcomes.
METHODS: We retrospectively studied 149 patients who underwent EUS and esophagectomy for adenocarcinoma between January 2000 and December 2008. Computed tomography (CT) was performed in all patients, whereas positron emission tomography (PET) was performed in 91\%. Clinical stage (c), pathologic stage (p), operative mortality, and survival were recorded.
RESULTS: Unanticipated pathologic nodal disease was similar in patients with cT1N0 and cT2N0 tumors (6/25 [24\%] versus 7/18 [38.8\%]; p=0.6). Among the 18 cases of cT2N0 disease, 9 (50\%) were pathologically staged as T1N0, 8 (44\%) were upstaged to pT3N0-1, and 1 (6\%) was pT2N0. One case of cT1N0 tumor (4\%) was upstaged to pT3N0. Among patients with cT1-2N0 tumors, 5-year disease-free survival for the group that was appropriately staged was 89.8\% versus 39.9\% for the group that had a higher pathologic stage than their clinical stage (ie, {\textgreater}T2N0) (p{\textless}0.001). Operative mortality for patients with cT1-2N0 tumors was 0/43 (0\%), which was no different from that in the higher clinical stage groups with (1/37, 2.7\%) or without (2/68, 2.9\%) induction therapy (p=0.5). Multivariate analysis identified marked/intense uptake on staging PET (odds ratio, 5.76, 95\%; confidence interval, 1.25 to 26.52; p=0.021) to be a factor predictive of upstaging of cT1-2N0 tumors.
CONCLUSIONS: Current staging techniques are inadequate for predicting T1-2N0 disease in esophageal adenocarcinoma. Survival is excellent with operation alone in patients with tumors appropriately staged as T1-2N0, although patients with tumors upstaged to greater than T2N0 have significantly worse survival. Other preoperative factors such as PET uptake may help select patients with cT1-2N0 tumors that will be upstaged at resection.},
	language = {eng},
	number = {5},
	journal = {The Annals of Thoracic Surgery},
	author = {Crabtree, Traves D. and Yacoub, Wael N. and Puri, Varun and Azar, Riad and Zoole, Jennifer Bell and Patterson, G. Alexander and Krupnick, A. Sasha and Kreisel, Daniel and Meyers, Bryan F.},
	month = may,
	year = {2011},
	pmid = {21435632},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Risk Assessment, Cohort Studies, Neoplasm Invasiveness, Survival Analysis, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Biopsy, Needle, Immunohistochemistry, Multivariate Analysis, Positron-Emission Tomography, Endosonography, Hospital Mortality, Odds Ratio, Confidence Intervals, Diagnostic Imaging},
	pages = {1509--1515; discussion 1515--1516},
}

@article{hardacker3739,
	title = {Treatment of clinical {T2N0M0} esophageal cancer},
	volume = {21},
	issn = {1534-4681},
	doi = {10.1245/s10434-014-3929-6},
	abstract = {BACKGROUND: Management of clinical T2N0M0 (cT2N0M0) esophageal cancer remains controversial. We reviewed our institutional experience over 21 years (1990-2011) to determine clinical staging accuracy, optimal treatment approaches, and factors predictive of survival in this patient population.
METHODS: Patients with cT2N0M0 esophageal cancer determined by endoscopic ultrasound (EUS) were identified through a prospectively collected database. Demographics, perioperative data, and outcomes were examined. Cox regression model and Kaplan-Meier plots were used for statistical survival analysis.
RESULTS: A total of 731 patients underwent esophagectomy, of whom 68 cT2N0M0 patients (9 \%) were identified. Fifty-seven patients (84 \%) had adenocarcinoma. Thirty-three patients (48.5 \%) were treated with neoadjuvant chemoradiation followed by surgery, and 35 underwent surgical resection alone. All resections except one included a transthoracic approach with two-field lymph node dissection. Thirty-day operative mortality was 2.9 \%. Only 3 patients (8.5 \%) who underwent surgery alone had T2N0M0 disease identified by pathology: the disease of 15 (42.8 \%) was found to be overstaged and 17 (48.5 \%) understaged after surgery. Understaging was more common in poorly differentiated tumors (p = 0.03). Nine patients (27.2 \%) had complete pathologic response after chemoradiotherapy. Absence of lymph node metastases (pN0) was significantly more frequent in the neoadjuvant group (29 of 33 vs. 21 of 35, p = 0.01). Median follow-up was 44.2 months. Overall 5-year survival was 50.8 \%. On multivariate analysis, adenocarcinoma (p = 0.001) and pN0 after resection (p = 0.01) were significant predictors of survival.
CONCLUSIONS: EUS was inaccurate in staging cT2N0M0 esophageal cancer in this study. Poorly differentiated tumors were more frequently understaged. Adenocarcinoma and absence of lymph node metastases (pN0) were independently predictive of long-term survival. pN0 status was significantly more common in patients undergoing neoadjuvant therapy, but long-term survival was not affected by neoadjuvant therapy. A strategy of neoadjuvant therapy followed by resection may be optimal in this group, especially in patients with disease likely to be understaged.},
	language = {eng},
	number = {12},
	journal = {Annals of Surgical Oncology},
	author = {Hardacker, Thomas J. and Ceppa, DuyKhanh and Okereke, Ikenna and Rieger, Karen M. and Jalal, Shadia I. and LeBlanc, Julia K. and DeWitt, John M. and Kesler, Kenneth A. and Birdas, Thomas J.},
	month = nov,
	year = {2014},
	pmid = {25047477},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Survival Rate, Prognosis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Lymphatic Metastasis, Lymph Node Excision, Radiotherapy, Endosonography},
	pages = {3739--3743},
}

@article{dolan320,
	title = {Significant understaging is seen in clinically staged {T2N0} esophageal cancer patients undergoing esophagectomy},
	volume = {29},
	issn = {1442-2050},
	doi = {10.1111/dote.12334},
	abstract = {This study aimed to determine the impact of preoperative staging on the treatment of clinical T2N0 (cT2N0) esophageal cancer patients undergoing esophagectomy. We reviewed a retrospective cohort of 27 patients treated at a single institution between 1999 and 2011. Clinical staging was performed with computed tomography, positron emission tomography, and endoscopic ultrasound. Patients were separated into two groups: neoadjuvant therapy followed by surgery (NEOSURG) and surgery alone (SURG). There were 11 patients (41\%) in the NEOSURG group and 16 patients (59\%) in the SURG group. In the NEOSURG group, three of 11 patients (27\%) had a pathological complete response and eight (73\%) were partial or nonresponders after neoadjuvant therapy. In the SURG group, nine of 16 patients (56\%) were understaged, 6 (38\%) were overstaged, and 1 (6\%) was correctly staged. In the entire cohort, despite being clinically node negative, 14 of 27 patients (52\%) had node-positive disease (5/11 [45\%] in the NEOSURG group, and 9/16 [56\%] in the SURG group). Overall survival rate was not statistically significant between the two groups (P = 0.96). Many cT2N0 patients are clinically understaged and show no preoperative evidence of node-positive disease. Consequently, neoadjuvant therapy may have a beneficial role in treatment.},
	language = {eng},
	number = {4},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Dolan, J. P. and Kaur, T. and Diggs, B. S. and Luna, R. A. and Sheppard, B. C. and Schipper, P. H. and Tieu, B. H. and Bakis, G. and Vaccaro, G. M. and Holland, J. M. and Gatter, K. M. and Conroy, M. A. and Thomas, C. A. and Hunter, J. G.},
	month = may,
	year = {2016},
	pmid = {25707341},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasm Staging, Survival Rate, Adult, chemotherapy, United States, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagectomy, Lymphatic Metastasis, Esophagoscopy, esophageal cancer, esophagectomy, Positron-Emission Tomography, neoadjuvant therapy, oesophageal cancer, Outcome and Process Assessment, Health Care, Preoperative Period, radiation therapy},
	pages = {320--325},
}

@article{markar59,
	title = {Role of neoadjuvant treatment in clinical {T2N0M0} oesophageal cancer: results from a retrospective multi-center {European} study},
	volume = {56},
	issn = {1879-0852},
	shorttitle = {Role of neoadjuvant treatment in clinical {T2N0M0} oesophageal cancer},
	doi = {10.1016/j.ejca.2015.11.024},
	abstract = {AIMS: The aims of this study were to compare short- and long-term outcomes for clinical T2N0 oesophageal cancer with analysis of (i) primary surgery (S) versus neoadjuvant therapy plus surgery (NS), (ii) squamous cell carcinoma and adenocarcinoma subsets; and (iii) neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy.
METHODS: Data were collected from 30 European centres from 2000 to 2010. Among 2944 included patients, 355 patients (12.1\%) had cT2N0 disease; 285 (S) and 70 (NS), were compared in terms of short- and long-term outcomes. Propensity score matching analyses were used to compensate for differences in baseline characteristics.
RESULTS: No significant differences between the groups were shown in terms of in hospital morbidity and mortality. Nodal disease was observed in 50\% of S-group at the time of surgery, with 20\% pN2/N3. Utilisation of neoadjuvant therapy was associated with significant tumour downstaging as reflected by increases in pT0, pN0 and pTNM stage 0 disease, this effect was further enhanced with neoadjuvant chemoradiotherapy. After adjustment on propensity score and confounding factors, for all patients and subset analysis of squamous cell and adenocarcinoma, neoadjuvant therapy had no significant effect upon survival or recurrence (overall, loco-regional, distant or mixed) compared to surgery alone. There were no significant differences between neoadjuvant chemotherapy and chemoradiotherapy in short- or long-term outcomes.
CONCLUSION: The results of this study suggest that a surgery alone treatment approach should be recommended as the primary treatment approach for cT2N0 oesophageal cancer despite 50\% of patients having nodal disease at the time of surgery.},
	language = {eng},
	journal = {European Journal of Cancer (Oxford, England: 1990)},
	author = {Markar, Sheraz R. and Gronnier, Caroline and Pasquer, Arnaud and Duhamel, Alain and Beal, Hélène and Théreaux, Jérémie and Gagnière, Johan and Lebreton, Gil and Brigand, Cécile and Meunier, Bernard and Collet, Denis and Mariette, Christophe and {FREGAT working group – FRENCH – AFC}},
	month = mar,
	year = {2016},
	pmid = {26808298},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Risk Factors, Time Factors, Chemotherapy, Adjuvant, Chi-Square Distribution, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Oesophageal cancer, Esophageal Squamous Cell Carcinoma, Incidence, Lymphatic Metastasis, Logistic Models, Surgery, cT2N0M0, Europe, Neoadjuvant treatment, Propensity Score, Review, Survival},
	pages = {59--68},
}

@article{xuAnalysisDefinitiveChemoradiotherapy2018,
	title = {Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on {CT} in a single institutional retrospective study: {A} propensity score matching analysis},
	volume = {13},
	issn = {1748-717X},
	shorttitle = {Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on {CT} in a single institutional retrospective study},
	doi = {10.1186/s13014-018-1145-4},
	abstract = {BACKGROUND: The prognostic value of supra-clavicular lymph node (SCLN) metastases in esophageal cancer (EC) is still not clear. METHOD: From January 2009 to December 2015, a survival analysis was performed to retrospectively identify the prognostic value of SCLN metastasis on survival on 751 patients with EC treated with definitive chemo-radiotherapy (dCRT). RESULTS: The median follow-up duration for living patients was 56.6 months. The median overall survival (OS) for all patients was 16.6 months. Patients with SCLN metastasis had a much poorer prognosis for OS (χ2 = 17.342, P {\textless} 0.001), distant metastasis-free survival (DMFS) (χ2 = 24.793, P {\textless} 0.001) and progression-free survival (PFS) (χ2 = 25.802, P {\textless} 0.001) than those without SCLN metastasis. The same results were found after propensity score matching. Nonetheless, the prognosis of patients with cervical or upper thoracic EC metastasis in SCLN was better than those of patients with middle or lower thoracic EC metastasis in SCLN for OS (χ2 = 4.516, P = 0.038), DMFS (χ2 = 8.326, P = 0.004) and PFS (χ2 = 6.255, P = 0.012). Univariate analysis showed that gender, middle or lower thoracic EC with SCLN metastasis, tumor length, tumor diameter, concurrent chemo-radiotherapy (CCR) and number of lymph nodes were prognostic factors for PFS. Gender, age, middle or lower thoracic EC with SCLN metastasis, tumor diameter, tumor length, and number of lymph nodes were prognostic factors for DMFS. According to the multivariate analysis, only middle or lower thoracic EC with SCLN metastasis and number of lymph nodes were independent prognostic factors for DMFS and PFS. CONCLUSION: For patients with cervical or upper thoracic EC, metastasis in SCLN should be considered to be regional lymph nodes and treated with curative intent if the total number of lymph nodes is limited. However, for patients with middle or lower thoracic EC, metastasis should be considered to be a higher level N stage or M1 stage, and it is thus necessary to provide consolidation chemotherapy after dCRT.},
	language = {English},
	number = {1},
	journal = {Radiation Oncology},
	author = {Xu, Hong-Yao and Wu, Sheng-Xi and Luo, He-San and Chen, Chu-Yun and Lin, Lian-Xing and Huang, He-Cheng},
	month = oct,
	year = {2018},
	pmid = {30326912},
	note = {tex.pmcid: PMC6192107},
	keywords = {Humans, Aged, Female, Male, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Esophageal Neoplasms, Chemoradiotherapy, Esophageal cancer, Lymphatic Metastasis, Lymph Nodes, Carcinoma, Clavicle, Definitive chemo-radiotherapy, Squamous Cell, Supra-clavicular lymph node, Tomography, X-Ray Computed},
	pages = {200},
	file = {Xu et al. - 2018 - Analysis of definitive chemo-radiotherapy for esop:/Users/jcsal/Zotero/storage/XMX7K26T/Xu et al. - 2018 - Analysis of definitive chemo-radiotherapy for esop.pdf:application/pdf},
}

@article{noordmanImpactSurgicalApproach2018,
	title = {Impact of {Surgical} {Approach} on {Long}-{Term} {Survival} in {Esophageal} {Adenocarcinoma} {Patients} {With} or {Without} {Neoadjuvant} {Chemoradiotherapy}},
	volume = {267},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000002240},
	abstract = {OBJECTIVE: To compare overall survival in patients with esophageal adenocarcinoma who underwent transhiatal esophagectomy (THE) with limited lymphadenectomy or transthoracic esophagectomy (TTE) with extended lymphadenectomy with or without neoadjuvant chemoradiotherapy (nCRT). BACKGROUND: The application of neoadjuvant therapy might change the association between the extent of lymphadenectomy and survival in patients with esophageal adenocarcinoma. This may influence the choice of surgical approach in patients treated with nCRT. METHODS: Patients with potentially curable subcarinal esophageal adenocarcinoma treated with surgery alone or nCRT followed by surgery in 7 centers were included. The effect of surgical approach on overall survival, differentiated by the addition or omission of nCRT, was analyzed using a multivariable Cox regression model that included well-known prognostic factors and factors that might have influenced the choice of surgical approach. RESULTS: In total, 701 patients were included, of whom 318 had TTE with extended lymphadenectomy and 383 had THE with limited lymphadenectomy. TTE had differential effects on survival (P for interaction = 0.02), with a more favorable prognostic effect in patients who were treated with surgery alone [hazard ratio (HR) = 0.77, 95\% confidence interval (CI) 0.58-1.03]. This association was statistically significant in a subgroup of patients with 1 to 8 positive lymph nodes in the resection specimen (HR = 0.62, 95\% CI 0.43-0.90). The favorable prognostic effect of TTE over THE was absent in the nCRT and surgery group (HR = 1.16, 95\% CI 0.80-1.66) and in the subgroup of nCRT patients with 1 to 8 positive lymph nodes in the resection specimen (HR = 1.00, 95\% CI 0.61-1.68). CONCLUSIONS: Compared to surgery alone, the addition of nCRT may reduce the need for TTE with extended lymphadenectomy to improve long-term survival in patients with esophageal adenocarcinoma.},
	language = {English},
	number = {5},
	journal = {Annals of Surgery},
	author = {Noordman, Bo Jan and van Klaveren, David and van Berge Henegouwen, Mark I. and Wijnhoven, Bas P. L. and Gisbertz, Suzanne S. and Lagarde, Sjoerd M. and van der Gaast, Ate and Hulshof, Maarten C. C. M. and Biermann, Katharina and Steyerberg, Ewout W. and van Lanschot, J. Jan B. and {also on behalf of the CROSS-study group}},
	month = may,
	year = {2018},
	pmid = {28350565},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Time Factors, Survival Rate, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Netherlands, Ultrasonography, Positron-Emission Tomography, Adjuvant},
	pages = {892--897},
}

@article{jordanNutritionalTherapyPatients2018,
	title = {Nutritional {Therapy} for {Patients} with {Esophageal} {Cancer}},
	volume = {70},
	issn = {1532-7914},
	doi = {10.1080/01635581.2017.1374417},
	abstract = {Malnutrition develops in 79\% patients with esophageal cancer. Thus, these patients represent a group of cancer patients, which is the most nutritionally compromised. Dysphagia and more than 10\% loss of body weight are already present at the time of diagnosis. Treatments for esophageal cancer contribute significantly to the development of malnutrition. This paper describes the nutritional treatment of patients and nutritional strategies in patients with dysphagia and other nutritional problems that accompany the treatment of patients with esophageal cancer. Here are shown the types and methods of nutritional support, which are suitable for this group of patients. Nutritional support of patients with esophageal cancer is performed as a parallel therapeutic route.},
	language = {English},
	number = {1},
	journal = {Nutrition and Cancer-an International Journal},
	author = {Jordan, Taja and Mastnak, Denis Mlakar and Palamar, Nizra and Kozjek, Nada Rotovnik},
	month = jan,
	year = {2018},
	pmid = {29016197},
	keywords = {Body Composition, Humans, Nutrition Assessment, Esophageal Neoplasms, Esophagectomy, Deglutition Disorders, Enteral Nutrition, Nutritional Status, Dietary Supplements, Nutritional Support, Parenteral Nutrition},
	pages = {23--29},
}

@article{honmaClinicalOutcomesResectable2017,
	title = {Clinical {Outcomes} of {Resectable} {Esophageal} {Cancer} with {Supraclavicular} {Lymph} {Node} {Metastases} {Treated} with {Curative} {Intent}},
	volume = {37},
	issn = {1791-7530},
	doi = {10.21873/anticanres.11748},
	abstract = {BACKGROUND: In the seventh edition of the Union for International Cancer Control (UICC) TNM classification, supraclavicular lymph node (SCLN) in regard to thoracic esophageal cancer (EC) is regarded as a distant organ, therefore, if resectable, SCLN metastasis is considered a candidate for systemic chemotherapy. The purpose of this study was to clarify the survival outcome in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated with curative intent. PATIENTS AND METHODS: Clinical outcomes in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated by esophagectomy or definitive chemoradiotherapy (dCRT) were retrospectively analyzed. RESULTS: A total of 102 patients were divided in three groups: Surgery with perioperative therapy, n=45; surgery alone, n=19; and dCRT, n=38. Overall, median progression-free survival and median survival time were 9.3 and 26.7 months, respectively. The median survival time was 27.5 months in the group treated with surgery with perioperative treatment, 50.6 months in those treated with surgery alone, and 22 months in the dCRT group. No significant survival difference was seen among the three groups. CONCLUSION: Over 30\% of patients with resectable M1LYM treated with curative intent achieved long-term survival.},
	language = {English},
	number = {7},
	journal = {Anticancer Research},
	author = {Honma, Yoshitaka and Hokamura, Nobukazu and Nagashima, Kengo and Sudo, Kazuki and Shoji, Hirokazu and Iwasa, Satoru and Takashima, Atsuo and Kato, Ken and Hamaguchi, Tetsuya and Boku, Narikazu and Umezawa, Rei and Ito, Yoshinori and Itami, Jun and Koyanagi, Kazuo and Igaki, Hiroyasu and Tachimori, Yuji},
	month = jul,
	year = {2017},
	pmid = {28668869},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Adult, Fluorouracil, Cisplatin, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Esophageal cancer, Lymphatic Metastasis, Lymph Nodes, 80 and over, Antimetabolites, Antineoplastic, chemoradiotherapy, supraclavicular lymph node metastases, surgery},
	pages = {3741--3749},
	file = {Honma et al. - 2017 - Clinical Outcomes of Resectable Esophageal Cancer:/Users/jcsal/Zotero/storage/WRQXFW6P/Honma et al. - 2017 - Clinical Outcomes of Resectable Esophageal Cancer .pdf:application/pdf},
}

@article{yuen,
	title = {Long-term pharyngeal dysphagia after esophagectomy for esophageal cancer-an investigation using videofluoroscopic swallow studies},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30085000},
	doi = {10.1093/dote/doy068},
	journal = {Dis Esophagus},
	author = {Yuen, M. T. Y. and Tsang, R. K. and Wong, I. Y. H. and Chan, D. K. K. and Chan, F. S. Y. and Law, S. Y. K.},
	year = {2018},
	note = {Type: Journal Article},
}

@article{yoshida346,
	title = {Original scoring system for predicting postoperative morbidity after esophagectomy for esophageal cancer},
	volume = {45},
	issn = {1436-2813 (Electronic) 0941-1291 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24997754},
	doi = {10.1007/s00595-014-0958-5},
	number = {3},
	journal = {Surg Today},
	author = {Yoshida, N. and Baba, Y. and Watanabe, M. and Ida, S. and Ishimoto, T. and Karashima, R. and Iwagami, S. and Imamura, Y. and Sakamoto, Y. and Miyamoto, Y. and Baba, H.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {346--54},
}

@article{yi-frazier51,
	title = {A {Person}-{Focused} {Analysis} of {Resilience} {Resources} and {Coping} in {Diabetes} {Patients}},
	volume = {26},
	issn = {1532-2998 (Electronic) 1532-3005 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20526415},
	number = {1},
	journal = {Stress Health},
	author = {Yi-Frazier, J. P. and Smith, R. E. and Vitaliano, P. P. and Yi, J. C. and Mai, S. and Hillman, M. and Weinger, K.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {51--60},
}

@article{yibulayin304,
	title = {Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis},
	volume = {14},
	issn = {1477-7819 (Electronic) 1477-7819 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27927246},
	doi = {10.1186/s12957-016-1062-7},
	number = {1},
	journal = {World J Surg Oncol},
	author = {Yibulayin, W. and Abulizi, S. and Lv, H. and Sun, W.},
	year = {2016},
	pmcid = {PMC5143462},
	pmid = {27927246},
	note = {tex.ids= yibulayin304a
type: Journal Article},
	keywords = {Humans, Length of Stay, Treatment Outcome, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Hospital Mortality, Mortality, Minimally Invasive Surgical Procedures, Odds Ratio, Complications, Blood Loss, Surgical, Minimally invasive esophagectomy, Open esophagectomy, Operative Time},
	pages = {304},
	file = {Yibulayin et al_2016_Minimally invasive oesophagectomy versus open esophagectomy for resectable.pdf:/Users/jcsal/Zotero/storage/BKTXVEV5/Yibulayin et al_2016_Minimally invasive oesophagectomy versus open esophagectomy for resectable.pdf:application/pdf},
}

@article{webster79,
	title = {The {Functional} {Assessment} of {Chronic} {Illness} {Therapy} ({FACIT}) {Measurement} {System}: properties, applications, and interpretation},
	volume = {1},
	issn = {1477-7525 (Electronic) 1477-7525 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/14678568},
	doi = {10.1186/1477-7525-1-79},
	journal = {Health Qual Life Outcomes},
	author = {Webster, K. and Cella, D. and Yost, K.},
	year = {2003},
	note = {Type: Journal Article},
	pages = {79},
}

@article{weiss304,
	title = {Validation of patient and nurse short forms of the {Readiness} for {Hospital} {Discharge} {Scale} and their relationship to return to the hospital},
	volume = {49},
	issn = {1475-6773 (Electronic) 0017-9124 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23855675},
	doi = {10.1111/1475-6773.12092},
	number = {1},
	journal = {Health Serv Res},
	author = {Weiss, M. E. and Costa, L. L. and Yakusheva, O. and Bobay, K. L.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {304--17},
}

@article{weeks321,
	title = {Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial},
	volume = {287},
	issn = {0098-7484 (Print) 0098-7484 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11790211},
	number = {3},
	journal = {JAMA},
	author = {Weeks, J. C. and Nelson, H. and Gelber, S. and Sargent, D. and Schroeder, G. and Clinical Outcomes of Surgical Therapy Study, Group},
	year = {2002},
	note = {Type: Journal Article},
	pages = {321--8},
}

@article{watanabe160,
	title = {Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer},
	volume = {15},
	issn = {1612-9067 (Electronic) 1612-9059 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29951987},
	doi = {10.1007/s10388-018-0617-9},
	number = {3},
	journal = {Esophagus},
	author = {Watanabe, M. and Okamura, A. and Toihata, T. and Yamashita, K. and Yuda, M. and Hayami, M. and Fukudome, I. and Imamura, Y. and Mine, S.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {160--164},
}

@article{wang2053,
	title = {Validation and application of a module of the {M}. {D}. {Anderson} {Symptom} {Inventory} for measuring multiple symptoms in patients with gastrointestinal cancer (the {MDASI}-{GI})},
	volume = {116},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20166216},
	doi = {10.1002/cncr.24920},
	number = {8},
	journal = {Cancer},
	author = {Wang, X. S. and Williams, L. A. and Eng, C. and Mendoza, T. R. and Shah, N. A. and Kirkendoll, K. J. and Shah, P. K. and Trask, P. C. and Palos, G. R. and Cleeland, C. S.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {2053--63},
}

@article{watson421,
	title = {Jejunostomy at the time of esophagectomy is associated with improved short-term perioperative outcomes: analysis of the {NSQIP} database},
	volume = {11},
	issn = {2078-6891 (Print) 2078-6891 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32399282},
	doi = {10.21037/jgo.2020.02.06},
	number = {2},
	journal = {J Gastrointest Oncol},
	author = {Watson, M. and Trufan, S. and Benbow, J. H. and Gower, N. L. and Hill, J. and Salo, J. C.},
	year = {2020},
	pmcid = {PMC7212114},
	pmid = {32399282},
	note = {tex.ids= watson421a
type: Journal Article},
	keywords = {Jejunostomy},
	pages = {421--430},
	file = {Watson et al_2020_Jejunostomy at the time of esophagectomy is associated with improved short-term.pdf:/Users/jcsal/Zotero/storage/NDYWXZCF/Watson et al_2020_Jejunostomy at the time of esophagectomy is associated with improved short-term.pdf:application/pdf},
}

@article{walston1173,
	title = {Frailty and the older man},
	volume = {83},
	issn = {0025-7125 (Print) 0025-7125 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10503059},
	number = {5},
	journal = {Med Clin North Am},
	author = {Walston, J. and Fried, L. P.},
	year = {1999},
	note = {Type: Journal Article},
	pages = {1173--94},
}

@article{wagnild165,
	title = {Development and psychometric evaluation of the {Resilience} {Scale}},
	volume = {1},
	issn = {1061-3749 (Print) 1061-3749 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/7850498},
	number = {2},
	journal = {J Nurs Meas},
	author = {Wagnild, G. M. and Young, H. M.},
	year = {1993},
	note = {Type: Journal Article},
	pages = {165--78},
}

@incollection{walvekar,
	edition = {2nd edition},
	title = {Complications of {Percutaneous} {Gastrostomy}},
	booktitle = {Complications in {Head} and {Neck} {Surgery} ({Second} {Edition})},
	publisher = {Elsevier B.V.},
	author = {Walvekar, Rohan R. and Ferris, Robert L.},
	editor = {Eisele, David W. and Smith, Richard V.},
	year = {2009},
	doi = {10.1016/B978-1-4160-4220-4.X5001-9},
	note = {Type: Book Section},
}

@article{vondobelne53,
	title = {Pulmonary function and cardiac stress test after multimodality treatment of esophageal cancer},
	volume = {6},
	issn = {1879-8519 (Electronic) 1879-8500 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26725962},
	doi = {10.1016/j.prro.2015.10.015},
	number = {3},
	journal = {Pract Radiat Oncol},
	author = {von Dobeln, G. A. and Nilsson, M. and Adell, G. and Johnsen, G. and Hatlevoll, I. and Tsai, J. and Lundell, L. and Lund, M. and Lind, P.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {e53--e59},
}

@article{vanveer600,
	title = {Validation of a new approach for mortality risk assessment in oesophagectomy for cancer based on age- and gender-corrected body mass index},
	volume = {48},
	issn = {1873-734X (Electronic) 1010-7940 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25564215},
	doi = {10.1093/ejcts/ezu503},
	number = {4},
	journal = {Eur J Cardiothorac Surg},
	author = {Van Veer, H. and Moons, J. and Darling, G. and Lerut, T. and Coosemans, W. and Waddell, T. and De Leyn, P. and Nafteux, P.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {600--7},
}

@article{vanheijl23,
	title = {Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer},
	volume = {17},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19830496},
	doi = {10.1245/s10434-009-0731-y},
	number = {1},
	journal = {Ann Surg Oncol},
	author = {van Heijl, M. and Sprangers, M. A. and de Boer, A. G. and Lagarde, S. M. and Reitsma, H. B. and Busch, O. R. and Tilanus, H. W. and van Lanschot, J. J. and van Berge Henegouwen, M. I.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {23--30},
}

@article{vanblarigan218,
	title = {Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors ({Smart} {Pace}): a pilot randomized controlled trial},
	volume = {19},
	issn = {1471-2407 (Electronic) 1471-2407 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30866859},
	doi = {10.1186/s12885-019-5427-5},
	number = {1},
	journal = {BMC Cancer},
	author = {Van Blarigan, E. L. and Chan, H. and Van Loon, K. and Kenfield, S. A. and Chan, J. M. and Mitchell, E. and Zhang, L. and Paciorek, A. and Joseph, G. and Laffan, A. and Atreya, C. E. and Fukuoka, Y. and Miaskowski, C. and Meyerhardt, J. A. and Venook, A. P.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {218},
}

@article{tisdale301,
	title = {Amiodarone for prevention of atrial fibrillation following esophagectomy},
	volume = {158},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30853230},
	doi = {10.1016/j.jtcvs.2019.01.095},
	number = {1},
	journal = {J Thorac Cardiovasc Surg},
	author = {Tisdale, J. E. and Jaynes, H. A. and Watson, M. R. and Corya, A. L. and Shen, C. and Kesler, K. A.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {301--310 e1},
}

@article{teoh1,
	title = {Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial},
	volume = {253},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21233603},
	doi = {10.1097/SLA.0b013e3181fcd991},
	number = {1},
	journal = {Ann Surg},
	author = {Teoh, A. Y. and Yan Chiu, P. W. and Wong, T. C. and Liu, S. Y. and Hung Wong, S. K. and Ng, E. K.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {1--5},
}

@article{then55,
	title = {Esophageal {Cancer}: {An} {Updated} {Surveillance} {Epidemiology} and {End} {Results} {Database} {Analysis}},
	volume = {11},
	issn = {1920-454X (Electronic) 1920-4531 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32284773},
	doi = {10.14740/wjon1254},
	number = {2},
	journal = {World J Oncol},
	author = {Then, E. O. and Lopez, M. and Saleem, S. and Gayam, V. and Sunkara, T. and Culliford, A. and Gaduputi, V.},
	year = {2020},
	note = {Type: Journal Article},
	pages = {55--64},
}

@article{tevis505,
	title = {Postdischarge complications are an important predictor of postoperative readmissions},
	volume = {208},
	issn = {1879-1883 (Electronic) 0002-9610 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25150195},
	doi = {10.1016/j.amjsurg.2014.05.013},
	number = {4},
	journal = {Am J Surg},
	author = {Tevis, S. E. and Kohlnhofer, B. M. and Weber, S. M. and Kennedy, G. D.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {505--10},
}

@article{tatematsu47,
	title = {Association between physical activity and postoperative complications after esophagectomy for cancer: a prospective observational study},
	volume = {14},
	issn = {2476-762X (Electronic) 1513-7368 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23534776},
	doi = {10.7314/apjcp.2013.14.1.47},
	number = {1},
	journal = {Asian Pac J Cancer Prev},
	author = {Tatematsu, N. and Park, M. and Tanaka, E. and Sakai, Y. and Tsuboyama, T.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {47--51},
}

@article{taioli377,
	title = {Quality of {Life} after {Open} or {Minimally} {Invasive} {Esophagectomy} in {Patients} {With} {Esophageal} {Cancer}-{A} {Systematic} {Review}},
	volume = {29},
	issn = {1532-9488 (Electronic) 1043-0679 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28939239},
	doi = {10.1053/j.semtcvs.2017.08.013},
	number = {3},
	journal = {Semin Thorac Cardiovasc Surg},
	author = {Taioli, E. and Schwartz, R. M. and Lieberman-Cribbin, W. and Moskowitz, G. and van Gerwen, M. and Flores, R.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {377--390},
}

@article{stein383,
	title = {Was {This} {Readmission} {Preventable}? {Qualitative} {Study} of {Patient} and {Provider} {Perceptions} of {Readmissions}},
	volume = {109},
	issn = {1541-8243 (Electronic) 0038-4348 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27255098},
	doi = {10.14423/SMJ.0000000000000465},
	number = {6},
	journal = {South Med J},
	author = {Stein, J. and Ossman, P. and Viera, A. and Moore, C. and Brubaker, B. A. and French, J. and Liles, E. A.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {383--9},
}

@article{sun852,
	title = {Wireless {Monitoring} {Program} of {Patient}-{Centered} {Outcomes} and {Recovery} {Before} and {After} {Major} {Abdominal} {Cancer} {Surgery}},
	volume = {152},
	issn = {2168-6262 (Electronic) 2168-6254 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28593266},
	doi = {10.1001/jamasurg.2017.1519},
	number = {9},
	journal = {JAMA Surg},
	author = {Sun, V. and Dumitra, S. and Ruel, N. and Lee, B. and Melstrom, L. and Melstrom, K. and Woo, Y. and Sentovich, S. and Singh, G. and Fong, Y.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {852--859},
}

@article{stewart199,
	title = {A systematic review of resilience in the physically ill},
	volume = {52},
	issn = {1545-7206 (Electronic) 0033-3182 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21565591},
	doi = {10.1016/j.psym.2011.01.036},
	number = {3},
	journal = {Psychosomatics},
	author = {Stewart, D. E. and Yuen, T.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {199--209},
}

@article{steffens510,
	title = {Is preoperative physical activity level of patients undergoing cancer surgery associated with postoperative outcomes? {A} systematic review and meta-analysis},
	volume = {45},
	issn = {1532-2157 (Electronic) 0748-7983 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30910052},
	doi = {10.1016/j.ejso.2018.10.063},
	number = {4},
	journal = {Eur J Surg Oncol},
	author = {Steffens, D. and Beckenkamp, P. R. and Young, J. and Solomon, M. and da Silva, T. M. and Hancock, M. J.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {510--518},
}

@article{splaingard637,
	title = {Aspiration in rehabilitation patients: videofluoroscopy vs bedside clinical assessment},
	volume = {69},
	issn = {0003-9993 (Print) 0003-9993 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/3408337},
	number = {8},
	journal = {Arch Phys Med Rehabil},
	author = {Splaingard, M. L. and Hutchins, B. and Sulton, L. D. and Chaudhuri, G.},
	year = {1988},
	note = {Type: Journal Article},
	pages = {637--40},
}

@article{smithe74373,
	title = {Skill set or mind set? {Associations} between health literacy, patient activation and health},
	volume = {8},
	issn = {1932-6203 (Electronic) 1932-6203 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24023942},
	doi = {10.1371/journal.pone.0074373},
	number = {9},
	journal = {PLoS One},
	author = {Smith, S. G. and Curtis, L. M. and Wardle, J. and von Wagner, C. and Wolf, M. S.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {e74373},
}

@article{siegel7,
	title = {Cancer statistics, 2020},
	volume = {70},
	issn = {1542-4863 (Electronic) 0007-9235 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31912902},
	doi = {10.3322/caac.21590},
	number = {1},
	journal = {CA Cancer J Clin},
	author = {Siegel, R. L. and Miller, K. D. and Jemal, A.},
	year = {2020},
	note = {Type: Journal Article},
	pages = {7--30},
}

@article{shaker1314,
	title = {Rehabilitation of swallowing by exercise in tube-fed patients with pharyngeal dysphagia secondary to abnormal {UES} opening},
	volume = {122},
	issn = {0016-5085 (Print) 0016-5085 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11984518},
	number = {5},
	journal = {Gastroenterology},
	author = {Shaker, R. and Easterling, C. and Kern, M. and Nitschke, T. and Massey, B. and Daniels, S. and Grande, B. and Kazandjian, M. and Dikeman, K.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {1314--21},
}

@article{shewale1114,
	title = {Impact of a {Fast}-track {Esophagectomy} {Protocol} on {Esophageal} {Cancer} {Patient} {Outcomes} and {Hospital} {Charges}},
	volume = {261},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25243545},
	doi = {10.1097/SLA.0000000000000971},
	number = {6},
	journal = {Ann Surg},
	author = {Shewale, J. B. and Correa, A. M. and Baker, C. M. and Villafane-Ferriol, N. and Hofstetter, W. L. and Jordan, V. S. and Kehlet, H. and Lewis, K. M. and Mehran, R. J. and Summers, B. L. and Schaub, D. and Wilks, S. A. and Swisher, S. G. and University of Texas, M. D. Anderson Esophageal Cancer Collaborative Group},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1114--23},
}

@article{shapiro807,
	title = {Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer},
	volume = {260},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25379852},
	doi = {10.1097/SLA.0000000000000966},
	number = {5},
	journal = {Ann Surg},
	author = {Shapiro, J. and van Hagen, P. and Lingsma, H. F. and Wijnhoven, B. P. and Biermann, K. and ten Kate, F. J. and Steyerberg, E. W. and van der Gaast, A. and van Lanschot, J. J. and Group, Cross Study},
	year = {2014},
	note = {Type: Journal Article},
	pages = {807--13; discussion 813--4},
}

@article{seder1646,
	title = {The {Society} of {Thoracic} {Surgeons} {General} {Thoracic} {Surgery} {Database} {Update} on {Outcomes} and {Quality}},
	volume = {101},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27041451},
	doi = {10.1016/j.athoracsur.2016.02.099},
	number = {5},
	journal = {Ann Thorac Surg},
	author = {Seder, C. W. and Wright, C. D. and Chang, A. C. and Han, J. M. and McDonald, D. and Kozower, B. D.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1646--54},
}

@article{scarpa156,
	title = {Sleep disturbances and quality of life in postoperative management after esophagectomy for esophageal cancer},
	volume = {12},
	issn = {1477-7819 (Electronic) 1477-7819 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24886219},
	doi = {10.1186/1477-7819-12-156},
	journal = {World J Surg Oncol},
	author = {Scarpa, M. and Pinto, E. and Saadeh, L. M. and Parotto, M. and Da Roit, A. and Pizzolato, E. and Alfieri, R. and Cagol, M. and Saraceni, E. and Baratto, F. and Castoro, C.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {156},
}

@article{sato1008,
	title = {Impact of preoperative hand grip strength on morbidity following gastric cancer surgery},
	volume = {19},
	issn = {1436-3305 (Electronic) 1436-3291 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26466832},
	doi = {10.1007/s10120-015-0554-4},
	number = {3},
	journal = {Gastric Cancer},
	author = {Sato, T. and Aoyama, T. and Hayashi, T. and Segami, K. and Kawabe, T. and Fujikawa, H. and Yamada, T. and Yamamoto, N. and Oshima, T. and Rino, Y. and Masuda, M. and Ogata, T. and Cho, H. and Yoshikawa, T.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1008--15},
}

@article{salo188,
	title = {{ASO} {Author} {Reflections}: {Quality} {Improvement} in {Minimally} {Invasive} {Esophagectomy}},
	volume = {26},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30478633},
	doi = {10.1245/s10434-018-7079-0},
	number = {1},
	journal = {Ann Surg Oncol},
	author = {Salo, J. C.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {188--189},
}

@article{rockwood17,
	title = {Frailty defined by deficit accumulation and geriatric medicine defined by frailty},
	volume = {27},
	issn = {1879-8853 (Electronic) 0749-0690 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21093719},
	doi = {10.1016/j.cger.2010.08.008},
	number = {1},
	journal = {Clin Geriatr Med},
	author = {Rockwood, K. and Mitnitski, A.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {17--26},
}

@article{rutten630,
	title = {Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer},
	volume = {8},
	issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28513088},
	doi = {10.1002/jcsm.12180},
	number = {4},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Rutten, I. J. G. and Ubachs, J. and Kruitwagen, Rfpm and Beets-Tan, R. G. H. and Olde Damink, S. W. M. and Van Gorp, T.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {630--638},
}

@article{rosenberg337,
	title = {Sarcopenia: origins and clinical relevance},
	volume = {27},
	issn = {1879-8853 (Electronic) 0749-0690 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21824550},
	doi = {10.1016/j.cger.2011.03.003},
	number = {3},
	journal = {Clin Geriatr Med},
	author = {Rosenberg, I. H.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {337--9},
}

@article{rosenbek93,
	title = {A penetration-aspiration scale},
	volume = {11},
	issn = {0179-051X (Print) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8721066},
	number = {2},
	journal = {Dysphagia},
	author = {Rosenbek, J. C. and Robbins, J. A. and Roecker, E. B. and Coyle, J. L. and Wood, J. L.},
	year = {1996},
	note = {Type: Journal Article},
	pages = {93--8},
}

@article{rice317,
	title = {{T2N0M0} esophageal cancer},
	volume = {133},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17258554},
	doi = {10.1016/j.jtcvs.2006.09.023},
	number = {2},
	journal = {J Thorac Cardiovasc Surg},
	author = {Rice, T. W. and Mason, D. P. and Murthy, S. C. and Zuccaro, G., Jr. and Adelstein, D. J. and Rybicki, L. A. and Blackstone, E. H.},
	year = {2007},
	note = {Type: Journal Article},
	pages = {317--24},
}

@article{rice1953,
	title = {Posterior {Intercostal} {Nerve} {Block} {With} {Liposomal} {Bupivacaine}: {An} {Alternative} to {Thoracic} {Epidural} {Analgesia}},
	volume = {99},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25912739},
	doi = {10.1016/j.athoracsur.2015.02.074},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Rice, D. C. and Cata, J. P. and Mena, G. E. and Rodriguez-Restrepo, A. and Correa, A. M. and Mehran, R. J.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1953--60},
}

@article{reichert11856,
	title = {Ivor {Lewis} esophagectomy patients are particularly vulnerable to respiratory impairment - a comparison to major lung resection},
	volume = {9},
	issn = {2045-2322 (Electronic) 2045-2322 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/31413282},
	doi = {10.1038/s41598-019-48234-w},
	number = {1},
	journal = {Sci Rep},
	author = {Reichert, M. and Schistek, M. and Uhle, F. and Koch, C. and Bodner, J. and Hecker, M. and Horbelt, R. and Grau, V. and Padberg, W. and Weigand, M. A. and Hecker, A.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {11856},
}

@article{redelmeier1278,
	title = {Interpreting small differences in functional status: the {Six} {Minute} {Walk} test in chronic lung disease patients},
	volume = {155},
	issn = {1073-449X (Print) 1073-449X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9105067},
	doi = {10.1164/ajrccm.155.4.9105067},
	number = {4},
	journal = {Am J Respir Crit Care Med},
	author = {Redelmeier, D. A. and Bayoumi, A. M. and Goldstein, R. S. and Guyatt, G. H.},
	year = {1997},
	note = {Type: Journal Article},
	pages = {1278--82},
}

@article{raymond207,
	title = {Predictors of {Major} {Morbidity} or {Mortality} {After} {Resection} for {Esophageal} {Cancer}: {A} {Society} of {Thoracic} {Surgeons} {General} {Thoracic} {Surgery} {Database} {Risk} {Adjustment} {Model}},
	volume = {102},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27240449},
	doi = {10.1016/j.athoracsur.2016.04.055},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Raymond, D. P. and Seder, C. W. and Wright, C. D. and Magee, M. J. and Kosinski, A. S. and Cassivi, S. D. and Grogan, E. L. and Blackmon, S. H. and Allen, M. S. and Park, B. J. and Burfeind, W. R. and Chang, A. C. and DeCamp, M. M. and Wormuth, D. W. and Fernandez, F. G. and Kozower, B. D.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {207--14},
}

@article{raber-durlacher433,
	title = {Swallowing dysfunction in cancer patients: {Dysphagia} {Section}, {Oral} {Care} {Study} {Group} {Multinational} {Association} of {Supportive} {Care} in {Cancer} {International} {Society} of {Oral} {Oncology}},
	volume = {20},
	issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22205548},
	doi = {10.1007/s00520-011-1342-2},
	number = {3},
	journal = {Support Care Cancer},
	author = {Raber-Durlacher, J. E. and Brennan, M. T. and Verdonck-de Leeuw, I. M. and Gibson, R. J. and Eilers, J. G. and Waltimo, T. and Bots, C. P. and Michelet, M. and Sollecito, T. P. and Rouleau, T. S. and Sewnaik, A. and Bensadoun, R. J. and Fliedner, M. C. and Silverman, S., Jr. and Spijkervet, F. K.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {433--43},
}

@article{prado2920,
	title = {Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment},
	volume = {15},
	issn = {1078-0432 (Print) 1078-0432 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/19351764},
	doi = {10.1158/1078-0432.CCR-08-2242},
	number = {8},
	journal = {Clin Cancer Res},
	author = {Prado, C. M. and Baracos, V. E. and McCargar, L. J. and Reiman, T. and Mourtzakis, M. and Tonkin, K. and Mackey, J. R. and Koski, S. and Pituskin, E. and Sawyer, M. B.},
	year = {2009},
	note = {Type: Journal Article},
	pages = {2920--6},
}

@article{porteous139,
	title = {A standardized anesthetic and surgical clinical pathway for esophageal resection: impact on length of stay and major outcomes},
	volume = {40},
	issn = {1532-8651 (Electronic) 1098-7339 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25658034},
	doi = {10.1097/AAP.0000000000000197},
	number = {2},
	journal = {Reg Anesth Pain Med},
	author = {Porteous, G. H. and Neal, J. M. and Slee, A. and Schmidt, H. and Low, D. E.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {139--49},
}

@article{persinger1632,
	title = {Consistency of the talk test for exercise prescription},
	volume = {36},
	issn = {0195-9131 (Print) 0195-9131 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15354048},
	number = {9},
	journal = {Med Sci Sports Exerc},
	author = {Persinger, R. and Foster, C. and Gibson, M. and Fater, D. C. and Porcari, J. P.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {1632--6},
}

@article{phua488,
	title = {Patients with gastro-oesophageal reflux disease and cough have impaired laryngopharyngeal mechanosensitivity},
	volume = {60},
	issn = {0040-6376 (Print) 0040-6376 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15923249},
	doi = {10.1136/thx.2004.033894},
	number = {6},
	journal = {Thorax},
	author = {Phua, S. Y. and McGarvey, L. P. and Ngu, M. C. and Ing, A. J.},
	year = {2005},
	note = {Type: Journal Article},
	pages = {488--91},
}

@article{pennathurS2159,
	title = {Technique of minimally invasive {Ivor} {Lewis} esophagectomy},
	volume = {89},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20494002},
	doi = {10.1016/j.athoracsur.2010.03.069},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Pennathur, A. and Awais, O. and Luketich, J. D.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {S2159--62},
}

@article{park13,
	title = {Prognostic value of preoperative total psoas muscle area on long-term outcome in surgically treated oesophageal cancer patients},
	volume = {24},
	issn = {1569-9285 (Electronic) 1569-9285 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27587471},
	doi = {10.1093/icvts/ivw274},
	number = {1},
	journal = {Interact Cardiovasc Thorac Surg},
	author = {Park, S. Y. and Yoon, J. K. and Lee, S. J. and Haam, S. and Jung, J.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {13--19},
}

@article{peng439,
	title = {Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis},
	volume = {13},
	issn = {1477-2574 (Electronic) 1365-182X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21689226},
	doi = {10.1111/j.1477-2574.2011.00301.x},
	number = {7},
	journal = {HPB (Oxford)},
	author = {Peng, P. D. and van Vledder, M. G. and Tsai, S. and de Jong, M. C. and Makary, M. and Ng, J. and Edil, B. H. and Wolfgang, C. L. and Schulick, R. D. and Choti, M. A. and Kamel, I. and Pawlik, T. M.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {439--46},
}

@article{participants156,
	title = {Shall we operate? {Preoperative} assessment in elderly cancer patients ({PACE}) can help. {A} {SIOG} surgical task force prospective study},
	volume = {65},
	issn = {1040-8428 (Print) 1040-8428 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18082416},
	doi = {10.1016/j.critrevonc.2007.11.001},
	number = {2},
	journal = {Crit Rev Oncol Hematol},
	author = {participants, Pace and Audisio, R. A. and Pope, D. and Ramesh, H. S. and Gennari, R. and van Leeuwen, B. L. and West, C. and Corsini, G. and Maffezzini, M. and Hoekstra, H. J. and Mobarak, D. and Bozzetti, F. and Colledan, M. and Wildiers, H. and Stotter, A. and Capewell, A. and Marshall, E.},
	year = {2008},
	note = {Type: Journal Article},
	pages = {156--63},
}

@article{palazzo1683,
	title = {Minimally invasive esophagectomy with extracorporeal gastric conduit creation–how {I} do it},
	volume = {17},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23835730},
	doi = {10.1007/s11605-013-2272-8},
	number = {9},
	journal = {J Gastrointest Surg},
	author = {Palazzo, F. and Evans, N. R., 3rd and Rosato, E. L.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {1683--8},
}

@article{palanivelu7,
	title = {Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position–experience of 130 patients},
	volume = {203},
	issn = {1072-7515 (Print) 1072-7515 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16798482},
	doi = {10.1016/j.jamcollsurg.2006.03.016},
	number = {1},
	journal = {J Am Coll Surg},
	author = {Palanivelu, C. and Prakash, A. and Senthilkumar, R. and Senthilnathan, P. and Parthasarathi, R. and Rajan, P. S. and Venkatachlam, S.},
	year = {2006},
	note = {Type: Journal Article},
	pages = {7--16},
}

@article{okumura543,
	title = {Functional outcome assessment of swallowing ({FOAMS}) scoring and videofluoroscopic evaluation of perioperative swallowing rehabilitation in radical esophagectomy},
	volume = {46},
	issn = {1436-2813 (Electronic) 0941-1291 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26077288},
	doi = {10.1007/s00595-015-1203-6},
	number = {5},
	journal = {Surg Today},
	author = {Okumura, T. and Shimada, Y. and Watanabe, T. and Nakamichi, N. and Nagata, T. and Tsukada, K.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {543--51},
}

@article{nishigori678,
	title = {Sarcopenia as a predictor of pulmonary complications after esophagectomy for thoracic esophageal cancer},
	volume = {113},
	issn = {1096-9098 (Electronic) 0022-4790 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26936808},
	doi = {10.1002/jso.24214},
	number = {6},
	journal = {J Surg Oncol},
	author = {Nishigori, T. and Okabe, H. and Tanaka, E. and Tsunoda, S. and Hisamori, S. and Sakai, Y.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {678--84},
}

@incollection{oxenberg29,
	address = {London},
	title = {Prevention and {Management} of {Complications} from {Esophagectomy}},
	booktitle = {Esophageal {Cancer} and {Beyond}},
	publisher = {IntechOpen},
	author = {Oxenberg, Jacqueline},
	editor = {Chai, Jianyuan},
	year = {2018},
	note = {Type: Book Section},
	pages = {29--47},
}

@article{nguyen253,
	title = {Minimally invasive intrathoracic esophagogastric anastomosis: circular stapler technique with transoral placement of the anvil},
	volume = {22},
	issn = {1532-9488 (Electronic) 1043-0679 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21167461},
	doi = {10.1053/j.semtcvs.2010.10.012},
	number = {3},
	journal = {Semin Thorac Cardiovasc Surg},
	author = {Nguyen, N. T. and Nguyen, X. M. and Masoomi, H.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {253--5},
}

@article{nanson340,
	title = {Synchronous combined abdomino- thoraco-cervical (oesophagectomy)},
	volume = {45},
	issn = {0004-8682 (Print) 0004-8682 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1061553},
	number = {4},
	journal = {Aust N Z J Surg},
	author = {Nanson, E. M.},
	year = {1975},
	note = {Type: Journal Article},
	pages = {340--8},
}

@article{nagamatsu1064,
	title = {Preoperative evaluation of cardiopulmonary reserve with the use of expired gas analysis during exercise testing in patients with squamous cell carcinoma of the thoracic esophagus},
	volume = {121},
	issn = {0022-5223 (Print) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11385372},
	doi = {10.1067/mtc.2001.113596},
	number = {6},
	journal = {J Thorac Cardiovasc Surg},
	author = {Nagamatsu, Y. and Shima, I. and Yamana, H. and Fujita, H. and Shirouzu, K. and Ishitake, T.},
	year = {2001},
	note = {Type: Journal Article},
	pages = {1064--8},
}

@article{mulligan313,
	title = {Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit},
	volume = {30},
	issn = {0748-7983 (Print) 0748-7983 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15028315},
	doi = {10.1016/j.ejso.2003.11.009},
	number = {3},
	journal = {Eur J Surg Oncol},
	author = {Mulligan, E. D. and Dunne, B. and Griffin, M. and Keeling, N. and Reynolds, J. V.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {313--7},
}

@article{moyes125,
	title = {Cardiopulmonary exercise testing as a predictor of complications in oesophagogastric cancer surgery},
	volume = {95},
	issn = {1478-7083 (Electronic) 0035-8843 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23484995},
	doi = {10.1308/003588413X13511609954897},
	number = {2},
	journal = {Ann R Coll Surg Engl},
	author = {Moyes, L. H. and McCaffer, C. J. and Carter, R. C. and Fullarton, G. M. and Mackay, C. K. and Forshaw, M. J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {125--30},
}

@article{motz,
	title = {Minimally {Invasive} {Ivor} {Lewis} {Esophagectomy} {Without} {Patient} {Repositioning}},
	issn = {1873-4626 (Electronic) 1091-255X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30623378},
	doi = {10.1007/s11605-018-4063-8},
	journal = {J Gastrointest Surg},
	author = {Motz, B. M. and Lorimer, P. D. and Boselli, D. and Symanowski, J. T. and Reames, M. K. and Hill, J. S. and Salo, J. C.},
	year = {2019},
	note = {Type: Journal Article},
}

@article{mendoza1186,
	title = {The rapid assessment of fatigue severity in cancer patients: use of the {Brief} {Fatigue} {Inventory}},
	volume = {85},
	issn = {0008-543X (Print) 0008-543X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10091805},
	number = {5},
	journal = {Cancer},
	author = {Mendoza, T. R. and Wang, X. S. and Cleeland, C. S. and Morrissey, M. and Johnson, B. A. and Wendt, J. K. and Huber, S. L.},
	year = {1999},
	note = {Type: Journal Article},
	pages = {1186--96},
}

@article{morley392,
	title = {Frailty consensus: a call to action},
	volume = {14},
	issn = {1538-9375 (Electronic) 1525-8610 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23764209},
	doi = {10.1016/j.jamda.2013.03.022},
	number = {6},
	journal = {J Am Med Dir Assoc},
	author = {Morley, J. E. and Vellas, B. and van Kan, G. A. and Anker, S. D. and Bauer, J. M. and Bernabei, R. and Cesari, M. and Chumlea, W. C. and Doehner, W. and Evans, J. and Fried, L. P. and Guralnik, J. M. and Katz, P. R. and Malmstrom, T. K. and McCarter, R. J. and Gutierrez Robledo, L. M. and Rockwood, K. and von Haehling, S. and Vandewoude, M. F. and Walston, J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {392--7},
}

@article{mitchell325,
	title = {Health literacy and 30-day postdischarge hospital utilization},
	volume = {17 Suppl 3},
	issn = {1087-0415 (Electronic) 1081-0730 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23030580},
	doi = {10.1080/10810730.2012.715233},
	journal = {J Health Commun},
	author = {Mitchell, S. E. and Sadikova, E. and Jack, B. W. and Paasche-Orlow, M. K.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {325--38},
}

@article{mehrane595,
	title = {Pain {Management} in an {Enhanced} {Recovery} {Pathway} {After} {Thoracic} {Surgical} {Procedures}},
	volume = {102},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27847094},
	doi = {10.1016/j.athoracsur.2016.05.050},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Mehran, R. J. and Martin, L. W. and Baker, C. M. and Mena, G. E. and Rice, D. C.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {e595--e596},
}

@article{mattioli255,
	title = {Patient position for a synchronous cervicothoracoabdominal two-team esophagectomy},
	volume = {63},
	issn = {0003-4975 (Print) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8993287},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Mattioli, S. and D'Ovidio, F. and Di Simone, M. P. and Lazzari, A. and Paladini, R. and Begliomini, B.},
	year = {1997},
	note = {Type: Journal Article},
	pages = {255--7},
}

@article{martin-harris136,
	title = {Clinical utility of the modified barium swallow},
	volume = {15},
	issn = {0179-051X (Print) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10839826},
	doi = {10.1007/s004550010015},
	number = {3},
	journal = {Dysphagia},
	author = {Martin-Harris, B. and Logemann, J. A. and McMahon, S. and Schleicher, M. and Sandidge, J.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {136--41},
}

@article{martin1,
	title = {The association of swallowing dysfunction and aspiration pneumonia},
	volume = {9},
	issn = {0179-051X (Print) 0179-051X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8131418},
	doi = {10.1007/BF00262751},
	number = {1},
	journal = {Dysphagia},
	author = {Martin, B. J. and Corlew, M. M. and Wood, H. and Olson, D. and Golopol, L. A. and Wingo, M. and Kirmani, N.},
	year = {1994},
	note = {Type: Journal Article},
	pages = {1--6},
}

@article{markar250,
	title = {Systematic review and pooled analysis assessing the association between elderly age and outcome following surgical resection of esophageal malignancy},
	volume = {26},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22591068},
	doi = {10.1111/j.1442-2050.2012.01353.x},
	number = {3},
	journal = {Dis Esophagus},
	author = {Markar, S. R. and Karthikesalingam, A. and Thrumurthy, S. and Ho, A. and Muallem, G. and Low, D. E.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {250--62},
}

@article{mariette2416,
	title = {Surgery alone versus chemoradiotherapy followed by surgery for stage {I} and {II} esophageal cancer: final analysis of randomized controlled phase {III} trial {FFCD} 9901},
	volume = {32},
	issn = {1527-7755 (Electronic) 0732-183X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24982463},
	doi = {10.1200/JCO.2013.53.6532},
	number = {23},
	journal = {J Clin Oncol},
	author = {Mariette, C. and Dahan, L. and Mornex, F. and Maillard, E. and Thomas, P. A. and Meunier, B. and Boige, V. and Pezet, D. and Robb, W. B. and Le Brun-Ly, V. and Bosset, J. F. and Mabrut, J. Y. and Triboulet, J. P. and Bedenne, L. and Seitz, J. F.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {2416--22},
}

@article{maeda515,
	title = {Sarcopenia is an independent risk factor of dysphagia in hospitalized older people},
	volume = {16},
	issn = {1447-0594 (Electronic) 1447-0594 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25807861},
	doi = {10.1111/ggi.12486},
	number = {4},
	journal = {Geriatr Gerontol Int},
	author = {Maeda, K. and Akagi, J.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {515--21},
}

@article{lorimer177,
	title = {Quality {Improvement} in {Minimally} {Invasive} {Esophagectomy}: {Outcome} {Improvement} {Through} {Data} {Review}},
	volume = {26},
	issn = {1534-4681 (Electronic) 1068-9265 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30382434},
	doi = {10.1245/s10434-018-6938-z},
	number = {1},
	journal = {Ann Surg Oncol},
	author = {Lorimer, P. D. and Motz, B. M. and Boselli, D. M. and Reames, M. K. and Hill, J. S. and Salo, J. C.},
	year = {2019},
	note = {Type: Journal Article},
	pages = {177--187},
}

@article{luketich95,
	title = {Outcomes after minimally invasive esophagectomy: review of over 1000 patients},
	volume = {256},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22668811},
	doi = {10.1097/SLA.0b013e3182590603},
	number = {1},
	journal = {Ann Surg},
	author = {Luketich, J. D. and Pennathur, A. and Awais, O. and Levy, R. M. and Keeley, S. and Shende, M. and Christie, N. A. and Weksler, B. and Landreneau, R. J. and Abbas, G. and Schuchert, M. J. and Nason, K. S.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {95--103},
}

@article{luketich486,
	title = {Minimally invasive esophagectomy: outcomes in 222 patients},
	volume = {238},
	issn = {0003-4932 (Print) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/14530720},
	doi = {10.1097/01.sla.0000089858.40725.68},
	number = {4},
	journal = {Ann Surg},
	author = {Luketich, J. D. and Alvelo-Rivera, M. and Buenaventura, P. O. and Christie, N. A. and McCaughan, J. S. and Litle, V. R. and Schauer, P. R. and Close, J. M. and Fernando, H. C.},
	year = {2003},
	note = {Type: Journal Article},
	pages = {486--94; discussion 494--5},
}

@article{lin1107,
	title = {Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies},
	volume = {29},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26542065},
	doi = {10.1111/dote.12432},
	number = {8},
	journal = {Dis Esophagus},
	author = {Lin, G. and Han, S. Y. and Xu, Y. P. and Mao, W. M.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1107--1114},
}

@article{lakenman652,
	title = {Handgrip {Strength} {Is} {Associated} {With} {Treatment} {Modifications} {During} {Neoadjuvant} {Chemoradiation} in {Patients} {With} {Esophageal} {Cancer}},
	volume = {32},
	issn = {1941-2452 (Electronic) 0884-5336 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28459652},
	doi = {10.1177/0884533617700862},
	number = {5},
	journal = {Nutr Clin Pract},
	author = {Lakenman, P. and Ottens-Oussoren, K. and Witvliet-van Nierop, J. and van der Peet, D. and de van der Schueren, M.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {652--657},
}

@article{laboratories111,
	title = {{ATS} statement: guidelines for the six-minute walk test},
	volume = {166},
	issn = {1073-449X (Print) 1073-449X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12091180},
	doi = {10.1164/ajrccm.166.1.at1102},
	number = {1},
	journal = {Am J Respir Crit Care Med},
	author = {Laboratories, A. T. S. Committee on Proficiency Standards for Clinical Pulmonary Function},
	year = {2002},
	note = {Type: Journal Article},
	pages = {111--7},
}

@article{kuwano328,
	title = {Gastric involvement of oesophageal squamous cell carcinoma},
	volume = {79},
	issn = {0007-1323 (Print) 0007-1323 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1576500},
	number = {4},
	journal = {Br J Surg},
	author = {Kuwano, H. and Baba, K. and Ikebe, M. and Kitamura, K. and Adachi, Y. and Mori, M. and Sugimachi, K.},
	year = {1992},
	note = {Type: Journal Article},
	pages = {328--30},
}

@article{kukreja242,
	title = {Patient-{Reported} {Outcomes} {Are} {Associated} {With} {Enhanced} {Recovery} {Status} in {Patients} {With} {Bladder} {Cancer} {Undergoing} {Radical} {Cystectomy}},
	volume = {25},
	issn = {1553-3514 (Electronic) 1553-3506 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29557251},
	doi = {10.1177/1553350618764218},
	number = {3},
	journal = {Surg Innov},
	author = {Kukreja, J. B. and Shi, Q. and Chang, C. M. and Seif, M. A. and Sterling, B. M. and Chen, T. Y. and Creel, K. M. and Kamat, A. M. and Dinney, C. P. and Navai, N. and Shah, J. B. and Wang, X. S.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {242--250},
}

@article{koh480,
	title = {Functional assessment of the cervical esophagus after gastric transposition and cervical esophagogastrostomy},
	volume = {25},
	issn = {1010-7940 (Print) 1010-7940 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15037258},
	doi = {10.1016/j.ejcts.2003.12.034},
	number = {4},
	journal = {Eur J Cardiothorac Surg},
	author = {Koh, P. and Turnbull, G. and Attia, E. and LeBrun, P. and Casson, A. G.},
	year = {2004},
	note = {Type: Journal Article},
	pages = {480--5},
}

@article{kim207,
	title = {Does the timing of esophagectomy after chemoradiation affect outcome?},
	volume = {93},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21962263},
	doi = {10.1016/j.athoracsur.2011.05.021},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Kim, J. Y. and Correa, A. M. and Vaporciyan, A. A. and Roth, J. A. and Mehran, R. J. and Walsh, G. L. and Rice, D. C. and Ajani, J. A. and Maru, D. M. and Bhutani, M. S. and Welsh, J. and Marom, E. M. and Swisher, S. G. and Hofstetter, W. L.},
	year = {2012},
	note = {Type: Journal Article},
	pages = {207--12; discussion 212--3},
}

@article{khalil2013,
	title = {Operative {Intercostal} {Nerve} {Blocks} {With} {Long}-{Acting} {Bupivacaine} {Liposome} for {Pain} {Control} {After} {Thoracotomy}},
	volume = {100},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26507422},
	doi = {10.1016/j.athoracsur.2015.08.017},
	number = {6},
	journal = {Ann Thorac Surg},
	author = {Khalil, K. G. and Boutrous, M. L. and Irani, A. D. and Miller, C. C., 3rd and Pawelek, T. R. and Estrera, A. L. and Safi, H. J.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {2013--8},
}

@article{kelsen1979,
	title = {Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer},
	volume = {339},
	issn = {0028-4793 (Print) 0028-4793 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/9869669},
	doi = {10.1056/NEJM199812313392704},
	number = {27},
	journal = {N Engl J Med},
	author = {Kelsen, D. P. and Ginsberg, R. and Pajak, T. F. and Sheahan, D. G. and Gunderson, L. and Mortimer, J. and Estes, N. and Haller, D. G. and Ajani, J. and Kocha, W. and Minsky, B. D. and Roth, J. A.},
	year = {1998},
	note = {Type: Journal Article},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Treatment Failure},
	pages = {1979--84},
}

@article{kawata,
	title = {Multidisciplinary team management for prevention of pneumonia and long-term weight loss after esophagectomy: a single-center retrospective study},
	issn = {1612-9067 (Electronic) 1612-9059 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32026048},
	doi = {10.1007/s10388-020-00721-0},
	journal = {Esophagus},
	author = {Kawata, S. and Hiramatsu, Y. and Shirai, Y. and Watanabe, K. and Nagafusa, T. and Matsumoto, T. and Kikuchi, H. and Kamiya, K. and Takeuchi, H.},
	year = {2020},
	note = {Type: Journal Article},
}

@article{kaya707,
	title = {Patients' readiness for discharge: {Predictors} and effects on unplanned readmissions, emergency department visits and death},
	volume = {26},
	issn = {1365-2834 (Electronic) 0966-0429 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29573007},
	doi = {10.1111/jonm.12605},
	number = {6},
	journal = {J Nurs Manag},
	author = {Kaya, S. and Sain Guven, G. and Aydan, S. and Kar, A. and Teles, M. and Yildiz, A. and Koca, G. S. and Kartal, N. and Korku, C. and Urek, D. and Demir, I. B. and Toka, O.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {707--716},
}

@article{kato4249,
	title = {Videofluoroscopic evaluation in oropharyngeal swallowing after radical esophagectomy with lymphadenectomy for esophageal cancer},
	volume = {27},
	issn = {0250-7005 (Print) 0250-7005 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18214027},
	number = {6C},
	journal = {Anticancer Res},
	author = {Kato, H. and Miyazaki, T. and Sakai, M. and Sano, A. and Tanaka, N. and Kimura, H. and Inose, T. and Faried, A. and Saito, K. and Sohda, M. and Nakajima, M. and Fukai, Y. and Masuda, N. and Fukuchi, M. and Manda, R. and Ojima, H. and Tsukada, K. and Kuwano, H.},
	year = {2007},
	note = {Type: Journal Article},
	pages = {4249--54},
}

@article{jones245,
	title = {Patient-{Reported} {Outcomes} {Measurement} {Information} {System} ({PROMIS}) {Use} in {Surgical} {Care}: {A} {Scoping} {Study}},
	volume = {224},
	issn = {1879-1190 (Electronic) 1072-7515 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27965131},
	doi = {10.1016/j.jamcollsurg.2016.11.015},
	number = {3},
	journal = {J Am Coll Surg},
	author = {Jones, R. S. and Stukenborg, G. J.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {245--254 e1},
}

@article{jones327,
	title = {Transitional care interventions and hospital readmissions in surgical populations: a systematic review},
	volume = {212},
	issn = {1879-1883 (Electronic) 0002-9610 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27353404},
	doi = {10.1016/j.amjsurg.2016.04.004},
	number = {2},
	journal = {Am J Surg},
	author = {Jones, C. E. and Hollis, R. H. and Wahl, T. S. and Oriel, B. S. and Itani, K. M. and Morris, M. S. and Hawn, M. T.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {327--35},
}

@article{kaneoka,
	title = {Presentation of oropharyngeal dysphagia and rehabilitative intervention following esophagectomy: a systematic review},
	volume = {31},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29788321},
	doi = {10.1093/dote/doy050},
	number = {8},
	journal = {Dis Esophagus},
	author = {Kaneoka, A. and Yang, S. and Inokuchi, H. and Ueha, R. and Yamashita, H. and Nito, T. and Seto, Y. and Haga, N.},
	year = {2018},
	note = {Type: Journal Article},
}

@article{jonesO20,
	title = {Simple psoas cross-sectional area measurement is a quick and easy method to assess sarcopenia and predicts major surgical complications},
	volume = {17},
	issn = {1463-1318 (Electronic) 1462-8910 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25328119},
	doi = {10.1111/codi.12805},
	number = {1},
	journal = {Colorectal Dis},
	author = {Jones, K. I. and Doleman, B. and Scott, S. and Lund, J. N. and Williams, J. P.},
	year = {2015},
	pmid = {25328119},
	note = {tex.ids= jonesO20a
type: Journal Article},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Retrospective Studies, Risk Factors, CRC, Aged, 80 and over, Colectomy, computed tomography, Postoperative Complications, Elective Surgical Procedures, Psoas Muscles, complications, Anatomy, Cross-Sectional},
	pages = {O20--6},
}

@article{irving370,
	title = {{NIH} {ImageJ} and {Slice}-{O}-{Matic} computed tomography imaging software to quantify soft tissue},
	volume = {15},
	issn = {1930-7381 (Print) 1930-7381 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17299110},
	doi = {10.1038/oby.2007.573},
	number = {2},
	journal = {Obesity (Silver Spring)},
	author = {Irving, B. A. and Weltman, J. Y. and Brock, D. W. and Davis, C. K. and Gaesser, G. A. and Weltman, A.},
	year = {2007},
	note = {Type: Journal Article},
	pages = {370--6},
}

@article{iqbal,
	title = {Cost {Effectiveness} of a {Novel} {Attempt} to {Reduce} {Readmission} after {Ileostomy} {Creation}},
	volume = {21},
	issn = {1938-3797 (Electronic) 1086-8089 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28144122},
	doi = {10.4293/JSLS.2016.00082},
	number = {1},
	journal = {JSLS},
	author = {Iqbal, A. and Raza, A. and Huang, E. and Goldstein, L. and Hughes, S. J. and Tan, S. A.},
	year = {2017},
	note = {Type: Journal Article},
}

@article{inoue34,
	title = {Changes in exercise capacity, muscle strength, and health-related quality of life in esophageal cancer patients undergoing esophagectomy},
	volume = {8},
	issn = {2052-1847 (Print) 2052-1847 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27822378},
	doi = {10.1186/s13102-016-0060-y},
	journal = {BMC Sports Sci Med Rehabil},
	author = {Inoue, T. and Ito, S. and Ando, M. and Nagaya, M. and Aso, H. and Mizuno, Y. and Hattori, K. and Nakajima, H. and Nishida, Y. and Niwa, Y. and Kodera, Y. and Koike, M. and Hasegawa, Y.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {34},
}

@article{inoue68,
	title = {Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer},
	volume = {26},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/22409435},
	doi = {10.1111/j.1442-2050.2012.01336.x},
	number = {1},
	journal = {Dis Esophagus},
	author = {Inoue, J. and Ono, R. and Makiura, D. and Kashiwa-Motoyama, M. and Miura, Y. and Usami, M. and Nakamura, T. and Imanishi, T. and Kuroda, D.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {68--74},
}

@article{hutcheson1127,
	title = {Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it},
	volume = {139},
	issn = {2168-619X (Electronic) 2168-6181 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/24051544},
	doi = {10.1001/jamaoto.2013.4715},
	number = {11},
	journal = {JAMA Otolaryngol Head Neck Surg},
	author = {Hutcheson, K. A. and Bhayani, M. K. and Beadle, B. M. and Gold, K. A. and Shinn, E. H. and Lai, S. Y. and Lewin, J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {1127--34},
}

@article{hutcheson62,
	title = {Dynamic {Imaging} {Grade} of {Swallowing} {Toxicity} ({DIGEST}): {Scale} development and validation},
	volume = {123},
	issn = {1097-0142 (Electronic) 0008-543X (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27564246},
	doi = {10.1002/cncr.30283},
	number = {1},
	journal = {Cancer},
	author = {Hutcheson, K. A. and Barrow, M. P. and Barringer, D. A. and Knott, J. K. and Lin, H. Y. and Weber, R. S. and Fuller, C. D. and Lai, S. Y. and Alvarez, C. P. and Raut, J. and Lazarus, C. L. and May, A. and Patterson, J. and Roe, J. W. and Starmer, H. M. and Lewin, J. S.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {62--70},
}

@article{howard-anderson1870,
	title = {Readmissions in the era of patient engagement},
	volume = {174},
	issn = {2168-6114 (Electronic) 2168-6106 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25264930},
	doi = {10.1001/jamainternmed.2014.4782},
	number = {11},
	journal = {JAMA Intern Med},
	author = {Howard-Anderson, J. and Lonowski, S. and Vangala, S. and Tseng, C. H. and Busuttil, A. and Afsar-Manesh, N.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {1870--2},
}

@article{hibbard1918,
	title = {Development and testing of a short form of the patient activation measure},
	volume = {40},
	issn = {0017-9124 (Print) 0017-9124 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/16336556},
	doi = {10.1111/j.1475-6773.2005.00438.x},
	number = {6 Pt 1},
	journal = {Health Serv Res},
	author = {Hibbard, J. H. and Mahoney, E. R. and Stockard, J. and Tusler, M.},
	year = {2005},
	note = {Type: Journal Article},
	pages = {1918--30},
}

@article{humbert347,
	title = {Swallowing intentional off-state in aging and {Alzheimer}'s disease: preliminary study},
	volume = {26},
	issn = {1875-8908 (Electronic) 1387-2877 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21654061},
	doi = {10.3233/JAD-2011-110380},
	number = {2},
	journal = {J Alzheimers Dis},
	author = {Humbert, I. A. and McLaren, D. G. and Malandraki, G. and Johnson, S. C. and Robbins, J.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {347--54},
}

@article{hibbard207,
	title = {What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs},
	volume = {32},
	issn = {1544-5208 (Electronic) 0278-2715 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23381511},
	doi = {10.1377/hlthaff.2012.1061},
	number = {2},
	journal = {Health Aff (Millwood)},
	author = {Hibbard, J. H. and Greene, J.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {207--14},
}

@article{hayes95,
	title = {Comparison of conventional {Lewis}-{Tanner} two-stage oesophagectomy with the synchronous two-team approach},
	volume = {82},
	issn = {0007-1323 (Print) 0007-1323 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/7881969},
	number = {1},
	journal = {Br J Surg},
	author = {Hayes, N. and Shaw, I. H. and Raimes, S. A. and Griffin, S. M.},
	year = {1995},
	note = {Type: Journal Article},
	pages = {95--7},
}

@article{harris377,
	title = {Research electronic data capture ({REDCap})–a metadata-driven methodology and workflow process for providing translational research informatics support},
	volume = {42},
	issn = {1532-0480 (Electronic) 1532-0464 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18929686},
	doi = {10.1016/j.jbi.2008.08.010},
	number = {2},
	journal = {J Biomed Inform},
	author = {Harris, P. A. and Taylor, R. and Thielke, R. and Payne, J. and Gonzalez, N. and Conde, J. G.},
	year = {2009},
	note = {Type: Journal Article},
	pages = {377--81},
}

@article{hardiman1302,
	title = {Patient autonomy-centered self-care checklist reduces hospital readmissions after ileostomy creation},
	volume = {160},
	issn = {1532-7361 (Electronic) 0039-6060 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27320065},
	doi = {10.1016/j.surg.2016.05.007},
	number = {5},
	journal = {Surgery},
	author = {Hardiman, K. M. and Reames, C. D. and McLeod, M. C. and Regenbogen, S. E.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {1302--1308},
}

@article{harter2525,
	title = {Nutritional and functional factors as prognostic of surgical cancer patients},
	volume = {25},
	issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28303380},
	doi = {10.1007/s00520-017-3661-4},
	number = {8},
	journal = {Support Care Cancer},
	author = {Harter, J. and Orlandi, S. P. and Gonzalez, M. C.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {2525--2530},
}

@article{haisleye162743,
	title = {Association of {Intervals} {Between} {Neoadjuvant} {Chemoradiation} and {Surgical} {Resection} {With} {Pathologic} {Complete} {Response} and {Survival} in {Patients} {With} {Esophageal} {Cancer}},
	volume = {151},
	issn = {2168-6262 (Electronic) 2168-6254 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/27627765},
	doi = {10.1001/jamasurg.2016.2743},
	number = {11},
	journal = {JAMA Surg},
	author = {Haisley, K. R. and Laird, A. E. and Nabavizadeh, N. and Gatter, K. M. and Holland, J. M. and Vaccaro, G. M. and Thomas, C. R., Jr. and Schipper, P. H. and Hunter, J. G. and Dolan, J. P.},
	year = {2016},
	note = {Type: Journal Article},
	pages = {e162743},
}

@article{gurtner1620,
	title = {Two-team synchronous oesophagectomy},
	volume = {81},
	issn = {0007-1323 (Print) 0007-1323 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/7827888},
	number = {11},
	journal = {Br J Surg},
	author = {Gurtner, G. C. and Robertson, C. S. and Chung, S. C. and Li, A. K.},
	year = {1994},
	note = {Type: Journal Article},
	pages = {1620--2},
}

@article{guinan1569,
	title = {Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance},
	volume = {26},
	issn = {1433-7339 (Electronic) 0941-4355 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29197960},
	doi = {10.1007/s00520-017-3993-0},
	number = {5},
	journal = {Support Care Cancer},
	author = {Guinan, E. M. and Doyle, S. L. and Bennett, A. E. and O'Neill, L. and Gannon, J. and Elliott, J. A. and O'Sullivan, J. and Reynolds, J. V. and Hussey, J.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {1569--1576},
	file = {Guinan et al. - 2018 - Sarcopenia during neoadjuvant therapy for oesophag.pdf:/Users/jcsal/Zotero/storage/4CKMDLGF/Guinan et al. - 2018 - Sarcopenia during neoadjuvant therapy for oesophag.pdf:application/pdf},
}

@article{hanna521,
	title = {Minimally invasive esophagectomy in the community hospital setting},
	volume = {20},
	issn = {1558-5042 (Electronic) 1055-3207 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21640919},
	doi = {10.1016/j.soc.2011.01.009},
	number = {3},
	journal = {Surg Oncol Clin N Am},
	author = {Hanna, E. M. and Norton, H. J. and Reames, M. K. and Salo, J. C.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {521--30, ix},
}

@article{guralnikM221,
	title = {Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery},
	volume = {55},
	issn = {1079-5006 (Print) 1079-5006 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10811152},
	number = {4},
	journal = {J Gerontol A Biol Sci Med Sci},
	author = {Guralnik, J. M. and Ferrucci, L. and Pieper, C. F. and Leveille, S. G. and Markides, K. S. and Ostir, G. V. and Studenski, S. and Berkman, L. F. and Wallace, R. B.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {M221--31},
}

@article{gemmill173,
	title = {Systematic review of enhanced recovery after gastro-oesophageal cancer surgery},
	volume = {97},
	issn = {1478-7083 (Electronic) 0035-8843 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26263799},
	doi = {10.1308/003588414X14055925061630},
	number = {3},
	journal = {Ann R Coll Surg Engl},
	author = {Gemmill, E. H. and Humes, D. J. and Catton, J. A.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {173--9},
}

@article{fromer92,
	title = {Integrated medical processes: redesigning transitions of care},
	volume = {42},
	issn = {2154-8331 (Print) 2154-8331 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/25502133},
	doi = {10.3810/hp.2014.10.1146},
	number = {4},
	journal = {Hosp Pract (1995)},
	author = {Fromer, L. and Pollack, C.},
	year = {2014},
	note = {Type: Journal Article},
	pages = {92--8},
}

@article{fried255,
	title = {Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care},
	volume = {59},
	issn = {1079-5006 (Print) 1079-5006 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/15031310},
	number = {3},
	journal = {J Gerontol A Biol Sci Med Sci},
	author = {Fried, L. P. and Ferrucci, L. and Darer, J. and Williamson, J. D. and Anderson, G.},
	year = {2004},
	pmid = {15031310},
	note = {tex.ids= fried255a
type: Journal Article},
	keywords = {Humans, Aged, Health Status, Prognosis, Comorbidity, Frailty, Frail Elderly, Disabled Persons, Geriatrics},
	pages = {255--63},
	file = {Fried et al_2004_Untangling the concepts of disability, frailty, and comorbidity.pdf:/Users/jcsal/Zotero/storage/VKEQG255/Fried et al_2004_Untangling the concepts of disability, frailty, and comorbidity.pdf:application/pdf},
}

@article{forshaw294,
	title = {Is cardiopulmonary exercise testing a useful test before esophagectomy?},
	volume = {85},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/18154826},
	doi = {10.1016/j.athoracsur.2007.05.062},
	number = {1},
	journal = {Ann Thorac Surg},
	author = {Forshaw, M. J. and Strauss, D. C. and Davies, A. R. and Wilson, D. and Lams, B. and Pearce, A. and Botha, A. J. and Mason, R. C.},
	year = {2008},
	note = {Type: Journal Article},
	pages = {294--9},
}

@article{fish379,
	title = {Readmission {After} {Ileostomy} {Creation}: {Retrospective} {Review} of a {Common} and {Significant} {Event}},
	volume = {265},
	issn = {1528-1140 (Electronic) 0003-4932 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28059966},
	doi = {10.1097/SLA.0000000000001683},
	number = {2},
	journal = {Ann Surg},
	author = {Fish, D. R. and Mancuso, C. A. and Garcia-Aguilar, J. E. and Lee, S. W. and Nash, G. M. and Sonoda, T. and Charlson, M. E. and Temple, L. K.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {379--387},
}

@article{fiorelli,
	title = {Ultrasound-{Guided} {Erector} {Spinae} {Plane} {Block} {Versus} {Intercostal} {Nerve} {Block} for {Post}-{Minithoracotomy} {Acute} {Pain} {Management}: {A} {Randomized} {Controlled} {Trial}},
	issn = {1532-8422 (Electronic) 1053-0770 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32144056},
	doi = {10.1053/j.jvca.2020.01.026},
	journal = {J Cardiothorac Vasc Anesth},
	author = {Fiorelli, S. and Leopizzi, G. and Menna, C. and Teodonio, L. and Ibrahim, M. and Rendina, E. A. and Ricci, A. and De Blasi, R. A. and Rocco, M. and Massullo, D.},
	year = {2020},
	note = {Type: Journal Article},
}

@article{fernando1144,
	title = {The {Society} of {Thoracic} {Surgeons} practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary},
	volume = {92},
	issn = {1552-6259 (Electronic) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21871327},
	doi = {10.1016/j.athoracsur.2011.06.104},
	number = {3},
	journal = {Ann Thorac Surg},
	author = {Fernando, H. C. and Jaklitsch, M. T. and Walsh, G. L. and Tisdale, J. E. and Bridges, C. D. and Mitchell, J. D. and Shrager, J. B.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {1144--52},
}

@article{ferguson661,
	title = {Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer},
	volume = {123},
	issn = {0022-5223 (Print) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/11986593},
	doi = {10.1067/mtc.2002.120350},
	number = {4},
	journal = {J Thorac Cardiovasc Surg},
	author = {Ferguson, M. K. and Durkin, A. E.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {661--9},
}

@article{feeney489,
	title = {Preoperative physical activity levels and postoperative pulmonary complications post-esophagectomy},
	volume = {24},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21309920},
	doi = {10.1111/j.1442-2050.2010.01171.x},
	number = {7},
	journal = {Dis Esophagus},
	author = {Feeney, C. and Reynolds, J. V. and Hussey, J.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {489--94},
}

@article{feeney529,
	title = {Assessment of physical fitness for esophageal surgery, and targeting interventions to optimize outcomes},
	volume = {23},
	issn = {1442-2050 (Electronic) 1120-8694 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/20459443},
	doi = {10.1111/j.1442-2050.2010.01058.x},
	number = {7},
	journal = {Dis Esophagus},
	author = {Feeney, C. and Hussey, J. and Carey, M. and Reynolds, J. V.},
	year = {2010},
	note = {Type: Journal Article},
	pages = {529--39},
}

@article{fagundes613,
	title = {Symptom recovery after thoracic surgery: {Measuring} patient-reported outcomes with the {MD} {Anderson} {Symptom} {Inventory}},
	volume = {150},
	issn = {1097-685X (Electronic) 0022-5223 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26088408},
	doi = {10.1016/j.jtcvs.2015.05.057},
	number = {3},
	journal = {J Thorac Cardiovasc Surg},
	author = {Fagundes, C. P. and Shi, Q. and Vaporciyan, A. A. and Rice, D. C. and Popat, K. U. and Cleeland, C. S. and Wang, X. S.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {613--9 e2},
}

@article{easterling989,
	title = {Pharyngeal dysphagia in postesophagectomy patients: correlation with deglutitive biomechanics},
	volume = {69},
	issn = {0003-4975 (Print) 0003-4975 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/10800780},
	number = {4},
	journal = {Ann Thorac Surg},
	author = {Easterling, C. S. and Bousamra, M., 2nd and Lang, I. M. and Kern, M. K. and Nitschke, T. and Bardan, E. and Shaker, R.},
	year = {2000},
	note = {Type: Journal Article},
	pages = {989--92},
}

@article{fearon489,
	title = {Definition and classification of cancer cachexia: an international consensus},
	volume = {12},
	issn = {1474-5488 (Electronic) 1470-2045 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/21296615},
	doi = {10.1016/S1470-2045(10)70218-7},
	number = {5},
	journal = {Lancet Oncol},
	author = {Fearon, K. and Strasser, F. and Anker, S. D. and Bosaeus, I. and Bruera, E. and Fainsinger, R. L. and Jatoi, A. and Loprinzi, C. and MacDonald, N. and Mantovani, G. and Davis, M. and Muscaritoli, M. and Ottery, F. and Radbruch, L. and Ravasco, P. and Walsh, D. and Wilcock, A. and Kaasa, S. and Baracos, V. E.},
	year = {2011},
	note = {Type: Journal Article},
	pages = {489--95},
	file = {Fearon et al_2011_Definition and classification of cancer cachexia.pdf:/Users/jcsal/Zotero/storage/AFZX2TJN/Fearon et al_2011_Definition and classification of cancer cachexia.pdf:application/pdf},
}

@article{dutta164,
	title = {Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder},
	volume = {168},
	issn = {0022-5347 (Print) 0022-5347 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/12050514},
	number = {1},
	journal = {J Urol},
	author = {Dutta, S. C. and Chang, S. C. and Coffey, C. S. and Smith, J. A., Jr. and Jack, G. and Cookson, M. S.},
	year = {2002},
	note = {Type: Journal Article},
	pages = {164--7},
}

@article{dronkers67,
	title = {The association of pre-operative physical fitness and physical activity with outcome after scheduled major abdominal surgery},
	volume = {68},
	issn = {1365-2044 (Electronic) 0003-2409 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23121372},
	doi = {10.1111/anae.12066},
	number = {1},
	journal = {Anaesthesia},
	author = {Dronkers, J. J. and Chorus, A. M. and van Meeteren, N. L. and Hopman-Rock, M.},
	year = {2013},
	note = {Type: Journal Article},
	pages = {67--73},
}

@incollection{dimitriosschizas,
	title = {Esophageal {Abnormalities}},
	url = {https://www.intechopen.com/books/esophageal-abnormalities/nutritional-management-of-esophageal-cancer-patients},
	booktitle = {Nutritional {Management} of {Esophageal} {Cancer} {Patients}},
	author = {Dimitrios Schizas, Irene Lidoriki, Demetrios Moris and Liakakos, Theodore},
	editor = {Chai, Jianyuan},
	year = {2017},
	note = {Type: Book Section},
}

@article{dieterich365,
	title = {Postoperative {Complications} {Predict} 30-{Day} {Readmission} in {Geriatric} {General} {Surgery} {Patients}},
	volume = {83},
	issn = {1555-9823 (Electronic) 0003-1348 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28424131},
	number = {4},
	journal = {Am Surg},
	author = {Dieterich, J. D. and Divino, C. M.},
	year = {2017},
	note = {Type: Journal Article},
	pages = {365--370},
}

@article{delmonico769,
	title = {Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women},
	volume = {55},
	issn = {0002-8614 (Print) 0002-8614 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/17493199},
	doi = {10.1111/j.1532-5415.2007.01140.x},
	number = {5},
	journal = {J Am Geriatr Soc},
	author = {Delmonico, M. J. and Harris, T. B. and Lee, J. S. and Visser, M. and Nevitt, M. and Kritchevsky, S. B. and Tylavsky, F. A. and Newman, A. B. and Health, Aging and Body Composition, Study},
	year = {2007},
	note = {Type: Journal Article},
	pages = {769--74},
}

@article{davis391,
	title = {Rapid estimate of adult literacy in medicine: a shortened screening instrument},
	volume = {25},
	issn = {0742-3225 (Print) 0742-3225 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/8349060},
	number = {6},
	journal = {Fam Med},
	author = {Davis, T. C. and Long, S. W. and Jackson, R. H. and Mayeaux, E. J. and George, R. B. and Murphy, P. W. and Crouch, M. A.},
	year = {1993},
	note = {Type: Journal Article},
	pages = {391--5},
}

@article{deftereose035824,
	title = {Nutritional {Outcomes} of patients {Undergoing} {Resection} for upper {gastroIntestinal} cancer in {AuStralian} {Hospitals} ({NOURISH}): protocol for a multicentre point prevalence study},
	volume = {10},
	issn = {2044-6055 (Electronic) 2044-6055 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/32385064},
	doi = {10.1136/bmjopen-2019-035824},
	number = {5},
	journal = {BMJ Open},
	author = {Deftereos, I. and Yeung, J. M. C. and Carter, V. M. and Isenring, E. and Kiss, N. K. and Group, Nourish Point Prevalence Study},
	year = {2020},
	note = {Type: Journal Article},
	pages = {e035824},
}

@article{day1023,
	title = {Patient-{Reported} {Outcomes} {Accurately} {Measure} the {Value} of an {Enhanced} {Recovery} {Program} in {Liver} {Surgery}},
	volume = {221},
	issn = {1879-1190 (Electronic) 1072-7515 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/26611799},
	doi = {10.1016/j.jamcollsurg.2015.09.011},
	number = {6},
	journal = {J Am Coll Surg},
	author = {Day, R. W. and Cleeland, C. S. and Wang, X. S. and Fielder, S. and Calhoun, J. and Conrad, C. and Vauthey, J. N. and Gottumukkala, V. and Aloia, T. A.},
	year = {2015},
	note = {Type: Journal Article},
	pages = {1023--30 e1--2},
}

@article{daly315,
	title = {Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer},
	volume = {9},
	issn = {2190-6009 (Electronic) 2190-5991 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/29318756},
	doi = {10.1002/jcsm.12267},
	number = {2},
	journal = {J Cachexia Sarcopenia Muscle},
	author = {Daly, L. E. and Ni Bhuachalla, E. B. and Power, D. G. and Cushen, S. J. and James, K. and Ryan, A. M.},
	year = {2018},
	note = {Type: Journal Article},
	pages = {315--325},
	file = {Daly et al. - Loss of skeletal muscle during systemic chemothera.pdf:/Users/jcsal/Zotero/storage/JR3VTVDM/Daly et al. - Loss of skeletal muscle during systemic chemothera.pdf:application/pdf},
}

@article{cuschieri7,
	title = {Endoscopic oesophagectomy through a right thoracoscopic approach},
	volume = {37},
	issn = {0035-8835 (Print) 0035-8835 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/1573620},
	number = {1},
	journal = {J R Coll Surg Edinb},
	author = {Cuschieri, A. and Shimi, S. and Banting, S.},
	year = {1992},
	note = {Type: Journal Article},
	pages = {7--11},
}

@article{suzuki347,
	title = {Localized gastric cancer treated with chemoradation without surgery: {UTMD} {Anderson} {Cancer} {Center} experience},
	volume = {82},
	issn = {1423-0232},
	shorttitle = {Localized gastric cancer treated with chemoradation without surgery},
	doi = {10.1159/000338318},
	abstract = {BACKGROUND: In patients with localized gastric cancer (LGC) who are unfit for surgery, decline surgery, or have unresectable cancer, chemoradiotherapy may provide palliation; however, data in the literature are sparse.
METHODS: We identified 66 LGC patients who had definitive chemoradiation but no surgery. All patients had baseline and postchemoradiation staging including an endoscopic biopsy. Multiple statistical methods were used to analyze outcomes.
RESULTS: Most patients were men and most had stage III or IV cancer. Five patients were surgery eligible but declined to have surgery. The median follow-up time was 33.9 months (95\% CI 18.3-49.6). The median survival time (MST) for 66 patients was only 14.5 months (95\% CI 10.8-19.7) and the median relapse-free survival (RFS) was 5.03 months (95\% CI 4.67-6.40). The estimated overall survival (OS) and RFS rates at 3 years were 22.6\% (95\% CI 13.7-37.3) and 7.7\% (95\% CI 3.2-18.6), respectively. Twenty-three (35\%) patients who achieved a clinical complete response (cCR; negative postchemoradiation biopsy and no progression by imaging) fared better than those who achieved less than cCR ({\textless}cCR) [cCR: MST 30.7 months (95\% CI 20.4-NA); {\textless}cCR: MST 10.6 months (95\% CI 8.43-14.9); p {\textless} 001]. In multivariate analysis, cCR was the only independent prognosticator for OS [hazard ratio (HR) = 0.32, p {\textless} 0.0012] and RFS (HR = 0.12, p {\textless} 0.0001).
CONCLUSION: Our data demonstrate that in the absence of surgery, outcomes with definitive chemoradiation are only modest. A third of the patients achieved cCR and had a longer OS and RFS than those who achieved {\textless}cCR.},
	language = {eng},
	number = {6},
	journal = {Oncology},
	author = {Suzuki, Akihiro and Xiao, Lianchun and Taketa, Takashi and Blum, Mariela A. and Matamoros, Aurelio and Chien, Pamela L. and Mansfield, Paul F. and Fournier, Keith F. and Weston, Brian and Lee, Jeffrey H. and Bhutani, Manoop S. and Estrella, Jeannelyn S. and Delclos, Marc E. and Krishnan, Sunil and Das, Prajnan and Ajani, Jaffer A.},
	year = {2012},
	pmid = {22677933},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Disease Progression, Survival Rate, Prognosis, Stomach Neoplasms, Disease-Free Survival, Chemoradiotherapy, dCRT},
	pages = {347--351},
}

@article{malik1,
	title = {Metabolic tumor volume provides complementary prognostic information to {EUS} staging in esophageal and junctional cancer},
	volume = {30},
	issn = {1442-2050},
	doi = {10.1111/dote.12505},
	abstract = {To determine the correlation between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) derived esophageal tumor parameters [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV)] and endoscopic ultrasound (EUS) derived tumor parameters (T stage, N stage) and their prognostic implications. 150 consecutive patients with cancer of the esophagus or esophagogastric junction underwent staging PET-CT and staging EUS. PET-CT derived SUVmax and MTV of the primary tumor was recorded. EUS evaluated T and N stage. Relationships between parameters were investigated using the Mann-Whitney U tests, survival analysis performed using Kaplan-Meier and independent prognostic factors determined using Cox regression multivariate analysis. A significant difference in MTV was noted between EUS T1/T2 tumors (median 6.7 cm3) and EUS T3/T4 tumors (median 35.7 cm3; P {\textless} 0.0001). An MTV of {\textless}23.4 cm3 (P = 0.0001), SUVmax {\textless} 4.1 (P = 0014), EUS T stage (P {\textless} 0.0001), EUS N stage (P {\textless} 0.0001), and clinical stage (P {\textless} 0.0001) were all significantly associated with survival, with MTV {\textless}23.4 cm3 (P = 0.004), EUS T stage (P = 0.01), and EUS N stage (P = 0.01) significant in multivariate analysis. MTV, a volumetric parameter of PET-CT, has more prognostic importance than SUVmax and provides valuable prognostic information in esophageal and junctional cancer, along with EUS T and N stage. MTV provides complementary information to EUS and should be included in the staging of esophageal and junctional cancer.},
	language = {eng},
	number = {3},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Malik, Vinod and Johnston, Ciaran and O'Toole, Dermot and Lucey, Julie and O'Farrell, Naoimh and Claxton, Zieta and Reynolds, John V.},
	month = feb,
	year = {2017},
	pmid = {27862622},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Proportional Hazards Models, Prospective Studies, Prognosis, Aged, 80 and over, Adult, Statistics, Nonparametric, Young Adult, Esophageal Neoplasms, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Radiopharmaceuticals, Esophagogastric Junction, Esophagoscopy, esophageal cancer, endoscopic ultrasound, Endosonography, PET, 18F-FDG PET-CT, Regression Analysis, staging, Tumor Burden},
	pages = {1--8},
}

@article{ripley226,
	title = {Pretreatment {Dysphagia} in {Esophageal} {Cancer} {Patients} {May} {Eliminate} the {Need} for {Staging} by {Endoscopic} {Ultrasonography}},
	volume = {101},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2015.06.062},
	abstract = {BACKGROUND: Neoadjuvant therapy is commonly administered to patients with localized disease who have T3-4 esophageal disease as staged by endoscopic ultrasound (EUS). Previously, we noted that patients who present with dysphagia have a higher EUS T stage. We hypothesized that the presence of dysphagia is predictive of EUS T3-4 disease and that staging EUS could be forgone for esophageal cancer patients with dysphagia.
METHODS: We performed a prospective, intent-to-treat, single-cohort study in which patients with potentially resectable esophageal cancer completed a standardized four-tier dysphagia score survey. EUS was performed as part of our standard evaluation. To determine whether the presence of dysphagia predicted EUS T3-4 disease, the dysphagia score was compared with EUS T stage.
RESULTS: The study enrolled 114 consecutive patients between August 2012 and February 2014: 77\% (88 of 114) received neoadjuvant therapy, 18\% (20 of 114) did not, and 5\% (6 of 114) pursued treatment elsewhere. In total, 70\% (80 of 114) underwent esophagectomy; of these, 54\% (61 of 114) had dysphagia and 46\% (53 of 114) did not. Dysphagia scores were 66\% (40 of 61) grade 1, 25\% (15 of 61) grade 2, and 10\% (6 of 61) grade 3 to 4. Among patients with dysphagia, 89\% (54 of 61) had T3-4 disease by EUS; among those without dysphagia, only 53\% (28 of 53) had T3-4 disease by EUS (p {\textless} 0.001).
CONCLUSIONS: The presence of dysphagia in patients with esophageal cancer was highly predictive of T3-4 disease by EUS. On the basis of this finding, approximately 50\% of patients currently undergoing staging EUS at our institution could potentially forgo EUS before neoadjuvant therapy. Patients without dysphagia, however, should still undergo EUS.},
	language = {eng},
	number = {1},
	journal = {The Annals of Thoracic Surgery},
	author = {Ripley, R. Taylor and Sarkaria, Inderpal S. and Grosser, Rachel and Sima, Camelia S. and Bains, Manjit S. and Jones, David R. and Adusumilli, Prasad S. and Huang, James and Finley, David J. and Rusch, Valerie W. and Rizk, Nabil P.},
	month = jan,
	year = {2016},
	pmid = {26603024},
	pmcid = {PMC4765728},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Prospective Studies, Esophageal Neoplasms, Endosonography, Dysphonia, Unnecessary Procedures},
	pages = {226--230},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/MY6K9FC9/Ripley et al. - 2016 - Pretreatment Dysphagia in Esophageal Cancer Patien.pdf:application/pdf},
}

@article{chirieac1347,
	title = {Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation},
	volume = {103},
	issn = {0008-543X},
	doi = {10.1002/cncr.20916},
	abstract = {BACKGROUND: In patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent preoperative chemoradiation, it is unclear whether survival was better predicted by pretherapy clinical stage or by posttherapy pathologic stage.
METHODS: The authors studied 235 consecutive patients with pretherapy clinical Stage II, III, or IVA (according to American Joint Committee on Cancer criteria) carcinoma of the esophagus or esophagogastric junction who were treated with chemoradiation followed by esophagectomy. Posttherapy cancer status was classified using pathologic stage and semiquantitative assessment of residual carcinoma. Clinicopathologic features, residual carcinoma status, and pretherapy and posttherapy stage were compared with disease-free and overall survival.
RESULTS: Posttherapy pathologic stage was Stage 0 in 29\% of patients, Stage I in 11\% of patients, Stage II in 34\% of patients, Stage III in 20\% of patients, and Stage IV in 6\% of patients. Cancer downstaging occurred in 56\% of patients. In univariate analysis, disease-free and overall survival were predicted by posttherapy pathologic stage (both with P {\textless} 0.001), margin status (P = 0.002 and P = 0.01, respectively), extent of residual carcinoma (both with P {\textless} 0.001), and downstaging (both with P = 0.001), but not by age, gender, type of cancer, pretherapy clinical stage, or preoperative regimen. However, in multivariate analysis, disease-free and overall survival were independently predicted by posttherapy pathologic stage (both with P = 0.02). Extent of residual carcinoma was a marginally significant predictor of overall survival (P = 0.04).
CONCLUSIONS: Posttherapy pathologic stage was the best available predictor of outcome for patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent chemoradiation therapy followed by esophagectomy. The findings in the current study supported the concept of downstaging by preoperative therapy.},
	language = {eng},
	number = {7},
	journal = {Cancer},
	author = {Chirieac, Lucian R. and Swisher, Stephen G. and Ajani, Jaffer A. and Komaki, Ritsuko R. and Correa, Arlene M. and Morris, Jeffrey S. and Roth, Jack A. and Rashid, Asif and Hamilton, Stanley R. and Wu, Tsung-Teh},
	month = apr,
	year = {2005},
	pmid = {15719440},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Survival Rate, Prognosis, Chemotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Lymphatic Metastasis, Radiotherapy, Adjuvant, Carcinoma, naCRT},
	pages = {1347--1355},
}

@article{taketa95,
	title = {Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation},
	volume = {85},
	issn = {1423-0232},
	doi = {10.1159/000351999},
	abstract = {BACKGROUND: Trimodality therapy (TMT; chemoradiation plus surgery) has level-1 evidence for survival advantage for TMT-eligible esophagogastric cancer patients. Some patients, however, decline surgery after preoperative chemoradiation. The question of which patient should have esophagectomy and which one should not is unlikely to be answered by a prospective comparison; therefore, we matched the clinical covariates of several patients who had surgery with those who declined surgery (DS).
METHODS: Between 2002 and 2011, we identified 623 patients in our databases. Of 623 patients, 244 patients had TMT and 61 TMT-eligible patients were in the DS group. Using the propensity-score method, we matched 16 covariates between 36 DS patients and 36 TMT patients.
RESULTS: Baseline characteristics between the two groups were balanced (p = NS). The median overall survival times were: 57.9 months (95\% CI: 27.7 to not applicable, NA) for the DS group and 50.8 months (95\% CI: 30.7 to NA) for the TMT group (p = 0.28). The median relapse-free survival times were: 18.5 (95\% CI: 11.5-30.4) for the DS group and 26.5 months (95\% CI: 15.5-NA) for the TMT group (p = 0.45). Eleven (31\%) of 36 patients in the DS group had salvage surgery.
CONCLUSIONS: Our results are intriguing but skewed by the patients who had salvage surgery in the DS group. Until highly reliable predictive models are developed for esophageal preservation, TMT must be encouraged for all TMT-eligible gastroesophageal cancer patients.},
	language = {eng},
	number = {2},
	journal = {Oncology},
	author = {Taketa, Takashi and Xiao, Lianchun and Sudo, Kazuki and Suzuki, Akihiro and Wadhwa, Roopma and Blum, Mariela A. and Lee, Jeffrey H. and Weston, Brian and Bhutani, Manoop S. and Skinner, Heath and Komaki, Ritsuko and Maru, Dipen M. and Rice, David C. and Swisher, Stephen G. and Hofstetter, Wayne L. and Ajani, Jaffer A.},
	year = {2013},
	pmid = {23860252},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Retrospective Studies, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Preoperative Period, Treatment Refusal},
	pages = {95--99},
	file = {Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer_A Systematic Review and Individual Patient Data Meta-analysis:/Users/jcsal/Downloads/Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer_A Systematic Review and Individual Patient Data Meta-analysis.pdf:application/pdf},
}

@article{bonvalot1366,
	title = {Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma ({EORTC}-62092: {STRASS}): a multicentre, open-label, randomised, phase 3 trial},
	volume = {21},
	issn = {1474-5488},
	shorttitle = {Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma ({EORTC}-62092},
	doi = {10.1016/S1470-2045(20)30446-0},
	abstract = {BACKGROUND: Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival.
METHODS: EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged ≥18 years) with histologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and had a WHO performance status and American Society of Anesthesiologists score of 2 or lower, were centrally randomly assigned (1:1), using an interactive web response system and a minimisation algorithm, to receive either surgery alone or preoperative radiotherapy followed by surgery. Randomisation was stratified by hospital and performance status. Radiotherapy was delivered as 50·4 Gy (in 28 daily fractions of 1·8 Gy) in either 3D conformal radiotherapy or intensity modulated radiotherapy, and the objective of surgery was a macroscopically complete resection of the tumour mass with en-bloc organ resection as necessary. The primary endpoint was abdominal recurrence-free survival, as assessed by the investigator, and was analysed in the intention-to-treat population. Safety was analysed in all patients who started their allocated treatment. This trial is registered with ClinicalTrials.gov, NCT01344018.
FINDINGS: Between Jan 18, 2012 and April 10, 2017, 266 patients were enrolled, of whom 133 were randomly assigned to each group. The median follow-up was 43·1 months (IQR 28·8-59·2). 128 (96\%) patients from the surgery alone group had surgery, and 119 (89\%) patients in the radiotherapy and surgery group had both radiotherapy and surgery. Median abdominal recurrence-free survival was 4·5 years (95\% CI 3·9 to not estimable) in the radiotherapy plus surgery group and 5·0 years (3·4 to not estimable) in the surgery only group (hazard ratio 1·01, 95\% CI 0·71-1·44; log rank p=0·95). The most common grade 3-4 adverse events were lymphopenia (98 [77\%] of 127 patients in the radiotherapy plus surgery group vs one [1\%] of 128 patients in the surgery alone group), anaemia (15 [12\%] vs ten [8\%]), and hypoalbuminaemia (15 [12\%] vs five [4\%]). Serious adverse events were reported in 30 (24\%) of 127 patients in the radiotherapy plus surgery group, and in 13 (10\%) of 128 patients in the surgery alone group. One (1\%) of 127 patients in the radiotherapy plus surgery group died due to treatment-related serious adverse events (gastropleural fistula), and no patients in the surgery alone group died due to treatment-related serious adverse events.
INTERPRETATION: Preoperative radiotherapy should not be considered as standard of care treatment for retroperitoneal sarcoma.
FUNDING: European Organisation for Research and Treatment of Cancer, and European Clinical Trials in Rare Sarcomas.},
	language = {eng},
	number = {10},
	journal = {The Lancet. Oncology},
	author = {Bonvalot, Sylvie and Gronchi, Alessandro and Le Péchoux, Cécile and Swallow, Carol J. and Strauss, Dirk and Meeus, Pierre and van Coevorden, Frits and Stoldt, Stephan and Stoeckle, Eberhard and Rutkowski, Piotr and Rastrelli, Marco and Raut, Chandrajit P. and Hompes, Daphne and De Paoli, Antonino and Sangalli, Claudia and Honoré, Charles and Chung, Peter and Miah, Aisha and Blay, Jean Yves and Fiore, Marco and Stelmes, Jean-Jacques and Dei Tos, Angelo P. and Baldini, Elizabeth H. and Litière, Saskia and Marreaud, Sandrine and Gelderblom, Hans and Haas, Rick L.},
	month = oct,
	year = {2020},
	pmid = {32941794},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Disease-Free Survival, Radiotherapy, Adjuvant, Europe, North America, Radiotherapy, Conformal, Retroperitoneal Neoplasms, Sarcoma, PreopRT},
	pages = {1366--1377},
}

@article{cardona1257,
	title = {The {STRASS} trial: an important step in the right direction},
	volume = {21},
	issn = {1474-5488},
	shorttitle = {The {STRASS} trial},
	doi = {10.1016/S1470-2045(20)30429-0},
	language = {eng},
	number = {10},
	journal = {The Lancet. Oncology},
	author = {Cardona, Kenneth},
	month = oct,
	year = {2020},
	pmid = {32941793},
	keywords = {Humans, Retroperitoneal Neoplasms, Sarcoma, PreopRT, Connective Tissue Diseases, Soft Tissue Neoplasms},
	pages = {1257--1258},
}

@article{borch64,
	title = {Gastric {Carcinoids}},
	volume = {242},
	issn = {0003-4932},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1357706/},
	doi = {10.1097/01.sla.0000167862.52309.7d},
	abstract = {Gastric carcinoids can be divided into different subtypes. Sixty-five prospectively followed cases were studied regarding biologic behavior, treatment, and prognosis. Tumor aggressiveness varied significantly in relation to type. Differentiated management strategy is recommended as used in the present study.},
	number = {1},
	urldate = {2021-12-14},
	journal = {Annals of Surgery},
	author = {Borch, Kurt and Ahrén, Bo and Ahlman, Håkan and Falkmer, Sture and Granérus, Göran and Grimelius, Lars},
	month = jul,
	year = {2005},
	pmid = {15973103},
	pmcid = {PMC1357706},
	keywords = {carcinoid},
	pages = {64--73},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/4YDAPAV6/Borch et al. - 2005 - Gastric Carcinoids.pdf:application/pdf},
}

@article{asgestandardsofpracticecommittee1,
	title = {The role of endoscopy in the management of premalignant and malignant conditions of the stomach},
	volume = {82},
	issn = {1097-6779},
	doi = {10.1016/j.gie.2015.03.1967},
	language = {eng},
	number = {1},
	journal = {Gastrointestinal Endoscopy},
	author = {{ASGE Standards of Practice Committee} and Evans, John A. and Chandrasekhara, Vinay and Chathadi, Krishnavel V. and Decker, G. Anton and Early, Dayna S. and Fisher, Deborah A. and Foley, Kimberly and Hwang, Joo Ha and Jue, Terry L. and Lightdale, Jenifer R. and Pasha, Shabana F. and Sharaf, Ravi and Shergill, Amandeep K. and Cash, Brooks D. and DeWitt, John M.},
	month = jul,
	year = {2015},
	pmid = {25935705},
	keywords = {Humans, Stomach Neoplasms, Adenocarcinoma, Stomach, Precancerous Conditions, Metaplasia, Gastrointestinal Stromal Tumors, Gastroscopy, GIST, Lymphoma, B-Cell, Marginal Zone, Polyps},
	pages = {1--8},
}

@article{martin4376,
	title = {Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction},
	volume = {28},
	issn = {1527-7755},
	shorttitle = {Prognostic factors in patients with advanced cancer},
	doi = {10.1200/JCO.2009.27.1916},
	abstract = {PURPOSE: To determine whether elements of a standard nutritional screening assessment are independently prognostic of survival in patients with advanced cancer.
PATIENTS AND METHODS: A prospective nested cohort of patients with metastatic cancer were accrued from different units of a Regional Palliative Care Program. Patients completed a nutritional screen on admission. Data included age, sex, cancer site, height, weight history, dietary intake, 13 nutrition impact symptoms, and patient- and physician-reported performance status (PS). Univariate and multivariate survival analyses were conducted. Concordance statistics (c-statistics) were used to test the predictive accuracy of models based on training and validation sets; a c-statistic of 0.5 indicates the model predicts the outcome as well as chance; perfect prediction has a c-statistic of 1.0.
RESULTS: A training set of patients in palliative home care (n = 1,164) was used to identify prognostic variables. Primary disease site, PS, short-term weight change (either gain or loss), dietary intake, and dysphagia predicted survival in multivariate analysis (P {\textless} .05). A model including only patients separated by disease site and PS with high c-statistics between predicted and observed responses for survival in the training set (0.90) and validation set (0.88; n = 603). The addition of weight change, dietary intake, and dysphagia did not further improve the c-statistic of the model. The c-statistic was also not altered by substituting physician-rated palliative PS for patient-reported PS.
CONCLUSION: We demonstrate a high probability of concordance between predicted and observed survival for patients in distinct palliative care settings (home care, tertiary inpatient, ambulatory outpatient) based on patient-reported information.},
	language = {eng},
	number = {28},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Martin, Lisa and Watanabe, Sharon and Fainsinger, Robin and Lau, Francis and Ghosh, Sunita and Quan, Hue and Atkins, Marlis and Fassbender, Konrad and Downing, G. Michael and Baracos, Vickie},
	month = oct,
	year = {2010},
	pmid = {20805456},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Risk Factors, Palliative Care, Prospective Studies, Risk Assessment, Neoplasms, Prognosis, Predictive Value of Tests, Survival Analysis, Nutrition Assessment, Regression Analysis, Home Care Services},
	pages = {4376--4383},
}

@article{zhang2881,
	title = {Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: {A} prospective cohort study},
	volume = {38},
	issn = {1532-1983},
	shorttitle = {Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer},
	doi = {10.1016/j.clnu.2018.12.025},
	abstract = {BACKGROUND \& AIMS: Sarcopenia has been widely recognized as an important predictor of poor outcomes in patients with cancer after surgery, but the controversy remains, and its impact on surgical and oncologic outcomes in patients after abdominal surgery for digestive tract cancer is poorly described. The aim of this study was to evaluate the prognostic impact of sarcopenia on surgical and oncologic outcomes in patients after abdominal surgery for digestive tract cancer.
METHODS: Six thousand four hundred and forty-seven consecutive patients who underwent abdominal surgery for digestive tract cancer in our institution were prospectively included. Sarcopenia was defined as skeletal muscle index below the lowest sex-specific quartile using computed tomography scan at L3 before surgery. The surgical and oncologic outcomes were recorded, and univariate and multivariate analyses were performed.
RESULTS: Sarcopenia was present in 1638 of 6447 patients (25.4\%) with digestive tract cancer before surgery based on the diagnostic cut-off values (43.13 cm2/m2 for men and 37.81 cm2/m2 for women). The incidence of postoperative total and pulmonary complications, and 30-day readmission were significantly higher in sarcopenic group than in nonsarcopenic group (37.4\% vs 12.9\%, P {\textless} 0.001; 3.1\% vs 2.1\%, P = 0.026; 1.1\% vs 0.4\%, P = 0.003, respectively). The postoperative hospital stay was significantly longer in sarcopenic patients (9.42 ± 3.40 vs 8.51 ± 3.17 days, P {\textless} 0.001). There were significantly more patients receiving postoperative chemotherapy or radiotherapy in sarcopenic group than in nonsarcopenic group (73.1\% vs 69.2\%, P = 0.003; 10.6\% vs 8.8\%, P = 0.038, respectively), and patients with sarcopenia had significantly more chemotherapy modifications including delay, dose reduction, or termination (48.5\% vs 44.2\%, P = 0.018). In addition, during the follow-up period, sarcopenic patients had significantly lower rate of overall survival and disease-free survival than nonsarcopenic patients (53.9\% vs 69.3\%, P = 0.002; 36.8\% vs 59.7\%, P = 0.000, respectively). In multivariate analysis, sarcopenia was found to be a risk factor for postoperative complications [odds ratio (OR) = 5.418, 95\% confidence interval (CI) = 2.986-9.828, P {\textless} 0.001], and was an unfavorable prognostic factor for poor overall survival [hazard ratio (HR) = 0.649, 95\% CI = 0.426-0.991, P = 0.045] and disease-free survival (HR = 0.514, 95\% CI = 0.348-0.757, P = 0.001).
CONCLUSIONS: Sarcopenia could be used as a strong and independent prognostic factor for poor surgical and oncologic outcomes in patients after abdominal surgery for digestive tract cancer. Identification of preoperative sarcopenia in digestive surgery for cancer and targeted approaches may improve its negative outcomes.},
	language = {eng},
	number = {6},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Zhang, Shuze and Tan, Shanjun and Jiang, Yi and Xi, Qiulei and Meng, Qingyang and Zhuang, Qiulin and Han, Yusong and Sui, Xiangyu and Wu, Guohao},
	month = dec,
	year = {2019},
	pmid = {30630709},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Gastrointestinal Neoplasms, Length of Stay, Male, Middle Aged, Sarcopenia, Risk Factors, Prospective Studies, Prognosis, Cohort Studies, Survival Analysis, Comorbidity, Postoperative Complications, Abdominal surgery, China, Digestive tract cancer, Gastrointestinal Tract, Patient Readmission, Skeletal muscle index},
	pages = {2881--2888},
}

@article{dijksterhuis199,
	title = {Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy},
	volume = {10},
	issn = {2190-6009},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/jcsm.12371},
	doi = {10.1002/jcsm.12371},
	abstract = {Background Palliative systemic treatment in patients with advanced or metastatic esophagogastric cancer may result in improved overall survival and quality of life but can also lead to considerable toxicity. In various cancer types, severe muscle mass depletion (sarcopenia) and poor muscle strength are associated with decreased survival and increased chemotherapy-related toxicity. The aim of this study is to determine the impact of body composition on survival and chemotherapy toxicity in esophagogastric cancer patients treated with first-line palliative chemotherapy. Methods A total of 88 patients with advanced esophagogastric cancer treated with standard first-line palliative systemic therapy consisting of capecitabine and oxaliplatin (CapOx) between January 2010 and February 2017 were included. Skeletal muscle index (SMI), reflecting muscle mass, and skeletal muscle density (SMD), associated with muscle strength, were measured using pre-treatment of all patients and evaluation computed tomography scans after three treatment cycles of 65 patients and were used to determine sarcopenia and sarcopenic obesity (i.e. sarcopenia and body mass index {\textgreater}25 kg/m2). The associations between body composition (SMI, SMD, sarcopenia, and sarcopenic obesity) and survival and toxicity were assessed using univariable and multivariable Cox and logistic regression analyses, respectively. Results Of 88 patients, 75\% was male, and median age was 63 (interquartile range 56–69) years. The majority of patients had an adenocarcinoma (83\%). Before start of treatment, 49\% of the patients were sarcopenic, and 20\% had sarcopenic obesity. Low SMD was observed in 50\% of patients. During three cycles CapOx, SMI significantly decreased, with a median decrease of 4\% (interquartile range −8.6–−0.4). Median progression-free and overall survival were 6.9 and 10.1 months. SMI, SMD, sarcopenia, and sarcopenic obesity (both pre-treatment and after three cycles) were neither associated with progression-free nor overall survival. Pre-treatment SMD was independently associated with grade 3–4 toxicity (odds ratio 0.94; 95\% confidence interval 0.89–1.00) and sarcopenic obesity with grade 2–4 neuropathy (odds ratio 3.82; 95\% confidence interval 1.20–12.18). Conclusions Sarcopenia was not associated with survival or treatment-related toxicity in advanced esophagogastric cancer patients treated with CapOx. Pre-treatment sarcopenic obesity was independently associated with the occurrence of grade 2–4 neurotoxicity and skeletal muscle density with grade 3–4 toxicity.},
	language = {en},
	number = {1},
	urldate = {2021-12-18},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Dijksterhuis, Willemieke P.M. and Pruijt, Maarten J. and van der Woude, Stephanie O. and Klaassen, Remy and Kurk, Sophie A. and van Oijen, Martijn G.H. and van Laarhoven, Hanneke W.M.},
	year = {2019},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcsm.12371},
	keywords = {Sarcopenia, Body composition, Skeletal muscle mass, Gastric cancer, Esophageal cancer, Palliative treatment},
	pages = {199--206},
	file = {Dijksterhuis et al. - Association between body composition, survival, an.pdf:/Users/jcsal/Zotero/storage/PKFAI9K6/Dijksterhuis et al. - Association between body composition, survival, an.pdf:application/pdf;Full Text PDF:/Users/jcsal/Zotero/storage/H4RJEKLA/Dijksterhuis et al. - 2019 - Association between body composition, survival, an.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/ZZJU985R/jcsm.html:text/html},
}

@article{jarvinen27,
	title = {Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study},
	volume = {16},
	issn = {1477-7819},
	shorttitle = {Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer},
	doi = {10.1186/s12957-018-1327-4},
	abstract = {BACKGROUND: Nutritional deficits, cachexia, and sarcopenia are extremely common in esophageal cancer. The aim of this article was to assess the effect of loss of skeletal muscle mass during neoadjuvant treatment on the prognosis of esophageal cancer patients.
METHODS: Esophageal cancer patients (N = 115) undergoing neoadjuvant therapy and surgery between 2010 and 2014 were identified from our surgery database and retrospectively analyzed. Computed tomography imaging of the total cross-sectional muscle tissue measured at the third lumbar level defined the skeletal muscle index, which defined sarcopenia (SMI {\textless} 52.4 cm2/m2 for men and {\textless} 38.5 cm2/m2 for women). Images were collected before and after neoadjuvant treatments.
RESULTS: Sarcopenia in preoperative imaging was prevalent in 92 patients (80\%). Median overall survival was 900 days (interquartile range 334-1447) with no difference between sarcopenic (median = 900) and non-sarcopenic (median = 914) groups (p = 0.872). Complication rates did not differ (26.1\% vs 32.6\%, p = 0.725). A 2.98\% decrease in skeletal muscle index during neoadjuvant treatment correlated with poor 2-year survival (log-rank p = 0.04).
CONCLUSION: Loss of skeletal muscle tissue during neoadjuvant treatment correlates with worse overall survival.},
	language = {eng},
	number = {1},
	journal = {World Journal of Surgical Oncology},
	author = {Järvinen, Tommi and Ilonen, Ilkka and Kauppi, Juha and Salo, Jarmo and Räsänen, Jari},
	month = feb,
	year = {2018},
	pmid = {29433514},
	pmcid = {PMC5809976},
	keywords = {Humans, Muscle, Skeletal, Female, Male, Middle Aged, Neoadjuvant Therapy, Sarcopenia, Follow-Up Studies, Retrospective Studies, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Cachexia, Survival Rate, Prognosis, Body composition, Cross-Sectional Studies, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Malnutrition, Esophageal neoplasms, Thoracic surgery},
	pages = {27},
	file = {Full Text:/Users/jcsal/Zotero/storage/QZEDQJTX/Järvinen et al. - 2018 - Loss of skeletal muscle mass during neoadjuvant tr.pdf:application/pdf},
}

@article{nagai2995,
	title = {Skeletal {Muscle} {Mass} {Reduction} {Velocity} as a {Simple} {Prognostic} {Indicator} for {Patients} with {Metastatic} {Urothelial} {Carcinoma} {Receiving} {Second}-{Line} {Chemotherapy}},
	volume = {20},
	issn = {2476-762X},
	doi = {10.31557/APJCP.2019.20.10.2995},
	abstract = {BACKGROUND: Patients with metastatic urothelial carcinoma (mUC) have an uncertain prognosis. The aim of the current study was to evaluate the prognostic potential of a skeletal muscle mass reduction index measured by computed tomography (CT) for mUC patients undergoing second-line gemcitabine and docetaxel (GD) chemotherapy.
METHODS: We retrospectively reviewed 44 patients with mUC who received second-line GD chemotherapy between 2006 and 2015 in our hospital. Skeletal muscle area (SMA) at the third lumbar vertebra was measured using CT images obtained from medical records, and a skeletal muscle index (SMI) was calculated for each patient as: SMI = SMA / height2. Changes in SMI across timepoints (SMI inclination) were calculated as: SMI inclination = [( SMI/SMI)/duration of the interval between imaging visits]. Patients were then divided into two groups: a "steep" group (SMI inclination {\textless} -0.01) and a "gentle" group (SMI inclination ≥ -0.01). Kaplan-Meier curves and multivariate Cox proportional hazards regression models were used to evaluate the relationship between SMI inclination and overall survival (OS).
RESULTS: There were no differences in patient characteristics between the two groups with respect to median age, gender, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), disease control rate or first-line treatment regimen. OS from the start of second-line GD therapy group was significantly shorter in the "steep" group relative to the "gentle" group. The multivariate analysis revealed that "steep" SMI inclination and presence of anemia were strong predictors of poor prognosis.
CONCLUSION: Higher values of SMI inclination, indicating a faster rate of skeletal muscle mass reduction, may serve as a useful predictive marker for OS in mUC patients undergoing second-line GD chemotherapy.},
	language = {eng},
	number = {10},
	journal = {Asian Pacific journal of cancer prevention: APJCP},
	author = {Nagai, Takashi and Naiki, Taku and Iida, Keitaro and Nozaki, Satoshi and Etani, Toshiki and Sugiyama, Yosuke and Ando, Ryosuke and Yanase, Takahiro and Chaya, Ryosuke and Moritoki, Yoshinobu and Kobayashi, Daichi and Akita, Hidetoshi and Okamura, Takehiko and Yasui, Takahiro},
	month = oct,
	year = {2019},
	pmid = {31653146},
	pmcid = {PMC6982681},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Follow-Up Studies, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Prognosis, Aged, 80 and over, Adult, sarcopenia, Deoxycytidine, Docetaxel, Methods, Carcinoma, Transitional Cell, metastatic urothelial carcinoma, Prognostic factor, second-line chemotherapy, skeletal mass index, Urologic Neoplasms},
	pages = {2995--3000},
	file = {Full Text:/Users/jcsal/Zotero/storage/M3CU2EJN/Nagai et al. - 2019 - Skeletal Muscle Mass Reduction Velocity as a Simpl.pdf:application/pdf;Nagai et al. - Skeletal Muscle Mass Reduction Velocity as a Simpl.pdf:/Users/jcsal/Zotero/storage/SU3RZQZU/Nagai et al. - Skeletal Muscle Mass Reduction Velocity as a Simpl.pdf:application/pdf},
}

@article{martin1539,
	title = {Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index},
	volume = {31},
	issn = {1527-7755},
	shorttitle = {Cancer cachexia in the age of obesity},
	doi = {10.1200/JCO.2012.45.2722},
	abstract = {PURPOSE: Emerging evidence suggests muscle depletion predicts survival of patients with cancer.
PATIENTS AND METHODS: At a cancer center in Alberta, Canada, consecutive patients with cancer (lung or GI; N = 1,473) were assessed at presentation for weight loss history, lumbar skeletal muscle index, and mean muscle attenuation (Hounsfield units) by computed tomography (CT). Univariate and multivariate analyses were conducted. Concordance (c) statistics were used to test predictive accuracy of survival models.
RESULTS: Body mass index (BMI) distribution was 17\% obese, 35\% overweight, 36\% normal weight, and 12\% underweight. Patients in all BMI categories varied widely in weight loss, muscle index, and muscle attenuation. Thresholds defining associations between these three variables and survival were determined using optimal stratification. High weight loss, low muscle index, and low muscle attenuation were independently prognostic of survival. A survival model containing conventional covariates (cancer diagnosis, stage, age, performance status) gave a c statistic of 0.73 (95\% CI, 0.67 to 0.79), whereas a model ignoring conventional variables and including only BMI, weight loss, muscle index, and muscle attenuation gave a c statistic of 0.92 (95\% CI, 0.88 to 0.95; P {\textless} .001). Patients who possessed all three of these poor prognostic variables survived 8.4 months (95\% CI, 6.5 to 10.3), regardless of whether they presented as obese, overweight, normal weight, or underweight, in contrast to patients who had none of these features, who survived 28.4 months (95\% CI, 24.2 to 32.6; P {\textless} .001).
CONCLUSION: CT images reveal otherwise occult muscle depletion. Patients with cancer who are cachexic by the conventional criterion (involuntary weight loss) and by two additional criteria (muscle depletion and low muscle attenuation) share a poor prognosis, regardless of overall body weight.},
	language = {eng},
	number = {12},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Martin, Lisa and Birdsell, Laura and Macdonald, Neil and Reiman, Tony and Clandinin, M. Thomas and McCargar, Linda J. and Murphy, Rachel and Ghosh, Sunita and Sawyer, Michael B. and Baracos, Vickie E.},
	month = apr,
	year = {2013},
	pmid = {23530101},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Obesity, Body Mass Index, Follow-Up Studies, Neoplasm Staging, Risk Factors, Cachexia, Lung Neoplasms, Survival Rate, Prognosis, Adult, Age Factors, Canada, Cancer Care Facilities},
	pages = {1539--1547},
	file = {Martin et al_2013_Cancer cachexia in the age of obesity.pdf:/Users/jcsal/Zotero/storage/3UK457E7/Martin et al_2013_Cancer cachexia in the age of obesity.pdf:application/pdf},
}

@article{miki,
	title = {Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer},
	volume = {n/a},
	issn = {1743-7563},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/ajco.13669},
	doi = {10.1111/ajco.13669},
	abstract = {Aim Progression of cachexia indicated by decreased body weight and composition is associated with poor survival of advanced pancreatic cancer (APC). There are limited data concerning the prognostic effect of cachexia on second-line chemotherapy (L2). We aimed to assess the impact of cachexia progression during first-line therapy (L1) on survival after L2. Methods We reviewed patients with gemcitabine/nab-paclitaxel (GEM/nabPTX)-refractory APC who underwent L2 with modified FOLFIRINOX or S-1 between 2015 and 2019 in our institution. We determined clinicopathological data including body composition parameters: subcutaneous fat area (SFA), visceral fat area (VFA), and skeletal muscle index (SMI). Correlations of changes in these parameters, as well as their effect on overall survival after L2 (OS2), were examined. Results Median rates of change in SMI, SFA, and VFA were 0.19\%, −4.17\%, and −18.39\%, respectively, in 59 patients during L1. Although there was moderate correlation in rate of change between SFA and VFA, there was no correlation between SMI and other parameters. We defined loss of SFA, VFA, and SMI as decreases greater than 8.5\%, 34.1\%, and 8.7\%, respectively. Median OS2 of patients with loss in any of these parameters was significantly shorter than in patients without loss (3.83 vs. 8.73 months). Multivariate analysis revealed that loss in any parameters, performance status, and C-reactive protein/albumin ratio were independent negative prognostic factors. Conclusion Loss of adipose tissue or skeletal muscle during L1 had a considerable impact on OS2 in APC refractory to GEM/nabPTX.},
	language = {en},
	number = {n/a},
	urldate = {2021-12-23},
	journal = {Asia-Pacific Journal of Clinical Oncology},
	author = {Miki, Masami and Lee, Lingaku and Hisano, Terumasa and Sugimoto, Rie and Furukawa, Masayuki},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13669},
	keywords = {chemotherapy, adipose tissue, cachexia, pancreatic cancer, skeletal muscle, Pancreas},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/IAQJIE7L/Miki et al. - Loss of adipose tissue or skeletal muscle during f.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/SQ4A79LR/ajco.html:text/html},
}

@article{kurk909,
	title = {Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients},
	volume = {9},
	issn = {2190-6009},
	doi = {10.1002/jcsm.12337},
	abstract = {BACKGROUND: Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy-related toxicity, poor quality of life, and poor survival in metastatic colorectal cancer (mCRC) patients. Little is known about the evolution of SMM during palliative systemic therapy. We investigated changes in SMM during various consecutive palliative systemic treatment regimens using repeated abdominal computed tomography scans of mCRC patients who participated in the randomized phase 3 CAIRO3 study.
METHODS: In the CAIRO3 study, mCRC patients with stable disease or better after 6 cycles of first-line treatment with capecitabine + oxaliplatin + bevacizumab (CAPOX-B) were randomized between maintenance treatment with capecitabine + bevacizumab (CAP-B) or observation. Upon first disease progression, in both groups, CAPOX-B or other treatment was reintroduced until the second disease progression, which was the primary study endpoint. We analysed 1355 computed tomography scans of 450 (81\%) CAIRO3 patients (64 ± 9.0 years, CAP-B n = 223; observation n = 227) for SMM at four time points (i.e. prior to the start of pre-randomization initial treatment, at randomization, and at first and at second disease progression) using the Slice-o-matic software and single slice evaluation at the lumbar 3 level. By using accepted and widely used formulas, whole body SMM was calculated. A linear mixed effects model, adjusted for relevant confounders, was used to assess SMM changes for the total group and within and between study arms.
RESULTS: During 6 cycles of initial treatment with CAPOX-B prior to randomization, SMM decreased significantly in all patients [CAP-B arm: -0.53 kg (95\% CI -1.12; -0.07) and observation arm: -0.85 kg (-1.45; -0.25)]. After randomization, SMM recovered during CAP-B treatment by 1.32 kg (0.73; 1.90) and observation by 1.20 kg (0.63; 1.78) (median time from randomization to first disease progression 8.6 and 4.1 months for CAP-B arm and observation arm, respectively). After first progression and during reintroduction treatment with CAPOX-B or other treatment, SMM again decreased significantly and comparable in both arms, CAP-B: -2.71 kg (-3.37; -2.03), and observation: -2.01 kg (-2.64; -1.41) (median time from first progression until second progression CAP-B arm: 4.7 months and observation arm: 6.6 months).
CONCLUSIONS: This longitudinal study provides a unique insight in SMM changes in mCRC patients during palliative systemic treatment regimens, including observation. Our data show that muscle loss is reversible and may be influenced by the intensity of systemic regimens. Although studies have shown prognostic capacity for SMM, the effects of subsequent changes in SMM are unknown and may be clues for new future therapeutic interventions.},
	language = {eng},
	number = {5},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Kurk, Sophie A. and Peeters, Petra H. M. and Dorresteijn, Bram and de Jong, Pim A. and Jourdan, Marion and Kuijf, Hugo J. and Punt, Cornelis J. A. and Koopman, Miriam and May, Anne M.},
	month = oct,
	year = {2018},
	pmid = {30144305},
	pmcid = {PMC6204584},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Palliative Care, Organ Size, Aged, 80 and over, Body composition, Chemotherapy, Metastatic colorectal cancer, Body Weights and Measures, Skeletal muscle},
	pages = {909--919},
	file = {Full Text:/Users/jcsal/Zotero/storage/IPHQ9FXU/Kurk et al. - 2018 - Impact of different palliative systemic treatments.pdf:application/pdf},
}

@article{jang557,
	title = {Skeletal {Muscle} {Mass} {Loss} {During} {Cancer} {Treatment}: {Differences} by {Race} and {Cancer} {Site}},
	volume = {47},
	issn = {0190-535X},
	shorttitle = {Skeletal {Muscle} {Mass} {Loss} {During} {Cancer} {Treatment}},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793555/},
	doi = {10.1188/20.ONF.557-566},
	abstract = {OBJECTIVES:
To examine skeletal muscle mass change in a racially diverse sample of patients undergoing cancer treatment, determine significant predictors of muscle mass loss, and explore the interaction of race and cancer site.

SAMPLE \& SETTING:
A retrospective analysis was conducted for 212 patients seeking treatment at a university hospital clinic.

METHODS \& VARIABLES:
Skeletal muscle mass index (SMI) was determined by computed tomography at the time of cancer diagnosis and with cancer treatment.

RESULTS:
One hundred thirty-four patients (63\%) had SMI loss with cancer treatment. Race and cancer site were found to be significant predictors of SMI loss. Compared to other racial groups, non-Hispanic Black (NHB) patients had the greatest SMI loss (p {\textless} 0.001) with cancer treatment. NHB patients with rectal cancer experienced the greatest SMI loss compared to patients of other races and cancer types.

IMPLICATIONS FOR NURSING:
To improve survivorship care for patients with cancer, it is essential to develop strategies for assessing and managing skeletal muscle mass loss throughout treatment, particularly for NHB patients with rectal cancer.},
	number = {5},
	urldate = {2022-01-19},
	journal = {Oncology nursing forum},
	author = {Jang, Min Kyeong and Park, Chang Gi and Hong, Susan and Laddu, Deepika and Li, Hongjin and Rhee, Esther and Doorenbos, Ardith Z.},
	month = sep,
	year = {2020},
	pmid = {32830799},
	pmcid = {PMC7793555},
	keywords = {Disparities},
	pages = {557--566},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/XPYEZ4H8/Jang et al. - 2020 - Skeletal Muscle Mass Loss During Cancer Treatment.pdf:application/pdf},
}

@article{xiao615,
	title = {The association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer},
	volume = {109},
	issn = {1938-3207},
	doi = {10.1093/ajcn/nqy328},
	abstract = {BACKGROUND: Sarcopenia and low skeletal muscle radiodensity (SMD) have been associated with adverse outcomes in patients with colorectal cancer (CRC); however, factors contributing to these 2 muscle abnormalities are unclear.
OBJECTIVES: The aim of this study was to investigate the association of medical and demographic characteristics with muscle abnormalities among patients with nonmetastatic CRC.
METHODS: Patients with stage I-III invasive CRC (2006-11) who had diagnostic computed tomography (CT) available from Kaiser Permanente Northern California electronic medical records were included. CT-assessed sarcopenia and low SMD were defined according to optimal stratification. Logistic regressions including age, stage, site, total adipose tissue (TAT), race/ethnicity, neutrophil-lymphocyte ratio, smoking history, alcohol use, and Charlson Comorbidity Score were performed to identify characteristics associated with muscle abnormalities.
RESULTS: The study included 3262 patients (49.9\% females) with a mean ± SD age of 62.6 ± 11.4 y. Sarcopenia and low SMD were highly prevalent (42.4\% and 29.6\%, respectively). Age and sex interactions were noted for muscle mass, but not SMD. Age was associated with higher odds of muscle abnormalities in a dose-response manner. Compared with those aged ≤50 y, patients aged 70-80 y had considerably higher odds (OR: 6.19; 95\% CI: 4.72, 8.11) of sarcopenia, and low SMD (OR: 17.81; 95\% CI: 11.73, 27.03). High TAT was related to a higher odds of low SMD (OR: 9.62; 95\% CI: 7.37, 12.56), but lower odds of sarcopenia (OR: 0.59; 95\% CI: 0.48, 0.71). Compared with Caucasians, African Americans had lower odds of sarcopenia and low SMD. Patients with a higher neutrophil-lymphocyte ratio had higher odds of having both muscle abnormalities. Patients who were smokers or had any comorbidity had higher odds of low SMD, but not sarcopenia.
CONCLUSIONS: Muscle abnormalities were common in patients with nonmetastatic CRC, with great variability in muscle mass and SMD across age, TAT, and race/ethnicity. Factors associated with muscle abnormalities may be used to facilitate risk stratification and the guidance of targeted strategies to counteract these abnormalities.},
	language = {eng},
	number = {3},
	journal = {The American Journal of Clinical Nutrition},
	author = {Xiao, Jingjie and Caan, Bette J. and Cespedes Feliciano, Elizabeth M. and Meyerhardt, Jeffrey A. and Kroenke, Candyce H. and Baracos, Vickie E. and Weltzien, Erin and Kwan, Marilyn L. and Alexeeff, Stacey E. and Castillo, Adrienne L. and Prado, Carla M.},
	month = mar,
	year = {2019},
	pmid = {30850836},
	pmcid = {PMC6408202},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Aged, 80 and over, Adult, sarcopenia, Young Adult, Adolescent, adiposity, computed tomography (CT), Demography, inflammation, muscle radiodensity, nonmetastatic colorectal cancer, race/ethnicity, Disparities;Colorectal},
	pages = {615--625},
	file = {Full Text:/Users/jcsal/Zotero/storage/Q9ZRSELU/Xiao et al. - 2019 - The association of medical and demographic charact.pdf:application/pdf},
}

@article{vanderschaaf490,
	title = {The influence of preoperative weight loss on the postoperative course after esophageal cancer resection},
	volume = {147},
	issn = {1097-685X},
	doi = {10.1016/j.jtcvs.2013.07.072},
	abstract = {OBJECTIVE: Preoperative weight loss might increase the risk of postoperative morbidity and mortality after esophagectomy for cancer. We hypothesized that patients with esophageal cancer with {\textgreater}10\% weight loss during the 3 months before their diagnosis would be at an increased risk of postoperative complications, have a longer length of stay, and have worse overall survival.
METHODS: In the present hospital-based cohort study, all patients who had undergone surgery for esophageal cancer in 1990 to 2010 at the Erasmus University Medical Center Rotterdam were included. Weight loss was defined as "no, or limited" (≤10\%) or "severe" ({\textgreater}10\%). Logistic regression analysis was used to estimate the relative risk of complications, expressed as odds ratios (ORs) with 95\% confidence intervals (CIs). Hazard ratios were calculated to assess the length of hospital stay and survival. The risk estimates were adjusted for potential confounding factors.
RESULTS: Of 922 included patients, 155 (17\%) had experienced severe weight loss. These patients had no increased risk of early surgical, early nonsurgical, or late surgical complications (OR, 0.83 and 95\% CI, 0.54-1.24; OR, 0.90 and 95\% CI, 0.63-1.30; OR, 1.14 and 95\% CI, 0.79-1.66, respectively) and had no increased length of stay (hazard ratio, 1.09; 95\% CI, 0.89-1.35). Preoperative weight loss was followed by increased 5-year mortality (hazard ratio, 1.34; 95\% CI, 1.02-1.74).
CONCLUSIONS: A {\textgreater}10\% preoperative weight loss was followed by decreased 5-year survival after esophageal cancer surgery but no increased risk of postoperative complications.},
	language = {eng},
	number = {1},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {van der Schaaf, Maartje K. and Tilanus, Hugo W. and van Lanschot, Jan J. B. and Johar, Asif M. and Lagergren, Pernilla and Lagergren, Jesper and Wijnhoven, Bas P. L.},
	month = jan,
	year = {2014},
	pmid = {24060365},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Risk Factors, Time Factors, Weight Loss, body mass index, Chi-Square Distribution, Esophageal Neoplasms, Esophagectomy, Netherlands, Postoperative Complications, Logistic Models, Multivariate Analysis, 7, Hospital Mortality, Odds Ratio, Weight Loss;GE, Academic Medical Centers, BMI, CI, confidence interval, hazard ratio, HR, odds ratio, OR},
	pages = {490--495},
	file = {Full Text:/Users/jcsal/Zotero/storage/4UBCDHQZ/van der Schaaf et al. - 2014 - The influence of preoperative weight loss on the p.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/MAS99SQ2/van der Schaaf et al. - 2014 - The influence of preoperative weight loss on the p.pdf:application/pdf},
}

@article{anandavadivelan185,
	title = {Cachexia in patients with oesophageal cancer},
	volume = {13},
	issn = {1759-4782},
	doi = {10.1038/nrclinonc.2015.200},
	abstract = {Oesophageal cancer is a debilitating disease with a poor prognosis, and weight loss owing to malnutrition prevails in the majority of patients. Cachexia, a multifactorial syndrome characterized by the loss of fat and skeletal muscle mass and systemic inflammation arising from complex host-tumour interactions is a major contributor to malnutrition, which is a determinant of tolerance to treatment and survival. In patients with oesophageal cancer, cachexia is further compounded by eating difficulties owing to the stage and location of the tumour, and the effects of neoadjuvant therapy. Treatment with curative intent involves exceptionally extensive and invasive surgery, and the subsequent anatomical changes often lead to eating difficulties and severe postoperative malnutrition. Thus, screening for cachexia by means of percentage weight loss and BMI during the cancer trajectory and survivorship periods is imperative. Additionally, markers of inflammation (such as C-reactive protein), dysphagia and appetite loss should be assessed at diagnosis. Routine assessments of body composition are also necessary in patients with oesophageal cancer to enable assessment of skeletal muscle loss, which might be masked by sarcopenic obesity in these patients. A need exists for clinical trials examining the effectiveness of therapeutic and physical-activity-based interventions in mitigating muscle loss and counteracting cachexia in these patients.},
	language = {eng},
	number = {3},
	journal = {Nature Reviews. Clinical Oncology},
	author = {Anandavadivelan, Poorna and Lagergren, Pernilla},
	month = mar,
	year = {2016},
	pmid = {26573424},
	keywords = {Body Composition, Humans, Treatment Outcome, Risk Factors, Cachexia, Risk Assessment, Weight Loss, Predictive Value of Tests, Nutrition Assessment, Esophageal Neoplasms, Nutritional Status, Quality of Life, Chachexia, GE},
	pages = {185--198},
}

@article{zheng4427,
	title = {Optimal timing and route of nutritional support after esophagectomy: {A} review of the literature},
	volume = {25},
	issn = {2219-2840},
	shorttitle = {Optimal timing and route of nutritional support after esophagectomy},
	doi = {10.3748/wjg.v25.i31.4427},
	abstract = {Some controversy surrounds the postoperative feeding regimen utilized in patients who undergo esophagectomy. Variation in practices during the perioperative period exists including the type of nutrition started, the delivery route, and its timing. Adequate nutrition is essential for this patient population as these patients often present with weight loss and have altered eating patterns after surgery, which can affect their ability to regain or maintain weight. Methods of feeding after an esophagectomy include total parenteral nutrition, nasoduodenal/nasojejunal tube feeding, jejunostomy tube feeding, and oral feeding. Recent evidence suggests that early oral feeding is associated with shorter LOS, faster return of bowel function, and improved quality of life. Enhanced recovery pathways after surgery pathways after esophagectomy with a component of early oral feeding also seem to be safe, feasible, and cost-effective, albeit with limited data. However, data on anastomotic leaks is mixed, and some studies suggest that the incidence of leaks may be higher with early oral feeding. This risk of anastomotic leak with early feeding may be heavily modulated by surgical approach. No definitive data is currently available to definitively answer this question, and further studies should look at how these early feeding regimens vary by surgical technique. This review aims to discuss the existing literature on the optimal route and timing of feeding after esophagectomy.},
	language = {eng},
	number = {31},
	journal = {World Journal of Gastroenterology},
	author = {Zheng, Richard and Devin, Courtney L. and Pucci, Michael J. and Berger, Adam C. and Rosato, Ernest L. and Palazzo, Francesco},
	month = aug,
	year = {2019},
	pmid = {31496622},
	pmcid = {PMC6710171},
	keywords = {Humans, Treatment Outcome, Cachexia, Time Factors, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Incidence, Anastomotic Leak, Enteral nutrition, Enteral Nutrition, Nutrition, Quality of Life, Parenteral Nutrition, Anastomosis, Surgical, Delayed feeding, Early feeding, Enhanced Recovery After Surgery, Intubation, Gastrointestinal, Jejunostomy, Jejunostomy tube, Oral feeding, Postoperative complications, Standard of Care},
	pages = {4427--4436},
	file = {Full Text:/Users/jcsal/Zotero/storage/5A5B6JKJ/Zheng et al. - 2019 - Optimal timing and route of nutritional support af.pdf:application/pdf},
}

@article{porporatoe200,
	title = {Understanding cachexia as a cancer metabolism syndrome},
	volume = {5},
	issn = {2157-9024},
	doi = {10.1038/oncsis.2016.3},
	abstract = {Metabolic reprogramming occurs in tumors to foster cancer cell proliferation, survival and metastasis, but as well at a systemic level affecting the whole organism, eventually leading to cancer cachexia. Indeed, as cancer cells rely on external sources of nitrogen and carbon skeleton to grow, systemic metabolic deregulation promoting tissue wasting and metabolites mobilization ultimately supports tumor growth. Cachectic patients experience a wide range of symptoms affecting several organ functions such as muscle, liver, brain, immune system and heart, collectively decreasing patients' quality of life and worsening their prognosis. Moreover, cachexia is estimated to be the direct cause of at least 20\% of cancer deaths. The main aspect of cachexia syndrome is the unstoppable skeletal muscle and fat storage wasting, even with an adequate caloric intake, resulting in nutrient mobilization - both directly as lipid and amino acids and indirectly as glucose derived from the exploitation of liver gluconeogenesis - that reaches the tumor through the bloodstream. From a metabolic standpoint, cachectic host develops a wide range of dysfunctions, from increased insulin and IGF-1 resistance to induction of mitochondrial uncoupling proteins and fat tissue browning resulting in an increased energy expenditure and heat generation, even at rest. For a long time, cachexia has been merely considered an epiphenomenon of end-stage tumors. However, in specific tumor types, such as pancreatic cancers, it is now clear that patients present markers of tissue wasting at a stage in which tumor is not yet clinically detectable, and that host amino acid supply is required for tumor growth. Indeed, tumor cells actively promote tissue wasting by secreting specific factors such as parathyroid hormone-related protein and micro RNAs. Understanding the molecular and metabolic mediators of cachexia will not only advance therapeutic approaches against cancer, but also improve patients' quality of life.},
	language = {eng},
	journal = {Oncogenesis},
	author = {Porporato, P. E.},
	month = feb,
	year = {2016},
	pmid = {26900952},
	pmcid = {PMC5154342},
	keywords = {Cachexia},
	pages = {e200},
	file = {Full Text:/Users/jcsal/Zotero/storage/9HWEI3C4/Porporato - 2016 - Understanding cachexia as a cancer metabolism synd.pdf:application/pdf},
}

@article{ahmadi1443,
	title = {Accurate detection of metabolically active "brown" and "white" adipose tissues with computed tomography},
	volume = {20},
	issn = {1878-4046},
	doi = {10.1016/j.acra.2013.08.012},
	abstract = {BACKGROUND: Adipose tissues (AT) are highly metabolically active complex endocrine organs and are classified into white (WAT) and brown AT (BAT) with proinflammatory and anti-inflammatory characteristics. The current study investigated the accuracy of computed tomography (CT) to quantitatively detect BAT and WAT based on Hounsfield unit (HU) threshold compared to standardized uptake values (SUVs) of corresponding AT with the use of positron emission tomography (PET).
METHODS: One hundred twenty-four patients who underwent whole-body (18)F-fluorodeoxyglucose ((18)F-FDG) PET/CT were studied. The SUVs and HUs of regions of BAT and WAT were measured and compared in these scans. The receiver operator characteristic (ROC) analysis was used to detect the HU threshold values for the detection of BAT and WAT.
RESULTS: The CT HU of BAT, with high (18)F-FDG uptake, was significantly higher compared to WAT (-67.1 ± 8.2 [-10 to -87] versus -93.5 ± 10.1 [-88 to -190], P = .0006). Generalized linear-regression models revealed that mean CT HU of BAT was 26.4 HU higher than that of WAT (P = .001). A strong agreement between CT HU and PET SUV in measuring metabolically active AT (r(2) = 0.81, P = .0001) was observed. The ROC curve showed that the optimal cutoff value of CT HU to detect BAT was HU ≥-87 with sensitivity of 83.3\% and specificity of 100\%, and the negative CT HU below -87 is highly specific for WAT.
CONCLUSION: In our study, CT can accurately and quantitatively detect BAT and WAT based on CT HU threshold, which is -10 to -87 for BAT and -88 to -190 for WAT.},
	language = {eng},
	number = {11},
	journal = {Academic Radiology},
	author = {Ahmadi, Naser and Hajsadeghi, Fereshteh and Conneely, Mark and Mingos, Mark and Arora, Rohit and Budoff, Matthew and Ebrahimi, Ramin},
	month = nov,
	year = {2013},
	pmid = {24119358},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Male, Adult, computed tomography, Fluorodeoxyglucose F18, Radiopharmaceuticals, Sensitivity and Specificity, Positron-Emission Tomography, positron emission tomography, Adipose Tissue, Brown, Adipose Tissue, White, Brown adipose tissue, Hounsfield units, Multimodal Imaging, standard uptake value, white adipose tissue, Brown Adipose Tissue},
	pages = {1443--1447},
}

@article{charette134,
	title = {Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase {II} trials},
	volume = {19},
	issn = {1471-2407},
	shorttitle = {Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer},
	doi = {10.1186/s12885-019-5319-8},
	abstract = {BACKGROUND: The prognostic value of body composition in cancer patients has been widely studied during the last decade. The main finding of these studies is that sarcopenia, or skeletal muscle depletion, assessed by CT imaging correlates with a reduced overall survival (OS). By contrast, the prognostic value of fat mass remains ill-defined. This study aims to analyze the influence of body composition including both muscle mass and adipose tissue on OS in a homogeneous population of advanced colorectal cancer (CRC) patients.
METHODS: Among 235 patients with chemorefractory advanced CRC included in the SoMore and RegARd-C trials, body composition was assessed in 217 patients on baseline CT images. The relationship between body composition (sarcopenia, muscle density, subcutaneous and visceral fat index and density), body mass index (BMI) and OS were evaluated.
RESULTS: Patients with a higher BMI had a better OS (≥30 versus {\textless} 30, HR: 0.50; 0.33-0.76). Those with low muscle index and muscle density had an increased mortality (HR: 2.06; 1.45-2.93 and HR: 1.54; 1.09-2.18, respectively). Likewise, low subcutaneous and visceral fat index were associated with an increased risk of dying (HR: 1.63; 1.23-2.17 and 1.48; 1.09-2.02 respectively), as were a high subcutaneous and visceral adipose tissue density (HR: 1.93; 1.44-2.57 and 2.40; 1.79-3.20 respectively). In multivariate analysis, a high visceral fat density was the main predictor of poor survival.
CONCLUSIONS: Our results confirm the protective role of obesity in CRC patients at an advanced stage, as well as the negative prognostic impact of muscle depletion on survival. More importantly, our data show for the first time that visceral adipose tissue density is an important prognostic factor in metastatic CRC.
TRIAL REGISTRATION: NCT01290926 , 07/02/2011 and NCT01929616 , 28/08/2013.},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Charette, Nicolas and Vandeputte, Caroline and Ameye, Lieveke and Bogaert, Camille Van and Krygier, Jonathan and Guiot, Thomas and Deleporte, Amélie and Delaunoit, Thierry and Geboes, Karen and Van Laethem, Jean-Luc and Peeters, Marc and Demolin, Gauthier and Holbrechts, Stéphane and Flamen, Patrick and Paesmans, Marianne and Hendlisz, Alain},
	month = feb,
	year = {2019},
	pmid = {30744591},
	pmcid = {PMC6371452},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Obesity, Sarcopenia, Body Mass Index, Colorectal Neoplasms, Proportional Hazards Models, Prognosis, Organ Size, Image Processing, Computer-Assisted, Aged, 80 and over, Adult, Chemotherapy, Myosteatosis, Positron Emission Tomography Computed Tomography, Brown Adipose Tissue, Adipose tissue, Biomarkers, Clinical Trials, Phase II as Topic, Colorectal cancer},
	pages = {134},
	file = {Charette et al. - 2019 - Prognostic value of adipose tissue and muscle mass.pdf:/Users/jcsal/Zotero/storage/LD5A4K3W/Charette et al. - 2019 - Prognostic value of adipose tissue and muscle mass.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/E4NWUS9D/Charette et al. - 2019 - Prognostic value of adipose tissue and muscle mass.pdf:application/pdf},
}

@article{mao-de-ferro409,
	title = {Stents in patients with esophageal cancer before chemoradiotherapy: high risk of complications and no impact on the nutritional status},
	volume = {70},
	issn = {1476-5640},
	shorttitle = {Stents in patients with esophageal cancer before chemoradiotherapy},
	doi = {10.1038/ejcn.2015.206},
	abstract = {Preoperative chemoradiotherapy is the standard of care for locally advanced esophageal cancer, causing persistent deterioration in the nutritional status. We performed a prospective study to evaluate the safety and efficacy of esophageal double-covered self-expandable metal stents in patients with esophageal cancer before chemoradiotherapy. The nutritional status and dysphagia were prospectively recorded. Eleven patients were included: eight were moderate and three were severely malnourished. After stent placement, dysphagia improved in all patients. With regard to complications, one patient developed an esophageal perforation that required urgent esophagectomy. Four patients presented stent migration. Three of these patients required enteral nutrition and none was submitted to surgery because of poor nutritional status. Of the other six patients, only four were operated upon. Stent placement presented a high complication rate and did not prevent weight loss or malnutrition. Other alternatives, including naso-gastric tube placement or endoscopic percutaneous gastrostomy or jejunostomy, should be considered.},
	language = {eng},
	number = {3},
	journal = {European Journal of Clinical Nutrition},
	author = {Mão-de-Ferro, S. and Serrano, M. and Ferreira, S. and Rosa, I. and Lage, P. and Alexandre, D. P. and Freire, J. and Mirones, L. and Casaca, R. and Bettencourt, A. and Pereira, A. D.},
	month = mar,
	year = {2016},
	pmid = {26669568},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Esophageal Neoplasms, Chemoradiotherapy, Malnutrition, Deglutition Disorders, Stents, Enteral Nutrition, Nutritional Status, Stent; Stage IV},
	pages = {409--410},
}

@article{kubo184,
	title = {Prognostic {Implication} of {Postoperative} {Weight} {Loss} {After} {Esophagectomy} for {Esophageal} {Squamous} {Cell} {Cancer}},
	volume = {28},
	issn = {1534-4681},
	url = {https://doi.org/10.1245/s10434-020-08762-6},
	doi = {10.1245/s10434-020-08762-6},
	abstract = {Preoperative weight loss in esophageal cancer is reported to be associated with a poor prognosis. However, the impact of postoperative weight loss on the prognosis of patients with esophageal cancer remains unclear.},
	language = {en},
	number = {1},
	urldate = {2022-01-22},
	journal = {Annals of Surgical Oncology},
	author = {Kubo, Yuto and Miyata, Hiroshi and Sugimura, Keijiro and Shinno, Naoki and Asukai, Kei and Hasegawa, Shinitiro and Yanagimoto, Yoshitomo and Yamada, Daisaku and Yamamoto, Kazuyoshi and Nishimura, Junichi and Wada, Hiroshi and Takahashi, Hidenori and Yasui, Masayoshi and Omori, Takeshi and Ohue, Masayuki and Yano, Masahiko},
	month = jan,
	year = {2021},
	pages = {184--193},
}

@article{takahashi3727,
	title = {Prognostic {Significance} of {Skeletal} {Muscle} {Loss} {During} {Early} {Postoperative} {Period} in {Elderly} {Patients} with {Esophageal} {Cancer}},
	volume = {26},
	issn = {1534-4681},
	url = {https://doi.org/10.1245/s10434-019-07616-0},
	doi = {10.1245/s10434-019-07616-0},
	abstract = {Skeletal muscle loss during the early postoperative period frequently occurs during post-esophagectomy. Preoperative sarcopenia is a known prognostic factor. However, the prognostic significance of postoperative skeletal muscle loss remains unclear. This study was designed to clarify the impact of skeletal muscle loss during the early postoperative period on the prognosis of elderly patients undergoing esophagectomy.},
	language = {en},
	number = {11},
	urldate = {2022-01-22},
	journal = {Annals of Surgical Oncology},
	author = {Takahashi, Keita and Watanabe, Masayuki and Kozuki, Ryotaro and Toihata, Tasuku and Okamura, Akihiko and Imamura, Yu and Mine, Shinji and Ishizuka, Naoki},
	month = oct,
	year = {2019},
	keywords = {Esophagectomy},
	pages = {3727--3735},
}

@article{djourno527,
	title = {Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer},
	volume = {25},
	issn = {1120-8694},
	url = {https://doi.org/10.1111/j.1442-2050.2011.01282.x},
	doi = {10.1111/j.1442-2050.2011.01282.x},
	abstract = {Malnutrition is common 1 year after esophageal cancer surgery. However, the prognostic impact of this malnutrition on long-term outcome has been poorly reported. This study aims at determining the potential effect on disease-free survival (DFS) of weight loss observed at 1 year in disease-free survivors after curative esophageal resection. From a prospective single-institution database, 304 patients having undergone a transthoracic esophagectomy with two-field lymphadenectomy and gastric reconstruction between 1996 to 2008 were identified. Patients who died during the postoperative course (n= 24), patients who died within the first postoperative year (n= 12), patients who presented with an early recurrence within the first postoperative year (n= 20), and those who were lost to follow-up (n= 22) were excluded from the study, as well as those for whom the follow-up was shorter than 1 year (n= 21). The remaining 205 patients constituted a homogeneous group of 1-year disease-free survivors after full postoperative work-up and formed the material of the present study. Body weight (BW) values were collected before any treatment at the onset of symptoms (initial BW) and 1 year after esophagectomy. A 1-year weight loss (1-YWL) exceeding 10\% of the initial BW defined an important malnutrition. Impact of the 1-YWL≥ or \&lt;10\% of the initial BW on DFS was investigated. Logistic regression was performed to identify factors affecting DFS. The mean initial BW was 69.1 ± 12 kg, corresponding to a mean body mass index (BMI) of 23.8 ± 3 kg/m2. Preoperatively, 32 (15\%) patients were in the underweight category (BMI \&lt; 20 kg/m2), 110 (54\%) were in normal (BMI = 20–24 kg/m2), and 63 (31\%) were in the overweight category (BMI ≥ 25 kg/m2). Mean 1-year BW was 63.5 ± 12 kg. 1-YWL was \&lt;10\% of the initial BW in 92 patients (45\%) and ≥10\% in 113 patients (55\%). Accordingly, 5-year DFS rates were 66\% (median: 80 months) and 48\% (median: 51 months), respectively (P= 0.005). On multivariate analysis, only three independent variables affected the DFS significantly: clinical N stage (cN) status (P= 0.007; odds ratio: 1.99, 1.2–3.3), incomplete resection (P= 0.008, OR: 3.6, 1.3–9.3), and 1-YWL ≥ 10\% (P= 0.004, OR: 2.1: 1.2–3.4). 1-YWL of or exceeding 10\% of the initial BW in 1-year disease-free survivors has a negative prognostic impact on DFS after esophagectomy for cancer. This information offers another view on the objectives of the perioperative nutritional care of these patients. Special vigilance program on the nutritional status in post-esophagectomy patients should be the rule.},
	number = {6},
	urldate = {2022-01-22},
	journal = {Diseases of the Esophagus},
	author = {D’Journo, X. B. and Ouattara, M. and Loundou, A. and Trousse, D. and Dahan, L. and Nathalie, T. and Doddoli, C. and Seitz, J. F. and Thomas, P.-A.},
	month = aug,
	year = {2012},
	keywords = {Weight Loss; GE},
	pages = {527--534},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/Q8NTH4KZ/D’Journo et al. - 2012 - Prognostic impact of weight loss in 1-year survivo.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/9Z3UK2KA/2328558.html:text/html},
}

@article{argiles477,
	title = {The metabolic basis of cancer cachexia},
	volume = {17},
	issn = {0198-6325},
	doi = {10.1002/(sici)1098-1128(199709)17:5<477::aid-med3>3.0.co;2-r},
	language = {eng},
	number = {5},
	journal = {Medicinal Research Reviews},
	author = {Argilés, J. M. and Alvarez, B. and López-Soriano, F. J.},
	month = sep,
	year = {1997},
	pmid = {9276862},
	keywords = {Adipose Tissue, Humans, Muscle, Skeletal, Cachexia, Neoplasms, Carbohydrate Metabolism, Energy Metabolism, Insulin Resistance},
	pages = {477--498},
}

@article{bozzetti698,
	title = {Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support},
	volume = {26},
	issn = {1532-1983},
	shorttitle = {Postoperative complications in gastrointestinal cancer patients},
	doi = {10.1016/j.clnu.2007.06.009},
	abstract = {BACKGROUND \& AIMS: This study investigated the effects of nutritional support on postoperative complications, in relation with demographic and nutritional factors, intraoperative factors, type and routes of nutritional regimens.
METHODS: A series of 1410 subjects underwent major abdominal surgery for gastrointestinal cancer and received various types of nutritional support: standard intravenous fluids (SIF; n=149), total parenteral nutrition (TPN; n=368), enteral nutrition (EN; n=393), and immune-enhancing enteral nutrition (IEEN; n=500). Postoperative complications, considered as major (if lethal or requiring re-operation, or transfer to intensive care unit), or otherwise minor, were recorded.
RESULTS: Major and minor complications occurred in 101 (7.2\%) and 446 (31.6\%) patients, respectively. Factors correlated with postoperative complications at multivariate analysis were pancreatic surgery, (p{\textless}0.001), advanced age (p=0.002), weight loss (p=0.019), low serum albumin (p=0.019) and nutritional support (p=0.001). Nutritional support reduced morbidity versus SIF with an increasing protective effect of TPN, EN, and IEEN. This effect remained valid regardless the severity of risk factors identified at the multivariate analysis and it was more evident by considering infectious complications only.
CONCLUSIONS: Pancreatic surgery, advanced age, weight loss and low serum albumin are independent risk factors for the onset of postoperative complications. Nutritional support, particularly IEEN, significantly reduced postoperative morbidity.},
	language = {eng},
	number = {6},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Bozzetti, Federico and Gianotti, Luca and Braga, Mario and Di Carlo, Valerio and Mariani, Luigi},
	month = dec,
	year = {2007},
	pmid = {17683831},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Postoperative Care, Treatment Outcome, Colorectal Neoplasms, Risk Factors, Time Factors, Pancreatic Neoplasms, Weight Loss, Age Factors, Survival Analysis, Stomach Neoplasms, Postoperative Complications, Multivariate Analysis, Enteral Nutrition, Nutrition, Nutritional Status, Perioperative Care, Nutritional Support, Fluid Therapy, Immune System, Morbidity, Parenteral Nutrition, Total, Serum Albumin},
	pages = {698--709},
}

@article{hoyo1706,
	title = {Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the {International} {BEACON} {Consortium}},
	volume = {41},
	issn = {1464-3685},
	shorttitle = {Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas},
	doi = {10.1093/ije/dys176},
	abstract = {BACKGROUND: Previous studies suggest an association between obesity and oesophageal (OA) and oesophagogastric junction adenocarcinomas (OGJA). However, these studies have been limited in their ability to assess whether the effects of obesity vary by gender or by the presence of gastro-oesophageal reflux (GERD) symptoms.
METHODS: Individual participant data from 12 epidemiological studies (8 North American, 3 European and 1 Australian) comprising 1997 OA cases, 1900 OGJA cases and 11 159 control subjects were pooled. Logistic regression was used to estimate study-specific odds ratios (ORs) and 95\% confidence intervals (CIs) for the association between body mass index (BMI, kg/m(2)) and the risk of OA and OGJA. Random-effects meta-analysis was used to combine these ORs. We also investigated effect modification and synergistic interaction of BMI with GERD symptoms and gender.
RESULTS: The association of OA and OGJA increased directly with increasing BMI (P for trend {\textless}0.001). Compared with individuals with a BMI {\textless}25, BMI ≥40 was associated with both OA (OR 4.76, 95\% CI 2.96-7.66) and OGJA (OR 3.07, 95\% CI 1.89-4.99). These associations were similar when stratified by gender and GERD symptoms. There was evidence for synergistic interaction between BMI and GERD symptoms in relation to OA/OGJA risk.
CONCLUSIONS: These data indicate that BMI is directly associated with OA and OGJA risk in both men and women and in those with and without GERD symptoms. Disentangling the relationship between BMI and GERD will be important for understanding preventive efforts for OA and OGJA.},
	language = {eng},
	number = {6},
	journal = {International Journal of Epidemiology},
	author = {Hoyo, Cathrine and Cook, Michael B. and Kamangar, Farin and Freedman, Neal D. and Whiteman, David C. and Bernstein, Leslie and Brown, Linda M. and Risch, Harvey A. and Ye, Weimin and Sharp, Linda and Wu, Anna H. and Ward, Mary H. and Casson, Alan G. and Murray, Liam J. and Corley, Douglas A. and Nyrén, Olof and Pandeya, Nirmala and Vaughan, Thomas L. and Chow, Wong-Ho and Gammon, Marilie D.},
	month = dec,
	year = {2012},
	pmid = {23148106},
	pmcid = {PMC3535758},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Adult, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Logistic Models, Sex Distribution, Gastroesophageal Reflux, GE},
	pages = {1706--1718},
	file = {Full Text:/Users/jcsal/Zotero/storage/QPVEQMFU/Hoyo et al. - 2012 - Body mass index in relation to oesophageal and oes.pdf:application/pdf},
}

@article{kitagawa5409,
	title = {Analysis of {Factors} {Associated} with {Weight} {Loss} {After} {Esophagectomy} for {Esophageal} {Cancer}},
	volume = {36},
	issn = {1791-7530},
	doi = {10.21873/anticanres.11117},
	abstract = {AIM: To investigate the factors associated with weight loss (WL) after esophagectomy for esophageal cancer.
PATIENTS AND METHODS: We retrospectively reviewed 136 patients who underwent esophagectomy for esophageal cancer. Preoperative characteristics, surgical methods, postoperative outcomes and weight changes at 6 months after surgery were analyzed.
RESULTS: Seventy-eight patients had more than 10\% WL compared to their weight at surgery. On univariate analysis, higher body mass index [(BMI): ≥20.8; p=0.012] and shorter length of hospitalization [(LOH); p=0.041] demonstrated an association with more than 10\% WL. On multivariate analysis, higher BMI [odds ratio (OR)=2.821; 95\% confidence interval (CI)=1.238-6.426; p=0.014] and shorter LOH (OR=2.953; 95\% CI=1.009-8.646; p=0.048) were independently associated with more than 10\% WL.
CONCLUSION: Higher BMI and shorter LOH were unfavorable risk factors for WL after esophagectomy for esophageal cancer.},
	language = {eng},
	number = {10},
	journal = {Anticancer Research},
	author = {Kitagawa, Hiroyuki and Namikawa, Tsutomu and Munekage, Masaya and Fujisawa, Kazune and Munekage, Eri and Kawanishi, Yasuhiro and Kobayashi, Michiya and Hanazaki, Kazuhiro},
	month = oct,
	year = {2016},
	pmid = {27798907},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Weight Loss, Esophageal Neoplasms, Esophagectomy, esophageal cancer, esophagectomy, Weight loss, GE},
	pages = {5409--5412},
	file = {Full Text:/Users/jcsal/Zotero/storage/SCKE2TPH/Kitagawa et al. - 2016 - Analysis of Factors Associated with Weight Loss Af.pdf:application/pdf},
}

@article{knyrim1302,
	title = {A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer},
	volume = {329},
	issn = {0028-4793},
	doi = {10.1056/NEJM199310283291803},
	abstract = {BACKGROUND: Esophageal obstruction due to cancer can produce debilitating dysphagia. Rapid palliation is usually possible with endoscopic placement of a plastic esophageal prosthesis, but this device has a high rate of complications. A new alternative is a metal-mesh stent that collapses to 3 mm in diameter at placement but can then expand up to 16 mm.
METHODS: Patients with esophageal carcinoma (39 patients) or malignant extrinsic obstruction (3 patients) were randomly assigned to treatment with either a plastic prosthesis (16 mm in diameter) or an expansile metal-mesh stent. The patients were evaluated every six weeks until death. The degree of palliation was expressed as a dysphagia score and a Karnofsky performance score.
RESULTS: Complications were significantly less frequent with the metal stents than with the plastic prostheses (no complications vs. nine; P {\textless} 0.001). The dysphagia and Karnofsky scores improved significantly and to a similar degree in both treatment groups. The most common causes of recurrent dysphagia were migration of the plastic prostheses (five patients) and ingrowth or overgrowth of the metal stents by tumor (five patients). The rates of reintervention were similar in both treatment groups, as were the 30-day mortality rates. The period of hospitalization after placement of a prosthesis was significantly longer in the group given plastic prostheses than in the group given metal stents (mean +/- SE, 12.5 +/- 2.1 vs. 5.4 +/- 1.0 days; P = 0.005). Despite their higher initial cost, the metal stents were cost effective because of the absence of fatal complications and the decrease in the hospital stay.
CONCLUSIONS: Expansile metal stents are a safe and cost-effective alternative to conventional plastic endoprostheses in the treatment of esophageal obstruction due to inoperable cancer.},
	language = {eng},
	number = {18},
	journal = {The New England Journal of Medicine},
	author = {Knyrim, K. and Wagner, H. J. and Bethge, N. and Keymling, M. and Vakil, N.},
	month = oct,
	year = {1993},
	pmid = {7692297},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Palliative Care, Esophageal Neoplasms, Cost-Benefit Analysis, Deglutition Disorders, Stents, Recurrence, Esophageal Stenosis, Metals, Plastics, Prosthesis Design},
	pages = {1302--1307},
}

@article{koterazawa407,
	title = {Severe weight loss after minimally invasive oesophagectomy is associated with poor survival in patients with oesophageal cancer at 5 years},
	volume = {20},
	issn = {1471-230X},
	doi = {10.1186/s12876-020-01543-1},
	abstract = {BACKGROUND: Patients often experience severe weight loss after oesophagectomy. Enteral nutrition via a feeding jejunostomy tube (FT) is commonly practised. This study aimed to assess the effect of severe weight loss postoperatively and enteral nutrition via an FT on long-term prognosis after oesophagectomy.
METHODS: This study analysed 317 patients who underwent minimally invasive oesophagectomy at Kobe University Hospital and Hyogo Cancer Center from 2010 to 2015. The patients' body weight was evaluated at 3 months postoperatively. They were organised into the severe weight loss (n = 65) and moderate weight loss (n = 252) groups. Furthermore, they were categorised into the FT group (184 patients who had an FT placed during oesophagectomy) and no-FT group (133 patients without FT). Patients (119 per group) matched for the FT and no-FT groups were identified via propensity score matching.
RESULTS: The 5-year overall survival (OS) rate in the severe weight loss group was significantly lower (p = 0.024). In the multivariate analysis, tumour invasion depth (pT3-4), preoperative therapy and severe weight loss had a worse OS (hazard ratio = 1.89; 95\% confidence interval = 1.12-3.17, hazard ratio = 2.11; 95\% confidence interval = 1.25-3.54, hazard ratio = 1.82; 95\% confidence interval = 1.02-3.524, respectively). No significant differences in the number of severe weight loss patients and OS were found between the FT and no-FT groups.
CONCLUSION: Severe weight loss is significantly associated with poor OS. In addition, enteral nutrition via an FT did not improve the severe weight loss and OS.},
	language = {eng},
	number = {1},
	journal = {BMC gastroenterology},
	author = {Koterazawa, Yasufumi and Oshikiri, Taro and Takiguchi, Gosuke and Urakawa, Naoki and Hasegawa, Hiroshi and Yamamoto, Masashi and Kanaji, Shingo and Yamashita, Kimihiro and Matsuda, Takeru and Nakamura, Tetsu and Suzuki, Satoshi and Kakeji, Yoshihiro},
	month = dec,
	year = {2020},
	pmid = {33272220},
	pmcid = {PMC7713340},
	keywords = {Humans, Treatment Outcome, Weight Loss, Esophageal Neoplasms, Esophagectomy, Enteral nutrition, Enteral Nutrition, Minimally invasive oesophagectomy, Severe weight loss},
	pages = {407},
	file = {Full Text:/Users/jcsal/Zotero/storage/2WAK4ZTF/Koterazawa et al. - 2020 - Severe weight loss after minimally invasive oesoph.pdf:application/pdf},
}

@article{nakashima492,
	title = {Skeletal {Muscle} {Loss} {After} {Esophagectomy} {Is} an {Independent} {Risk} {Factor} for {Patients} with {Esophageal} {Cancer}},
	volume = {27},
	issn = {1534-4681},
	doi = {10.1245/s10434-019-07850-6},
	abstract = {BACKGROUND: Postoperative changes in skeletal muscle and their influence on outcomes after esophagectomy for patients with esophageal cancer have not been fully investigated. This study aimed to confirm that postoperative skeletal muscle decrease influences long-term patient outcomes.
METHODS: Data were collected from 218 patients who underwent curative esophagectomy for esophageal cancer whose data were available before and 6 months after surgery. The skeletal muscle index (SMI) was measured at the level of the L3 vertebrae, and the postoperative change in the SMI compared with preoperative values was calculated as the delta SMI.
RESULTS: The mean SMI value was - 11.64\%, and the median delta SMI value was - 11.88\%. The first and third quartiles were defined as cutoffs, and 218 patients were classified as the mild-loss group (54 patients), moderate-loss group (110 patients), and severe-loss group (54 patients). The patients with a more severely reduced SMI had a worse prognosis (5-year overall survival rates: mild loss, 66.6\%; moderate loss, 58.8\%; and severe loss, 48.5\%; p = 0.0314). This correlation between reduced SMI and prognosis also was observed for the patients with preoperative sarcopenia (p {\textless} 0.0001), but not for those without preoperative sarcopenia.
CONCLUSIONS: Postoperative reduced SMI and worse prognosis were significantly associated in esophageal cancer patients.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Nakashima, Yuichiro and Saeki, Hiroshi and Hu, Qingjiang and Tsuda, Yasuo and Zaitsu, Yoko and Hisamatsu, Yuichi and Ando, Koji and Kimura, Yasue and Oki, Eiji and Mori, Masaki},
	month = feb,
	year = {2020},
	pmid = {31549319},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Follow-Up Studies, Retrospective Studies, Risk Factors, Survival Rate, Prognosis, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Esophageal Squamous Cell Carcinoma, Postoperative Complications, GE},
	pages = {492--498},
}

@article{park1137,
	title = {Risk {Factors} for {Weight} {Loss} 1 {Year} {After} {Esophagectomy} and {Gastric} {Pull}-up for {Esophageal} {Cancer}},
	volume = {22},
	issn = {1873-4626},
	doi = {10.1007/s11605-018-3749-2},
	abstract = {BACKGROUND: Loss of body weight is regarded as a marker of malnutrition after esophagectomy. This study investigated changes in body weight and risk factors for weight loss after esophagectomy for esophageal cancer.
METHODS: We retrospectively reviewed records of 181 patients who underwent esophagectomy and gastric pull-up from 2012 to June 2016. Patients with operative mortality and recurrences were excluded. Percent change in body weight was defined as change in body weight (\%) = (1-year body weight - preoperative body weight) × 100/preoperative body weight.
RESULTS: Mean age of patients was 62.98 ± 8.23 years with 164 men (90.6\%). Mean preoperative body weight was 63.12 ± 9.42 kg, and body weight at 1 year was 56.04 ± 8.59 kg. Mean change in body weight was - 10.95 ± 7.50\%, and 98 (54.1\%) patients showed weight loss more than 10\% compared to initial body weight. Univariable analysis showed that initial body weight, narrow gastric tube, thoracotomy, laparotomy, and postoperative vocal cord palsy (VCP) were related to more than 10\% weight loss. Multivariable analysis showed that initial body weight (odds ratio [OR] = 1.041, p = 0.031) and postoperative VCP (OR = 2.772, p = 0.025) were adverse risk factors for weight loss 1 year after esophagectomy, whereas conduit type, route of reconstruction, postoperative complications, anastomotic complications, minimally invasive esophagectomy, and adjuvant therapy were not.
CONCLUSIONS: Initial body weight and postoperative VCP were related to weight loss. Patients with VCP need additional nutritional monitoring and support.},
	language = {eng},
	number = {7},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Park, Seong Yong and Kim, Dae Joon and Suh, Jee Won and Byun, Go Eun},
	month = jul,
	year = {2018},
	pmid = {29611091},
	keywords = {Humans, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Risk Factors, Body Weight, Weight Loss, Esophagectomy, Esophageal Squamous Cell Carcinoma, Postoperative Complications, Esophagus, Malnutrition, Laparotomy, GE, Gastrostomy, Republic of Korea},
	pages = {1137--1143},
}

@article{tisdale243S,
	title = {Wasting in cancer},
	volume = {129},
	issn = {0022-3166},
	doi = {10.1093/jn/129.1.243S},
	abstract = {Progressive weight loss is a common feature of many types of cancer and is responsible not only for a poor quality of life and poor response to chemotherapy, but also a shorter survival time than is found in patients with comparable tumors without weight loss. Although anorexia is common, a decreased food intake alone is unable to account for the changes in body composition seen in cancer patients, and increasing nutrient intake is unable to reverse the wasting syndrome. Although energy expenditure is increased in some patients, cachexia can occur even with a normal energy expenditure. Various factors have been investigated as mediators of tissue wasting in cachexia. These include cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interferon-gamma (IFN-gamma) and leukemia inhibitory factor (LIF), as well as tumor-derived factors such as lipid mobilizing factor (LMF) and protein mobilizing factor (PMF), which can directly mobilize fatty acids and amino acids from adipose tissue and skeletal muscle respectively. Induction of lipolysis by the cytokines is thought to result from an inhibition of lipoprotein lipase (LPL), although clinical studies provide no evidence for an inhibition of LPL in the adipose tissue of cancer patients. Instead there is an increased expression of hormone sensitive lipase, the enzyme activated by LMF. Protein degradation in cachexia is associated with an increased activity of the ATP-ubiquitin-proteasome pathway. The biological activity of both the LMF and PMF was shown to be attenuated by eicosapentaenoic acid (EPA). Clinical studies show that this polyunsaturated fatty acid is able to stabilize the rate of weight loss and adipose tissue and muscle mass in cachectic patients with unresectable pancreatic cancer. Knowledge of the mechanism of cancer cachexia should lead to the development of new therapeutic agents.},
	language = {eng},
	number = {1S Suppl},
	journal = {The Journal of Nutrition},
	author = {Tisdale, M. J.},
	month = jan,
	year = {1999},
	pmid = {9915907},
	keywords = {Humans, Weight Loss, Muscles, Anorexia, Energy Metabolism, HIV Wasting Syndrome, Lipid Metabolism},
	pages = {243S--246S},
	file = {Full Text:/Users/jcsal/Zotero/storage/9Z43I6S7/Tisdale - 1999 - Wasting in cancer.pdf:application/pdf},
}

@article{wang209,
	title = {Analysis of the associated factors for severe weight loss after minimally invasive {McKeown} esophagectomy},
	volume = {10},
	issn = {1759-7714},
	doi = {10.1111/1759-7714.12934},
	abstract = {BACKGROUND: This study investigated the risk factors for severe weight loss (SWL) within one year after minimally invasive McKeown esophagectomy.
METHODS: Esophageal cancer patients who underwent McKeown esophagectomy between January and July 2017 were prospectively enrolled. Preoperative body weight (PBW) was chosen as the initial body weight.
RESULTS: Forty-four patients were enrolled and successfully followed up for one year. Median weight loss was 7.4\% (quartile: 5.3-8.1\%) and 12.6\% (quartile: 8.8-17.7\%) four weeks and one year after surgery, respectively. Accelerated weight loss occurred during the first two weeks after discharge, with median weight loss of 5.6\% (quartile: 4.2-7.1\%). Multivariable analysis showed that age ≥ 70 years (odds ratio [OR] 7.65; P = 0.030), preoperative sarcopenia (OR 7.18; P = 0.030), the first surgery in the daily schedule (OR 6.87; P = 0.032) and vocal cord paralysis (OR 12.30; P = 0.046) were independent risk factors for short-term (4 weeks) SWL ({\textgreater} 7.5\% PBW), while an American Society of Anesthesiologists score of 3-4 (OR 6.58; P = 0.047), a high fat-free mass (OR 21.91; P = 0.003), and vocal cord paralysis (OR 25.83; P = 0.017) were independent risk factors for long-term (1 year) SWL ({\textgreater} 13.0\% PBW) after esophagectomy. Postoperative symptoms of insomnia, appetite loss, dysphagia, eating difficulties, and taste issues were also related to SWL.
CONCLUSIONS: In esophageal cancer patients who have undergone esophagectomy, the first two weeks after hospital discharge is a key period for nutrition intervention. Patients with associated factors for SWL require postoperative nutrition support.},
	language = {eng},
	number = {2},
	journal = {Thoracic Cancer},
	author = {Wang, Peiyu and Li, Yin and Sun, Haibo and Zhang, Ruixiang and Liu, Xianben and Liu, Shilei and Wang, Zongfei and Zheng, Yan and Yu, Yongkui and Chen, Xiankai and Li, Haomiao and Zhang, Jun and Liu, Qi},
	month = feb,
	year = {2019},
	pmid = {30578600},
	pmcid = {PMC6360231},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Risk Factors, Prospective Studies, Prognosis, Weight Loss, Aged, 80 and over, Adult, Young Adult, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Severity of Illness Index, esophagectomy, Quality of Life, Adolescent, GE, Esophageal neoplasm, risk factor, weight loss},
	pages = {209--218},
	file = {Full Text:/Users/jcsal/Zotero/storage/MMYUUH5F/Wang et al. - 2019 - Analysis of the associated factors for severe weig.pdf:application/pdf},
}

@article{zhang2894,
	title = {The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis},
	volume = {109},
	issn = {1532-1827},
	shorttitle = {The impact of body mass index on complication and survival in resected oesophageal cancer},
	doi = {10.1038/bjc.2013.666},
	abstract = {BACKGROUND: Body mass index (BMI) has been associated with the risk of oesophageal cancer. But the influence of BMI on postoperative complication and prognosis has always been controversial.
METHODS: In total, 2031 consecutive patients who underwent oesophagectomy between 1998 and 2008 were classified according to Asian-specific BMI (kg m(-2)) cutoff values. The impact of BMI on overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazard models. We performed a meta-analysis to examine the association of BMI with OS and postoperative complication.
RESULTS: Patients with higher BMI had more postoperative complication (P=0.002), such as anastomotic leakage (P=0.016) and cardiovascular diseases (P{\textless}0.001), but less incidence of chylous leakage (P=0.010). Logistic regression analysis showed that BMI (P=0.005) was a confounding factor associated with postoperative complication. Multivariate analysis showed that overweight and obese patients had a more favourable survival than normal weight patients (HR (hazard ratio) = 0.80, 95\% CI (confidence interval): 0.70-0.92, P=0.001). Subgroup analysis showed that the association with higher BMI and increased OS was observed in patients with oesophageal squamous cell carcinoma (ESCC) (P{\textless}0.001), oesophageal adenocarcinoma (EA) (P=0.034), never-smoking (P=0.035), ever-smoking (P=0.035), never alcohol consumption (P=0.005), weight loss (P=0.003) and advanced pathological stage (P{\textless}0.001). The meta-analysis further corroborated that higher BMI was associated with increased complication of anastomotic leakage (RR (risk ratio)=1.04, 95\% CI: 1.02-1.06, P=0.001), wound infection (RR=1.03, 95\% CI: 1.00-1.05, P=0.031) and cardiovascular diseases (RR=1.02, 95\% CI: 1.00-1.05, P=0.039), but decreased incidence of chylous leakage (RR=0.98, 95\% CI: 0.96-0.99, P{\textless}0.001). In addition, high BMI could significantly improved OS (HR=0.78, 95\% CI: 0.71-0.85, P{\textless}0.001).
CONCLUSION: Preoperative BMI was an independent prognostic factor for survival, and strongly associated with postoperative complications in oesophageal cancer.},
	language = {eng},
	number = {11},
	journal = {British Journal of Cancer},
	author = {Zhang, S. S. and Yang, H. and Luo, K. J. and Huang, Q. Y. and Chen, J. Y. and Yang, F. and Cai, X. L. and Xie, X. and Liu, Q. W. and Bella, A. E. and Hu, R. G. and Wen, J. and Hu, Y. and Fu, J. H.},
	month = nov,
	year = {2013},
	pmid = {24201750},
	pmcid = {PMC3844915},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Prognosis, Cohort Studies, Aged, 80 and over, Adult, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Postoperative Complications, China, GE},
	pages = {2894--2903},
	file = {Full Text:/Users/jcsal/Zotero/storage/D48XZT6K/Zhang et al. - 2013 - The impact of body mass index on complication and .pdf:application/pdf},
}

@article{vaughan95,
	title = {Cancer cachexia: impact, mechanisms and emerging treatments},
	volume = {4},
	issn = {2190-5991},
	shorttitle = {Cancer cachexia},
	doi = {10.1007/s13539-012-0087-1},
	abstract = {Many forms of cancer present with a complex metabolic profile characterised by loss of lean body mass known as cancer cachexia. The physical impact of cachexia contributes to decreased patient quality of life, treatment success and survival due to gross alterations in protein metabolism, increased oxidative stress and systemic inflammation. The psychological impact also contributes to decreased quality of life for both patients and their families. Combination therapies that target multiple pathways, such as eicosapentaenoic acid administered in combination with exercise, appetite stimulants, antioxidants or anti-inflammatories, have potential in the treatment of this complex syndrome and require further development.},
	language = {eng},
	number = {2},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Vaughan, Vanessa C. and Martin, Peter and Lewandowski, Paul A.},
	month = jun,
	year = {2013},
	pmid = {23097000},
	pmcid = {PMC3684701},
	keywords = {GE},
	pages = {95--109},
	file = {Full Text:/Users/jcsal/Zotero/storage/JIB7JJG2/Vaughan et al. - 2013 - Cancer cachexia impact, mechanisms and emerging t.pdf:application/pdf},
}

@article{gu3029,
	title = {Prognostic significance of combined pretreatment body mass index ({BMI}) and {BMI} loss in patients with esophageal cancer},
	volume = {11},
	issn = {1179-1322},
	doi = {10.2147/CMAR.S197820},
	abstract = {Background: Body mass index (BMI) has been associated with a risk of esophageal cancer. However, the influence of BMI and BMI loss on people with esophageal cancer that were treated with different therapies has not been described in China. Methods: In total, 615 consecutive patients that underwent esophagectomy and/or chemotherapy/radiotherapy were classified according to the Asian-specific BMI (kg/m2) cutoff values. The impact of BMI and BMI loss on long-term overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazard models. Results: Multivariate analysis showed that overweight and obese patients had a more favorable survival than normal weight and underweight patients (p=0.017). Patients with a low BMI and high BMI loss before therapy had worse OS than others (p=0.001). Subgroup analysis showed that patients with a high BMI were more likely to suffer hypertension (p{\textless}0.001) and receive only surgery (p{\textless}0.001), and they were less likely to be smokers (p=0.007) and anemic (p{\textless}0.001). Conversely, patients with high BMI loss were more likely to be anemic (p=0.001), to have advanced pathological stage (p=0.012), and to receive chemotherapy and radiotherapy (p=0.001). Moreover, the mortality rate was higher when patients had a high BMI loss. There is no survival benefit of higher BMI in the non-esophageal squamous cell carcinoma (ESCC) group. Conclusion: Pretreatment BMI was an independent prognostic factor for long-term survival in esophageal cancer patients treated with different treatments. The overall survival was increased in esophageal cancer patients with a high pretreatment BMI and no BMI loss. There is no survival benefit of higher BMI in the non-ESCC group.},
	language = {eng},
	journal = {Cancer Management and Research},
	author = {Gu, Wen-Shen and Fang, Wei-Zhen and Liu, Chun-Yue and Pan, Kun-Yi and Ding, Rui and Li, Xiao-Hui and Duan, Chao-Hui},
	year = {2019},
	pmid = {31114349},
	pmcid = {PMC6489636},
	keywords = {esophageal cancer, BMI, BMI loss, long-term survival},
	pages = {3029--3041},
	file = {Full Text:/Users/jcsal/Zotero/storage/9XDY788Y/Gu et al. - 2019 - Prognostic significance of combined pretreatment b.pdf:application/pdf},
}

@article{voeten6344,
	title = {Length of hospital stay after uncomplicated esophagectomy. {Hospital} variation shows room for nationwide improvement},
	volume = {35},
	issn = {1432-2218},
	url = {https://doi.org/10.1007/s00464-020-08103-4},
	doi = {10.1007/s00464-020-08103-4},
	abstract = {Within the scope of value-based health care, this study aimed to analyze Dutch hospital performance in terms of length of hospital stay after esophageal cancer surgery and its association with 30-day readmission rates. Since both parameters are influenced by the occurrence of complications, this study only included patients with an uneventful recovery after esophagectomy.},
	language = {en},
	number = {11},
	urldate = {2022-01-22},
	journal = {Surgical Endoscopy},
	author = {Voeten, Daan M. and van der Werf, Leonie R. and van Sandick, Johanna W. and van Hillegersberg, Richard and van Berge Henegouwen, Mark I. and {on behalf of the Dutch Upper Gastrointestinal Cancer Audit Group}},
	month = nov,
	year = {2021},
	keywords = {MIE},
	pages = {6344--6357},
	file = {Springer Full Text PDF:/Users/jcsal/Zotero/storage/9TY57EFJ/Voeten et al. - 2021 - Length of hospital stay after uncomplicated esopha.pdf:application/pdf},
}

@article{takesueS802,
	title = {A {Prospective} {Randomized} {Trial} of {Enteral} {Nutrition} {After} {Thoracoscopic} {Esophagectomy} for {Esophageal} {Cancer}},
	volume = {22 Suppl 3},
	issn = {1534-4681},
	doi = {10.1245/s10434-015-4767-x},
	abstract = {BACKGROUND: Several studies have reported that postoperative enteral nutrition (EN) reduced complications and decreased weight loss and hospital stay periods; however, the majority of patients analyzed in these studies underwent open thoracic surgery. No studies have been conducted regarding EN in patients after thoracoscopic esophagectomy as a less invasive surgery. The aim of this study was to investigate the efficacy of EN after thoracoscopic esophagectomy.
METHODS: Fifty patients who underwent thoracoscopic esophagectomy for esophageal cancer were divided into two groups: parenteral nutrition (PN; n = 25) and EN (n = 25). The rate of weight loss at postoperative day (POD) 14, levels of prealbumin at POD 10, postoperative complications until POD 14, and other perioperative data were collected for each group.
RESULTS: This study analyzed data for 47 patients. The rate of weight loss at POD 14 was significantly lower in the EN group (3.0 ± 3.2 \%) than in the PN group (5.1 ± 3.7 \%; p = 0.020). Prealbumin levels were 21.0 ± 7.5 mg/dL in the PN group and 18.4 ± 5.8 mg/dL in the EN group at POD 10, with no significant differences between the groups. However, the incidence of postoperative pneumonia was higher in the PN group (30.4 \%) than in the EN group (12.5 \%).
CONCLUSIONS: EN could suppress weight loss and reduce the incidence of pneumonia after thoracoscopic esophagectomy.},
	language = {eng},
	journal = {Annals of Surgical Oncology},
	author = {Takesue, Tomoko and Takeuchi, Hiroya and Ogura, Masaharu and Fukuda, Kazumasa and Nakamura, Rieko and Takahashi, Tsunehiro and Wada, Norihito and Kawakubo, Hirofumi and Kitagawa, Yuko},
	month = dec,
	year = {2015},
	pmid = {26219242},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Neoplasm Metastasis, Prospective Studies, Prognosis, Neoplasm Invasiveness, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Enteral Nutrition, Neutropenia, Thoracic Surgical Procedures},
	pages = {S802--809},
}

@article{srpcic237,
	title = {Sarcopenia and {Myosteatosis} at {Presentation} {Adversely} {Affect} {Survival} {After} {Esophagectomy} for {Esophageal} {Cancer}},
	volume = {54},
	issn = {1318-2099},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276641/},
	doi = {10.2478/raon-2020-0016},
	abstract = {Background
Esophageal cancer remains a disease with poor survival and many complications. Measuring muscle mass and quality can identify patients with diminished muscle mass (sarcopenia) and muscle fat infiltration (myosteatosis). We studied the impact of sarcopenia and myosteatosis in resectable esophageal cancer on overall survival and complications.

Patients and methods
139 patients received a radical esophagectomy. Skeletal muscle area (SMA) and muscle attenuation (MA) in CT images at L3 level were recorded and groups with and without sarcopenia and myosteatosis were compared for overall survival (OS), perioperative mortality, conduit complications, pleuropulmonary complications, respiratory failure requiring mechanical ventilation and other significant complications.

Results
Prevalence of sarcopenia and myosteatosis at presentation was 16.5\% and 51.8\%, respectively. Both were associated with decreased OS. Median survival was 18.3 months (CI 5.4–31.1) vs 31.0 months (CI 7.4–54.6) for sarcopenia/no sarcopenia (log rank p = 0.042) and 19.0 months (CI 13.3–24.7) vs 57.1 months (CI 15.2–99.0) for myosteatosis (log rank p = 0.044), respectively. A relationship between sarcopenia and myosteatosis and other negative outcomes after esophagectomy could not be established.

Conclusions
Sarcopenia and myosteatosis before esophagectomy are associated with decreased overall survival but not with more frequent perioperative complications. Identification of patients at risk can guide therapeutic decisions and interventions aimed at replenishing muscle reserves.},
	number = {2},
	urldate = {2022-01-23},
	journal = {Radiology and Oncology},
	author = {Srpcic, Matevz and Jordan, Taja and Popuri, Karteek and Sok, Mihael},
	month = mar,
	year = {2020},
	pmid = {32229679},
	pmcid = {PMC7276641},
	keywords = {Adult, Aged, Aged, 80 and over, Body Composition, esophageal cancer, Esophageal Neoplasms, esophagectomy, Esophagectomy, Female, GE, Humans, Kaplan-Meier Estimate, Male, Middle Aged, muscle depletion, Muscular Diseases, myosteatosis, Postoperative Complications, Prospective Studies, sarcopenia, Sarcopenia, survival},
	pages = {237--246},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/VMPDVSIS/Srpcic et al. - 2020 - Sarcopenia and Myosteatosis at Presentation Advers.pdf:application/pdf;Srpcic et al. - Sarcopenia and myosteatosis at presentation advers.pdf:/Users/jcsal/Zotero/storage/Q34EEI95/Srpcic et al. - Sarcopenia and myosteatosis at presentation advers.pdf:application/pdf},
}

@article{gabiatti6967,
	title = {Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer},
	volume = {8},
	issn = {2045-7634},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.2593},
	doi = {10.1002/cam4.2593},
	abstract = {Increased adiposity and its attendant metabolic features as well as systemic inflammation have been associated with prognosis in locally advanced esophageal cancer (LAEC). However, whether myosteatosis and its combination with systemic inflammatory markers are associated with prognosis of esophageal cancer is unknown. Our study aimed to investigate the influence of myosteatosis and its association with systemic inflammation on progression-free survival (PFS) and overall survival (OS) in LAEC patients treated with definitive chemoradiotherapy (dCRT). We retrospectively gathered information on 123 patients with LAEC submitted to dCRT at the University of Campinas Hospital. Computed tomography (CT) images at the level of L3 were analyzed to assess muscularity and adiposity. Systemic inflammation was mainly measured by calculating the neutrophil-to-lymphocyte ratio (NLR). Median PFS for patients with myosteatosis (n = 72) was 11.0 months vs 4.0 months for patients without myosteatosis (n = 51) (hazard ratio [HR]: 0.53; 95\% confidence interval [CI], 0.34-0.83; P = .005). Myosteatosis was also independently associated with a favorable OS. Systemic inflammation (NLR {\textgreater} 2.8) was associated with a worse prognosis. The combination of myosteatosis with systemic inflammation revealed that the subgroup of patients with myosteatosis and without inflammation presented less than half the risk of disease progression (HR: 0.47; 95\% CI: 0.26-0.85; P = .013) and death (HR: 0.39; 95\% CI, 0.21-0.72; P = .003) compared with patients with inflammation. This study demonstrated that myosteatosis without systemic inflammation was independently associated with favorable PFS and OS in LAEC patients treated with dCRT.},
	language = {en},
	number = {16},
	urldate = {2022-01-23},
	journal = {Cancer Medicine},
	author = {Gabiatti, Camila T. B. and Martins, Mariane C. L. and Miyazaki, Daniela L. and Silva, Leandro P. and Lascala, Fabiana and Macedo, Ligia T. and Mendes, Maria Carolina Santos and Carvalheira, José Barreto Campello},
	year = {2019},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2593},
	keywords = {sarcopenia, cachexia, esophageal neoplasms, myosteatosis, survival analysis, Myosteatosis; GE},
	pages = {6967--6976},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/U35RF4TC/Gabiatti et al. - 2019 - Myosteatosis in a systemic inflammation-dependent .pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/EYY2IQDB/cam4.html:text/html},
}

@article{nattenmueller4131,
	title = {{CT}-based compartmental quantification of adipose tissue versus body metrics in colorectal cancer patients},
	volume = {26},
	issn = {1432-1084},
	doi = {10.1007/s00330-016-4231-8},
	abstract = {PURPOSE: While obesity is considered a prognostic factor in colorectal cancer (CRC), there is increasing evidence that not simply body mass index (BMI) alone but specifically abdominal fat distribution is what matters. As part of the ColoCare study, this study measured the distribution of adipose tissue compartments in CRC patients and aimed to identify the body metric that best correlates with these measurements as a useful proxy for adipose tissue distribution.
MATERIALS AND METHODS: In 120 newly-diagnosed CRC patients who underwent multidetector computed tomography (CT), densitometric quantification of total (TFA), visceral (VFA), intraperitoneal (IFA), retroperitoneal (RFA), and subcutaneous fat area (SFA), as well as the M. erector spinae and psoas was performed to test the association with gender, age, tumor stage, metabolic equivalents, BMI, waist-to-height (WHtR) and waist-to-hip ratio (WHR).
RESULTS: VFA was 28.8 \% higher in men (pVFA{\textless}0.0001) and 30.5 \% higher in patients older than 61 years (pVFA{\textless}0.0001). WHtR correlated best with all adipose tissue compartments (rVFA=0.69, rTFA=0.84, p{\textless}0.0001) and visceral-to-subcutaneous-fat-ratio (VFR, rVFR=0.22, p={\textless}0.05). Patients with tumor stages III/IV showed significantly lower overall adipose tissue than I/II. Increased M. erector spinae mass was inversely correlated with all compartments.
CONCLUSION: Densitometric quantification on CT is a highly reproducible and reliable method to show fat distribution across adipose tissue compartments. This distribution might be best reflected by WHtR, rather than by BMI or WHR.
KEY POINTS: • Densitometric quantification of adipose tissue on CT is highly reproducible and reliable. • Waist-to-height ratio better correlates with adipose tissue compartments and VFR than BMI or waist-to-hip ratio. • Men have higher a higher visceral fat area than women. • Patients older than 61 years have higher visceral fat area. • Patients with tumor stages III/IV have significantly lower adipose tissue than those in stages I/II.},
	language = {eng},
	number = {11},
	journal = {European Radiology},
	author = {Nattenmueller, Johanna and Hoegenauer, Hanna and Boehm, Juergen and Scherer, Dominique and Paskow, Michael and Gigic, Biljana and Schrotz-King, Petra and Grenacher, Lars and Ulrich, Cornelia and Kauczor, Hans-Ulrich},
	month = nov,
	year = {2016},
	pmid = {26852215},
	pmcid = {PMC5587125},
	keywords = {Adipose Tissue, Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Obesity, Body Mass Index, Colorectal Neoplasms, Adult, Intra-Abdominal Fat, Methods, Abdominal Fat, Body mass index, Colorectal neoplasms, Multidetector computed tomography, Multidetector Computed Tomography, Subcutaneous Fat, Waist-Hip Ratio, Waist-to-height ratio},
	pages = {4131--4140},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/J3PKC9MC/Nattenmueller et al. - 2016 - CT-based compartmental quantification of adipose t.pdf:application/pdf},
}

@article{goodpaster18,
	title = {Composition of skeletal muscle evaluated with computed tomography},
	volume = {904},
	issn = {0077-8923},
	doi = {10.1111/j.1749-6632.2000.tb06416.x},
	abstract = {Computed tomography (CT) can yield quantitative imaging data from detailed maps of linear attenuation coefficients within tissue. The attenuation characteristics of skeletal muscle and adipose tissue can be quantified in vivo to provide information about the composition of skeletal muscle and the distribution of adipose tissue within muscle. Several studies have taken advantage of this utility to quantify skeletal muscle composition and fatty infiltration of muscle, in particular to quantify the attenuation characteristics of muscle as a marker of its lipid content. In this manner we found that the mean muscle attenuation of skeletal muscle reflects an increase in its fat content in obesity, and that this regional body composition parameter is strongly related to insulin-resistant glucose metabolism. In addition, muscle composition and adipose tissue distribution within muscle may be altered with clinical weight-loss interventions. CT may also provide important information about the changes in muscle mass and composition with aging and disease, which may, in turn, affect the muscle's function. In summary, CT can provide important quantitative data on the composition of muscle, and the distribution of adipose tissue within it, and this may be important in examining the relationships among skeletal muscle metabolism, lipid accumulation within muscle, and muscle function.},
	language = {eng},
	journal = {Annals of the New York Academy of Sciences},
	author = {Goodpaster, B. H. and Thaete, F. L. and Kelley, D. E.},
	month = may,
	year = {2000},
	pmid = {10865705},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Methods},
	pages = {18--24},
}

@article{aleixo102839,
	title = {Myosteatosis and prognosis in cancer: {Systematic} review and meta-analysis},
	volume = {145},
	issn = {1879-0461},
	shorttitle = {Myosteatosis and prognosis in cancer},
	doi = {10.1016/j.critrevonc.2019.102839},
	abstract = {BACKGROUND: The evidence that body composition parameters influence multiple cancer outcomes is rapidly expanding. Excess adiposity deposits in muscle tissue, termed myosteatosis, can be detected in CT scans through variations in the density of muscle tissues (Hounsfield Units). Patients with similar muscle mass but different amounts of intramuscular adipose infiltration have increased chemotherapy toxicity, time to tumor progression and other adverse outcomes among different cancer types. Our review examines the impact of myosteatosis on overall survival (OS) in patients with cancer.
METHODS: A systematic search of the literature was conducted on PubMed/ MEDLINE, Cochrane CENTRAL, and EMBASE. Meta-analysis was conducted using a random-effects model. Risk of bias was evaluated using the Newcastle-Ottawa Quality assessment for cohort studies, funnel plot (publication bias), and GRADE summary of findings tool from Cochrane.
RESULTS: A total of 4880 articles were screened from which 40 articles selected, including 21,222 patients. The overall mean proportion of patients with myosteatosis was 48 \% (range 11-85 \%). Using skeletal muscle density (SMD), patients classified as having myosteatosis had 75 \% greater mortality risk compared to non-myosteatosis patients (HR 1.75 95 \% CI 1.60-1.92, 40 studies) (p {\textless} .00001) (i2 = 62 \%). Specifically, myosteatosis was prognostic for worse OS in patients with gynecological, renal, periampullary/pancreatic, hepatocellular, gastroesophageal, and colorectal carcinoma, and lymphomas.
CONCLUSION: Our analysis of the literature shows that cancer patients with myosteatosis have shorter survival. Our findings suggest that in oncological practice, muscle density assessment is valuable as a prognostic parameter.},
	language = {eng},
	journal = {Critical Reviews in Oncology/Hematology},
	author = {Aleixo, G. F. P. and Shachar, S. S. and Nyrop, K. A. and Muss, H. B. and Malpica, Luis and Williams, G. R.},
	month = jan,
	year = {2020},
	pmid = {31877534},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Obesity, Neoplasms, Prognosis, Cohort Studies, Body composition, Myosteatosis, Muscle mass, Adipose tissue infiltration, Cancer, Muscular Diseases},
	pages = {102839},
}

@article{wang25,
	title = {Myosteatosis reduces overall survival in patients with digestive system malignancies: a meta-analysis with trial sequential analysis},
	volume = {94},
	issn = {1879-0739},
	shorttitle = {Myosteatosis reduces overall survival in patients with digestive system malignancies},
	doi = {10.1016/j.nutres.2021.08.003},
	abstract = {The impact of myosteatosis on the outcomes of digestive malignancies has gained great attention recently. However, studies on the impact of myosteatosis show inconsistent results. We conducted a meta-analysis to clarify the relationship between myosteatosis and the overall survival of digestive cancer patients. The systematic literature search was conducted on PubMed/MEDLINE, Web of Science, and Embase from inception through March 27, 2021. Meta-analysis was performed using the random-effects model. Out of 3451 studies screened, 47 studies including 21,194 patients passed the screening criteria. The average prevalence of myosteatosis was 46.4\%. Patients with myosteatosis had 44\% increased mortality risk compared with non-myosteatosis patients (HR: 1.44, 95\% CI: 1.33-1.55, P {\textless} .05). The predictive value of myosteatosis held regardless of country zone, study design, statistical model, Newcastle-Ottawa Scale (NOS) scores, treatment, sample size, and tumor stage. Nevertheless, the predictive value of myosteatosis was only evident for patients with esophagogastric cancers, cholangiocarcinoma/pancreatic cancers, or colorectal cancers. Overall, the results of this meta-analysis were robust based on sensitivity, subgroup, meta-regression, and trial sequential analyses and suggested that myosteatosis predicted worse overall survival (OS) in digestive malignancies patients.},
	language = {eng},
	journal = {Nutrition Research (New York, N.Y.)},
	author = {Wang, Yue and Tian, Guangwei and Chen, Song and Li, Nan},
	month = oct,
	year = {2021},
	pmid = {34583210},
	keywords = {Adipose Tissue, Adiposity, Body Composition, Humans, Muscle, Skeletal, Female, Male, Prognosis, Body composition, Myosteatosis, Meta-analysis, Overall survival, Digestive malignancy, Digestive System Neoplasms},
	pages = {25--33},
}

@article{malietzis320,
	title = {Low {Muscularity} and {Myosteatosis} {Is} {Related} to the {Host} {Systemic} {Inflammatory} {Response} in {Patients} {Undergoing} {Surgery} for {Colorectal} {Cancer}},
	volume = {263},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000001113},
	abstract = {OBJECTIVE: We examined the relationships between computed tomography (CT)-defined skeletal muscle parameters and the systemic inflammatory response (SIR) in patients with operable primary colorectal cancer (CRC).
BACKGROUND: Muscle depletion is characterized by a reduced muscle mass (myopenia) and increased infiltration by inter- and intramuscular fat (myosteatosis). It is recognized as a poor prognostic indicator in patients with cancer, but the underlying factors remain unclear.
METHODS: A total of 763 patients diagnosed with CRC undergoing elective surgical resection between 2006 and 2013 were included. Image analysis of CT scans was used to calculate Lumbar skeletal muscle index (LSMI), and mean muscle attenuation (MA). The SIR was quantified by the preoperative neutrophil to lymphocyte ratio (NLR) and albumin levels. Correlation and multivariate regression analysis was performed to identify independent relationships between patient SIR and muscle characteristics.
RESULTS: Patients with NLR {\textgreater} 3 had significantly lower LSMI and lower MA than those with NLR {\textless} 3 [LSMI = 42.07 cmm vs 44.27 cmm (P = 0.002) and MA = 30.04 Hounsfield unit (HU) vs 28.36 HU (P = 0.016)]. Multivariate logistic regression analysis showed that high NLR [odds ratio (OR) = 1.78 (95\% confidence interval [CI]: 1.29-2.45), P {\textless} 0.001] and low albumin [OR = 1.80 (95\% CI: 1.17-2.74), P = 0.007] were independent predictors of reduced muscle mass. High NLR was significantly related with a low mean MA and hence myosteatosis [OR = 1.60 (95\% CI: 1.03-2.49), P = 0.038].
CONCLUSIONS: These results highlight a direct association between myopenia, myosteatosis, and the host SIR in patients with operable CRC. A better understanding of factors that regulate muscle changes such as myopenia and myosteatosis may lead to the development of novel therapies that influence a more metabolically "healthy" skeletal muscle and potentially alter cancer outcomes.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Malietzis, George and Johns, Neil and Al-Hassi, Hafid O. and Knight, Stella C. and Kennedy, Robin H. and Fearon, Kenneth C. H. and Aziz, Omer and Jenkins, John T.},
	month = feb,
	year = {2016},
	pmid = {25643288},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Prognosis, Aged, 80 and over, Adult, Myosteatosis, Multivariate Analysis, Muscular Diseases, Elective Surgical Procedures, Systemic Inflammatory Response Syndrome},
	pages = {320--325},
	annote = {NLR
},
	file = {Malietzis et al. - 2015 - Low Muscularity and Myosteatosis Is Related to the.pdf:/Users/jcsal/Zotero/storage/M7CCILI7/Malietzis et al. - 2015 - Low Muscularity and Myosteatosis Is Related to the.pdf:application/pdf},
}

@article{teigen933,
	title = {Impact of {Software} {Selection} and {ImageJ} {Tutorial} {Corrigendum} on {Skeletal} {Muscle} {Measures} at the {Third} {Lumbar} {Vertebra} on {Computed} {Tomography} {Scans} in {Clinical} {Populations}},
	volume = {42},
	issn = {1941-2444},
	doi = {10.1002/jpen.1036},
	abstract = {BACKGROUND: There is growing interest in computed tomography (CT) measures of skeletal muscle cross-sectional area (CSA) for nutrition assessment. Multiple software programs are available, but little work has been done comparing programs. We aimed to determine if CT-derived measures of skeletal muscle CSA at the level of the L3 are influenced by the software program used. We also demonstrate the importance of the ImageJ corrigendum published in this journal.
METHODS: Two software programs, National Institutes of Health ImageJ and Tomovision sliceOmatic, were compared. ImageJ measures were obtained using both the original tutorial and corrigendum instructions. Skeletal muscle CSA at the level of the L3 was measured in advanced heart failure and head and neck cancer populations by 3 different investigators. Intraclass correlation coefficients were used to calculate intrarater and interrater reliability. Bland-Altman analysis was used to assess agreement.
RESULTS: Both software programs yielded excellent intrarater and interrater reliability scores (intraclass correlation coefficients, 0.985-1.000). The overall mean difference (ImageJ tutorial with corrigendum - sliceOmatic) for the entire sample (N = 51) was found to be 1.53 cm2 (95\% CI, 0.59-2.47 cm2 ). The overall mean difference (ImageJ corrected - original) for the entire sample (N = 51) was found to be -11.35 cm2 (95\% CI, -12.75 to -9.95 cm2 ).
CONCLUSION: Measures of skeletal muscle CSA at the L3 were found to be ∼1.53 cm2 higher with ImageJ than sliceOmatic. This difference was not found to affect interpretation against a published cut point. The importance of accounting for the ImageJ tutorial corrigendum was shown to be clinically significant when applied to published cut points.},
	language = {eng},
	number = {5},
	journal = {JPEN. Journal of parenteral and enteral nutrition},
	author = {Teigen, Levi M. and Kuchnia, Adam J. and Nagel, Emily and Deuth, Christopher and Vock, David M. and Mulasi, Urvashi and Earthman, Carrie P.},
	month = jul,
	year = {2018},
	pmid = {30001463},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Sarcopenia, Reproducibility of Results, body composition, computed tomography, Methods, skeletal muscle, Head and Neck Neoplasms, Heart Failure, Lumbar Vertebrae, malnutrition, software, Software},
	pages = {933--941},
}

@article{murnane2295,
	title = {Myosteatosis predicts higher complications and reduced overall survival following radical oesophageal and gastric cancer surgery},
	volume = {47},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2021.02.008},
	abstract = {INTRODUCTION: Low muscle attenuation, as governed by increased intramuscular fat infiltration (myosteatosis), may associate with adverse surgical outcomes. We aimed to determine whether myosteatosis is associated with an increased risk of postoperative complications and reduced long-term survival after oesophago-gastric (OG) cancer surgery.
METHODS: Patients who underwent radical OG cancer surgery with preoperative abdominal computed tomography (CT) imaging were included. Myosteatosis was evaluated using previously defined cut-points for low skeletal muscle attenuation measured by CT. Oncological, surgical, complications, and outcome data were obtained from a prospective database.
RESULTS: Of 108 patients, 56\% (n = 61) had myosteatosis. Patients with myosteatosis were older (69.1 ± 9.1 vs. 62.8 ± 9.8 years, p = 0.001) and had a similar body mass index (BMI) (23.4 ± 5.3 vs. 25.9 ± 6.7 kg/m2, p = 0.766) compared to patients with normal muscle attenuation. Patients with myosteatosis had a higher rate of anastomotic leaks (15\% vs. 2\%, p = 0.041). On multivariate analysis, myosteatosis was an independent predictor of overall (OR 3.03, 95\% CI 1.31-6.99, p = 0.009) and severe complications (OR 4.33, 95\% CI 1.26-14.9, p = 0.020). Patients with myosteatosis had reduced 5 year overall (54.1\% vs. 83\%, p = 0.004) and disease-free (55.2\% vs. 87.2\%, p = 0.007) survival.
CONCLUSION: Myosteatosis is associated with a significantly increased risk of overall and severe complications as well as substantially reduced long-term survival. Assessment of muscle attenuation provides analysis beyond standard anthropometrics and may form part of preoperative physiological staging tools used to improve surgical outcomes.},
	language = {eng},
	number = {9},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Murnane, Lisa C. and Forsyth, Adrienne K. and Koukounaras, Jim and Pilgrim, Charles Hc and Shaw, Kalai and Brown, Wendy A. and Mourtzakis, Marina and Tierney, Audrey C. and Burton, Paul R.},
	month = sep,
	year = {2021},
	pmid = {33640171},
	keywords = {Adipose Tissue, Adiposity, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Length of Stay, Male, Middle Aged, Retrospective Studies, Risk Factors, Survival Rate, Stomach Neoplasms, Adenocarcinoma, Myosteatosis, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Postoperative Complications, Gastrectomy, Anastomotic Leak, Preoperative Period, GE, Complications, Muscle attenuation},
	pages = {2295--2303},
}

@article{anandavadivelan410,
	title = {Impact of weight loss and eating difficulties on health-related quality of life up to 10 years after oesophagectomy for cancer},
	volume = {105},
	issn = {1365-2168},
	doi = {10.1002/bjs.10686},
	abstract = {BACKGROUND: Severe weight loss is experienced by patients with eating difficulties after surgery for oesophageal cancer. The aim of this prospective cohort study was to asssess the influence of eating difficulties and severe weight loss on health-related quality of life (HRQoL) up to 10 years after oesophagectomy.
METHODS: Data on bodyweight and HRQoL were collected at 6 months, 3, 5 and 10 years in patients who underwent surgery for oesophageal cancer in Sweden between 2001 and 2005. Exposures were percentage weight loss, and eating difficulties defined by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-OES18 questionnaire. Outcomes were HRQoL scores from the EORTC QLQ-C30 questionnaire. Repeated-measures ANOVA, adjusting for potential confounders, was used to assess the association between eating difficulties and weight loss (4 exposure groups) and HRQoL scores at each time point. Mean score differences (MDs) between time points or exposure groups were defined as clinically relevant in accordance with evidence-based interpretation guidelines.
RESULTS: In total, 92 of 104 10-year survivors (88·5 per cent) responded to the questionnaires. Weight loss was greatest within 6 months of surgery. Patients with eating difficulties with or without weight loss reported clinically and statistically significantly worsened HRQoL in almost all aspects. The largest MD was seen between 5 and 10 years after surgery for global quality of life, physical, role and social function (MD -22 to -30), as well for fatigue, nausea, dyspnoea, insomnia, appetite loss and diarrhoea (MD 24-36).
CONCLUSION: Eating difficulties are associated with deterioration in several aspects of HRQoL up to 10 years after surgery for oesophageal cancer.},
	language = {eng},
	number = {4},
	journal = {The British Journal of Surgery},
	author = {Anandavadivelan, P. and Wikman, A. and Johar, A. and Lagergren, P.},
	month = mar,
	year = {2018},
	pmid = {29160918},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Prospective Studies, Weight Loss, Aged, 80 and over, Adult, Esophagectomy, Postoperative Complications, Quality of Life, GE, Feeding and Eating Disorders, Health Status Indicators},
	pages = {410--418},
}

@article{martin610,
	title = {Risk factors for weight loss among patients surviving 5 years after esophageal cancer surgery},
	volume = {22},
	issn = {1534-4681},
	doi = {10.1245/s10434-014-3973-2},
	abstract = {BACKGROUND: This study aimed to identify factors influencing postoperative weight loss ≥15 \% in long-term survivors after esophageal cancer surgery.
METHODS: A population-based study was conducted in Sweden between 2001 and 2005, with regular follow-up for 5 years. Current weight, weight at operation, and average weight were assessed and dichotomized as weight loss of ≥15 \%. Logistic regression estimated relative risks of weight loss between pre- and 5 years postoperatively, expressed as odds ratios (ORs) with 95 \% confidence intervals (CIs). Statistically significant differences in nutritional symptoms between weight loss groups were analyzed using linear regression models to likewise test as risk factors. Body mass index (BMI) at operation ({\textless} or ≥25), sex, and preoperative weight loss ({\textless} or ≥10 \%) were tested as risk factors. Nutritional symptoms were selected from the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-OES18, including fatigue, nausea and vomiting, dyspnoea, appetite loss, diarrhea, and dysphagia, eating difficulties, reflux and pain.
RESULTS: A total of 117 patients were included. Patients with preoperative BMI ≥25 were at a threefold increased risk (OR 3.2; 95 \% CI 1.4-7.3) for postoperative weight loss of ≥15 \% 5 years after operation. Moreover, eating difficulties, pain, fatigue, nausea and vomiting, and appetite loss were clinically relevant and statistically significantly worse symptoms experienced among those with a weight loss of ≥15 \% (all at p {\textless} 0.05).
CONCLUSIONS: Overweight at the time of operation is associated with postoperative weight loss from a long-term perspective. Several nutritional symptoms are associated with weight loss of {\textgreater}15 \% 5 years postoperatively.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Martin, Lena and Lagergren, Pernilla},
	month = feb,
	year = {2015},
	pmid = {25120247},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Risk Factors, Prospective Studies, Weight Loss, Case-Control Studies, Esophageal Neoplasms, Esophagectomy, Survivors, Quality of Life, GE},
	pages = {610--616},
}

@article{hynes1559,
	title = {The impact of pre- and post-operative weight loss and body mass index on prognosis in patients with oesophageal cancer},
	volume = {43},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2017.05.023},
	abstract = {BACKGROUND: Weight loss is a cardinal symptom of oesophageal cancer and is often continued after surgery. High body mass index (BMI) is a strong risk factor for oesophageal adenocarcinoma. This study aimed to assess the impact of pre- and post-operative weight loss and BMI on long-term mortality after resection for oesophageal cancer.
METHODS: This prospective and nationwide cohort study included 390 patients, operated on for oesophageal cancer in Sweden in 2001-2005 with follow-up until 2016, who responded to a questionnaire on weight history 6 months after surgery. Multivariable Cox proportional hazard models provided hazard ratios (HRs) and 95\% confidence intervals (95\% CIs) of mortality while adjusting for several prognostic factors, including tumour stage.
RESULTS: Compared to weight stable patients, pre-surgery weight loss indicated increased HRs of overall all-cause mortality (HR = 1.32, 95\% CI 0.94-1.86) and disease-specific mortality (HR = 1.36, 95\% CI 0.93-1.98). Patients with {\textgreater}20\% weight loss post-surgery had worse overall all-cause mortality (HR = 1.71, 95\% CI 1.01-2.88) and disease-specific mortality (HR = 2.20, 95\% CI 1.24-3.89). Compared to patients with normal BMI, decreased HRs were indicated for patients who were obese at the time of surgery (overall all-cause mortality HR 0.87 95\% CI, 0.58-1.31 and disease-specific mortality HR = 0.89, 95\% CI 0.57-1.40), while patients with BMI ≤19.9 at 6 months post-surgery had increased all-cause mortality (HR = 1.41, 95\% CI 1.03-1.95) and disease-specific mortality (HR = 1.55, 95\% CI 1.09-2.21).
CONCLUSION: Post-operative weight loss and low BMI at 6 months post-surgery are independent markers of poor prognosis in patients who undergo surgery for oesophageal cancer.},
	language = {eng},
	number = {8},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Hynes, O. and Anandavadivelan, P. and Gossage, J. and Johar, A. M. and Lagergren, J. and Lagergren, P.},
	month = aug,
	year = {2017},
	pmid = {28655483},
	keywords = {Humans, Aged, Female, Male, Body Mass Index, Neoplasm Staging, Risk Factors, Prospective Studies, Weight Loss, Esophageal Neoplasms, Mortality, Sweden, Survival, BMI, GE, Oesophageal neoplasm, Surveys and Questionnaires, Weight change},
	pages = {1559--1565},
}

@article{martin1362,
	title = {Risk factors for malnutrition after oesophageal and cardia cancer surgery},
	volume = {95},
	issn = {1365-2168},
	doi = {10.1002/bjs.6374},
	abstract = {BACKGROUND: Oesophageal cancer surgery is often followed by malnutrition, but the factors causing weight loss are unknown. The aim of this population-based study was to identify such risk factors.
METHODS: Data were collected from a nationwide Swedish organization for research on surgery for oesophageal cancer. A total of 340 patients (75.9 per cent of those eligible) responded to a study-specific questionnaire concerning height and weight, just before and 6 months after surgery. Factors influencing malnutrition, defined as loss of body mass index of at least 15 per cent 6 months after operation, were identified by logistic regression.
RESULTS: Neoadjuvant therapy (received by 10.6 per cent of all patients) and female sex were associated with at least a twofold increased risk of weight loss (odds ratio (OR) 2.41 (95 per cent confidence interval 1.01 to 5.77) and 2.14 (1.07 to 4.28) respectively), whereas preoperative weight loss was associated with a decreased risk (OR 0.13 (0.03 to 0.65)). Age, tumour stage and location, type of oesophageal substitute, suture technique and postoperative complications did not influence the risk.
CONCLUSION: Neoadjuvant therapy and female sex appear to be associated with an increased risk of malnutrition after oesophageal cancer surgery.},
	language = {eng},
	number = {11},
	journal = {The British Journal of Surgery},
	author = {Martin, L. and Jia, C. and Rouvelas, I. and Lagergren, P.},
	month = nov,
	year = {2008},
	pmid = {18844265},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Risk Factors, Sex Factors, Prospective Studies, Cohort Studies, Weight Loss, Stomach Neoplasms, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Cardia, Gastrectomy, Malnutrition, Regression Analysis, GE},
	pages = {1362--1368},
}

@article{schandl2385,
	title = {Predicting the {Risk} of {Weight} {Loss} {After} {Esophageal} {Cancer} {Surgery}},
	volume = {26},
	issn = {1534-4681},
	doi = {10.1245/s10434-019-07352-5},
	abstract = {BACKGROUND: Malnutrition after esophageal cancer surgery is associated with reduced health-related qualify of life. Therefore, a prediction model identifying patients at risk for severe weight loss after surgery was developed.
METHODS: Data from a Swedish population-based cohort study, including 616 patients undergoing esophageal cancer surgery in 2001-2005, was used. Candidate predictors included risk factors available before and immediately after surgery. Severe weight loss was defined as ≥ 15\% loss of body weight between the time of surgery and 6 months postoperatively. The prediction model was developed using multivariable models. The accuracy of the model was measured by the area under the receiver operating characteristics curve (AUC) with bootstrap validation. The model was externally validated in a hospital-based cohort of 91 surgically treated esophageal cancer patients in the United Kingdom in 2011-2016. Each predictor in the final model was assigned a corresponding risk score. The sum of risk scores was equivalent to an estimated probability for severe weight loss.
RESULTS: Among the 351 patients with 6 months follow-up data, 125 (36\%) suffered from severe postoperative weight loss. The final prediction model included body mass index at diagnosis, preoperative weight loss, and neoadjuvant therapy. The AUC for the model was 0.78 (95\% CI 0.74-0.83). In the validation cohort, the AUC was 0.76. A clinical risk assessment guide was derived from the prediction model.
CONCLUSIONS: This prediction model can preoperatively identify individuals with high risk of severe weight loss after esophageal cancer surgery. Intensive nutritional interventions for these patients are recommended.},
	language = {eng},
	number = {8},
	journal = {Annals of Surgical Oncology},
	author = {Schandl, Anna and Kauppila, Joonas H. and Anandavadivelan, Poorna and Johar, Asif and Lagergren, Pernilla},
	month = aug,
	year = {2019},
	pmid = {31004297},
	pmcid = {PMC6611892},
	keywords = {Humans, Aged, Female, Male, Body Mass Index, Follow-Up Studies, Risk Factors, Risk Assessment, Cohort Studies, Weight Loss, Predictive Value of Tests, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Malnutrition, Quality of Life, Models, Statistical, ROC Curve},
	pages = {2385--2391},
}

@article{soriano192,
	title = {Long-{Term} {Nutritional} {Outcome} and {Health} {Related} {Quality} of {Life} of {Patients} {Following} {Esophageal} {Cancer} {Surgery}: {A} {Meta}-{Analysis}},
	volume = {70},
	issn = {1532-7914},
	shorttitle = {Long-{Term} {Nutritional} {Outcome} and {Health} {Related} {Quality} of {Life} of {Patients} {Following} {Esophageal} {Cancer} {Surgery}},
	doi = {10.1080/01635581.2018.1412471},
	abstract = {Long term health related quality of life (HRQL) and nutritional outcome of patients following esophagectomy for cancer has become increasingly significant as the 5-year survival rate in this patient group is increasing. This meta-analysis aims to investigate the HRQOL, nutritional impact symptoms and nutritional outcomes of patients following an esophagectomy at greater than 12 months after surgery. In studies reporting on HRQL as an outcome, global QOL score at 6-month compare to greater than 12-month showed no statistically significant difference (65.92 vs. 75.78, p = 0.07). Forty-one percent of patients reported a greater than 10\% weight loss at six-month follow-up (95\% CI: 20-65\%; I2 = 94.27, p {\textless} 0.001), and at the greater than 12-month follow-up, 33\% of patients had the greater than 10\% weight loss (95\% CI: 15-57\%; I2 = 96.18, p {\textless} 0.001). At the 12-month or longer post esophagectomy, just over half the patients reported dysphagia (51\%, 95\% CI: 25-76\%; I2 = 95.70, p {\textless} 0.001), nausea was reported by 11\% (95\% CI: 7-19\%; I2 = 59.31, p = 0.09), dumping syndrome reported by 60\% (95\% CI: 43-76\%; I2 = 96.92, p {\textless} 0.001). Symptoms such as dysphagia, diarrhea, reflux, dumping syndrome, and nausea were found to persist following esophagectomy. There were insufficient robust research investigating how these symptoms impact on the adequacy of dietary intake and micronutrient status.},
	language = {eng},
	number = {2},
	journal = {Nutrition and Cancer},
	author = {Soriano, Trang Thuy and Eslick, Guy D. and Vanniasinkam, Thiru},
	month = mar,
	year = {2018},
	pmid = {29281327},
	keywords = {Humans, Body Mass Index, Esophageal Neoplasms, Esophagectomy, Deglutition Disorders, Diet, Nutritional Status, Quality of Life, Mortality, GE, Dumping Syndrome, Nausea},
	pages = {192--203},
}

@article{martin1496,
	title = {Malnutrition after oesophageal cancer surgery in {Sweden}},
	volume = {94},
	issn = {1365-2168},
	doi = {10.1002/bjs.5881},
	abstract = {BACKGROUND: Oesophageal cancer resection carries a risk of nutritional disorders. The aim of this study was to estimate weight change after surgery in a population-based setting and to identify nutritional problems that might correlate with weight loss.
METHODS: Data were collected through the Swedish Esophageal and Cardia Cancer Register, a nationwide registry of oesophageal cancer surgery. Patients who underwent oesophageal cancer surgery between 2001 and 2004 were followed up until April 2005, and data on patient and tumour characteristics and surgical treatment were collected. Six months after surgery the patients were asked to complete a questionnaire about weight and a health-related quality of life questionnaire (European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) with an oesophageal-specific module (EORTC QLQ-OES18)).
RESULTS: The response rate to the questionnaire was 76.9 per cent and weight change in 226 patients was analysed. Six months after operation 63.7 per cent had lost more than 10 per cent of their preoperative BMI, and 20.4 per cent had lost more than 20 per cent. Appetite loss, eating difficulties and odynophagia were significantly linked to postoperative weight loss, whereas dysphagia or reflux did not correlate with malnutrition.
CONCLUSION: Malnutrition is a considerable problem after oesophagectomy, and is linked to appetite loss, eating difficulties and odynophagia.},
	language = {eng},
	number = {12},
	journal = {The British Journal of Surgery},
	author = {Martin, L. and Lagergren, J. and Lindblad, M. and Rouvelas, I. and Lagergren, P.},
	month = dec,
	year = {2007},
	pmid = {17668914},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Prognosis, Aged, 80 and over, Adult, Esophageal Neoplasms, Postoperative Complications, Malnutrition, Deglutition Disorders, Sweden, Feeding and Eating Disorders, Weight Gain},
	pages = {1496--1500},
}

@article{matsui6378,
	title = {Relationship {Between} {Early} {Postoperative} {Change} in {Total} {Psoas} {Muscle} {Area} and {Long}-term {Prognosis} in {Esophagectomy} for {Patients} with {Esophageal} {Cancer}},
	volume = {28},
	issn = {1534-4681},
	doi = {10.1245/s10434-021-09623-6},
	abstract = {PURPOSE: Postoperative sarcopenia following esophagectomy for esophageal cancer has become a severe problem due to the increasing number of elderly patients undergoing surgery. This study aimed to clarify the relationship between early postoperative skeletal muscle change and cancer prognosis, and propose effective interventions to prevent sarcopenia.
METHODS: This study retrospectively analyzed 152 patients who underwent esophagectomy for esophageal cancer. Total psoas muscle area (TPA) was measured before surgery as baseline and on postoperative day 7 (± 2). The effect of early postoperative skeletal muscle loss on 5-year survival was investigated. Moreover, 5-year survival in patients with postoperative complications and a high inflammatory status, which were previously reported as poor prognostic factors of esophageal cancer, was also investigated.
RESULTS: Among the 152 patients, 52 (34.2\%) showed a decrease in TPA, while 100 (65.8\%) maintained their TPA. The TPA decreasing group exhibited poor 5-year overall survival (OS) (p = 0.003) and 5-year recurrence-free survival (RFS) (p {\textless} 0.001). The TPA decreasing group also showed a poor 5-year OS in patients who developed severe postoperative complications (p = 0.015). Multivariate analyses showed that decreased TPA was found to be independently associated with OS (p = 0.017) as well as RFS (p = 0.002).
CONCLUSIONS: Our findings suggested a relationship between decreased TPA within 1 week after esophagectomy and long-term prognosis among patients with esophageal cancer. If TPA can be maintained, the prognosis was better even in cases with serious complications.},
	language = {eng},
	number = {11},
	journal = {Annals of Surgical Oncology},
	author = {Matsui, Kazuaki and Kawakubo, Hirofumi and Hirata, Yuki and Matsuda, Satoru and Mayanagi, Shuhei and Irino, Tomoyuki and Fukuda, Kazumasa and Nakamura, Rieko and Wada, Norihito and Kitagawa, Yuko},
	month = oct,
	year = {2021},
	pmid = {33786679},
	keywords = {Humans, Aged, Sarcopenia, Retrospective Studies, Risk Factors, Survival Rate, Prognosis, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, GE, Psoas, Psoas Muscles},
	pages = {6378--6387},
}

@article{maas1986,
	title = {Quality of {Life} and {Late} {Complications} {After} {Minimally} {Invasive} {Compared} to {Open} {Esophagectomy}: {Results} of a {Randomized} {Trial}},
	volume = {39},
	issn = {1432-2323},
	shorttitle = {Quality of {Life} and {Late} {Complications} {After} {Minimally} {Invasive} {Compared} to {Open} {Esophagectomy}},
	url = {https://doi.org/10.1007/s00268-015-3100-y},
	doi = {10.1007/s00268-015-3100-y},
	abstract = {The minimally invasive esophagectomy (MIE) is widely being implemented for esophageal cancer in order to reduce morbidity and improve quality of life. Non-randomized studies investigating the mid-term quality of life after MIE show conflicting results at 1-year follow-up. Therefore, the aim of this study is to determine whether MIE has a continuing better mid-term 1-year quality of life than open esophagectomy (OE) indicating both a faster recovery and less procedure-related symptoms.},
	language = {en},
	number = {8},
	urldate = {2022-01-24},
	journal = {World Journal of Surgery},
	author = {Maas, K. W. and Cuesta, M. A. and van Berge Henegouwen, M. I. and Roig, J. and Bonavina, L. and Rosman, C. and Gisbertz, S. S. and Biere, S. S. A. Y. and van der Peet, D. L.},
	month = aug,
	year = {2015},
	keywords = {MIE},
	pages = {1986--1993},
}

@article{mariette152,
	title = {Hybrid {Minimally} {Invasive} {Esophagectomy} for {Esophageal} {Cancer}},
	volume = {380},
	issn = {0028-4793},
	url = {https://doi.org/10.1056/NEJMoa1805101},
	doi = {10.1056/NEJMoa1805101},
	abstract = {Hybrid Minimally Invasive Surgery for Esophageal Cancer Open esophagectomy involves laparotomy and thoracotomy. Laparoscopic abdominal surgery may be useful for reducing complications, but does it control the cancer? A trial suggests that morbidity is lower and cancer outcomes are at least as good with the hybrid procedure as with the open procedure.},
	number = {2},
	urldate = {2022-01-24},
	journal = {New England Journal of Medicine},
	author = {Mariette, Christophe and Markar, Sheraz R. and Dabakuyo-Yonli, Tienhan S. and Meunier, Bernard and Pezet, Denis and Collet, Denis and D’Journo, Xavier B. and Brigand, Cécile and Perniceni, Thierry and Carrère, Nicolas and Mabrut, Jean-Yves and Msika, Simon and Peschaud, Frédérique and Prudhomme, Michel and Bonnetain, Franck and Piessen, Guillaume},
	month = jan,
	year = {2019},
	pmid = {30625052},
	note = {Publisher: Massachusetts Medical Society
\_eprint: https://doi.org/10.1056/NEJMoa1805101},
	pages = {152--162},
	file = {Snapshot:/Users/jcsal/Zotero/storage/Z6BR96XI/NEJMoa1805101.html:text/html},
}

@article{guo68,
	title = {A comparative study of the therapeutic effect in two protocols: video-assisted thoracic surgery combined with laparoscopy versus right open transthoracic esophagectomy for esophageal cancer management},
	volume = {12},
	issn = {1613-9089},
	shorttitle = {A comparative study of the therapeutic effect in two protocols},
	url = {https://doi.org/10.1007/s10330-012-0966-0},
	doi = {10.1007/s10330-012-0966-0},
	abstract = {The aim was to evaluate the best intra-thoracoscopic surgery technique between video-assisted thoracic surgery (VATS) combined with laparoscopy and right open transthoracic esophagectomy, in patients with esophageal cancer.},
	language = {en},
	number = {2},
	urldate = {2022-01-24},
	journal = {The Chinese-German Journal of Clinical Oncology},
	author = {Guo, Ming and Xie, Baiyi and Sun, Xiaoyan and Hu, Meng and Yang, Qingjie and Lei, Yunhong},
	month = feb,
	year = {2013},
	keywords = {MIE},
	pages = {68--71},
}

@article{elliott82,
	title = {Weight {Loss}, {Satiety}, and the {Postprandial} {Gut} {Hormone} {Response} {After} {Esophagectomy}: {A} {Prospective} {Study}},
	volume = {266},
	issn = {1528-1140},
	shorttitle = {Weight {Loss}, {Satiety}, and the {Postprandial} {Gut} {Hormone} {Response} {After} {Esophagectomy}},
	doi = {10.1097/SLA.0000000000001918},
	abstract = {OBJECTIVE: To prospectively characterize changes in body weight, satiety, and postprandial gut hormone profiles following esophagectomy.
BACKGROUND: With improved oncologic outcomes in esophageal cancer, there is an increasing focus on functional status and health-related quality of life in survivorship. Early satiety and weight loss are common after esophagectomy, but the pathophysiology of these phenomena remains poorly understood.
METHODS: In this prospective study, consecutive patients undergoing esophagectomy with gastric conduit reconstruction were studied preoperatively and at 10 days, 6 weeks, and 3 months postoperatively. Glucagon-like peptide 1 (GLP-1) immunoreactivity of plasma collected immediately before and at 15, 30, 60, 90, 120, 150, and 180 minutes after a standardized 400-kcal mixed meal was determined. Gastrointestinal symptom scores were computed using European Organization for Research and Treatment of Cancer questionnaires.
RESULTS: Body weight loss at 6 weeks and 3 months postoperatively among 13 patients undergoing esophagectomy was 11.1 ± 2.3\% (P {\textless} 0.001) and 16.3 ± 2.2\% (P {\textless} 0.0001), respectively. Early satiety (P = 0.043), gastrointestinal pain and discomfort (P = 0.01), altered taste (P= 0.006), and diarrhea (P= 0.038) scores increased at 3 months postoperatively. Area under the curve for the satiety gut hormone GLP-1 was significantly increased from 10 days postoperatively (2.4 ± 0.2-fold increase, P {\textless} 0.01), and GLP-1 peak increased 3.8 ± 0.6-, 4.7 ± 0.8-, and 4.4 ± 0.5-fold at 10 days, 6 weeks, and 3 months postoperatively (all P {\textless} 0.0001). Three months postoperatively, GLP-1 area under the curve was associated with early satiety (P = 0.0002, R = 0.74), eating symptoms (P = 0.007, R = 0.54), and trouble enjoying meals (P = 0.0004, R = 0.73).
CONCLUSIONS: After esophagectomy, patients demonstrate an exaggerated postprandial satiety gut hormone response, which may mediate postoperative changes in satiety, body weight, and gastrointestinal quality of life.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgery},
	author = {Elliott, Jessie A. and Docherty, Neil G. and Eckhardt, Hans-Georg and Doyle, Suzanne L. and Guinan, Emer M. and Ravi, Narayanasamy and Reynolds, John V. and Roux, Carel W. le},
	month = jul,
	year = {2017},
	pmid = {27455150},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Prospective Studies, Weight Loss, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Quality of Life, Blood Glucose, Gastrointestinal Diseases, Glucagon-Like Peptide 1, Insulin, Pain, Postprandial Period, Satiety Response, Taste Disorders},
	pages = {82--90},
}

@article{murphydoaa098,
	title = {Exaggerated postprandial {GLP}-1 secretion following esophagectomy is not associated with gastric emptying and intestinal transit},
	volume = {34},
	issn = {1442-2050},
	doi = {10.1093/dote/doaa098},
	abstract = {Esophagectomy causes postprandial symptoms associated with an exaggerated postprandial gut hormone response. This study aimed to compare the gastrointestinal transit time of patients 1 year after esophagectomy with unoperated controls, including its relation to satiety gut hormone release. In this cross-sectional study, consecutive, disease-free patients after esophagectomy with pyloroplasty were compared with unoperated control subjects to assess gastric emptying (GE) and cecal arrival time (CAT). Serial plasma samples were collected before, and for 300 minutes after, a mixed-meal challenge. Body composition was assessed, and symptom scores were calculated. Eleven patients 1 year post-esophagectomy (age: 62.6 ± 9.8, male: 82\%) did not show a significantly different GE pattern compared with 10 control subjects (P = 0.245). Rather, patients could be categorized bimodally as exhibiting either rapid or slow GE relative to controls. Those with rapid GE trended toward a higher postprandial symptom burden (P = 0.084) without higher postprandial glucagon-like peptide-1 (GLP-1) secretion (P = 0.931). CAT was significantly shorter after esophagectomy (P = 0.043) but was not significantly associated with GE, GLP-1 secretion, or symptom burden. Neither early nutrient delivery to the proximal small intestine nor to the colon explains the exaggerated postprandial GLP-1 response after esophagectomy. GE varies significantly in these patients despite consistent pyloric management.},
	language = {eng},
	number = {7},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Murphy, C. F. and Elliott, J. A. and Docherty, N. G. and Mohamed, A. A. and Vincent, R. P. and Ravi, N. and Reynolds, J. V. and le Roux, C. W.},
	month = jul,
	year = {2021},
	pmid = {32944747},
	keywords = {Humans, Male, Cross-Sectional Studies, Esophagectomy, esophagectomy, weight loss, Glucagon-Like Peptide 1, Postprandial Period, enteroendocrine signaling, esophageal cancer surgery, Gastric Emptying, gastrointestinal transit, gut hormones, health-related quality of life, survivorship, GLP-1},
	pages = {doaa098},
}

@article{sato1413,
	title = {Resting energy expenditure in patients undergoing transhiatal or transthoracic oesophagectomy for carcinoma of the thoracic oesophagus},
	volume = {80},
	issn = {0007-1323},
	doi = {10.1002/bjs.1800801119},
	abstract = {Resting energy expenditure (REE) was studied in five patients undergoing transhiatal and in 14 undergoing transthoracic oesophagectomy for carcinoma. All resections were performed with an intention to cure. REE was measured by indirect calorimetry before operation and on days 1, 3, 5 and 7 after surgery. Following transthoracic oesophagectomy, REE increased significantly on days 1, 3, 5 and 7 after operation, and on day 7 the value was significantly higher (P {\textless} 0.05) than that obtained after transhiatal surgery. Energy expenditure following transhiatal oesophagectomy is lower than that after transthoracic oesophagectomy; this may be a result of reduced surgical stress.},
	language = {eng},
	number = {11},
	journal = {The British Journal of Surgery},
	author = {Sato, N. and Kusama, A. and Ohkawa, A. and Koyama, Y. and Oyamatsu, M. and Kayama, S. and Yoshikawa, K. and Tanaka, O. and Muto, T.},
	month = nov,
	year = {1993},
	pmid = {8252352},
	keywords = {Humans, Aged, Male, Middle Aged, Time Factors, Basal Metabolism, Calorimetry, Indirect, Adult, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, REE, Stress, Physiological},
	pages = {1413--1415},
}

@article{elia597,
	title = {Differences in fat, carbohydrate, and protein metabolism between lean and obese subjects undergoing total starvation},
	volume = {7},
	issn = {1071-7323},
	doi = {10.1002/j.1550-8528.1999.tb00720.x},
	abstract = {Despite extensive experimental studies on total starvation, many of the findings relating to protein, fat (plus ketone body), and carbohydrate metabolism remain confusing, although they become more consistent when considered in relation to the degree of initial obesity. During prolonged starvation, protein loss and percent energy derived from protein oxidation are 2- to 3-fold less in the obese than in the lean; percent urine N excreted as urea is 2-fold less in the obese; and the contribution of protein to net glucose production is only about half in the obese compared to lean subjects. During short-term starvation (first few days) the following differences are reported: hyperketonaemia is typically 2-fold greater in lean subjects, but associated with a 2-fold lower uptake of ketone bodies by forearm muscle; glucose tolerance becomes impaired more in lean subjects; and both protein turnover and leucine oxidation increase in the lean, but may show no significant change in the obese. It is no longer acceptable to describe the metabolic response to starvation as a single typical response. The differences between lean and obese subjects have important physiological implications, some of which are of obvious relevance to survival.},
	language = {eng},
	number = {6},
	journal = {Obesity Research},
	author = {Elia, M. and Stubbs, R. J. and Henry, C. J.},
	month = nov,
	year = {1999},
	pmid = {10574520},
	keywords = {Humans, Obesity, Body Weight, Thinness, Carbohydrate Metabolism, Lipid Metabolism, Blood Glucose, Ketone Bodies, Proteins, Starvation},
	pages = {597--604},
}

@article{gallagher21S,
	title = {Body composition (sarcopenia) in obese patients: implications for care in the intensive care unit},
	volume = {35},
	issn = {1941-2444},
	shorttitle = {Body composition (sarcopenia) in obese patients},
	doi = {10.1177/0148607111413773},
	abstract = {The study of body composition is a rapidly evolving science. In today's environment, there is a great deal of interest in assessing body composition, especially in the obese subject, as a guide to clinical and nutrition interventions. There are some strikingly different compartments of body composition between the obese and the lean patient. We do have the ability to measure body composition accurately, although these techniques can be labor intensive and expensive. The recognition of patients with sarcopenic obesity has identified a potential high-risk patient population. These body composition abnormalities may have even greater importance in the intensive care patient.},
	language = {eng},
	number = {5 Suppl},
	journal = {JPEN. Journal of parenteral and enteral nutrition},
	author = {Gallagher, Dympna and DeLegge, Mark},
	month = sep,
	year = {2011},
	pmid = {21807929},
	pmcid = {PMC3306216},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Obesity, Sarcopenia, Nutrition Assessment, Energy Metabolism, Intensive Care Units, Obesity Paradox, Phenotype},
	pages = {21S--8S},
}

@article{gonzalez999,
	title = {Obesity paradox in cancer: new insights provided by body composition},
	volume = {99},
	issn = {1938-3207},
	shorttitle = {Obesity paradox in cancer},
	doi = {10.3945/ajcn.113.071399},
	abstract = {BACKGROUND: Obesity, defined by body mass index (BMI), appears to have a paradoxical protective effect in several chronic diseases.
OBJECTIVE: We investigated the obesity paradox in cancer patients by using body composition.
DESIGN: The study was an observational study of 175 cancer patients assessed before chemotherapy. Obesity was defined as BMI (in kg/m(2)) ≥30 or fat mass index (FMI; fat mass divided by the square of height) ≥5.2 (men) and ≥8.2 (women) measured by using a bioelectrical impedance analysis. Low muscle mass (sarcopenia) was defined as fat-free mass index (fat-free mass divided by the square of height) {\textless}17.5 (men) and {\textless}15.1 (women).
RESULTS: Most patients were women (65.7\%) and had a mean (±SD) age of 56.9 ± 12.8 y. According to BMI criteria, 60\% of patients were overweight or obese. The median survival time for overweight (2.64 y; range: 0.23-3.16 y) and obese (2.61 y; range: 0.26-3.20 y) patients was significantly higher than for patients with a normal (2.04 y; range: 0.06-3.05 y) or low (0.52 y; range: 0.19-0.98 y) BMI (P {\textless} 0.001). Sarcopenic patients had shorter survival, regardless of their FMI. Obesity predicted higher survival rates only when sarcopenia was absent. In a multivariate Cox regression model, sarcopenia was an independent predictor of higher mortality (HR: 5.19; 95\% CI: 2.58, 10.43) after we controlled for BMI, age, and tumor stage.
CONCLUSIONS: The obesity paradox is present in cancer patients only when obesity is defined by BMI. Patients with sarcopenic obesity had the poorest prognosis. Cancer patients with high mortality risk can be identified by a body-composition assessment.},
	language = {eng},
	number = {5},
	journal = {The American Journal of Clinical Nutrition},
	author = {Gonzalez, Maria Cristina and Pastore, Carla A. and Orlandi, Silvana P. and Heymsfield, Steven B.},
	month = may,
	year = {2014},
	pmid = {24572565},
	keywords = {Adiposity, Body Composition, Humans, Aged, Female, Male, Middle Aged, Obesity, Sarcopenia, Body Mass Index, Follow-Up Studies, Proportional Hazards Models, Prospective Studies, Neoplasms, Prognosis, Electric Impedance, Adult, Multivariate Analysis},
	pages = {999--1005},
}

@article{harrell361,
	title = {Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors},
	volume = {15},
	issn = {0277-6715},
	shorttitle = {Multivariable prognostic models},
	doi = {10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4},
	abstract = {Multivariable regression models are powerful tools that are used frequently in studies of clinical outcomes. These models can use a mixture of categorical and continuous variables and can handle partially observed (censored) responses. However, uncritical application of modelling techniques can result in models that poorly fit the dataset at hand, or, even more likely, inaccurately predict outcomes on new subjects. One must know how to measure qualities of a model's fit in order to avoid poorly fitted or overfitted models. Measurement of predictive accuracy can be difficult for survival time data in the presence of censoring. We discuss an easily interpretable index of predictive discrimination as well as methods for assessing calibration of predicted survival probabilities. Both types of predictive accuracy should be unbiasedly validated using bootstrapping or cross-validation, before using predictions in a new data series. We discuss some of the hazards of poorly fitted and overfitted regression models and present one modelling strategy that avoids many of the problems discussed. The methods described are applicable to all regression models, but are particularly needed for binary, ordinal, and time-to-event outcomes. Methods are illustrated with a survival analysis in prostate cancer using Cox regression.},
	language = {eng},
	number = {4},
	journal = {Statistics in Medicine},
	author = {Harrell, F. E. and Lee, K. L. and Mark, D. B.},
	month = feb,
	year = {1996},
	pmid = {8668867},
	keywords = {Humans, Male, Treatment Outcome, Survival Analysis, Multivariate Analysis, Clinical Trials as Topic, Regression Analysis, Software, Models, Statistical, C-statistic, Computer Graphics, Computer Simulation, Data Interpretation, Statistical, Discriminant Analysis, Linear Models, Mathematical Computing, Prostatic Neoplasms},
	pages = {361--387},
}

@article{martin90,
	title = {Diagnostic criteria for the classification of cancer-associated weight loss},
	volume = {33},
	issn = {1527-7755},
	doi = {10.1200/JCO.2014.56.1894},
	abstract = {PURPOSE: Existing definitions of clinically important weight loss (WL) in patients with cancer are unclear and heterogeneous and do not consider current trends toward obesity.
METHODS: Canadian and European patients with cancer (n = 8,160) formed a population-based data set. Body mass index (BMI) and percent WL (\%WL) were recorded, and patients were observed prospectively until death. Data were entered into a multivariable analysis controlling for age, sex, cancer site, stage, and performance status. Relationships for BMI and \%WL to overall survival were examined to develop a grading system.
RESULTS: Mean overall \%WL was -9.7\% ± 8.4\% and BMI was 24.4 ± 5.1 kg/m(2), and both \%WL and BMI independently predicted survival (P {\textless} .01). Differences in survival were observed across five categories of BMI ({\textless} 20.0, 20.0 to 21.9, 22.0 to 24.9, 25.0 to 27.9, and ≥ 28.0 kg/m(2); P {\textless} .001) and five categories of \%WL (-2.5\% to -5.9\%, -6.0\% to -10.9\%, -11.0\% to -14.9\%, ≥ -15.0\%, and weight stable (± 2.4\%); P {\textless} .001). A 5 × 5 matrix representing the five \%WL categories within each of the five BMI categories was graded based on median survival and prognostic significance. Weight-stable patients with BMI ≥ 25.0 kg/m(2) (grade 0) had the longest survival (20.9 months; 95\% CI, 17.9 to 23.9 months), and \%WL values associated with lowered categories of BMI were related to shorter survival (P {\textless} .001), as follows: grade 1, 14.6 months (95\% CI, 12.9 to 16.2 months); grade 2, 10.8 months (95\% CI, 9.7 to 11.9 months); grade 3, 7.6 months (95\% CI, 7.0 to 8.2 months); and grade 4, 4.3 months (95\% CI, 4.1 to 4.6 months). Survival discrimination by grade was observed within specific cancers, stages, ages, and performance status and in an independent validation sample (n = 2,963).
CONCLUSION: A robust grading system incorporating the independent prognostic significance of both BMI and \%WL was developed.},
	language = {eng},
	number = {1},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Martin, Lisa and Senesse, Pierre and Gioulbasanis, Ioannis and Antoun, Sami and Bozzetti, Federico and Deans, Chris and Strasser, Florian and Thoresen, Lene and Jagoe, R. Thomas and Chasen, Martin and Lundholm, Kent and Bosaeus, Ingvar and Fearon, Kenneth H. and Baracos, Vickie E.},
	month = jan,
	year = {2015},
	pmid = {25422490},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Neoplasm Staging, Cachexia, Prospective Studies, Neoplasms, Prognosis, Weight Loss, Canada, Databases, Factual, Survival Analysis, Population Surveillance, Multivariate Analysis, Europe},
	pages = {90--99},
	file = {Martin et al. - Diagnostic Criteria for the Classification of Canc.pdf:/Users/jcsal/Zotero/storage/KQYVQ29S/Martin et al. - Diagnostic Criteria for the Classification of Canc.pdf:application/pdf},
}

@article{vogel148,
	title = {The {American} {Society} of {Colon} and {Rectal} {Surgeons} {Clinical} {Practice} {Guidelines} for the {Management} of {Colon} {Cancer}},
	volume = {65},
	issn = {1530-0358},
	doi = {10.1097/DCR.0000000000002323},
	language = {eng},
	number = {2},
	journal = {Diseases of the Colon and Rectum},
	author = {Vogel, Jon D. and Felder, Seth I. and Bhama, Anuradha R. and Hawkins, Alexander T. and Langenfeld, Sean J. and Shaffer, Virginia O. and Thorsen, Amy J. and Weiser, Martin R. and Chang, George J. and Lightner, Amy L. and Feingold, Daniel L. and Paquette, Ian M.},
	month = feb,
	year = {2022},
	pmid = {34775402},
	keywords = {Humans, Magnetic Resonance Imaging, Tomography, X-Ray Computed, Neoplasm Staging, Colectomy, Colonic Neoplasms, Combined Modality Therapy, Patient Selection, Guidelines},
	pages = {148--177},
}

@article{miholic73,
	title = {Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection},
	volume = {54},
	issn = {0012-2823},
	doi = {10.1159/000201016},
	abstract = {Postprandial concentrations of glucose and the immunoreactivity of insulin, glucagon-like peptide-1 (GLP-1), and pancreatic glucagon were measured in 10 patients who had undergone esophageal resection (ER) and replacement by the stomach. Emptying of the esophageal substitute was assessed by scintigraphy using a 99Tc-labeled solid test meal. The data were compared with measurements performed in 14 controls, in 7 of whom gastric emptying was measured. The gastric emptying half time was 6.8 +/- 6.2 min (median 144 s) in ER cases, significantly shorter than in controls: 70 +/- 29 min (median 51 min). The early integrated (first 30 min) and total integrated insulin and GLP-1 concentrations were significantly higher than in controls. In 3 of 10 esophagectomy patients the blood glucose concentration fell below 3.8 mmol/l postprandially. High GLP-1 concentrations in the first 30 min were associated with low serum glucose during the 2nd h postprandially when all the hypoglycemic episodes occurred. It is concluded that rapid emptying of the esophageal substitute induces the exaggerated GLP-1 response, which is a main factor for reactive hypoglycemia.},
	language = {eng},
	number = {2},
	journal = {Digestion},
	author = {Miholic, J. and Orskov, C. and Holst, J. J. and Kotzerke, J. and Pichlmayr, R.},
	year = {1993},
	pmid = {8319842},
	keywords = {Humans, Female, Male, Middle Aged, Esophageal Neoplasms, Esophagus, Stomach, Esophagoplasty, Pancreas, Eating, Blood Glucose, Glucagon-Like Peptide 1, Insulin, Gastric Emptying, GLP-1, Glucagon, Peptide Fragments, Protein Precursors},
	pages = {73--78},
}

@article{kadouhdgz140,
	title = {{GLP}-1 {Analog} {Modulates} {Appetite}, {Taste} {Preference}, {Gut} {Hormones}, and {Regional} {Body} {Fat} {Stores} in {Adults} with {Obesity}},
	volume = {105},
	issn = {1945-7197},
	doi = {10.1210/clinem/dgz140},
	abstract = {PURPOSE: Obesity is associated with alterations in appetite, gastrointestinal hormone levels and excessive fat mass. We previously published a double-blind, placebo-controlled, randomized, 16-week trial on effects of once-daily glucagon-like peptide-1 (GLP-1) analog, liraglutide on weight, satiation, and gastric functions in obese volunteers. The aim of this substudy is to compare to placebo the effects of liraglutide on appetite, taste preference, regional body fat stores, and anthropometric measurements.
METHODS: Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily). At baseline and 16 weeks, the following were measured: appetite and taste preferences rated every 30 min for 5 h after ingesting 300 mL Ensure®; maximal tolerated volume (MTV) with a nutrient drink test; fasting and postprandial bioactive GLP-1 (7-36) and peptide YY (PYY) levels; total and regional body fat with dual-energy X-ray absorptiometry, and waist and hip circumference.
RESULTS: Thirty-five participants (17 liraglutide; 18 placebo) completed the trial. Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness. Postprandial plasma levels of GLP-1 decreased and PYY levels increased with liraglutide relative to baseline. Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed.
CONCLUSION: Liraglutide 3 mg SQ modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity without reduction in lean body mass.},
	language = {eng},
	number = {5},
	journal = {The Journal of Clinical Endocrinology and Metabolism},
	author = {Kadouh, Hoda and Chedid, Victor and Halawi, Houssam and Burton, Duane D. and Clark, Matthew M. and Khemani, Disha and Vella, Adrian and Acosta, Andres and Camilleri, Michael},
	month = may,
	year = {2020},
	pmid = {31665455},
	pmcid = {PMC7105351},
	keywords = {Adipose Tissue, Body Composition, Humans, Aged, Female, Male, Middle Aged, Obesity, Adult, Young Adult, Adolescent, Glucagon-Like Peptide 1, GLP-1, appetite, Appetite, body fat, Double-Blind Method, Food Preferences, Gastrointestinal Hormones, GLP-1 analog, Hypoglycemic Agents, liraglutide, Liraglutide, obesity, Placebos, Satiation, Taste, taste preference},
	pages = {dgz140},
}

@article{khan97,
	title = {How {I} {Treat} {Vitamin} {D} {Deficiency}},
	volume = {6},
	issn = {1554-7477},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835491/},
	doi = {10.1200/JOP.091087},
	abstract = {Vitamin D plays an important role in the homeostasis of a variety of organ systems, but its role in prevention of cancer and recurrence—along with necessary blood levels—has yet to be defined.},
	number = {2},
	urldate = {2022-03-12},
	journal = {Journal of Oncology Practice},
	author = {Khan, Qamar J. and Fabian, Carol J.},
	month = mar,
	year = {2010},
	pmid = {20592785},
	pmcid = {PMC2835491},
	keywords = {Survivorship},
	pages = {97--101},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/8K769C79/Khan and Fabian - 2010 - How I Treat Vitamin D Deficiency.pdf:application/pdf},
}

@article{revels1136,
	title = {Racial disparities in esophageal cancer outcomes},
	volume = {20},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547835/},
	doi = {10.1245/s10434-012-2807-3},
	abstract = {Racial disparities in outcomes have been documented among patients with esophageal cancer. The purpose of this study is to identify mechanisms for ethnicity/race-related differences in the use of cancer-directed surgery and mortality.Data from the Surveillance, ...},
	language = {en},
	number = {4},
	urldate = {2022-03-29},
	journal = {Annals of surgical oncology},
	author = {Revels, Sha’Shonda L. and Morris, Arden M. and Reddy, Rishindra M. and Akateh, Clifford and Wong, Sandra L.},
	month = apr,
	year = {2013},
	pmid = {23263780},
	note = {Publisher: NIH Public Access},
	keywords = {Disparities},
	pages = {1136},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/FMICPVWL/Revels et al. - 2013 - Racial disparities in esophageal cancer outcomes.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/6HS43GGG/PMC4547835.html:text/html},
}

@article{sebag-montefiore811,
	title = {Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer ({MRC} {CR07} and {NCIC}-{CTG} {C016}): a multicentre, randomised trial},
	volume = {373},
	issn = {0140-6736, 1474-547X},
	shorttitle = {Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer ({MRC} {CR07} and {NCIC}-{CTG} {C016})},
	url = {https://www.thelancet.com/journals/lancet/article/PIIS0140673609604840/fulltext},
	doi = {10.1016/S0140-6736(09)60484-0},
	language = {English},
	number = {9666},
	urldate = {2022-03-15},
	journal = {The Lancet},
	author = {Sebag-Montefiore, David and Stephens, Richard J. and Steele, Robert and Monson, John and Grieve, Robert and Khanna, Subhash and Quirke, Phil and Couture, Jean and Metz, Catherine de and Myint, Arthur Sun and Bessell, Eric and Griffiths, Gareth and Thompson, Lindsay C. and Parmar, Mahesh},
	month = mar,
	year = {2009},
	pmid = {19269519},
	note = {Publisher: Elsevier},
	keywords = {Rectal;Adjuvant},
	pages = {811--820},
	file = {Snapshot:/Users/jcsal/Zotero/storage/BUKM6DM2/fulltext.html:text/html},
}

@article{taylor34,
	title = {Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the {MERCURY} study},
	volume = {32},
	issn = {1527-7755},
	shorttitle = {Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence},
	doi = {10.1200/JCO.2012.45.3258},
	abstract = {PURPOSE: The prognostic relevance of preoperative high-resolution magnetic resonance imaging (MRI) assessment of circumferential resection margin (CRM) involvement is unknown. This follow-up study of 374 patients with rectal cancer reports the relationship between preoperative MRI assessment of CRM staging, American Joint Committee on Cancer (AJCC) TNM stage, and clinical variables with overall survival (OS), disease-free survival (DFS), and time to local recurrence (LR).
PATIENTS AND METHODS: Patients underwent protocol high-resolution pelvic MRI. Tumor distance to the mesorectal fascia of ≤ 1 mm was recorded as an MRI-involved CRM. A Cox proportional hazards model was used in multivariate analysis to determine the relationship of MRI assessment of CRM to survivorship after adjusting for preoperative covariates.
RESULTS: Surviving patients were followed for a median of 62 months. The 5-year OS was 62.2\% in patients with MRI-clear CRM compared with 42.2\% in patients with MRI-involved CRM with a hazard ratio (HR) of 1.97 (95\% CI, 1.27 to 3.04; P {\textless} .01). The 5-year DFS was 67.2\% (95\% CI, 61.4\% to 73\%) for MRI-clear CRM compared with 47.3\% (95\% CI, 33.7\% to 60.9\%) for MRI-involved CRM with an HR of 1.65 (95\% CI, 1.01 to 2.69; P {\textless} .05). Local recurrence HR for MRI-involved CRM was 3.50 (95\% CI, 1.53 to 8.00; P {\textless} .05). MRI-involved CRM was the only preoperative staging parameter that remained significant for OS, DFS, and LR on multivariate analysis.
CONCLUSION: High-resolution MRI preoperative assessment of CRM status is superior to AJCC TNM-based criteria for assessing risk of LR, DFS, and OS. Furthermore, MRI CRM involvement is significantly associated with distant metastatic disease; therefore, colorectal cancer teams could intensify treatment and follow-up accordingly to improve survival outcomes.},
	language = {eng},
	number = {1},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Taylor, Fiona G. M. and Quirke, Philip and Heald, Richard J. and Moran, Brendan J. and Blomqvist, Lennart and Swift, Ian R. and Sebag-Montefiore, David and Tekkis, Paris and Brown, Gina and {Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group}},
	month = jan,
	year = {2014},
	pmid = {24276776},
	keywords = {Humans, Magnetic Resonance Imaging, Aged, Female, Male, Middle Aged, Follow-Up Studies, Kaplan-Meier Estimate, Neoplasm Staging, Disease Progression, Proportional Hazards Models, Prognosis, Aged, 80 and over, Adult, Predictive Value of Tests, Analysis of Variance, Disease-Free Survival, Neoplasm Recurrence, Local, Research Design, Odds Ratio, Preoperative Period, Europe, Rectal Neoplasms, Confounding Factors, Epidemiologic, Rectal; MRI},
	pages = {34--43},
}

@article{swedishrectalcancertrial980,
	title = {Improved survival with preoperative radiotherapy in resectable rectal cancer},
	volume = {336},
	issn = {0028-4793},
	doi = {10.1056/NEJM199704033361402},
	abstract = {BACKGROUND: Adjuvant radiotherapy for rectal cancer has been extensively studied, but no trial has unequivocally demonstrated improved overall survival with radiotherapy, despite a reduction in the rate of local recurrence.
METHODS: Between March 1987 and February 1990, we randomly assigned 1168 patients younger than 80 years of age who had resectable rectal cancer to undergo preoperative irradiation (25 Gy delivered in five fractions in one week) followed by surgery within one week or to have surgery alone.
RESULTS: The irradiation did not increase postoperative mortality. After five years of follow-up, the rate of local recurrence was 11 percent (63 of 553 patients) in the group that received radiotherapy before surgery and 27 percent (150 of 557) in the group treated with surgery alone (P{\textless}0.001). This difference was found in all subgroups defined according to Dukes' stage. The overall five-year survival rate was 58 percent in the radiotherapy-plus-surgery group and 48 percent in the surgery-alone group (P=0.004). The cancer-specific survival rates at nine years among patients treated with curative resection were 74 percent and 65 percent, respectively (P=0.002).
CONCLUSIONS: A short-term regimen of high-dose preoperative radiotherapy reduces rates of local recurrence and improves survival among patients with resectable rectal cancer.},
	language = {eng},
	number = {14},
	journal = {The New England Journal of Medicine},
	author = {{Swedish Rectal Cancer Trial} and Cedermark, B. and Dahlberg, M. and Glimelius, B. and Påhlman, L. and Rutqvist, L. E. and Wilking, N.},
	month = apr,
	year = {1997},
	pmid = {9091798},
	keywords = {Humans, Follow-Up Studies, Neoplasm Staging, Survival Rate, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Radiation Dosage, Preoperative Care, Rectal Neoplasms, Rectal;RT},
	pages = {980--987},
}

@article{sauer173,
	title = {Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. {A} progress report of a phase-{III} randomized trial (protocol {CAO}/{ARO}/{AIO}-94)},
	volume = {177},
	issn = {0179-7158},
	doi = {10.1007/pl00002396},
	abstract = {AIM: The standard treatment for patients with clinically resectable rectal cancer is surgery. Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+). In recent years, encouraging results of preoperative radiotherapy have been reported. This prospective randomized phase-III trial (CAO/ARO/AIO-94) compares the efficacy of neoadjuvant radiochemotherapy to standard postoperative radiochemotherapy. We report on the design of the study and first results with regard to toxicity of radiochemotherapy and postoperative morbidity.
PATIENTS AND METHODS: Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre- or postoperative radiochemotherapy: A total dose of 50.4 Gy (single dose 1.8 Gy) was applied to the tumor and the pelvic lymph nodes. 5-FU (1,000 mg/m2/d) was administered concomitantly in the first and fifth week of radiation as 120-h continuous infusion. Four additional cycles of 5-FU chemotherapy (500 mg/m2/d, i.v. bolus) were applied. Radiochemotherapy was identical in both arms except for a small-volume boost of 5.4 Gy in the postoperative setting. Time interval between radiochemotherapy and surgery was 4-6 weeks in both arms. Techniques of surgery were standardized and included total mesorectal excision. In addition, stratification according to surgeons involved has been provided for. Primary endpoints of the study are 5-year overall-survival, local and distant control, secondary endpoints include rate of curative (R0) resections and sphincter saving procedures, toxicity of radiochemotherapy, surgical complications and quality of life.
RESULTS: As of 15th November 2000, 628 patients were randomized from 26 participating institutions: 310 patients were randomized to postoperative radiochemotherapy, 318 patients to preoperative radiochemotherapy. Acute toxicity (WHO) of radiochemotherapy was low, with less than 15\% of patients experiencing Grade 3 or higher toxicity: The principal toxicity was diarrhea, with 12\% in the postoperative radiochemotherapy arm and 10\% in the preoperative radiochemotherapy arm having Grade-3, and 1\% in either arm having Grade-4 diarrhea. Erythema, nausea and leukopenia were the next common toxicities, with less than 3\% of patients in either arm suffering Grade 3 or greater leukopenia or nausea. Postoperative complication rates were similar in both arms, with 12\% (postoperative radiochemotherapy) and 13\% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4\% (postoperative radiochemotherapy) and 3\% (preoperative radiochemotherapy) from postoperative bleeding, and 6\% (postoperative radiochemotherapy) and 5\% (preoperative radiochemotherapy) from delayed wound healing.
CONCLUSION: The patient accrual of our trial is satisfactory, neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.},
	language = {eng},
	number = {4},
	journal = {Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft ... [et Al]},
	author = {Sauer, R. and Fietkau, R. and Wittekind, C. and Martus, P. and Rödel, C. and Hohenberger, W. and Jatzko, G. and Sabitzer, H. and Karstens, J. H. and Becker, H. and Hess, C. and Raab, R.},
	month = apr,
	year = {2001},
	pmid = {11370551},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Neoplasm Staging, Adult, Chemotherapy, Adjuvant, Fluorouracil, Survival Analysis, Postoperative Complications, Radiotherapy, Adjuvant, Radiotherapy Dosage, Patient Selection, Quality of Life, Antimetabolites, Antineoplastic, Rectal Neoplasms, Adjuvant;Rectal},
	pages = {173--181},
}

@article{mercurystudygroup779,
	title = {Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study},
	volume = {333},
	issn = {1756-1833},
	shorttitle = {Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer},
	doi = {10.1136/bmj.38937.646400.55},
	abstract = {OBJECTIVE: To assess the accuracy of preoperative staging of rectal cancer with magnetic resonance imaging to predict surgical circumferential resection margins.
DESIGN: Prospective observational study of rectal cancers treated by colorectal multidisciplinary teams between January 2002 and October 2003.
SETTING: 11 colorectal units in four European countries.
PARTICIPANTS: 408 consecutive patients presenting with all stages of rectal cancer and undergoing magnetic resonance imaging before total mesorectal excision surgery and histopathological assessment of the surgical specimen.
MAIN OUTCOME MEASURES: Accuracy of magnetic resonance imaging in predicting a curative resection based on the histological yardstick of presence or absence of tumour at the margins of the specimen.
RESULTS: 354 of the 408 patients had a clear circumferential resection margin (87\%, 95\% confidence interval 83\% to 90\%). Specificity for prediction of a clear margin by magnetic resonance imaging was 92\% (327/354, 90\% to 95\%). High resolution scans were technically satisfactory in 93\% (379/408). Surgical specimens were histopathologically graded as complete or moderate in 80\% (328/408), and the median lymph node harvest was 12 (range 0-49). Magnetic resonance imaging predicted clear margins in 349 patients. At surgery 327 had clear margins (94\%, 91\% to 96\%).
CONCLUSION: High resolution magnetic resonance imaging accurately predicts whether the surgical resection margins will be clear or affected by tumour. This technique can be reproduced accurately in multiple centres to predict curative resection and warns the multidisciplinary team of potential failure of surgery, thus enabling selection of patients for preoperative treatment.},
	language = {eng},
	number = {7572},
	journal = {BMJ (Clinical research ed.)},
	author = {{MERCURY Study Group}},
	month = oct,
	year = {2006},
	pmid = {16984925},
	pmcid = {PMC1602032},
	keywords = {Humans, Magnetic Resonance Imaging, Aged, Female, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Aged, 80 and over, Adult, Sensitivity and Specificity, Preoperative Care, Rectal Neoplasms, Feasibility Studies, Rectal;MRI},
	pages = {779},
	file = {Full Text:/Users/jcsal/Zotero/storage/W7VK8YBZ/MERCURY Study Group - 2006 - Diagnostic accuracy of preoperative magnetic reson.pdf:application/pdf},
}

@article{717,
	title = {Short-{Course} {Versus} {Standard} {Chemoradiation} in {T3} {Rectal} {Cancer}},
	volume = {16},
	issn = {1083-7159},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228203/},
	doi = {10.1634/theoncologist.2011-0052},
	abstract = {The pros and cons of short-course radiation therapy and standard chemoradiation in T3 rectal cancer are presented.},
	number = {5},
	urldate = {2022-05-15},
	journal = {The Oncologist},
	month = may,
	year = {2011},
	pmid = {21586661},
	pmcid = {PMC3228203},
	keywords = {Rectal;RT},
	pages = {717--721},
	file = {Full Text:/Users/jcsal/Zotero/storage/K6MLX5U7/2011 - Short-Course Versus Standard Chemoradiation in T3 .pdf:application/pdf},
}

@article{pettersson972,
	title = {Tumour regression in the randomized {Stockholm} {III} {Trial} of radiotherapy regimens for rectal cancer},
	volume = {102},
	issn = {1365-2168},
	doi = {10.1002/bjs.9811},
	abstract = {BACKGROUND: The Stockholm III Trial randomized patients with primary operable rectal cancers to either short-course radiotherapy (RT) with immediate surgery (SRT), short-course RT with surgery delayed 4-8 weeks (SRT-delay) or long-course RT with surgery delayed 4-8 weeks. This preplanned interim analysis examined the pathological outcome of delaying surgery.
METHODS: Patients randomized to the SRT and SRT-delay arms in the Stockholm III Trial between October 1998 and November 2010 were included, and data were collected in a prospective register. Additional data regarding tumour regression grade, according to Dworak, and circumferential margin were obtained by reassessment of histopathological slides.
RESULTS: A total of 462 of 545 randomized patients had specimens available for reassessment. Patients randomized to SRT-delay had earlier ypT categories, and a higher rate of pathological complete responses (11·8 versus 1·7 per cent; P = 0·001) and Dworak grade 4 tumour regression (10·1 versus 1·7 per cent; P {\textless} 0·001) than patients randomized to SRT without delay. Positive circumferential resection margins were uncommon (6·3 per cent) and rates did not differ between the two treatment arms.
CONCLUSION: Short-course RT induces tumour downstaging if surgery is performed after an interval of 4-8 weeks.},
	language = {eng},
	number = {8},
	journal = {The British Journal of Surgery},
	author = {Pettersson, D. and Lörinc, E. and Holm, T. and Iversen, H. and Cedermark, B. and Glimelius, B. and Martling, A.},
	month = jul,
	year = {2015},
	pmid = {26095256},
	pmcid = {PMC4744683},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Prospective Studies, Time Factors, Aged, 80 and over, Adult, Adenocarcinoma, Radiotherapy, Adjuvant, Preoperative Care, Rectal Neoplasms, Rectal;RT},
	pages = {972--978; discussion 978},
	file = {Full Text:/Users/jcsal/Zotero/storage/RZ32I59E/Pettersson et al. - 2015 - Tumour regression in the randomized Stockholm III .pdf:application/pdf},
}

@article{roh5124,
	title = {Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: {NSABP} {R}-03},
	volume = {27},
	issn = {1527-7755},
	shorttitle = {Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum},
	doi = {10.1200/JCO.2009.22.0467},
	abstract = {PURPOSE: Although chemoradiotherapy plus resection is considered standard treatment for operable rectal carcinoma, the optimal time to administer this therapy is not clear. The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant chemoradiotherapy in the treatment of locally advanced rectal carcinoma.
PATIENTS AND METHODS: Patients with clinical T3 or T4 or node-positive rectal cancer were randomly assigned to preoperative or postoperative chemoradiotherapy. Chemotherapy consisted of fluorouracil and leucovorin with 45 Gy in 25 fractions with a 5.40-Gy boost within the original margins of treatment. In the preoperative group, surgery was performed within 8 weeks after completion of radiotherapy. In the postoperative group, chemotherapy began after recovery from surgery but no later than 4 weeks after surgery. The primary end points were disease-free survival (DFS) and overall survival (OS).
RESULTS: From August 1993 to June 1999, 267 patients were randomly assigned to NSABP R-03. The intended sample size was 900 patients. Excluding 11 ineligible and two eligible patients without follow-up data, the analysis used data on 123 patients randomly assigned to preoperative and 131 to postoperative chemoradiotherapy. Surviving patients were observed for a median of 8.4 years. The 5-year DFS for preoperative patients was 64.7\% v 53.4\% for postoperative patients (P = .011). The 5-year OS for preoperative patients was 74.5\% v 65.6\% for postoperative patients (P = .065). A complete pathologic response was achieved in 15\% of preoperative patients. No preoperative patient with a complete pathologic response has had a recurrence.
CONCLUSION: Preoperative chemoradiotherapy, compared with postoperative chemoradiotherapy, significantly improved DFS and showed a trend toward improved OS.},
	language = {eng},
	number = {31},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Roh, Mark S. and Colangelo, Linda H. and O'Connell, Michael J. and Yothers, Greg and Deutsch, Melvin and Allegra, Carmen J. and Kahlenberg, Morton S. and Baez-Diaz, Luis and Ursiny, Carol S. and Petrelli, Nicholas J. and Wolmark, Norman},
	month = nov,
	year = {2009},
	pmid = {19770376},
	pmcid = {PMC2773471},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Fluorouracil, Leucovorin, Disease-Free Survival, Combined Modality Therapy, Radiotherapy, Adjuvant, Digestive System Surgical Procedures, Preoperative Care, Rectal Neoplasms, Rectal;RT},
	pages = {5124--5130},
	file = {Full Text:/Users/jcsal/Zotero/storage/5JTW4E96/Roh et al. - 2009 - Preoperative multimodality therapy improves diseas.pdf:application/pdf},
}

@article{bahadoer29,
	title = {Short-course radiotherapy followed by chemotherapy before total mesorectal excision ({TME}) versus preoperative chemoradiotherapy, {TME}, and optional adjuvant chemotherapy in locally advanced rectal cancer ({RAPIDO}): a randomised, open-label, phase 3 trial},
	volume = {22},
	issn = {1474-5488},
	shorttitle = {Short-course radiotherapy followed by chemotherapy before total mesorectal excision ({TME}) versus preoperative chemoradiotherapy, {TME}, and optional adjuvant chemotherapy in locally advanced rectal cancer ({RAPIDO})},
	doi = {10.1016/S1470-2045(20)30555-6},
	abstract = {BACKGROUND: Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control.
METHODS: In this multicentre, open-label, randomised, controlled, phase 3 trial, participants were recruited from 54 centres in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA. Patients were eligible if they were aged 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, had a biopsy-proven, newly diagnosed, primary, locally advanced rectal adenocarcinoma, which was classified as high risk on pelvic MRI (with at least one of the following criteria: clinical tumour [cT] stage cT4a or cT4b, extramural vascular invasion, clinical nodal [cN] stage cN2, involved mesorectal fascia, or enlarged lateral lymph nodes), were mentally and physically fit for chemotherapy, and could be assessed for staging within 5 weeks before randomisation. Eligible participants were randomly assigned (1:1), using a management system with a randomly varying block design (each block size randomly chosen to contain two to four allocations), stratified by centre, ECOG performance status, cT stage, and cN stage, to either the experimental or standard of care group. All investigators remained masked for the primary endpoint until a prespecified number of events was reached. Patients allocated to the experimental treatment group received short-course radiotherapy (5 × 5 Gy over a maximum of 8 days) followed by six cycles of CAPOX chemotherapy (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, and a chemotherapy-free interval between days 15-21) or nine cycles of FOLFOX4 (oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin [folinic acid] 200 mg/m2 intravenously on days 1 and 2, followed by bolus fluorouracil 400 mg/m2 intravenously and fluorouracil 600 mg/m2 intravenously for 22 h on days 1 and 2, and a chemotherapy-free interval between days 3-14) followed by total mesorectal excision. Choice of CAPOX or FOLFOX4 was per physician discretion or hospital policy. Patients allocated to the standard of care group received 28 daily fractions of 1·8 Gy up to 50·4 Gy or 25 fractions of 2·0 Gy up to 50·0 Gy (per physician discretion or hospital policy), with concomitant twice-daily oral capecitabine 825 mg/m2 followed by total mesorectal excision and, if stipulated by hospital policy, adjuvant chemotherapy with eight cycles of CAPOX or 12 cycles of FOLFOX4. The primary endpoint was 3-year disease-related treatment failure, defined as the first occurrence of locoregional failure, distant metastasis, new primary colorectal tumour, or treatment-related death, assessed in the intention-to-treat population. Safety was assessed by intention to treat. This study is registered with the EudraCT, 2010-023957-12, and ClinicalTrials.gov, NCT01558921, and is now complete.
FINDINGS: Between June 21, 2011, and June 2, 2016, 920 patients were enrolled and randomly assigned to a treatment, of whom 912 were eligible (462 in the experimental group; 450 in the standard of care group). Median follow-up was 4·6 years (IQR 3·5-5·5). At 3 years after randomisation, the cumulative probability of disease-related treatment failure was 23·7\% (95\% CI 19·8-27·6) in the experimental group versus 30·4\% (26·1-34·6) in the standard of care group (hazard ratio 0·75, 95\% CI 0·60-0·95; p=0·019). The most common grade 3 or higher adverse event during preoperative therapy in both groups was diarrhoea (81 [18\%] of 460 patients in the experimental group and 41 [9\%] of 441 in the standard of care group) and neurological toxicity during adjuvant chemotherapy in the standard of care group (16 [9\%] of 187 patients). Serious adverse events occurred in 177 (38\%) of 460 participants in the experimental group and, in the standard of care group, in 87 (34\%) of 254 patients without adjuvant chemotherapy and in 64 (34\%) of 187 with adjuvant chemotherapy. Treatment-related deaths occurred in four participants in the experimental group (one cardiac arrest, one pulmonary embolism, two infectious complications) and in four participants in the standard of care group (one pulmonary embolism, one neutropenic sepsis, one aspiration, one suicide due to severe depression).
INTERPRETATION: The observed decreased probability of disease-related treatment failure in the experimental group is probably indicative of the increased efficacy of preoperative chemotherapy as opposed to adjuvant chemotherapy in this setting. Therefore, the experimental treatment can be considered as a new standard of care in high-risk locally advanced rectal cancer.
FUNDING: Dutch Cancer Foundation, Swedish Cancer Society, Spanish Ministry of Economy and Competitiveness, and Spanish Clinical Research Network.},
	language = {eng},
	number = {1},
	journal = {The Lancet. Oncology},
	author = {Bahadoer, Renu R. and Dijkstra, Esmée A. and van Etten, Boudewijn and Marijnen, Corrie A. M. and Putter, Hein and Kranenbarg, Elma Meershoek-Klein and Roodvoets, Annet G. H. and Nagtegaal, Iris D. and Beets-Tan, Regina G. H. and Blomqvist, Lennart K. and Fokstuen, Tone and Ten Tije, Albert J. and Capdevila, Jaume and Hendriks, Mathijs P. and Edhemovic, Ibrahim and Cervantes, Andrés and Nilsson, Per J. and Glimelius, Bengt and van de Velde, Cornelis J. H. and Hospers, Geke A. P. and {RAPIDO collaborative investigators}},
	month = jan,
	year = {2021},
	pmid = {33301740},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Time Factors, United States, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Dose Fractionation, Radiation, Neoplasm Recurrence, Local, Treatment Failure, Digestive System Surgical Procedures, Europe, Rectal Neoplasms, Rectal;TNT},
	pages = {29--42},
	file = {Full Text:/Users/jcsal/Zotero/storage/X9YP39PC/Bahadoer et al. - 2021 - Short-course radiotherapy followed by chemotherapy.pdf:application/pdf},
}

@article{andre2207,
	title = {Pembrolizumab in {Microsatellite}-{Instability}-{High} {Advanced} {Colorectal} {Cancer}},
	volume = {383},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2017699},
	abstract = {BACKGROUND: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H-dMMR advanced or metastatic colorectal cancer is unknown.
METHODS: In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks. Patients receiving chemotherapy could cross over to pembrolizumab therapy after disease progression. The two primary end points were progression-free survival and overall survival.
RESULTS: At the second interim analysis, after a median follow-up (from randomization to data cutoff) of 32.4 months (range, 24.0 to 48.3), pembrolizumab was superior to chemotherapy with respect to progression-free survival (median, 16.5 vs. 8.2 months; hazard ratio, 0.60; 95\% confidence interval [CI], 0.45 to 0.80; P = 0.0002). The estimated restricted mean survival after 24 months of follow-up was 13.7 months (range, 12.0 to 15.4) as compared with 10.8 months (range, 9.4 to 12.2). As of the data cutoff date, 56 patients in the pembrolizumab group and 69 in the chemotherapy group had died. Data on overall survival were still evolving (66\% of required events had occurred) and remain blinded until the final analysis. An overall response (complete or partial response), as evaluated with Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was observed in 43.8\% of the patients in the pembrolizumab group and 33.1\% in the chemotherapy group. Among patients with an overall response, 83\% in the pembrolizumab group, as compared with 35\% of patients in the chemotherapy group, had ongoing responses at 24 months. Treatment-related adverse events of grade 3 or higher occurred in 22\% of the patients in the pembrolizumab group, as compared with 66\% (including one patient who died) in the chemotherapy group.
CONCLUSIONS: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.).},
	language = {eng},
	number = {23},
	journal = {The New England Journal of Medicine},
	author = {André, Thierry and Shiu, Kai-Keen and Kim, Tae Won and Jensen, Benny Vittrup and Jensen, Lars Henrik and Punt, Cornelis and Smith, Denis and Garcia-Carbonero, Rocio and Benavides, Manuel and Gibbs, Peter and de la Fouchardiere, Christelle and Rivera, Fernando and Elez, Elena and Bendell, Johanna and Le, Dung T. and Yoshino, Takayuki and Van Cutsem, Eric and Yang, Ping and Farooqui, Mohammed Z. H. and Marinello, Patricia and Diaz, Luis A. and {KEYNOTE-177 Investigators}},
	month = dec,
	year = {2020},
	pmid = {33264544},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Progression-Free Survival, Fluorouracil, Antibodies, Monoclonal, Humanized, Immunotherapy, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Brain Neoplasms, Immune Checkpoint Inhibitors, Microsatellite Instability, Mutation, Neoplastic Syndromes, Hereditary, StageIV},
	pages = {2207--2218},
	file = {Full Text:/Users/jcsal/Zotero/storage/4WDJWKEP/André et al. - 2020 - Pembrolizumab in Microsatellite-Instability-High A.pdf:application/pdf},
}

@article{hu38,
	title = {Neoadjuvant {PD}-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer ({PICC}): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial},
	volume = {7},
	issn = {2468-1253},
	shorttitle = {Neoadjuvant {PD}-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer ({PICC})},
	doi = {10.1016/S2468-1253(21)00348-4},
	abstract = {BACKGROUND: PD-1 blockade is highly effective in patients with mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 blockade in the neoadjuvant setting for resectable mismatch repair-deficient or microsatellite instability-high colorectal cancer remains unclear. We investigated the efficacy and safety of PD-1 blockade with toripalimab, with or without the COX-2 inhibitor celecoxib, as neoadjuvant treatment for mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancers.
METHODS: The PD-1 Inhibitor in Microsatellite Instability Colorectal Cancer (PICC) trial was a single-centre, open-label, parallel-group, non-comparative, randomised, phase 2 study undertaken at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Eligible patients were aged 18-75 years, had histologically confirmed mismatch repair-deficient or microsatellite instability-high colorectal cancer, had clinical stage T3-T4 or any T with lymph node positivity (N+), Eastern Cooperative Oncology Group performance score of 0 or 1, and adequate haematological, hepatic, and renal function. Participants were randomly assigned (1:1), without any stratification or balanced blocking, to receive toripalimab 3 mg/kg intravenously on day 1, with or without celecoxib 200 mg orally twice daily from day 1 to 14 of each 14-day cycle, for six cycles before surgical resection. Adjuvant treatment with toripalimab with or without celecoxib was permitted at the investigators' discretion. The primary endpoint was the proportion of patients with pathological complete response, defined as tumours without any viable tumour cells in the resected primary tumour sample and all sampled regional lymph nodes. All efficacy and safety analyses were assessed in the modified intention-to-treat population, which included all patients who were randomly assigned to treatment and who received at least one dose of toripalimab. This trial is registered with ClinicalTrials.gov, NCT03926338, and is ongoing.
FINDINGS: Between May 1, 2019, and April 1, 2021, 53 patients were screened, of whom 34 were randomly assigned to either the toripalimab plus celecoxib group (n=17) or the toripalimab monotherapy group (n=17). As of data cutoff (Aug 10, 2021), median follow-up was 14·9 months (IQR 8·8-17·0). All patients received study treatment and underwent surgical resection; there were no treatment-related surgical delays. All 34 patients had an R0 resection ({\textgreater}1 mm resection margin). 15 of 17 patients (88\% [95\% CI 64-99]) in the toripalimab plus celecoxib group and 11 of 17 patients (65\% [38-86]) in the toripalimab monotherapy group had a pathological complete response. All patients continued to receive adjuvant toripalimab with or without celecoxib for a total perioperative duration of 6 months and were alive and free of recurrence at data cutoff. During neoadjuvant treatment, ten (59\%) patients in the toripalimab plus celecoxib group and ten (59\%) in the toripalimab monotherapy group had grade 1-2 treatment-related adverse events. Only one (3\%) of 34 patients, who was in the toripalimab plus celecoxib group, had a grade 3 or higher treatment-related adverse event during the neoadjuvant phase, which was grade 3 increased aspartate aminotransferase levels. In the adjuvant phase, only one (3\%) of 34 patients, who was in the toripalimab monotherapy group, had a grade 3 or higher treatment-related adverse events, which was grade 3 increased aspartate aminotransferase and alanine aminotransferase levels.
INTERPRETATION: Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer. This treatment was associated with a high pathological complete response rate and an acceptable safety profile, which did not compromise surgery. Longer term follow-up is needed to assess effects on survival-related endpoints.
FUNDING: The National Key R\&D Program of China, the National Natural Science Foundation of China, and the Chinese Society of Clinical Oncology-Junshi Biosciences Oncology Immunity Research.
TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.},
	language = {eng},
	number = {1},
	journal = {The Lancet. Gastroenterology \& Hepatology},
	author = {Hu, Huabin and Kang, Liang and Zhang, Jianwei and Wu, Zehua and Wang, Hui and Huang, Meijin and Lan, Ping and Wu, Xiaojian and Wang, Chao and Cao, Wuteng and Hu, Jiancong and Huang, Yan and Huang, Liang and Wang, Huaiming and Shi, Lishuo and Cai, Yue and Shen, Cailu and Ling, Jiayu and Xie, Xiaoyu and Cai, Yonghua and He, Xiaowen and Dou, Ruoxu and Zhou, Jiaming and Ma, Tenghui and Zhang, Xingwei and Luo, Shuangling and Deng, Weihao and Ling, Li and Liu, Hao and Deng, Yanhong},
	month = jan,
	year = {2022},
	pmid = {34688374},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemotherapy, Adjuvant, Colectomy, Antibodies, Monoclonal, Humanized, Young Adult, Lymphatic Metastasis, Lymph Node Excision, Microsatellite Instability, Celecoxib, DNA Mismatch Repair, DNA-Binding Proteins, Mismatch Repair Endonuclease PMS2, MutL Protein Homolog 1, MutS Homolog 2 Protein, Programmed Cell Death 1 Receptor},
	pages = {38--48},
}

@article{vangijn575,
	title = {Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled {TME} trial},
	volume = {12},
	issn = {1474-5488},
	shorttitle = {Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer},
	doi = {10.1016/S1470-2045(11)70097-3},
	abstract = {BACKGROUND: The TME trial investigated the value of preoperative short-term radiotherapy in combination with total mesorectal excision (TME). Long-term results are reported after a median follow-up of 12 years.
METHODS: Between Jan 12, 1996, and Dec 31, 1999, 1861 patients with resectable rectal cancer without evidence of distant disease were randomly assigned to TME preceded by 5 × 5 Gy radiotherapy or TME alone (ratio 1:1). Randomisation was based on permuted blocks of six with stratification according to centre and expected type of surgery. The primary endpoint was local recurrence, analysed for all eligible patients who underwent a macroscopically complete local resection.
FINDINGS: 10-year cumulative incidence of local recurrence was 5\% in the group assigned to radiotherapy and surgery and 11\% in the surgery-alone group (p{\textless}0·0001). The effect of radiotherapy became stronger as the distance from the anal verge increased. However, when patients with a positive circumferential resection margin were excluded, the relation between distance from the anal verge and the effect of radiotherapy disappeared. Patients assigned to radiotherapy had a lower overall recurrence and when operated with a negative circumferential resection margin, cancer-specific survival was higher. Overall survival did not differ between groups. For patients with TNM stage III cancer with a negative circumferential resection margin, 10-year survival was 50\% in the preoperative radiotherapy group versus 40\% in the surgery-alone group (p=0·032).
INTERPRETATION: For all eligible patients, preoperative short-term radiotherapy reduced 10-year local recurrence by more than 50\% relative to surgery alone without an overall survival benefit. For patients with a negative resection margin, the effect of radiotherapy was irrespective of the distance from the anal verge and led to an improved cancer-specific survival, which was nullified by an increase in other causes of death, resulting in an equal overall survival. Nevertheless, preoperative short-term radiotherapy significantly improved 10-year survival in patients with a negative circumferential margin and TNM stage III. Future staging techniques should offer possibilities to select patient groups for which the balance between benefits and side-effects will result in sufficiently large gains.
FUNDING: The Dutch Cancer Society, the Dutch National Health Council, and the Swedish Cancer Society.},
	language = {eng},
	number = {6},
	journal = {The Lancet. Oncology},
	author = {van Gijn, Willem and Marijnen, Corrie A. M. and Nagtegaal, Iris D. and Kranenbarg, Elma Meershoek-Klein and Putter, Hein and Wiggers, Theo and Rutten, Harm J. T. and Påhlman, Lars and Glimelius, Bengt and van de Velde, Cornelis J. H. and {Dutch Colorectal Cancer Group}},
	month = jun,
	year = {2011},
	pmid = {21596621},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Aged, 80 and over, Adult, Neoplasm Recurrence, Local, Combined Modality Therapy, Rectum, Rectal Neoplasms, Rectal, TME},
	pages = {575--582},
}

@article{poultsides35,
	title = {Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective},
	volume = {3},
	issn = {1758-8359},
	shorttitle = {Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer},
	doi = {10.1177/1758834010386283},
	abstract = {In the absence of symptoms, primary tumor resection in patients who present with unresectable metastatic colorectal cancer is of uncertain benefit. Prophylactic surgery has been traditionally considered in this setting in order to prevent subsequent complications of perforation, obstruction, or bleeding later during the treatment course, which may require urgent surgery associated with higher mortality. However, recent data have called into question the efficacy of this upfront surgical strategy. We provide a brief overview of how current combinations of systemic chemotherapy including fluorouracil, oxaliplatin, irinotecan, and targeted biologic agents have allowed improved local (in addition to distant) tumor control, significantly decreasing the incidence of late primary-related complications requiring surgery from roughly 20\% in the era of single-agent fluoropyrimidine chemotherapy to almost 7\% in the era of modern triple-drug chemotherapy. In addition, we attempt to highlight those factors most associated with subsequent primary tumor-related complications in an effort to identify the subset of patients with synchronous metastatic colorectal cancer who might benefit from a surgery-first approach. Finally, we discuss modern nonsurgical options available for palliation of the primary colorectal tumor and review the outcome of patients for which emergent surgery is eventually required to address primary-related symptoms.},
	language = {eng},
	number = {1},
	journal = {Therapeutic Advances in Medical Oncology},
	author = {Poultsides, George A. and Paty, Phillip B.},
	month = jan,
	year = {2011},
	pmid = {21789154},
	pmcid = {PMC3126037},
	keywords = {chemotherapy, Stage4, colorectal cancer, primary tumor, stage IV},
	pages = {35--42},
	file = {Full Text:/Users/jcsal/Zotero/storage/WKDH46VW/Poultsides and Paty - 2011 - Reassessing the need for primary tumor surgery in .pdf:application/pdf},
}

@article{jin1681,
	title = {Multicenter, {Randomized}, {Phase} {III} {Trial} of {Short}-{Term} {Radiotherapy} {Plus} {Chemotherapy} {Versus} {Long}-{Term} {Chemoradiotherapy} in {Locally} {Advanced} {Rectal} {Cancer} ({STELLAR})},
	volume = {40},
	issn = {1527-7755},
	doi = {10.1200/JCO.21.01667},
	abstract = {PURPOSE: To ascertain if preoperative short-term radiotherapy followed by chemotherapy is not inferior to a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer.
MATERIALS AND METHODS: Patients with distal or middle-third, clinical primary tumor stage 3-4 and/or regional lymph node-positive rectal cancer were randomly assigned (1:1) to short-term radiotherapy (25 Gy in five fractions over 1 week) followed by four cycles of chemotherapy (total neoadjuvant therapy [TNT]) or chemoradiotherapy (50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine [chemoradiotherapy; CRT]). Total mesorectal excision was undertaken 6-8 weeks after preoperative treatment, with two additional cycles of CAPOX (intravenous oxaliplatin [130 mg/m2, once a day] on day 1 and capecitabine [1,000 mg/m2, twice a day] from days 1 to 14) in the TNT group and six cycles of CAPOX in the CRT group. The primary end point was 3-year disease-free survival (DFS).
RESULTS: Between August 2015 and August 2018, a total of 599 patients were randomly assigned to receive TNT (n = 302) or CRT (n = 297). At a median follow-up of 35.0 months, 3-year DFS was 64.5\% and 62.3\% in TNT and CRT groups, respectively (hazard ratio, 0.883; one-sided 95\% CI, not applicable to 1.11; P {\textless} .001 for noninferiority). There was no significant difference in metastasis-free survival or locoregional recurrence, but the TNT group had better 3-year overall survival than the CRT group (86.5\% v 75.1\%; P = .033). Treatment effects on DFS and overall survival were similar regardless of prognostic factors. The prevalence of acute grade III-V toxicities during preoperative treatment was 26.5\% in the TNT group versus 12.6\% in the CRT group (P {\textless} .001).
CONCLUSION: Short-term radiotherapy with preoperative chemotherapy followed by surgery was efficacious with acceptable toxicity and could be used as an alternative to CRT for locally advanced rectal cancer.},
	language = {eng},
	number = {15},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Jin, Jing and Tang, Yuan and Hu, Chen and Jiang, Li-Ming and Jiang, Jun and Li, Ning and Liu, Wen-Yang and Chen, Si-Lin and Li, Shuai and Lu, Ning-Ning and Cai, Yong and Li, Yong-Heng and Zhu, Yuan and Cheng, Guang-Hui and Zhang, Hong-Yan and Wang, Xin and Zhu, Su-Yu and Wang, Jun and Li, Gao-Feng and Yang, Jia-Lin and Zhang, Kuan and Chi, Yihebali and Yang, Lin and Zhou, Hai-Tao and Zhou, Ai-Ping and Zou, Shuang-Mei and Fang, Hui and Wang, Shu-Lian and Zhang, Hai-Zeng and Wang, Xi-Shan and Wei, Li-Chun and Wang, Wen-Ling and Liu, Shi-Xin and Gao, Yuan-Hong and Li, Ye-Xiong},
	month = may,
	year = {2022},
	pmid = {35263150},
	pmcid = {PMC9113208},
	keywords = {Humans, Neoadjuvant Therapy, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Neoplasm Recurrence, Local, Chemoradiotherapy, Capecitabine, Rectal Neoplasms, Rectal;TNT, Neoplasms, Second Primary},
	pages = {1681--1692},
	file = {Full Text:/Users/jcsal/Zotero/storage/7RFWGVDJ/Jin et al. - 2022 - Multicenter, Randomized, Phase III Trial of Short-.pdf:application/pdf},
}

@article{vandervalk75,
	title = {Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - {Results} of the international randomized {RAPIDO}-trial},
	volume = {147},
	issn = {1879-0887},
	doi = {10.1016/j.radonc.2020.03.011},
	abstract = {BACKGROUND: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision is widely accepted as the standard of care for high-risk rectal cancer. Adjuvant chemotherapy is advised in several international guidelines, although the survival benefit remains unclear and compliance is poor. The current multidisciplinary approach has led to major improvements in local control, yet the occurrence of distant metastases has not decreased accordingly. The combination of short-course radiotherapy (SCRT) and chemotherapy in the waiting period before surgery might have several benefits, including higher compliance, downstaging and better effect of systemic therapy.
METHODS: This is an investigator-initiated, international multicentre randomized phase III trial. High-risk rectal cancer patients were randomized to SCRT followed by chemotherapy (6 cycles CAPOX or alternatively 9 cycles FOLFOX4) and subsequent surgery, or long-course radiotherapy (25-28 × 2-1.8 Gy) with concomitant capecitabine followed by surgery and optional postoperative chemotherapy (8 cycles CAPOX or 12 cycles FOLFOX4) according to local institutions' policy. The primary endpoint is time to disease-related treatment failure. Here, we report the compliance, toxicity and postoperative complications in both study groups.
FINDINGS: Between June 2011 and June 2016, 920 patients were enrolled. Of these, 901 were evaluable (460 in the experimental arm and 441 in the standard arm). All patients in the experimental arm received 5 × 5 Gy radiotherapy, and 84\% of all patients received at least 75\% of the prescribed chemotherapy. In the standard arm, the compliance for CRT was 93\% and 58\% for postoperative chemotherapy. Toxicity ≥grade 3 occurred in 48\% of patients in the experimental arm, compared to 25\% of patients in the standard arm during preoperative treatment and 35\% of patients during postoperative chemotherapy. No statistically significant differences in surgical procedures or postoperative complications were observed.
INTERPRETATION: High compliance (84\%) of preoperative systemic treatment could be achieved with the experimental approach. Although considerable toxicity was observed during preoperative therapy, this did not lead to differences in surgical procedures or postoperative complications. Longer follow-up time is needed to assess the primary endpoint and related outcomes.},
	language = {eng},
	journal = {Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology},
	author = {van der Valk, Maxime J. M. and Marijnen, Corrie A. M. and van Etten, Boudewijn and Dijkstra, Esmée A. and Hilling, Denise E. and Kranenbarg, Elma Meershoek-Klein and Putter, Hein and Roodvoets, Annet G. H. and Bahadoer, Renu R. and Fokstuen, Tone and Ten Tije, Albert Jan and Capdevila, Jaume and Hendriks, Mathijs P. and Edhemovic, Ibrahim and Cervantes, Andrès M. R. and de Groot, Derk Jan A. and Nilsson, Per J. and Glimelius, Bengt and van de Velde, Cornelis J. H. and Hospers, Geke A. P. and {Collaborative investigators}},
	month = jun,
	year = {2020},
	pmid = {32240909},
	keywords = {Humans, Neoadjuvant Therapy, Treatment Outcome, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Chemotherapy, Adjuvant, Fluorouracil, Chemoradiotherapy, Rectal Neoplasms, Rectal;TNT, Multimodal treatment, Preoperative radiotherapy, Rectal cancer},
	pages = {75--83},
	file = {Full Text:/Users/jcsal/Zotero/storage/3RD49MU7/van der Valk et al. - 2020 - Compliance and tolerability of short-course radiot.pdf:application/pdf},
}

@article{nowak3142,
	title = {End-to-end automated body composition analyses with integrated quality control for opportunistic assessment of sarcopenia in {CT}},
	volume = {32},
	issn = {1432-1084},
	doi = {10.1007/s00330-021-08313-x},
	abstract = {OBJECTIVES: To develop a pipeline for automated body composition analysis and skeletal muscle assessment with integrated quality control for large-scale application in opportunistic imaging.
METHODS: First, a convolutional neural network for extraction of a single slice at the L3/L4 lumbar level was developed on CT scans of 240 patients applying the nnU-Net framework. Second, a 2D competitive dense fully convolutional U-Net for segmentation of visceral and subcutaneous adipose tissue (VAT, SAT), skeletal muscle (SM), and subsequent determination of fatty muscle fraction (FMF) was developed on single CT slices of 1143 patients. For both steps, automated quality control was integrated by a logistic regression model classifying the presence of L3/L4 and a linear regression model predicting the segmentation quality in terms of Dice score. To evaluate the performance of the entire pipeline end-to-end, body composition metrics, and FMF were compared to manual analyses including 364 patients from two centers.
RESULTS: Excellent results were observed for slice extraction (z-deviation = 2.46 ± 6.20 mm) and segmentation (Dice score for SM = 0.95 ± 0.04, VAT = 0.98 ± 0.02, SAT = 0.97 ± 0.04) on the dual-center test set excluding cases with artifacts due to metallic implants. No data were excluded for end-to-end performance analyses. With a restrictive setting of the integrated segmentation quality control, 39 of 364 patients were excluded containing 8 cases with metallic implants. This setting ensured a high agreement between manual and fully automated analyses with mean relative area deviations of ΔSM = 3.3 ± 4.1\%, ΔVAT = 3.0 ± 4.7\%, ΔSAT = 2.7 ± 4.3\%, and ΔFMF = 4.3 ± 4.4\%.
CONCLUSIONS: This study presents an end-to-end automated deep learning pipeline for large-scale opportunistic assessment of body composition metrics and sarcopenia biomarkers in clinical routine.
KEY POINTS: • Body composition metrics and skeletal muscle quality can be opportunistically determined from routine abdominal CT scans. • A pipeline consisting of two convolutional neural networks allows an end-to-end automated analysis. • Machine-learning-based quality control ensures high agreement between manual and automatic analysis.},
	language = {eng},
	number = {5},
	journal = {European Radiology},
	author = {Nowak, Sebastian and Theis, Maike and Wichtmann, Barbara D. and Faron, Anton and Froelich, Matthias F. and Tollens, Fabian and Geißler, Helena L. and Block, Wolfgang and Luetkens, Julian A. and Attenberger, Ulrike I. and Sprinkart, Alois M.},
	month = may,
	year = {2022},
	pmid = {34595539},
	pmcid = {PMC9038788},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Sarcopenia, Body composition, Deep learning, MacineLearning, Quality control, Quality Control, Tomography, X-ray computed},
	pages = {3142--3151},
	file = {Full Text:/Users/jcsal/Zotero/storage/8TZDSZS5/Nowak et al. - 2022 - End-to-end automated body composition analyses wit.pdf:application/pdf},
}

@article{magudia319,
	title = {Population-{Scale} {CT}-based {Body} {Composition} {Analysis} of a {Large} {Outpatient} {Population} {Using} {Deep} {Learning} to {Derive} {Age}-, {Sex}-, and {Race}-specific {Reference} {Curves}},
	volume = {298},
	issn = {1527-1315},
	doi = {10.1148/radiol.2020201640},
	abstract = {Background Although CT-based body composition (BC) metrics may inform disease risk and outcomes, obtaining these metrics has been too resource intensive for large-scale use. Thus, population-wide distributions of BC remain uncertain. Purpose To demonstrate the validity of fully automated, deep learning BC analysis from abdominal CT examinations, to define demographically adjusted BC reference curves, and to illustrate the advantage of use of these curves compared with standard methods, along with their biologic significance in predicting survival. Materials and Methods After external validation and equivalency testing with manual segmentation, a fully automated deep learning BC analysis pipeline was applied to a cross-sectional population cohort that included any outpatient without a cardiovascular disease or cancer who underwent abdominal CT examination at one of three hospitals in 2012. Demographically adjusted population reference curves were generated for each BC area. The z scores derived from these curves were compared with sex-specific thresholds for sarcopenia by using χ2 tests and used to predict 2-year survival in multivariable Cox proportional hazards models that included weight and body mass index (BMI). Results External validation showed excellent correlation (R = 0.99) and equivalency (P {\textless} .001) of the fully automated deep learning BC analysis method with manual segmentation. With use of the fully automated BC data from 12 128 outpatients (mean age, 52 years; 6936 [57\%] women), age-, race-, and sex-normalized BC reference curves were generated. All BC areas varied significantly with these variables (P {\textless} .001 except for subcutaneous fat area vs age [P = .003]). Sex-specific thresholds for sarcopenia demonstrated that age and race bias were not present if z scores derived from the reference curves were used (P {\textless} .001). Skeletal muscle area z scores were significantly predictive of 2-year survival (P = .04) in combined models that included BMI. Conclusion Fully automated body composition (BC) metrics vary significantly by age, race, and sex. The z scores derived from reference curves for BC parameters better capture the demographic distribution of BC compared with standard methods and can help predict survival. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Summers in this issue.},
	language = {eng},
	number = {2},
	journal = {Radiology},
	author = {Magudia, Kirti and Bridge, Christopher P. and Bay, Camden P. and Babic, Ana and Fintelmann, Florian J. and Troschel, Fabian M. and Miskin, Nityanand and Wrobel, William C. and Brais, Lauren K. and Andriole, Katherine P. and Wolpin, Brian M. and Rosenthal, Michael H.},
	month = feb,
	year = {2021},
	pmid = {33231527},
	pmcid = {PMC8128280},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Female, Male, Middle Aged, Cohort Studies, Image Processing, Computer-Assisted, Reproducibility of Results, Cross-Sectional Studies, Sex Distribution, Age Distribution, Deep Learning, Outpatients, Racial Groups, Radiography, Abdominal, Reference Values},
	pages = {319--329},
}

@article{wong239,
	title = {Development and {Assessment} of a {Systematic} {Approach} for {Detecting} {Disparities} in {Surgical} {Access}},
	volume = {156},
	issn = {2168-6262},
	doi = {10.1001/jamasurg.2020.5668},
	abstract = {Importance: Although optimal access is accepted as the key to quality care, an accepted methodology to ascertain potential disparities in surgical access has not been defined.
Objective: To develop a systematic approach to detect surgical access disparities.
Design, Setting, and Participants: This cross-sectional study used publicly available data from the Health Cost and Utilization Project State Inpatient Database from 2016. Using the surgical rate observed in the 5 highest-ranked counties (HRCs), the expected surgical rate in the 5 lowest-ranked counties (LRCs) in North Carolina were calculated. Patients 18 years and older who underwent an inpatient general surgery procedure and patients who underwent emergency inpatient cholecystectomy, herniorrhaphy, or bariatric surgery in 2016 were included. Data were collected from January to December 2016, and data were analyzed from March to July 2020.
Exposures: Health outcome county rank as defined by the Robert Wood Johnson Foundation.
Main Outcomes and Measures: The primary outcome was the proportional surgical ratio (PSR), which was the disparity in surgical access defined as the observed number of surgical procedures in the 5 LRCs relative to the expected number of procedures using the 5 HRCs as the standardized reference population.
Results: In 2016, approximately 1.9 million adults lived in the 5 HRCs, while approximately 246 854 lived in the 5 LRCs. A total of 28 924 inpatient general surgical procedures were performed, with 4521 being performed in those living in the 5 LRCs and 24 403 in those living in the 5 HRCs. The rate of general surgery in the 5 HRCs was 13.09 procedures per 1000 population. Using the 5 HRCs as the reference, the PSR for the 5 LRCs was 1.40 (95\% CI, 1.35-1.44). For emergent/urgent cholecystectomy, the PSR for the 5 LRCs was 2.26 (95\% CI, 2.02-2.51), and the PSR for emergent/urgent herniorrhaphy was 1.83 (95\% CI, 1.33-2.45). Age-adjusted rate of obesity (body mass index [calculated as weight in kilograms divided by height in meters squared] greater than 30), on average, was 36.6\% (SD, 3.4) in the 5 LRCs vs 25.4\% (SD, 4.6) in the 5 HRCs (P = .002). The rate of bariatric surgery in the 5 HRCs was 33.07 per 10 000 population with obesity. For the 5 LRCs, the PSR was 0.60 (95\% CI, 0.51-0.69).
Conclusions and Relevance: The PSR is a systematic approach to define potential disparities in surgical access and should be useful for identifying, investigating, and monitoring interventions intended to mitigate disparities in surgical access that effects the health of vulnerable populations.},
	language = {eng},
	number = {3},
	journal = {JAMA surgery},
	author = {Wong, Jan H. and Irish, William D. and DeMaria, Eric J. and Vohra, Nasreen A. and Pories, Walter J. and Brownstein, Michelle R. and Altieri, Maria S. and Akram, Warqaa and Haisch, Carl E. and Leeser, David B. and Tuttle, Janet E.},
	month = mar,
	year = {2021},
	pmid = {33326009},
	pmcid = {PMC7745135},
	keywords = {Humans, Aged, Female, Hospitalization, Male, Middle Aged, Adult, Databases, Factual, Cross-Sectional Studies, Surgical Procedures, Operative, Health Services Accessibility, Healthcare Disparities, North Carolina, Procedures and Techniques Utilization, Race, Socioeconomic Factors},
	pages = {239--245},
}

@article{felicianoe172319,
	title = {Association of {Systemic} {Inflammation} and {Sarcopenia} {With} {Survival} in {Nonmetastatic} {Colorectal} {Cancer}: {Results} {From} the {C} {SCANS} {Study}},
	volume = {3},
	issn = {2374-2445},
	shorttitle = {Association of {Systemic} {Inflammation} and {Sarcopenia} {With} {Survival} in {Nonmetastatic} {Colorectal} {Cancer}},
	doi = {10.1001/jamaoncol.2017.2319},
	abstract = {Importance: Systemic inflammation and sarcopenia are easily evaluated, predict mortality in many cancers, and are potentially modifiable. The combination of inflammation and sarcopenia may be able to identify patients with early-stage colorectal cancer (CRC) with poor prognosis.
Objective: To examine associations of prediagnostic systemic inflammation with at-diagnosis sarcopenia, and determine whether these factors interact to predict CRC survival, adjusting for age, ethnicity, sex, body mass index, stage, and cancer site.
Design, Setting, and Participants: A prospective cohort of 2470 Kaiser Permanente patients with stage I to III CRC diagnosed from 2006 through 2011.
Exposures: Our primary measure of inflammation was the neutrophil to lymphocyte ratio (NLR). We averaged NLR in the 24 months before diagnosis (mean count = 3 measures; mean time before diagnosis = 7 mo). The reference group was NLR of less than 3, indicating low or no inflammation.
Main Outcomes and Measures: Using computed tomography scans, we calculated skeletal muscle index (muscle area at the third lumbar vertebra divided by squared height). Sarcopenia was defined as less than 52 cm2/m2 and less than 38 cm2/m2 for normal or overweight men and women, respectively, and less than 54 cm2/m2 and less than 47 cm2/m2 for obese men and women, respectively. The main outcome was death (overall or CRC related).
Results: Among 2470 patients, 1219 (49\%) were female; mean (SD) age was 63 (12) years. An NLR of 3 or greater and sarcopenia were common (1133 [46\%] and 1078 [44\%], respectively). Over a median of 6 years of follow-up, we observed 656 deaths, 357 from CRC. Increasing NLR was associated with sarcopenia in a dose-response manner (compared with NLR {\textless} 3, odds ratio, 1.35; 95\% CI, 1.10-1.67 for NLR 3 to {\textless}5; 1.47; 95\% CI, 1.16-1.85 for NLR ≥ 5; P for trend {\textless} .001). An NLR of 3 or greater and sarcopenia independently predicted overall (hazard ratio [HR], 1.64; 95\% CI, 1.40-1.91 and HR, 1.28; 95\% CI, 1.10-1.53, respectively) and CRC-related death (HR, 1.71; 95\% CI, 1.39-2.12 and HR, 1.42; 95\% CI, 1.13-1.78, respectively). Patients with both sarcopenia and NLR of 3 or greater (vs neither) had double the risk of death, overall (HR, 2.12; 95\% CI, 1.70-2.65) and CRC related (HR, 2.43; 95\% CI, 1.79-3.29).
Conclusions and Relevance: Prediagnosis inflammation was associated with at-diagnosis sarcopenia. Sarcopenia combined with inflammation nearly doubled risk of death, suggesting that these commonly collected biomarkers could enhance prognostication. A better understanding of how the host inflammatory/immune response influences changes in skeletal muscle may open new therapeutic avenues to improve cancer outcomes.},
	language = {eng},
	number = {12},
	journal = {JAMA oncology},
	author = {Feliciano, Elizabeth M. Cespedes and Kroenke, Candyce H. and Meyerhardt, Jeffrey A. and Prado, Carla M. and Bradshaw, Patrick T. and Kwan, Marilyn L. and Xiao, Jingjie and Alexeeff, Stacey and Corley, Douglas and Weltzien, Erin and Castillo, Adrienne L. and Caan, Bette J.},
	month = dec,
	year = {2017},
	pmid = {28796857},
	pmcid = {PMC5824285},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Neoplasm Staging, Risk Factors, Proportional Hazards Models, Prospective Studies, Prognosis, Cohort Studies, Survival Analysis, Lymphocyte Count, Neutrophils, Sarcopenia;Inflammation},
	pages = {e172319},
}

@article{kroenke3008,
	title = {Muscle radiodensity and mortality in patients with colorectal cancer},
	volume = {124},
	issn = {1097-0142},
	doi = {10.1002/cncr.31405},
	abstract = {BACKGROUND: Low skeletal muscle radiodensity (SMD) is related to higher mortality in several cancers, but the association with colorectal cancer (CRC) prognosis is unclear.
METHODS: This observational study included 3262 men and women from the Kaiser Permanente Northern California population diagnosed between 2006 and 2011 with AJCC stages I to III CRC. The authors evaluated hazard ratios (HRs) of low SMD for all-cause and CRC-specific mortality, assessed by computed tomography using optimal stratification, compared with patients with normal SMD. They also evaluated the cross-classification of categories of low versus normal SMD and muscle mass (MM) with outcomes.
RESULTS: The median follow-up was 6.9 years. Optimal stratification cutpoints for SMD were 32.5 in women and 35.5 in men. In multivariate-adjusted analyses, among patients with CRC, those with low SMD demonstrated higher overall (HR, 1.61; 95\% confidence interval [95\% CI], 1.36-1.90) and CRC-specific (HR, 1.74; 95\% CI, 1.38-2.21) mortality when compared with those with normal SMD levels. Patients with low SMD and low MM (ie, sarcopenia) were found to have the highest overall (HR, 2.02; 95\% CI, 1.65-2.47) and CRC-specific (HR, 2.54; 95\% CI, 1.91-3.37) mortality rates.
CONCLUSIONS: In patients with CRC, those with low SMD were found to have elevated risks of disease-specific and overall mortality, independent of MM or adiposity. Clinical practice should incorporate body composition measures into the evaluation of the health status of patients with CRC. Cancer 2018;124:3008-15. © 2018 American Cancer Society.},
	language = {eng},
	number = {14},
	journal = {Cancer},
	author = {Kroenke, Candyce H. and Prado, Carla M. and Meyerhardt, Jeffrey A. and Weltzien, Erin K. and Xiao, Jingjie and Cespedes Feliciano, Elizabeth M. and Caan, Bette J.},
	month = jul,
	year = {2018},
	pmid = {29797673},
	pmcid = {PMC6033621},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Colorectal Neoplasms, Follow-Up Studies, Neoplasm Staging, Risk Factors, Survival Rate, Prognosis, survival, body composition, Myosteatosis, adiposity, muscle radiodensity, myosteatosis, North Carolina, colorectal cancer (CRC), mortality, muscle},
	pages = {3008--3015},
	annote = {Quartiles of body composition. Restricted cubic splines.
},
	file = {Full Text:/Users/jcsal/Zotero/storage/FZGRQJEF/Kroenke et al. - 2018 - Muscle radiodensity and mortality in patients with.pdf:application/pdf},
}

@article{ellis25,
	title = {Racial and {Ethnic} {Disparities} in {Cancer} {Survival}: {The} {Contribution} of {Tumor}, {Sociodemographic}, {Institutional}, and {Neighborhood} {Characteristics}},
	volume = {36},
	issn = {1527-7755},
	shorttitle = {Racial and {Ethnic} {Disparities} in {Cancer} {Survival}},
	doi = {10.1200/JCO.2017.74.2049},
	abstract = {Purpose Racial/ethnic disparities in cancer survival in the United States are well documented, but the underlying causes are not well understood. We quantified the contribution of tumor, treatment, hospital, sociodemographic, and neighborhood factors to racial/ethnic survival disparities in California. Materials and Methods California Cancer Registry data were used to estimate population-based cancer-specific survival for patients diagnosed with breast, prostate, colorectal, or lung cancer between 2000 and 2013 for each racial/ethnic group (non-Hispanic black, Hispanic, Asian American and Pacific Islander, and separately each for Chinese, Japanese, and Filipino) compared with non-Hispanic whites. The percentage contribution of factors to overall racial/ethnic survival disparities was estimated from a sequence of multivariable Cox proportional hazards models. Results In baseline models, black patients had the lowest survival for all cancer sites, and Asian American and Pacific Islander patients had the highest, compared with whites. Mediation analyses suggested that stage at diagnosis had the greatest influence on overall racial/ethnic survival disparities accounting for 24\% of disparities in breast cancer, 24\% in prostate cancer, and 16\% to 30\% in colorectal cancer. Neighborhood socioeconomic status was an important factor in all cancers, but only for black and Hispanic patients. The influence of marital status on racial/ethnic disparities was stronger in men than in women. Adjustment for all covariables explained approximately half of the overall survival disparities in breast, prostate, and colorectal cancer, but it explained only 15\% to 40\% of disparities in lung cancer. Conclusion Overall reductions in racial/ethnic survival disparities were driven largely by reductions for black compared with white patients. Stage at diagnosis had the largest effect on racial/ethnic survival disparities, but earlier detection would not entirely eliminate them. The influences of neighborhood socioeconomic status and marital status suggest that social determinants, support mechanisms, and access to health care are important contributing factors.},
	language = {eng},
	number = {1},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Ellis, Libby and Canchola, Alison J. and Spiegel, David and Ladabaum, Uri and Haile, Robert and Gomez, Scarlett Lin},
	month = jan,
	year = {2018},
	pmid = {29035642},
	pmcid = {PMC5756323},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Risk Factors, Lung Neoplasms, Neoplasms, Survival Analysis, United States, Registries, Prostatic Neoplasms, African Americans, Asian Americans, Breast Neoplasms, California, Educational Status, Health Status Disparities, Hispanic or Latino, Residence Characteristics, Social Class, Whites},
	pages = {25--33},
	file = {Full Text:/Users/jcsal/Zotero/storage/LE64NVKW/Ellis et al. - 2018 - Racial and Ethnic Disparities in Cancer Survival .pdf:application/pdf},
}

@article{erhunmwunsee234,
	title = {Socioeconomic {Status}, {Not} {Race}, {Is} {Associated} {With} {Reduced} {Survival} in {Esophagectomy} {Patients}},
	volume = {104},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2017.01.049},
	abstract = {BACKGROUND: Black patients with esophageal cancer have worse survival than white patients. This study examines this racial disparity in conjunction with socioeconomic status (SES) and explores whether race-based outcome differences exist using a national database.
METHODS: The associations between race and SES with overall survival of patients treated with esophagectomy for stages I to III esophageal cancer between 2003 and 2011 in the National Cancer Data Base were investigated using the Kaplan-Meier method and proportional hazards analyses. Median income by zip code and proportion of the zip code residents without a high school diploma were grouped into income and education quartiles, respectively and used as surrogates for SES. The association between race and overall survival stratified by SES is explored.
RESULTS: Of 11,599 esophagectomy patients who met study criteria, 3,503 (30.2\%) were in the highest income quartile, 2,847 (24.5\%) were in the highest education quartile, and 610 patients (5\%) were black. Before adjustment for SES, black patients had worse overall survival than white patients (median survival 23.0 versus 34.7 months, log rank p {\textless} 0.001), and overall, survival times improved with increasing income and education (p {\textless} 0.001 for both). After adjustment for putative prognostic factors, SES was associated with overall survival, whereas race was not.
CONCLUSIONS: Prior studies have suggested that survival of esophageal cancer patients after esophagectomy is associated with race. Our study suggests that race is not significantly related to overall survival when adjusted for other prognostic variables. Socioeconomic status, however, remains significantly related to overall survival in our model.},
	language = {eng},
	number = {1},
	journal = {The Annals of Thoracic Surgery},
	author = {Erhunmwunsee, Loretta and Gulack, Brian C. and Rushing, Christel and Niedzwiecki, Donna and Berry, Mark F. and Hartwig, Matthew G.},
	month = jul,
	year = {2017},
	pmid = {28410639},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Risk Factors, Survival Rate, Prognosis, Aged, 80 and over, Adult, United States, Young Adult, Esophageal Neoplasms, Esophagectomy, Adolescent, Racial Groups, Race, Socioeconomic Factors, Social Class},
	pages = {234--244},
	file = {Full Text:/Users/jcsal/Zotero/storage/XB638PX3/Erhunmwunsee et al. - 2017 - Socioeconomic Status, Not Race, Is Associated With.pdf:application/pdf},
}

@article{tran3,
	title = {The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: {A} population-based analysis},
	volume = {16},
	issn = {1477-3163},
	shorttitle = {The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer},
	doi = {10.4103/jcar.JCar_4_17},
	abstract = {BACKGROUND: African Americans and Hispanics are reported to have higher mortality from esophageal cancer (EC) than Caucasians. In this study, we analyzed the independent effects of race, gender, treatment, and socioeconomic status (SES) on overall survival (OS).
METHODS: Data for all EC cases between 2004 and 2010 with follow-up through 2012 were obtained from the California Cancer Registry. We conducted descriptive analyses of clinical variables and survival analyses by Kaplan-Meier and Cox proportional hazards methods.
RESULTS: African Americans and Hispanics were more likely to be in the lower SES strata and less likely to receive surgery than Caucasians in this cohort. The proportion of patients receiving chemotherapy and radiotherapy was similar across different racial/ethnic groups. After adjustment for stage, grade, histology, treatments, and SES in multivariate analyses, the mortality risk in African Americans (hazard ratio [HR] 0.96, 95\% confidence interval [CI] 0.85-1.07) and Hispanics (HR 0.96, 95\% CI 0.89-1.07) did not differ from Caucasians (HR = 1.00, referent), with histology, SES, and surgery largely accounting for unadjusted OS differences. We also observed that African American men had higher adjusted risk of death relative to Caucasian men (HR 1.24, 95\% CI 1.07-1.42), but this effect was not observed for African American women compared to Caucasian women (HR 1.12, 95\% CI 0.94-1.35).
CONCLUSIONS: Race is not an independent risk factor for OS in our population-based analysis of EC cases. Rather, observed differences in OS by race/ethnicity result from differences in cancer histology, SES, surgery, and gender. Our findings support further health disparities research for this disease.},
	language = {eng},
	journal = {Journal of Carcinogenesis},
	author = {Tran, Phu N. and Taylor, Thomas H. and Klempner, Samuel J. and Zell, Jason A.},
	year = {2017},
	pmid = {28974922},
	pmcid = {PMC5615860},
	keywords = {Esophageal cancer, Race, ethnicity, outcomes, race, survival disparity},
	pages = {3},
	annote = {Black patients less likely to receive surgery, but this appeard to be due to histology. Multivariable analysis not done
Emphasis in study was on overall survival
},
	file = {PDF:/Users/jcsal/Zotero/storage/ZLLEGTGE/Tran et al. - 2017 - The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer A.pdf:application/pdf},
}

@article{schlottmanndoz045,
	title = {Disparities in esophageal cancer: less treatment, less surgical resection, and poorer survival in disadvantaged patients},
	volume = {33},
	issn = {1442-2050},
	shorttitle = {Disparities in esophageal cancer},
	doi = {10.1093/dote/doz045},
	abstract = {The incidence of esophageal cancer has increased steadily in the last decades in the United States. The aim of this paper was to characterize disparities in esophageal cancer treatment in different racial and socioeconomic population groups and compare long-term survival among different treatment modalities. A retrospective analysis of the National Cancer Database was performed including adult patients (≥18 years old) with a diagnosis of resectable (stages I-III) esophageal cancer between 2004 and 2015. Multivariable logistic regression models were used to determine the odds of being offered no treatment at all and surgical treatment across race, primary insurance, travel distance, income, and education levels. Multivariable Cox proportional hazards models were used to compare 5-year survival rates across different treatment modalities. A total of 60,621 esophageal cancer patients were included. Black patients, uninsured patients, and patients living in areas with lower levels of education were more likely to be offered no treatment. Similarly, black race, female patients, nonprivately insured patients, and those living in areas with lower median residential income and lower education levels were associated with lower rates of surgery. Patients receiving surgical treatment, compared to both no treatment and definitive chemoradiation, had significant better long-term survival in stage I, II, and III esophageal cancer. In conclusion, underserved patients with esophageal cancer appear to have limited access to surgical care, and are, in fact, more likely to not be offered any treatment at all. Considering the survival benefits associated with surgical resection, greater public health efforts to reduce disparities in esophageal cancer are needed.},
	language = {eng},
	number = {2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Schlottmann, Francisco and Gaber, Charles and Strassle, Paula D. and Herbella, Fernando A. M. and Molena, Daniela and Patti, Marco G.},
	month = mar,
	year = {2020},
	pmid = {31076759},
	pmcid = {PMC8205620},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Proportional Hazards Models, Survival Rate, Aged, 80 and over, Adult, survival, Databases, Factual, United States, Young Adult, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Logistic Models, esophageal cancer, Adolescent, surgery, Health Services Accessibility, Healthcare Disparities, Race, Socioeconomic Factors, Health Status Disparities, disparity, Ethnicity, Social Determinants of Health, Vulnerable Populations},
	pages = {doz045},
	file = {PDF:/Users/jcsal/Zotero/storage/H7Y87JDB/Schlottmann et al. - 2020 - Disparities in esophageal cancer less treatment, less surgical resection, and poorer survival in di.pdf:application/pdf},
}

@article{okerekedoab083,
	title = {Disparities in esophageal cancer care based on race: a {National} {Cancer} {Database} analysis},
	issn = {1442-2050},
	shorttitle = {Disparities in esophageal cancer care based on race},
	doi = {10.1093/dote/doab083},
	abstract = {Esophageal cancer is one of the most common cancer killers in our country. The effects of racial disparities on care for esophageal cancer patients are incompletely understood. Using the National Cancer Database, we investigated racial disparities in treatment and outcome of esophageal cancer patients. The National Cancer Database was queried from 2004 to 2017. Logistic regression and survival analysis were used to determine racial differences in access, treatment and outcome. A total of 127,098 patients were included. All minority groups were more likely to be diagnosed at advanced stages versus Caucasians after adjusting for covariates (African American OR-1.64 [95\% confidence interval 1.53-1.76], Hispanic OR-1.19 [1.08-1.32], Asian OR-1.78 [1.55-2.06]). After adjustment, all minorities were less likely at every stage to receive surgery. Despite these disparities, Hispanics and Asians had improved survival compared with Caucasians. African Americans had worse survival. Racial disparities for receiving surgery were present in both academic and community institutions, and at high-volume and low-volume institutions. Surgery partially mediated the survival difference between African Americans and Caucasians (HR-1.13 [1.10-1.16] and HR-1.04 [1.02-1.07], without and with adjustment of surgery).There are racial disparities in the treatment of esophageal cancer. Despite these disparities, Hispanics and Asians have improved overall survival versus Caucasians. African Americans have the worst overall survival. Racial disparities likely affect outcome in esophageal cancer. But other factors, such as epigenetics and tumor biology, may correlate more strongly with outcome for patients with esophageal cancer.},
	language = {eng},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Okereke, Ikenna C. and Westra, Jordan and Tyler, Douglas and Klimberg, Suzanne and Jupiter, Daniel and Venkatesan, Rohit and Brooks, Kaelyn and Kuo, Yong-Fang},
	month = dec,
	year = {2021},
	pmid = {34918057},
	keywords = {esophageal cancer, Race, cancer epidemiology, cancer treatment},
	pages = {doab083},
	file = {PDF:/Users/jcsal/Zotero/storage/ZRPJ4Y5L/Okereke et al. - 2021 - Disparities in esophageal cancer care based on race a National Cancer Database analysis.pdf:application/pdf},
}

@misc{zotero-825,
	title = {Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes: analysis of the nationwide inpatient sample - {PubMed}},
	url = {https://pubmed.ncbi.nlm.nih.gov/27595733/},
	urldate = {2022-05-26},
	keywords = {Race},
	file = {Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes\: analysis of the nationwide inpatient sample - PubMed:/Users/jcsal/Zotero/storage/5GZYITMC/27595733.html:text/html},
}

@article{giaquinto202,
	title = {Cancer statistics for {African} {American}/{Black} {People} 2022},
	volume = {72},
	issn = {1542-4863},
	doi = {10.3322/caac.21718},
	abstract = {African American/Black individuals have a disproportionate cancer burden, including the highest mortality and the lowest survival of any racial/ethnic group for most cancers. Every 3 years, the American Cancer Society estimates the number of new cancer cases and deaths for Black people in the United States and compiles the most recent data on cancer incidence (herein through 2018), mortality (through 2019), survival, screening, and risk factors using population-based data from the National Cancer Institute and the Centers for Disease Control and Prevention. In 2022, there will be approximately 224,080 new cancer cases and 73,680 cancer deaths among Black people in the United States. During the most recent 5-year period, Black men had a 6\% higher incidence rate but 19\% higher mortality than White men overall, including an approximately 2-fold higher risk of death from myeloma, stomach cancer, and prostate cancer. The overall cancer mortality disparity is narrowing between Black and White men because of a steeper drop in Black men for lung and prostate cancers. However, the decline in prostate cancer mortality in Black men slowed from 5\% annually during 2010 through 2014 to 1.3\% during 2015 through 2019, likely reflecting the 5\% annual increase in advanced-stage diagnoses since 2012. Black women have an 8\% lower incidence rate than White women but a 12\% higher mortality; further, mortality rates are 2-fold higher for endometrial cancer and 41\% higher for breast cancer despite similar or lower incidence rates. The wide breast cancer disparity reflects both later stage diagnosis (57\% localized stage vs 67\% in White women) and lower 5-year survival overall (82\% vs 92\%, respectively) and for every stage of disease (eg, 20\% vs 30\%, respectively, for distant stage). Breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in 2019. Targeted interventions are needed to reduce stark cancer inequalities in the Black community.},
	language = {eng},
	number = {3},
	journal = {CA: a cancer journal for clinicians},
	author = {Giaquinto, Angela N. and Miller, Kimberly D. and Tossas, Katherine Y. and Winn, Robert A. and Jemal, Ahmedin and Siegel, Rebecca L.},
	month = may,
	year = {2022},
	pmid = {35143040},
	keywords = {Humans, Female, Male, United States, Prostatic Neoplasms, Race, mortality, African Americans, Breast Neoplasms, American Cancer Society, Black people, cancer statistics, incidence, National Cancer Institute (U.S.)},
	pages = {202--229},
	file = {Full Text:/Users/jcsal/Zotero/storage/XLANDLXR/Giaquinto et al. - 2022 - Cancer statistics for African AmericanBlack Peopl.pdf:application/pdf},
}

@article{esnaola549,
	title = {Underuse of surgical resection in black patients with nonmetastatic colorectal cancer: location, location, location},
	volume = {250},
	issn = {1528-1140},
	shorttitle = {Underuse of surgical resection in black patients with nonmetastatic colorectal cancer},
	doi = {10.1097/SLA.0b013e3181b732a5},
	abstract = {OBJECTIVES: Studies have reported potential underuse of surgical resection in black patients with nonmetastatic colorectal cancer. Our objective was to determine the independent, adverse effect of race on surgical resection, controlling for tumor location, comorbidity, and socioeconomic/insurance status.
METHODS: All cases of nonmetastatic colon/rectal cancer reported to our state's Central Cancer Registry from 1996 to 2002 were identified and linked to Inpatient/Outpatient Surgery Files and the 2000 Census. Comorbidity (Deyo-Charlson Index) was calculated using ICD-9-CM codes and educational level/income were estimated at the zip code level. Characteristics between whites and blacks were compared using [chi]2 tests. Odds ratios (OR) of resection were calculated using logistic regression analysis.
RESULTS: We identified 5590/1932 white and 1906/466 black patients with colon/rectal cancer. Blacks were more likely to be younger, not married, rural, less educated, live in poverty, and uninsured/covered by Medicaid compared with whites (all P {\textless} 0.001). Underuse of surgery was far greater among blacks with rectal cancer (82.0\% vs. 89.3\% in whites, P{\textless} 0.001) compared with blacks with colon cancer (92.9\% vs. 94.5\% in whites, P {\textless} 0.001). After controlling for comorbidity/socioeconomic/insurance status and tumor location, the adjusted OR (95\% CI) for resection for blacks with colon cancer and blacks with rectal cancer living in poverty were 0.67 (0.51–0.88) and 0.20 (0.07–0.57), respectively.
CONCLUSIONS: Black race is a powerful, independent predictor of underuse of surgery in rectal cancer patients living in poverty. It is incumbent on the gastroenterology/surgical community to determine whether misperceptions about rectal surgery or barriers to successfully navigating multidisciplinary, rectal cancer care may account for these disparities.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Esnaola, Nestor F. and Gebregziabher, Mulugeta and Finney, Chris and Ford, Marvella E.},
	month = oct,
	year = {2009},
	pmid = {19730243},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Risk Factors, Chi-Square Distribution, United States, Comorbidity, Logistic Models, Registries, Race, Socioeconomic Factors, African Americans, Educational Status, Whites, Colorectal Surgery, Income, Medically Uninsured, Poverty Areas, South Carolina},
	pages = {549--557},
}

@article{gill1059,
	title = {Colon cancer treatment: are there racial disparities in an equal-access healthcare system?},
	volume = {57},
	issn = {1530-0358},
	shorttitle = {Colon cancer treatment},
	doi = {10.1097/DCR.0000000000000177},
	abstract = {BACKGROUND: In the general US population, blacks and whites have been shown to undergo colon cancer treatment at disproportionate rates. Accessibility to medical care may be the most important factor influencing differences in colon cancer treatment rates among whites and blacks.
OBJECTIVE: We assessed whether racial disparities in colon cancer surgery and chemotherapy existed in an equal-access health care system. In addition, we sought to examine whether racial differences varied according to demographic and tumor characteristics.
DESIGN AND SETTING: Database research using the Department of Defense Military Health System.
PATIENTS: Patients included 2560 non-Hispanic whites (NHW) and non-Hispanic blacks (NHB) with colon cancer diagnosed from 1998 to 2007.
MAIN OUTCOME MEASURES: Logistic regression was used to assess the associations between race and the receipt of colon cancer surgery or chemotherapy while controlling for available potential confounders, both overall and stratified by age at diagnosis, sex, and tumor stage.
RESULTS: After multivariate adjustment, the odds of receiving colon cancer surgery or chemotherapy for NHBs versus NHWs were similar (OR, 0.75 [95\% CI, 0.37-1.53]; OR, 0.79 [95\% CI, 0.59-1.04]). In addition, no effect modifications by age at diagnosis, sex, and tumor stage were observed.
LIMITATIONS: Treatment data might not be complete for beneficiaries who also had non-Department of Defense health insurance.
CONCLUSIONS: When access to medical care is equal, racial disparities in the provision of colon cancer surgery and chemotherapy were not apparent. Thus, it is possible that the inequalities in access to care play a major role in the racial disparities seen in colon cancer treatment in the general population.},
	language = {eng},
	number = {9},
	journal = {Diseases of the Colon and Rectum},
	author = {Gill, Abegail A. and Enewold, Lindsey and Zahm, Shelia H. and Shriver, Craig D. and Stojadinovic, Alexander and McGlynn, Katherine A. and Zhu, Kangmin},
	month = sep,
	year = {2014},
	pmid = {25101601},
	pmcid = {PMC4126203},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Adult, Colonic Neoplasms, United States, Adenocarcinoma, Health Services Accessibility, Healthcare Disparities, Race, Whites, Blacks},
	pages = {1059--1065},
}

@article{deyo613,
	title = {Adapting a clinical comorbidity index for use with {ICD}-9-{CM} administrative databases},
	volume = {45},
	issn = {0895-4356},
	doi = {10.1016/0895-4356(92)90133-8},
	abstract = {Administrative databases are increasingly used for studying outcomes of medical care. Valid inferences from such data require the ability to account for disease severity and comorbid conditions. We adapted a clinical comorbidity index, designed for use with medical records, for research relying on International Classification of Diseases (ICD-9-CM) diagnosis and procedure codes. The association of this adapted index with health outcomes and resource use was then examined with a sample of Medicare beneficiaries who underwent lumbar spine surgery in 1985 (n = 27,111). The index was associated in the expected direction with postoperative complications, mortality, blood transfusion, discharge to nursing home, length of hospital stay, and hospital charges. These associations were observed whether the index incorporated data from multiple hospitalizations over a year's time, or just from the index surgical admission. They also persisted after controlling for patient age. We conclude that the adapted comorbidity index will be useful in studies of disease outcome and resource use employing administrative databases.},
	language = {eng},
	number = {6},
	journal = {Journal of Clinical Epidemiology},
	author = {Deyo, R. A. and Cherkin, D. C. and Ciol, M. A.},
	month = jun,
	year = {1992},
	pmid = {1607900},
	keywords = {Humans, Aged, Female, Male, Treatment Outcome, Databases, Factual, United States, Comorbidity, Medicare, Lumbar Vertebrae, Cormorbidity, Medical Records, Spinal Diseases},
	pages = {613--619},
}

@article{dejager276,
	title = {Disparities in {Surgical} {Access}: {A} {Systematic} {Literature} {Review}, {Conceptual} {Model}, and {Evidence} {Map}},
	volume = {228},
	issn = {1879-1190},
	shorttitle = {Disparities in {Surgical} {Access}},
	doi = {10.1016/j.jamcollsurg.2018.12.028},
	language = {eng},
	number = {3},
	journal = {Journal of the American College of Surgeons},
	author = {de Jager, Elzerie and Levine, Adele A. and Udyavar, N. Rhea and Burstin, Helen R. and Bhulani, Nizar and Hoyt, David B. and Ko, Clifford Y. and Weissman, Joel S. and Britt, L. D. and Haider, Adil H. and Maggard-Gibbons, Melinda A.},
	month = mar,
	year = {2019},
	pmid = {30803548},
	pmcid = {PMC6391739},
	keywords = {Humans, United States, Surgical Procedures, Operative, Health Services Accessibility, Healthcare Disparities, Race},
	pages = {276--298},
	file = {PDF:/Users/jcsal/Zotero/storage/VCSUHQAZ/de Jager et al. - 2019 - Disparities in Surgical Access A Systematic Literature Review, Conceptual Model, and Evidence Map.pdf:application/pdf},
}

@article{swords333,
	title = {Size and {Importance} of {Socioeconomic} {Status}-{Based} {Disparities} in {Use} of {Surgery} in {Nonadvanced} {Stage} {Gastrointestinal} {Cancers}},
	volume = {27},
	issn = {1534-4681},
	doi = {10.1245/s10434-019-07922-7},
	abstract = {BACKGROUND: The size and importance of socioeconomic status (SES)-based disparities in use of surgery for non-advanced stage gastrointestinal (GI) cancers have not been quantified.
METHODS: The exposure in this study of patients age 18-80 with one of nine non-advanced stage GI cancers in the 2007-2015 SEER database was a census tract-level SES composite. Multivariable models assessed associations of SES with use of surgery. Causal mediation analysis was used to estimate the proportion of survival disparities in SES quintiles 1 versus 5 that were mediated by disparities in use of surgery.
RESULTS: Lowest SES quintile patients underwent surgery at significantly lower rates than highest quintile patients in each cancer. SES-based disparities in use of surgery were large and graded in esophagus adenocarcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma. Smaller but clinically relevant disparities were present in stomach, ampulla, and small bowel adenocarcinoma, whereas disparities were small in colorectal adenocarcinoma. Five-year all-stage overall survival (OS) was correlated with the size of disparities in use of surgery in SES quintiles 1 versus 5 (r = - 0.87; p = 0.003). Mean OS was significantly longer (range 3.5-8.9 months) in SES quintile 5 versus 1. Approximately one third of SES-based survival disparities in poor prognosis GI cancers were mediated by disparities in use of surgery. The size of disparities in use of surgery in SES quintiles 1 versus 5 was correlated with the proportion mediated (r = 0.98; p {\textless} 0.001).
CONCLUSIONS: Low SES patients with poor prognosis GI cancers are at substantial risk of undertreatment. Disparities in use of surgery contribute to diminished survival.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Swords, Douglas S. and Mulvihill, Sean J. and Brooke, Benjamin S. and Firpo, Matthew A. and Scaife, Courtney L.},
	month = feb,
	year = {2020},
	pmid = {31605347},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Aged, 80 and over, Adult, Young Adult, Adolescent, Healthcare Disparities, Race, Socioeconomic Factors, Social Class, SEER Program},
	pages = {333--341},
	file = {PDF:/Users/jcsal/Zotero/storage/UJA4WSIS/Swords et al. - 2020 - Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage.pdf:application/pdf},
}

@article{quirke996,
	title = {Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. {Histopathological} study of lateral tumour spread and surgical excision},
	volume = {2},
	issn = {0140-6736},
	doi = {10.1016/s0140-6736(86)92612-7},
	abstract = {In 52 patients with rectal adenocarcinoma whole-mount sections of the entire operative specimen were examined by transverse slicing. There was spread to the lateral resection margin in 14 of 52 (27\%) patients and 12 of these proceeded to local pelvic recurrence. The specificity, sensitivity, and positive predictive values were 92\%, 95\%, and 85\%, respectively. In a retrospective stage-matched and grade-matched control group there was local recurrence in the same proportion of patients, but in this series no patient had been shown by routine sampling to have lateral spread. In rectal adenocarcinoma, local recurrence is mainly due to lateral spread of the tumour and has previously been underestimated.},
	language = {eng},
	number = {8514},
	journal = {Lancet (London, England)},
	author = {Quirke, P. and Durdey, P. and Dixon, M. F. and Williams, N. S.},
	month = nov,
	year = {1986},
	pmid = {2430152},
	keywords = {Humans, Female, Male, Retrospective Studies, Palliative Care, Prospective Studies, Adenocarcinoma, Neoplasm Recurrence, Local, Methods, Rectal Neoplasms, Rectal; TME},
	pages = {996--999},
}

@article{kapiteijn638,
	title = {Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer},
	volume = {345},
	issn = {0028-4793},
	doi = {10.1056/NEJMoa010580},
	abstract = {BACKGROUND: Short-term preoperative radiotherapy and total mesorectal excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of total mesorectal excision.
METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by total mesorectal excision (924 patients) or to total mesorectal excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques.
RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P{\textless}0.001).
CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized total mesorectal excision.},
	language = {eng},
	number = {9},
	journal = {The New England Journal of Medicine},
	author = {Kapiteijn, E. and Marijnen, C. A. and Nagtegaal, I. D. and Putter, H. and Steup, W. H. and Wiggers, T. and Rutten, H. J. and Pahlman, L. and Glimelius, B. and van Krieken, J. H. and Leer, J. W. and van de Velde, C. J. and {Dutch Colorectal Cancer Group}},
	month = aug,
	year = {2001},
	pmid = {11547717},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Survival Rate, Aged, 80 and over, Adult, Analysis of Variance, Adenocarcinoma, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Preoperative Care, Rectum, Rectal Neoplasms, Colorectal Surgery, Rectal; RT},
	pages = {638--646},
	file = {Full Text:/Users/jcsal/Zotero/storage/BLAENGIA/Kapiteijn et al. - 2001 - Preoperative radiotherapy combined with total meso.pdf:application/pdf},
}

@article{heald1479,
	title = {Recurrence and survival after total mesorectal excision for rectal cancer},
	volume = {1},
	issn = {0140-6736},
	doi = {10.1016/s0140-6736(86)91510-2},
	abstract = {A 7 1/2-year consecutive series is presented from a district hospital with a policy of referring all rectal carcinomas to one surgical firm. The performance of lower anterior resections has limited the rate of abdominoperineal excision with permanent colostomy to 11\%. Of 115 patients in whom curative resection was attempted, 69 had anastomoses below 5 cm and 39 had mural resection margins of less than 2.5 cm. Surgical priority, however, was given to complete excision of the visceral rectal mesentery or mesorectum. At an average of 4.2 years postoperatively, three pelvic recurrences have developed but there have been no staple-line recurrences in patients who had "curative" surgery. The corrected cumulative probability of survival at 5 years is 87\% and the tumour-free survival by Dukes stage is A 94\%, B 87\%, and C 58\%. Patients with low tumours did no less well than those with high tumours, when treated by anterior resection. On this evidence, it is often safe to limit mural clearance and thus preserve the anal sphincters, provided that the mesorectum is excised intact with the cancer.},
	language = {eng},
	number = {8496},
	journal = {Lancet (London, England)},
	author = {Heald, R. J. and Ryall, R. D.},
	month = jun,
	year = {1986},
	pmid = {2425199},
	keywords = {Humans, Follow-Up Studies, Neoplasm Staging, Palliative Care, Neoplasm Recurrence, Local, Postoperative Complications, Methods, Rectum, Rectal Neoplasms, Rectal; TME, Surgical Staplers},
	pages = {1479--1482},
}

@article{savitch581,
	title = {Racial {Disparities} in {Rates} of {Surgery} for {Esophageal} {Cancer}: a {Study} from the {National} {Cancer} {Database}},
	volume = {25},
	issn = {1873-4626},
	shorttitle = {Racial {Disparities} in {Rates} of {Surgery} for {Esophageal} {Cancer}},
	doi = {10.1007/s11605-020-04653-z},
	abstract = {BACKGROUND: Treatment guidelines for stage I-III esophageal cancer indicate that management should include surgery in appropriate patients. Variations in utilization of surgery may contribute to racial differences observed in survival. We sought to identify factors associated with racial disparities in surgical resection of esophageal cancer and evaluate associated survival differences.
METHODS: Patients diagnosed with stage I-III esophageal cancer from 2004 to 2015 were identified using the National Cancer Database. Matched patient cohorts were created to reduce confounding. Multivariate logistic regression was used to identify factors associated with receipt of surgery. Multi-level modeling was performed to control for random effects of individual hospitals on surgical utilization.
RESULTS: A total of 60,041 patients were included (4402 black; 55,639 white). After 1:1 matching, there were 5858 patients evenly distributed across race. For all stages, significantly fewer black than white patients received surgery. Black race independently conferred lower likelihood of receiving surgery in single-level multivariable analysis (OR (95\% CI); stage I, 0.67 (0.48-0.94); stage II, 0.76 (0.60-0.96); stage III, 0.62 (0.50-0.76)) and after controlling for hospital random effects. Hospital-level random effects accounted for one third of the unexplained variance in receipt of surgery. Risk-adjusted 1-, 3-, and 5-year mortality was higher for patients who did not undergo surgery.
CONCLUSION: Black patients with esophageal cancer are at higher risk of mortality compared to white patients. This increased risk may be influenced by decreased likelihood of receiving surgical intervention for resectable disease, in part because of between-hospital differences. Improving access to surgical care may improve disparities in esophageal cancer survival.},
	language = {eng},
	number = {3},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Savitch, Samantha L. and Grenda, Tyler R. and Scott, Walter and Cowan, Scott W. and Posey, James and Mitchell, Edith P. and Cohen, Steven J. and Yeo, Charles J. and Evans, Nathaniel R.},
	month = mar,
	year = {2021},
	pmid = {32500418},
	keywords = {Humans, Databases, Factual, United States, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Healthcare Disparities, Race, African Americans, Whites, NCDB, Racial disparities},
	pages = {581--592},
	file = {PDF:/Users/jcsal/Zotero/storage/FJA456YB/Savitch et al. - 2021 - Racial Disparities in Rates of Surgery for Esophageal Cancer a Study from the National Cancer Datab.pdf:application/pdf},
}

@article{paniaguacruze498,
	title = {Association {Between} {Marital} {Status} and {Racial} {Disparities} in {Esophageal} {Cancer} {Care}},
	volume = {16},
	issn = {2688-1535},
	doi = {10.1200/JOP.19.00561},
	abstract = {PURPOSE: This study was designed to examine the impact of marital status on racial disparities in esophageal cancer care.
PATIENTS AND METHODS: We performed a secondary analysis of data collected from the state cancer registry maintained by the Michigan Department of Health and Human Services. We identified patients with an esophageal cancer diagnosis between January 1, 2000, and December 31, 2013. χ2 test and logistics regression were used to analyze 6,809 patients who met our eligibility criteria. Statistical significance was defined as P ≤ .05.
RESULTS: Approximately 88.4\% of our patients were White and 11.6\% were Black. A significantly higher number of White patients were married when compared with Blacks (62.9\% v 31.8\%, respectively; P {\textless} .0001). There was no significant difference in cancer staging between the 2 groups (P = .0671). Married Blacks had similar rates of esophagectomy, chemotherapy, and radiation as married Whites. Both single groups had lower rates of esophagectomy and chemotherapy than married Whites, but single Blacks were the least likely to undergo esophagectomy. Single patients were more likely to refuse treatment.
CONCLUSION: Marital status differs significantly in Black and White patients with esophageal cancer and may help explain racial disparities in cancer care. Further research is needed to explore reasons for care underutilization in single patients and whether these differences translate into clinical outcomes.},
	language = {eng},
	number = {6},
	journal = {JCO oncology practice},
	author = {Paniagua Cruz, Alan and Haug, Karlie L. and Zhao, Lili and Reddy, Rishindra M.},
	month = jun,
	year = {2020},
	pmid = {32369408},
	pmcid = {PMC7291542},
	keywords = {Humans, Esophageal Neoplasms, Michigan, Race, African Americans, Whites, Marital Status},
	pages = {e498--e506},
	file = {Full Text:/Users/jcsal/Zotero/storage/EDRHBJEI/Paniagua Cruz et al. - 2020 - Association Between Marital Status and Racial Disp.pdf:application/pdf},
}

@article{sridhar1472,
	title = {Esophageal {Cancer} {Presentation}, {Treatment}, and {Outcomes} {Vary} {With} {Hospital} {Safety}-{Net} {Burden}},
	volume = {107},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2018.11.065},
	abstract = {BACKGROUND: Social determinants of health affect diagnosis and delivery of care to patients with esophageal cancer. This study hypothesized that hospital safety-net burden affects presentation, treatment, and outcomes in patients with esophageal cancer.
METHODS: The National Cancer Database was queried for patients with esophageal cancer (2004 to 2013). Treating facilities were categorized according to their relative burden of uninsured or Medicaid-insured patients. Hospitals with low (LBH), medium (MBH), and high (HBH) safety-net burden were compared with respect to patient demographics, disease and treatment characteristics, and survival using χ2 analysis, Kaplan-Meier survival analysis, and multivariable modeling.
RESULTS: There were 56,115 patients from 1,215 facilities. HBH treated a greater proportion of racial and ethnic minorities and patients with lower socioeconomic status. Patients at HBH presented at later stages and received primary surgical therapy less often than at MBH and LBH. Survival for patients with esophageal adenocarcinoma did not differ significantly between HBH and LBH after adjusting for age, sex, race, ethnicity, income, comorbidity, stage, histologic type, tumor location, facility type, insurance status, and treatment modality (hazard ratio, 1.06; 95\% confidence interval, 0.99 to 1.14; p = 0.093). HBH were associated with a higher mortality risk than LBH for patients with squamous cell carcinoma (hazard ratio, 1.11; 95\% confidence interval, 1.02 to 1.20; p = 0.014).
CONCLUSIONS: There is a mortality risk for patients with squamous cell carcinoma, but not for adenocarcinoma at HBH compared with LBH. Further analysis of unadjusted variables such as performance status, completion of therapy, and continuity of care, and others should be undertaken among safety-net hospitals with the goal of creating appropriate clinical pathways for care of esophageal cancer in vulnerable populations.},
	language = {eng},
	number = {5},
	journal = {The Annals of Thoracic Surgery},
	author = {Sridhar, Praveen and Bhatt, Maunil and Qureshi, Muhammad M. and Asokan, Sainath and Truong, Minh Tam and Suzuki, Kei and Mak, Kimberley S. and Litle, Virginia R.},
	month = may,
	year = {2019},
	pmid = {30605641},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Survival Rate, Databases, Factual, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Race, Socioeconomic Factors, Safety-net Providers},
	pages = {1472--1479},
}

@article{tramontano2880,
	title = {Survival {Disparities} by {Race} and {Ethnicity} in {Early} {Esophageal} {Cancer}},
	volume = {63},
	issn = {1573-2568},
	doi = {10.1007/s10620-018-5238-6},
	abstract = {BACKGROUND: Survival outcome disparities among esophageal cancer patients exist, but are not fully understood.
AIMS: We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to determine whether survival differences among racial/ethnic patient populations persist after adjusting for demographic and clinical characteristics.
METHODS: Our study included T1-3N0M0 adenocarcinoma and squamous cell cancer patients diagnosed between 2003 and 2011. We compared survival among two racial/ethnic patient subgroups using Cox proportional hazards methods, adjusting for age, sex, histology, marital status, socioeconomics, SEER region, comorbidities, T stage, tumor location, diagnosis year, and treatment received.
RESULTS: Among 2025 patients, 87.9\% were White and 12.1\% were Nonwhite. Median survival was 18.7 months for Whites vs 13.8 months for Nonwhites (p = 0.01). In the unadjusted model, Nonwhite patients had higher risk of mortality (HR = 1.29, 95\% CI 1.11-1.49, p {\textless} 0.0001) when compared to White patients; however, in the Cox regression adjusted model there was no significant difference (HR = 0.94, 95\% CI 0.80-1.10, p = 0.44). Surgery, chemotherapy, younger age, lower T stage, and lower Charlson comorbidity score were significant predictors in the full adjusted model.
CONCLUSIONS: Differences in mortality risk by race/ethnicity appear to be largely explained by additional factors. In particular, associations were seen in surgery and T stage. Further research is needed to understand potential mechanisms underlying the differences and to better target patients who can benefit from treatment options.},
	language = {eng},
	number = {11},
	journal = {Digestive Diseases and Sciences},
	author = {Tramontano, Angela C. and Nipp, Ryan and Mercaldo, Nathaniel D. and Kong, Chung Yin and Schrag, Deborah and Hur, Chin},
	month = nov,
	year = {2018},
	pmid = {30109578},
	pmcid = {PMC6738563},
	keywords = {Humans, Aged, Female, Male, Aged, 80 and over, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophageal cancer, Survival, Disparities, Race, SEER Program, Outcomes, SEER-Medicare},
	pages = {2880--2888},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/NLTSEKJD/Tramontano et al. - 2018 - Survival Disparities by Race and Ethnicity in Earl.pdf:application/pdf},
}

@article{corona883,
	title = {Trends in {Esophageal} {Cancer} {Mortality} and {Stage} at {Diagnosis} by {Race} and {Ethnicity} in the {United} {States}},
	volume = {32},
	issn = {1573-7225},
	doi = {10.1007/s10552-021-01443-z},
	abstract = {INTRODUCTION: Esophageal cancer (EC) is an aggressive malignancy with poor prognosis. Mortality and disease stage at diagnosis are important indicators of improvements in cancer prevention and control. We examined United States trends in esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) mortality and stage at diagnosis by race and ethnicity.
METHODS: We used Surveillance, Epidemiology, and End Results (SEER) data to identify individuals with histologically confirmed EAC and ESCC between 1 January 1992 and 31 December 2016. For both EAC and ESCC, we calculated age-adjusted mortality and the proportion presenting at each stage by race/ethnicity, sex, and year. We then calculated the annual percent change (APC) in each indicator by race/ethnicity and examined changes over time.
RESULTS: The study included 19,257 EAC cases and 15,162 ESCC cases. EAC mortality increased significantly overall and in non-Hispanic Whites from 1993 to 2012 and from 1993 to 2010, respectively. EAC mortality continued to rise among non-Hispanic Blacks (NHB) (APC = 1.60, p = 0.01). NHB experienced the fastest decline in ESCC mortality (APC = - 4.53, p {\textless} 0.001) yet maintained the highest mortality at the end of the study period. Proportions of late stage disease increased overall by 18.5 and 24.5 percentage points for EAC and ESCC respectively; trends varied by race/ethnicity.
CONCLUSION: We found notable differences in trends in EAC and ESCC mortality and stage at diagnosis by race/ethnicity. Stage migration resulting from improvements in diagnosis and treatment may partially explain recent trends in disease stage at diagnosis. Future efforts should identify factors driving current esophageal cancer disparities.},
	language = {eng},
	number = {8},
	journal = {Cancer causes \& control: CCC},
	author = {Corona, Edgar and Yang, Liu and Esrailian, Eric and Ghassemi, Kevin A. and Conklin, Jeffrey L. and May, Folasade P.},
	month = aug,
	year = {2021},
	pmid = {34003396},
	pmcid = {PMC8236464},
	keywords = {Humans, Female, Male, Adult, United States, Adenocarcinoma, Esophageal Neoplasms, Esophageal cancer, Esophageal Squamous Cell Carcinoma, Incidence, Mortality, Head and Neck Neoplasms, Race, Ethnicity, Health disparities, Stage at diagnosis},
	pages = {883--894},
	file = {Full Text:/Users/jcsal/Zotero/storage/UGGJ54G9/Corona et al. - 2021 - Trends in Esophageal Cancer Mortality and Stage at.pdf:application/pdf},
}

@article{sonoda8,
	title = {Total {Lesion} {Glycolysis} {Ratio} in {Positron} {Emission} {Tomography}/{Computed} {Tomography} {Images} {During} {Neoadjuvant} {Chemotherapy} {Can} {Predict} {Pathological} {Tumor} {Regression} {Grade} and {Prognosis} in {Patients} with {Locally} {Advanced} {Squamous} {Cell} {Carcinoma} of the {Esophagus}},
	abstract = {Background. The usefulness of quantitating tumor lesion glycolysis (TLG) from 18F-ﬂuorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/ CT) ﬁndings as a tool for determining the effect of neoadjuvant chemotherapy (NAC) in esophageal squamous cell carcinoma (ESCC) has not yet been established.},
	language = {en},
	author = {Sonoda, Akari},
	pages = {8},
	file = {Sonoda - Total Lesion Glycolysis Ratio in Positron Emission.pdf:/Users/jcsal/Zotero/storage/7NHRUFY3/Sonoda - Total Lesion Glycolysis Ratio in Positron Emission.pdf:application/pdf},
}

@article{mauricio11,
	title = {Nutritional {Status} {Parameters} as {Risk} {Factors} for {Mortality} in {Cancer} {Patients}},
	abstract = {The aim of this study was to verify the relationship between weight loss, handgrip strength (HGS) and phase angle (PA) before the beginning of chemotherapy with overall survival in cancer patients. Patients diagnosed with gastrointestinal and breast cancer who were over 18 years old and were scheduled to undergo adjuvant treatment at Hospital Borges da Costa/Brazil were evaluated. The exclusion criteria were neoadjuvant treatment, patients with kidney and liver disease and using diuretics. Weight, HGS and PA tests were performed by trained dietitians. The KaplanMeier survival method and the log-rank test, cox regression and ROC curve were used and p {\textless} 0.05 was considered signiﬁcant. Two-hundred and twenty-eight patients were evaluated.The median survival time was higher among the patients who showed weight loss of less than 10\% of usual body weight (p {\textless} 0.05). Regarding HGS, patients with decreased HGS had a 22.0 month survival versus 34.2 months for those with normal values (p {\textless} 0.05). 146 patients had normal PA values, and these patients had increased survival time compared to those with inappropriate values (p {\textless} 0.05). In the Cox regression, weight loss and PA were predictors of mortality, HGS wasn’t signiﬁcantly associated with mortality. ROC analysis revealed that weight loss was the nutritional status parameter with the most predictive power.},
	language = {en},
	author = {Mauricio, Sílvia Fernandes},
	pages = {11},
	file = {Mauricio - Nutritional Status Parameters as Risk Factors for .pdf:/Users/jcsal/Zotero/storage/ME7BI6E8/Mauricio - Nutritional Status Parameters as Risk Factors for .pdf:application/pdf},
}

@article{hong8,
	title = {Total {Lesion} {Glycolysis} {Using} {18F}-{FDG} {PET}/{CT} as a {Prognostic} {Factor} for {Locally} {Advanced} {Esophageal} {Cancer}},
	language = {en},
	author = {Hong, Ji Hyung and Kim, Hyon Ho and Han, Eun Ji and Byun, Jae Ho and Jang, Hong Seok and Choi, Eun Kyoung and Kang, Jin Hyoung and Yoo, Ie Ryung},
	pages = {8},
	file = {Hong et al. - Total Lesion Glycolysis Using 18F-FDG PETCT as a .pdf:/Users/jcsal/Zotero/storage/4HDVN345/Hong et al. - Total Lesion Glycolysis Using 18F-FDG PETCT as a .pdf:application/pdf},
}

@article{findlay11,
	title = {Predicting {Pathologic} {Response} of {Esophageal} {Cancer} to {Neoadjuvant} {Chemotherapy}: {The} {Implications} of {Metabolic} {Nodal} {Response} for {Personalized} {Therapy}},
	language = {en},
	number = {5},
	author = {Findlay, John M and Bradley, Kevin M and Wang, Lai Mun and Franklin, James M and Teoh, Eugene J and Gleeson, Fergus V and Maynard, Nicholas D and Gillies, Richard S and Middleton, Mark R},
	pages = {11},
	file = {Findlay et al. - Predicting Pathologic Response of Esophageal Cance.pdf:/Users/jcsal/Zotero/storage/T7EVK7JR/Findlay et al. - Predicting Pathologic Response of Esophageal Cance.pdf:application/pdf},
}

@article{collins200,
	title = {Physical performance and muscle mass in the assessment of sarcopenia and its association with receipt and completion of planned treatment in non-small cell lung cancer},
	language = {en},
	author = {Collins, Jemima Tunung Tagal},
	pages = {200},
	file = {Collins - Physical performance and muscle mass in the assess.pdf:/Users/jcsal/Zotero/storage/P7DAWKE5/Collins - Physical performance and muscle mass in the assess.pdf:application/pdf},
}

@article{harada7,
	title = {Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma},
	abstract = {Recently, depletion of skeletal muscle mass (sarcopenia) has been linked to poor prognosis in several types of cancers, but has not been investigated in esophageal squamous cell carcinoma (ESCC). This retrospective study investigates the relationship between sarcopenia and clinical outcome in ESCC patients treated by surgical resection or deﬁnitive chemoradiation therapy (dCRT). The study was retrospectively conducted in a single academic hospital in Kumamoto, Japan, and involved 325 ESCC patients (256 surgical cases and 69 dCRT cases) treated between April 2005 and April 2011. Skeletal muscle mass was quantiﬁed by radiologic measures using standard computed tomography scans. The skeletal muscle tissue in the 325 ESCC patients was distributed as follows: mean: 47.10; median: 46.88; standard deviation (SD): 7.39; range: 31.48–71.11; interquartile range, 46.29–47.90. Skeletal muscle tissue was greater in male patients than in female patients (P {\textless} 0.0001), but was independent of other clinical and tumor features. Sarcopenia was not signiﬁcantly associated with overall survival (log rank P = 0.54). Lymph node involvement signiﬁcantly altered the relationship between sarcopenia and survival rate (P for interaction = 0.026). Sarcopenia signiﬁcantly reduced the overall survival of patients without lymph node involvement (log rank P = 0.035), but was uncorrelated with overall survival in patients with lymph involvement (log rank, P = 0.31). The anastomosis leakage rate was signiﬁcantly higher in the sarcopenia group than in the non-sarcopenia group (P = 0.032), but other surgical complications did not signiﬁcantly differ between the two groups. Sarcopenia in ESCC patients without lymph node involvement is associated with poor prognosis, indicating sarcopenia as a potential biomarker for identifying patients likely to experience an inferior outcome. Moreover, sarcopenia was associated with anastomosis leakage but no other short-term surgical outcome.},
	language = {en},
	author = {Harada, K and Ida, S and Baba, Y and Ishimoto, T and Kosumi, K and Tokunaga, R and Izumi, D and Ohuchi, M and Nakamura, K and Kiyozumi, Y and Imamura, Y and Iwatsuki, M and Iwagami, S and Miyamoto, Y and Sakamoto, Y and Yoshida, N and Watanabe, M and Baba, H},
	year = {2015},
	pages = {7},
	file = {Harada et al. - 2015 - Prognostic and clinical impact of sarcopenia in es.pdf:/Users/jcsal/Zotero/storage/VLT29CWL/Harada et al. - 2015 - Prognostic and clinical impact of sarcopenia in es.pdf:application/pdf},
}

@article{gannon7,
	title = {Reduced fitness and physical functioning are long-term sequelae after curative treatment for esophageal cancer: a matched control study},
	abstract = {Reduced physical functioning is common following resections for esophageal cancer; however, objective data on physical performance outcomes in this cohort are rare. The aim of this study was to assess the physical performance and health related quality of life (HRQOL) of disease free survivors and compare findings in a case matched noncancer control group. Twenty-five males (mean (±SD) aged 63 (±6) years) who were over 6 months postesophagectomy and disease-free were compared with 25 controls (60 ± 6 years). Physical functioning was assessed through hand grip strength (dynamometry), exercise capacity (incremental shuttle walk test), physical activity levels (RT3 accelerometer), and body composition (bio-electrical impedance analysis). Health-related quality of life was measured using the EORTC QLQ-C30 questionnaire. Esophageal cancer survivors demonstrated significantly lower fitness (P {\textless} 0.001) and time spent in moderate (P {\textless} 0.001) and vigorous (P {\textless} 0.001) intensity physical activity compared with controls. Global health status and quality of life were similar in both groups (P = 0.245); however, physical and role functioning domains were lower in the cancer survivors (P {\textless} 0.001, and P = 0.001, respectively). These data show that disease-free survivors of curative esophageal cancer treatment demonstrate a significant compromise in physical functioning compared with controls, thus highlighting the multiple, complex rehabilitative needs of this cohort.},
	language = {en},
	author = {Gannon, J A and Guinan, E M and Doyle, S L and Beddy, P and Reynolds, J V and Hussey, J},
	pages = {7},
	file = {Gannon et al. - Reduced fitness and physical functioning are long-.pdf:/Users/jcsal/Zotero/storage/NTBCJEMK/Gannon et al. - Reduced fitness and physical functioning are long-.pdf:application/pdf},
}

@article{sjoblom8,
	title = {Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer},
	abstract = {Background \& aims: Recent research indicates that severe muscular depletion (sarcopenia) is frequent in cancer patients and linked to cachexia and poor survival. Our aim was to investigate if measures of skeletal muscle hold prognostic information in advanced non-small cell lung cancer (NSCLC).
Methods: We included NSCLC patients with disease stage IIIB/IV, performance status 0e2, enrolled in three randomised trials of ﬁrst-line chemotherapy (n ¼ 1305). Computed tomography (CT) images obtained before start of treatment were used for body composition analyses at the level of the third lumbar vertebra (L3). Skeletal muscle mass was assessed by measures of the cross sectional muscle area, from which the skeletal muscle index (SMI) was obtained. Skeletal muscle radiodensity (SMD) was measured as the mean Hounsﬁeld unit (HU) of the measured muscle area. A high level of mean HU indicates a high SMD.
Results: Complete data were available for 734 patients, mean age 65 years. Both skeletal muscle index (SMI) and muscle radiodensity (SMD) varied largely. Mean SMI and SMD were 47.7 cm2/m2 and 37.4 HU in men (n ¼ 420), 39.6 cm2/m2 and 37.0 HU in women (n ¼ 314). Multivariable Cox regression analyses, adjusted for established prognostic factors, showed that SMD was independently prognostic for survival (Hazard ratio (HR) 0.98, 95\% CI 0.97e0.99, p ¼ 0.001), whereas SMI was not (HR 0.99, 95\% CI 0.98e1.01, p ¼ 0.329).
Conclusion: Low SMD is associated with poorer survival in advanced NSCLC. Further research is warranted to establish whether muscle measures should be integrated into routine practice to improve prognostic accuracy.},
	language = {en},
	journal = {Clinical Nutrition},
	author = {Sjøblom, Bjørg},
	year = {2016},
	pages = {8},
	file = {Sjøblom - 2016 - Skeletal muscle radiodensity is prognostic for sur.pdf:/Users/jcsal/Zotero/storage/EJ6TAQK7/Sjøblom - 2016 - Skeletal muscle radiodensity is prognostic for sur.pdf:application/pdf},
}

@article{eyck12,
	title = {Accuracy of {Detecting} {Residual} {Disease} {After} {Neoadjuvant} {Chemoradiotherapy} for {Esophageal} {Cancer}},
	volume = {271},
	language = {en},
	number = {2},
	journal = {Annals of Surgery},
	author = {Eyck, Ben M and Onstenk, Barbera D and Noordman, Bo J and Nieboer, Daan and Spaander, Manon C W and Wijnhoven, Bas P L},
	year = {2020},
	pages = {12},
	file = {Eyck et al. - 2020 - Accuracy of Detecting Residual Disease After Neoad.pdf:/Users/jcsal/Zotero/storage/MC6KFAVT/Eyck et al. - 2020 - Accuracy of Detecting Residual Disease After Neoad.pdf:application/pdf},
}

@article{nakajo10,
	title = {Texture analysis of {18F}-{FDG} {PET}/{CT} to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy},
	abstract = {Purpose This retrospective study was done to examine whether the heterogeneity in primary tumour F-18fluorodeoxyglucose (18F-FDG) distribution can predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy (CRT).},
	language = {en},
	journal = {Eur J Nucl Med Mol Imaging},
	author = {Nakajo, Masatoyo},
	year = {2017},
	pages = {10},
	file = {Nakajo - 2017 - Texture analysis of 18F-FDG PETCT to predict tumo.pdf:/Users/jcsal/Zotero/storage/ZPPWMRID/Nakajo - 2017 - Texture analysis of 18F-FDG PETCT to predict tumo.pdf:application/pdf},
}

@article{heneghan8,
	title = {Can {CT}-{PET} and {Endoscopic} {Assessment} {PostNeoadjuvant} {Chemoradiotherapy} {Predict} {Residual} {Disease} in {Esophageal} {Cancer}?},
	volume = {264},
	abstract = {Objective: The aim of this study is to assess CT-PET and endoscopic assessment postneoadjuvant chemoradiotherapy (nCRT) in predicting complete pathologic response (pCR) in locally advanced esophageal cancer (LAEC). Design: A prospective cohort study.
Background: nCRT is increasingly standard of care in LAEC, with pCR a surrogate for excellent outcome. Predicting pCR before surgery, with metabolic imaging and endoscopy, may spare patients’ operative intervention.
Methods: One hundred thirty-eight consecutive patients [mean age 61 Æ 8, 99 male (72\%), 103 (75\%) adenocarcinoma] underwent nCRT with CT-PET and endoscopy 4 to 6 weeks later, and surgery subsequently. A complete metabolic response (cMR) was defined as SUVmax of {\textless}4. A complete endoscopic response (cER) was no residual mucosal abnormality. The association of pCR with cMR and cER was analyzed.
Results: pCR was achieved in 30 patients (22\%); 37\% SCC and 17\% adenocarcinoma. A cMR was evident in 63 (46\%), of whom 17 (27\%) had a pCR and 17(27\%) were ypNþ. A cER was observed in 45 (33\%). The Spearman correlation for cER and cMR was 0.066 (P ¼ 0.479), for cER and pCR was 0.004 (P ¼ 0.969), and cMR and pCR –0.120 (P ¼ 0.160). The sensitivity, specificity, positive predictive value, and negative predictive value of cMR was 57\%, 57\%, 27\%, and 82\%, respectively, and for combined cMR and cER was 24\%, 83\%, 28\%, and 79\%, respectively.
Conclusions: The prediction of pCR through CT-PET and endoscopy independently or combined is limited by low sensitivity and poor positive predictive value. Protocols to avoid surgery in patients with apparent complete clinical complete based on these criteria should be adopted with considerable caution.},
	language = {en},
	number = {5},
	journal = {Annals of Surgery},
	author = {Heneghan, Helen M and Donohoe, Claire and Elliot, Jessie and Ahmed, Zuhair and Malik, Vinod and Ravi, Narayamasamy and Reynolds, John V},
	year = {2016},
	pages = {8},
	file = {Heneghan et al. - 2016 - Can CT-PET and Endoscopic Assessment PostNeoadjuva.pdf:/Users/jcsal/Zotero/storage/5428HY6V/Heneghan et al. - 2016 - Can CT-PET and Endoscopic Assessment PostNeoadjuva.pdf:application/pdf},
}

@article{beukinga8,
	title = {Predicting {Response} to {Neoadjuvant} {Chemoradiotherapy} in {Esophageal} {Cancer} with {Textural} {Features} {Derived} from {Pretreatment} {18F}-{FDG} {PET}/{CT} {Imaging}},
	language = {en},
	author = {Beukinga, Roelof J and Hulshoff, Jan B and van Dijk, Lisanne V and Muijs, Christina T and Burgerhof, Johannes G M and Kats-Ugurlu, Gursah},
	pages = {8},
	file = {Beukinga et al. - Predicting Response to Neoadjuvant Chemoradiothera.pdf:/Users/jcsal/Zotero/storage/J2Q4U2X2/Beukinga et al. - Predicting Response to Neoadjuvant Chemoradiothera.pdf:application/pdf},
}

@article{facs6,
	title = {Procedure-based postoperative risk prediction using {NSQIP} data},
	abstract = {Background: The National Surgical Quality Improvement Program (NSQIP) has proposed using procedure-based hierarchical models to predict adverse outcomes, but it is not clear whether this approach was used to develop the NSQIP “Surgical Risk Calculator”. We therefore wished to demonstrate how procedure-based hierarchical models can be constructed and to describe their results.
Methods: NSQIP data from 2015 were used to construct statistical models predicting 30-day postoperative mortality and morbidity, using two-level logistic regression with preoperative patient-level variables as ﬁxed effects and procedure-speciﬁc codes as a random intercept. Model performance was validated using NSQIP data from 2014.
Results: NSQIP for 2015 contained records for 885,502 patients, of whom 8986 died (1.0\%) and 104,836 suffered a complication (11.8\%). Complete model speciﬁcations and results are presented, including odds ratios for patient-level variable effects and random procedure effects. Most comorbidities were associated with increased morbidity and mortality, but overweight and obesity were associated with lower risk. Odds ratios for individual procedures ranged from 0.117 to 10.85 for mortality and from 0.615 to 8.09 for morbidity. Validation C-statistics were 0.940 for the mortality model and 0.833 for the morbidity model; Brier Scores were 0.0086 and 0.085, respectively. Graphs for 20 quantiles showed good conformity of observed and predicted risk.
Conclusions: Procedure-based hierarchical logistic regression models of NSQIP outcomes had satisfactory overall performance statistics. Model speciﬁcations and results are provided for criticism and improvement, and several possible reﬁnements are suggested.},
	language = {en},
	journal = {j o u r n a l o f s u r g i c a l r e s e a r c h},
	author = {Facs, David E Clark},
	pages = {6},
	file = {Facs - Procedure-based postoperative risk prediction usin.pdf:/Users/jcsal/Zotero/storage/MJYQ4WVN/Facs - Procedure-based postoperative risk prediction usin.pdf:application/pdf},
}

@article{subramaniam17,
	title = {New 5-{Factor} {Modified} {Frailty} {Index} {Using} {American} {College} of {Surgeons} {NSQIP} {Data}},
	abstract = {BACKGROUND: The modiﬁed frailty index (mFI-11) is a NSQIP-based 11-factor index that has been proven to adequately reﬂect frailty and predict mortality and morbidity. These 11 factors, made of 16 variables, map to the original 70-item Canada Study of Health and Aging Frailty Index. In past years, certain NSQIP variables have been removed from the database; as of 2015, only 5 of the original 11 factors remained. The predictive power and usefulness of these 5 factors in an index (mFI-5) have not been proven in past literature. The goal of our study was to compare the mFI-5 to the mFI-11 in terms of value and predictive ability for mortality, postoperative infection, and unplanned 30-day readmission. STUDY DESIGN: The mFI was calculated by dividing the number of factors present for a patient by the number of available factors for which there were no missing data. Spearman’s rho was used to assess correlation between the mFI-5 and mFI-11. Predictive models, using both unadjusted and adjusted logistic regressions, were created for each outcome for 9 surgical subspecialties using 2012 NSQIP data, the last year all mFI-11 variables existed.
RESULTS: Correlation between the mFI-5 and mFI-11 was above 0.9 across all surgical specialties except for cardiac and vascular surgery. Adjusted and unadjusted models showed similar c-statistics for mFI-5 and mFI-11, and strong predictive ability for mortality and postoperative complications.
CONCLUSIONS: The mFI-5 and the mFI-11 are equally effective predictors in all sub-specialties and the mFI5 is a strong predictor of mortality and postoperative complications. It has credibility for future use to study frailty within the NSQIP database. It also has potential in other databases and for clinical use. (J Am Coll Surg 2018;226:173e182. Ó 2017 Published by Elsevier Inc. on behalf of the American College of Surgeons.)},
	language = {en},
	author = {Subramaniam, Sneha},
	year = {2012},
	pages = {17},
	file = {Subramaniam - 2012 - New 5-Factor Modified Frailty Index Using American.pdf:/Users/jcsal/Zotero/storage/IIFRQCVT/Subramaniam - 2012 - New 5-Factor Modified Frailty Index Using American.pdf:application/pdf},
}

@article{yoon10,
	title = {Predicting unintentional weight loss in patients with gastrointestinal cancer},
	abstract = {Background Unintentional weight loss is a major problem for patients with gastrointestinal (GI) cancers because it affects treatment, survival outcomes, and quality of life. To date, little is known about the trajectory of weight loss and the relationship between baseline body mass index (BMI), location of the cancer, and outcomes. The aims of this study were to investigate patterns of weight loss over time in patients with GI cancer according to BMI groups (low, normal, and high) and location of cancer.
Methods We examined de-identiﬁed electronic medical record data of 801 adults ({\textgreater}21 years) with GI cancer using ICD-9 codes (150–159). Descriptive statistics and linear mixed models were used to examine unintentional weight loss over time by BMI group (low, normal, and high) and to determine the effect of primary cancer site and patient characteristics on weight loss.
Results The mean age of patients was 66.5 ± 11.9 years (21–95 years), with 58\% male and 86\% White. Mean weight loss over 3 years was 21.39 kg. At the ﬁrst observation point, 7.8\% were in the low BMI group, 30.1\% were in the normal, and 62\% were in the high group. At the end of observation, a majority of deaths (35.5\%) occurred in the low BMI group (BMI {\textless} 20 kg/m2). Signiﬁcant weight loss was observed in patients with gastric (t = À5.11, P {\textless} 0.001), oesophageal (t = À4.18, P {\textless} 0.001), and pancreatic (35.8\%, t = À3.58, P {\textless} 0.001) cancers. Predictors of weight change were gender (F = 64.93, P {\textless} 0.001), cancer stage (F = 7.28, P {\textless} 0.001), and site by days (F = 8.24, P {\textless} 0.001). Weight loss rates were similar among the three BMI groups, but patterns were different based on primary cancer type as a function of days within each group.
Conclusions Weight loss in patients with GI cancers has implications for survival. Patients with upper GI cancers experienced more weight loss and decreased survival rates compared with patients with lower GI cancers. Patients with a combination of upper GI cancer (oesophagogastric or pancreatic) and low baseline BMI had the fewest survival days and worst patient outcomes. Early intervention for weight management plays a critical role for improving the health outcomes and fatality rates of these patients.},
	language = {en},
	author = {Yoon, Saunjoo L and Kim, Jung A and Kelly, Debra Lynch and Lyon, Debra and George, Thomas J},
	pages = {10},
	file = {Yoon et al. - Predicting unintentional weight loss in patients w.pdf:/Users/jcsal/Zotero/storage/BH873RZ8/Yoon et al. - Predicting unintentional weight loss in patients w.pdf:application/pdf},
}

@article{rechinelli9,
	title = {Presence of dynapenia and association with anthropometric variables in cancer patients},
	abstract = {Background: Dynapenia is defined as an age-related loss of muscle strength. There is little information on dynapenia in cancer patients and on how it relates to anthropometric variables. The aim of this study was to analyze the presence of dynapenia and its association with anthropometric variables in hospitalized cancer patients. Methods: Participants comprised adult and elderly cancer patients evaluated within the first 48 h of hospital admission to a tertiary public hospital, a referral center for gastrointestinal tract surgery. Anthropometric variables were measured according to standardized protocols. Dynapenia was identified based on handgrip strength (HGS), according to the cutoff points defined by the European Working Group on Sarcopenia in Older People (EWGSOP2), with values for women {\textless} 16 kg and for men {\textless} 27 kg. Statistical analysis was performed using SPSS software, version 22.0, with a significance level of 5\%.},
	language = {en},
	author = {Rechinelli, Ana Beatriz},
	year = {2020},
	pages = {9},
	file = {Rechinelli - 2020 - Presence of dynapenia and association with anthrop.pdf:/Users/jcsal/Zotero/storage/Z8HV7N86/Rechinelli - 2020 - Presence of dynapenia and association with anthrop.pdf:application/pdf},
}

@article{kalff,
	title = {Long-{Term} {Survival} {After} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}: {A} {Nationwide} {Propensity}-{Score} {Matched} {Analysis}},
	volume = {Publish Ahead of Print},
	issn = {1528-1140},
	shorttitle = {Long-{Term} {Survival} {After} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}},
	doi = {10.1097/SLA.0000000000004708},
	abstract = {OBJECTIVES: This study aimed to compare long-term survival following minimally invasive esophagectomy (MIE) versus open esophagectomy (OE) for esophageal cancer using a nationwide propensity-score matched cohort.
SUMMARY BACKGROUND DATA: MIE provides lower postoperative morbidity and mortality, and similar short-term oncological quality compared to OE.
METHODS: Data was acquired from the Dutch Upper Gastrointestinal Cancer Audit. Patients undergoing minimally invasive or open, transthoracic or transhiatal esophagectomy for primary esophageal cancer between 2011-2015 were included. A propensity-score matching analysis for MIE versus OE was performed separately for transthoracic and transhiatal esophagectomies.
RESULTS: A total of 1036 transthoracic MIE and OE patients, and 582 transhiatal MIE and OE patients were matched. Long-term survival was comparable for MIE and OE for both transthoracic and transhiatal procedures (5-year overall survival: transthoracic MIE 49.2\% vs. OE 51.1\%, p 0.695; transhiatal MIE 48.4\% vs. OE 50.7\%, p 0.832). For both procedures, MIE yielded more lymph nodes (transthoracic median 21 vs. 18, p {\textless} 0.001; transhiatal 15 vs. 13, p 0.007). Post-operative morbidity was comparable after transthoracic MIE and OE (60.8\% vs. 64.9\%, p 0.177), with a reduced length of stay after transthoracic MIE (median 12 vs. 15 days, p {\textless} 0.001). After transhiatal MIE, more postoperative complications (64.9\% vs. 56.4\%, p 0.034) were observed, without subsequent difference in length of stay.
CONCLUSION: Long-term survival after minimally invasive esophagectomy was equivalent to open in both propensity-score matched cohorts of patients undergoing transthoracic or transhiatal esophageal resections. Transhiatal minimally invasive esophagectomy was accompanied with more post-operative morbidity. Both transthoracic and transhiatal minimally invasive esophagectomy resulted in a more extended lymphadenectomy.},
	language = {eng},
	journal = {Annals of Surgery},
	author = {Kalff, Marianne C. and Fransen, Laura F. C. and de Groot, Eline M. and Gisbertz, Suzanne S. and Nieuwenhuijzen, Grard A. P. and Ruurda, Jelle P. and Verhoeven, Rob H. A. and Luyer, Misha D. P. and van Hillegersberg, Richard and van Berge Henegouwen, Mark I. and {Dutch Upper Gastrointestinal Cancer Audit group}},
	month = dec,
	year = {2020},
	pmid = {33378310},
	keywords = {MIE},
}

@article{kumar6,
	title = {Muscle composition measured by {CT} scan is a measurable predictor of overall survival in advanced ovarian cancer},
	abstract = {Objectives. To assess the impact of muscle composition and sarcopenia on overall survival in advanced epithelial ovarian cancer (EOC) after primary debulking surgery (PDS).
Methods. Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/1/2006 and 12/ 31/2012 were included. Patient variables and vital status were abstracted. Body composition was evaluated in a semi-automated process using Slice-O-Matic software v4.3 (TomoVision). Skeletal muscle area and mean skeletal muscle attenuation were recorded. Associations with overall survival were evaluated using Cox proportional hazards models and recursive partitioning.
Results. We identiﬁed 296 patients and 132 (44.6\%) were classiﬁed as sarcopenic. The average mean skeletal muscle attenuation of the entire cohort was 33.4 Hounsﬁeld units (HU). A multivariate model of overall risk of death included histology, residual disease, and mean skeletal attenuation. Among patients without residual disease, overall survival, but not progression free survival was signiﬁcantly different between patients with low versus high mean skeletal attenuation (median survival, 2.8 vs. 3.3 years). Among patients with residual disease, overall survival was signiﬁcantly different between patients with low versus high mean skeletal attenuation ≥36.40 vs. b36.40 HU (median survival, 2.0 vs. 3.3 years).
Conclusions. Sarcopenia and low mean skeletal muscle attenuation are common in women undergoing PDS for advanced EOC. These factors are associated with poorer outcomes, and can be used in preoperative risk stratiﬁcation and patient counseling. Further research into body composition and whether this risk factor can be altered via nutrition or ﬁtness in this population is warranted.},
	language = {en},
	journal = {Gynecologic Oncology},
	author = {Kumar, Amanika and Moynagh, Michael R and Multinu, Francesco and Cliby, William A and McGree, Michaela E and Weaver, Amy L and Young, Phillip M and Bakkum-Gamez, Jamie N and Langstraat, Carrie L and Dowdy, Sean C and Jatoi, Aminah and Mariani, Andrea},
	year = {2016},
	pages = {6},
	file = {Kumar et al. - 2016 - Muscle composition measured by CT scan is a measur.pdf:/Users/jcsal/Zotero/storage/CHXJVTHP/Kumar et al. - 2016 - Muscle composition measured by CT scan is a measur.pdf:application/pdf},
}

@article{sjoblom7,
	title = {Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer},
	abstract = {Background: Recent research suggests a signiﬁcant relationship between lean body mass (LBM) and toxicity from chemotherapeutic agents. We investigated if higher drug doses per kg LBM were associated with increased toxicity in stage IIIB/IV non-small cell lung cancer (NSCLC) patients receiving a ﬁrst-line chemotherapy regimen dosed according to body surface area (BSA).
Methods: Data from patients randomised to receive intravenous gemcitabine 1000 mg/m2 plus orally vinorelbine 60 mg/m2 days 1 and 8 in a phase III trial comparing two chemotherapy regimens were analysed. LBM was estimated from assessment of the cross-sectional muscle area at the third lumbar level (L3) on computed tomography images obtained before chemotherapy commenced. Common terminology criteria for adverse events (CTCAE) grade 3–4 haematological toxicity and dose reduction and/or stop of treatment after the ﬁrst course of chemotherapy were deﬁned as primary and secondary toxicity outcomes.
Results: The study sample included 153 patients, mean age was 66 years, 55\% were men, 87\% had disease stage IV and 75\% had performance status (PS) 0–1. Gemcitabine doses per kg LBM varied from 23.2 to 53.1 mg/kg LBM, and vinorelbine doses from 1.5 to 3.3 mg/kg LBM. Higher doses of gemcitabine per kg LBM were signiﬁcantly associated with grade 3–4 haematological toxicity in bivariate (OR = 1.12, 95\% CI 1.03–1.23, p = 0.008) and multivariate analyses (OR = 1.15, 95\% CI 1.01–1.29, p = 0.018), as were also higher doses of vinorelbine per kg LBM. No signiﬁcant association was found between drug doses per kg LBM and dose reduction and/or stop of treatment.
Conclusion: The study showed that dose estimates according to BSA lead to a substantial variation in drug dose per kg LBM, and higher doses per kg LBM are a signiﬁcant predictor for chemotherapy-induced haematological toxicity. The results indicate that taking LBM into account may lead to a better dose individualisation of chemotherapy.},
	language = {en},
	journal = {Lung Cancer},
	author = {Sjøblom, Bjørg and Grønberg, Bjørn H and Fløtten, Øystein and Hjermstad, Marianne J and Aass, Nina and Jordhøy, Marit},
	year = {2015},
	pages = {7},
	file = {Sjøblom et al. - 2015 - Low muscle mass is associated with chemotherapy-in.pdf:/Users/jcsal/Zotero/storage/SW8Q2DL2/Sjøblom et al. - 2015 - Low muscle mass is associated with chemotherapy-in.pdf:application/pdf},
}

@article{kurita9,
	title = {Handgrip {Strength} {Predicts} {Postoperative} {Pneumonia} {After} {Thoracoscopic}–{Laparoscopic} {Esophagectomy} for {Patients} with {Esophageal} {Cancer}},
	abstract = {Background. Despite advances in minimally invasive surgery, postoperative pneumonia after esophagectomy remains a frequent complication. Sarcopenia, deﬁned as low muscle strength and quantity, has been associated with adverse surgical outcomes in numerous cancers. The recent deﬁnition and diagnostic criteria for sarcopenia have emphasized muscle strength rather than muscle quantity as the primary indicator of sarcopenia, although most studies have focused only on muscle quantity. This study aimed to determine the association of muscle strength and quantity with postoperative pneumonia after thoracoscopic–laparoscopic esophagectomy (TLE).},
	language = {en},
	author = {Kurita, Daisuke},
	pages = {9},
	file = {Kurita - Handgrip Strength Predicts Postoperative Pneumonia.pdf:/Users/jcsal/Zotero/storage/E896VHXT/Kurita - Handgrip Strength Predicts Postoperative Pneumonia.pdf:application/pdf},
}

@article{jang8,
	title = {Characteristics of sarcopenia by {European} consensuses and a phenotype score},
	abstract = {Background We aimed to assess the clinical characteristics of sarcopenia by the original and revised European Working Group on Sarcopenia in Older People (EWGSOP 1 and 2), and to propose a new sarcopenia phenotype score (SPS) to improve relevance of clinical outcomes.
Methods Analyses were performed in 1408 older adults of the Aging Study of PyeongChang Rural Area, a community-based cohort in Korea. For sarcopenia deﬁnitions, we used EWGSOP 1, EWGSOP 2, and SPS, a new index counting number of abnormal domains among components of grip strength, gait speed, or muscle mass. Frailty status by the frailty index and the Cardiovascular Health Study frailty score was compared with sarcopenia measures. Prediction ability for composite outcome combining death and institutionalization due to functional decline was assessed among sarcopenia measures.
Results Generally, sarcopenia spectrum by both EWGSOP 1 and 2 was associated with worse functional status in parameters of geriatric assessments. However, population who were considered as sarcopenic by EWGSOP 1, but not by EWGSOP 2, showed increased risk of composite outcome and worse frailty status, compared with people who were classiﬁed as not sarcopenic by both EWGSOP 1 and 2. With SPS, dose–response relationship was observed with both frailty status and outcome prediction. Prediction for composite outcome was better in SPS than in EWGSOP 2 classiﬁcation.
Conclusions A new SPS might be used to classify sarcopenic burden in older adults to resolve possible inconsistencies in phenotype correlation and outcome prediction of EWGSOP 2 criteria.},
	language = {en},
	author = {Jang, Il‐Young and Lee, Eunju and Lee, Heayon and Park, Hyungchul and Kim, Sunyoung and Kim, Kwang‐il and Jung, Hee‐Won and Kim, Dae Hyun},
	pages = {8},
	file = {Jang et al. - Characteristics of sarcopenia by European consensu.pdf:/Users/jcsal/Zotero/storage/CWYCPDHX/Jang et al. - Characteristics of sarcopenia by European consensu.pdf:application/pdf},
}

@article{okumura13,
	title = {Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies},
	volume = {159},
	abstract = {Background. Skeletal muscle depletion, referred to as sarcopenia, predicts mortality after major surgery. This study investigated the impact of preoperative skeletal muscle quantity and quality on outcomes in patients undergoing resection of extrahepatic biliary cancer.
Methods. We performed a retrospective analysis of 207 patients undergoing resection for biliary cancer between 2004 and 2013. The quantity and quality of skeletal muscle, indicated by the psoas muscle mass index (PMI) and intramuscular adipose tissue content (IMAC), were measured on preoperative images of computed tomography. Overall survival (OS) and recurrence-free survival (RFS) rates were compared by PMI and IMAC, and prognostic factors after operation were assessed.
Results. The OS and RFS rates were less in patients with low PMI (low muscle quantity) than in those with normal PMI (P {\textless} .001 and P {\textless} .001; 5-year OS, 15.7 vs 53.5\%). The OS and RFS rates were also less in patients with high IMAC (low muscle quality) than in those with normal IMAC (P {\textless} .001 and P {\textless} .001; 5-year OS, 23.8 vs 55.9\%). Low PMI and high IMAC were independent factors predictive of poor OS (hazard ratio [HR], 2.921 [95\% CI, 1.920–4.470; P {\textless} .001] and HR, 1.725 [95\% CI, 1.159–2.590; P = .007]) and RFS (HR, 2.141 [95\% CI, 1.464–3.129, P {\textless} .001] and HR, 1.492 [95\% CI, 1.032–2.166, P = .034]).
Conclusion. Preoperative sarcopenia, indicating a low quantity and quality of skeletal muscle, is related closely to mortality after resection of biliary cancer. (Surgery 2016;159:821-33.)},
	language = {en},
	number = {3},
	author = {Okumura, Shinya},
	year = {2016},
	pages = {13},
	file = {Okumura - 2016 - Impact of the preoperative quantity and quality of.pdf:/Users/jcsal/Zotero/storage/MFBWBYC2/Okumura - 2016 - Impact of the preoperative quantity and quality of.pdf:application/pdf},
}

@article{okumura11,
	title = {Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer},
	volume = {157},
	abstract = {Background. Skeletal muscle depletion, referred to as sarcopenia, is predictive of mortality in patients undergoing digestive operations. The impact of muscle quality on outcomes, however, is unclear. This retrospective study investigated the impact of preoperative skeletal muscle quantity and quality on survival in patients undergoing resection of pancreatic cancer.
Methods. We investigated 230 patients who underwent resection of pancreatic cancer between 2004 and 2013. The quantity and quality of skeletal muscle, indicated by psoas muscle mass index (PMI) and intramuscular adipose tissue content (IMAC), were measured in preoperative computed tomography images. Overall survival (OS) and recurrence-free survival (RFS) rates were compared according to PMI and IMAC, and prognostic factors after pancreatic resection were assessed.
Results. The OS and RFS rates in patients with low PMI were lesser than in those with normal/high PMI (P {\textless} .001, P {\textless} .001), with a mean survival time of 17.7 and 33.2 months, respectively. The OS and RFS rates in patients with high IMAC also were less than in those with normal/low IMAC (P {\textless} .001, P = .003) (mean survival time = 21.5 and 56.5 months, respectively). Low PMI (low muscle mass) and high IMAC (low muscle quality) were independent prognostic factors of poor OS (hazard ratio [HR] = 1.999, P {\textless} .001; HR = 2.527, P {\textless} .001) and RFS (HR = 1.607, P = .007; HR = 1.640, P = .004), respectively.
Conclusion. Preoperative sarcopenia, indicating low quality and quantity of skeletal muscle, is closely related to mortality after resection of pancreatic cancer. (Surgery 2015;157:1088-98.)},
	language = {en},
	number = {6},
	author = {Okumura, Shinya},
	year = {2015},
	pages = {11},
	file = {Okumura - 2015 - Impact of preoperative quality as well as quantity.pdf:/Users/jcsal/Zotero/storage/KZ38Y8W4/Okumura - 2015 - Impact of preoperative quality as well as quantity.pdf:application/pdf},
}

@article{hayashi6,
	title = {Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer},
	abstract = {Low skeletal muscle density (SMD) and low skeletal muscle index (SMI) are associated with poor overall survival (OS) in patients with various types of cancer. We retrospectively studied SMD and SMI using computed tomographic (CT) scans in patients with gastric cancer receiving chemotherapy to evaluate its prognostic significance. SMD and SMI were obtained from CT-based analysis using Slice-O-Matic® medical imaging software in patients who received S-1 plus cisplatin chemotherapy for metastatic gastric cancer. The CT images taken within 1 month before starting chemotherapy were used. The cut-off values for determining low SMD [{\textless}33 Hounsfield units (HU) in obese and {\textless}41 HU in non-obese patients] and low SMI ({\textless}41 cm2/m2 in females, {\textless}43 cm2/m2 in non-obese males and {\textless}53 cm2/m2 in obese males) were referenced from a large population based study. The CT images of 53 patients were reviewed. The median SMD was 36.8 HU (range, 19.5-59.3 HU), and the median SMI was 39.8 cm2/m2 (range, 23.7-60.0 cm2/m2). Patients with low SMD had significantly shorter OS compared with patients having normal SMD (8.9 vs. 12.8 months, P=0.03). However, OS did not differ significantly between patients with low and normal SMI (11.1 and 14.3 months, P= 0.18). Multivariate analyses confirmed that low SMD was an independent predictor of poor outcomes (P{\textless}0.01). SMD is an important prognosticator of survival in patients with metastatic gastric cancer receiving chemotherapy.},
	language = {en},
	journal = {ONCOLOGY REPORTS},
	author = {Hayashi, Naomi and Ando, Yuichi and Gyawali, Bishal and Shimokata, Tomoya and Maeda, Osamu and Fukaya, Masahide and Goto, Hidemi and Nagino, Masato and Kodera, Yasuhiro},
	year = {2016},
	pages = {6},
	file = {Hayashi et al. - 2016 - Low skeletal muscle density is associated with poo.pdf:/Users/jcsal/Zotero/storage/67BG8IY8/Hayashi et al. - 2016 - Low skeletal muscle density is associated with poo.pdf:application/pdf},
}

@article{gerard12,
	title = {{BODY} {COMPOSITION} {AND} {ANTI}-{NEOPLASTIC} {TREATMENT} {IN} {ADULT} {AND} {OLDER} {SUBJECTS} - {A} {SYSTEMATIC} {REVIEW}},
	abstract = {Background: The estimation of the risk of poor tolerance and overdose of antineoplastic agents protocols represents a major challenge in oncology, particularly in older patients. We hypothesize that agerelated modifications of body composition (i.e. increased fat mass and decreased lean mass) may significantly affect tolerance to chemotherapy. Method: We conducted a systematic review for the last 25 years (between 1990 and 2015), using US National library of Medicine Medline electronic bibliographic database and Embase database of cohorts or clinical trials exploring (i) the interactions of body composition (assessed by Dual X-ray Absorptiometry, Bioelectrical Impedance Analyses, or Computerized Tomography) with pharmacokinetics parameters, (ii) the tolerance to chemotherapy, and (iii) the consequences of chemotherapies or targeted therapies on body composition. Results: Our search identified 1879 articles. After a selection (using pre-established criteria) on titles and abstract, 24 original articles were selected with 3 domains of interest: impact of body composition on pharmacokinetics (7 articles), relationship between body composition and chemotoxicity (14 articles), and effect of anti-cancer chemotherapy on body composition (11 articles). The selected studies suggested that pharmacokinetic was influenced by lean mass, that lower lean mass could be correlated with toxicity, and that sarcopenic patients experienced more toxicities that non-sarcopenic patients. Regarding fat mass, results were less conclusive. No studies specifically explored the topic of body composition in older cancer patients. Conclusions: Plausible pathophysiological pathways linking body composition, toxicity, and pharmacokinetics are sustained by the actual review. However, despite the growing number of older cancer patients, our review highlighted the lack of specific studies in the field of anti-neoplastic agents toxicity regarding body composition conducted in elderly.},
	language = {en},
	journal = {J Nutr Health Aging},
	author = {Gérard, S and Bréchemier, D and Lefort, A and Lozano, S and Kan, G Abellan Van and Filleron, T and Mourey, L and Bernard-Marty, C and Rougé-Bugat, M E and Soler, V and Vellas, B and Cesari, M and Rolland, Y and Balardy, L},
	pages = {12},
	file = {Gérard et al. - BODY COMPOSITION AND ANTI-NEOPLASTIC TREATMENT IN .pdf:/Users/jcsal/Zotero/storage/ADAZ4FW6/Gérard et al. - BODY COMPOSITION AND ANTI-NEOPLASTIC TREATMENT IN .pdf:application/pdf},
}

@article{devasconcellos8,
	title = {Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status},
	abstract = {Background: The benefit of palliative chemotherapy (PC) in patients with advanced solid tumors and poor performance status (ECOG-PS) has not been prospectively validated, which makes treatment decision challenging. We aimed to evaluate the overall survival, factors associated with early mortality, and adoption of additional procedures in hospitalized patients with advanced cancer and poor ECOG-PS treated with PC.
Methods: We analyzed a retrospective cohort of patients with advanced cancer treated with PC during hospitalization at an academic cancer center in Brazil from 2014 to 2016. Eligibility criteria included: ECOG-PS 3–4 and start of first-line PC; or ECOG-PS ≥ 2 and start of second or subsequent lines. Primary endpoint was 30-day survival from start of PC. Kaplan-Meier method was used for survival estimates and Cox regression for factors associated with 30-day mortality.
Results: Two hundred twenty-eight patients were eligible. 21.9, 66.7 and 11.4\% of patients had ECOG-PS 2, 3 and 4, respectively. 49.6\% had gastrointestinal tumors. Median follow-up was 49 days (range 1–507). 98.2\% of patients had died, 32\% during the index hospitalization. The 30-day and 60-day survival rates were 55.7 and 38.5\%, respectively. 30\% of patients were admitted to the intensive care unit. In a multivariable analysis, ECOG-PS 3/4 (HR 2.01; P = 0.016), hypercalcemia (HR 2.19; P = 0.005), and elevated bilirubin (HR 3.17; P {\textless} 0.001) were significantly associated with 30-day mortality.
Conclusions: Patients with advanced cancer and poor ECOG-PS had short survival after treatment with inpatient PC. Inpatient PC was associated with aggressive end-of-life care. Prognostic markers such as ECOG-PS, hypercalcemia and elevated bilirubin can contribute to the decision-making process for these patients.},
	language = {en},
	author = {de Vasconcellos, Vitor Fiorin and Bonadio, Renata RCC and Avanço, Guilherme and Negrão, Marcelo Vailati and Riechelmann, Rachel Pimenta},
	year = {2019},
	pages = {8},
	file = {de Vasconcellos et al. - 2019 - Inpatient palliative chemotherapy is associated wi.pdf:/Users/jcsal/Zotero/storage/ITQJIV9B/de Vasconcellos et al. - 2019 - Inpatient palliative chemotherapy is associated wi.pdf:application/pdf},
}

@article{wallington14,
	title = {30-day mortality after systemic anticancer treatment for breast and lung cancer in {England}: a population-based, observational study},
	volume = {17},
	abstract = {Background 30-day mortality might be a useful indicator of avoidable harm to patients from systemic anticancer treatments, but data for this indicator are limited. The Systemic Anti-Cancer Therapy (SACT) dataset collated by Public Health England allows the assessment of factors aﬀecting 30-day mortality in a national patient population. The aim of this ﬁrst study based on the SACT dataset was to establish national 30-day mortality benchmarks for breast and lung cancer patients receiving SACT in England, and to start to identify where patient care could be improved.},
	language = {en},
	author = {Wallington, Michael},
	year = {2016},
	pages = {14},
	file = {Wallington - 2016 - 30-day mortality after systemic anticancer treatme.pdf:/Users/jcsal/Zotero/storage/6AB7IL9T/Wallington - 2016 - 30-day mortality after systemic anticancer treatme.pdf:application/pdf},
}

@article{rijssen9,
	title = {Skeletal {Muscle} {Quality} is {Associated} with {Worse} {Survival} {After} {Pancreatoduodenectomy} for {Periampullary}, {Nonpancreatic} {Cancer}},
	abstract = {Background. Body composition measures may predict outcomes of cancer surgery. Whereas low muscle mass shown on preoperative computed tomography (CT) scans has been associated with worse outcomes after surgery for pancreatic cancer, less consideration has been given to low muscle attenuation, reﬂecting poor muscle quality. Studies relating muscle mass and muscle attenuation with outcomes for patients with periampullary, nonpancreatic cancer are lacking.},
	language = {en},
	author = {Rijssen, L B Van and Haverkort, E B and Nio, C Y and Busch, O R and Besselink, M G},
	pages = {9},
	file = {Rijssen et al. - Skeletal Muscle Quality is Associated with Worse S.pdf:/Users/jcsal/Zotero/storage/CR8ULY6I/Rijssen et al. - Skeletal Muscle Quality is Associated with Worse S.pdf:application/pdf},
}

@article{dijk10,
	title = {Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer},
	abstract = {Background Cancer cachexia and skeletal muscle wasting are related to poor survival. In this study, quantitative body composition measurements using computed tomography (CT) were investigated in relation to survival, post-operative complications, and surgical site infections in surgical patients with cancer of the head of the pancreas.
Methods A prospective cohort of 199 patients with cancer of the head of the pancreas was analysed by CT imaging at the L3 level to determine (i) muscle radiation attenuation (average Hounsﬁeld units of total L3 skeletal muscle); (ii) visceral adipose tissue area; (iii) subcutaneous adipose tissue area; (iv) intermuscular adipose tissue area; and (v) skeletal muscle area. Sexspeciﬁc cut-offs were determined at the lower tertile for muscle radiation attenuation and skeletal muscle area and the higher tertile for adipose tissues. These variables of body composition were related to overall survival, severe post-operative complications (Dindo–Clavien ≥ 3), and surgical site infections (wounds inspected daily by an independent trial nurse) using Coxregression analysis and multivariable logistic regression analysis, respectively.
Results Low muscle radiation attenuation was associated with shorter survival in comparison with moderate and high muscle radiation attenuation [median survival 10.8 (95\% CI: 8.8–12.8) vs. 17.4 (95\% CI: 14.7–20.1), and 18.5 (95\% CI: 9.2–27.8) months, respectively; P {\textless} 0.008]. Patient subgroups with high muscle radiation attenuation combined with either low visceral adipose tissue or age {\textless}70 years had longer survival than other subgroups (P = 0.011 and P = 0.001, respectively). Muscle radiation attenuation was inversely correlated with intermuscular adipose tissue (rp = À0.697, P {\textless} 0.001). High visceral adipose tissue was associated with an increased surgical site infection rate, OR: 2.4 (95\% CI: 1.1–5.3; P = 0.027).
Conclusions Low muscle radiation attenuation was associated with reduced survival, and high visceral adiposity was associated with an increase in surgical site infections. The strong correlation between muscle radiation attenuation and intermuscular adipose tissue suggests the presence of ectopic fat in muscle, warranting further investigation. CT image analysis could be implemented in pre-operative risk assessment to assist in treatment decision-making.},
	language = {en},
	author = {Dijk, David P J},
	pages = {10},
	file = {Dijk - Low skeletal muscle radiation attenuation and visc.pdf:/Users/jcsal/Zotero/storage/T3X28F6Q/Dijk - Low skeletal muscle radiation attenuation and visc.pdf:application/pdf},
}

@article{shachar8,
	title = {Body {Composition} as a {Predictor} of {Toxicity} in {Patients} {Receiving} {Anthracycline} and {Taxane}–{Based} {Chemotherapy} for {Early}-{Stage} {Breast} {Cancer}},
	abstract = {Purpose: Poor body composition metrics (BCM) are associated with inferior cancer outcomes; however, in early breast cancer (EBC), there is a paucity of evidence regarding the impact of BCM on toxicities. This study investigates associations between BCM and treatment-related toxicity in patients with EBC receiving anthracyclines and taxane–based chemotherapy.},
	language = {en},
	journal = {Clinical Cancer Research},
	author = {Shachar, Shlomit Strulov and Deal, Allison M and Weinberg, Marc and Williams, Grant R and Nyrop, Kirsten A and Popuri, Karteek and Choi, Seul Ki and Muss, Hyman B},
	pages = {8},
	file = {Shachar et al. - Body Composition as a Predictor of Toxicity in Pat.pdf:/Users/jcsal/Zotero/storage/7F5Q3B9Q/Shachar et al. - Body Composition as a Predictor of Toxicity in Pat.pdf:application/pdf},
}

@article{seo9,
	title = {Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients},
	abstract = {Background: Malnutrition in gastrectomized patients receiving chemotherapy is associated with the susceptibility to chemotherapy-related adverse events. This study evaluated pre-operative nutritional status-related indices associated with adverse events in post-operation gastric cancer patients receiving chemotherapy.
Methods: Medical records of 234 gastrectomized patients under adjuvant tegafur/gimeracil/oteracil chemotherapy with extended lymph node dissection were analyzed. Nutritional status assessment included Patient-Generated Subjective Global Assessment (PG-SGA), body weight, body mass index, serum albumin concentration, and Nutrition Risk Index (NRI). Chemotherapy-originated adverse events were determined using Common Terminology Criteria for Adverse Events.
Results: PG-SGA indicated 59\% of the patients were malnourished, and 27.8\% of the patients revealed serious malnutrition with PG-SGA score of ≥9. Fifteen \% of patients lost ≥10\% of the initial body weight, 14.5\% of the patients had hypoalbuminemia ({\textless}3.5 g/dL), and 66.2\% had NRI score less than 97.5 indicating moderate to severe malnutrition. Hematological adverse events were present in 94\% (≥grade 1) and 16.2\% (≥grade 3). Non-hematological adverse events occurred in 95.7\% (≥grade1) and 16.7\% (≥grade 3) of the patients. PG-SGA and NRI score was not associated with treatment-induced adverse events. Multivariate analyses indicated that female, low body mass index, and hypoalbuminemia were independent risk factors for grade 3/4 hematological adverse events. Age was an independent risk factor for grade 3/4 non-hematological adverse events. Neutropenia was the most frequently occurring adverse event, and associated risk factors were female, total gastrectomy, and hypoalbuminemia.
Conclusions: Hypoalbuminemia, not PG-SGA or NRI may predict chemotherapy-induced adverse events in gastrectomized cancer patients.},
	language = {en},
	author = {Seo, Seung Hee},
	year = {2016},
	pages = {9},
	file = {Seo - 2016 - Association of nutritional status-related indices .pdf:/Users/jcsal/Zotero/storage/XGRI5CE7/Seo - 2016 - Association of nutritional status-related indices .pdf:application/pdf},
}

@article{schnipper10,
	title = {American {Society} of {Clinical} {Oncology} {Identifies} {Five} {Key} {Opportunities} to {Improve} {Care} and {Reduce} {Costs}: {The} {Top} {Five} {List} for {Oncology}},
	language = {en},
	journal = {JOURNAL OF CLINICAL ONCOLOGY},
	author = {Schnipper, Lowell E and Smith, Thomas J and Raghavan, Derek and Blayney, Douglas W and Ganz, Patricia A and Mulvey, Therese Marie and Wollins, Dana S},
	pages = {10},
	file = {Schnipper et al. - American Society of Clinical Oncology Identifies F.pdf:/Users/jcsal/Zotero/storage/WX3I9Q2W/Schnipper et al. - American Society of Clinical Oncology Identifies F.pdf:application/pdf},
}

@article{shachar18,
	title = {Skeletal {Muscle} {Measures} as {Predictors} of {Toxicity}, {Hospitalization}, and {Survival} in {Patients} with {Metastatic} {Breast} {Cancer} {Receiving} {Taxane} {Based} {Chemotherapy}},
	abstract = {Purpose—Severe skeletal muscle (SM) loss (sarcopenia), is associated with poor cancer outcomes including reduced survival and increased toxicity. This study investigates SM measures in metastatic breast cancer (MBC) patients receiving first line taxane-based chemotherapy and evaluates associations with treatment toxicity and other outcomes. Experimental Design—Using computerized tomography (CT) images taken for the evaluation of disease burden, skeletal muscle area (SMA) and density (SMD) were measured at the 3rd lumbar vertebrae. Sarcopenia was defined as Skeletal Muscle Index (SMI=SMA/height2) ≤41. Skeletal Muscle Gauge (SMG) was created by multiplying SMI x SMD. Fisher’s exact tests, ttests, the Kaplan-Meier method, and Cox regression modeling were used.
Results—MBC patients (N=40), median age 55 (rang 34–80), 58\% sarcopenic, median SMG 1296 AU (SD 522). Grade 3–4 toxicity was found in 57\% of sarcopenic vs 18\% of non-sarcopenic patients (p=0.02). Toxicity-related hospitalizations were also higher in sarcopenic patients (39\% vs 0\%, p=0.005) as were any adverse events -- defined as any grade 3–4 toxicities, hospitalizations, dose reductions, or dose delay -- (74\% vs 35\%, p=0.02). Low SMG was associated with grade 3–4 toxicity (p=0.04), hospitalization (p=0.01) and time to treatment failure (for progression or toxicity) (p=0.03). Low SMG had a borderline significant association with any adverse event (p=0.06) and overall survival (p=0.07).
Conclusions—SM measures are associated with toxicity outcomes and survival in MBC patients receiving first line taxane-based chemotherapy. Further studies are needed to explore how routinely obtained CT scans can be used to individualize dosing and improve treatment planning.},
	language = {en},
	author = {Shachar, Shlomit Strulov and Deal, Allison M and Weinberg, Marc and Nyrop, Kirsten A and Williams, Grant R and Nishijima, Tomohiro F and Benbow, Julia M and Muss, Hyman B},
	year = {2017},
	pmcid = {PMC5290138},
	pmid = {27489287},
	note = {tex.ids= shachar658},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Hospitalization, Middle Aged, Sarcopenia, Body Mass Index, Follow-Up Studies, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, Prognosis, Organ Size, Aged, 80 and over, Adult, Body Surface Area, Adenocarcinoma, Taxoids, Breast Neoplasms, SMG, Antineoplastic Agents, Phytogenic, Specific Gravity},
	pages = {18},
	file = {Shachar et al_2017_Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and.pdf:/Users/jcsal/Zotero/storage/TI3YQS8Q/Shachar et al_2017_Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and.pdf:application/pdf;Shachar et al. - 2017 - Skeletal Muscle Measures as Predictors of Toxicity.pdf:/Users/jcsal/Zotero/storage/C7UYKN8V/Shachar et al. - 2017 - Skeletal Muscle Measures as Predictors of Toxicity.pdf:application/pdf},
}

@article{ryan14,
	title = {Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later},
	language = {en},
	journal = {Proceedings of the Nutrition Society},
	author = {Ryan, Aoife M and Power, Derek G and Daly, Louise and Cushen, Samantha J and Prado, Carla M},
	pages = {14},
	file = {Ryan et al. - Cancer-associated malnutrition, cachexia and sarco.pdf:/Users/jcsal/Zotero/storage/ZPAA8KGX/Ryan et al. - Cancer-associated malnutrition, cachexia and sarco.pdf:application/pdf},
}

@article{rosa-caldwell17,
	title = {Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review},
	language = {en},
	journal = {J Appl Physiol},
	author = {Rosa-Caldwell, Megan E and Fix, Dennis K and Washington, Tyrone A and Greene, Nicholas P},
	pages = {17},
	file = {Rosa-Caldwell et al. - Muscle alterations in the development and progress.pdf:/Users/jcsal/Zotero/storage/H9M6GYRI/Rosa-Caldwell et al. - Muscle alterations in the development and progress.pdf:application/pdf},
}

@article{kim5,
	title = {Prognostic {Significance} of {CT}-{Determined} {Sarcopenia} in {Patients} with {Small}-{Cell} {Lung} {Cancer}},
	volume = {10},
	abstract = {Introduction: The primary objective of this study was to determine the prognostic significance of computed tomography (CT)determined sarcopenia in small-cell lung cancer (SCLC) patients.
Methods: This retrospective study consisted of a total of 149 consecutive SCLC patients. The cross-sectional area of muscle at the level of the third lumbar vertebra (L3) was measured using baseline CT images. Sarcopenia was defined as a L3 muscle index of less than 55 cm2/m2 for men and of less than 39 cm2/m2 for women as proposed by international consensus of cancer cachexia. In addition, Korean-specific cutoffs for sarcopenia was also applied (49 cm2/m2 for men and 31 cm2/m2 for women). Overall survival (OS) and clinical characteristics of patients with or without sarcopenia were compared.
Results: Mean patient age was 68.6 ± 9.5 years. Most were male (85.3\%) and 67.8\% had extensive disease at time of diagnosis. Sarcopenia was present in 118 patients (79.2\%) and was significantly related to an advanced age (p = 0.028), male sex (p {\textless} 0.001), lower body mass index (p {\textless} 0.001), and poor performance status (p = 0.049). Sarcopenic patients had shorter OS than nonsarcopenic patients (median: 8.6 months versus 16.8 months; p = 0.031). Multivariable analysis revealed that sarcopenia was an independent prognostic factor of poor survival (hazards ratio: 1.68; 95\% confidence interval: 1.04–2.72; p = 0.034), along with extensive stage (p {\textless} 0.001), supportive care only (p {\textless} 0.001), and an elevated lactate dehydrogenase level (p = 0.020). Using Korean sarcopenia cutoffs, sarcopenic patients were also found to have poorer OS than nonsarcopenic patients, however, the survival difference was not statistically significant (median: 8.4 months versus 12.7 months; p = 0.144 by the log-rank test).
Conclusions: Sarcopenia as determined by CT could be used to predict prognosis in patients with SCLC. Optimum reference values},
	language = {en},
	number = {12},
	journal = {Journal of Thoracic Oncology},
	author = {Kim, Eun Young},
	year = {2015},
	pages = {5},
	file = {Kim - 2015 - Prognostic Significance of CT-Determined Sarcopeni.pdf:/Users/jcsal/Zotero/storage/CSSRKH2Y/Kim - 2015 - Prognostic Significance of CT-Determined Sarcopeni.pdf:application/pdf},
}

@article{katoh20,
	title = {Prediction models for patients with esophageal or gastric cancer: {A} systematic review and meta-analysis},
	abstract = {Background Clinical prediction models are increasingly used to predict outcomes such as survival in cancer patients. The aim of this study was threefold. First, to perform a systematic review to identify available clinical prediction models for patients with esophageal and/or gastric cancer. Second, to evaluate sources of bias in the included studies. Third, to investigate the predictive performance of the prediction models using meta-analysis.},
	language = {en},
	author = {Katoh, Masaru},
	pages = {20},
	file = {Katoh - Prediction models for patients with esophageal or .pdf:/Users/jcsal/Zotero/storage/DF5QDYU7/Katoh - Prediction models for patients with esophageal or .pdf:application/pdf},
}

@article{pamoukdjian13,
	title = {Frailty {Parameters}, {Morbidity} and {Mortality} in {Older} {Adults} with {Cancer}: {A} {Structural} {Equation} {Modelling} {Approach} {Based} on the {Fried} {Phenotype}},
	abstract = {Background: to distinguish direct and indirect pathways to frailty phenotype, and quantify associations between two frailty components (i.e., sarcopenia and cachexia) regarding mortality and morbidity in older adults with cancer. Methods: all consecutive older outpatients with cancer were included in a prospective two-centre cohort study between 2013 and 2017 and had geriatric assessment. We used the frailty phenotype. Sarcopenia and cachexia were built as latent variables by including observed variables related to physical performances and related to nutrition and inﬂammation respectively. Structural equation modelling was used to distinguish between direct and indirect eﬀects of the frailty parameters on the risk of death (Model 1) and the risk of morbidity (deﬁned by unplanned hospitalization and/or disability and/or a fall; Model 2). The root mean square error of approximation (RMSEA) and the comparative ﬁt index (CFI) were used to assess the model ﬁt. Results: 603 older outpatients were included (mean age: 81.2 ± 6.1; women: 54\%; frailty phenotype: 58\%). The 6-month mortality and morbidity rates were 18\% and 64\%, respectively. The ﬁt was good for both models (RMSEA and CFI = 0.029 [0.017–0.039] and 0.99 for Model 1, and 0.028 [0.017–0.039] and 0.99 for Model 2, respectively). Sarcopenia and cachexia were both directly and signiﬁcantly associated with 6-month mortality (βsarcopenia = 0.18, p = 0.01; βcachexia = 0.52, p {\textless} 0.0001) and morbidity (βsarcopenia = 0.37, p {\textless} 0.0001; βcachexia = 0.19, p {\textless} 0.02). Conclusions: sarcopenia and cachexia had a direct pathway with 6-month mortality and morbidity in older cancer patients.},
	language = {en},
	author = {Pamoukdjian, Frederic and Laurent, Marie and Martinez-Tapia, Claudia and Rolland, Yves and Paillaud, Elena and Canoui-Poitrine, Florence},
	year = {2020},
	pages = {13},
	file = {Pamoukdjian et al. - 2020 - Frailty Parameters, Morbidity and Mortality in Old.pdf:/Users/jcsal/Zotero/storage/4LWPLMHM/Pamoukdjian et al. - 2020 - Frailty Parameters, Morbidity and Mortality in Old.pdf:application/pdf},
}

@article{onishi14,
	title = {Prognostic {Impact} of {Sarcopenic} {Obesity} after {Neoadjuvant} {Chemotherapy} {Followed} by {Surgery} in {Elderly} {Patients} with {Esophageal} {Squamous} {Cell} {Carcinoma}},
	abstract = {We evaluated the impact of body composition on clinical outcomes after neoadjuvant chemotherapy (NAC) followed by surgery for elderly cStage II/III esophageal squamous cell carcinoma (ESCC). Ninety-one patients ≥70 years old and 116 patients {\textless}70 years old with ECSS who underwent NAC between January 2013 and June 2018 at the Aichi Cancer Center were included. Body composition as assessed from computed tomography (CT), American Society of Anesthesiologists physical status (ASA-PS), and subjective global assessment (SGA) was assessed before initiation of NAC. Although elderly patients showed signiﬁcantly poorer ASA-PS (p {\textless} 0.01) and SGA (p {\textless} 0.01), and signiﬁcantly more frequent history of malignancy (p {\textless} 0.05), no signiﬁcant diﬀerences were identiﬁed in the frequencies of adverse events, postoperative complications, or in cancer-speciﬁc survival (p = 0.65, hazard ratio 1.15), or overall survival (p = 0.42, hazard ratio 1.26). However, multivariate analysis identiﬁed sarcopenic obesity as the only independent predictor of prognosis in elderly patients. Sarcopenic obesity was associated with higher body mass index (p = 0.04), better SGA (p {\textless} 0.01), and lower pre-treatment weight loss (p = 0.03). NAC was as eﬀective and safe for elderly patients without sarcopenic obesity as for young patients. However, diagnosing sarcopenic obesity based on clinical ﬁndings is diﬃcult, so the preoperative CT assessment of sarcopenic obesity is important.},
	language = {en},
	author = {Onishi, Sachiyo and Tajika, Masahiro and Tanaka, Tsutomu and Yamada, Keisaku and Abe, Tetsuya and Higaki, Eiji and Hosoi, Takahiro and Inaba, Yoshitaka and Muro, Kei and Shimizu, Masahito and Niwa, Yasumasa},
	year = {2020},
	pages = {14},
	file = {Onishi et al. - 2020 - Prognostic Impact of Sarcopenic Obesity after Neoa.pdf:/Users/jcsal/Zotero/storage/QCFYGJZA/Onishi et al. - 2020 - Prognostic Impact of Sarcopenic Obesity after Neoa.pdf:application/pdf},
}

@article{norman8,
	title = {Hand grip strength: {Outcome} predictor and marker of nutritional status},
	abstract = {Background \& aims: Among all muscle function tests, measurement of hand grip strength has gained attention as a simple, non-invasive marker of muscle strength of upper extremities, well suitable for clinical use. This review outlines the prognostic relevance of grip strength in various clinical and epidemiologic settings and investigates its suitability as marker of nutritional status in cross-sectional as well as intervention studies.},
	language = {en},
	journal = {Clinical Nutrition},
	author = {Norman, Kristina},
	year = {2011},
	pages = {8},
	file = {Norman - 2011 - Hand grip strength Outcome predictor and marker o.pdf:/Users/jcsal/Zotero/storage/QURQCWPL/Norman - 2011 - Hand grip strength Outcome predictor and marker o.pdf:application/pdf},
}

@article{newman6,
	title = {Strength, {But} {Not} {Muscle} {Mass}, {Is} {Associated} {With} {Mortality} in the {Health}, {Aging} and {Body} {Composition} {Study} {Cohort}},
	abstract = {Background. Although muscle strength and mass are highly correlated, the relationship between direct measures of low muscle mass (sarcopenia) and strength in association with mortality has not been examined.
Methods. Total mortality rates were examined in the Health, Aging and Body Composition (Health ABC) Study in 2292 participants (aged 70–79 years, 51.6\% women, and 38.8\% black). Knee extension strength was measured with isokinetic dynamometry, grip strength with isometric dynamometry. Thigh muscle area was measured by computed tomography (CT) scan, and leg and arm lean soft tissue mass were determined by dual energy x-ray absorptiometry (DXA). Both strength and muscle size were assessed as in gender-speciﬁc Cox proportional hazards models, with age, race, comorbidities, smoking status, level of physical activity, fat area by CT or fat mass by DXA, height, and markers of inﬂammation, including interleukin-6, C-reactive protein, and tumor necrosis factor-a considered as potential confounders.
Results. There were 286 deaths over an average of 4.9 (standard deviation ¼ 0.9) years of follow-up. Both quadriceps and grip strength were strongly related to mortality. For quadriceps strength (per standard deviation of 38 Nm), the crude hazard ratio for men was 1.51 (95\% conﬁdence interval, 1.28–1.79) and 1.65 (95\% conﬁdence interval, 1.19–2.30) for women. Muscle size, determined by either CT area or DXA regional lean mass, was not strongly related to mortality. In the models of quadriceps strength and mortality, adjustment for muscle area or regional lean mass only slightly attenuated the associations. Further adjustment for other factors also had minimal effect on the association of quadriceps strength with mortality. Associations of grip strength with mortality were similar.
Conclusion. Low muscle mass did not explain the strong association of strength with mortality, demonstrating that muscle strength as a marker of muscle quality is more important than quantity in estimating mortality risk. Grip strength provided risk estimates similar to those of quadriceps strength.},
	language = {en},
	author = {Newman, Anne B and Kupelian, Varant and Visser, Marjolein and Simonsick, Eleanor M and Goodpaster, Bret H and Kritchevsky, Stephen B and Tylavsky, Frances A and Rubin, Susan M and Harris, Tamara B},
	pages = {6},
	file = {Newman et al. - Strength, But Not Muscle Mass, Is Associated With .pdf:/Users/jcsal/Zotero/storage/UIIHSED4/Newman et al. - Strength, But Not Muscle Mass, Is Associated With .pdf:application/pdf},
}

@article{nakata7,
	title = {Outcomes of {Cervical} {End}-to-{Side} {Triangulating} {Esophagogastric} {Anastomosis} with {Minimally} {Invasive} {Esophagectomy}},
	abstract = {Background Esophagogastric anastomosis after esophagectomy has been performed with a variety of techniques during the past decade. However, anastomotic leakage and stricture are still important clinical problems after esophagogastric anastomosis, causing burdensome symptoms and poor quality of life. Herein, we describe a novel cervical end-to-side triangulating esophagogastric anastomoasis using linear stapler.
Methods A total of 90 patients (85 \% male; mean age 63 years) with thoracic esophageal cancer who underwent cervical end-to-side esophagogastric triangular anastomosis using a linear stapler after minimally invasive esophagectomy between November 2006 and April 2013 were retrospectively reviewed.
Results The median operation time was 602 min (range 424–936 min). The volume of blood loss during the entire operative procedure was 127 ml (range 0–700 ml). There were no cases of anastomotic leakage in this study, although four patients (4.4 \%) developed dysphagia associated with benign anastomotic stricture formation. All patients with a benign anastomotic stricture underwent balloon dilation, which resulted in improvement in their symptoms.
Conclusions Considering the absence of anastomotic leakage and low rate of anastomotic stricture formation in this study, our modiﬁed triangular esophagogastric anastomosis technique appears promising and may contribute to reduced morbidity and mortality rates following esophagectomy.},
	language = {en},
	journal = {World J Surg},
	author = {Nakata, Kohei and Nagai, Eishi and Ohuchida, Kenoki and Nakamura, Katsuya and Tanaka, Masao},
	year = {2015},
	pages = {7},
	file = {Nakata et al. - 2015 - Outcomes of Cervical End-to-Side Triangulating Eso.pdf:/Users/jcsal/Zotero/storage/MJS25W4S/Nakata et al. - 2015 - Outcomes of Cervical End-to-Side Triangulating Eso.pdf:application/pdf},
}

@article{cooper8,
	title = {Characterization of {Anthropometric} {Changes} that {Occur} {During} {Neoadjuvant} {Therapy} for {Potentially} {Resectable} {Pancreatic} {Cancer}},
	abstract = {Background. Little is known about changes in body composition that may occur during neoadjuvant therapy for pancreatic cancer. This study was designed to characterize these changes and their potential relationships with therapeutic outcomes.},
	language = {en},
	author = {Cooper, Amanda B and Slack, Rebecca and Fogelman, David and Holmes, Holly M and Petzel, Maria and Parker, Nathan and Balachandran, Aparna and Garg, Naveen and Ngo-Huang, An and Varadhachary, Gauri and Evans, Douglas B and Lee, Jeffrey E and Aloia, Thomas and Conrad, Claudius and Vauthey, Jean-Nicolas and Fleming, Jason B and Katz, Matthew H G},
	pages = {8},
	file = {Cooper et al. - Characterization of Anthropometric Changes that Oc.pdf:/Users/jcsal/Zotero/storage/7WWM6EAL/Cooper et al. - Characterization of Anthropometric Changes that Oc.pdf:application/pdf},
}

@article{bril8,
	title = {Interobserver agreement of skeletal muscle mass measurement on head and neck {CT} imaging at the level of the third cervical vertebra},
	abstract = {Objectives  Skeletal muscle mass (SMM) is most often assessed in cancer patients on abdominal computed tomography (CT) imaging at the level of the third lumbar vertebra (L3). Abdominal CT imaging is not routinely performed in head and neck cancer (HNC) patients. Recently, a novel method to assess SMM on a single transversal CT slice at the level of the third cervical vertebra (C3) was published. The objective of this study was to assess the robustness of this novel C3 measurement method in terms of interobserver agreement. Patients and methods  Patients diagnosed with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at our center between 2007 and 2011 were evaluated. Fifty-four patients with were randomly selected for analysis. Six observers independently measured the cross-sectional muscle area (CSMA) at the level of C3 using a predefined, written protocol as instruction. Interobserver agreement was assessed using intraclass correlation coefficients (ICCs), a Bland–Altman plot and Fleiss’ kappa (κ).
Results  The agreement in vertebra selection between all observers was excellent (Fleiss’ κ: 0.96). There was a substantial agreement between all observers in single slice selection (Fleiss’ κ: 0.61). For all CSMA measurements, ICCs were excellent (0.763–0.969; all p {\textless} 0.001). The Bland–Altman plot showed good agreement between measurements, with narrow limits of agreement.
Conclusion  Interobserver agreement for SMM measurement at the level of C3 was excellent. Assessment of SMM at the level of C3 is easy and robust and can performed on routinely available imaging in HNC patients.},
	language = {en},
	author = {Bril, S I},
	year = {2019},
	pages = {8},
	annote = {Annotations(8/3/2022, 7:58:06 PM)
“Delineation of CSMA was manually performed using the Volumetool v.1.6.5 Research Software Package, designed in our center as an image evaluation, registration, and delineation system for radiotherapy planning [25].” (Bril, 2019, p. 1176)“Differences in skeletal muscle area measurements between observers were calculated using a repeated measures ANOVA. Agreement between different observers was assessed by calculating Fleiss’ kappa (κ) and intraclass correlation coefficients (ICCs) using a two-way mixed single measures model with absolute agreement and. The κ values were graded as slight (0.01–0.20), fair (0.21–0.40), moderate (0.41–0.60), substantial (0.61–0.80), or almost perfect (0.81–0.99) agreement [26]. The ICCs were rated as poor (0.00–0.49), fair to good (0.50–0.74), and excellent (0.75–1.00) [27]. Bland–Altman plots were constructed to visualize agreement [28].” (Bril, 2019, p. 1177)“org/10.1245/s10434-010-0985-4 25. Bol GH, Kotte A, Lagendijk JJW (2003) Volumetool. An image evaluation, registration, and delineation system for radiotherapy. Phys Med 19:80” (Bril, 2019, p. 1182)“27. Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428 28. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307–310” (Bril, 2019, p. 1182)},
	file = {Bril - 2019 - Interobserver agreement of skeletal muscle mass me.pdf:/Users/jcsal/Zotero/storage/VPYBEXJB/Bril - 2019 - Interobserver agreement of skeletal muscle mass me.pdf:application/pdf},
}

@article{dahya7,
	title = {Computed tomography–derived skeletal muscle index: {A} novel predictor of frailty and hospital length of stay after transcatheter aortic valve replacement},
	volume = {182},
	abstract = {Objectives To determine the prevalence of low skeletal muscle mass in patients undergoing transcatheter aortic valve replacement (TAVR) and whether skeletal muscle mass measured from preoperative computed tomography (CT) images provides value in predicting postoperative length of stay (LOS).
Background There are limited data on the use of body composition as a frailty measure in TAVR patients and no studies have determined if this measure predicts LOS.
Methods We studied 104 consecutive patients who underwent TAVR at Tallahassee Memorial Hospital from 2012 to 2016. Patient demographics, standard frailty measures (hand grip, albumin, and 5-m walk test), clinical comorbidities, echocardiographic data, and Valve Academic Research Consortium II major complications were recorded prospectively. Skeletal muscle index (SMI) [skeletal muscle mass cross-sectional area at L3/height2] was measured from CT images using Slice-O-Matic software (Tomovision, Montreal, Quebec, Canada). Clinical outcomes were assessed and multivariate methods used to determine predictors of LOS.
Results Sarcopenia was prevalent in men (83\%) and women (56\%). Patients who suffered from a major complication had significantly longer length of stay (13 vs 4.6 days, P b .0001). Skeletal muscle index correlated with age, sex, body mass index, handgrip strength, and previous coronary artery bypass graft surgery, but not major complications. A multivariate model including all univariate predictors of LOS showed SMI, major complications, transapical access, atrial fibrillation, and chronic obstructive pulmonary syndrome as independent predictors of LOS. For every 14-cm2/m2 increase in SMI, there was a 1-day reduction in LOS. None of the standard measures of frailty predicted LOS.
Conclusions Skeletal muscle index, a measure of sarcopenia readily determined from pre-TAVR CT scans, independently predicts TAVR LOS better than standard frailty testing. Further evaluation of SMI as a frailty measure after TAVR and other cardiovascular procedures is warranted. (Am Heart J 2016;182:21-7.)},
	language = {en},
	journal = {American Heart Journal},
	author = {Dahya, Vishal and Xiao, Jingjie and Prado, Carla M and Burroughs, Penny and McGee, Dan and Silva, Aline C and Hurt, Julian E and Mohamed, Shafi G and Noel, Thomas and Batchelor, Wayne},
	year = {2016},
	pages = {7},
	annote = {Annotations(7/30/2022, 12:44:10 PM)
(Dahya et al., 2016, p. 21) Sarcopenia (Prado) assoc with LOS after TAVR()
},
	annote = {Annotations(7/30/2022, 12:46:51 PM)
(Dahya et al., 2016, p. 21) Sarcopenia (Prado) assoc with LOS after TAVR},
	annote = {Another note() here
“There are limited data on the use of body composition as a frailty measure in TAVR patients and no studies have determined if this measure predicts LOS.” (Dahya et al., 2016, p. 21)

},
	file = {Dahya et al. - 2016 - Computed tomography–derived skeletal muscle index.pdf:/Users/jcsal/Zotero/storage/TXQKBX4M/Dahya et al. - 2016 - Computed tomography–derived skeletal muscle index.pdf:application/pdf},
}

@article{li539,
	title = {Peritoneal {Metastases} from {Malignant} {Mesothelioma}},
	volume = {27},
	issn = {1558-5042},
	doi = {10.1016/j.soc.2018.02.010},
	abstract = {Diffuse malignant peritoneal mesothelioma (MPM) is a rare cancer that is ultimately fatal in almost all afflicted individuals. Morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. Patients with MPM most commonly present with nonspecific abdominal symptoms that usually lead to diagnosis when the condition is relatively advanced. MPM is considered a chemotherapy-resistant malignancy.},
	language = {eng},
	number = {3},
	journal = {Surgical Oncology Clinics of North America},
	author = {Li, Claire Yue and Alexander, H. Richard},
	month = jul,
	year = {2018},
	pmid = {29935688},
	keywords = {Humans, Treatment Outcome, Lung Neoplasms, Peritoneal Neoplasms, Combined Modality Therapy, Diffuse malignant peritoneal mesothelioma, Early postoperative intraperitoneal chemotherapy, Hyperthermic intraoperative peritoneal chemotherapy, Mesothelioma, Mesothelioma, Malignant, Operative cytoreduction, Peritoneal metastases},
	pages = {539--549},
}

@article{bridda32,
	title = {Peritoneal {Mesothelioma}: {A} {Review}},
	volume = {9},
	issn = {1531-0132},
	shorttitle = {Peritoneal {Mesothelioma}},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994863/},
	abstract = {Background
Malignant peritoneal mesothelioma (MPM) is a rare aggressive tumor of the peritoneum, regarded as a universally fatal disease. It is poorly described and the knowledge of its natural history is very limited. Occupational and environmental asbestos exposure still remains a public health problem around the world. The incidence has increased in the past 2 decades. Only 20\% to 33\% of all mesotheliomas arise from the peritoneum itself; the pleura is the most common site of origin.},
	number = {2},
	urldate = {2022-07-19},
	journal = {Medscape General Medicine},
	author = {Bridda, Alessio and Padoan, Ilaria and Mencarelli, Roberto and Frego, Mauro},
	month = may,
	year = {2007},
	pmid = {17955087},
	pmcid = {PMC1994863},
	keywords = {Mesothelioma},
	pages = {32},
}

@article{hyun115,
	title = {Prognostic value of metabolic tumor volume measured by {18F}-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma},
	volume = {17},
	issn = {1534-4681},
	doi = {10.1245/s10434-009-0719-7},
	abstract = {PURPOSE: The aim of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) in patients with esophageal carcinoma.
METHODS: We retrospectively reviewed 151 patients with pathologically proven esophageal carcinoma (146 squamous cell carcinomas and 5 adenocarcinomas) who underwent pretreatment (18)F-FDG PET. MTV and maximum standardized uptake value (SUVmax) for the primary tumors were measured by (18)F-FDG PET. The prognostic significance of MTV, SUVmax, and other clinicopathological variables was assessed by Cox proportional hazards regression analysis. To further evaluate and compare the predictive performance of PET parameters, MTV and SUVmax, time-dependent receiver operating characteristic curve (ROC) analysis was used.
RESULTS: In the univariate analysis, age, American Joint Committee on Cancer (AJCC) stage, tumor-node-metastasis (TNM) factors, MTV, and SUVmax of primary tumor were significant predictors of survival. On multivariate analysis adjusted for age, sex, and treatment modality, independent predictive factors associated with decreased overall survival were T stage [hazard ratio (HR) 4.325, P = 0.006], M stage (HR 2.009, P = 0.007), and MTV (HR 1.013, P = 0.021). SUVmax was not a significant factor (HR 0.97, P = 0.061). On time-dependent ROC analysis, MTV showed good predictive performance for overall survival consistently better than SUVmax.
CONCLUSION: MTV, a volumetric parameter of (18)F-FDG PET, is an important independent prognostic factor for survival and a better predictor of survival than SUVmax for the primary tumor in patients with esophageal carcinoma.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgical Oncology},
	author = {Hyun, Seung Hyup and Choi, Joon Young and Shim, Young Mog and Kim, Kwhanmien and Lee, Su Jin and Cho, Young Seok and Lee, Ji Young and Lee, Kyung-Han and Kim, Byung-Tae},
	month = jan,
	year = {2010},
	pmid = {19826877},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Survival Rate, Prognosis, Cohort Studies, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Fluorodeoxyglucose F18, Radiopharmaceuticals, Positron-Emission Tomography},
	pages = {115--122},
	file = {Hyun et al. - 2010 - Prognostic value of metabolic tumor volume measure.pdf:/Users/jcsal/Zotero/storage/Q5F78DQZ/Hyun et al. - 2010 - Prognostic value of metabolic tumor volume measure.pdf:application/pdf},
}

@article{swisher1152,
	title = {Utility of {PET}, {CT}, and {EUS} to identify pathologic responders in esophageal cancer},
	volume = {78},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2004.04.046},
	abstract = {BACKGROUND: This study evaluates the utility of positron emission tomography (PET), endoscopic ultrasonography (EUS), and computed tomographic (CT) scans to predict pathologic response and survival following preoperative chemoradiation (CRT) in esophageal cancer.
METHODS: One hundred three sequential patients with locoregionally advanced esophageal cancer, who were treated with CRT and esophageal resection between May 2001 and November 2003 at the University of Texas M.D. Anderson Cancer Center, were retrospectively reviewed. PET, EUS, and CT were performed before (pre) or after (post) CRT and before surgical resection. PET standardized uptake value (SUV) was defined as maximal uptake in primary tumor.
RESULTS: Most patients were male (91 [88\%]) with adenocarcinoma (90 [87\%]). Pretreatment clinical stages were: IIA (42 [41\%]), IIB (5 [5\%]), III (50 [49\%]), and IVA (6 [6\%]). At the time of surgery, 58 patients (56\%) had a pathologic response to CRT ({\textless} or =10\% viable cells). Post-CRT measurements that correlated with pathologic response were: CT esophageal wall thickness (13.3 vs 15.3 mm, p = 0.04), EUS mass size (0.7 vs 1.7 cm, p = 0.01) and PET SUV (3.1 vs 5.8, p = 0.01). Post-CRT PET SUV equal to or greater than 4 had the highest accuracy for pathologic response (76\%). Univariate and multivariate Cox regression analysis demonstrated that a post-CRT PET SUV equal to or greater than 4 was an independent predictor of survival (HR, 3.5, p = 0.04).
CONCLUSIONS: The FDG-PET SUV is the most accurate noninvasive test to predict long-term survival after preoperative CRT and before surgical resection. Post-CRT FDG-PET cannot, however, rule out residual microscopic disease so esophagectomy should remain a therapeutic option even if the post-CRT imaging modalities are normal.},
	language = {eng},
	number = {4},
	journal = {The Annals of Thoracic Surgery},
	author = {Swisher, Stephen G. and Maish, Mary and Erasmus, Jeremy J. and Correa, Arlene M. and Ajani, Jaffer A. and Bresalier, Robert and Komaki, Ritsuko and Macapinlac, Homer and Munden, Reginald F. and Putnam, Joe B. and Rice, David and Smythe, W. Roy and Vaporciyan, Ara A. and Walsh, Garrett L. and Wu, Tsung T. and Roth, Jack A.},
	month = oct,
	year = {2004},
	pmid = {15464463},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, Prognosis, Adult, Chemotherapy, Adjuvant, Fluorouracil, Survival Analysis, Camptothecin, Irinotecan, Adenocarcinoma, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Esophagectomy, Fluorodeoxyglucose F18, Radiopharmaceuticals, Combined Modality Therapy, Sensitivity and Specificity, Paclitaxel, Radiotherapy, Adjuvant, Positron-Emission Tomography, Taxoids, Endosonography, Docetaxel, Preoperative Care, Carboplatin, Life Tables},
	pages = {1152--1160; discussion 1152--1160},
	file = {Swisher et al. - 2004 - Utility of PET, CT, and EUS to identify pathologic.pdf:/Users/jcsal/Zotero/storage/UKFRNVPG/Swisher et al. - 2004 - Utility of PET, CT, and EUS to identify pathologic.pdf:application/pdf},
}

@article{valkema1553,
	title = {Accuracy of {18F}-{FDG} {PET}/{CT} in {Predicting} {Residual} {Disease} {After} {Neoadjuvant} {Chemoradiotherapy} for {Esophageal} {Cancer}},
	volume = {60},
	issn = {1535-5667},
	doi = {10.2967/jnumed.118.224196},
	abstract = {Our purpose was to prospectively investigate optimal evaluation of qualitative and quantitative 18F-FDG PET/CT in response evaluations 12-14 wk after neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer patients. Methods: This was a side study of the prospective diagnostic pre-SANO trial. 18F-FDG PET/CT scans at baseline and at 12-14 wk after nCRT were qualitatively assessed for the presence of tumor. Maximum SUVs normalized for lean body mass (SULmax) were measured in all scans. The primary endpoint was the proportion of false-negative patients with tumor regression grade (TRG) 3-4 ({\textgreater}10\% vital residual tumor) in qualitative and quantitative analyses. Receiver-operating-characteristic curve analysis for TRG1 versus TRG3-4 using SULmax, SULmax tumor-to-esophagus ratio, and Δ\%SULmax was performed to define optimal cutoffs. Secondary endpoints were sensitivity, specificity, negative predictive value, and positive predictive value for TRG1 versus TRG2-4. Results: In total, 129 of 219 patients were analyzed. Qualitative 18F-FDG PET/CT was unable to detect TRG3-4 in 15\% of patients. Sensitivity, specificity, negative predictive value, and positive predictive value in qualitative analysis for detecting TRG1 versus TRG2-4 was 80\%, 37\%, 42\%, and 77\%, respectively. In 18 of 190 patients (10\%) with follow-up scans after nCRT, 18F-FDG PET/CT identified new interval metastases. Quantitative parameters did not detect TRG3-4 tumor in 27\%-61\% of patients. The optimal cutoff for detecting TRG1 versus TRG2-4 was a post-nCRT SULmax of 2.93 (area under receiver-operating-characteristic curve, 0.70). Conclusion: Qualitative and quantitative analyses of 18F-FDG PET/CT are unable to accurately detect TRG3-4 and to discriminate substantial residual disease from benign inflammation-induced 18F-FDG uptake after nCRT. However, 18F-FDG PET/CT is useful for the detection of interval metastases and might become useful in an active surveillance strategy with serial 18F-FDG PET/CT scanning.},
	language = {eng},
	number = {11},
	journal = {Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine},
	author = {Valkema, Maria J. and Noordman, Bo Jan and Wijnhoven, Bas P. L. and Spaander, Manon C. W. and Biermann, Katharina and Lagarde, Sjoerd M. and Bennink, Roel J. and Schreurs, Wendy M. J. and Roef, Mark J. and Hobbelink, Monique G. G. and Janssen, Marcel J. R. and Graven, Laura H. and van Lanschot, J. Jan B. and Valkema, Roelf},
	month = nov,
	year = {2019},
	pmid = {30877177},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Esophageal Neoplasms, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Sensitivity and Specificity, Neoplasm, Residual, esophageal cancer, 18F-FDG PET/CT, neoadjuvant chemoradiotherapy, response evaluation, tumor regression grade},
	pages = {1553--1559},
	file = {Full Text:/Users/jcsal/Zotero/storage/HLXQM4IE/Valkema et al. - 2019 - Accuracy of 18F-FDG PETCT in Predicting Residual .pdf:application/pdf},
}

@article{vanrossum691,
	title = {The {Incremental} {Value} of {Subjective} and {Quantitative} {Assessment} of {18F}-{FDG} {PET} for the {Prediction} of {Pathologic} {Complete} {Response} to {Preoperative} {Chemoradiotherapy} in {Esophageal} {Cancer}},
	volume = {57},
	issn = {1535-5667},
	doi = {10.2967/jnumed.115.163766},
	abstract = {A reliable prediction of a pathologic complete response (pathCR) to chemoradiotherapy before surgery for esophageal cancer would enable investigators to study the feasibility and outcome of an organ-preserving strategy after chemoradiotherapy. So far no clinical parameters or diagnostic studies are able to accurately predict which patients will achieve a pathCR. The aim of this study was to determine whether subjective and quantitative assessment of baseline and postchemoradiation (18)F-FDG PET can improve the accuracy of predicting pathCR to preoperative chemoradiotherapy in esophageal cancer beyond clinical predictors.
METHODS: This retrospective study was approved by the institutional review board, and the need for written informed consent was waived. Clinical parameters along with subjective and quantitative parameters from baseline and postchemoradiation (18)F-FDG PET were derived from 217 esophageal adenocarcinoma patients who underwent chemoradiotherapy followed by surgery. The associations between these parameters and pathCR were studied in univariable and multivariable logistic regression analysis. Four prediction models were constructed and internally validated using bootstrapping to study the incremental predictive values of subjective assessment of (18)F-FDG PET, conventional quantitative metabolic features, and comprehensive (18)F-FDG PET texture/geometry features, respectively. The clinical benefit of (18)F-FDG PET was determined using decision-curve analysis.
RESULTS: A pathCR was found in 59 (27\%) patients. A clinical prediction model (corrected c-index, 0.67) was improved by adding (18)F-FDG PET-based subjective assessment of response (corrected c-index, 0.72). This latter model was slightly improved by the addition of 1 conventional quantitative metabolic feature only (i.e., postchemoradiation total lesion glycolysis; corrected c-index, 0.73), and even more by subsequently adding 4 comprehensive (18)F-FDG PET texture/geometry features (corrected c-index, 0.77). However, at a decision threshold of 0.9 or higher, representing a clinically relevant predictive value for pathCR at which one may be willing to omit surgery, there was no clear incremental value.
CONCLUSION: Subjective and quantitative assessment of (18)F-FDG PET provides statistical incremental value for predicting pathCR after preoperative chemoradiotherapy in esophageal cancer. However, the discriminatory improvement beyond clinical predictors does not translate into a clinically relevant benefit that could change decision making.},
	language = {eng},
	number = {5},
	journal = {Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine},
	author = {van Rossum, Peter S. N. and Fried, David V. and Zhang, Lifei and Hofstetter, Wayne L. and van Vulpen, Marco and Meijer, Gert J. and Court, Laurence E. and Lin, Steven H.},
	month = may,
	year = {2016},
	pmid = {26795288},
	keywords = {Humans, Female, Male, Middle Aged, Retrospective Studies, Adenocarcinoma, Esophageal Neoplasms, Chemoradiotherapy, Fluorodeoxyglucose F18, Multivariate Analysis, esophageal cancer, Positron-Emission Tomography, positron emission tomography, Preoperative Period, 18F-FDG PET, texture features, treatment response},
	pages = {691--700},
	file = {Full Text:/Users/jcsal/Zotero/storage/YYDZ6ELB/van Rossum et al. - 2016 - The Incremental Value of Subjective and Quantitati.pdf:application/pdf},
}

@article{walker166,
	title = {Integrated {PET}/{CT} fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer},
	volume = {13},
	issn = {1860-2002},
	doi = {10.1007/s11307-010-0306-0},
	abstract = {PURPOSE: Accurate staging of esophageal cancer (ECA) is critical in determining appropriate therapy. Endoscopic ultrasound (EUS), computed tomography (CT) and positron emission tomography (PET) scanning can be used, but limited data exists regarding the use of combined PET/CT fusion imaging and EUS in ECA staging. The objective of this study is to evaluate the role of integrated PET/CT imaging and EUS in the staging of ECA.
PROCEDURES: Identification of patients diagnosed with ECA from 2004 to 2007 that underwent staging PET/CT and EUS. Data regarding tumor detection, lymph node identification, presence of metastatic disease, and affect on patient management were collected and compared between PET/CT and EUS.
RESULTS: Eighty-one patients (65 male, 16 female) were identified with mean age of 63.5 years who underwent EUS and PET/CT to stage known ECA. PET/CT identified the primary tumor in 74/81 (91.4\%) of cases, compared to 81/81 (100\%) with EUS. Locoregional adenopathy was seen by PET/CT in 29/81 (35.8\%) of cases, compared to 49/81 (60.5\%) by EUS (p = 0.0001). PET/CT identified celiac axis adenopathy in 8/81 (9.9\%) of cases, compared to 11/81 (13.6\%) with EUS (p = 0.5050). PET/CT identified 17/81 (21.0\%) of patients with distant metastases who subsequently did not undergo attempt at curative surgical resection.
CONCLUSIONS: In ECA, EUS is superior to PET/CT for T staging and in identifying locoregional nodes, while PET/CT provides M staging. EUS and integrated PET/CT appear to independently affect treatment decisions, indicating complimentary and necessary roles in the staging of ECA.},
	language = {eng},
	number = {1},
	journal = {Molecular Imaging and Biology},
	author = {Walker, Andrew J. and Spier, Bret J. and Perlman, Scott B. and Stangl, Jason R. and Frick, Terrence J. and Gopal, Deepak V. and Lindstrom, Mary J. and Weigel, Tracey L. and Pfau, Patrick R.},
	month = feb,
	year = {2011},
	pmid = {20379789},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Male, Esophageal Neoplasms, Positron-Emission Tomography},
	pages = {166--171},
	file = {Walker et al. - 2011 - Integrated PETCT fusion imaging and endoscopic ul.pdf:/Users/jcsal/Zotero/storage/YVUZXYSY/Walker et al. - 2011 - Integrated PETCT fusion imaging and endoscopic ul.pdf:application/pdf},
}

@article{yanagawa872,
	title = {Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: {PET} response criteria in solid tumors versus response evaluation criteria in solid tumors},
	volume = {53},
	issn = {1535-5667},
	shorttitle = {Evaluation of response to neoadjuvant chemotherapy for esophageal cancer},
	doi = {10.2967/jnumed.111.098699},
	abstract = {Recently, PET response criteria in solid tumors (PERCIST) have been proposed as a new standardized method to assess chemotherapeutic response metabolically and quantitatively. The aim of this study was to evaluate therapeutic response to neoadjuvant chemotherapy for locally advanced esophageal cancer, comparing PERCIST with the currently widely used response evaluation criteria in solid tumors (RECIST).
METHODS: Fifty-one patients with locally advanced esophageal cancer who received neoadjuvant chemotherapy (5-fluorouracil, adriamycin, and cisplatin), followed by surgery were studied. Chemotherapeutic lesion responses were evaluated using (18)F-FDG PET and CT according to the RECIST and PERCIST methods. The PET/CT scans were obtained before chemotherapy and about 2 wk after completion of chemotherapy. Associations were statistically analyzed between survival (overall and disease-free survival) and clinicopathologic results (histology [well-, moderately, and poorly differentiated squamous cell carcinoma], lymphatic invasion, venous invasion, clinical stage, pathologic stage, resection level, reduction rate of tumor diameter, reduction rate of tumor uptake, chemotherapeutic responses in RECIST and PERCIST, and pathologic response).
RESULTS: There was a significant difference in response classification between RECIST and PERCIST (Wilcoxon signed-rank test, P {\textless} 0.0001). Univariate analysis showed that lymphatic invasion, venous invasion, resection level, pathologic stage, and PERCIST were significant factors associated with disease-free or overall survival in this study. Although multivariate analysis demonstrated that venous invasion (disease-free survival: hazard ratio [HR] = 4.519, P = 0.002; overall survival: HR = 5.591, P = 0.003) and resection level (disease-free survival: HR = 11.078, P = 0.001) were the significant predictors, PERCIST was also significant in noninvasive therapy response assessment before surgery (disease-free survival: HR = 4.060, P = 0.025; overall survival: HR = 8.953, P = 0.034).
CONCLUSION: RECIST based on the anatomic size reduction rate did not demonstrate the correlation between therapeutic responses and prognosis in patients with esophageal cancer receiving neoadjuvant chemotherapy. However, PERCIST was found to be the strongest independent predictor of outcomes. Given the significance of noninvasive radiologic imaging in formulating clinical treatment strategies, PERCIST might be considered more suitable for evaluation of chemotherapeutic response to esophageal cancer than RECIST.},
	language = {eng},
	number = {6},
	journal = {Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine},
	author = {Yanagawa, Masahiro and Tatsumi, Mitsuaki and Miyata, Hiroshi and Morii, Eiichi and Tomiyama, Noriyuki and Watabe, Tadashi and Isohashi, Kayako and Kato, Hiroki and Shimosegawa, Eku and Yamasaki, Makoto and Mori, Masaki and Doki, Yuichiro and Hatazawa, Jun},
	month = jun,
	year = {2012},
	pmid = {22582049},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Proportional Hazards Models, Chemotherapy, Adjuvant, Esophageal Neoplasms, Positron-Emission Tomography},
	pages = {872--880},
	file = {Full Text:/Users/jcsal/Zotero/storage/QC5NW4XD/Yanagawa et al. - 2012 - Evaluation of response to neoadjuvant chemotherapy.pdf:application/pdf},
}

@article{chiu794,
	title = {Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: {Early} results from the {Chinese} {University} {Research} {Group} for {Esophageal} {Cancer} ({CURE})},
	volume = {9},
	issn = {1873-4626},
	shorttitle = {Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer},
	url = {https://doi.org/10.1016/j.gassur.2005.05.005},
	doi = {10.1016/j.gassur.2005.05.005},
	abstract = {We conducted a prospective randomized trial to compare the efficacy and survival outcome by chemoradiation with that by esophagectomy as a curative treatment. From July 2000 to December 2004, 80 patients with potentially resectable squamous cell carcinoma of the mid or lower thoracic esophagus were randomized to esophagectomy or chemoradiotherapy. A two-or three-stage esophagectomy with two-field dissection was performed. Patients treated with chemoradiotherapy received continuous 5-.uorouracil infusion (200 mg/m2/day) from day 1 to 42 and cisplatin (60 mg/m2) on days 1 and 22. The tumor and regional lymphatics were concomitantly irradiated to a total of 50–60 Gy.Tumor response was assessed by endoscopy, endoscopic ultrasonography, and computed tomography scan. Salvage esophagectomy was performed for incomplete response or recurrence. Forty-four patients received standard esophagectomy, whereas 36 were treated with chemoradiotherapy. Median follow-up was 16.9 months. The operative mortality was 6.8\%. The incidence of postoperative complications was 38.6\%. No difference in the early cumulative survival was found between the two groups (RR = 0.89; 95\% confidence interval, 0.37-2.17; log-rank test P =0.45). There was no difference in the disease-free survival. Patients treated with surgery had a slightly higher proportion of recurrence in the mediastinum, whereas those treated with chemoradiation sustained a higher proportion of recurrence in the cervical or abdominal regions. Standard esophagectomy or chemoradiotherapy offered similar early clinical outcome and survival for patients with squamous cell carcinoma of the esophagus. The challenge lies in the detection of residue disease after chemoradiotherapy.},
	language = {en},
	number = {6},
	urldate = {2022-08-03},
	journal = {Journal of Gastrointestinal Surgery},
	author = {Chiu, Philip W. Y. and Chan, Angus C. W. and Leung, S. F. and Leong, H. T. and Kwong, K. H. and Li, Micheal K. W. and Au-Yeung, Alex C. M. and Chung, Sydney C. S. and Ng, Enders K. W.},
	month = aug,
	year = {2005},
	keywords = {esophagectomy, chemoradiotherapy, Carcinoma of esophagus, chemoradiation, squamous cell carcinoma},
	pages = {794--802},
}

@article{jiao278,
	title = {Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology},
	volume = {74},
	issn = {0003-4975},
	shorttitle = {Clinical significance of micrometastasis in lung and esophageal cancer},
	doi = {10.1016/s0003-4975(01)03376-8},
	abstract = {In the past decade, detection of micrometastatic disease in different clinical samples including pleural lavage, lymph node, bone marrow, and blood has become a rapidly growing area of interest in research of non-small cell lung cancer and esophageal cancer. The results of these studies support the concept that, just as in many other solid malignancies, systemic spread may happen at an early stage in non-small cell lung cancer and esophageal cancer. Such systemic spread is often occult (micrometastases) at the time of primary diagnosis, which may have adverse effects on survival. Improved staging can be expected with information on micrometastases, and a subgroup of patients who will benefit most from adjuvant therapy might be identified. Although reliable and standard methods need to be developed before detection of micrometastasis is incorporated in the routine clinical practice, we suggest that it be considered an important correlate in clinical trials in non-small cell lung cancer and esophageal cancer.},
	language = {eng},
	number = {1},
	journal = {The Annals of Thoracic Surgery},
	author = {Jiao, Xiaolong and Krasna, Mark J.},
	month = jul,
	year = {2002},
	pmid = {12118789},
	keywords = {Humans, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Prognosis, Esophageal Neoplasms, Lymphatic Metastasis, Immunohistochemistry, Lymph Nodes, Bone Marrow Neoplasms, Neoplastic Cells, Circulating, Pleural Neoplasms},
	pages = {278--284},
}

@article{internullo1096,
	title = {Outcome after esophagectomy for cancer of the esophagus and {GEJ} in patients aged over 75 years},
	volume = {33},
	issn = {1010-7940},
	doi = {10.1016/j.ejcts.2008.03.004},
	abstract = {OBJECTIVE: Though the surgical treatment of esophageal cancer is increasingly accepted for elderly people defined as aged over 70 years, less is reported about the results in patients over 75. This study is a single institution retrospective analysis of outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years.
METHODS: All consecutive patients 76 years old and over undergoing curative esophagectomy for cancer in the period 1991-2006 were analyzed as to comorbidities, outcome and long-term survival. All the data had been prospectively collected in a database. Postoperative mortality risk was assessed by P-POSSUM and O-POSSUM score for in-hospital mortality and by the recently published Steyerberg's score system [Steyerberg EW, Neville BA, Koppert LB, Lemmens VEPP, Tilanus HW, Coebergh JWW, Weeks JC, Earle CC. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24:4277-84.] for 30-day mortality. Five-year survival was compared to the standardized survival in the general population.
RESULTS: One hundred and eight patients fulfilling the abovementioned criteria were found (76 males and 32 females, mean age 79.5 years, mean standardized life-expectancy: 7.36 years). Among them, 69\% had esophageal tumors and 31\% GEJ tumors. The predominant histology was adenocarcinoma (74\%). Eighty-six (79.6\%) presented with one or more major comorbidities or a history of previous major upper-GI surgery, potentially affecting the surgical outcome. All underwent resection with curative intent (R(0) 83.3\%, R(1) 12\%, R(2) 4.6\%). The overall postoperative morbidity rate was 51.9\%, pulmonary complications (37\%) being the most frequent. Postoperative mortality, mainly due to cardiopulmonary complications, was 7.4\%, which was consistent with that predicted by P-POSSUM score (7.2\%) and lower than that predicted by O-POSSUM score (15.1\%). Thirty-day mortality was 5.5\%, being consistent with that predicted by the Steyerberg's score (6.8\%). Overall 5-year survival was 35.7\%, while R(0) overall survival 42\% and cancer specific R(0) survival 51.7\%.
CONCLUSIONS: Patients 76 years old and over with esophageal or GEJ cancer should not be denied surgery solely on the basis of age. Outcome and long-term results in the selected elderly are not differing from those reported for younger patients. However, despite thorough preoperative assessment being applied in the selection of the candidates for surgery, a practical and reliable individual risk-analysis stratification is still lacking.},
	language = {eng},
	number = {6},
	journal = {European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery},
	author = {Internullo, Eveline and Moons, Johnny and Nafteux, Philippe and Coosemans, Willy and Decker, Georges and De Leyn, Paul and Van Raemdonck, Dirk and Lerut, Toni},
	month = jun,
	year = {2008},
	pmid = {18407509},
	keywords = {Humans, Aged, Female, Male, Neoadjuvant Therapy, Treatment Outcome, Neoplasm Staging, Aged, 80 and over, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Severity of Illness Index, Epidemiologic Methods, Sex Distribution, Age Distribution},
	pages = {1096--1104},
	file = {Full Text:/Users/jcsal/Zotero/storage/E8QB3TKK/Internullo et al. - 2008 - Outcome after esophagectomy for cancer of the esop.pdf:application/pdf},
}

@article{sabel210,
	title = {Esophageal resection for carcinoma in patients older than 70 years},
	volume = {9},
	issn = {1068-9265},
	doi = {10.1007/BF02557376},
	abstract = {BACKGROUND: A larger number of older patients are presenting as candidates for esophageal resection. An aggressive surgical approach in this population is controversial.
METHODS: Four hundred thirteen patients with esophageal cancer who presented to Roswell Park Cancer Institute from 1991 to 1998 were retrospectively reviewed. Clinical data, perioperative details, and postoperative courses were compared for patients older and younger than 70 years.
RESULTS: One hundred forty-seven patients (36\%) were older than 70 years. Risk factors, clinical symptoms, histology, and stage at presentation were equivalent for both age groups. A higher percentage of patients {\textless}70 years were candidates for curative resection. There were no significant differences between groups for estimated blood loss, intraoperative transfusions, length of stay, overall morbidity, or mortality. Only postoperative myocardial infarction and atrial fibrillation were increased in the older group. Excluding stage IV disease, there was a significant and similar improvement in median survival after resection for patients both {\textless}70 years and {\textgreater}70 years.
CONCLUSIONS: In conclusion, esophageal cancer in older patients warrants surgical resection because the benefit to the patient is the same as it is for younger patients, without a significant increase in operative morbidity or mortality.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Sabel, Michael S. and Smith, Judy L. and Nava, Hector R. and Mollen, Kevin and Douglass, Harold O. and Gibbs, John F.},
	month = mar,
	year = {2002},
	pmid = {11888881},
	keywords = {Humans, Aged, Female, Male, Retrospective Studies, Survival Rate, Prognosis, Aged, 80 and over, Age Factors, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, New York, Patient Selection},
	pages = {210--214},
}

@article{carroll1706,
	title = {Elimination of {Routine} {Feeding} {Jejunostomy} {After} {Esophagectomy}},
	volume = {110},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2020.04.072},
	abstract = {BACKGROUND: Feeding jejunostomy is frequently used to ensure nutritional intake after esophagectomy. Early return to diet is demonstrated to enhance recovery in major abdominal surgery. Early oral feeding is safe and effective in recent randomized controlled trials in esophagectomy. This study assesses the implications of eliminating the insertion of jejunostomy after esophagectomy.
METHODS: A retrospective study was undertaken between 2014 and 2017 with follow-up over the first year. Fifty patients did not have a jejunostomy, compared with 46 patients who had conventional treatment. Outcomes measured included change in relative weight and body mass over 1 year, complications, and nutritional reinterventions.
RESULTS: Median weight loss at 1 year was 10.7 kg (range, -8 to 55.6) whereas median percent weight loss was 12\% (range, -10.1\% to 39.2\%). Patients without jejunostomy lost more weight during the first month (P = .002). Thereafter, at 6 of 12 months, there were no differences in actual or relative weight loss. Obese patients lost more weight in the group without jejunostomy compared with those who had it (9.9 versus 5 kg; P = .004). This effect was not seen in normal or overweight patients. Complications were similar, whereas leaks were more common in the jejunostomy group (15.2\% versus 2\%; P = .019). Nutritional reinterventions were similar during index admission and subsequent readmissions (7 versus 5 patients; P = .640).
CONCLUSIONS: Routine jejunostomy use delays rather than prevents weight loss after esophagectomy. Oral route nutrition allows patients to maintain sufficient nutrition and does not increase complications or requirement for nutritional interventions after surgery. Routine use of jejunostomy may not be required in modern practice.},
	language = {eng},
	number = {5},
	journal = {The Annals of Thoracic Surgery},
	author = {Carroll, Paul A. and Yeung, Jonathan C. and Darling, Gail E.},
	month = nov,
	year = {2020},
	pmid = {32504612},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Postoperative Care, Retrospective Studies, Weight Loss, Aged, 80 and over, Adult, Outcome Assessment, Health Care, Esophagectomy, Enteral Nutrition, Jejunostomy},
	pages = {1706--1713},
}

@article{martin2669,
	title = {Assessment of {Computed} {Tomography} ({CT})-{Defined} {Muscle} and {Adipose} {Tissue} {Features} in {Relation} to {Short}-{Term} {Outcomes} {After} {Elective} {Surgery} for {Colorectal} {Cancer}: {A} {Multicenter} {Approach}},
	volume = {25},
	issn = {1534-4681},
	shorttitle = {Assessment of {Computed} {Tomography} ({CT})-{Defined} {Muscle} and {Adipose} {Tissue} {Features} in {Relation} to {Short}-{Term} {Outcomes} {After} {Elective} {Surgery} for {Colorectal} {Cancer}},
	doi = {10.1245/s10434-018-6652-x},
	abstract = {BACKGROUND: Sarcopenia, visceral obesity (VO), and reduced muscle radiodensity (myosteatosis) are suggested risk factors for postoperative morbidity in colorectal cancer (CRC), but usually are not concurrently assessed. Published thresholds used to define these features are not CRC-specific and are defined in relation to mortality, not postoperative outcomes. This study aimed to evaluate body composition in relation to length of hospital stay (LOS) and postoperative outcomes.
METHODS: Pre-surgical computed tomography (CT) images were assessed for total area and radiodensity of skeletal muscle and visceral adipose tissue in a pooled Canadian and UK cohort (n = 2100). Sex- and age-specific values for these features were calculated. For 1139 of 2100 patients, LOS data were available, and sex- and age-specific thresholds for sarcopenia, myosteatosis, and VO were defined on the basis of LOS. Association of CT-defined features with LOS and readmissions was explored using negative binomial and logistic regression models, respectively.
RESULTS: In the multivariable analysis, the predictors of LOS (P {\textless} 0.001) were age, surgical approach, major complications (incidence rate ratio [IRR] 2.42; 95\% confidence interval [CI] 2.18-2.68), study cohort, and three body composition profiles characterized by myosteatosis combined with either sarcopenia (IRR, 1.27; 95\% CI 1.12-1.43) or VO (IRR, 1.25; 95\% CI 1.10-1.42), and myosteatosis combined with both sarcopenia and VO (IRR, 1.58; 95\% CI 1.29-1.93). In the multivariable analysis, risk of readmission was associated with VO alone (odds ratio [OR] 2.66; 95\% CI 1.18-6.00); P = 0.018), VO combined with myosteatosis (OR, 2.72; 95\% CI 1.36-5.46; P = 0.005), or VO combined with myosteatosis and sarcopenia (OR, 2.98; 95\% CI 1.06-5.46; P = 0.038). Importantly, the effect of body composition profiles on LOS and readmission was independent of major complications.
CONCLUSION: The findings showed that CT-defined multidimensional body habitus is independently associated with LOS and hospital readmission.},
	language = {eng},
	number = {9},
	journal = {Annals of Surgical Oncology},
	author = {Martin, Lisa and Hopkins, Jessica and Malietzis, Georgios and Jenkins, J. T. and Sawyer, Michael B. and Brisebois, Ron and MacLean, Anthony and Nelson, Gregg and Gramlich, Leah and Baracos, Vickie E.},
	month = sep,
	year = {2018},
	pmid = {30006691},
	keywords = {Body Composition, Sarcopenia, Survival Rate, Postoperative Complications, Patient Readmission, Colorectal, LOS, ICC},
	pages = {2669--2680},
	annote = {Annotations(8/3/2022, 8:17:30 PM)
“Pre-surgical computed tomography (CT) images were assessed for total area and radiodensity of skeletal muscle and visceral adipose tissue in a pooled Canadian and UK cohort (n = 2100)” (Martin et al., 2018, p. 2669)“predictors of LOS (P {\textbackslash} 0.001) were age, surgical approach, major complications (incidence rate ratio [IRR] 2.42; 95\% confidence interval [CI] 2.18–2.68), study cohort, and three body composition profiles characterized by myosteatosis combined with either sarcopenia (IRR, 1.27; 95\% CI 1.12–1.43) or VO (IRR, 1.25; 95\% CI 1.10–1.42), and myosteatosis combined with both sarcopenia and VO (IRR, 1.58; 95\% CI 1.29–1.93)” (Martin et al., 2018, p. 2669)“risk of readmission was associated with VO alone (odds ratio [OR] 2.66; 95\% CI 1.18–6.00); P = 0.018), VO combined with myosteatosis (OR, 2.72; 95\% CI 1.36–5.46; P = 0.005), or VO combined with myosteatosis and sarcopenia (OR, 2.98; 95\% CI 1.06–5.46; P = 0.038). Importantly, the effect of body composition profiles on LOS and readmission was independent of major complications” (Martin et al., 2018, p. 2669)“Findings for SM area (SMA), mean skeletal muscle radiodensity (SMR), and areas of VAT and SAT were reported. Data for SMA, VAT, and SAT were normalized for height2 and reported as SM index (SMI, cm2/m2), VAT index (VATI, cm2/m2), and SAT index (SATI, cm2/m2). Interrater coefficients of variation were within the expected ranges (SMI, 2\%; SMR, 4\%; VATI, 4–7\%).47,48 Because contrast agents can significantly alter SMR values,49,50 only contrast-enhanced images were used.” (Martin et al., 2018, p. 2671)“47. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006. 48. Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85:1–10. 49. van der Werf A, Dekker IM, Meijerink MR, Wierdsma NJ, de van der Schueren MAE, Langius JAE. Skeletal muscle analyses: agreement between non-contrast and contrast CT scan measurements of skeletal muscle area and mean muscle attenuation. Clin Physiol Funct Imaging. 2017;38:366–72. 50. van Vugt JLA, Coebergh van den Braak RRJ, Schippers HJW, et al. Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography. Clin Nutr. 2017. https://doi.org/10.1016/j.clnu.2017. 07.007.” (Martin et al., 2018, p. 2680)},
	file = {Martin et al_2018_Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue.pdf:/Users/jcsal/Zotero/storage/FRZBACYT/Martin et al_2018_Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue.pdf:application/pdf},
}

@article{shuster1,
	title = {The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis},
	volume = {85},
	issn = {1748-880X},
	shorttitle = {The clinical importance of visceral adiposity},
	doi = {10.1259/bjr/38447238},
	abstract = {As a result of the rising epidemic of obesity, understanding body fat distribution and its clinical implications is critical to timely treatment. Visceral adipose tissue is a hormonally active component of total body fat, which possesses unique biochemical characteristics that influence several normal and pathological processes in the human body. Abnormally high deposition of visceral adipose tissue is known as visceral obesity. This body composition phenotype is associated with medical disorders such as metabolic syndrome, cardiovascular disease and several malignancies including prostate, breast and colorectal cancers. Quantitative assessment of visceral obesity is important for evaluating the potential risk of development of these pathologies, as well as providing an accurate prognosis. This review aims to compare different methods of measuring visceral adiposity with emphasis on their advantages and drawbacks in clinical practice.},
	language = {eng},
	number = {1009},
	journal = {The British Journal of Radiology},
	author = {Shuster, A. and Patlas, M. and Pinthus, J. H. and Mourtzakis, M.},
	month = jan,
	year = {2012},
	pmid = {21937614},
	pmcid = {PMC3473928},
	keywords = {Humans, Magnetic Resonance Imaging, Tomography, X-Ray Computed, Absorptiometry, Photon, Intra-Abdominal Fat, Methods, ICC, Obesity, Abdominal, Plethysmography},
	pages = {1--10},
	file = {Shuster et al_2012_The clinical importance of visceral adiposity.pdf:/Users/jcsal/Zotero/storage/VIG5AWNG/Shuster et al_2012_The clinical importance of visceral adiposity.pdf:application/pdf},
}

@article{mourtzakis997,
	title = {A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care},
	volume = {33},
	issn = {1715-5312},
	doi = {10.1139/H08-075},
	abstract = {Human body composition is important in numerous cancer research domains. Our objective was to evaluate clinically accessible methods to achieve practical and precise measures of body composition in cancer patients. Dual-energy X-ray absorptiometry (DXA)-based analysis of fat and fat-free mass was performed in 50 cancer patients and compared with bioelectrical impedance analysis (BIA) and with regional computed tomography (CT) images available in the patients' medical records. BIA overestimated or underestimated fat-free mass substantially compared with DXA as the method of reference (up to 9.3 kg difference). Significant changes in fat-free mass over time detected with DXA in a subset of 21 patients (+2.2 +/- 3.2\%/100 days, p = 0.003), was beyond the limits of detection of BIA. Regional analysis of fat and fat-free tissue at the 3rd lumbar vertebra with either DXA or CT strongly predicted whole-body fat and fat-free mass (r = 0.86-0.94; p {\textless} 0.001). CT images provided detail on specific muscles, adipose tissues and organs, not provided by DXA or BIA. CT presents great practical significance due to the prevalence of these images in patient diagnosis and follow-up, thus marrying clinical accessibility with high precision to quantify specific tissues and to predict whole-body composition.},
	language = {eng},
	number = {5},
	journal = {Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme},
	author = {Mourtzakis, Marina and Prado, Carla M. M. and Lieffers, Jessica R. and Reiman, Tony and McCargar, Linda J. and Baracos, Vickie E.},
	month = oct,
	year = {2008},
	pmid = {18923576},
	keywords = {Adipose Tissue, Body Composition, Humans, Magnetic Resonance Imaging, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasms, Absorptiometry, Photon, Electric Impedance, Image Processing, Computer-Assisted, Methods},
	pages = {997--1006},
	file = {Mourtzakis et al_2008_A practical and precise approach to quantification of body composition in.pdf:/Users/jcsal/Zotero/storage/FINVIYVE/Mourtzakis et al_2008_A practical and precise approach to quantification of body composition in.pdf:application/pdf},
}

@article{simonsen58,
	title = {Sarcopenia and {Postoperative} {Complication} {Risk} in {Gastrointestinal} {Surgical} {Oncology}: {A} {Meta}-analysis},
	volume = {268},
	issn = {1528-1140},
	shorttitle = {Sarcopenia and {Postoperative} {Complication} {Risk} in {Gastrointestinal} {Surgical} {Oncology}},
	doi = {10.1097/SLA.0000000000002679},
	abstract = {OBJECTIVE: The aim of the study was to evaluate sarcopenia as a predictor of postoperative risk of major and total complications after surgery for gastrointestinal cancer.
BACKGROUND: Sarcopenia is associated with poor survival in gastrointestinal cancer patients, but the role of sarcopenia as prognostic tool in surgical oncology has not been established, and no consensus exists regarding assessment and management of sarcopenic patients.
METHODS: We performed a systematic search for citations in EMBASE, Web of Science, and PubMed from 2004 to January 31, 2017. Random effects meta-analyses were used to estimate the pooled risk ratio for postoperative complications by Clavien-Dindo grade (total complications: grade ≥2; major complications: grade ≥3) in patients with sarcopenia versus patients without sarcopenia. Stratified analyses were performed by sarcopenia criteria, cutoff level, assessment methods, study quality, cancer diagnosis, and "Enhanced Recovery After Surgery" care.
RESULTS: Twenty-nine studies (n = 7176) were included with sarcopenia prevalence ranging between 12\% and 78\%. Preoperative incidence of sarcopenia was associated with increased risk of major complications (risk ratio 1.40; 95\% confidence interval, 1.20-1.64; P {\textless} 0.001; I = 52\%) and total complications (risk ratio 1.35; 95\% confidence interval, 1.12-1.61; P = 0.001; I = 60\%). Moderate heterogeneity was found for both meta-analyses. Subgroup analyses showed that sarcopenia remained a consistent risk factor across stratification by sarcopenia criteria, assessment methods, study quality, and diagnoses.
CONCLUSIONS: Sarcopenia was associated with an increased risk of complications after gastrointestinal tumor resection, but lack of methodological consensus hampers the interpretation and clinical utilization of these findings. Combining assessment of muscle mass with measures of physical function may increase the prognostic value and accuracy in preoperative risk stratification.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgery},
	author = {Simonsen, Casper and de Heer, Pieter and Bjerre, Eik D. and Suetta, Charlotte and Hojman, Pernille and Pedersen, Bente K. and Svendsen, Lars B. and Christensen, Jesper F.},
	month = jul,
	year = {2018},
	pmid = {29373365},
	keywords = {Humans, Gastrointestinal Neoplasms, Prevalence, Sarcopenia, Risk Factors, Prognosis, Incidence, Postoperative Complications, Preoperative Period, Review, Models, Statistical, GI},
	pages = {58--69},
	file = {Simonsen et al_2018_Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical.pdf:/Users/jcsal/Zotero/storage/2NG8VSKH/Simonsen et al_2018_Sarcopenia and Postoperative Complication Risk in Gastrointestinal Surgical.pdf:application/pdf},
}

@article{amini1671,
	title = {Approaches to {Assessment} of {Muscle} {Mass} and {Myosteatosis} on {Computed} {Tomography}: {A} {Systematic} {Review}},
	volume = {74},
	issn = {1758-535X},
	shorttitle = {Approaches to {Assessment} of {Muscle} {Mass} and {Myosteatosis} on {Computed} {Tomography}},
	doi = {10.1093/gerona/glz034},
	abstract = {BACKGROUND/OBJECTIVE: There is increasing use of computed tomography (CT) in sarcopenia research using a wide variety of techniques. We performed a systematic review of the CT literature to identify the differences between approaches used.
METHODS: A comprehensive search of PubMed from 1983 to 2017 was performed to identify studies that used CT muscle measurements to assess muscle mass and myosteatosis. The CT protocols were evaluated based on anatomic landmark(s), thresholding, muscle(s) segmented, key measurement (ie, muscle attenuation, cross-sectional area, volume), derived variables, and analysis software. From the described search, 657 articles were identified and 388 studies met inclusion criteria for this systematic review.
RESULTS: Muscle mass was more commonly assessed than myosteatosis (330 vs. 125). The most commonly assessed muscle or muscle groups were total abdominal wall musculature (142/330 and 49/125 for muscle mass and myosteatosis, respectively) and total thigh musculature (90/330 and 48/125). The most commonly used landmark in the abdomen was the L3 vertebra (123/142 and 45/49 for muscle mass and myosteatosis, respectively). Skeletal muscle index and intermuscular adipose tissue were the most commonly used measures of abdominal wall muscle mass (114/142) and myosteatosis (27/49), respectively. Cut points varied across studies. A significant majority of studies failed to report important CT technical parameters, such as use of intravenous contrast and slice thickness (94\% and 63\%, respectively).
CONCLUSIONS: There is considerable variation in the CT approaches used for the assessment of muscle mass and myosteatosis. There is a need to develop consensus for CT-based evaluation of sarcopenia and myosteatosis.},
	language = {eng},
	number = {10},
	journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
	author = {Amini, Behrang and Boyle, Sean P. and Boutin, Robert D. and Lenchik, Leon},
	month = sep,
	year = {2019},
	pmid = {30726878},
	pmcid = {PMC7357454},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Sarcopenia, Body composition, Review, Imaging, Muscle},
	pages = {1671--1678},
	file = {Amini et al_2019_Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography.pdf:/Users/jcsal/Zotero/storage/33P3IH5S/Amini et al_2019_Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography.pdf:application/pdf},
}

@article{boutin575,
	title = {Imaging of {Sarcopenia}},
	volume = {60},
	issn = {1557-8275},
	doi = {10.1016/j.rcl.2022.03.001},
	abstract = {Sarcopenia is currently underdiagnosed and undertreated, but this is expected to change because sarcopenia is now recognized with a specific diagnosis code that can be used for billing in some countries, as well as an expanding body of research on prevention, diagnosis, and management. This article focuses on practical issues of increasing interest by highlighting 3 hot topics fundamental to understanding sarcopenia in older adults: definitions and terminology, current diagnostic imaging techniques, and the emerging role of opportunistic computed tomography.},
	language = {eng},
	number = {4},
	journal = {Radiologic Clinics of North America},
	author = {Boutin, Robert D. and Houston, Denise K. and Chaudhari, Akshay S. and Willis, Marc H. and Fausett, Cameron L. and Lenchik, Leon},
	month = jul,
	year = {2022},
	pmid = {35672090},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Sarcopenia, Review, Computed tomography (CT), Elderly, Frailty, Opportunistic imaging, Population health},
	pages = {575--582},
}

@article{yao543,
	title = {Diagnosing sarcopenia at the point of imaging care: analysis of clinical, functional, and opportunistic {CT} metrics},
	volume = {50},
	issn = {1432-2161},
	shorttitle = {Diagnosing sarcopenia at the point of imaging care},
	doi = {10.1007/s00256-020-03576-9},
	abstract = {OBJECTIVE: To determine the relationship between CT-derived muscle metrics and standardized metrics of sarcopenia in patients undergoing routine CT imaging.
MATERIALS AND METHODS: Data collected in 443 consecutive patients included body CT, grip strength, usual gait speed, and responses to SARC-F and FRAIL scale questionnaires. Functional and clinical metrics of sarcopenia were acquired at the time of CT. Metrics were analyzed using the diagnostic framework of the European Working Group on Sarcopenia in Older People (EWGSOP2). The skeletal muscle index (SMI) and skeletal muscle density (SMD) were measured at the T12 and L3 levels. Statistical methods include linear prediction models and ROC analysis.
RESULTS: T12-SMD and L3-SMD in women and T12-SMD and L3-SMI in men show weak but significant (p {\textless} 0.05) predictive value for gait speed, after adjusting for subject age and body mass index. The prevalence of abnormal CT SMI at T12 and L3 was 29\% and 71\%, respectively, corresponding to prevalences of confirmed sarcopenia by EWGSOP2 of 10\% and 15\%, respectively. The agreement of abnormal SARC-F and FRAIL scale screening and EWGSOP2 confirmed sarcopenia was slight to fair (kappa: 0.20-0.28). CT cutpoints, based on EWGSOP2 criteria for abnormal grip strength or gait speed, are generally lower than cutpoints based on normative population data.
CONCLUSION: Collection of clinical and functional sarcopenia information at the point of imaging care can be accomplished quickly and safely. CT-derived muscle metrics show convergent validity with gait speed. Only a minority of subjects with low CT metrics have confirmed sarcopenia by EWGSOP2 definition.},
	language = {eng},
	number = {3},
	journal = {Skeletal Radiology},
	author = {Yao, Lawrence and Petrosyan, Anahit and Fuangfa, Praman and Lenchik, Leon and Boutin, Robert D.},
	month = mar,
	year = {2021},
	pmid = {32892227},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Sarcopenia, Cross-Sectional Studies, Muscle, Frailty, Benchmarking, CT, Geriatric Assessment, Opportunistic CT, Screening, Physiometry},
	pages = {543--550},
}

@article{boutinW208,
	title = {{CT} of {Patients} {With} {Hip} {Fracture}: {Muscle} {Size} and {Attenuation} {Help} {Predict} {Mortality}},
	volume = {208},
	issn = {1546-3141},
	shorttitle = {{CT} of {Patients} {With} {Hip} {Fracture}},
	doi = {10.2214/AJR.16.17226},
	abstract = {OBJECTIVE: Our objective was to determine the association between muscle cross-sectional area and attenuation, as measured on routine CT scans, and mortality in older patients with hip fracture.
MATERIALS AND METHODS: A retrospective 10-year study of patients with hip fracture was conducted with the following inclusion criteria: age 65 years or older, first-time hip fracture treated with surgery, and CT of the chest, abdomen, or pelvis. This yielded 274 patients (70.4\% women; mean [± SD] age, 81.3 ± 8.3 years). On each CT scan, two readers independently measured the size (cross-sectional area, indexed for patient height) and attenuation of the paravertebral muscle at T12 and the psoas muscle at L4. We then determined the association between overall mortality and the muscle size and muscle attenuation, while adjusting for demographic variables (age, sex, ethnicity, and body mass index), American Society of Anesthesiologists (ASA) classification, and Charlson comorbidity index (CCI).
RESULTS: The overall mortality rate increased from 28.3\% at 1 year to 79.5\% at 5 years. Mortality was associated with decreased thoracic muscle size (odds ratio [OR], 0.66; 95\% CI, 0.49-0.87). This association persisted after adjusting for demographic variables (OR, 0.69; 95\% CI, 0.50-0.95), the ASA classification (OR, 0.70; CI, 0.51-0.97), and the CCI (OR, 0.72; 95\% CI, 0.52-1.00). Similarly, decreased survival was associated with decreased thoracic muscle attenuation after adjusting for all of these combinations of covariates (OR, 0.67-0.72; 95\% CI, 0.49-0.99). Decreased lumbar muscle size and attenuation trended with decreased survival but did not reach statistical significance.
CONCLUSION: In older adults with hip fractures, CT findings of decreased thoracic paravertebral muscle size and attenuation are associated with decreased overall survival.},
	language = {eng},
	number = {6},
	journal = {AJR. American journal of roentgenology},
	author = {Boutin, Robert D. and Bamrungchart, Sara and Bateni, Cyrus P. and Beavers, Daniel P. and Beavers, Kristen M. and Meehan, John P. and Lenchik, Leon},
	month = jun,
	year = {2017},
	pmid = {28267356},
	pmcid = {PMC5898447},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Male, Prevalence, Sarcopenia, Retrospective Studies, Proportional Hazards Models, Risk Assessment, Organ Size, Aged, 80 and over, Reproducibility of Results, sarcopenia, Survival Analysis, Comorbidity, Sensitivity and Specificity, mortality, muscle, California, ICC, CT, Causality, hip fracture, Hip Fractures},
	pages = {W208--W215},
	annote = {WFU: cross sectional area using iSite
“Measurements were made with the routine clinical PACS software (iSite version 3.6, Philips Healthcare) used by all physicians at our institution.” (Boutin et al., 2017, p. 5)
“Interreader reliability for thoracic muscle index, thoracic muscle density, lumbar muscle index, and lumbar muscle density were analyzed by calculating intraclass correlation coefficients and coefficients of variation.” (Boutin et al., 2017, p. 5)
“Interreader reliability was very good for all” (Boutin et al., 2017, p. 6)
“muscle metrics using intraclass correlation coefficients: thoracic muscle index (0.85), thoracic muscle density (0.93), lumbar muscle index (0.90), and lumbar muscle density (0.84).” (Boutin et al., 2017, p. 7)
},
	file = {Boutin et al_2017_CT of Patients With Hip Fracture.pdf:/Users/jcsal/Zotero/storage/SEUXZRN6/Boutin et al_2017_CT of Patients With Hip Fracture.pdf:application/pdf;boutinW208 - Annotations (832022, 90347 PM).md:C\:\\Users\\jcsal\\Documents\\Work\\boutinW208 - Annotations (832022, 90347 PM).md:text/plain},
}

@article{edwards113170L,
	title = {Abdominal muscle segmentation from {CT} using a convolutional neural network},
	volume = {11317},
	issn = {0277-786X},
	doi = {10.1117/12.2549406},
	abstract = {CT is widely used for diagnosis and treatment of a variety of diseases, including characterization of muscle loss. In many cases, changes in muscle mass, particularly abdominal muscle, indicate how well a patient is responding to treatment. Therefore, physicians use CT to monitor changes in muscle mass throughout the patient's course of treatment. In order to measure the muscle, radiologists must segment and review each CT slice manually, which is a time-consuming task. In this work, we present a fully convolutional neural network (CNN) for the segmentation of abdominal muscle on CT. We achieved a mean Dice similarity coefficient of 0.92, a mean precision of 0.93, and a mean recall of 0.91 in an independent test set. The CNN-based segmentation method can provide an automatic tool for the segmentation of abdominal muscle. As a result, the time required to obtain information about changes in abdominal muscle using the CNN takes a fraction of the time associated with manual segmentation methods and thus can provide a useful tool in the clinical application.},
	language = {eng},
	journal = {Proceedings of SPIE--the International Society for Optical Engineering},
	author = {Edwards, Ka'Toria and Chhabra, Avneesh and Dormer, James and Jones, Phillip and Boutin, Robert D. and Lenchik, Leon and Fei, Baowei},
	month = feb,
	year = {2020},
	pmid = {32577045},
	pmcid = {PMC7309562},
	keywords = {Deep Learning, CT, Convolutional Neural Networks, Image segmentation, Muscle imaging, Muscle Segmentation},
	pages = {113170L},
	file = {Edwards et al_2020_Abdominal muscle segmentation from CT using a convolutional neural network.pdf:/Users/jcsal/Zotero/storage/JHC5EGNM/Edwards et al_2020_Abdominal muscle segmentation from CT using a convolutional neural network.pdf:application/pdf},
}

@article{lenchik277,
	title = {Automated {Muscle} {Measurement} on {Chest} {CT} {Predicts} {All}-{Cause} {Mortality} in {Older} {Adults} {From} the {National} {Lung} {Screening} {Trial}},
	volume = {76},
	issn = {1758-535X},
	doi = {10.1093/gerona/glaa141},
	abstract = {BACKGROUND: Muscle metrics derived from computed tomography (CT) are associated with adverse health events in older persons, but obtaining these metrics using current methods is not practical for large datasets. We developed a fully automated method for muscle measurement on CT images. This study aimed to determine the relationship between muscle measurements on CT with survival in a large multicenter trial of older adults.
METHOD: The relationship between baseline paraspinous skeletal muscle area (SMA) and skeletal muscle density (SMD) and survival over 6 years was determined in 6,803 men and 4,558 women (baseline age: 60-69 years) in the National Lung Screening Trial (NLST). The automated machine learning pipeline selected appropriate CT series, chose a single image at T12, and segmented left paraspinous muscle, recording cross-sectional area and density. Associations between SMA and SMD with all-cause mortality were determined using sex-stratified Cox proportional hazards models, adjusted for age, race, height, weight, pack-years of smoking, and presence of diabetes, chronic lung disease, cardiovascular disease, and cancer at enrollment.
RESULTS: After a mean 6.44 ± 1.06 years of follow-up, 635 (9.33\%) men and 265 (5.81\%) women died. In men, higher SMA and SMD were associated with a lower risk of all-cause mortality, in fully adjusted models. A one-unit standard deviation increase was associated with a hazard ratio (HR) = 0.85 (95\% confidence interval [CI] = 0.79, 0.91; p {\textless} .001) for SMA and HR = 0.91 (95\% CI = 0.84, 0.98; p = .012) for SMD. In women, the associations did not reach significance.
CONCLUSION: Higher paraspinous SMA and SMD, automatically derived from CT exams, were associated with better survival in a large multicenter cohort of community-dwelling older men.},
	language = {eng},
	number = {2},
	journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
	author = {Lenchik, Leon and Barnard, Ryan and Boutin, Robert D. and Kritchevsky, Stephen B. and Chen, Haiying and Tan, Josh and Cawthon, Peggy M. and Weaver, Ashley A. and Hsu, Fang-Chi},
	month = jan,
	year = {2021},
	pmcid = {PMC7812435},
	pmid = {32504466},
	note = {tex.ids= lenchik277a},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Retrospective Studies, Proportional Hazards Models, Cohort Studies, Myosteatosis, Mortality, Machine Learning, Computed tomography, Machine learning, ML, Aging, Lung},
	pages = {277--285},
	file = {Lenchik et al_2021_Automated Muscle Measurement on Chest CT Predicts All-Cause Mortality in Older.pdf:/Users/jcsal/Zotero/storage/BGQ68WQY/Lenchik et al_2021_Automated Muscle Measurement on Chest CT Predicts All-Cause Mortality in Older.pdf:application/pdf;Lenchik et al_2021_Automated Muscle Measurement on Chest CT Predicts All-Cause Mortality in Older.pdf:/Users/jcsal/Zotero/storage/MP9P8BFH/Lenchik et al_2021_Automated Muscle Measurement on Chest CT Predicts All-Cause Mortality in Older.pdf:application/pdf;Lenchik et al. - 2021 - Automated Muscle Measurement on Chest CT Predicts .pdf:/Users/jcsal/Zotero/storage/LQC3QFIB/Lenchik et al. - 2021 - Automated Muscle Measurement on Chest CT Predicts .pdf:application/pdf},
}

@article{boutin1046,
	title = {Influence of {IV} {Contrast} {Administration} on {CT} {Measures} of {Muscle} and {Bone} {Attenuation}: {Implications} for {Sarcopenia} and {Osteoporosis} {Evaluation}},
	volume = {207},
	issn = {1546-3141},
	shorttitle = {Influence of {IV} {Contrast} {Administration} on {CT} {Measures} of {Muscle} and {Bone} {Attenuation}},
	doi = {10.2214/AJR.16.16387},
	abstract = {OBJECTIVE: The objective of our study was to characterize enhancement of muscle and bone that occurs on standardized four-phase contrast-enhanced CT.
MATERIALS AND METHODS: Two musculoskeletal radiologists reviewed standardized four-phase abdominal CT scans obtained with IV contrast material. The psoas area was measured, and the mean attenuation (in Hounsfield units) was recorded for the aorta, psoas muscles, posterior paraspinal muscles, and L4 vertebral body. CT attenuation measures were compared between anatomic regions and imaging phases with the paired t test; associations between measures were examined with the Pearson correlation coefficient (R).
RESULTS: The study included 201 patients (97 men, 104 women; mean age, 57.7 ± 12.5 [SD] years). Subject age was inversely correlated with unenhanced attenuation in the psoas muscles, posterior paraspinal muscles, and L4 (p {\textless} 0.001). The psoas muscles, posterior paraspinal muscles, and L4 enhanced significantly (p {\textless} 0.001) at all three contrast-enhanced phases. The greatest muscle enhancement was observed on delayed phase scans, whereas the greatest enhancement in L4 was seen on portal phase imaging. The unenhanced attenuation of the psoas muscles was significantly and negatively correlated with enhancement of the psoas muscles at the portal and delayed phases (p {\textless} 0.05 and p {\textless} 0.01, respectively), but these correlations were not seen for the posterior paraspinal muscles. Age was positively correlated with posterior paraspinal muscle enhancement at the portal and delayed phases in men (p {\textless} 0.05 and p {\textless} 0.01, respectively) but not in women.
CONCLUSION: Contrast enhancement of commonly measured muscle and bone regions is routinely observed and should be considered when using CT attenuation values as biomarkers of sarcopenia and osteoporosis. Furthermore, CT enhancement may be significantly influenced by age, sex, and unenhanced tissue attenuation.},
	language = {eng},
	number = {5},
	journal = {AJR. American journal of roentgenology},
	author = {Boutin, Robert D. and Kaptuch, Justin M. and Bateni, Cyrus P. and Chalfant, James S. and Yao, Lawrence},
	month = nov,
	year = {2016},
	pmid = {27556335},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Retrospective Studies, Aged, 80 and over, Adult, sarcopenia, Methods, skeletal muscle, Lumbar Vertebrae, Psoas Muscles, CT, Aorta, Abdominal, contrast media, Contrast Media, osteoporosis, Osteoporosis, Paraspinal Muscles},
	pages = {1046--1054},
	file = {Boutin et al_2016_Influence of IV Contrast Administration on CT Measures of Muscle and Bone.pdf:/Users/jcsal/Zotero/storage/TVCT8ZE9/Boutin et al_2016_Influence of IV Contrast Administration on CT Measures of Muscle and Bone.pdf:application/pdf},
}

@article{romanowski3,
	title = {Computed {Tomography} {Measurements} of {Sarcopenia} {Predict} {Length} of {Stay} in {Older} {Burn} {Patients}},
	volume = {42},
	issn = {1559-0488},
	doi = {10.1093/jbcr/iraa149},
	abstract = {Sarcopenia and frailty are associated with aging. In older burn patients, frailty has been associated with mortality and discharge disposition, but sarcopenia has not been examined. This study aims to investigate the relationship between frailty and computed tomography (CT)-derived sarcopenia with length of stay and mortality in older burn patients. Burn patients ≥60 years old admitted between 2008 and 2017 who had chest or abdomen CT scans within 1 week of admission were evaluated. Frailty was assessed using the Canadian Study of Health and Aging Clinical Frailty Scale (CFS). Sarcopenia was assessed on CT exams by measuring skeletal muscle index (SMI) of paraspinal muscles at T12 and all skeletal muscles at L3. The relationship between frailty scores and SMI with length of stay (LOS) and mortality was determined using logistic regression. Eighty-three patients (59 men; mean age 70.2 ± 8.5 years) had chest (n = 50) or abdomen (n = 60) CT scans. Mean TBSA = 14.3 ± 14.0\%, LOS = 25.8 ± 21.3 days, CFS = 4.36 ± 0.99. Sixteen patients (19.3\%) died while in the hospital. CT-derived measurement of SMI at T12 was significantly associated with LOS (P {\textless} .05), but not with mortality (P = .561). CT-derived metrics at L3 were not significantly associated with outcomes. CFS was not associated with LOS (P = .836) or mortality (P = .554). In older burn patients, low SMI of the paraspinal muscles at T12 was associated with longer LOS.},
	language = {eng},
	number = {1},
	journal = {Journal of Burn Care \& Research: Official Publication of the American Burn Association},
	author = {Romanowski, Kathleen S. and Fuanga, Praman and Siddiqui, Sheryar and Lenchik, Leon and Palmieri, Tina L. and Boutin, Robert D.},
	month = feb,
	year = {2021},
	pmid = {32841333},
	pmcid = {PMC7856456},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Length of Stay, Male, Middle Aged, Sarcopenia, Predictive Value of Tests, Hospital Mortality, Frailty, WFU, Burns},
	pages = {3--8},
	annote = {Annotations(8/5/2022, 5:21:45 AM)
“CSA of posterior paraspinal muscles at T12 (CSA-T12) (the sum of the right and left posterior paraspinal muscle areas at T12 [cm2]) was measured and then adjusted for patient height to yield a skeletal muscle index at T12 (SMIT12, calculated as CSA-T12 [cm2] divided by patient height [m2]). Skeletal muscle density at T12 (SMD-T12) also was recorded (the average density of the right and left posterior paraspinal muscles measured in Hounsfield units, HU). Similarly, CSA of skeletal muscles at L3 (CSA-L3, measured in cm2), skeletal muscle index at L3 (SMI-L3, calculated as CSA-L3 [cm2] divided by patient height [m2]), and skeletal muscle density at L3 (SMD-L3, measured in HU) were recorded. The intra-rater reliability of CT measurements was assessed from 25\% of the exams after a minimum latency period of 4 weeks.” (Romanowski et al., 2021, p. 4)“CT muscle metrics were dichotomized into normal and abnormal based on published cutpoints for abnormally low muscle mass (myopenia)22,23 and density (myosteatosis) (Tables  1 and 2).24,25 Two cutpoints were used for skeletal muscle index (SMI) values at the L3 level.22,23 For skeletal muscle density (SMD), the cutpoint from Aubrey et al 25 was used because the Derstine et  al24 L3 density cutpoint only identified two abnormal patients. For patients receiving intravenous contrast material, the CT values for muscle density were adjusted.21” (Romanowski et al., 2021, p. 5)“For a subset of patients who had a second analysis of CT scans by the same person, intra-rater reliability was greater than 0.95.” (Romanowski et al., 2021, p. 6)“22. Derstine BA, Holcombe SA, Goulson RL, et al. Quantifying sarcopenia reference values using lumbar and thoracic muscle areas in a healthy population. J Nutr Health Aging 2017;21:180–5. 23. Prado  CM, Lieffers  JR, McCargar  LJ, et  al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629–35. 24. Derstine  BA, Holcombe  SA, Ross  BE, Wang  NC, Su  GL, Wang  SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep 2018;8:11369. 25. Aubrey J, Esfandiari N, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf) 2014;210:489–97.” (Romanowski et al., 2021, p. 8)},
	file = {Romanowski et al_2021_Computed Tomography Measurements of Sarcopenia Predict Length of Stay in Older.pdf:/Users/jcsal/Zotero/storage/57I43L4N/Romanowski et al_2021_Computed Tomography Measurements of Sarcopenia Predict Length of Stay in Older.pdf:application/pdf},
}

@article{cox187,
	title = {Regression {Models} and {Life}‐{Tables}},
	journal = {Journal of the Royal Statistical Society  Series B  Methodological},
	author = {Cox, DR},
	year = {1972},
	pages = {187--202},
	file = {Journal of the Royal Statistical Society  Series B  Methodological - January 1972 - Cox - Regression Models and Life‐Tables.pdf:/Users/jcsal/Zotero/storage/D4VMRDYK/Journal of the Royal Statistical Society  Series B  Methodological - January 1972 - Cox - Regression Models and Life‐Tables.pdf:application/pdf},
}

@article{kaplan457,
	title = {Nonparametric {Estimation} from {Incomplete} {Observations}},
	volume = {53},
	issn = {0162-1459, 1537-274X},
	url = {http://www.tandfonline.com/doi/abs/10.1080/01621459.1958.10501452},
	doi = {10.1080/01621459.1958.10501452},
	language = {en},
	number = {282},
	urldate = {2022-08-06},
	journal = {Journal of the American Statistical Association},
	author = {Kaplan, E. L. and Meier, Paul},
	month = jun,
	year = {1958},
	pages = {457--481},
	file = {Kaplan and Meier - 1958 - Nonparametric Estimation from Incomplete Observati.pdf:/Users/jcsal/Zotero/storage/LPCAEQT5/Kaplan and Meier - 1958 - Nonparametric Estimation from Incomplete Observati.pdf:application/pdf},
}

@article{wang255,
	title = {Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma},
	volume = {106},
	issn = {1365-2168},
	doi = {10.1002/bjs.11004},
	abstract = {BACKGROUND: Whether there is a difference in survival after neoadjuvant chemoradiotherapy plus surgery (CRT-S) compared with definitive chemoradiotherapy (dCRT) in patients with locally advanced oesophageal squamous cell carcinoma (SCC) remains controversial.
METHODS: Patients with SCC who underwent curative treatment from 2008 to 2014 were identified from the Taiwan Cancer Registry. Propensity score matching was undertaken to balance pretreatment clinical variables. Overall survival was compared between patients undergoing CRT-S or dCRT. Univariable and multivariable analyses were performed to identify prognostic factors for overall survival.
RESULTS: A total of 5832 patients with clinical stage II and III oesophageal SCC receiving CRT-S (1754) or dCRT (4078) were included. After propensity score matching, each group included 1661 patients. The 3-year overall survival rate for patients treated with CRT-S was 41·1 per cent compared with 17·9 per cent for those who had dCRT (P {\textless} 0·001). In multivariable analysis, treatment modality was an independent prognostic factor in the overall cohort before propensity score matching: hazard ratio 0·45 (95 per cent c.i. 0·40 to 0·51) for CRT-S versus dCRT (P {\textless} 0·001). In separate analyses of patients with clinical stage II and those with stage III disease, CRT-S was associated with significantly better overall survival than dCRT.
CONCLUSION: Neoadjuvant chemoradiotherapy and oesophagectomy is associated with better overall survival than dCRT in patients with stage II and III oesophageal SCC.},
	language = {eng},
	number = {3},
	journal = {The British Journal of Surgery},
	author = {Wang, B.-Y. and Wu, S.-C. and Chen, H.-C. and Hung, W.-H. and Lin, C.-H. and Huang, C.-L. and Chen, H.-S.},
	month = feb,
	year = {2019},
	pmid = {30395362},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Survival Rate, Cohort Studies, Adult, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Esophageal Squamous Cell Carcinoma, Propensity Score, Taiwan, dCRT, Tri},
	pages = {255--262},
}

@article{farrow996,
	title = {Impact of {Age} on {Surgical} {Outcomes} for {Locally} {Advanced} {Esophageal} {Cancer}},
	volume = {111},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2020.06.055},
	abstract = {BACKGROUND: Older patients are often considered high-risk surgical candidates for locally advanced esophageal cancer, and the benefit of surgery in this population is unclear. This national analysis examines the effect of age on esophagectomy outcomes and compares surgery versus chemoradiation in older patients.
METHODS: The National Cancer Database was used to identify patients with clinical stage II to III esophageal adenocarcinoma undergoing surgery or definitive chemoradiation between 2004 and 2015. Restricted cubic splines were used to examine the relationship between age and survival after esophagectomy, and maximally selected rank statistics were used to identify an age at which survival worsened. We used Cox proportional hazard models including an interaction term between age and treatment to compare overall survival, as well as survival of patients receiving esophagectomy versus definitive chemoradiation.
RESULTS: Of 17,495 patients, 11,680 underwent esophagectomy and 5815 received chemoradiation. Survival after esophagectomy worsened with increasing age and decreased considerably after age 73 (hazard ratio = 1.05, 95\% confidence interval, 1.04-1.06, per increasing year after 73 versus hazard ratio = 1.01, 95\% confidence interval, 1.00-1.01, per increasing year to 73; both P {\textless} .001). Chemoradiation was increasingly used over surgery as age increased. The interaction between age and treatment was significant, and a graph of this interaction demonstrated a survival benefit for surgery over chemoradiation at most ages, including octogenarians.
CONCLUSIONS: Survival worsens with age after esophagectomy for locally advanced esophageal cancer. However, esophagectomy is associated with improved survival compared with definitive chemoradiation at most ages, including octogenarians. Esophagectomy may be considered over chemoradiation for patients who can tolerate surgery regardless of age.},
	language = {eng},
	number = {3},
	journal = {The Annals of Thoracic Surgery},
	author = {Farrow, Norma E. and Raman, Vignesh and Jawitz, Oliver K. and Voigt, Soraya L. and Tong, Betty C. and Harpole, David H. and D'Amico, Thomas A.},
	month = mar,
	year = {2021},
	pmid = {32853569},
	pmcid = {PMC8023276},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Risk Factors, Survival Rate, Age Factors, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, dCRT, California, Tri, Age},
	pages = {996--1003},
	file = {Farrow et al_2021_Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer.pdf:/Users/jcsal/Zotero/storage/YTK92LS2/Farrow et al_2021_Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer.pdf:application/pdf},
}

@article{sugawara2305,
	title = {Preoperative {Low} {Vital} {Capacity} {Influences} {Survival} {After} {Esophagectomy} for {Patients} with {Esophageal} {Carcinoma}},
	volume = {44},
	issn = {1432-2323},
	doi = {10.1007/s00268-020-05450-0},
	abstract = {BACKGROUND: Assessment of preoperative physiological status is crucial for optimizing clinical outcomes in patients undergoing surgery for esophageal carcinoma (EC). We aimed to evaluate the prognostic impact of pulmonary dysfunctions and their relationships with other physiological factors, especially sarcopenia, in EC patients receiving esophagectomy.
METHODS: In total, 411 EC patients who underwent esophagectomy between 2006 and 2016 were retrospectively reviewed. Preoperative pulmonary functions were evaluated based on \%vital capacity (\%VC) and forced expiratory volume (FEV) 1.0\%. The thresholds were set as the lowest quartile (99\% for \%VC and 68.6\% for FEV1.0\%) in this cohort.
RESULTS: One hundred and two patients (24.8\%) had low \%VC (\%VC {\textless} 99\%), which was significantly associated with age, comorbidity, sarcopenia and postoperative complications, while not correlating with pathological variables. The overall survival (OS) of patients in the low \%VC group was significantly poorer than that of those in the high \%VC group (P {\textless} 0.001), especially in those with pStage 0-II diseases (P {\textless} 0.001). In contrast, survival was not stratified by FEV1.0\% (P = 0.80). Notably, patients with both low \%VC and sarcopenia showed very poor 5-year OS (30.3\%). Multivariate analysis revealed low \%VC to be independently associated with poor OS (P = 0.03). In the cause-specific survival analyses, low \%VC was an independent predictor of deaths from non-EC-related causes (P = 0.03).
CONCLUSIONS: Preoperative low \%VC was independently associated with poor survival outcomes, especially when present in combination with sarcopenia, due to an increased risk of death from non-EC-related causes. Preoperative spirometry testing is useful for predicting long-term outcomes in EC patients undergoing esophagectomy.},
	language = {eng},
	number = {7},
	journal = {World Journal of Surgery},
	author = {Sugawara, Kotaro and Mori, Kazuhiko and Okumura, Yasuhiro and Yagi, Koichi and Aikou, Susumu and Uemura, Yukari and Yamashita, Hiroharu and Seto, Yasuyuki},
	month = jul,
	year = {2020},
	pmid = {32123980},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Follow-Up Studies, Retrospective Studies, Risk Factors, Prognosis, Aged, 80 and over, Adult, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Carcinoma, Preoperative Period, Health Status Indicators, Forced Expiratory Volume, Vital Capacity, PFT},
	pages = {2305--2313},
	file = {s00268-020-05450-0.pdf:C\:\\Users\\jcsal\\Downloads\\s00268-020-05450-0.pdf:application/pdf},
}

@article{kubo7173,
	title = {Influences of the {Charlson} {Comorbidity} {Index} and {Nutrition} {Status} on {Prognosis} {After} {Esophageal} {Cancer} {Surgery}},
	volume = {28},
	issn = {1534-4681},
	doi = {10.1245/s10434-021-09779-1},
	abstract = {BACKGROUND: The Charlson Comorbidity Index (CCI), an indicator that objectively quantifies comorbidities, reduces nutritional status; however, the impact of the CCI on the postoperative nutrition indexes of patients with esophageal cancer remains unclear.
METHODS: In total, 336 patients with esophageal cancer who underwent surgery between January 2011 and April 2017 were included in this study. We investigated the relationship between the CCI and postoperative nutrition indexes.
RESULTS: Patients were divided into two groups: CCI ≤1 (low CCI group) and CCI ≥2 (high CCI group). A high CCI was significantly associated with shortened overall survival (OS; 3-year OS rate of 77.9\% in the low CCI group versus 59.7\% in the high CCI group; p = 0.008). Nutritional indexes, such as the Prognostic Nutritional Index (PNI), at 1 month after esophagectomy were significantly lower in the high CCI group than in the low CCI group (p = 0.031); however, the PNI at 6 months after surgery was similar between the high and low CCI groups. Multivariate analysis identified high CCI as an independent risk factor associated with PNI {\textless}45 in esophageal cancer patients at 1 month after esophagectomy (p = 0.047).
CONCLUSION: This study showed that CCI ≥2 was significantly associated with poor PNI at 1 month after surgery for esophageal cancer, indicating that it is necessary to administer effective nutritional interventions for patients with postoperative malnutrition, especially those with multiple comorbidities.},
	language = {eng},
	number = {12},
	journal = {Annals of Surgical Oncology},
	author = {Kubo, Yuto and Tanaka, Koji and Yamasaki, Makoto and Yamashita, Kotaro and Makino, Tomoki and Saito, Takuro and Yamamoto, Kazuyoshi and Takahashi, Tsuyoshi and Kurokawa, Yukinori and Motoori, Masaaki and Kimura, Yutaka and Nakajima, Kiyokazu and Eguchi, Hidetoshi and Doki, Yuichiro},
	month = nov,
	year = {2021},
	pmid = {33835302},
	keywords = {Humans, Retrospective Studies, Prognosis, Nutrition Assessment, Esophageal Neoplasms, Comorbidity, Nutritional Status, Survival, CCI},
	pages = {7173--7182},
}

@article{faiz585,
	title = {{ASO} {Author} {Reflections}: {Implementation} of {Age} and {Co}-morbidity in the {Treatment} {Guideline} of {Patients} with {Esophageal} {Squamous} {Cell} {Carcinoma}},
	volume = {26},
	issn = {1534-4681},
	shorttitle = {{ASO} {Author} {Reflections}},
	doi = {10.1245/s10434-019-07361-4},
	language = {eng},
	number = {Suppl 3},
	journal = {Annals of Surgical Oncology},
	author = {Faiz, Z. and Plukker, J. T. M.},
	month = dec,
	year = {2019},
	pmid = {31011909},
	pmcid = {PMC6901411},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Comorbidity, Esophageal Squamous Cell Carcinoma},
	pages = {585--586},
	file = {Faiz_Plukker_2019_ASO Author Reflections.pdf:/Users/jcsal/Zotero/storage/MZUA9YHG/Faiz_Plukker_2019_ASO Author Reflections.pdf:application/pdf},
}

@article{jensen1,
	title = {Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities},
	issn = {1442-2050},
	doi = {10.1093/dote/doac050},
	abstract = {The addition of surgery to chemoradiation for esophageal cancer has not shown a survival benefit in randomized trials. Patients with more comorbidities or advanced age are more likely to be given definitive chemoradiation due to surgical risk. We aimed to identify subsets of patients in whom the addition of surgery to chemoradiation does not provide an overall survival (OS) benefit. The National Cancer Database was queried for patients with locally advanced esophageal cancer who received either definitive chemoradiation or neoadjuvant chemoradiation followed by surgery. Bivariate analysis was used to assess the association between patient characteristics and treatment groups. Log-rank tests and Cox proportional hazards models were performed to assess for differences in survival. A total of 15,090 with adenocarcinoma and 5,356 with squamous cell carcinoma met the inclusion criteria. Patients treated with neoadjuvant chemoradiation and surgery had significantly improved survival by Cox proportional hazards model regardless of histology if {\textless}50, 50-60, 61-70, or 71-80 years old. There was no significant benefit or detriment in patients 81-90 years old. Survival advantage was also significant with a Charlson/Deyo comorbidity condition score of 0, 1, 2, and ≥3 in adenocarcinoma squamous cell carcinoma with scores of 2 or ≥3 had no significant benefit or detriment. Patients 81-90 years old or with squamous cell carcinoma and a Charlson/Deyo comorbidity score ≥ 2 lacked an OS benefit from neoadjuvant chemoradiation followed by surgery compared with definitive chemoradiation. Careful consideration of esophagectomy-specific surgical risks should be used when recommending treatment for these patients.},
	language = {eng},
	number = {36},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Jensen, Garrett L. and Hammonds, Kendall P. and Haque, Waqar},
	month = jul,
	year = {2022},
	pmid = {35901451},
	keywords = {esophagectomy, elderly, performance status},
	pages = {1--8},
	file = {Jensen et al_2022_Neoadjuvant versus definitive chemoradiation in locally advanced esophageal.pdf:/Users/jcsal/Zotero/storage/MKAUL6UY/Jensen et al_2022_Neoadjuvant versus definitive chemoradiation in locally advanced esophageal.pdf:application/pdf},
}

@article{noordman965,
	title = {Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer ({preSANO}): a prospective multicentre, diagnostic cohort study},
	volume = {19},
	issn = {1474-5488},
	shorttitle = {Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer ({preSANO})},
	doi = {10.1016/S1470-2045(18)30201-8},
	abstract = {BACKGROUND: After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma have a pathological complete response of the primary tumour before surgery. Thus, the necessity of standard oesophagectomy after neoadjuvant chemoradiotherapy should be reconsidered for patients who respond sufficiently to neoadjuvant treatment. In this study, we aimed to establish the accuracy of detection of residual disease after neoadjuvant chemoradiotherapy with different diagnostic approaches, and the optimal combination of diagnostic techniques for clinical response evaluations.
METHODS: The preSANO trial was a prospective, multicentre, diagnostic cohort study at six centres in the Netherlands. Eligible patients were aged 18 years or older, had histologically proven, resectable, squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophagogastric junction, and were eligible for potential curative therapy with neoadjuvant chemoradiotherapy (five weekly cycles of carboplatin [area under the curve 2 mg/mL per min] plus paclitaxel [50 mg/m2 of body-surface area] combined with 41·4 Gy radiotherapy in 23 fractions) followed by oesophagectomy. 4-6 weeks after completion of neoadjuvant chemoradiotherapy, patients had oesophagogastroduodenoscopy with biopsies and endoscopic ultrasonography with measurement of maximum tumour thickness. Patients with histologically proven locoregional residual disease or no-pass during endoscopy and without distant metastases underwent immediate surgical resection. In the remaining patients a second clinical response evaluation was done (PET-CT, oesophagogastroduodenoscopy with biopsies, endoscopic ultrasonography with measurement of maximum tumour thickness, and fine-needle aspiration of suspicious lymph nodes), followed by surgery 12-14 weeks after completion of neoadjuvant chemoradiotherapy. The primary endpoint was the correlation between clinical response during clinical response evaluations and the final pathological response in resection specimens, as shown by the proportion of tumour regression grade (TRG) 3 or 4 ({\textgreater}10\% residual carcinoma in the resection specimen) residual tumours that was missed during clinical response evaluations. This study was registered with the Netherlands Trial Register (NTR4834), and has been completed.
FINDINGS: Between July 22, 2013, and Dec 28, 2016, 219 patients were included, 207 of whom were included in the analyses. Eight of 26 TRG3 or TRG4 tumours (31\% [95\% CI 17-50]) were missed by endoscopy with regular biopsies and fine-needle aspiration. Four of 41 TRG3 or TRG4 tumours (10\% [95\% CI 4-23]) were missed with bite-on-bite biopsies and fine-needle aspiration. Endoscopic ultrasonography with maximum tumour thickness measurement missed TRG3 or TRG4 residual tumours in 11 of 39 patients (28\% [95\% CI 17-44]). PET-CT missed six of 41 TRG3 or TRG4 tumours (15\% [95\% CI 7-28]). PET-CT detected interval distant histologically proven metastases in 18 (9\%) of 190 patients (one squamous cell carcinoma, 17 adenocarcinomas).
INTERPRETATION: After neoadjuvant chemoradiotherapy for oesophageal cancer, clinical response evaluation with endoscopic ultrasonography, bite-on-bite biopsies, and fine-needle aspiration of suspicious lymph nodes was adequate for detection of locoregional residual disease, with PET-CT for detection of interval metastases. Active surveillance with this combination of diagnostic modalities is now being assessed in a phase 3 randomised controlled trial (SANO trial; Netherlands Trial Register NTR6803).
FUNDING: Dutch Cancer Society.},
	language = {eng},
	number = {7},
	journal = {The Lancet. Oncology},
	author = {Noordman, Bo Jan and Spaander, Manon C. W. and Valkema, Roelf and Wijnhoven, Bas P. L. and van Berge Henegouwen, Mark I. and Shapiro, Joël and Biermann, Katharina and van der Gaast, Ate and van Hillegersberg, Richard and Hulshof, Maarten C. C. M. and Krishnadath, Kausilia K. and Lagarde, Sjoerd M. and Nieuwenhuijzen, Grard A. P. and Oostenbrug, Liekele E. and Siersema, Peter D. and Schoon, Erik J. and Sosef, Meindert N. and Steyerberg, Ewout W. and van Lanschot, J. Jan B. and {SANO study group}},
	month = jul,
	year = {2018},
	pmid = {29861116},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Prospective Studies, Risk Assessment, Survival Rate, Prognosis, Cohort Studies, Neoplasm Invasiveness, Disease-Free Survival, Esophageal Neoplasms, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Neoplasm, Residual, Endosonography, Area Under Curve, Biopsy, Fine-Needle},
	pages = {965--974},
}

@article{hategan612,
	title = {Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature},
	volume = {28},
	issn = {1442-2050},
	shorttitle = {Trimodality therapy and definitive chemoradiotherapy for esophageal cancer},
	doi = {10.1111/dote.12242},
	abstract = {In the UK, the standard of care for esophageal cancer has generally combined surgery with neoadjuvant chemotherapy, with definitive chemoradiotherapy (dCRT) being reserved for certain subgroups. Chemoradiotherapy followed by surgery (trimodality therapy) has not been widely adopted. The outcomes of patients undergoing dCRT or trimodality therapy at our cancer center between 2004 and 2012 were restrospectively analyzed. Trimodality therapy was offered to selected patients of good performance status (World Health Organisation performance status 0/1), with squamous cell carcinoma or bulky adenocarcinoma. dCRT was offered to patients of good PS but with comorbidities, upper third tumors or at patient's request. Patients received four cycles of chemotherapy with a platinum agent (mostly cisplatin) and a fluoropyrimidine (mostly 5-fluorouracil) over a total of 11 weeks. Cycles 3 and 4 were given concurrently with radiotherapy: 50 Gy in 25 fractions for dCRT and 45 Gy in 25 fractions in the trimodality group. Surgery occurred 8-10 weeks following the completion of chemoradiotherapy. The cut-off length for maximum gross tumor volume length was 10 cm. One hundred two patients were included (47 received dCRT, and 55 received trimodality treatment). The majority of tumors were stage III (80.4\%), and two-thirds were located in the distal esophagus (64.7\%). Median follow-up was 44 months. The 2-year overall survival (OS) was 57.3\% (median OS 39.7 months) for the dCRT group and 77.8\% (median not reached) for the trimodality group. The 5-year OS rates were 38\% and 58\%, respectively. Postoperative mortality rate was low at 1.8\%, and the pathological complete response rate was 23.6\%. In conclusion, trimodality treatment for patients with esophageal and junctional gastroesophageal tumors offers high rates of 2-year survival, and the potential for long-term cure. dCRT is an established alternative for patients that are not fit or suitable for surgery.},
	language = {eng},
	number = {7},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Hategan, M. and Cook, N. and Prewett, S. and Hindmarsh, A. and Qian, W. and Gilligan, D.},
	month = oct,
	year = {2015},
	pmid = {24863560},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Survival Rate, Antineoplastic Agents, Aged, 80 and over, Adult, chemotherapy, Chemotherapy, Adjuvant, Fluorouracil, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, Esophagogastric Junction, Remission Induction, esophageal cancer, Patient Selection, surgery, Antineoplastic Protocols, Carcinoma, Adenosquamous, England, radiotherapy, trimodality therapy},
	pages = {612--618},
}

@article{zhou1207,
	title = {Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma},
	volume = {108},
	issn = {1365-2168},
	doi = {10.1093/bjs/znab162},
	abstract = {BACKGROUND: Long-term survival outcomes of trimodal therapy (TMT; chemoradiation plus surgery) and bimodal therapy (BMT; chemoradiation) have seldom been analysed. In a selective-surgery paradigm, the benefit of TMT in patients with a complete clinical response is controversial. Factors associated with survival in patients with a clinical complete response to chemoradiation were evaluated.
METHODS: Patients with stage II-III oesophageal squamous cell carcinoma treated with TMT or BMT from 2002 to 2017 were evaluated. The BMT group consisted of patients who were otherwise eligible for surgery but underwent chemoradiation alone followed by observation. This group included patients who later had salvage oesophagectomy. Survival was evaluated and compared between TMT and BMT groups. Elastic net regularization was performed to select co-variables for Cox multivariable survival analysis in patients with a clinical complete response.
RESULTS: Of 143 patients, 60 (41.9 per cent) underwent TMT and 83 (58.0 per cent) BMT. Patients who underwent TMT had longer median overall survival than those who had BMT (77 versus 33 months; P = 0.019). For patients with a clinical complete response, TMT achieved longer median overall survival than BMT (123 versus 55 months; P = 0.04). BMT had a high locoregional recurrence rate (48 versus 6 per cent; P {\textless} 0.001); 26 of 29 patients with locoregional recurrence in the BMT groupunderwent salvage resection. Cox multivariable analysis demonstrated that upper-mid oesophageal tumour location (hazard ratio (HR) 2.04; P = 0.024) and tumour length (HR 1.18; P = 0.046) were associated with worse survival. Although TMT was not associated with survival, it was a predictor of reduced recurrence (HR 0.28; P = 0.028). The maximum standardized uptake value after chemoradiation also predicted recurrence (HR 1.33; P {\textless} 0.001).
CONCLUSION: In patients who achieve a clinical complete response, TMT reduces locoregional recurrence but may not prolong survival. The differences in survival outcomes may be due to patient selection; therefore, a selective-surgery strategy in oesophageal squamous cell carcinoma is a reasonable approach.},
	language = {eng},
	number = {10},
	journal = {The British Journal of Surgery},
	author = {Zhou, N. and Mitchell, K. G. and Corsini, E. M. and Truong, V. T. T. and Antonoff, M. B. and Mehran, R. J. and Rajaram, R. and Rice, D. C. and Roth, J. A. and Sepesi, B. and Swisher, S. G. and Vaporciyan, A. A. and Walsh, G. L. and Ajani, J. A. and Hofstetter, W. L.},
	month = oct,
	year = {2021},
	pmid = {34095952},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Neoplasm Metastasis, Proportional Hazards Models, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Esophageal Squamous Cell Carcinoma, Salvage Therapy},
	pages = {1207--1215},
}

@article{vellayappanCD010511,
	title = {Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer},
	volume = {8},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD010511.pub2},
	abstract = {BACKGROUND: Please see Appendix 4 for a glossary of terms.The outcome of patients with esophageal cancer is generally poor. Although multimodal therapy is standard, there is conflicting evidence regarding the addition of esophagectomy to chemoradiotherapy.
OBJECTIVES: To compare the effectiveness and safety of chemoradiotherapy plus surgery with that of chemoradiotherapy alone in people with nonmetastatic esophageal carcinoma.
SEARCH METHODS: We performed a computerized search for relevant studies, up to Feburary 2017, on the CENTRAL, MEDLINE, and Embase databases using MeSH headings and keywords. We searched five online databases of clinical trials, handsearched conference proceedings, and screened reference lists of retrieved papers.
SELECTION CRITERIA: We included randomized controlled trials (RCTs) comparing chemoradiotherapy plus esophagectomy with chemoradiotherapy alone for localized esophageal carcinoma. We excluded RCTs comparing chemotherapy or radiotherapy alone with esophagectomy.
DATA COLLECTION AND ANALYSIS: Two authors independently selected studies, extracted data, and assessed risk of bias and the quality of the evidence, using standardized Cochrane methodological procedures. The primary outcome was overall survival (OS), estimated with Hazard Ratio (HR). Secondary outcomes, estimated with risk ratio (RR), were local and distant progression-free survival (PFS), quality of life (QoL), treatment-related mortality and morbidity, and use of salvage procedures for dysphagia. Data were analyzed using a random effects model in Review Manager 5.3 software.
MAIN RESULTS: From 2667 references, we identified two randomized studies, in six reports, that included 431 participants. All participants were clinically staged to have at least T3 and/or node positive thoracic esophageal carcinoma, 93\% of which was squamous cell histology. The risk of methodological bias of the included studies was low to moderate.High-quality evidence found the addition of esophagectomy had little or no difference on overall survival (HR 0.99, 95\% CI 0.79 to 1.24; P = 0.92; I² = 0\%; two trials). Neither study reported PFS, therefore, freedom from loco-regional relapse was used as a proxy. Moderate-quality evidence suggested that the addition of esophagectomy probably improved freedom from locoregional relapse (HR 0.55, 95\% CI 0.39 to 0.76; P = 0.0004; I² = 0\%; two trials), but low-quality evidence suggested it may increase the risk of treatment-related mortality (RR 5.11, 95\% CI 1.74 to 15.02; P = 0.003; I² = 2\%; two trials).The other pre-specified outcomes (quality of life, treatment-related toxicity, and use of salvage procedures for dysphagia) were reported by only one study, which found very low-quality evidence that use of esophagectomy was associated with reduced short-term QoL (MD 0.93, 95\% CI 0.24 to 1.62), and low-quality evidence that it reduced use of salvage procedures for dysphagia (HR 0.52, 95\% CI 0.36 to 0.75). Neither study compared treatment-related morbidity between treatment groups.
AUTHORS' CONCLUSIONS: Based on the available evidence, the addition of esophagectomy to chemoradiotherapy in locally advanced esophageal squamous cell carcinoma, provides little or no difference on overall survival, and may be associated with higher treatment-related mortality. The addition of esophagectomy probably delays locoregional relapse, however, this end point was not well defined in the included studies. It is undetermined whether these results can be applied to the treatment of adenocarcinomas, tumors involving the distal esophagus and gastro-esophageal junction, and to people with poor response to chemoradiation.},
	language = {eng},
	journal = {The Cochrane Database of Systematic Reviews},
	author = {Vellayappan, Balamurugan A. and Soon, Yu Yang and Ku, Geoffrey Y. and Leong, Cheng Nang and Lu, Jiade J. and Tey, Jeremy Cs},
	month = aug,
	year = {2017},
	pmid = {28829911},
	pmcid = {PMC6483706},
	keywords = {Humans, Randomized Controlled Trials as Topic, Fluorouracil, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Chemoradiotherapy, Combined Modality Therapy, Deglutition Disorders, Carcinoma, Quality of Life},
	pages = {CD010511},
	file = {Vellayappan et al_2017_Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.pdf:/Users/jcsal/Zotero/storage/K98URFEM/Vellayappan et al_2017_Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.pdf:application/pdf},
}

@article{voeten1271,
	title = {Definitive {Chemoradiotherapy} {Versus} {Trimodality} {Therapy} for {Resectable} {Oesophageal} {Carcinoma}: {Meta}-analyses and {Systematic} {Review} of {Literature}},
	volume = {43},
	issn = {1432-2323},
	shorttitle = {Definitive {Chemoradiotherapy} {Versus} {Trimodality} {Therapy} for {Resectable} {Oesophageal} {Carcinoma}},
	doi = {10.1007/s00268-018-04901-z},
	abstract = {BACKGROUND: Standard therapy for loco-regionally advanced, resectable oesophageal carcinoma is trimodality therapy (TMT) consisting of neoadjuvant chemoradiotherapy and oesophagectomy. Evidence of survival advantage of TMT over organ-preserving definitive chemoradiotherapy (dCRT) is inconclusive. The aim of this study is to compare survival between TMT and dCRT.
METHODS: A systematic review and meta-analyses were conducted. Randomised controlled trials and observational studies on resectable, curatively treated, oesophageal carcinoma patients above 18 years were included. Three online databases were searched for studies comparing TMT with dCRT. Primary outcomes were 1-, 2-, 3- and 5-year overall survival rates. Risk of bias was assessed using the Cochrane risk of bias tools for RCTs and cohort studies. Quality of evidence was evaluated according to Grading of Recommendation Assessment, Development and Evaluation.
RESULTS: Thirty-two studies described in 35 articles were included in this systematic review, and 33 were included in the meta-analyses. Two-, three- and five-year overall survival was significantly lower in dCRT compared to TMT, with relative risks (RRs) of 0.69 (95\% CI 0.57-0.83), 0.76 (95\% CI 0.63-0.92) and 0.57 (95\% CI 0.47-0.71), respectively. When only analysing studies with equal patient groups at baseline, no significant differences for 2-, 3- and 5-year overall survival were found with RRs of 0.83 (95\% CI 0.62-1.10), 0.81 (95\% CI 0.57-1.14) and 0.63 (95\% CI 0.36-1.12).
CONCLUSION: These meta-analyses do not show clear survival advantage for TMT over dCRT. Only a non-significant trend towards better survival was seen, assuming comparable patient groups at baseline. Non-operative management of oesophageal carcinoma patients might be part of a personalised and tailored treatment approach in future. However, to date hard evidence proving its non-inferiority compared to operative management is lacking.},
	language = {eng},
	number = {5},
	journal = {World Journal of Surgery},
	author = {Voeten, Daan M. and den Bakker, Chantal M. and Heineman, David J. and Ket, Johannes C. F. and Daams, Freek and van der Peet, Donald L.},
	month = may,
	year = {2019},
	pmid = {30607604},
	keywords = {Humans, Neoadjuvant Therapy, Survival Rate, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy},
	pages = {1271--1285},
}

@article{lv8483,
	title = {The effect of surgery plus chemoradiotherapy on survival of elderly patients with stage Ⅱ-Ⅲ esophageal cancer: a {SEER}-based demographic analysis},
	volume = {10},
	issn = {2045-7634},
	shorttitle = {The effect of surgery plus chemoradiotherapy on survival of elderly patients with stage Ⅱ-Ⅲ esophageal cancer},
	doi = {10.1002/cam4.4352},
	abstract = {BACKGROUND: The optimal treatment for elderly patients with esophageal cancer (EC) remains controversial. In the present study, we aimed to investigate whether elderly patients with stage II-III EC could benefit from trimodal therapy.
METHODS: The selected elderly patients with stage II-III EC between 2004 and 2015 were included in a retrospective cohort study from the Surveillance, Epidemiology, and End Results database. The patients were divided into two groups based on whether or not they underwent surgery. The inverse probability of treatment weighting (IPTW) analysis was used to balance the confounding factors between the two groups. The Cox regression analysis, the log-rank test, and the Kaplan-Meier curves were conducted to identify the survival benefits of different treatment regimes.
RESULTS: A total of 1596 patients were included in this cohort study, in which 278 patients underwent surgery. In the combination of chemoradiotherapy and surgery group, there were more male patients, more patients aged between 75 and 79 years, and more married patients in the surgery group. Moreover, there were more patients with adenomatous carcinoma, more patients with a tumor size of less than 5 cm, and more patients with a T3 stage in the combination group. In the survival analysis, patients in the combination group had a longer overall survival (OS) and EC-specific survival (ECSS). After IPTW analysis, the survival analysis generated similar results. The competitive risk model found that our results were stable. There was still a significant difference in OS and ECSS between the combination group and chemoradiotherapy alone group for esophageal adenocarcinoma (p {\textless} 0.001).
CONCLUSIONS: Elderly patients with stage II-III EC, especially those with adenocarcinoma, could benefit from the combination of surgery and chemoradiotherapy.},
	language = {eng},
	number = {23},
	journal = {Cancer Medicine},
	author = {Lv, Hao and Chao, Ce and Wang, Bin and Wang, Zhigang and Qian, Yongxiang and Zhang, Xiaoying},
	month = dec,
	year = {2021},
	pmid = {34800005},
	pmcid = {PMC8633220},
	keywords = {Humans, Aged, Female, Male, Neoplasm Staging, Retrospective Studies, Survival Rate, Prognosis, survival, United States, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, esophageal cancer, chemoradiotherapy, surgery, SEER Program, elderly patients},
	pages = {8483--8496},
	file = {Lv et al_2021_The effect of surgery plus chemoradiotherapy on survival of elderly patients.pdf:/Users/jcsal/Zotero/storage/QGGW6JV5/Lv et al_2021_The effect of surgery plus chemoradiotherapy on survival of elderly patients.pdf:application/pdf},
}

@article{taketa300,
	title = {Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation},
	volume = {83},
	issn = {1423-0232},
	doi = {10.1159/000341353},
	abstract = {BACKGROUND: For patients with localized esophageal cancer (EC) who can withstand surgery, the preferred therapy is chemoradiation followed by surgery (trimodality). However, after achieving a clinical complete response [clinCR; defined as both post-chemoradiation endoscopic biopsy showing no cancer and physiologic uptake by positron emission tomography (PET)], some patients decline surgery. The literature on the outcome of such patients is sparse.
METHOD: Between 2002 and 2011, we identified 622 trimodality-eligible EC patients in our prospectively maintained databases. All patients had to be trimodality eligible and must have completed preoperative staging after chemoradiation that included repeat endoscopic biopsy and PET among other routine tests.
RESULTS: Out of 622 trimodality-eligible patients identified, 61 patients (9.8\%) declined surgery. All 61 patients had a clinCR. The median age was 69 years (range 47-85). Males (85.2\%) and Caucasians (88.5\%) were dominant. Baseline stage was II (44.2\%) or III (52.5\%), and histology was adenocarcinoma (65.6\%) or squamous cell carcinoma (29.5\%). Forty-two patients are alive at a median follow-up of 50.9 months (95\% CI 39.5-62.3). The 5-year overall and relapse-free survival rates were 58.1 ± 8.4 and 35.3 ± 7.6\%, respectively. Of 13 patients with local recurrence during surveillance, 12 had successful salvage resection.
CONCLUSION: Although the outcome of 61 EC patients with clinCR who declined surgery appears reasonable, in the absence of a validated prediction/prognosis model, surgery must be encouraged for all trimodality-eligible patients.},
	language = {eng},
	number = {5},
	journal = {Oncology},
	author = {Taketa, Takashi and Correa, Arlene M. and Suzuki, Akihiro and Blum, Mariela A. and Chien, Pamela and Lee, Jeffrey H. and Welsh, James and Lin, Steven H. and Maru, Dipen M. and Erasmus, Jeremy J. and Bhutani, Manoop S. and Weston, Brian and Rice, David C. and Vaporciyan, Ara A. and Hofstetter, Wayne L. and Swisher, Stephen G. and Ajani, Jaffer A.},
	year = {2012},
	pmcid = {PMC3832345},
	pmid = {22964903},
	note = {type: Journal Article
tex.ids= taketa6},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Prospective Studies, Aged, 80 and over, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Esophagogastric Junction, Esophagoscopy, Gastrectomy, Remission Induction, Salvage Therapy, Positron-Emission Tomography, Biopsy, Treatment Refusal, Gastroscopy},
	pages = {300--304},
	file = {taketa300.pdf:/Users/jcsal/Zotero/storage/469VTSGV/taketa300.pdf:application/pdf},
}

@article{vanhagen2074,
	title = {Preoperative chemoradiotherapy for esophageal or junctional cancer},
	volume = {366},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa1112088},
	abstract = {BACKGROUND: The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population.
METHODS: We randomly assigned patients with resectable tumors to receive surgery alone or weekly administration of carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), followed by surgery.
RESULTS: From March 2004 through December 2008, we enrolled 368 patients, 366 of whom were included in the analysis: 275 (75\%) had adenocarcinoma, 84 (23\%) had squamous-cell carcinoma, and 7 (2\%) had large-cell undifferentiated carcinoma. Of the 366 patients, 178 were randomly assigned to chemoradiotherapy followed by surgery, and 188 to surgery alone. The most common major hematologic toxic effects in the chemoradiotherapy-surgery group were leukopenia (6\%) and neutropenia (2\%); the most common major nonhematologic toxic effects were anorexia (5\%) and fatigue (3\%). Complete resection with no tumor within 1 mm of the resection margins (R0) was achieved in 92\% of patients in the chemoradiotherapy-surgery group versus 69\% in the surgery group (P{\textless}0.001). A pathological complete response was achieved in 47 of 161 patients (29\%) who underwent resection after chemoradiotherapy. Postoperative complications were similar in the two treatment groups, and in-hospital mortality was 4\% in both. Median overall survival was 49.4 months in the chemoradiotherapy-surgery group versus 24.0 months in the surgery group. Overall survival was significantly better in the chemoradiotherapy-surgery group (hazard ratio, 0.657; 95\% confidence interval, 0.495 to 0.871; P=0.003).
CONCLUSIONS: Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer. The regimen was associated with acceptable adverse-event rates. (Funded by the Dutch Cancer Foundation [KWF Kankerbestrijding]; Netherlands Trial Register number, NTR487.).},
	language = {eng},
	number = {22},
	journal = {The New England Journal of Medicine},
	author = {van Hagen, P. and Hulshof, M. C. C. M. and van Lanschot, J. J. B. and Steyerberg, E. W. and van Berge Henegouwen, M. I. and Wijnhoven, B. P. L. and Richel, D. J. and Nieuwenhuijzen, G. a. P. and Hospers, G. a. P. and Bonenkamp, J. J. and Cuesta, M. A. and Blaisse, R. J. B. and Busch, O. R. C. and ten Kate, F. J. W. and Creemers, G.-J. and Punt, C. J. A. and Plukker, J. T. M. and Verheul, H. M. W. and Spillenaar Bilgen, E. J. and van Dekken, H. and van der Sangen, M. J. C. and Rozema, T. and Biermann, K. and Beukema, J. C. and Piet, A. H. M. and van Rij, C. M. and Reinders, J. G. and Tilanus, H. W. and van der Gaast, A. and {CROSS Group}},
	month = may,
	year = {2012},
	pmid = {22646630},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagogastric Junction, Paclitaxel, Preoperative Care, Carboplatin},
	pages = {2074--2084},
	file = {van Hagen et al_2012_Preoperative chemoradiotherapy for esophageal or junctional cancer.pdf:/Users/jcsal/Zotero/storage/PE99HMXM/van Hagen et al_2012_Preoperative chemoradiotherapy for esophageal or junctional cancer.pdf:application/pdf},
}

@article{christensen947,
	title = {Muscle dysfunction in cancer patients},
	volume = {25},
	issn = {1569-8041},
	doi = {10.1093/annonc/mdt551},
	abstract = {BACKGROUND: Muscle dysfunction is a prevalent phenomenon in the oncology setting where patients across a wide range of diagnoses are subject to impaired muscle function regardless of tumor stage and nutritional state. Here, we review the current evidence describing the degree, causes and clinical implications of muscle dysfunction in cancer patients. The efficacy of exercise training to prevent and/or mitigate cancer-related muscle dysfunction is also discussed.
DESIGN: We identified 194 studies examining muscular outcomes in cancer patients by searching PubMed and EMBASE databases.
RESULTS: Muscle dysfunction is evident across all stages of the cancer trajectory. The causes of cancer-related muscle dysfunction are complex, but may involve a wide range of tumor-, therapy- and/or lifestyle-related factors, depending on the clinical setting of the individual patient. The main importance of muscle dysfunction in cancer patients lies in the correlation to vital clinical end points such as cancer-specific and all-cause mortality, therapy complications and quality of life (QoL). Such associations strongly emphasize the need for effective therapeutic countermeasures to be developed and implemented in oncology practice. Significant progress has been made over the last decade in the field of exercise oncology, indicating that exercise training constitutes a potent modulator of skeletal muscle function in patients with cancer.
CONCLUSION: There are clear associations between muscle dysfunction and critical clinical end points. Yet there is a discrepancy between timing of exercise intervention trials, which can improve muscle function, and study populations in whom muscle function are proven prognostic important for clinical end points. Thus, future exercise trials should in early-stage patients, be powered to evaluate clinical outcomes associated with improvements in muscle function, or be promoted in advanced stage settings, aiming to reverse cancer-related muscle dysfunction, and thus potentially improve time-to-progression, treatment toxicity and survival.},
	language = {eng},
	number = {5},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Christensen, J. F. and Jones, L. W. and Andersen, J. L. and Daugaard, G. and Rorth, M. and Hojman, P.},
	month = may,
	year = {2014},
	pmid = {24401927},
	keywords = {Humans, Muscle, Skeletal, Treatment Outcome, Neoplasms, Exercise Therapy, Animals, Quality of Life, skeletal muscle, cancer, exercise, muscle mass, muscle strength, Muscle Strength},
	pages = {947--958},
}

@article{crabtree382,
	title = {Evaluation of the reliability of clinical staging of {T2} {N0} esophageal cancer: a review of the {Society} of {Thoracic} {Surgeons} database},
	volume = {96},
	issn = {1552-6259},
	shorttitle = {Evaluation of the reliability of clinical staging of {T2} {N0} esophageal cancer},
	doi = {10.1016/j.athoracsur.2013.03.093},
	abstract = {BACKGROUND: Clinical staging of esophageal cancer has improved with positron-emission tomography/computed tomography and endoscopic ultrasound imaging. Despite such progress, small single-center studies have questioned the reliability of clinical staging of T2 N0 esophageal cancer. This study broadly examines the adequacy of clinical staging of T2 N0 disease using The Society of Thoracic Surgeons database.
METHODS: We retrospectively studied 810 clinical stage T2 N0 patients from 2002 to 2011, with 58 excluded because of incomplete pathologic staging data. Clinical stage, pathologic stage, and preoperative characteristics were recorded. Logistic regression analysis was used to identify factors associated with upstaging at the time of surgical intervention.
RESULTS: Among 752 clinical stage T2 N0 patients, 270 (35.9\%) received induction therapy before the operation. Of 482 patients who went directly to surgical intervention, 132 (27.4\%) were confirmed as pathologic T2 N0, 125 (25.9\%) were downstaged (ie, T0-1 N0), and 225 (46.7\%) were upstaged at the operation (T3-4 N0 or Tany N1-3). Exclusive tumor upstaging (ie, pathologic T3-4 N0) accounted for 41 patients (18.2\%), whereas exclusive nodal upstaging (ie, pathological T1-2 N1-3) accounted for 100 (44.5\%). Combined tumor and nodal upstaging (ie, pathological T3-4 N1-3) accounted for 84 patients (37.3\%). Among patients who received induction therapy, 103 (38.1\%) were upstaged vs 225 (46.7\%) without induction therapy (p = 0.026). Comparing the induction therapy group and the primary surgical group, postoperative 30-day mortality (3.7\% vs 3.7\%, p {\textgreater} 0.99) and morbidity (46.3\% vs 45\%, p = 0.76) were similar.
CONCLUSIONS: Despite advances in staging techniques, clinical staging of T2 N0 esophageal cancer remains unreliable. Recognizing T2 N0 as a threshold for induction therapy in esophageal cancer, many surgeons have opted to treat T2 N0 disease with induction therapy, even though one-quarter of these patients will be pathologic T1 N0. Although this study demonstrated similar perioperative morbidity and mortality with and without induction therapy, further study is needed to examine the effect of upstaging on long-term survival.},
	language = {eng},
	number = {2},
	journal = {The Annals of Thoracic Surgery},
	author = {Crabtree, Traves D. and Kosinski, Andrzej S. and Puri, Varun and Burfeind, William and Bharat, Ankit and Patterson, G. Alexander and Hofstetter, Wayne and Meyers, Bryan F.},
	month = aug,
	year = {2013},
	pmid = {23731608},
	pmcid = {PMC4017898},
	keywords = {Humans, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Reproducibility of Results, Databases, Factual, Adenocarcinoma, computed tomography, Carcinoma, Squamous Cell, Esophageal Neoplasms, 7, EMR, EUS, NPV, PET, positive predictive value, PPV, CI, confidence interval, odds ratio, OR, CT, American Society of Anesthesiologists, ASA, c, Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study, clinical staging, CROSS, esophageal mucosal resection, esophageal ultrasound, false negative, false positive, fine needle aspiration, FN, FNA, FP, G1, G2, G3, G4, General Thoracic Surgery Database, grade moderately differentiated, grade poorly differentiated, grade undetermined, grade undifferentiated, grade well differentiated, GTSDB, Gx, Negative predictive value, p, Pathologic staging, Positron emission tomography, SD, Society of Thoracic Surgeons, standard deviation, STS, TN, TP, true negative, True positive},
	pages = {382--390},
	file = {Crabtree et al_2013_Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer.pdf:/Users/jcsal/Zotero/storage/QMVXN4W3/Crabtree et al_2013_Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer.pdf:application/pdf},
}

@article{flamen3202,
	title = {Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma},
	volume = {18},
	issn = {0732-183X},
	doi = {10.1200/JCO.2000.18.18.3202},
	abstract = {PURPOSE: A prospective study of preoperative tumor-node-metastasis staging of patients with esophageal cancer (EC) was designed to compare the accuracy of 18-F-fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET) with conventional noninvasive modalities.
PATIENTS AND METHODS: Seventy-four patients with carcinomas of the esophagus (n = 43) or gastroesophageal junction (n = 31) were studied. All patients underwent attenuation-corrected FDG-PET imaging, a spiral computed tomography (CT) scan, and an endoscopic ultrasound (EUS).
RESULTS: FDG-PET demonstrated increased activity in the primary tumor in 70 of 74 patients (sensitivity: 95\%). False-negative PET images were found in four patients with T1 lesions. Thirty-four patients (46\%) had stage IV disease. FDG-PET had a higher accuracy for diagnosing stage IV disease compared with the combination of CT and EUS (82\% v 64\%, respectively; P: =.004). FDG-PET had additional diagnostic value in 16 (22\%) of 74 patients by upstaging 11 (15\%) and downstaging five (7\%) patients. Thirty-nine (53\%) of the 74 patients underwent a 2- or 3-field lymphadenectomy in conjunction with primary curative esophagectomy. In these patients, tumoral involvement was found in 21 local and 35 regional or distant lymph nodes (LN). For local LN, the sensitivity of FDG-PET was lower than EUS (33\% v 81\%, respectively; P: =.027), but the specificity may have been higher (89\% v 67\%, respectively; P: = not significant [NS]). For the assessment of regional and distant LN involvement, compared with the combined use of CT and EUS, FDG-PET had a higher specificity (90\% v 98\%, respectively; P: =. 025) and a similar sensitivity (46\% v 43\%, respectively; P: = NS).
CONCLUSION: PET significantly improves the detection of stage IV disease in EC compared with the conventional staging modalities. PET improves diagnostic specificity for LN staging.},
	language = {eng},
	number = {18},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Flamen, P. and Lerut, A. and Van Cutsem, E. and De Wever, W. and Peeters, M. and Stroobants, S. and Dupont, P. and Bormans, G. and Hiele, M. and De Leyn, P. and Van Raemdonck, D. and Coosemans, W. and Ectors, N. and Haustermans, K. and Mortelmans, L.},
	month = sep,
	year = {2000},
	pmid = {10986052},
	keywords = {Humans, Tomography, X-Ray Computed, Neoplasm Staging, Neoplasm Metastasis, Prospective Studies, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Fluorodeoxyglucose F18, Radiopharmaceuticals, Sensitivity and Specificity, Ultrasonography, Lymphatic Metastasis, Radionuclide Imaging},
	pages = {3202--3210},
	file = {Flamen et al_2000_Utility of positron emission tomography for the staging of patients with.pdf:/Users/jcsal/Zotero/storage/FTZBZCJA/Flamen et al_2000_Utility of positron emission tomography for the staging of patients with.pdf:application/pdf},
}

@article{tanaka146,
	title = {The significance of abdominal para-aortic lymph node metastasis in patients with lower thoracic esophageal cancer},
	volume = {25},
	issn = {1442-2050},
	doi = {10.1111/j.1442-2050.2011.01222.x},
	abstract = {Para-aortic lymph node (PALN) recurrence is often seen in patients with lower thoracic esophageal cancer treated by esophagectomy with extended lymph node dissection. However, the clinicopathological characteristics of patients with PALN metastasis and the significance of PALN dissection are unknown. A total of 283 patients with lower thoracic esophageal cancer underwent esophagectomy with lymphadenectomy at our hospital between April 1984 and March 2007. Among these 283 patients, 60 patients were enrolled in this retrospective study according to following criteria: (i) clinical T2 to T4 tumor, (ii) no clinical PALN metastasis, and (iii) received PALN dissection. PALN dissection was indicated by a tumor depth of at least T2 and no severe complications. The clinicopathological data, recurrence pattern, and overall survival were compared between patients with PALN and without PALN metastasis. The mean length of surgery was 587 min and the mean blood loss was 1383 mL. The morbidity was 33.3\% and mortality was 5\% in this series. Sixteen patients (26.7\%) had PALN metastasis; these showed significantly more lymph node metastases (15.8 ± 13.2 vs. 3.0 ± 3.2, P {\textless} 0.0001) and significantly worse survival rates (53.3\% vs. 79.9\% at 1 year, 6.7\% vs. 62.0\% at 3 years, P {\textless} 0.0001) than patients without PALN metastasis. The incidence of lymph node recurrence (P {\textless} 0.0001) and hematogenous recurrence (P= 0.0487) was also higher in patients with PALN metastasis than in patients without PALN metastasis. Among the 16 patients with PALN metastasis, a univariate analysis revealed total number of metastatic nodes {\textless} 8 (P= 0.0325) to be a significant prognostic factor. A multivariate logistic regression analysis of the regional lymph nodes identified the invasion of the lower mediastinal nodes (hazard ratio = 6.120) and retroperitoneal nodes (hazard ratio = 15.167) to be significantly correlated with PALN metastasis. PALN metastasis is suggested to be related to the systemic spread of lymphatic metastasis even in lower thoracic esophageal cancer. PALN dissection for pathological PALN(+) patients should not be performed. It remains to be determined in future prospective studies whether patients without pathological PALN metastasis, but showing PALN micrometastasis, could achieve improved survival with PALN dissection.},
	language = {eng},
	number = {2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Tanaka, K. and Yano, M. and Motoori, M. and Doki, Y. and Kishi, K. and Miyashiro, I. and Shingai, T. and Gotoh, K. and Noura, S. and Takahashi, H. and Ohue, M. and Yamada, T. and Ohigashi, H. and Ishikawa, O.},
	month = feb,
	year = {2012},
	pmid = {21762280},
	keywords = {Humans, Female, Male, Follow-Up Studies, Retrospective Studies, Prognosis, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Postoperative Complications, Lymphatic Metastasis, Lymph Node Excision, Lymph Nodes, PET, Abdominal Neoplasms, Nodes},
	pages = {146--152},
}

@article{ye1734,
	title = {Para-aortic lymph node metastasis in lower {Thoracic} {Esophageal} {Squamous} {Cell} {Carcinoma} after {Radical} {Esophagectomy}: a {CT}-based atlas and its clinical implications for {Adjuvant} {Radiotherapy}},
	volume = {12},
	issn = {1837-9664},
	shorttitle = {Para-aortic lymph node metastasis in lower {Thoracic} {Esophageal} {Squamous} {Cell} {Carcinoma} after {Radical} {Esophagectomy}},
	doi = {10.7150/jca.51212},
	abstract = {Background: Our previous work showed that para-aortic lymph node (PALN) metastasis was the major failure pattern in lower thoracic esophageal squamous cell carcinoma (LTESCC) patients who presented abdominal LN failure after curative surgery. We thereby aim to generate a computerized tomography (CT)-based documentation of PALNs and to propose a clinical target volume (CTV) for this region. Methods: Sixty-five patients were enrolled. The epicentre of each PALN was drawn onto an axial CT image of a standard patient with reference to the surrounding anatomical landmarks. A CTV for PALN was generated based on the final result of node distribution, and was evaluated for dosimetric performance in three simulated patients. Results: All the studied 248 LNs were below the level of 1.0 cm above the celiac artery (CA), and 94.76\% were above the bottom of vertebra L3. Horizontally, 93.33\% of the LNs in the celiac level were located within an expansion of 1.5 cm on the CA, and 94.12\% of the LNs in the superior mesenteric artery (SMA) level were within 1.5 cm on the left side of the SMA. Below the SMA, all the LNs were behind the left renal vein, left to the right border of the inferior vena cava, and 98.51\% of the LNs were medial to the lateral surface of the left psoas major. The proposed CTV could cover 92.74\% of the LNs and was dosimetrically feasible. Conclusions: The proposed CTV is the first one to focus on the high-risk area of abdominal failure in LTESCC patients after surgery and can serve as a reference in the adjuvant radiotherapy for LTESCC patients.},
	language = {eng},
	number = {6},
	journal = {Journal of Cancer},
	author = {Ye, Luxi and Zhou, Lijun and Wang, Shengping and Sun, Lining and Wang, Jiazhou and Liu, Quan and Yang, Xi and Chu, Li and Zhang, Xiaofei and Hu, Weigang and Lin, Jie and Zhu, Zhengfei},
	year = {2021},
	pmid = {33613762},
	pmcid = {PMC7890317},
	keywords = {computed tomography, PET, radiation therapy, Nodes, adjuvant radiotherapy, esophageal squamous cell carcinoma, lymph node},
	pages = {1734--1741},
	file = {Ye et al_2021_Para-aortic lymph node metastasis in lower Thoracic Esophageal Squamous Cell.pdf:/Users/jcsal/Zotero/storage/T8UHB5C9/Ye et al_2021_Para-aortic lymph node metastasis in lower Thoracic Esophageal Squamous Cell.pdf:application/pdf},
}

@article{fuchs2455,
	title = {Quantifying the effect of slice thickness, intravenous contrast and tube current on muscle segmentation: {Implications} for body composition analysis},
	volume = {28},
	issn = {1432-1084},
	shorttitle = {Quantifying the effect of slice thickness, intravenous contrast and tube current on muscle segmentation},
	doi = {10.1007/s00330-017-5191-3},
	abstract = {OBJECTIVES: To quantify the effect of IV contrast, tube current and slice thickness on skeletal muscle cross-sectional area (CSA) and density (SMD) on routine CT.
METHODS: CSA and SMD were computed on 216 axial CT images obtained at the L3 level in 72 patients with variations in IV contrast, slice thickness and tube current. Intra-patient mean difference (MD), 95 \% CI and limits of agreement were calculated using the Bland-Altman approach. Inter- and intra-analyst agreement was evaluated.
RESULTS: IV contrast significantly increased CSA by 1.88 \% (MD 2.33 cm2; 95 \% CI 1.76-2.89) and SMD by 5.99 \% (p{\textless}0.0001). Five mm slice thickness significantly increased mean CSA by 1.11 \% compared to 2 mm images (1.32 cm2; 0.78-1.85) and significantly decreased SMD by 11.64 \% (p{\textless}0.0001). Low tube current significantly decreased mean CSA by 4.79 \% (6.44 cm2; 3.78-9.10) and significantly increased SMD by 46.46 \% (p{\textless}0.0001). Inter- and intra-analyst agreement was excellent.
CONCLUSIONS: IV contrast, slice thickness and tube current significantly affect CSA and SMD. Investigators designing and analysing clinical trials using CT for body composition analysis should report CT acquisition parameters and consider the effect of slice thickness, IV contrast and tube current on myometric data.
KEY POINTS: • Intravenous contrast, slice thickness and tube current significantly affect myometric data. • Image acquisition parameter variations may obscure intrapatient muscle differences on serial measurements. • Investigators using CT for body composition analysis should report CT acquisition parameters.},
	language = {eng},
	number = {6},
	journal = {European Radiology},
	author = {Fuchs, Georg and Chretien, Yves R. and Mario, Julia and Do, Synho and Eikermann, Matthias and Liu, Bob and Yang, Kai and Fintelmann, Florian J.},
	month = jun,
	year = {2018},
	pmid = {29318425},
	keywords = {Abdomen, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Muscles, Aged, 80 and over, Adult, Body composition, Young Adult, Positron Emission Tomography Computed Tomography, Contrast Media, Anthropometry, Image Interpretation, Computer-Assisted, Infusions, Intravenous, Radiographic Image Interpretation, Computer-Assisted, Contrast},
	pages = {2455--2463},
}

@article{morsbach50,
	title = {Body composition evaluation with computed tomography: {Contrast} media and slice thickness cause methodological errors},
	volume = {59},
	issn = {1873-1244},
	shorttitle = {Body composition evaluation with computed tomography},
	doi = {10.1016/j.nut.2018.08.001},
	abstract = {OBJECTIVE: Although computed tomography (CT) is frequently used to determine body composition, the effects of using different CT protocols is not well known. The aim of this study was to determine whether contrast media phase, radiation dose, and slice thickness in CT affect body composition segmentation.
METHODS: Clinically indicated perfusion CTs of the upper abdomen in 20 patients (seven women) between 40 and 87 y of age with high suspicion of hepatocellular carcinoma were analyzed retrospectively. Axial images from the L3 level with varying imaging delay were reconstructed after contrast media injection (18 images per patient), slice thickness (5 images, 2-10 mm), and radiation dose (4 images with one-third to four-thirds of standard dose). Muscle and fat areas were segmented semiautomatically by drawing regions of interests and using established cutoff thresholds. Skeletal muscle index (SMI), steatotic muscle area, and adipose tissue index, as well as muscle attenuation and fat attenuation, were evaluated.
RESULTS: Average SMI increased by up to 2.8\% after contrast media injection. Steatotic muscle area decreased by ≤13.8\%, and adipose tissue index decreased by ≤6.5\%. Muscle attenuation increased after contrast media injection, whereas fat attenuation decreased (all P {\textless} 0.001). SMI decreased by 1.9\% on average when increasing slice thickness from 2 to 10 mm. Steatotic muscle area increased by ≤3.3\%, and adipose tissue index increased by ≤1.5\% (all P {\textless} 0.05). Muscle attenuation did not change significantly with reconstruction thickness. Radiation dose had no effect on estimated area of spinal muscle, fatty spinal muscle, or visceral fat.
CONCLUSIONS: Contrast media have a strong effect on the evaluation of body composition, whereas the influence of slice thickness is less pronounced. Radiation dose can be reduced by ≥66\% without significantly affecting segmentation.},
	language = {eng},
	journal = {Nutrition (Burbank, Los Angeles County, Calif.)},
	author = {Morsbach, Fabian and Zhang, Yi-Hua and Martin, Lena and Lindqvist, Catarina and Brismar, Torkel},
	month = mar,
	year = {2019},
	pmid = {30419500},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Retrospective Studies, Aged, 80 and over, Adult, Body composition, Liver Neoplasms, Radiation Dosage, Methods, Diagnostic Errors, Skeletal muscle index, Muscle, Contrast Media, Contrast, Carcinoma, Hepatocellular, Computed tomography, Fat, Segmentation},
	pages = {50--55},
}

@article{bae32,
	title = {Intravenous contrast medium administration and scan timing at {CT}: considerations and approaches},
	volume = {256},
	issn = {1527-1315},
	shorttitle = {Intravenous contrast medium administration and scan timing at {CT}},
	doi = {10.1148/radiol.10090908},
	abstract = {The continuing advances in computed tomographic (CT) technology in the past decades have provided ongoing opportunities to improve CT image quality and clinical practice and discover new clinical CT imaging applications. New CT technology, however, has introduced new challenges in clinical radiology practice. One of the challenges is with intravenous contrast medium administration and scan timing. In this article, contrast medium pharmacokinetics and patient, contrast medium, and CT scanning factors associated with contrast enhancement and scan timing are presented and discussed. Published data from clinical studies of contrast medium and physiology are reviewed and interpreted. Computer simulation data are analyzed to provide an in-depth analysis of various factors associated with contrast enhancement and scan timing. On the basis of basic principles and analysis of the factors, clinical considerations and modifications to protocol design that are necessary to optimize contrast enhancement for common clinical CT applications are proposed.},
	language = {eng},
	number = {1},
	journal = {Radiology},
	author = {Bae, Kyongtae T.},
	month = jul,
	year = {2010},
	pmid = {20574084},
	keywords = {Humans, Tomography, X-Ray Computed, Time Factors, Radiation Dosage, Computer Simulation, Contrast Media, Anthropometry, Infusions, Intravenous, Radiographic Image Interpretation, Computer-Assisted, Contrast, Clinical Protocols, Injections, Intravenous, Radiographic Image Enhancement},
	pages = {32--61},
}

@article{vanderwerf366,
	title = {Skeletal muscle analyses: agreement between non-contrast and contrast {CT} scan measurements of skeletal muscle area and mean muscle attenuation},
	volume = {38},
	issn = {1475-097X},
	shorttitle = {Skeletal muscle analyses},
	doi = {10.1111/cpf.12422},
	abstract = {Low skeletal muscle area (SMA) and muscle radiation attenuation (MRA) have been associated with poor prognosis in various patient populations. Both non-contrast and contrast CT scans are used to determine SMA and MRA. The effect of the use of a contrast agent on SMA and MRA is unknown. Therefore, we investigated agreement between these two scan options. SMA and MRA of 41 healthy individuals were analysed on a paired non-contrast and contrast single CT scan, and agreement between paired scan results was assessed with use of Bland-Altman plots, intraclass correlation coefficients (ICCs), standard error of measurements (SEM) and smallest detectable differences at a 95\% confidence level (SDD95 ). Analyses were stratified by tube voltage. Difference in SMA between non-contrast and contrast scans made with a different tube voltage was 7·0 ± 7·5 cm2 ; for scans made with the same tube voltage this was 2·3 ± 1·7 cm2 . Agreement was excellent for both methods: ICC: 0·952, SEM: 7·2 cm2 , SDD95 : 19·9 cm2 and ICC: 0·997, SEM: 2·0 cm2 , SDD95 : 5·6 cm2 , respectively. MRA of scans made with a different tube voltage differed 1·3 ± 11·3 HU, and agreement was poor (ICC: 0·207, SEM: 7·9 HU, SDD95 : 21·8 HU). For scans made with the same tube voltage the difference was 6·7 ± 3·2 HU, and agreement was good (ICC: 0·682, SEM: 5·3 HU, SDD95 : 14·6 HU). In conclusion, SMA and MRA can be slightly influenced by the use of contrast agent. To minimise measurement error, image acquisition parameters of the scans should be similar.},
	language = {eng},
	number = {3},
	journal = {Clinical Physiology and Functional Imaging},
	author = {van der Werf, Anne and Dekker, Ingeborg M. and Meijerink, Martijn R. and Wierdsma, Nicolette J. and de van der Schueren, Marian A. E. and Langius, Jacqueline A. E.},
	month = may,
	year = {2018},
	pmid = {28419687},
	keywords = {Humans, Muscle, Skeletal, Reproducibility of Results, Predictive Value of Tests, computed tomography, Multidetector Computed Tomography, Contrast Media, muscle mass, Contrast, Administration, Intravenous, contrast agent, Healthy Volunteers, muscle density, Observer Variation, single slice, Method},
	pages = {366--372},
	file = {van der Werf et al_2018_Skeletal muscle analyses.pdf:/Users/jcsal/Zotero/storage/BBT4S2W2/van der Werf et al_2018_Skeletal muscle analyses.pdf:application/pdf},
}

@article{vanvugt1707,
	title = {Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography},
	volume = {37},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2017.07.007},
	abstract = {BACKGROUND \& AIMS: Low skeletal muscle mass and density have recently been discovered as prognostic and predictive parameters to guide interventions in various populations, including cancer patients. The gold standard for body composition analysis in cancer patients is computed tomography (CT). To date, the effect of contrast-enhancement on muscle composition measurements has not been established. The aim of this study was to determine the effect of contrast-enhancement on skeletal muscle mass and density measurements on four-phase CT studies.
DESIGN: In this observational study, two observers measured cross-sectional skeletal muscle area corrected for patients' height (skeletal muscle index [SMI]) and density (SMD) at the level of the third lumbar vertebra on 50 randomly selected CT examinations with unenhanced, arterial, and portal-venous phases. The levels of agreement between enhancement phases for SMI and SMD were calculated using intra-class correlation coefficients (ICCs).
RESULTS: Mean SMI was 42.5 (±9.9) cm2/m2 on the unenhanced phase, compared with 42.8 (±9.9) and 43.6 (±9.9) cm2/m2 for the arterial and portal-venous phase, respectively (both p {\textless} 0.01). Mean SMD was lower for the unenhanced phase (30.9 ± 8.0 Hounsfield units [HU]) compared with the arterial (38.0 ± 9.9 HU) and portal-venous (38.7 ± 9.2 HU) phase (both p {\textless} 0.001). No significant difference was found between SMD in the portal-venous and arterial phase (p = 0.161). The ICCs were excellent (≥0.992) for all SMIs and for SMD between the contrast-enhanced phases (0.949). The ICCs for the unenhanced phase compared with the arterial (0.676) and portal-venous (0.665) phase were considered fair to good.
CONCLUSIONS: Statistically significant differences in SMI were observed between different enhancement phases. However, further work is needed to assess the clinical relevance of these small differences. Contrast-enhancement strongly influenced SMD values. Studies using this measure should therefore use the portal-venous phase of contrast-enhanced CT examinations.},
	language = {eng},
	number = {5},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {van Vugt, Jeroen L. A. and Coebergh van den Braak, Robert R. J. and Schippers, Henk J. W. and Veen, Kevin M. and Levolger, Stef and de Bruin, Ron W. F. and Koek, Marcel and Niessen, Wiro J. and IJzermans, Jan N. M. and Willemsen, François E. J. A.},
	month = oct,
	year = {2018},
	pmid = {28743427},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Male, Sarcopenia, Body Mass Index, Body Weight, Skeletal muscle mass, Methods, Contrast Media, Contrast, Computed tomography, Arteries, Body Height, Contrast-enhancement, Portal Vein, Skeletal muscle density},
	pages = {1707--1714},
}

@article{jang360,
	title = {Opportunistic {Osteoporosis} {Screening} at {Routine} {Abdominal} and {Thoracic} {CT}: {Normative} {L1} {Trabecular} {Attenuation} {Values} in {More} than 20 000 {Adults}},
	volume = {291},
	issn = {1527-1315},
	shorttitle = {Opportunistic {Osteoporosis} {Screening} at {Routine} {Abdominal} and {Thoracic} {CT}},
	doi = {10.1148/radiol.2019181648},
	abstract = {Background Abdominal and thoracic CT provide a valuable opportunity for osteoporosis screening regardless of the clinical indication for imaging. Purpose To establish reference normative ranges for first lumbar vertebra (L1) trabecular attenuation values across all adult ages to measure bone mineral density (BMD) at routine CT. Materials and Methods Reference data were constructed from 20 374 abdominal and/or thoracic CT examinations performed at 120 kV. Data were derived from adults (mean age, 60 years ± 12 [standard deviation]; 56.1\% [11 428 of 20 374] women). CT examinations were performed with (n = 4263) or without (n = 16 111) intravenous contrast agent administration for a variety of unrelated clinical indications between 2000 and 2018. L1 Hounsfield unit measurement was obtained either with a customized automated tool (n = 11 270) or manually by individual readers (n = 9104). The effects of patient age, sex, contrast agent, and manual region-of-interest versus fully automated L1 Hounsfield unit measurement were assessed using multivariable logistic regression analysis. Results Mean L1 attenuation decreased linearly with age at a rate of 2.5 HU per year, averaging 226 HU ± 44 for patients younger than 30 years and 89 HU ± 38 for patients 90 years or older. Women had a higher mean L1 attenuation compared with men (P {\textless} .008) until menopause, after which both groups had similar values. Administration of intravenous contrast agent resulted in negligible differences in mean L1 attenuation values except in patients younger than 40 years. The fully automated method resulted in measurements that were average 21 HU higher compared with manual measurement (P {\textless} .004); at intrapatient subanalysis, this difference was related to the level of transverse measurement used (midvertebra vs off-midline level). Conclusion Normative ranges of L1 vertebra trabecular attenuation were established across all adult ages, and these can serve as a quick reference at routine CT to identify adults with low bone mineral density who are at risk for osteoporosis. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Smith in this issue.},
	language = {eng},
	number = {2},
	journal = {Radiology},
	author = {Jang, Samuel and Graffy, Peter M. and Ziemlewicz, Timothy J. and Lee, Scott J. and Summers, Ronald M. and Pickhardt, Perry J.},
	month = may,
	year = {2019},
	pmid = {30912719},
	pmcid = {PMC6492986},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Retrospective Studies, Aged, 80 and over, Adult, Young Adult, Adolescent, Radiography, Abdominal, Contrast Media, Osteoporosis, ML, Cancellous Bone, Mass Screening, Radiography, Thoracic},
	pages = {360--367},
	file = {Jang et al_2019_Opportunistic Osteoporosis Screening at Routine Abdominal and Thoracic CT.pdf:/Users/jcsal/Zotero/storage/9IUZ2KWC/Jang et al_2019_Opportunistic Osteoporosis Screening at Routine Abdominal and Thoracic CT.pdf:application/pdf},
}

@article{lenchik1695,
	title = {Automated {Segmentation} of {Tissues} {Using} {CT} and {MRI}: {A} {Systematic} {Review}},
	volume = {26},
	issn = {1878-4046},
	shorttitle = {Automated {Segmentation} of {Tissues} {Using} {CT} and {MRI}},
	doi = {10.1016/j.acra.2019.07.006},
	abstract = {RATIONALE AND OBJECTIVES: The automated segmentation of organs and tissues throughout the body using computed tomography and magnetic resonance imaging has been rapidly increasing. Research into many medical conditions has benefited greatly from these approaches by allowing the development of more rapid and reproducible quantitative imaging markers. These markers have been used to help diagnose disease, determine prognosis, select patients for therapy, and follow responses to therapy. Because some of these tools are now transitioning from research environments to clinical practice, it is important for radiologists to become familiar with various methods used for automated segmentation.
MATERIALS AND METHODS: The Radiology Research Alliance of the Association of University Radiologists convened an Automated Segmentation Task Force to conduct a systematic review of the peer-reviewed literature on this topic.
RESULTS: The systematic review presented here includes 408 studies and discusses various approaches to automated segmentation using computed tomography and magnetic resonance imaging for neurologic, thoracic, abdominal, musculoskeletal, and breast imaging applications.
CONCLUSION: These insights should help prepare radiologists to better evaluate automated segmentation tools and apply them not only to research, but eventually to clinical practice.},
	language = {eng},
	number = {12},
	journal = {Academic Radiology},
	author = {Lenchik, Leon and Heacock, Laura and Weaver, Ashley A. and Boutin, Robert D. and Cook, Tessa S. and Itri, Jason and Filippi, Christopher G. and Gullapalli, Rao P. and Lee, James and Zagurovskaya, Marianna and Retson, Tara and Godwin, Kendra and Nicholson, Joey and Narayana, Ponnada A.},
	month = dec,
	year = {2019},
	pmid = {31405724},
	pmcid = {PMC6878163},
	keywords = {Humans, Magnetic Resonance Imaging, Tomography, X-Ray Computed, Review, CT, Segmentation, Algorithms, Machine learning, ML, Automation, MRI, Quantitative imaging},
	pages = {1695--1706},
	file = {Lenchik et al_2019_Automated Segmentation of Tissues Using CT and MRI.pdf:/Users/jcsal/Zotero/storage/AUTXIM6A/Lenchik et al_2019_Automated Segmentation of Tissues Using CT and MRI.pdf:application/pdf},
}

@article{kullberg10425,
	title = {Automated analysis of liver fat, muscle and adipose tissue distribution from {CT} suitable for large-scale studies},
	volume = {7},
	issn = {2045-2322},
	doi = {10.1038/s41598-017-08925-8},
	abstract = {Computed Tomography (CT) allows detailed studies of body composition and its association with metabolic and cardiovascular disease. The purpose of this work was to develop and validate automated and manual image processing techniques for detailed and efficient analysis of body composition from CT data. The study comprised 107 subjects examined in the Swedish CArdioPulmonary BioImage Study (SCAPIS) using a 3-slice CT protocol covering liver, abdomen, and thighs. Algorithms were developed for automated assessment of liver attenuation, visceral (VAT) and subcutaneous (SAT) abdominal adipose tissue, thigh muscles, subcutaneous, subfascial (SFAT) and intermuscular adipose tissue. These were validated using manual reference measurements. SFAT was studied in selected subjects were the fascia lata could be visually identified (approx. 5\%). In addition, precision of manual measurements of intra- (IPAT) and retroperitoneal adipose tissue (RPAT) and deep- and superficial SAT was evaluated using repeated measurements. Automated measurements correlated strongly to manual reference measurements. The SFAT depot showed the weakest correlation (r = 0.744). Automated VAT and SAT measurements were slightly, but significantly overestimated (≤4.6\%, p ≤ 0.001). Manual segmentation of abdominal sub-depots showed high repeatability (CV ≤ 8.1\%, r ≥ 0.930). We conclude that the low dose CT-scanning and automated analysis makes the setup suitable for large-scale studies.},
	language = {eng},
	number = {1},
	journal = {Scientific Reports},
	author = {Kullberg, Joel and Hedström, Anders and Brandberg, John and Strand, Robin and Johansson, Lars and Bergström, Göran and Ahlström, Håkan},
	month = sep,
	year = {2017},
	pmid = {28874743},
	pmcid = {PMC5585405},
	keywords = {Adipose Tissue, Adiposity, Body Composition, Humans, Tomography, X-Ray Computed, Female, Male, Middle Aged, Liver, Muscles, Image Processing, Computer-Assisted, Reproducibility of Results, Abdominal Fat, ML, Automation},
	pages = {10425},
	file = {Kullberg et al_2017_Automated analysis of liver fat, muscle and adipose tissue distribution from CT.pdf:/Users/jcsal/Zotero/storage/3ARKMCXK/Kullberg et al_2017_Automated analysis of liver fat, muscle and adipose tissue distribution from CT.pdf:application/pdf},
}

@article{hopkins1381,
	title = {Barriers to the {Interpretation} of {Body} {Composition} in {Colorectal} {Cancer}: {A} {Review} of the {Methodological} {Inconsistency} and {Complexity} of the {CT}-{Defined} {Body} {Habitus}},
	volume = {25},
	issn = {1534-4681},
	shorttitle = {Barriers to the {Interpretation} of {Body} {Composition} in {Colorectal} {Cancer}},
	doi = {10.1245/s10434-018-6395-8},
	abstract = {BACKGROUND: Measurement of body composition by computed tomography (CT) is an advancing field. Sarcopenia, myosteatosis, and visceral obesity (VO) have been identified as predictive of survival in colorectal cancer (CRC). We performed a systematic review of contemporary studies to characterize this association and highlight methodological inconsistencies.
METHODS: MEDLINE and PubMed were queried for articles published from January 2000 on, with populations of resectable CRC and with CT-measured body composition and survival data. The study quality was assessed by two independent reviewers using the Newcastle-Ottawa Scale.
RESULTS: Twenty studies met inclusion criteria, with a total of 8895 patients. Only two of the studies scored as high quality and nine as moderate quality. The remaining nine studies scored as low quality. Ten studies considered sarcopenia and 12 considered visceral obesity (VO). Cutoff points to define sarcopenia, myosteatosis, and VO were identified by optimal stratification, quartiles, or median values. The prevalence of sarcopenia varied from 15 to 60\%, which based on study population and cutoff value used. Sarcopenia was associated with worse overall and disease-free survival in eight of the included studies. Myosteatosis was considered in three studies with a prevalence of 19-78\%. It was significantly predictive of worse overall and disease-free survival in all three studies. VO had a prevalence of 14-70\% and was inconsistently predictive of survival outcomes.
CONCLUSIONS: There is a lack of methodological consistency within the currently published literature. Despite this, sarcopenia and myosteatosis, but not VO, are consistently associated with worse survival outcomes, when population and cancer-specific cutoffs are utilized.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgical Oncology},
	author = {Hopkins, Jessica J. and Skubleny, Daniel and Bigam, David L. and Baracos, Vickie E. and Eurich, Dean T. and Sawyer, Michael B.},
	month = may,
	year = {2018},
	pmid = {29488190},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Sarcopenia, Colorectal Neoplasms, Survival Rate, Disease-Free Survival, Methods, Review, Muscular Diseases, Obesity, Abdominal},
	pages = {1381--1394},
}

@article{martin227,
	title = {Cancer-{Associated} {Malnutrition} and {CT}-{Defined} {Sarcopenia} and {Myosteatosis} {Are} {Endemic} in {Overweight} and {Obese} {Patients}},
	volume = {44},
	issn = {1941-2444},
	doi = {10.1002/jpen.1597},
	abstract = {BACKGROUND: Overweight/obese patients' large fat mass can mask the loss of skeletal muscle, which is associated with mortality in the oncology setting. We investigated the prevalence of computed tomography (CT)-defined sarcopenia and myosteatosis across different levels of nutrition risk assessed by the Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF). We also evaluated whether the PG-SGA SF, sarcopenia, and myosteatosis were prognostic of overall survival.
METHODS: This was a prospective, observational study. Consecutive patients with body mass index ≥25.0 kg/m2 with newly diagnosed head and neck cancer (any stage) or lung and gastrointestinal tract cancer (locally recurrent or metastatic) were screened at presentation to oncology clinics. Nutrition risk was assigned based on PG-SGA SF triage recommendations. Based on CT, patients were classified with sarcopenia and/or myosteatosis using published cutoffs. Survival analyses were conducted.
RESULTS: Patients (n=1157) were 63.6 ± 11.4 years, 64\% male, and 61\% had stage IV disease. Sarcopenia and myosteatosis were prevalent across PG-SGA SF nutrition risk categories (scores 0-1 [no risk; 36\% sarcopenic; 44\% myosteatotic], scores 2-3 [37\%; 37\%], scores 4-8 [40\%; 41\%], and scores ≥9 [high risk; 50\%; 49\%]). In multivariable survival analysis, PG-SGA SF scores ≥9 (hazard ratio [HR] 2.08, 95\% confidence interval [CI] 1.66-2.60, P{\textless}0.001), sarcopenia (HR 1.25, 95\% CI 1.06-1.46, P=0.006), and myosteatosis (HR 1.25, 95\% CI 1.07-1.46, P{\textless}0.001) independently predicted reduced survival.
CONCLUSION: CT-defined sarcopenia and myosteatosis are prevalent across different levels of nutrition risk in overweight/obese patients with cancer. Assessment of skeletal muscle using CT adds prognostic value to the PG-SGA SF.},
	language = {eng},
	number = {2},
	journal = {JPEN. Journal of parenteral and enteral nutrition},
	author = {Martin, Lisa and Gioulbasanis, Ioannis and Senesse, Pierre and Baracos, Vickie E.},
	month = feb,
	year = {2020},
	pmid = {31012128},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Male, Obesity, Sarcopenia, Prospective Studies, Neoplasms, Overweight, Myosteatosis, Malnutrition},
	pages = {227--238},
}

@article{graffy20190327,
	title = {Deep learning-based muscle segmentation and quantification at abdominal {CT}: application to a longitudinal adult screening cohort for sarcopenia assessment},
	volume = {92},
	issn = {1748-880X},
	shorttitle = {Deep learning-based muscle segmentation and quantification at abdominal {CT}},
	doi = {10.1259/bjr.20190327},
	abstract = {OBJECTIVE: To investigate a fully automated abdominal CT-based muscle tool in a large adult screening population.
METHODS: A fully automated validated muscle segmentation algorithm was applied to 9310 non-contrast CT scans, including a primary screening cohort of 8037 consecutive asymptomatic adults (mean age, 57.1±7.8 years; 3555M/4482F). Sequential follow-up scans were available in a subset of 1171 individuals (mean interval, 5.1 years). Muscle tissue cross-sectional area and attenuation (Hounsfield unit, HU) at the L3 level were assessed, including change over time.
RESULTS: Mean values were significantly higher in males for both muscle area (190.6±33.6 vs 133.3±24.1 cm2, p{\textless}0.001) and density (34.3±11.1 HU vs 27.3±11.7 HU, p{\textless}0.001). Age-related losses were observed, with mean muscle area reduction of -1.5 cm2/year and attenuation reduction of -1.5 HU/year. Overall age-related muscle density (attenuation) loss was steeper than for muscle area for both sexes up to the age of 70 years. Between ages 50 and 70, relative muscle attenuation decreased significantly more in females (-30.6\% vs -18.0\%, p{\textless}0.001), whereas relative rates of muscle area loss were similar (-8\%). Between ages 70 and 90, males lost more density (-22.4\% vs -7.5\%) and area (-13.4\% vs -6.9\%, p{\textless}0.001). Of the 1171 patients with longitudinal follow-up, 1013 (86.5\%) showed a decrease in muscle attenuation, 739 (63.1\%) showed a decrease in area, and 1119 (95.6\%) showed a decrease in at least one of these measures.
CONCLUSION: This fully automated CT muscle tool allows for both individualized and population-based assessment. Such data could be automatically derived at abdominal CT regardless of study indication, allowing for opportunistic sarcopenia detection.
ADVANCES IN KNOWLEDGE: This fully automated tool can be applied to routine abdominal CT scans for prospective or retrospective opportunistic sarcopenia assessment, regardless of the original clinical indication. Mean values were significantly higher in males for both muscle area and muscle density. Overall age-related muscle density (attenuation) loss was steeper than for muscle area for both sexes, and therefore may be a more valuable predictor of adverse outcomes.},
	language = {eng},
	number = {1100},
	journal = {The British Journal of Radiology},
	author = {Graffy, Peter M. and Liu, Jiamin and Pickhardt, Perry J. and Burns, Joseph E. and Yao, Jianhua and Summers, Ronald M.},
	month = aug,
	year = {2019},
	pmid = {31199670},
	pmcid = {PMC6724622},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Male, Middle Aged, Sarcopenia, Retrospective Studies, Longitudinal Studies, Cohort Studies, Deep Learning, Radiography, Abdominal, Image Interpretation, Computer-Assisted, ML, Abdominal Muscles},
	pages = {20190327},
	file = {Graffy et al_2019_Deep learning-based muscle segmentation and quantification at abdominal CT.pdf:/Users/jcsal/Zotero/storage/UI54QGUW/Graffy et al_2019_Deep learning-based muscle segmentation and quantification at abdominal CT.pdf:application/pdf},
}

@article{burns311,
	title = {A {Machine} {Learning} {Algorithm} to {Estimate} {Sarcopenia} on {Abdominal} {CT}},
	volume = {27},
	issn = {1878-4046},
	doi = {10.1016/j.acra.2019.03.011},
	abstract = {RATIONALE AND OBJECTIVES: To assess whether a fully-automated deep learning system can accurately detect and analyze truncal musculature at multiple lumbar vertebral levels and muscle groupings on abdominal CT for potential use in the detection of central sarcopenia.
MATERIALS AND METHODS: A computer system for automated segmentation of truncal musculature groups was designed and created. Abdominal CT scans of 102 sequential patients (mean age 68 years, range 59-81 years; 53 women, 49 men) conducted between January 2015 and February 2015 were assembled as a data set. Truncal musculature was manually segmented on axial CT images at multiple lumbar vertebral levels as reference standard data, divided into training and testing subsets, and analyzed by the system. Dice similarity coefficients were calculated to evaluate system performance. IRB approval was obtained, with waiver of informed consent in this retrospective study.
RESULTS: System performance as gauged by the Dice coefficients, for detecting the total abdominal muscle cross-section at the level of the third and fourth lumbar vertebrae, were, respectively, 0.953 ± 0.015 and 0.953 ± 0.011 for the training set, and 0.938 ± 0.028 and 0.940 ± 0.026 for the testing set. Dice coefficients for detecting total psoas muscle cross-section at the level of the third and fourth lumbar vertebrae, were, respectively, 0.942 ± 0.040 and 0.951 ± 0.037 for the training set, and 0.939 ± 0.028 and 0.946 ± 0.032 for the testing set.
CONCLUSION: This system fully-automatically and accurately segments multiple muscle groups at all lumbar spine levels on abdominal CT for detection of sarcopenia.},
	language = {eng},
	number = {3},
	journal = {Academic Radiology},
	author = {Burns, Joseph E. and Yao, Jianhua and Chalhoub, Didier and Chen, Joseph J. and Summers, Ronald M.},
	month = mar,
	year = {2020},
	pmid = {31126808},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Retrospective Studies, Aged, 80 and over, Machine Learning, CT, Radiographic Image Interpretation, Computer-Assisted, Algorithms, ML, Adults, Computer applications-detection/diagnosis, Musculoskeletal, Oncology},
	pages = {311--320},
}

@article{hemke387,
	title = {Deep learning for automated segmentation of pelvic muscles, fat, and bone from {CT} studies for body composition assessment},
	volume = {49},
	issn = {1432-2161},
	doi = {10.1007/s00256-019-03289-8},
	abstract = {OBJECTIVE: To develop a deep convolutional neural network (CNN) to automatically segment an axial CT image of the pelvis for body composition measures. We hypothesized that a deep CNN approach would achieve high accuracy when compared to manual segmentations as the reference standard.
MATERIALS AND METHODS: We manually segmented 200 axial CT images at the supra-acetabular level in 200 subjects, labeling background, subcutaneous adipose tissue (SAT), muscle, inter-muscular adipose tissue (IMAT), bone, and miscellaneous intra-pelvic content. The dataset was randomly divided into training (180/200) and test (20/200) datasets. Data augmentation was utilized to enlarge the training dataset and all images underwent preprocessing with histogram equalization. Our model was trained for 50 epochs using the U-Net architecture with batch size of 8, learning rate of 0.0001, Adadelta optimizer and a dropout of 0.20. The Dice (F1) score was used to assess similarity between the manual segmentations and the CNN predicted segmentations.
RESULTS: The CNN model with data augmentation of N = 3000 achieved accurate segmentation of body composition for all classes. The Dice scores were as follows: background (1.00), miscellaneous intra-pelvic content (0.98), SAT (0.97), muscle (0.95), IMAT (0.91), and bone (0.92). Mean time to automatically segment one CT image was 0.07 s (GPU) and 2.51 s (CPU).
CONCLUSIONS: Our CNN-based model enables accurate automated segmentation of multiple tissues on pelvic CT images, with promising implications for body composition studies.},
	language = {eng},
	number = {3},
	journal = {Skeletal Radiology},
	author = {Hemke, Robert and Buckless, Colleen G. and Tsao, Andrew and Wang, Benjamin and Torriani, Martin},
	month = mar,
	year = {2020},
	pmid = {31396667},
	pmcid = {PMC6980503},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Male, Middle Aged, Retrospective Studies, Body composition, Deep learning, Muscle, Contrast Media, Computed tomography, Segmentation, ML, Datasets as Topic, Neural Networks, Computer, Pelvis},
	pages = {387--395},
	file = {Hemke et al_2020_Deep learning for automated segmentation of pelvic muscles, fat, and bone from.pdf:/Users/jcsal/Zotero/storage/34DISEU8/Hemke et al_2020_Deep learning for automated segmentation of pelvic muscles, fat, and bone from.pdf:application/pdf},
}

@article{koster2520,
	title = {Snakemake--a scalable bioinformatics workflow engine},
	volume = {28},
	issn = {1367-4811},
	doi = {10.1093/bioinformatics/bts480},
	abstract = {SUMMARY: Snakemake is a workflow engine that provides a readable Python-based workflow definition language and a powerful execution environment that scales from single-core workstations to compute clusters without modifying the workflow. It is the first system to support the use of automatically inferred multiple named wildcards (or variables) in input and output filenames.
AVAILABILITY: http://snakemake.googlecode.com.
CONTACT: johannes.koester@uni-due.de.},
	language = {eng},
	number = {19},
	journal = {Bioinformatics (Oxford, England)},
	author = {Köster, Johannes and Rahmann, Sven},
	month = oct,
	year = {2012},
	pmid = {22908215},
	keywords = {Methods, Software, ML, Computational Biology, Electronic Data Processing, Programming Languages, Workflow},
	pages = {2520--2522},
	file = {Köster_Rahmann_2012_Snakemake--a scalable bioinformatics workflow engine.pdf:/Users/jcsal/Zotero/storage/VHPQ529N/Köster_Rahmann_2012_Snakemake--a scalable bioinformatics workflow engine.pdf:application/pdf},
}

@article{islame363,
	title = {Fully automated deep-learning section-based muscle segmentation from {CT} images for sarcopenia assessment},
	volume = {77},
	issn = {1365-229X},
	doi = {10.1016/j.crad.2022.01.036},
	abstract = {AIM: To develop a fully automated deep-learning-based approach to measure muscle area for assessing sarcopenia on standard-of-care computed tomography (CT) of the abdomen without any case exclusion criteria, for opportunistic screening for frailty.
MATERIALS AND METHODS: This ethically approved retrospective study used publicly available and institutional unselected abdominal CT images (n=1,070 training, n=31 testing). The method consisted of two sequential steps: section detection from CT volume followed by muscle segmentation on single-section. Both stages used fully convolutional neural networks (FCNN), based on a UNet-like architecture. Input data consisted of CT volumes with a variety of fields of view, section thicknesses, occlusions, artefacts, and anatomical variations. Output consisted of segmented muscle area on a CT section at the L3 vertebral level. The muscle was segmented into erector spinae, psoas, and rectus abdominus muscle groups. Output was tested against expert manual segmentation.
RESULTS: Threefold cross-validation was used to evaluate the model. Section detection cross-validation error was 1.41 ± 5.02 (in sections). Segmentation cross-validation Dice overlaps were 0.97 ± 0.02, 0.95 ± 0.04, and 0.94 ± 0.04 for erector spinae, psoas, and rectus abdominus, respectively, and 0.96 ± 0.02 for the combined muscle area, with R2 = 0.95/0.98 for muscle attenuation/area in 28/31 hold-out test cases. No statistical difference was found between the automated output and a second annotator. Fully automated processing took {\textless}1 second per CT examination.
CONCLUSIONS: A FCNN pipeline accurately and efficiently automates muscle segmentation at the L3 vertebral level from unselected abdominal CT volumes, with no manual processing step. This approach is promising as a generalisable tool for opportunistic screening for frailty on standard-of-care CT.},
	language = {eng},
	number = {5},
	journal = {Clinical Radiology},
	author = {Islam, S. and Kanavati, F. and Arain, Z. and Da Costa, O. Fadeeva and Crum, W. and Aboagye, E. O. and Rockall, A. G.},
	month = may,
	year = {2022},
	pmid = {35260232},
	keywords = {Humans, Tomography, X-Ray Computed, Sarcopenia, Retrospective Studies, Muscles, Image Processing, Computer-Assisted, L3, Deep Learning, Frailty, ML},
	pages = {e363--e371},
}

@article{perthen142,
	title = {Intra- and interobserver variability in skeletal muscle measurements using computed tomography images},
	volume = {109},
	issn = {1872-7727},
	doi = {10.1016/j.ejrad.2018.10.031},
	abstract = {PURPOSE: The progressive loss of skeletal muscle and function (known as sarcopenia) has been shown to be associated with various adverse outcome measures. Sophisticated measurements of body composition are increasingly being incorporated into research studies to stratify patients into those with or without sarcopenia, monitor treatment effects, and predict complications. A typical approach is to select axial image(s) at the mid-lumbar level and use semi-automated software to identify and quantify the skeletal muscle area. This area is then used to estimate whole-body parameters. This approach is somewhat subjective, and in this study we investigate its reproducibility, both within and between observers.
MATERIALS AND METHODS: Repeated muscle measurements were performed on a cohort of 29 patients by 3 radiologists, to examine their intra- and interobserver reproducibility.
RESULTS AND DISCUSSION: Mean muscle area for the cohort was 156 cm2, with a wide range (98 - 261 cm2). There was good intraobserver agreement between measurements, with a mean absolute difference between repeated measurements on the same patient of 0.98 cm2, and a measurement variability of 2.92 cm2. Much of the variability was shown to be due to the choice of a different slice when performing the repeated measurement. Averaging two slices provided a small but non-significant improvement in comparison to the single slice approach. Interobserver results showed good agreement, though there was a small bias for one observer, who measured slightly larger volumes compared to the other two. We conclude that the approach described provides reproducible skeletal muscle area measurements, and offer three specific recommendations to minimise variability.},
	language = {eng},
	journal = {European Journal of Radiology},
	author = {Perthen, Joanna E. and Ali, Tamir and McCulloch, David and Navidi, Maziar and Phillips, Alexander W. and Sinclair, Rhona C. F. and Griffin, S. Michael and Greystoke, Alastair and Petrides, George},
	month = dec,
	year = {2018},
	pmid = {30527297},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Prospective Studies, Cohort Studies, Reproducibility of Results, Body composition, Chemotherapy, Adjuvant, Stomach Neoplasms, Esophageal Neoplasms, Esophagogastric Junction, Methods, Skeletal muscle, Body mass index, Software, ICC, CT, Observer Variation},
	pages = {142--146},
}

@article{lee487,
	title = {Pixel-{Level} {Deep} {Segmentation}: {Artificial} {Intelligence} {Quantifies} {Muscle} on {Computed} {Tomography} for {Body} {Morphometric} {Analysis}},
	volume = {30},
	issn = {1618-727X},
	shorttitle = {Pixel-{Level} {Deep} {Segmentation}},
	doi = {10.1007/s10278-017-9988-z},
	abstract = {Pretreatment risk stratification is key for personalized medicine. While many physicians rely on an "eyeball test" to assess whether patients will tolerate major surgery or chemotherapy, "eyeballing" is inherently subjective and difficult to quantify. The concept of morphometric age derived from cross-sectional imaging has been found to correlate well with outcomes such as length of stay, morbidity, and mortality. However, the determination of the morphometric age is time intensive and requires highly trained experts. In this study, we propose a fully automated deep learning system for the segmentation of skeletal muscle cross-sectional area (CSA) on an axial computed tomography image taken at the third lumbar vertebra. We utilized a fully automated deep segmentation model derived from an extended implementation of a fully convolutional network with weight initialization of an ImageNet pre-trained model, followed by post processing to eliminate intramuscular fat for a more accurate analysis. This experiment was conducted by varying window level (WL), window width (WW), and bit resolutions in order to better understand the effects of the parameters on the model performance. Our best model, fine-tuned on 250 training images and ground truth labels, achieves 0.93 ± 0.02 Dice similarity coefficient (DSC) and 3.68 ± 2.29\% difference between predicted and ground truth muscle CSA on 150 held-out test cases. Ultimately, the fully automated segmentation system can be embedded into the clinical environment to accelerate the quantification of muscle and expanded to volume analysis of 3D datasets.},
	language = {eng},
	number = {4},
	journal = {Journal of Digital Imaging},
	author = {Lee, Hyunkwang and Troschel, Fabian M. and Tajmir, Shahein and Fuchs, Georg and Mario, Julia and Fintelmann, Florian J. and Do, Synho},
	month = aug,
	year = {2017},
	pmid = {28653123},
	pmcid = {PMC5537099},
	keywords = {Adipose Tissue, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Length of Stay, Male, Middle Aged, Obesity, Body Mass Index, Sex Factors, Time Factors, Age Factors, Deep learning, Machine Learning, Computed tomography, ML, Artificial intelligence, Artificial Intelligence, Computer-aided diagnosis (CAD), Convolutional neural networks, Muscle segmentation},
	pages = {487--498},
	file = {Lee et al_2017_Pixel-Level Deep Segmentation.pdf:/Users/jcsal/Zotero/storage/MITDUUA3/Lee et al_2017_Pixel-Level Deep Segmentation.pdf:application/pdf},
}

@article{popuri512,
	title = {Body {Composition} {Assessment} in {Axial} {CT} {Images} {Using} {FEM}-{Based} {Automatic} {Segmentation} of {Skeletal} {Muscle}},
	volume = {35},
	issn = {1558-254X},
	doi = {10.1109/TMI.2015.2479252},
	abstract = {The proportions of muscle and fat tissues in the human body, referred to as body composition is a vital measurement for cancer patients. Body composition has been recently linked to patient survival and the onset/recurrence of several types of cancers in numerous cancer research studies. This paper introduces a fully automatic framework for the segmentation of muscle and fat tissues from CT images to estimate body composition. We developed a novel finite element method (FEM) deformable model that incorporates a priori shape information via a statistical deformation model (SDM) within the template-based segmentation framework. The proposed method was validated on 1000 abdominal and 530 thoracic CT images and we obtained very good segmentation results with Jaccard scores in excess of 90\% for both the muscle and fat regions.},
	language = {eng},
	number = {2},
	journal = {IEEE transactions on medical imaging},
	author = {Popuri, Karteek and Cobzas, Dana and Esfandiari, Nina and Baracos, Vickie and Jägersand, Martin},
	month = feb,
	year = {2016},
	pmid = {26415164},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Image Processing, Computer-Assisted, Reproducibility of Results, Radiography, Abdominal, ML, Radiography, Thoracic, Finite Element Analysis},
	pages = {512--520},
}

@article{huerter948,
	title = {Enteral {Access} is not {Required} for {Esophageal} {Cancer} {Patients} {Undergoing} {Neoadjuvant} {Therapy}},
	volume = {102},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2016.03.041},
	abstract = {BACKGROUND: The nutritional status of esophageal cancer patients during neoadjuvant therapy remains a challenging problem. The objective of this study was to determine whether routine enteral feeding tube placement improved nutritional status and perioperative outcomes for patients undergoing neoadjuvant therapy for esophageal cancer.
METHODS: The Society of Thoracic Surgeons database was used to identify patients who underwent neoadjuvant therapy and esophagectomy at our institution between 2010 and 2014. Nutritional status before and after neoadjuvant therapy was determined through standardized nutrition consultations. Predictors of change in nutrition and adverse events were evaluated with multivariable and univariate logistic regressions.
RESULTS: Two hundred thirty-four esophagectomy patients were identified, and 127 (54\%) received neoadjuvant therapy. Of those receiving neoadjuvant therapy, 80\% (102/127) presented with dysphagia, and 48\% (61/127) received enteral feeding access (EA). Multivariable regression revealed that high initial albumin level, high initial body mass index, and presence of EA were associated with nutritional stability during neoadjuvant therapy. However, 27.9\% (17/61) of patients who received EA did not use their access at all or did not use it consistently during the course of preoperative treatment. The preoperative grades of malnutrition and esophagectomy outcomes were similar between groups (EA vs no EA).
CONCLUSIONS: EA is associated with improved nutritional status for patients undergoing neoadjuvant therapy for esophageal cancer. However, adverse events and suboptimal use are common. Esophagectomy outcomes were similar for patients with and without EA. These results support judicious patient selection for EA, expedited neoadjuvant therapy, and close collaboration with nutritionists.},
	language = {eng},
	number = {3},
	journal = {The Annals of Thoracic Surgery},
	author = {Huerter, Mary E. and Charles, Eric J. and Downs, Emily A. and Hu, Yinin and Lau, Christine L. and Isbell, James M. and McMurry, Timothy L. and Kozower, Benjamin D.},
	month = sep,
	year = {2016},
	pmid = {27209608},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Esophageal Neoplasms, Esophagectomy, Stents, Enteral Nutrition, Nutritional Status},
	pages = {948--954},
}

@article{bower82,
	title = {Nutritional management during neoadjuvant therapy for esophageal cancer},
	volume = {100},
	issn = {1096-9098},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/jso.21289},
	doi = {10.1002/jso.21289},
	abstract = {Patients undergoing neoadjuvant therapy for esophageal cancer are at a high risk for malnutrition due to the effects of chemoradiation, dysphagia, and malignancy induced cachexia. Preparation for esophagectomy requires careful assessment of nutritional risk and adequate supplementation as indicated. Supplementation via the enteral route is preferred to the parenteral route but requires feeding tube placement. Endoscopically placed silicone stents have also shown promise as a means to alleviate malnutrition and avoid invasive feeding tubes. J. Surg. Oncol. 2009;100:82–87. © 2009 Wiley-Liss, Inc.},
	language = {en},
	number = {1},
	urldate = {2022-10-25},
	journal = {Journal of Surgical Oncology},
	author = {Bower, Matthew R. and Martin II, Robert C.G.},
	year = {2009},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.21289},
	keywords = {enteral nutrition, esophageal stenting, parenteral nutrition},
	pages = {82--87},
}

@article{white730,
	title = {Consensus statement of the {Academy} of {Nutrition} and {Dietetics}/{American} {Society} for {Parenteral} and {Enteral} {Nutrition}: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition)},
	volume = {112},
	issn = {2212-2672},
	shorttitle = {Consensus statement of the {Academy} of {Nutrition} and {Dietetics}/{American} {Society} for {Parenteral} and {Enteral} {Nutrition}},
	doi = {10.1016/j.jand.2012.03.012},
	abstract = {The Academy of Nutrition and Dietetics (Academy) and the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) recommend that a standardized set of diagnostic characteristics be used to identify and document adult malnutrition in routine clinical practice. An etiologically based diagnostic nomenclature that incorporates a current understanding of the role of the inflammatory response on malnutrition's incidence, progression, and resolution is proposed. Universal use of a single set of diagnostic characteristics will facilitate malnutrition's recognition, contribute to more valid estimates of its prevalence and incidence, guide interventions, and influence expected outcomes. This standardized approach will also help to more accurately predict the human and financial burdens and costs associated with malnutrition's prevention and treatment, and further ensure the provision of high quality, cost effective nutritional care.},
	language = {eng},
	number = {5},
	journal = {Journal of the Academy of Nutrition and Dietetics},
	author = {White, Jane V. and Guenter, Peggi and Jensen, Gordon and Malone, Ainsley and Schofield, Marsha and {Academy of Nutrition and Dietetics Malnutrition Work Group} and {A.S.P.E.N. Malnutrition Task Force} and {A.S.P.E.N. Board of Directors}},
	month = may,
	year = {2012},
	pmid = {22709779},
	keywords = {Humans, Adult, Incidence, Terminology as Topic, Malnutrition, Severity of Illness Index},
	pages = {730--738},
}

@article{shaw47,
	title = {Comparison of a novel, simple nutrition screening tool for adult oncology inpatients and the {Malnutrition} {Screening} {Tool} ({MST}) against the {Patient}-{Generated} {Subjective} {Global} {Assessment} ({PG}-{SGA})},
	volume = {23},
	issn = {1433-7339},
	doi = {10.1007/s00520-014-2319-8},
	abstract = {BACKGROUND: Oncology inpatients are at high risk of malnutrition. Identification of at risk patients by nutrition screening requires a practical and easy to use tool. In this study, we have compared a simple, novel nutrition screening tool designed for an oncology inpatient setting and the Malnutrition Screening Tool (MST) against the Patient-Generated Subjective Global Assessment (PG-SGA).
METHODS: This was an observational study to compare assessment of nutritional status by PG-SGA with nutrition screening using the Royal Marsden Nutrition Screening Tool (RMNST) and the MST. Patients were recruited from a single tertiary cancer centre.
RESULTS: One hundred and twenty-six oncology inpatients underwent a full nutritional assessment and nutrition screening. The PG-SGA tool identified 90 (71\%) patients as malnourished or at risk and 36 (29\%) patients as well-nourished. The RMNST had a sensitivity of 93\% and a specificity of 53\%, and the MST had a sensitivity of 66\% and a specificity of 83 \%. Predictive value (ROC AUC) of both screening tools was excellent at 0.84 and 0.83 for RMNST and MST, respectively.
CONCLUSIONS: This study identified a high prevalence of malnutrition in the population with 71\% of patients being identified as malnourished or at risk of malnutrition. The RMNST had an excellent sensitivity for identifying patients who were malnourished or at risk of malnutrition in the inpatient setting although it had a poor specificity. The MST had a poorer sensitivity of 66 \%. We would recommend that the RMNST is trialled in other oncology inpatient settings and also in the outpatient setting.},
	language = {eng},
	number = {1},
	journal = {Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer},
	author = {Shaw, Clare and Fleuret, Catherine and Pickard, Jennifer M. and Mohammed, Kabir and Black, Gayle and Wedlake, Linda},
	month = jan,
	year = {2015},
	pmid = {24947056},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prevalence, Neoplasms, Risk, Reproducibility of Results, Adult, Nutrition Assessment, Malnutrition, Nutritional Status, Surveys and Questionnaires, Outpatients, Mass Screening, Inpatients},
	pages = {47--54},
}

@article{feray311,
	title = {{PROSPECT} guidelines for video-assisted thoracoscopic surgery: a systematic review and procedure-specific postoperative pain management recommendations},
	volume = {77},
	issn = {1365-2044},
	shorttitle = {{PROSPECT} guidelines for video-assisted thoracoscopic surgery},
	doi = {10.1111/anae.15609},
	abstract = {Video-assisted thoracoscopic surgery has become increasingly popular due to faster recovery times and reduced postoperative pain compared with thoracotomy. However, analgesic regimens for video-assisted thoracoscopic surgery vary significantly. The goal of this systematic review was to evaluate the available literature and develop recommendations for optimal pain management after video-assisted thoracoscopic surgery. A systematic review was undertaken using procedure-specific postoperative pain management (PROSPECT) methodology. Randomised controlled trials published in the English language, between January 2010 and January 2021 assessing the effect of analgesic, anaesthetic or surgical interventions were identified. We retrieved 1070 studies of which 69 randomised controlled trials and two reviews met inclusion criteria. We recommend the administration of basic analgesia including paracetamol and non-steroidal anti-inflammatory drugs or cyclo-oxygenase-2-specific inhibitors pre-operatively or intra-operatively and continued postoperatively. Intra-operative intravenous dexmedetomidine infusion may be used, specifically when basic analgesia and regional analgesic techniques could not be given. In addition, a paravertebral block or erector spinae plane block is recommended as a first-choice option. A serratus anterior plane block could also be administered as a second-choice option. Opioids should be reserved as rescue analgesics in the postoperative period.},
	language = {eng},
	number = {3},
	journal = {Anaesthesia},
	author = {Feray, S. and Lubach, J. and Joshi, G. P. and Bonnet, F. and Van de Velde, M. and {PROSPECT Working Group *of the European Society of Regional Anaesthesia and Pain Therapy}},
	month = mar,
	year = {2022},
	pmid = {34739134},
	pmcid = {PMC9297998},
	keywords = {Humans, Randomized Controlled Trials as Topic, analgesia, Analgesics, Analgesics, Opioid, Anti-Inflammatory Agents, Non-Steroidal, Drug Therapy, Combination, evidence-based medicine, Nerve Block, Pain Management, Pain, Postoperative, postoperative pain, Practice Guidelines as Topic, systematic review, Thoracic Surgery, Video-Assisted, video-assisted thoracoscopic surgery},
	pages = {311--325},
	file = {Feray et al_2022_PROSPECT guidelines for video-assisted thoracoscopic surgery.pdf:/Users/jcsal/Zotero/storage/C9Q7A8CT/Feray et al_2022_PROSPECT guidelines for video-assisted thoracoscopic surgery.pdf:application/pdf},
}

@article{bausys2096,
	title = {The {Role} of {Prehabilitation} in {Modern} {Esophagogastric} {Cancer} {Surgery}: {A} {Comprehensive} {Review}},
	volume = {14},
	issn = {2072-6694},
	shorttitle = {The {Role} of {Prehabilitation} in {Modern} {Esophagogastric} {Cancer} {Surgery}},
	doi = {10.3390/cancers14092096},
	abstract = {Esophagogastric cancer is among the most common malignancies worldwide. Surgery with or without neoadjuvant therapy is the only potentially curative treatment option. Although esophagogastric resections remain associated with major surgical trauma and significant postoperative morbidity. Prehabilitation has emerged as a novel strategy to improve clinical outcomes by optimizing physical and psychological status before major surgery through exercise and nutritional and psychological interventions. Current prehabilitation programs may be unimodal, including only one intervention, or multimodal, combining the benefits of different types of interventions. However, it still is an investigational treatment option mostly limited to clinical trials. In this comprehensive review, we summarize the current evidence for the role of prehabilitation in modern esophagogastric cancer surgery. The available studies are very heterogeneous in design, type of interventions, and measured outcomes. Yet, all of them confirm at least some positive effects of prehabilitation in terms of improved physical performance, nutritional status, quality of life, or even reduced postoperative morbidity. However, the optimal interventions for prehabilitation remain unclear; thus, they cannot be standardized and widely adopted. Future studies on multimodal prehabilitation are necessary to develop optimal programs for patients with esophagogastric cancer.},
	language = {eng},
	number = {9},
	journal = {Cancers},
	author = {Bausys, Augustinas and Mazeikaite, Morta and Bickaite, Klaudija and Bausys, Bernardas and Bausys, Rimantas and Strupas, Kestutis},
	month = apr,
	year = {2022},
	pmid = {35565226},
	pmcid = {PMC9102916},
	keywords = {gastric cancer, esophageal cancer, esophagectomy, exercise, gastrectomy, prehabilitation},
	pages = {2096},
	file = {Bausys et al_2022_The Role of Prehabilitation in Modern Esophagogastric Cancer Surgery.pdf:/Users/jcsal/Zotero/storage/2G6QAEGI/Bausys et al_2022_The Role of Prehabilitation in Modern Esophagogastric Cancer Surgery.pdf:application/pdf},
}

@article{chmelo173,
	title = {A feasibility trial of prehabilitation before oesophagogastric cancer surgery using a multi-component home-based exercise programme: the {ChemoFit} study},
	volume = {8},
	issn = {2055-5784},
	shorttitle = {A feasibility trial of prehabilitation before oesophagogastric cancer surgery using a multi-component home-based exercise programme},
	doi = {10.1186/s40814-022-01137-6},
	abstract = {BACKGROUND: Treatment for locally advanced oesophagogastric adenocarcinoma involves neoadjuvant chemotherapy which has a negative impact on patient fitness. Using 'prehabilitation' to increase activity levels and fitness may affect physiology, postoperative outcomes and improve patient wellbeing and quality of life. The aims of the trial were to address the feasibility and acceptability of recruiting participants to a home-based prehabilitation programme and provide data to allow design of future studies.
METHODS: We recruited patients to a single-arm feasibility trial of home-based exercise prehabilitation. Eligible patients were aged ≥18years, had operable oesophageal or gastric adenocarcinoma and were receiving neoadjuvant chemotherapy at our tertiary referral hospital. All participants commenced a home-based exercise programme utilising pedometers and step counting to target daily aerobic exercise sessions alongside daily strengthening exercises. A weekly telephone consultation directed the exercise programme and facilitated weekly data collection. The primary (feasibility) outcomes for the trial were (a) recruitment rate, (b) completion rate, (c) engagement with the programme (use of pedometers, recording step counts, telephone consultations) and (d) compliance with exercise sessions, exercise intensity and strengthening exercises.
RESULTS: There were 42 patients recruited, and the recruitment rate was 72.4\% (42/58). 92.3\% (36/39) of patients completed the exercise programme. There was 98.7\% (IQR 93.2-100.0\%) compliance with wearing a pedometer and recording data, and 100.0\% (IQR 93.1-100.0\%) compliance with a weekly telephone consultation. Exercise sessions and strengthening exercises were completed 70.2\% (IQR 53.1-88.9\%) and 69.4\% (IQR 52.1-84.3\%) of the time, respectively. Appropriate exercise intensity was recorded 96\% (IQR 85.4-99.4\%) of the time. There were no adverse events. Participants were enrolled in the exercise programme for a median of 91 days (IQR 84 to 105 days).
CONCLUSIONS: The results of this trial support the feasibility and acceptability of recruiting participants to an appropriately powered randomised controlled trial of prehabilitation.
TRIAL REGISTRATION: Clinicaltrials.gov NCT04194463 . Registered on 11th December 2019-retrospectively registered.},
	language = {eng},
	number = {1},
	journal = {Pilot and Feasibility Studies},
	author = {Chmelo, Jakub and Phillips, Alexander W. and Greystoke, Alastair and Charman, Sarah J. and Avery, Leah and Hallsworth, Kate and Welford, Jenny and Cooper, Matthew and Sinclair, Rhona C. F.},
	month = aug,
	year = {2022},
	pmid = {35945625},
	pmcid = {PMC9360697},
	keywords = {Exercise, Feasibility, Home-based training, Oesophagogastric cancer, Prehabilitation, Surgical oncology},
	pages = {173},
	file = {Chmelo et al_2022_A feasibility trial of prehabilitation before oesophagogastric cancer surgery.pdf:/Users/jcsal/Zotero/storage/R9DEQAJI/Chmelo et al_2022_A feasibility trial of prehabilitation before oesophagogastric cancer surgery.pdf:application/pdf},
}

@article{niels1812,
	title = {Does {VO2peak} {Provide} a {Prognostic} {Value} in {Esophagectomy} and {Gastrectomy} for {Post}-operative {Outcomes}?},
	volume = {36},
	issn = {1791-7549},
	doi = {10.21873/invivo.12897},
	abstract = {BACKGROUND/AIM: Esophagectomy and gastrectomy are procedures with considerable physical burden and intense post-operative care of which the patient's physical condition seems to be a relevant predictor. The gold standard of the cardiorespiratory fitness is the peak oxygen consumption (VO2peak). This pilot study examined the prognostic value of VO2peak on post-surgery outcomes in esophageal and gastric cancer patients.
PATIENTS AND METHODS: In this prospective cross-sectional study, patients scheduled for esophagectomy or gastrectomy were examined 24 h before the surgery regarding their VO2peak. The post-operative complications according to Clavien-Dindo grade IIIb/IV/V, Intensive-Care-Unit days, and overall hospital stay were documented following surgery. In a subset, body weight changes from surgery until hospital discharge and first aftercare visit were recorded.
RESULTS: The functional capacity was significantly reduced in 34/35 of the included patients compared to matched norm-values (p{\textless}0.01). The only significant correlation was found between VO2peak values and body weight change from surgery to the first aftercare visit. A subgroup comparison of patients with a VO2peak {\textless}17 ml/min/kg and ≥17 ml/min/kg suggested small, non-significant differences in post-surgery outcomes and significant differences in the body weight change from surgery to hospital discharge, favoring the higher-VO2peak subgroup.
CONCLUSION: The impaired functional capacity following esophagectomy or gastrectomy may strengthen the rational for exercise programs during neoadjuvant and pre-surgery phases. The prognostic value of VO2peak on post-operative outcomes remains uncertain due to noticeable descriptive differences, but no significant correlations, potentially limited by the smallsized population. Nonetheless, a correlation between VO2peak and body weight change post-surgery was observed and indicates a potential prognostic value of VO2peak.},
	language = {eng},
	number = {4},
	journal = {In Vivo (Athens, Greece)},
	author = {Niels, Timo and Baltin, Christoph T. and Kosanke, Guido and Fetzner, Ulrich K. and Hoelscher, Arnulf H. and Bollschweiler, Elfriede and Naendrup, Jan-Hendrik and Baumann, Freerk T.},
	month = aug,
	year = {2022},
	pmid = {35738612},
	pmcid = {PMC9301424},
	keywords = {Humans, Pilot Projects, Body Weight, Prospective Studies, Prognosis, Cross-Sectional Studies, Stomach Neoplasms, Esophageal Neoplasms, Esophagectomy, Gastrectomy, cardiopulmonary fitness, post-surgery outcomes, tumor surgery, VO2peak},
	pages = {1812--1819},
	file = {Niels et al_2022_Does VO2peak Provide a Prognostic Value in Esophagectomy and Gastrectomy for.pdf:/Users/jcsal/Zotero/storage/ZE5Q9CFR/Niels et al_2022_Does VO2peak Provide a Prognostic Value in Esophagectomy and Gastrectomy for.pdf:application/pdf},
}

@article{inouedoz050a,
	title = {Preoperative six-minute walk distance as a predictor of postoperative complication in patients with esophageal cancer},
	volume = {33},
	issn = {1442-2050},
	doi = {10.1093/dote/doz050},
	abstract = {Surgery for esophageal cancer is associated with high morbidity and mortality. Reduced pulmonary functions and exercise capacity are known as risk factors for complications after esophagectomy. The 6-minute walk distance (6MWD) measured by the 6-minute walk test (6MWT) is a simple field test that can be used to evaluate the functional exercise capacity of patients who undergo thoracic surgery. The aim of this study was to evaluate the association of the preoperative 6MWD with postoperative complications in patients with esophageal cancer. Records of a total of 111 patients who underwent thoracic surgery followed by postoperative rehabilitation from January 2013 to December 2015 were retrospectively reviewed. Data of patients who experienced Clavien-Dindo grade II or severer (grade ≥ II) complications were compared with those who experienced grade ≤I complications. The 6MWD was significantly correlated with age, serum albumin concentration, hemoglobin concentration, and hand grip strength. A total of 42 patients experienced grade ≥II. The 6MWD of patients with grade ≥ II complications was significantly shorter than that of those with grade ≤I complications. In receiver operating characteristic analysis, 6MWD ≤ 454 m was a threshold for predicting grade ≥II complications with 71.0\% sensitivity and 54.8\% specificity. The incidence of grade ≥II complications led to delayed ambulation and longer stays in hospital. In the multiple regression analysis, the preoperative risk factors for incidence of grade ≥II complications included lower levels of preoperative 6MWD and \% of the predicted value of forced expiratory volume in 1 second. Our results indicate that the 6MWT is useful to assess preoperative physical status in patients with esophageal cancer.},
	language = {eng},
	number = {2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Inoue, Takayuki and Ito, Satoru and Kanda, Mitsuro and Niwa, Yukiko and Nagaya, Motoki and Nishida, Yoshihiro and Hasegawa, Yoshinori and Koike, Masahiko and Kodera, Yasuhiro},
	month = mar,
	year = {2020},
	pmid = {31111872},
	note = {tex.ids= inouedoz050a},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Risk Factors, Esophageal Neoplasms, Esophagectomy, Sensitivity and Specificity, Incidence, Postoperative Complications, Carcinoma, Preoperative Care, surgery, Health Status Indicators, esophageal cancer surgery, complications, Physical Fitness, rehabilitation, Walk Test},
	pages = {doz050},
}

@article{yeungCD009121,
	title = {Paravertebral block versus thoracic epidural for patients undergoing thoracotomy},
	volume = {2},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD009121.pub2},
	abstract = {BACKGROUND: Operations on structures in the chest (usually the lungs) involve cutting between the ribs (thoracotomy). Severe post-thoracotomy pain can result from pleural (lung lining) and muscular damage, costovertebral joint (ribcage) disruption and intercostal nerve (nerves that run along the ribs) damage during surgery. Poor pain relief after surgery can impede recovery and increase the risks of developing complications such as lung collapse, chest infections and blood clots due to ineffective breathing and clearing of secretions. Effective management of acute pain following thoracotomy may prevent these complications and reduce the likelihood of developing chronic pain. A multi-modal approach to analgesia is widely employed by thoracic anaesthetists using a combination of regional anaesthetic blockade and systemic analgesia, with both non-opioid and opioid medications and local anaesthesia blockade.There is some evidence that blocking the nerves as they emerge from the spinal column (paravertebral block, PVB) may be associated with a lower risk of major complications in thoracic surgery but the majority of thoracic anaesthetists still prefer to use a thoracic epidural blockade (TEB) as analgesia for their patients undergoing thoracotomy. In order to bring about a change in practice, anaesthetists need a review that evaluates the risk of all major complications associated with thoracic epidural and paravertebral block in thoracotomy.
OBJECTIVES: To compare the two regional techniques of TEB and PVB in adults undergoing elective thoracotomy with respect to:1. analgesic efficacy;2. the incidence of major complications (including mortality);3. the incidence of minor complications;4. length of hospital stay;5. cost effectiveness.
SEARCH METHODS: We searched for studies in the Cochrane Central Register of Controlled Trials (CENTRAL 2013, Issue 9); MEDLINE via Ovid (1966 to 16 October 2013); EMBASE via Ovid (1980 to 16 October 2013); CINAHL via EBSCO host (1982 to 16 October 2013); and reference lists of retrieved studies. We handsearched the Journal of Cardiothoracic Surgery and Journal of Cardiothoracic and Vascular Anesthesia (16 October 2013). We reran the search on 31st January 2015. We found one additional study which is awaiting classification and will be addressed when we update the review.
SELECTION CRITERIA: We included all randomized controlled trials (RCTs) comparing PVB with TEB in thoracotomy, including upper gastrointestinal surgery.
DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. Two review authors (JY and SG) independently assessed the studies for inclusion and then extracted data as eligible for inclusion in qualitative and quantitative synthesis (meta-analysis).
MAIN RESULTS: We included 14 studies with a total of 698 participants undergoing thoracotomy. There are two studies awaiting classification. The studies demonstrated high heterogeneity in insertion and use of both regional techniques, reflecting real-world differences in the anaesthesia techniques. Overall, the included studies have a moderate to high potential for bias, lacking details of randomization, group allocation concealment or arrangements to blind participants or outcome assessors. There was low to very low-quality evidence that showed no significant difference in 30-day mortality (2 studies, 125 participants. risk ratio (RR) 1.28, 95\% confidence interval (CI) 0.39 to 4.23, P value = 0.68) and major complications (cardiovascular: 2 studies, 114 participants. Hypotension RR 0.30, 95\% CI 0.01 to 6.62, P value = 0.45; arrhythmias RR 0.36, 95\% CI 0.04 to 3.29, P value = 0.36, myocardial infarction RR 3.19, 95\% CI 0.13, 76.42, P value = 0.47); respiratory: 5 studies, 280 participants. RR 0.62, 95\% CI 0.26 to 1.52, P value = 0.30). There was moderate-quality evidence that showed comparable analgesic efficacy across all time points both at rest and after coughing or physiotherapy (14 studies, 698 participants). There was moderate-quality evidence that showed PVB had a better minor complication profile than TEB including hypotension (8 studies, 445 participants. RR 0.16, 95\% CI 0.07 to 0.38, P value {\textless} 0.0001), nausea and vomiting (6 studies, 345 participants. RR 0.48, 95\% CI 0.30 to 0.75, P value = 0.001), pruritis (5 studies, 249 participants. RR 0.29, 95\% CI 0.14 to 0.59, P value = 0.0005) and urinary retention (5 studies, 258 participants. RR 0.22, 95\% CI 0.11 to 0.46, P value {\textless} 0.0001). There was insufficient data in chronic pain (six or 12 months). There was no difference found in and length of hospital stay (3 studies, 124 participants). We found no studies that reported costs.
AUTHORS' CONCLUSIONS: Paravertebral blockade reduced the risks of developing minor complications compared to thoracic epidural blockade. Paravertebral blockade was as effective as thoracic epidural blockade in controlling acute pain. There was a lack of evidence in other outcomes. There was no difference in 30-day mortality, major complications, or length of hospital stay. There was insufficient data on chronic pain and costs. Results from this review should be interpreted with caution due to the heterogeneity of the included studies and the lack of reliable evidence. Future studies in this area need well-conducted, adequately-powered RCTs that focus not only on acute pain but also on major complications, chronic pain, length of stay and costs.},
	language = {eng},
	journal = {The Cochrane Database of Systematic Reviews},
	author = {Yeung, Joyce H. Y. and Gates, Simon and Naidu, Babu V. and Wilson, Matthew J. A. and Gao Smith, Fang},
	month = feb,
	year = {2016},
	pmid = {26897642},
	pmcid = {PMC7151756},
	keywords = {Humans, Length of Stay, Randomized Controlled Trials as Topic, Thoracotomy, Nerve Block, Pain, Postoperative, Acute Pain, Anesthesia, Epidural, Delirium, Hypotension, Lung Diseases},
	pages = {CD009121},
	file = {Yeung et al_2016_Paravertebral block versus thoracic epidural for patients undergoing thoracotomy.pdf:/Users/jcsal/Zotero/storage/FNJBYISX/Yeung et al_2016_Paravertebral block versus thoracic epidural for patients undergoing thoracotomy.pdf:application/pdf},
}

@article{weijs1,
	title = {Nasogastric decompression following esophagectomy: a systematic literature review and meta-analysis},
	volume = {30},
	issn = {1442-2050},
	shorttitle = {Nasogastric decompression following esophagectomy},
	doi = {10.1111/dote.12530},
	abstract = {Routine use of nasogastric tubes for gastric decompression has been abolished in nearly all types of gastro-intestinal surgery after introduction of enhanced recovery after surgery programs. However, in esophagectomy the routine use of nasogastric decompression is still a matter of debate. To determine the effects of routine nasogastric decompression following esophagectomy compared with early or peroperative removal of the nasogastric tube on pulmonary complications, anastomotic leakage, mortality, and postoperative recovery. A systematic literature review and meta-analysis of studies comparing early or peroperative versus late removal of nasogastric tubes. A total of seven comparative studies were included (n = 608). In two randomized trials, and one retrospective cohort study, peroperative removal of the nasogastric tube was compared with routine nasogastric decompression. In one randomized trial early removal of the nasogastric tube (on postoperative day 2) was compared with removal of the nasogastric tube on the 6th-10th postoperative day. In the remaining three trials a fast-track protocol without a nasogastric tube was compared with conventional care with a nasogastric tube during the first postoperative days. Peroperative or early removal of the nasogastric tube did not result in a significantly different rate of anastomotic leakage, pulmonary complications or mortality in individual studies, nor in the meta-analysis. In the meta-analysis, hospital stay was significantly shorter with peroperative or early removal of the nasogastric tube when all studies were included, but not when the meta-analysis was limited to randomized trials. This systematic review did not find a difference in adverse outcomes between nasogastric decompression or no nasogastric decompression following esophagectomy.},
	language = {eng},
	number = {3},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Weijs, Teus J. and Kumagai, Koshi and Berkelmans, Gijs H. K. and Nieuwenhuijzen, Grard A. P. and Nilsson, Magnus and Luyer, Misha D. P.},
	month = feb,
	year = {2017},
	pmid = {27627872},
	keywords = {Humans, Female, Length of Stay, Male, Middle Aged, Postoperative Care, Time Factors, Adult, Esophagectomy, Postoperative Complications, Anastomotic Leak, esophagectomy, Intubation, Gastrointestinal, anastomotic leak, Decompression, Surgical, nasogatric tube, pneumonia},
	pages = {1--8},
	file = {Weijs et al_2017_Nasogastric decompression following esophagectomy.pdf:/Users/jcsal/Zotero/storage/TDSPX9XC/Weijs et al_2017_Nasogastric decompression following esophagectomy.pdf:application/pdf},
}

@article{thanh415,
	title = {An economic evaluation of the {Enhanced} {Recovery} {After} {Surgery} ({ERAS}) multisite implementation program for colorectal surgery in {Alberta}},
	volume = {59},
	issn = {1488-2310},
	doi = {10.1503/cjs.006716},
	abstract = {BACKGROUND: In February 2013, Alberta Health Services established an Enhanced Recovery After Surgery (ERAS) implementation program for adopting the ERAS Society colorectal guidelines into 6 sites (initial phase) that perform more than 75\% of all colorectal surgeries in the province. We conducted an economic evaluation of this initiative to not only determine its cost-effectiveness, but also to inform strategy for the spread and scale of ERAS to other surgical protocols and sites.
METHODS: We assessed the impact of ERAS on patients\&\#8217; health services utilization (HSU; length of stay [LOS], readmissions, emergency department visits, general practitioner and specialist visits) within 30 days of discharge by comparing pre- and post-ERAS groups using multilevel negative binomial regressions. We estimated the net health care costs/savings and the return on investment (ROI) associated with those impacts for post-ERAS patients using a decision analytic modelling technique.
RESULTS: We included 331 pre- and 1295 post-ERAS patients in our analyses. ERAS was associated with a reduction in all HSU outcomes except visits to specialists. However, only the reduction in primary LOS was significant. The net health system savings were estimated at \$2 290 000 (range \$1 191 000\&\#8211;\$3 391 000), or \$1768 (range \$920\&\#8211;\$2619) per patient. The probability for the program to be cost-saving was 73\%\&\#8211;83\%. In terms of ROI, every \$1 invested in ERAS would bring \$3.8 (range \$2.4\&\#8211;\$5.1) in return.
CONCLUSION: The initial phase of ERAS implementation for colorectal surgery in Alberta is cost-saving. The total savings has the potential to be more substantial when ERAS is spread for other surgical protocols and across additional sites.},
	language = {eng},
	number = {6},
	journal = {Canadian Journal of Surgery. Journal Canadien De Chirurgie},
	author = {Thanh, Nguyen X. and Chuck, Anderson W. and Wasylak, Tracy and Lawrence, Jeannette and Faris, Peter and Ljungqvist, Olle and Nelson, Gregg and Gramlich, Leah M.},
	month = dec,
	year = {2016},
	pmcid = {PMC5125924},
	pmid = {28445024},
	note = {tex.ids= thanh415a},
	keywords = {CRC, ERAS},
	pages = {415--421},
	file = {Thanh et al_2016_An economic evaluation of the Enhanced Recovery After Surgery (ERAS) multisite.pdf:/Users/jcsal/Zotero/storage/RSPEYJKT/Thanh et al_2016_An economic evaluation of the Enhanced Recovery After Surgery (ERAS) multisite.pdf:application/pdf},
}

@article{taniguchi184,
	title = {Effects of goal-directed fluid therapy on enhanced postoperative recovery: {An} interventional comparative observational study with a historical control group on oesophagectomy combined with {ERAS} program},
	volume = {23},
	issn = {2405-4577},
	shorttitle = {Effects of goal-directed fluid therapy on enhanced postoperative recovery},
	doi = {10.1016/j.clnesp.2017.10.002},
	abstract = {BACKGROUND AND AIMS: The Enhanced Recovery after Surgery (ERAS) program has been proposed as a postoperative recovery-enhancing strategy. We frequently apply the Modified-ERAS program following oesophagectomy. This study aims to elucidate the impact of goal-directed fluid therapy (GDT) for the perioperative management of oesophageal cancer on the postoperative recovery of patients undergoing oesophagectomy.
METHODS: This is an interventional before-after comparative observational study conducted at Kanagawa Cancer Centre, Japan. Patients who underwent elective oesophagectomy for oesophageal cancer were recruited. Group H (retrospectively collected) received intraoperative and postoperative management consisting of fluid administration without haemodynamic monitoring and the M-ERAS program, while Group S prospectively received management consisting of GDT and the M-ERAS program. The primary endpoint was the speed of gastrointestinal functional recovery, while secondary endpoints were the level of postoperative mobilisation, incidence of complications, postoperative length of hospital stay (LOS), and nutritional status after discharge.
RESULTS: The proportion of patients who completely egested Gastrografin by postoperative day 4, the level of postoperative mobilisation, and achievement ratio for a 100-m walk on the first postoperative attempt were significantly higher in Group S than in Group H (P = 0.034, P = 0.0197, and P {\textless} 0.0001, respectively). No significant differences were observed in the postoperative LOS and incidence of complications within 30 days between the groups. The serum albumin levels at 6 months after discharge was higher in Group S than in Group H (P = 0.0002).
CONCLUSIONS: The GDT-ERAS program enhanced postoperative gastrointestinal recovery and mobilisation, as well as postoperative nutritional status and protein synthesis. The program did not affect either postoperative LOS or the incidence of complications.
TRIAL REGISTRATION: UMIN registration number: UMIN000013705, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr\_view.cgi?recptno=R000015999.},
	language = {eng},
	journal = {Clinical nutrition ESPEN},
	author = {Taniguchi, Hideki and Sasaki, Toshio and Fujita, Hisae and Kobayashi, Hiroko and Kawasaki, Rieko and Ogata, Takashi and Cho, Haruhiko and Yoshikawa, Takaki and Ushigome, Keiko and Tanaka, Akemi and Takano, Osami},
	month = feb,
	year = {2018},
	pmid = {29460796},
	note = {tex.ids= taniguchi184a},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Treatment Outcome, Body Mass Index, Retrospective Studies, Esophagectomy, Enteral Nutrition, Nutritional Status, Elective Surgical Procedures, Intensive Care Units, Enhanced recovery after surgery (ERAS), Goal-directed fluid therapy (GDT), Japan, Oesophagectomy, Patient Discharge, Postoperative gastrointestinal recovery, Postoperative mobilisation, Postoperative Period},
	pages = {184--193},
	file = {Taniguchi et al_2018_Effects of goal-directed fluid therapy on enhanced postoperative recovery.pdf:/Users/jcsal/Zotero/storage/HRHUVYZJ/Taniguchi et al_2018_Effects of goal-directed fluid therapy on enhanced postoperative recovery.pdf:application/pdf},
}

@article{visser1,
	title = {Postoperative pain management after esophagectomy: a systematic review and meta-analysis},
	volume = {30},
	issn = {1442-2050},
	shorttitle = {Postoperative pain management after esophagectomy},
	doi = {10.1093/dote/dox052},
	abstract = {Effective pain management after esophagectomy is essential for patient comfort, early recovery, low surgical morbidity, and short hospitalization. This systematic review and meta-analysis aims to determine the best pain management modality focusing on the balance between benefits and risks. Medline, Embase, and the Cochrane library were systematically searched to identify all studies investigating different pain management modalities after esophagectomy in relation to primary outcomes (postoperative pain scores at 24 and 48 hours, technical failure, and opioid consumption), and secondary outcomes (pulmonary complications, nausea and vomiting, hypotension, urinary retention, and length of hospital stay). Ten studies investigating systemic, epidural, intrathecal, intrapleural and paravertebral analgesia involving 891 patients following esophagectomy were included. No significant differences were found in postoperative pain scores between systemic and epidural analgesia at 24 (mean difference (MD) 0.89; 95\% confidence interval (CI) -0.47-2.24) and 48 hours (MD 0.15; 95\%CI -0.60-0.91), nor described for systemic and other regional analgesia. Also, no significant differences in pulmonary complication rates were identified between systemic and epidural analgesia (relative risk (RR) 1.69; 95\%CI 0.86-3.29), or between systemic and paravertebral analgesia (RR 1.49; 95\%CI 0.31-7.12). Technical failure ranged from 17\% to 22\% for epidural analgesia. Sample sizes were too small to draw inferences on opioid consumption, the risk of nausea and vomiting, hypotension, urinary retention, and length of hospital stay when comparing the different pain management modalities including systemic, epidural, intrathecal, intrapleural, and paravertebral analgesia. This systematic review and meta-analysis shows no differences in postoperative pain scores or pulmonary complications after esophagectomy between systemic and epidural analgesia, and between systemic and paravertebral analgesia. Further randomized controlled trails are warranted to determine the optimal pain management modality after esophagectomy.},
	language = {eng},
	number = {10},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Visser, E. and Marsman, M. and van Rossum, P. S. N. and Cheong, E. and Al-Naimi, K. and van Klei, W. A. and Ruurda, J. P. and van Hillegersberg, R.},
	month = oct,
	year = {2017},
	pmid = {28859388},
	keywords = {Humans, Esophagectomy, esophagectomy, Analgesics, Analgesics, Opioid, Nerve Block, Pain Management, Pain, Postoperative, complications, Lung Diseases, Analgesia, Epidural, pain management, pain scores},
	pages = {1--11},
}

@article{neto272,
	title = {Association between driving pressure and development of postoperative pulmonary complications in patients undergoing mechanical ventilation for general anaesthesia: a meta-analysis of individual patient data},
	volume = {4},
	issn = {2213-2619},
	shorttitle = {Association between driving pressure and development of postoperative pulmonary complications in patients undergoing mechanical ventilation for general anaesthesia},
	doi = {10.1016/S2213-2600(16)00057-6},
	abstract = {BACKGROUND: Protective mechanical ventilation strategies using low tidal volume or high levels of positive end-expiratory pressure (PEEP) improve outcomes for patients who have had surgery. The role of the driving pressure, which is the difference between the plateau pressure and the level of positive end-expiratory pressure is not known. We investigated the association of tidal volume, the level of PEEP, and driving pressure during intraoperative ventilation with the development of postoperative pulmonary complications.
METHODS: We did a meta-analysis of individual patient data from randomised controlled trials of protective ventilation during general anesthaesia for surgery published up to July 30, 2015. The main outcome was development of postoperative pulmonary complications (postoperative lung injury, pulmonary infection, or barotrauma).
FINDINGS: We included data from 17 randomised controlled trials, including 2250 patients. Multivariate analysis suggested that driving pressure was associated with the development of postoperative pulmonary complications (odds ratio [OR] for one unit increase of driving pressure 1·16, 95\% CI 1·13-1·19; p{\textless}0·0001), whereas we detected no association for tidal volume (1·05, 0·98-1·13; p=0·179). PEEP did not have a large enough effect in univariate analysis to warrant inclusion in the multivariate analysis. In a mediator analysis, driving pressure was the only significant mediator of the effects of protective ventilation on development of pulmonary complications (p=0·027). In two studies that compared low with high PEEP during low tidal volume ventilation, an increase in the level of PEEP that resulted in an increase in driving pressure was associated with more postoperative pulmonary complications (OR 3·11, 95\% CI 1·39-6·96; p=0·006).
INTERPRETATION: In patients having surgery, intraoperative high driving pressure and changes in the level of PEEP that result in an increase of driving pressure are associated with more postoperative pulmonary complications. However, a randomised controlled trial comparing ventilation based on driving pressure with usual care is needed to confirm these findings.
FUNDING: None.},
	language = {eng},
	number = {4},
	journal = {The Lancet. Respiratory Medicine},
	author = {Neto, Ary Serpa and Hemmes, Sabrine N. T. and Barbas, Carmen S. V. and Beiderlinden, Martin and Fernandez-Bustamante, Ana and Futier, Emmanuel and Gajic, Ognjen and El-Tahan, Mohamed R. and Ghamdi, Abdulmohsin A. Al and Günay, Ersin and Jaber, Samir and Kokulu, Serdar and Kozian, Alf and Licker, Marc and Lin, Wen-Qian and Maslow, Andrew D. and Memtsoudis, Stavros G. and Reis Miranda, Dinis and Moine, Pierre and Ng, Thomas and Paparella, Domenico and Ranieri, V. Marco and Scavonetto, Federica and Schilling, Thomas and Selmo, Gabriele and Severgnini, Paolo and Sprung, Juraj and Sundar, Sugantha and Talmor, Daniel and Treschan, Tanja and Unzueta, Carmen and Weingarten, Toby N. and Wolthuis, Esther K. and Wrigge, Hermann and Amato, Marcelo B. P. and Costa, Eduardo L. V. and de Abreu, Marcelo Gama and Pelosi, Paolo and Schultz, Marcus J. and {PROVE Network Investigators}},
	month = apr,
	year = {2016},
	pmid = {26947624},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Adult, Randomized Controlled Trials as Topic, Postoperative Complications, Lung Diseases, Anesthesia, General, Intraoperative Period, Positive-Pressure Respiration, Tidal Volume},
	pages = {272--280},
	file = {Neto et al_2016_Association between driving pressure and development of postoperative pulmonary.pdf:/Users/jcsal/Zotero/storage/2TY49VEY/Neto et al_2016_Association between driving pressure and development of postoperative pulmonary.pdf:application/pdf},
}

@article{nelson1092,
	title = {Implementation of {Enhanced} {Recovery} {After} {Surgery} ({ERAS}) {Across} a {Provincial} {Healthcare} {System}: {The} {ERAS} {Alberta} {Colorectal} {Surgery} {Experience}},
	volume = {40},
	issn = {1432-2323},
	shorttitle = {Implementation of {Enhanced} {Recovery} {After} {Surgery} ({ERAS}) {Across} a {Provincial} {Healthcare} {System}},
	doi = {10.1007/s00268-016-3472-7},
	abstract = {BACKGROUND: Enhanced recovery after surgery (ERAS) colorectal guideline implementation has occurred primarily in standalone institutions worldwide. We implemented the guideline in a single provincial healthcare system, and our study examined the effect of the guideline on patient outcomes [length of stay (LOS), complications, and 30-day post-discharge readmissions] across a healthcare system.
METHODS: We compared pre- and post-guideline implementation in consecutive elective colorectal patients, ≥ 18 years, from six Alberta hospitals between February 2013 and December 2014. Participants were followed up to 30 days post discharge. We used summary statistics, to assess the LOS and complications, and multivariate regression methods to assess readmissions and to estimate cost impacts.
RESULTS: A total of 1333 patients (350 pre- and 983 post-ERAS) were analysed. Of this number, 55 \% were males. Median overall guideline compliance was 39 \% in pre- and 60 \% in post-ERAS patients. Median LOS was 6 days for pre-ERAS compared to 4.5 days in post-ERAS patients with the longest implementation (p value {\textless}0.0001). Adjusted risk ratio (RR) was 1.71, 95 \% CI 1.09-2.68 for 30-day readmission, comparing pre- to post-ERAS patients. The proportion of patients who developed at least one complication was significantly reduced, from pre- to post-ERAS, difference in proportions = 11.7 \%, 95 \% CI 2.5-21.0, p value: 0.0139. The net cost savings attributable to guideline implementation ranged between \$2806 and \$5898 USD per patient.
CONCLUSION: The findings in our study have shown that ERAS colorectal guideline implementation within a healthcare system resulted in patient outcome improvements, similar to those obtained in smaller standalone implementations. There was a significant beneficial impact of ERAS on scarce health system resources.},
	language = {eng},
	number = {5},
	journal = {World Journal of Surgery},
	author = {Nelson, Gregg and Kiyang, Lawrence N. and Crumley, Ellen T. and Chuck, Anderson and Nguyen, Thanh and Faris, Peter and Wasylak, Tracy and Basualdo-Hammond, Carlota and McKay, Susan and Ljungqvist, Olle and Gramlich, Leah M.},
	month = may,
	year = {2016},
	pmid = {26928854},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Postoperative Complications, Rectum, Perioperative Care, Patient Readmission, Colon, Clinical Protocols, ERAS, Alberta, Guideline Adherence},
	pages = {1092--1103},
}

@article{nuytens232,
	title = {Five-{Year} {Survival} {Outcomes} of {Hybrid} {Minimally} {Invasive} {Esophagectomy} in {Esophageal} {Cancer}: {Results} of the {MIRO} {Randomized} {Clinical} {Trial}},
	volume = {156},
	issn = {2168-6262},
	shorttitle = {Five-{Year} {Survival} {Outcomes} of {Hybrid} {Minimally} {Invasive} {Esophagectomy} in {Esophageal} {Cancer}},
	url = {https://pubmed.ncbi.nlm.nih.gov/33595631/},
	doi = {10.1001/jamasurg.2020.7081},
	abstract = {ClinicalTrials.gov Identifier: NCT00937456.},
	language = {en},
	number = {4},
	urldate = {2022-10-24},
	journal = {JAMA surgery},
	author = {Nuytens, Frederiek and Dabakuyo-Yonli, Tienhan S. and B, Meunier and J, Gagnière and D, Collet and Xb, D'Journo and C, Brigand and T, Perniceni and N, Carrère and Jy, Mabrut and S, Msika and F, Peschaud and M, Prudhomme and Sr, Markar and G, Piessen},
	month = apr,
	year = {2021},
	pmid = {33595631},
	note = {Publisher: JAMA Surg},
	pages = {232--332},
	file = {F et al_2021_Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in.pdf:/Users/jcsal/Zotero/storage/DL86WLQB/F et al_2021_Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/2YZCBT2K/33595631.html:text/html},
}

@article{klevebroS692,
	title = {Application of standardized hemodynamic protocols within enhanced recovery after surgery programs to improve outcomes associated with anastomotic leak and conduit necrosis in patients undergoing esophagectomy},
	volume = {11},
	issn = {2072-1439},
	doi = {10.21037/jtd.2018.11.141},
	abstract = {Esophagectomy for cancer is associated with high risk for postoperative morbidity. The most serious regularly encountered complication is anastomotic leak and the most feared individual complication is conduit necrosis. Both of these complications affect the length of stay, mortality, quality of life, and survival for patients undergoing esophageal resection. The maintenance of conduit viability is of primary importance in the perioperative care of patients following esophageal resection. It has been shown that restrictive fluid management may be associated with improved postoperative outcomes in abdominal and other types of surgery, but many factors can affect the incidence of anastomotic leak and the viability of the gastric conduit. We have performed a comprehensive review with the aim to give an overview of the available evidence for the use of standardized hemodynamic protocols (SHPs) for esophagectomy and review the hemodynamic protocol, which has been applied within a standardized clinical pathway (SCP) at the Department of Thoracic surgery at the Virginia Mason Medical Center between 2004-2018 where the anastomotic leak rate over the period has been 5.2\% and the incidence of conduit necrosis requiring surgical management is zero. The literature review demonstrates that there are few high quality studies that provide scientific evidence for the use of a SHP. The evidence indicates that the use of goal-directed hemodynamic monitoring might be associated with a reduced risk for postoperative complications, shortened length of stay, and decreased need for intensive care unit stay. We propose that the routine application of a SHP can provide a uniform infrastructure to optimize conduit perfusion and decrease the incidence of anastomotic leak.},
	language = {eng},
	number = {Suppl 5},
	journal = {Journal of Thoracic Disease},
	author = {Klevebro, Fredrik and Boshier, Piers R. and Low, Donald E.},
	month = apr,
	year = {2019},
	pmid = {31080646},
	pmcid = {PMC6503292},
	keywords = {Esophageal cancer, esophagectomy, goal-directed therapy, hemodynamic protocol, perioperative care, postoperative complications},
	pages = {S692--S701},
	file = {Klevebro et al_2019_Application of standardized hemodynamic protocols within enhanced recovery.pdf:/Users/jcsal/Zotero/storage/NEGVSAKX/Klevebro et al_2019_Application of standardized hemodynamic protocols within enhanced recovery.pdf:application/pdf},
}

@article{briez310,
	title = {Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase {III} trial - the {MIRO} trial},
	volume = {11},
	issn = {1471-2407},
	shorttitle = {Open versus laparoscopically-assisted oesophagectomy for cancer},
	doi = {10.1186/1471-2407-11-310},
	abstract = {BACKGROUND: Open transthoracic oesophagectomy is the standard treatment for infracarinal resectable oesophageal carcinomas, although it is associated with high mortality and morbidity rates of 2 to 10\% and 30 to 50\%, respectively, for both the abdominal and thoracic approaches. The worldwide popularity of laparoscopic techniques is based on promising results, including lower postoperative morbidity rates, which are related to the reduced postoperative trauma. We hypothesise that the laparoscopic abdominal approach (laparoscopic gastric mobilisation) in oesophageal cancer surgery will decrease the major postoperative complication rate due to the reduced surgical trauma.
METHODS/DESIGN: The MIRO trial is an open, controlled, prospective, randomised multicentre phase III trial. Patients in study arm A will receive laparoscopic-assisted oesophagectomy, i.e., a transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation. Patients in study arm B will receive the same procedure, but with the conventional open abdominal approach. The primary objective of the study is to evaluate the major postoperative 30-day morbidity. Secondary objectives are to assess the overall 30-day morbidity, 30-day mortality, 30-day pulmonary morbidity, disease-free survival, overall survival as well as quality of life and to perform medico-economic analysis. A total of 200 patients will be enrolled, and two safety analyses will be performed using 25 and 50 patients included in arm A.
DISCUSSION: Postoperative morbidity remains high after oesophageal cancer surgery, especially due to major pulmonary complications, which are responsible for 50\% of the postoperative deaths. This study represents the first randomised controlled phase III trial to evaluate the benefits of the minimally invasive approach with respect to the postoperative course and oncological outcomes in oesophageal cancer surgery.
TRIAL REGISTRATION: NCT00937456 (ClinicalTrials.gov).},
	language = {eng},
	journal = {BMC cancer},
	author = {Briez, Nicolas and Piessen, Guillaume and Bonnetain, Franck and Brigand, Cécile and Carrere, Nicolas and Collet, Denis and Doddoli, Christophe and Flamein, Renaud and Mabrut, Jean-Yves and Meunier, Bernard and Msika, Simon and Perniceni, Thierry and Peschaud, Frédérique and Prudhomme, Michel and Triboulet, Jean-Pierre and Mariette, Christophe},
	month = jul,
	year = {2011},
	pmid = {21781337},
	pmcid = {PMC3156811},
	keywords = {Humans, Aged, Middle Aged, Postoperative Care, Follow-Up Studies, Kaplan-Meier Estimate, Prospective Studies, Adult, Young Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Esophagus, Stomach, Lymph Node Excision, Preoperative Care, Thoracotomy, RCT},
	pages = {310},
	file = {Briez et al_2011_Open versus laparoscopically-assisted oesophagectomy for cancer.pdf:/Users/jcsal/Zotero/storage/7VMHRS64/Briez et al_2011_Open versus laparoscopically-assisted oesophagectomy for cancer.pdf:application/pdf},
}

@article{straatman232,
	title = {Minimally {Invasive} {Versus} {Open} {Esophageal} {Resection}: {Three}-year {Follow}-up of the {Previously} {Reported} {Randomized} {Controlled} {Trial}: the {TIME} {Trial}},
	volume = {266},
	issn = {1528-1140},
	shorttitle = {Minimally {Invasive} {Versus} {Open} {Esophageal} {Resection}},
	doi = {10.1097/SLA.0000000000002171},
	abstract = {OBJECTIVE: The aim of this study was to investigate 3-year survival following a randomized controlled trial comparing minimally invasive with open esophagectomy in patients with esophageal cancer.
BACKGROUND: Research on minimally invasive esophagectomy (MIE) has shown faster postoperative recovery and a marked decrease in pulmonary complications. Debate is ongoing as to whether the procedure is equivalent to open resection regarding oncologic outcomes. The study is a follow-up study of the TIME-trial (traditional invasive vs minimally invasive esophagectomy, a multicenter, randomized trial).
METHODS: Between June 2009 and March 2011, patients with a resectable intrathoracic esophageal carcinoma, including the gastroesophageal junction tumors (Siewert I), were randomized between open and MI esophagectomy with curative intent. Primary outcome was 3-year disease-free survival. Secondary outcomes include overall survival, lymph node yield, short-term morbidity, mortality, complications, radicality, local recurrence, and metastasis. Analysis was by intention-to-treat. This trial is registered with the Netherlands Trial Register, NTR TC 2452. Both trial protocol and short-term results have been published previously.
RESULTS: One hundred fifteen patients were included from 5 European hospitals and randomly assigned to open (n = 56) or MI esophagectomy (n = 59). Combined overall 3-year survival was 40.4\% (SD 7.7\%) in the open group versus 50.5\% (SD 8\%) in the minimally invasive group (P = 0.207). The hazard ratio (HR) is 0.883 (0.540 to 1.441) for MIE compared with open surgery. Disease-free 3-year survival was 35.9\% (SD 6.8\%) in the open versus 40.2\% (SD 6.9\%) in the MI group [HR 0.691 (0.389 to 1.239).
CONCLUSIONS: The study presented here depicted no differences in disease-free and overall 3-year survival for open and MI esophagectomy. These results, together with short-term results, further support the use of minimally invasive surgical techniques in the treatment of esophageal cancer.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Straatman, Jennifer and van der Wielen, Nicole and Cuesta, Miguel A. and Daams, Freek and Roig Garcia, Josep and Bonavina, Luigi and Rosman, Camiel and van Berge Henegouwen, Mark I. and Gisbertz, Suzanne S. and van der Peet, Donald L.},
	month = aug,
	year = {2017},
	pmid = {28187044},
	keywords = {Humans, Female, Length of Stay, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Postoperative Complications, Quality of Life, RCT, Patient Reported Outcome Measures},
	pages = {232--236},
}

@article{lv6751,
	title = {Minimally invasive esophagectomy versus open esophagectomy for esophageal cancer: a meta-analysis},
	volume = {9},
	issn = {1178-6930},
	shorttitle = {Minimally invasive esophagectomy versus open esophagectomy for esophageal cancer},
	doi = {10.2147/OTT.S112105},
	abstract = {BACKGROUND AND OBJECTIVES: The safety and effectiveness of minimally invasive esophagectomy (MIE) in comparison with the open esophagectomy (OE) remain uncertain in esophageal cancer treatment. The purpose of this meta-analysis is to compare the outcomes of the two surgical modalities.
METHODS: Searches were conducted in MEDLINE, EMBASE, and ClinicalTrials.gov with the following index words: "esophageal cancer", "VATS", "MIE", "thoracoscopic esophagectomy", and "open esophagectomy" for relative studies that compared the effects between MIE and OE. Random-effect models were used, and heterogeneity was assessed.
RESULTS: A total of 20 studies were included in the analysis, consisting of four randomized controlled trials and 16 prospective studies. MIE has reduced operative blood loss (P=0.0009) but increased operation time (P=0.009) in comparison with OE. Patients get less respiratory complications (risk ratio =0.74, 95\% CI =0.58-0.94, P=0.01) and better overall survival (hazard ratio =0.54, 95\% CI =0.42-0.70, P{\textless}0.00001) in the MIE group than the OE group. No statistical difference was observed between the two groups in terms of lymph node harvest, R0 resection, and other major complications.
CONCLUSION: MIE is a better choice for esophageal cancer because patients undergoing MIE may benefit from reduced blood loss, less respiratory complications, and also improved overall survival condition compared with OE. However, more randomized controlled trials are still needed to verify these differences.},
	language = {eng},
	journal = {OncoTargets and Therapy},
	author = {Lv, Lu and Hu, Weidong and Ren, Yanchen and Wei, Xiaoxuan},
	year = {2016},
	pmid = {27826201},
	pmcid = {PMC5096744},
	keywords = {laparoscopic esophagectomy, postoperative prognosis, thoracoscopic esophagectomy},
	pages = {6751--6762},
	file = {Lv et al_2016_Minimally invasive esophagectomy versus open esophagectomy for esophageal cancer.pdf:/Users/jcsal/Zotero/storage/UVHUUYSB/Lv et al_2016_Minimally invasive esophagectomy versus open esophagectomy for esophageal cancer.pdf:application/pdf},
}

@article{nagpal1621,
	title = {Is minimally invasive surgery beneficial in the management of esophageal cancer? {A} meta-analysis},
	volume = {24},
	issn = {1432-2218},
	shorttitle = {Is minimally invasive surgery beneficial in the management of esophageal cancer?},
	doi = {10.1007/s00464-009-0822-7},
	abstract = {INTRODUCTION: Open esophagectomy for cancer is a major oncological procedure, associated with significant morbidity and mortality. Recently, thoracoscopic procedures have offered a potentially advantageous alternative because of less operative trauma compared with thoracotomy. The aim of this study was to utilize meta-analysis to compare outcomes of open esophagectomy with those of minimally invasive esophagectomy (MIE) and hybrid minimally invasive esophagectomy (HMIE).
METHODS: Literature search was performed using Medline, Embase, Cochrane Library, and Google Scholar databases for comparative studies assessing different techniques of esophagectomy. A random-effects model was used for meta-analysis, and heterogeneity was assessed. Primary outcomes of interest were 30-day mortality and anastomotic leak. Secondary outcomes included operative outcomes, other postoperative outcomes, and oncological outcomes in terms of lymph nodes retrieved.
RESULTS: A total of 12 studies were included in the analysis. Studies included a total of 672 patients for MIE and HMIE, and 612 for open esophagectomy. There was no significant difference in 30-day mortality; however, MIE had lower blood loss, shorter hospital stay, and reduced total morbidity and respiratory complications. For all other outcomes, there was no significant difference between the two groups.
CONCLUSION: Minimally invasive esophagectomy is a safe alternative to the open technique. Patients undergoing MIE may benefit from shorter hospital stay, and lower respiratory complications and total morbidity compared with open esophagectomy. Multicenter, prospective large randomized controlled trials are required to confirm these findings in order to base practice on sound clinical evidence.},
	language = {eng},
	number = {7},
	journal = {Surgical Endoscopy},
	author = {Nagpal, Kamal and Ahmed, Kamran and Vats, Amit and Yakoub, Danny and James, David and Ashrafian, Hutan and Darzi, Ara and Moorthy, Krishna and Athanasiou, Thanos},
	month = jul,
	year = {2010},
	pmid = {20108155},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Minimally Invasive Surgical Procedures, Thoracoscopy},
	pages = {1621--1629},
}

@article{sgourakis3031,
	title = {Minimally invasive versus open esophagectomy: meta-analysis of outcomes},
	volume = {55},
	issn = {1573-2568},
	shorttitle = {Minimally invasive versus open esophagectomy},
	doi = {10.1007/s10620-010-1153-1},
	abstract = {BACKGROUND: A meta-analysis of the current literature was performed to compare the perioperative outcome measures and oncological impact between minimally invasive and open esophagectomy.
METHODS: Using the electronic databases Medline, Embase, Pubmed and the Cochrane Library, we performed a meta-analysis pooling the effects of outcomes of 1,008 patients enrolled into eight comparative studies, using classic and modern meta-analytic methods.
RESULTS: Two comparisons were considered for this systematic review: (I) open thoracotomy vs. VATS/laparoscopy esophagectomy and (II) open thoracotomy vs. VATS esophagectomy. In comparison I: both procedures report equally comparable outcomes (removed lymph nodes, 30-day mortality, 3-year survival) with the exception of overall morbidity (P = 0.038; in favor of the MIE arm) and anastomotic stricture (P {\textless} 0.001; in favor of the open thoracotomy arm). In comparison II: No differences were noted between treatment arms concerning postoperative outcomes and survival.
CONCLUSIONS: In summary, both arms were comparable with regard to perioperative results and prognosis. Further prospective comparative or randomized-controlled trials focusing on the oncological impact of MIE are needed.},
	language = {eng},
	number = {11},
	journal = {Digestive Diseases and Sciences},
	author = {Sgourakis, George and Gockel, Ines and Radtke, Arnold and Musholt, Thomas J. and Timm, Stephan and Rink, Andreas and Tsiamis, Achilleas and Karaliotas, Constantine and Lang, Hauke},
	month = nov,
	year = {2010},
	pmid = {20186484},
	keywords = {Humans, Treatment Outcome, Prognosis, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Laparotomy, Thoracotomy, ROC Curve, Thoracic Surgery, Video-Assisted},
	pages = {3031--3040},
}

@article{gillis391,
	title = {Effects of {Nutritional} {Prehabilitation}, {With} and {Without} {Exercise}, on {Outcomes} of {Patients} {Who} {Undergo} {Colorectal} {Surgery}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {155},
	issn = {1528-0012},
	shorttitle = {Effects of {Nutritional} {Prehabilitation}, {With} and {Without} {Exercise}, on {Outcomes} of {Patients} {Who} {Undergo} {Colorectal} {Surgery}},
	doi = {10.1053/j.gastro.2018.05.012},
	abstract = {BACKGROUND \& AIMS: Although there have been meta-analyses of the effects of exercise-only prehabilitation on patients undergoing colorectal surgery, little is known about the effects of nutrition-only (oral nutritional supplements with and without counseling) and multimodal (oral nutritional supplements with and without counseling and with exercise) prehabilitation on clinical outcomes and patient function after surgery. We performed a systemic review and meta-analysis to determine the individual and combined effects of nutrition-only and multimodal prehabilitation compared with no prehabilitation (control) on outcomes of patients undergoing colorectal resection.
METHODS: We searched Medline, EMBASE, CINAHL, CENTRAL, and ProQuest for cohort and randomized controlled studies of adults awaiting colorectal surgery who received at least 7 days of nutrition prehabilitation with or without exercise. We performed a random-effects meta-analysis to estimate the pooled risk ratio for categorical data and the weighted mean difference for continuous variables. The primary outcome was length of hospital stay; the secondary outcome was recovery of functional capacity based on results of a 6-minute walk test.
RESULTS: We identified 9 studies (5 randomized controlled studies and 4 cohort studies) composed of 914 patients undergoing colorectal surgery (438 received prehabilitation and 476 served as controls). Receipt of any prehabilitation significantly decreased days spent in the hospital compared with controls (weighted mean difference of length of hospital stay = -2.2 days; 95\% confidence interval = -3.5 to -0.9). Only 3 studies reported on functional outcomes but could not be pooled owing to methodologic heterogeneity. In the individual studies, multimodal prehabilitation significantly improved results of the 6-minute walk test at 4 and 8 weeks after surgery compared with standard Enhanced Recovery Pathway care and at 8 weeks compared with standard Enhanced Recovery Pathway care with added rehabilitation. The 4 observational studies had a high risk of bias.
CONCLUSIONS: In a systematic review and meta-analysis, we found that nutritional prehabilitation alone or combined with an exercise program significantly decreased length of hospital stay by 2 days in patients undergoing colorectal surgery. There is some evidence that multimodal prehabilitation accelerated the return to presurgical functional capacity.},
	language = {eng},
	number = {2},
	journal = {Gastroenterology},
	author = {Gillis, Chelsia and Buhler, Katherine and Bresee, Lauren and Carli, Francesco and Gramlich, Leah and Culos-Reed, Nicole and Sajobi, Tolulope T. and Fenton, Tanis R.},
	month = aug,
	year = {2018},
	pmid = {29750973},
	keywords = {Humans, Length of Stay, Treatment Outcome, CRC, Exercise Therapy, Combined Modality Therapy, Postoperative Complications, Digestive System Surgical Procedures, Preoperative Care, Enhanced Recovery After Surgery, Counseling, Diet Therapy, Enhanced Recovery Pathway, Prehab, Preoperative Nutrition, Recovery of Function, Surgery Preparation},
	pages = {391--410.e4},
	file = {Gillis et al_2018_Effects of Nutritional Prehabilitation, With and Without Exercise, on Outcomes.pdf:/Users/jcsal/Zotero/storage/N67ZJU7T/Gillis et al_2018_Effects of Nutritional Prehabilitation, With and Without Exercise, on Outcomes.pdf:application/pdf},
}

@article{mosquera272,
	title = {Impact of frailty on surgical outcomes: {The} right patient for the right procedure},
	volume = {160},
	issn = {1532-7361},
	shorttitle = {Impact of frailty on surgical outcomes},
	doi = {10.1016/j.surg.2016.04.030},
	abstract = {BACKGROUND: Measuring frailty may improve patient selection for high-risk procedures.
METHODS: Data were obtained from the American College of Surgeons National Surgical Quality Improvement Program for patients who underwent elective high-risk operative procedures, and a frailty index was used to classify the patients.
RESULTS: Our study analyzed 232,352 patients with a mean age of 65 years; the majority of patients were males (54\%) and white (78\%). The most common procedure was colectomy (41\%), followed by lower extremity bypass (25\%), gastrectomy (8\%), endovascular abdominal aneurism repair (7\%), pancreatectomy (7\%), cardiac operation (6\%), nephrectomy (3\%), and pulmonary resection (2\%). A majority of the patients were classified as mildly frail (34\%), followed by nonfrail (29\%), moderately frail (21\%), and severely frail (15\%). On univariate analysis, age, race, procedure, sex, and frailty scores were associated with complications, prolonged duration of stay, and 30-day mortality (P {\textless} .0001). On multivariate analysis, frailty was associated with complications, prolonged duration of stay, and 30-day mortality. Increasing frailty disproportionately impacted mortality; colectomy showed the greatest mortality in severely frail patients (9.36\%), followed by esophagectomy (8.2\%), pulmonary resection (6.4\%), pancreatectomy (5.8\%), cardiac procedures (4.4\%), gastrectomy (4.3\%), nephrectomy (3.32\%), endovascular abdominal aneurism repair (2.49\%), and lower extremity bypass (2.41\%; P = .0001). A similar association between duration of stay and morbidity with frailty was noted.
CONCLUSION: Frailty has a significant impact on postoperative outcomes that varies with type of procedure.},
	language = {eng},
	number = {2},
	journal = {Surgery},
	author = {Mosquera, Catalina and Spaniolas, Konstantinos and Fitzgerald, Timothy L.},
	month = aug,
	year = {2016},
	pmid = {27267548},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Retrospective Studies, Risk Factors, Health Status, Aged, 80 and over, Adult, Databases, Factual, United States, Young Adult, Postoperative Complications, Hospital Mortality, Patient Selection, Adolescent, Elective Surgical Procedures, Frailty, Frail Elderly, Quality Improvement},
	pages = {272--280},
	file = {Mosquera et al_2016_Impact of frailty on surgical outcomes.pdf:/Users/jcsal/Zotero/storage/77RH7365/Mosquera et al_2016_Impact of frailty on surgical outcomes.pdf:application/pdf},
}

@article{mcisaac538,
	title = {Association of {Frailty} and 1-{Year} {Postoperative} {Mortality} {Following} {Major} {Elective} {Noncardiac} {Surgery}: {A} {Population}-{Based} {Cohort} {Study}},
	volume = {151},
	issn = {2168-6262},
	shorttitle = {Association of {Frailty} and 1-{Year} {Postoperative} {Mortality} {Following} {Major} {Elective} {Noncardiac} {Surgery}},
	doi = {10.1001/jamasurg.2015.5085},
	abstract = {IMPORTANCE: Single-center studies identify frailty as a risk factor for 30-day postoperative mortality. The long-term and population-level effect of frailty on postoperative mortality is, to our knowledge, poorly described, as are the interactions of frailty with important predictors of mortality.
OBJECTIVE: To measure the population-level effect of patient frailty on, and its association with, 1-year postoperative mortality.
DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study in Ontario, Canada, with data collected between April 1, 2002 and March 31, 2012. Analysis was performed from December 2014 to March 2015. All patients were community-dwelling individuals aged 65 years or older on the day of elective, major noncardiac surgery.
EXPOSURE: Frailty, as defined by the Johns Hopkins Adjusted Clinical Groups (ACG) frailty-defining diagnoses indicator. The ACG frailty-defining diagnoses indicator is a binary variable that uses 12 clusters of frailty-defining diagnoses.
MAIN OUTCOMES AND MEASURES: One-year all-cause postoperative mortality.
RESULTS: Of 202 811 patients, 6289 (3.1\%) were frail (mean [SD] age, 77 [7] years). Within 1 year, 13.6\% (n = 855) of frail and 4.8\% (n = 9433) of nonfrail patients died. Adjustment for sociodemographic and surgical confounders resulted in a hazard ratio of 2.23 (95\% CI, 2.08-2.40). The interaction between frailty and postoperative time demonstrated an increased relative hazard for death in frail patients (hazard ratio, 35.58; 95\% CI, 29.78-40.19) on postoperative day 3. The association between frailty and increased risk of death decreased with patient age (HR, 2.66; 95\% CI, 2.28-3.10 at age 65; HR, 1.63; 95\% CI, 1.36-1.95 at age 90). Significant variations in the increased risk for death in frail patients existed between different surgery types and was strongest after total joint arthroplasty (HR, 3.79; 95\% CI, 3.21-4.47 for hip replacement; HR, 2.68; 95\% CI, 2.10-3.42 for knee replacement).
CONCLUSIONS AND RELEVANCE: At a population level, preoperative frailty-defining diagnoses were associated with a significantly increased risk of 1-year mortality that was particularly notable in the early postoperative period, in younger patients, and after joint arthroplasty.},
	language = {eng},
	number = {6},
	journal = {JAMA surgery},
	author = {McIsaac, Daniel I. and Bryson, Gregory L. and van Walraven, Carl},
	month = jun,
	year = {2016},
	pmid = {26791334},
	keywords = {Humans, Aged, Female, Male, Cause of Death, Retrospective Studies, Risk Factors, Health Status, Time Factors, Aged, 80 and over, Age Factors, Surgical Procedures, Operative, Elective Surgical Procedures, Frailty, Postoperative Period, Frail Elderly, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Ontario},
	pages = {538--545},
	file = {McIsaac et al_2016_Association of Frailty and 1-Year Postoperative Mortality Following Major.pdf:/Users/jcsal/Zotero/storage/6AVYJM2F/McIsaac et al_2016_Association of Frailty and 1-Year Postoperative Mortality Following Major.pdf:application/pdf},
}

@article{rockwood489,
	title = {A global clinical measure of fitness and frailty in elderly people},
	volume = {173},
	issn = {1488-2329},
	doi = {10.1503/cmaj.050051},
	abstract = {BACKGROUND: There is no single generally accepted clinical definition of frailty. Previously developed tools to assess frailty that have been shown to be predictive of death or need for entry into an institutional facility have not gained acceptance among practising clinicians. We aimed to develop a tool that would be both predictive and easy to use.
METHODS: We developed the 7-point Clinical Frailty Scale and applied it and other established tools that measure frailty to 2305 elderly patients who participated in the second stage of the Canadian Study of Health and Aging (CSHA). We followed this cohort prospectively; after 5 years, we determined the ability of the Clinical Frailty Scale to predict death or need for institutional care, and correlated the results with those obtained from other established tools.
RESULTS: The CSHA Clinical Frailty Scale was highly correlated (r = 0.80) with the Frailty Index. Each 1-category increment of our scale significantly increased the medium-term risks of death (21.2\% within about 70 mo, 95\% confidence interval [CI] 12.5\%-30.6\%) and entry into an institution (23.9\%, 95\% CI 8.8\%-41.2\%) in multivariable models that adjusted for age, sex and education. Analyses of receiver operating characteristic curves showed that our Clinical Frailty Scale performed better than measures of cognition, function or comorbidity in assessing risk for death (area under the curve 0.77 for 18-month and 0.70 for 70-month mortality).
INTERPRETATION: Frailty is a valid and clinically important construct that is recognizable by physicians. Clinical judgments about frailty can yield useful predictive information.},
	language = {eng},
	number = {5},
	journal = {CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne},
	author = {Rockwood, Kenneth and Song, Xiaowei and MacKnight, Chris and Bergman, Howard and Hogan, David B. and McDowell, Ian and Mitnitski, Arnold},
	month = aug,
	year = {2005},
	pmid = {16129869},
	pmcid = {PMC1188185},
	keywords = {Humans, Aged, Female, Male, Health Status, Prospective Studies, Prognosis, Aged, 80 and over, Predictive Value of Tests, Mortality, Frailty, Geriatric Assessment, Physical Fitness, Frail Elderly, Institutionalization},
	pages = {489--495},
	file = {Rockwood et al_2005_A global clinical measure of fitness and frailty in elderly people.pdf:/Users/jcsal/Zotero/storage/FJ2CPNUB/Rockwood et al_2005_A global clinical measure of fitness and frailty in elderly people.pdf:application/pdf},
}

@article{minnella1081,
	title = {Effect of {Exercise} and {Nutrition} {Prehabilitation} on {Functional} {Capacity} in {Esophagogastric} {Cancer} {Surgery}: {A} {Randomized} {Clinical} {Trial}},
	volume = {153},
	issn = {2168-6262},
	shorttitle = {Effect of {Exercise} and {Nutrition} {Prehabilitation} on {Functional} {Capacity} in {Esophagogastric} {Cancer} {Surgery}},
	doi = {10.1001/jamasurg.2018.1645},
	abstract = {Importance: Preserving functional capacity is a key element in the care continuum for patients with esophagogastric cancer. Prehabilitation, a preoperative conditioning intervention aiming to optimize physical status, has not been tested in upper gastrointestinal surgery to date.
Objective: To investigate whether prehabilitation is effective in improving functional status in patients undergoing esophagogastric cancer resection.
Design, Setting, and Participants: A randomized clinical trial (available-case analysis based on completed assessments) was conducted at McGill University Health Centre (Montreal, Quebec, Canada) comparing prehabilitation with a control group. Intervention consisted of preoperative exercise and nutrition optimization. Participants were adults awaiting elective esophagogastric resection for cancer. The study dates were February 13, 2013, to February 10, 2017.
Main Outcomes and Measures: The primary outcome was change in functional capacity, measured with absolute change in 6-minute walk distance (6MWD). Preoperative (end of the prehabilitation period) and postoperative (from 4 to 8 weeks after surgery) data were compared between groups.
Results: Sixty-eight patients were randomized, and 51 were included in the primary analysis. The control group were a mean (SD) age, 68.0 (11.6) years and 20 (80\%) men. Patients in the prehabilitation group were a mean (SD) age, 67.3 (7.4) years and 18 (69\%) men. Compared with the control group, the prehabilitation group had improved functional capacity both before surgery (mean [SD] 6MWD change, 36.9 [51.4] vs -22.8 [52.5] m; P {\textless} .001) and after surgery (mean [SD] 6MWD change, 15.4 [65.6] vs -81.8 [87.0] m; P {\textless} .001).
Conclusions and Relevance: Prehabilitation improves perioperative functional capacity in esophagogastric surgery. Keeping patients from physical and nutritional status decline could have a significant effect on the cancer care continuum.
Trial Registration: ClinicalTrials.gov Identifier: NCT01666158.},
	language = {eng},
	number = {12},
	journal = {JAMA surgery},
	author = {Minnella, Enrico M. and Awasthi, Rashami and Loiselle, Sarah-Eve and Agnihotram, Ramanakumar V. and Ferri, Lorenzo E. and Carli, Francesco},
	month = dec,
	year = {2018},
	pmcid = {PMC6583009},
	pmid = {30193337},
	note = {tex.ids= minnella1081a},
	keywords = {Aged, Esophageal Neoplasms, Exercise, Female, Humans, Male, Middle Aged, Nutritional Status, Prehabilitation, Preoperative Care, Stomach Neoplasms, Walking},
	pages = {1081--1089},
	file = {Minnella et al_2018_Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in.pdf:/Users/jcsal/Zotero/storage/H8ZDI237/Minnella et al_2018_Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in.pdf:application/pdf},
}

@article{ohnmacht311,
	title = {Percutaneous endoscopic gastrostomy risks rendering the gastric conduit unusable for esophagectomy},
	volume = {19},
	issn = {1120-8694},
	doi = {10.1111/j.1442-2050.2006.00588.x},
	abstract = {Surgical treatment for cancer of the esophagus most often involves replacement of the esophagus with a gastric conduit. This gastric tube relies upon the continuity of the gastroepiploic artery for its blood supply. This case report involves a patient whose gastroepiploic artery became thrombosed by a percutaneous endoscopic gastrostomy, rendering his gastric conduit unusable.},
	language = {eng},
	number = {4},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Ohnmacht, G. A. and Allen, M. S. and Cassivi, S. D. and Deschamps, C. and Nichols, F. C. and Pairolero, P. C.},
	year = {2006},
	pmid = {16866867},
	note = {tex.ids= ohnmacht311a},
	keywords = {Humans, Aged, Male, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Deglutition Disorders, Equipment Failure, Enteral Nutrition, Intubation, Gastrointestinal, Jejunostomy, Gastrostomy, Gastroepiploic Artery, PEG},
	pages = {311--312},
	file = {Ohnmacht et al_2006_Percutaneous endoscopic gastrostomy risks rendering the gastric conduit.pdf:/Users/jcsal/Zotero/storage/D2SVM7QF/Ohnmacht et al_2006_Percutaneous endoscopic gastrostomy risks rendering the gastric conduit.pdf:application/pdf},
}

@article{margolis1694,
	title = {Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer},
	volume = {76},
	issn = {0003-4975},
	url = {https://www.sciencedirect.com/science/article/pii/S0003497502048907},
	doi = {10.1016/S0003-4975(02)04890-7},
	abstract = {Background
Percutaneous endoscopic gastrostomy (PEG) has not been widely used in esophageal cancer because of concerns about safety of dilatation, suitability of the stomach as an esophageal replacement, and potential for inoculation metastasis.
Methods
Experience with PEG in consecutive patients presenting with new esophageal cancer from March 1991 to March 2001 was reviewed retrospectively. PEG was planned in 119 of 179 (66\%) of these patients excluding those presenting moribund and those for whom early resection was planned. The PEG was placed using an endoscopic method with wire-guided endoscopic bougienage or laser ablation or both as needed. Success of placement, requirement for dilatation and ablation, PEG-related complications, tolerance of enteral feeds, and impact on therapy were evaluated.
Results
PEG placement was possible in 87\% of patients (103 of 119). Dilatation or laser ablation or both was required in 46\% (47 of 103). There was no procedure-related mortality. Thirty-day mortality was 13.5\%. Major PEG-related complications were observed in 4\% (4 of 103) and minor PEG-related complications in 12\% (12 of 103). PEG removal was required in 4 patients and interruption of enteral feeds required in 33 (32\%). No instances of esophageal disruption or tumor inoculation metastasis were noted. PEG takedown and site closure at the time of operation was uncomplicated and use of the stomach as an esophageal substitute was possible in all 61 resected patients. Rates of anastomotic leak, stricture, and gastric emptying delay were similar to those for patients proceeding to resection without prior PEG (leak: PEG = 8\% [5 of 61] versus non-PEG = 10.5\% [2 of 19]), (stricture: PEG = 37\% [22 of 61] versus non-PEG = 32.5\% [6 of 19]), (delay: PEG = 9.8\% [6 of 61] versus non-PEG = 10.5\% [2 of 19]). Analysis of variables showed PEG to be significantly related to attainment of target doses of chemoradiotherapy (p = 0.034), and survival at 12 months (p = 0.02).
Conclusions
PEG in esophageal cancer is safe and useful and does not compromise the stomach or esophagogastric anastomosis. Further study is required to define the efficacy of PEG as a means of nutritional support and its impact on survival.},
	language = {en},
	number = {5},
	urldate = {2022-10-18},
	journal = {The Annals of Thoracic Surgery},
	author = {Margolis, Marc and Alexander, Pendleton and Trachiotis, Gregory D and Gharagozloo, Farid and Lipman, Timothy},
	month = nov,
	year = {2003},
	keywords = {7, PEG},
	pages = {1694--1698},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/DA43D6D8/S0003497502048907.html:text/html},
}

@article{ellrichmann526,
	title = {Prospective evaluation of malignant cell seeding after percutaneous endoscopic gastrostomy in patients with oropharyngeal/esophageal cancers},
	volume = {45},
	issn = {1438-8812},
	doi = {10.1055/s-0033-1344023},
	abstract = {BACKGROUND AND STUDY AIMS: Insertion of a percutaneous endoscopic gastrostomy (PEG) is standard care for many patients with oropharyngeal (ENT) and esophageal malignancies in order to ensure enteral feeding. The current pull-through insertion technique involves direct contact with the tumor and case reports have demonstrated the presence of metastases at insertion sites. The aim of the current study was to prospectively evaluate the risk of malignant cell seeding and the development of abdominal wall metastases after PEG placement.
PATIENTS AND METHODS: A total of 50 consecutive patients with ENT/esophageal tumors were included. After PEG placement (40 pull-through technique, 10 direct insertion), brush cytology was taken from the PEG tubing and the transcutaneous incision site. A second cytological assessment was performed after a follow-up period of 3 - 6 months.
RESULTS: In total, 26 patients with ENT cancer, 13 with esophageal cancer, and one with esophageal infiltration of lung cancer underwent pull-through PEG placement with no immediate complications. Cytology following brushing of tubing and incision sites demonstrated malignant cells in 9 /40 cases (22.5 \%). Correlation analyses revealed a higher rate of malignant seeding in older patients and in those with higher tumor stages. At follow-up, cytology was undertaken in 32 /40 patients who had undergone pull-through PEG placement. Malignant cells were present in three on cytology, resulting in a metastatic seeding rate of 9.4 \%.
CONCLUSION: This study showed that malignant cells were present in 22.5 \% of patients immediately after pull-through PEG placement; local metastases were verified at follow-up in 9.4 \%, all of which were from esophageal squamous cell carcinoma. This risk is particularly high in the older age group and in patients with higher tumor stages. Therefore, pull-through PEG placement should be avoided in these patients and direct access PEG favored instead.},
	language = {eng},
	number = {7},
	journal = {Endoscopy},
	author = {Ellrichmann, M. and Sergeev, P. and Bethge, J. and Arlt, A. and Topalidis, T. and Ambrosch, P. and Wiltfang, J. and Fritscher-Ravens, A.},
	month = jul,
	year = {2013},
	pmid = {23780843},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Risk Factors, Prospective Studies, Survival Rate, Carcinoma, Squamous Cell, Esophageal Neoplasms, Endoscopy, Gastrointestinal, Gastrostomy, Abdominal Neoplasms, PEG, Abdominal Wall, Cytodiagnosis, Neoplasm Seeding, Oropharyngeal Neoplasms},
	pages = {526--531},
}

@article{schmidt931,
	title = {Accelerated {Recovery} {Within} {Standardized} {Recovery} {Pathways} {After} {Esophagectomy}: {A} {Prospective} {Cohort} {Study} {Assessing} the {Effects} of {Early} {Discharge} on {Outcomes}, {Readmissions}, {Patient} {Satisfaction}, and {Costs}},
	volume = {102},
	issn = {1552-6259},
	shorttitle = {Accelerated {Recovery} {Within} {Standardized} {Recovery} {Pathways} {After} {Esophagectomy}},
	doi = {10.1016/j.athoracsur.2016.04.005},
	abstract = {BACKGROUND: After esophagectomy, some patients exceed targeted discharge goal within enhanced recovery after surgery programs. This study reviews the demographics, outcomes, cost, readmission rates, and patient satisfaction for the accelerated recovery (AR) group.
METHODS: Between 2010 and 2013, 137 consecutive esophagectomy patients were compared according to the length of hospital stay: AR 5 to 6 days, targeted recovery (TR) 7 to 8 days, and delayed recovery (DR) 9 days or more.
RESULTS: The AR patients increased from 3\% to 46\% during the study period. The AR patients were younger, but all groups were comparable regarding comorbidities (Charlson, American Society of Anesthesiologists, and Eastern Cooperative Oncology Group score), cancer stage, and treatment approach. The AR patients were more likely to have neoadjuvant therapy, shorter operations, and less blood loss. The DR patients were more likely to have complications (40\% AR versus 45\% TR versus 90\% DR, p {\textless} 0.001). Inhospital and 90-day mortality was 1.5\%. All AR patients were discharged home (100\% AR versus 87\% TR versus 63\% DR, p {\textless} 0.001), and 30-day readmission rates were comparable between groups (14\% AR versus 19\% TR versus 5\% DR, p = 0.122). Overall mean costs (\$38,385 AR versus \$41,607 TR versus \$61,199 DR, p {\textless} 0.001) as well as readmission costs (\$7,470 AR versus \$27,695 TR versus \$33,398 DR, p = 0.202) were lower in the AR group. Patient satisfaction scores were comparable between groups.
CONCLUSIONS: Accelerated recovery is achievable in a significant proportion of patients undergoing esophagectomy. Accelerated recovery is associated with decreased treatment costs but does not lead to increased readmissions or decreased patient satisfaction. Enhanced recovery after surgery programs should be designed to accommodate patients appropriate for AR.},
	language = {eng},
	number = {3},
	journal = {The Annals of Thoracic Surgery},
	author = {Schmidt, Henner M. and El Lakis, Mustapha A. and Markar, Sheraz R. and Hubka, Michal and Low, Donald E.},
	month = sep,
	year = {2016},
	pmid = {27283109},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Prospective Studies, Time Factors, Cohort Studies, Aged, 80 and over, Adult, Esophagectomy, Health Care Costs, Patient Readmission, Patient Discharge, Patient Satisfaction},
	pages = {931--939},
	file = {Schmidt et al_2016_Accelerated Recovery Within Standardized Recovery Pathways After Esophagectomy.pdf:/Users/jcsal/Zotero/storage/CD2UC9NI/Schmidt et al_2016_Accelerated Recovery Within Standardized Recovery Pathways After Esophagectomy.pdf:application/pdf},
}

@article{zwischenberger489,
	title = {Venous {Thromboembolism} {Prophylaxis} {For} {Esophagectomy}: {A} {Survey} of {Practice} {Patterns} {Among} {Thoracic} {Surgeons}},
	volume = {101},
	issn = {1552-6259},
	shorttitle = {Venous {Thromboembolism} {Prophylaxis} {For} {Esophagectomy}},
	doi = {10.1016/j.athoracsur.2015.07.023},
	abstract = {BACKGROUND: Current guidelines for gastrointestinal cancer surgical intervention in high-risk patients recommend postoperative venous thromboembolism (VTE) chemical prophylaxis for 4 weeks with low-dose unfractionated heparin or low-molecular-weight heparin, but specific guidelines for esophagectomy are lacking. This survey identified the clinical patterns affecting postesophagectomy VTE chemoprophylaxis use among general thoracic surgeons.
METHODS: General Thoracic Surgery Club members were invited to complete an online survey on VTE prophylaxis to analyze clinical factors affecting their choices.
RESULTS: Seventy-seven surgeons (37\% membership) responded; of these, 94\% (72 of 77) completed fellowships, and 76\% (58 of 77) worked at universities. VTE chemoprophylaxis administration varied widely in drug, dosing, and duration, with 30\% using suboptimal dosing of unfractionated heparin (every 12 hours). Participants agreed that esophagectomy patients are at high VTE risk, yet 29\% (22 of 76) of surgeons delay VTE chemoprophylaxis until postoperative day 1. Only 13\% (10 of 77) prescribe postdischarge chemoprophylaxis. Minimally invasive surgeons ({\textgreater}90\% of cases) were more likely to prescribe postdischarge prophylaxis (p = 0.007). Epidurals, routinely used by 65\% (51 of 78), led to less compliance with recommended dosing. Only 53\% (27 of 51) of pain teams allow unfractionated heparin every 8 hours, yet 73\% (37 of 51) allow suboptimal dosing (every 12 h). Postoperative major complications were identified as a VTE risk factor by only 21\% (15 of 72) of surgeons. Most (92\% [68 of 74]) would follow esophagectomy-specific guidelines, if developed.
CONCLUSIONS: Thoracic surgeons agree that VTE chemoprophylaxis is necessary for esophagectomy, yet substantial variability exists in current practice. A noteworthy proportion use suboptimal dosing, and very few choose postdischarge prophylaxis. To improve postesophagectomy morbidity and mortality outcomes, thoracic surgeons are willing to follow evidence-based guidelines for VTE chemoprophylaxis.},
	language = {eng},
	number = {2},
	journal = {The Annals of Thoracic Surgery},
	author = {Zwischenberger, Brittany A. and Tzeng, Ching-Wei D. and Ward, Nicholas D. and Zwischenberger, Joseph B. and Martin, Jeremiah T.},
	month = feb,
	year = {2016},
	pmid = {26409709},
	keywords = {Humans, Esophagectomy, Postoperative Complications, Surveys and Questionnaires, Anticoagulants, Heparin, Practice Patterns, Physicians', Thoracic Surgery, Venous Thromboembolism, VTE},
	pages = {489--494},
	file = {Zwischenberger et al_2016_Venous Thromboembolism Prophylaxis For Esophagectomy.pdf:/Users/jcsal/Zotero/storage/EWFGX2F2/Zwischenberger et al_2016_Venous Thromboembolism Prophylaxis For Esophagectomy.pdf:application/pdf},
}

@article{whibley594,
	title = {Poor performance in incremental shuttle walk and cardiopulmonary exercise testing predicts poor overall survival for patients undergoing esophago-gastric resection},
	volume = {44},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2018.01.242},
	abstract = {INTRODUCTION: Esophageal and gastric cancer have a poor prognosis and surgical intervention is associated with considerable morbidity, highlighting the need for careful preoperative assessment. The Incremental Shuttle Walk Test (ISWT) and Cardiopulmonary exercise testing (CPET) can assess preoperative fitness. This study aims to investigate their correlation with both postoperative respiratory complications and overall survival.
PATIENTS AND METHODS: Patients were identified who underwent esophageal or gastric resections for cancer between 2010 and 2014 and had ISWT and/or CPET assessments. Tumor differentiation, stage, postoperative respiratory complications, and outcome were documented and then correlated with the results of the preoperative fitness assessments.
RESULTS: Neither the ISWT result, anaerobic threshold (AT) nor VO2 Max correlated well with perioperative complications. However, ISWT (p {\textless} 0.001), AT (p {\textless} 0.001) and VO2 Max (p {\textless} 0.001) all correlated strongly with overall survival. No patient with a score of less than 350 m on ISWT survived beyond 3 years. In a subset of patients with ISWT results both pre and post chemotherapy (n = 49), those that had an improvement in result had a 19\% incidence of post-operative respiratory complications compared to 45\% where the result did not change or declined, though due to small numbers this only approached significance (p = 0.08).
CONCLUSION: ISWT and CPET can be useful preoperative tools to predict overall survival for patients undergoing esophago-gastric resection. Furthermore, patients that improve their functional status during chemotherapy seem to do better than those where it remains static or declines.},
	language = {eng},
	number = {5},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Whibley, Jessica and Peters, Christopher J. and Halliday, Laura J. and Chaudry, Asif M. and Allum, William H.},
	month = may,
	year = {2018},
	pmid = {29459017},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Survival Rate, Prognosis, Aged, 80 and over, Adult, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Incidence, Postoperative Complications, Gastrectomy, Esophageal neoplasms, Survival, Postoperative complications, Walk Test, Exercise test, Exercise Test, Exercise tolerance, Exercise Tolerance, Preoperative care, Respiratory Tract Diseases, Stomach neoplasms, Survival rate},
	pages = {594--599},
}

@article{urschel160,
	title = {Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials},
	volume = {19},
	issn = {0253-4886},
	shorttitle = {Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy},
	doi = {10.1159/000064206},
	abstract = {BACKGROUND/AIM: A gastric conduit is usually used to reconstruct the foregut after esophagectomy for cancer. The gastric emptying may be impaired after this operation, so some esophageal surgeons routinely add a pyloric drainage procedure (pyloroplasty or pyloromyotomy). We performed a meta-analysis of randomized controlled trials (RCTs) to determine the effect of pyloric drainage on patient outcomes.
METHODS: Medline and manual searches were done (completed independently and in duplicate) to identify all published RCTs that addressed the issue of pyloric drainage procedures during gastric conduit reconstruction of the esophagus. The selection process was inclusive; no trials were excluded. Trial validity assessment was done, and a trial quality score was assigned. Early outcomes assessed by meta-analysis included operative mortality, esophagogastric anastomotic leaks, pulmonary morbidity, pyloric drainage complications, fatal pulmonary aspiration, and gastric outlet obstruction. A random-effects model was used, and the relative risk was the principal measure of effect. Systematic semiquantitative review was used for late outcomes such as gastric emptying, bile reflux, nutritional status, and obstructive foregut symptoms.
RESULTS: Nine RCTs, that included a total of 553 patients, were selected, with quality scores ranging from 1 to 4 (5-point Jadad scale). Selection and validity agreement was strong. The relative risk (95\% CI; p value), expressed as pyloric drainage versus no drainage (treatment vs. control), was 0.92 (0.34, 2.44; p = 0.86) for operative mortality, 0.90 (0.47, 1.76; p = 0.77) for esophagogastric anastomotic leaks, 0.69 (0.42, 1.14; p = 0.15) for pulmonary morbidity, 2.55 (0.34, 18.98; p = 0.36) for pyloric drainage complications, 0.25 (0.04, 1.60; p = 0.14) for fatal pulmonary aspiration, and 0.18 (0.03, 0.97; p = 0.046) for gastric outlet obstruction. Systematic semiquantitative review showed a nonsignificant trend favoring pyloric drainage for the late outcomes of gastric emptying, nutritional status, and obstructive foregut symptoms. For the late outcome of bile reflux, there was a nonsignificant trend favoring the no-drainage group. The scintographic gastric emptying time, expressed as a ratio (pyloric drainage/no drainage), was 0.53.
CONCLUSIONS: Data synthesized from existing RCTs show that pyloric drainage procedures reduce the occurrence of early postoperative gastric outlet obstruction after esophagectomy with gastric reconstruction, but they have little effect on other early and late patient outcomes.},
	language = {eng},
	number = {3},
	journal = {Digestive Surgery},
	author = {Urschel, John D. and Blewett, Chris J. and Young, J. Edward M. and Miller, John D. and Bennett, W. Frederick},
	year = {2002},
	pmid = {12119515},
	keywords = {Humans, Treatment Outcome, Randomized Controlled Trials as Topic, Esophageal Neoplasms, Esophagectomy, Drainage, Gastroplasty, Pyloris, Pylorus},
	pages = {160--164},
}

@article{older355,
	title = {Cardiopulmonary exercise testing as a screening test for perioperative management of major surgery in the elderly},
	volume = {116},
	issn = {0012-3692},
	doi = {10.1378/chest.116.2.355},
	abstract = {STUDY OBJECTIVE: To develop an integrated strategy for the identification and subsequent management of high-risk patients in order to reduce both morbidity and mortality.
DESIGN: Prospective consecutive series in which all patients underwent cardiopulmonary exercise (CPX) testing.
SETTING: CPX laboratory and level 3 ICU and high-dependency unit (HDU) of a metropolitan teaching hospital.
PATIENTS: Five hundred forty-eight patients {\textgreater}60 years of age (or younger with known cardiopulmonary disease) scheduled for major intra-abdominal surgery.
INTERVENTIONS: The patients were assigned to one of three management strategies (ICU, HDU, or ward) based on the anaerobic threshold (deltaT) and ECG evidence of myocardial ischemia as determined by CPX testing that was performed as part of the presurgery evaluation, and by the expected oxygen demand stress of the surgical procedure.
RESULTS: Overall mortality was 3.9\%. Forty-three percent of deaths were attributed to poor cardiopulmonary function, as detected preoperatively. There were no deaths related to cardiopulmonary complications in any patient deemed fit for major abdominal surgery and ward management, as determined by CPX testing.
CONCLUSIONS: In elderly patients undergoing major intra-abdominal surgery, the AT, as determined by CPX testing, is an excellent predictor of mortality from cardiopulmonary causes in the postoperative period. Preoperative screening using CPX testing allowed the identification of high-risk patients and the appropriate selection of perioperative management.},
	language = {eng},
	number = {2},
	journal = {Chest},
	author = {Older, P. and Hall, A. and Hader, R.},
	month = aug,
	year = {1999},
	pmid = {10453862},
	keywords = {Humans, Aged, Middle Aged, Postoperative Care, Risk Assessment, Aged, 80 and over, Predictive Value of Tests, Postoperative Complications, Digestive System Surgical Procedures, Exercise Test, Anaerobic Threshold, Aortic Aneurysm, Abdominal},
	pages = {355--362},
}

@article{joshi1026,
	title = {A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia},
	volume = {107},
	issn = {1526-7598},
	doi = {10.1213/01.ane.0000333274.63501.ff},
	abstract = {BACKGROUND: Thoracotomy induces severe postoperative pain and impairment of pulmonary function, and therefore regional analgesia has been intensively studied in this procedure. Thoracic epidural analgesia is commonly considered the "gold standard" in this setting; however, evaluation of the evidence is needed to assess the comparative benefits of alternative techniques, guide clinical practice and identify areas requiring further research.
METHODS: In this systematic review of randomized trials we evaluated thoracic epidural, paravertebral, intrathecal, intercostal, and interpleural analgesic techniques, compared to each other and to systemic opioid analgesia, in adult thoracotomy. Postoperative pain, analgesic use, and complications were analyzed.
RESULTS: Continuous paravertebral block was as effective as thoracic epidural analgesia with local anesthetic (LA) but was associated with a reduced incidence of hypotension. Paravertebral block reduced the incidence of pulmonary complications compared with systemic analgesia, whereas thoracic epidural analgesia did not. Thoracic epidural analgesia was superior to intrathecal and intercostal techniques, although these were superior to systemic analgesia; interpleural analgesia was inadequate.
CONCLUSIONS: Either thoracic epidural analgesia with LA plus opioid or continuous paravertebral block with LA can be recommended. Where these techniques are not possible, or are contraindicated, intrathecal opioid or intercostal nerve block are recommended despite insufficient duration of analgesia, which requires the use of supplementary systemic analgesia. Quantitative meta-analyses were limited by heterogeneity in study design, and subject numbers were small. Further well designed studies are required to investigate the optimum components of the epidural solution and to rigorously evaluate the risks/benefits of continuous infusion paravertebral and intercostal techniques compared with thoracic epidural analgesia.},
	language = {eng},
	number = {3},
	journal = {Anesthesia and Analgesia},
	author = {Joshi, Girish P. and Bonnet, Francis and Shah, Rajesh and Wilkinson, Roseanne C. and Camu, Frederic and Fischer, Barrie and Neugebauer, Edmund A. M. and Rawal, Narinder and Schug, Stephan A. and Simanski, Christian and Kehlet, Henrik},
	month = sep,
	year = {2008},
	pmid = {18713924},
	keywords = {Humans, Treatment Outcome, Randomized Controlled Trials as Topic, Odds Ratio, Thoracotomy, Analgesics, Opioid, Nerve Block, Pain, Postoperative, Hypotension, Analgesia, Epidural, Analgesia},
	pages = {1026--1040},
}

@article{futier428,
	title = {A trial of intraoperative low-tidal-volume ventilation in abdominal surgery},
	volume = {369},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa1301082},
	abstract = {BACKGROUND: Lung-protective ventilation with the use of low tidal volumes and positive end-expiratory pressure is considered best practice in the care of many critically ill patients. However, its role in anesthetized patients undergoing major surgery is not known.
METHODS: In this multicenter, double-blind, parallel-group trial, we randomly assigned 400 adults at intermediate to high risk of pulmonary complications after major abdominal surgery to either nonprotective mechanical ventilation or a strategy of lung-protective ventilation. The primary outcome was a composite of major pulmonary and extrapulmonary complications occurring within the first 7 days after surgery.
RESULTS: The two intervention groups had similar characteristics at baseline. In the intention-to-treat analysis, the primary outcome occurred in 21 of 200 patients (10.5\%) assigned to lung-protective ventilation, as compared with 55 of 200 (27.5\%) assigned to nonprotective ventilation (relative risk, 0.40; 95\% confidence interval [CI], 0.24 to 0.68; P=0.001). Over the 7-day postoperative period, 10 patients (5.0\%) assigned to lung-protective ventilation required noninvasive ventilation or intubation for acute respiratory failure, as compared with 34 (17.0\%) assigned to nonprotective ventilation (relative risk, 0.29; 95\% CI, 0.14 to 0.61; P=0.001). The length of the hospital stay was shorter among patients receiving lung-protective ventilation than among those receiving nonprotective ventilation (mean difference, -2.45 days; 95\% CI, -4.17 to -0.72; P=0.006).
CONCLUSIONS: As compared with a practice of nonprotective mechanical ventilation, the use of a lung-protective ventilation strategy in intermediate-risk and high-risk patients undergoing major abdominal surgery was associated with improved clinical outcomes and reduced health care utilization. (IMPROVE ClinicalTrials.gov number, NCT01282996.).},
	language = {eng},
	number = {5},
	journal = {The New England Journal of Medicine},
	author = {Futier, Emmanuel and Constantin, Jean-Michel and Paugam-Burtz, Catherine and Pascal, Julien and Eurin, Mathilde and Neuschwander, Arthur and Marret, Emmanuel and Beaussier, Marc and Gutton, Christophe and Lefrant, Jean-Yves and Allaouchiche, Bernard and Verzilli, Daniel and Leone, Marc and De Jong, Audrey and Bazin, Jean-Etienne and Pereira, Bruno and Jaber, Samir and {IMPROVE Study Group}},
	month = aug,
	year = {2013},
	pmid = {23902482},
	keywords = {Abdomen, Humans, Female, Male, Middle Aged, Postoperative Complications, Digestive System Surgical Procedures, Intention to Treat Analysis, Double-Blind Method, Operative Time, Positive-Pressure Respiration, Tidal Volume, Respiratory Insufficiency},
	pages = {428--437},
}

@article{drummond515,
	title = {Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated for oesophagogastric cancer surgery},
	volume = {100},
	issn = {1478-7083},
	doi = {10.1308/rcsann.2018.0067},
	abstract = {Introduction There is a known correlation between anaerobic threshold (AT) during cardiopulmonary exercise testing and development of cardiopulmonary complications in high-risk patients undergoing oesophagogastric cancer surgery. This study aimed to assess the value of routine retesting following neoadjuvant chemotherapy. Methods Patients undergoing neoadjuvant chemotherapy with subsequent oesophagogastric cancer surgery with pre- and post-neoadjuvant chemotherapy cardiopulmonary exercise data were identified from a prospectively maintained database. Measured cardiopulmonary exercise variables included AT and maximum oxygen uptake at peak exercise (VO2 peak). Anaerobic threshold values within 1 ml/kg/minute were considered static. Patients were grouped into AT ranges of less than 9 ml/kg/minute, 9-11 ml/kg/minute and greater than 11 ml/kg/minute. Outcome measures were unplanned intensive care stay, postoperative cardiovascular morbidity and mortality. Results Between May 2008 and August 2017, 42 patients from 675 total resections were identified, with a mean age of 65 years (range 49-84 years). Mean pre-neoadjuvant chemotherapy AT was 11.07 ml/kg/minute (standard deviation, SD, 3.24 ml/kg/minute, range 4.6-19.3 ml/kg/minute) while post-neoadjuvant chemotherapy AT was 11.19 ml/kg/minute (SD 3.05 ml/kg/minute, range 5.2-18.1 ml/kg/minute). Mean pre-neoadjuvant chemotherapy VO2 peak was 17.13 ml/kg/minute, while post-chemotherapy this mean fell to 16.59 ml/kg/minute. Some 44.4\% of patients with a pre-chemotherapy AT less than 9 ml/kg/minute developed cardiorespiratory complications compared with 42.2\% of those whose AT was greater than 9 ml/kg/minute (P = 0.914); 63.6\% of patients in the post-neoadjuvant chemotherapy group with an AT less than 9 ml/kg/minute developed cardiorespiratory complications. There was no correlation between direction of change in AT and outcome. Conclusion In our patient population, neoadjuvant chemotherapy does not appear to result in a significant mean reduction in cardiorespiratory fitness. Routine pre- and post-neoadjuvant chemotherapy cardiopulmonary exercise testing is currently not indicated; however, larger studies are required to demonstrate this conclusively.},
	language = {eng},
	number = {7},
	journal = {Annals of the Royal College of Surgeons of England},
	author = {Drummond, R. J. and Vass, D. and Wadhawan, H. and Craig, C. F. and MacKay, C. K. and Fullarton, G. M. and Forshaw, M. J.},
	month = sep,
	year = {2018},
	pmid = {29692190},
	pmcid = {PMC6214048},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Neoadjuvant Therapy, Prospective Studies, Survival Rate, Antineoplastic Agents, Aged, 80 and over, Chemotherapy, Stomach Neoplasms, Esophageal Neoplasms, Postoperative Complications, Gastrectomy, Oesophagectomy, Exercise Test, Anaerobic Threshold, Critical Care, Cardiorespiratory Fitness, Exercise testing},
	pages = {515--519},
	file = {Drummond et al_2018_Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated.pdf:/Users/jcsal/Zotero/storage/PLSI4I6D/Drummond et al_2018_Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated.pdf:application/pdf},
}

@article{baidya626,
	title = {Analgesic efficacy and safety of thoracic paravertebral and epidural analgesia for thoracic surgery: a systematic review and meta-analysis},
	volume = {18},
	issn = {1569-9285},
	shorttitle = {Analgesic efficacy and safety of thoracic paravertebral and epidural analgesia for thoracic surgery},
	doi = {10.1093/icvts/ivt551},
	abstract = {Though once considered the gold standard, epidural anaesthesia has complications that may be significant and include hypotension, urinary retention, partial or patchy block and, in rare cases, devastating neurological injuries also. Paravertebral block (PVB) is an alternative technique for unilateral surgical procedures like thoracotomy, which may offer similar analgesic effectiveness and a more favourable side-effect profile than epidural analgesia. This systematic review and meta-analysis of published randomized clinical trials aims to compare thoracic paravertebral with thoracic epidural analgesia (TEA) in thoracotomy for lung surgery. Five hundred and forty-one patients from 12 clinical trials have been included in this systematic review and meta-analysis. We found that visual analogue scale (VAS) scores at rest and during activity/coughing at 4-8, 24 and 48 h postoperatively were similar in both the PVB and TEA groups. Considering studies not included in the previous meta-analysis, a VAS score on activity at 48 h is significantly better in the PVB group (mean difference 0.40 cm; 95\% confidence interval [95\% CI] 0.77, 0.02; Mantel-Haenszel (M-H) fixed). Hypotension (odds ratio 0.13; 95\% CI 0.06, 0.31; M-H fixed) and urinary retention are more common in the epidural analgesia group. So, we conclude that thoracic PVB may be as effective as thoracic epidural analgesia for post-thoracotomy pain relief and is also associated with fewer complications.},
	language = {eng},
	number = {5},
	journal = {Interactive Cardiovascular and Thoracic Surgery},
	author = {Baidya, Dalim Kumar and Khanna, Puneet and Maitra, Souvik},
	month = may,
	year = {2014},
	pmid = {24488821},
	keywords = {Humans, Treatment Outcome, Risk Factors, Time Factors, Chi-Square Distribution, Odds Ratio, Thoracotomy, Nerve Block, Pain, Postoperative, Analgesia, Epidural, Anesthetics, Local, Pain Measurement, Post-thoracotomy pain, Thoracic epidural, Thoracic paravertebral},
	pages = {626--635},
}

@article{akkerman1512,
	title = {Surgical techniques to prevent delayed gastric emptying after esophagectomy with gastric interposition: a systematic review},
	volume = {98},
	issn = {1552-6259},
	shorttitle = {Surgical techniques to prevent delayed gastric emptying after esophagectomy with gastric interposition},
	doi = {10.1016/j.athoracsur.2014.06.057},
	abstract = {Delayed gastric emptying is observed in 10\% to 50\% of patients after esophagectomy with gastric interposition. The effects of gastric interposition diameter, pyloric drainage, reconstructive route, and anastomotic site on postoperative gastric emptying were systematically reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Most studies showed superior passage of the gastric tube compared with the whole stomach. Pyloric drainage is not significantly associated with the risk of developing delayed gastric emptying after esophagectomy. For reconstructive route and anastomotic site, available evidence on delayed gastric emptying is limited. Prospectively randomized studies with standardized outcome measurements are recommended.},
	language = {eng},
	number = {4},
	journal = {The Annals of Thoracic Surgery},
	author = {Akkerman, Ronald D. L. and Haverkamp, Leonie and van Hillegersberg, Richard and Ruurda, Jelle P.},
	month = oct,
	year = {2014},
	pmid = {25152385},
	keywords = {Humans, Esophagectomy, Postoperative Complications, Stomach, Gastric Emptying},
	pages = {1512--1519},
}

@article{markar1,
	title = {Component analysis of enhanced recovery pathways for esophagectomy},
	volume = {30},
	issn = {1442-2050},
	doi = {10.1093/dote/dox090},
	abstract = {The objective of this systematic review is to identify key components of enhanced recovery protocols (ERP) that lead to improved length of hospital stay (LOS) following esophagectomy. Relevant electronic databases were searched for studies comparing clinical outcome from esophagectomy followed by a conventional pathway versus ERP. Relevant outcome measures were compared and metaregression was performed to identify the key ERP components associated with reduced in LOS. Thirteen publications were included, ERP was associated with no changes in in-hospital mortality, total complications, anastomotic leak, or pulmonary complications compared with a conventional pathway, however LOS was reduced in the ERP group. Metaregression identified that immediate extubation was associated with reduced LOS (OR = -0.51, 95\%CI -0.77 to -0.25; P {\textless} 0.01). Several postoperative factors were associated with a significant reduction in length of hospital stay, and in order of most important were (i) gastrograffin swallow ≤5 days (OR = -4.27, 95\%CI -4.50 to -4.03); (ii) mobilization on postoperative day ≤1 (OR = -2.49, 95\%CI -2.63 to -2.34); (iii) removal of urinary catheter ≤2 days (OR = -0.99, 95\%CI -1.15 to -0.84); (iv) oral intake with at least sips of fluid ≤1 day (OR = -0.96, 95\%CI -1.24 to -0.68); (v) enteral diet with feeding jejunostomy or gastrostomy ≤ 1 day (OR = -0.57, 95\%CI -0.80 to -0.35) and (vi) epidural removal ≤ 4 days (OR = -0.17, 95\%CI -0.27 to -0.07). Several core ERP components and principles appear to be associated with LOS reduction. These elements should form a part of the core ERP for the specialty, while surgical teams incorporate other elements through an iterative process.},
	language = {eng},
	number = {10},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Markar, S. R. and Naik, R. and Malietzis, G. and Halliday, L. and Athanasiou, T. and Moorthy, K.},
	month = oct,
	year = {2017},
	pmid = {28859398},
	keywords = {Humans, Length of Stay, Postoperative Care, Time Factors, Esophagectomy, Postoperative Complications, Early Ambulation, esophageal cancer, Hospital Mortality, Enteral Nutrition, esophageal cancer surgery, Contrast Media, Analgesia, Epidural, Airway Extubation, Diatrizoate Meglumine, Drinking, supportive care, Urinary Catheterization},
	pages = {1--10},
	file = {Markar et al_2017_Component analysis of enhanced recovery pathways for esophagectomy.pdf:/Users/jcsal/Zotero/storage/3F7I6J9K/Markar et al_2017_Component analysis of enhanced recovery pathways for esophagectomy.pdf:application/pdf},
}

@article{finlayson729,
	title = {Outcomes in octogenarians undergoing high-risk cancer operation: a national study},
	volume = {205},
	issn = {1879-1190},
	shorttitle = {Outcomes in octogenarians undergoing high-risk cancer operation},
	doi = {10.1016/j.jamcollsurg.2007.06.307},
	abstract = {BACKGROUND: Current information about outcomes in octogenarians undergoing cancer operations is limited largely to case series from selected centers. Population-based data can provide more realistic estimates of the risks and benefits of operations in this group.
STUDY DESIGN: We performed a retrospective cohort study of patients undergoing major resections for lung, esophageal, and pancreas cancer. Using the Nationwide Inpatient Sample (1994 to 2003), we examined operative mortality and discharge disposition in octogenarians (aged 80+ years), relative to younger patients (aged 65 to 69 years) (n = 272,662). We then used the Surveillance and End Results-Medicare-linked database (1992 to 2001) to measure late survival in the elderly (n = 14,088).
RESULTS: Operative mortality among octogenarians was substantially higher than that of younger patients (aged 65 to 69 years) for all three cancers (esophagectomy, 19.9\% versus 8.8\%, p {\textless} 0.0001; pancreatectomy, 15.5\% versus 6.7\%, p {\textless} 0.0001; lung resection, 6.9\% versus 3.7\%, p {\textless} 0.0001). A large proportion of octogenarians were transferred to extended care facilities after operation, ranging from 24\% after lung resection to 44\% after esophagectomy. Five-year survival in octogenarians was low for all three cancers: 11\% after pancreatectomy, 18\% after esophagectomy and 31\% after lung cancer resection. Survival among octogenarians with two or more comorbidities was worse than those with fewer comorbid diagnoses--10\% versus 14\% for pancreatectomy, 15\% versus 23\% for esophagectomy, and 27\% versus 37\% for lung resection.
CONCLUSIONS: Population-based outcomes after high-risk cancer operation in octogenarians are considerably worse than typically reported in case series and published survival statistics. Such information might better inform clinical decision making in this high-risk group.},
	language = {eng},
	number = {6},
	journal = {Journal of the American College of Surgeons},
	author = {Finlayson, Emily and Fan, Zhaohui and Birkmeyer, John D.},
	month = dec,
	year = {2007},
	pmid = {18035254},
	keywords = {Humans, Aged, Female, Male, Treatment Outcome, Retrospective Studies, Lung Neoplasms, Pancreatic Neoplasms, Cohort Studies, Aged, 80 and over, Age Factors, United States, Esophageal Neoplasms, Esophagectomy, Comorbidity, SEER Program, Pancreatectomy, Pneumonectomy},
	pages = {729--734},
}

@article{baijal358,
	title = {Understanding frailty in cancer patients},
	volume = {20},
	issn = {1540-336X},
	doi = {10.1097/PPO.0000000000000068},
	abstract = {As population ages, the number of older adults with cancer is increasing rapidly. Chronological age per se is a poor guide for an oncologist to determine tolerance to cancer treatment. Older adults have been underrepresented in cancer clinical trials, leading to paucity of guidelines to meet the treatment challenges in this population. To evaluate an older adult with cancer, oncologists must understand age-related changes and identify the subset of population who is vulnerable and at risk of cancer treatment toxicity. Comprehensive geriatric assessments focusing on functional status, multimorbidity, nutritional status, cognitive impairment, and psychosocial support help recognize heterogeneity among older adults, leading to individualized approaches toward cancer treatment. The treatment decisions need to be made in collaboration with the patient's values and preferences.},
	language = {eng},
	number = {5},
	journal = {Cancer Journal (Sudbury, Mass.)},
	author = {Baijal, Pooja and Periyakoil, Vyjeyanthi},
	month = oct,
	year = {2014},
	pmid = {25299146},
	keywords = {Humans, Aged, Neoplasms, Aged, 80 and over, Frailty, Geriatric Assessment, Frail Elderly, Disease Management, Syndrome},
	pages = {358--366},
}

@article{cassidy740,
	title = {I {COUGH}: reducing postoperative pulmonary complications with a multidisciplinary patient care program},
	volume = {148},
	issn = {2168-6262},
	shorttitle = {I {COUGH}},
	doi = {10.1001/jamasurg.2013.358},
	abstract = {IMPORTANCE: Postoperative pulmonary complications can be a devastating consequence of surgery. Validated strategies to reduce these adverse outcomes are needed.
OBJECTIVES: To design, implement, and determine the efficacy of a suite of interventions for reducing postoperative pulmonary complications.
DESIGN: A before-after trial comparing our National Surgical Quality Improvement Program (NSQIP) pulmonary outcomes before and after implementing I COUGH, a multidisciplinary pulmonary care program.
SETTING: An urban, academic, safety-net hospital.
PARTICIPANTS: All patients who underwent general or vascular surgery at our institution during a 1-year period before and after implementation of I COUGH.
INTERVENTIONS: A multidisciplinary team developed a strategy to reduce pulmonary complications based on comprehensive patient and family education and a set of standardized electronic physician orders to specify early postoperative mobilization and pulmonary care. Designated by the acronym I COUGH, the program emphasizes incentive spirometry, coughing and deep breathing, oral care (brushing teeth and using mouthwash twice daily), understanding (patient and family education), getting out of bed at least 3 times daily, and head-of-bed elevation. Nursing and physician education promoted a culture of mobilization and I COUGH interventions. I COUGH was implemented for all general surgery and vascular surgery patients at our institution in August 2010.
MAIN OUTCOMES AND MEASURES: The NSQIP-reported incidence and risk-adjusted ratios of postoperative pneumonia and unplanned intubation, which NSQIP reports as observed-expected (OE) ratios for the 1-year period before implementing I COUGH and as odds ratios (ORs, statistically comparable to OE ratios) for the period after its implementation.
RESULTS: Before implementation of I COUGH, our incidence of postoperative pneumonia was 2.6\%, falling to 1.6\% after its implementation, and risk-adjusted outcomes fell from an OE ratio of 2.13 to an OR of 1.58. The incidence of unplanned intubations was 2.0\% before I COUGH and 1.2\% after I COUGH, with risk-adjusted outcomes decreasing from an OE ratio of 2.10 to an OR of 1.31.
CONCLUSIONS AND RELEVANCE: I COUGH, a standardized postoperative care program emphasizing patient education, early mobilization, and pulmonary interventions, reduced the incidence of postoperative pneumonia and unplanned intubation among our patients.},
	language = {eng},
	number = {8},
	journal = {JAMA surgery},
	author = {Cassidy, Michael R. and Rosenkranz, Pamela and McCabe, Karen and Rosen, Jennifer E. and McAneny, David},
	month = aug,
	year = {2013},
	pmid = {23740240},
	keywords = {Humans, Female, Hospitalization, Male, Postoperative Care, Cohort Studies, Postoperative Complications, Lung Diseases, Comprehensive Health Care, Cough, Intubation, Intratracheal, Patient Care Team, Program Evaluation, Respiration, Artificial, Respiratory},
	pages = {740--745},
	file = {Cassidy et al_2013_I COUGH.pdf:/Users/jcsal/Zotero/storage/DD67P3XR/Cassidy et al_2013_I COUGH.pdf:application/pdf},
}

@article{carli49,
	title = {Surgical {Prehabilitation} in {Patients} with {Cancer}: {State}-of-the-{Science} and {Recommendations} for {Future} {Research} from a {Panel} of {Subject} {Matter} {Experts}},
	volume = {28},
	issn = {1558-1381},
	shorttitle = {Surgical {Prehabilitation} in {Patients} with {Cancer}},
	doi = {10.1016/j.pmr.2016.09.002},
	abstract = {This review by a 10-member panel of experts in surgical prehabilitation addresses processes that may improve oncologic care. Surgical prehabilitation is the process on the continuum of care that occurs between the time of cancer diagnosis and the beginning of surgical treatment. The panel focused on the current state-of-the-science and recommended future research that would help to identify the elements that enhance preoperative physical, nutritional, and psychological health in anticipation of surgery, mitigate the burden of disease, facilitate the return of patient health status to baseline values, decrease postoperative morbidity, and reduce health care costs.},
	language = {eng},
	number = {1},
	journal = {Physical Medicine and Rehabilitation Clinics of North America},
	author = {Carli, Francesco and Silver, Julie K. and Feldman, Liane S. and McKee, Andrea and Gilman, Sean and Gillis, Chelsia and Scheede-Bergdahl, Celena and Gamsa, Ann and Stout, Nicole and Hirsch, Bradford},
	month = feb,
	year = {2017},
	pmid = {27913000},
	keywords = {Humans, Neoplasms, Nutrition, Surgery, Preoperative Care, Cancer, Exercise, Prehabilitation, Prehab, Anxiety, Outcome},
	pages = {49--64},
}

@article{gillis937,
	title = {Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer},
	volume = {121},
	issn = {1528-1175},
	shorttitle = {Prehabilitation versus rehabilitation},
	doi = {10.1097/ALN.0000000000000393},
	abstract = {BACKGROUND: The preoperative period (prehabilitation) may represent a more appropriate time than the postoperative period to implement an intervention. The impact of prehabilitation on recovery of function al exercise capacity was thus studied in patients undergoing colorectal resection for cancer.
METHODS: A parallel-arm single-blind superiority randomized controlled trial was conducted. Seventy-seven patients were randomized to receive either prehabilitation (n = 38) or rehabilitation (n = 39). Both groups received a home-based intervention of moderate aerobic and resistance exercises, nutritional counseling with protein supplementation, and relaxation exercises initiated either 4 weeks before surgery (prehabilitation) or immediately after surgery (rehabilitation), and continued for 8 weeks after surgery. Patients were managed with an enhanced recovery pathway. Primary outcome was functional exercise capacity measured using the validated 6-min walk test.
RESULTS: Median duration of prehabilitation was 24.5 days. While awaiting surgery, functional walking capacity increased (≥ 20 m) in a higher proportion of the prehabilitation group compared with the rehabilitation group (53 vs. 15\%, adjusted P = 0.006). Complication rates and duration of hospital stay were similar. The difference between baseline and 8-week 6-min walking test was significantly higher in the prehabilitation compared with the rehabilitation group (+23.7 m [SD, 54.8] vs. -21.8 m [SD, 80.7]; mean difference 45.4 m [95\% CI, 13.9 to 77.0]). A higher proportion of the prehabilitation group were also recovered to or above baseline exercise capacity at 8 weeks compared with the rehabilitation group (84 vs. 62\%, adjusted P = 0.049).
CONCLUSION: Meaningful changes in postoperative functional exercise capacity can be achieved with a prehabilitation program.},
	language = {eng},
	number = {5},
	journal = {Anesthesiology},
	author = {Gillis, Chelsia and Li, Chao and Lee, Lawrence and Awasthi, Rashami and Augustin, Berson and Gamsa, Ann and Liberman, A. Sender and Stein, Barry and Charlebois, Patrick and Feldman, Liane S. and Carli, Francesco},
	month = nov,
	year = {2014},
	pmid = {25076007},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Postoperative Care, Treatment Outcome, Colorectal Neoplasms, Exercise Therapy, Preoperative Care, Exercise, Prehab, Walking, Exercise Tolerance, Nutrition Therapy, Resistance Training, Single-Blind Method},
	pages = {937--947},
}

@article{goulde227S,
	title = {Prevention of {VTE} in nonorthopedic surgical patients: {Antithrombotic} {Therapy} and {Prevention} of {Thrombosis}, 9th ed: {American} {College} of {Chest} {Physicians} {Evidence}-{Based} {Clinical} {Practice} {Guidelines}},
	volume = {141},
	issn = {1931-3543},
	shorttitle = {Prevention of {VTE} in nonorthopedic surgical patients},
	doi = {10.1378/chest.11-2297},
	abstract = {BACKGROUND: VTE is a common cause of preventable death in surgical patients.
METHODS: We developed recommendations for thromboprophylaxis in nonorthopedic surgical patients by using systematic methods as described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement.
RESULTS: We describe several alternatives for stratifying the risk of VTE in general and abdominal-pelvic surgical patients. When the risk for VTE is very low ({\textless} 0.5\%), we recommend that no specific pharmacologic (Grade 1B) or mechanical (Grade 2C) prophylaxis be used other than early ambulation. For patients at low risk for VTE (∼1.5\%), we suggest mechanical prophylaxis, preferably with intermittent pneumatic compression (IPC), over no prophylaxis (Grade 2C). For patients at moderate risk for VTE (∼3\%) who are not at high risk for major bleeding complications, we suggest low-molecular-weight heparin (LMWH) (Grade 2B), low-dose unfractionated heparin (Grade 2B), or mechanical prophylaxis with IPC (Grade 2C) over no prophylaxis. For patients at high risk for VTE (∼6\%) who are not at high risk for major bleeding complications, we recommend pharmacologic prophylaxis with LMWH (Grade 1B) or low-dose unfractionated heparin (Grade 1B) over no prophylaxis. In these patients, we suggest adding mechanical prophylaxis with elastic stockings or IPC to pharmacologic prophylaxis (Grade 2C). For patients at high risk for VTE undergoing abdominal or pelvic surgery for cancer, we recommend extended-duration, postoperative, pharmacologic prophylaxis (4 weeks) with LMWH over limited-duration prophylaxis (Grade 1B). For patients at moderate to high risk for VTE who are at high risk for major bleeding complications or those in whom the consequences of bleeding are believed to be particularly severe, we suggest use of mechanical prophylaxis, preferably with IPC, over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated (Grade 2C). For patients in all risk groups, we suggest that an inferior vena cava filter not be used for primary VTE prevention (Grade 2C) and that surveillance with venous compression ultrasonography should not be performed (Grade 2C). We developed similar recommendations for other nonorthopedic surgical populations.
CONCLUSIONS: Optimal thromboprophylaxis in nonorthopedic surgical patients will consider the risks of VTE and bleeding complications as well as the values and preferences of individual patients.},
	language = {eng},
	number = {2 Suppl},
	journal = {Chest},
	author = {Gould, Michael K. and Garcia, David A. and Wren, Sherry M. and Karanicolas, Paul J. and Arcelus, Juan I. and Heit, John A. and Samama, Charles M.},
	month = feb,
	year = {2012},
	pmid = {22315263},
	pmcid = {PMC3278061},
	keywords = {Risk Factors, United States, Combined Modality Therapy, Postoperative Complications, Surgical Procedures, Operative, Heparin, Venous Thromboembolism, VTE, Evidence-Based Medicine, Fibrinolytic Agents, Hemorrhage, Heparin, Low-Molecular-Weight, Intermittent Pneumatic Compression Devices, Pulmonary Embolism, Societies, Medical, Stockings, Compression},
	pages = {e227S--e277S},
	file = {Gould et al_2012_Prevention of VTE in nonorthopedic surgical patients.pdf:/Users/jcsal/Zotero/storage/KW7CUGGW/Gould et al_2012_Prevention of VTE in nonorthopedic surgical patients.pdf:application/pdf},
}

@article{refai820,
	title = {The impact of chest tube removal on pain and pulmonary function after pulmonary resection},
	volume = {41},
	issn = {1873-734X},
	doi = {10.1093/ejcts/ezr126},
	abstract = {OBJECTIVE: The aim of this study was to assess the immediate influence of chest tube removal on chest pain and forced expiratory volume in 1 s (FEV1) after pulmonary resection.
METHODS: Prospective longitudinal investigation on 104 consecutive patients (53 wedge/segmentectomies and 51 lobectomies; 69 muscle and nerve-sparing lateral thoracotomy and 35 video-assisted thoracoscopic surgery (VATS)). Post-operative chest pain was controlled in all patients by a standardized combination of oral and intravenous non-opioid analgesics. All patients had one chest tube (24 French). Static and dynamic (after forced expiratory effort) pain and FEV1 were assessed before and 1 h after the chest tube removal by the same operator. No additional analgesics were administered before or after the chest tube removal. The pain level was assessed by the numeric pain scale [range: 0 (no pain)-10 (excruciating pain)]. FEV1 was assessed by a portable spirometer. Bronchodilators were not used in these patients. Pre- and post-removal measurements were compared by the Wilcoxon signed rank test.
RESULTS: The average pre-removal static and dynamic pain scores were 2.6 and 4.1, respectively. The static and dynamic pain scores decreased by 42 and 41\%, respectively, after the tube removal (P {\textless} 0.0001). The average FEV1 before the chest tube removal was 1.5 l or 53\% of the predicted value and increased by 13\% after the tube removal (P = 0.0004). In total, 56 and 78\% of patients reported static and dynamic pain scores improvement and 67\% showed an FEV1 improvement after the chest tube removal. Similar results were observed in patients operated on through VATS or thoracotomy. Compared with patients whose chest tube was removed later, those who had their chest tube removed before post operative day 3 (POD3), showed a greater reduction in the static pain score (41 vs. 31\%, P = 0.05) and greater improvement in FEV1 (18 vs. 0.01\%, P = 0.02).
CONCLUSIONS: The removal of a chest tube reduces pain and improves ventilatory function, independent of surgical access and particularly in the early post-operative phase. A fast track chest tube removal policy may favour patients' recovery.},
	language = {eng},
	number = {4},
	journal = {European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery},
	author = {Refai, Majed and Brunelli, Alessandro and Salati, Michele and Xiumè, Francesco and Pompili, Cecilia and Sabbatini, Armando},
	month = apr,
	year = {2012},
	pmid = {22219425},
	keywords = {Aged, Analgesics, Chest Pain, Chest Tubes, Device Removal, Drug Administration Schedule, Female, Forced Expiratory Volume, Humans, Male, Middle Aged, Pain Measurement, Pain, Postoperative, Pneumonectomy, Postoperative Care, Postoperative Period, Prospective Studies},
	pages = {820--822; discussion 823},
	file = {Refai et al_2012_The impact of chest tube removal on pain and pulmonary function after pulmonary.pdf:/Users/jcsal/Zotero/storage/F8845FXB/Refai et al_2012_The impact of chest tube removal on pain and pulmonary function after pulmonary.pdf:application/pdf},
}

@article{dinge96233,
	title = {A comparison of the analgesia efficacy and side effects of paravertebral compared with epidural blockade for thoracotomy: an updated meta-analysis},
	volume = {9},
	issn = {1932-6203},
	shorttitle = {A comparison of the analgesia efficacy and side effects of paravertebral compared with epidural blockade for thoracotomy},
	doi = {10.1371/journal.pone.0096233},
	abstract = {OBJECTIVE: The most recent systematic review and meta-analysis comparing the analgesic efficacy and side effects of paravertebral and epidural blockade for thoracotomy was published in 2006. Nine well-designed randomized trials with controversial results have been published since then. The present report constitutes an updated meta-analysis of this issue.
SUMMARY OF BACKGROUND: Thoracotomy is a major surgical procedure and is associated with severe postoperative pain. Epidural analgesia is the gold standard for post-thoracotomy pain management, but has its limitations and contraindications, and paravertebral blockade is increasingly popular. However, it has not been decided whether the analgesic effect of the two methods is comparable, or whether paravertebral blockade leads to a lower incidence of adverse side effects after thoracotomy.
METHODS: Two reviewers independently searched the databases PubMed, EMBASE, and the Cochrane Library (last performed on 1 February, 2013) for reports of studies comparing post-thoracotomy epidural analgesia and paravertebral blockade. The same individuals independently extracted data from the appropriate studies.
RESULT: Eighteen trials involving 777 patients were included in the current analysis. There was no significant difference in pain scores between paravertebral blockade and epidural analgesia at 4-8, 24, 48 hours, and the rates of pulmonary complications and morphine usage during the first 24 hours were also similar. However, paravertebral blockade was better than epidural analgesia in reducing the incidence of urinary retention (p{\textless}0.0001), nausea and vomiting (p = 0.01), hypotension (p{\textless}0.00001), and rates of failed block were lower in the paravertebral blockade group (p = 0.01).
CONCLUSIONS: This meta-analysis showed that PVB can provide comparable pain relief to traditional EPI, and may have a better side-effect profile for pain relief after thoracic surgery. Further high-powered randomized trials are to need to determine whether PVB truly offers any advantages over EPI.},
	language = {eng},
	number = {5},
	journal = {PloS One},
	author = {Ding, Xibing and Jin, Shuqing and Niu, Xiaoyin and Ren, Hao and Fu, Shukun and Li, Quan},
	year = {2014},
	pmid = {24797238},
	pmcid = {PMC4010440},
	keywords = {Humans, Female, Male, Randomized Controlled Trials as Topic, Nausea, Pain Management, Pain, Postoperative, Analgesia, Epidural, Pain Measurement, Thoracostomy, Urinary Retention, Vomiting},
	pages = {e96233},
	file = {Ding et al_2014_A comparison of the analgesia efficacy and side effects of paravertebral.pdf:/Users/jcsal/Zotero/storage/SHSTBDHX/Ding et al_2014_A comparison of the analgesia efficacy and side effects of paravertebral.pdf:application/pdf},
}

@article{michelet911,
	title = {Protective ventilation influences systemic inflammation after esophagectomy: a randomized controlled study},
	volume = {105},
	issn = {0003-3022},
	shorttitle = {Protective ventilation influences systemic inflammation after esophagectomy},
	doi = {10.1097/00000542-200611000-00011},
	abstract = {BACKGROUND: Esophagectomy induces a systemic inflammatory response whose extent has been recognized as a predictive factor of postoperative respiratory morbidity. The aim of this study was to determine the effectiveness of a protective ventilatory strategy to reduce systemic inflammation in patients undergoing esophagectomy.
METHODS: The authors prospectively investigated 52 patients undergoing planned esophagectomy for cancer. Patients were randomly assigned to a conventional ventilation strategy (n = 26; tidal volume of 9 ml/kg during two-lung and one-lung ventilation; no positive end-expiratory pressure) or a protective ventilation strategy (n = 26; tidal volume of 9 ml/kg during two-lung ventilation, reduced to 5 ml/kg during one-lung ventilation; positive end-expiratory pressure 5 cm H2O throughout the operative time).
RESULTS: Plasmatic levels of interleukin (IL)-1beta, IL-6, IL-8, and tumor necrosis factor alpha were measured perioperatively and postoperatively. Pulmonary function and postoperative evolution were also evaluated. Patients who received protective strategy had lower blood levels of IL-1beta, IL-6, and IL-8 at the end of one-lung ventilation (0.24 [0.15-0.40] vs. 0.56 [0.38-0.89] pg/ml, P {\textless} 0.001; 91 [61-117] vs. 189 [127-294] pg/ml, P {\textless} 0.001; and 30 [22-45] vs. 49 [29-69] pg/ml, P {\textless} 0.05, respectively) and 18 h postoperatively (0.18 [0.13-0.30] vs. 0.43 [0.34-0.54] pg/ml, P {\textless} 0.001; 54 [36-89] vs. 116 [78-208] pg/ml, P {\textless} 0.001; 16 [11-24] vs. 35 [28-53] pg/ml, P {\textless} 0.001, respectively). Protective strategy resulted in higher oxygen partial pressure to inspired oxygen fraction ratio during one-lung ventilation and 1 h postoperatively and in a reduction of postoperative mechanical ventilation duration (115 +/- 38 vs. 171 +/- 57 min, P {\textless} 0.001).
CONCLUSION: A protective ventilatory strategy decreases the proinflammatory systemic response after esophagectomy, improves lung function, and results in earlier extubation.},
	language = {eng},
	number = {5},
	journal = {Anesthesiology},
	author = {Michelet, Pierre and D'Journo, Xavier-Benoît and Roch, Antoine and Doddoli, Christophe and Marin, Valerie and Papazian, Laurent and Decamps, Isabelle and Bregeon, Fabienne and Thomas, Pascal and Auffray, Jean-Pierre},
	month = nov,
	year = {2006},
	pmid = {17065884},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Esophageal Neoplasms, Esophagectomy, Systemic Inflammatory Response Syndrome, Positive-Pressure Respiration, Tidal Volume, Respiration, Artificial, Inflammation Mediators, Interleukin-1beta, Interleukin-6, Interleukin-8, Tumor Necrosis Factor-alpha},
	pages = {911--919},
}

@article{shen1267,
	title = {The impact of tidal volume on pulmonary complications following minimally invasive esophagectomy: a randomized and controlled study},
	volume = {146},
	issn = {1097-685X},
	shorttitle = {The impact of tidal volume on pulmonary complications following minimally invasive esophagectomy},
	doi = {10.1016/j.jtcvs.2013.06.043},
	abstract = {BACKGROUND: Minimally invasive esophagectomy (MIE) has been advantageous for lowering pulmonary complications compared with open approaches.(1) However, pulmonary complications remain the most common morbidity after surgical resection of esophageal cancer.(2,3) The aim of this prospective, randomized, controlled, clinical trial was designed to see whether low tidal volume (VT) could further minimize pulmonary complications after MIE.
METHODS: Between June 2011 and July 2012, a total of 101 patients who underwent MIE received left-lung ventilation during thoracoscopic esophagectomy. All patients received left-lung ventilation during thoracoscopic esophagectomy. Patients were randomly assigned to a low VT (5 mL/kg + 5 cm H2O positive end-expiratory pressure) preserved ventilation (PV) group (n = 53) and a conventional VT (8 mL/kg) controlled ventilation (CV) group (n = 48) in the thoracic stage. Alveolar lavage fluid was harvested from the ventilated lung at intubation and at 18 hours after surgery for analysis of interleukin (IL)-1ß, IL-6, and IL-8 levels. Clinical characteristics, including patient demographics, operation features, and changes in oxygenation index, were recorded and analyzed. Pulmonary complications were identified and statistically compared between the 2 groups.
RESULTS: The clinical characteristics and operation features were comparable between the 2 groups. IL-1ß, IL-6, and IL-8 expressions in preoperative alveolar lavage fluid were similar between the 2 groups. Significantly lower IL expressions were observed in the PV group than those in the CV group at 18 hours after MIE (IL-1ß, 25.42 ± 31.01 vs 94.96 ± 118.24 pg/mL; IL-6, 30.86 ± 75.78 vs 92.99 ± 72.90 pg/mL; IL-8, 258.75 ± 188.24 vs 403.95 ± 151.44 pg/mL; all P {\textless} .05). The 18-hour postoperative oxygenation index was lower in the CV group than that in the PV group (292.85 ± 28.74 vs 326.35 ± 34.43; P = .046). Pulmonary complications were observed in 18 cases of our series, occurring more frequently on the ventilation side (right, 6 cases; and left, 12 cases). All patients were cured by conservative therapy without severe sequelae. The occurrence of pulmonary complications in the PV group was lower than that in the CV group (9.43\% vs 27.08\%; P = .021).
CONCLUSIONS: Lung injury due to intraoperative single-lung ventilation may contribute to pulmonary complications after MIE. Low VT ventilation could decrease ventilation-associated lung inflammation, thus minimizing pulmonary complications after MIE. Further studies, based on a larger volume of populations, are required to confirm these findings.},
	language = {eng},
	number = {5},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Shen, Yaxing and Zhong, Ming and Wu, Wei and Wang, Hao and Feng, Mingxiang and Tan, Lijie and Wang, Qun},
	month = nov,
	year = {2013},
	pmid = {23993028},
	keywords = {Humans, Treatment Outcome, Prospective Studies, Time Factors, Chi-Square Distribution, Esophageal Neoplasms, Esophagectomy, 7, China, MIE, Lung, Positive-Pressure Respiration, Tidal Volume, Thoracoscopy, Inflammation Mediators, Interleukin-1beta, Interleukin-6, Interleukin-8, 28, 41.2, Bronchoalveolar Lavage Fluid, controlled ventilation, CV, end-tidal carbon dioxide concentration, EtCO(2), ICS, IL, intercostal space, interleukin, minimally invasive esophagectomy, OI, oxygenation index, PC, PEEP, positive end-expiratory pressure, preserved ventilation, pulmonary complication, PV, single-lung ventilation, SLV, tidal volume, Ventilator-Induced Lung Injury, VT},
	pages = {1267--1273; discussion 1273--1274},
	file = {Shen et al_2013_The impact of tidal volume on pulmonary complications following minimally.pdf:/Users/jcsal/Zotero/storage/A688KF3D/Shen et al_2013_The impact of tidal volume on pulmonary complications following minimally.pdf:application/pdf},
}

@article{lindstrom739,
	title = {Effects of a perioperative smoking cessation intervention on postoperative complications: a randomized trial},
	volume = {248},
	issn = {1528-1140},
	shorttitle = {Effects of a perioperative smoking cessation intervention on postoperative complications},
	doi = {10.1097/SLA.0b013e3181889d0d},
	abstract = {OBJECTIVE: To determine whether an intervention with smoking cessation starting 4 weeks before general and orthopedic surgery would reduce the frequency of postoperative complications.
SUMMARY BACKGROUND DATA: Complications are a major concern after elective surgery and smokers have an increased risk. There is insufficient evidence concerning how the duration of preoperative smoking intervention affects postoperative complications.
METHODS: A randomized controlled trial, conducted between February 2004 and December 2006 at 4 university-affiliated hospitals in the Stockholm region, Sweden. The outcome assessment was blinded. The follow-up period for the primary outcome was 30 days. Eligibility criteria were active daily smokers, aged 18 to 79 years. Of the 238 patients assessed, 76 refused participating, and 117 men and women undergoing surgery for primary hernia repair, laparoscopic cholecystectomy, or a hip or knee prosthesis were enrolled.
INTERVENTION: Smoking cessation therapy with individual counseling and nicotine substitution started 4 weeks before surgery and continued 4 weeks postoperatively. The control group received standard care. The main outcome measure was frequency of any postoperative complication.
RESULTS: An intention-to-treat analysis showed that the overall complication rate in the control group was 41\%, and in the intervention group, it was 21\% (P = 0.03). Relative risk reduction for the primary outcome of any postoperative complication was 49\% and number needed to treat was 5 (95\% CI, 3-40). An analysis per protocol showed that abstainers had fewer complications (15\%) than those who continued to smoke or only reduced smoking (35\%), although this difference was not statistically significant.
CONCLUSION: Perioperative smoking cessation seems to be an effective tool to reduce postoperative complications even if it is introduced as late as 4 weeks before surgery.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Lindström, David and Sadr Azodi, Omid and Wladis, Andreas and Tønnesen, Hanne and Linder, Stefan and Nåsell, Hans and Ponzer, Sari and Adami, Johanna},
	month = nov,
	year = {2008},
	pmid = {18948800},
	keywords = {Aged, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Cholecystectomy, Laparoscopic, Clinical Protocols, Female, Hernia, Inguinal, Hernia, Umbilical, Humans, Male, Middle Aged, Postoperative Complications, Preoperative Care, Smoking Cessation, Time Factors},
	pages = {739--745},
}

@article{melis114,
	title = {Correlations between neoadjuvant treatment, anemia, and perioperative complications in patients undergoing esophagectomy for cancer},
	volume = {153},
	issn = {1095-8673},
	doi = {10.1016/j.jss.2008.06.005},
	abstract = {INTRODUCTION: The influence of preoperative hemoglobin levels on outcomes of patients undergoing esophagectomy for cancer is not clearly defined. The goal of this article was to explore the association between combined modality therapy, preoperative anemia status, and perioperative blood transfusion and risk of postoperative complications among patients undergoing esophageal resection.
METHODS: From a retrospective esophageal database, 413 patients were identified. Anemia was defined according to the World Health Organization classification of {\textless}13 g/dL or {\textless}12 g/dL for men or women, respectively. Statistical analysis was performed with analysis of variance, Pearson's chi(2), or Fisher exact test as appropriate. The independent association of anemia, blood transfusion, and combined modality treatment on risk of postoperative complications were examined using multiple logistic regression.
RESULTS: Information on combined modality treatment, preoperative hemoglobin levels, and blood transfusion was available for 413 patients, of whom 57\% received combined modality treatment. Overall 197 (47.6\%) patients were preoperatively found to be anemic, and those who had received combined modality treatment were more likely to be anemic (60.6\% versus 30.7\%, P {\textless} 0.001). Anemic patients required more blood transfusions than nonanemic patients (46.7\% versus 29.6\%, P {\textless} 0.001). Seventy-five percent of patients who required transfusion during the hospital stay had received combined modality treatment (P = 0.01). Combined modality treatment and anemia were not associated with increased risk of complications. Patients with any perioperative complication and surgical site infections were more likely to have received blood transfusion compared to patients without complications (OR = 1.73; 95\% CI 1.04-2.87 and OR = 2.98; 95\% CI 1.04-8.55; respectively).
CONCLUSIONS: Overall, we determined that administration of neoadjuvant treatment to esophageal cancer patients was not associated with an increased rate of perioperative complications. Preoperative anemia did not predict worsened short-term outcomes, but increased the chances of red blood cell transfusion, which were significantly associated with higher overall complications and increased risk of surgical site infections. These data confirm previous studies that allogenic red blood cell transfusions are independent risk factors for increased morbidity and mortality and should be minimized during surgery for esophageal cancer.},
	language = {eng},
	number = {1},
	journal = {The Journal of Surgical Research},
	author = {Melis, Marcovalerio and McLoughlin, James M. and Dean, E. Michelle and Siegel, Erin M. and Weber, Jill M. and Shah, Nilay and Kelley, Scott T. and Karl, Richard C.},
	month = may,
	year = {2009},
	pmid = {19201421},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Anemia, Hemoglobins, Transfusion Reaction},
	pages = {114--120},
	file = {Melis et al_2009_Correlations between neoadjuvant treatment, anemia, and perioperative.pdf:/Users/jcsal/Zotero/storage/83DHIY9N/Melis et al_2009_Correlations between neoadjuvant treatment, anemia, and perioperative.pdf:application/pdf},
}

@article{pisarskae0174382,
	title = {Enhanced recovery after surgery protocol in oesophageal cancer surgery: {Systematic} review and meta-analysis},
	volume = {12},
	issn = {1932-6203},
	shorttitle = {Enhanced recovery after surgery protocol in oesophageal cancer surgery},
	doi = {10.1371/journal.pone.0174382},
	abstract = {BACKGROUND: Enhanced Recovery After Surgery (ERAS) protocol are well established in many surgical disciplines, leading to decrease in morbidity and length of hospital stay. These multi-modal protocols have been also introduced to oesophageal cancer surgery. This review aimed to evaluate current literature on ERAS in oesophageal cancer surgery and conduct a meta-analysis on primary and secondary outcomes.
METHODS: MEDLINE, Embase, Scopus and Cochrane Library were searched for eligible studies. We analyzed data up to May 2016. Eligible studies had to contain four described ERAS protocol elements. The primary outcome was overall morbidity. Secondary outcomes included length of hospital stay, specific complications, mortality and readmissions. Random effect meta-analyses were undertaken.
RESULTS: Initial search yielded 1,064 articles. Thorough evaluation resulted in 13 eligible articles which were analyzed. A total of 2,042 patients were included in the analysis (1,058 ERAS group and 984 treated with traditional protocols). Analysis of overall morbidity as well as complication rate did not show any significant reduction. Non-surgical complications and pulmonary complications were significantly lower in the ERAS group, RR = 0.71 95\% CI 0.62-0.80, p {\textless} 0.00001 and RR = 0.75, 95\% CI 0.60-0.94, p = 0.01, respectively. Meta-analysis on length of stay presented significant reduction Mean difference = -3.55, 95\% CI -4.41 to -2.69, p for effect{\textless}0.00001.
CONCLUSIONS: This systematic review with a meta-analysis on ERAS in oesophageal surgery indicates a reduction of non-surgical complications and no negative influence on overall morbidity. Moreover, a reduction in the length of hospital stay was presented.},
	language = {eng},
	number = {3},
	journal = {PloS One},
	author = {Pisarska, Magdalena and Małczak, Piotr and Major, Piotr and Wysocki, Michał and Budzyński, Andrzej and Pędziwiatr, Michał},
	year = {2017},
	pmid = {28350805},
	pmcid = {PMC5370110},
	keywords = {Esophageal Neoplasms, Esophagus, Humans, Length of Stay, Postoperative Complications, Recovery of Function, Systematic Reviews as Topic, Treatment Outcome},
	pages = {e0174382},
	file = {Pisarska et al_2017_Enhanced recovery after surgery protocol in oesophageal cancer surgery.pdf:/Users/jcsal/Zotero/storage/SEJA9D4U/Pisarska et al_2017_Enhanced recovery after surgery protocol in oesophageal cancer surgery.pdf:application/pdf},
}

@article{low299,
	title = {Guidelines for {Perioperative} {Care} in {Esophagectomy}: {Enhanced} {Recovery} {After} {Surgery} ({ERAS}®) {Society} {Recommendations}},
	volume = {43},
	issn = {1432-2323},
	shorttitle = {Guidelines for {Perioperative} {Care} in {Esophagectomy}},
	doi = {10.1007/s00268-018-4786-4},
	abstract = {INTRODUCTION: Enhanced recovery after surgery (ERAS) programs provide a format for multidisciplinary care and has been shown to predictably improve short term outcomes associated with surgical procedures. Esophagectomy has historically been associated with significant levels of morbidity and mortality and as a result routine application and audit of ERAS guidelines specifically designed for esophageal resection has significant potential to improve outcomes associated with this complex procedure.
METHODS: A team of international experts in the surgical management of esophageal cancer was assembled and the existing literature was identified and reviewed prior to the production of the guidelines. Well established procedure specific components of ERAS were reviewed and updated with changes relevant to esophagectomy. Procedure specific, operative and technical sections were produced utilizing the best current level of evidence. All sections were rated regarding the level of evidence and overall recommendation according to the evaluation (GRADE) system.
RESULTS: Thirty-nine sections were ultimately produced and assessed for quality of evidence and recommendations. Some sections were completely new to ERAS programs due to the fact that esophagectomy is the first guideline with a thoracic component to the procedure.
CONCLUSIONS: The current ERAS society guidelines should be reviewed and applied in all centers looking to improve outcomes and quality associated with esophageal resection.},
	language = {eng},
	number = {2},
	journal = {World Journal of Surgery},
	author = {Low, Donald E. and Allum, William and De Manzoni, Giovanni and Ferri, Lorenzo and Immanuel, Arul and Kuppusamy, MadhanKumar and Law, Simon and Lindblad, Mats and Maynard, Nick and Neal, Joseph and Pramesh, C. S. and Scott, Mike and Mark Smithers, B. and Addor, Valérie and Ljungqvist, Olle},
	month = feb,
	year = {2019},
	pmid = {30276441},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Lymph Node Excision, Enteral Nutrition, Minimally Invasive Surgical Procedures, Perioperative Care, Practice Guidelines as Topic, ERAS, Recovery of Function},
	pages = {299--330},
	file = {Low et al_2019_Guidelines for Perioperative Care in Esophagectomy.pdf:/Users/jcsal/Zotero/storage/XD88I55Q/Low et al_2019_Guidelines for Perioperative Care in Esophagectomy.pdf:application/pdf},
}

@article{hovaguimian46,
	title = {Restrictive versus {Liberal} {Transfusion} {Strategy} in the {Perioperative} and {Acute} {Care} {Settings}: {A} {Context}-specific {Systematic} {Review} and {Meta}-analysis of {Randomized} {Controlled} {Trials}},
	volume = {125},
	issn = {1528-1175},
	shorttitle = {Restrictive versus {Liberal} {Transfusion} {Strategy} in the {Perioperative} and {Acute} {Care} {Settings}},
	doi = {10.1097/ALN.0000000000001162},
	abstract = {BACKGROUND: Blood transfusions are associated with morbidity and mortality. However, restrictive thresholds could harm patients less able to tolerate anemia. Using a context-specific approach (according to patient characteristics and clinical settings), the authors conducted a systematic review to quantify the effects of transfusion strategies.
METHODS: The authors searched MEDLINE, EMBASE, CENTRAL, and grey literature sources to November 2015 for randomized controlled trials comparing restrictive versus liberal transfusion strategies applied more than 24 h in adult surgical or critically ill patients. Data were independently extracted. Risk ratios were calculated for 30-day complications, defined as inadequate oxygen supply (myocardial, cerebral, renal, mesenteric, and peripheral ischemic injury; arrhythmia; and unstable angina), mortality, composite of both, and infections. Statistical combination followed a context-specific approach. Additional analyses explored transfusion protocol heterogeneity and cointerventions effects.
RESULTS: Thirty-one trials were regrouped into five context-specific risk strata. In patients undergoing cardiac/vascular procedures, restrictive strategies seemed to increase the risk of events reflecting inadequate oxygen supply (risk ratio [RR], 1.09; 95\% CI, 0.97 to 1.22), mortality (RR, 1.39; 95\% CI, 0.95 to 2.04), and composite events (RR, 1.12; 95\% CI, 1.01 to 1.24-3322, 3245, and 3322 patients, respectively). Similar results were found in elderly orthopedic patients (inadequate oxygen supply: RR, 1.41; 95\% CI, 1.03 to 1.92; mortality: RR, 1.09; 95\% CI, 0.80 to 1.49; composite outcome: RR, 1.24; 95\% CI, 1.00 to 1.54-3465, 3546, and 3749 patients, respectively), but not in critically ill patients. No difference was found for infections, although a protective effect may exist. Risk estimates varied with successful/unsuccessful transfusion protocol implementation.
CONCLUSIONS: Restrictive transfusion strategies should be applied with caution in high-risk patients undergoing major surgery.},
	language = {eng},
	number = {1},
	journal = {Anesthesiology},
	author = {Hovaguimian, Frédérique and Myles, Paul S.},
	month = jul,
	year = {2016},
	pmid = {27167445},
	keywords = {Humans, Treatment Outcome, Randomized Controlled Trials as Topic, Surgery, Perioperative Care, Acute Disease, Blood Transfusion},
	pages = {46--61},
}

@article{chong252,
	title = {Should {Transfusion} {Trigger} {Thresholds} {Differ} for {Critical} {Care} {Versus} {Perioperative} {Patients}? {A} {Meta}-{Analysis} of {Randomized} {Trials}},
	volume = {46},
	issn = {1530-0293},
	shorttitle = {Should {Transfusion} {Trigger} {Thresholds} {Differ} for {Critical} {Care} {Versus} {Perioperative} {Patients}?},
	doi = {10.1097/CCM.0000000000002873},
	abstract = {OBJECTIVE: To address the significant uncertainty as to whether transfusion thresholds for critical care versus surgical patients should differ.
DESIGN: Meta-analysis of randomized controlled trials.
SETTING: Medline, EMBASE, and Cochrane Library searches were performed up to 15 June 2016.
PATIENTS: Trials had to enroll adult surgical or critically ill patients for inclusion.
INTERVENTIONS: Studies had to compare a liberal versus restrictive threshold for the transfusion of allogeneic packed RBCs.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was 30-day all-cause mortality, sub-grouped by surgical and critical care patients. Secondary outcomes included myocardial infarction, stroke, renal failure, allogeneic blood exposure, and length of stay. Odds ratios and weighted mean differences were calculated using random effects meta-analysis. To assess whether subgroups were significantly different, tests for subgroup interaction were used. Subgroup analysis by trials enrolling critically ill versus surgical patients was performed. Twenty-seven randomized controlled trials (10,797 patients) were included. In critical care patients, restrictive transfusion resulted in significantly reduced 30-day mortality compared with liberal transfusion (odds ratio, 0.82; 95\% CI, 0.70-0.97). In surgical patients, a restrictive transfusion strategy led to the opposite direction of effect for mortality (odds ratio, 1.31; 95\% CI, 0.94-1.82). The subgroup interaction test was significant (p = 0.04), suggesting that the effect of restrictive transfusion on mortality is statistically different for critical care (decreased risk) versus surgical patients (potentially increased risk or no difference). Regarding secondary outcomes, for critically ill patients, a restrictive strategy resulted in reduced risk of stroke/transient ischemic attack, packed RBC exposure, transfusion reactions, and hospital length of stay. In surgical patients, restrictive transfusion resulted in reduced packed RBC exposure.
CONCLUSIONS: The safety of restrictive transfusion strategies likely differs for critically ill patients versus perioperative patients. Further trials investigating transfusion strategies in the perioperative setting are necessary.},
	language = {eng},
	number = {2},
	journal = {Critical Care Medicine},
	author = {Chong, Matthew A. and Krishnan, Rohin and Cheng, Davy and Martin, Janet},
	month = feb,
	year = {2018},
	pmid = {29189348},
	pmcid = {PMC5770109},
	keywords = {Humans, Randomized Controlled Trials as Topic, Surgery, Perioperative Care, Critical Care, Blood Transfusion},
	pages = {252--263},
	file = {Chong et al_2018_Should Transfusion Trigger Thresholds Differ for Critical Care Versus.pdf:/Users/jcsal/Zotero/storage/H8JX3SH5/Chong et al_2018_Should Transfusion Trigger Thresholds Differ for Critical Care Versus.pdf:application/pdf},
}

@article{mojdehbakhsh101059,
	title = {Efficacy and safety of a restrictive blood transfusion protocol in gynecologic surgical patients},
	volume = {43},
	issn = {2352-5789},
	doi = {10.1016/j.gore.2022.101059},
	abstract = {Objectives: This study sought to compare differences in blood transfusion and surgical complication rates before and after the implementation of a restrictive blood transfusion protocol.
Methods: On July 1, 2018, our institution implemented a restrictive blood transfusion protocol utilizing a hemoglobin trigger of less than 7 g/dL. Retrospective chart review was completed to review patients undergoing major abdominal surgery by the gynecology and gynecologic oncology services 18 months before, and after initiation of the transfusion protocol. Outcomes included number of patients, units transfused and postoperative complication rates. Complications included reoperation on the day of admission, surgical site infections, wound disruptions, pulmonary, renal, central nervous system, and cardiovascular complications, as well as deep venous thromboses, readmissions, and 30-day mortality.
Results: There were 290 people in the pre- and 449 patients in the post-protocol group. A similar number of patients received blood transfusions in both groups (9.3\% versus 10.6\% p = 0.57). However, significantly fewer units of blood were given post-protocol initiation. For every patient who received a transfusion pre-protocol, 2.66 units were administered compared to 1.2 units after the protocol was initiated (p = 0.003). All postoperative complications were not significantly different between groups (p {\textgreater} 0.05). Individual postoperative complications were combined and analyzed using a clustered approach to detect rates of complications more conservatively. Both the 7-system (5.1\% versus 4.9\%, p = 0.90) and 8-system (5.5\% versus 4.9\%, p = 0.72) clustered analyses were not significantly different before and after the initiation of the transfusion protocol.
Conclusions: A restrictive transfusion protocol is effective in decreasing the number of units of blood transfused without affecting postoperative complication rates in gynecologic surgery patients.},
	language = {eng},
	journal = {Gynecologic Oncology Reports},
	author = {Mojdehbakhsh, Rachel P. and Al-Rubaye, Rana and Huang, Dandi S. and Connor, Joseph and Al-Niaimi, Ahmed},
	month = oct,
	year = {2022},
	pmid = {36039064},
	pmcid = {PMC9418048},
	keywords = {Mortality, Postoperative complications, Gynecologic oncology, Gynecology, Restrictive blood transfusion, GynSurgery},
	pages = {101059},
	file = {Mojdehbakhsh et al_2022_Efficacy and safety of a restrictive blood transfusion protocol in gynecologic.pdf:/Users/jcsal/Zotero/storage/CAQHN2W2/Mojdehbakhsh et al_2022_Efficacy and safety of a restrictive blood transfusion protocol in gynecologic.pdf:application/pdf},
}

@article{dealmeida29,
	title = {Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial},
	volume = {122},
	issn = {1528-1175},
	shorttitle = {Transfusion requirements in surgical oncology patients},
	doi = {10.1097/ALN.0000000000000511},
	abstract = {BACKGROUND: Several studies have indicated that a restrictive erythrocyte transfusion strategy is as safe as a liberal one in critically ill patients, but there is no clear evidence to support the superiority of any perioperative transfusion strategy in patients with cancer.
METHODS: In a randomized, controlled, parallel-group, double-blind (patients and outcome assessors) superiority trial in the intensive care unit of a tertiary oncology hospital, the authors evaluated whether a restrictive strategy of erythrocyte transfusion (transfusion when hemoglobin concentration {\textless}7 g/dl) was superior to a liberal one (transfusion when hemoglobin concentration {\textless}9 g/dl) for reducing mortality and severe clinical complications among patients having major cancer surgery. All adult patients with cancer having major abdominal surgery who required postoperative intensive care were included and randomly allocated to treatment with the liberal or the restrictive erythrocyte transfusion strategy. The primary outcome was a composite endpoint of mortality and morbidity.
RESULTS: A total of 198 patients were included as follows: 101 in the restrictive group and 97 in the liberal group. The primary composite endpoint occurred in 19.6\% (95\% CI, 12.9 to 28.6\%) of patients in the liberal-strategy group and in 35.6\% (27.0 to 45.4\%) of patients in the restrictive-strategy group (P = 0.012). Compared with the restrictive strategy, the liberal transfusion strategy was associated with an absolute risk reduction for the composite outcome of 16\% (3.8 to 28.2\%) and a number needed to treat of 6.2 (3.5 to 26.5).
CONCLUSION: A liberal erythrocyte transfusion strategy with a hemoglobin trigger of 9 g/dl was associated with fewer major postoperative complications in patients having major cancer surgery compared with a restrictive strategy.},
	language = {eng},
	number = {1},
	journal = {Anesthesiology},
	author = {de Almeida, Juliano Pinheiro and Vincent, Jean-Louis and Galas, Filomena Regina Barbosa Gomes and de Almeida, Elisangela Pinto Marinho and Fukushima, Julia T. and Osawa, Eduardo A. and Bergamin, Fabricio and Park, Clarice Lee and Nakamura, Rosana Ely and Fonseca, Silvia M. R. and Cutait, Guilherme and Alves, Joseane Inacio and Bazan, Mellik and Vieira, Silvia and Sandrini, Ana C. Vieira and Palomba, Henrique and Ribeiro, Ulysses and Crippa, Alexandre and Dalloglio, Marcos and Diz, Maria del Pilar Estevez and Kalil Filho, Roberto and Auler, Jose Otavio Costa and Rhodes, Andrew and Hajjar, Ludhmila Abrahao},
	month = jan,
	year = {2015},
	pmid = {25401417},
	keywords = {Humans, Female, Male, Middle Aged, Follow-Up Studies, Prospective Studies, Risk, Outcome Assessment, Health Care, Postoperative Complications, Intensive Care Units, Double-Blind Method, Abdominal Neoplasms, Hemoglobins, Brazil, Erythrocyte Transfusion, SurgOnc},
	pages = {29--38},
}

@article{catae043453,
	title = {International multicentre observational study to evaluate the association between perioperative red blood cell transfusions and 1-year mortality after major cancer surgery ({ARCA}-1): study design, statistical analysis plan and study protocol},
	volume = {11},
	issn = {2044-6055},
	shorttitle = {International multicentre observational study to evaluate the association between perioperative red blood cell transfusions and 1-year mortality after major cancer surgery ({ARCA}-1)},
	doi = {10.1136/bmjopen-2020-043453},
	abstract = {INTRODUCTION: Blood transfusion is still common in patients undergoing major cancer surgery. Blood transfusion can be associated with poor prognosis in patients with cancer. Perioperative Care in the Cancer Patient -1 (ARCA-1) aims to assess in a large cohort of patients the current incidence, pattern of practice and associations between perioperative blood transfusions and 1-year survival in patients undergoing major cancer surgery.
METHODS AND ANALYSIS: ARCA-1 is a prospective international multicentre observational study that will include adult patients scheduled to have major cancer surgical procedures with the intention to cure, and an overnight planned hospital admission. The study will be opened for 1 year for enrolment (7 January 2020-7 February 2021). Each centre will enrol patients for 30 days. The primary endpoint of this study is all-cause mortality 1 year after major cancer surgery. Secondary endpoints are rate of perioperative blood product use, cancer-specific mortality at 1 year and PFSs and 30-day morbidity and mortality.
ETHICS AND DISSEMINATION: This study was approved by the Institutional Review Board at The University of Texas-MD Anderson Cancer Center. The study results will be published in peer-reviewed journals and disseminated at international conferences.
TRIAL REGISTRATION NUMBER: NCT04491409.},
	language = {eng},
	number = {3},
	journal = {BMJ open},
	author = {Cata, Juan and Ramirez, Maria and Forget, Patrice and Chen, Lee-Lynn and Diaz-Cambronero, Oscar and Chen, Wankun and Warner, Matthew A. and Knopfelmacher Couchonal, Adriana and Pelosi, Paolo and Cuellar, Luis and Corrales, German and Romero, Carlos and Lobo, Francisco and Saager, Leif and Castro Tapia, Jorge and Kiberenge, Roy and Feng, Lei and Serpa Neto, Ary},
	month = mar,
	year = {2021},
	pmid = {33737431},
	pmcid = {PMC7978332},
	keywords = {Humans, Prospective Studies, Neoplasms, Adult, Multicenter Studies as Topic, Perioperative Care, surgery, Morbidity, Observational Studies as Topic, Blood Transfusion, Erythrocyte Transfusion, SurgOnc, adult oncology, blood bank \& transfusion medicine},
	pages = {e043453},
	file = {Cata et al_2021_International multicentre observational study to evaluate the association.pdf:/Users/jcsal/Zotero/storage/LAKJWD6U/Cata et al_2021_International multicentre observational study to evaluate the association.pdf:application/pdf},
}

@article{bustiE94,
	title = {Anemia and {Iron} {Deficiency} in {Cancer} {Patients}: {Role} of {Iron} {Replacement} {Therapy}},
	volume = {11},
	issn = {1424-8247},
	shorttitle = {Anemia and {Iron} {Deficiency} in {Cancer} {Patients}},
	doi = {10.3390/ph11040094},
	abstract = {Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and overall prognosis. The pathogenesis is complex and typically multifactorial, with iron deficiency (ID) often being a major and potentially treatable contributor. In turn, ID in cancer patients can be due to multiple concurring mechanisms, including bleeding (e.g., in gastrointestinal cancers or after surgery), malnutrition, medications, and hepcidin-driven iron sequestration into macrophages with subsequent iron-restricted erythropoiesis. Indeed, either absolute or functional iron deficiency (AID or FID) can occur. While for absolute ID there is a general consensus regarding the laboratory definition (that is ferritin levels {\textless}100 ng/mL ± transferrin saturation (TSAT) {\textless}20\%), a shared definition of functional ID is still lacking. Current therapeutic options in cancer anemia include iron replacement, erythropoietic stimulating agents (ESAs), and blood transfusions. The latter should be kept to a minimum, because of concerns regarding risks, costs, and limited resources. Iron therapy has proved to be a valid approach to enhance efficacy of ESAs and to reduce transfusion need. Available guidelines focus mainly on patients with chemotherapy-associated anemia, and generally suggest intravenous (IV) iron when AID or FID is present. However, in the case of FID, the upper limit of ferritin in association with TSAT {\textless}20\% at which iron should be prescribed is a matter of controversy, ranging up to 800 ng/mL. An increasingly recognized indication to IV iron in cancer patients is represented by preoperative anemia in elective oncologic surgery. In this setting, the primary goal of treatment is to decrease the need of blood transfusions in the perioperative period, rather than improving anemia-related symptoms as in chemotherapy-associated anemia. Protocols are mainly based on experiences of Patient Blood Management (PBM) in non-oncologic surgery, but no specific guidelines are available for oncologic surgery. Here we discuss some possible approaches to the management of ID in cancer patients in different clinical settings, based on current guidelines and recommendations, emphasizing the need for further research in the field.},
	language = {eng},
	number = {4},
	journal = {Pharmaceuticals (Basel, Switzerland)},
	author = {Busti, Fabiana and Marchi, Giacomo and Ugolini, Sara and Castagna, Annalisa and Girelli, Domenico},
	month = sep,
	year = {2018},
	pmid = {30274354},
	pmcid = {PMC6315653},
	keywords = {Cancer, cancer, anemia, hepcidin, iron deficiency, patient blood management, Iron},
	pages = {E94},
	file = {Busti et al_2018_Anemia and Iron Deficiency in Cancer Patients.pdf:/Users/jcsal/Zotero/storage/WR9I6TIN/Busti et al_2018_Anemia and Iron Deficiency in Cancer Patients.pdf:application/pdf},
}

@article{prescott1,
	title = {How low should we go: {A} systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology},
	volume = {46},
	issn = {1532-1967},
	shorttitle = {How low should we go},
	doi = {10.1016/j.ctrv.2016.03.010},
	abstract = {BACKGROUND: Most non-oncologic clinical practice guidelines recommend restrictive allogeneic blood transfusion practices; however, there is a lack of consensus regarding the best transfusion practice in oncology. We conducted a systematic review of the literature to compare the efficacy and safety of restrictive versus liberal transfusion strategies in patients with cancer.
METHODS: A literature search using MEDLINE, PUBMED and EMBASE identified all controlled studies comparing the use of restrictive with liberal transfusion in adult oncology participants up to August 10, 2015. Two review authors independently assessed studies for inclusion, extracted data and appraised the quality of the included studies. The primary outcomes of interest were blood utilization and all-cause mortality.
RESULTS: Out of 4241 citations, six studies (3 randomized and 3 non-randomized) involving a total of 983 patients were included in the final review. The clinical context of the studies varied with 3 chemotherapy and 3 surgical studies. The overall risk of bias in all studies was moderate to high. Restrictive transfusion strategies were associated with a 36\% reduced risk of receiving a perioperative transfusion (risk ratio (RR) 0.64, 95\% confidence interval (CI) 0.49-0.83). There was no difference in mortality between the strategies (RR 1.00, 95\% CI 0.32-3.18). There were no differences in adverse events reported between the restrictive and liberal transfusion strategies.
CONCLUSION: Restrictive strategy appears to decrease blood utilization without increasing morbidity or mortality in oncology. This review is limited by a paucity of high quality studies on this topic. Better designed studies are warranted.},
	language = {eng},
	journal = {Cancer Treatment Reviews},
	author = {Prescott, Lauren S. and Taylor, Jolyn S. and Lopez-Olivo, Maria A. and Munsell, Mark F. and VonVille, Helena M. and Lairson, David R. and Bodurka, Diane C.},
	month = may,
	year = {2016},
	pmid = {27046422},
	pmcid = {PMC4884540},
	keywords = {Humans, Neoplasms, Randomized Controlled Trials as Topic, Cancer, Anemia, Erythrocyte Transfusion, SurgOnc, Blood, Medical Oncology, Systematic review, Transfusion, Transplantation, Homologous},
	pages = {1--8},
	file = {Prescott et al_2016_How low should we go.pdf:/Users/jcsal/Zotero/storage/TXU7IVTA/Prescott et al_2016_How low should we go.pdf:application/pdf},
}

@article{hallet205,
	title = {The impact of perioperative iron on the use of red blood cell transfusions in gastrointestinal surgery: a systematic review and meta-analysis},
	volume = {28},
	issn = {1532-9496},
	shorttitle = {The impact of perioperative iron on the use of red blood cell transfusions in gastrointestinal surgery},
	doi = {10.1016/j.tmrv.2014.05.004},
	abstract = {Perioperative anemia is common, yet detrimental, in surgical patients. However, red blood cell transfusions (RBCTs) used to treat anemia are associated with significant postoperative risks and worse oncologic outcomes. Perioperative iron has been suggested to mitigate perioperative anemia. This meta-analysis examined the impact of perioperative iron compared to no intervention on the need for RBCT in gastrointestinal surgery. We systematically searched Medline, Embase, Web of Science, Cochrane Central, and Scopus to identify relevant randomized controlled trials (RCTs) and nonrandomized studies (NRSs). We excluded studies investigating autologous RBCT or erythropoietin. Two independent reviewers selected the studies, extracted data, and assessed the risk of bias using the Cochrane tool and Newcastle-Ottawa scale. Primary outcomes were proportion of patients getting allogeneic RBCT and number of transfused patient. Secondary outcomes were hemoglobin change, 30-day postoperative morbidity and mortality, length of stay, and oncologic outcomes. A meta-analysis using random effects models was performed. The review was registered in PROSPERO (CRD42013004805). From 883 citations, we included 2 RCTs and 2 NRSs (n = 325 patients), all pertaining to colorectal cancer surgery. Randomized controlled trials were at high risk for bias and underpowered. One RCT and 1 NRS using preoperative oral iron reported a decreased proportion of patients needing RBCT. One RCT on preoperative intravenous iron and 1 NRS on postoperative PO iron did not observe a difference. Only 1 study revealed a difference in number of transfused patients. One RCT reported significantly increased postintervention hemoglobin. Among 3 studies reporting length of stay, none observed a difference. Other secondary outcomes were not reported. Meta-analysis revealed a trend toward fewer patients requiring RBCT with iron supplementation (risk ratio, 0.66 [0.42, 1.02]), but no benefit on the number of RBCT per patient (weighted mean difference, -0.91 [-1.61, -0.18]). Although preliminary evidence suggests that it may be a promising strategy, there is insufficient evidence to support the routine use of perioperative iron to decrease the need for RBCT in colorectal cancer surgery. Well-designed RCTs focusing on the need for RBCT and including long-term outcomes are warranted.},
	language = {eng},
	number = {4},
	journal = {Transfusion Medicine Reviews},
	author = {Hallet, Julie and Hanif, Asad and Callum, Jeannie and Pronina, Ioulia and Wallace, David and Yohanathan, Lavanya and McLeod, Robin and Coburn, Natalie},
	month = oct,
	year = {2014},
	pmid = {24997001},
	keywords = {Humans, Female, Male, Treatment Outcome, Randomized Controlled Trials as Topic, Surgery, Perioperative Period, Gastrointestinal Tract, Colorectal cancer, Anemia, Hemoglobins, Observational Studies as Topic, Erythrocyte Transfusion, Iron, Transfusion, Transplantation, Homologous, Erythrocytes, Perioperative},
	pages = {205--211},
}

@article{elhenawy29,
	title = {Role of preoperative intravenous iron therapy to correct anemia before major surgery: study protocol for systematic review and meta-analysis},
	volume = {4},
	issn = {2046-4053},
	shorttitle = {Role of preoperative intravenous iron therapy to correct anemia before major surgery},
	doi = {10.1186/s13643-015-0016-4},
	abstract = {BACKGROUND: Preoperative anemia is a common and potentially serious hematological problem in elective surgery and increases the risk for perioperative red blood cell (RBC) transfusion. Transfusion is associated with postoperative morbidity and mortality. Preoperative intravenous (IV) iron therapy has been proposed as an intervention to reduce perioperative transfusion; however, studies are generally small, limited, and inconclusive.
METHODS/DESIGN: We propose performing a systematic review and meta-analysis. We will search MEDLINE, EMBASE, EBM Reviews, Cochrane-controlled trial registry, Scopus, registries of health technology assessment and clinical trials, Web of Science, ProQuest Dissertations and Theses, and conference proceedings in transfusion, hematology, and surgery. We will contact our study drug manufacturer for unpublished trials. Titles and abstracts will be identified and assessed by two reviewers for potential relevance. Eligible studies are: randomized or quasi-randomized clinical trials comparing preoperative administration of IV iron with placebo or standard of care to reduce perioperative blood transfusion in anemic patients undergoing major surgery. Screening, data extraction, and quality appraisal will be conducted independently by two authors. Data will be presented in evidence tables and in meta-analytic forest plots. Primary efficacy outcomes are change in hemoglobin concentration and proportion of patients requiring RBC transfusion. Secondary outcomes include number of units of blood or blood products transfused perioperatively, transfusion-related acute lung injury, neurologic complications, adverse events, postoperative infections, cardiopulmonary complications, intensive care unit (ICU) admission/readmission, length of hospital stay, acute kidney injury, and mortality. Dichotomous outcomes will be reported as pooled relative risks and 95\% confidence intervals. Continuous outcomes will be reported using calculated weighted mean differences. Meta-regression will be performed to evaluate the impact of potential confounding variables on study effect estimates.
DISCUSSION: Reducing unnecessary RBC transfusions in perioperative medicine is a clinical priority. This involves the identification of patients at risk of receiving transfusions along with blood conservation strategies. Of potential pharmacological blood conservation strategies, IV iron is a compelling intervention to treat preoperative anemia; however, existing data are uncertain. We propose performing a systematic review and meta-analysis evaluating the efficacy and safety of IV iron administration to anemic patients undergoing major surgery to reduce transfusion and perioperative morbidity and mortality.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42015016771.},
	language = {eng},
	journal = {Systematic Reviews},
	author = {Elhenawy, Abdelsalam M. and Meyer, Steven R. and Bagshaw, Sean M. and MacArthur, Roderick G. and Carroll, Linda J.},
	month = mar,
	year = {2015},
	pmid = {25874460},
	pmcid = {PMC4369835},
	keywords = {Humans, Length of Stay, Research Design, Postoperative Complications, Surgery, Preoperative Care, Clinical Protocols, Administration, Intravenous, Anemia, Hemoglobins, Systematic Reviews as Topic, Erythrocyte Transfusion, Iron},
	pages = {29},
	file = {Elhenawy et al_2015_Role of preoperative intravenous iron therapy to correct anemia before major.pdf:/Users/jcsal/Zotero/storage/DVXJUD7K/Elhenawy et al_2015_Role of preoperative intravenous iron therapy to correct anemia before major.pdf:application/pdf},
}

@article{lin221,
	title = {Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review},
	volume = {27},
	issn = {1532-9496},
	shorttitle = {Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management},
	doi = {10.1016/j.tmrv.2013.09.001},
	abstract = {The use of erythropoietin (EPO) and intravenous (IV) iron as bloodless therapeutic modalities is being explored in the current era of restrictive transfusion strategies and perioperative blood management. It is unclear, however, whether the evidence in the literature supports their safety and efficacy in reducing perioperative red cell transfusions. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, we conducted a systematic review to evaluate their use in a variety of perioperative settings. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Only studies with a comparator group were eligible for inclusion. Twenty-four randomized controlled trials (RCTs) and 15 nonrandomized studies were included in the final review. Using the Cochrane risk of bias tool, 8 RCTs were assessed to be at low risk for methodological bias. Of these, however, only 4 RCTs were adequately powered to detect a reduction in transfusion rates. Patients with preoperative iron deficiency anemia may have an earlier and more robust hemoglobin recovery with preoperative IV iron therapy than with oral iron supplementation. A short preoperative regimen of EPO, or a single dose of EPO plus IV iron in the preoperative or intraoperative period, may significantly reduce transfusion rates (number needed to treat to avoid any transfusion ranged from 3 to 6). With regard to the safety of erythropoietin-stimulating agent therapy, IV iron appears to be as well tolerated as oral iron; however, the incidence of severe anaphylactic-type reactions attributable to IV iron is difficult to estimate in prospective trials because of its relatively infrequent occurrence. Furthermore, EPO may increase the risk of thromboembolism in spinal surgery patients who receive mechanical antithrombotic prophylaxis in the perioperative period so pharmacological thromboprophylaxis is advised. Future low risk of bias, adequately powered prospective efficacy, and safety trials in various surgical settings that traditionally require red cell transfusions would be required to make evidenced-based conclusions about the clinical significance of erythropoietin-stimulating agent as a transfusion avoidance strategy in perioperative blood management.},
	language = {eng},
	number = {4},
	journal = {Transfusion Medicine Reviews},
	author = {Lin, David M. and Lin, Estelle S. and Tran, Minh-Ha},
	month = oct,
	year = {2013},
	pmid = {24135037},
	keywords = {Humans, Treatment Outcome, Risk, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Surgery, Surgical Procedures, Operative, Clinical Trials as Topic, Perioperative Period, Infusions, Intravenous, Patient Safety, Erythrocyte Transfusion, Iron, Erythropoietin, Thromboembolism},
	pages = {221--234},
}

@article{mhaskarCD009624,
	title = {The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents},
	volume = {2},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD009624.pub2},
	abstract = {BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are commonly used to treat chemotherapy-induced anemia (CIA). However, about half of patients do not benefit.
OBJECTIVES: To evaluate the benefits and harms related to the use of iron as a supplement to ESA and iron alone compared with ESA alone in the management of CIA.
SEARCH METHODS: We searched for relevant trials from the Cochrane Central Register of Controlled Trials (CENTRAL) (issue 1 January 2016), MEDLINE (1950 to February 2016), and www.clinicaltrials.gov without using any language limits.
SELECTION CRITERIA: All randomized controlled trials (RCTs) comparing 'iron plus ESA' or 'iron alone' versus 'ESA alone' in people with CIA were eligible for inclusion.
DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane.
MAIN RESULTS: We included eight RCTs (12 comparisons) comparing ESA plus iron versus ESA alone enrolling 2087 participants. We did not find any trial comparing iron alone versus ESAs alone in people with CIA. None of the included RCTs reported overall survival. There was a beneficial effect of iron supplementation to ESAs compared with ESAs alone on hematopoietic response (risk ratio (RR) 1.17, 95\% confidence interval (CI) 1.09 to 1.26; P {\textless} 0.0001; 1712 participants; 11 comparisons; high-quality evidence). Assuming a baseline risk of 35\% to 80\% for hematopoietic response without iron supplementation, between seven and 16 patients should be treated to achieve hematopoietic response in one patient. In subgroup analyses, RCTs that used intravenous (IV) iron favored ESAs and iron (RR 1.20 (95\% CI 1.10 to 1.31); P {\textless} 0.00001; 1321 participants; eight comparisons), whereas we found no evidence for a difference in hematopoietic response in RCTs using oral iron (RR 1.04 (95\% CI 0.87 to 1.24); P = 0.68; 391 participants; three comparisons). There was no evidence for a difference between the subgroups of IV and oral iron (P = 0.16). There was no evidence for a difference between the subgroups of types of iron (P = 0.31) and types of ESAs (P = 0.16) for hematopoietic response.The iron supplementation to ESAs might be beneficial as fewer participants treated with iron supplementation required red blood cell (RBC) transfusions compared to the number of participants treated with ESAs alone (RR 0.74 (95\% CI 0.60 to 0.92); P = 0.007; 1719 participants; 11 comparisons; moderate-quality evidence). Assuming a baseline risk of 7\% to 40\% for RBC transfusion without iron supplementation, between 10 and 57 patients should be treated to avoid RBC transfusion in one patient.We found no evidence for a difference in the median time to hematopoietic response with addition of iron to ESAs (hazard ratio (HR) 0.93 (95\% CI 0.67 to 1.28); P = 0.65; 1042 participants; seven comparisons; low-quality evidence). In subgroup analyses, RCTs in which dextran (HR 0.95 (95\% CI 0.36 to 2.52); P = 0.92; 340 participants; three comparisons), sucrose iron (HR 1.15 (95\% CI 0.60 to 2.21); P = 0.67; 102 participants; one comparison) and sulfate iron (HR 1.24 (95\% CI 0.99 to 1.56); P = 0.06; 55 participants; one comparison) were used showed no evidence for difference between iron supplementation versus ESAs alone compared with RCTs in which gluconate (HR 0.78 (95\% CI 0.65 to 0.94); P = 0.01; 464 participants; two comparisons) was used for median time to hematopoietic response (P = 0.02). There was no evidence for a difference between the subgroups of route of iron administration (P = 0.13) and types of ESAs (P = 0.46) for median time to hematopoietic response.Our results indicated that there could be improvement in the hemoglobin (Hb) levels with addition of iron to ESAs (mean difference (MD) 0.48 (95\% CI 0.10 to 0.86); P = 0.01; 827 participants; seven comparisons; low-quality evidence). In RCTs in which IV iron was used there was evidence for a difference (MD 0.84 (95\% CI 0.21 to 1.46); P = 0.009; 436 participants; four comparisons) compared with oral iron (MD 0.07 (95\% CI -0.19 to 0.34); P = 0.59; 391 participants; three comparisons) for mean change in Hb level (P = 0.03). RCTs in which dextran (MD 1.55 (95\% CI 0.62 to 2.47); P = 0.001; 102 participants; two comparisons) was used showed evidence for a difference with iron supplementation versus ESAs alone compared with RCTs in which gluconate (MD 0.54 (95\% CI -0.15 to 1.22); P = 0.12; 334 participants; two comparisons) and sulfate iron (MD 0.07 (95\% CI -0.19 to 0.34); P = 0.59; 391 participants; three comparisons) were used for mean change in Hb level (P = 0.007). RCTs in which epoetin was used showed evidence for a difference with iron supplementation versus ESAs alone (MD 0.77 (95\% CI 0.25 to 1.29); P = 0.004; 337 participants; five comparisons) compared with darbepoetin use (MD 0.10 (95\% CI -0.13 to 0.33); P = 0.38; 490 participants; two comparisons) for mean change in Hb level (P = 0.02).We found no evidence for a difference in quality of life with addition of iron to ESAs (standardized mean difference 0.01 (95\% CI -0.10 to 0.12); P = 0.88; 1124 participants; three RCTs; high-quality evidence).We found no evidence for a difference in risk of grade III-IV thromboembolic events (RR 0.95 (95\% CI 0.54 to 1.65); P = 0.85; 783 participants; three RCTs; moderate-quality evidence). The incidence of treatment-related mortality (TRM) was 0\% (997 participants; four comparisons; high-quality evidence).Other common adverse events included vomiting, asthenia, and leukopenia, and were similar in both arms.Overall the risk of bias across outcomes was high to low. Since the included RCTs had shorter follow-up duration (up to 20 weeks), the long-term effects of iron supplementation are unknown. Our main reasons for downgrading the quality of evidence were inconsistency across the included studies and imprecision of results.
AUTHORS' CONCLUSIONS: Our systematic review shows that addition of iron to ESAs offers superior hematopoietic response, reduces the risk of RBC transfusions, and improves Hb levels, and appears to be well tolerated. None of the included RCTs reported overall survival. We found no evidence for a difference in quality of life with iron supplementation.},
	language = {eng},
	journal = {The Cochrane Database of Systematic Reviews},
	author = {Mhaskar, Rahul and Wao, Hesborn and Miladinovic, Branko and Kumar, Ambuj and Djulbegovic, Benjamin},
	month = feb,
	year = {2016},
	pmid = {26845108},
	pmcid = {PMC8765740},
	keywords = {Humans, Neoplasms, Antineoplastic Agents, Randomized Controlled Trials as Topic, Administration, Oral, Injections, Intravenous, Oncology, Anemia, Erythrocyte Transfusion, Iron, Hematinics, Hematopoiesis, Epo},
	pages = {CD009624},
}

@article{kangaspunta449,
	title = {Preoperative intravenous iron treatment reduces postoperative complications and postoperative anemia in preoperatively anemic patients with colon carcinoma},
	volume = {37},
	issn = {1432-1262},
	doi = {10.1007/s00384-021-04080-9},
	abstract = {PURPOSE: Anemia is common among patients with colorectal cancer and is associated with an increased risk of complications and poorer survival rate. The main objective of our study was to determine the effect of preoperative intravenous iron supplementation therapy on the need for red blood cell transfusions, other postoperative complications, and length of hospital stay in colon cancer patients undergoing colon resection.
METHODS: In this retrospective cohort study, data were collected from medical records of all 549 colon carcinoma patients who underwent a colon resection in Helsinki University Hospital during the years 2017 and 2018. The patients were divided into two cohorts: one with anemic patients treated with preoperative intravenous iron supplementation therapy (180 patients) and one with anemic patients without preoperative intravenous iron supplementation therapy (138 patients). Non-anemic patients and patients requiring emergency surgery were excluded (231 patients).
RESULTS: Patients treated with intravenous iron had less postoperative complications (33.9\% vs. 45.9\%, p = 0.045) and a lower prevalence of anemia at 1 month after surgery (38.7\% vs. 65.3\%, p {\textless} 0.01) when compared with patients without preoperative iv iron treatment. No difference was found in the amount of red blood cell transfusions, length of stay, or mortality between the groups.
CONCLUSION: This is the first study demonstrating a significant decrease in postoperative complications in anemic colon cancer patients receiving preoperative intravenous iron supplementation therapy. This treatment also diminishes the rate of postoperative anemia, which is often associated with a facilitated recovery.},
	language = {eng},
	number = {2},
	journal = {International Journal of Colorectal Disease},
	author = {Kangaspunta, Mikael and Mäkijärvi, Jorma and Koskensalo, Selja and Kokkola, Arto and Arkkila, Perttu and Scheinin, Tom and Rasilainen, Suvi},
	month = feb,
	year = {2022},
	pmid = {34931280},
	pmcid = {PMC8803765},
	keywords = {Humans, Retrospective Studies, Colonic Neoplasms, Postoperative Complications, Carcinoma, Surgery, Preoperative Care, Anemia, Hemoglobins, Iron, Colon cancer, Colorectal surgery, Intravenous iron},
	pages = {449--455},
	file = {Kangaspunta et al_2022_Preoperative intravenous iron treatment reduces postoperative complications and.pdf:/Users/jcsal/Zotero/storage/QJHBV5VX/Kangaspunta et al_2022_Preoperative intravenous iron treatment reduces postoperative complications and.pdf:application/pdf},
}

@article{richards1,
	title = {Preoperative intravenous iron for anaemia in elective major open abdominal surgery: the {PREVENTT} {RCT}},
	volume = {25},
	issn = {2046-4924},
	shorttitle = {Preoperative intravenous iron for anaemia in elective major open abdominal surgery},
	doi = {10.3310/hta25110},
	abstract = {BACKGROUND: Anaemia affects 30-50\% of patients before they undergo major surgery. Preoperative anaemia is associated with increased need for blood transfusion, postoperative complications and worse patient outcomes after surgery. International guidelines support the use of intravenous iron to correct anaemia in patients before surgery. However, the use of preoperative intravenous iron for patient benefit has not been assessed in the setting of a formal clinical trial.
OBJECTIVES: To assess if intravenous iron given to patients with anaemia before major abdominal surgery is beneficial by reducing transfusion rates, postoperative complications, hospital stay and re-admission to hospital, and improving quality of life outcomes.
DESIGN: A multicentre, double-blinded, randomised, controlled, Phase III clinical trial, with 1 : 1 randomisation comparing placebo (normal saline) with intravenous iron (intravenous ferric carboxymaltose 1000 mg). Randomisation and treatment allocation were by a secure web-based service.
SETTING: The study was conducted across 46 hospitals in England, Scotland and Wales between September 2013 and September 2018.
PARTICIPANTS: Patients aged {\textgreater} 18 years, undergoing elective major open abdominal surgery, with anaemia [Hb level of {\textgreater} 90 g/l and {\textless} 120 g/l (female patients) and {\textless} 130 g/l (male patients)] who could undergo randomisation and treatment 10-42 days before their operation.
INTERVENTION: Double-blinded study comparing placebo of normal saline with 1000 mg of ferric carboxymaltose administered 10-42 days prior to surgery.
MAIN OUTCOME MEASURES: Co-primary end points were risk of blood transfusion or death at 30 days postoperatively, and rate of blood transfusions at 30 days post operation.
RESULTS: A total of 487 patients were randomised (243 given placebo and 244 given intravenous iron), of whom 474 completed the trial and provided data for the analysis of the co-primary end points. The use of intravenous iron increased preoperative Hb levels (mean difference 4.7 g/l, 95\% confidence interval 2.7 to 6.8 g/l; p {\textless} 0.0001), but had no effect compared with placebo on risk of blood transfusion or death (risk ratio 1.03, 95\% confidence interval 0.78 to 1.37; p = 0.84; absolute risk difference +0.8\%, 95\% confidence interval -7.3\% to 9.0\%), or rates of blood transfusion (rate ratio 0.98, 95\% confidence interval 0.68 to 1.43; p = 0.93; absolute rate difference 0.00, 95\% confidence interval -0.14 to 0.15). There was no difference in postoperative complications or hospital stay. The intravenous iron group had higher Hb levels at the 8-week follow-up (difference in mean 10.7 g/l, 95\% confidence interval 7.8 to 13.7 g/l; p {\textless} 0.0001). There were a total of 71 re-admissions to hospital for postoperative complications in the placebo group, compared with 38 re-admissions in the intravenous iron group (rate ratio 0.54, 95\% confidence interval 0.34 to 0.85; p = 0.009). There were no differences between the groups in terms of mortality (two per group at 30 days post operation) or in any of the prespecified safety end points or serious adverse events.
CONCLUSIONS: In patients with anaemia prior to elective major abdominal surgery, there was no benefit from giving intravenous iron before the operation.
FUTURE WORK: The impact of iron repletion on recovery from postoperative anaemia, and the association with reduced re-admission to hospital for complications, should be investigated.
LIMITATIONS: In the preoperative intravenous iron to treat anaemia in major surgery (PREVENTT) trial, all patients included had anaemia and only 20\% had their anaemia corrected before surgery. The definition and causality of iron deficiency in this setting is not clear.
TRIAL REGISTRATION: Current Controlled Trials ISRCTN67322816 and ClinicalTrials.gov NCT01692418.
FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25 No. 11. See the NIHR Journals Library website for further project information.},
	language = {eng},
	number = {11},
	journal = {Health Technology Assessment (Winchester, England)},
	author = {Richards, Toby and Baikady, Ravishankar Rao and Clevenger, Ben and Butcher, Anna and Abeysiri, Sandy and Chau, Marisa and Swinson, Rebecca and Collier, Tim and Dodd, Matthew and Dyck, Laura Van and Macdougall, Iain and Murphy, Gavin and Browne, John and Bradbury, Andrew and Klein, Andrew},
	month = feb,
	year = {2021},
	pmid = {33632377},
	pmcid = {PMC7957457},
	keywords = {Abdomen, Humans, Female, Male, Quality of Life, Surgery, Elective Surgical Procedures, Anemia, Iron, ANAEMIA, BLOOD TRANSFUSION, INTRAVENOUS IRON, PATIENT BLOOD MANAGEMENT, RANDOMISED CONTROLLED TRIAL, SURGERY},
	pages = {1--58},
	file = {Richards et al_2021_Preoperative intravenous iron for anaemia in elective major open abdominal.pdf:/Users/jcsal/Zotero/storage/LYVNF8V9/Richards et al_2021_Preoperative intravenous iron for anaemia in elective major open abdominal.pdf:application/pdf},
}

@article{richards1353,
	title = {Preoperative intravenous iron to treat anaemia before major abdominal surgery ({PREVENTT}): a randomised, double-blind, controlled trial},
	volume = {396},
	issn = {1474-547X},
	shorttitle = {Preoperative intravenous iron to treat anaemia before major abdominal surgery ({PREVENTT})},
	doi = {10.1016/S0140-6736(20)31539-7},
	abstract = {BACKGROUND: Preoperative anaemia affects a high proportion of patients undergoing major elective surgery and is associated with poor outcomes. We aimed to test the hypothesis that intravenous iron given to anaemic patients before major open elective abdominal surgery would correct anaemia, reduce the need for blood transfusions, and improve patient outcomes.
METHODS: In a double-blind, parallel-group randomised trial, we recruited adult participants identified with anaemia at preoperative hospital visits before elective major open abdominal surgery at 46 UK tertiary care centres. Anaemia was defined as haemoglobin less than 130 g/L for men and 120 g/L for women. We randomly allocated participants (1:1) via a secure web-based service to receive intravenous iron or placebo 10-42 days before surgery. Intravenous iron was administered as a single 1000 mg dose of ferric carboxymaltose in 100 mL normal saline, and placebo was 100 mL normal saline, both given as an infusion over 15 min. Unblinded study personnel prepared and administered the study drug; participants and other clinical and research staff were blinded to treatment allocation. Coprimary endpoints were risk of the composite outcome of blood transfusion or death, and number of blood transfusions from randomisation to 30 days postoperatively. The primary analysis included all randomly assigned patients with data available for the primary endpoints; safety analysis included all randomly assigned patients according to the treatment received. This study is registered, ISRCTN67322816, and is closed to new participants.
FINDINGS: Of 487 participants randomly assigned to placebo (n=243) or intravenous iron (n=244) between Jan 6, 2014, and Sept 28, 2018, complete data for the primary endpoints were available for 474 (97\%) individuals. Death or blood transfusion occurred in 67 (28\%) of the 237 patients in the placebo group and 69 (29\%) of the 237 patients in the intravenous iron group (risk ratio 1·03, 95\% CI 0·78-1·37; p=0·84). There were 111 blood transfusions in the placebo group and 105 in the intravenous iron group (rate ratio 0·98, 95\% CI 0·68-1·43; p=0·93). There were no significant differences between the two groups for any of the prespecified safety endpoints.
INTERPRETATION: Preoperative intravenous iron was not superior to placebo to reduce need for blood transfusion when administered to patients with anaemia 10-42 days before elective major abdominal surgery.
FUNDING: UK National Institute of Health Research Health Technology Assessment Program.},
	language = {eng},
	number = {10259},
	journal = {Lancet (London, England)},
	author = {Richards, Toby and Baikady, Ravishankar Rao and Clevenger, Ben and Butcher, Anna and Abeysiri, Sandy and Chau, Marisa and Macdougall, Iain C. and Murphy, Gavin and Swinson, Rebecca and Collier, Tim and Van Dyck, Laura and Browne, John and Bradbury, Andrew and Dodd, Matthew and Evans, Richard and Brealey, David and Anker, Stefan D. and Klein, Andrew},
	month = oct,
	year = {2020},
	pmid = {32896294},
	pmcid = {PMC7581899},
	keywords = {Abdomen, Humans, Aged, Female, Male, Treatment Outcome, Surgery, Preoperative Care, United Kingdom, Elective Surgical Procedures, Double-Blind Method, Administration, Intravenous, Anemia, Iron},
	pages = {1353--1361},
	file = {Richards et al_2020_Preoperative intravenous iron to treat anaemia before major abdominal surgery.pdf:/Users/jcsal/Zotero/storage/XZBBFKKA/Richards et al_2020_Preoperative intravenous iron to treat anaemia before major abdominal surgery.pdf:application/pdf},
}

@article{ngCD011588,
	title = {Iron therapy for pre-operative anaemia},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD011588.pub2},
	abstract = {BACKGROUND: Pre-operative anaemia is common and occurs in up to 76\% of patients. It is associated with increased peri-operative allogeneic blood transfusions, longer hospital lengths of stay and increased morbidity and mortality. Iron deficiency is one of the most common causes of this anaemia. Oral iron therapy has traditionally been used to treat anaemia but newer, safer parenteral iron preparations have been shown to be more effective in other conditions such as inflammatory bowel disease, chronic heart failure and post-partum haemorrhage. A limited number of studies look at iron therapy for the treatment of pre-operative anaemia. The aim of this Cochrane review is to summarise the evidence for use of iron supplementation, both enteral and parenteral, for the management of pre-operative anaemia.
OBJECTIVES: The objective of this review is to evaluate the effects of pre-operative iron therapy (enteral or parenteral) in reducing the need for allogeneic blood transfusions in anaemic patients undergoing surgery.
SEARCH METHODS: We ran the search on 25 March 2015. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process \& Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R), EMBASE Classic and EMBASE (Ovid), CINAHL Plus (EBSCO), PubMed, clinical trials registries, conference abstracts, and we screened reference lists.
SELECTION CRITERIA: We included all randomised controlled trials (RCTs) which compared pre-operative iron monotherapy to placebo, no treatment, standard of care or another form of iron therapy for anaemic adults undergoing surgery. Anaemia was defined by haemoglobin values less than 13 g/dL for males and 12 g/dL for non-pregnant females.
DATA COLLECTION AND ANALYSIS: Data were collected by two authors on the proportion of patients who receive a blood transfusion, amount of blood transfused per patient (units) and haemoglobin measured as continuous variables at pre-determined time-points: pre-treatment, pre-operatively but post-treatment, and post-operatively. Statistical analysis was performed using the Cochrane statistical software, Review Manager 2014. Outcome data were summarised in tables and a forest plot.
MAIN RESULTS: Three prospective randomised controlled studies evaluated pre-operative iron therapy to correct anaemia (two in colorectal and one in gynaecological surgery) and included 114 patients in total. One compared oral iron versus standard care (Lidder 2007); one intravenous iron versus control (Edwards 2009); and one study compared oral versus intravenous iron (Kim 2009). Both colorectal trials reported the primary outcome (proportion of patients who received allogeneic blood transfusions) and meta-analysis showed a reduction in blood transfusions with the administration of iron therapy, but the reduction was not statistically significant (risk ratio (RR) 0.56, 95\% confidence interval (CI) 0.27 to 1.18). All studies reported haemoglobin change but data for the anaemic patients were only available for two studies (Edwards 2009 and Kim 2009). Edwards 2009 showed no difference in haemoglobin at the end of treatment pre-operatively. The intravenous versus oral iron study showed an increase in haemoglobin with intravenous iron at the end of treatment pre-operatively (MD 1.90 g/dL, 95\% CI 1.16 to 2.64; participants = 56), but the results are at high risk of bias because participants with less than 80\% compliance with therapy were excluded from the analysis and compliance was lower in the oral iron group due to the side-effects of treatment (Kim 2009).None of the studies reported quality of life, short- or long-term mortality or post-operative morbidity.
AUTHORS' CONCLUSIONS: The use of iron therapy for pre-operative anaemia does not show a statistically significant reduction in the proportion of patients who received an allogeneic blood transfusion compared to no iron therapy. However, the 38 patients in our analysis falls far short of the 819 patients our information size calculation recommended to detect a 30\% reduction in blood transfusions. Intravenous iron may be more effective than oral iron at increasing haemoglobin. However, all these conclusions are drawn from only three small randomised controlled studies. Further well designed, adequately powered randomised controlled studies are required to determine the true effectiveness of iron therapy for pre-operative anaemia.},
	language = {eng},
	number = {12},
	journal = {The Cochrane Database of Systematic Reviews},
	author = {Ng, Oliver and Keeler, Barrie D. and Mishra, Amitabh and Simpson, Alastair and Neal, Keith and Brookes, Matthew J. and Acheson, Austin G.},
	month = dec,
	year = {2015},
	pmid = {26694949},
	keywords = {Humans, Adult, Randomized Controlled Trials as Topic, Surgery, Administration, Oral, Surgical Procedures, Operative, Preoperative Care, Injections, Intravenous, Anemia, Blood Transfusion, Iron, Ferritins, Hematocrit, Hemoglobin A, Reticulocyte Count},
	pages = {CD011588},
	file = {Ng et al_2015_Iron therapy for pre-operative anaemia.pdf:/Users/jcsal/Zotero/storage/VBHAEZDZ/Ng et al_2015_Iron therapy for pre-operative anaemia.pdf:application/pdf},
}

@article{kaufnerCD012451,
	title = {Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery},
	volume = {8},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD012451.pub2},
	abstract = {BACKGROUND: Approximately 30\% of adults undergoing non-cardiac surgery suffer from preoperative anaemia. Preoperative anaemia is a risk factor for mortality and adverse outcomes in different surgical specialties and is frequently the reason for blood transfusion. The most common causes are renal, chronic diseases, and iron deficiency. International guidelines recommend that the cause of anaemia guide preoperative anaemia treatment. Recombinant human erythropoietin (rHuEPO) with iron supplementation has frequently been used to increase preoperative haemoglobin concentrations in patients in order to avoid the need for perioperative allogeneic red blood cell (RBC) transfusion.
OBJECTIVES: To evaluate the efficacy of preoperative rHuEPO therapy (subcutaneous or parenteral) with iron (enteral or parenteral) in reducing the need for allogeneic RBC transfusions in preoperatively anaemic adults undergoing non-cardiac surgery.
SEARCH METHODS: We searched CENTRAL, Ovid MEDLINE(R), Ovid Embase, ISI Web of Science: SCI-EXPANDED and CPCI-S, and clinical trial registries WHO ICTRP and ClinicalTrials.gov on 29 August 2019.
SELECTION CRITERIA: We included all randomized controlled trials (RCTs) that compared preoperative rHuEPO + iron therapy to control treatment (placebo, no treatment, or standard of care with or without iron) for preoperatively anaemic adults undergoing non-cardiac surgery. We used the World Health Organization (WHO) definition of anaemia: haemoglobin concentration (g/dL) less than 13 g/dL for males, and 12 g/dL for non-pregnant females (decision of inclusion based on mean haemoglobin concentration). We defined two subgroups of rHuEPO dosage: 'low' for 150 to 300 international units (IU)/kg body weight, and 'high' for 500 to 600 IU/kg body weight.
DATA COLLECTION AND ANALYSIS: Two review authors collected data from the included studies. Our primary outcome was the need for RBC transfusion (no autologous transfusion, fresh frozen plasma or platelets), measured in transfused participants during surgery (intraoperative) and up to five days after surgery. Secondary outcomes of interest were: haemoglobin concentration (directly before surgery), number of RBC units (where one unit contains 250 to 450 mL) transfused per participant (intraoperative and up to five days after surgery), mortality (within 30 days after surgery), length of hospital stay, and adverse events (e.g. renal dysfunction, thromboembolism, hypertension, allergic reaction, headache, fever, constipation).
MAIN RESULTS: Most of the included trials were in orthopaedic, gastrointestinal, and gynaecological surgery and included participants with mild and moderate preoperative anaemia (haemoglobin from 10 to 12 g/dL). The duration of preoperative rHuEPO treatment varied across the trials, ranging from once a week to daily or a 5-to-10-day period, and in one trial preoperative rHuEPO was given on the morning of surgery and for five days postoperatively. We included 12 trials (participants = 1880) in the quantitative analysis of the need for RBC transfusion following preoperative treatment with rHuEPO + iron to correct preoperative anaemia in non-cardiac surgery; two studies were multiarmed trials with two different dose regimens. Preoperative rHuEPO + iron given to anaemic adults reduced the need RBC transfusion (risk ratio (RR) 0.55, 95\% confidence interval (CI) 0.38 to 0.80; participants = 1880; studies = 12; I2 = 84\%; moderate-quality evidence due to inconsistency). This analysis suggests that on average, the combined administration of rHuEPO + iron will mean 231 fewer individuals will need transfusion for every 1000 individuals compared to the control group. Preoperative high-dose rHuEPO + iron given to anaemic adults increased the haemoglobin concentration (mean difference (MD) 1.87 g/dL, 95\% CI 1.26 to 2.49; participants = 852; studies = 3; I2 = 89\%; low-quality evidence due to inconsistency and risk of bias) but not low-dose rHuEPO + iron (MD 0.11 g/dL, 95\% CI -0.46 to 0.69; participants = 334; studies = 4; I2 = 69\%; low-quality evidence due to inconsistency and risk of bias). There was probably little or no difference in the number of RBC units when rHuEPO + iron was given preoperatively (MD -0.09, 95\% CI -0.23 to 0.05; participants = 1420; studies = 6; I2 = 2\%; moderate-quality evidence due to imprecision).  There was probably little or no difference in the risk of mortality within 30 days of surgery (RR 1.19, 95\% CI 0.39 to 3.63; participants = 230; studies = 2; I2 = 0\%; moderate-quality evidence due to imprecision) or of adverse events including local rash, fever, constipation, or transient hypertension (RR 0.93, 95\% CI 0.68 to 1.28; participants = 1722; studies = 10; I2 = 0\%; moderate-quality evidence due to imprecision). The administration of rHuEPO + iron before non-cardiac surgery did not clearly reduce the length of hospital stay of preoperative anaemic adults (MD -1.07, 95\% CI -4.12 to 1.98; participants = 293; studies = 3; I2 = 87\%; low-quality evidence due to inconsistency and imprecision).
AUTHORS' CONCLUSIONS: Moderate-quality evidence suggests that preoperative rHuEPO + iron therapy for anaemic adults prior to non-cardiac surgery reduces the need for RBC transfusion and, when given at higher doses, increases the haemoglobin concentration preoperatively. The administration of rHuEPO + iron treatment did not decrease the mean number of units of RBC transfused per patient. There were no important differences in the risk of adverse events or mortality within 30 days, nor in length of hospital stay. Further, well-designed, adequately powered RCTs are required to estimate the impact of this combined treatment more precisely.},
	language = {eng},
	journal = {The Cochrane Database of Systematic Reviews},
	author = {Kaufner, Lutz and von Heymann, Christian and Henkelmann, Anne and Pace, Nathan L. and Weibel, Stephanie and Kranke, Peter and Meerpohl, Joerg J. and Gill, Ravi},
	month = aug,
	year = {2020},
	pmid = {32790892},
	pmcid = {PMC8095002},
	keywords = {Humans, Female, Length of Stay, Male, Adult, Randomized Controlled Trials as Topic, Surgery, Digestive System Surgical Procedures, Surgical Procedures, Operative, Preoperative Care, Placebos, Anemia, Erythrocyte Transfusion, Iron, Erythropoietin, Epo, Hemoglobin A, Gynecologic Surgical Procedures, Orthopedic Procedures, Recombinant Proteins},
	pages = {CD012451},
}

@article{laermans224,
	title = {Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review},
	volume = {11},
	issn = {2046-4053},
	shorttitle = {Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients},
	doi = {10.1186/s13643-022-02081-5},
	abstract = {BACKGROUND: Iron supplementation and erythropoiesis-stimulating agent (ESA) administration represent the hallmark therapies in preoperative anemia treatment, as reflected in a set of evidence-based treatment recommendations made during the 2018 International Consensus Conference on Patient Blood Management. However, little is known about the safety of these therapies. This systematic review investigated the occurrence of adverse events (AEs) during or after treatment with iron and/or ESAs.
METHODS: Five databases (The Cochrane Library, MEDLINE, Embase, Transfusion Evidence Library, Web of Science) and two trial registries (ClinicalTrials.gov, WHO ICTRP) were searched until 23 May 2022. Randomized controlled trials (RCTs), cohort, and case-control studies investigating any AE during or after iron and/or ESA administration in adult elective surgery patients with preoperative anemia were eligible for inclusion and judged using the Cochrane Risk of Bias tools. The GRADE approach was used to assess the overall certainty of evidence.
RESULTS: Data from 26 RCTs and 16 cohort studies involving a total of 6062 patients were extracted, on 6 treatment comparisons: (1) intravenous (IV) versus oral iron, (2) IV iron versus usual care/no iron, (3) IV ferric carboxymaltose versus IV iron sucrose, (4) ESA+iron versus control (placebo and/or iron, no treatment), (5) ESA+IV iron versus ESA+oral iron, and (6) ESA+IV iron versus ESA+IV iron (different ESA dosing regimens). Most AE data concerned mortality/survival (n=24 studies), thromboembolic (n=22), infectious (n=20), cardiovascular (n=19) and gastrointestinal (n=14) AEs. Very low certainty evidence was assigned to all but one outcome category. This uncertainty results from both the low quantity and quality of AE data due to the high risk of bias caused by limitations in the study design, data collection, and reporting.
CONCLUSIONS: It remains unclear if ESA and/or iron therapy is associated with AEs in preoperatively anemic elective surgery patients. Future trial investigators should pay more attention to the systematic collection, measurement, documentation, and reporting of AE data.},
	language = {eng},
	number = {1},
	journal = {Systematic Reviews},
	author = {Laermans, Jorien and Van Remoortel, Hans and Avau, Bert and Bekkering, Geertruida and Georgsen, Jørgen and Manzini, Paola Maria and Meybohm, Patrick and Ozier, Yves and De Buck, Emmy and Compernolle, Veerle and Vandekerckhove, Philippe},
	month = oct,
	year = {2022},
	pmid = {36253838},
	pmcid = {PMC9578279},
	keywords = {Humans, Adult, Surgery, Elective Surgical Procedures, Preoperative care, Anemia, Iron, Systematic review, Hematinics, Epo, Adverse events, Blood transfusion, Elective surgery, Erythropoiesis, Erythropoiesis-stimulating agents, Ferric Oxide, Saccharated},
	pages = {224},
	file = {Laermans et al_2022_Adverse events of iron and-or erythropoiesis-stimulating agent therapy in.pdf:/Users/jcsal/Zotero/storage/HTZ6C3MX/Laermans et al_2022_Adverse events of iron and-or erythropoiesis-stimulating agent therapy in.pdf:application/pdf},
}

@article{vanremoortel103,
	title = {Effectiveness of {Iron} {Supplementation} {With} or {Without} {Erythropoiesis}-{Stimulating} {Agents} on {Red} {Blood} {Cell} {Utilization} in {Patients} {With} {Preoperative} {Anaemia} {Undergoing} {Elective} {Surgery}: {A} {Systematic} {Review} and {Meta}-{Analysis}},
	volume = {35},
	issn = {1532-9496},
	shorttitle = {Effectiveness of {Iron} {Supplementation} {With} or {Without} {Erythropoiesis}-{Stimulating} {Agents} on {Red} {Blood} {Cell} {Utilization} in {Patients} {With} {Preoperative} {Anaemia} {Undergoing} {Elective} {Surgery}},
	doi = {10.1016/j.tmrv.2021.03.004},
	abstract = {Patient Blood Management (PBM) is an evidence-based, multidisciplinary, patient-centred approach to optimizing the care of patients who might need a blood transfusion. This systematic review aimed to collect the best available evidence on the effectiveness of preoperative iron supplementation with or without erythropoiesis-stimulating agents (ESAs) on red blood cell (RBC) utilization in all-cause anaemic patients scheduled for elective surgery. Five databases and two trial registries were screened. Primary outcomes were the number of patients and the number of RBC units transfused. Effect estimates were synthesized by conducting meta-analyses. GRADE (Grades of Recommendation, Assessment, Development and Evaluation) was used to assess the certainty of evidence. We identified 29 randomized controlled trials (RCTs) and 2 non-RCTs comparing the effectiveness of preoperative iron monotherapy, or iron + ESAs, to control (no treatment, usual care, placebo). We found that: (1) IV and/or oral iron monotherapy may not result in a reduced number of units transfused and IV iron may not reduce the number of patients transfused (low-certainty evidence); (2) uncertainty exists whether the administration route of iron therapy (IV vs oral) differentially affects RBC utilization (very low-certainty evidence); (3) IV ferric carboxymaltose monotherapy may not result in a different number of patients transfused compared to IV iron sucrose monotherapy (low-certainty evidence); (4) oral iron + ESAs probably results in a reduced number of patients transfused and number of units transfused (moderate-certainty evidence); (5) IV iron + ESAs may result in a reduced number of patients transfused (low-certainty evidence); (6) oral and/or IV iron + ESAs probably results in a reduced number of RBC units transfused in transfused patients (moderate-certainty evidence); (7) uncertainty exists about the effect of oral and/or IV iron + ESAs on the number of patients requiring transfusion of multiple units (very low-certainty evidence). Effect estimates of different haematological parameters and length of stay were synthesized as secondary outcomes. In conclusion, in patients with anaemia of any cause scheduled for elective surgery, the preoperative administration of iron monotherapy may not result in a reduced number of patients or units transfused (low-certainty evidence). Iron supplementation in addition to ESAs probably results in a reduced RBC utilization (moderate-certainty evidence).},
	language = {eng},
	number = {2},
	journal = {Transfusion Medicine Reviews},
	author = {Van Remoortel, Hans and Laermans, Jorien and Avau, Bert and Bekkering, Geertruida and Georgsen, Jørgen and Manzini, Paola Maria and Meybohm, Patrick and Ozier, Yves and De Buck, Emmy and Compernolle, Veerle and Vandekerckhove, Philippe},
	month = apr,
	year = {2021},
	pmid = {33965294},
	keywords = {Humans, Surgery, Preoperative Care, Dietary Supplements, Elective Surgical Procedures, Anemia, Hemoglobins, Blood Transfusion, Iron, Erythrocytes, Hematinics, Epo, Erythropoiesis, Systematic Review [Publication Type]},
	pages = {103--124},
	file = {Van Remoortel et al_2021_Effectiveness of Iron Supplementation With or Without.pdf:/Users/jcsal/Zotero/storage/H8NYYVWW/Van Remoortel et al_2021_Effectiveness of Iron Supplementation With or Without.pdf:application/pdf},
}

@article{holsth1354,
	title = {Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis},
	volume = {350},
	issn = {1756-1833},
	shorttitle = {Restrictive versus liberal transfusion strategy for red blood cell transfusion},
	doi = {10.1136/bmj.h1354},
	abstract = {OBJECTIVE: To compare the benefit and harm of restrictive versus liberal transfusion strategies to guide red blood cell transfusions.
DESIGN: Systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.
DATA SOURCES: Cochrane central register of controlled trials, SilverPlatter Medline (1950 to date), SilverPlatter Embase (1980 to date), and Science Citation Index Expanded (1900 to present). Reference lists of identified trials and other systematic reviews were assessed, and authors and experts in transfusion were contacted to identify additional trials.
TRIAL SELECTION: Published and unpublished randomised clinical trials that evaluated a restrictive compared with a liberal transfusion strategy in adults or children, irrespective of language, blinding procedure, publication status, or sample size.
DATA EXTRACTION: Two authors independently screened titles and abstracts of trials identified, and relevant trials were evaluated in full text for eligibility. Two reviewers then independently extracted data on methods, interventions, outcomes, and risk of bias from included trials. random effects models were used to estimate risk ratios and mean differences with 95\% confidence intervals.
RESULTS: 31 trials totalling 9813 randomised patients were included. The proportion of patients receiving red blood cells (relative risk 0.54, 95\% confidence interval 0.47 to 0.63, 8923 patients, 24 trials) and the number of red blood cell units transfused (mean difference -1.43, 95\% confidence interval -2.01 to -0.86) were lower with the restrictive compared with liberal transfusion strategies. Restrictive compared with liberal transfusion strategies were not associated with risk of death (0.86, 0.74 to 1.01, 5707 patients, nine lower risk of bias trials), overall morbidity (0.98, 0.85 to 1.12, 4517 patients, six lower risk of bias trials), or fatal or non-fatal myocardial infarction (1.28, 0.66 to 2.49, 4730 patients, seven lower risk of bias trials). Results were not affected by the inclusion of trials with unclear or high risk of bias. Using trial sequential analyses on mortality and myocardial infarction, the required information size was not reached, but a 15\% relative risk reduction or increase in overall morbidity with restrictive transfusion strategies could be excluded.
CONCLUSIONS: Compared with liberal strategies, restrictive transfusion strategies were associated with a reduction in the number of red blood cell units transfused and number of patients being transfused, but mortality, overall morbidity, and myocardial infarction seemed to be unaltered. Restrictive transfusion strategies are safe in most clinical settings. Liberal transfusion strategies have not been shown to convey any benefit to patients.
TRIAL REGISTRATION: PROSPERO CRD42013004272.},
	language = {eng},
	journal = {BMJ (Clinical research ed.)},
	author = {Holst, Lars B. and Petersen, Marie W. and Haase, Nicolai and Perner, Anders and Wetterslev, Jørn},
	month = mar,
	year = {2015},
	pmid = {25805204},
	pmcid = {PMC4372223},
	keywords = {Humans, Randomized Controlled Trials as Topic, Odds Ratio, Models, Statistical, Erythrocyte Transfusion},
	pages = {h1354},
	file = {Holst et al_2015_Restrictive versus liberal transfusion strategy for red blood cell transfusion.pdf:/Users/jcsal/Zotero/storage/QZWTVURM/Holst et al_2015_Restrictive versus liberal transfusion strategy for red blood cell transfusion.pdf:application/pdf},
}

@article{carson2453,
	title = {Liberal or restrictive transfusion in high-risk patients after hip surgery},
	volume = {365},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa1012452},
	abstract = {BACKGROUND: The hemoglobin threshold at which postoperative red-cell transfusion is warranted is controversial. We conducted a randomized trial to determine whether a higher threshold for blood transfusion would improve recovery in patients who had undergone surgery for hip fracture.
METHODS: We enrolled 2016 patients who were 50 years of age or older, who had either a history of or risk factors for cardiovascular disease, and whose hemoglobin level was below 10 g per deciliter after hip-fracture surgery. We randomly assigned patients to a liberal transfusion strategy (a hemoglobin threshold of 10 g per deciliter) or a restrictive transfusion strategy (symptoms of anemia or at physician discretion for a hemoglobin level of {\textless}8 g per deciliter). The primary outcome was death or an inability to walk across a room without human assistance on 60-day follow-up.
RESULTS: A median of 2 units of red cells were transfused in the liberal-strategy group and none in the restrictive-strategy group. The rates of the primary outcome were 35.2\% in the liberal-strategy group and 34.7\% in the restrictive-strategy group (odds ratio in the liberal-strategy group, 1.01; 95\% confidence interval [CI], 0.84 to 1.22), for an absolute risk difference of 0.5 percentage points (95\% CI, -3.7 to 4.7). The rates of in-hospital acute coronary syndrome or death were 4.3\% and 5.2\%, respectively (absolute risk difference, -0.9\%; 99\% CI, -3.3 to 1.6), and rates of death on 60-day follow-up were 7.6\% and 6.6\%, respectively (absolute risk difference, 1.0\%; 99\% CI, -1.9 to 4.0). The rates of other complications were similar in the two groups.
CONCLUSIONS: A liberal transfusion strategy, as compared with a restrictive strategy, did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk. (Funded by the National Heart, Lung, and Blood Institute; FOCUS ClinicalTrials.gov number, NCT00071032.).},
	language = {eng},
	number = {26},
	journal = {The New England Journal of Medicine},
	author = {Carson, Jeffrey L. and Terrin, Michael L. and Noveck, Helaine and Sanders, David W. and Chaitman, Bernard R. and Rhoads, George G. and Nemo, George and Dragert, Karen and Beaupre, Lauren and Hildebrand, Kevin and Macaulay, William and Lewis, Courtland and Cook, Donald Richard and Dobbin, Gwendolyn and Zakriya, Khwaja J. and Apple, Fred S. and Horney, Rebecca A. and Magaziner, Jay and {FOCUS Investigators}},
	month = dec,
	year = {2011},
	pmid = {22168590},
	pmcid = {PMC3268062},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Risk Factors, Aged, 80 and over, Postoperative Complications, Mortality, Surgery, Hip Fractures, Anemia, Hemoglobins, Blood Transfusion, Erythrocyte Transfusion, Wound Infection},
	pages = {2453--2462},
	file = {Carson et al_2011_Liberal or restrictive transfusion in high-risk patients after hip surgery.pdf:/Users/jcsal/Zotero/storage/C7E6V85R/Carson et al_2011_Liberal or restrictive transfusion in high-risk patients after hip surgery.pdf:application/pdf},
}

@article{waters966,
	title = {A {Different} {Perspective} on {Transfusion} {Requirements} in {Surgical} {Oncology} {Patients}},
	volume = {123},
	issn = {1528-1175},
	doi = {10.1097/ALN.0000000000000799},
	language = {eng},
	number = {4},
	journal = {Anesthesiology},
	author = {Waters, Jonathan H. and Triulzi, Darrell J. and Yazer, Mark H.},
	month = oct,
	year = {2015},
	pmid = {26372127},
	keywords = {Humans, Female, Male, Abdominal Neoplasms, Erythrocyte Transfusion, SurgOnc},
	pages = {966--967},
}

@article{xue967,
	title = {Association of {Postoperative} {Transfusion} {Strategy} with {Short}-term {Outcomes} in {Surgical} {Oncology} {Patients}},
	volume = {123},
	issn = {1528-1175},
	doi = {10.1097/ALN.0000000000000800},
	language = {eng},
	number = {4},
	journal = {Anesthesiology},
	author = {Xue, Fu-Shan and Liu, Gao-Pu and Li, Rui-Ping},
	month = oct,
	year = {2015},
	pmid = {26372128},
	keywords = {Humans, Female, Male, Abdominal Neoplasms, Erythrocyte Transfusion, SurgOnc},
	pages = {967--968},
}

@article{hall970,
	title = {Transfusion {Threshold} {Trials}: {The} {Need} to {Establish} a {Clear} {Difference} in {Transfusion} {Practice} between {Study} {Groups}},
	volume = {123},
	issn = {1528-1175},
	shorttitle = {Transfusion {Threshold} {Trials}},
	doi = {10.1097/ALN.0000000000000802},
	language = {eng},
	number = {4},
	journal = {Anesthesiology},
	author = {Hall, Suzanne M. and Desborough, Michael J.},
	month = oct,
	year = {2015},
	pmid = {26372130},
	keywords = {Humans, Female, Male, Abdominal Neoplasms, Erythrocyte Transfusion, SurgOnc},
	pages = {970--971},
}

@article{vonheymann971,
	title = {Liberal {Transfusion} {Practice} or {Perioperative} {Treatment} of {Anemia} to {Avoid} {Transfusion}?},
	volume = {123},
	issn = {1528-1175},
	doi = {10.1097/ALN.0000000000000803},
	language = {eng},
	number = {4},
	journal = {Anesthesiology},
	author = {von Heymann, Christian and Rosenthal, Christoph and Sander, Michael and Balzer, Felix and Kraemer, Michael and Kaufner, Lutz},
	month = oct,
	year = {2015},
	pmid = {26372131},
	keywords = {Humans, Female, Male, Abdominal Neoplasms, Erythrocyte Transfusion, SurgOnc},
	pages = {971--973},
}

@article{vincent714,
	title = {Transfusion thresholds: the dangers of guidelines based on randomized controlled trials},
	volume = {46},
	issn = {1432-1238},
	shorttitle = {Transfusion thresholds},
	doi = {10.1007/s00134-019-05889-3},
	language = {eng},
	number = {4},
	journal = {Intensive Care Medicine},
	author = {Vincent, Jean-Louis},
	month = apr,
	year = {2020},
	pmid = {31912204},
	keywords = {Humans, Randomized Controlled Trials as Topic, Blood Transfusion, Erythrocyte Transfusion},
	pages = {714--716},
	file = {Vincent_2020_Transfusion thresholds.pdf:/Users/jcsal/Zotero/storage/TKK2S9RS/Vincent_2020_Transfusion thresholds.pdf:application/pdf},
}

@article{carsonCD002042,
	title = {Transfusion thresholds for guiding red blood cell transfusion},
	volume = {12},
	issn = {1469-493X},
	doi = {10.1002/14651858.CD002042.pub5},
	abstract = {BACKGROUND: The optimal haemoglobin threshold for use of red blood cell (RBC) transfusions in anaemic patients remains an active field of research. Blood is a scarce resource, and in some countries, transfusions are less safe than in others because of inadequate testing for viral pathogens. If a liberal transfusion policy does not improve clinical outcomes, or if it is equivalent, then adopting a more restrictive approach could be recognised as the standard of care.  OBJECTIVES: The aim of this review update was to compare 30-day mortality and other clinical outcomes for participants randomised to restrictive versus liberal red blood cell (RBC) transfusion thresholds (triggers) for all clinical conditions. The restrictive transfusion threshold uses a lower haemoglobin concentration as a threshold for transfusion (most commonly, 7.0 g/dL to 8.0 g/dL), and the liberal transfusion threshold uses a higher haemoglobin concentration as a threshold for transfusion (most commonly, 9.0 g/dL to 10.0 g/dL).
SEARCH METHODS: We identified trials through updated searches: CENTRAL (2020, Issue 11), MEDLINE (1946 to November 2020), Embase (1974 to November 2020), Transfusion Evidence Library (1950 to November 2020), Web of Science Conference Proceedings Citation Index (1990 to November 2020), and trial registries (November 2020). We  checked the reference lists of other published reviews and relevant papers to identify additional trials. We were aware of one trial identified in earlier searching that was in the process of being published (in February 2021), and we were able to include it before this review was finalised.
SELECTION CRITERIA: We included randomised trials of surgical or medical participants that recruited adults or children, or both. We excluded studies that focused on neonates. Eligible trials assigned intervention groups on the basis of different transfusion schedules or thresholds or 'triggers'. These thresholds would be defined by a haemoglobin (Hb) or haematocrit (Hct) concentration below which an RBC transfusion would be administered; the haemoglobin concentration remains the most commonly applied marker of the need for RBC transfusion in clinical practice. We included trials in which investigators had allocated participants to higher thresholds or more liberal transfusion strategies compared to more restrictive ones, which might include no transfusion. As in previous versions of this review, we did not exclude unregistered trials published after 2010 (as per the policy of the Cochrane Injuries Group, 2015), however, we did conduct analyses to consider the differential impact of results of trials for which prospective registration could not be confirmed.   DATA COLLECTION AND ANALYSIS: We identified trials for inclusion and extracted data using Cochrane methods. We pooled risk ratios of clinical outcomes across trials using a random-effects model. Two review authors independently extracted data and assessed risk of bias. We conducted predefined analyses by clinical subgroups. We defined participants randomly allocated to the lower transfusion threshold as being in the 'restrictive transfusion' group and those randomly allocated to the higher transfusion threshold as being in the 'liberal transfusion' group.
MAIN RESULTS: A total of 48 trials, involving data from 21,433 participants (at baseline), across a range of clinical contexts (e.g. orthopaedic, cardiac, or vascular surgery; critical care; acute blood loss (including gastrointestinal bleeding); acute coronary syndrome; cancer; leukaemia; haematological malignancies), met the eligibility criteria. The haemoglobin concentration used to define the restrictive transfusion group in most trials (36) was between 7.0 g/dL and 8.0 g/dL.  Most trials included only adults; three trials focused on children. The included studies were generally at low risk of bias for key domains including allocation concealment and incomplete outcome data. Restrictive transfusion strategies reduced the risk of receiving at least one RBC transfusion by 41\% across a broad range of clinical contexts (risk ratio (RR) 0.59, 95\% confidence interval (CI) 0.53 to 0.66; 42 studies, 20,057 participants; high-quality evidence), with a large amount of heterogeneity between trials (I² = 96\%). Overall, restrictive transfusion strategies did not increase or decrease the risk of 30-day mortality compared with liberal transfusion strategies (RR 0.99, 95\% CI 0.86 to 1.15; 31 studies, 16,729 participants; I² = 30\%; moderate-quality evidence) or any of the other outcomes assessed (i.e. cardiac events (low-quality evidence), myocardial infarction, stroke, thromboembolism (all high-quality evidence)). High-quality evidence shows that the liberal transfusion threshold did not affect the risk of infection (pneumonia, wound infection, or bacteraemia). Transfusion-specific reactions are uncommon and were inconsistently reported within trials. We noted less certainty in the strength of evidence to support the safety of restrictive transfusion thresholds for the following predefined clinical subgroups: myocardial infarction, vascular surgery, haematological malignancies, and chronic bone-marrow disorders.
AUTHORS' CONCLUSIONS: Transfusion at a restrictive haemoglobin concentration decreased the proportion of people exposed to RBC transfusion by 41\% across a broad range of clinical contexts. Across all trials, no evidence suggests that a restrictive transfusion strategy impacted 30-day mortality, mortality at other time points, or morbidity (i.e. cardiac events, myocardial infarction, stroke, pneumonia, thromboembolism, infection) compared with a liberal transfusion strategy. Despite including 17 more randomised trials (and 8846 participants), data remain insufficient to inform the safety of transfusion policies in important and selected clinical contexts, such as myocardial infarction, chronic cardiovascular disease, neurological injury or traumatic brain injury, stroke, thrombocytopenia, and cancer or haematological malignancies, including chronic bone marrow failure.  Further work is needed to improve our understanding of outcomes other than mortality. Most trials compared only two separate thresholds for haemoglobin concentration, which may not identify the actual optimal threshold for transfusion in a particular patient. Haemoglobin concentration may not be the most informative marker of the need for transfusion in individual patients with different degrees of physiological adaptation to anaemia. Notwithstanding these issues, overall findings provide good evidence that transfusions with allogeneic RBCs can be avoided in most patients with haemoglobin thresholds between the range of 7.0 g/dL and 8.0 g/dL. Some patient subgroups might benefit from RBCs to maintain higher haemoglobin concentrations; research efforts should focus on these clinical contexts.},
	language = {eng},
	journal = {The Cochrane Database of Systematic Reviews},
	author = {Carson, Jeffrey L. and Stanworth, Simon J. and Dennis, Jane A. and Trivella, Marialena and Roubinian, Nareg and Fergusson, Dean A. and Triulzi, Darrell and Dorée, Carolyn and Hébert, Paul C.},
	month = dec,
	year = {2021},
	pmid = {34932836},
	pmcid = {PMC8691808},
	keywords = {Humans, Prospective Studies, Randomized Controlled Trials as Topic, Anemia, Hemoglobins, Erythrocyte Transfusion, Hematocrit},
	pages = {CD002042},
}

@article{bergamin766,
	title = {Liberal {Versus} {Restrictive} {Transfusion} {Strategy} in {Critically} {Ill} {Oncologic} {Patients}: {The} {Transfusion} {Requirements} in {Critically} {Ill} {Oncologic} {Patients} {Randomized} {Controlled} {Trial}},
	volume = {45},
	issn = {1530-0293},
	shorttitle = {Liberal {Versus} {Restrictive} {Transfusion} {Strategy} in {Critically} {Ill} {Oncologic} {Patients}},
	doi = {10.1097/CCM.0000000000002283},
	abstract = {OBJECTIVE: To assess whether a restrictive strategy of RBC transfusion reduces 28-day mortality when compared with a liberal strategy in cancer patients with septic shock.
DESIGN: Single center, randomized, double-blind controlled trial.
SETTING: Teaching hospital.
PATIENTS: Adult cancer patients with septic shock in the first 6 hours of ICU admission.
INTERVENTIONS: Patients were randomized to the liberal (hemoglobin threshold, {\textless} 9 g/dL) or to the restrictive strategy (hemoglobin threshold, {\textless} 7 g/dL) of RBC transfusion during ICU stay.
MEASUREMENTS AND MAIN RESULTS: Patients were randomized to the liberal (n = 149) or to the restrictive transfusion strategy (n = 151) group. Patients in the liberal group received more RBC units than patients in the restrictive group (1 [0-3] vs 0 [0-2] unit; p {\textless} 0.001). At 28 days after randomization, mortality rate in the liberal group (primary endpoint of the study) was 45\% (67 patients) versus 56\% (84 patients) in the restrictive group (hazard ratio, 0.74; 95\% CI, 0.53-1.04; p = 0.08) with no differences in ICU and hospital length of stay. At 90 days after randomization, mortality rate in the liberal group was lower (59\% vs 70\%) than in the restrictive group (hazard ratio, 0.72; 95\% CI, 0.53-0.97; p = 0.03).
CONCLUSIONS: We observed a survival trend favoring a liberal transfusion strategy in patients with septic shock when compared with the restrictive strategy. These results went in the opposite direction of the a priori hypothesis and of other trials in the field and need to be confirmed.},
	language = {eng},
	number = {5},
	journal = {Critical Care Medicine},
	author = {Bergamin, Fabricio S. and Almeida, Juliano P. and Landoni, Giovanni and Galas, Filomena R. B. G. and Fukushima, Julia T. and Fominskiy, Evgeny and Park, Clarice H. L. and Osawa, Eduardo A. and Diz, Maria P. E. and Oliveira, Gisele Q. and Franco, Rafael A. and Nakamura, Rosana E. and Almeida, Elisangela M. and Abdala, Edson and Freire, Maristela P. and Filho, Roberto K. and Auler, Jose Otavio C. and Hajjar, Ludhmila A.},
	month = may,
	year = {2017},
	pmid = {28240687},
	keywords = {Humans, Aged, Female, Length of Stay, Middle Aged, Proportional Hazards Models, Time Factors, Neoplasms, Severity of Illness Index, Intensive Care Units, Double-Blind Method, Critical Care, Erythrocyte Transfusion, Blood, Critical Illness, Hospitals, University, Shock, Septic},
	pages = {766--773},
}

@article{fominskiy511,
	title = {Liberal transfusion strategy improves survival in perioperative but not in critically ill patients. {A} meta-analysis of randomised trials},
	volume = {115},
	issn = {1471-6771},
	doi = {10.1093/bja/aev317},
	abstract = {BACKGROUND: Guidelines support the use of a restrictive strategy in blood transfusion management in a variety of clinical settings. However, recent randomized controlled trials (RCTs) performed in the perioperative setting suggest a beneficial effect on survival of a liberal strategy. We aimed to assess the effect of liberal and restrictive blood transfusion strategies on mortality in perioperative and critically ill adult patients through a meta-analysis of RCTs.
METHODS: We searched PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, Transfusion Evidence Library, and Google Scholar up to 27 March 2015, for RCTs performed in perioperative or critically ill adult patients, receiving a restrictive or liberal transfusion strategy, and reporting all-cause mortality. We used a fixed or random-effects model to calculate the odds ratio (OR) and 95\% confidence interval (CI) for pooled data. We assessed heterogeneity using Cochrane's Q and I(2) tests. The primary outcome was all-cause mortality within 90-day follow-up.
RESULTS: Patients in the perioperative period receiving a liberal transfusion strategy had lower all-cause mortality when compared with patients allocated to receive a restrictive transfusion strategy (OR 0.81; 95\% CI 0.66‒1.00; P=0.05; I(2)=25\%; Number needed to treat=97) with 7552 patients randomized in 17 trials. There was no difference in mortality among critically ill patients receiving a liberal transfusion strategy when compared with the restrictive transfusion strategy (OR 1.10; 95\% CI 0.99‒1.23; P=0.07; I(2)=34\%) with 3469 patients randomized in 10 trials.
CONCLUSION: According to randomized published evidence, perioperative adult patients have an improved survival when receiving a liberal blood transfusion strategy.},
	language = {eng},
	number = {4},
	journal = {British Journal of Anaesthesia},
	author = {Fominskiy, E. and Putzu, A. and Monaco, F. and Scandroglio, A. M. and Karaskov, A. and Galas, F. R. B. G. and Hajjar, L. A. and Zangrillo, A. and Landoni, G.},
	month = oct,
	year = {2015},
	pmid = {26385661},
	keywords = {Humans, Treatment Outcome, Randomized Controlled Trials as Topic, Survival Analysis, Surgery, Perioperative Care, mortality, perioperative care, Critical Care, Blood Transfusion, Critical Illness, anesthesia, blood transfusion, critical illness},
	pages = {511--519},
	file = {Fominskiy et al_2015_Liberal transfusion strategy improves survival in perioperative but not in.pdf:/Users/jcsal/Zotero/storage/6RZAQ5TW/Fominskiy et al_2015_Liberal transfusion strategy improves survival in perioperative but not in.pdf:application/pdf},
}

@article{keeler214,
	title = {Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer},
	volume = {104},
	issn = {1365-2168},
	doi = {10.1002/bjs.10328},
	abstract = {BACKGROUND: Treatment of preoperative anaemia is recommended as part of patient blood management, aiming to minimize perioperative allogeneic red blood cell transfusion. No clear evidence exists outlining which treatment modality should be used in patients with colorectal cancer. The study aimed to compare the efficacy of preoperative intravenous and oral iron in reducing blood transfusion use in anaemic patients undergoing elective colorectal cancer surgery.
METHODS: Anaemic patients with non-metastatic colorectal adenocarcinoma were recruited at least 2 weeks before surgery and randomized to receive oral (ferrous sulphate) or intravenous (ferric carboxymaltose) iron. Perioperative changes in haemoglobin, ferritin, transferrin saturation and blood transfusion use were recorded until postoperative outpatient review.
RESULTS: Some 116 patients were included in the study. There was no difference in blood transfusion use from recruitment to trial completion in terms of either volume of blood administered (P = 0·841) or number of patients transfused (P = 0·470). Despite this, increases in haemoglobin after treatment were higher with intravenous iron (median 1·55 (i.q.r. 0·93-2·58) versus 0·50 (-0·13 to 1·33) g/dl; P {\textless} 0·001), which was associated with fewer anaemic patients at the time of surgery (75 versus 90 per cent; P = 0·048). Haemoglobin levels were thus higher at surgery after treatment with intravenous than with oral iron (mean 11·9 (95 per cent c.i. 11·5 to 12·3) versus 11·0 (10·6 to 11·4) g/dl respectively; P = 0·002), as were ferritin (P {\textless} 0·001) and transferrin saturation (P {\textless} 0·001) levels.
CONCLUSION: Intravenous iron did not reduce the blood transfusion requirement but was more effective than oral iron at treating preoperative anaemia and iron deficiency in patients undergoing colorectal cancer surgery.},
	language = {eng},
	number = {3},
	journal = {The British Journal of Surgery},
	author = {Keeler, B. D. and Simpson, J. A. and Ng, O. and Padmanabhan, H. and Brookes, M. J. and Acheson, A. G. and {IVICA Trial Group}},
	month = feb,
	year = {2017},
	pmid = {28092401},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Follow-Up Studies, Prospective Studies, Aged, 80 and over, Adult, Adenocarcinoma, Postoperative Complications, Surgery, Administration, Oral, Preoperative Care, Elective Surgical Procedures, Injections, Intravenous, Erythrocyte Transfusion, Iron, Hematinics, Anemia, Iron-Deficiency, Ferric Compounds, Ferrous Compounds, Maltose},
	pages = {214--221},
}

@article{mueller983,
	title = {Patient {Blood} {Management}: {Recommendations} {From} the 2018 {Frankfurt} {Consensus} {Conference}},
	volume = {321},
	issn = {1538-3598},
	shorttitle = {Patient {Blood} {Management}},
	doi = {10.1001/jama.2019.0554},
	abstract = {IMPORTANCE: Blood transfusion is one of the most frequently used therapies worldwide and is associated with benefits, risks, and costs.
OBJECTIVE: To develop a set of evidence-based recommendations for patient blood management (PBM) and for research.
EVIDENCE REVIEW: The scientific committee developed 17 Population/Intervention/Comparison/Outcome (PICO) questions for red blood cell (RBC) transfusion in adult patients in 3 areas: preoperative anemia (3 questions), RBC transfusion thresholds (11 questions), and implementation of PBM programs (3 questions). These questions guided the literature search in 4 biomedical databases (MEDLINE, EMBASE, Cochrane Library, Transfusion Evidence Library), searched from inception to January 2018. Meta-analyses were conducted with the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology and the Evidence-to-Decision framework by 3 panels including clinical and scientific experts, nurses, patient representatives, and methodologists, to develop clinical recommendations during a consensus conference in Frankfurt/Main, Germany, in April 2018.
FINDINGS: From 17 607 literature citations associated with the 17 PICO questions, 145 studies, including 63 randomized clinical trials with 23 143 patients and 82 observational studies with more than 4 million patients, were analyzed. For preoperative anemia, 4 clinical and 3 research recommendations were developed, including the strong recommendation to detect and manage anemia sufficiently early before major elective surgery. For RBC transfusion thresholds, 4 clinical and 6 research recommendations were developed, including 2 strong clinical recommendations for critically ill but clinically stable intensive care patients with or without septic shock (recommended threshold for RBC transfusion, hemoglobin concentration {\textless}7 g/dL) as well as for patients undergoing cardiac surgery (recommended threshold for RBC transfusion, hemoglobin concentration {\textless}7.5 g/dL). For implementation of PBM programs, 2 clinical and 3 research recommendations were developed, including recommendations to implement comprehensive PBM programs and to use electronic decision support systems (both conditional recommendations) to improve appropriate RBC utilization.
CONCLUSIONS AND RELEVANCE: The 2018 PBM International Consensus Conference defined the current status of the PBM evidence base for practice and research purposes and established 10 clinical recommendations and 12 research recommendations for preoperative anemia, RBC transfusion thresholds for adults, and implementation of PBM programs. The relative paucity of strong evidence to answer many of the PICO questions supports the need for additional research and an international consensus for accepted definitions and hemoglobin thresholds, as well as clinically meaningful end points for multicenter trials.},
	language = {eng},
	number = {10},
	journal = {JAMA},
	author = {Mueller, Markus M. and Van Remoortel, Hans and Meybohm, Patrick and Aranko, Kari and Aubron, Cécile and Burger, Reinhard and Carson, Jeffrey L. and Cichutek, Klaus and De Buck, Emmy and Devine, Dana and Fergusson, Dean and Folléa, Gilles and French, Craig and Frey, Kathrine P. and Gammon, Richard and Levy, Jerrold H. and Murphy, Michael F. and Ozier, Yves and Pavenski, Katerina and So-Osman, Cynthia and Tiberghien, Pierre and Volmink, Jimmy and Waters, Jonathan H. and Wood, Erica M. and Seifried, Erhard and {ICC PBM Frankfurt 2018 Group}},
	month = mar,
	year = {2019},
	pmid = {30860564},
	keywords = {Humans, Preoperative Care, Guidelines, Hip Fractures, Blood Loss, Surgical, Critical Care, Anemia, Hemoglobins, Blood Transfusion, Erythrocyte Transfusion, Iron, Hematinics, Anemia, Iron-Deficiency, Cardiac Surgical Procedures, Gastrointestinal Hemorrhage},
	pages = {983--997},
}

@article{munoz233,
	title = {International consensus statement on the peri-operative management of anaemia and iron deficiency},
	volume = {72},
	issn = {1365-2044},
	doi = {10.1111/anae.13773},
	abstract = {Despite current recommendations on the management of pre-operative anaemia, there is no pragmatic guidance for the diagnosis and management of anaemia and iron deficiency in surgical patients. A number of experienced researchers and clinicians took part in an expert workshop and developed the following consensus statement. After presentation of our own research data and local policies and procedures, appropriate relevant literature was reviewed and discussed. We developed a series of best-practice and evidence-based statements to advise on patient care with respect to anaemia and iron deficiency in the peri-operative period. These statements include: a diagnostic approach for anaemia and iron deficiency in surgical patients; identification of patients appropriate for treatment; and advice on practical management and follow-up. We urge anaesthetists and peri-operative physicians to embrace these recommendations, and hospital administrators to enable implementation of these concepts by allocating adequate resources.},
	language = {eng},
	number = {2},
	journal = {Anaesthesia},
	author = {Muñoz, M. and Acheson, A. G. and Auerbach, M. and Besser, M. and Habler, O. and Kehlet, H. and Liumbruno, G. M. and Lasocki, S. and Meybohm, P. and Rao Baikady, R. and Richards, T. and Shander, A. and So-Osman, C. and Spahn, D. R. and Klein, A. A.},
	month = feb,
	year = {2017},
	pmid = {27996086},
	keywords = {Humans, Perioperative Care, Health Care Costs, Guidelines, Injections, Intravenous, Anemia, Iron, anaemia, Consensus, iron, Iron Deficiencies, pre-operative assessment, transfusion},
	pages = {233--247},
	file = {Muñoz et al_2017_International consensus statement on the peri-operative management of anaemia.pdf:/Users/jcsal/Zotero/storage/XMZNS5GQ/Muñoz et al_2017_International consensus statement on the peri-operative management of anaemia.pdf:application/pdf},
}

@article{spahn2201,
	title = {Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial},
	volume = {393},
	issn = {1474-547X},
	shorttitle = {Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery},
	doi = {10.1016/S0140-6736(18)32555-8},
	abstract = {BACKGROUND: Anaemia and iron deficiency are frequent in patients scheduled for cardiac surgery. This study assessed whether immediate preoperative treatment could result in reduced perioperative red blood cell (RBC) transfusions and improved outcome.
METHODS: In this single-centre, randomised, double-blind, parallel-group controlled study, patients undergoing elective cardiac surgery with anaemia (n=253; haemoglobin concentration (Hb) {\textless}120 g/L in women and Hb {\textless}130 g/L in men) or isolated iron deficiency (n=252; ferritin {\textless}100 mcg/L, no anaemia) were enrolled. Participants were randomly assigned (1:1) with the use of a computer-generated range minimisation (allocation probability 0·8) to receive either placebo or combination treatment consisting of a slow infusion of 20 mg/kg ferric carboxymaltose, 40 000 U subcutaneous erythropoietin alpha, 1 mg subcutaneous vitamin B12, and 5 mg oral folic acid or placebo on the day before surgery. Primary outcome was the number of RBC transfusions during the first 7 days. This trial is registered with ClinicalTrials.gov, number NCT02031289.
FINDINGS: Between Jan 9, 2014, and July 19, 2017, 1006 patients were enrolled; 505 with anaemia or isolated iron deficiency and 501 in the registry. The combination treatment significantly reduced RBC transfusions from a median of one unit in the placebo group (IQR 0-3) to zero units in the treatment group (0-2, during the first 7 days (odds ratio 0·70 [95\% CI 0·50-0·98] for each threshold of number of RBC transfusions, p=0·036) and until postoperative day 90 (p=0·018). Despite fewer RBC units transfused, patients in the treatment group had a higher haemoglobin concentration, higher reticulocyte count, and a higher reticulocyte haemoglobin content during the first 7 days (p≤0·001). Combined allogeneic transfusions were less in the treatment group (0 [IQR 0-2]) versus the placebo group (1 [0-3]) during the first 7 days (p=0·038) and until postoperative day 90 (p=0·019). 73 (30\%) serious adverse events were reported in the treatment group group versus 79 (33\%) in the placebo group.
INTERPRETATION: An ultra-short-term combination treatment with intravenous iron, subcutaneous erythropoietin alpha, vitamin B12, and oral folic acid reduced RBC and total allogeneic blood product transfusions in patients with preoperative anaemia or isolated iron deficiency undergoing elective cardiac surgery.
FUNDING: Vifor Pharma and Swiss Foundation for Anaesthesia Research.},
	language = {eng},
	number = {10187},
	journal = {Lancet (London, England)},
	author = {Spahn, Donat R. and Schoenrath, Felix and Spahn, Gabriela H. and Seifert, Burkhardt and Stein, Philipp and Theusinger, Oliver M. and Kaserer, Alexander and Hegemann, Inga and Hofmann, Axel and Maisano, Francesco and Falk, Volkmar},
	month = jun,
	year = {2019},
	pmid = {31036337},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Time Factors, Aged, 80 and over, Heart Diseases, Surgery, Administration, Oral, Preoperative Care, Double-Blind Method, Administration, Intravenous, Drug Therapy, Combination, Erythrocyte Transfusion, Iron, Erythropoietin, Anemia, Iron-Deficiency, Ferric Compounds, Maltose, Cardiac Surgical Procedures, Folic Acid, Vitamin B 12},
	pages = {2201--2212},
}

@article{blum293,
	title = {The impact of intravenous iron supplementation in elderly patients undergoing major surgery},
	volume = {22},
	issn = {1471-2318},
	doi = {10.1186/s12877-022-02983-y},
	abstract = {BACKGROUND: Age and preoperative anaemia are risk factors for poor surgical outcome and blood transfusion. The aim of this study was to examine the effect of iron supplementation in iron-deficient (ID) elderly patients undergoing major surgery.
METHOD: In this single-centre observational study, patients ≥ 65 years undergoing major surgery were screened for anaemia and ID. Patients were assigned to the following groups: A- (no anaemia); A-,ID+,T+ (no anaemia, iron-deficient, intravenous iron supplementation); A+ (anaemia); and A+,ID+,T+ (anaemia, iron-deficient, intravenous iron supplementation).
RESULTS: Of 4,381 patients screened at the anaemia walk-in clinic, 2,381 (54\%) patients were ≥ 65 years old and 2,191 cases were included in analysis. The ID prevalence was 63\% in patients with haemoglobin (Hb) {\textless} 8 g/dl, 47.2\% in patients with Hb from 8.0 to 8.9 g/dl, and 44.3\% in patients with Hb from 9 to 9.9 g/dl. In severely anaemic patients, an Hb increase of 0.6 (0.4; 1.2) and 1.2 (0.7; 1.6) g/dl was detected with iron supplementation 6-10 and {\textgreater} 10 days before surgery, respectively. Hb increased by 0 (-0.1; 0) g/dl with iron supplementation 1-5 days before surgery, 0.2 (-0.1; 0.5) g/dl with iron supplementation 6-10 days before surgery, and 0.2 (-0.2; 1.1) g/dl with supplementation {\textgreater} 10 days before surgery (p {\textless} 0.001 for 1-5 vs. 6-10 days). Overall, 58\% of A+,ID+,T+ patients showed an Hb increase of {\textgreater} 0.5 g/dl. The number of transfused red blood cell units was significantly lower in patients supplemented with iron (0 (0; 3)) compared to non-treated anaemic patients (1 (0; 4)) (p = 0.03). Patients with iron supplementation {\textgreater} 6 days before surgery achieved mobility 2 days earlier than patients with iron supplementation {\textless} 6 days.
CONCLUSIONS: Intravenous iron supplementation increases Hb level and thereby reduces blood transfusion rate in elderly surgical patients with ID anaemia.},
	language = {eng},
	number = {1},
	journal = {BMC geriatrics},
	author = {Blum, Lea Valeska and Zierentz, Philipp and Hof, Lotta and Kloka, Jan Andreas and Messroghli, Leila and Zacharowski, Kai and Meybohm, Patrick and Choorapoikayil, Suma},
	month = apr,
	year = {2022},
	pmid = {35392839},
	pmcid = {PMC8988356},
	keywords = {Humans, Aged, Surgery, Dietary Supplements, Elderly, Anemia, Hemoglobins, Erythrocyte Transfusion, Iron, Intravenous iron, Geriatric patients, Iron deficiency, Patient care},
	pages = {293},
	file = {Blum et al_2022_The impact of intravenous iron supplementation in elderly patients undergoing.pdf:/Users/jcsal/Zotero/storage/4XYN927K/Blum et al_2022_The impact of intravenous iron supplementation in elderly patients undergoing.pdf:application/pdf},
}

@article{jensen32,
	title = {{GLIM} {Criteria} for the {Diagnosis} of {Malnutrition}: {A} {Consensus} {Report} {From} the {Global} {Clinical} {Nutrition} {Community}},
	volume = {43},
	issn = {1941-2444},
	shorttitle = {{GLIM} {Criteria} for the {Diagnosis} of {Malnutrition}},
	doi = {10.1002/jpen.1440},
	abstract = {BACKGROUND: This initiative aims to build a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings.
METHODS: The Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications.
RESULTS: A 2-step approach for the malnutrition diagnosis was selected, that is, first screening to identify at risk status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among GLIM participants that selected 3 phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and 2 etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least 1 phenotypic criterion and 1 etiologic criterion should be present. Phenotypic metrics for grading severity are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories.
CONCLUSIONS: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The construct should be re-considered every 3-5 years.},
	language = {eng},
	number = {1},
	journal = {JPEN. Journal of parenteral and enteral nutrition},
	author = {Jensen, Gordon L. and Cederholm, Tommy and Correia, M. Isabel T. D. and Gonzalez, M. Christina and Fukushima, Ryoji and Higashiguchi, Takashi and de Baptista, Gertrudis Adrianza and Barazzoni, Rocco and Blaauw, Renée and Coats, Andrew J. S. and Crivelli, Adriana and Evans, David C. and Gramlich, Leah and Fuchs-Tarlovsky, Vanessa and Keller, Heather and Llido, Luisito and Malone, Ainsley and Mogensen, Kris M. and Morley, John E. and Muscaritoli, Maurizio and Nyulasi, Ibolya and Pirlich, Matthias and Pisprasert, Veeradej and de van der Schueren, Marian and Siltharm, Soranit and Singer, Pierre and Tappenden, Kelly A. and Velasco, Nicolas and Waitzberg, Dan L. and Yamwong, Preyanuj and Yu, Jianchun and Compher, Charlene and Van Gossum, Andre},
	month = jan,
	year = {2019},
	pmid = {30175461},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Cachexia, Weight Loss, Muscles, Adult, Nutrition Assessment, Malnutrition, Nutritional Status, malnutrition, Phenotype, Mass Screening, Practice Guidelines as Topic, Societies, Scientific, Consensus, assessment, diagnosis, Leadership, screening, GLIM},
	pages = {32--40},
	file = {Jensen et al_2019_GLIM Criteria for the Diagnosis of Malnutrition.pdf:/Users/jcsal/Zotero/storage/BWFUQQV2/Jensen et al_2019_GLIM Criteria for the Diagnosis of Malnutrition.pdf:application/pdf},
}

@article{friedM146,
	title = {Frailty in older adults: evidence for a phenotype},
	volume = {56},
	issn = {1079-5006},
	shorttitle = {Frailty in older adults},
	doi = {10.1093/gerona/56.3.m146},
	abstract = {BACKGROUND: Frailty is considered highly prevalent in old age and to confer high risk for falls, disability, hospitalization, and mortality. Frailty has been considered synonymous with disability, comorbidity, and other characteristics, but it is recognized that it may have a biologic basis and be a distinct clinical syndrome. A standardized definition has not yet been established.
METHODS: To develop and operationalize a phenotype of frailty in older adults and assess concurrent and predictive validity, the study used data from the Cardiovascular Health Study. Participants were 5,317 men and women 65 years and older (4,735 from an original cohort recruited in 1989-90 and 582 from an African American cohort recruited in 1992-93). Both cohorts received almost identical baseline evaluations and 7 and 4 years of follow-up, respectively, with annual examinations and surveillance for outcomes including incident disease, hospitalization, falls, disability, and mortality.
RESULTS: Frailty was defined as a clinical syndrome in which three or more of the following criteria were present: unintentional weight loss (10 lbs in past year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity. The overall prevalence of frailty in this community-dwelling population was 6.9\%; it increased with age and was greater in women than men. Four-year incidence was 7.2\%. Frailty was associated with being African American, having lower education and income, poorer health, and having higher rates of comorbid chronic diseases and disability. There was overlap, but not concordance, in the cooccurrence of frailty, comorbidity, and disability. This frailty phenotype was independently predictive (over 3 years) of incident falls, worsening mobility or ADL disability, hospitalization, and death, with hazard ratios ranging from 1.82 to 4.46, unadjusted, and 1.29-2.24, adjusted for a number of health, disease, and social characteristics predictive of 5-year mortality. Intermediate frailty status, as indicated by the presence of one or two criteria, showed intermediate risk of these outcomes as well as increased risk of becoming frail over 3-4 years of follow-up (odds ratios for incident frailty = 4.51 unadjusted and 2.63 adjusted for covariates, compared to those with no frailty criteria at baseline).
CONCLUSIONS: This study provides a potential standardized definition for frailty in community-dwelling older adults and offers concurrent and predictive validity for the definition. It also finds that there is an intermediate stage identifying those at high risk of frailty. Finally, it provides evidence that frailty is not synonymous with either comorbidity or disability, but comorbidity is an etiologic risk factor for, and disability is an outcome of, frailty. This provides a potential basis for clinical assessment for those who are frail or at risk, and for future research to develop interventions for frailty based on a standardized ascertainment of frailty.},
	language = {eng},
	number = {3},
	journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
	author = {Fried, L. P. and Tangen, C. M. and Walston, J. and Newman, A. B. and Hirsch, C. and Gottdiener, J. and Seeman, T. and Tracy, R. and Kop, W. J. and Burke, G. and McBurnie, M. A. and {Cardiovascular Health Study Collaborative Research Group}},
	month = mar,
	year = {2001},
	pmid = {11253156},
	keywords = {Humans, Aged, Female, Male, Prevalence, Sarcopenia, Cohort Studies, Weight Loss, Aged, 80 and over, United States, Incidence, Sex Distribution, Phenotype, Frail Elderly, Disabled Persons, Fatigue, Muscle Weakness, Grip},
	pages = {M146--156},
	file = {Fried et al_2001_Frailty in older adults.pdf:/Users/jcsal/Zotero/storage/GZXJR3JC/Fried et al_2001_Frailty in older adults.pdf:application/pdf},
}

@article{lauretani1851,
	title = {Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia},
	volume = {95},
	issn = {8750-7587},
	shorttitle = {Age-associated changes in skeletal muscles and their effect on mobility},
	doi = {10.1152/japplphysiol.00246.2003},
	abstract = {Sarcopenia, the reduction of muscle mass and strength that occurs with aging, is widely considered one of the major causes of disability in older persons. Surprisingly, criteria that may help a clinician to identify persons with impaired muscle function are still lacking. Using data from a large representative sample of the general population, we examined how muscle function and calf muscle area change with aging and affect mobility in men and women free of neurological conditions. We tested several putative indicators of sarcopenia, including knee extension isometric torque, handgrip, lower extremity muscle power, and calf muscle area. For each indicator, sarcopenia was considered to be present when the measure was {\textgreater}2 SDs below the mean. For all four measures, the prevalence of sarcopenia increased with age, both in men and women. The age-associated gradient in prevalence was maximum for muscle power and minimum for calf-muscle area. However, lower extremity muscle power was no better than knee-extension torque or handgrip in the early identification of poor mobility, defined either as walking speed {\textless}0.8 m/s or inability to walk at least 1 km without difficulty and without developing symptoms. Optimal cutoff values that can be used in the clinical practice to identify older persons with poor mobility were developed. The findings of the study lay the basis for a cost-effective, clinical marker of sarcopenia based on a measure of isometric handgrip strength. Our findings should be verified in a longitudinal study.},
	language = {eng},
	number = {5},
	journal = {Journal of Applied Physiology (Bethesda, Md.: 1985)},
	author = {Lauretani, Fulvio and Russo, Cosimo Roberto and Bandinelli, Stefania and Bartali, Benedetta and Cavazzini, Chiara and Di Iorio, Angelo and Corsi, Anna Maria and Rantanen, Taina and Guralnik, Jack M. and Ferrucci, Luigi},
	month = nov,
	year = {2003},
	pmid = {14555665},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Muscular Atrophy, Aged, 80 and over, Adult, Sex Distribution, Age Distribution, Aging, Walking, Grip, Hand Strength, Muscle Contraction, Torque},
	pages = {1851--1860},
}

@article{linden1794,
	title = {Drain {Amylase}: {A} {Simple} and {Versatile} {Method} of {Detecting} {Esophageal} {Anastomotic} {Leaks}},
	volume = {113},
	issn = {1552-6259},
	shorttitle = {Drain {Amylase}},
	doi = {10.1016/j.athoracsur.2021.07.062},
	abstract = {BACKGROUND: Anastomotic leak after esophagectomy is a significant cause of morbidity. Perianastomotic drain amylase is accurate in detecting leaks, but it is unclear whether its accuracy is affected by comorbid conditions, anastomotic method, or anastomotic location. We hypothesized that drain amylase would accurately discriminate leak in a variety of settings.
METHODS: We reviewed 290 consecutive patients undergoing esophagectomy with gastric conduit reconstruction. Patient comorbidities, operative variables, and drain amylase were collected. The diagnosis of a leak was based on the level of intervention required, and was characterized as clinically significant if it required wound opening or endoscopic or surgical intervention. Receiver-operating characteristic curves analysis was performed to determine the accuracy of amylase to detect leak for each patient variable.
RESULTS: A total of 53 (18.3\%) of 290 esophagectomies had an anastomotic leak, of which 33 (11.4\%) of 290 were clinically significant. Drain amylase was a strong predictor of anastomotic leak on postoperative day (POD) 3 to POD 7, regardless of patient comorbidities, location of anastomosis, or technique of anastomosis, but was less accurate in the diagnosis of leak in current smokers (area under the receiver-operating characteristic curve, 0.530 vs 0.752; P = .006). A maximum drain amylase value no higher than 35 on POD 3, POD 4, or POD 5 was 88\% sensitive in detecting leak at any point postoperatively. A value greater than or equal to 150 was 88\% specific in diagnosing leak.
CONCLUSIONS: Drain amylase is a versatile method for early detection of anastomotic leaks. Its accuracy is unaffected by neoadjuvant treatment, location or type of anastomosis, or patient comorbidities but may be less accurate in active smokers.},
	language = {eng},
	number = {6},
	journal = {The Annals of Thoracic Surgery},
	author = {Linden, Philip A. and Towe, Christopher W. and Worrell, Stephanie G. and Jiang, Boxiang and Ho, Vanessa P. and Argote-Greene, Luis and Bachman, Katelynn and Perry, Yaron},
	month = jun,
	year = {2022},
	pmid = {34437855},
	pmcid = {PMC8863952},
	keywords = {Humans, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Anastomotic Leak, Anastomosis, Surgical, Drainage, Amylases},
	pages = {1794--1800},
	file = {Linden et al_2022_Drain Amylase.pdf:/Users/jcsal/Zotero/storage/J5BFW7WU/Linden et al_2022_Drain Amylase.pdf:application/pdf},
}

@article{javeri624,
	title = {Influence of the baseline {18F}-fluoro-2-deoxy-{D}-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation},
	volume = {115},
	issn = {0008-543X},
	doi = {10.1002/cncr.24056},
	abstract = {BACKGROUND: In patients with esophageal cancer who receive chemoradiation, tools to predict/prognosticate outcome before administering therapy are lacking. The authors evaluated initial standardized unit value (iSUV) of 18F-fluoro-2-deoxy-D-glucose positron emission tomography and its association with overall survival and the degree of pathologic response after surgery.
METHODS: The authors analyzed 161 patients with esophageal adenocarcinoma who had chemoradiation followed by surgery. The log-rank test, univariate Cox proportional hazards model, Kaplan-Meier survival plot, and Fisher exact test were used to analyze dichotomized iSUV and its association with overall survival and pathologic response.
RESULTS: The median age of 161 patients was 61 years (range, 26-80 years) and the majority of patients had lower esophageal or gastroesophageal junction involvement. All patients received fluoropyrimidine and, most commonly, a taxane or platinum compound with concomitant radiation. The median radiation dose was 45 grays (Gy) (range, 45 Gy-50.4 Gy). The median iSUV for all patients was 10.1 (range, 0-58). Using the Fisher exact test, iSUV was not found to be associated with the location of the primary cancer. iSUV higher than the median (10.1) was associated with a better pathologic response (P = .06). Patients with primary cancer with iSUV {\textgreater}10.1 had a lower risk for death (hazards ratio of 0.56) compared with those with iSUV {\textless} or = 10.1. Higher iSUV was nonsignificantly associated with improved survival (P = .07).
CONCLUSIONS: Data from the current study suggest that lower iSUV is associated with poor survival and lower probability of response to chemoradiation. iSUV needs to be further evaluated because it may be used to complement other imaging or biomarker assessments to individualize therapy.},
	language = {eng},
	number = {3},
	journal = {Cancer},
	author = {Javeri, Heta and Xiao, Lianchun and Rohren, Eric and Komaki, Ritsuko and Hofstetter, Wayne and Lee, Jeffrey H. and Maru, Dipen and Bhutani, Manoop S. and Swisher, Stephen G. and Wang, Xuemei and Ajani, Jaffer A.},
	month = feb,
	year = {2009},
	pmid = {19130466},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Survival Rate, Antineoplastic Agents, Prognosis, Aged, 80 and over, Adult, Predictive Value of Tests, Outcome Assessment, Health Care, Adenocarcinoma, Esophageal Neoplasms, Fluorodeoxyglucose F18, Combined Modality Therapy, Neoplasm, Residual, Positron-Emission Tomography, PET, CHemoRT},
	pages = {624--630},
}

@article{suzuki2854,
	title = {Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation},
	volume = {24},
	issn = {1569-8041},
	doi = {10.1093/annonc/mdt340},
	abstract = {BACKGROUND: Patients with localized esophageal adenocarcinoma (EAC) who achieve a clinical complete response (clinCR) after preoperative chemoradiation (trimodality therapy; TMT) or definitive chemoradiation (bimodality therapy; BMT) live longer than those who achieve a {\textless}clinCR (Suzuki A, Xiao LC, Hayashi Y et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011; 117: 4823-4833; Cheedella NK, Suzuki A, Xiao L et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 2013; 24: 1262-1266; Ajani JA, Correa AM, Hofstetter WL et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012; 23: 2638-2642). We hypothesized that the initial standardized uptake value (iSUV) of positron emission tomography will define novel subsets of clinCR patients.
METHODS: We analyzed 323 EAC patients, from our prospective database, who achieved a clinCR. Various statistical methods were used to assess the influence of iSUV on patient outcome.
RESULTS: The median follow-up of 323 patients was 40.8 months [95\% confidence interval (CI) 35.6-47.3 months]. Two hundred six (63.8\%) patients had TMT and 117 (36.2\%) had BMT. If iSUV was ≥6, TMT patients had a longer median OS (94.8 months; 95\% CI 66.07-NA) than BMT patients (31.4 months; 95\% CI 21.7-42.1; P ≤ 0.001). However, if iSUV was {\textless}6, the median OS of TMT and BMT patients was similar (P = 0.62). iSVU did not influence the pathologic complete response rate in TMT patients (P = 0.85).
CONCLUSION: clinCR patients with iSUV of {\textless}6 are identified as a new subset that fared equally well when treated with TMT or BMT. Future esophageal preservation strategy may be best suited for this newly identified subset of EAC patients.},
	language = {eng},
	number = {11},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Suzuki, A. and Xiao, L. and Taketa, T. and Sudo, K. and Wadhwa, R. and Blum, M. A. and Skinner, H. and Komaki, R. and Weston, B. and Lee, J. H. and Bhutani, M. S. and Rice, D. C. and Maru, D. M. and Erasmus, J. and Swisher, S. G. and Hofstetter, W. L. and Ajani, J. A.},
	month = nov,
	year = {2013},
	pmid = {23994746},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Prospective Studies, Radiography, Prognosis, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Chemoradiotherapy, Combined Modality Therapy, Remission Induction, esophageal cancer, Positron-Emission Tomography, PET, chemoradiation, ChemoRT, clinical biology, imaging, organ preservation, subpopulations},
	pages = {2854--2859},
}

@article{ludwig1886,
	title = {Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia},
	volume = {24},
	issn = {1569-8041},
	doi = {10.1093/annonc/mdt118},
	abstract = {BACKGROUND: Only limited data on the prevalence of iron deficiency (ID) and its correlation with clinical parameters are available in cancer. ID frequently contributes to the pathogenesis of anemia in patients with cancer and may lead to several symptoms such as impaired physical function, weakness and fatigue.
PATIENTS AND METHODS: Parameters of iron status and clinical parameters were evaluated in 1528 patients with cancer who presented consecutively within a four-month period at our center. One thousand fifty-three patients had solid tumors and 475 hematological malignancies.
RESULTS: ID [transferrin saturation (TSAT) {\textless} 20\%] was noted in 645 (42.6\%) of the 1513 patients with TSAT tests available and 500 (33.0\%) were anemic. ID rates were highest in pancreatic (63.2\%), colorectal (51.9\%) and lung cancers (50.7\%). Of the 409 iron-deficient patients in whom serum ferritin levels were available additionally to TSAT, 335 (81.9\%) presented with functional ID (FID) (TSAT {\textless} 20\%, serum ferritin ≥30 ng/ml) and 74 (18.1\%) with absolute ID. In patients with solid tumors, prevalence of ID correlated with cancer stage at diagnosis (P = 0.001), disease status (P = 0.001) and ECOG performance status (P = 0.005).
CONCLUSIONS: ID was frequently noted in cancer and was associated with advanced disease, close proximity to cancer therapy, and poor performance status in patients with solid tumors.},
	language = {eng},
	number = {7},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Ludwig, H. and Müldür, E. and Endler, G. and Hübl, W.},
	month = jul,
	year = {2013},
	pmid = {23567147},
	pmcid = {PMC3690908},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prevalence, Neoplasms, CRC, Aged, 80 and over, Adult, Young Adult, Severity of Illness Index, iron deficiency, Anemia, Iron-Deficiency, absolute iron deficiency, cancer-related anemia, chemotherapy-induced anemia, functional iron deficiency, iron deficiency anemia, Anemia Diagnosis},
	pages = {1886--1892},
	file = {Ludwig et al_2013_Prevalence of iron deficiency across different tumors and its association with.pdf:/Users/jcsal/Zotero/storage/RZRNQTK7/Ludwig et al_2013_Prevalence of iron deficiency across different tumors and its association with.pdf:application/pdf},
}

@article{auerbach1301,
	title = {Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial},
	volume = {22},
	issn = {0732-183X},
	shorttitle = {Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia},
	doi = {10.1200/JCO.2004.08.119},
	abstract = {PURPOSE: Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients.
METHODS: This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb {\textless}or= 105 g/L, serum ferritin {\textless}or= 450 pmol/L or {\textless}or= 675 pmol/L with transferrin saturation {\textless}or= 19\%) receiving subcutaneously rHuEPO 40000 U once weekly to: (1). no-iron; (2). oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI). Hb and quality of life (QOL) were measured at baseline and throughout.
RESULTS: All groups showed Hb (P {\textless}.0001) increases from baseline. Mean Hb increases for both IV iron groups were greater (P {\textless}.02) than for no-iron and oral iron groups. The percentage of patients with hematopoietic responses was higher (P {\textless}.01) in both IV iron groups (each case 68\%) compared with no-iron (25\%) and oral iron (36\%) groups. IV iron groups showed increases in energy, activity, and overall QOL from baseline, compared with a decrease in energy and activity for no-iron group and no change in activity or overall QOL for oral iron group.
CONCLUSION: rHuEPO increases Hb levels and improves QOL in patients with chemotherapy-related anemia. Magnitude of Hb increase and QOL improvement is significantly greater if IV iron is added.},
	language = {eng},
	number = {7},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Auerbach, Michael and Ballard, Harold and Trout, J. Richard and McIlwain, Marilyn and Ackerman, Alan and Bahrain, Huzefa and Balan, Stefan and Barker, Lance and Rana, Jeevindra},
	month = apr,
	year = {2004},
	pmid = {15051778},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Neoplasms, Antineoplastic Agents, Quality of Life, Administration, Oral, Cancer, Infusions, Intravenous, Anemia, Iron, Erythropoietin, Recombinant Proteins, Abnormalities, Drug-Induced, Iron-Dextran Complex},
	pages = {1301--1307},
}

@article{bastit1611,
	title = {Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia},
	volume = {26},
	issn = {1527-7755},
	doi = {10.1200/JCO.2006.10.4620},
	abstract = {PURPOSE: The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is controversial. This study was designed to evaluate the efficacy and safety of darbepoetin alpha given with IV iron versus with local standard practice (oral iron or no iron).
PATIENTS AND METHODS: In this multicenter, randomized, open-label, phase III study, 396 patients with nonmyeloid malignancies and hemoglobin (Hb) less than 11 g/dL received darbepoetin alpha 500 microg with (n = 200) or without (n = 196) IV iron once every 3 weeks (Q3W) for 16 weeks.
RESULTS: The hematopoietic response rate (proportion of patients achieving Hb {\textgreater}or= 12 g/dL or Hb increase of {\textgreater}or= 2 g/dL from baseline) was significantly higher in the IV iron group: 86\% versus 73\% in the standard practice group (difference of 13\% [95\% CI, 3\% to 23\%]; P = .011). Fewer RBC transfusions (week 5 to the end of the treatment period) occurred in the IV iron group: 9\% versus 20\% in the standard practice group (difference of -11\% [95\% CI, -18\% to -3\%]; P = .005). Both treatments were well tolerated with no notable differences in adverse events. Serious adverse events related to iron occurred in 3\% of patients in the IV iron group and were mostly gastrointestinal in nature.
CONCLUSION: Addition of IV iron to darbepoetin alpha Q3W in patients with chemotherapy-induced anemia was well tolerated, resulting in an improved hematopoietic response rate and lower incidence of transfusions compared with darbepoetin alpha alone.},
	language = {eng},
	number = {10},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Bastit, Laurent and Vandebroek, An and Altintas, Sevilay and Gaede, Bernd and Pintér, Tamás and Suto, Tamas S. and Mossman, Tony W. and Smith, Kay E. and Vansteenkiste, Johan F.},
	month = apr,
	year = {2008},
	pmid = {18375890},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Neoplasms, Antineoplastic Agents, Cancer, Infusions, Intravenous, Drug Therapy, Combination, Anemia, Iron, Erythropoietin, Hematinics, Darbepoetin alfa},
	pages = {1611--1618},
}

@article{luporsi225,
	title = {Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: {French} healthcare payer perspective},
	volume = {15},
	issn = {1941-837X},
	shorttitle = {Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion},
	doi = {10.3111/13696998.2011.639823},
	abstract = {OBJECTIVE: To evaluate the economic impact of intravenous iron (in the form of intravenous iron preparation of ferric carboxymaltose) in three different clinical settings of iron deficiency anemia: chemotherapy-induced anemia in breast cancer, chemotherapy-induced anemia in digestive cancer, and perioperative anemia in knee and hip surgery.
METHODS: The economic model compared the usual therapeutic strategies of anemia without intravenous iron and strategies including intravenous iron, in each of the three clinical settings selected. Costs related to anemia treatment by erythropoiesis-stimulating agents (ESA), blood transfusion, and intravenous iron were estimated and compared inside each setting. Cost savings were calculated from the French healthcare payer perspective. Data included in the economic model were obtained from scientific literature, public health agencies, and medical experts.
RESULTS: The most prominent annual cost savings were observed in chemotherapy-induced anemia in breast cancer (€997 and €360 per patient for metastatic and non-metastatic breast cancers, respectively; global cost saving, €33.6 million). This large impact of intravenous iron on costs was mainly explained by both a lower number of women treated and lower ESA dosing. Mean annual cost saving in digestive cancers and knee and hip surgery were estimated to €168 and €216 per patient and global cost savings of €7.5 and €12.1 million, respectively. Overall, annual cost savings in these three settings were estimated to €53 million including €39 million for ESA cost savings. Sensitivity analysis showed that strategies including intravenous iron remained cost-effective even with wide variations in the assumptions, particularly for cost savings on ESA.
LIMITATIONS: Economic model based on literature data and expert opinions.
CONCLUSIONS: The present economic model suggests that use of intravenous iron, according to recommendations of international guidelines, is cost saving, particularly in chemotherapy-induced anemia in breast cancers.},
	language = {eng},
	number = {2},
	journal = {Journal of Medical Economics},
	author = {Luporsi, Elisabeth and Mahi, Lamine and Morre, Camille and Wernli, Jorge and de Pouvourville, Gérard and Bugat, Roland},
	year = {2012},
	pmid = {22077267},
	keywords = {Humans, Female, Dose-Response Relationship, Drug, France, Anemia, Blood Transfusion, Iron, Hematinics, Erythropoiesis, Ferric Compounds, Maltose, Cost Savings, Costs and Cost Analysis, Models, Economic, EPO},
	pages = {225--232},
	file = {Luporsi et al_2012_Evaluation of cost savings with ferric carboxymaltose in anemia treatment.pdf:/Users/jcsal/Zotero/storage/L434LRFZ/Luporsi et al_2012_Evaluation of cost savings with ferric carboxymaltose in anemia treatment.pdf:application/pdf},
}

@article{tobllie0125528,
	title = {Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status},
	volume = {10},
	issn = {1932-6203},
	shorttitle = {Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose},
	doi = {10.1371/journal.pone.0125528},
	abstract = {BACKGROUND: Patients with non-dialysis-dependent chronic kidney disease (ND-CKD) often receive an erythropoiesis-stimulating agent (ESA) and oral iron treatment. This study evaluated whether a switch from oral iron to intravenous ferric carboxymaltose can reduce ESA requirements and improve iron status and hemoglobin in patients with ND-CKD.
METHODS: This prospective, single arm and single-center study included adult patients with ND-CKD (creatinine clearance ≤40 mL/min), hemoglobin 11-12 g/dL and iron deficiency (ferritin {\textless}100 μg/L or transferrin saturation {\textless}20\%), who were regularly treated with oral iron and ESA during 6 months prior to inclusion. Study patients received an intravenous ferric carboxymaltose dose of 1,000 mg iron, followed by a 6-months ESA/ ferric carboxymaltose maintenance regimen (target: hemoglobin 12 g/dL, transferrin saturation {\textgreater}20\%). Outcome measures were ESA dose requirements during the observation period after initial ferric carboxymaltose treatment (primary endpoint); number of hospitalizations and transfusions, renal function before and after ferric carboxymaltose administration, number of adverse reactions (secondary endpoints). Hemoglobin, mean corpuscular volume, ferritin and transferrin saturation were measured monthly from baseline until end of study. Creatinine clearance, proteinuria, C-reactive protein, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase bimonthly from baseline until end of study.
RESULTS: Thirty patients were enrolled (age 70.1±11.4 years; mean±SD). Mean ESA consumption was significantly reduced by 83.2±10.9\% (from 41,839±3,668 IU/patient to 6,879±4,271 IU/patient; p{\textless}0.01). Hemoglobin increased by 0.7±0.3 g/dL, ferritin by 196.0±38.7 μg/L and transferrin saturation by 5.3±2.9\% (month 6 vs. baseline; all p{\textless}0.01). No ferric carboxymaltose-related adverse events were reported and no patient withdrew or required transfusions during the study.
CONCLUSION: Among patients with ND-CKD and stable normal or borderline hemoglobin, switching from oral iron to intravenous ferric carboxymaltose was associated with significant improvements in hematological and iron parameters and a significant reduction in ESA dose requirements in this single-center pilot study.
TRIAL REGISTRATION: ClinicalTrials.gov NCT02232906.},
	language = {eng},
	number = {4},
	journal = {PloS One},
	author = {Toblli, Jorge Eduardo and Di Gennaro, Federico},
	year = {2015},
	pmid = {25928811},
	pmcid = {PMC4415953},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Aged, 80 and over, Administration, Oral, Administration, Intravenous, Hemoglobins, Iron, Erythropoiesis, Ferric Compounds, Maltose, Renal Insufficiency, Chronic, CRF},
	pages = {e0125528},
	file = {Toblli_Di Gennaro_2015_Switching patients with non-dialysis chronic kidney disease from oral iron to.pdf:/Users/jcsal/Zotero/storage/GM3XY87H/Toblli_Di Gennaro_2015_Switching patients with non-dialysis chronic kidney disease from oral iron to.pdf:application/pdf},
}

@article{petrelli179,
	title = {Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials},
	volume = {138},
	issn = {1432-1335},
	shorttitle = {Addition of iron to erythropoiesis-stimulating agents in cancer patients},
	doi = {10.1007/s00432-011-1072-3},
	abstract = {BACKGROUND: Iron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia.
METHODS: We performed a meta-analysis of randomized, controlled trials by comparing parenteral or oral iron and no iron, when added to ESAs in anemic cancer patients, in order to calculate the relative risk (RR) of hematopoietic response and transfusions, the time required to reach this response, and toxicity.
RESULTS: A total of 1,606 patients out of eight trials were available for meta-analysis. The RR of obtaining an hematopoietic response was 1.29 (P = 0.0001) with parenteral iron and 1.04 for oral iron (P = 0.59). The risk of transfusion was reduced with parenteral iron versus no iron (RR 0.77; P = 0.02) but not with oral iron (RR 0.68; P = 0.08). The time to reach hematopoietic response was 1 month shorter and no increased toxicity appeared with iron supplementation.
CONCLUSION: Overall parenteral iron reduces the risk of transfusions by 23\% and increases the chance of hematopoietic response by 29\% when compared with ESAs alone. On the contrary, oral iron does not increase hematopoietic response nor transfusion rate. The significance of these results is that the proportion of non-responders to ESAs will have strongly improved and quality of life and cost ameliorated.},
	language = {eng},
	number = {2},
	journal = {Journal of Cancer Research and Clinical Oncology},
	author = {Petrelli, Fausto and Borgonovo, Karen and Cabiddu, Mary and Lonati, Veronica and Barni, Sandro},
	month = feb,
	year = {2012},
	pmid = {21972052},
	keywords = {Humans, Neoplasms, Antineoplastic Agents, Randomized Controlled Trials as Topic, Anemia, Blood Transfusion, Iron, Hematinics},
	pages = {179--187},
}

@article{paireder478,
	title = {Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer},
	volume = {43},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2016.11.015},
	abstract = {BACKGROUND: Nutritional status and body composition parameters such as sarcopenia are important risk factors for impaired outcome in patients with esophageal cancer. This study was conducted to evaluate the effect of sarcopenia on long-term outcome after esophageal resection following neoadjuvant treatment.
METHODS: Skeletal muscle index (SMI) and body composition parameters were measured in patients receiving neoadjuvant treatment for locally advanced esophageal cancer. Endpoints included relapse-free survival (RFS) and overall survival (OS).
RESULTS: The study included 130 patients. Sarcopenia was found in 80 patients (61.5\%). Patients with squamous-cell cancer (SCC) showed a decreased median SMI of 48 (range 28.4-60.8) cm/m2 compared with that of patients with adenocarcinoma (AC) of 52 (range 34.4-74.2) cm/m2, P {\textless} 0.001. The presence of sarcopenia had a significant impact on patient outcome: HR 1.69 (1.04-2.75), P = 0.036. Median OS was 20.5 (7.36-33.64) versus 52.1 (13.55-90.65) months in sarcopenic and non-sarcopenic patients, respectively. Sarcopenia was identified as an independent risk factor: HR 1.72 (1.049-2.83), P = 0.032.
CONCLUSION: Our data provide evidence that sarcopenia impacts long-term outcome after esophageal resection in patients who have undergone neoadjuvant therapy. Assessment of the body composition parameter can be a reasonable part of patient selection and may influence treatment methods.},
	language = {eng},
	number = {2},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Paireder, M. and Asari, R. and Kristo, I. and Rieder, E. and Tamandl, D. and Ba-Ssalamah, A. and Schoppmann, S. F.},
	month = feb,
	year = {2017},
	pmid = {28024944},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Sarcopenia, Treatment Outcome, Risk Factors, Survival Rate, Adult, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Body composition parameter},
	pages = {478--484},
}

@article{tamandl1359,
	title = {Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer},
	volume = {26},
	issn = {1432-1084},
	doi = {10.1007/s00330-015-3963-1},
	abstract = {OBJECTIVES: To assess the impact of sarcopenia and alterations in body composition parameters (BCPs) on survival after surgery for oesophageal and gastro-oesophageal junction cancer (OC).
METHODS: 200 consecutive patients who underwent resection for OC between 2006 and 2013 were selected. Preoperative CTs were used to assess markers of sarcopenia and body composition (total muscle area [TMA], fat-free mass index [FFMi], fat mass index [FMi], subcutaneous, visceral and retrorenal fat [RRF], muscle attenuation). Cox regression was used to assess the primary outcome parameter of overall survival (OS) after surgery.
RESULTS: 130 patients (65\%) had sarcopenia based on preoperative CT examinations. Sarcopenic patients showed impaired survival compared to non-sarcopenic individuals (hazard ratio [HR] 1.87, 95\% confidence interval [CI] 1.15-3.03, p = 0.011). Furthermore, low skeletal muscle attenuation (HR 1.91, 95\% CI 1.12-3.28, p = 0.019) and increased FMi (HR 3.47, 95\% CI 1.27-9.50, p = 0.016) were associated with impaired outcome. In the multivariate analysis, including a composite score (CSS) of those three parameters and clinical variables, only CSS, T-stage and surgical resection margin remained significant predictors of OS.
CONCLUSION: Patients who show signs of sarcopenia and alterations in BCPs on preoperative CT images have impaired long-term outcome after surgery for OC.
KEY POINTS: • Sarcopenia is associated with impaired OS after surgery for oesophageal cancer. • Other body composition parameters are also associated with impaired survival. • This influence on survival is independent of established clinical parameters. • Sarcopenia provides a better estimation of cachexia than BMI. • Sarcopenia assessment could be considered in risk/benefit stratification before oesophagectomy.},
	language = {eng},
	number = {5},
	journal = {European Radiology},
	author = {Tamandl, Dietmar and Paireder, Matthias and Asari, Reza and Baltzer, Pascal A. and Schoppmann, Sebastian F. and Ba-Ssalamah, Ahmed},
	month = may,
	year = {2016},
	pmid = {26334504},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Treatment Outcome, Retrospective Studies, Proportional Hazards Models, Prognosis, Survival Analysis, Stomach Neoplasms, Esophageal Neoplasms, Esophagectomy, Oesophageal cancer, Esophagogastric Junction, Postoperative Complications, Esophagus, Computed tomography, Body composition measurements, Outcome analysis},
	pages = {1359--1367},
}

@article{tan333,
	title = {Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer},
	volume = {41},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2014.11.040},
	abstract = {BACKGROUND: Patients with potentially curative oesophago-gastric cancer typically undergo neo-adjuvant chemotherapy prior to surgery. The majority of anti-cancer drugs have a narrow therapeutic index. The aim of this study was to determine if features of body composition, assessed using computed tomography (CT) scans, may be predictive of dose-limiting toxicity (DLT) in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. The influence of sarcopenia and DLT on overall survival was also evaluated.
METHODS: 89 Patients having potentially curative oesophago-gastric cancer surgery were studied. Patients studied had histologically confirmed oesophago-gastric cancer with no evidence of distant metastasis on pre-operative staging. CT scan was performed in all cases at diagnosis. DLT was defined as toxicity leading to postponement of treatment, a drug dose reduction or definitive interruption of drug administration.
RESULTS: DLT occurred in 37 out of 89 patients (41.6\%) undergoing chemotherapy. Sarcopenia (odds ratio, 2.95; 95\% confidence interval, 1.23-7.09; p = 0.015) was associated with DLT on multivariate analysis. Median overall survival for patients who were sarcopenic was 569 days (IQ range: 357-1230 days) vs. 1013 days (IQ range: 496-1318 days) for patients who were not sarcopenic (p = 0.04). There was no significant difference in overall survival in patients who experienced DLT compared with those that did not (p = 0.665).
CONCLUSIONS: Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy. These results raise the potential for use of assessment of skeletal muscle mass using CT scans to predict toxicity and individualize chemotherapy dosing.},
	language = {eng},
	number = {3},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Tan, B. H. L. and Brammer, K. and Randhawa, N. and Welch, N. T. and Parsons, S. L. and James, E. J. and Catton, J. A.},
	month = mar,
	year = {2015},
	pmid = {25498359},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Sarcopenia, Antineoplastic Combined Chemotherapy Protocols, Prognosis, Body composition, Fluorouracil, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Esophagogastric Junction, Capecitabine, Deoxycytidine, Epirubicin, Chemotherapy toxicity, Oesophago-gastric cancer},
	pages = {333--338},
	file = {Tan - 2015 - Sarcopenia is associated with toxicity in patients.pdf:/Users/jcsal/Zotero/storage/BTD4W4ZT/Tan - 2015 - Sarcopenia is associated with toxicity in patients.pdf:application/pdf},
}

@article{mayanagi3741,
	title = {Negative {Impact} of {Skeletal} {Muscle} {Wasting} {After} {Neoadjuvant} {Chemotherapy} {Followed} by {Surgery} on {Survival} for {Patients} with {Thoracic} {Esophageal} {Cancer}},
	volume = {24},
	issn = {1534-4681},
	doi = {10.1245/s10434-017-6020-2},
	abstract = {BACKGROUND: Skeletal muscle wasting during curative treatment is an important issue faced by esophageal cancer patients. However, it has not been clarified whether skeletal muscle change during neoadjuvant chemotherapy followed by surgery adversely affects prognosis. This study aimed to determine the relation between skeletal muscle change and survival for patients with advanced esophageal cancer who underwent neoadjuvant chemotherapy followed by surgery.
METHODS: This study retrospectively analyzed 66 patients with thoracic esophageal cancer who had undergone neoadjuvant chemotherapy followed by esophagectomy. The study investigated the correlation between the change in the total muscle cross-sectional area at the third lumbar vertebra before and 4 months after surgery as well as the postoperative recurrence and overall survival (OS).
RESULTS: Of the 66 patients, 39 (59\%) showed a skeletal muscle decrease from baseline to 4 months after esophagectomy. The change in the skeletal muscle index from baseline to 4 months after surgery was -1.2 cm2/m2. Multivariable analysis showed that nonsquamous cell carcinoma subtype (hazard ratio [HR] 2.57; p = 0.029), pathologic stage (HR 5.73; p {\textless} 0.01), and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.16; p = 0.015) were the independent prognostic factors associated with worse OS. Additionally, pathologic stage (HR 6.03; p {\textless} 0.01) and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.11; p = 0.048) also were found to be independent prognostic factors associated with worse recurrence-free survival.
CONCLUSIONS: The study findings suggest that skeletal muscle wasting from baseline has a negative impact on cancer recurrence and survival.},
	language = {eng},
	number = {12},
	journal = {Annals of Surgical Oncology},
	author = {Mayanagi, Shuhei and Tsubosa, Yasuhiro and Omae, Katsuhiro and Niihara, Masahiro and Uchida, Tsuneyuki and Tsushima, Takahiro and Yokota, Tomoya and Sato, Hiroshi and Naito, Tateaki and Yasui, Hirofumi},
	month = nov,
	year = {2017},
	pmid = {28861809},
	pmcid = {PMC5658455},
	keywords = {Humans, Muscle, Skeletal, Female, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Thoracic Neoplasms},
	pages = {3741--3747},
	file = {Mayanagi et al_2017_Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy.pdf:/Users/jcsal/Zotero/storage/HQ97KUUU/Mayanagi et al_2017_Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy.pdf:application/pdf},
}

@article{grotenhuis2698,
	title = {Sarcopenia/{Muscle} {Mass} is not a {Prognostic} {Factor} for {Short}- and {Long}-{Term} {Outcome} {After} {Esophagectomy} for {Cancer}},
	volume = {40},
	issn = {1432-2323},
	doi = {10.1007/s00268-016-3603-1},
	abstract = {BACKGROUND: Recent studies have suggested that sarcopenia is a prognostic risk indicator of postoperative complications and predicts survival in cancer patients. The aim of this study is to investigate whether sarcopenia is associated with postoperative short-term outcome (morbidity and mortality) and long-term survival in patients undergoing esophagectomy for cancer after neoadjuvant chemoradiotherapy.
METHODS: All patients who underwent neoadjuvant chemoradiotherapy followed by esophagectomy for cancer, and of whom an adequate CT scan was available, were included in the current study. The presence of sarcopenia was defined by CT imaging using cut-off values of the total cross-sectional muscle tissue measured transversely at the third lumbar level.
RESULTS: A total number of 120 patients were eligible for analysis. Almost half of the patients (N = 54, 45 \%) were classified as having sarcopenia; 24 sarcopenic patients (44 \%) had overweight and 5 sarcopenic patients (9 \%) were obese. Overall morbidity and mortality rate did not differ significantly between sarcopenic and non-sarcopenic patients, nor did long-term overall or disease-free survival. Also sarcopenic obesity was not associated with worse outcome.
CONCLUSION: The presence of sarcopenia was not associated with a negative short- and long-term outcome in this selected group of esophageal cancer patients after neoadjuvant chemoradiotherapy followed by esophagectomy.},
	language = {eng},
	number = {11},
	journal = {World Journal of Surgery},
	author = {Grotenhuis, Brechtje A. and Shapiro, Joël and van Adrichem, Stefan and de Vries, Marianne and Koek, Marcel and Wijnhoven, Bas P. L. and van Lanschot, J. Jan B.},
	month = nov,
	year = {2016},
	pmid = {27272482},
	pmcid = {PMC5073118},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Sarcopenia, Treatment Outcome, Risk Factors, Prognosis, Overweight, Adult, Randomized Controlled Trials as Topic, Cross-Sectional Studies, Young Adult, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Morbidity},
	pages = {2698--2704},
	file = {Grotenhuis et al_2016_Sarcopenia-Muscle Mass is not a Prognostic Factor for Short- and Long-Term.pdf:/Users/jcsal/Zotero/storage/42VZJ9UC/Grotenhuis et al_2016_Sarcopenia-Muscle Mass is not a Prognostic Factor for Short- and Long-Term.pdf:application/pdf},
}

@article{su82,
	title = {{CT}-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis},
	volume = {19},
	issn = {1470-7330},
	shorttitle = {{CT}-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients},
	doi = {10.1186/s40644-019-0270-0},
	abstract = {BACKGROUND: The impact of sarcopenia on the outcome of gastrointestinal (GI) oncological patients is still controversial. We aim to discuss the prevalence of sarcopenia and its relation to the oncological outcome.
METHODS: Embase, Medline, PubMed, and the Cochrane library were systematically searched for related keywords. Studies using CT to assess sarcopenia and evaluate its relationship with the outcome of GI oncological patients were included. Long-term outcomes, including overall survival and disease-free survival, were compared by hazard ratios (HRs) with 95\% confidence intervals (CIs). Short-term outcomes, including total complications and major complications (Clavien-Dindo ≥IIIa) after curable surgery, were compared by the risk ratio (RR) and 95\% CI.
RESULTS: A total of 70 studies including 21,875 patients were included in our study. The median incidence of sarcopenia was 34.7\% (range from 2.1 to 83.3\%). A total of 88.4\% of studies used skeletal muscle index (SMI) in the third lumbar level on CT to define sarcopenia, and a total of 19 cut-offs were used to define sarcopenia. An increasing trend was found in the prevalence of sarcopenia when the cut-off of SMI increased (β = 0.22, 95\% CI = 0.12-0.33, p {\textless} 0.001). The preoperative incidence of sarcopenia was associated both with an increased risk of overall mortality (HR = 1.602, 95\% CI = 1.369-1.873, P {\textless} 0.001) and with disease-free mortality (HR = 1.461, 95\% CI = 1.297-1.646, P {\textless} 0.001). Moreover, preoperative sarcopenia was a risk factor for both total complications (RR = 1.188, 95\% CI = 1.083-1.303, P {\textless} 0.001) and major complications (RR = 1.228, 95\% CI = 1.042-1.448, P = 0.014).
CONCLUSION: The prevalence of sarcopenia depends mostly on the diagnostic cut-off points of different criteria. Preoperative sarcopenia is a risk factor for both long-term and short-term outcomes.},
	language = {eng},
	number = {1},
	journal = {Cancer Imaging: The Official Publication of the International Cancer Imaging Society},
	author = {Su, Huaiying and Ruan, Junxian and Chen, Tianfeng and Lin, Enyi and Shi, Lijing},
	month = dec,
	year = {2019},
	pmid = {31796090},
	pmcid = {PMC6892174},
	keywords = {Humans, Tomography, X-Ray Computed, Gastrointestinal Neoplasms, Sarcopenia, Gastrointestinal oncology, Nutrient, Operation},
	pages = {82},
	file = {Su et al_2019_CT-assessed sarcopenia is a predictive factor for both long-term and short-term.pdf:/Users/jcsal/Zotero/storage/AAZLIMEF/Su et al_2019_CT-assessed sarcopenia is a predictive factor for both long-term and short-term.pdf:application/pdf},
}

@article{elliott822,
	title = {Sarcopenia: {Prevalence}, and {Impact} on {Operative} and {Oncologic} {Outcomes} in the {Multimodal} {Management} of {Locally} {Advanced} {Esophageal} {Cancer}},
	volume = {266},
	issn = {1528-1140},
	shorttitle = {Sarcopenia},
	doi = {10.1097/SLA.0000000000002398},
	abstract = {OBJECTIVE: The aim of this article was to study the prevalence and significance of sarcopenia in the multimodal management of locally advanced esophageal cancer (LAEC), and to assess its independent impact on operative and oncologic outcomes.
SUMMARY OF BACKGROUND DATA: Sarcopenia in cancer may confer negative outcomes, but its prevalence and impact on modern multimodal regimens for LAEC have not been systematically studied.
METHODS: Two hundred fifty-two consecutive patients were studied. Lean body mass (LBM), skeletal muscle index (SMI), and fat mass (FM) were determined pre-treatment, preoperatively, and 1 year postoperatively. Sarcopenia was defined by computed tomography (CT) at L3 as SMI {\textless} 52.4 cm/m for males and SMI {\textless} 38.5 cm/m for females. All complications were recorded prospectively, including comprehensive complications index (CCI), Clavien-Dindo complication (CDC), and pulmonary complications (PPCs). Multivariable linear, logistic, and Cox regression analysis was performed.
RESULTS: In-hospital mortality was 1\%, and CCI was 21 ± 19. Sarcopenia increased (P = 0.02) from 16\% at diagnosis to 31\% post-neoadjuvant therapy, with loss of LBM (-3.0 ± 5.4 kg, P {\textless} 0.0001), but not FM (-0.3 ± 2.7 kg, P= 0.31) during treatment. On multivariable analysis, preoperative sarcopenia was associated with CCI (P = 0.043), and CDC ≥IIIb (P = 0.003). PPCs occurred in 36\% nonsarcopenic versus 55\% sarcopenic patients (P = 0.01). Sarcopenia did not impact disease-specific (P = 0.14) or overall survival (P = 0.11) after resection. At 1 year, 35\% had sarcopenia, significantly associated with pre-treatment BMI (P = 0.013) but not complications (P = 0.20).
CONCLUSIONS: Sarcopenia increases through multimodal therapy, is associated with an increased risk of major postoperative complications, and is prevalent in survivorship. These data highlight a potentially modifiable marker of risk that should be assessed and targeted in modern multimodal care pathways.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Elliott, Jessie A. and Doyle, Suzanne L. and Murphy, Conor F. and King, Sinead and Guinan, Emer M. and Beddy, Peter and Ravi, Narayanasamy and Reynolds, John V.},
	month = nov,
	year = {2017},
	pmid = {28796017},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Prevalence, Sarcopenia, Treatment Outcome, Follow-Up Studies, Risk Factors, Proportional Hazards Models, Prospective Studies, Adult, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Incidence, Postoperative Complications, Logistic Models, Multivariate Analysis, Hospital Mortality, Linear Models},
	pages = {822--830},
	file = {Elliott et al_2017_Sarcopenia.pdf:/Users/jcsal/Zotero/storage/78FHYWWV/Elliott et al_2017_Sarcopenia.pdf:application/pdf},
}

@article{crestcollaborativegroup1073,
	title = {Colorectal {Endoscopic} {Stenting} {Trial} ({CReST}) for obstructing left-sided colorectal cancer: randomized clinical trial},
	volume = {109},
	issn = {0007-1323},
	shorttitle = {Colorectal {Endoscopic} {Stenting} {Trial} ({CReST}) for obstructing left-sided colorectal cancer},
	url = {https://doi.org/10.1093/bjs/znac141},
	doi = {10.1093/bjs/znac141},
	abstract = {Colorectal cancer often presents with obstruction needing urgent, potentially life-saving decompression. The comparative efficacy and safety of endoluminal stenting versus emergency surgery as initial treatment for such patients is uncertain.Patients with left-sided colonic obstruction and radiological features of carcinoma were randomized to endoluminal stenting using a combined endoscopic/fluoroscopic technique followed by elective surgery 1–4 weeks later, or surgical decompression with or without tumour resection. Treatment allocation was via a central randomization service using a minimization procedure stratified by curative intent, primary tumour site, and severity score (Acute Physiology And Chronic Health Evaluation). Co-primary outcome measures were duration of hospital stay and 30-day mortality. Secondary outcomes were stoma formation, stenting completion and complication rates, perioperative morbidity, 6-month survival, 3-year recurrence, resource use, adherence to chemotherapy, and quality of life. Analyses were undertaken by intention to treat.Between 23 April 2009 and 22 December 2014, 245 patients from 39 hospitals were randomized. Stenting was attempted in 119 of 123 allocated patients (96.7 per cent), achieving relief of obstruction in 98 of 119 (82.4 per cent). For the 89 per cent treated with curative intent, there were no significant differences in 30-day postoperative mortality (3.6 per cent (4 of 110) versus 5.6 per cent (6 of 107); P = 0.48), or duration of hospital stay (median 19 (i.q.r. 11–34) versus 18 (10–28) days; P = 0.94) between stenting followed by delayed elective surgery and emergency surgery. Among patients undergoing potentially curative treatment, stoma formation occurred less frequently in those allocated to stenting than those allocated to immediate surgery (47 of 99 (47.5 per cent) versus 72 of 106 (67.9 per cent); P = 0.003). There were no significant differences in perioperative morbidity, critical care use, quality of life, 3-year recurrence or mortality between treatment groups.Stenting as a bridge to surgery reduces stoma formation without detrimental effects. Registration number: ISRCTN13846816 (http://www.controlled-trials.com).},
	number = {11},
	urldate = {2022-11-15},
	journal = {British Journal of Surgery},
	author = {{CReST Collaborative Group}},
	month = nov,
	year = {2022},
	keywords = {Stage IV},
	pages = {1073--1080},
	file = {Snapshot:/Users/jcsal/Zotero/storage/JRYKA4JJ/6672717.html:text/html},
}

@article{glantz1,
	title = {Biostatistics: how to detect, correct and prevent errors in the medical literature},
	volume = {61},
	issn = {0009-7322},
	shorttitle = {Biostatistics},
	doi = {10.1161/01.cir.61.1.1},
	abstract = {Approximately half the articles published in medical journals that use statistical methods use them incorrectly. These errors are so widespread that the present system of peer review has not been able to control them. This article presents a few rules of thumb to help readers identify questionable statistical analysis and estimate what the authors would have concluded had they used appropriate statistical methods. To prevent such errors from appearing, journals should secure review by someone knowledgeable in statistics before accepting a manuscript. In addition, human research committees should insist that an investigator define an appropriate strategy for data analysis before approving a protocol. Such policies should quickly and effectively increase the reliability of the clinical and scientific literature.},
	language = {eng},
	number = {1},
	journal = {Circulation},
	author = {Glantz, S. A.},
	month = jan,
	year = {1980},
	pmid = {7349923},
	keywords = {Humans, Research Design, Peer Review, Statistics as Topic},
	pages = {1--7},
	file = {Glantz_1980_Biostatistics.pdf:/Users/jcsal/Zotero/storage/VTABZC4W/Glantz_1980_Biostatistics.pdf:application/pdf},
}

@article{becher,
	title = {The {Incidence} and {Cumulative} {Risk} of {Major} {Surgery} in {Older} {Persons} in the {United} {States}},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000005077},
	abstract = {OBJECTIVE: The objective of this study was to estimate the incidence and cumulative risk of major surgery in older persons over a 5-year period and evaluate how these estimates differ according to key demographic and geriatric characteristics.
BACKGROUND: As the population of the United States ages, there is considerable interest in ensuring safe, high-quality surgical care for older persons. Yet, valid, generalizable data on the occurrence of major surgery in the geriatric population are sparse.
METHODS: We evaluated data from a prospective longitudinal study of 5,571 community-living fee-for-service Medicare beneficiaries, aged 65 or older, from the National Health and Aging Trends Study (NHATS) from 2011 to 2016. Major surgeries were identified through linkages with Centers for Medicare \& Medicaid Services data. Population-based incidence and cumulative risk estimates incorporated NHATS analytic sampling weights and cluster and strata variables.
RESULTS: The nationally-representative incidence of major surgery per 100 person-years was 8.8, with estimates of 5.2 and 3.7 for elective and non-elective surgeries. The adjusted incidence of major surgery peaked at 10.8 in persons 75-79 years, increased from 6.6 in the non-frail group to 10.3 in the frail group, and was similar by sex and dementia. The 5-year cumulative risk of major surgery was 13.8\%, representing nearly 5 million unique older persons, including 12.1\% in persons 85-89 years, 9.1\% in those ≥90 years, 12.1\% in those with frailty, and 12.4\% in those with probable dementia.
CONCLUSIONS: Major surgery is a common event in the lives of community-living older persons, including high-risk vulnerable subgroups.},
	language = {eng},
	journal = {Annals of Surgery},
	author = {Becher, Robert D. and Wyk, Brent Vander and Leo-Summers, Linda and Desai, Mayur M. and Gill, Thomas M.},
	month = jul,
	year = {2021},
	pmid = {34261884},
	pmcid = {PMC8758792},
	keywords = {Geriatric},
	file = {Becher et al_2021_The Incidence and Cumulative Risk of Major Surgery in Older Persons in the.pdf:/Users/jcsal/Zotero/storage/AQ93UPIG/Becher et al_2021_The Incidence and Cumulative Risk of Major Surgery in Older Persons in the.pdf:application/pdf},
}

@article{gille225155,
	title = {Population-{Based} {Estimates} of 1-{Year} {Mortality} {After} {Major} {Surgery} {Among} {Community}-{Living} {Older} {US} {Adults}},
	issn = {2168-6262},
	doi = {10.1001/jamasurg.2022.5155},
	abstract = {IMPORTANCE: Despite their importance to guiding public health decision-making and policies and to establishing programs aimed at improving surgical care, contemporary nationally representative mortality data for geriatric surgery are lacking.
OBJECTIVE: To calculate population-based estimates of mortality after major surgery in community-living older US adults and to determine how these estimates differ according to key demographic, surgical, and geriatric characteristics.
DESIGN, SETTING, AND PARTICIPANTS: Prospective longitudinal cohort study with 1 year of follow-up in the continental US from 2011 to 2018. Participants included 5590 community-living fee-for-service Medicare beneficiaries, aged 65 years or older, from the National Health and Aging Trends Study (NHATS). Data analysis was conducted from February 22, 2021, to March 16, 2022.
MAIN OUTCOMES AND MEASURES: Major surgeries and mortality over 1 year were identified through linkages with data from the Centers for Medicare \& Medicaid Services. Data on frailty and dementia were obtained from the annual NHATS assessments.
RESULTS: From 2011 to 2017, of the 1193 major surgeries (from 992 community-living participants), the mean (SD) age was 79.2 (7.1) years; 665 were women (55.7\%), and 30 were Hispanic (2.5\%), 198 non-Hispanic Black (16.6\%), and 915 non-Hispanic White (76.7\%). Over the 1-year follow-up period, there were 206 deaths representing 872 096 survey-weighted deaths and 13.4\% (95\% CI, 10.9\%-15.9\%) mortality. Mortality rates were 7.4\% (95\% CI, 4.9\%-9.9\%) for elective surgeries and 22.3\% (95\% CI, 17.4\%-27.1\%) for nonelective surgeries. For geriatric subgroups, 1-year mortality was 6.0\% (95\% CI, 2.6\%-9.4\%) for persons who were nonfrail, 27.8\% (95\% CI, 21.2\%-34.3\%) for those who were frail, 11.6\% (95\% CI, 8.8\%-14.4\%) for persons without dementia, and 32.7\% (95\% CI, 24.3\%-41.0\%) for those with probable dementia. The age- and sex-adjusted hazard ratios for 1-year mortality were 4.41 (95\% CI, 2.53-7.69) for frailty with a reduction in restricted mean survival time of 48.8 days and 2.18 (95\% CI, 1.40-3.40) for probable dementia with a reduction in restricted mean survival time of 44.9 days.
CONCLUSIONS AND RELEVANCE: In this study, the population-based estimate of 1-year mortality after major surgery among community-living older adults in the US was 13.4\% but was 3-fold higher for nonelective than elective procedures. Mortality was considerably elevated among older persons who were frail or who had probable dementia, highlighting the potential prognostic value of geriatric conditions after major surgery.},
	language = {eng},
	journal = {JAMA surgery},
	author = {Gill, Thomas M. and Vander Wyk, Brent and Leo-Summers, Linda and Murphy, Terrence E. and Becher, Robert D.},
	month = oct,
	year = {2022},
	pmid = {36260323},
	pmcid = {PMC9582971},
	keywords = {Geriatric},
	pages = {e225155},
}

@article{dale336,
	title = {How {Is} {Geriatric} {Assessment} {Used} in {Clinical} {Practice} for {Older} {Adults} {With} {Cancer}? {A} {Survey} of {Cancer} {Providers} by the {American} {Society} of {Clinical} {Oncology}},
	volume = {17},
	issn = {2688-1535},
	shorttitle = {How {Is} {Geriatric} {Assessment} {Used} in {Clinical} {Practice} for {Older} {Adults} {With} {Cancer}?},
	doi = {10.1200/OP.20.00442},
	abstract = {PURPOSE: For patients with cancer who are older than 65 years, the 2018 ASCO Guideline recommends geriatric assessment (GA) be performed. However, there are limited data on providers' practices using GA. Therefore, ASCO's Geriatric Oncology Task Force conducted a survey of providers to assess practice patterns and barriers to GA.
METHODS: Cancer providers treating adult patients including those ≥ 65 years completed an online survey. Questions included those asking about awareness of ASCO's Geriatric Oncology Guideline (2018), use of validated GA tools, and perceived barriers to using GA. Descriptive statistics and statistical comparisons between those aware of the Guideline and those who were not were conducted. Statistical significance was set at P {\textless} .05.
RESULTS: Participants (N = 1,277) responded between April 5 and June 5, 2019. Approximately half (53\%) reported awareness of the Guideline. The most frequently used GA tools, among those aware of the Guideline and those who were not, assessed functional status (69\% v 50\%; P {\textless} .001) and falls (62\% v 45\%; P {\textless} .001). Remaining tools were used {\textless} 50\% of the time, including tools assessing weight loss, comorbidities, cognition, life expectancy, chemotherapy toxicity, mood, and noncancer mortality risk. GA use was two to four times higher among those who are aware of the Guideline. The most frequent barriers for those who reported being Guideline aware were lack of resources, specifically time (81.7\%) and staff (77.0\%). In comparison, those who were unaware of the Guideline most often reported the following barriers: lack of knowledge or training (78.4\%), lack of awareness about tools (75.2\%), and uncertainty about use of tools (75.0\%).
CONCLUSION: Among providers caring for older adults, 52\% were aware of the ASCO Guideline. Some domains were assessed frequently (eg, function, falls), whereas other domains were assessed rarely (eg, mood, cognition). Guideline awareness was associated with two to four times increased use of GA and differing perceived barriers. Interventions facilitating Guideline-consistent implementation will require various strategies to change behavior.},
	language = {eng},
	number = {6},
	journal = {JCO oncology practice},
	author = {Dale, William and Williams, Grant R. and R MacKenzie, Amy and Soto-Perez-de-Celis, Enrique and Maggiore, Ronald J. and Merrill, Janette K. and Katta, Sweatha and Smith, Kimberly T. and Klepin, Heidi D.},
	month = jun,
	year = {2021},
	pmid = {33064058},
	pmcid = {PMC8462667},
	keywords = {Humans, Aged, Neoplasms, United States, Surveys and Questionnaires, Geriatric Assessment, Medical Oncology, Accidental Falls, CGA},
	pages = {336--344},
	file = {Dale et al_2021_How Is Geriatric Assessment Used in Clinical Practice for Older Adults With.pdf:/Users/jcsal/Zotero/storage/VBCDQWX2/Dale et al_2021_How Is Geriatric Assessment Used in Clinical Practice for Older Adults With.pdf:application/pdf},
}

@article{rocquee935,
	title = {Choosing {Wisely} in {Oncology}: {Are} {We} {Ready} {For} {Value}-{Based} {Care}?},
	volume = {13},
	issn = {1935-469X},
	shorttitle = {Choosing {Wisely} in {Oncology}},
	doi = {10.1200/JOP.2016.019281},
	abstract = {INTRODUCTION: In 2012, ASCO created the Top Five Choosing Wisely (CW) list of low-value tests and procedures for which there is little evidence of benefit. ASCO's Quality Oncology Practice Initiative, an oncologist-led practice-based quality assessment program, includes measures on the basis of these recommendations.
METHODS: CW test measures from spring and fall 2013, spring 2014, and spring 2015 were evaluated for concordance rates, change in the concordance over time, and variability by practice characteristics. Practice characteristics recorded included geographic location, academic affiliation, number of new cases, number of medical oncologists, and rounds of participation in Quality Oncology Practice Initiative. Medians, interquartile ranges, and percentages were calculated for concordance with recommendations and practice characteristics. Change in recommendation concordance over time was assessed using linear regression models.
RESULTS: From 2013 to 2015, 341 unique oncology practices abstracted the CW measures. Performance varied for specific recommendations. The median concordance was best for measure 1 (patients with low or undocumented performance status who received chemotherapy), where concordance ranged from 78.4\% to 83.3\%. The lowest concordance was for measure 3 (use of biomarkers or advanced imaging tests for surveillance in early breast cancer), where concordance ranged from 67.7\% to 74.2\%. Performance on CW measures varied markedly by individual practice. Variability over time and by practice characteristics was observed.
CONCLUSION: Performance on ASCO's CW demonstrates room for improvement. Concordance rates varied substantially by practice. Further education on CW measures is needed to improve patient care and enhance value.},
	language = {eng},
	number = {11},
	journal = {Journal of Oncology Practice},
	author = {Rocque, Gabrielle and Blayney, Douglas W. and Jahanzeb, Mohammad and Knape, August and Markham, Merry Jennifer and Pham, Trang and Shelton, Jeremy and Sudheendra, Preeti and Evans, Tracey},
	month = nov,
	year = {2017},
	pmid = {28783425},
	keywords = {Humans, Neoplasms, United States, Cost-Benefit Analysis, Practice Guidelines as Topic, Medical Oncology, Quality Assurance, Health Care, ECOG},
	pages = {e935--e943},
	file = {Rocque et al_2017_Choosing Wisely in Oncology.pdf:/Users/jcsal/Zotero/storage/I5HPC93F/Rocque et al_2017_Choosing Wisely in Oncology.pdf:application/pdf},
}

@article{ludmir1769,
	title = {Factors {Associated} {With} {Age} {Disparities} {Among} {Cancer} {Clinical} {Trial} {Participants}},
	volume = {5},
	issn = {2374-2445},
	doi = {10.1001/jamaoncol.2019.2055},
	abstract = {IMPORTANCE: Seminal investigation 2 decades ago alerted the oncology community to age disparities in participation in cooperative group trials; less is known about whether these disparities persist in industry-funded research.
OBJECTIVE: To characterize the age disparities among trial enrollees on randomized clinical trials (RCTs) of common cancers in clinical oncology and identify factors associated with wider age imbalances.
DATA SOURCES: Phase 3 clinical oncology RCTs were identified through ClinicalTrials.gov.
STUDY SELECTION: Multiarm RCTs assessing a therapeutic intervention for patients with breast, prostate, colorectal, or lung cancer (the 4 most common cancer disease sites) were included.
DATA EXTRACTION AND SYNTHESIS: Trial data were extracted from ClinicalTrials.gov. Trial screening and parameter identification were independently performed by 2 individuals. Data were analyzed in 2018.
MAIN OUTCOMES AND MEASURES: The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was determined for each trial.
RESULTS: Three hundred two trials met inclusion criteria. The trials collectively enrolled 262 354 participants; 249 trials (82.5\%) were industry-funded. For all trials, the trial median age of trial participants was a mean of 6.49 years younger than the population median age (95\% CI, -7.17 to -5.81 years; P {\textless} .001). Age disparities were heightened among industry-funded trials compared with non-industry-funded trials (mean DMA, -6.84 vs -4.72 years; P = .002). Enrollment criteria restrictions based on performance status or age cutoffs were associated with age disparities; however, industry-funded trials were not more likely to use these enrollment restrictions than non-industry-funded trials. Age disparities were also larger among trials that evaluated a targeted systemic therapy and among lung cancer trials. Linear regression modeling revealed a widening gap between trial and population median ages over time at a rate of -0.19 years annually (95\% CI, -0.37 to -0.01 years; P = .04).
CONCLUSIONS AND RELEVANCE: Age disparities between trial participants and the incident disease population are pervasive across trials and appear to be increasing over time. Industry sponsorship of trials is associated with heightened age imbalances among trial participants. With an increasing role of industry funding among cancer trials, efforts to understand and address age disparities are necessary to ensure generalizability of trial results as well as equity in trial access.},
	language = {eng},
	number = {12},
	journal = {JAMA oncology},
	author = {Ludmir, Ethan B. and Mainwaring, Walker and Lin, Timothy A. and Miller, Austin B. and Jethanandani, Amit and Espinoza, Andres F. and Mandel, Jacob J. and Lin, Steven H. and Smith, Benjamin D. and Smith, Grace L. and VanderWalde, Noam A. and Minsky, Bruce D. and Koong, Albert C. and Stinchcombe, Thomas E. and Jagsi, Reshma and Gomez, Daniel R. and Thomas, Charles R. and Fuller, C. David},
	month = dec,
	year = {2019},
	pmid = {31158272},
	pmcid = {PMC6547133},
	keywords = {Humans, Risk Assessment, Neoplasms, Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Age Factors, Linear Models},
	pages = {1769--1773},
	file = {Ludmir et al_2019_Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.pdf:/Users/jcsal/Zotero/storage/NMYIPWRQ/Ludmir et al_2019_Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.pdf:application/pdf},
}

@article{bellieni243,
	title = {Different {Impact} of {Definitions} of {Sarcopenia} in {Defining} {Frailty} {Status} in a {Population} of {Older} {Women} with {Early} {Breast} {Cancer}},
	volume = {11},
	issn = {2075-4426},
	doi = {10.3390/jpm11040243},
	abstract = {Sarcopenia is a geriatric syndrome characterized by losses of quantity and quality of skeletal muscle, which is associated with negative outcomes in older adults and in cancer patients. Different definitions of sarcopenia have been used, with quantitative data more frequently used in oncology, while functional measures have been advocated in the geriatric literature. Little is known about the correlation between frailty status as assessed by comprehensive geriatric assessment (CGA) and sarcopenia in cancer patients. We retrospectively analyzed data from 96 older women with early breast cancer who underwent CGAs and Dual X-ray Absorptiometry (DXA) scans for muscle mass assessment before cancer treatment at a single cancer center from 2016 to 2019 to explore the correlation between frailty status as assessed by CGA and sarcopenia using different definitions. Based on the results of the CGA, 35 patients (36.5\%) were defined as frail. Using DXA Appendicular Skeletal Mass (ASM) or the Skeletal Muscle Index (SMI=ASM/height{\textasciicircum}2), 41 patients were found to be sarcopenic (42.7\%), with no significant difference in prevalence between frail and nonfrail subjects. Using the European Working Group on Sarcopenia in Older People (EWGSOP2) definition of sarcopenia (where both muscle function and mass are required), 58 patients were classified as "probably" sarcopenic; among these, 25 were sarcopenic and 17 "severely" sarcopenic. Only 13 patients satisfied both the requirements for being defined as sarcopenic and frail. Grade 3-4 treatment-related toxicities (according to Common Terminology Criteria for Adverse Events) were more common in sarcopenic and frail sarcopenic patients. Our data support the use of a definition of sarcopenia that includes both quantitative and functional data in order to identify frail patients who need tailored treatment.},
	language = {eng},
	number = {4},
	journal = {Journal of Personalized Medicine},
	author = {Bellieni, Andrea and Fusco, Domenico and Sanchez, Alejandro Martin and Franceschini, Gianluca and Di Capua, Beatrice and Allocca, Elena and Di Stasio, Enrico and Marazzi, Fabio and Tagliaferri, Luca and Masetti, Riccardo and Bernabei, Roberto and Colloca, Giuseppe Ferdinando},
	month = mar,
	year = {2021},
	pmid = {33810556},
	pmcid = {PMC8066315},
	keywords = {sarcopenia, frailty, older cancer patients, physical performance, Cancer; CGA},
	pages = {243},
	file = {Bellieni et al_2021_Different Impact of Definitions of Sarcopenia in Defining Frailty Status in a.pdf:/Users/jcsal/Zotero/storage/WIFIRXIP/Bellieni et al_2021_Different Impact of Definitions of Sarcopenia in Defining Frailty Status in a.pdf:application/pdf},
}

@article{sun924,
	title = {Sarcopenia among older patients with cancer: {A} scoping review of the literature},
	volume = {13},
	issn = {1879-4076},
	shorttitle = {Sarcopenia among older patients with cancer},
	doi = {10.1016/j.jgo.2022.03.008},
	abstract = {INTRODUCTION: In the older patients with cancer, the combination of aging and cancer makes sarcopenia more likely to occur. However, previous studies paid less attention to the sarcopenia of older patients with cancer. To address these gaps, we conducted a scoped review of the prevalence, measurement, prognostic value, and clinical interventions of sarcopenia in this population.
MATERIALS AND METHODS: A comprehensive search of PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, Embase, China National Knowledge Infrastructure (CNKI) and Wangfang electronic databases was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews. Two independent reviewers screened all abstracts and full-text studies for inclusion.
RESULTS: We identified 10,850 studies, and 39 met the inclusion criteria. Two reviewers extracted data on study characteristics, study design, measuring tools and main outcomes. This review included works from 11 countries. All studies were quantitative and most used a cross-sectional (n = 17) or retrospective (n = 16) design. The prevalence of sarcopenia in elderly cancer survivors ranged from 18.5\% to 83\%, and skeletal muscle mass index (SMI) by computed tomography (CT) scan at lumbar 3 (L3) was the most commonly used way to define sarcopenia. Meanwhile, pre-therapeutic sarcopenia was significantly related to postoperative complications, lower overall survival and impaired physical function.
DISCUSSION: This review emphasizes sarcopenia is highly prevalent in older patients with cancer, which leads to poor outcomes and urgently needs attention from nutritionists, surgeons, oncologists, psychologists and nurses.},
	language = {eng},
	number = {7},
	journal = {Journal of Geriatric Oncology},
	author = {Sun, Qian and Jiang, Xiaohan and Qin, Rui and Yang, Yuanyuan and Gong, Yabo and Wang, Kunyuan and Peng, Junsheng},
	month = sep,
	year = {2022},
	pmid = {35644850},
	keywords = {Humans, Muscle, Skeletal, Aged, Sarcopenia, Retrospective Studies, Neoplasms, Cross-Sectional Studies, Cancer, Aging, Older adults},
	pages = {924--934},
}

@article{sedrak78,
	title = {Older adult participation in cancer clinical trials: {A} systematic review of barriers and interventions},
	volume = {71},
	issn = {0007-9235},
	shorttitle = {Older adult participation in cancer clinical trials},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854940/},
	doi = {10.3322/caac.21638},
	abstract = {Cancer is a disease of aging and, as the world’s population ages, the number of older persons with cancer is increasing and will make up a growing share of the oncology population in virtually every country. Despite this, older patients remain vastly underrepresented in research that sets the standards for cancer treatments. Consequently, most of what we know about cancer therapeutics is based on clinical trials conducted in younger, healthier patients, and effective strategies to improve clinical trial participation of older adults with cancer remain sparse. This systematic review evaluated published studies regarding barriers to participation and interventions to improve participation of older adults in cancer trials. The quality of the available evidence was low and, despite a literature describing multifaceted barriers, only one intervention study aimed to increase enrollment of older adults in trials. Our findings starkly amplify the paucity of evidence-based effective strategies to improve participation of this underrepresented population in cancer trials. Within these limitations, we provide our opinion on how the current cancer research infrastructure must be modified to accommodate the needs of older patients. We offer several underutilized solutions to expand clinical trials to include older adults with cancer. However, as currently constructed, these recommendations alone will not solve the evidence gap in geriatric oncology, and efforts are needed to meet older and frail adults where they are by expanding clinical trials designed specifically for this population and leveraging real-world data.},
	number = {1},
	urldate = {2022-12-10},
	journal = {CA: a cancer journal for clinicians},
	author = {Sedrak, Mina S. and Freedman, Rachel A. and Cohen, Harvey J. and Muss, Hyman B. and Jatoi, Aminah and Klepin, Heidi D. and Wildes, Tanya M. and Le-Rademacher, Jennifer G. and Kimmick, Gretchen G. and Tew, William P. and George, Kevin and Padam, Simran and Liu, Jennifer and Wong, Andrew R. and Lynch, Andrea and Djulbegovic, Benjamin and Mohile, Supriya G. and Dale, William},
	month = jan,
	year = {2021},
	pmid = {33002206},
	pmcid = {PMC7854940},
	keywords = {Cancer},
	pages = {78--92},
	file = {Sedrak et al_2021_Older adult participation in cancer clinical trials.pdf:/Users/jcsal/Zotero/storage/MT7W8EDW/Sedrak et al_2021_Older adult participation in cancer clinical trials.pdf:application/pdf},
}

@article{bernard1535,
	title = {Inclusion {Across} the {Lifespan}: {NIH} {Policy} for {Clinical} {Research}},
	volume = {320},
	issn = {1538-3598},
	shorttitle = {Inclusion {Across} the {Lifespan}},
	doi = {10.1001/jama.2018.12368},
	language = {eng},
	number = {15},
	journal = {JAMA},
	author = {Bernard, Marie A. and Clayton, Janine A. and Lauer, Michael S.},
	month = oct,
	year = {2018},
	pmid = {30326521},
	keywords = {Humans, Aged, Female, Male, United States, Clinical Trials as Topic, Adolescent, Data Interpretation, Statistical, Age Distribution, Child, Guidelines as Topic, Infant, National Institutes of Health (U.S.), Organizational Policy, Research Support as Topic, Cancer;Elderly},
	pages = {1535--1536},
}

@article{tisminetzky1549,
	title = {Research {Priorities} to {Advance} the {Health} and {Health} {Care} of {Older} {Adults} with {Multiple} {Chronic} {Conditions}},
	volume = {65},
	issn = {1532-5415},
	doi = {10.1111/jgs.14943},
	abstract = {OBJECTIVES: To prioritize research topics relevant to the care of the growing population of older adults with multiple chronic conditions (MCCs).
DESIGN: Survey of experts in MCC practice, research, and policy. Topics were derived from white papers, funding announcements, or funded research projects relating to older adults with MCCs.
SETTING: Survey conducted through the Health Care Systems Research Network (HCSRN) and Claude D. Pepper Older Americans Independence Centers (OAICs) Advancing Geriatrics Infrastructure and Network Growth Initiative, a joint endeavor of the HCSRN and OAICs.
PARTICIPANTS: Individuals affiliated with the HCSRN or OAICs and national MCC experts, including individuals affiliated with funding agencies having MCC-related grant portfolios.
MEASUREMENTS: A "top box" methodology was used, counting the number of respondents selecting the top response on a 5-point Likert scale and dividing by the total number of responses to calculate a top box percentage for each of 37 topics.
RESULTS: The highest-ranked research topics relevant to the health and healthcare of older adults with MCCs were health-related quality of life in older adults with MCCs; development of assessment tools (to assess, e.g., symptom burden, quality of life, function); interactions between medications, disease processes, and health outcomes; disability; implementation of novel (and scalable) models of care; association between clusters of chronic conditions and clinical, financial, and social outcomes; role of caregivers; symptom burden; shared decision-making to enhance care planning; and tools to improve clinical decision-making.
CONCLUSION: Study findings serve to inform the development of a comprehensive research agenda to address the challenges relating to the care of this "high-need, high-cost" population and the healthcare delivery systems responsible for serving it.},
	language = {eng},
	number = {7},
	journal = {Journal of the American Geriatrics Society},
	author = {Tisminetzky, Mayra and Bayliss, Elizabeth A. and Magaziner, Jay S. and Allore, Heather G. and Anzuoni, Kathryn and Boyd, Cynthia M. and Gill, Thomas M. and Go, Alan S. and Greenspan, Susan L. and Hanson, Leah R. and Hornbrook, Mark C. and Kitzman, Dalane W. and Larson, Eric B. and Naylor, Mary D. and Shirley, Benjamin E. and Tai-Seale, Ming and Teri, Linda and Tinetti, Mary E. and Whitson, Heather E. and Gurwitz, Jerry H.},
	month = jul,
	year = {2017},
	pmid = {28555750},
	pmcid = {PMC5507733},
	keywords = {Humans, Quality of Life, Outcome and Process Assessment, Health Care, Surveys and Questionnaires, Elderly, aging, Caregivers, Chronic Disease, Delivery of Health Care, Drug Interactions, geriatrics, Health Services Research, multimorbidity, multiple chronic conditions, Multiple Chronic Conditions, Research},
	pages = {1549--1553},
	file = {Tisminetzky et al_2017_Research Priorities to Advance the Health and Health Care of Older Adults with.pdf:/Users/jcsal/Zotero/storage/DU7FJAEE/Tisminetzky et al_2017_Research Priorities to Advance the Health and Health Care of Older Adults with.pdf:application/pdf},
}

@article{mohile2326,
	title = {Practical {Assessment} and {Management} of {Vulnerabilities} in {Older} {Patients} {Receiving} {Chemotherapy}: {ASCO} {Guideline} for {Geriatric} {Oncology}},
	volume = {36},
	issn = {1527-7755},
	shorttitle = {Practical {Assessment} and {Management} of {Vulnerabilities} in {Older} {Patients} {Receiving} {Chemotherapy}},
	doi = {10.1200/JCO.2018.78.8687},
	abstract = {Purpose To provide guidance regarding the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. Methods An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Results A total of 68 studies met eligibility criteria and form the evidentiary basis for the recommendations. Recommendations In patients ≥ 65 years receiving chemotherapy, geriatric assessment (GA) should be used to identify vulnerabilities that are not routinely captured in oncology assessments. Evidence supports, at a minimum, assessment of function, comorbidity, falls, depression, cognition, and nutrition. The Panel recommends instrumental activities of daily living to assess for function, a thorough history or validated tool to assess comorbidity, a single question for falls, the Geriatric Depression Scale to screen for depression, the Mini-Cog or the Blessed Orientation-Memory-Concentration test to screen for cognitive impairment, and an assessment of unintentional weight loss to evaluate nutrition. Either the CARG (Cancer and Aging Research Group) or CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) tools are recommended to obtain estimates of chemotherapy toxicity risk; the Geriatric-8 or Vulnerable Elders Survey-13 can help to predict mortality. Clinicians should use a validated tool listed at ePrognosis to estimate noncancer-based life expectancy ≥ 4 years. GA results should be applied to develop an integrated and individualized plan that informs cancer management and to identify nononcologic problems amenable to intervention. Collaborating with caregivers is essential to implementing GA-guided interventions. The Panel suggests that clinicians take into account GA results when recommending chemotherapy and that the information be provided to patients and caregivers to guide treatment decision making. Clinicians should implement targeted, GA-guided interventions to manage nononcologic problems. Additional information is available at www.asco.org/supportive-care-guidelines .},
	language = {eng},
	number = {22},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Mohile, Supriya G. and Dale, William and Somerfield, Mark R. and Schonberg, Mara A. and Boyd, Cynthia M. and Burhenn, Peggy S. and Canin, Beverly and Cohen, Harvey Jay and Holmes, Holly M. and Hopkins, Judith O. and Janelsins, Michelle C. and Khorana, Alok A. and Klepin, Heidi D. and Lichtman, Stuart M. and Mustian, Karen M. and Tew, William P. and Hurria, Arti},
	month = aug,
	year = {2018},
	pmid = {29782209},
	pmcid = {PMC6063790},
	keywords = {Humans, Aged, Female, Male, Neoplasms, Aged, 80 and over, Age Factors, Geriatric Assessment, Geriatrics, Medical Oncology, CGA;Elderly;Chemo},
	pages = {2326--2347},
	file = {Mohile et al_2018_Practical Assessment and Management of Vulnerabilities in Older Patients.pdf:/Users/jcsal/Zotero/storage/RBILPA9A/Mohile et al_2018_Practical Assessment and Management of Vulnerabilities in Older Patients.pdf:application/pdf},
}

@article{hurria3826,
	title = {Improving the {Evidence} {Base} for {Treating} {Older} {Adults} {With} {Cancer}: {American} {Society} of {Clinical} {Oncology} {Statement}},
	volume = {33},
	issn = {1527-7755},
	shorttitle = {Improving the {Evidence} {Base} for {Treating} {Older} {Adults} {With} {Cancer}},
	doi = {10.1200/JCO.2015.63.0319},
	abstract = {The American Society of Clinical Oncology (ASCO) convened a subcommittee to develop recommendations on improving the evidence base for treating older adults with cancer in response to a critical need identified by the Institute of Medicine. Older adults experience the majority of cancer diagnoses and deaths and make up the majority of cancer survivors. Older adults are also the fastest growing segment of the US population. However, the evidence base for treating this population is sparse, because older adults are underrepresented in clinical trials, and trials designed specifically for older adults are rare. The result is that clinicians have less evidence on how to treat older adults, who represent the majority of patients with cancer. Clinicians and patients are forced to extrapolate from trials conducted in younger, healthier populations when developing treatment plans. This has created a dearth of knowledge regarding the risk of toxicity in the average older patient and about key end points of importance to older adults. ASCO makes five recommendations to improve evidence generation in this population: (1) Use clinical trials to improve the evidence base for treating older adults with cancer, (2) leverage research designs and infrastructure for generating evidence on older adults with cancer, (3) increase US Food and Drug Administration authority to incentivize and require research involving older adults with cancer, (4) increase clinicians' recruitment of older adults with cancer to clinical trials, and (5) use journal policies to improve researchers' reporting on the age distribution and health risk profiles of research participants.},
	language = {eng},
	number = {32},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Hurria, Arti and Levit, Laura A. and Dale, William and Mohile, Supriya G. and Muss, Hyman B. and Fehrenbacher, Louis and Magnuson, Allison and Lichtman, Stuart M. and Bruinooge, Suanna S. and Soto-Perez-de-Celis, Enrique and Tew, William P. and Postow, Michael A. and Cohen, Harvey J. and {American Society of Clinical Oncology}},
	month = nov,
	year = {2015},
	pmid = {26195697},
	keywords = {Humans, Aged, Neoplasms, Aged, 80 and over, United States, Research Design, Patient Selection, Clinical Trials as Topic, Aging, Evidence-Based Medicine, Societies, Medical, Medical Oncology, Chemo, Editorial Policies, Periodicals as Topic, Research Report, United States Food and Drug Administration},
	pages = {3826--3833},
}

@article{extermann1824,
	title = {Comprehensive geriatric assessment for older patients with cancer},
	volume = {25},
	issn = {1527-7755},
	doi = {10.1200/JCO.2007.10.6559},
	abstract = {PURPOSE: During the last decade, oncologists and geriatricians have begun to work together to integrate the principles of geriatrics into oncology care. The increasing use of a comprehensive geriatric assessment (CGA) is one example of this effort. A CGA includes an evaluation of an older individual's functional status, comorbid medical conditions, cognition, nutritional status, psychological state, and social support; and a review of the patient's medications. This article discusses recent advances on the use of a CGA in older patients with cancer.
METHODS: In this article, we provide an update on the studies that address the domains of a geriatric assessment applied to the oncology patient, review the results of the first studies evaluating the use of a CGA in developing interventions to improve the care of older adults with cancer, and discuss future research directions.
RESULTS: The evidence from recent studies demonstrates that a CGA can predict morbidity and mortality in older patients with cancer. Accumulating data show the benefits of incorporating a CGA in the evaluation of older patients with cancer. Prospective trials evaluating the utility of a CGA to guide interventions to improve the quality of cancer care in older adults are justified.
CONCLUSION: Growing evidence demonstrates that the variables examined in a CGA can predict morbidity and mortality in older patients with cancer, and uncover problems relevant to cancer care that would otherwise go unrecognized.},
	language = {eng},
	number = {14},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Extermann, Martine and Hurria, Arti},
	month = may,
	year = {2007},
	pmid = {17488980},
	keywords = {Humans, Aged, Neoplasms, Comorbidity, Nutritional Status, Geriatric Assessment, Disease Management, Medical Oncology, Chemo, CGA, Cognition, Polypharmacy, Social Support},
	pages = {1824--1831},
}

@article{normann948,
	title = {Effect of comprehensive geriatric assessment for frail elderly patients operated for colorectal cancer-the colorectal cancer frailty study: study protocol for a randomized, controlled, multicentre trial},
	volume = {23},
	issn = {1745-6215},
	shorttitle = {Effect of comprehensive geriatric assessment for frail elderly patients operated for colorectal cancer-the colorectal cancer frailty study},
	doi = {10.1186/s13063-022-06883-9},
	abstract = {BACKGROUND: Colorectal cancer (CRC) is the third most common cancer worldwide, with a median age of 72-75 years at diagnosis. Curative treatment usually involves surgery; if left untreated, symptoms may require emergency surgery. Therefore, most patients will be accepted for surgery, despite of high age or comorbidity. It is known that elderly patients suffer higher risks after surgery than younger patients, in terms of complications and mortality. Assessing frailty and offering frail elderly patients individualized treatment according to the comprehensive geriatric assessment (CGA) and care concept has been shown to improve the outcome for frail elderly patients in other clinical contexts.
METHODS: This randomized controlled multicentre trial aims to investigate if CGA and care prior to curatively intended surgery for CRC in frail elderly patients will improve postoperative outcome. All patients ≥ 70 years with surgically curable CRC will be screened for frailty using the Clinical Frailty Scale (CFS-9). Frail patients will be offered inclusion. Randomization is stratified for colon or rectal cancer. Patients in the intervention group are, in addition to standard protocol, treated according to CGA and care. This consists of individualized assessments and interventions, established by a multiprofessional team. Patients in the control group are treated according to best known practice as stipulated by Swedish colorectal cancer treatment guidelines, within an enhanced recovery after surgery (ERAS) setting. The primary outcome is 90-day mortality. Secondary outcomes are the length of hospital stay and total number of hospital days within 3 months, discharge destination, 30-day readmission, ADL, safe medication assessment, CFS-9 score, complications, Health-Related Quality of Life (HRQoL) at 2-month follow-up in comparison to baseline measurements, health economical calculations including cost-effectiveness analysis based on costs of hospital care and primary care, mortality and HRQoL at baseline, 2- and 12-month follow-up and all-cause 1-year mortality.
DISCUSSION: The trial is the first of its size and extent to investigate intervention with CGA and care prior to surgery for CRC in frail elderly patients. If this addition proves to be favourable, it could have implications on future care of frail elderly patients with CRC.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04358328. Registered on 4 February 2020.},
	language = {eng},
	number = {1},
	journal = {Trials},
	author = {Normann, Maria and Ekerstad, Niklas and Angenete, Eva and Prytz, Mattias},
	month = nov,
	year = {2022},
	pmid = {36397083},
	pmcid = {PMC9670054},
	keywords = {Humans, Aged, Sarcopenia, Colorectal Neoplasms, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Quality of Life, Surgery, Elderly, Frailty, Geriatric Assessment, ERAS, Frail Elderly, CGA, CGA and care, Colorectal neoplasm, Fatigue Syndrome, Chronic, PICO (patient-intervention-comparison-outcome), RCT (randomised controlled trial)},
	pages = {948},
	file = {Normann et al_2022_Effect of comprehensive geriatric assessment for frail elderly patients.pdf:/Users/jcsal/Zotero/storage/7VAEXG3L/Normann et al_2022_Effect of comprehensive geriatric assessment for frail elderly patients.pdf:application/pdf},
}

@article{iida753,
	title = {Risk factors for non-gastric-cancer-related death after gastrectomy in elderly patients},
	volume = {6},
	issn = {2475-0328},
	doi = {10.1002/ags3.12588},
	abstract = {AIM: To identify preoperative factors, especially other diseases that cause death, that are associated with the prognosis of gastrectomy in elderly patients with gastric cancer.
METHODS: This retrospective study included a total of 211 consecutive patients aged ≥75 years who underwent radical gastrectomy due to gastric cancer. Time-dependent receiver operating characteristic curve analysis was performed to determine the optimal cutoff values for various perioperative factors. Risk factors for the overall survival and death from other diseases were analyzed using the Cox proportional hazards model.
RESULTS: Among the all perioperative factors, sex, neutrophil-to-lymphocyte ratio, skeletal muscle mass index, and lymph node dissection in accordance with guidelines or not extracted as independent risk factors for death from other diseases. In an analysis restricted to the preoperative factors, sex, neutrophil-to-lymphocyte ratio, and skeletal muscle mass index of the patients were extracted as independent risk factors for death from other diseases and overall survival. We divided the patients into four groups according to the number of preoperative risk factors for death from other diseases and found that the 5-year non-gastric-cancer-related survival was different among the four groups (risk factor 0, 91.7\%; risk factor 1, 83.3\%; risk factor 2, 56.3\%; risk factor 3, 27.2\%; P {\textless} 0.001).
CONCLUSION: Male sex, low skeletal muscle mass index, and high neutrophil-to-lymphocyte ratio are risk factors for non-gastric-cancer-related death and the overall survival of elderly patients undergoing gastrectomy. Cautious treatment strategies are needed for elderly gastric cancer patients with many risk factors.},
	language = {eng},
	number = {6},
	journal = {Annals of Gastroenterological Surgery},
	author = {Iida, Michihisa and Takeda, Shigeru and Nakashima, Chiyo and Nishiyama, Mitsuo and Watanabe, Yusaku and Suzuki, Nobuaki and Yoshino, Shigefumi and Nakagami, Yuki and Tanabe, Tsuyoshi and Nagano, Hiroaki},
	month = nov,
	year = {2022},
	pmid = {36338595},
	pmcid = {PMC9628222},
	keywords = {Sarcopenia, gastric cancer, elderly, gastrectomy, risk factors, prognosis, NLR},
	pages = {753--766},
	file = {Iida et al_2022_Risk factors for non-gastric-cancer-related death after gastrectomy in elderly.pdf:/Users/jcsal/Zotero/storage/RF5M57D7/Iida et al_2022_Risk factors for non-gastric-cancer-related death after gastrectomy in elderly.pdf:application/pdf},
}

@article{ko,
	title = {Low {Rates} of {Medical} {Oncology} {Consultation} for {Older} {Women} (≥ 70 {Years}) with {Newly} {Diagnosed}, {Non}-{Metastatic} {Breast} {Cancer}: {A} {Population}-{Based} {Study}},
	issn = {1534-4681},
	shorttitle = {Low {Rates} of {Medical} {Oncology} {Consultation} for {Older} {Women} (≥ 70 {Years}) with {Newly} {Diagnosed}, {Non}-{Metastatic} {Breast} {Cancer}},
	doi = {10.1245/s10434-022-12640-8},
	abstract = {BACKGROUND: Curative intent cancer treatment needs to be balanced with patient comorbidities and quality of life when treating older women with breast cancer. We examined consultation patterns and association of age at diagnosis with lack of specialist cancer consultations for older women with breast cancer.
METHODS: We conducted a population-based retrospective cohort study of older women (≥ 70 years of age) with incident, non-metastatic breast cancer (2010-2018) by linking administrative databases in Ontario, Canada. The outcomes of interest were lack of specialist cancer consultation (surgeon, medical oncology, or radiation oncology) within 12 months of diagnosis. Association of age with lack of specialist cancer consultation was examined using Poisson regression modeling.
RESULTS: Of 21,849 older women, 2.4\% (n = 517) did not have any specialist cancer consultation within 12 months of diagnosis; lack of any specialist cancer consultation increased with age (0.8\% for age 70-74 years, 1.3\% for age 75-79 years, 2.5\% for age 80-84 years, and 7.0\% for age ≥ 85 years; p {\textless} 0.001). The proportion of patients who did not have consultations with surgeons, medical oncologists, and radiation oncologists was 8.6\% (n = 1888), 34.4\% (n = 7510), and 24.7\% (n = 5404), respectively. Older age group was independently associated with an increased likelihood of lacking any specialist consultation, as well as not receiving surgical and medical oncology consultations.
CONCLUSION: More than one-third of women ≥ 70 years of age with non-metastatic breast cancer did not have a consultation with a medical oncologist, with women aged ≥ 85 years least likely to have a medical oncology consultation.},
	language = {eng},
	journal = {Annals of Surgical Oncology},
	author = {Ko, Gary and Hallet, Julie and Jerzak, Katarzyna J. and Chan, Wing and Coburn, Natalie and Barabash, Victoria and Wright, Frances C. and Look Hong, Nicole J.},
	month = oct,
	year = {2022},
	pmid = {36255513},
	keywords = {BreastCancer},
}

@article{hurria1708,
	title = {Reply to {N}. {Lowy} et al and to {J}. {Dhanda} et al},
	volume = {34},
	issn = {1527-7755},
	doi = {10.1200/JCO.2015.66.3740},
	language = {eng},
	number = {14},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Hurria, Arti and Levit, Laura A. and Dale, William and Mohile, Supriya G. and Muss, Hyman B. and Fehrenbacher, Louis and Magnuson, Allison and Lichtman, Stuart M. and Bruinooge, Suanna S. and Soto-Perez-de-Celis, Enrique and Tew, William P. and Postow, Michael A. and Cohen, Harvey J.},
	month = may,
	year = {2016},
	pmid = {27001583},
	keywords = {Chemo},
	pages = {1708--1709},
}

@article{foster584,
	title = {How does older age influence oncologists' cancer management?},
	volume = {15},
	issn = {1549-490X},
	doi = {10.1634/theoncologist.2009-0198},
	abstract = {BACKGROUND: Over half of new cancer cases occur in patients aged {\textgreater} or = 65 years. Many older patients can benefit from intensive cancer therapies, yet evidence suggests that this population is undertreated.
METHODS: To assess preferences and influential factors in geriatric cancer management, practicing U.S. medical oncologists completed a survey containing four detailed vignettes exploring colon, breast, lung, and prostate cancer treatment. Participants were randomly assigned one of two surveys with vignettes that were identical except for patient age ({\textless}65 years or {\textgreater}70 years).
RESULTS: Physicians in each survey group (n = 200) were demographically similar. Intensive therapy was significantly less likely to be recommended for an older than for a younger, but otherwise identical, patient in two of the scenarios. For a woman with metastatic colon cancer (Eastern Cooperative Oncology Group [ECOG] score, 1) for whom chemotherapy was recommended, nearly all oncologists chose an intensive regimen if the patient's age was 63; but if her age was 85, one fourth of the oncologists chose a less intensive treatment. Likewise, for stage IIA breast cancer (ECOG score, 0), 93\% recommended intensive adjuvant treatment for a previously healthy patient aged 63; but only 66\% said they would do so if the patient's age was 75. Oncologists commonly identified patient age as an influence on treatment choice, but were even more likely to cite performance status as a determining factor.
CONCLUSIONS: Advanced age can deter oncologists from choosing intensive cancer therapy, even if patients are highly functional and lack comorbidities. Education on tailoring cancer treatment and a greater use of comprehensive geriatric assessment may reduce cancer undertreatment in the geriatric population.},
	language = {eng},
	number = {6},
	journal = {The Oncologist},
	author = {Foster, Jill A. and Salinas, Gregory D. and Mansell, Dorcas and Williamson, James C. and Casebeer, Linda L.},
	year = {2010},
	pmid = {20495217},
	pmcid = {PMC3227998},
	keywords = {Humans, Aged, Female, Male, Treatment Outcome, Neoplasms, Age Factors, Chemotherapy, Adjuvant, Surveys and Questionnaires, Elderly, Geriatric Assessment, Practice Patterns, Physicians', Medical Oncology, Health Care Surveys},
	pages = {584--592},
	file = {Foster et al_2010_How does older age influence oncologists' cancer management.pdf:/Users/jcsal/Zotero/storage/7UG547Z7/Foster et al_2010_How does older age influence oncologists' cancer management.pdf:application/pdf},
}

@article{keating2532,
	title = {Adjuvant chemotherapy for stage {III} colon cancer: do physicians agree about the importance of patient age and comorbidity?},
	volume = {26},
	issn = {1527-7755},
	shorttitle = {Adjuvant chemotherapy for stage {III} colon cancer},
	doi = {10.1200/JCO.2007.15.9434},
	abstract = {PURPOSE: We surveyed cancer physicians to understand how patients' age and comorbidity influence adjuvant chemotherapy recommendations and whether physician or practice characteristics also affect these recommendations.
METHODS: National survey of surgeons and medical oncologists caring for patients with colorectal cancer regarding whether they would recommend adjuvant chemotherapy for hypothetical patients with stage III colon cancer who varied by age (55 v 80 years) and comorbid illness (none, moderate, severe congestive heart failure [CHF]). Repeated measures logistic regression was used to assess the influence of patient, physician, and practice characteristics on chemotherapy recommendations.
RESULTS: Of 1,096 physicians, nearly all recommended chemotherapy for patients who were 55 years old with no comorbidity (99.0\%), 55-years old with moderate CHF (88.6\%), or 80 years old with no comorbidity (92.6\%); many fewer recommended chemotherapy for 55-year-old patients with severe CHF (24.9\%) or 80-year-old patients with moderate (47.2\%) or severe (9.0\%) CHF (P {\textless} .001). Younger physicians (P {\textless} .001) were more likely than others to recommend adjuvant chemotherapy overall, although physician factors explained little of the variability in recommendations.
CONCLUSION: Physicians agree with guidelines recommending adjuvant chemotherapy for young, healthy patients with stage III colon cancer but differ widely on recommendations for patients who are older and sicker. Few physician or practice characteristics were associated with recommendations. For older and sicker patients, the individual physicians seen may have a substantial impact on the likelihood of receiving chemotherapy. Understanding better the sources of variation not explained by patients' clinical characteristics may allow improved tailoring of therapy to patients most likely to benefit.},
	language = {eng},
	number = {15},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Keating, Nancy L. and Landrum, Mary Beth and Klabunde, Carrie N. and Fletcher, Robert H. and Rogers, Selwyn O. and Doucette, William R. and Tisnado, Diana and Clauser, Steven and Kahn, Katherine L.},
	month = may,
	year = {2008},
	pmid = {18487570},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Lung Neoplasms, Antineoplastic Agents, CRC, Aged, 80 and over, Adult, Age Factors, Chemotherapy, Adjuvant, Colonic Neoplasms, Comorbidity, Decision Making, Physicians},
	pages = {2532--2537},
}

@article{rosati578,
	title = {Oxaliplatin-{Based} {Chemotherapy} in {Patients} with {Metastatic} {Colorectal} {Cancer} {Aged} at {Least} 75 {Years}: {A} {Post}-{Hoc} {Subgroup} {Analysis} of {Three} {Phase} {II} {Trials}},
	volume = {11},
	issn = {2072-6694},
	shorttitle = {Oxaliplatin-{Based} {Chemotherapy} in {Patients} with {Metastatic} {Colorectal} {Cancer} {Aged} at {Least} 75 {Years}},
	doi = {10.3390/cancers11040578},
	abstract = {Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45\%, comparable to younger patients (51\%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3-4 adverse events included diarrhea (13\%), fatigue (13\%), peripheral neuropathy (10\%), and neutropenia (7\%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.},
	language = {eng},
	number = {4},
	journal = {Cancers},
	author = {Rosati, Gerardo and Cordio, Stefano and Reggiardo, Giorgio and Aprile, Giuseppe and Butera, Alfredo and Avallone, Antonio and Tucci, Aniello and Novello, Giuseppe and Blanco, Giuseppina and Caputo, Giuseppe and Bilancia, Domenico and Bordonaro, Roberto},
	month = apr,
	year = {2019},
	pmid = {31022922},
	pmcid = {PMC6521155},
	keywords = {CRC, oxaliplatin, colorectal cancer, elderly patients, doublet chemotherapy},
	pages = {578},
	file = {Rosati et al_2019_Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.pdf:/Users/jcsal/Zotero/storage/56YYA8GF/Rosati et al_2019_Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.pdf:application/pdf},
}

@article{chen3395,
	title = {Evaluation of determinants for age disparities in the survival improvement of colon cancer: results from a cohort of more than 486,000 patients in the {United} {States}},
	volume = {10},
	issn = {2156-6976},
	shorttitle = {Evaluation of determinants for age disparities in the survival improvement of colon cancer},
	abstract = {Over the past two decades, elderly colon cancer patients experienced less improvement in survival than their younger counterparts, yet the contributing factors remain unknown. We aimed to evaluate factors that may contribute to the age disparity of survival improvement among patients with colon cancer. Using data from the National Cancer Database, we identified patients diagnosed with colon cancer between 2004 and 2012 with follow-up data up to 2017. The hazard ratios (HR) and 95\% confidence intervals (CI) for 5-year OS associated with study variables were estimated using multivariable Cox regression. Among 486,284 patients included in this study, elderly patients (aged ≥75) had a lower adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines (\% of non-adherence: 45.3\%) than younger patients (aged {\textless}50, 19.3\%; P{\textless}0.001). After adjusting for demographics, access to care and clinical characteristics, compared with patients diagnosed between 2004 and 2006, younger and older patients diagnosed between 2010 and 2012 experienced 16\% (HR: 0.84, 95\% CI: 0.81-0.88) and 6\% (HR: 0.94, 95\% CI: 0.93-0.95) reductions in mortality (P for interaction=1.42×10-5), respectively. After an additional adjustment for guideline adherence status, no significant difference in the improvement of survival was noted (P for interaction=0.17). The association patterns were similar regardless of tumor stage, race, and high comorbidity scores (all P for interaction{\textgreater}0.05). Several patient-related factors were identified in association with noncompliance to NCCN guidelines, including comorbidity status. However, over 60\% of noncompliance elderly patients had a Charlson comorbidity score of 0. The observed age disparity in survival improvement among colon cancer patients was primarily explained by a slower improvement in adherence to NCCN treatment guidelines in elderly than younger patients. Many older adults were not receiving recommended therapies despite minimal comorbidities. Our findings call for measures to increase adherence to treatment guidelines among elderly patients to improve survival.},
	language = {eng},
	number = {10},
	journal = {American Journal of Cancer Research},
	author = {Chen, Fa and Wang, Fei and Bailey, Christina E. and Murff, Harvey J. and Berlin, Jordan D. and Shu, Xiao-Ou and Zheng, Wei},
	year = {2020},
	pmid = {33163278},
	pmcid = {PMC7642646},
	keywords = {CRC, Colon cancer, elderly populations, guideline adherence, survival improvement},
	pages = {3395--3405},
}

@article{crosarateixeira52,
	title = {The effects of palliative chemotherapy in metastatic colorectal cancer patients with an {ECOG} performance status of 3 and 4},
	volume = {14},
	issn = {1938-0674},
	doi = {10.1016/j.clcc.2014.09.010},
	abstract = {BACKGROUND: Although chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS {\textgreater} 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only.
PATIENTS AND METHODS: We retrospectively analyzed all consecutive mCRC patients who started first-line chemotherapy at our institution in a 4-year period. A multivariable Cox regression model was used to adjust for prognostic factors and logistic regression, to identify predictive factors of Grade 3/4 toxicity.
RESULTS: From June 2008 to June 2012, 240 consecutive patients were included: 100 (41.7\%) had an ECOG PS of 0/1, 75 (31.3\%) ECOG PS of 2, and 65 (27\%) ECOG PS of 3/4. Median survival for patients treated with chemotherapy was 18.4 months for patients with ECOG PS of 0/1, 10.8 months for those with ECOG PS of 2, and 6.8 months for patients with ECOG PS of 3/4. Among those with ECOG PS of 3/4, chemotherapy use led to a nonsignificant survival gain (median, 6.8 vs. 2.3 months for BSC; P = .13). Factors significantly associated with worse survival in an adjusted analysis were right-sided tumors (hazard ratio [HR], 2.97; P = .005) and ECOG PS status (ECOG PS 2 vs. 0/1; HR, 1.67; P = .025, and ECOG PS 3/4 vs. 0/1; HR, 2.67; P {\textless} .0001). The rate of Grade ≥ 3 toxicities during the first cycle did not differ significantly across ECOG groups; likely because 40\% of ECOG PS 3/4 patients received upfront dose-reduced therapy. The rates of treatment-related hospitalization were similar across all ECOG groups. All deaths were disease-associated.
CONCLUSION: Our retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized.},
	language = {eng},
	number = {1},
	journal = {Clinical Colorectal Cancer},
	author = {Crosara Teixeira, Marcela and Marques, Daniel Fernandes and Ferrari, Anezka Celis and Alves, Michel Fabiano Silva and Alex, Alexandra Khichfy and Sabbaga, Jorge and Hoff, Paulo M. and Riechelmann, Rachel P.},
	month = mar,
	year = {2015},
	pmid = {25442812},
	keywords = {Humans, Aged, Female, Hospitalization, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Retrospective Studies, Neoplasm Metastasis, Palliative Care, Survival Rate, Antineoplastic Agents, Prognosis, Aged, 80 and over, Adult, Chemotherapy, Dose-Response Relationship, Drug, Logistic Models, Colorectal cancer, Best supportive care, Drug Monitoring, Poor performance status},
	pages = {52--57},
}

@article{simmonds531,
	title = {Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. {Colorectal} {Cancer} {Collaborative} {Group}},
	volume = {321},
	issn = {0959-8138},
	shorttitle = {Palliative chemotherapy for advanced colorectal cancer},
	doi = {10.1136/bmj.321.7260.531},
	abstract = {OBJECTIVES: To determine the benefits and harms of palliative chemotherapy in patients with locally advanced or metastatic colorectal cancer and to compare the outcomes for elderly and younger patients.
DESIGN: Meta-analysis of individual patient data and published summary statistics from trials for which individual patient data could not be obtained from the investigators.
STUDIES: All randomised controlled trials comparing palliative chemotherapy with supportive care in patients with advanced colorectal cancer that were identified by computerised and hand searches of the literature, scanning references, and contacting investigators.
MAIN OUTCOME MEASURES: Survival, disease progression, quality of life, and toxicity.
RESULTS: 13 randomised controlled trials including a total of 1365 patients met the inclusion criteria. Meta-analysis of seven trials that provided individual patient data (866 patients) showed that palliative chemotherapy was associated with a 35\% reduction in the risk of death (95\% confidence interval 24\% to 44\%). This translates into an absolute improvement in survival of 16\% at both six and 12 months and an improvement in median survival of 3.7 months. No age related differences were found in the effectiveness of chemotherapy, but elderly patients were under represented in trials. The overall quality of evidence relating to treatment toxicity, symptom control, and quality of life was poor.
CONCLUSIONS: Chemotherapy is effective in prolonging time to disease progression and survival in patients with advanced colorectal cancer. The survival benefit may be underestimated in this analysis as some patients in the control arms received chemotherapy.},
	language = {eng},
	number = {7260},
	journal = {BMJ (Clinical research ed.)},
	author = {Simmonds, P. C.},
	month = sep,
	year = {2000},
	pmid = {10968812},
	pmcid = {PMC27466},
	keywords = {Humans, Aged, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Disease Progression, Palliative Care, Proportional Hazards Models, CRC, Randomized Controlled Trials as Topic, Fluorouracil, Survival Analysis, Antimetabolites, Antineoplastic, Odds Ratio, ECOG, Databases, Bibliographic},
	pages = {531--535},
	file = {Simmonds_2000_Palliative chemotherapy for advanced colorectal cancer.pdf:/Users/jcsal/Zotero/storage/EP5HUFWD/Simmonds_2000_Palliative chemotherapy for advanced colorectal cancer.pdf:application/pdf},
}

@article{barnard1686,
	title = {Machine {Learning} for {Automatic} {Paraspinous} {Muscle} {Area} and {Attenuation} {Measures} on {Low}-{Dose} {Chest} {CT} {Scans}},
	volume = {26},
	issn = {1878-4046},
	doi = {10.1016/j.acra.2019.06.017},
	abstract = {RATIONALE AND OBJECTIVES: To develop and evaluate an automated machine learning (ML) algorithm for segmenting the paraspinous muscles on chest computed tomography (CT) scans to evaluate for presence of sarcopenia.
MATERIALS AND METHODS: A convolutional neural network based on the U-Net architecture was trained to perform muscle segmentation on a dataset of 1875 single slice CT images and was tested on 209 CT images of participants in the National Lung Screening Trial. Low-dose, noncontrast CT examinations were obtained at 33 clinical sites, using scanners from four manufacturers. The study participants had a mean age of 71.6 years (range, 70-74 years). Ground truth was obtained by manually segmenting the left paraspinous muscle at the level of the T12 vertebra. Muscle cross-sectional area (CSA) and muscle attenuation (MA) were recorded. Comparison between the ML algorithm and ground truth measures of muscle CSA and MA were obtained using Dice similarity coefficients and Pearson correlations.
RESULTS: Compared to ground truth segmentation, the ML algorithm achieved median (standard deviation) Dice scores of 0.94 (0.04) in the test set. Mean (SD) muscle CSA was 14.3 (3.6) cm2 for ground truth and 13.7 (3.5) cm2 for ML segmentation. Mean (SD) MA was 41.6 (7.6) Hounsfield units (HU) for ground truth and 43.5 (7.9) HU for ML segmentation. There was high correlation between ML algorithm and ground truth for muscle CSA (r2 = 0.86; p {\textless} 0.0001) and MA (r2 = 0.95; p {\textless} 0.0001).
CONCLUSION: The ML algorithm for measurement of paraspinous muscles compared favorably to manual ground truth measurements in the NLST. The algorithm generalized well to a heterogeneous set of low-dose CT images and may be capable of automated quantification of muscle metrics to screen for sarcopenia on routine chest CT examinations.},
	language = {eng},
	number = {12},
	journal = {Academic Radiology},
	author = {Barnard, Ryan and Tan, Josh and Roller, Brandon and Chiles, Caroline and Weaver, Ashley A. and Boutin, Robert D. and Kritchevsky, Stephen B. and Lenchik, Leon},
	month = dec,
	year = {2019},
	pmid = {31326311},
	pmcid = {PMC6878160},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Myosteatosis, Radiation Dosage, Machine Learning, Muscle, Paraspinal Muscles, Algorithms, Chest CT, Machine learning, chest, ML},
	pages = {1686--1694},
	annote = {ContentsAbstractINTRODUCTIONMETHODSDatasetCT AcquisitionGround Truth SegmentationPre-processingConvolutional Neural Network ModelTrainingTestingImplementationRESULTSDISCUSSIONLimitationsFuture DirectionsCONCLUSIONReferencesFigure 1.Figure 2.Figure 3.Figure 4.Figure 5.Figure 6Table 1:},
	annote = {WFU: ML Segmentation of L paraspinus muscle from Natl Lung Cancer Screening Trial.  Manual slice selection. UU-Net architecture.
},
	file = {Barnard et al_2019_Machine Learning for Automatic Paraspinous Muscle Area and Attenuation Measures.pdf:/Users/jcsal/Zotero/storage/BI4NH6UT/Barnard et al_2019_Machine Learning for Automatic Paraspinous Muscle Area and Attenuation Measures.pdf:application/pdf},
}

@article{jack1313,
	title = {The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery},
	volume = {40},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2014.03.010},
	abstract = {BACKGROUND: Neoadjuvant chemotherapy (NAC) followed by surgery for resectable oesophageal or gastric cancer improves outcome when compared with surgery alone. However NAC has adverse effects. We assess here whether NAC adversely affects physical fitness and whether such an effect is associated with impaired survival following surgery.
METHODS: We prospectively studied 116 patients with oesophageal or gastric cancer to assess the effect of NAC on physical fitness, of whom 89 underwent cardiopulmonary exercise testing (CPET) before NAC and proceeded to surgery. 39 patients were tested after all cycles of NAC but prior to surgery. Physical fitness was assessed by measuring oxygen uptake (VO₂ in ml kg(-1) min(-1)) at the estimated lactate threshold (θL) and at peak exercise (VO₂ peak in ml kg(-1) min(-1)).
RESULTS: VO₂ at θL and at peak were significantly lower after NAC compared to pre-NAC values: VO₂ at θL 14.5 ± 3.8 (baseline) vs. 12.3 ± 3.0 (post-NAC) ml kg(-1) min(-1); p ≤ 0.001; VO₂ peak 20.8 ± 6.0 vs. 18.3 ± 5.1 ml kg(-1) min(-1); p ≤ 0.001; absolute VO₂ (ml min(-1)) at θL and peak were also lower post-NAC; p ≤ 0.001. Decreased baseline VO₂ at θL and peak were associated with increased one year mortality in patients who completed a full course of NAC and had surgery; p = 0.014.
CONCLUSION: NAC before cancer surgery significantly reduced physical fitness in the overall cohort. Lower baseline fitness was associated with reduced one-year-survival in patients completing NAC and surgery, but not in patients who did not complete NAC. It is possible that in some patients the harms of NAC may outweigh the benefits. Trials Registry Number: NCT01335555.},
	language = {eng},
	number = {10},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Jack, S. and West, M. A. and Raw, D. and Marwood, S. and Ambler, G. and Cope, T. M. and Shrotri, M. and Sturgess, R. P. and Calverley, P. M. A. and Ottensmeier, C. H. and Grocott, M. P. W.},
	month = oct,
	year = {2014},
	pmid = {24731268},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Prospective Studies, Antineoplastic Agents, Cohort Studies, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Stomach Neoplasms, Esophageal Neoplasms, Survival, Physical Fitness, Exercise Test, Exercise Tolerance, Cancer surgery, Cardiopulmonary exercise testing, Neoadjuvant chemotherapy, Oesphagogastric, Oxygen Consumption, Physical fitness, CPT},
	pages = {1313--1320},
}

@article{sargent1948,
	title = {Pooled {Safety} and {Efficacy} {Analysis} {Examining} the {Effect} of {Performance} {Status} on {Outcomes} in {Nine} {First}-{Line} {Treatment} {Trials} {Using} {Individual} {Data} {From} {Patients} {With} {Metastatic} {Colorectal} {Cancer}},
	volume = {27},
	issn = {0732-183X},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669760/},
	doi = {10.1200/JCO.2008.20.2879},
	abstract = {Purpose
Performance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical trials typically enroll less than 10\% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain.

Patients and Methods
Individual data from 6,286 patients (509 PS2 patients) from nine clinical trials were used to compare treatment efficacy by PS. Progression-free survival (PFS), grade ≥ 3 adverse events, 60-day all-cause mortality, overall survival (OS), and response rate (RR) were explored in the full set of nine trials and in the five trials comparing first-line monotherapy with combination therapy.

Results
Compared with patients with PS of 0 or 1, PS2 patients had significantly higher rates of grade ≥ 3 nausea (8.5\% v 16.4\%, respectively; P {\textless} .0001) and vomiting (7.6\% v 11.9\%, respectively; P = .006) and 60-day all-cause mortality (2.8\% v 12.0\%, respectively; P {\textless} .0001). PS2 was prognostic for PFS (hazard ratio [HR] = 1.52; P {\textless} .0001; median PFS, 7.6 months for PS 0 or 1 v 4.9 months for PS2), OS (HR = 2.18; P {\textless} .0001; median OS, 17.3 months for PS 0 or 1 v 8.5 months for PS2), and RR (odds ratio = 0.61; P {\textless} .0001; 43.8\% for PS 0 or 1 v 32.0\% for PS2). The relative benefit and toxicity of experimental versus control treatment and monotherapy versus combination therapy were not different in PS 0 or 1 patients versus PS2 patients.

Conclusion
In clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to 1 but with an increased risk of toxicities and 12\% 60-day mortality. Although current treatment provides benefit, new approaches are required to approach 1-year median survival for PS2 patients.},
	number = {12},
	urldate = {2022-12-10},
	journal = {Journal of Clinical Oncology},
	author = {Sargent, Daniel J. and Köhne, Claus Henning and Sanoff, Hanna Kelly and Bot, Brian M. and Seymour, Matthew T. and de Gramont, Aimery and Porschen, Ranier and Saltz, Leonard B. and Rougier, Philippe and Tournigand, Christopher and Douillard, Jean-Yves and Stephens, Richard J. and Grothey, Axel and Goldberg, Richard M.},
	month = apr,
	year = {2009},
	pmid = {19255311},
	pmcid = {PMC2669760},
	keywords = {CRC},
	pages = {1948--1955},
	file = {Sargent et al_2009_Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status.pdf:/Users/jcsal/Zotero/storage/ZRBP7NZ8/Sargent et al_2009_Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status.pdf:application/pdf},
}

@article{lavin1536,
	title = {Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an {Eastern} {Cooperative} {Oncology} {Group} report},
	volume = {46},
	issn = {0008-543X},
	shorttitle = {Survival and response to chemotherapy for advanced colorectal adenocarcinoma},
	doi = {10.1002/1097-0142(19801001)46:7<1536::aid-cncr2820460707>3.0.co;2-k},
	abstract = {A series of 1,314 cases of advanced measurable colon or rectal cancer were evaluated for objective tumor response and survival. All patients received chemotherapy according to protocols conducted by the Eastern Cooperative Oncology Group during the period between 1974 and 1977. For those patients who had not received chemotherapy prior to study entry, no therapy program under evaluations was significantly more active than the oral or intravenous 5-fluorouracil treatment programs with respect to survival or objective tumor response. The survival and response rates therapy programs under study, including methyl-CCNU, appeared to be comparable. Initial performance status (P {\textless} 0.01), weight loss in the six months prior to study entry (P {\textless} 0.001), and prior chemotherapy status were shown to be most prognostic for survival, and thus merit inclusion as stratification factors in any comparative trial involving this population. These factors were shown to have a cumulatively greater influence upon survival than the treatment program. Treatment differences were most accentuated within the favorable subgroups of the leading prognostic factors. The location of the primary tumor had a significant effect upon the eventual sites of metastatic disease involvement at the time of study entry (P {\textless} 0.001). The consequences of this analysis suggest that investigators need to address characteristics of the population under study. It is also noted that patients with chemotherapy prior to study entry are best suited for survival studies, while patients with no chemotherapy prior to study entry are well suited for both objective tumor response and survival studies.},
	language = {eng},
	number = {7},
	journal = {Cancer},
	author = {Lavin, P. and Mittelman, A. and Douglass, H. and Engstrom, P. and Klaassen, D.},
	month = oct,
	year = {1980},
	pmid = {6998557},
	keywords = {Humans, Neoplasm Metastasis, Antineoplastic Agents, Prognosis, Colonic Neoplasms, Drug Administration Schedule, Neoplasm Recurrence, Local, Clinical Trials as Topic, Rectal Neoplasms, Drug Therapy, Combination, ECOG},
	pages = {1536--1543},
}

@article{kemeny786,
	title = {Prognostic factors in advanced colorectal carcinoma. {Importance} of lactic dehydrogenase level, performance status, and white blood cell count},
	volume = {74},
	issn = {0002-9343},
	doi = {10.1016/0002-9343(83)91066-5},
	abstract = {In 220 patients with advanced colorectal carcinoma, objective tumor response to chemotherapy and survival were related to the following parameters: age, sex, performance status, time interval from diagnosis to metastases, initial site of metastases, and initial white blood cell count, lactic dehydrogenase, alkaline phosphatase, and carcinoembryonic antigen levels. Each variable was first evaluated separately. By conventional statistical methods, none of the variables significantly predicted response, although the following parameters significantly (p less than 0.01) predicted survival: Patients with an initially normal level of lactic dehydrogenase versus those with an abnormal level of lactic dehydrogenase had median survivals of 16 and 7.0 months, respectively; normal versus abnormal carcinoembryonic antigen levels, 23 and 9.2 months, respectively; white blood cell count of less than 10,000 versus greater than 10,000 cells/mm3, 11 and 7.0 months, respectively; performance status of greater than 70 versus less than 60, 11 and 6.6 months, respectively; and lung versus liver metastases, 12 and 8.0 months, respectively. By studying the variables together with multivariate analysis, we found that the most important variables in predicting response were the lactic dehydrogenase level and the white blood cell count. In predicting survival, the most important variables were the lactic dehydrogenase level, performance status, and lung involvement. We recommend that future randomized therapeutic trials for advanced colorectal carcinoma should delineate and perhaps stratify for the lactic dehydrogenase level, performance status, white blood cell count, and/or the presence of lung involvement.},
	language = {eng},
	number = {5},
	journal = {The American Journal of Medicine},
	author = {Kemeny, N. and Braun, D. W.},
	month = may,
	year = {1983},
	pmid = {6837602},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Metastasis, Lung Neoplasms, Prognosis, Adult, Colonic Neoplasms, Rectal Neoplasms, Carcinoembryonic Antigen, L-Lactate Dehydrogenase, Leukocyte Count},
	pages = {786--794},
}

@article{kohne308,
	title = {Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients},
	volume = {13},
	issn = {0923-7534},
	shorttitle = {Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer},
	doi = {10.1093/annonc/mdf034},
	abstract = {BACKGROUND: Patients with metastatic colorectal cancer are usually offered systemic chemotherapy as palliative treatment. A multivariate analysis was performed in order to identify predictors and their constellation that allow a valid prediction of the outcome in patients treated with 5-fluorouracil (5-FU)-based therapy.
PATIENTS AND METHODS: A total of 3825 patients treated with 5-FU within 19 prospective randomised and three phase II trials were separated into learning (n = 2549) and validation (n = 1276) samples. Data were analysed by tree analysis using the recursive partition and amalgamation method (RECPAM). A predictor could only enter the RECPAM analysis if the number of patients with missing values was {\textless} 33.3\% within a node, and the minimal node size was set to 50 patients. Twenty-three potential predictors were grouped into subsets of laboratory variables (11 parameters), tumour-related variables (seven parameters) and clinical variables (five parameters). In the first step, tree analysis was performed separately for each predictor subset. The selected prognostic parameters of the resulting partial models (the 'winners') were entered into the general model. The classification rule from the data of the learning set was applied to the independent validation set.
RESULTS: Winners of the subgroup analysis for laboratory variables were: platelets {\textgreater} or = 400 x 10(9)/l, alkaline phosphatase {\textgreater} or = 300 U/l, white blood cell (WBC) count {\textgreater} or = 10 x 10(9)/l and haemoglobin {\textless} 11 x 10(9)/l, and all predicted a worse outcome. Negative predictors within the subgroup of tumour parameters were: number of tumour sites more than one or more than two, presence of liver metastases or peritoneal carcinomatosis, which predicted a worse outcome. Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting. Among the clinical parameters only performance status of ECOG 0 or 1 predicted better outcome. In the final regression tree, three risk groups could be identified: low risk group (n = 1111) with a median survival of 15 months for patients with ECOG 0/1 and only one tumour site; intermediate risk group (n = 904) with a median survival of 10.7 months for patients with ECOG 0/1 and more than one tumour site and alkaline phosphatase {\textless} 300 U/l or patients with ECOG {\textgreater} 1, WBC count {\textless} 10 x 10(9)/l and only one tumour site; high risk group (n = 534) with a median survival of 6.1 months for patients with ECOG 0/1 and more than one tumour site and alkaline phosphatase of {\textgreater} or = 300 U/l or patients with ECOG {\textgreater} 1 and more than one tumour site or WBC count {\textgreater} 10 x 10(9)/l. The median survival times for the good, intermediate and high risk groups in the validation sample were 14.7, 10.5 and 6.4 months, respectively.
CONCLUSIONS: Patients can be divided into at least three risk groups depending on the four baseline clinical parameters: performance status, WBC count, alkaline phosphatase and number of metastatic sites. Any molecular or biological marker should be validated against these clinical parameters and decisions for more or less intensive treatments may be studied separately in these three risk groups. Also, clinical trials should be stratified according to the three risk groups.},
	language = {eng},
	number = {2},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Köhne, C. H. and Cunningham, D. and Di Costanzo, F. and Glimelius, B. and Blijham, G. and Aranda, E. and Scheithauer, W. and Rougier, P. and Palmer, M. and Wils, J. and Baron, B. and Pignatti, F. and Schöffski, P. and Micheel, S. and Hecker, H.},
	month = feb,
	year = {2002},
	pmid = {11886010},
	keywords = {Humans, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Prospective Studies, CRC, Fluorouracil, Multivariate Analysis, Leukocyte Count, Alkaline Phosphatase},
	pages = {308--317},
}

@article{sohalpkx009,
	title = {Clinical {Predictors} of {Early} {Mortality} in {Colorectal} {Cancer} {Patients} {Undergoing} {Chemotherapy}: {Results} {From} a {Global} {Prospective} {Cohort} {Study}},
	volume = {1},
	issn = {2515-5091},
	shorttitle = {Clinical {Predictors} of {Early} {Mortality} in {Colorectal} {Cancer} {Patients} {Undergoing} {Chemotherapy}},
	doi = {10.1093/jncics/pkx009},
	abstract = {BACKGROUND: Early mortality is a major problem in colorectal cancer (CRC). We have shown that Khorana Score is predictive of early mortality in other cancers. Here, we evaluated the value of this score and other prognostic variables in predicting early mortality in CRC.
METHODS: CANTARISK was a prospective, noninterventional, global cohort study in patients with CRC initiating a new chemotherapy regimen. Data were collected at zero, two, four, and six months. Early mortality was defined as death within six months of enrollment. All data were compiled centrally and analyzed after the study closed. Statistically significant univariate associations were tested in multivariable models; adjusted odds ratios (ORs) are presented. Statistical tests were two-sided.
RESULTS: From 2011 to 2012, 1789 CRC patients were enrolled. The median age was 62 years; 71\% were Caucasian. One-third (35\%) had a rectal primary, and 65\% had metastatic disease. There were 184 (10.3\%) patients who died during their first six months in the study. For low, intermediate, and high Khorana Score, there were 8.1\%, 11.2\% and 32.5\% deaths, respectively. In multivariable analyses, Khorana Score was an independent predictor of early death (OR for high/intermediate vs low score = 1.70, P = .0027), in addition to age (OR for each incremental year = 1.03, P = .0014), presence of metastatic disease (OR = 3.28, P {\textless} .0001), and Easter Cooperative Oncology Group Performance Status Score of 2 or higher (OR = 3.85, P {\textless} .0001).
CONCLUSIONS: This study demonstrates that Khorana Score is predictive of early mortality in CRC patients. Intermediate- or high-risk patients, as defined by this score, may benefit from additional interventions aimed at reducing early mortality.},
	language = {eng},
	number = {1},
	journal = {JNCI cancer spectrum},
	author = {Sohal, Davendra P. S. and Kuderer, Nicole M. and Shepherd, Frances A. and Pabinger, Ingrid and Agnelli, Giancarlo and Liebman, Howard A. and Meyer, Guy and Kalady, Matthew F. and McCrae, Keith and Lyman, Gary H. and Khorana, Alok A.},
	month = sep,
	year = {2017},
	pmid = {31360835},
	pmcid = {PMC6649852},
	keywords = {CRC},
	pages = {pkx009},
	file = {Sohal et al_2017_Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing.pdf:/Users/jcsal/Zotero/storage/68964A7Z/Sohal et al_2017_Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing.pdf:application/pdf},
}

@article{chibaudel1228,
	title = {Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a {GERCOR} study},
	volume = {16},
	issn = {1549-490X},
	shorttitle = {Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer},
	doi = {10.1634/theoncologist.2011-0039},
	abstract = {BACKGROUND: The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer.
PATIENTS AND METHODS: Eight hundred three patients treated with FOLFOX or FOLFIRI in three prospective trials were randomly separated into learning (n = 535) and validation (n = 268) samples. Eleven baseline variables were evaluated in univariate and multivariate analysis as prognostic factors for overall survival, and a prognostic score was developed.
RESULTS: Independent prognostic factors identified in multivariate analysis for overall survival were performance status (PS) (p {\textless} .001), serum lactate dehydrogenase (LDH) (p {\textless} .001), and number of metastatic sites (p = .005). A prognostic score based on these three variables was found efficient (Harrell's C index 0.61). This new model was improved by selecting only PS and LDH (Harrell's C index 0.64). Three risk groups for death could be identified: a low-risk group (n = 184; median overall survival [OS] 29.8 months), an intermediate-risk group (n = 223; median OS 19.5 months), and a high-risk group (n = 128; median OS 13.9 months). Median survival for the low-, intermediate-, and high-risk groups were 26.8, 21.1, and 16.5 months, respectively, in the validation sample (Harrell's C index 0.63).
CONCLUSIONS: Serum LDH level was the main prognostic factor in predicting survival, followed by WHO PS. We identified three risk groups for death depending on these two baseline parameters. This simple prognostic model can be useful for clinician's use and patient stratification in future clinical trials.},
	language = {eng},
	number = {9},
	journal = {The Oncologist},
	author = {Chibaudel, Benoist and Bonnetain, Franck and Tournigand, Christophe and Bengrine-Lefevre, Leila and Teixeira, Luis and Artru, Pascal and Desramé, Jérôme and Larsen, Annette K. and André, Thierry and Louvet, Christophe and de Gramont, Aimery},
	year = {2011},
	pmid = {21859820},
	pmcid = {PMC3228179},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Prognosis, CRC, Aged, 80 and over, Adult, Fluorouracil, Leucovorin, Organoplatinum Compounds, Survival Analysis, Camptothecin, Irinotecan, Disease-Free Survival, Oxaliplatin, Models, Statistical, L-Lactate Dehydrogenase},
	pages = {1228--1238},
	file = {Chibaudel et al_2011_Simplified prognostic model in patients with oxaliplatin-based or.pdf:/Users/jcsal/Zotero/storage/XNZWXSA8/Chibaudel et al_2011_Simplified prognostic model in patients with oxaliplatin-based or.pdf:application/pdf},
}

@article{bosch,
	title = {Time intervals in the care pathway to cancer diagnosis during the {COVID}-19 pandemic: {A} large retrospective study from a high-volume center},
	issn = {1097-0215},
	shorttitle = {Time intervals in the care pathway to cancer diagnosis during the {COVID}-19 pandemic},
	doi = {10.1002/ijc.34260},
	abstract = {Despite extensive research on cancer care during the COVID-19 pandemic, evidence on the impact on prediagnostic time intervals is lacking. To better understand how COVID-19 changed the pathway to diagnosis of cancer, we examined the length of intervals from symptom onset to diagnosis for 13 common cancer types with known clinical stage over 1-year nonpandemic period (March 2019 to March 2020; N = 844) and three biannual COVID periods (March 2020 to September 2021; N = 1172). We analyzed the patient interval (from first symptoms to presentation to a physician), the primary care/emergency department interval (from presentation with relevant symptoms to a primary care or emergency department physician to referral to a hospital-based diagnosis center) and the hospital interval (from referral to diagnosis). Compared to nonpandemic data, there were significant changes across COVID periods. The pandemic mostly impacted patient intervals for cancers diagnosed over the first 6 months after onset in March 2020. Overall median patient intervals were longest in the early COVID period (39 [IQR 22-64] days) and shortest in the nonpandemic period (20 [IQR 13-30] days; Kruskal-Wallis test [χ2 ], P {\textless} .0001). Differences in clinical stage between periods were relevant, with cancers from the mid-period (September 2020 to March 2021) showing the most advanced stage. A shift to later stage was plausibly a result of delayed intervals in the early COVID period. Since intervals are eventually relevant to prognosis, our results provide a baseline against which the impact of improvement strategies to minimize the negative outcomes of COVID-19-associated cancer delays can be assessed and implemented.},
	language = {eng},
	journal = {International Journal of Cancer},
	author = {Bosch, Xavier and Montori-Palacin, Elisabet and Martínez-Ferrer, Rosa and Aldea, Anna and Moreno, Pedro and López-Soto, Alfonso},
	month = aug,
	year = {2022},
	pmid = {36053784},
	pmcid = {PMC9539134},
	keywords = {COVID-19, diagnostic interval, patient interval, primary care interval, stage, Covid},
	file = {Bosch et al_2022_Time intervals in the care pathway to cancer diagnosis during the COVID-19.pdf:/Users/jcsal/Zotero/storage/QZ5Y9T58/Bosch et al_2022_Time intervals in the care pathway to cancer diagnosis during the COVID-19.pdf:application/pdf},
}

@article{extermann241,
	title = {Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on {CGA} of the {International} {Society} of {Geriatric} {Oncology} ({SIOG})},
	volume = {55},
	issn = {1040-8428},
	shorttitle = {Use of comprehensive geriatric assessment in older cancer patients},
	doi = {10.1016/j.critrevonc.2005.06.003},
	abstract = {BACKGROUND: As more and more cancers occur in elderly people, oncologists are increasingly confronted with the necessity of integrating geriatric parameters in the treatment of their patients.
METHODS: The International Society of Geriatric Oncology (SIOG) created a task force to review the evidence on the use of a comprehensive geriatric assessment (CGA) in cancer patients. A systematic review of the evidence was conducted.
RESULTS: Several biological and clinical correlates of aging have been identified. Their relative weight and clinical usefulness is still poorly defined. There is strong evidence that a CGA detects many problems missed by a regular assessment in general geriatric and in cancer patients. There is also strong evidence that a CGA improves function and reduces hospitalization in the elderly. There is heterogeneous evidence that it improves survival and that it is cost-effective. There is corroborative evidence from a few studies conducted in cancer patients. Screening tools exist and were successfully used in settings such as the emergency room, but globally were poorly tested. The article contains recommendations for the use of CGA in research and clinical care for older cancer patients.
CONCLUSIONS: A CGA, with or without screening, and with follow-up, should be used in older cancer patients, in order to detect unaddressed problems, improve their functional status, and possibly their survival. The task force cannot recommend any specific tool or approach above others at this point and general geriatric experience should be used.},
	language = {eng},
	number = {3},
	journal = {Critical Reviews in Oncology/Hematology},
	author = {Extermann, Martine and Aapro, Matti and Bernabei, Roberto and Cohen, Harvey Jay and Droz, Jean-Pierre and Lichtman, Stuart and Mor, Vincent and Monfardini, Silvio and Repetto, Lazzaro and Sørbye, Liv and Topinkova, Eva and {Task Force on CGA of the International Society of Geriatric Oncology}},
	month = sep,
	year = {2005},
	pmid = {16084735},
	keywords = {Humans, Aged, Female, Male, Geriatric Assessment, Geriatrics, Societies, Medical, Medical Oncology, Advisory Committees, Health Planning Guidelines},
	pages = {241--252},
}

@article{ruden2918,
	title = {Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma},
	volume = {29},
	issn = {1527-7755},
	doi = {10.1200/JCO.2011.34.9852},
	abstract = {PURPOSE: Identifying strong markers of prognosis are critical to optimize treatment and survival outcomes in patients with malignant recurrent glioma. We investigated the prognostic significance of exercise behavior and functional capacity in this population.
PATIENTS AND METHODS: Using a prospective design, 243 patients with WHO grades 3 to 4 recurrent malignant glioma and Karnofsky performance status (KPS) ≥ 70 completed a self-administered questionnaire that assessed exercise behavior and performed a 6-minute walk test (6MWT) to assess functional capacity. Cox proportional models were used to estimate the risk of all-cause mortality according to 6MWT distance (6MWD; {\textless} 390 meters, 390-489 meters, {\textgreater} 489 meters) and exercise behavior (metabolic equivalent [MET] -h/wk) adjusted for KPS and other important clinical factors.
RESULTS: Median follow-up was 27.43 months. During this period, 149 deaths were recorded (61\% of the total sample). Exercise behavior was an independent predictor of survival (P = .0081). Median survival was 13.03 months for patients reporting {\textless} 9 MET-h/wk relative to 21.84 months for those reporting ≥ 9 MET-h/wk. Exercise behavior added incremental prognostic value beyond that provided by KPS, age, sex, grade, and number of prior progressions (P {\textless} .001). Compared with patients reporting {\textless} 9 MET-h/wk, the adjusted hazard ratio for mortality was 0.64 (95\% CI, 0.46 to 0.91) for patients reporting ≥ 9 MET-h/wk. Functional capacity was not an independent predictor of prognosis.
CONCLUSION: Exercise behavior is a strong independent predictor of survival that provides incremental prognostic value to KPS as well as traditional markers of prognosis in malignant recurrent glioma.},
	language = {eng},
	number = {21},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Ruden, Emily and Reardon, David A. and Coan, April D. and Herndon, James E. and Hornsby, Whitney E. and West, Miranda and Fels, Diane R. and Desjardins, Annick and Vredenburgh, James J. and Waner, Emily and Friedman, Allan H. and Friedman, Henry S. and Peters, Katherine B. and Jones, Lee W.},
	month = jul,
	year = {2011},
	pmid = {21690470},
	pmcid = {PMC3138718},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Risk Factors, Proportional Hazards Models, Prospective Studies, Risk Assessment, Time Factors, Survival Rate, Adult, Predictive Value of Tests, Survival Analysis, Neoplasm Recurrence, Local, Karnofsky Performance Status, Surveys and Questionnaires, Brain Neoplasms, North Carolina, Exercise, Walking, Exercise Test, Glioma, Health Behavior, METs},
	pages = {2918--2923},
	file = {Ruden et al_2011_Exercise behavior, functional capacity, and survival in adults with malignant.pdf:/Users/jcsal/Zotero/storage/ADW89BUB/Ruden et al_2011_Exercise behavior, functional capacity, and survival in adults with malignant.pdf:application/pdf},
}

@article{krishnane175,
	title = {Impact of {Performance} {Status} on {Response} and {Survival} {Among} {Patients} {Receiving} {Checkpoint} {Inhibitors} for {Advanced} {Solid} {Tumors}},
	volume = {18},
	issn = {2688-1535},
	doi = {10.1200/OP.20.01055},
	abstract = {PURPOSE: Clinical trials, which led to the approval of immune checkpoint inhibitors (ICI), have been almost exclusively performed in patients with good Eastern Cooperative Oncology Group performance status (ECOG PS of 0-1). However, ICI remains an attractive option for patients with advanced tumors and poor PS. We hypothesized that patients with ECOG PS ≥ 2 would have worse outcomes with ICI.
METHODS: We retrospectively identified patients with advanced solid tumors who were treated with ICI at our institution. The log-rank test compared the survival among patients with different ECOG PS. We used a proportional hazards model to assess association between ECOG PS and overall survival (OS) with adjustment for covariates including age, sex, malignancy type, time from advance disease diagnosis, and line of therapy. We compared overall response rates between groups with Pearson chi-square exact test. We also analyzed in-hospital mortality and hospice referral rates.
RESULTS: We identified 257 patients treated with ICI. One hundred eighty-two patients had ECOG PS 0-1, and 75 had ECOG PS ≥ 2. The median overall survival was 12.6 months for the ECOG PS 0-1 group compared with 3.1 months for the ECOG PS ≥ 2 group (P {\textless} .001). The overall response rate for patients with ECOG PS 0-1 was 23\% compared with 8\% for those with poor PS (P = .005). Patients with poor PS treated with ICI had similar hospice referral rates (67\% for ECOG PS ≥ 2 v 61.9\% for ECOG PS 0-1, P = .50) but were more likely to have in-hospital death as compared with the good PS group (28.6\% v 15.1\%, P = .035).
CONCLUSION: Despite the appeal of ICI in patients with advanced malignancy and poor PS, outcomes in this cohort were poor. Prospective trials defining the activity and role of ICI in poor PS are urgently needed.},
	language = {eng},
	number = {1},
	journal = {JCO oncology practice},
	author = {Krishnan, Mridula and Kasinath, Pooja and High, Robin and Yu, Fang and Teply, Benjamin A.},
	month = jan,
	year = {2022},
	pmid = {34351819},
	keywords = {Humans, Retrospective Studies, Prospective Studies, Neoplasms, Cohort Studies, Hospital Mortality, ICI},
	pages = {e175--e182},
}

@article{kapoore25115,
	title = {Immune checkpoint inhibitors in patients with solid tumors and poor performance status: {A} prospective data from the real-world settings},
	volume = {100},
	issn = {1536-5964},
	shorttitle = {Immune checkpoint inhibitors in patients with solid tumors and poor performance status},
	doi = {10.1097/MD.0000000000025115},
	abstract = {Immune checkpoint inhibitors (ICIs) are rapidly being incorporated as treatment option either alone or in combination with chemotherapy in most of the solid tumors. Since there is very limited data of ICI in patients with poor performance status (PS) from the real world settings, we performed a retrospective audit of patients who received ICI and report the analysis based on ECOG PS of these patients.This study is a retrospective audit of a prospectively collected database of patients receiving ICIs for advanced solid tumors in any line between August 2015 and November 2018 at Tata Memorial Hospital, Mumbai, India. All statistical calculations were performed using SPSS statistical software for windows version 20.0.A total of 155 patients who received ICIs during the specified period were evaluated for this study. Baseline ECOG PS 0-1 (n = 103, 66.4\%) patients was associated with median OS 9.1 (95\% CI [confidence interval], 4.4-NR) months when compared to ECOG 2-4 (n = 52, 33.5\%) which had a median OS of 2.9 (95\% CI; 1.8-5.5) months (HR, 1.7, 95\% CI, 1.1-2.7, log rank P = .017). The disease control rate for the poor PS group was 34.6\%. However, 27.3\% patients (95\% CI: 20.3-34.3) were still alive at 1 year. Median OS in patients with PS 2 was 3.7 months (95\% CI: 0-11.6) as compared to 1.8 months (95\% CI: 0.2-3.4) for those with PS 3-4 (HR-2.0; 95\% CI: 1.0-3.9, P = .041). The tolerance to ICIs was good with no grade 3/4 toxicities in 44 (84.6\%) patients.Immune checkpoint inhibitors are a safe and effective therapeutic option even in solid tumor patients with poor performance status.},
	language = {eng},
	number = {13},
	journal = {Medicine},
	author = {Kapoor, Akhil and Noronha, Vanita and Patil, Vijay M. and Menon, Nandini and Joshi, Amit and Abraham, George and Prabhash, Kumar},
	month = apr,
	year = {2021},
	pmid = {33787593},
	pmcid = {PMC8021372},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Retrospective Studies, Prospective Studies, Neoplasms, Outcome Assessment, Health Care, Databases, Factual, Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Medical Oncology, ICI, Medical Audit},
	pages = {e25115},
	file = {Kapoor et al_2021_Immune checkpoint inhibitors in patients with solid tumors and poor performance.pdf:/Users/jcsal/Zotero/storage/E92M2JPM/Kapoor et al_2021_Immune checkpoint inhibitors in patients with solid tumors and poor performance.pdf:application/pdf},
}

@article{yange2012534,
	title = {Association of {Sex}, {Age}, and {Eastern} {Cooperative} {Oncology} {Group} {Performance} {Status} {With} {Survival} {Benefit} of {Cancer} {Immunotherapy} in {Randomized} {Clinical} {Trials}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {3},
	issn = {2574-3805},
	shorttitle = {Association of {Sex}, {Age}, and {Eastern} {Cooperative} {Oncology} {Group} {Performance} {Status} {With} {Survival} {Benefit} of {Cancer} {Immunotherapy} in {Randomized} {Clinical} {Trials}},
	doi = {10.1001/jamanetworkopen.2020.12534},
	abstract = {IMPORTANCE: Sex, age, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) may affect immune response. However, the association of these factors with the survival benefit of cancer immunotherapy with immune checkpoint inhibitors (ICIs) remains unclear.
OBJECTIVE: To assess the potential sex, age, and ECOG PS differences of immunotherapy survival benefit in patients with advanced cancer.
DATA SOURCES: PubMed, Web of Science, Embase, and Scopus were searched from inception to August 31, 2019.
STUDY SELECTION: Published randomized clinical trials comparing overall survival (OS) in patients with advanced cancer treated with ICI immunotherapy vs non-ICI control therapy were included.
DATA EXTRACTION AND SYNTHESIS: Pooled OS hazard ratio (HR) and 95\% CI for patients of different sex, age ({\textless}65 and ≥65 years) or ECOG PS (0 and ≥1) were calculated separately using a random-effects model, and the heterogeneity between paired estimates was assessed using an interaction test by pooling study-specific interaction HRs. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline.
MAIN OUTCOMES AND MEASURES: The difference in survival benefit of ICIs between sex, age ({\textless}65 vs ≥65 years), and ECOG PS (0 vs ≥1), as well as the difference stratified by cancer type, line of therapy, agent of immunotherapy, and immunotherapy strategy in the intervention arm.
RESULTS: Thirty-seven phase 2 or 3 randomized clinical trials involving 23 760 patients were included. An OS benefit of immunotherapy was found for both men (HR, 0.75; 95\% CI, 0.71-0.81) and women (HR, 0.79; 95\% CI, 0.72-0.88); for both younger ({\textless}65 years: HR, 0.77; 95\% CI, 0.71-0.83) and older (≥65 years: HR, 0.78; 95\% CI, 0.72-0.84) patients; and for both patients with ECOG PS 0 (HR, 0.81; 95\% CI, 0.73-0.90) and PS greater than or equal to 1 (HR, 0.79; 95\% CI, 0.74-0.84). No significant difference of relative benefit from immunotherapy over control therapy was found in patients of different sex (P = .25, I2 = 19.02\%), age (P = .94, I2 = 15.57\%), or ECOG PS (P = .74, I2 = 0\%). No significant difference was found in subgroup analyses by cancer type, line of therapy, agent of immunotherapy, and immunotherapy strategy in the intervention arm.
CONCLUSIONS AND RELEVANCE: This meta-analysis found no evidence of an association of sex, age ({\textless}65 vs ≥65 years), or ECOG PS (0 vs ≥1) with cancer immunotherapy survival benefit. This finding suggests that the use of ICIs in advanced cancer should not be restricted to certain patients in sex, age, or ECOG PS categories.},
	language = {eng},
	number = {8},
	journal = {JAMA network open},
	author = {Yang, Fang and Markovic, Svetomir N. and Molina, Julian R. and Halfdanarson, Thorvardur R. and Pagliaro, Lance C. and Chintakuntlawar, Ashish V. and Li, Rutian and Wei, Jia and Wang, Lifeng and Liu, Baorui and Nowakowski, Grzegorz S. and Wang, Michael L. and Wang, Yucai},
	month = aug,
	year = {2020},
	pmid = {32766800},
	pmcid = {PMC7414387},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Sex Factors, Neoplasms, Randomized Controlled Trials as Topic, Age Factors, Immunotherapy, ICI},
	pages = {e2012534},
	file = {Yang et al_2020_Association of Sex, Age, and Eastern Cooperative Oncology Group Performance.pdf:/Users/jcsal/Zotero/storage/8NZYN5C5/Yang et al_2020_Association of Sex, Age, and Eastern Cooperative Oncology Group Performance.pdf:application/pdf},
}

@article{wong385,
	title = {Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma},
	volume = {13},
	issn = {1743-7563},
	doi = {10.1111/ajco.12702},
	abstract = {BACKGROUND: Antiprogrammed death-1 antibodies (anti-PD1) have response rates of 40\% in metastatic melanoma. Patients with poor performance status (PS) were excluded from clinical trials, yet use of anti-PD1 is widespread in clinical practice. Literature regarding clinical and palliative care outcomes in patients with poor PS treated with anti-PD1 is lacking.
METHODS: Retrospective review of outcomes for all patients with advanced melanoma treated with anti-PD1 between 2012 and June 2015 at Peter MacCallum Cancer Centre, a tertiary specialist cancer center in Australia.
RESULTS: Between 2012 and 2015, 91 patients received anti-PD1: median age 63, 65\% males, 77\% elevated LDH{\textgreater}1xULN (37/48 patients). Fifty-eight patients had baseline ECOG PS of 0-1 (64\%), 24 patients ECOG PS 2-3 (26\%) and ECOG PS was not recorded in nine patients (10\%). Median overall survival (OS) for the ECOG PS 0-1 group was 19.5 months and 1.8 months for ECOG PS 2-3 (HR 5.5; 95\% CI, 9.1-50.3; P = 0.0001). Tumor response was 23/58 (39\%) in ECOG PS 0-1, 2/16 (12\%) in ECOG PS 2 and 0/8 in ECOG PS 3. Toxicity did not differ between different groups. ECOG PS 2-3 patients were more likely to be treated and hospitalized within the last month of life compared to ECOG PS 0-1 patients, RR 1.75 (95\% CI, 1.04-2.56, P = 0.019) and RR 1.73 (95\% CI, 1.10-2.16, P = 0.009), respectively. ECOG PS 2-3 patients were more likely to die in an acute hospital RR 2.68 (95\% CI, 1.17-6.51, P = 0.016).
CONCLUSIONS: Patients with poor baseline PS have a significantly lower OS and reduced response to anti-PD1. Further quality of life and palliative care research is needed.},
	language = {eng},
	number = {6},
	journal = {Asia-Pacific Journal of Clinical Oncology},
	author = {Wong, Annie and Williams, Molly and Milne, Donna and Morris, Kortnye and Lau, Peter and Spruyt, Odette and Fullerton, Sonia and McArthur, Grant},
	month = dec,
	year = {2017},
	pmid = {28661584},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Palliative Care, Aged, 80 and over, Adult, Survival Analysis, ICI, Antibodies, Monoclonal, antiprogrammed death-1, immunotherapy, melanoma, Melanoma, palliative care},
	pages = {385--390},
	file = {Wong et al_2017_Clinical and palliative care outcomes for patients of poor performance status.pdf:/Users/jcsal/Zotero/storage/X5YTBJHB/Wong et al_2017_Clinical and palliative care outcomes for patients of poor performance status.pdf:application/pdf},
}

@article{vangestel371,
	title = {Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients},
	volume = {20},
	issn = {1534-4681},
	doi = {10.1245/s10434-012-2663-1},
	abstract = {BACKGROUND: Studies on the impact of comorbidity and age on postoperative outcome after gastrointestinal tumor resection are scarce. In this study we investigated the impact of comorbidity and age on 30-, 60-, and 90-day mortality after resection of esophageal, gastric, periampullary, colon, and rectal cancer.
METHODS: The study included 8,583 patients recorded in the population-based Netherlands Cancer Registry, regions Eindhoven (Eindhoven Cancer Registry) and Mid and South Limburg, who underwent resection for cancer stage I-III. Patients were diagnosed between 2005 and 2010. Age was categorized as {\textless}65, 65-74, and ≥75 years.
RESULTS: Comorbidity was present in more than two-thirds (n = 5,910) of patients. The 30-day mortality rates ranged from 0.5 \% for rectal cancer patients {\textless}65 years to 12.8 \% for gastric cancer patients ≥75 years. Patients with comorbidity who underwent esophageal tumor resection had the highest mortality rates, ranging from 8.4 \% for 30-day to 12.0 \% for 90-day mortality, while rectal cancer patients had the lowest rates, that is, 4.3-6.4 \%, respectively. In multivariable analyses, cardiac disease (odds ratio [OR] = 1.74, 95 \% confidence interval [95 \% CI] = 1.32-2.30), vascular disease (OR = 1.41, 95 \% CI = 1.02-1.95) and previous malignancies (OR = 1.38, 95 \% CI = 1.02-1.86) in colon cancer, and cardiac disease (OR = 1.81, 95 \% CI = 1.10-2.98) and vascular disease (OR = 1.95, 95 \% CI = 1.11-3.42) in rectal cancer were associated with the highest 30-day mortality.
CONCLUSIONS: Postoperative mortality extends beyond 30 days. Comorbidity and older age are associated with early postoperative mortality after gastrointestinal cancer resection. Underlying comorbidity should be identified preoperatively with attention to patients' specific needs to optimally attenuate risk prior to surgery. A less aggressive treatment approach may well be considered in these groups.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {van Gestel, Yvette R. B. M. and Lemmens, Valery E. P. P. and de Hingh, Ignace H. J. T. and Steevens, Jessie and Rutten, Harm J. T. and Nieuwenhuijzen, Grard A. P. and van Dam, Ronald M. and Siersema, Peter D.},
	month = feb,
	year = {2013},
	pmid = {22987098},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Male, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Risk Factors, Survival Rate, Prognosis, Age Factors, Chemotherapy, Adjuvant, United States, Combined Modality Therapy, Comorbidity, Netherlands, Radiotherapy, Adjuvant, Heart Diseases, Lung Diseases, Postoperative Period, Diabetes Mellitus, Vascular Diseases},
	pages = {371--380},
}

@article{canoui-poitrine2236,
	title = {The {Prognostic} {Value} of {Eight} {Comorbidity} {Indices} in {Older} {Patients} with {Cancer}: {The} {ELCAPA} {Cohort} {Study}},
	volume = {14},
	issn = {2072-6694},
	shorttitle = {The {Prognostic} {Value} of {Eight} {Comorbidity} {Indices} in {Older} {Patients} with {Cancer}},
	doi = {10.3390/cancers14092236},
	abstract = {BACKGROUND: A prognostic assessment is crucial for making cancer treatment decisions in older patients. We assessed the prognostic performance (relative to one-year mortality) of eight comorbidity indices in a cohort of older patients with cancer.
METHODS: We studied patients with cancer aged ≥70 included in the Elderly Cancer Patient (ELCAPA) cohort between 2007 and 2010. We assessed seven nonspecific indices (Charlson Comorbidity Index (CCI), three modified versions of the CCI, the Elixhauser Comorbidity Index, the Gagne index, and the Cumulative Illness Rating Scale for Geriatrics (CIRS-G)) and the National Cancer Institute Comorbidity Index.
RESULTS: Overall, 510 patients were included. Among patients with nonmetastatic cancer, all the comorbidity indices were independently associated with 1-year mortality (adjusted hazard ratios (aHRs) of 1.44 to 2.51 for one standard deviation increment; p \&lt; 0.05 for all) and had very good discriminant ability (Harrell's C \&gt; 0.8 for the eight indices), but were poorly calibrated. Among patients with metastatic cancer, only the CIRS-G was independently associated with 1-year mortality (aHR (95\% confidence interval): 1.26 [1.06-1.50]). Discriminant ability was moderate (0.61 to 0.70) for the subsets of patients with metastatic cancer and colorectal cancer.
CONCLUSION: Comorbidity indices had strong prognostic value and discriminative ability for one-year mortality in older patients with nonmetastatic cancer, although calibration was poor. In older patients with metastatic cancer, only the CIRS-G was predictive of one-year mortality.},
	language = {eng},
	number = {9},
	journal = {Cancers},
	author = {Canoui-Poitrine, Florence and Segaux, Lauriane and Benderra, Marc-Antoine and About, Frédégonde and Tournigand, Christophe and Laurent, Marie and Caillet, Philippe and Audureau, Etienne and Ferrat, Emilie and Lagrange, Jean-Leon and Paillaud, Elena and Bastuji-Garin, Sylvie and On Behalf Of The Elcapa Study Group, null},
	month = apr,
	year = {2022},
	pmid = {35565364},
	pmcid = {PMC9105640},
	keywords = {mortality, cancer, comorbidities, indices, older patients, Prognostic Scales},
	pages = {2236},
	file = {Canoui-Poitrine et al_2022_The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer.pdf:/Users/jcsal/Zotero/storage/CYHSP938/Canoui-Poitrine et al_2022_The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer.pdf:application/pdf},
}

@article{baranov131,
	title = {Outcomes of curative esophageal cancer surgery in elderly: {A} meta-analysis},
	volume = {13},
	issn = {1948-5204},
	shorttitle = {Outcomes of curative esophageal cancer surgery in elderly},
	doi = {10.4251/wjgo.v13.i2.131},
	abstract = {BACKGROUND: An increasing number of older patients is undergoing curative, surgical treatment of esophageal cancer. Previous meta-analyses have shown that older patients suffered from more postoperative morbidity and mortality compared to younger patients, which may lead to patient selection based on age. However, only studies including patients that underwent open esophagectomy were included. Therefore, it remains unknown whether there is an association between age and outcome in patients undergoing minimally invasive esophagectomy.
AIM: To perform a systematic review on age and postoperative outcome in esophageal cancer patients undergoing esophagectomy.
METHODS: Studies comparing older with younger patients with primary esophageal cancer undergoing curative esophagectomy were included. Meta-analysis of studies using a 75-year age threshold are presented in the manuscript, studies using other age thresholds in the Supplementary material. MEDLINE, Embase and the Cochrane Library were searched for articles published between 1995 and 2020. Risk of bias was assessed with the Newcastle-Ottawa Scale. Primary outcomes were anastomotic leak, pulmonary and cardiac complications, delirium, 30- and 90-d, and in-hospital mortality. Secondary outcomes included pneumonia and 5-year overall survival.
RESULTS: Seven studies (4847 patients) using an age threshold of 75 years were included for meta-analysis with 755 older and 4092 younger patients. Older patients (9.05\%) had higher rates of 90-d mortality compared with younger patients (3.92\%), (confidence interval = 1.10-5.56). In addition, older patients (9.45\%) had higher rates of in-hospital mortality compared with younger patients (3.68\%), (confidence interval = 1.01-5.91). In the subgroup of 2 studies with minimally invasive esophagectomy, older and younger patients had comparable 30-d, 90-d and in-hospital mortality rates.
CONCLUSION: Older patients undergoing curative esophagectomy for esophageal cancer have a higher postoperative mortality risk. Minimally invasive esophagectomy may be important for minimizing mortality in older patients.},
	language = {eng},
	number = {2},
	journal = {World Journal of Gastrointestinal Oncology},
	author = {Baranov, Nikolaj S. and Slootmans, Cettela and van Workum, Frans and Klarenbeek, Bastiaan R. and Schoon, Yvonne and Rosman, Camiel},
	month = feb,
	year = {2021},
	pmid = {33643529},
	pmcid = {PMC7896422},
	keywords = {Esophageal cancer, Elderly, Age, Minimally invasive esophagectomy, Open esophagectomy, Clinical outcome, Perioperative mortality},
	pages = {131--146},
	file = {Baranov et al_2021_Outcomes of curative esophageal cancer surgery in elderly.pdf:/Users/jcsal/Zotero/storage/72I2KLDH/Baranov et al_2021_Outcomes of curative esophageal cancer surgery in elderly.pdf:application/pdf},
}

@article{mantziari2104,
	title = {Esophageal {Cancer} in {Elderly} {Patients}, {Current} {Treatment} {Options} and {Outcomes}; {A} {Systematic} {Review} and {Pooled} {Analysis}},
	volume = {13},
	issn = {2072-6694},
	doi = {10.3390/cancers13092104},
	abstract = {Esophageal cancer, despite its tendency to increase among younger patients, remains a disease of the elderly, with the peak incidence between 70-79 years. In spite of that, elderly patients are still excluded from major clinical trials and they are frequently offered suboptimal treatment even for curable stages of the disease. In this review, a clear survival benefit is demonstrated for elderly patients treated with neoadjuvant treatment, surgery, and even definitive chemoradiation compared to palliative or no treatment. Surgery in elderly patients is often associated with higher morbidity and mortality compared to younger patients and may put older frail patients at increased risk of autonomy loss. Definitive chemoradiation is the predominant modality offered to elderly patients, with very promising results especially for squamous cell cancer, although higher rates of acute toxicity might be encountered. Based on the all the above, and although the best available evidence comes from retrospective studies, it is not justified to refrain from curative treatment for elderly patients based on their age alone. Thorough assessment and an adapted treatment plan as well as inclusion of elderly patients in ongoing clinical trials will allow better understanding and management of esophageal cancer in this heterogeneous and often frail population.},
	language = {eng},
	number = {9},
	journal = {Cancers},
	author = {Mantziari, Styliani and Teixeira Farinha, Hugo and Bouygues, Vianney and Vignal, Jean-Charles and Deswysen, Yannick and Demartines, Nicolas and Schäfer, Markus and Piessen, Guillaume},
	month = apr,
	year = {2021},
	pmid = {33925512},
	pmcid = {PMC8123886},
	keywords = {esophageal cancer, esophagectomy, surgery, Age, elderly, definitive chemoradiation},
	pages = {2104},
	file = {Mantziari et al_2021_Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes\;.pdf:/Users/jcsal/Zotero/storage/LW8XQPX3/Mantziari et al_2021_Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes\;.pdf:application/pdf},
}

@article{lyu839516,
	title = {Effects of {Enteral} {Nutrition} on {Patients} {With} {Oesophageal} {Carcinoma} {Treated} {With} {Concurrent} {Chemoradiotherapy}: {A} {Prospective}, {Multicentre}, {Randomised}, {Controlled} {Study}},
	volume = {12},
	issn = {2234-943X},
	shorttitle = {Effects of {Enteral} {Nutrition} on {Patients} {With} {Oesophageal} {Carcinoma} {Treated} {With} {Concurrent} {Chemoradiotherapy}},
	doi = {10.3389/fonc.2022.839516},
	abstract = {BACKGROUND: The oesophageal carcinoma patients show high incidence of malnutrition, which negatively affects their therapy outcome. Moreover, benefits of enteral nutrition remain to be studied in details in these patients. Therefore, we set to assess the effects of enteral nutrition on the nutritional status, treatment toxicities and survival in the oesophageal carcinoma patients treated with concurrent chemoradiotherapy (CCRT).
MATERIALS AND METHODS: Eligible patients were randomly assigned to either the experimental or control group. The patients in the experimental group were treated with a whole-course enteral nutrition management, while the control group were provided a unsystematic nutrition without setting intake goals for energy and protein. The primary endpoint was a change in body weight, while the secondary endpoints included nutrition-related haematological indicators, toxicities, completion rate of treatment and survival.
RESULTS: A total of 222 patients were randomised to either the experimental (n=148) or control (n=74) group. Patients in the experimental group showed significantly less decrease in body weight, serum albumin and haemoglobin levels, a lower incidence rates of grade ≥3 myelosuppression and infection, and a higher completion rate of CCRT than those in the control group. While analyses of the 2 and 3 year overall survival (OS) and progression-free survival (PFS) did not reveal differences between these groups, we observed a significantly higher OS at 1 year (83.6\% vs. 70.0\%). In the subgroup analysis, patients with patient-generated subjective global assessment (PG-SGA)=C were likely to have better OS and PFS with enteral nutrition.
CONCLUSIONS: In EC patients treated with CCRT, enteral nutrition conferred positive effects on the nutritional status, treatment toxicities and prognosis, which mandate its inclusion in clinical practice.
CLINICAL TRIAL REGISTRATION: This prospective trial has been registered with www.clinicaltrials.gov as NCT02399306.},
	language = {eng},
	journal = {Frontiers in Oncology},
	author = {Lyu, Jiahua and Shi, Anhui and Li, Tao and Li, Jie and Zhao, Ren and Zhu, Shuchai and Wang, Jianhua and Xing, Ligang and Yang, Daoke and Xie, Conghua and Shen, Liangfang and Zhang, Hailin and Zhu, Guangying and Wang, Jing and Pan, Wenyan and Li, Fang and Lang, Jinyi and Shi, Hanping},
	year = {2022},
	pmid = {35280748},
	pmcid = {PMC8914079},
	keywords = {chemoradiotherapy, enteral nutrition, prognosis, nutritional status, oesophageal carcinoma, EN},
	pages = {839516},
	file = {Lyu et al_2022_Effects of Enteral Nutrition on Patients With Oesophageal Carcinoma Treated.pdf:/Users/jcsal/Zotero/storage/BR9PQRWG/Lyu et al_2022_Effects of Enteral Nutrition on Patients With Oesophageal Carcinoma Treated.pdf:application/pdf},
}

@article{petrillo2288,
	title = {Performance status and end-of-life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors},
	volume = {126},
	issn = {1097-0142},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32782},
	doi = {10.1002/cncr.32782},
	abstract = {Background Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non–small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end-of-life care. Methods This was a retrospective, single-site study of 237 patients with advanced NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression was used to compare the overall survival (OS) of patients who had impaired PS (≥2) at the start of ICI treatment with those who had PS 0 or 1 using Cox regression. Logistic regression was conducted to analyze the association between ICI use in the last 30 days of life and the use of end-of-life health care. Results The patient mean age at ICI initiation was 67 years (range, 37-91 years), and 35.4\% of patients had PS ≥2. Most patients (80.8\%) received ICI as second-line or later therapy. The median OS was 4.5 months in patients with PS ≥2 and 14.3 months in those with PS 0 or 1 (hazard ratio, 2.5; P {\textless} .0001). Among the patients who died (n = 184), 28.8\% who had PS ≥2 received ICIs in their last 30 days of life compared with 10.8\% of those who had PS 0 or 1 (P = .002). Receipt of ICI in the last 30 days of life was associated with decreased hospice referral (odds ratio, 0.29; P = .008) and increased in-hospital deaths (odds ratio, 6.8; P = .001), independent of PS. Conclusions Adults with advanced NSCLC and impaired PS experience significantly shorter survival after ICI treatment and receive ICIs near death more often than those with better PS. Receipt of an ICI near death was associated with lower hospice use and an increased risk of death in the hospital. These results underscore the need for high-quality communication about potential tradeoffs of ICIs, particularly among adults receiving ICIs as second-line or later therapy.},
	language = {en},
	number = {10},
	urldate = {2022-12-11},
	journal = {Cancer},
	author = {Petrillo, Laura A. and El-Jawahri, Areej and Nipp, Ryan D. and Lichtenstein, Morgan R. L. and Durbin, Sienna M. and Reynolds, Kerry L. and Greer, Joseph A. and Temel, Jennifer S. and Gainor, Justin F.},
	year = {2020},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32782},
	keywords = {supportive care, ICI, immunotherapy, hospice care, non–small cell lung carcinoma, terminal care},
	pages = {2288--2295},
	file = {Petrillo et al_2020_Performance status and end-of-life care among adults with non–small cell lung.pdf:/Users/jcsal/Zotero/storage/5SMH5LAE/Petrillo et al_2020_Performance status and end-of-life care among adults with non–small cell lung.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/P97CYENQ/cncr.html:text/html},
}

@article{facchinetti155,
	title = {First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status},
	volume = {130},
	issn = {1879-0852},
	doi = {10.1016/j.ejca.2020.02.023},
	abstract = {BACKGROUND: Pembrolizumab is the first-line standard of care for advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) ≥ 50\%. Eastern Cooperative Oncology Group performance status (PS) 2 patients may receive pembrolizumab, despite the absence of sustaining evidence.
PATIENTS AND METHODS: GOIRC-2018-01 is a multicentre, retrospective, observational study. PS 2 NSCLC patients with a PD-L1 TPS ≥50\% receiving first-line pembrolizumab from June 2017 to December 2018 at 21 Italian institutions were included. Clinical-pathological characteristics were correlated with disease response and survival outcomes; adverse events were recorded. The primary objective was 6-months progression-free rate (6-months PFR).
RESULTS: One hundred fifty-three patients (median age 70 years) were enrolled. At a median follow-up of 18.2 months, median progression-free survival (PFS) and overall survival (OS) were 2.4 (95\% confidence interval, 95\% CI, 1.6-2.5) and 3.0 months (95\% CI 2.4-3.5), respectively. 6-months PFR was 27\% (95\% CI 21-35\%). Patients with a PS 2 determined by comorbidities (n = 41) had significantly better outcomes compared with disease burden-induced PS 2 (n = 112). Indeed, 6-months PFR was 49\% versus 19\%, median PFS 5.6 versus 1.8 months and OS 11.8 versus 2.8 months, respectively. Additional potential prognostic factors (radiotherapy, antibiotics, steroids received before pembrolizumab) correlated with clinical outcomes. The determinant of PS 2 resulted the only factor independently impacting on both PFS and OS. No toxicity issues emerged.
CONCLUSIONS: Outcomes of PS 2 NSCLC patients with PD-L1 TPS ≥50\% receiving first-line pembrolizumab were globally dismal but strongly dependent on the reason conditioning the poor PS itself.},
	language = {eng},
	journal = {European Journal of Cancer (Oxford, England: 1990)},
	author = {Facchinetti, Francesco and Mazzaschi, Giulia and Barbieri, Fausto and Passiglia, Francesco and Mazzoni, Francesca and Berardi, Rossana and Proto, Claudia and Cecere, Fabiana Letizia and Pilotto, Sara and Scotti, Vieri and Rossi, Sabrina and Del Conte, Alessandro and Vita, Emanuele and Bennati, Chiara and Ardizzoni, Andrea and Cerea, Giulio and Migliorino, Maria Rita and Sala, Elisa and Camerini, Andrea and Bearz, Alessandra and De Carlo, Elisa and Zanelli, Francesca and Guaitoli, Giorgia and Garassino, Marina Chiara and Ciccone, Lucia Pia and Sartori, Giulia and Toschi, Luca and Dall'Olio, Filippo Gustavo and Landi, Lorenza and Pizzutilo, Elio Gregory and Bartoli, Gabriele and Baldessari, Cinzia and Novello, Silvia and Bria, Emilio and Cortinovis, Diego Luigi and Rossi, Giulio and Rossi, Antonio and Banna, Giuseppe Luigi and Camisa, Roberta and Di Maio, Massimo and Tiseo, Marcello},
	month = may,
	year = {2020},
	pmid = {32220780},
	keywords = {Humans, Aged, Female, Male, Retrospective Studies, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Immunotherapy, Programmed Cell Death 1 Receptor, ICI, ECOG PS 2, Immune checkpoint inhibitors, NSCLC, PD-1},
	pages = {155--167},
	file = {Facchinetti et al_2020_First-line pembrolizumab in advanced non-small cell lung cancer patients with.pdf:/Users/jcsal/Zotero/storage/PK72TPXM/Facchinetti et al_2020_First-line pembrolizumab in advanced non-small cell lung cancer patients with.pdf:application/pdf},
}

@article{glisch179,
	title = {Immune {Checkpoint} {Inhibitor} {Use} {Near} the {End} of {Life} {Is} {Associated} {With} {Poor} {Performance} {Status}, {Lower} {Hospice} {Enrollment}, and {Dying} in the {Hospital}},
	volume = {37},
	issn = {1049-9091},
	url = {https://doi.org/10.1177/1049909119862785},
	doi = {10.1177/1049909119862785},
	abstract = {Background:Immune checkpoint inhibitors have changed the landscape of cancer care by increasing progression-free and overall survival in some patients with cancer. We evaluated use and variables contributing to immune checkpoint inhibitor treatment near the end of life.Methods:We studied 157 patients who received immune checkpoint inhibitors and died between January 2015 and December 2018. All patients had a palliative care consult any time between starting an immune checkpoint inhibitor and death. Univariate and multivariate models were used to examine variables related to immune checkpoint inhibitor use near the end of life.Results:Among 157 patients studied, 42 (27\%) received a dose of immune checkpoint inhibitor in the last 30 days of life. Those who received treatment in the last 30 days of life had lower hospice enrollment (19 [45\%] vs 78 [69\%], P = .007) and higher rates of dying in the hospital (23 [56\%] vs 33 [29\%], P = .002). The percentage of patients with Eastern Cooperative Oncology Group (ECOG) ≥3 at the time of last immune checkpoint inhibitor dose was higher in the group that received immune checkpoint inhibitor treatment in the last 30 days of life (11 [26\%] vs 9 [8\%], P = .003). Lack of traditional chemotherapy after immune checkpoint inhibitor, ECOG ≥3, and lack of hospice enrollment were independently associated with receiving immune checkpoint inhibitor in the last 30 days of life.Conclusion:Immune checkpoint inhibitor use in the last 30 days of life is common and associated with poor performance status, lower hospice enrollment, and dying in the hospital.},
	language = {en},
	number = {3},
	urldate = {2022-12-11},
	journal = {American Journal of Hospice and Palliative Medicine®},
	author = {Glisch, Chad and Hagiwara, Yuya and Gilbertson-White, Stephanie and Gao, Yubo and Lyckholm, Laurel},
	month = mar,
	year = {2020},
	note = {Publisher: SAGE Publications Inc},
	keywords = {ICI},
	pages = {179--184},
}

@article{sanoff2624,
	title = {Effect of adjuvant chemotherapy on survival of patients with stage {III} colon cancer diagnosed after age 75 years},
	volume = {30},
	issn = {1527-7755},
	doi = {10.1200/JCO.2011.41.1140},
	abstract = {PURPOSE: Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group is unknown.
METHODS: A total of 5,489 patients ≥ 75 years of age with resected stage III CC, diagnosed between 2004 and 2007, were selected from four data sets containing demographic, stage, treatment, and survival information. These data sets included SEER-Medicare, a linkage between the New York State Cancer Registry (NYSCR) and its Medicare programs, and prospective cohort studies Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) and the National Comprehensive Cancer Network. Data sets were analyzed in parallel using covariate adjusted and propensity score (PS) matched proportional hazards models to evaluate the effect of treatment on survival. PS trimming was used to mitigate the effects of selection bias.
RESULTS: Use of adjuvant therapy declined with age and comorbidity. Chemotherapy receipt was associated with a survival benefit of comparable magnitude to clinical trials results (SEER-Medicare PS-matched mortality, hazard ratio [HR], 0.60; 95\% CI, 0.53 to 0.68). The incremental benefit of oxaliplatin over non-oxaliplatin-containing regimens was also of similar magnitude to clinical trial results (SEER-Medicare, HR, 0.84; 95\% CI, 0.69 to 1.04; NYSCR-Medicare, HR, 0.82, 95\% CI, 0.51 to 1.33) in two of three examined data sources. However, statistical significance was inconsistent. The beneficial effect of chemotherapy and oxaliplatin did not seem solely attributable to confounding.
CONCLUSION: The noninvestigational experience suggests patients with stage III CC ≥ 75 years of age may anticipate a survival benefit from adjuvant chemotherapy. Oxaliplatin offers no more than a small incremental benefit. Use of adjuvant chemotherapy after the age of 75 years merits consideration in discussions that weigh individual risks and preferences.},
	language = {eng},
	number = {21},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Sanoff, Hanna K. and Carpenter, William R. and Stürmer, Til and Goldberg, Richard M. and Martin, Christopher F. and Fine, Jason P. and McCleary, Nadine Jackson and Meyerhardt, Jeffrey A. and Niland, Joyce and Kahn, Katherine L. and Schymura, Maria J. and Schrag, Deborah},
	month = jul,
	year = {2012},
	pmid = {22665536},
	pmcid = {PMC3412313},
	keywords = {Humans, Aged, Female, Male, Treatment Outcome, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, Aged, 80 and over, Age Factors, Chemotherapy, Adjuvant, Colonic Neoplasms, Organoplatinum Compounds, United States, Oxaliplatin, Medicare, Odds Ratio, SEER Program, Practice Patterns, Physicians', Medical Record Linkage},
	pages = {2624--2634},
	file = {Sanoff et al_2012_Effect of adjuvant chemotherapy on survival of patients with stage III colon.pdf:/Users/jcsal/Zotero/storage/QYZUF4GL/Sanoff et al_2012_Effect of adjuvant chemotherapy on survival of patients with stage III colon.pdf:application/pdf},
}

@article{zuckerman1403,
	title = {Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with {Stage} {III} colon cancer},
	volume = {57},
	issn = {1532-5415},
	doi = {10.1111/j.1532-5415.2009.02355.x},
	abstract = {OBJECTIVES: To estimate the modifying effect of age on the survival benefit associated with adjuvant chemotherapy receipt in elderly patients with a diagnosis of Stage III colon cancer.
DESIGN: Observational, retrospective cohort study using two samples: an overall sample of 7,182 patients to provide externally valid analyses and a propensity score-matched sample of 3,016 patients to provide more internally valid analyses by reducing the presence of treatment endogeneity. An interval-censored survival model with a complementary log-log link was used. Hazard ratios and 95\% confidence intervals were obtained for all regressions.
SETTINGS: Data from the National Cancer Institute's Surveillance, Epidemiology and End Results database and the linked Medicare enrollment and claims database were used.
PARTICIPANTS: Selected patients were aged 66 and older and had a diagnosis of Stage III colon cancer. Patients were followed from surgery to time of death or censorship.
MEASUREMENTS: The outcome was colon cancer-specific death during the follow-up period. Receipt of adjuvant chemotherapy was measured according to the presence of a claim for 5-fluorouracil or leucovorin within 6 months after surgery.
RESULTS: All elderly patients had a significant survival benefit associated with adjuvant chemotherapy receipt, although the survival benefit of adjuvant chemotherapy was not uniform across all age groups.
CONCLUSION: These findings have important clinical and policy implications for the risk-benefit calculation induced by treatment in older patients with Stage III colon cancer. The results suggest that there is a benefit from chemotherapy, but the benefit is lower with older age.},
	language = {eng},
	number = {8},
	journal = {Journal of the American Geriatrics Society},
	author = {Zuckerman, Ilene H. and Rapp, Thomas and Onukwugha, Ebere and Davidoff, Amy and Choti, Michael A. and Gardner, James and Seal, Brian and Mullins, C. Daniel},
	month = aug,
	year = {2009},
	pmid = {19563521},
	keywords = {Humans, Aged, Female, Male, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, CRC, Aged, 80 and over, Age Factors, Chemotherapy, Adjuvant, Colonic Neoplasms, Fluorouracil, Leucovorin, Survival Analysis, United States, Logistic Models, Medicare, SEER Program},
	pages = {1403--1410},
}

@article{soto-perez-de-celise305,
	title = {Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer},
	volume = {19},
	issn = {1474-5488},
	shorttitle = {Functional versus chronological age},
	doi = {10.1016/S1470-2045(18)30348-6},
	abstract = {As the worldwide population ages, oncologists are often required to make difficult and complex decisions regarding the treatment of older people (aged 65 years and older) with cancer. Chronological age alone is often a poor indicator of the physiological and functional status of older adults, and thus should not be the main factor guiding treatment decisions in oncology. By contrast, a geriatric assessment can provide a much more comprehensive understanding of the functional and physiological age of an older person with cancer. The geriatric assessment is a multidimensional tool that evaluates several domains, including physical function, cognition, nutrition, comorbidities, psychological status, and social support. In this Series paper, we discuss the use of a geriatric assessment-based approach to cancer care, and provide clinicians with tools to better assess the risks and benefits of treatment to engage in shared decision making and provide better personalised care for older people with cancer.},
	language = {eng},
	number = {6},
	journal = {The Lancet. Oncology},
	author = {Soto-Perez-de-Celis, Enrique and Li, Daneng and Yuan, Yuan and Lau, Yat Ming and Hurria, Arti},
	month = jun,
	year = {2018},
	pmid = {29893262},
	keywords = {Humans, Aged, Female, Male, Risk Factors, Neoplasms, Prognosis, Aged, 80 and over, Predictive Value of Tests, Age Factors, Nutrition Assessment, Comorbidity, Patient Selection, Nutritional Status, Quality of Life, Biomarkers, Geriatric Assessment, Aging, CGA, Polypharmacy, Clinical Decision-Making},
	pages = {e305--e316},
}

@article{perez-de-acha1377,
	title = {All-{Cause} {Mortality} {Risk} {Prediction} in {Older} {Adults} with {Cancer}: {Practical} {Approaches} and {Limitations}},
	volume = {24},
	issn = {1534-6269},
	shorttitle = {All-{Cause} {Mortality} {Risk} {Prediction} in {Older} {Adults} with {Cancer}},
	doi = {10.1007/s11912-022-01303-2},
	abstract = {PURPOSE OF REVIEW: The prediction of all-cause mortality is an important component of shared decision-making across the cancer care continuum, particularly in older adults with limited life expectancy, for whom there is an increased risk of over-diagnosis and treatment.
RECENT FINDINGS: Currently, several international societies recommend the use of all-cause mortality risk prediction tools when making decisions regarding screening and treatment in geriatric oncology. Here, we review some practical aspects of the utilization of those tools and dissect the characteristics of those most employed in geriatric oncology, highlighting both their advantages and their limitations.},
	language = {eng},
	number = {11},
	journal = {Current Oncology Reports},
	author = {Perez-de-Acha, Andrea and Pilleron, Sophie and Soto-Perez-de-Celis, Enrique},
	month = nov,
	year = {2022},
	pmid = {35648341},
	keywords = {Humans, Aged, Neoplasms, Prognosis, Mortality, Cancer, Geriatric Assessment, Mass Screening, Older adults, Decision Making, Clinical decision rules, Decision Making, Shared, Decision-making, Life expectancy, Life Expectancy},
	pages = {1377--1385},
}

@article{verduzco-aguirre68,
	title = {Predicting {Life} {Expectancy} for {Older} {Adults} with {Cancer} in {Clinical} {Practice}: {Implications} for {Shared} {Decision}-making},
	volume = {21},
	issn = {1534-6269},
	shorttitle = {Predicting {Life} {Expectancy} for {Older} {Adults} with {Cancer} in {Clinical} {Practice}},
	doi = {10.1007/s11912-019-0821-3},
	abstract = {PURPOSE OF REVIEW: The calculation of noncancer-specific life expectancy can guide shared decision-making and avoid over- and undertreatment in older adults with cancer. Several factors determine life expectancy, including socio-demographic background, comorbidities, physical performance, and geriatric assessment variables. We present an overview of existing tools to estimate life expectancy, as well as practical examples of how to take into account the patient's noncancer-specific life expectancy when discussing screening decisions, initiation of treatment, and end-of-life care.
RECENT FINDINGS: Life expectancy prognostication has been recently recommended by international societies as part of the initial assessment of all older adults with cancer. Additionally, online resources have been created in order to make life expectancy calculation tools accessible for clinicians. Understanding available methods to estimate life expectancy, as well as how to utilize them, is a fundamental part of geriatric oncology that should be integrated into everyday clinical practice.},
	language = {eng},
	number = {8},
	journal = {Current Oncology Reports},
	author = {Verduzco-Aguirre, Haydee Cristina and Gomez-Moreno, Carolina and Chavarri-Guerra, Yanin and Soto-Perez-de-Celis, Enrique},
	month = jun,
	year = {2019},
	pmid = {31240500},
	keywords = {Humans, Aged, Neoplasms, Prognosis, Mortality, Geriatric Assessment, Geriatrics, Medical Oncology, Older adults, Decision Making, Shared, Decision-making, Life expectancy, Life Expectancy, Adjuvant chemotherapy, Benefit risk assessment, Cancer screening, Early Detection of Cancer, End of life care, Geriatric assessment, Survival analysis},
	pages = {68},
}

@article{liu525421,
	title = {Oncologic {Outcome} and {Efficacy} of {Chemotherapy} in {Colorectal} {Cancer} {Patients} {Aged} 80 {Years} or {Older}},
	volume = {7},
	issn = {2296-858X},
	doi = {10.3389/fmed.2020.525421},
	abstract = {Purpose: The present study aimed to evaluate the oncologic outcomes of patients 80 years or older compared with younger patients, and we then further investigated the efficacy of chemotherapy in individuals 80 years or older. Methods: A retrospective analysis was conducted using the Surveillance, Epidemiology and End Results database. The χ2 test was used to analyze the different clinicopathologic and demographic variables between 65- and 79-year and ≥80-year groups. Kaplan-Meier analysis and log-rank testing were used to compare colorectal cancer (CRC)-specific survival (CCSS) curves between different groups. Multivariate and univariate Cox proportional hazards models with hazard ratios (HRs) and 95\% confidence intervals (CIs) were also used to assess CCSS and OS. Results: A total of 189,926 patients were included in our study. Compared with 65- to 79-year-old patients, age 80 years or older was associated with 48.4\% increased CRC-specific mortality (HR = 1.484, 95\% CI = 1.453-1.516, P {\textless} 0.0001; using 65-79 years old as the reference). Moreover, not receiving chemotherapy was significantly associated with an increased risk of CRC-related death, independent of other prognostic factors (HR = 0.615, 95\% CI = 0.589-0.643, P {\textless} 0.0001) in individuals 80 years or older. Conclusions: This large population-based study showed that older age was associated with worse oncologic outcomes compared to younger age. Chemotherapy could offer survival benefit for very old patients diagnosed with CRC, and we strongly believed that very old patients were undertreated in the present medical practices.},
	language = {eng},
	journal = {Frontiers in Medicine},
	author = {Liu, Wenting and Zhang, Mengyuan and Wu, Jun and Tang, Ran and Hu, Liqun},
	year = {2020},
	pmid = {33195291},
	pmcid = {PMC7645236},
	keywords = {chemotherapy, survival, colorectal cancer, Elderly, 80 years, population-based},
	pages = {525421},
	file = {Liu et al_2020_Oncologic Outcome and Efficacy of Chemotherapy in Colorectal Cancer Patients.pdf:/Users/jcsal/Zotero/storage/K5KDFHXW/Liu et al_2020_Oncologic Outcome and Efficacy of Chemotherapy in Colorectal Cancer Patients.pdf:application/pdf},
}

@article{chan147,
	title = {Population-{Based} {Patterns} and {Factors} {Associated} {With} {Underuse} of {Palliative} {Systemic} {Therapy} in {Elderly} {Patients} {With} {Metastatic} {Colon} {Cancer}},
	volume = {16},
	issn = {1938-0674},
	doi = {10.1016/j.clcc.2016.08.004},
	abstract = {BACKGROUND: We compared the patterns and factors associated with chemotherapy and bevacizumab use in elderly versus young patients with metastatic colon cancer (mCC) and determined the effect of systemic therapy on overall survival (OS) according to age.
MATERIALS AND METHODS: Patients diagnosed with mCC from 2009 to 2010 in British Columbia, Canada were reviewed and categorized as elderly patients (age ≥ 70 years) and young patients (age {\textless} 70 years). Cox regression models adjusted for age and confounders were used to determine the effect of systemic therapy on OS.
RESULTS: We identified 1013 patients with a median age of 67 years. Of the 1013 patients, 42\% were elderly and 58\% were young; 57\% were men; and 66\% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Fewer elderly patients were offered systemic therapy compared with young patients (48\% vs. 77\%; P {\textless} .001). Among those treated, elderly patients were less likely than young patients to receive combination chemotherapy (47\% vs. 81\%; P {\textless} .0001) and bevacizumab (19\% vs. 47\%; P {\textless} .0001). The most common reasons for no treatment were similar for the elderly and young patients: patient choice, poor ECOG PS, and significant comorbidities. Advanced age alone was also cited as a reason for elderly but not for young patients (7\% vs. 0\%). When treated, the risk of adverse events and treatment interruptions was comparable between age groups. The receipt of systemic therapy was associated with improved OS in both elderly (hazard ratio [HR], 0.45; 95\% confidence interval [CI], 0.37-0.56; P {\textless} .0001) and young (HR, 0.43; 95\% CI, 0.35-0.53; P {\textless} .0001) patients, regardless of age (interaction P {\textgreater} .05).
CONCLUSION: In carefully selected elderly patients, the outcomes from systemic therapy were comparable to those for young patients. Thus, age alone should not be a barrier to treatment of mCC.},
	language = {eng},
	number = {2},
	journal = {Clinical Colorectal Cancer},
	author = {Chan, Matthew and Hugh-Yeun, Kiara and Gresham, Gillian and Speers, Caroline H. and Kennecke, Hagen F. and Cheung, Winson Y.},
	month = jun,
	year = {2017},
	pmid = {27670894},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Palliative Care, Proportional Hazards Models, Survival Rate, Aged, 80 and over, Adult, Age Factors, Colonic Neoplasms, Young Adult, FOLFOX, Capecitabine, Patient Selection, Outcomes, Elderly, Bevacizumab, British Columbia, FOLFIRI, mCC},
	pages = {147--153},
}

@article{yang101,
	title = {Prognostic {Value} of {Sarcopenia} in {Lung} {Cancer}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {156},
	issn = {1931-3543},
	shorttitle = {Prognostic {Value} of {Sarcopenia} in {Lung} {Cancer}},
	doi = {10.1016/j.chest.2019.04.115},
	abstract = {BACKGROUND: Evidence regarding the association between sarcopenia (skeletal muscle depletion) and outcomes in patients with lung cancer varies across studies. We aimed to systematically review the prognostic value of sarcopenia in lung cancer.
METHODS: We searched Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials through July 23, 2018 to identify retrospective or prospective cohort studies. We applied the Quality in Prognostic Studies instrument to assess the risk of bias in individual studies. We examined the heterogeneity and publication bias and performed subgroup analyses and sensitivity analyses.
RESULTS: We included 13 studies (1,810 participants). The pooled prevalence of sarcopenia was 43\% in patients with non-small cell lung cancer (NSCLC) and 52\% in patients with small cell lung cancer (SCLC). Sarcopenia was associated with a shorter overall survival (OS) in patients with lung cancer (hazard ratio [HR], 2.23; 95\% CI, 1.68-2.94). This association existed for both NSCLC (HR, 2.57; 95\% CI, 1.79-3.68) and SCLC (HR, 1.59; 95\% CI, 1.17-2.14). Sarcopenia was an independent predictor of shorter OS in both stage I-II NSCLC (HR, 3.23; 95\% CI, 1.68-6.23) and stage III-IV NSCLC (HR, 2.19; 95\% CI, 1.14-4.24). However, sarcopenia was not an independent predictor of disease-free survival in patients with NSCLC (HR, 1.28; 95\% CI, 0.44-3.69).
CONCLUSIONS: Sarcopenia is highly prevalent in patients with lung cancer (approximately one in two) and an important predictor of impaired OS in patients with SCLC or with different stages of NSCLC.},
	language = {eng},
	number = {1},
	journal = {Chest},
	author = {Yang, Ming and Shen, Yanjiao and Tan, Lingling and Li, Weimin},
	month = jul,
	year = {2019},
	pmid = {31128115},
	keywords = {Humans, Sarcopenia, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Prognosis, sarcopenia, Survival Analysis, Lung, systematic review, prognosis, Carcinoma, Small Cell, lung cancer},
	pages = {101--111},
}

@article{lin115,
	title = {Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review},
	volume = {13},
	issn = {2730-6011},
	shorttitle = {Impact of sarcopenia on the prognosis and treatment of lung cancer},
	doi = {10.1007/s12672-022-00576-0},
	abstract = {BACKGROUND: Lung cancer is the leading cause of cancer-related mortality worldwide. Sarcopenia, defined as the loss of muscle mass and function, is known to cause adverse health outcomes. The purpose of this umbrella review was to integrate published systematic reviews and meta-analyses exploring sarcopenia and lung cancer to provide comprehensive knowledge on their relationship.
METHODS: Eligible studies were searched from scientific databases until June 28, 2022. Critical appraisal was performed using A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2. The impact of sarcopenia on the pathophysiology, prevalence, and prognosis of lung cancer is summarized at the level of systematic reviews or meta-analyses.
RESULTS: Fourteen reviews and meta-analyses were conducted. The methodological quality was high for one review, low for nine, and critically low for four. The most common standard for diagnosing sarcopenia in the lung cancer population is computed tomography (CT) to measure the skeletal muscle index at the third lumbar vertebra (L3). Sarcopenia was highly prevalent among patients with lung cancer, with a pooled prevalence ranging from 42.8\% to 45.0\%. The association between sarcopenia and increased postoperative complications and decreased disease control rates with immune checkpoint inhibitors has been demonstrated. Mortality was significantly higher in sarcopenic patients than in non-sarcopenic patients with lung cancer, regardless of the stage of disease or type of treatment.
CONCLUSIONS: Sarcopenia is a poor prognostic factor for lung cancer. Future studies are necessary to clarify the pathophysiology of sarcopenia and develop effective interventions for sarcopenia in patients with lung cancer.},
	language = {eng},
	number = {1},
	journal = {Discover. Oncology},
	author = {Lin, Ting-Yu and Chen, Yen-Fu and Wu, Wei-Ting and Han, Der-Sheng and Tsai, I.-Chen and Chang, Ke-Vin and Özçakar, Levent},
	month = oct,
	year = {2022},
	pmid = {36307591},
	pmcid = {PMC9616989},
	keywords = {Prognosis, Frailty, Lung, Malignancy, Muscle loss, Pulmonary},
	pages = {115},
	file = {Lin et al_2022_Impact of sarcopenia on the prognosis and treatment of lung cancer.pdf:/Users/jcsal/Zotero/storage/FUHFIZE3/Lin et al_2022_Impact of sarcopenia on the prognosis and treatment of lung cancer.pdf:application/pdf},
}

@article{buentzel4603,
	title = {Sarcopenia as {Prognostic} {Factor} in {Lung} {Cancer} {Patients}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {39},
	issn = {1791-7530},
	shorttitle = {Sarcopenia as {Prognostic} {Factor} in {Lung} {Cancer} {Patients}},
	doi = {10.21873/anticanres.13640},
	abstract = {BACKGROUND/AIM: Sarcopenia describes the loss of skeletal muscle mass. While this condition is associated with a high mortality in cancer patients, its influence on survival is still underestimated.
PATIENTS AND METHODS: A systematic review for articles was performed using the PubMed database, Cochrane Library, Biomed Central, Science Direct and by manual search. We used data of overall survival in sarcopenic patients for assessing the death risk. We extracted hazard ratio estimates from univariate and multivariate Cox proportional hazards models for meta-analysis.
RESULTS: A total of 15 studies were eligible for meta-analysis including a total of 2,521 lung cancer patients. Univariate meta-analysis revealed a two-fold increased death risk in sarcopenic patients; multivariate meta-analysis yielded a significant, three-fold elevated risk of death. This higher mortality is independent of tumour stage.
CONCLUSION: Muscle loss is an independent risk factor for increased death risk in lung cancer patients independent of cancer stage. This argues for implementing screening for sarcopenia into cancer care.},
	language = {eng},
	number = {9},
	journal = {Anticancer Research},
	author = {Buentzel, Judith and Heinz, Judith and Bleckmann, Annalen and Bauer, Christoph and Röver, Christian and Bohnenberger, Hanibal and Saha, Shekhar and Hinterthaner, Marc and Baraki, Hassina and Kutschka, Ingo and Emmert, Alexander},
	month = sep,
	year = {2019},
	pmid = {31519557},
	keywords = {Humans, Muscle, Skeletal, Sarcopenia, Neoplasm Staging, Proportional Hazards Models, Lung Neoplasms, Prognosis, Organ Size, Lung, prognosis, lung cancer, meta-analysis, review},
	pages = {4603--4612},
	file = {Buentzel et al_2019_Sarcopenia as Prognostic Factor in Lung Cancer Patients.pdf:/Users/jcsal/Zotero/storage/36PYZKKE/Buentzel et al_2019_Sarcopenia as Prognostic Factor in Lung Cancer Patients.pdf:application/pdf},
}

@article{kim4721,
	title = {Evaluation of sarcopenia in small-cell lung cancer patients by routine chest {CT}},
	volume = {24},
	issn = {1433-7339},
	doi = {10.1007/s00520-016-3321-0},
	abstract = {BACKGROUND: Single cross-sectional area of muscle at the third lumbar vertebra (L3MA) is gold standard to estimate skeletal muscle mass (SMM), and L3 muscle index (L3MI, L3MA/height(2)) is used to determine sarcopenia. The purposes of this study were to evaluate the relationship between SMM indices determined by routine chest CT and L3MI in patients with small-cell lung cancer (SCLC) and to suggest chest CT-derived diagnostic criteria for sarcopenia.
METHODS: Area of pectoralis muscles at the aortic arch (PMA) and at L1 (L1MA) was retrospectively measured on chest CT images of 90 consecutive SCLC patients. Pearson's correlation and multiple linear regression analysis were used to assess relationships between L3MI determined by PET/CT and pectoralis muscle index (PMI) and L1 muscle index (L1MI) determined by chest CT.
RESULTS: The correlation between L1MI and L3MI was stronger than that between PMI and L3MI (r = 0.851 vs. r = 0.447, p {\textless} 0.001). Multivariable regression analysis showed that L1MI was the only significant predictor of L3MI; L3MI = 0.963 × L1MI + 10.336 (R (2)  = 0.689, p {\textless} 0.001) for male and L3MI = 0.772 × L1MI + 16.518 (R (2)  = 0.777, p {\textless} 0.001) for female. Using this relationship, estimated cutoffs of L1MI for sarcopenia were 46 cm(2)/m(2) for male and 29 cm(2)/m(2) for female (L3MI cutoffs for sarcopenia are 55 cm(2)/m(2) for male and 39 cm(2)/m(2) for female). The sensitivity and specificity of L1MI cutoffs to determine sarcopenia were 98.2 and 100 \%, respectively.
CONCLUSIONS: Chest CT-determined L1MI is highly correlated with L3MI in SCLC patients. L1MI, as determined by chest CT, could be used to determine the presence of sarcopenia with suggested cutoffs of 46 cm(2)/m(2) for men and 29 cm(2)/m(2) for women.},
	language = {eng},
	number = {11},
	journal = {Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer},
	author = {Kim, Eun Young and Kim, Young Saing and Park, Inkeun and Ahn, Hee Kyung and Cho, Eun Kyung and Jeong, Yu Mi and Kim, Jeong Ho},
	month = nov,
	year = {2016},
	pmid = {27364150},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Sarcopenia, Retrospective Studies, Lung Neoplasms, Skeletal muscle mass, Tomography, Lung, Cancer cachexia, Small Cell Lung Carcinoma, Small-cell lung cancer, X-ray computed},
	pages = {4721--4726},
}

@article{dengdoy115,
	title = {Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta-analysis},
	volume = {32},
	issn = {1442-2050},
	shorttitle = {Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy},
	doi = {10.1093/dote/doy115},
	abstract = {The impact of preoperative sarcopenia on long-term survival of esophageal cancer patients after esophagectomy remains unclear. We conducted an updated meta-analysis focusing on current topic comprehensively. We systematically searched relevant studies investigating the impact of preoperative sarcopenia on survival of patients with surgically treated esophageal cancer in PubMed, Embase, and Web of Science up to July 20, 2018. Data of 3-year and 5-year overall survival (OS) rates as well as hazard ratio (HR) of OS and disease-free survival (DFS) were collected for analysis by using the STATA 12.0 package. Finally, a total of 11 cohort studies consisting of 1520 patients (795 sarcopenic patients and 725 nonsarcopenic patients) were included for analysis. Our meta-analysis showed that patients with sarcopenia had a significantly lower 3-year (51.6\% vs. 65.4\%, P {\textless} 0.001) and 5-year OS rate (41.2\% vs. 52.2\%, P = 0.018) than those without sarcopenia. Sarcopenia was found to be an independent predictor of poor OS (HR = 1.58; 95\% confidence interval (CI) = [1.35, 1.85]; P {\textless} 0.001) and DFS (HR = 1.46; 95\% CI = [1.12, 1.90]; P = 0.005) in esophageal cancer patients after esophagectomy. No obvious heterogeneities or publication bias were observed during analysis. Therefore, patients with sarcopenia had a significantly worse prognosis than those without after surgical resection of esophageal cancer. Preoperative sarcopenia is an independent unfavorable prognostic factor for esophageal cancer patients after esophagectomy. However, high-quality studies with appropriate adjustments for confounding factors are needed to confirm our conclusions.},
	language = {eng},
	number = {3},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Deng, Han-Yu and Zha, Panpan and Peng, Lei and Hou, Liang and Huang, Kai-Li and Li, Xiao-Yun},
	month = mar,
	year = {2019},
	pmid = {30496385},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Risk Factors, Proportional Hazards Models, Survival Rate, Prognosis, Aged, 80 and over, Adult, sarcopenia, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Preoperative Period, prognosis, meta-analysis, esophageal cancer, esophagectomy},
	pages = {doy115},
	file = {Deng et al_2019_Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer.pdf:/Users/jcsal/Zotero/storage/M8XDQ6J4/Deng et al_2019_Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer.pdf:application/pdf},
}

@article{makiura430,
	title = {Preoperative sarcopenia is a predictor of postoperative pulmonary complications in esophageal cancer following esophagectomy: {A} retrospective cohort study},
	volume = {7},
	issn = {1879-4076},
	shorttitle = {Preoperative sarcopenia is a predictor of postoperative pulmonary complications in esophageal cancer following esophagectomy},
	doi = {10.1016/j.jgo.2016.07.003},
	abstract = {OBJECTIVES: The number of geriatric patients with esophageal cancer has been increasing. Geriatric syndromes such as sarcopenia might adversely affect postoperative recovery. The aim of this study was to evaluate the relationships between sarcopenia and postoperative complications, and the associations between sarcopenia and perioperative functional changes in patients with esophageal cancer following esophagectomy.
MATERIALS AND METHODS: Participants comprised 104 patients who underwent esophagectomy from July 2011 to April 2015. Preoperative sarcopenia was diagnosed by the presence of low muscle mass and low physical functions according to Asian Working Group for Sarcopenia criteria. Low physical function was defined by loss of grip strength and/or slow walking speed. Postoperative pulmonary, cardiac, infectious, and surgical complications were extracted. Perioperative functional changes were calculated (value at postoperative day 30-value before surgery). For statistical analyses, both uni- and multivariate logistic regression analyses were performed.
RESULTS: Twenty-nine patients (27.9\%) were diagnosed with sarcopenia. The incidence of postoperative pulmonary complications was significantly higher in the sarcopenia group (37.9\%) than in the non-sarcopenia group (17.3\%; P=0.04). There was no relationship between sarcopenia and other complications or perioperative functional changes. Multivariate analysis identified sarcopenia (odds ratio (OR), 3.13; 95\% confidence interval (CI), 1.12-8.93) and high Brinkman index (OR, 3.46; 95\% CI, 1.20-11.77) as independent risk factors for the development of pulmonary complications.
CONCLUSION: The assessment of sarcopenia may be useful to predict the postoperative pulmonary complications following esophagectomy. On the other hand, sarcopenia does not predict cardiac, infectious, and surgical complications or perioperative function.},
	language = {eng},
	number = {6},
	journal = {Journal of Geriatric Oncology},
	author = {Makiura, Daisuke and Ono, Rei and Inoue, Junichiro and Kashiwa, Miyuki and Oshikiri, Taro and Nakamura, Tetsu and Kakeji, Yoshihiro and Sakai, Yoshitada and Miura, Yasushi},
	month = nov,
	year = {2016},
	pmid = {27452909},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Aged, Female, Length of Stay, Male, Sarcopenia, Treatment Outcome, Retrospective Studies, Risk Factors, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Postoperative Complications, Quality of Life, Preoperative Care, Muscle Strength, Blood Loss, Surgical, Operative Time, Lung Diseases, Fatigue, Functional status, Postoperative pulmonary complications, Rehabilitation},
	pages = {430--436},
}

@article{makiura456,
	title = {Impact of {Sarcopenia} on {Unplanned} {Readmission} and {Survival} {After} {Esophagectomy} in {Patients} with {Esophageal} {Cancer}},
	volume = {25},
	issn = {1534-4681},
	doi = {10.1245/s10434-017-6294-4},
	abstract = {BACKGROUND: Although sarcopenia increases postoperative complications following esophagectomy, its effects on prognosis remain unclear. This study was performed to identify the effect of sarcopenia on 90-day unplanned readmission and overall survival (OS) after esophagectomy.
METHODS: Ninety-eight patients with esophageal cancer who underwent esophagectomy were enrolled in this study. Unplanned readmission was defined as any emergent hospitalization within 90 days after discharge. Sarcopenia, defined as low muscle mass plus low muscle strength and/or low physical performance according to the Asian consensus definition, was assessed prior to esophagectomy. Multivariate logistic regression analysis was performed to identify factors that contributed to 90-day unplanned readmission. OS was estimated using the Kaplan-Meier method, and a Cox proportional hazards model was used to assess the relationship between sarcopenia and OS.
RESULTS: Thirty-one patients (31.6\%) were diagnosed with sarcopenia. The 90-day unplanned readmission rate was significantly higher in patients with sarcopenia than those without (42.9\% vs. 16.4\%, respectively; p = 0.01). Multivariable logistic regression analysis showed that sarcopenia was an independent predictor of 90-day unplanned readmission [odds ratio 3.71, 95\% confidence interval (CI) 1.29-11.05; p = 0.02], and the log-rank test showed that sarcopenia was associated with OS (p = 0.01). Moreover, sarcopenia was a significant predictor of OS after adjustment for age, sex, and pathological stage (hazard ratio 2.35, 95\% CI 1.21-4.54; p = 0.01).
CONCLUSIONS: Sarcopenia is a risk factor for 90-day unplanned readmission and OS following esophagectomy. Assessment of sarcopenia could help to identify patients at higher risk of a poor prognosis after esophagectomy.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Makiura, Daisuke and Ono, Rei and Inoue, Junichiro and Fukuta, Akimasa and Kashiwa, Miyuki and Miura, Yasushi and Oshikiri, Taro and Nakamura, Tetsu and Kakeji, Yoshihiro and Sakai, Yoshitada},
	month = feb,
	year = {2018},
	pmid = {29214454},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Follow-Up Studies, Retrospective Studies, Risk Factors, Survival Rate, Prognosis, Esophageal Neoplasms, Esophagectomy, Patient Readmission, Muscle Strength, Patient Discharge},
	pages = {456--464},
}

@article{studenski50,
	title = {Gait speed and survival in older adults},
	volume = {305},
	issn = {1538-3598},
	doi = {10.1001/jama.2010.1923},
	abstract = {CONTEXT: Survival estimates help individualize goals of care for geriatric patients, but life tables fail to account for the great variability in survival. Physical performance measures, such as gait speed, might help account for variability, allowing clinicians to make more individualized estimates.
OBJECTIVE: To evaluate the relationship between gait speed and survival.
DESIGN, SETTING, AND PARTICIPANTS: Pooled analysis of 9 cohort studies (collected between 1986 and 2000), using individual data from 34,485 community-dwelling older adults aged 65 years or older with baseline gait speed data, followed up for 6 to 21 years. Participants were a mean (SD) age of 73.5 (5.9) years; 59.6\%, women; and 79.8\%, white; and had a mean (SD) gait speed of 0.92 (0.27) m/s.
MAIN OUTCOME MEASURES: Survival rates and life expectancy.
RESULTS: There were 17,528 deaths; the overall 5-year survival rate was 84.8\% (confidence interval [CI], 79.6\%-88.8\%) and 10-year survival rate was 59.7\% (95\% CI, 46.5\%-70.6\%). Gait speed was associated with survival in all studies (pooled hazard ratio per 0.1 m/s, 0.88; 95\% CI, 0.87-0.90; P {\textless} .001). Survival increased across the full range of gait speeds, with significant increments per 0.1 m/s. At age 75, predicted 10-year survival across the range of gait speeds ranged from 19\% to 87\% in men and from 35\% to 91\% in women. Predicted survival based on age, sex, and gait speed was as accurate as predicted based on age, sex, use of mobility aids, and self-reported function or as age, sex, chronic conditions, smoking history, blood pressure, body mass index, and hospitalization.
CONCLUSION: In this pooled analysis of individual data from 9 selected cohorts, gait speed was associated with survival in older adults.},
	language = {eng},
	number = {1},
	journal = {JAMA},
	author = {Studenski, Stephanie and Perera, Subashan and Patel, Kushang and Rosano, Caterina and Faulkner, Kimberly and Inzitari, Marco and Brach, Jennifer and Chandler, Julie and Cawthon, Peggy and Connor, Elizabeth Barrett and Nevitt, Michael and Visser, Marjolein and Kritchevsky, Stephen and Badinelli, Stefania and Harris, Tamara and Newman, Anne B. and Cauley, Jane and Ferrucci, Luigi and Guralnik, Jack},
	month = jan,
	year = {2011},
	pmid = {21205966},
	pmcid = {PMC3080184},
	keywords = {Humans, Aged, Female, Male, Cohort Studies, Survival Analysis, United States, Geriatric Assessment, Life Expectancy, Gait},
	pages = {50--58},
	file = {Studenski et al_2011_Gait speed and survival in older adults.pdf:/Users/jcsal/Zotero/storage/KH2EQ52J/Studenski et al_2011_Gait speed and survival in older adults.pdf:application/pdf},
}

@article{hershman313,
	title = {Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women},
	volume = {99},
	issn = {0167-6806},
	doi = {10.1007/s10549-006-9206-z},
	abstract = {BACKGROUND: Delay in the diagnosis of breast cancer is associated with worse stage distribution at diagnosis and decreased survival. However, the occurrence of delay in the delivery of adjuvant therapy and its impact on prognosis is not well understood.
METHODS: To investigate the timeliness of initiation of adjuvant chemotherapy following surgery for breast cancer, we used data from the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database. Among women {\textgreater} or = 65 years diagnosed between 1992 and 1999 with stages I-II breast cancer, we used linear regression and Cox proportional hazards models to investigate the time intervals between surgery and initiation of adjuvant chemotherapy, factors associated with delay, and the effect of delay on survival.
RESULTS: Our sample consisted of 5003 women who received adjuvant chemotherapy. Of these, 47\% initiated chemotherapy within 1 month, 37\% between 1 and 2 months, 6\% between 2 and 3 months and 10\% {\textgreater}3 months (delay) following surgery. Delay was associated with increasing age, residing in a rural location, being unmarried, earlier tumor stage, hormone receptor positivity, mastectomy, and non-receipt of radiation therapy. Survival did not differ among patients who initiated chemotherapy within 1, 2, or 3 months after surgery. Delay beyond 3 months was, however, associated with increased disease-specific mortality (HR 1.69; 95\% CI 1.31-2.19) and overall mortality (HR 1.46; 95\% CI 1.21-1.75).
CONCLUSIONS: Among older patients, moderate delays in the receipt of adjuvant chemotherapy occur frequently, but long delays ({\textgreater}3 months) are uncommon. While early initiation of therapy is no benefit, significant delays are associated with increased mortality. Whether this reflects the medical impact of the delay of chemotherapy or factors associated with delay is unclear, but until this is clarified, patients should be encouraged to initiate treatment without significant delay.},
	language = {eng},
	number = {3},
	journal = {Breast Cancer Research and Treatment},
	author = {Hershman, Dawn L. and Wang, Xiaoyan and McBride, Russell and Jacobson, Judith S. and Grann, Victor R. and Neugut, Alfred I.},
	month = oct,
	year = {2006},
	pmid = {16583264},
	keywords = {Humans, Aged, Female, Kaplan-Meier Estimate, Risk Factors, Proportional Hazards Models, Time Factors, Antineoplastic Agents, Prognosis, Aged, 80 and over, Age Factors, Chemotherapy, Adjuvant, Drug Administration Schedule, United States, Evaluation Studies as Topic, Medicare, Linear Models, Breast Neoplasms, SEER Program, DoseIntensity},
	pages = {313--321},
}

@article{bonadonna901,
	title = {Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up},
	volume = {332},
	issn = {0028-4793},
	shorttitle = {Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer},
	doi = {10.1056/NEJM199504063321401},
	abstract = {BACKGROUND: Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil was administered after radical mastectomy for primary breast cancer with histologically positive axillary lymph nodes to assess whether it would improve treatment outcome as compared with surgery alone. Here we report a 20-year follow-up of this investigation.
METHODS: In 1973 we began a trial involving 386 women who were randomly assigned to receive either no further treatment after radical mastectomy (179 women) or 12 monthly cycles of adjuvant combination chemotherapy (207 women). All patients were admitted to the Istituto Nazionale Tumori in Milan, Italy. Adjuvant chemotherapy was delivered in the outpatient clinic of the Division of Medical Oncology.
RESULTS: After a median follow-up of 19.4 years, the patients given adjuvant combination chemotherapy had significantly better rates of relapse-free survival (unadjusted relative risk of relapse, 0.71; 95 percent confidence interval, 0.56 to 0.90; P = 0.004; adjusted relative risk, 0.65, 95 percent confidence interval, 0.51 to 0.83; P {\textless} 0.001) and total survival (unadjusted relative risk of death, 0.78; 95 percent confidence interval, 0.62 to 0.99; P = 0.04; adjusted relative risk, 0.76; 95 percent confidence interval, 0.60 to 0.97; P = 0.03). With the exception of postmenopausal women, a benefit from adjuvant chemotherapy was evident in all subgroups of patients.
CONCLUSIONS: The long-term results of this trial of adjuvant combination chemotherapy confirm our preliminary observations of the effectiveness of the treatment in women with node-positive breast cancer.},
	language = {eng},
	number = {14},
	journal = {The New England Journal of Medicine},
	author = {Bonadonna, G. and Valagussa, P. and Moliterni, A. and Zambetti, M. and Brambilla, C.},
	month = apr,
	year = {1995},
	pmid = {7877646},
	keywords = {Humans, Aged, Female, Middle Aged, Treatment Outcome, Follow-Up Studies, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemotherapy, Adjuvant, Fluorouracil, Disease-Free Survival, Lymphatic Metastasis, Lymph Nodes, Regression Analysis, Breast Neoplasms, Cyclophosphamide, Mastectomy, Radical, Methotrexate, Dose Intensity},
	pages = {901--906},
}

@article{hu1062,
	title = {Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-{III} colon cancer},
	volume = {28},
	issn = {1559-131X},
	doi = {10.1007/s12032-010-9644-7},
	abstract = {Randomized trials conducted in the 1980s have established the effectiveness of 5-fluorouracil-based adjuvant chemotherapy in treating stage-III colon cancer. However, the initiation of adjuvant chemotherapy is just the first step for survival improvement. Little is known about the actual completion rate of such a therapy in the community. The objectives of this study were to measure the initiation and completion rate of adjuvant chemotherapy and to identify the associated factors. We studied 12,265 patients aged 65+ diagnosed with stage-III colon cancer between 1991 and 2005 who were identified from the Surveillance, Epidemiology, and End Results-Medicare linked database. Chemotherapy initiation was defined as at least one claim indicating the use of chemotherapy. The first and last claims were used to measure the length of chemotherapy. A complete course of chemotherapy was defined as 8-13 months for 1991-1995 cohort and 5-7 months for 1996-2005 cohort according to clinical guideline. Of the 12,265 patients, 64.4\% received adjuvant chemotherapy within 3 months after tumor resection. Among those who had chemotherapy initiated, 62.2\% (or 38.0\% of 12,265 patients) received a complete course of chemotherapy. Patient's age at diagnosis, marital status, and comorbidity score were the significant predictors for chemotherapy initiation. These variables remained significant in predicting chemotherapy completion after adjusting for year of diagnosis and other factors. In conclusion, initiation and completion of chemotherapy was largely influenced by patient's age, marital status and comorbidity. Further investigation is needed to explore the cause of these differences in adherence to standard treatment that is essential for better quality of cancer care.},
	language = {eng},
	number = {4},
	journal = {Medical Oncology (Northwood, London, England)},
	author = {Hu, Chung-Yuan and Delclos, George L. and Chan, Wenyaw and Du, Xianglin L.},
	month = dec,
	year = {2011},
	pmid = {20714945},
	keywords = {Humans, Aged, Female, Male, Neoplasm Staging, Antineoplastic Agents, Cohort Studies, Aged, 80 and over, Age Factors, Chemotherapy, Adjuvant, Colonic Neoplasms, Fluorouracil, Comorbidity, SEER Program, DoseIntensity},
	pages = {1062--1074},
}

@article{crawford925,
	title = {Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer},
	volume = {28},
	issn = {1433-7339},
	doi = {10.1007/s00520-019-04875-1},
	abstract = {PURPOSE: The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively analyzed dose delays/reduction, relative dose intensity (RDI), and the association between chemotherapy intensity and survival in advanced NSCLC.
METHODS: This retrospective cohort study included adults with advanced lung cancer who received first-line myelosuppressive platinum-based chemotherapy (January 2007-December 2010) in {\textasciitilde} 230 US Oncology Network community practices. Dose delays ≥ 7 days, dose reductions ≥ 15\%, and RDI relative to standard regimens were described. Overall survival (OS) was measured using Kaplan-Meier and Cox proportional hazard (PH) models.
RESULTS: Among 3866 patients with advanced NSCLC, 32.4\% experienced dose delays ≥ 7 days, 50.1\% experienced dose reductions ≥ 15\%, and 40.4\% had RDI {\textless} 85\%. Reduced RDI was also common regardless of baseline ECOG PS (ECOG PS ≥ 2, 56.2\%; ECOG PS 0, 33.6\%) and tumor subgroup (squamous cell carcinoma, 52.2\%; adenocarcinoma, 36.0\%). When stratified by chemotherapy intensity measures, significant OS differences were observed only for dose delays. Median (95\% CI) OS was 1.02 years (0.96-1.12) for dose delays ≥ 7 days and 0.71 years (0.66-0.77) for dose delays {\textless} 7 days. In multivariable Cox PH analysis, dose delays ≥ 7 days (HR = 0.71; 95\% CI = 0.63-0.80) and RDI ≥ 85\% (HR = 1.18; 95\% CI = 1.05-1.32) were significantly associated with decreased mortality.
CONCLUSIONS: Dose delays, dose reductions, and reduced RDI were common, and dose delays ≥ 7 days and high RDI were significantly associated with decreased mortality. These results can help identify potential risk factors and characterize the effect of chemotherapy dose modification strategies on mortality.},
	language = {eng},
	number = {2},
	journal = {Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer},
	author = {Crawford, Jeffrey and Denduluri, Neelima and Patt, Debra and Jiao, Xiaolong and Morrow, Phuong Khanh and Garcia, Jacob and Barron, Richard and Lyman, Gary H.},
	month = feb,
	year = {2020},
	pmid = {31172284},
	pmcid = {PMC6954126},
	keywords = {Humans, Aged, Female, Male, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Chemotherapy, DoseIntensity, Community health services, Lung cancer, Retrospective studies},
	pages = {925--932},
	file = {Crawford et al_2020_Relative dose intensity of first-line chemotherapy and overall survival in.pdf:/Users/jcsal/Zotero/storage/8LIJPGT8/Crawford et al_2020_Relative dose intensity of first-line chemotherapy and overall survival in.pdf:application/pdf},
}

@article{nielsone1609,
	title = {Relative {Dose} {Intensity} of {Chemotherapy} and {Survival} in {Patients} with {Advanced} {Stage} {Solid} {Tumor} {Cancer}: {A} {Systematic} {Review} and {Meta}-{Analysis}},
	volume = {26},
	issn = {1549-490X},
	shorttitle = {Relative {Dose} {Intensity} of {Chemotherapy} and {Survival} in {Patients} with {Advanced} {Stage} {Solid} {Tumor} {Cancer}},
	doi = {10.1002/onco.13822},
	abstract = {BACKGROUND: Chemotherapy-induced toxicities lead to therapy dose reduction or delay, affecting patient outcomes. This systematic review and meta-analysis evaluated the impact of relative dose intensity (RDI) on survival in adult patients with solid tumor cancer on nonadjuvant-based chemotherapy regimens.
METHODS: PubMed, Embase, and Web of Science databases were searched for peer-reviewed English journal articles or congress abstracts evaluating association between RDI and survival; observational studies, case series of ≥20 patients, and clinical trials published between 2013 and 2020 were eligible. Meta-analyses were conducted to quantify the association between RDI levels and overall survival (OS) among studies reporting a hazard ratio (HR) for OS by similar tumor types, regimens, and RDI. Forest plots represented summary HR and 95\% confidence interval (CI); Cochran's Q and I2 tests evaluated study heterogeneity.
RESULTS: Overall, 919 articles were reviewed and 22 included; seven were eligible for meta-analysis. Significantly shorter OS at RDI {\textless}80\% versus ≥80\% and {\textless}85\% versus ≥85\% was observed upon meta-analysis of four carboplatin-based studies for breast, non-small cell lung, or ovarian cancer (HR 1.17; 95\% CI: 1.07-1.27) and three FOLFOX-, FOLFIRI-, or FOLFIRINOX-based studies for colorectal or pancreatic cancer (HR 1.39; 95\% CI: 1.03-1.89). Grade 3 or higher hematologic toxicities were higher for carboplatin-based regimens (thrombocytopenia: 14\%-22\%; anemia: 15\%-19\%; neutropenia: 24\%-58\%) than FOLFOX-, FOLFIRI-, or FOLFIRINOX-based regimens (thrombocytopenia: 1\%-4\%; anemia: 5\%-19\%; neutropenia: 19\%-47\%).
CONCLUSION: The results suggested longer OS with RDI ≥80\% or ≥85\% for both regimens, indicating that management of toxicities across treatment modalities may contribute to maintenance of higher RDI and benefit survival for patients with advanced solid tumors.
IMPLICATIONS FOR PRACTICE: Chemotherapy-induced toxicities lead to dose reduction and/or treatment delay, thus affecting patient outcomes. Results of this systematic review and meta-analysis, evaluating the impact of relative dose intensity (RDI) on survival of patients with solid tumors on nonadjuvant-based chemotherapy regimens, demonstrate a longer overall survival with RDI levels of at least 80\% for patients with solid tumors on carboplatin-based and FOLFOX-, FOLFIRI-, or FOLFIRINOX-based chemotherapy regimens, suggesting a protective effect of maintaining RDI ≥80\% or ≥ -85\%. Although grade 3 or higher hematologic toxicities occurred more in carboplatin-based studies, managing toxicities across treatment regimens may contribute to maintenance of higher RDI and ultimately benefit overall survival.},
	language = {eng},
	number = {9},
	journal = {The Oncologist},
	author = {Nielson, Carrie M. and Bylsma, Lauren C. and Fryzek, Jon P. and Saad, Hossam A. and Crawford, Jeffrey},
	month = sep,
	year = {2021},
	pmid = {33973301},
	pmcid = {PMC8417866},
	keywords = {Humans, Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms, Meta-analysis, Carboplatin, Overall survival, DoseIntensity, Carboplatin-based regimens, FOLFOX/FOLFIRI-based regimens, Progression-free survival, Relative dose intensity},
	pages = {e1609--e1618},
	file = {Nielson et al_2021_Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced.pdf:/Users/jcsal/Zotero/storage/FBIUYJ9J/Nielson et al_2021_Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced.pdf:application/pdf},
}

@article{komici485,
	title = {Frailty in {Patients} {With} {Lung} {Cancer}: {A} {Systematic} {Review} and {Meta}-{Analysis}},
	volume = {162},
	issn = {0012-3692},
	shorttitle = {Frailty in {Patients} {With} {Lung} {Cancer}},
	url = {https://www.sciencedirect.com/science/article/pii/S0012369222003919},
	doi = {10.1016/j.chest.2022.02.027},
	abstract = {Background
Previous studies regarding the prevalence of frailty in patients with lung cancer and mortality in frail patients with lung cancer are inconsistent and require clarification.
Research Question
What is the prevalence and impact of frailty in patients with lung cancer?
Study Design and Methods
This systematic review and meta-analysis used a combination of free-text terms and medical subject headings terms, according to the database requirements in MEDLINE/PubMed, Scopus, and Cochrane Library from inception until November 15, 2020.
Results
A total of 2,571 articles were identified, and 16 articles involving 4,183 patients were included for study. The prevalence of frailty in lung cancer was 45\% (95\% CI, 28-61; I2 = 99.5\%; P {\textless} .0001). In patients with lung cancer, frailty was associated with an increased hazard ratio for mortality (hazard ratio, 3.01; 95\% CI, 1.77-5.10; P {\textless} .001).
Interpretation
The prevalence of frailty in lung cancer is 45\%, which has a significant negative impact on survival of patients with lung cancer. These results highlight the importance of measuring frailty, which provides important prognostic information, and may provide opportunities for interventions to improve outcomes in patients with lung cancer.},
	language = {en},
	number = {2},
	urldate = {2022-12-31},
	journal = {Chest},
	author = {Komici, Klara and Bencivenga, Leonardo and Navani, Neal and D’Agnano, Vito and Guerra, Germano and Bianco, Andrea and Rengo, Giuseppe and Perrotta, Fabio},
	month = aug,
	year = {2022},
	keywords = {mortality, elderly, Lung, frailty, lung cancer, outcome},
	pages = {485--497},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/JUULQIFY/S0012369222003919.html:text/html},
}

@article{vanamsterdam1191,
	title = {The {Association} between {Muscle} {Quantity} and {Overall} {Survival} {Depends} on {Muscle} {Radiodensity}: {A} {Cohort} {Study} in {Non}-{Small}-{Cell} {Lung} {Cancer} {Patients}},
	volume = {12},
	issn = {2075-4426},
	shorttitle = {The {Association} between {Muscle} {Quantity} and {Overall} {Survival} {Depends} on {Muscle} {Radiodensity}},
	doi = {10.3390/jpm12071191},
	abstract = {The prognostic value of CT-derived muscle quantity for overall survival (OS) in patients with non-small-cell lung cancer (NSCLC) is uncertain due to conflicting evidence. We hypothesize that increased muscle quantity is associated with better OS in patients with normal muscle radiodensity but not in patients with fatty degeneration of muscle tissue and low muscle radiodensity. We performed an observational cohort study in NSCLC patients treated with radiotherapy. A deep learning algorithm was used to measure muscle quantity as psoas muscle index (PMI) and psoas muscle radiodensity (PMD) on computed tomography. The potential interaction between PMI and PMD for OS was investigated using Cox proportional-hazards regression. Baseline adjustment variables were age, sex, histology, performance score and body mass index. We investigated non-linear effects of continuous variables and imputed missing values using multiple imputation. We included 2840 patients and observed 1975 deaths in 5903 patient years. The average age was 68.9 years (standard deviation 10.4, range 32 to 96) and 1692 patients (59.6\%) were male. PMI was more positively associated with OS for higher values of PMD (hazard ratio for interaction 0.915; 95\% confidence interval 0.861-0.972; p-value 0.004). We found evidence that high muscle quantity is associated with better OS when muscle radiodensity is higher, in a large cohort of NSCLC patients treated with radiotherapy. Future studies on the association between muscle status and OS should accommodate this interaction in their analysis for more accurate and more generalizable results.},
	language = {eng},
	number = {7},
	journal = {Journal of Personalized Medicine},
	author = {van Amsterdam, Wouter A. C. and Harlianto, Netanja I. and Verhoeff, Joost J. C. and Moeskops, Pim and de Jong, Pim A. and Leiner, Tim},
	month = jul,
	year = {2022},
	pmid = {35887688},
	pmcid = {PMC9322608},
	keywords = {Myosteatosis, cachexia, survival analysis, Lung, prognosis, carcinoma, non-small-cell lung},
	pages = {1191},
	file = {van Amsterdam et al_2022_The Association between Muscle Quantity and Overall Survival Depends on Muscle.pdf:/Users/jcsal/Zotero/storage/R7U6CY6G/van Amsterdam et al_2022_The Association between Muscle Quantity and Overall Survival Depends on Muscle.pdf:application/pdf},
}

@article{dolly1413,
	title = {Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?},
	volume = {11},
	issn = {2190-6009},
	shorttitle = {Cancer cachexia and skeletal muscle atrophy in clinical studies},
	doi = {10.1002/jcsm.12633},
	abstract = {Research investigators have shown a growing interest in investigating alterations underlying skeletal muscle wasting in patients with cancer. However, skeletal muscle dysfunctions associated with cancer cachexia have mainly been studied in preclinical models. In the present review, we summarize the results of clinical studies in which skeletal muscle biopsies were collected from cachectic vs. non-cachectic cancer patients. Most of these studies suggest the presence of significant physiological alterations in skeletal muscle from cachectic cancer patients. We suggest a hypothesis, which connects structural and metabolic parameters that may, at least in part, be responsible for the skeletal muscle atrophy characteristic of cancer cachexia. Finally, we discuss the importance of a better standardization of the diagnostic criteria for cancer cachexia, as well as the requirement for additional clinical studies to improve the robustness of these conclusions.},
	language = {eng},
	number = {6},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Dolly, Adeline and Dumas, Jean-François and Servais, Stéphane},
	month = dec,
	year = {2020},
	pmid = {33053604},
	pmcid = {PMC7749617},
	keywords = {Humans, Muscle, Skeletal, Cachexia, Muscular Atrophy, Neoplasms, Myosteatosis, Cancer cachexia, Clinical studies, Mitochondria, Skeletal muscle alterations},
	pages = {1413--1428},
	file = {Dolly et al_2020_Cancer cachexia and skeletal muscle atrophy in clinical studies.pdf:/Users/jcsal/Zotero/storage/2Z86E73W/Dolly et al_2020_Cancer cachexia and skeletal muscle atrophy in clinical studies.pdf:application/pdf},
}

@article{blum1635,
	title = {Validation of the {Consensus}-{Definition} for {Cancer} {Cachexia} and evaluation of a classification model--a study based on data from an international multicentre project ({EPCRC}-{CSA})},
	volume = {25},
	issn = {1569-8041},
	doi = {10.1093/annonc/mdu086},
	abstract = {BACKGROUND: Weight loss limits cancer therapy, quality of life and survival. Common diagnostic criteria and a framework for a classification system for cancer cachexia were recently agreed upon by international consensus. Specific assessment domains (stores, intake, catabolism and function) were proposed. The aim of this study is to validate this diagnostic criteria (two groups: model 1) and examine a four-group (model 2) classification system regarding these domains as well as survival.
PATIENTS AND METHODS: Data from an international patient sample with advanced cancer (N = 1070) were analysed. In model 1, the diagnostic criteria for cancer cachexia [weight loss/body mass index (BMI)] were used. Model 2 classified patients into four groups 0-III, according to weight loss/BMI as a framework for cachexia stages. The cachexia domains, survival and sociodemographic/medical variables were compared across models.
RESULTS: Eight hundred and sixty-one patients were included. Model 1 consisted of 399 cachectic and 462 non-cachectic patients. Cachectic patients had significantly higher levels of inflammation, lower nutritional intake and performance status and shorter survival. In model 2, differences were not consistent; appetite loss did not differ between group III and IV, and performance status not between group 0 and I. Survival was shorter in group II and III compared with other groups. By adding other cachexia domains to the model, survival differences were demonstrated.
CONCLUSION: The diagnostic criteria based on weight loss and BMI distinguish between cachectic and non-cachectic patients concerning all domains (intake, catabolism and function) and is associated with survival. In order to guide cachexia treatment a four-group classification model needs additional domains to discriminate between cachexia stages.},
	language = {eng},
	number = {8},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Blum, D. and Stene, G. B. and Solheim, T. S. and Fayers, P. and Hjermstad, M. J. and Baracos, V. E. and Fearon, K. and Strasser, F. and Kaasa, S. and {Euro-Impact}},
	month = aug,
	year = {2014},
	pmid = {24562443},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Cachexia, Neoplasms, Prognosis, Weight Loss, Survival Analysis, Decision Support Techniques, cachexia, cancer, Algorithms, Consensus, classification, International Cooperation, validation},
	pages = {1635--1642},
	file = {Blum et al_2014_Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a.pdf:/Users/jcsal/Zotero/storage/PZPRLN2E/Blum et al_2014_Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a.pdf:application/pdf},
}

@article{shaoe31113,
	title = {Pretreatment "prognostic nutritional index" as an indicator of outcome in lung cancer patients receiving {ICI}-based treatment: {Systematic} review and meta-analysis},
	volume = {101},
	issn = {1536-5964},
	shorttitle = {Pretreatment "prognostic nutritional index" as an indicator of outcome in lung cancer patients receiving {ICI}-based treatment},
	doi = {10.1097/MD.0000000000031113},
	abstract = {BACKGROUND: The pretreatment prognostic nutritional index (PNI) is an indicator of nutritional and immune status, and has potential use as a predictor of survival in cancer patients. Several retrospective studies have used the PNI to predict the outcome of lung cancer patients receiving different immune checkpoint inhibitors (ICIs), but the results have been inconsistent. The objective of our study is to assess the relationship of pretreatment PNI with survival outcomes in lung cancer patients who received ICI-based treatments by meta-analysis.
METHODS: We searched the EMBASE, PubMed, Cochrane Library, American Society of Clinical Oncology, and European Society of Medical Oncology databases to identify studies that reported overall survival (OS) or progression-free survival (PFS) in eligible patients. Eight studies were eligible based on predefined inclusion and exclusion criteria. Data and pooled indicators were extracted from these studies. Meta-analysis was used to analyze hazard ratios (HRs) and 95\% confidence intervals (CIs) for OS and/or PFS and the prognostic value of pretreatment PNI. We completed the registration of the research protocol (Registration number: INPLASY202240087, DOI number: 10.37766/inplasy2022.4.0087).
RESULTS: We analyzed data from 8 eligible studies (831 patients). Meta-analysis showed that relative to patients with low pretreatment PNI, those with a high pretreatment PNI had better OS (HR = 2.50, 95\% CI = 1.44-4.33, P = .001) and better PFS (HR = 1.94, 95\% CI = 1.56-2.42, P {\textless} .001). Sensitivity analysis indicated these results were robust. There was also no evidence of publication bias.
CONCLUSION: Lung cancer patients receiving ICI-based treatments who had higher pretreatment PNI had better OS and PFS.},
	language = {eng},
	number = {43},
	journal = {Medicine},
	author = {Shao, Yifeng and Cao, Wei and Gao, Xinliang and Tang, Mingbo and Zhu, Dongshan and Liu, Wei},
	month = oct,
	year = {2022},
	pmid = {36316884},
	pmcid = {PMC9622676},
	keywords = {Humans, Retrospective Studies, Proportional Hazards Models, Lung Neoplasms, Prognosis, Nutrition Assessment, Lung, PNI},
	pages = {e31113},
	file = {Shao et al_2022_Pretreatment prognostic nutritional index as an indicator of outcome in lung.pdf:/Users/jcsal/Zotero/storage/3JRLERQJ/Shao et al_2022_Pretreatment prognostic nutritional index as an indicator of outcome in lung.pdf:application/pdf},
}

@article{jine035031,
	title = {Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis},
	volume = {10},
	issn = {2044-6055},
	shorttitle = {Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy},
	doi = {10.1136/bmjopen-2019-035031},
	abstract = {OBJECTIVES: To explore the relationship between the pretreatment or post-treatment neutrophil to lymphocyte ratio (NLR) and overall survival (OS)/progression-free survival (PFS) in patients with lung cancer receiving immunotherapy.
DESIGN: We searched several databases to collect relevant studies conducted until July 2019. We carefully reviewed the full text of the included publications and combined the HRs and 95\% CIs to assess the association between the NLR and survival time in patients with lung cancer receiving immunotherapy.
DATA SOURCES: PubMed, the Cochrane Library, Embase and Web of Science ELIGIBILITY CRITERIA: Studies reporting the prognostic value of the NLR in patients with lung cancer receiving immunotherapy were enrolled.
DATA EXTRACTION AND SYNTHESIS: Basic information on the articles and patients (NLR cut-off value, NLR at baseline and HRs with 95\% CIs for OS and PFS) was extracted by two authors independently. The pooled HRs of OS and PFS were synthesised using the random effects or fixed effects model.
RESULTS: Twenty-three studies with 2068 patients were enrolled. Among all patients, 1305 (64.0\%) were men and 643 (31.4\%) were diagnosed with squamous cell carcinoma (SCC). In a pooled analysis of OS and PFS from all studies, an elevated NLR predicted poor OS (HR=1.62; 95\% CI: 1.41 to 1.87; p{\textless}0.001) and PFS (HR=1.47; 95\% CI: 1.25 to 1.72; p{\textless}0.001). Subgroup analyses stratified showed that the post-treatment NLR was not significantly related to OS and that patients in Asia had significantly higher HRs than those in Europe and America. Furthermore, the proportion of SCC and baseline NLR could affect the prognostic value of the NLR.
CONCLUSIONS: Our study found that an elevated NLR was associated with poor OS and PFS in patients with lung cancer receiving immunotherapy and that several clinical factors might have an impact on the predictive value of the NLR in the survival of patients with lung cancer.},
	language = {eng},
	number = {6},
	journal = {BMJ open},
	author = {Jin, Jing and Yang, Lan and Liu, Dan and Li, Weimin},
	month = jun,
	year = {2020},
	pmid = {32499266},
	pmcid = {PMC7282333},
	keywords = {Humans, Lung Neoplasms, Survival Rate, Prognosis, Carcinoma, Squamous Cell, Immunotherapy, Lymphocyte Count, Neutrophils, Lung, NLR, Leukocyte Count, Correlation of Data, epidemiology, immunology, respiratory tract tumours},
	pages = {e035031},
	file = {Jin et al_2020_Association of the neutrophil to lymphocyte ratio and clinical outcomes in.pdf:/Users/jcsal/Zotero/storage/KJ9A9V7C/Jin et al_2020_Association of the neutrophil to lymphocyte ratio and clinical outcomes in.pdf:application/pdf},
}

@article{rockwood722,
	title = {Frailty in relation to the accumulation of deficits},
	volume = {62},
	issn = {1079-5006},
	doi = {10.1093/gerona/62.7.722},
	abstract = {This review article summarizes how frailty can be considered in relation to deficit accumulation. Recalling that frailty is an age-associated, nonspecific vulnerability, we consider symptoms, signs, diseases, and disabilities as deficits, which are combined in a frailty index. An individual's frailty index score reflects the proportion of potential deficits present in that person, and indicates the likelihood that frailty is present. Although based on a simple count, the frailty index shows several interesting properties, including a characteristic rate of accumulation, a submaximal limit, and characteristic changes with age in its distribution. The frailty index, as a state variable, is able to quantitatively summarize vulnerability. Future studies include the application of network analyses and stochastic analytical techniques to the evaluation of the frailty index and the description of other state variables in relation to frailty.},
	language = {eng},
	number = {7},
	journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
	author = {Rockwood, Kenneth and Mitnitski, Arnold},
	month = jul,
	year = {2007},
	pmid = {17634318},
	keywords = {Humans, Aged, Aged, 80 and over, Aging, Frail Elderly, Mathematics, Models, Theoretical, eFI},
	pages = {722--727},
	file = {Rockwood_Mitnitski_2007_Frailty in relation to the accumulation of deficits.pdf:/Users/jcsal/Zotero/storage/RPH87P89/Rockwood_Mitnitski_2007_Frailty in relation to the accumulation of deficits.pdf:application/pdf},
}

@article{dale3420,
	title = {"{Staging} the aging" when considering androgen deprivation therapy for older men with prostate cancer},
	volume = {27},
	issn = {1527-7755},
	doi = {10.1200/JCO.2009.22.9104},
	language = {eng},
	number = {21},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Dale, William},
	month = jul,
	year = {2009},
	pmid = {19506150},
	keywords = {Humans, Male, Prostatic Neoplasms, Aging, Fatigue, Androgen Antagonists, Health Services for the Aged, Hot Flashes, Testosterone},
	pages = {3420--3422},
}

@article{shachar1203,
	title = {The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: {An} {Israeli} prospective study},
	volume = {13},
	issn = {1879-4068},
	shorttitle = {The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer},
	url = {https://www.sciencedirect.com/science/article/pii/S1879406822001989},
	doi = {10.1016/j.jgo.2022.08.007},
	abstract = {Introduction
We investigated the associations among frailty, as determined via the comprehensive geriatric assessment (CGA), muscle measures (i.e., sarcopenia), and treatment-related toxicity in older adults with cancer in Israel.
Materials and methods
This prospective cohort study enrolled patients ≥65 years with newly-diagnosed stage IV lung, breast, or genitourinary cancer. Patients were enrolled and completed CGA before their first line of systemic therapy (chemotherapy, biologic therapy, immunologic therapy, or a combination thereof). CGA was used to classify patients as robust, pre-frail, or frail, and routine pre-treatment computed tomography (CT) images were used to quantify skeletal muscle index (SMI) and skeletal muscle density (SMD) at L3 cross-section. Two sarcopenia definitions were used: i. for women SMI {\textless}41 cm2/m2 regardless of body mass index (BMI), and for men SMI {\textless}43 cm2/m2 for those with BMI of {\textless}25 and {\textless} 53 cm2/m2 for those with BMI ≥25; and ii. SMI {\textless}38 cm2/m2 for women and {\textless} 41 cm2/m2 for men, regardless of BMI. The associations between frailty and muscle measures with the occurrence of at least one adverse event (AE) grade ≥ 2 were examined using the chi-square test, and logistic regression to determine odds ratio (OR) and 95\% confidence interval (CI).
Results
In total, 51 patients were included in the analysis. The median (interquartile range) age was 72 (68–76) years, 30 (59\%) were male, and 26 (51\%) had lung cancer. CGA data were available for 48 patients: fifteen (31\%), thirteen (27\%), and twenty (42\%) were defined as robust, pre-frail, and frail, respectively. Overall, 33 (65\%) were sarcopenic by the first aforementioned definition, and sixteen (31\%) by the second. No statistically significant associations were identified between frailty and having at least one AE grade ≥ 2, or between frailty and sarcopenia. Statistically significant associations were found between having sarcopenia (the second definition) and having at least one AE grade ≥ 2 (P = 0.0217). The corresponding odds ratio (95\% CI) was 4.2 (1.2–15.0), P = 0.026.
Discussion
Our findings suggests that sarcopenia is significantly associated with treatment-related toxicity. Further studies with larger sample sizes are warranted.},
	language = {en},
	number = {8},
	urldate = {2022-12-31},
	journal = {Journal of Geriatric Oncology},
	author = {Shachar, Shlomit S. and Bar-Sela, Gil and Peer, Avivit and Moskovitz, Mor Tal and Bareket-Samish, Avital and Epstein, Jessica and Wollner, Mira and Shafran, Itamar and Boukal, Amit and Williams, Grant R.},
	month = nov,
	year = {2022},
	pmid = {35989184},
	keywords = {Sarcopenia, Skeletal muscle index, Cancer, Aging, CGA, Geriatric assessment, Geriatric oncology, Israel, Toxicity, SMI},
	pages = {1203--1207},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/CREJVMTY/S1879406822001989.html:text/html},
}

@article{decoster288,
	title = {Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on {SIOG} recommendations†},
	volume = {26},
	issn = {1569-8041},
	shorttitle = {Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients},
	doi = {10.1093/annonc/mdu210},
	abstract = {BACKGROUND: Screening tools are proposed to identify those older cancer patients in need of geriatric assessment (GA) and multidisciplinary approach. We aimed to update the International Society of Geriatric Oncology (SIOG) 2005 recommendations on the use of screening tools.
MATERIALS AND METHODS: SIOG composed a task group to review, interpret and discuss evidence on the use of screening tools in older cancer patients. A systematic review was carried out and discussed by an expert panel, leading to a consensus statement on their use.
RESULTS: Forty-four studies reporting on the use of 17 different screening tools in older cancer patients were identified. The tools most studied in older cancer patients are G8, Flemish version of the Triage Risk Screening Tool (fTRST) and Vulnerable Elders Survey-13 (VES-13). Across all studies, the highest sensitivity was observed for: G8, fTRST, Oncogeriatric screen, Study of Osteoporotic Fractures, Eastern Cooperative Oncology Group-Performance Status, Senior Adult Oncology Program (SAOP) 2 screening and Gerhematolim. In 11 direct comparisons for detecting problems on a full GA, the G8 was more or equally sensitive than other instruments in all six comparisons, whereas results were mixed for the VES-13 in seven comparisons. In addition, different tools have demonstrated associations with outcome measures, including G8 and VES-13.
CONCLUSIONS: Screening tools do not replace GA but are recommended in a busy practice in order to identify those patients in need of full GA. If abnormal, screening should be followed by GA and guided multidisciplinary interventions. Several tools are available with different performance for various parameters (including sensitivity for addressing the need for further GA). Further research should focus on the ability of screening tools to build clinical pathways and to predict different outcome parameters.},
	language = {eng},
	number = {2},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Decoster, L. and Van Puyvelde, K. and Mohile, S. and Wedding, U. and Basso, U. and Colloca, G. and Rostoft, S. and Overcash, J. and Wildiers, H. and Steer, C. and Kimmick, G. and Kanesvaran, R. and Luciani, A. and Terret, C. and Hurria, A. and Kenis, C. and Audisio, R. and Extermann, M.},
	month = feb,
	year = {2015},
	pmid = {24936581},
	keywords = {Humans, Aged, Female, Male, Neoplasms, Aged, 80 and over, Geriatric Assessment, Screening, Mass Screening, Geriatrics, Medical Oncology, older cancer patients, geriatric assessment, screening tools},
	pages = {288--300},
	file = {Decoster et al_2015_Screening tools for multidimensional health problems warranting a geriatric.pdf:/Users/jcsal/Zotero/storage/CCTMH6WF/Decoster et al_2015_Screening tools for multidimensional health problems warranting a geriatric.pdf:application/pdf},
}

@article{fuscoe13347,
	title = {Comprehensive geriatric assessment in older adults with cancer: {Recommendations} by the {Italian} {Society} of {Geriatrics} and {Gerontology} ({SIGG})},
	volume = {51},
	issn = {1365-2362},
	shorttitle = {Comprehensive geriatric assessment in older adults with cancer},
	doi = {10.1111/eci.13347},
	abstract = {INTRODUCTION: Optimizing the approach to older adults with cancer is now a priority given the increasing frequency of new cancer diagnoses that are made in the older population. The comprehensive geriatric assessment (CGA) represents the gold-standard for (1) defining prognosis and ability to withstand cancer treatments, (2) exploring the multiple aspects that define the complexity of frail older persons, and (3) designing person-tailored interventions.
MATERIALS AND METHODS: In this document, based on a comprehensive revision of the literature, the Italian Society for Geriatrics and Gerontology proposes a CGA model (ONCOGER CGA) to be adopted by oncology centers for their routine approach to older patients with cancer.
RESULTS AND DISCUSSION: A widespread use of this standardized CGA format will facilitate comparisons across institutions, promote studies based on a multidimensional patient assessment, and foster the inclusion of geriatric endpoints in oncological clinical trials. Furthermore, we predict that the use of a standardized CGA approach will increase the integration of geriatricians into oncology care teams with the final result of improving therapeutic choices and clinical outcomes.},
	language = {eng},
	number = {1},
	journal = {European Journal of Clinical Investigation},
	author = {Fusco, Domenico and Ferrini, Alessandro and Pasqualetti, Giuseppe and Giannotti, Chiara and Cesari, Matteo and Laudisio, Alice and Ballestrero, Alberto and Scabini, Stefano and Odetti, Patrizio R. and Colloca, Giuseppe F. and Monzani, Fabio and Nencioni, Alessio and Antonelli Incalzi, Raffaele and Monacelli, Fiammetta and {Oncogeriatrics Group of the Italian Society of Gerontology, Geriatrics}},
	month = jan,
	year = {2021},
	pmid = {32648990},
	keywords = {Humans, Aged, Sarcopenia, Neoplasms, Aged, 80 and over, Nutritional Status, Quality of Life, Socioeconomic Factors, Geriatric Assessment, Geriatrics, Societies, Medical, CGA, Cognition, Polypharmacy, comphrehensive geriatric assessment, Delphi Technique, Depression, Functional Status, Italy, Multimorbidity, older adult with cancer, Physical Functional Performance, reccomendations of the Italian Geriatric Society},
	pages = {e13347},
	file = {Fusco et al_2021_Comprehensive geriatric assessment in older adults with cancer.pdf:/Users/jcsal/Zotero/storage/LUB4CF5L/Fusco et al_2021_Comprehensive geriatric assessment in older adults with cancer.pdf:application/pdf},
}

@article{aparicio249,
	title = {Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment},
	volume = {71},
	issn = {1879-0461},
	doi = {10.1016/j.critrevonc.2008.11.006},
	abstract = {BACKGROUND: Several database studies report a lack of care in elderly patients with colorectal cancer.
PURPOSE: To describe the management of elderly patients admitted for colorectal cancer; to identify factors associated with standard management according to recommendations and to study factors influencing the survival.
PATIENTS AND METHODS: All consecutive patients over 75 years managed for a colorectal adenocarcinoma in our hospital from 1995 to 2000 and followed until 2006 were retrospectively included. The appropriateness of the management of their disease according to the recommendations available at that time was assessed. Several risk factors in receiving the standard cancer treatment were tested using univariate and then multivariate logistic regression. Risk factors of survival were studied using univariate and then multivariate survival analysis.
RESULTS: One hundred and ten patients were included. Median age was 82 years (range: 75-96). A surgical treatment was performed in 96 patients. The median overall survival was 32 (1-108) months. A standard cancer treatment according to recommendations was performed in 53 (48\%) patients: adjuvant chemotherapy in 6/23 patients with stage III tumour, palliative chemotherapy in 3/18 patients with stage IV tumour and adjuvant radiotherapy in 4/14 patients who had a rectal tumour resection. Multivariate analysis retains tumour stage I or II (OR=7.6, 95\% C.I.=[2.9-19.9], p{\textless}0.0001) as the only factor associated with standard treatment and presence of metastasis (HR=3.9, 95\% C.I. [1.4-10.8], p=0.005), and Charlson's score {\textgreater}3 (HR=28.9, 95\% C.I. [2.5-335.6], p=0.001) as independent risk factors of poor survival.
CONCLUSIONS: Fifty two percent of elderly patients have had a sub-standard cancer treatment. The majority had a surgical treatment, but only a few received chemotherapy or radiotherapy. Metastasis, older age and Charlson's comorbidity score are the main prognosis factors of poor survival.},
	language = {eng},
	number = {3},
	journal = {Critical Reviews in Oncology/Hematology},
	author = {Aparicio, Thomas and Navazesh, Atika and Boutron, Isabelle and Bouarioua, Nadia and Chosidow, Denis and Mion, Mathieu and Choudat, Laurence and Sobhani, Iradj and Mentré, France and Soulé, Jean Claude},
	month = sep,
	year = {2009},
	pmid = {19131256},
	keywords = {Humans, Aged, Female, Male, Colorectal Neoplasms, Follow-Up Studies, Retrospective Studies, Risk Factors, Cohort Studies, Aged, 80 and over, Survival Analysis, Comorbidity, Carcinoma, Elderly, Antineoplastic Protocols},
	pages = {249--257},
}

@article{clegg353,
	title = {Development and validation of an electronic frailty index using routine primary care electronic health record data},
	volume = {45},
	issn = {1468-2834},
	doi = {10.1093/ageing/afw039},
	abstract = {BACKGROUND: frailty is an especially problematic expression of population ageing. International guidelines recommend routine identification of frailty to provide evidence-based treatment, but currently available tools require additional resource.
OBJECTIVES: to develop and validate an electronic frailty index (eFI) using routinely available primary care electronic health record data.
STUDY DESIGN AND SETTING: retrospective cohort study. Development and internal validation cohorts were established using a randomly split sample of the ResearchOne primary care database. External validation cohort established using THIN database.
PARTICIPANTS: patients aged 65-95, registered with a ResearchOne or THIN practice on 14 October 2008.
PREDICTORS: we constructed the eFI using the cumulative deficit frailty model as our theoretical framework. The eFI score is calculated by the presence or absence of individual deficits as a proportion of the total possible. Categories of fit, mild, moderate and severe frailty were defined using population quartiles.
OUTCOMES: outcomes were 1-, 3- and 5-year mortality, hospitalisation and nursing home admission.
STATISTICAL ANALYSIS: hazard ratios (HRs) were estimated using bivariate and multivariate Cox regression analyses. Discrimination was assessed using receiver operating characteristic (ROC) curves. Calibration was assessed using pseudo-R(2) estimates.
RESULTS: we include data from a total of 931,541 patients. The eFI incorporates 36 deficits constructed using 2,171 CTV3 codes. One-year adjusted HR for mortality was 1.92 (95\% CI 1.81-2.04) for mild frailty, 3.10 (95\% CI 2.91-3.31) for moderate frailty and 4.52 (95\% CI 4.16-4.91) for severe frailty. Corresponding estimates for hospitalisation were 1.93 (95\% CI 1.86-2.01), 3.04 (95\% CI 2.90-3.19) and 4.73 (95\% CI 4.43-5.06) and for nursing home admission were 1.89 (95\% CI 1.63-2.15), 3.19 (95\% CI 2.73-3.73) and 4.76 (95\% CI 3.92-5.77), with good to moderate discrimination but low calibration estimates.
CONCLUSIONS: the eFI uses routine data to identify older people with mild, moderate and severe frailty, with robust predictive validity for outcomes of mortality, hospitalisation and nursing home admission. Routine implementation of the eFI could enable delivery of evidence-based interventions to improve outcomes for this vulnerable group.},
	language = {eng},
	number = {3},
	journal = {Age and Ageing},
	author = {Clegg, Andrew and Bates, Chris and Young, John and Ryan, Ronan and Nichols, Linda and Ann Teale, Elizabeth and Mohammed, Mohammed A. and Parry, John and Marshall, Tom},
	month = may,
	year = {2016},
	pmid = {26944937},
	pmcid = {PMC4846793},
	keywords = {Humans, Aged, Female, Hospitalization, Male, Retrospective Studies, Proportional Hazards Models, Cohort Studies, Aged, 80 and over, Predictive Value of Tests, Outcome Assessment, Health Care, Databases, Factual, Survival Analysis, United Kingdom, Geriatric Assessment, Frail Elderly, frailty, eFI, cumulative deficit, electronic frailty index, electronic health record, Electronic Health Records, Homes for the Aged, Nursing Homes, older people, primary care, Primary Health Care},
	pages = {353--360},
	file = {Clegg et al_2016_Development and validation of an electronic frailty index using routine primary.pdf:/Users/jcsal/Zotero/storage/8FCHYIUN/Clegg et al_2016_Development and validation of an electronic frailty index using routine primary.pdf:application/pdf},
}

@article{pajewski1771,
	title = {Frailty {Screening} {Using} the {Electronic} {Health} {Record} {Within} a {Medicare} {Accountable} {Care} {Organization}},
	volume = {74},
	issn = {1758-535X},
	doi = {10.1093/gerona/glz017},
	abstract = {BACKGROUND: The accumulation of deficits model for frailty has been used to develop an electronic health record (EHR) frailty index (eFI) that has been incorporated into British guidelines for frailty management. However, there have been limited applications of EHR-based approaches in the United States.
METHODS: We constructed an adapted eFI for patients in our Medicare Accountable Care Organization (ACO, N = 12,798) using encounter, diagnosis code, laboratory, medication, and Medicare Annual Wellness Visit (AWV) data from the EHR. We examined the association of the eFI with mortality, health care utilization, and injurious falls.
RESULTS: The overall cohort was 55.7\% female, 85.7\% white, with a mean age of 74.9 (SD = 7.3) years. In the prior 2 years, 32.1\% had AWV data. The eFI could be calculated for 9,013 (70.4\%) ACO patients. Of these, 46.5\% were classified as prefrail (0.10 {\textless} eFI ≤ 0.21) and 40.1\% frail (eFI {\textgreater} 0.21). Accounting for age, comorbidity, and prior health care utilization, the eFI independently predicted all-cause mortality, inpatient hospitalizations, emergency department visits, and injurious falls (all p {\textless} .001). Having at least one functional deficit captured from the AWV was independently associated with an increased risk of hospitalizations and injurious falls, controlling for other components of the eFI.
CONCLUSIONS: Construction of an eFI from the EHR, within the context of a managed care population, is feasible and can help to identify vulnerable older adults. Future work is needed to integrate the eFI with claims-based approaches and test whether it can be used to effectively target interventions tailored to the health needs of frail patients.},
	language = {eng},
	number = {11},
	journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
	author = {Pajewski, Nicholas M. and Lenoir, Kristin and Wells, Brian J. and Williamson, Jeff D. and Callahan, Kathryn E.},
	month = oct,
	year = {2019},
	pmid = {30668637},
	pmcid = {PMC6777083},
	keywords = {Humans, Aged, Female, Hospitalization, Male, Prevalence, Sex Factors, Risk Assessment, Longitudinal Studies, Cohort Studies, Aged, 80 and over, Age Factors, Survival Analysis, United States, Medicare, Frailty, Mass Screening, Accidental Falls, eFI, Electronic Health Records, Accountable Care Organizations, Falls, Health Services, Multimorbidities, Patient Acceptance of Health Care},
	pages = {1771--1777},
	file = {glz017_suppl_supplementary_figures_and_tables.docx:/Users/jcsal/Zotero/storage/VVSGU93L/glz017_suppl_supplementary_figures_and_tables.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;glz017_suppl_supplementary_table_1a.docx:/Users/jcsal/Zotero/storage/SU3YIXI5/glz017_suppl_supplementary_table_1a.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;glz017_suppl_supplementary_table_1b.docx:/Users/jcsal/Zotero/storage/68FSF4B4/glz017_suppl_supplementary_table_1b.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;glz017_suppl_supplementary_table_1c.docx:/Users/jcsal/Zotero/storage/4MQIHMNF/glz017_suppl_supplementary_table_1c.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;Pajewski et al_2019_Frailty Screening Using the Electronic Health Record Within a Medicare.pdf:/Users/jcsal/Zotero/storage/6QVKPTEP/Pajewski et al_2019_Frailty Screening Using the Electronic Health Record Within a Medicare.pdf:application/pdf},
}

@article{rejeski629,
	title = {An automated electronic health-record derived frailty index is associated with adverse events after endoscopy},
	volume = {70},
	issn = {1532-5415},
	doi = {10.1111/jgs.17537},
	language = {eng},
	number = {2},
	journal = {Journal of the American Geriatrics Society},
	author = {Rejeski, Jared and Xiao, Ted and Wheless, William and Pajewski, Nicholas M. and Jensen, Elizabeth and Callahan, Kathryn E.},
	month = feb,
	year = {2022},
	pmid = {34716701},
	pmcid = {PMC8979651},
	keywords = {Humans, Aged, Retrospective Studies, Risk Assessment, Endoscopy, Gastrointestinal, Frailty, Geriatric Assessment, eFI, Electronic Health Records},
	pages = {629--631},
	file = {Rejeski et al_2022_An automated electronic health-record derived frailty index is associated with.pdf:/Users/jcsal/Zotero/storage/H5AX2KGH/Rejeski et al_2022_An automated electronic health-record derived frailty index is associated with.pdf:application/pdf},
}

@article{callahan1357,
	title = {Automated {Frailty} {Screening} {At}-{Scale} for {Pre}-{Operative} {Risk} {Stratification} {Using} the {Electronic} {Frailty} {Index}},
	volume = {69},
	issn = {0002-8614},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127394/},
	doi = {10.1111/jgs.17027},
	abstract = {BACKGROUND:
Frailty is associated with numerous post-operative adverse outcomes in older adults. Current pre-operative frailty screening tools require additional data collection or objective assessments, adding expense and limiting large-scale implementation.

OBJECTIVE:
To evaluate the association of an automated measure of frailty integrated within the Electronic Health Record (EHR) with post-operative outcomes for nonemergency surgeries.

DESIGN:
Retrospective cohort study.

SETTING:
Academic Medical Center.

PARTICIPANTS:
Patients 65 years or older that underwent nonemergency surgery with an inpatient stay 24 hours or more between October 8th, 2017 and June 1st, 2019.

EXPOSURES:
Frailty as measured by a 54-item electronic frailty index (eFI).

OUTCOMES AND MEASUREMENTS:
Inpatient length of stay, requirements for post-acute care, 30-day readmission, and 6-month all-cause mortality.

RESULTS:
Of 4,831 unique patients (2,281 females (47.3\%); mean (SD) age, 73.2 (5.9) years), 4,143 (85.7\%) had sufficient EHR data to calculate the eFI, with 15.1\% categorized as frail (eFI {\textgreater} 0.21) and 50.9\% pre-frail (0.10 {\textless} eFI ≤ 0.21). For all outcomes, there was a generally a gradation of risk with higher eFI scores. For example, adjusting for age, sex, race/ethnicity, and American Society of Anesthesiologists class, and accounting for variability by service line, patients identified as frail based on the eFI, compared to fit patients, had greater needs for post-acute care (odds ratio (OR) = 1.68; 95\% confidence interval (CI) = 1.36–2.08), higher rates of 30-day readmission (hazard ratio (HR) = 2.46; 95\%CI = 1.72–3.52) and higher all-cause mortality (HR = 2.86; 95\%CI = 1.84–4.44) over 6 months’ follow-up.

CONCLUSIONS:
The eFI, an automated digital marker for frailty integrated within the EHR, can facilitate pre-operative frailty screening at scale.},
	number = {5},
	urldate = {2023-01-03},
	journal = {Journal of the American Geriatrics Society},
	author = {Callahan, Kathryn E. and Clark, Clancy J. and Edwards, Angela F. and Harwood, Timothy N. and Williamson, Jeff D. and Moses, Adam W. and Willard, James J. and Cristiano, Joseph A. and Meadows, Kellice and Hurie, Justin and High, Kevin P. and Meredith, J. Wayne and Pajewski, Nicholas M.},
	month = may,
	year = {2021},
	pmid = {33469933},
	pmcid = {PMC8127394},
	keywords = {eFI},
	pages = {1357--1362},
	file = {Callahan et al_2021_Automated Frailty Screening At-Scale for Pre-Operative Risk Stratification.pdf:/Users/jcsal/Zotero/storage/GB5F8Q7E/Callahan et al_2021_Automated Frailty Screening At-Scale for Pre-Operative Risk Stratification.pdf:application/pdf},
}

@article{kohne10259,
	title = {Creating learning health systems and the emerging role of biomedical informatics},
	volume = {6},
	issn = {2379-6146},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/lrh2.10259},
	doi = {10.1002/lrh2.10259},
	abstract = {Introduction The nature of information used in medicine has changed. In the past, we were limited to routine clinical data and published clinical trials. Today, we deal with massive, multiple data streams and easy access to new tests, ideas, and capabilities to process them. Whereas in the past getting information for decision-making was a challenge, now, it is how to analyze, evaluate and prioritize all that is readily available through the multitude of data-collecting devices. Clinicians must become adept with the tools needed to deal with the era of big data, requiring a major change in how we learn to make decisions. Major change is often met with resistance and questions about value. A Learning Health System is an enabler to encourage the development of such tools and demonstrate value in improved decision-making. Methods We describe how we are developing a Biomedical Informatics program to help our medical institution's evolution as an academic Learning Health System, including strategy, training for house staff and examples of the role of informatics from operations to research. Results We described an array of learning health system implementations and educational programs to improve healthcare and prepare a cadre of physicians with basic information technology skills. The programs have been well accepted with, for example, increasing interest and enrollment in the educational programs. Conclusions We are now in an era when large volumes of a wide variety of data are readily available. The challenge is not so much in the acquisition of data, but in assessing the quality, relevance and value of the data. The data we can get may not be the data we need. In the past, sources of data were limited, and trial results published in journals were the major source of evidence for decision making. The advent of powerful analytics systems has changed the concept of evidence. Clinicians will have to develop the skills necessary to work in the era of big data. It is not reasonable to expect that all clinicians will also be data scientists. However, understanding the role of AI and predictive analytics, and how to apply them, will become progressively more important. Programs such as the one being implemented at Wake Forest fill that need.},
	language = {en},
	number = {1},
	urldate = {2023-01-03},
	journal = {Learning Health Systems},
	author = {Kohn, Martin S. and Topaloglu, Umit and Kirkendall, Eric S. and Dharod, Ajay and Wells, Brian J. and Gurcan, Metin},
	year = {2022},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/lrh2.10259},
	keywords = {aLHS, eFI, biomedical informatics, learning health systems, physician education},
	pages = {e10259},
	file = {Kohn et al_2021_Creating learning health systems and the emerging role of biomedical informatics.pdf:/Users/jcsal/Zotero/storage/LT6S2IZC/Kohn et al_2021_Creating learning health systems and the emerging role of biomedical informatics.pdf:application/pdf;Kohn et al_2022_Creating learning health systems and the emerging role of biomedical informatics.pdf:/Users/jcsal/Zotero/storage/TCJ6PACL/Kohn et al_2022_Creating learning health systems and the emerging role of biomedical informatics.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/BWWFGBFN/lrh2.html:text/html},
}

@article{daly135,
	title = {A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes},
	volume = {77},
	issn = {1475-2719},
	shorttitle = {A window beneath the skin},
	doi = {10.1017/S0029665118000046},
	abstract = {Advancements in image-based technologies and body composition research over the past decade has led to increased understanding of the importance of muscle abnormalities, such as low muscle mass (sarcopenia), and more recently low muscle attenuation (MA), as important prognostic indicators of unfavourable outcomes in patients with cancer. Muscle abnormalities can be highly prevalent in patients with cancer (ranging between 10 and 90 \%), depending on the cohort under investigation and diagnostic criteria used. Importantly, both low muscle mass and low MA have been associated with poorer tolerance to chemotherapy, increased risk of post-operative infectious and non-infectious complications, increased length of hospital stay and poorer survival in patients with cancer. Studies have shown that systemic antineoplastic treatment can exacerbate losses in muscle mass and MA, with reported loss of skeletal muscle between 3 and 5 \% per 100 d, which are increased exponentially with progressive disease and proximity to death. At present, no effective medical intervention to improve muscle mass and MA exists. Most research to date has focused on treating muscle depletion as part of the cachexia syndrome using nutritional, exercise and pharmacological interventions; however, these single-agent therapies have not provided promising results. Rehabilitation care to modify body composition, either increasing muscle mass and/or MA should be conducted, and its respective impact on oncology outcomes explored. Although the optimal timing and treatment strategy for preventing or delaying the development of muscle abnormalities are yet to be determined, multimodal interventions initiated early in the disease trajectory appear to hold the most promise.},
	language = {eng},
	number = {2},
	journal = {The Proceedings of the Nutrition Society},
	author = {Daly, L. E. and Prado, C. M. and Ryan, A. M.},
	month = may,
	year = {2018},
	pmid = {29745361},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Sarcopenia, Cachexia, Muscular Atrophy, Neoplasms, Body composition, Myosteatosis, Survival, Cancer, Muscle attenuation, CT computed tomography, DLT dose-limiting toxicity, GI gastrointestinal, HR hazard ratio, HU Hounsfield unit, MA muscle attenuation, SMA skeletal muscle area, SMI skeletal muscle index, Wasting Syndrome},
	pages = {135--151},
	file = {Daly et al_2018_A window beneath the skin.pdf:/Users/jcsal/Zotero/storage/7BZ4HD4N/Daly et al_2018_A window beneath the skin.pdf:application/pdf},
}

@article{bundred1603,
	title = {Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis},
	volume = {21},
	issn = {1365-182X},
	shorttitle = {Body composition assessment and sarcopenia in patients with pancreatic cancer},
	url = {https://www.sciencedirect.com/science/article/pii/S1365182X19305684},
	doi = {10.1016/j.hpb.2019.05.018},
	abstract = {Background
Numerous studies have suggested an association between sarcopenia in pancreatic cancer and adverse outcomes. This systematic review examines the evidence for the impact of sarcopenia on post-operative complications and survival
Methods
A systematic literature search was conducted to identify randomised and non-randomised studies of sarcopenia in pancreatic cancer. Meta-analyses of intra- and post-operative outcomes were performed (operating time, all complications, major complications, pancreatic fistulae, peri-operative mortality, overall survival).
Results
Forty-two studies reported the assessment of body composition in 7619 patients. Methods used to assess body composition in patients with pancreatic cancers were computerized tomography (n = 34), bioelectrical impedance analysis (n = 7), and dual-energy-X-ray-absorptiometry (n = 1). Only 10 studies reported the impact of pre-operative sarcopenia upon post-operative outcomes. Sarcopenia was associated with increased peri-operative mortality (OR: 2.40, CI95\%:1.19–4.85, p {\textless} 0.01) and decreased overall survival by univariable (HR: 1.95, CI95\%:1.35–2.81, p {\textless} 0.001) and multivariable analysis (HR: 1.78, CI95\%:1.54–2.05). Sarcopenia was not significantly associated with all complications (OR: 0.96, CI95\%:0.78–1.19) or pancreatic fistula (OR: 0.95, CI95\%: 0.59–1.54).
Conclusions
Assessment of sarcopenia in pancreatic cancer provides prognostic value but, more importantly, may provide a basis for therapeutic intervention. However, variation in the methods of assessing and reporting sarcopenia in this patient group limits the assessment of post-operative outcomes currently.},
	language = {en},
	number = {12},
	urldate = {2023-01-04},
	journal = {HPB},
	author = {Bundred, James and Kamarajah, Sivesh K. and Roberts, Keith J.},
	month = dec,
	year = {2019},
	keywords = {Pancreas},
	pages = {1603--1612},
	file = {Bundred et al_2019_Body composition assessment and sarcopenia in patients with pancreatic cancer.pdf:/Users/jcsal/Zotero/storage/K53G8HMW/Bundred et al_2019_Body composition assessment and sarcopenia in patients with pancreatic cancer.pdf:application/pdf;ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/FALFAH88/S1365182X19305684.html:text/html},
}

@article{rollins1103,
	title = {The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma},
	volume = {35},
	issn = {0261-5614},
	url = {https://www.sciencedirect.com/science/article/pii/S0261561415002265},
	doi = {10.1016/j.clnu.2015.08.005},
	abstract = {Background \& aims
Patients with pancreatic cancer have a poor prognosis, are often cachectic, and frequently demonstrate features of systemic inflammation, which may contribute to the phenomenon of myosteatosis. Analysis of body composition from CT scans has been used to study sarcopenia and its association with prognosis in a number of types of cancer, particular in combination with obesity. It has also been suggested that myosteatosis, defined as attenuated mean skeletal muscle Hounsfield units (HU), is associated with reduced survival in cancer. This study aimed to assess the association between body composition (sarcopenia and myosteatosis) and outcome in patients with unresectable pancreatic cancer.
Methods
All patients diagnosed with unresectable pancreatic cancer at Nottingham University Hospitals NHS Trust between 2006 and 2013 were considered for the study. A total of 228 patients were included retrospectively. Body composition was assessed using cross-sectional CT analysis to calculate a skeletal muscle index (SMI) for sarcopenia and use mean skeletal muscle HU for myosteatosis.
Results
The prevalence of sarcopenia in the whole patient group at baseline was 60.5\% (138/228). Overall, patients who were sarcopenic had no significant difference in overall survival versus those who were not (p = 0.779). However, patients who were overweight/obese and sarcopenic had a significantly lower survival (p = 0.013). Of the 58 patients who were overweight or obese and sarcopenic, 32 were also myosteatotic. The prevalence of myosteatosis overall at baseline was 55.3\% (126/228) and this was associated with significant reduction in overall survival (p = 0.049). Univariate Cox regression revealed myosteatosis but not sarcopenia to be predictive of reduced survival, however this relationship was lost on multivariate testing. Myosteatosis was associated with significantly greater levels of systemic inflammation (white cell count, neutrophil-lymphocyte ratio and C-reactive protein), anaemia and worsening of baseline blood urea. This relationship was not seen with sarcopenia.
Conclusions
This is the largest study on the association between body composition and survival in patients with unresectable pancreatic cancer and has shown that although sarcopenia alone did not have a bearing on survival, the presence of myosteatosis was associated significantly with the presence of systemic inflammation and reduced survival.},
	language = {en},
	number = {5},
	urldate = {2023-01-04},
	journal = {Clinical Nutrition},
	author = {Rollins, Katie E. and Tewari, Nilanjana and Ackner, Abigail and Awwad, Amir and Madhusudan, Srinivasan and Macdonald, Ian A. and Fearon, Kenneth C. H. and Lobo, Dileep N.},
	month = oct,
	year = {2016},
	keywords = {Sarcopenia, Cholangiocarcinoma, Myosteatosis, Survival, Inflammation, Pancreatic cancer, Pancreatic},
	pages = {1103--1109},
	file = {Rollins - 2016 - The impact of sarcopenia and myosteatosis on outco.pdf:/Users/jcsal/Zotero/storage/GWEACYPB/Rollins - 2016 - The impact of sarcopenia and myosteatosis on outco.pdf:application/pdf;ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/L3NDDD3A/S0261561415002265.html:text/html},
}

@article{kurita127,
	title = {Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving {FOLFIRINOX} chemotherapy},
	volume = {19},
	issn = {1424-3903},
	url = {https://www.sciencedirect.com/science/article/pii/S1424390318307464},
	doi = {10.1016/j.pan.2018.11.001},
	abstract = {Background/objectives
FOLFIRINOX is the reliable treatments for pancreatic cancer, but it has a relatively high toxicity and the selection of suitable patients for this regimen remains challenge. On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer. The aim of this study was to investigate the effect of sarcopenia on overall survival (OS) and time to treatment failure (TTF) in patients with pancreatic cancer who received FOLFIRINOX.
Methods
Clinical data of consecutive patients treated with FOLFIRINOX at our institution from 2011 to 2017 was retrospectively reviewed. Skeletal muscle index (SMI) and adipose tissue index (ATI) at the third lumbar spine level was calculated from computed tomography (CT) images. The association between clinical factors (SMI and ATI), and OS and TTF were determined using univariate and multivariate analyses.
Results
We assessed 82 patients. The median OS of sarcopenia and the non-sarcopenia patients were 11.3 and 17.0 months, respectively (hazard ratio [HR], 2.49; 95\% confidence interval [CI], 1.43–4.32; p = 0.001). Median TTF was 3.0 and 6.1 months in the sarcopenia and the non-sarcopenia patients, respectively (HR, 1.67; 95\% CI, 1.03–2.71; p = 0.032). Multivariate analyses revealed that sarcopenia (HR, 1.37; 95\% CI, 1.01–1.87; p = 0.045) was an independent prognostic factor of OS. High ATI (p = 0.022) and sarcopenic obesity (p = 0.008) were significantly associated with hematologic toxicity.
Conclusions
Sarcopenia is an independent indicator of poor prognosis in patients with pancreatic cancer who received FOLFIRINOX, while ATI and sarcopenic obesity predicted severe hematologic toxicity.},
	language = {en},
	number = {1},
	urldate = {2023-01-04},
	journal = {Pancreatology},
	author = {Kurita, Yusuke and Kobayashi, Noritoshi and Tokuhisa, Motohiko and Goto, Ayumu and Kubota, Kensuke and Endo, Itaru and Nakajima, Atsushi and Ichikawa, Yasushi},
	month = jan,
	year = {2019},
	keywords = {Sarcopenia, Pancreatic cancer, Pancreatic, FOLFIRINOX},
	pages = {127--135},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/P8G5AN68/S1424390318307464.html:text/html},
}

@article{wu862,
	title = {Comparing {Western} and {Eastern} criteria for sarcopenia and their association with survival in patients with pancreatic cancer},
	volume = {38},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2018.02.016},
	abstract = {BACKGROUND \& AIMS: Sarcopenia and cachexia are associated with pancreatic cancer and serve as important adverse prognostic factors. Body composition can be analyzed by routine computed tomography (CT) for cancer staging and has been used to study many types of cancer. The CT measurements are robust, but the diagnostic criteria for sarcopenia vary among different studies. Age, sex and race are important factors that affect muscle and fat masses. This study aimed to analyze the effect of different sarcopenia diagnostic criteria on the prognosis of patients with pancreatic cancer.
METHODS: Patients with newly diagnosed pancreatic cancer at National Taiwan University Hospital between October 2013 and October 2016 were retrospectively reviewed in this study. Body composition was assessed using cross-sectional CT images to calculate the total skeletal muscle (TSM) index. The concordance and interobserver variability of the TSM measurements were evaluated using both the Western criteria and the Eastern criteria. Kaplan-Meier analyses and the Cox proportional hazard ratio with two different diagnostic criteria for sarcopenia were used to compare the effect on overall survival (OS).
RESULTS: A total of 146 patients with pancreatic cancer were enrolled. The TSM index measured by the Western institute was highly correlated with that measured by the Eastern institute (r = 0.953, p {\textless} 0.001). The prevalence of sarcopenia in the patient group at baseline was 66.4\% (97/146) by the Western criteria and 11.0\% (16/146) by the Eastern criteria, and only low agreement was found between the Western and Eastern criteria (Kappa value = 0.028, p = 0.149). Patients who were sarcopenic by the Western criteria showed no significant difference in OS versus those who were not sarcopenic (p = 0.807). However, patients who were sarcopenic by the Eastern criteria showed a significant difference in OS versus those who were not sarcopenic in a univariate analysis (p = 0.008) and multivariate analysis after adjustment for AJCC stage (p = 0.014).
CONCLUSIONS: Our study demonstrates that different diagnostic criteria may result in different diagnoses and that sarcopenia is an important poor prognostic factor for pancreatic cancer when appropriate diagnostic criteria are selected.},
	language = {eng},
	number = {2},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Wu, Chih-Horng and Chang, Ming-Chu and Lyadov, Vladimir K. and Liang, Po-Chin and Chen, Chyi-Mong and Shih, Tiffany Ting-Fang and Chang, Yu-Ting},
	month = apr,
	year = {2019},
	pmid = {29503056},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Kaplan-Meier Estimate, Retrospective Studies, Pancreatic Neoplasms, Prognosis, Aged, 80 and over, Adult, Taiwan, X-ray computed, Pancreatic, Body compositions, Intra-abdominal fat, Pancreatic neoplasms, Tomography scanners},
	pages = {862--869},
}

@article{kim77,
	title = {Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study},
	volume = {21},
	issn = {1471-2407},
	shorttitle = {Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814715/},
	doi = {10.1186/s12885-020-07753-w},
	abstract = {Background
To investigate the clinical impact of sarcopenia and skeletal muscle density (SMD) among patients with metastatic pancreatic adenocarcinoma who underwent palliative first line gemcitabine-based chemotherapy.

Methods
A total of 330 patients treated with first line gemcitabine-based chemotherapy between January 2010 and March 2017 were included. CT scans before chemotherapy and after 8±2 weeks were evaluated. The L3 skeletal muscle index (SMI) was used to detect sarcopenia and calculated as the total area of the L3 skeletal muscle divided by the height-squared (cm2/m2). SMD was quantified as the mean muscle radiation attenuation of the muscle cross-sectional area across the L3 vertebral body level and was assessed between − 29 and + 150 Hounsfield units.

Results
A SMI to SMD comparison revealed a positive correlation (R2 = 0.058, P {\textless} 0.001). Compared with high SMD, the risks of low SMI were 1.516 (95\% confidence interval [CI]: 1.164–1.973) among patients with low SMD. Kaplan–Meier analysis showed that the low SMD was related to poor overall survival (OS, median, 6.1 versus [vs.] 7.9 months, P = 0.010). Multivariate analysis using Cox regression showed that low SMI (hazard ratio [HR]: 1.35, 95\% CI: 1.03–1.78, P = 0.032) and low SMD (HR: 1.45, 95\% CI: 1.09–1.93, P = 0.011) were poor prognostic factors for OS, respectively. Co-presence of low SMI and low SMD had more powerful prognostic implication for OS (HR: 1.58, 95\% CI: 1.12–2.23, P = 0.010). Grade 3 or higher toxicity of chemotherapy was more frequently observed in patients who have a low SMI (43\% vs. 59\%, P = 0.019) and low SMD (44\% vs. 60\%, P = 0.023). OS was not related to SMD status among patients who were chemotherapy responders (complete or partial responses). However, among non-responders (stable or progressive disease), low SMD groups had significantly poorer OS in comparison with high SMD groups (median, 5.6 vs 7.4 months, P = 0.006).

Conclusions
Sarcopenia and SMD status can be considered a prognostic factor in patients with metastatic pancreatic adenocarcinoma who received palliative first line gemcitabine-based chemotherapy. Severe chemotherapy toxicity occurred in the sarcopenia and low SMD groups. Our data suggest that a comprehensive assessment of skeletal muscle parameters may be more useful prognostic factors.

Supplementary Information
The online version contains supplementary material available at 10.1186/s12885-020-07753-w.},
	urldate = {2023-01-04},
	journal = {BMC Cancer},
	author = {Kim, In-Ho and Choi, Moon Hyung and Lee, In Seok and Hong, Tae Ho and Lee, Myung Ah.},
	month = jan,
	year = {2021},
	pmid = {33461517},
	pmcid = {PMC7814715},
	keywords = {Pancreatic},
	pages = {77},
	file = {Kim et al_2021_Clinical significance of skeletal muscle density and sarcopenia in patients.pdf:/Users/jcsal/Zotero/storage/5AB24AE6/Kim et al_2021_Clinical significance of skeletal muscle density and sarcopenia in patients.pdf:application/pdf},
}

@article{rizzo974116,
	title = {Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: {A} systematic review},
	volume = {12},
	issn = {2234-943X},
	shorttitle = {Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556864/},
	doi = {10.3389/fonc.2022.974116},
	abstract = {Objectives
The objective of this systematic review was to assess associations between quantitative body composition measures extracted from imaging examinations and chemotherapy-related toxicity in pancreatic cancer patients. A secondary objective was to evaluate the different definitions of sarcopenia across included studies.

Methods
This systematic review was conducted according to the PRISMA statement. A comprehensive literature search of three electronic databases was performed by two authors. For each eligible article, information was collected concerning the clinical setting; basic study; population characteristics; technical; body composition features evaluated; CA 19.9 tumor marker levels; chemotherapy drugs administered; toxicities (hematologic, nausea/vomiting, diarrhea, neuropathy, reduction of number of cycles, overall toxicity); association of body composition values with toxicities. The overall quality of the included studies was critically evaluated.

Results
After the initial retrieval of 1137 articles, the systematic review included 12 articles (1/12 in the neo-adjuvant setting; 2/12 in the adjuvant setting; 3/12 in the metastatic setting; 2/12 in the unresectable setting; the other 4/12 included more than one clinical setting). The number of patients included ranged between 17 and 251; mean/median age ranged between 63 and 77 years; the percentage of sarcopenic patients ranged between 23 and 76\%. The most frequent body composition parameter evaluated was skeletal muscle index (11/12). Chemotherapy regimens included gemcitabine (as monotherapy or in combination with other drugs); FOLFIRINOX and S-1. Among the trials including gemcitabine, 2/9 demonstrated an association with toxicity, whereas 7/9 did not; among those including FOLFIRINOX, one demonstrated associated toxicity whereas the others did not. Altogether, 4/12 papers demonstrated an association between the body composition values and the development of chemotherapy-related toxicities.

Conclusions
There is a wide variability of results about the association of body composition and chemotherapy-related toxicity in PC patients. Furthermore, cut-off values to define sarcopenia in PC patients are not yet uniformly defined.

Systematic Review Registration

https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42022337753, identifier CRD42022337753.},
	urldate = {2023-01-04},
	journal = {Frontiers in Oncology},
	author = {Rizzo, Stefania and Scala, Isabel and Robayo, Angela Rodriguez and Cefalì, Marco and De Dosso, Sara and Cappio, Stefano and Xhepa, Genti and Del Grande, Filippo},
	month = sep,
	year = {2022},
	pmid = {36249069},
	pmcid = {PMC9556864},
	keywords = {Pancreatic},
	pages = {974116},
	file = {Rizzo et al_2022_Body composition as a predictor of chemotherapy-related toxicity in pancreatic.pdf:/Users/jcsal/Zotero/storage/MX7BK4GB/Rizzo et al_2022_Body composition as a predictor of chemotherapy-related toxicity in pancreatic.pdf:application/pdf},
}

@article{miyata3053,
	title = {Clinical {Assessment} of {Sarcopenia} and {Changes} in {Body} {Composition} {During} {Neoadjuvant} {Chemotherapy} for {Esophageal} {Cancer}},
	volume = {37},
	issn = {1791-7530},
	doi = {10.21873/anticanres.11660},
	abstract = {AIM: The aim of this study was to assess changes in body composition during neoadjuvant chemotherapy (NAC) and investigate whether chemotherapy-related toxicities affect body composition in patients with esophageal cancer.
PATIENTS AND METHODS: In ninety-four patients who underwent NAC for esophageal cancer, body composition was assessed before and after NAC. Associations between the incidence of toxicities and change in body composition during NAC were investigated.
RESULTS: Forty-four (46.8\%) and 50 (53.2\%) out of 94 patients were defined as having sarcopenia before and after NAC, respectively. There was no significant difference in the incidence of any toxicity pre-treatment between patients with sarcopenia and those without sarcopenia. No significant reduction in skeletal muscle mass or fat mass was observed in the patients during NAC (p=0.501 and p=0.072). However, patients who experienced grade 4 neutropenia or febrile neutropenia during NAC showed a significantly larger decrease in change of skeletal muscle mass compared to patients who did not experience those toxicities (p=0.013 and 0.036, respectively).
CONCLUSION: The incidence of serious adverse events such as febrile neutropenia and grade 4 neutropenia is associated with a significant reduction of skeletal muscle mass during NAC. We should make an effort to reduce the incidence of adverse events in order to maintain an appropriate body composition during NAC.},
	language = {eng},
	number = {6},
	journal = {Anticancer Research},
	author = {Miyata, Hiroshi and Sugimura, Keijiro and Motoori, Masaaki and Fujiwara, Yoshiyuki and Omori, Takeshi and Yanagimoto, Yoshitomo and Ohue, Masayuki and Yasui, Masayoshi and Miyoshi, Norikatsu and Tomokuni, Akira and Akita, Hirofumi and Kobayashi, Shogo and Takahashi, Hidenori and Yano, Masahiko},
	month = jun,
	year = {2017},
	pmid = {28551644},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Sarcopenia, Antineoplastic Combined Chemotherapy Protocols, sarcopenia, chemotherapy, body composition, Fluorouracil, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Esophageal cancer, Taxoids, Docetaxel, Neutropenia, bioelectrical impedance analysis, Doxorubicin, toxicity},
	pages = {3053--3059},
	file = {Miyata et al_2017_Clinical Assessment of Sarcopenia and Changes in Body Composition During.pdf:/Users/jcsal/Zotero/storage/KSWLZGQI/Miyata et al_2017_Clinical Assessment of Sarcopenia and Changes in Body Composition During.pdf:application/pdf},
}

@article{ida4432,
	title = {Sarcopenia is a {Predictor} of {Postoperative} {Respiratory} {Complications} in {Patients} with {Esophageal} {Cancer}},
	volume = {22},
	issn = {1534-4681},
	doi = {10.1245/s10434-015-4559-3},
	abstract = {BACKGROUND: Depletion of skeletal muscle mass (sarcopenia) indicates a poor prognosis for patients with several kinds of cancer, but it remains unclear whether esophageal squamous cell carcinoma (ESCC) is among these cancers. The aim of this study was to clarify the relationship between sarcopenia and postoperative outcome in patients with ESCC treated by esophagectomy.
METHODS: Skeletal muscle mass was assessed in 138 patients who underwent esophagectomy from August 2009 to May 2014. A multifrequency bioelectrical impedance analysis (InBody 720; Biospace, Tokyo, Japan) was used to assess skeletal muscle mass just before surgery. Postoperative complications were graded according to the Clavien-Dindo classification, and univariate and multivariate analyses were performed for postoperative respiratory complications.
RESULTS: Sarcopenia was determined in 61 patients (44.2 \%). Preoperative pulmonary function was significantly lower and the rate of respiratory complications significantly higher in the sarcopenia group than in the non-sarcopenia group (p {\textless} 0.01). For other complications, the differences were not significant. Multivariate analysis showed that sarcopenia [odds ratio (OR) 5.82; p = 0.0001] and longer operation time (OR 3.09; p = 0.04) were risk factors for the occurrence of respiratory complications.
CONCLUSIONS: Sarcopenia may be a predictor of pulmonary complications after esophagectomy. Further analysis is needed to clarify whether nutritional intervention improves skeletal muscle mass and thus contributes to reducing postoperative respiratory complications in sarcopenic patients.},
	language = {eng},
	number = {13},
	journal = {Annals of Surgical Oncology},
	author = {Ida, Satoshi and Watanabe, Masayuki and Yoshida, Naoya and Baba, Yoshifumi and Umezaki, Naoki and Harada, Kazuto and Karashima, Ryuichi and Imamura, Yu and Iwagami, Shiro and Baba, Hideo},
	month = dec,
	year = {2015},
	pmid = {25862583},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Follow-Up Studies, Neoplasm Staging, Risk Factors, Prospective Studies, Prognosis, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Postoperative Complications},
	pages = {4432--4437},
}

@article{komatsu14922,
	title = {Night home enteral nutrition as a novel enforced and physiologically effective nutrition therapy following total gastrectomy for gastric cancer},
	volume = {12},
	issn = {2045-2322},
	doi = {10.1038/s41598-022-17420-8},
	abstract = {Enteral nutrition has been reported to be safe and effective in malnourished patients undergoing upper gastrointestinal surgery. In this study, we devised night home enteral nutrition (N-HEN) as a novel nutritional strategy and evaluated the efficacy in gastric cancer patients following total gastrectomy. Between January 2017 and March 2021, 24 patients were prospectively included in the protocol and supported by N-HEN for three postoperative months through a jejunostomy during the night (Elental:1200 kcal/day), and 22 patients without N-HEN were followed as a control group (CG). Body weight loss, nutritional indicators and tolerance to chemotherapy were evaluated. After 3 and 6 months, patients with N-HEN had significantly less body weight loss than CG (3 months P \&lt; 0.0001: N-HEN 4.0\% vs. CG 15.2\%, 6 months P \&lt; 0.0001: N-HEN 7.7\% vs. CG 17.7\%). Prealbumin was significantly higher in patients with N-HEN than CG after 3 and 6 months (3 months P \&lt; 0.0001, 6 months P = 0.0037). Albumin, total protein and hemoglobin, tended to be higher after 3 and 6 months in patients with N-HEN than CG, and total cholesterol after 6 months. Concerning the tolerance to adjuvant chemotherapy in Stage II-III patients, patients with N-HEN significantly had a higher completion rate (P = 0.0420: N-HEN 70\% vs. CG 29\%) and longer duration (P = 0.0313: N-HEN 458 days vs. CG 261 days) as planned. Continuous monitoring of blood glucose concentration in patients with N-HEN did not show nocturnal hypoglycemia or hyperglycemia. N-HEN could be a novel enforced and physiologically effective nutritional strategy to support potentially malnourished patients following total gastrectomy.},
	language = {eng},
	number = {1},
	journal = {Scientific Reports},
	author = {Komatsu, Shuhei and Konishi, Tomoki and Matsubara, Daiki and Soga, Koji and Shimomura, Katsumi and Ikeda, Jun and Taniguchi, Fumihiro and Iwase, Hiroya and Kubota, Takeshi and Shioaki, Yasuhiro and Otsuji, Eigo},
	month = sep,
	year = {2022},
	pmid = {36056110},
	pmcid = {PMC9440117},
	keywords = {Humans, Weight Loss, Stomach Neoplasms, Gastrectomy, Malnutrition, Enteral Nutrition, Jejunostomy, Enteral},
	pages = {14922},
	file = {Komatsu et al_2022_Night home enteral nutrition as a novel enforced and physiologically effective.pdf:/Users/jcsal/Zotero/storage/WFPZLQKE/Komatsu et al_2022_Night home enteral nutrition as a novel enforced and physiologically effective.pdf:application/pdf},
}

@misc{zotero-1956,
	title = {Prognostic value of sarcopenia in adults with solid tumours: {A} meta-analysis and systematic review - {PubMed}},
	url = {https://pubmed.ncbi.nlm.nih.gov/26882087/},
	urldate = {2023-01-04},
	keywords = {Prognosis},
	file = {Prognostic value of sarcopenia in adults with solid tumours\: A meta-analysis and systematic review - PubMed:/Users/jcsal/Zotero/storage/CIK8YWKN/26882087.html:text/html},
}

@article{he794969,
	title = {Three-{Dimensional} {Liver} {Image} {Segmentation} {Using} {Generative} {Adversarial} {Networks} {Based} on {Feature} {Restoration}},
	volume = {8},
	issn = {2296-858X},
	url = {https://www.frontiersin.org/articles/10.3389/fmed.2021.794969},
	doi = {10.3389/fmed.2021.794969},
	abstract = {Medical imaging provides a powerful tool for medical diagnosis. In the process of computer-aided diagnosis and treatment of liver cancer based on medical imaging, accurate segmentation of liver region from abdominal CT images is an important step. However, due to defects of liver tissue and limitations of CT imaging procession, the gray level of liver region in CT image is heterogeneous, and the boundary between the liver and those of adjacent tissues and organs is blurred, which makes the liver segmentation an extremely difficult task. In this study, aiming at solving the problem of low segmentation accuracy of the original 3D U-Net network, an improved network based on the three-dimensional (3D) U-Net, is proposed. Moreover, in order to solve the problem of insufficient training data caused by the difficulty of acquiring labeled 3D data, an improved 3D U-Net network is embedded into the framework of generative adversarial networks (GAN), which establishes a semi-supervised 3D liver segmentation optimization algorithm. Finally, considering the problem of poor quality of 3D abdominal fake images generated by utilizing random noise as input, deep convolutional neural networks (DCNN) based on feature restoration method is designed to generate more realistic fake images. By testing the proposed algorithm on the LiTS-2017 and KiTS19 dataset, experimental results show that the proposed semi-supervised 3D liver segmentation method can greatly improve the segmentation performance of liver, with a Dice score of 0.9424 outperforming other methods.},
	language = {eng},
	journal = {Frontiers in Medicine},
	author = {He, Runnan and Xu, Shiqi and Liu, Yashu and Li, Qince and Liu, Yang and Zhao, Na and Yuan, Yongfeng and Zhang, Henggui},
	year = {2021},
	pmid = {35071275},
	pmcid = {PMC8777029},
	keywords = {ML, 3D segmentation of liver, CT image, feature restoration, generative adversarial networks, semi-supervised},
	pages = {794969},
	file = {He et al_2021_Three-Dimensional Liver Image Segmentation Using Generative Adversarial.pdf:/Users/jcsal/Zotero/storage/WCIBD8AV/He et al_2021_Three-Dimensional Liver Image Segmentation Using Generative Adversarial.pdf:application/pdf},
}

@article{extermann3377,
	title = {Predicting the risk of chemotherapy toxicity in older patients: the {Chemotherapy} {Risk} {Assessment} {Scale} for {High}-{Age} {Patients} ({CRASH}) score},
	volume = {118},
	issn = {1097-0142},
	shorttitle = {Predicting the risk of chemotherapy toxicity in older patients},
	doi = {10.1002/cncr.26646},
	abstract = {BACKGROUND: Tools are lacking to assess the individual risk of severe toxicity from chemotherapy. Such tools would be especially useful for older patients, who vary considerably in terms of health status and functional reserve.
METHODS: The authors conducted a prospective, multicentric study of patients aged ≥70 years who were starting chemotherapy. Grade 4 hematologic (H) or grade 3/4 nonhematologic (NH) toxicity according to version 3.0 of the Common Terminology Criteria for Adverse Events was defined as severe. Twenty-four parameters were assessed. Toxicity of the regimen (Chemotox) was adjusted using an index to estimate the average per-patient risk of chemotherapy toxicity (the MAX2 index). In total, 562 patients were accrued, and 518 patients were evaluable and were split randomly (2:1 ratio) into a derivation cohort and a validation cohort.
RESULTS: Severe toxicity was observed in 64\% of patients. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score was constructed along 2 subscores: H toxicity and NH toxicity. Predictors of H toxicity were lymphocytes, aspartate aminotransferase level, Instrumental Activities of Daily Living score, lactate dehydrogenase level, diastolic blood pressure, and Chemotox. The best model included the 4 latter predictors (risk categories: low, 7\%; medium-low, 23\%; medium-high, 54\%; and high, 100\%, respectively; P(trend) {\textless} .001). Predictors of NH toxicity were hemoglobin, creatinine clearance, albumin, self-rated health, Eastern Cooperative Oncology Group performance, Mini-Mental Status score, Mini-Nutritional Assessment score, and Chemotox. The 4 latter predictors provided the best model (risk categories: 33\%, 46\%, 67\%, and 93\%, respectively; P(trend) {\textless} .001). The combined risk categories were 50\%, 58\%, 77\%, and 79\%, respectively; P(trend) {\textless} .001). Bootstrap internal validation and independent sample validation demonstrated stable risk categorization and P(trend) {\textless} .001.
CONCLUSIONS: The CRASH score distinguished several risk levels of severe toxicity. The split score discriminated better than the combined score. To the authors' knowledge, this is the first score systematically integrating both chemotherapy and patient risk for older patients and has a potential for future clinical application.},
	language = {eng},
	number = {13},
	journal = {Cancer},
	author = {Extermann, Martine and Boler, Ivette and Reich, Richard R. and Lyman, Gary H. and Brown, Richard H. and DeFelice, Joseph and Levine, Richard M. and Lubiner, Eric T. and Reyes, Pablo and Schreiber, Frederic J. and Balducci, Lodovico},
	month = jul,
	year = {2012},
	pmid = {22072065},
	keywords = {Humans, Aged, Female, Male, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Risk Assessment, Antineoplastic Agents, Aged, 80 and over, CRASH},
	pages = {3377--3386},
}

@article{balducci1695,
	title = {New {Advances} in {Supportive} {Care}: {Chemoprotective} {Agents} as {Novel} {Opportunities} in {Geriatric} {Oncology}},
	volume = {24},
	issn = {1534-6269},
	shorttitle = {New {Advances} in {Supportive} {Care}},
	doi = {10.1007/s11912-022-01324-x},
	abstract = {PURPOSE OF REVIEW: To explore the effectiveness of trilaciclib and ALRN-6924 in the prevention of cancer chemotherapy-induced toxicity in older patients. New chemoprotective agents are necessary because age is the main risk factor for chemotherapy complications that account largely for the poorer outcome of cancer in the elderly. Trilaciclib and ALRN-6924 cause a reversible block of the proliferation of normal cells through cell cycle arrest (CCA). With this mechanism, they may prevent the toxicity of cycle-active cancer treatment including neutropenia, anemia, thrombocytopenia, lymphopenia, mucositis, and alopecia.
RECENT FINDINGS: Myelopoietic growth factors may prevent neutropenia in the aged, but they may cause severe bone pain, may aggravate thrombocytopenia and anemia, and may cause myelodysplasia and acute leukemia as a late complication. The prevention of thrombocytopenia, anemia, mucositis, and alopecia is unsatisfactory at present. These complications may jeopardize the treatment outcome as they require a reduction of treatment dose/intensity and because many patients find the resulting symptoms intolerable. In three studies of patients with extensive disease small cell lung cancer (ES-SCLC), trilaciclib reduced the severity and duration of neutropenia and thrombocytopenia as well as the need for blood transfusions. In addition, it produced a significant expansion of T-cell clones. Trilaciclib received FDA approval for the prevention of chemotherapy-induced myelosuppression in patients with ES-SCLC. ALRN-6924 is currently studied in phase II study of ES-SCLC. In a phase IB of 38 patients, ALRN-6924 prevented myelosuppression to an extent comparable with trilaciclib. Both drugs proved as effective in patients 65 and older as they were in the younger ones. In an "ex vivo" study, ALRN-6924 protected the epithelial stem cells of hair follicles from taxanes and promised to prevent alopecia. The possibility that CCA of tumor cells may reduce the effectiveness of cycle-active chemotherapy is a major concern. For this reason, the use of trilaciclib, an inhibitor of CDK 4/6, should be limited to tumors with inactivated RB1, and the use of ALRN-6924, an inhibitor of P53, should be limited to tumors with inactivated P53. Chemotherapy-related toxicities limit dose intensity and contribute to significant morbidity and mortality in elderly cancer patients. Trilaciclib and ALRN-6924 are of particular interest to geriatric oncologists because of their novel mechanism of action. Ameliorating chemotherapy-induced toxicities holds the promise of transforming the practice of geriatric oncology by enabling chemotherapeutic regimens that are currently not feasible for this patient population. Specifically, these agents may prevent chemotherapy-induced neutropenia and thrombocytopenia, perhaps the most life-threatening complications of cytotoxic chemotherapy, thereby obviating the need for the use of rescue strategies such as hematopoietic growth factors. In addition, these agents offer the potential for broad tissue protection from other chemotherapy-related toxicities, including mucositis, diarrhea, and alopecia, which historically have been poorly managed. Importantly, by preventing a spectrum of chemotherapy-related toxicities, these agents may permit the administration of chemotherapy at full-dose intensity, prevent functional decline, and grant maintenance of resilience to older cancer patients. As a result, the successful prevention of chemotherapy-induced side effects may not only mitigate the costs of care but also improve patient outcomes and quality of life. Finally, chemoprotective strategies offer the opportunity to apply geriatric principles to clinical trials of cancer treatment. In particular, they may allow the testing of prolongation of "active life expectancy" as a major goal of clinical trials in elderly patients. They may also enable novel and more practical forms of clinical trials. By assessing the risk of chemotherapy-related toxicity with the Chemotherapy Risk Assessment Scale for High Age Patients (CRASH) or the Cancer and Aging Research Group (CARG) instruments, these agents may permit researchers to utilize patients as their own controls and endorse the approval of supportive care drugs based upon the risk profile of individual patients.},
	language = {eng},
	number = {12},
	journal = {Current Oncology Reports},
	author = {Balducci, Lodovico and Falandry, Claire and List, Alan},
	month = dec,
	year = {2022},
	pmid = {35986858},
	keywords = {Humans, Aged, Lung Neoplasms, Antineoplastic Agents, Quality of Life, Clinical Trials, Phase II as Topic, Neutropenia, Elderly, Anemia, Small Cell Lung Carcinoma, Alopecia, Cancer chemotherapy, CDK 4/6, Cell cycle arrest, Chemoprotection, Mucositis, Novel chemoprotective agents, P53, Thrombocytopenia, Trilaciclib, ALRN-6924, Tumor Suppressor Protein p53, ChemoProtective},
	pages = {1695--1703},
}

@article{belharbi95,
	title = {Spotting {L3} slice in {CT} scans using deep convolutional network and transfer learning},
	volume = {87},
	issn = {1879-0534},
	doi = {10.1016/j.compbiomed.2017.05.018},
	abstract = {In this article, we present a complete automated system for spotting a particular slice in a complete 3D Computed Tomography exam (CT scan). Our approach does not require any assumptions on which part of the patient's body is covered by the scan. It relies on an original machine learning regression approach. Our models are learned using the transfer learning trick by exploiting deep architectures that have been pre-trained on imageNet database, and therefore it requires very little annotation for its training. The whole pipeline consists of three steps: i) conversion of the CT scans into Maximum Intensity Projection (MIP) images, ii) prediction from a Convolutional Neural Network (CNN) applied in a sliding window fashion over the MIP image, and iii) robust analysis of the prediction sequence to predict the height of the desired slice within the whole CT scan. Our approach is applied to the detection of the third lumbar vertebra (L3) slice that has been found to be representative to the whole body composition. Our system is evaluated on a database collected in our clinical center, containing 642 CT scans from different patients. We obtained an average localization error of 1.91±2.69 slices (less than 5 mm) in an average time of less than 2.5 s/CT scan, allowing integration of the proposed system into daily clinical routines.},
	language = {eng},
	journal = {Computers in Biology and Medicine},
	author = {Belharbi, Soufiane and Chatelain, Clément and Hérault, Romain and Adam, Sébastien and Thureau, Sébastien and Chastan, Mathieu and Modzelewski, Romain},
	month = aug,
	year = {2017},
	pmid = {28558319},
	keywords = {Humans, Tomography, X-Ray Computed, Sarcopenia, Lumbar Vertebrae, Deep learning, Machine Learning, ML, Neural Networks, Computer, Convolutional neural networks, Maximum intensity projection, Radiology Information Systems, Slice detection},
	pages = {95--103},
	file = {Belharbi et al_2017_Spotting L3 slice in CT scans using deep convolutional network and transfer.pdf:/Users/jcsal/Zotero/storage/KQYPEFNC/Belharbi et al. - 2017 - Spotting L3 slice in CT scans using deep convoluti.pdf:application/pdf},
}

@article{nakashima1100,
	title = {Assessment of {Sarcopenia} as a {Predictor} of {Poor} {Outcomes} {After} {Esophagectomy} in {Elderly} {Patients} {With} {Esophageal} {Cancer}},
	volume = {267},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000002252},
	abstract = {OBJECTIVE: The objective of the study was to elucidate the impact of sarcopenia in elderly patients with esophageal cancer on postoperative complications and long-term survival after surgery for esophageal cancer.
SUMMARY BACKGROUND DATA: Sarcopenia, defined as loss of skeletal muscle mass with age, has been identified as a poor prognostic factor for malignancies. This retrospective study investigated the effect of sarcopenia on surgical outcomes among young and elderly patients with esophageal cancer.
METHODS: Data were collected for 341 consecutive patients who underwent esophagectomy for esophageal cancer. Patients were assigned to 2 groups according to age (younger than 65 years and 65 years or older) and the presence of sarcopenia.
RESULTS: Sarcopenia was present in 170 of 341 patients (49.9\%) with esophageal cancer and in 74 of 166 elderly patients (44.6\%). The incidence of anastomotic leak and in-hospital death was significantly higher in the elderly sarcopenia group than in the elderly nonsarcopenia group (31.5\% vs 15.2\%, P = 0.015, 6.8 vs 0.0\%, P = 0.037, respectively), and the overall survival rate in patients with sarcopenia correlated with a significantly poor prognosis in the elderly group (P {\textless} 0.001). Multivariate analysis revealed that sarcopenia was a risk factor for an anastomotic leak (P = 0.034) and was an unfavorable prognostic factor for survival (P {\textless} 0.001). Those correlations between sarcopenia and surgical outcomes were not observed in the young group.
CONCLUSIONS: Sarcopenia and worse surgical outcomes were significantly associated patients with in esophageal cancer aged 65 years and older but not in those younger than 65 years.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Nakashima, Yuichiro and Saeki, Hiroshi and Nakanishi, Ryota and Sugiyama, Masahiko and Kurashige, Junji and Oki, Eiji and Maehara, Yoshihiko},
	month = jun,
	year = {2018},
	pmid = {28437312},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Retrospective Studies, Risk Factors, Survival Rate, Prognosis, Age Factors, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Anastomotic Leak, Hospital Mortality},
	pages = {1100--1104},
}

@article{sullivan1702,
	title = {Association of {Early} {Palliative} {Care} {Use} {With} {Survival} and {Place} of {Death} {Among} {Patients} {With} {Advanced} {Lung} {Cancer} {Receiving} {Care} in the {Veterans} {Health} {Administration}},
	volume = {5},
	issn = {2374-2445},
	doi = {10.1001/jamaoncol.2019.3105},
	abstract = {IMPORTANCE: Palliative care is a patient-centered approach associated with improvements in quality of life; however, results regarding its association with a survival benefit have been mixed, which may be a factor in its underuse.
OBJECTIVE: To assess whether early palliative care is associated with a survival benefit among patients with advanced lung cancer.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective population-based cohort study was conducted among patients with lung cancer who were diagnosed with cancer between January 1, 2007, and December 31, 2013, with follow-up until January 23, 2017. Participants comprised 23 154 patients with advanced lung cancer (stage IIIB and stage IV) who received care in the Veterans Affairs health care system. Data were analyzed from February 15, 2019, to April 28, 2019.
EXPOSURE: Palliative care defined as a specialist-delivered palliative care encounter received after lung cancer diagnosis.
MAIN OUTCOMES AND MEASURES: The primary outcome was survival. The association between palliative care and place of death was also examined. Propensity score and time-varying covariate methods were used to calculate Cox proportional hazards and to perform regression modeling.
RESULTS: Of the 23 154 patients enrolled in the study, 57\% received palliative care. The mean (SD) age of participants was 68 (9.5) years, and 98\% of participants were men. An examination of the timing of palliative care receipt relative to cancer diagnosis found that palliative care received 0 to 30 days after diagnosis was associated with decreases in survival (adjusted hazard ratio [aHR], 2.13; 95\% CI, 1.97-2.30), palliative care received 31 to 365 days after diagnosis was associated with increases in survival (aHR, 0.47; 95\% CI, 0.45-0.49), and palliative care received more than 365 days after diagnosis was associated with no difference in survival (aHR, 1.00; 95\% CI, 0.94-1.07) compared with nonreceipt of palliative care. Receipt of palliative care was also associated with a reduced risk of death in an acute care setting (adjusted odds ratio, 0.57; 95\% CI, 0.52-0.64) compared with nonreceipt of palliative care.
CONCLUSIONS AND RELEVANCE: The results suggest that palliative care was associated with a survival benefit among patients with advanced lung cancer. Palliative care should be considered a complementary approach to disease-modifying therapy in patients with advanced lung cancer.},
	language = {eng},
	number = {12},
	journal = {JAMA oncology},
	author = {Sullivan, Donald R. and Chan, Benjamin and Lapidus, Jodi A. and Ganzini, Linda and Hansen, Lissi and Carney, Patricia A. and Fromme, Erik K. and Marino, Miguel and Golden, Sara E. and Vranas, Kelly C. and Slatore, Christopher G.},
	month = dec,
	year = {2019},
	pmid = {31536133},
	pmcid = {PMC6753505},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Palliative Care, Lung Neoplasms, Survival Analysis, Propensity Score, Complementary Therapies, Time-to-Treatment, Veterans Health, Veterans Health Services},
	pages = {1702--1709},
	file = {Sullivan et al_2019_Association of Early Palliative Care Use With Survival and Place of Death Among.pdf:/Users/jcsal/Zotero/storage/7Q4ZWX6X/Sullivan et al_2019_Association of Early Palliative Care Use With Survival and Place of Death Among.pdf:application/pdf},
}

@misc{zotero-1972,
	title = {Timed {Stair} {Climbing} {Is} the {Single} {Strongest} {Predictor} of {Perioperative} {Complications} in {Patients} {Undergoing} {Abdominal} {Surgery} - {PubMed}},
	url = {https://pubmed.ncbi.nlm.nih.gov/26920993/},
	urldate = {2023-01-14},
	keywords = {Stairs},
	file = {Timed Stair Climbing Is the Single Strongest Predictor of Perioperative Complications in Patients Undergoing Abdominal Surgery - PubMed:/Users/jcsal/Zotero/storage/YK7ELDWI/26920993.html:text/html},
}

@article{podsiadlo142,
	title = {The timed "{Up} \& {Go}": a test of basic functional mobility for frail elderly persons},
	volume = {39},
	issn = {0002-8614},
	shorttitle = {The timed "{Up} \& {Go}"},
	doi = {10.1111/j.1532-5415.1991.tb01616.x},
	abstract = {This study evaluated a modified, timed version of the "Get-Up and Go" Test (Mathias et al, 1986) in 60 patients referred to a Geriatric Day Hospital (mean age 79.5 years). The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The results indicate that the time score is (1) reliable (inter-rater and intra-rater); (2) correlates well with log-transformed scores on the Berg Balance Scale (r = -0.81), gait speed (r = -0.61) and Barthel Index of ADL (r = -0.78); and (3) appears to predict the patient's ability to go outside alone safely. These data suggest that the timed "Up \& Go" test is a reliable and valid test for quantifying functional mobility that may also be useful in following clinical change over time. The test is quick, requires no special equipment or training, and is easily included as part of the routine medical examination.},
	language = {eng},
	number = {2},
	journal = {Journal of the American Geriatrics Society},
	author = {Podsiadlo, D. and Richardson, S.},
	month = feb,
	year = {1991},
	pmid = {1991946},
	keywords = {Humans, Aged, Female, Male, Time Factors, Aged, 80 and over, Walking, Activities of Daily Living, Canes, Parkinson Disease},
	pages = {142--148},
}

@article{orkaby1257,
	title = {The {Burden} of {Frailty} {Among} {U}.{S}. {Veterans} and {Its} {Association} {With} {Mortality}, 2002-2012},
	volume = {74},
	issn = {1758-535X},
	doi = {10.1093/gerona/gly232},
	abstract = {BACKGROUND: Frailty is a key determinant of clinical outcomes. We sought to describe frailty among U.S. Veterans and its association with mortality.
METHODS: Nationwide retrospective cohort study of regular Veterans Affairs (VA) users, aged at least 65 years in 2002-2012, followed through 2014, using national VA administrative and Medicare and Medicaid data. A frailty index (FI) for VA (VA-FI) was calculated using the cumulative deficit method. Thirty-one age-related deficits in health from diagnostic and procedure codes were included and were updated biennially. Survival analysis assessed associations between VA-FI and mortality.
RESULTS: A VA-FI was calculated for 2,837,152 Veterans over 10 years. In 2002, 35.5\% were non-frail (FI = 0-0.10), 32.6\% were pre-frail (FI = 0.11-0.20), 18.9\% were mildly frail (FI = 0.21-0.30), 8.7\% were moderately frail (FI = 0.31-0.40), and 4.3\% were severely frail (FI {\textgreater} 0.40). From 2002 to 2012, the prevalence of moderate frailty increased to 12.7\%and severe frailty to 14.1\%. Frailty was strongly associated with survival and was independent of age, sex, race, and smoking; the VA-FI better predicted mortality than age alone. Although prevalence of frailty rose over time, compared to non-frail Veterans, 2 years' hazard ratios (95\% confidence intervals) for mortality declined from a peak in 2004 of 2.01 (1.97-2.04), 3.49 (3.44-3.55), 5.88 (5.79-5.97), and 10.39 (10.23-10.56) for pre-frail, mildly, moderately, and severely frail, respectively, to 1.51 (1.49-1.53), 2.36 (2.33-2.39), 3.68 (3.63-3.73), 6.62 (6.53-6.71) in 2012. At every frailty level, risk of mortality was lower for women versus men and higher for blacks versus whites.
CONCLUSIONS: Frailty affects at least 3 of every 10 U.S. Veterans aged 65 years and older, and is strongly associated with mortality. The VA-FI could be used to more accurately estimate life expectancy and individualize care for Veterans.},
	language = {eng},
	number = {8},
	journal = {The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences},
	author = {Orkaby, Ariela R. and Nussbaum, Lisa and Ho, Yuk-Lam and Gagnon, David and Quach, Lien and Ward, Rachel and Quaden, Rachel and Yaksic, Enzo and Harrington, Kelly and Paik, Julie M. and Kim, Dae H. and Wilson, Peter W. and Gaziano, J. Michael and Djousse, Luc and Cho, Kelly and Driver, Jane A.},
	month = jul,
	year = {2019},
	pmid = {30307533},
	pmcid = {PMC6625596},
	keywords = {Humans, Aged, Female, Male, Retrospective Studies, United States, Mortality, Frailty, Geriatric Assessment, Frail Elderly, Epidemiology, Veterans},
	pages = {1257--1264},
	file = {Orkaby et al_2019_The Burden of Frailty Among U.pdf:/Users/jcsal/Zotero/storage/XL3ANP4N/Orkaby et al_2019_The Burden of Frailty Among U.pdf:application/pdf},
}

@article{kharrazi1499,
	title = {The {Value} of {Unstructured} {Electronic} {Health} {Record} {Data} in {Geriatric} {Syndrome} {Case} {Identification}},
	volume = {66},
	issn = {1532-5415},
	doi = {10.1111/jgs.15411},
	abstract = {OBJECTIVES: To examine the value of unstructured electronic health record (EHR) data (free-text notes) in identifying a set of geriatric syndromes.
DESIGN: Retrospective analysis of unstructured EHR notes using a natural language processing (NLP) algorithm.
SETTING: Large multispecialty group.
PARTICIPANTS: Older adults (N=18,341; average age 75.9, 58.9\% female).
MEASUREMENTS: We compared the number of geriatric syndrome cases identified using structured claims and structured and unstructured EHR data. We also calculated these rates using a population-level claims database as a reference and identified comparable epidemiological rates in peer-reviewed literature as a benchmark.
RESULTS: Using insurance claims data resulted in a geriatric syndrome prevalence ranging from 0.03\% for lack of social support to 8.3\% for walking difficulty. Using structured EHR data resulted in similar prevalence rates, ranging from 0.03\% for malnutrition to 7.85\% for walking difficulty. Incorporating unstructured EHR notes, enabled by applying the NLP algorithm, identified considerably higher rates of geriatric syndromes: absence of fecal control (2.1\%, 2.3 times as much as structured claims and EHR data combined), decubitus ulcer (1.4\%, 1.7 times as much), dementia (6.7\%, 1.5 times as much), falls (23.6\%, 3.2 times as much), malnutrition (2.5\%, 18.0 times as much), lack of social support (29.8\%, 455.9 times as much), urinary retention (4.2\%, 3.9 times as much), vision impairment (6.2\%, 7.4 times as much), weight loss (19.2\%, 2.9 as much), and walking difficulty (36.34\%, 3.4 as much). The geriatric syndrome rates extracted from structured data were substantially lower than published epidemiological rates, although adding the NLP results considerably closed this gap.
CONCLUSION: Claims and structured EHR data give an incomplete picture of burden related to geriatric syndromes. Geriatric syndromes are likely to be missed if unstructured data are not analyzed. Pragmatic NLP algorithms can assist with identifying individuals at high risk of experiencing geriatric syndromes and improving coordination of care for older adults.},
	language = {eng},
	number = {8},
	journal = {Journal of the American Geriatrics Society},
	author = {Kharrazi, Hadi and Anzaldi, Laura J. and Hernandez, Leilani and Davison, Ashwini and Boyd, Cynthia M. and Leff, Bruce and Kimura, Joe and Weiner, Jonathan P.},
	month = aug,
	year = {2018},
	pmid = {29972595},
	keywords = {Humans, Aged, Female, Male, Prevalence, Retrospective Studies, Aged, 80 and over, Databases, Factual, Frailty, Algorithms, Frail Elderly, Syndrome, Social Support, Electronic Health Records, case identification, electronic health records, geriatric syndromes, Mobility Limitation, Natural Language Processing, natural language processing and text-mining, unstructured free-text data},
	pages = {1499--1507},
}

@article{dumontier3053,
	title = {Contemporary {Analysis} of {Electronic} {Frailty} {Measurement} in {Older} {Adults} with {Multiple} {Myeloma} {Treated} in the {National} {US} {Veterans} {Affairs} {Healthcare} {System}},
	volume = {13},
	issn = {2072-6694},
	doi = {10.3390/cancers13123053},
	abstract = {Electronic frailty indices based on data from administrative claims and electronic health records can be used to estimate frailty in large populations of older adults with cancer where direct frailty measures are lacking. The objective of this study was to use the electronic Veterans Affairs Frailty Index (VA-FI-10)-developed and validated to measure frailty in the national United States (US) VA Healthcare System-to estimate the prevalence and impact of frailty in older US veterans newly treated for multiple myeloma (MM) with contemporary therapies. We designed a retrospective cohort study of 4924 transplant-ineligible veterans aged ≥ 65 years initiating MM therapy within VA from 2004 to 2017. Initial MM therapy was measured using inpatient and outpatient treatment codes from pharmacy data in the VA Corporate Data Warehouse. In total, 3477 veterans (70.6\%) were classified as frail (VA-FI-10 {\textgreater} 0.2), with 1510 (30.7\%) mildly frail (VA-FI-10 {\textgreater} 0.2-0.3), 1105 (22.4\%) moderately frail (VA-FI-10 {\textgreater} 0.3-0.4), and 862 (17.5\%) severely frail (VA-FI-10 {\textgreater} 0.4). Survival and time to hospitalization decreased with increasing VA-FI-10 severity (log-rank p-value {\textless} 0.001); the VA-FI-10 predicted mortality and hospitalizations independently of age, sociodemographic variables, and measures of disease risk. Varying data sources and assessment periods reclassified frailty severity for a substantial portion of veterans but did not substantially affect VA-FI-10's association with mortality. Our study supports use of the VA-FI-10 in future research involving older veterans with MM and provides insights into its potential use in identifying frailty in clinical practice.},
	language = {eng},
	number = {12},
	journal = {Cancers},
	author = {DuMontier, Clark and Fillmore, Nathanael R. and Yildirim, Cenk and Cheng, David and La, Jennifer and Orkaby, Ariela R. and Charest, Brian and Cirstea, Diana and Yellapragada, Sarvari and Gaziano, John Michael and Do, Nhan and Brophy, Mary T. and Kim, Dae H. and Munshi, Nikhil C. and Driver, Jane A.},
	month = jun,
	year = {2021},
	pmid = {34207459},
	pmcid = {PMC8233717},
	keywords = {frailty, geriatric assessment, frailty index, multiple myeloma},
	pages = {3053},
	file = {DuMontier et al_2021_Contemporary Analysis of Electronic Frailty Measurement in Older Adults with.pdf:/Users/jcsal/Zotero/storage/VHQZG5JF/DuMontier et al_2021_Contemporary Analysis of Electronic Frailty Measurement in Older Adults with.pdf:application/pdf},
}

@article{daddimanie30951,
	title = {A {Prospective} {Study} {Correlating} {Preoperative} {Modified} {Frailty} {Index} {With} {One}-{Year} {Mortality} in the {Elderly} {With} {Hip} {Fractures}},
	volume = {14},
	issn = {2168-8184},
	doi = {10.7759/cureus.30951},
	abstract = {Background Hip fractures occur frequently in the elderly population over the age of 60 years following low-energy domestic falls. The postoperative mortality after hip fracture surgery depends on numerous factors like comorbidities, pre-fall ambulatory status, nutritional status, cognition, and overall physical health. In this context, the physiological age and reserve play a vital role in mortality after hip fracture surgeries. This physiological reserve is measured in terms of "frailty." There are many frailty indices that assess the physiological reserves of an elderly patient. The modified frailty index (MFI) is one of the validated indexes predicting postoperative complications and mortality. So we concluded there is a need to assess the patients with MFI preoperatively, based on which mortality and postoperative complications could be predicted in our patients. Materials and methods We included 100 patients aged more than 60 years with intertrochanteric and neck of the femur fractures, who were managed surgically. We followed the patients for one year and observed the immediate and late complications and mortality at the end of one year. To reduce bias, patients with pathological fractures, revision surgeries, contralateral fractures, high-energy trauma, younger than 60 years of age, and previous proximal femur fracture surgery on the side of injury were excluded from the study. Results The primary objective was to study the correlation between the MFI with one-year mortality. We observe that the MFI score had a significant effect on mortality at one year (p-value = 0.0316). With a unit increase in the MFI score, the odds of death increase by a factor of 1.52. Conclusion There is a strong correlation between MFI with one-year mortality and postoperative complications after hip fracture surgeries in the elderly. This MFI can be used as a preoperative predictive model to predict the mortality and postoperative complications after hip fractures in the elderly. It will also help patients and their caretakers in decision-making and elucidating surgery choices.},
	language = {eng},
	number = {10},
	journal = {Cureus},
	author = {Daddimani, Ravi M. and Madhava Murthy, Srinath K. and Sharan, Prateek M. and Patil, Arvind D.},
	month = oct,
	year = {2022},
	pmid = {36465740},
	pmcid = {PMC9711920},
	keywords = {odds ratio, mortality, elderly, postoperative complications, elderly hip fractures, modified frailty index},
	pages = {e30951},
	file = {Daddimani et al_2022_A Prospective Study Correlating Preoperative Modified Frailty Index With.pdf:/Users/jcsal/Zotero/storage/PYUYMFXD/Daddimani et al_2022_A Prospective Study Correlating Preoperative Modified Frailty Index With.pdf:application/pdf},
}

@article{abel515,
	title = {Frailty and the management of hematologic malignancies},
	volume = {131},
	issn = {1528-0020},
	doi = {10.1182/blood-2017-09-746420},
	abstract = {The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematologist, we propose elements of a new research agenda for geriatric hematology: the exchange of age limits for rigorous frailty screening, development of disease-specific measures, and inclusion of functional and patient-reported outcomes alongside survival.},
	language = {eng},
	number = {5},
	journal = {Blood},
	author = {Abel, Gregory A. and Klepin, Heidi D.},
	month = feb,
	year = {2018},
	pmid = {29141942},
	keywords = {Humans, Aged, Aged, 80 and over, Frailty, Frail Elderly, Hematologic Neoplasms, Late Onset Disorders},
	pages = {515--524},
	file = {Abel_Klepin_2018_Frailty and the management of hematologic malignancies.pdf:/Users/jcsal/Zotero/storage/NRBWC449/Abel_Klepin_2018_Frailty and the management of hematologic malignancies.pdf:application/pdf},
}

@article{choie0139749,
	title = {Skeletal {Muscle} {Depletion} {Predicts} the {Prognosis} of {Patients} with {Advanced} {Pancreatic} {Cancer} {Undergoing} {Palliative} {Chemotherapy}, {Independent} of {Body} {Mass} {Index}},
	volume = {10},
	issn = {1932-6203},
	doi = {10.1371/journal.pone.0139749},
	abstract = {INTRODUCTION: Body composition has emerged as a prognostic factor in cancer patients. We investigated whether sarcopenia at diagnosis and loss of skeletal muscle during palliative chemotherapy were associated with survival in patients with pancreatic cancer.
METHODS: We retrospectively reviewed the clinical outcomes of pancreatic cancer patients receiving palliative chemotherapy between 2003 and 2010. The cross-sectional area of skeletal muscle at L3 by computed tomography was analyzed with Rapidia 3D software. We defined sarcopenia as a skeletal muscle index (SMI){\textless} 42.2 cm2/m2 (male) and {\textless} 33.9 cm2/m2 (female) using ROC curve.
RESULTS: Among 484 patients, 103 (21.3\%) patients were sarcopenic at diagnosis. Decrease in SMI during chemotherapy was observed in 156 (60.9\%) male and 65 (40.6\%) female patients. Decrease in body mass index (BMI) was observed in 149 patients (37.3\%), with no gender difference. By multivariate analysis, sarcopenia (P{\textless} 0.001), decreasedBMI and SMI during chemotherapy (P = 0.002, P = 0.004, respectively) were poor prognostic factors for overall survival (OS). While the OS of male patients was affected with sarcopenia (P{\textless} 0.001) and decreased SMI (P = 0.001), the OS of female patients was influenced with overweight at diagnosis (P = 0.006), decreased BMI (P = 0.032) and decreased SMI (P = 0.014). Particularly, while the change of BMI during chemotherapy did not have impact on OS within the patients with maintained SMI (P = 0.750), decrease in SMI was associated with poor OS within the patients with maintained BMI (HR 1.502; P = 0.002).
CONCLUSIONS: Sarcopenia at diagnosis and depletion of skeletal muscle, independent of BMI change, during chemotherapy were poor prognostic factors in advanced pancreatic cancer.},
	language = {eng},
	number = {10},
	journal = {PloS One},
	author = {Choi, Younak and Oh, Do-Youn and Kim, Tae-Yong and Lee, Kyung-Hun and Han, Sae-Won and Im, Seock-Ah and Kim, Tae-You and Bang, Yung-Jue},
	year = {2015},
	pmid = {26437072},
	pmcid = {PMC4593598},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Retrospective Studies, Muscular Atrophy, Palliative Care, Radiography, Pancreatic Neoplasms, Prognosis, Aged, 80 and over, Adult, Young Adult},
	pages = {e0139749},
	file = {Choi et al_2015_Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced.pdf:/Users/jcsal/Zotero/storage/CPVGMWC9/Choi et al_2015_Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced.pdf:application/pdf},
}

@article{fogelman307,
	title = {Does {IGFR1} inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?},
	volume = {5},
	issn = {2190-5991},
	doi = {10.1007/s13539-014-0145-y},
	abstract = {BACKGROUND: IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown.
METHODS: We evaluated muscle mass at L3 in patients enrolled in a randomized phase II study of MK-0646 (M), a monoclonal antibody directed against the IGF-1 protein, in patients with metastatic pancreatic cancer (MPC). Two different doses of M were tested, 5 and 10 mg/kg. We used the Slice-o-matic (ver 4.3) software to segregate CT images into muscle and fat components and measured muscle area (cm(2)) at baseline and after 2 and 4 months of treatment. Patients received either gemcitabine with erlotinib (G + E), G + E + M, or G + M. Differences between the groups were compared using t tests.
RESULTS: Fifty-three patients had both baseline and 2-month imaging available for analysis. Of these, 42 received M with their chemo, and 11 had G + E only. After 2 months of treatment, both groups demonstrated decrease in muscle mass. G + E patients lost 5.6 \% of muscle mass; M patients lost 9.1 and 8.6 \% after treatment with 5 and 10 mg/kg, respectively (p = 0.53). Patients demonstrating a response lost less muscle (median 4.6 \%) than those with stable disease (9.6 \%) and progressive disease (8.9 \%, p = 0.14). Muscle retention from baseline to 2-month imaging, defined as loss of {\textless}6 cm(2) of muscle, correlated with better survival than those patients demonstrating a muscle loss (HR 0.51, p = 0.03).
CONCLUSIONS: MPC patients can be expected to lose muscle mass even while having clinical benefit (PR or SD) from chemotherapy. Muscle loss correlated with a risk of study drop-out and death. There was a non-significant trend toward greater muscle mass loss in patients on anti-IGF-1R therapy. However, it is unclear if this loss translates into functional differences between patients.},
	language = {eng},
	number = {4},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Fogelman, David R. and Holmes, Holly and Mohammed, Khalil and Katz, Matthew H. G. and Prado, Carla M. and Lieffers, Jessica and Garg, Naveen and Varadhachary, Gauri R. and Shroff, Rachna and Overman, Michael J. and Garrett, Christopher and Wolff, Robert A. and Javle, Milind},
	month = dec,
	year = {2014},
	pmid = {24740741},
	pmcid = {PMC4248412},
	pages = {307--313},
	file = {Fogelman et al_2014_Does IGFR1 inhibition result in increased muscle mass loss in patients.pdf:/Users/jcsal/Zotero/storage/L4QKBY29/Fogelman et al_2014_Does IGFR1 inhibition result in increased muscle mass loss in patients.pdf:application/pdf},
}

@article{fang155a,
	title = {Percutaneous endoscopic gastrostomy prior to esophagectomy for esophageal cancer - a systematic review and meta-analysis},
	volume = {16},
	issn = {1747-4132},
	doi = {10.1080/17474124.2022.2027754},
	abstract = {BACKGROUND: For resectable esophageal cancer (EC), it remains controversial whether to place percutaneous endoscopic gastrostomy (PEG) before the curative surgery to provide nutritional support during the neoadjuvant therapy.
OBJECTIVE: To compare surgical outcomes for patients who received preoperative PEG and those without PEG placement (No-PEG) insertion prior to surgery in a potentially operable EC.
METHODS: A comprehensive literature search was conducted to identify randomized and non-randomized studies comparing PEG and No-PEG groups.
RESULTS: Four retrospective studies with a total number of 1,027 patients were identified and included in this meta-analysis. The differences in anastomotic leakage, anastomotic stricture, morbidity, pulmonary complications, wound infection, and hospital stay were not statistically significant between the two groups. Operation time was significantly shorter in the PEG group. There was no PEG-related gastric conduit failure and no leak from the PEG site in the PEG group.
CONCLUSION: We conclude preoperative PEG for resectable EC is a safe procedure with no adverse effect on the gastric tube construction and anastomosis, it can be selectively inserted for EC patients with marked weight loss and malnutrition or those at risk of developing malnutrition during neoadjuvant therapy.},
	language = {eng},
	number = {2},
	journal = {Expert Review of Gastroenterology \& Hepatology},
	author = {Fang, Hua-Chen and Farah, Musa Hassan and Shiue, Sheng-Jie and Cheng, Sheng-Wei and Shiue, Han-Shiang and Cheng, Chao-Ling and Chan, Tze-Sian and Liao, Ai-Ho and Wu, Ming-Shun},
	month = feb,
	year = {2022},
	pmid = {35048757},
	note = {tex.ids= fang155a},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, neoadjuvant therapy, Nutritional Support, Gastroscopy, Gastrostomy, Operative Time, esophagus cancer, Percutaneous endoscopic gastrostomy, systematic review and meta-analysis},
	pages = {155--162},
}

@misc{zotero-1987,
	title = {Percutaneous endoscopic gastrostomy risks rendering the gastric conduit unusable for esophagectomy - {Ohnmacht} - 2006 - {Diseases} of the {Esophagus} - {Wiley} {Online} {Library}},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1442-2050.2006.00588.x},
	urldate = {2023-01-14},
	keywords = {PEG},
	file = {Percutaneous endoscopic gastrostomy risks rendering the gastric conduit unusable for esophagectomy - Ohnmacht - 2006 - Diseases of the Esophagus - Wiley Online Library:/Users/jcsal/Zotero/storage/SPX47VU4/j.1442-2050.2006.00588.html:text/html},
}

@article{cederholm1,
	title = {{GLIM} criteria for the diagnosis of malnutrition - {A} consensus report from the global clinical nutrition community},
	volume = {38},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2018.08.002},
	abstract = {RATIONALE: This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings.
METHODS: In January 2016, the Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. GLIM appointed a core leadership committee and a supporting working group with representatives bringing additional global diversity and expertise. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications.
RESULTS: A two-step approach for the malnutrition diagnosis was selected, i.e., first screening to identify "at risk" status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present. Phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories.
CONCLUSION: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure further collaboration and endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The diagnostic construct should be re-considered every 3-5 years.},
	language = {eng},
	number = {1},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Cederholm, T. and Jensen, G. L. and Correia, M. I. T. D. and Gonzalez, M. C. and Fukushima, R. and Higashiguchi, T. and Baptista, G. and Barazzoni, R. and Blaauw, R. and Coats, A. and Crivelli, A. and Evans, D. C. and Gramlich, L. and Fuchs-Tarlovsky, V. and Keller, H. and Llido, L. and Malone, A. and Mogensen, K. M. and Morley, J. E. and Muscaritoli, M. and Nyulasi, I. and Pirlich, M. and Pisprasert, V. and de van der Schueren, M. a. E. and Siltharm, S. and Singer, P. and Tappenden, K. and Velasco, N. and Waitzberg, D. and Yamwong, P. and Yu, J. and Van Gossum, A. and Compher, C. and {GLIM Core Leadership Committee} and {GLIM Working Group}},
	month = feb,
	year = {2019},
	pmid = {30181091},
	keywords = {Humans, Adult, Nutrition Assessment, Malnutrition, Nutritional Status, Screening, Societies, Scientific, Consensus, Leadership, Assessment, Diagnosis, Internationality},
	pages = {1--9},
	file = {Cederholm et al_2019_GLIM criteria for the diagnosis of malnutrition - A consensus report from the.pdf:/Users/jcsal/Zotero/storage/FLBP7M29/Cederholm et al_2019_GLIM criteria for the diagnosis of malnutrition - A consensus report from the.pdf:application/pdf},
}

@article{varadhan488,
	title = {A meta-analysis of randomised controlled trials of intravenous fluid therapy in major elective open abdominal surgery: getting the balance right},
	volume = {69},
	issn = {1475-2719},
	shorttitle = {A meta-analysis of randomised controlled trials of intravenous fluid therapy in major elective open abdominal surgery},
	doi = {10.1017/S0029665110001734},
	abstract = {The terminology used for describing intervention groups in randomised controlled trials (RCT) on the effect of intravenous fluid on outcome in abdominal surgery has been imprecise, and the lack of standardised definitions of the terms 'standard', 'restricted' and 'liberal' has led to some confusion and difficulty in interpreting the literature. The aims of this paper were to clarify these definitions and to use them to perform a meta-analysis of nine RCT on primarily crystalloid-based peri-operative intravenous fluid therapy in 801 patients undergoing elective open abdominal surgery. Patients who received more or less fluids than those who received a 'balanced' amount were considered to be in a state of 'fluid imbalance'. When 'restricted' fluid regimens were compared with 'standard or liberal' fluid regimens, there was no difference in post-operative complication rates (risk ratio 0.83 (95\% CI 0.49, 1.39, P = 0.47) [corrected] or length of hospital stay (weighted mean difference (WMD) - 1.77 (95\% CI - 4.36, 0.81) d, P = 0.18). However, when the fluid regimens were reclassified and patients were grouped into those who were managed in a state of fluid 'balance' or 'imbalance', the former group had significantly fewer complications (risk ratio 0·59 (95\% CI 0·44, 0·81), P=0·0008) and a shorter length of stay (WMD -3·44 (95\% CI -6·33, -0·54) d, P=0·02) than the latter. Using imprecise terminology, there was no apparent difference between the effects of fluid-restricted and standard or liberal fluid regimens on outcome in patients undergoing elective open abdominal surgery. However, patients managed in a state of fluid balance fared better than those managed in a state of fluid imbalance.},
	language = {eng},
	number = {4},
	journal = {The Proceedings of the Nutrition Society},
	author = {Varadhan, Krishna K. and Lobo, Dileep N.},
	month = nov,
	year = {2010},
	pmid = {20515521},
	keywords = {Abdomen, Humans, Length of Stay, Randomized Controlled Trials as Topic, Postoperative Complications, Terminology as Topic, Digestive System Surgical Procedures, Fluid Therapy, Elective Surgical Procedures, Infusions, Intravenous, Water-Electrolyte Balance},
	pages = {488--498},
	file = {Varadhan_Lobo_2010_A meta-analysis of randomised controlled trials of intravenous fluid therapy in.pdf:/Users/jcsal/Zotero/storage/SDJDUBA5/Varadhan_Lobo_2010_A meta-analysis of randomised controlled trials of intravenous fluid therapy in.pdf:application/pdf},
}

@article{skipper709,
	title = {Position of the {Academy} of {Nutrition} and {Dietetics}: {Malnutrition} ({Undernutrition}) {Screening} {Tools} for {All} {Adults}},
	volume = {120},
	issn = {2212-2672},
	shorttitle = {Position of the {Academy} of {Nutrition} and {Dietetics}},
	doi = {10.1016/j.jand.2019.09.011},
	abstract = {It is the position of the Academy of Nutrition and Dietetics that, based upon current evidence, the Malnutrition Screening Tool should be used to screen adults for malnutrition (undernutrition) regardless of their age, medical history, or setting. Malnutrition (undernutrition) screening is a simple process intended to quickly recognize individuals who may have a malnutrition diagnosis. While numerous malnutrition screening tools are in use, their levels of validity, agreement, reliability, and generalizability vary. The Academy of Nutrition and Dietetics reviewed the body of evidence supporting malnutrition screening tools and determined a single tool for identifying adults in all settings who may have malnutrition, regardless of their age or medical history. The Nutrition Screening for Adults Workgroup conducted a systematic review of the most robust evidence to promote using the highest-quality malnutrition screening tool available.},
	language = {eng},
	number = {4},
	journal = {Journal of the Academy of Nutrition and Dietetics},
	author = {Skipper, Annalynn and Coltman, Anne and Tomesko, Jennifer and Charney, Pamela and Porcari, Judith and Piemonte, Tami A. and Handu, Deepa and Cheng, Feon W.},
	month = apr,
	year = {2020},
	pmid = {31866359},
	keywords = {Humans, Female, Male, Reproducibility of Results, Adult, Nutrition Assessment, Malnutrition, Mass Screening, Dietetics, Academies and Institutes},
	pages = {709--713},
}

@article{kauppila1131,
	title = {Meta-analysis of health-related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer},
	volume = {104},
	issn = {1365-2168},
	doi = {10.1002/bjs.10577},
	abstract = {BACKGROUND: The aim of this systematic review and meta-analysis was to compare health-related quality of life (HRQoL) outcomes between minimally invasive and open oesophagectomy for cancer at different postoperative time points.
METHODS: A search of PubMed (MEDLINE), Web of Science, Embase, Scopus, CINAHL and the Cochrane Library was performed for studies that compared open with minimally invasive oesophagectomy. A random-effects meta-analysis was conducted for studies that measured HRQoL scores using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-OES18 questionnaires. Mean differences (MDs) greater than 10 in scores were considered clinically relevant. Pooled effects of MDs with 95 per cent confidence intervals were estimated to assess statistical significance.
RESULTS: Nine studies were included in the qualitative analysis, involving 1157 patients who had minimally invasive surgery and 907 patients who underwent open surgery. Minimally invasive surgery resulted in better scores for global quality of life (MD 11·61, 95 per cent c.i. 3·84 to 19·39), physical function (MD 11·88, 3·92 to 19·84), fatigue (MD -13·18, -17·59 to -8·76) and pain (MD -15·85, -20·45 to -11·24) compared with open surgery at 3 months after surgery. At 6 and 12 months, no significant differences remained.
CONCLUSION: Patients report better global quality of life, physical function, fatigue and pain 3 months after minimally invasive surgery compared with open surgery. No such differences remain at longer follow-up of 6 and 12 months.},
	language = {eng},
	number = {9},
	journal = {The British Journal of Surgery},
	author = {Kauppila, J. H. and Xie, S. and Johar, A. and Markar, S. R. and Lagergren, P.},
	month = aug,
	year = {2017},
	pmid = {28632926},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Esophagoscopy, Quality of Life, Pain, Postoperative, Fatigue},
	pages = {1131--1140},
	file = {Kauppila et al_2017_Meta-analysis of health-related quality of life after minimally invasive versus.pdf:/Users/jcsal/Zotero/storage/UNBYRPTV/Kauppila et al_2017_Meta-analysis of health-related quality of life after minimally invasive versus.pdf:application/pdf},
}

@article{shen9113,
	title = {The effect of enhanced recovery after minimally invasive esophagectomy: a randomized controlled trial},
	volume = {36},
	issn = {1432-2218},
	shorttitle = {The effect of enhanced recovery after minimally invasive esophagectomy},
	doi = {10.1007/s00464-022-09385-6},
	abstract = {BACKGROUND: The purpose of this randomized controlled trial was to determine if enhanced recovery after surgery (ERAS) would improve outcomes for three-stage minimally invasive esophagectomy (MIE).
METHODS: Patients with esophageal cancer undergoing MIE between March 2016 and August 2018 were consecutively enrolled, and were randomly divided into 2 groups: ERAS+group that received a guideline-based ERAS protocol, and ERAS- group that received standard care. The primary endpoint was morbidity after MIE. The secondary endpoints were the length of stay (LOS) and time to ambulation after the surgery. The perioperative results including the Surgical Apgar Score (SAS) and Visualized Analgesia Score (VAS) were also collected and compared.
RESULTS: A total of 60 patients in the ERAS+ group and 58 patients in the ERAS- group were included. Postoperatively, lower morbidity and pulmonary complication rate were recorded in the ERAS+ group (33.3\% vs. 51.7\%; p = 0.04, 16.7\% vs. 32.8\%; p = 0.04), while the incidence of anastomotic leakage remained comparable (11.7\% vs. 15.5\%; p = 0.54). There was an earlier ambulation (3 [2-3] days vs. 3 [3-4] days, p = 0.001), but comparable LOS (10 [9-11.25] days vs. 10 [9-13] days; p = 0.165) recorded in ERAS+ group. The ERAS protocol led to close scores in both SAS (7.80 ± 1.03 vs. 8.07 ± 0.89, p = 0.21) and VAS (1.74 ± 0.85 vs. 1.78 ± 1.06, p = 0.84).
CONCLUSIONS: Implementation of an ERAS protocol for patients undergoing MIE resulted in earlier ambulation and lower pulmonary complications, without a change in anastomotic leakage or length of hospital stay. Further studies on minimizing leakage should be addressed in ERAS for MIE.},
	language = {eng},
	number = {12},
	journal = {Surgical Endoscopy},
	author = {Shen, Yaxing and Chen, Xiaosang and Hou, Junyi and Chen, Youwen and Fang, Yong and Xue, Zhanggang and D'Journo, Xavier Benoit and Cerfolio, Robert J. and Fernando, Hiran C. and Fiorelli, Alfonso and Brunelli, Alessandro and Cang, Jing and Tan, Lijie and Wang, Hao and {Written on behalf of the AME Thoracic Surgery Collaborative Group}},
	month = dec,
	year = {2022},
	pmid = {35773604},
	pmcid = {PMC9652161},
	keywords = {Humans, Length of Stay, Treatment Outcome, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Anastomotic Leak, Minimally Invasive Surgical Procedures, Morbidity, Enhanced recovery after surgery, ERAS, Length of stay, LOS, Minimally invasive esophagectomy, MIE},
	pages = {9113--9122},
	file = {Shen et al_2022_The effect of enhanced recovery after minimally invasive esophagectomy.pdf:/Users/jcsal/Zotero/storage/IT9BHIQN/Shen et al_2022_The effect of enhanced recovery after minimally invasive esophagectomy.pdf:application/pdf},
}

@article{fransen919,
	title = {Direct {Oral} {Feeding} {After} a {Minimally} {Invasive} {Esophagectomy}: {A} {Single}-{Center} {Prospective} {Cohort} {Study}},
	volume = {275},
	issn = {1528-1140},
	shorttitle = {Direct {Oral} {Feeding} {After} a {Minimally} {Invasive} {Esophagectomy}},
	doi = {10.1097/SLA.0000000000004036},
	abstract = {OBJECTIVE: The aim of this single-center cohort study was to compare direct oral feeding (DOF) to standard of care after a minimally invasive esophagectomy (MIE) performed in a center with a stable and acceptable postoperative complication rate.
BACKGROUND: A recent multicenter, international randomized controlled trial showed that DOF following a MIE is comparable to standard of care (nil-by-mouth). However, the effect of DOF was potentially influenced by postoperative complications.
METHODS: Patients in this single-center prospective cohort study received either DOF (intervention) or nil-by-mouth for 5 days postoperative and tube feeding (standard of care, control group) following a MIE with intrathoracic anastomosis. Primary outcome was time to functional recovery and length of hospital stay. Secondary outcomes included anastomotic leakage, pneumonia, and other surgical complications.
RESULTS: Baseline characteristics were similar in the intervention (n = 85) and control (n = 111) group. Median time to functional recovery was 7 and 9 days in the intervention and control group (P {\textless} 0.001), respectively. Length of hospital stay was 8 versus 10 days (P {\textless} 0.001), respectively. Thirty-day postoperative complication rate was significantly reduced in the intervention group (57.6\% vs 73.0\%, P = 0.024). Chyle leakage only occurred in the control group (18.9\%, P {\textless} 0.001). Anastomotic leakage, pneumonia, and other postoperative complications did not differ between groups.
CONCLUSION: Direct oral feeding following a MIE results in a faster time to functional recovery and lower 30-day postoperative complication rate compared to patients that were orally fasted.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Fransen, Laura F. C. and Janssen, Thijs H. J. B. and Aarnoudse, Martijn and Nieuwenhuijzen, Grard A. P. and Luyer, Misha D. P.},
	month = may,
	year = {2022},
	pmid = {32541215},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Prospective Studies, Cohort Studies, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Anastomotic Leak, Minimally Invasive Surgical Procedures, Pneumonia},
	pages = {919--923},
}

@article{berkelmans41,
	title = {Direct {Oral} {Feeding} {Following} {Minimally} {Invasive} {Esophagectomy} ({NUTRIENT} {II} trial): {An} {International}, {Multicenter}, {Open}-label {Randomized} {Controlled} {Trial}},
	volume = {271},
	issn = {1528-1140},
	shorttitle = {Direct {Oral} {Feeding} {Following} {Minimally} {Invasive} {Esophagectomy} ({NUTRIENT} {II} trial)},
	doi = {10.1097/SLA.0000000000003278},
	abstract = {OBJECTIVE: Patients undergoing an esophagectomy are often kept nil-by-mouth postoperatively out of fear for increasing anastomotic leakage and pulmonary complications. This study investigates the effect of direct start of oral feeding following minimally invasive esophagectomy (MIE) compared with standard of care.
BACKGROUND: Elements of enhanced recovery after surgery (ERAS) protocols have been successfully introduced in patients undergoing an esophagectomy. However, start of oral intake, which is an essential part of the ERAS protocols, remains a matter of debate.
METHODS: Patients in this multicenter, international randomized controlled trial were randomized to directly start oral feeding (intervention) after a MIE with intrathoracic anastomosis or to receive nil-by-mouth and tube feeding for 5 days postoperative (control group). Primary outcome was time to functional recovery. Secondary outcome parameters included anastomotic leakage, pneumonia rate, and other surgical complications scored by predefined definitions.
RESULTS: Baseline characteristics were similar in the intervention (n = 65) and control (n = 67) group. Functional recovery was 7 days for patients receiving direct oral feeding compared with 8 days in the control group (P = 0.436). Anastomotic leakage rate did not differ in the intervention (18.5\%) and control group (16.4\%, P = 0.757). Pneumonia rates were comparable between the intervention (24.6\%) and control group (34.3\%, P = 0.221). Other morbidity rates were similar, except for chyle leakage, which was more prevalent in the standard of care group (P = 0.032).
CONCLUSION: Direct oral feeding after an esophagectomy does not affect functional recovery and did not increase incidence or severity of postoperative complications.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgery},
	author = {Berkelmans, Gijs H. K. and Fransen, Laura F. C. and Dolmans-Zwartjes, Annemarie C. P. and Kouwenhoven, Ewout A. and van Det, Marc J. and Nilsson, Magnus and Nieuwenhuijzen, Grard A. P. and Luyer, Misha D. P.},
	month = jan,
	year = {2020},
	pmid = {31090563},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Postoperative Care, Treatment Outcome, Follow-Up Studies, Prospective Studies, Esophageal Neoplasms, Esophagectomy, Anastomotic Leak, Enteral Nutrition, Quality of Life, Minimally Invasive Surgical Procedures, Recovery of Function},
	pages = {41--47},
}

@article{johansson667,
	title = {Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial},
	volume = {250},
	issn = {1528-1140},
	shorttitle = {Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction},
	doi = {10.1097/SLA.0b013e3181bcb139},
	abstract = {OBJECTIVE: The primary aim of this study was to evaluate if the use of proton pump inhibitors (PPIs) reduced the prevalence of benign anastomotic strictures after uncomplicated esophagectomies with gastric tube reconstruction and circular stapled anastomoses.
SUMMARY BACKGROUND DATA: Benign anastomotic strictures are associated with anastomotic leaks or conduit ischemia. Also patients without those complications develop benign anastomotic strictures. We hypothesize that patients without postoperative anastomotic complications may develop benign anastomotic strictures due to exposure of acid gastric tube contents to the anastomotic area, and that the formation of such strictures may be reduced by prophylactic use of PPIs.
METHODS: Eighty patients without preoperative chemo- or radiotherapy, without clinical or radiological signs of anastomotic leaks were included in this clinical trial. The patients were randomized to b.i.d. PPIs or no treatment for 1 year. Benign anastomotic strictures were defined as anastomotic narrowing not allowing a standard diagnostic endoscope to pass without dilatation. The study was registered in the EudraCT database (2009-009997-28) for clinical trials.
RESULTS: : Seventy-nine patients were evaluated. Benign anastomotic strictures developed in 5/39 (13\%) patients in the PPI group and in 18/40 (45\%) in the control group (RR 5.6, 95\% CI: 2.0-15.9, P = 0.001). The use of a narrower 25 mm cartridge as compared to a wider 28 or 31 mm cartridge significantly increased stricture formations (RR 2.9, 95\% CI: 1.1-7.6, P = 0.025).
CONCLUSIONS: Prophylactic PPI treatment reduced the prevalence of benign anastomotic strictures following esophagectomy with gastric tube reconstruction and circular stapled anastomoses. Larger sized circular staple cartridges additionally reduced the stricture prevalence.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Johansson, Jan and Oberg, Stefan and Wenner, Jörgen and Zilling, Thomas and Johnsson, Folke and von Holstein, Christer Staël and Walther, Bruno},
	month = nov,
	year = {2009},
	pmid = {19801933},
	keywords = {Humans, Female, Male, Esophageal Neoplasms, Esophagectomy, Esophagus, Stomach, Anastomosis, Surgical, Esophageal Stenosis, Dilatation, Esophageal pH Monitoring, Proton Pump Inhibitors, Surgical Stapling},
	pages = {667--673},
}

@article{guerard894,
	title = {Frailty {Index} {Developed} {From} a {Cancer}-{Specific} {Geriatric} {Assessment} and the {Association} {With} {Mortality} {Among} {Older} {Adults} {With} {Cancer}},
	volume = {15},
	issn = {1540-1413},
	doi = {10.6004/jnccn.2017.0122},
	abstract = {Background: An objective measure is needed to identify frail older adults with cancer who are at increased risk for poor health outcomes. The primary objective of this study was to develop a frailty index from a cancer-specific geriatric assessment (GA) and evaluate its ability to predict all-cause mortality among older adults with cancer. Patients and Methods: Using a unique and novel data set that brings together GA data with cancer-specific and long-term mortality data, we developed the Carolina Frailty Index (CFI) from a cancer-specific GA based on the principles of deficit accumulation. CFI scores (range, 0-1) were categorized as robust (0-0.2), pre-frail (0.2-0.35), and frail ({\textgreater}0.35). The primary outcome for evaluating predictive validity was all-cause mortality. The Kaplan-Meier method and log-rank tests were used to compare survival between frailty groups, and Cox proportional hazards regression models were used to evaluate associations. Results: In our sample of 546 older adults with cancer, the median age was 72 years, 72\% were women, 85\% were white, and 47\% had a breast cancer diagnosis. Overall, 58\% of patients were robust, 24\% were pre-frail, and 18\% were frail. The estimated 5-year survival rate was 72\% in robust patients, 58\% in pre-frail patients, and 34\% in frail patients (log-rank test, P{\textless}.0001). Frail patients had more than a 2-fold increased risk of all-cause mortality compared with robust patients (adjusted hazard ratio, 2.36; 95\% CI, 1.51-3.68). Conclusions: The CFI was predictive of all-cause mortality in older adults with cancer, a finding that was independent of age, sex, cancer type and stage, and number of medical comorbidities. The CFI has the potential to become a tool that oncologists can use to objectively identify frailty in older adults with cancer.},
	language = {eng},
	number = {7},
	journal = {Journal of the National Comprehensive Cancer Network: JNCCN},
	author = {Guerard, Emily J. and Deal, Allison M. and Chang, YunKyung and Williams, Grant R. and Nyrop, Kirsten A. and Pergolotti, Mackenzi and Muss, Hyman B. and Sanoff, Hanna K. and Lund, Jennifer L.},
	month = jul,
	year = {2017},
	pmid = {28687577},
	keywords = {Humans, Aged, Female, Male, Follow-Up Studies, Neoplasms, Aged, 80 and over, Comorbidity, Registries, Mortality, North Carolina, Frailty, Geriatric Assessment, Frail Elderly, cFI},
	pages = {894--902},
	file = {Guerard et al_2017_Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the.pdf:/Users/jcsal/Zotero/storage/QMMXDLY4/Guerard et al_2017_Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the.pdf:application/pdf},
}

@article{delaney819,
	title = {Clinical outcomes and resource utilization associated with laparoscopic and open colectomy using a large national database},
	volume = {247},
	issn = {1528-1140},
	doi = {10.1097/SLA.0b013e31816d950e},
	abstract = {OBJECTIVES: To clarify national clinical and economic laparoscopic colectomy outcomes, we conducted a study of patients who underwent colectomy by laparoscopic or open approaches.
BACKGROUND: Laparoscopy is becoming the preferred approach for colectomy in benign and malignant diseases. Although it is associated with significant clinical benefits, economic outcomes have varied.
METHODS: We analyzed cohorts of patient-level data from Premier Inc.'s Perspective Rx Comparative Database, which collects data from more than 500 hospitals throughout the United States. By reviewing hospital charge data, patients who underwent elective colectomies from July 1, 2004, through June 30, 2006, were identified using International Classification of Diseases, 9th Revision, Clinical Modification procedure codes. The colectomy had to be listed as the primary or secondary procedure of the hospitalization. Primary outcomes included transfusion rates, in-hospital complications, readmissions within 30 days, reoperations, length of stay, total hospitalization costs, and discharge dispositions and services.
RESULTS: We identified 32,733 patients who had elective colectomies throughout 402 hospitals; 11,044 (33.7\%) were laparoscopic and 21,689 (66.3\%) were open colectomies. The mean age was 64.2 +/- 13.9 years and 53.8\% were women. Laparoscopic colectomy patients had a longer mean operative time (195 +/- 76 vs. 178 +/- 80 minutes; P {\textless} 0.0001) and higher total hospital costs (\$8076 vs. \$7678; P = 0.0002). Laparoscopic patients had shorter mean length of stay (7.0 vs. 8.1; P {\textless} 0.0001) and fewer mean intensive care unit days (0.7 +/- 3.8 vs. 1.3 +/- 5.2 days; P {\textless} 0.0001). The laparoscopic cohort also had lower rates of transfusions (odds ratio [OR] = 0.68; P {\textless} 0.0001), in-hospital complications (OR = 0.89; P {\textless} 0.0001), and readmissions within 30 days (OR = 0.89; P = 0.0051), although reoperation rates were slightly, but significantly increased (OR = 1.78; P = 0.002). Laparoscopic colectomy patients were more likely to be discharged home without nursing care (OR = 0.70; P {\textless} 0.0001).
CONCLUSION: Evaluation of a national administrative data set showed that patients who underwent laparoscopic colectomy had shorter intensive care unit and total hospital stays, fewer complications, lower mortality, fewer readmissions, and less use of skilled nursing facilities after discharge. There was a small but significant increase in reoperation rates and in-hospital costs with laparoscopic colectomy. Improved application of enhanced recovery programs and operative efficiencies may further improve resource utilization associated with laparoscopic colectomy.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Delaney, Conor P. and Chang, Eunice and Senagore, Anthony J. and Broder, Michael},
	month = may,
	year = {2008},
	pmid = {18438119},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Cohort Studies, CRC, Colectomy, Databases, Factual, United States, Laparoscopy, Health Care Costs, Colonic Diseases, Health Resources},
	pages = {819--824},
	annote = {Lap colectomy had 7\% transfusion rate vs 11\% open
},
}

@article{liuS11,
	title = {Data {That} {Drive}: {Closing} the {Loop} in the {Learning} {Hospital} {System}},
	volume = {11},
	issn = {1553-5592},
	shorttitle = {Data {That} {Drive}},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510651/},
	doi = {10.1002/jhm.2651},
	abstract = {The learning healthcare system describes a vision of US healthcare that capitalizes on science, information technology, incentives, and care culture to drive improvements in the quality of health care. The inpatient setting, one of the most costly and impactful domains of healthcare, is an ideal setting in which to use data and information technology to foster continuous learning and quality improvement. The rapid digitization of inpatient medicine offers incredible new opportunities to use data from routine care to generate new discovery and thus close the virtuous cycle of learning. We use an object lesson—sepsis care within the 21 hospitals of the Kaiser Permanente Northern California integrated healthcare delivery system—to offer insight into the critical elements necessary for developing a learning hospital system. We then describe how a hospital-wide data-driven approach to inpatient care can facilitate improvements in the quality of hospital care.},
	number = {Suppl 1},
	urldate = {2023-01-26},
	journal = {Journal of hospital medicine},
	author = {Liu, Vincent X. and Morehouse, John W. and Baker, Jennifer M. and Greene, John D. and Kipnis, Patricia and Escobar, Gabriel J.},
	month = nov,
	year = {2016},
	pmid = {27805797},
	pmcid = {PMC5510651},
	keywords = {Sepsis},
	pages = {S11--S17},
	file = {Liu et al_2016_Data That Drive.pdf:/Users/jcsal/Zotero/storage/ZDN8NLS7/Liu et al_2016_Data That Drive.pdf:application/pdf},
}

@article{clancy574,
	title = {Prospective evaluation of social risks, physical function, and cognitive function in prediction of non-elective rehospitalization and post-discharge mortality},
	volume = {22},
	issn = {1472-6963},
	doi = {10.1186/s12913-022-07910-w},
	abstract = {BACKGROUND: Increasing evidence suggests that social factors and problems with physical and cognitive function may contribute to patients' rehospitalization risk. Understanding a patient's readmission risk may help healthcare providers develop tailored treatment and post-discharge care plans to reduce readmission and mortality. This study aimed to evaluate whether including patient-reported data on social factors; cognitive status; and physical function improves on a predictive model based on electronic health record (EHR) data alone.
METHODS: We conducted a prospective study of 1,547 hospitalized adult patients in 3 Kaiser Permanente Northern California hospitals. The main outcomes were non-elective rehospitalization or death within 30 days post-discharge. Exposures included patient-reported social factors and cognitive and physical function (obtained in a pre-discharge interview) and EHR-derived data for comorbidity burden, acute physiology, care directives, prior utilization, and hospital length of stay. We performed bivariate comparisons using Chi-square, t-tests, and Wilcoxon rank-sum tests and assessed correlations between continuous variables using Spearman's rho statistic. For all models, the results reported were obtained after fivefold cross validation.
RESULTS: The 1,547 adult patients interviewed were younger (age, p = 0.03) and sicker (COPS2, p {\textless} 0.0001) than the rest of the hospitalized population. Of the 6 patient-reported social factors measured, 3 (not living with a spouse/partner, transportation difficulties, health or disability-related limitations in daily activities) were significantly associated (p {\textless} 0.05) with the main outcomes, while 3 (living situation concerns, problems with food availability, financial problems) were not. Patient-reported cognitive (p = 0.027) and physical function (p = 0.01) were significantly lower in patients with the main outcomes. None of the patient-reported variables, singly or in combination, improved predictive performance of a model that included acute physiology and longitudinal comorbidity burden (area under the receiver operator characteristic curve was 0.716 for both the EHR model and maximal performance of a random forest model including all predictors).
CONCLUSIONS: In this insured population, incorporating patient-reported social factors and measures of cognitive and physical function did not improve performance of an EHR-based model predicting 30-day non-elective rehospitalization or mortality. While incorporating patient-reported social and functional status data did not improve ability to predict these outcomes, such data may still be important for improving patient outcomes.},
	language = {eng},
	number = {1},
	journal = {BMC health services research},
	author = {Clancy, Heather A. and Zhu, Zheng and Gordon, Nancy P. and Kipnis, Patricia and Liu, Vincent X. and Escobar, Gabriel J.},
	month = apr,
	year = {2022},
	pmid = {35484624},
	pmcid = {PMC9052530},
	keywords = {Humans, Prospective Studies, Adult, Patient Readmission, Patient Discharge, Cognition, Aftercare, Cognitive function, Physical function, Post-discharge outcomes, Predictive modeling, Readmission, Readmission risk, Social determinants of health, Social factors},
	pages = {574},
	file = {Clancy et al_2022_Prospective evaluation of social risks, physical function, and cognitive.pdf:/Users/jcsal/Zotero/storage/W2IMSTSD/Clancy et al_2022_Prospective evaluation of social risks, physical function, and cognitive.pdf:application/pdf},
}

@article{sultana2607,
	title = {Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer},
	volume = {25},
	issn = {1527-7755},
	doi = {10.1200/JCO.2006.09.2551},
	abstract = {PURPOSE: There are a large number of randomized controlled trials involving chemotherapy in the management of advanced pancreatic cancer. Several chemotherapeutic agents, either alone or in combination with other chemotherapy or novel agents, have been used. The aim of these meta-analyses was to examine the different therapeutic approaches, and the comparisons examined were as follows: chemotherapy versus best supportive care; fluorouracil (FU) versus FU combination chemotherapy; gemcitabine versus FU; and gemcitabine versus gemcitabine combination chemotherapy.
METHODS: Relevant trials were identified by searching databases, trial registers, and conference proceedings. The primary end point was overall survival.
RESULTS: One hundred thirteen randomized controlled trials were identified, of which 51 trials involving 9,970 patients met the inclusion criteria. Chemotherapy improved survival compared with best supportive care (hazard ratio [HR] = 0.64; 95\% CI, 0.42 to 0.98). FU-based combination chemotherapy did not result in better overall survival compared with FU alone (HR = 0.94; 95\% CI, 0.82 to 1.08). There was insufficient evidence of a survival difference between gemcitabine and FU, but the wide CI includes clinically important differences in both directions, making a clear conclusion difficult (HR = 0.75; 95\% CI, 0.42 to 1.31). Survival was improved after gemcitabine combination chemotherapy compared with gemcitabine alone (HR = 0.91; 95\% CI, 0.85 to 0.97).
CONCLUSION: There was a significant survival benefit for chemotherapy over best supportive care and gemcitabine combinations over gemcitabine alone. This supports the use of gemcitabine-based combination chemotherapy in the treatment of advanced pancreatic cancer.},
	language = {eng},
	number = {18},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Sultana, Asma and Smith, Catrin Tudur and Cunningham, David and Starling, Naureen and Neoptolemos, John P. and Ghaneh, Paula},
	month = jun,
	year = {2007},
	pmid = {17577041},
	keywords = {Humans, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Pancreatic Neoplasms, Antineoplastic Agents, Outcome Assessment, Health Care, Randomized Controlled Trials as Topic, Fluorouracil, Deoxycytidine, Gemcitabine},
	pages = {2607--2615},
}

@article{akinyemiju715,
	title = {Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes: analysis of the nationwide inpatient sample},
	volume = {16},
	issn = {1471-2407},
	shorttitle = {Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes},
	doi = {10.1186/s12885-016-2738-7},
	abstract = {BACKGROUND: The purpose of this study was to examine racial and socio-economic differences in the receipt of laparoscopic or open surgery among patients with colorectal cancer, and to determine if racial and socio-economic differences exist in post-surgical complications, in-hospital mortality and hospital length of stay among patients who received surgery.
METHODS: We conducted a cross-sectional analysis of hospitalized patients with a primary diagnosis of colorectal cancer between 2007 and 2011 using data from Nationwide Inpatient Sample. ICD-9 codes were used to capture primary diagnosis, surgical procedures, and health outcomes during hospitalization. We used logistic regression analysis to determine racial and socio-economic predictors of surgery type, post-surgical complications and mortality, and linear regression analysis to assess hospital length of stay.
RESULTS: A total of 122,631 patients were admitted with a primary diagnosis of malignant colorectal cancer between 2007 and 2011. Of these, 17,327 (14.13 \%) had laparoscopic surgery, 70,328 (57.35 \%) received open surgery, while 34976 (28.52 \%) did not receive any surgery. Black (36 \%) and Hispanic (34 \%) patients were more likely to receive no surgery compared with Whites (27 \%) patients. However, among patients that received any surgery, there were no racial differences in which surgery was received (laparoscopic versus open, p = 0.2122), although socio-economic differences remained, with patients from lower residential income areas significantly less likely to receive laparoscopic surgery compared with patients from higher residential income areas (OR: 0.74, 95 \% CI: 0.70-0.78). Among patients who received any surgery, Black patients (OR = 1.07, 95 \% CI: 1.01-1.13), and patients with Medicare (OR = 1.16, 95 \% CI: 1.11-1.22) and Medicaid (OR = 1.15, 95 \% CI: 1.07-1.25) insurance experienced significantly higher post-surgical complications, in-hospital mortality (Black OR = 1.18, 95 \% CI: 1.00-1.39), and longer hospital stay (Black β = 1.33, 95 \% CI: 1.16-1.50) compared with White patients or patients with private insurance.
CONCLUSION: Racial and socio-economic differences were observed in the receipt of surgery and surgical outcomes among hospitalized patients with malignant colorectal cancer in the US.},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Akinyemiju, Tomi and Meng, Qingrui and Vin-Raviv, Neomi},
	month = sep,
	year = {2016},
	pmid = {27595733},
	pmcid = {PMC5011892},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Colorectal Neoplasms, CRC, Adult, United States, Cross-Sectional Studies, Laparoscopy, Postoperative Complications, Hospital Mortality, Digestive System Surgical Procedures, Racial Groups, Healthcare Disparities, Socioeconomic Factors, Ethnicity, Inpatients},
	pages = {715},
	file = {Akinyemiju et al_2016_Race-ethnicity and socio-economic differences in colorectal cancer surgery.pdf:/Users/jcsal/Zotero/storage/732GSSW3/Akinyemiju et al_2016_Race-ethnicity and socio-economic differences in colorectal cancer surgery.pdf:application/pdf},
}

@article{uspreventiveservicestaskforce1965,
	title = {Screening for {Colorectal} {Cancer}: {US} {Preventive} {Services} {Task} {Force} {Recommendation} {Statement}},
	volume = {325},
	issn = {1538-3598},
	shorttitle = {Screening for {Colorectal} {Cancer}},
	doi = {10.1001/jama.2021.6238},
	abstract = {IMPORTANCE: Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5\% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15\% from 2000-2002 to 2014-2016. In 2016, 26\% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31\% were not up to date with screening.
OBJECTIVE: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies.
POPULATION: Asymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]).
EVIDENCE ASSESSMENT: The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit.
RECOMMENDATION: The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences. (C recommendation).},
	language = {eng},
	number = {19},
	journal = {JAMA},
	author = {{US Preventive Services Task Force} and Davidson, Karina W. and Barry, Michael J. and Mangione, Carol M. and Cabana, Michael and Caughey, Aaron B. and Davis, Esa M. and Donahue, Katrina E. and Doubeni, Chyke A. and Krist, Alex H. and Kubik, Martha and Li, Li and Ogedegbe, Gbenga and Owens, Douglas K. and Pbert, Lori and Silverstein, Michael and Stevermer, James and Tseng, Chien-Wen and Wong, John B.},
	month = may,
	year = {2021},
	pmid = {34003218},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Risk, Aged, 80 and over, Age Factors, Screening, Early Detection of Cancer, Colonoscopy, Occult Blood, Sigmoidoscopy},
	pages = {1965--1977},
	file = {US Preventive Services Task Force et al_2021_Screening for Colorectal Cancer.pdf:/Users/jcsal/Zotero/storage/RRUFEPFX/US Preventive Services Task Force et al_2021_Screening for Colorectal Cancer.pdf:application/pdf},
}

@article{derstine279,
	title = {Optimal body size adjustment of {L3} {CT} skeletal muscle area for sarcopenia assessment},
	volume = {11},
	issn = {2045-2322},
	doi = {10.1038/s41598-020-79471-z},
	abstract = {Measurements of skeletal muscle cross-sectional area (SMA) at the level of the third lumbar (L3) vertebra derived from clinical computed tomography (CT) scans are commonly used in assessments of sarcopenia, the loss of skeletal muscle mass and function associated with aging. As SMA is correlated with height and Body Mass Index (BMI), body size adjustment is necessary to fairly assess sarcopenic low muscle mass in individuals of different height and BMI. The skeletal muscle index, a widely used measure, adjusts for height as [Formula: see text] but uses no BMI adjustment. There is no agreed upon standard for body size adjustment. We extracted L3 SMA using non-contrast-enhanced CT scans from healthy adults, split into 'Under-40' and 'Over-40' cohorts. Sex-specific allometric analysis showed that height to the power of one was the optimal integer coefficient for height adjusted SMA in both males and females. We computed two height-adjusted measures [Formula: see text] and [Formula: see text], comparing their Pearson correlations versus age, height, weight, and BMI separately by sex and cohort. Finally, in the 'Under-40' cohort, we used linear regression to convert each height-adjusted measure into a z-score ([Formula: see text], [Formula: see text]) adjusted for BMI. [Formula: see text] was less correlated with height in both males and females ([Formula: see text], [Formula: see text] and [Formula: see text], [Formula: see text]) than [Formula: see text] ([Formula: see text] and [Formula: see text], [Formula: see text]). [Formula: see text] was uncorrelated with BMI and weight, and minimally correlated with height in males and females ([Formula: see text], [Formula: see text] and [Formula: see text], [Formula: see text]). The final [Formula: see text] equation was: [Formula: see text], where [Formula: see text], [Formula: see text], [Formula: see text], and sex = 1 if male, 0 if female. We propose [Formula: see text] for optimal height adjustment and the [Formula: see text] score for optimal height and BMI adjustment. By minimizing correlations with height and BMI, the [Formula: see text] score produces unbiased assessments of relative L3 skeletal muscle area across the full range of body sizes.},
	language = {eng},
	number = {1},
	journal = {Scientific Reports},
	author = {Derstine, Brian A. and Holcombe, Sven A. and Ross, Brian E. and Wang, Nicholas C. and Su, Grace L. and Wang, Stewart C.},
	month = jan,
	year = {2021},
	pmid = {33431971},
	pmcid = {PMC7801425},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Male, Middle Aged, Sarcopenia, Body Mass Index, Adult, Methods, Body Size, Reference Standards},
	pages = {279},
	file = {Derstine et al_2021_Optimal body size adjustment of L3 CT skeletal muscle area for sarcopenia.pdf:/Users/jcsal/Zotero/storage/UBN6IHVC/Derstine et al_2021_Optimal body size adjustment of L3 CT skeletal muscle area for sarcopenia.pdf:application/pdf},
}

@article{brown203,
	title = {Scaling of computed tomography body composition to height: relevance of height-normalized indices in patients with colorectal cancer},
	volume = {13},
	issn = {2190-6009},
	shorttitle = {Scaling of computed tomography body composition to height},
	doi = {10.1002/jcsm.12847},
	abstract = {BACKGROUND: Body weight scales to height with a power of ≈2 (weight/height2 ), forming the basis of body mass index (BMI). The corresponding scaling of body composition measured by abdominal computed tomography (CT) to height has not been established. The objective of this analysis was to quantify the scaling of body composition measured by a single-slice axial abdominal CT image (skeletal muscle, and visceral, subcutaneous, and total adipose tissue) to height in patients with colorectal cancer (CRC).
METHODS: This cross-sectional study included non-Hispanic white males and females, aged 18-80 years, who were diagnosed with stage I-III CRC at an integrated health care system in North America between January 2006 and December 2011. Body composition was measured by a single-slice axial CT image of the third lumbar vertebra and analysed with a semi-automated threshold segmentation procedure. Allometric regression models were used to quantify height scaling powers (β ± standard error) for each body composition measure, adjusted for age, for males and females. An interaction test was used to determine if height scaling powers were statistically significantly different between males and females.
RESULTS: Among 2036 subjects, the mean (standard deviation) age was 64 ± 11 years, 1008 (49.5\%) were female, and the mean (standard deviation) BMI was 27.9 ± 5.4 kg/m2 . Powers for skeletal muscle area were 1.06 ± 0.12 for males and 0.80 ± 0.12 for females (P = 0.049). Powers for visceral adipose tissue area were 1.81 ± 0.64 for males and 0.57 ± 0.79 for females (P = 0.16). Powers for subcutaneous adipose tissue area were 2.04 ± 0.42 for males and 0.81 ± 0.45 for females (P = 0.056). Powers for total abdominal adipose tissue area were 1.80 ± 0.46 for males and 0.76 ± 0.50 for females (P = 0.20).
CONCLUSIONS: Body composition measured by single-slice axial abdominal CT, particularly muscle area, scales to height with age-adjusted powers that are different than 2 and are distinct between males and females. These observations may have implications for the development of height-adjusted body composition indices in patients with cancer.},
	language = {eng},
	number = {1},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Brown, Justin C. and Heymsfield, Steven B. and Caan, Bette J.},
	month = feb,
	year = {2022},
	pmid = {34741439},
	pmcid = {PMC8818649},
	keywords = {Adiposity, Body Composition, Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Obesity, Colorectal Neoplasms, Aged, 80 and over, Adult, Cross-Sectional Studies, Young Adult, Methods, Adolescent, Skeletal muscle, Body Height, Allometric analysis, Height, Nutritional assessment, Scaling powers},
	pages = {203--209},
	file = {Brown et al_2022_Scaling of computed tomography body composition to height.pdf:/Users/jcsal/Zotero/storage/PSS995DR/Brown et al_2022_Scaling of computed tomography body composition to height.pdf:application/pdf},
}

@article{lieffers931,
	title = {Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery},
	volume = {107},
	issn = {1532-1827},
	doi = {10.1038/bjc.2012.350},
	abstract = {BACKGROUND: Skeletal muscle depletion (sarcopenia) predicts morbidity and mortality in the elderly and cancer patients.
METHODS: We tested whether sarcopenia predicts primary colorectal cancer resection outcomes in stage II-IV patients (n=234). Sarcopenia was assessed using preoperative computed tomography images. Administrative hospitalisation data encompassing the index surgical admission, direct transfers for inpatient rehabilitation care and hospital re-admissions within 30 days was searched for International Classification of Disease (ICD)-10 codes for postoperative infections and inpatient rehabilitation care and used to calculate length of stay (LOS).
RESULTS: Overall, 38.9\% were sarcopenic; 16.7\% had an infection and 9.0\% had inpatient rehabilitation care. Length of stay was longer for sarcopenic patients overall (15.9 ± 14.2 days vs 12.3 ± 9.8 days, P=0.038) and especially in those ≥ 65 years (20.2 ± 16.9 days vs 13.1 ± 8.3 days, P=0.008). Infection risk was greater for sarcopenic patients overall (23.7\% vs 12.5\%; P=0.025), and especially those ≥ 65 years (29.6\% vs 8.8\%, P=0.005). Most (90\%) inpatient rehabilitation care was in patients ≥ 65 years. Inpatient rehabilitation was more common in sarcopenic patients overall (14.3\% vs 5.6\%; P=0.024) and those ≥ 65 years (24.1\% vs 10.7\%, P=0.06). In a multivariate model in patients ≥ 65 years, sarcopenia was an independent predictor of both infection (odds ratio (OR) 4.6, (95\% confidence interval (CI) 1.5, 13.9) P{\textless}0.01) and rehabilitation care (OR 3.1 (95\% CI 1.04, 9.4) P{\textless}0.04).
CONCLUSION: Sarcopenia predicts postoperative infections, inpatient rehabilitation care and consequently a longer LOS.},
	language = {eng},
	number = {6},
	journal = {British Journal of Cancer},
	author = {Lieffers, J. R. and Bathe, O. F. and Fassbender, K. and Winget, M. and Baracos, V. E.},
	month = sep,
	year = {2012},
	pmid = {22871883},
	pmcid = {PMC3464761},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Length of Stay, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Neoplasm Staging, Risk Factors, Adult, Predictive Value of Tests, Canada, Colectomy, Survival Analysis, Comorbidity, Postoperative Complications, Logistic Models, Multivariate Analysis, Odds Ratio, Patient Readmission, Surgical Wound Infection},
	pages = {931--936},
	file = {Lieffers et al_2012_Sarcopenia is associated with postoperative infection and delayed recovery from.pdf:/Users/jcsal/Zotero/storage/K67862EQ/Lieffers et al_2012_Sarcopenia is associated with postoperative infection and delayed recovery from.pdf:application/pdf},
}

@article{james516,
	title = {Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus ({ACT} {II}): a randomised, phase 3, open-label, 2 × 2 factorial trial},
	volume = {14},
	issn = {1474-5488},
	shorttitle = {Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus ({ACT} {II})},
	doi = {10.1016/S1470-2045(13)70086-X},
	abstract = {BACKGROUND: Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50\%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival.
METHODS: In this 2 × 2 factorial trial, we enrolled patients with histologically confirmed squamous-cell carcinoma of the anus without metastatic disease from 59 centres in the UK. Patients were randomly assigned to one of four groups, to receive either mitomycin (12 mg/m(2) on day 1) or cisplatin (60 mg/m(2) on days 1 and 29), with fluorouracil (1000 mg/m(2) per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions); with or without two courses of maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14). The random allocation was generated by computer and patients assigned by telephone. Randomisation was done by minimisation and stratified by tumour site, T and N stage, sex, age, and renal function. Neither patients nor investigators were masked to assignment. Primary endpoints were complete response at 26 weeks and acute toxic effects (for chemoradiation), and progression-free survival (for maintenance). The primary analyses were done by intention to treat. This study is registered at controlled-trials.com, number 26715889.
FINDINGS: We enrolled 940 patients: 472 were assigned to mitomycin, of whom 246 were assigned to no maintenance, 226 to maintenance; 468 were assigned to cisplatin, of whom 246 were assigned to no maintenance, 222 to maintenance. Median follow-up was 5.1 years (IQR 3.9-6.9). 391 of 432 (90.5\%) patients in the mitomycin group versus 386 of 431 (89.6\%) in the cisplatin group had a complete response at 26 weeks (difference -0.9\%, 95\% CI -4.9 to 3.1; p=0.64). Overall, toxic effects were similar in each group (334/472 [71\%] for mitomycin vs 337/468 [72\%] for cisplatin). The most common grade 3-4 toxic effects were skin (228/472 [48\%] vs 222/468 [47\%]), pain (122/472 [26\%] vs 135/468 [29\%]), haematological (124/472 [26\%] vs 73/468 [16\%]), and gastrointestinal (75/472 [16\%] vs 85/468 [18\%]). 3-year progression-free survival was 74\% (95\% CI 69-77; maintenance) versus 73\% (95\% CI 68-77; no maintenance; hazard ratio 0.95, 95\% CI 0.75-1.21; p=0.70).
INTERPRETATION: The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fractions should remain standard practice in the UK.
FUNDING: Cancer Research UK.},
	language = {eng},
	number = {6},
	journal = {The Lancet. Oncology},
	author = {James, Roger D. and Glynne-Jones, Robert and Meadows, Helen M. and Cunningham, David and Myint, Arthur Sun and Saunders, Mark P. and Maughan, Timothy and McDonald, Alec and Essapen, Sharadah and Leslie, Martin and Falk, Stephen and Wilson, Charles and Gollins, Simon and Begum, Rubina and Ledermann, Jonathan and Kadalayil, Latha and Sebag-Montefiore, David},
	month = may,
	year = {2013},
	pmid = {23578724},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, Time Factors, Drug Administration Schedule, Fluorouracil, Carcinoma, Squamous Cell, Cisplatin, Disease-Free Survival, Dose Fractionation, Radiation, Neoplasm Recurrence, Local, Chemoradiotherapy, Intention to Treat Analysis, United Kingdom, Anus Neoplasms, Mitomycin},
	pages = {516--524},
	file = {James et al_2013_Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy.pdf:/Users/jcsal/Zotero/storage/JL7GB5PV/James et al_2013_Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy.pdf:application/pdf},
}

@article{nigro1826,
	title = {Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal},
	volume = {51},
	issn = {0008-543X},
	url = {https://pubmed.ncbi.nlm.nih.gov/6831348/},
	doi = {10.1002/1097-0142(19830515)51:10<1826::aid-cncr2820511012>3.0.co;2-l},
	abstract = {Twenty-eight patients with squamous cell carcinoma of the anal canal were treated by preoperative radiation therapy and chemotherapy. The radiation therapy was given for 3000 rad (30 Gy) at 200 rad per day, 5 days a week, to the primary tumor with margin and to the pelvic and inguinal lymph nodes. C …},
	language = {en},
	number = {10},
	urldate = {2023-02-14},
	journal = {Cancer},
	author = {Nigro, Nd and Seydel, Hg and Considine, B and Vaitkevicius, Vk and Leichman, L and Kinzie, Jj},
	month = may,
	year = {1983},
	pmid = {6831348},
	note = {Publisher: Cancer},
	pages = {1826},
	file = {Snapshot:/Users/jcsal/Zotero/storage/EQP65KFK/6831348.html:text/html},
}

@article{ma307,
	title = {A retrospective study evaluating single-unit red blood cell transfusions in reducing allogeneic blood exposure},
	volume = {15},
	issn = {0958-7578},
	doi = {10.1111/j.0958-7578.2005.00592.x},
	abstract = {Although guidelines recommend the use of single-unit red blood cell (RBC) transfusions to minimize allogeneic blood exposure, clinical practice remains dominated by two-unit transfusions. This study assesses the potential impact of a single-unit transfusion policy on reducing RBC utilization. We performed a retrospective analysis of adult patients admitted to a tertiary care hospital who received one or two RBC units. In subjects transfused two units, the effect of one unit was estimated by dividing the change in haemoglobin by 2. The proportion of patients reaching a haemoglobin threshold of 70, 75, 80, 85 and 90 g L(-1) with a single RBC unit was estimated. Of 302 included patients, only 65 received a one-unit transfusion. Based on thresholds of {\textgreater} or = 90, {\textgreater} or = 80 and {\textgreater} or = 70 g L(-1), a single-unit transfusion would be sufficient in 42.0\% (RRR = 0.54), 79.6\% (RRR = 0.23) and 98.0\% (RRR = 0.02) of cases, respectively. This corresponds to 0.21, 0.57 and 0.82 mean RBC units saved per patient. In the orthopaedic subpopulation, the mean RBC units saved are 0.53, 0.88 and 1.00 for the same haemoglobin targets. Adopting a policy of transfusing RBC in single-unit aliquots could significantly improve RBC utilization and decrease patient exposure to allogeneic blood.},
	language = {eng},
	number = {4},
	journal = {Transfusion Medicine (Oxford, England)},
	author = {Ma, M. and Eckert, K. and Ralley, F. and Chin-Yee, I.},
	month = aug,
	year = {2005},
	pmid = {16101808},
	keywords = {Humans, Retrospective Studies, Guideline Adherence, Hemoglobins, Erythrocyte Transfusion, Orthopedic Procedures, Medical Audit, Health Care Rationing},
	pages = {307--312},
}

@article{sadana116,
	title = {Promoting {High}-{Value} {Practice} by {Reducing} {Unnecessary} {Transfusions} {With} a {Patient} {Blood} {Management} {Program}},
	volume = {178},
	issn = {2168-6114},
	doi = {10.1001/jamainternmed.2017.6369},
	abstract = {Although blood transfusion is a lifesaving therapy for some patients, transfusion has been named 1 of the top 5 overused procedures in US hospitals. As unnecessary transfusions only increase risk and cost without providing benefit, improving transfusion practice is an effective way of promoting high-value care. Most high-quality clinical trials supporting a restrictive transfusion strategy have been published in the past 5 to 10 years, so the value of a successful patient blood management program has only recently been recognized. We review the most recent transfusion practice guidelines and the evidence supporting these guidelines. We also discuss several medical societies' Choosing Wisely campaigns to reduce or eliminate overuse of transfusions. A blueprint is presented for developing a patient blood management program, which includes discussion of specific methods for optimizing transfusion practice.},
	language = {eng},
	number = {1},
	journal = {JAMA internal medicine},
	author = {Sadana, Divyajot and Pratzer, Ariella and Scher, Lauren J. and Saag, Harry S. and Adler, Nicole and Volpicelli, Frank M. and Auron, Moises and Frank, Steven M.},
	month = jan,
	year = {2018},
	pmid = {29159367},
	keywords = {Humans, United States, Unnecessary Procedures, Blood Transfusion, Medical Audit, Medical Overuse, Program Development},
	pages = {116--122},
}

@article{shih2841,
	title = {Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies},
	volume = {58},
	issn = {1537-2995},
	doi = {10.1111/trf.14952},
	abstract = {BACKGROUND: Recent recommendations indicate that one red blood cell (RBC) unit should be transfused at a time, with reassessment after each transfusion, which may be extrapolated from literature supporting restrictive transfusion triggers rather than specific evidence. Therefore, two systematic reviews were performed to identify the following: 1) RBC transfusion guidelines and review articles to determine if single- or multiple-unit transfusion strategies are recommended and 2) studies comparing strategies for evidence of benefit.
STUDY DESIGN AND METHODS: MEDLINE, EMBASE, CINAHL, Web of Science, National Guideline Clearinghouse, and Trip Database were searched (inception to June 2017). For the first review, the proportion of articles with single/multiple-unit recommendations was assessed and stratified by article type. For the second review, the primary outcome was RBC use. Secondary outcomes included proportion of transfusion episodes using a single-unit strategy, length of stay, and mortality.
RESULTS: The first review identified 145 articles for analysis, with 51 transfusion guidelines. Only 14 guidelines (27\%) made a recommendation, with most (93\%) recommending single-unit transfusions. The second review identified seven cohort studies comparing preimplementation and postimplementation of a policy encouraging single-unit transfusion strategies. Meta-analysis could not be performed for outcomes given inconsistencies in reporting. RBC use decreased by approximately 10 to 41\% across studies.
CONCLUSION: Transfusion guidelines lack recommendations to transfuse to a single-unit strategy. Mostly retrospective cohort studies (six of seven) are inconsistent in outcome reporting but suggest improved RBC use. Further high-quality studies could identify the benefits of a single-unit transfusion strategy, determine the applicability to different clinical settings, and inform future practice guidelines.},
	language = {eng},
	number = {12},
	journal = {Transfusion},
	author = {Shih, Andrew W. and Liu, Aixin and Elsharawi, Radwa and Crowther, Mark A. and Cook, Richard J. and Heddle, Nancy M.},
	month = dec,
	year = {2018},
	pmid = {30345619},
	keywords = {Humans, Female, Male, Practice Guidelines as Topic, Erythrocyte Transfusion, SingleUnit},
	pages = {2841--2860},
}

@article{amarasinghe580806,
	title = {A {Deep} {Learning} {Model} to {Automate} {Skeletal} {Muscle} {Area} {Measurement} on {Computed} {Tomography} {Images}},
	volume = {11},
	issn = {2234-943X},
	doi = {10.3389/fonc.2021.580806},
	abstract = {BACKGROUND: Muscle wasting (Sarcopenia) is associated with poor outcomes in cancer patients. Early identification of sarcopenia can facilitate nutritional and exercise intervention. Cross-sectional skeletal muscle (SM) area at the third lumbar vertebra (L3) slice of a computed tomography (CT) image is increasingly used to assess body composition and calculate SM index (SMI), a validated surrogate marker for sarcopenia in cancer. Manual segmentation of SM requires multiple steps, which limits use in routine clinical practice. This project aims to develop an automatic method to segment L3 muscle in CT scans.
METHODS: Attenuation correction CTs from full body PET-CT scans from patients enrolled in two prospective trials were used. The training set consisted of 66 non-small cell lung cancer (NSCLC) patients who underwent curative intent radiotherapy. An additional 42 NSCLC patients prescribed curative intent chemo-radiotherapy from a second trial were used for testing. Each patient had multiple CT scans taken at different time points prior to and post- treatment (147 CTs in the training and validation set and 116 CTs in the independent testing set). Skeletal muscle at L3 vertebra was manually segmented by two observers, according to the Alberta protocol to serve as ground truth labels. This included 40 images segmented by both observers to measure inter-observer variation. An ensemble of 2.5D fully convolutional neural networks (U-Nets) was used to perform the segmentation. The final layer of U-Net produced the binary classification of the pixels into muscle and non-muscle area. The model performance was calculated using Dice score and absolute percentage error (APE) in skeletal muscle area between manual and automated contours.
RESULTS: We trained five 2.5D U-Nets using 5-fold cross validation and used them to predict the contours in the testing set. The model achieved a mean Dice score of 0.92 and an APE of 3.1\% on the independent testing set. This was similar to inter-observer variation of 0.96 and 2.9\% for mean Dice and APE respectively. We further quantified the performance of sarcopenia classification using computer generated skeletal muscle area. To meet a clinical diagnosis of sarcopenia based on Alberta protocol the model achieved a sensitivity of 84\% and a specificity of 95\%.
CONCLUSIONS: This work demonstrates an automated method for accurate and reproducible segmentation of skeletal muscle area at L3. This is an efficient tool for large scale or routine computation of skeletal muscle area in cancer patients which may have applications on low quality CTs acquired as part of PET/CT studies for staging and surveillance of patients with cancer.},
	language = {eng},
	journal = {Frontiers in Oncology},
	author = {Amarasinghe, Kaushalya C. and Lopes, Jamie and Beraldo, Julian and Kiss, Nicole and Bucknell, Nicholas and Everitt, Sarah and Jackson, Price and Litchfield, Cassandra and Denehy, Linda and Blyth, Benjamin J. and Siva, Shankar and MacManus, Michael and Ball, David and Li, Jason and Hardcastle, Nicholas},
	year = {2021},
	pmid = {34026597},
	pmcid = {PMC8138051},
	keywords = {sarcopenia, skeletal muscle, ML, lung cancer, convolutional neural networks, deep learning, image segmentation},
	pages = {580806},
	file = {Amarasinghe et al_2021_A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed.pdf:/Users/jcsal/Zotero/storage/2M6ERGTI/Amarasinghe et al_2021_A Deep Learning Model to Automate Skeletal Muscle Area Measurement on Computed.pdf:application/pdf},
}

@article{park8451,
	title = {Skeletal muscle gauge as a prognostic factor in patients with colorectal cancer},
	volume = {10},
	issn = {2045-7634},
	doi = {10.1002/cam4.4354},
	abstract = {BACKGROUND: Although skeletal muscle index (SMI) and radiodensity (SMD) are well-known prognostic factors, the clinical impact of the integrated measure, known as skeletal muscle gauge (SMG), has been limited in patients with colorectal cancer (CRC).
PATIENTS AND METHODS: A total of 727 and 268 patients with CRC at two tertiary centers were included and allocated into the training and test sets, respectively. Preoperative slice computed tomography images of the third lumbar area were evaluated for SMI and SMD. SMG was calculated as SMI × SMD and expressed as an arbitrary unit (AU). The optimal cutoff SMG value was determined to maximize the overall survival (OS) difference between the groups with respect to sex in the training set. The multivariate Cox proportional hazard model evaluated the association of its clinical significance.
RESULTS: With regard to SMG, 1640 and 1523 AU were identified as cutoff values for males and females, respectively. The patients with low SMG values showed significantly worse 5-year OS than those with high SMG values in the two datasets (both p {\textless} 0.001). In the multivariate analysis, low SMG was identified as an independent poor prognostic factor of OS in the training set (hazard ratio 2.18, 95\% confidence interval 1.43-3.32, p {\textless} 0.001) and test set (hazard ratio 1.79, 95\% confidence interval 1.07-3.00, p = 0.025), whereas SMI and SMD were not.
CONCLUSION: SMG acts synergistically to improve its prognostic predictive accuracy as compared with SMI or SMD alone in patients with CRC. Additional research is warranted to define its significance in different ethnic groups.},
	language = {eng},
	number = {23},
	journal = {Cancer Medicine},
	author = {Park, In Kyu and Yang, Song Soo and Chung, Eric and Cho, Eun-Suk and Lee, Hye Sun and Shin, Su-Jin and Im, Yeong Cheol and Park, Eun Jung and Baik, Seung Hyuk and Lee, Kang Young and Kang, Jeonghyun},
	month = dec,
	year = {2021},
	pmid = {34643052},
	pmcid = {PMC8633260},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Prognosis, Adult, sarcopenia, Survival Analysis, myosteatosis, colorectal cancer, skeletal muscle gauge, skeletal muscle index, skeletal muscle radiodensity},
	pages = {8451--8461},
	file = {Park et al_2021_Skeletal muscle gauge as a prognostic factor in patients with colorectal cancer.pdf:/Users/jcsal/Zotero/storage/L5HMWIGS/Park et al_2021_Skeletal muscle gauge as a prognostic factor in patients with colorectal cancer.pdf:application/pdf},
}

@article{prado629,
	title = {Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study},
	volume = {9},
	issn = {1474-5488},
	shorttitle = {Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts},
	doi = {10.1016/S1470-2045(08)70153-0},
	abstract = {BACKGROUND: Emerging evidence on body composition suggests that sarcopenic obesity (obesity with depleted muscle mass) might be predictive of morbidity and mortality in non-malignant disease and also of toxicity to chemotherapy. We aimed to assess the prevalence and clinical implications of sarcopenic obesity in patients with cancer.
METHODS: Between Jan 13, 2004, and Jan 19, 2007, 2115 patients with solid tumours of the respiratory or gastrointestinal tract from a cancer treatment centre serving northern Alberta, Canada, were identified. Available lumbar CT images of the obese patients were analysed for total skeletal muscle cross-sectional area; these values were also used to estimate total body fat-free mass (FFM).
FINDINGS: Of the 2115 patients initially identified, 325 (15\%) were classified as obese (body-mass index [BMI] {\textgreater} or =30). Of these obese patients, 250 had CT images that met the criteria for analysis. The remaining 75 patients were recorded as without assessable scans. Obese patients had a wide range of muscle mass. Sex-specific cut-offs that defined a significant association between low muscle mass with mortality were ascertained by optimum stratification analysis: 38 (15\%) of 250 patients who had assessable CT images that met the criteria for analysis were below these cut-offs and were classified as having sarcopenia. Sarcopenic obesity was associated with poorer functional status compared with obese patients who did not have sarcopenia (p=0.009), and was an independent predictor of survival (hazard ratio [HR] 4.2 [95\% CI 2.4-7.2], p{\textless}0.0001). Estimated FFM showed a poor association with body-surface area (r(2)=0.37). Assuming that FFM represents the volume of distribution of many cytotoxic chemotherapy drugs, we estimated that individual variation in FFM could account for up to three-times variation in effective volume of distribution for chemotherapy administered per unit body-surface area, in this population.
INTERPRETATION: This study provides evidence of the great variability of body composition in patients with cancer and links body composition, especially sarcopenic obesity, to clinical implications such as functional status, survival, and potentially, chemotherapy toxicity.},
	language = {eng},
	number = {7},
	journal = {The Lancet. Oncology},
	author = {Prado, Carla M. M. and Lieffers, Jessica R. and McCargar, Linda J. and Reiman, Tony and Sawyer, Michael B. and Martin, Lisa and Baracos, Vickie E.},
	month = jul,
	year = {2008},
	pmid = {18539529},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Obesity, Prevalence, Lung Neoplasms, Cohort Studies, Aged, 80 and over, Adult, Muscular Diseases, Alberta},
	pages = {629--635},
	file = {Prado et al_2008_Prevalence and clinical implications of sarcopenic obesity in patients with.pdf:/Users/jcsal/Zotero/storage/QWHIUV2S/Prado et al_2008_Prevalence and clinical implications of sarcopenic obesity in patients with.pdf:application/pdf},
}

@article{colcord3040,
	title = {Preoperative {Muscle} {Strength} {Is} a {Predictor} of {Outcomes} {After} {Esophagectomy}},
	volume = {25},
	issn = {1873-4626},
	doi = {10.1007/s11605-021-05183-y},
	abstract = {BACKGROUND: Sarcopenia, loss of muscle mass and strength, has been associated with more frequent complications after esophagectomy. This study compared hand-grip strength, muscle mass, and intramuscular adipose tissue as predictors of postoperative outcomes and mortality after esophagectomy.
METHODS: Minimally invasive esophagectomy was performed on 175 patients with esophageal cancer. Skeletal muscle index and skeletal muscle density were derived from preoperative CTs. Hand-grip strength was measured using dynamometer. Univariate and multivariable analyses were performed.
RESULTS: Preoperative hand-grip strength was normal in 91 (52\%), intermediate in 43 (25\%), and weak in 41 (23\%) patients. Hand-grip strength was significantly correlated with both skeletal muscle index and skeletal muscle density. Postoperative pneumonia occurred in 8/41 (20\%) patients with weak strength compared to 4/91 (4\%) with normal strength (p = 0.006; Cochran-Armitage Test). Prolonged postoperative ventilation occurred in 11/41 (27\%) patients with weak strength compared to 11/91 (12\%) with normal strength (p = 0.036). Median length of stay was 9 days in patients with weak strength compared to 7 days for those with normal strength (p = 0.005; Kruskal-Wallis Test). Discharge to non-home location occurred in 15/41 (37\%) with weak strength compared to 8/91 (9\%) with normal strength (p {\textless} 0.001). Postoperative mortality at 90 days was 4/41 (10\%) with weak strength compared with no mortalities (0/91) in the normal strength group (p = 0.004). Mortality at 1 year was 18/39 (46\%) in patients with weak strength compared to 6/81 (7\%) with normal strength, among 158 patients with 1-year follow-up (p {\textless} 0.001).
CONCLUSIONS: Preoperative hand-grip strength was found to be a powerful predictor of postoperative pneumonia, length of stay, discharge to non-home location, and mortality after esophagectomy.},
	language = {eng},
	number = {12},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Colcord, Madison E. and Benbow, Jennifer H. and Trufan, Sally and Gower, Nicole L. and Byrne, Meredith E. and Shea, Reilly E. and Watson, Michael D. and Hill, Joshua S. and Squires, M. Hart and Salo, Jonathan C.},
	month = dec,
	year = {2021},
	pmid = {34729696},
	keywords = {Humans, Muscle, Skeletal, Sarcopenia, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Hand Strength, Hand-grip strength},
	pages = {3040--3048},
}

@article{gomez-perez419,
	title = {Tutorial: {A} {Step}-by-{Step} {Guide} ({Version} 2.0) for {Measuring} {Abdominal} {Circumference} and {Skeletal} {Muscle} {From} a {Single} {Cross}-{Sectional} {Computed}-{Tomography} {Image} {Using} the {National} {Institutes} of {Health} {ImageJ}},
	volume = {44},
	issn = {1941-2444},
	shorttitle = {Tutorial},
	doi = {10.1002/jpen.1721},
	abstract = {BACKGROUND: In patients with acute and chronic illness, depleted skeletal muscle (SM) mass, also referred to as sarcopenia, is a condition associated with an underlying disease process and adverse outcomes. Because of software upgrades and errors related to installation, clarifications and a revised tutorial were needed for calculating SM cross-sectional area (CSA) using the National Institutes of Health (NIH) ImageJ.
METHODS: A pilot study was conducted to determine the usability of the tutorial version 2.0. Eight adults (≥18 years of age) who had no previous experience or background in body composition or computed-tomography imaging and owned a personal laptop computer (Mac or PC) were included in the pilot study. Participants were tested on the completion of 4 tasks: (1) installation of software, (2) updating the software, (3) following revised tutorial (version 2.0), and (4) transferring information from the software to a spreadsheet for calculation of SM CSA.
RESULTS: All participants completed the tutorial and all assigned tasks, 4/4 (100\%). However, 38\% (3/8) of the participants made errors while cutting and pasting values from the ImageJ results box to a spreadsheet for calculating SM CSA.
CONCLUSION: The tutorial version 2.0 was easy to follow and provided sufficient information for adults to install, update, and perform the steps of body composition for the NIH ImageJ software without major issues. Care should be taken when cutting and pasting results from the software as well as when using the Microsoft Excel spreadsheet for calculating SM CSA.},
	language = {eng},
	number = {3},
	journal = {JPEN. Journal of parenteral and enteral nutrition},
	author = {Gomez-Perez, Sandra and McKeever, Liam and Sheean, Patricia},
	month = mar,
	year = {2020},
	pmid = {31617218},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Pilot Projects, Sarcopenia, Adult, body composition, United States, computed tomography, skeletal muscle, National Institutes of Health (U.S.), NIH ImageJ},
	pages = {419--424},
}

@article{law205,
	title = {Resistance {Exercise} to {Prevent} and {Manage} {Sarcopenia} and {Dynapenia}},
	volume = {36},
	issn = {0198-8794},
	doi = {10.1891/0198-8794.36.205},
	abstract = {For well over twenty centuries the muscle wasting (sarcopenia) and weakness (dynapenia) that occurs with old age has been a predominant concern of mankind. Exercise has long been suggested as a treatment to combat sarcopenia and dynapenia, as it exerts effects on both the nervous and muscular systems that are critical to positive physiological and functional adaptations (e.g., enhanced muscle strength). For more than two decades scientists have recognized the profound role that progressive resistance exercise training can have on increasing muscle strength, muscle size and functional capacity in older adults. In this review article we discuss how resistance exercise training can be used in the management and prevention of sarcopenia and dynapenia. We first provide an overview of the evidence for this notion and highlight certain critical factors- namely exercise intensity, volume and progression- that are key to optimizing the resistance exercise prescription. We then highlight how many, if not most, of the commonly prescribed exercise programs for seniors are not the 'best practices', and subsequently present easy-to-read guidelines for a well-rounded resistance exercise training program designed for the management and prevention of sarcopenia and dynapenia, including example training programs for the beginner through the advanced senior resistance exerciser. These guidelines have been written for the academician as well as the student and health care provider across a variety of disciplines, including those in the long term care industry, such as wellness instructors or activity directors.},
	language = {eng},
	number = {1},
	journal = {Annual Review of Gerontology \& Geriatrics},
	author = {Law, Timothy D. and Clark, Leatha A. and Clark, Brian C.},
	year = {2016},
	pmid = {27134329},
	pmcid = {PMC4849483},
	keywords = {Sarcopenia, Muscle, Aging, Exercise, Dynapenia, Strength, Weakness},
	pages = {205--228},
	file = {Law et al_2016_Resistance Exercise to Prevent and Manage Sarcopenia and Dynapenia.pdf:/Users/jcsal/Zotero/storage/5KKIZ9HE/Law et al_2016_Resistance Exercise to Prevent and Manage Sarcopenia and Dynapenia.pdf:application/pdf},
}

@article{sheetz716,
	title = {Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer},
	volume = {26},
	issn = {1442-2050},
	doi = {10.1111/dote.12020},
	abstract = {Preoperative risk assessment, particularly for patient frailty, remains largely subjective. This study evaluated the relationship between core muscle size and patient outcomes following esophagectomy for malignancy. Using preoperative computed tomography scans in 230 subjects who had undergone transhiatal esophagectomy for cancer between 2001 and 2010, lean psoas area (LPA), measured at the fourth lumbar vertebra, was determined. Cox proportional hazards regression was employed to analyze overall survival (OS) and disease-free survival (DFS) adjusted for age, gender, and stage, and the Akaike information criterion was used to determine each covariate contribution to OS and DFS. Univariate analysis demonstrated that increasing LPA correlated with both OS (P = 0.017) and DFS (P = 0.038). In multivariate analysis controlling for patient and tumor characteristics, LPA correlated with OS and DFS in patients who had not received neoadjuvant treatment (n = 64), with higher LPA associated with improved OS and DFS. Moreover, LPA was of equivalent, or slightly higher importance than pathologic stage. These measures were not predictive among patients (n = 166) receiving neoadjuvant chemoradiation. Core muscle size appears to be an independent predictor of both OS and DFS, as significant as tumor stage, in patients following transhiatal esophagectomy. Changes in muscle mass related to preoperative treatment may confound this effect. Assessment of core muscle size may provide an additional objective measure for risk stratification prior to undergoing esophagectomy.},
	language = {eng},
	number = {7},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Sheetz, K. H. and Zhao, L. and Holcombe, S. A. and Wang, S. C. and Reddy, R. M. and Lin, J. and Orringer, M. B. and Chang, A. C.},
	year = {2013},
	pmid = {23350746},
	pmcid = {PMC4171877},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Risk Factors, Proportional Hazards Models, Prognosis, Organ Size, Adenocarcinoma, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, Multivariate Analysis, esophageal cancer, Psoas Muscles, esophageal surgery, risk stratification},
	pages = {716--722},
	file = {Sheetz et al_2013_Decreased core muscle size is associated with worse patient survival following.pdf:/Users/jcsal/Zotero/storage/P4DQBXSP/Sheetz et al_2013_Decreased core muscle size is associated with worse patient survival following.pdf:application/pdf},
}

@article{dengdoz100,
	title = {It is time to consider incorporating sarcopenia assessment in the management of esophageal cancer},
	volume = {32},
	issn = {1442-2050},
	doi = {10.1093/dote/doz100},
	language = {eng},
	number = {12},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Deng, Han-Yu and Jiang, Rui},
	month = dec,
	year = {2019},
	pmid = {31907511},
	keywords = {Humans, Sarcopenia, Prognosis, sarcopenia, Esophageal Neoplasms, Esophagectomy, Esophageal Squamous Cell Carcinoma, esophageal cancer},
	pages = {doz100},
}

@article{boshier,
	title = {Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis},
	volume = {31},
	issn = {1442-2050},
	shorttitle = {Assessment of body composition and sarcopenia in patients with esophageal cancer},
	doi = {10.1093/dote/doy047},
	abstract = {There has recently been increased interest in the assessment of body composition in patients with esophageal cancer for the purpose of nutritional evaluation and prognostication. This systematic review and meta-analysis intends to summarize and critically evaluate the current literature concerning the assessment of body composition in patients with esophageal cancer and to assess its potential implication upon early and late outcomes. A systematic literature search (up to August, 2017) was conducted for studies describing the assessment of body composition in patients with esophageal and gastroesophageal junctional cancer. Meta-analysis of postoperative outcomes including long-term survival was performed using random effects models. Twenty-nine studies reported the assessment of body composition in 3193 patients. Methods used to assess body composition in patients with esophageal cancer included computerized tomography (n = 18 studies), bioelectrical impedance analysis (n = 10), and dual-energy X-ray absorptiometry (n = 1). Significant variability was observed in regard to study design and the criteria used to define individual parameters of body composition. Sarcopenic patients had a higher incidence of postoperative pulmonary complications (7 studies, OR 2.03, 95\% CI 1.32-3.11, P = 0.001) after esophagectomy. Meta-analysis of six studies presenting long-term outcomes after esophagectomy identified significantly worse survival in patients who were sarcopenic (HR 1.70, 95\% CI 1.33- 2.17, P {\textless} 0.0001). The assessment of body composition has the potential to become a clinically useful tool that could support decision-making in patients with esophageal cancer. Current evidence is however weakened by inconsistencies in methods of assessing and reporting body composition in this patient group.},
	language = {eng},
	number = {8},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Boshier, P. R. and Heneghan, R. and Markar, S. R. and Baracos, V. E. and Low, D. E.},
	month = aug,
	year = {2018},
	pmid = {29846548},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Female, Male, Sarcopenia, Survival Rate, Nutrition Assessment, Esophageal Neoplasms, Esophagectomy, Postoperative Complications},
	file = {Boshier et al_2018_Assessment of body composition and sarcopenia in patients with esophageal cancer.pdf:/Users/jcsal/Zotero/storage/3SV8VBHV/Boshier et al_2018_Assessment of body composition and sarcopenia in patients with esophageal cancer.pdf:application/pdf},
}

@article{ganjuE420,
	title = {Skeletal {Muscle} {Gauge} {Measured} at the {C3} {Vertebral} {Body} {Predicts} for {Outcomes} in {Men} with {P16}-{Positive} {Oropharynx} {Cancer}},
	volume = {105},
	issn = {0360-3016},
	url = {https://www.redjournal.org/article/S0360-3016(19)32363-6/fulltext},
	doi = {10.1016/j.ijrobp.2019.06.1528},
	language = {English},
	number = {1},
	urldate = {2023-03-12},
	journal = {International Journal of Radiation Oncology, Biology, Physics},
	author = {Ganju, R. G. and Morse, R. and Tennapel, M. J. and Hoover, A. and Kakarala, K. and Shnayder, L. and Bur, A. and Lominska, C. E.},
	month = sep,
	year = {2019},
	note = {Publisher: Elsevier},
	keywords = {SMG},
	pages = {E420},
	file = {Ganju et al_2019_Skeletal Muscle Gauge Measured at the C3 Vertebral Body Predicts for Outcomes.pdf:/Users/jcsal/Zotero/storage/YD284HT8/Ganju et al_2019_Skeletal Muscle Gauge Measured at the C3 Vertebral Body Predicts for Outcomes.pdf:application/pdf},
}

@article{huang110642,
	title = {Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer},
	volume = {72},
	issn = {0899-9007},
	url = {https://www.sciencedirect.com/science/article/pii/S0899900719302254},
	doi = {10.1016/j.nut.2019.110642},
	abstract = {Objectives
The prognostic role of sarcopenia or myosteatosis is controversial in advanced-stage epithelial ovarian cancer (EOC). The phase of computed tomography (CT) could influence muscle measurement and confound its association with outcomes. This study evaluated the prognostic value of muscle measurement in patients with stage III EOC using a standardized phase of computed tomography.
Methods
Pretreatment CT images of 147 patients with stage III EOC were analyzed. All CT images were contrast-enhanced and acquired according to the standardized protocol. Skeletal muscle index (SMI) and radiodensity (SMD) were measured using CT images at the level of the third lumbar vertebra. The skeletal muscle gauge (SMG) was calculated by multiplying SMI and SMD. Harrell's concordance index (C-index) and time-dependent receiver operating characteristic curves were used to measure the predictive value of the models.
Results
The median follow-up period was 37.5 mo. SMI, SMD, and SMG were independently associated with overall survival when adjusted for clinical variables. Adding SMG to the model including stage, residual tumor, and malignant ascites significantly improved C-indices (0.704 vs. 0.629; P {\textless} 0.001). Models including SMG had a superior C-index compared with models including SMI and SMD (0.704 vs. 0.668; P = 0.01). The SMG model achieved the highest area under the curve for 5-year overall survival prediction (0.619 for clinical model, 0.702 for SMI model, and 0.710 for SMG model).
Conclusions
Muscle measurements obtained from a standardized phase of CT images were associated with survival in advanced-stage EOC. The integration of SMI and SMD into SMG may improve prognostication and unify findings in future studies.},
	language = {en},
	urldate = {2023-03-12},
	journal = {Nutrition},
	author = {Huang, Chueh-Yi and Sun, Fang-Ju and Lee, Jie},
	month = apr,
	year = {2020},
	keywords = {Sarcopenia, Body composition, Myosteatosis, Survival, Skeletal muscle, Computed tomography, Ovarian cancer, SMD},
	pages = {110642},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/99PLZBVJ/S0899900719302254.html:text/html},
}

@article{weinberg278,
	title = {Beyond sarcopenia: {Characterization} and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population},
	volume = {24},
	issn = {1524-4741},
	shorttitle = {Beyond sarcopenia},
	doi = {10.1111/tbj.12952},
	abstract = {Skeletal muscle loss, commonly known as sarcopenia, is highly prevalent and prognostic of adverse outcomes in oncology. However, there is limited information on adults with early breast cancer and examination of other skeletal muscle indices, despite the potential prognostic importance. This study characterizes and examines age-related changes in body composition of adults with early breast cancer and describes the creation of a novel integrated muscle measure. Female patients diagnosed with stage I-III breast cancer with abdominal computerized tomography (CT) scans within 12 weeks from diagnosis were identified from local tumor registry (N = 241). Skeletal muscle index (muscle area per height [cm2 /m2 ]), skeletal muscle density, and subcutaneous and visceral adipose tissue areas, were determined from CT L3 lumbar segments. We calculated a novel integrated skeletal measure, skeletal muscle gauge, which combines skeletal muscle index and density (SMI × SMD). 241 patients were identified with available CT imaging. Median age 52 years and range of 23-87. Skeletal muscle index and density significantly decreased with age. Using literature based cut-points, older adults (≥65 years) had significantly higher proportions of sarcopenia (63 vs 28\%) and myosteatosis (90 vs 11\%) compared to younger adults ({\textless}50 years). Body mass index was positively correlated with skeletal muscle index and negatively correlated with muscle density. Skeletal muscle gauge correlated better with increasing age (ρ = 0.52) than with either skeletal muscle index (ρ = 0.20) or density (ρ = 0.46). Wide variations and age-related changes in body composition metrics were found using routinely obtained abdominal CT imaging. Skeletal muscle index and density provide independent, complementary information, and the product of the two metrics, skeletal muscle gauge, requires further research to explore its impact on outcomes in women with curable breast cancer.},
	language = {eng},
	number = {3},
	journal = {The Breast Journal},
	author = {Weinberg, Marc S. and Shachar, Shlomit S. and Muss, Hyman B. and Deal, Allison M. and Popuri, Karteek and Yu, Hyeon and Nyrop, Kirsten A. and Alston, Shani M. and Williams, Grant R.},
	month = may,
	year = {2018},
	pmid = {29139618},
	pmcid = {PMC6414810},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Middle Aged, Sarcopenia, Body Mass Index, Aged, 80 and over, Adult, sarcopenia, Breast Neoplasms, Aging, aging, skeletal muscle index, SMG, breast cancer, geriatric oncology},
	pages = {278--284},
	file = {Weinberg et al_2018_Beyond sarcopenia.pdf:/Users/jcsal/Zotero/storage/64KMM7HL/Weinberg et al_2018_Beyond sarcopenia.pdf:application/pdf},
}

@article{polen-de1289,
	title = {Quality is more important than quantity: preoperative sarcopenia is associated with poor survival in advanced ovarian cancer},
	volume = {32},
	issn = {1048-891X},
	shorttitle = {Quality is more important than quantity},
	url = {http://www.scopus.com/inward/record.url?scp=85132152581&partnerID=8YFLogxK},
	doi = {10.1136/ijgc-2022-003387},
	abstract = {Background Sarcopenia is prevalent among older patients with cancer and is associated with poor outcomes. Objective To explore the relationship between muscle mass, quality, and patient age with overall survival after surgery for advanced ovarian cancer. Methods Patients with advanced stage (IIIC/IV) ovarian cancer who underwent primary cytoreductive surgery between January 2006 and July 2016 were included. Body composition measures were calculated from pre-operative CT imaging: skeletal muscle index (skeletal muscle index=skeletal muscle area normalized for height), skeletal muscle density, and skeletal muscle gauge (product of skeletal muscle index and skeletal muscle density). Each measure was transformed to a z-score and evaluated for association with risk of death using Cox proportional hazards models. Recursive partitioning was used to classify patients into homogeneous subgroups considering age and skeletal muscle gauge as predictors of overall survival. Results The study included 429 patients (mean age 64.2 years). Increased age moderately correlated with decreased skeletal muscle gauge (r=−0.45). Decreasing skeletal muscle density and skeletal muscle gauge were significantly associated with increased risk of death; HR (95\% CI) per 1-unit decrease in z-score of 1.24 (1.10 to 1.39) for skeletal muscle density and 1.27 (1.12 to 1.44) for skeletal muscle gauge. Associations were diluted after adjusting for age (1.13 (1.00 to 1.29) skeletal muscle density and 1.14 (0.99 to 1.30) skeletal muscle gauge). Recursive partitioning identified three subgroups: {\textless}60 years old, ≥60 years old with skeletal muscle gauge ≥937.3, and ≥60 years old with skeletal muscle gauge {\textless}937.3; median overall survival was 5.8, 3.3, and 2.3 years, respectively (p{\textless}0.001). Conclusions Skeletal muscle gauge, a novel sarcopenia measure incorporating quantity and quality, was associated with poorer survival in patients with advanced ovarian cancer, particularly among patients older than 60. Expanding our knowledge of how sarcopenia relates to solid tumor outcomes among high-risk patients can modify our treatment approach.},
	number = {10},
	urldate = {2023-03-12},
	journal = {International Journal of Gynecological Cancer},
	author = {Polen-De, Clarissa and Fadadu, Priyal and Weaver, Amy L. and Moynagh, Michael and Takahashi, Naoki and Jatoi, Aminah and LeBrasseur, Nathan K. and McGree, Michaela and Cliby, William and Kumar, Amanika},
	month = jun,
	year = {2022},
	keywords = {SMG},
	pages = {1289--1296},
	annote = {Funding Information:Funding provided to Dr Cliby by the Virgil S. Counsellor MD Professorship in Surgery, Mayo Clinic.Publisher Copyright:© IGCS and ESGO 2022.},
}

@article{chung,
	title = {Automated segmentation of muscle and adipose tissue on {CT} images for human body composition analysis.},
	journal = {SPIE Medical Imaging},
	author = {Chung, Howard and Cobzas, Dana and Lieffers, Jessica and Birdsell, Laura and Baracos, Vickie},
	year = {2009},
	keywords = {ML},
	file = {Chung et al_2009_Automated segmentation of muscle and adipose tissue on CT images for human body.pdf:/Users/jcsal/Zotero/storage/BJRTHKYR/Chung et al. - 2009 - Automated segmentation of muscle and adipose tissu.pdf:application/pdf},
}

@article{leening122,
	title = {Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide},
	volume = {160},
	issn = {1539-3704},
	shorttitle = {Net reclassification improvement},
	doi = {10.7326/M13-1522},
	abstract = {The net reclassification improvement (NRI) is an increasingly popular measure for evaluating improvements in risk predictions. This article details a review of 67 publications in high-impact general clinical journals that considered the NRI. Incomplete reporting of NRI methods, incorrect calculation, and common misinterpretations were found. To aid improved applications of the NRI, the article elaborates on several aspects of the computation and interpretation in various settings. Limitations and controversies are discussed, including the effect of miscalibration of prediction models, the use of the continuous NRI and “clinical NRI,” and the relation with decision analytic measures. A systematic approach toward presenting NRI analysis is proposed: Detail and motivate the methods used for computation of the NRI, use clinically meaningful risk cutoffs for the category-based NRI, report both NRI components, address issues of calibration, and do not interpret the overall NRI as a percentage of the study population reclassified. Promising NRI findings need to be followed with decision analytic or formal cost-effectiveness evaluations.},
	language = {eng},
	number = {2},
	journal = {Annals of Internal Medicine},
	author = {Leening, Maarten J. G. and Vedder, Moniek M. and Witteman, Jacqueline C. M. and Pencina, Michael J. and Steyerberg, Ewout W.},
	month = jan,
	year = {2014},
	pmid = {24592497},
	keywords = {Humans, Risk Assessment, Decision Support Techniques, Models, Statistical, Data Interpretation, Statistical, NRI},
	pages = {122--131},
	file = {Leening et al_2014_Net reclassification improvement.pdf:/Users/jcsal/Zotero/storage/HQW5DUJ5/Leening et al_2014_Net reclassification improvement.pdf:application/pdf},
}

@article{hilden3405,
	title = {A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index},
	volume = {33},
	issn = {1097-0258},
	shorttitle = {A note on the evaluation of novel biomarkers},
	doi = {10.1002/sim.5804},
	abstract = {The 'integrated discrimination improvement' (IDI) and the 'net reclassification index' (NRI) are statistics proposed as measures of the incremental prognostic impact that a new biomarker will have when added to an existing prediction model for a binary outcome. By design, both measures were meant to be intuitively appropriate, and the IDI and NRI formulae do look intuitively plausible. Both have become increasingly popular. We shall argue, however, that their use is not always safe. If IDI and NRI are used to measure gain in prediction performance, then poorly calibrated models may appear advantageous, and in a simulation study, even the model that actually generates the data (and hence is the best possible model) can be improved on without adding measured information. We illustrate these shortcomings in actual cancer data as well as by Monte Carlo simulations. In these examples, we contrast IDI and NRI with the area under ROC and the Brier score. Unlike IDI and NRI, these traditional measures have the characteristic that prognostic performance cannot be accidentally or deliberately inflated.},
	language = {eng},
	number = {19},
	journal = {Statistics in Medicine},
	author = {Hilden, Jørgen and Gerds, Thomas A.},
	month = aug,
	year = {2014},
	pmid = {23553436},
	keywords = {Humans, Female, Antineoplastic Agents, Prognosis, Epirubicin, Regression Analysis, Biomarkers, Models, Statistical, ROC Curve, Computer Simulation, Discriminant Analysis, Breast Neoplasms, NRI, biomarker, Biostatistics, IDI, Monte Carlo Method, prediction, prognostic models, proper scoring rules, Receptors, Estrogen},
	pages = {3405--3414},
}

@article{borkan673,
	title = {Age changes in body composition revealed by computed tomography},
	volume = {38},
	issn = {0022-1422},
	doi = {10.1093/geronj/38.6.673},
	abstract = {Computed tomography scans were taken of 21 middle-aged men (M age 46.3 years) and 20 older men (M age 69.4 years) to measure differences in body composition with age. Overall, the older men weighed 8.2 kg less than the middle-aged men, and this difference was primarily the result of their having less lean tissue. Although fat mass was only slightly less in older men, there were clear distributional differences in fat between the age groups. Total abdomen fat area was similar in both groups, although the subcutaneous portion of the abdomen fat was less in the older men, and they had correspondingly greater intra-abdominal fat. Muscle areas of the leg and arm were significantly less in the older men, as were all lean tissues of the abdomen and chest. Analysis of fat accumulation between muscles of the abdomen and leg indicated fat infiltration into lean tissue in the older men. Causes of this apparent fat redistribution and lean body mass decline with age are presently unknown.},
	language = {eng},
	number = {6},
	journal = {Journal of Gerontology},
	author = {Borkan, G. A. and Hults, D. E. and Gerzof, S. G. and Robbins, A. H. and Silbert, C. K.},
	month = nov,
	year = {1983},
	pmid = {6630900},
	keywords = {Adipose Tissue, Humans, Tomography, X-Ray Computed, Aged, Male, Middle Aged, Adult, Anthropometry, Aging},
	pages = {673--677},
	file = {Borkan et al_1983_Age changes in body composition revealed by computed tomography.pdf:/Users/jcsal/Zotero/storage/4QT49DPB/Borkan et al_1983_Age changes in body composition revealed by computed tomography.pdf:application/pdf},
}

@article{xiao654,
	title = {Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer},
	volume = {9},
	issn = {2190-6009},
	doi = {10.1002/jcsm.12301},
	abstract = {BACKGROUND AND AIM: Co-morbidities and computerized tomography-measured muscle abnormalities are both common in cancer patients and independently adversely influence clinical outcomes. Muscle abnormalities are also evident in other diseases, such as diabetes and obesity. This study examined for the first time the association between co-morbidities and muscle abnormalities in patients diagnosed with colorectal cancer (CRC).
METHODS: This cross-sectional study included 3051 non-metastatic patients with Stages I-III CRC. Muscle abnormalities, measured at diagnosis, were defined as low skeletal muscle mass index (SMI) or low skeletal muscle radiodensity (SMD) quantified using computerized tomography images using optimal stratification. Co-morbidities included in the Charlson index were ascertained. χ2 tests were used to compare the prevalence of co-morbidities by the presence or absence of each muscle abnormality. Logistic regressions were performed to evaluate which co-morbidities predicted muscle abnormalities adjusting for age, sex, body mass index, weight change, cancer stage, cancer site, race/ethnicity, and smoking.
RESULTS: Mean age was 63 years; 50\% of patients were male. The prevalence of low SMI and low SMD were 43.1\% and 30.2\%, respectively. Co-morbidities examined were more prevalent in patients with low SMD than in those with normal SMD, and most remained independent predictors of low SMD after adjustment for covariates. Co-morbidities associated with higher odds of low SMD included myocardial infarction [odds ratio (OR) = 1.77, P = 0.023], congestive heart failure (OR = 3.27, P {\textless} 0.001), peripheral vascular disease (OR = 2.15, P = 0.002), diabetes with or without complications (OR = 1.61, P = 0.008; OR = 1.46, P = 0.003, respectively), and renal disease (OR = 2.21, P {\textless} 0.001). By contrast, only diabetes with complications was associated with lower odds of low SMI (OR = 0.64, P = 0.007).
CONCLUSIONS: Prevalence of muscle abnormalities was high in patients with non-metastatic CRC. Pre-existing co-morbidities were associated with low SMD, suggestive of a potential shared mechanism between fat infiltration into muscle and each of these co-morbidities.},
	language = {eng},
	number = {4},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Xiao, Jingjie and Caan, Bette J. and Weltzien, Erin and Cespedes Feliciano, Elizabeth M. and Kroenke, Candyce H. and Meyerhardt, Jeffrey A. and Baracos, Vickie E. and Kwan, Marilyn L. and Castillo, Adrienne L. and Prado, Carla M.},
	month = aug,
	year = {2018},
	pmid = {29675984},
	pmcid = {PMC6104112},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Neoplasm Staging, Prognosis, Comorbidity, Odds Ratio, California, SMD, Charlson co-morbidities, CT imaging, Muscle abnormalities, Muscular Disorders, Atrophic, Non-metastatic colorectal cancer, Public Health Surveillance, Radiation Tolerance},
	pages = {654--663},
	file = {Xiao et al_2018_Associations of pre-existing co-morbidities with skeletal muscle mass and.pdf:/Users/jcsal/Zotero/storage/TG6DLTPM/Xiao et al_2018_Associations of pre-existing co-morbidities with skeletal muscle mass and.pdf:application/pdf},
}

@article{margadant1654,
	title = {Lower muscle density is associated with major postoperative complications in older patients after surgery for colorectal cancer},
	volume = {42},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2016.05.040},
	abstract = {BACKGROUND: Reduced muscle density is associated with an increased risk of postoperative complications. We examined the prognostic value of muscle density as a predictor of postoperative complications in elderly patients undergoing surgery for colorectal cancer.
METHODS: Patients (≥70 years) who underwent surgery for colorectal cancer between 2006 and 2013 were selected from a prospective single centre database. The Hounsfield Unit Average (HUA or HU/mm2) of the psoas muscles at the level of the third lumbar vertebra was calculated on the scan. High and low muscle density groups were identified based on the lowest gender specific HUAC quartile. Major postoperative complications (Clavien-Dindo (CD) ≥3) within 30 days after surgery were retrospectively documented. Logistic regression analysis was used to identify risk factors for postoperative complications.
RESULTS: A total of 373 patients (median age = 78 years) were included in this study. The mean muscle density score was 24.5 ± 4.3 HU/mm2 for males and 26.3 ± 5.0 HU/mm2 for females. The cut-off point for the lowest gender specific quartile was ≤22.0 HU/mm2 for males and ≤23.5 HU/mm2 for females. After multivariable regression, there was a statistically significant association between muscle density and CD ≥ 3 (OR = 1.84 (95\% CI 1.11-3.06), p = 0.019). Anastomotic leakage in patients with a primary anastomosis (n = 287) occurred more often in patients with low muscle density (11.7\% vs 23.3\%, p = 0.016). The associations remained significant after correction for confounders.
CONCLUSION: Low muscle density is associated with major postoperative complications in older patients who undergo surgery for colorectal cancer.},
	language = {eng},
	number = {11},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Margadant, C. C. and Bruns, E. R. J. and Sloothaak, D. a. M. and van Duijvendijk, P. and van Raamt, A. F. and van der Zaag, H. J. and Buskens, C. J. and van Munster, B. C. and van der Zaag, E. S.},
	month = nov,
	year = {2016},
	pmid = {27554247},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Sarcopenia, Colorectal Neoplasms, Aged, 80 and over, Muscle density, Postoperative Complications, Surgery, Postoperative complications, Colorectal cancer, Older adults},
	pages = {1654--1659},
}

@article{anyene2974,
	title = {Body composition from single versus multi-slice abdominal computed tomography: {Concordance} and associations with colorectal cancer survival},
	volume = {13},
	issn = {2190-6009},
	shorttitle = {Body composition from single versus multi-slice abdominal computed tomography},
	doi = {10.1002/jcsm.13080},
	abstract = {BACKGROUND: Computed tomography (CT) scans are routinely obtained in oncology and provide measures of muscle and adipose tissue predictive of morbidity and mortality. Automated segmentation of CT has advanced past single slices to multi-slice measurements, but the concordance of these approaches and their associations with mortality after cancer diagnosis have not been compared.
METHODS: A total of 2871 patients with colorectal cancer diagnosed during 2012-2017 at Kaiser Permanente Northern California underwent abdominal CT scans as part of routine clinical care from which mid-L3 cross-sectional areas and multi-slice T12-L5 volumes of skeletal muscle (SKM), subcutaneous adipose (SAT), visceral adipose (VAT) and intermuscular adipose (IMAT) tissues were assessed using Data Analysis Facilitation Suite, an automated multi-slice segmentation platform. To facilitate comparison between single-slice and multi-slice measurements, sex-specific z-scores were calculated. Pearson correlation coefficients and Bland-Altman analysis were used to quantify agreement. Cox models were used to estimate hazard ratios (HRs) and 95\% confidence intervals (CIs) for death adjusting for age, sex, race/ethnicity, height, and tumour site and stage.
RESULTS: Single-slice area and multi-slice abdominal volumes were highly correlated for all tissues (SKM R = 0.92, P {\textless} 0.001; SAT R = 0.97, P {\textless} 0.001; VAT R = 0.98, P {\textless} 0.001; IMAT R = 0.89, P {\textless} 0.001). Bland-Altman plots had a bias of 0 (SE: 0.00), indicating high average agreement between measures. The limits of agreement were narrowest for VAT ( ±  0.42 SD) and SAT ( ±  0.44 SD), and widest for SKM ( ±  0.78 SD) and IMAT ( ±  0.92 SD). The HRs had overlapping CIs, and similar magnitudes and direction of effects; for example, a 1-SD increase in SKM area was associated with an 18\% decreased risk of death (HR = 0.82; 95\% CI: 0.72-0.92), versus 15\% for volume from T12 to L5 (HR = 0.85; 95\% CI: 0.75-0.96).
CONCLUSIONS: Single-slice L3 areas and multi-slice T12-L5 abdominal volumes of SKM, VAT, SAT and IMAT are highly correlated. Associations between area and volume measures with all-cause mortality were similar, suggesting that they are equivalent tools for population studies if body composition is assessed at a single timepoint. Future research should examine longitudinal changes in multi-slice tissues to improve individual risk prediction.},
	language = {eng},
	number = {6},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Anyene, Ijeamaka and Caan, Bette and Williams, Grant R. and Popuri, Karteek and Lenchik, Leon and Giri, Smith and Chow, Vincent and Beg, Mirza Faisal and Cespedes Feliciano, Elizabeth M.},
	month = dec,
	year = {2022},
	pmid = {36052755},
	pmcid = {PMC9745558},
	keywords = {Abdomen, Body Composition, Humans, Tomography, X-Ray Computed, Female, Male, Obesity, Colorectal Neoplasms, body composition, Intra-Abdominal Fat, computed tomography, adipose tissue, colorectal cancer, muscle, ML, Voronoi, automated segmentation},
	pages = {2974--2984},
	file = {Anyene et al_2022_Body composition from single versus multi-slice abdominal computed tomography.pdf:/Users/jcsal/Zotero/storage/B7Q3WZAS/Anyene et al_2022_Body composition from single versus multi-slice abdominal computed tomography.pdf:application/pdf},
}

@article{malietzis186,
	title = {The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review},
	volume = {41},
	issn = {1532-2157},
	shorttitle = {The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes},
	doi = {10.1016/j.ejso.2014.10.056},
	abstract = {BACKGROUND: Strong evidence indicates that excessive adipose tissue distribution or reduced muscle influence short-, mid-, and long-term colorectal cancer outcomes. Computerized tomography-based body composition (CTBC) analysis quantifies this in a reproducible parameter. We reviewed the evidence linking computerized tomography (CT) based quantification of BC with short and long-term outcomes in colorectal cancer (CRC).
METHODS: A systematic review was performed according to PRISMA guidelines. A literature search was performed by two independent reviewers on all studies that included CTBC analysis in patients undergoing treatment for CRC using Medline, EMBASE, Google Scholar, and Cochrane databases. Outcomes of interest included short-term recovery, oncological outcomes, and survival.
RESULTS: Seventy-five studies were identified; sixteen met the inclusion criteria. None were randomized controlled trials and all were cohort studies of small sample size. Several types of CTBC image analysis software were identified, reporting subcutaneous, visceral and skeletal muscle tissues. Visceral obesity and reduced muscle mass were categorical parameters quantified by CTBC analysis. Due to marked study heterogeneity, quantitative data synthesis was not possible. High visceral adipose tissue and reduced skeletal muscle resulted in poorer short-term recovery (eleven studies), poorer oncological outcomes (six studies), and poorer survival (six studies).
CONCLUSIONS: CTBC techniques may be linked to outcomes in colorectal cancer patients, however larger studies are required. CTBC based assessment may allow early identification of high-risk patients, allowing early optimisation of patients undergoing cancer treatments.},
	language = {eng},
	number = {2},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Malietzis, G. and Aziz, O. and Bagnall, N. M. and Johns, N. and Fearon, K. C. and Jenkins, J. T.},
	month = feb,
	year = {2015},
	pmid = {25468746},
	keywords = {Adiposity, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Length of Stay, Sarcopenia, Treatment Outcome, Colorectal Neoplasms, Survival Rate, Body composition, Intra-Abdominal Fat, Postoperative Complications, Colorectal cancer, Outcomes, Operative Time},
	pages = {186--196},
}

@article{kim4022,
	title = {Age-related changes in muscle quality and development of diagnostic cutoff points for myosteatosis in lumbar skeletal muscles measured by {CT} scan},
	volume = {40},
	issn = {0261-5614},
	url = {https://www.sciencedirect.com/science/article/pii/S0261561421002090},
	doi = {10.1016/j.clnu.2021.04.017},
	abstract = {Background \& aims
We have sought to develop proper and useful indices for muscle quality measurements other than muscle attenuation (Hounsfield unit; HU) and to determine the diagnostic cutoff points for myosteatosis by using those indices measured at the L3 lumbar vertebrae level by CT scan.
Methods
This cross-sectional analysis included 20,664 healthy adult subjects (12,697 men and 7967 women) who underwent abdominal CT scans. Total abdominal muscle area (TAMA), on the L3 vertebra was demarcated using predetermined thresholds. Intermuscular adipose tissue area (IMAT) and skeletal muscle area (SMA) were measured. SMA was divided into normal attenuation muscle area (NAMA) and low attenuation muscle area (LAMA). Their various indices were calculated. We identified the sex-specific mean values of NAMA, LAMA, IMAT, and their indices and the cutoff points equivalent to the T-scores in the young reference group.
Results
The mean values of the NAMA and NAMA indices decreased with age in both sexes, LAMA, IMAT, and their indices showed an increasing tendency with age in both sexes. When using T-score {\textless} −2.0 as the cutoff for myosteatosis, the sex-specific cutoff points of NAMA, NAMA/BMI, NAMA/TAMA index, and SMA and TAMA attenuation in men and women were 103.0 and 64.5 cm2, 4.0 and 2.8, 66.4 and 65.1, 40.2 and 39.9 HU, and 34.1 and 33.5 HU, respectively. Using these cutoff points, the prevalence of myosteatosis by NAMA, NAMA/BMI, NAMA/TAMA index, or SMA or TAMA attenuation ranged from 5.9 to 8.8\% in men and from 10.2 to 20.5\% in women.
Conclusions
The NAMA/TAMA index developed in this study was useful for assessing myosteatosis. This is the first study to report the sex-specific diagnostic cutoff points for myosteatosis of trunk muscles based on T-scores measured by CT scans in healthy population. These diagnostic cutoff points may be particularly useful in the treatment and prevention of sarcopenia and myosteatosis.},
	language = {en},
	number = {6},
	urldate = {2023-03-25},
	journal = {Clinical Nutrition},
	author = {Kim, Hong-Kyu and Kim, Kyung Won and Kim, Eun Hee and Lee, Min Jung and Bae, Sung-Jin and Ko, Yousun and Park, Taeyoung and Shin, Yongbin and Kim, Ye-Jee and Choe, Jaewon},
	month = jun,
	year = {2021},
	keywords = {Myosteatosis, L3 lumbar spine level, Skeletal muscle quality},
	pages = {4022--4028},
	file = {Kim et al_2021_Age-related changes in muscle quality and development of diagnostic cutoff.pdf:/Users/jcsal/Zotero/storage/Y5RY7PGT/Kim et al. - 2021 - Age-related changes in muscle quality and developm.pdf:application/pdf;ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/3HVS786U/S0261561421002090.html:text/html},
}

@article{silva76,
	title = {Ethnicity-related skeletal muscle differences across the lifespan},
	volume = {22},
	issn = {1520-6300},
	doi = {10.1002/ajhb.20956},
	abstract = {Despite research and clinical significance, limited information is available on the relations between skeletal muscle (SM) and age in adults, specifically among Hispanics, African Americans (AA), and Asians. The aim was to investigate possible sex and ethnic SM differences in adults over an age range of 60 years. Subjects were 468 male and 1280 female adults ({\textgreater} or =18 years). SM was estimated based on DXA-measured appendicular lean-soft tissue using a previously reported prediction equation. Locally weighted regression smoothing lines were fit to examine SM trends and to localize age cutoffs; piecewise multiple linear regression models were then applied, controlling for weight and height, to identify age cutoffs for sex-specific changes in SM among the ethnic groups. The age of 27 years was identified for women and men as the cut-off after which SM starts to show a negative association with age. Both sexes had a similar ethnic pattern for expected mean SM at the age cutoff, with AA presenting the highest SM values, followed by Whites, Hispanics, and Asians. After the age cutoffs, the lowering of SM differed by ethnicity and sex: AA women showed the greatest SM lowering whereas Hispanic women had the least. Hispanic men tended to show a higher negative association of SM with age followed by AA and Whites. To conclude, significant sex and ethnic differences exist in the magnitude of negative associations of SM with age {\textgreater}27 years. Further studies using a longitudinal design are needed to explore the associations of ethnicity-related decline of SM with health risks.},
	language = {eng},
	number = {1},
	journal = {American Journal of Human Biology: The Official Journal of the Human Biology Council},
	author = {Silva, Analiza M. and Shen, Wei and Heo, Moonseong and Gallagher, Dympna and Wang, Zimian and Sardinha, Luis B. and Heymsfield, Steven B.},
	year = {2010},
	pmid = {19533617},
	pmcid = {PMC2795070},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Aged, 80 and over, Adult, United States, Cross-Sectional Studies, Young Adult, Adolescent, Hispanic or Latino, Asian, Black or African American, Longevity, Sex Characteristics},
	pages = {76--82},
	file = {Silva et al_2010_Ethnicity-related skeletal muscle differences across the lifespan.pdf:/Users/jcsal/Zotero/storage/L33PK9LB/Silva et al_2010_Ethnicity-related skeletal muscle differences across the lifespan.pdf:application/pdf},
}

@article{gruenewald1525,
	title = {Allostatic {Load} and {Frailty} in {Older} {Adults}},
	volume = {57},
	issn = {0002-8614},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650612/},
	doi = {10.1111/j.1532-5415.2009.02389.x},
	abstract = {OBJECTIVE
To examine the association between allostatic load (AL), an index of multisystem physiological dysregulation, and frailty development over a 3-year follow-up in a sample of older adults.

DESIGN
Longitudinal cohort study.

SETTING
Community.

PARTICIPANTS
High-functioning men and women aged 70–79 at study entry.

MEASUREMENTS
Multisystem physiological dysregulation, or AL, was assessed according to 13 biomarkers of cardiovascular, endocrine, immune, and metabolic function. An AL score was computed as the total number of biomarkers for which participant values fell into high-risk biomarker quartiles. Frailty status (not frail, intermediate frail, frail) was determined according to the total number of five indicators of frailty: weight loss, exhaustion, weak grip, slow gait, and low physical activity. The association between level of AL at baseline and frailty status 3 years later was examined using ordinal logistic regression in 803 participants not frail at baseline.

RESULTS
In a multivariable model adjusting for sociodemographic, health, and behavioral characteristics, each 1-unit increase in AL at baseline was associated with a 10\% greater likelihood of frailty at the 3-year follow-up (cumulative adjusted odds ratio = 1.10, 95\% confidence interval = 1.03–1.19).

CONCLUSION
These findings support the hypothesis that dysregulation across multiple physiological systems is associated with greater risk of frailty. Greater levels of multisystem physiological dysregulation may serve as a warning sign of frailty development in later life.},
	number = {9},
	urldate = {2023-03-24},
	journal = {Journal of the American Geriatrics Society},
	author = {Gruenewald, Tara L. and Seeman, Teresa E. and Karlamangla, Arun S. and Sarkisian, Catherine A.},
	month = sep,
	year = {2009},
	pmid = {19682116},
	pmcid = {PMC3650612},
	keywords = {Allostatic},
	pages = {1525--1531},
	file = {Gruenewald et al_2009_Allostatic Load and Frailty in Older Adults.pdf:/Users/jcsal/Zotero/storage/LGWQ4MAM/Gruenewald et al_2009_Allostatic Load and Frailty in Older Adults.pdf:application/pdf},
}

@article{gronberg1347,
	title = {Associations between severe co‐morbidity and muscle measures in advanced non‐small cell lung cancer patients},
	volume = {10},
	issn = {2190-5991},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903441/},
	doi = {10.1002/jcsm.12469},
	abstract = {Background
Studies show that low skeletal muscle index (SMI) and low skeletal muscle density (SMD) are negative prognostic factors and associated with more toxicity from systemic therapy in cancer patients. However, muscle depletion can be caused by a range of diseases, and many cancer patients have significant co‐morbidity. The aim of this study was to investigate whether there were associations between co‐morbidity and muscle measures in patients with advanced non‐small cell lung cancer.

Methods
Patients in a Phase III trial comparing two chemotherapy regimens in advanced non‐small cell lung cancer were analysed (n = 436). Co‐morbidity was assessed using the Cumulative Illness Rating Scale for Geriatrics (CIRS‐G), which rates co‐morbidity from 0 to 4 on 14 different organ scales. Severe co‐morbidity was defined as having any grades 3 and 4 CIRS‐G score. Muscle measures were assessed from baseline computed tomography slides at the L3 level using the SliceOMatic software.

Results
Complete data were available for 263 patients (60\%). Median age was 66, 57.0\% were men, 78.7\% had performance status 0–1, 25.9\% Stage IIIB, 11.4\% appetite loss, 92.4\% were current/former smokers, 22.8\% were underweight, 43.7\% had normal weight, 26.6\% were overweight, and 6.8\% obese. The median total CIRS‐G score was 7 (range: 0–16), and 48.2\% had severe co‐morbidity. Mean SMI was 44.7 cm2/m2 (range: 27–71), and the mean SMD was 37.3 Hounsfield units (HU) (range: 16–60). When comparing patients with and without severe co‐morbidity, there were no significant differences in median SMI (44.5 vs. 44.1 cm2/m2; 0.70), but patients with severe co‐morbidity had a significantly lower median SMD (36 HU vs. 39 HU; 0.001), mainly due to a significant difference in SMD between those with severe heart disease and those without (32.5 vs. 37.9 HU; 0.002). Linear regression analyses confirmed the association between severe co‐morbidity and SMD both in the simple analysis (0.001) and the multiple analysis (0.037) adjusting for baseline characteristics. Stage of disease, gender, and body mass index (BMI) were significantly associated with SMI in both the simple and multiple analyses. Age and BMI were significantly associated with SMD in the simple analysis; and age, gender, and BMI were significantly associated in the multiple analysis.

Conclusions
There were no significant differences in SMI between patients with and patients without severe co‐morbidity, but patients with severe co‐morbidity had lower SMD than other patients, mainly due to severe heart disease. Co‐morbidity might be a confounder in studies of the clinical role of SMD in cancer patients.},
	number = {6},
	urldate = {2023-03-24},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Grønberg, Bjørn H. and Valan, Christine Damgaard and Halvorsen, Tarje and Sjøblom, Bjørg and Jordhøy, Marit S.},
	month = dec,
	year = {2019},
	pmid = {31385663},
	pmcid = {PMC6903441},
	keywords = {Myosteatosis, Disparities},
	pages = {1347--1355},
	file = {Grønberg et al_2019_Associations between severe co‐morbidity and muscle measures in advanced.pdf:/Users/jcsal/Zotero/storage/LHSA5ECC/Grønberg et al_2019_Associations between severe co‐morbidity and muscle measures in advanced.pdf:application/pdf},
}

@article{he473,
	title = {Relationship of sarcopenia and body composition with osteoporosis},
	volume = {27},
	issn = {1433-2965},
	doi = {10.1007/s00198-015-3241-8},
	abstract = {The purpose of the study is to investigate the relationship between sarcopenia and body composition and osteoporosis in cohorts of three different races with a total of 17,891 subjects. Lean mass and grip strength were positively associated with bone mineral densities (BMDs). Subjects with sarcopenia were two times more likely to have osteoporosis compared with normal subjects.
INTRODUCTION: The relationship between sarcopenia and osteoporosis is not totally clear. First, the present study assessed this relationship by using two different definitions for sarcopenia. Second, we examined the associations of body composition (including muscle mass as a major and important component) and muscle strength on regional and whole-body BMDs.
METHODS: In total, 17,891 subjects of African American, Caucasian, and Chinese ethnicities were analyzed. Sarcopenia was defined by relative appendicular skeletal muscle mass (RASM) cut points and also by the definition of the European Working Group on Sarcopenia in Older People (low RASM plus low muscle function). Multiple regression analyses were conducted to examine the association of fat mass, lean mass (including muscle mass), and grip strength with regional and whole-body BMDs. Multivariate logistic regression analysis was performed to explore the association between sarcopenia and osteopenia/osteoporosis.
RESULTS: BMDs were positively associated with lean mass and negatively associated with fat mass, after controlling for potential confounders. Grip strength was significantly associated with higher BMDs. Each standard deviation (SD) increase in RASM resulted in a {\textasciitilde}37 \% reduction in risk of osteopenia/osteoporosis (odds ratio (OR) = 0.63; 95 \% confidence interval (CI) = 0.59, 0.66). Subjects with sarcopenia defined by RASM were two times more likely to have osteopenia/osteoporosis compared with the normal subjects (OR = 2.04; 95 \% CI = 1.61, 2.60). Similarly, subjects with sarcopenia (low muscle mass and low grip strength) were {\textasciitilde}1.8 times more likely to have osteopenia/osteoporosis than normal subjects (OR = 1.87; 95 \% CI = 1.09, 3.20).
CONCLUSIONS: High lean mass and muscle strength were positively associated with BMDs. Sarcopenia is associated with low BMD and osteoporosis.},
	language = {eng},
	number = {2},
	journal = {Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA},
	author = {He, H. and Liu, Y. and Tian, Q. and Papasian, C. J. and Hu, T. and Deng, H.-W.},
	month = feb,
	year = {2016},
	pmid = {26243357},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Sex Factors, Aged, 80 and over, Adult, Body composition, United States, Young Adult, Adolescent, Osteoporosis, Muscle Strength, Anthropometry, Hand Strength, Asian, Black or African American, Bone Density, Muscle strength, Relative appendicular skeletal muscle mass, White People},
	pages = {473--482},
}

@article{bloome849,
	title = {Administration of {Immune} {Checkpoint} {Inhibitors} {Near} the {End} of {Life}},
	volume = {18},
	issn = {2688-1535},
	doi = {10.1200/OP.21.00689},
	abstract = {PURPOSE: Recent literature suggests an increasing use of systemic treatment in patients with advanced cancer near the end of life (EOL), partially driven by the increasing adoption of immune checkpoint inhibitors (ICIs). While studies have identified this trend, additional variables associated with ICI use at EOL are limited. Our aim was to characterize a population of patients who received a dose of ICI in the last 30 days of life.
METHODS: We performed a manual retrospective chart review of patients ≥ 18 years who died within 30 days of receiving a dose of ICI. Metrics such as Eastern Cooperative Oncology Group performance status (ECOG PS), number of ICI doses, need for hospitalization, and numerous other variables were evaluated.
RESULTS: Over a 4-year time period, 97 patients received an ICI at EOL. For 40\% of patients, the ICI given in the 30 days before death was their only dose. Over 50\% of patients had an ECOG PS of ≥ 2, including 17\% of patients with an ECOG PS of 3. Over 60\% were hospitalized, 65\% visited the emergency department, 20\% required intensive care unit admission, and 25\% died in the hospital.
CONCLUSION: Our study contributes to the ongoing literature regarding the risks and benefits of ICI use in patients with advanced cancer near the EOL. While accurate predictions regarding the EOL are challenging, oncologists may routinely use clinical factors such as ECOG PS along with patient preferences to guide recommendations and shared decision making. Ultimately, further follow-up studies to better characterize and prognosticate this population of patients are needed.},
	language = {eng},
	number = {6},
	journal = {JCO oncology practice},
	author = {Bloom, Matthew D. and Saker, Haneen and Glisch, Chad and Ramnaraign, Brian and George, Thomas J. and Markham, Merry J. and Kelkar, Amar H.},
	month = jun,
	year = {2022},
	pmid = {35254868},
	keywords = {Humans, Retrospective Studies, Neoplasms, Death, Immune Checkpoint Inhibitors, ICI, Patient Preference},
	pages = {e849--e856},
}

@article{hiramoto709,
	title = {Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life},
	volume = {19},
	issn = {1478-9523},
	doi = {10.1017/S147895152100002X},
	abstract = {BACKGROUND: In recent years, the use of both molecular targeting agents (MTAs) and immune-checkpoint inhibitors (ICIs) tend to occupy important positions in systemic anticancer therapy (SACT). The objective of this study is to describe the predictors of SACT include both MTAs and ICIs near the end of life (EOL) and the effect on EOL care in patients with advanced cancer.
METHODS: We analyzed all patients who died of advanced cancer from August 2016 to August 2019, and we analyzed the survival time of patients who underwent anticancer agents excluded due to the loss of information about the last administration of SACT. The primary endpoint of this study was to identify predictors during the last administration of SACT near EOL.
RESULTS: In a multivariate analysis, the Eastern Cooperative Oncology Group performance status (ECOG-PS) (ORs 33.781) was significantly related factors within 14 days of death from the last administration of SACT. Age (ORs 0.412), ECOG-PS (ORs 11.533), primary cancer site of upper GI cancers (ORs 2.205), the number of comorbidities (ORs 0.207), MTAs (ORs 3.139), and ICIs (ORs 3.592) were significantly related factors within 30 days of death. The median survival time (MST) of patients with PS 3-4 was 29 days, while that of patients with both PS 0-2 was 76 days. The prevalence rate of delirium with MTAs was 17.5\%, which was significantly lower than that of patients without it (31.8\%). The prevalence rate of the mean dose of opioids in patients with ICIs was 97.9 mg/day, which was significantly higher than that of patients without it (44.9 mg/day).
CONCLUSIONS: Age, ECOG-PS, primary cancer site, the number of comorbidities, MTAs, and ICIs use were significant associated with SACT near EOL. Information on these factors may aid clinical decision making in referral to palliative care institutes.},
	language = {eng},
	number = {6},
	journal = {Palliative \& Supportive Care},
	author = {Hiramoto, Shuji and Taniyama, Tomohiko and Kikuchi, Ayako and Hori, Tetsuo and Yoshioka, Akira and Inoue, Akira},
	month = dec,
	year = {2021},
	pmid = {33729120},
	keywords = {Humans, Retrospective Studies, Lung Neoplasms, Neoplasms, Death, Immune Checkpoint Inhibitors, ICI, End of life, Immune-checkpoint inhibitors, Molecular targeted agents, Molecular Targeted Therapy, Systemic anticancer therapy},
	pages = {709--714},
}

@article{raimondi2839,
	title = {{TremelImumab} and {Durvalumab} {Combination} for the {Non}-{OperatIve} {Management} ({NOM}) of {Microsatellite} {InstabiliTY} ({MSI})-{High} {Resectable} {Gastric} or {Gastroesophageal} {Junction} {Cancer}: {The} {Multicentre}, {Single}-{Arm}, {Multi}-{Cohort}, {Phase} {II} {INFINITY} {Study}},
	volume = {13},
	issn = {2072-6694},
	shorttitle = {{TremelImumab} and {Durvalumab} {Combination} for the {Non}-{OperatIve} {Management} ({NOM}) of {Microsatellite} {InstabiliTY} ({MSI})-{High} {Resectable} {Gastric} or {Gastroesophageal} {Junction} {Cancer}},
	doi = {10.3390/cancers13112839},
	abstract = {In resectable gastric or gastroesophageal junction cancer (GC/GEJC), the powerful positive prognostic effect and the potential predictive value for a lack of benefit from the combination of adjuvant/peri-operative chemotherapy for the MSI-high status was demonstrated. Given the high sensitivity of MSI-high tumors for immunotherapy, exploratory trials showed that combination immunotherapy induces a high rate of complete pathological response (pCR), potentially achieving cancer cure without surgery. INFINITY is an ongoing phase II, multicentre, single-arm, multi-cohort trial investigating the activity and safety of tremelimumab and durvalumab as neoadjuvant (Cohort 1) or potentially definitive (Cohort 2) treatment for MSI-high/dMMR/EBV-negative, resectable GC/GEJC. About 310 patients will be pre-screened, to enroll a total of 31 patients, 18 and 13 in Cohort 1 and 2, at 25 Italian Centres. The primary endpoint of Cohort 1 is rate of pCR (ypT0N0) and negative ctDNA after neoadjuvant immunotherapy, of Cohort 2 is 2-year complete response rate, defined as absence of macroscopic or microscopic residual disease (locally/regionally/distantly) at radiological examinations, tissue and liquid biopsy, during non-operative management without salvage gastrectomy. The ongoing INFINITY proof-of-concept study may provide evidence on immunotherapy and the potential omission of surgery in localized/locally advanced GC/GEJC patients selected for dMMR/MSI-high status eligible for radical resection.},
	language = {eng},
	number = {11},
	journal = {Cancers},
	author = {Raimondi, Alessandra and Palermo, Federica and Prisciandaro, Michele and Aglietta, Massimo and Antonuzzo, Lorenzo and Aprile, Giuseppe and Berardi, Rossana and Cardellino, Giovanni G. and De Manzoni, Giovanni and De Vita, Ferdinando and Di Maio, Massimo and Fornaro, Lorenzo and Frassineti, Giovanni L. and Granetto, Cristina and Iachetta, Francesco and Lonardi, Sara and Murialdo, Roberto and Ongaro, Elena and Pucci, Francesca and Ratti, Margherita and Silvestris, Nicola and Smiroldo, Valeria and Spallanzani, Andrea and Strippoli, Antonia and Tamberi, Stefano and Tamburini, Emiliano and Zaniboni, Alberto and Di Bartolomeo, Maria and Cremolini, Chiara and Sposito, Carlo and Mazzaferro, Vincenzo and Pietrantonio, Filippo},
	month = jun,
	year = {2021},
	pmid = {34200267},
	pmcid = {PMC8201030},
	keywords = {gastric cancer, Immunotherapy, CTLA4, microsatellite instability, non-operative management, PD-L1, pre-operative treatment},
	pages = {2839},
	file = {Raimondi et al_2021_TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM).pdf:/Users/jcsal/Zotero/storage/LCCC7KN4/Raimondi et al_2021_TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM).pdf:application/pdf},
}

@article{sheetz3234,
	title = {Centralization of {High}-{Risk} {Cancer} {Surgery} {Within} {Existing} {Hospital} {Systems}},
	volume = {37},
	issn = {1527-7755},
	doi = {10.1200/JCO.18.02035},
	abstract = {PURPOSE: Centralization is often proposed as a strategy to improve the quality of certain high-risk health care services. We evaluated the extent to which existing hospital systems centralize high-risk cancer surgery and whether centralization is associated with short-term clinical outcomes.
PATIENTS AND METHODS: We merged data from the American Hospital Association's annual survey on hospital system affiliation with Medicare claims to identify patients undergoing surgery for pancreatic, esophageal, colon, lung, or rectal cancer between 2005 and 2014. We calculated the degree to which systems centralized each procedure by calculating the annual proportion of surgeries performed at the highest-volume hospital within each system. We then estimated the independent effect of centralization on the incidence of postoperative complications, death, and readmissions after accounting for patient, hospital, and system characteristics.
RESULTS: The average degree of centralization varied from 25.2\% (range, 6.6\% to 100\%) for colectomy to 71.2\% (range, 8.3\% to 100\%) for pancreatectomy. Greater centralization was associated with lower rates of postoperative complications and death for lung resection, esophagectomy, and pancreatectomy. For example, there was a 1.1\% (95\% CI, 0.8\% to 1.4\%) absolute reduction in 30-day mortality after pancreatectomy for each 20\% increase in the degree of centralization within systems. Independent of volume and hospital quality, postoperative mortality for pancreatectomy was two times higher in the least centralized systems than in the most centralized systems (8.9\% v 3.7\%, P {\textless} .01). Centralization was not associated with better outcomes for colectomy or proctectomy.
CONCLUSION: Greater centralization of complex cancer surgery within existing hospital systems was associated with better outcomes. As hospitals affiliate in response to broader financial and organization pressures, these systems may also present unique opportunities to improve the quality of high-risk cancer care.},
	language = {eng},
	number = {34},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Sheetz, Kyle H. and Dimick, Justin B. and Nathan, Hari},
	month = dec,
	year = {2019},
	pmid = {31251691},
	pmcid = {PMC7351344},
	keywords = {Humans, Aged, Female, Male, Treatment Outcome, Risk Factors, Risk Assessment, Time Factors, Neoplasms, Aged, 80 and over, Databases, Factual, United States, Postoperative Complications, Medicare, Outcome and Process Assessment, Health Care, Quality Improvement, Centralized Hospital Services, Oncology Service, Hospital, Quality Indicators, Health Care, Surgical Oncology},
	pages = {3234--3242},
	file = {Sheetz et al_2019_Centralization of High-Risk Cancer Surgery Within Existing Hospital Systems.pdf:/Users/jcsal/Zotero/storage/CM4ZFKV5/Sheetz et al_2019_Centralization of High-Risk Cancer Surgery Within Existing Hospital Systems.pdf:application/pdf},
}

@article{diezroux125,
	title = {Neighborhoods and health},
	volume = {1186},
	issn = {1749-6632},
	doi = {10.1111/j.1749-6632.2009.05333.x},
	abstract = {Features of neighborhoods or residential environments may affect health and contribute to social and race/ethnic inequalities in health. The study of neighborhood health effects has grown exponentially over the past 15 years. This chapter summarizes key work in this area with a particular focus on chronic disease outcomes (specifically obesity and related risk factors) and mental health (specifically depression and depressive symptoms). Empirical work is classified into two main eras: studies that use census proxies and studies that directly measure neighborhood attributes using a variety of approaches. Key conceptual and methodological challenges in studying neighborhood health effects are reviewed. Existing gaps in knowledge and promising new directions in the field are highlighted.},
	language = {eng},
	journal = {Annals of the New York Academy of Sciences},
	author = {Diez Roux, Ana V. and Mair, Christina},
	month = feb,
	year = {2010},
	pmid = {20201871},
	keywords = {Humans, Risk Factors, Health Status, Residence Characteristics, Mental Health, SDI, Social Environment},
	pages = {125--145},
	file = {Diez Roux_Mair_2010_Neighborhoods and health.pdf:/Users/jcsal/Zotero/storage/FDXP28E5/Diez Roux_Mair_2010_Neighborhoods and health.pdf:application/pdf},
}

@article{pickhardt524,
	title = {Opportunistic {Screening} at {Abdominal} {CT}: {Use} of {Automated} {Body} {Composition} {Biomarkers} for {Added} {Cardiometabolic} {Value}},
	volume = {41},
	issn = {1527-1323},
	shorttitle = {Opportunistic {Screening} at {Abdominal} {CT}},
	doi = {10.1148/rg.2021200056},
	abstract = {Abdominal CT is a frequently performed imaging examination for a wide variety of clinical indications. In addition to the immediate reason for scanning, each CT examination contains robust additional data on body composition that generally go unused in routine clinical practice. There is now growing interest in harnessing this additional information. Prime examples of cardiometabolic information include measurement of bone mineral density for osteoporosis screening, quantification of aortic calcium for assessment of cardiovascular risk, quantification of visceral fat for evaluation of metabolic syndrome, assessment of muscle bulk and density for diagnosis of sarcopenia, and quantification of liver fat for assessment of hepatic steatosis. All of these relevant biometric measures can now be fully automated through the use of artificial intelligence algorithms, which provide rapid and objective assessment and allow large-scale population-based screening. Initial investigations into these measures of body composition have demonstrated promising performance for prediction of future adverse events that matches or exceeds the best available clinical prediction models, particularly when these CT-based measures are used in combination. In this review, the concept of CT-based opportunistic screening is discussed, and an overview of the various automated biomarkers that can be derived from essentially all abdominal CT examinations is provided, drawing heavily on the authors' experience. As radiology transitions from a volume-based to a value-based practice, opportunistic screening represents a promising example of adding value to services that are already provided. If the potentially high added value of these objective CT-based automated measures is ultimately confirmed in subsequent investigations, this opportunistic screening approach could be considered for intentional CT-based screening. ©RSNA, 2021.},
	language = {eng},
	number = {2},
	journal = {Radiographics: A Review Publication of the Radiological Society of North America, Inc},
	author = {Pickhardt, Perry J. and Graffy, Peter M. and Perez, Alberto A. and Lubner, Meghan G. and Elton, Daniel C. and Summers, Ronald M.},
	year = {2021},
	pmid = {33646902},
	pmcid = {PMC7924410},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Retrospective Studies, Review, Biomarkers, Radiography, Abdominal, Artificial Intelligence, Cardiovascular Diseases},
	pages = {524--542},
	file = {Pickhardt et al_2021_Opportunistic Screening at Abdominal CT.pdf:/Users/jcsal/Zotero/storage/VNGSC29E/Pickhardt et al_2021_Opportunistic Screening at Abdominal CT.pdf:application/pdf},
}

@article{butler539,
	title = {Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery},
	volume = {48},
	issn = {1475-6773},
	doi = {10.1111/j.1475-6773.2012.01449.x},
	abstract = {OBJECTIVE: To develop a measure of social deprivation that is associated with health care access and health outcomes at a novel geographic level, primary care service area.
DATA SOURCES/STUDY SETTING: Secondary analysis of data from the Dartmouth Atlas, AMA Masterfile, National Provider Identifier data, Small Area Health Insurance Estimates, American Community Survey, Area Resource File, and Behavioural Risk Factor Surveillance System. Data were aggregated to primary care service areas (PCSAs).
STUDY DESIGN: Social deprivation variables were selected from literature review and international examples. Factor analysis was used. Correlation and multivariate analyses were conducted between index, health outcomes, and measures of health care access. The derived index was compared with poverty as a predictor of health outcomes.
DATA COLLECTION/EXTRACTION METHODS: Variables not available at the PCSA level were estimated at block level, then aggregated to PCSA level.
PRINCIPAL FINDINGS: Our social deprivation index is positively associated with poor access and poor health outcomes. This pattern holds in multivariate analyses controlling for other measures of access. A multidimensional measure of deprivation is more strongly associated with health outcomes than a measure of poverty alone.
CONCLUSIONS: This geographic index has utility for identifying areas in need of assistance and is timely for revision of 35-year-old provider shortage and geographic underservice designation criteria used to allocate federal resources.},
	language = {eng},
	number = {2 Pt 1},
	journal = {Health Services Research},
	author = {Butler, Danielle C. and Petterson, Stephen and Phillips, Robert L. and Bazemore, Andrew W.},
	month = apr,
	year = {2013},
	pmid = {22816561},
	pmcid = {PMC3626349},
	keywords = {Humans, Mortality, Health Services Accessibility, Socioeconomic Factors, Vulnerable Populations, Diabetes Mellitus, Primary Health Care, SDI, Infant Mortality, Infant, Low Birth Weight, Infant, Newborn, Needs Assessment},
	pages = {539--559},
	file = {Butler et al_2013_Measures of social deprivation that predict health care access and need within.pdf:/Users/jcsal/Zotero/storage/PUNUCZYA/Butler et al_2013_Measures of social deprivation that predict health care access and need within.pdf:application/pdf},
}

@article{reid1039,
	title = {Socioeconomic disparities in ostomy reversal among older adults with diverticulitis are more substantial among non-{Hispanic} {Black} patients},
	volume = {170},
	issn = {1532-7361},
	doi = {10.1016/j.surg.2021.03.050},
	abstract = {BACKGROUND: While ostomies for diverticulitis are often intended to be temporary, ostomy reversal rates can be as low as 46\%. There are few comprehensive studies evaluating the effects of socioeconomic status as a disparity in ostomy reversal. We hypothesized that among the elderly Medicare population undergoing partial colectomy for diverticulitis, lower socioeconomic status would be associated with reduced reversal rates.
METHODS: Retrospective cohort study using a 20\% representative sample of Medicare beneficiaries {\textgreater}65 years old with diverticulitis who received ostomies between January 1, 2010, to December 31, 2017. We evaluated the effect of neighborhood socioeconomic status, measured by the Social Deprivation Index, on ostomy reversal within 1 year. Secondary outcomes were complications and mortality.
RESULTS: Of 10,572 patients, ostomy reversals ranged from 21.2\% (low socioeconomic status) to 29.8\% (highest socioeconomic status), with a shorter time to reversal among higher socioeconomic status groups. Patients with low socioeconomic status were less likely to have their ostomies reversed, compared with the highest socioeconomic status group (hazard ratio 0.83, 95\% confidence interval 0.74-0.93) and were more likely to die (hazard ratio 1.21, 95\% confidence interval 1.10-1.33). When stratified by race/ethnicity and socioeconomic status, non-Hispanic White patients at every socioeconomic status had a higher reversal rate than non-Hispanic Black patients (White patients 32.0\%-24.8\% vs Black patients 19.6\%-14.7\%). Socioeconomic status appeared to have a higher relative impact among non-Hispanic Black patients.
CONCLUSION: Among Medicare diverticulitis patients, ostomy reversal rates are low. Patients with lower socioeconomic status are less likely to undergo stoma reversal and are more likely to die; Black patients are least likely to have an ostomy reversal.},
	language = {eng},
	number = {4},
	journal = {Surgery},
	author = {Reid, Trista D. and Shrestha, Riju and Stone, Lucas and Gallaher, Jared and Charles, Anthony G. and Strassle, Paula D.},
	month = oct,
	year = {2021},
	pmid = {33933283},
	pmcid = {PMC8490310},
	keywords = {Humans, Aged, Female, Male, Retrospective Studies, Cohort Studies, CRC, Aged, 80 and over, Colectomy, United States, Medicare, Morbidity, Healthcare Disparities, Socioeconomic Factors, Social Class, Black or African American, Diverticulitis, Colonic, Ostomy},
	pages = {1039--1046},
	file = {Reid et al_2021_Socioeconomic disparities in ostomy reversal among older adults with.pdf:/Users/jcsal/Zotero/storage/PA5H2FEP/Reid et al_2021_Socioeconomic disparities in ostomy reversal among older adults with.pdf:application/pdf},
}

@article{tomasik97,
	title = {Effectiveness and safety of immunotherapy in {NSCLC} patients with {ECOG} {PS} score ≥2 - {Systematic} review and meta-analysis},
	volume = {158},
	issn = {1872-8332},
	doi = {10.1016/j.lungcan.2021.06.004},
	abstract = {BACKGROUND: Immune checkpoint inhibitors (ICIs) are standard of care in advanced non-small cell lung cancer (NSCLC), however their status in patients with poor performance status (PS) is poorly defined. We aimed to evaluate the efficacy and safety of ICIs in NSCLC patients with PS ≥ 2.
METHODS: We conducted a systematic review and meta-analysis of interventional and observational studies, which reported efficacy and safety data on ICIs in PS ≥ 2 comparing to PS ≤ 1 NSCLC patients. Efficacy endpoints included: Objective Response Rate (ORR), Disease-Control Rate (DCR), Overall Survival (OS), Progression-Free Survival (PFS). Safety endpoint was the incidence of severe (grade≥3) Adverse Events (AE). Random-effects model was applied for meta-analysis. Heterogeneity was assessed using I2. The review is registered on PROSPERO (CRD42020162668).
FINDINGS: Sixty-seven studies (n = 26,442 patients) were included. In PS ≥ 2 vs. PS ≤ 1 patients, the pooled odds ratios were: for ORR 0.46 (95 \%CI: 0.39-0.54, I2:0 \%); for DCR 0.39 (95 \%CI: 0.33-0.48, I2:50 \%) and for AEs 1.12 (95 \%CI: 0.84-1.48, I2:39 \%). The pooled hazard ratio for PFS was 2.17 (95 \%CI: 1.96-2.39, I2:65 \%) and for OS was 2.76 (95 \%CI: 2.43-3.14, I2:76 \%). The safety profile was comparable regardless of the PS status.
INTERPRETATION: Patients with impaired PS status are, on average, twice less likely to achieve a response when exposed to ICIs when compared with representative PS ≤ 1 population. For lung cancer patients treated with ICIs, the impaired PS is not only prognostic, but also predictive for response, while the safety profile is not affected. Prospective randomized studies are indispensable to determine whether poor PS patients derive benefit from ICIs.},
	language = {eng},
	journal = {Lung Cancer (Amsterdam, Netherlands)},
	author = {Tomasik, Bartłomiej and Bieńkowski, Michał and Braun, Marcin and Popat, Sanjay and Dziadziuszko, Rafał},
	month = aug,
	year = {2021},
	pmid = {34144405},
	keywords = {Humans, Prospective Studies, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Progression-Free Survival, Meta-analysis, Immunotherapy, ECOG2, Effectiveness and safety, Non-small cell lung cancer, Performance status},
	pages = {97--106},
}

@article{bayatzrac110,
	title = {Impact of surgeon and hospital factors on length of stay after colorectal surgery systematic review},
	volume = {6},
	issn = {2474-9842},
	url = {https://academic.oup.com/bjsopen/article/doi/10.1093/bjsopen/zrac110/6704875},
	doi = {10.1093/bjsopen/zrac110},
	abstract = {Background: Although length of stay (LOS) after colorectal surgery (CRS) is associated with worse patient and system level outcomes, the impact of surgeon and hospital-level factors on LOS after CRS has not been well investigated. The aim of this study was to synthesize the evidence for the impact of surgeon and hospital-level factors on LOS after CRS.
Methods: A comprehensive database search was conducted using terms related to LOS and CRS. Studies were included if they reported the effect of surgeon or hospital factors on LOS after elective CRS. The evidence for the effect of each surgeon and hospital factor on LOS was synthesized using vote counting by direction of effect, taking risk of bias into consideration.
Results: A total of 13 946 unique titles and abstracts were screened, and 69 studies met the inclusion criteria. All studies were retrospective and assessed a total of eight factors. Surgeon factors such as increasing surgeon volume, colorectal surgical specialty, and progression along a learning curve were significantly associated with decreased LOS (effect seen in 87.5 per cent, 100 per cent, and 93.3 per cent of studies respectively). In contrast, hospital factors such as hospital volume and teaching hospital status were not significantly associated with LOS.
Conclusion: Provider-related factors were found to be significantly associated with LOS after elective CRS. In particular, surgeonrelated factors related to experience specifically impacted LOS, whereas hospital-related factors did not. Understanding the mechanisms underlying these relationships may allow for tailoring of interventions to reduce LOS.},
	language = {en},
	number = {5},
	urldate = {2023-03-23},
	journal = {BJS Open},
	author = {Bayat, Zubair and Guidolin, Keegan and Elsolh, Basheer and De Castro, Charmaine and Kennedy, Erin and Govindarajan, Anand},
	month = sep,
	year = {2022},
	keywords = {LOS, MixedModel},
	pages = {zrac110},
	file = {Bayat et al. - 2022 - Impact of surgeon and hospital factors on length o.pdf:/Users/jcsal/Zotero/storage/K8CAR3P7/Bayat et al. - 2022 - Impact of surgeon and hospital factors on length o.pdf:application/pdf},
}

@article{krell815,
	title = {Extended length of stay after surgery: complications, inefficient practice, or sick patients?},
	volume = {149},
	issn = {2168-6262},
	shorttitle = {Extended length of stay after surgery},
	doi = {10.1001/jamasurg.2014.629},
	abstract = {IMPORTANCE: With the health policy focus on shifting risk to hospitals and physicians, hospital leaders are increasing efforts to reduce excessive resource use, such as patients with extended length of stay (LOS) after surgery. However, the degree to which extended LOS represents complications, patient illness, or inefficient practice style is unclear.
OBJECTIVE: To examine the influence of complications on the variance in hospitals' extended LOS rates after colorectal resections.
DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study performed from January 1 through December 31, 2009, we analyzed data from the 2009 American College of Surgeons National Surgical Quality Improvement Program. Study participants were 22 664 adults undergoing colorectal resections in 199 hospitals.
EXPOSURES: Inpatient complications recorded in the American College of Surgeons National Surgical Quality Improvement Program registry. Inpatient complications were identified by the association of the complication's postoperative date with the patient's surgical discharge date.
MAIN OUTCOME AND MEASURE: Hospitals' risk-adjusted extended LOS rates, defined as the proportion of patients with a hospital stay greater than the 75th percentile for the entire cohort.
RESULTS: A total of 2177 patients (42.8\%) with extended LOSs did not have a documented inpatient complication. Although there was wide variation in risk-adjusted extended LOS (14.5\%-35.3\%) and risk-adjusted inpatient complication (12.1\%-28.5\%) rates, there was only a weak correlation (Spearman ρ = 0.56, P {\textless} .001) between the two. Only 52.0\% of the variation in hospitals' extended LOS rates was attributable to hospitals' inpatient complication rates.
CONCLUSIONS AND RELEVANCE: Much of the variation in hospitals' risk-adjusted extended LOS rates is not attributable to patient illness or complications and therefore most likely represents differences in practice style. Efforts to reduce excess resource use should focus on efficiency of care, such as increased adoption of enhanced recovery pathways.},
	language = {eng},
	number = {8},
	journal = {JAMA surgery},
	author = {Krell, Robert W. and Girotti, Micah E. and Dimick, Justin B.},
	month = aug,
	year = {2014},
	pmid = {25074418},
	pmcid = {PMC4245077},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Retrospective Studies, Risk Factors, Health Status, Adult, Postoperative Complications, Clinical Protocols, Colonic Diseases, Quality of Health Care, Rectal Diseases, MixedModels},
	pages = {815--820},
	file = {Krell et al_2014_Extended length of stay after surgery.pdf:/Users/jcsal/Zotero/storage/TJM5FGDP/Krell et al_2014_Extended length of stay after surgery.pdf:application/pdf},
}

@article{bachmann477,
	title = {Comparison between abdominal fat measured by {CT} and anthropometric indices as prediction factors for mortality and morbidity after colorectal surgery},
	volume = {81},
	issn = {1784-3227},
	abstract = {AIM: This study aims to determine which anthropometric (body mass index (BMI), waist-hip-ratio (WHR) and waist-to-height ratio (WHtR)) and radiological (visceral fat area (VFA) measured by CT scan) measurements of adiposity correlated better with postoperative outcome of colorectal cancer (CRC) surgery. We also assessed which of these measurements best predicted overall survival (OS) and disease-free survival (DFS).
METHODS: Data from 90 consecutive Caucasian CRC patients who underwent surgery for colorectal cancer between 2010 and 2011 with a median follow-up of 53.25 months were analysed. The correlations of different adiposity measurements and postoperative outcomes were determined using logistic regression models and multivariate analyses.
RESULTS: Higher WHtR (p = 0.007) and VFA (p = 0.01) significantly increased the risk of overall morbidity, especially of Clavien-Dindo III or IV. The WHtR correlated best with VFA (p {\textless}0.0001), which is considered the gold standard for measuring visceral fat, whereas BMI (p = 0.15) was not a good predictor of postoperative morbidity. Multivariate analyses showed consistently significant results for postoperative complications for VFA in combination with all of the other variables analysed and for WHtR, confirming that VFA and WHtR were reliable independent prognostic factors of morbidity. VFA had a significant effect on OS (p = 0.012) but did not correlate with DFS (p = 0.51).
CONCLUSIONS: Both VFA and WHtR independently provided predictive data for potential postoperative complications after CRC surgery. In case CT scan was used for diagnostic purposes, VFA should be used in routine clinical practice.},
	language = {eng},
	number = {4},
	journal = {Acta Gastro-Enterologica Belgica},
	author = {Bachmann, R. and Leonard, D. and Nachit, M. and Remue, Ch and Abbes Orabi, N. and Desmet, L. and Faber, B. and Danse, E. and Trefois, P. and Kartheuser, A.},
	year = {2018},
	pmid = {30645915},
	keywords = {Adipose Tissue, Humans, Tomography, X-Ray Computed, Male, Obesity, Body Mass Index, Risk Factors, survival, Body Surface Area, Postoperative Complications, Hospital Mortality, Intraoperative Complications, Morbidity, Abdominal Fat, Waist-Hip Ratio, Colorectal Surgery, colorectal surgery, morbi-mortality, VAT, visceral fat area, waist to height ratio, waist to hip ratio, Waist-Height Ratio},
	pages = {477--483},
}

@article{yang507,
	title = {Impact of visceral obesity on outcomes of laparoscopic colorectal surgery: a meta-analysis},
	volume = {85},
	issn = {1445-2197},
	shorttitle = {Impact of visceral obesity on outcomes of laparoscopic colorectal surgery},
	doi = {10.1111/ans.13132},
	abstract = {BACKGROUND: Excessive visceral fat could influence surgical difficulty of laparoscopic colorectal surgery. With the use of visceral fat area measured by computed tomography, surgeons could quantify the amount of visceral fat. The aim of the present meta-analysis is to quantitatively combine studies in order to determine the impact of visceral obesity on laparoscopic colorectal surgery.
METHODS: A systematic search of literature (PubMed, EMBASE, the Cochrane Library) was performed to identify studies evaluating the impact of visceral obesity on laparoscopic colorectal surgery.
RESULTS: Four studies were included in this meta-analysis. Meta-analysis revealed that visceral obesity was associated with longer operative time (weighted mean difference (WMD) 24.42, 95\% confidence interval (CI) 12.98-35.86), less lymph nodes harvest (WMD -5.99, 95\% CI -8.31 to -3.67), more conversion to open procedure (odds ratio (OR) 2.24, 95\% CI 1.05-4.78), higher morbidity (OR 2.33, 95\% CI 1.56-3.48), more surgical site infection (OR 3.22, 95\% CI 1.95-5.32) and more anastomotic leakage (OR 2.40, 95\% CI 1.06-5.44).
CONCLUSION: The present study shows that visceral obesity is associated with increased surgical difficulty and post-operative morbidity of laparoscopic colorectal surgery but does not affect post-operative recovery thanks to laparoscopic procedure.},
	language = {eng},
	number = {7-8},
	journal = {ANZ journal of surgery},
	author = {Yang, Tinghan and Wei, Mingtian and He, Yazhou and Deng, Xiangbing and Wang, Ziqiang},
	year = {2015},
	pmid = {25902904},
	keywords = {Humans, Tomography, X-Ray Computed, Risk Factors, Laparoscopy, Postoperative Complications, Lymph Node Excision, Anastomotic Leak, Colorectal Surgery, Obesity, Abdominal, Operative Time, meta-analysis, Surgical Wound Infection, colorectal surgery, visceral fat area, laparoscopic surgery, visceral obesity},
	pages = {507--513},
}

@article{dong827481,
	title = {The {Association} {Between} {Visceral} {Obesity} and {Postoperative} {Outcomes} in {Elderly} {Patients} {With} {Colorectal} {Cancer}},
	volume = {9},
	issn = {2296-875X},
	doi = {10.3389/fsurg.2022.827481},
	abstract = {BACKGROUND: The impact of visceral obesity on the postoperative complications of colorectal cancer in elderly patients has not been well studied. This study aims to explore the influence of visceral obesity on surgical outcomes in elderly patients who have accepted a radical surgery for colorectal cancer.
METHODS: Patients aged over 65 year who had undergone colorectal cancer resections from January 2015 to September 2020 were enrolled. Visceral obesity is typically evaluated based on visceral fat area (VFA) which is measured by computed tomography (CT) imaging. Univariate and multivariate analyses were performed to analyze parameters related to short-term outcomes.
RESULTS: A total of 528 patients participated in this prospective study. Patients with visceral obesity exhibited the higher incidence of total (34.1\% vs. 18.0\%, P {\textless} 0.001), surgical (26.1\% vs. 14.6\%, P = 0.001) and medical (12.6\% vs. 6.7\%, P = 0.022) complications. Based on multivariate analysis, visceral obesity and preoperative poorly controlled hypoalbuminemia were considered as independent risk factors for postoperative complications in elderly patients after colorectal cancer surgery.
CONCLUSIONS: Visceral obesity, evaluated by VFA, was a crucial clinical predictor of short-term outcomes after colorectal cancer surgery in elderly patients. More attentions should be paid to these elderly patients before surgery.},
	language = {eng},
	journal = {Frontiers in Surgery},
	author = {Dong, Qiantong and Song, Haonan and Chen, Weizhe and Wang, Wenbin and Ruan, Xiaojiao and Xie, Tingting and Huang, Dongdong and Chen, Xiaolei and Xing, Chungen},
	year = {2022},
	pmid = {36034360},
	pmcid = {PMC9407030},
	keywords = {risk factor, colorectal cancer, elderly patients, VAT, visceral obesity, postoperative complication},
	pages = {827481},
	file = {Dong et al_2022_The Association Between Visceral Obesity and Postoperative Outcomes in Elderly.pdf:/Users/jcsal/Zotero/storage/LFFRLGPZ/Dong et al_2022_The Association Between Visceral Obesity and Postoperative Outcomes in Elderly.pdf:application/pdf},
}

@article{park436,
	title = {Short- and long-term impact of sarcopenia on outcomes after emergency laparotomy: {A} systematic review and meta-analysis},
	volume = {172},
	issn = {1532-7361},
	shorttitle = {Short- and long-term impact of sarcopenia on outcomes after emergency laparotomy},
	doi = {10.1016/j.surg.2022.02.014},
	abstract = {BACKGROUND: Sarcopenia refers to the progressive age and pathology-associated loss of skeletal muscle, which has been shown to independently predict mortality in patients undergoing major elective surgery. Emergency laparotomy is commonly performed for a range of procedures and is associated with high rates of mortality. However, the prognostic utility of sarcopenia after emergency laparotomy remains unknown. The aim of this study was to compare short and long-term survival between patients with and without sarcopenia undergoing emergency laparotomy.
METHODS: MEDLINE, EMBASE, and Scopus databases were systematically searched for articles comparing survival outcomes between adults with and without radiologically defined sarcopenia after emergency gastrointestinal surgery regardless of indication and approach (open/laparoscopic). The primary outcome was postoperative mortality. Sensitivity analysis of adjusted multivariate analyses was performed.
RESULTS: Twenty articles comprising 6,737 patients were included. Sarcopenia was most commonly assessed using axial abdominal computerized tomography at L3, although cut-off thresholds were heterogeneous and rarely sex-specific. Postoperative mortality was higher among patients with sarcopenia than without in the in-hospital setting, and at 30- and 90-day follow-up on univariate but not on multivariate meta-analysis. However, mortality was significantly higher among sarcopenic cohorts in the 1-year (odds ratio 2.8, 95\% confidence interval: 1.5-5.6; P = .002) follow-up period, despite adjusting for confounding preoperative and patient factors.
CONCLUSION: The meta-analysis has shown sarcopenia to provide useful long-term prognostic information following emergency laparotomy. This may aid with preoperative risk assessment, patient counseling, and in perioperative decision-making for patients undergoing emergency laparotomy.},
	language = {eng},
	number = {1},
	journal = {Surgery},
	author = {Park, Brittany and Bhat, Sameer and Wells, Cameron I. and Barazanchi, Ahmed W. H. and Hill, Andrew G. and MacCormick, Andrew D.},
	month = jul,
	year = {2022},
	pmid = {35379520},
	keywords = {Abdomen, Humans, Female, Male, Sarcopenia, Retrospective Studies, Risk Factors, Risk Assessment, Adult, Postoperative Complications, Laparotomy, EGS},
	pages = {436--445},
}

@article{castillo-angeles31,
	title = {Sarcopenia {Is} {Associated} {With} {Increased} {Mortality} in {Patients} {With} {Necrotizing} {Soft} {Tissue} {Infections}},
	volume = {276},
	issn = {1095-8673},
	doi = {10.1016/j.jss.2022.02.024},
	abstract = {INTRODUCTION: Necrotizing soft tissue infections (NSTIs) are surgical emergencies associated with high morbidity and mortality. Identifying risk factors for poor outcome is a critical part of preoperative decision-making and counseling. Sarcopenia, the loss of lean muscle mass, has been associated with an increased risk of mortality and can be measured using cross-sectional imaging. Our aim was to determine the impact of sarcopenia on mortality in patients with NSTI. We hypothesized that sarcopenia would be associated with an increased risk of mortality in patients with NSTI.
METHODS: This is a retrospective cohort study of NSTI patients admitted from 1995 to 2015 to two academic institutions. Operative and pathology reports were reviewed to confirm the diagnosis in all cases. Average bilateral psoas muscle cross-sectional area at L4, normalized for height (Total Psoas Index [TPI]), was calculated using computed tomography (CT). Sarcopenia was defined as TPI in the lowest sex-specific quartile. Primary outcome was in-hospital mortality. Multivariate logistic regression was performed to assess the association between sarcopenia and in-hospital mortality.
RESULTS: There were 115 patients with preoperative imaging, 61\% male and a median age of 57 y interquartile range (IQR 46.6-67.0). Overall in-hospital mortality was 12.1\%. There was no significant difference in sex, body mass index (BMI), comorbidities and American Society of Anesthesiologists classification (Table 1). After multivariate analysis, sarcopenia was independently associated with increased in-hospital mortality (Odds ratio, 3.5; 95\% Confidence Interval [CI], 1.05-11.8).
CONCLUSIONS: Sarcopenia is associated with increased risk of in-hospital mortality in patients with NSTIs. Sarcopenia identifies patients with higher likelihood of poor outcomes, which can possibly help surgeons in counseling their patients and families.},
	language = {eng},
	journal = {The Journal of Surgical Research},
	author = {Castillo-Angeles, Manuel and Uyeda, Jennifer W. and Seshadri, Anupamaa J. and Ramsis, Ramsis and Okafor, Barbara U. and Nitzschke, Stephanie and Rangel, Erika L. and Saillant, Noelle N. and Salim, Ali and Askari, Reza},
	month = aug,
	year = {2022},
	pmid = {35334381},
	keywords = {Humans, Female, Male, Sarcopenia, Retrospective Studies, Risk Factors, Mortality, Psoas Muscles, EGS, Necrotizing soft tissue infection, Soft Tissue Infections},
	pages = {31--36},
}

@article{hajibandeh370,
	title = {Meta-analysis of the effect of sarcopenia in predicting postoperative mortality in emergency and elective abdominal surgery},
	volume = {17},
	issn = {1479-666X},
	doi = {10.1016/j.surge.2018.09.003},
	abstract = {OBJECTIVES: To investigate the effect of sarcopenia on postoperative mortality in patients undergoing emergency abdominal procedures and to compare postoperative mortality in patients with sarcopenia undergoing emergency abdominal procedures with those undergoing elective abdominal procedures.
METHODS: A search of electronic information sources was conducted to identify all observational studies comparing sarcopenia with no sarcopenia in a) emergency abdominal surgery and b) elective abdominal surgery. We also identified the available cohort of patients in the literature with sarcopenia undergoing abdominal procedures and divided the entire cohort into two groups based on exposure to emergency surgery or elective surgery. The primary outcome measure of this study was postoperative 30-day mortality.
RESULTS: Overall, 4 studies, enrolling a total of 734 patients, were eligible for the comparison in emergency setting and 16 studies, enrolling a total of 4590 patients, were eligible for the comparison in elective setting. Sarcopenia is associated with significantly higher risk of 30-day mortality (RR: 2.15, P {\textless} 0.0001), 1-year mortality (RR:1.97, P {\textless} 0.0001), total complications (RR:2.07, P = 0.0008), and need for ICU admission (RR:1.38, P = 0.003) and significantly longer length of ICU stay (MD:2.26, P = 0.006) and length of hospital stay (MD:2.46, P {\textless} 0.00001) compared to no sarcopenia in patients undergoing emergency abdominal procedures. Sarcopenia was also associated with significantly higher risk of 30-day mortality in patients undergoing elective abdominal procedures (RR:2.15, P = 0.002). Emergency abdominal surgery in patients with sarcopenia was associated with significantly higher risk of 30-day mortality compared to elective surgery (OR:12.00, P {\textless} 0.00001).
CONCLUSIONS: Sarcopenia is an independent predictor of postoperative mortality in emergency abdominal surgery.},
	language = {eng},
	number = {6},
	journal = {The Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland},
	author = {Hajibandeh, Shahab and Hajibandeh, Shahin and Jarvis, Ross and Bhogal, Talvinder and Dalmia, Sanjush},
	month = dec,
	year = {2019},
	pmid = {30389220},
	keywords = {Abdomen, Humans, Sarcopenia, Postoperative Complications, Laparotomy, Elective Surgical Procedures, EGS, Elective surgical procedure, General surgery},
	pages = {370--380},
}

@article{edmundse0193241,
	title = {Advanced quantitative methods in correlating sarcopenic muscle degeneration with lower extremity function biometrics and comorbidities},
	volume = {13},
	issn = {1932-6203},
	doi = {10.1371/journal.pone.0193241},
	abstract = {Sarcopenic muscular degeneration has been consistently identified as an independent risk factor for mortality in aging populations. Recent investigations have realized the quantitative potential of computed tomography (CT) image analysis to describe skeletal muscle volume and composition; however, the optimum approach to assessing these data remains debated. Current literature reports average Hounsfield unit (HU) values and/or segmented soft tissue cross-sectional areas to investigate muscle quality. However, standardized methods for CT analyses and their utility as a comorbidity index remain undefined, and no existing studies compare these methods to the assessment of entire radiodensitometric distributions. The primary aim of this study was to present a comparison of nonlinear trimodal regression analysis (NTRA) parameters of entire radiodensitometric muscle distributions against extant CT metrics and their correlation with lower extremity function (LEF) biometrics (normal/fast gait speed, timed up-and-go, and isometric leg strength) and biochemical and nutritional parameters, such as total solubilized cholesterol (SCHOL) and body mass index (BMI). Data were obtained from 3,162 subjects, aged 66-96 years, from the population-based AGES-Reykjavik Study. 1-D k-means clustering was employed to discretize each biometric and comorbidity dataset into twelve subpopulations, in accordance with Sturges' Formula for Class Selection. Dataset linear regressions were performed against eleven NTRA distribution parameters and standard CT analyses (fat/muscle cross-sectional area and average HU value). Parameters from NTRA and CT standards were analogously assembled by age and sex. Analysis of specific NTRA parameters with standard CT results showed linear correlation coefficients greater than 0.85, but multiple regression analysis of correlative NTRA parameters yielded a correlation coefficient of 0.99 (P{\textless}0.005). These results highlight the specificities of each muscle quality metric to LEF biometrics, SCHOL, and BMI, and particularly highlight the value of the connective tissue regime in this regard.},
	language = {eng},
	number = {3},
	journal = {PloS One},
	author = {Edmunds, Kyle and Gíslason, Magnús and Sigurðsson, Sigurður and Guðnason, Vilmundur and Harris, Tamara and Carraro, Ugo and Gargiulo, Paolo},
	year = {2018},
	pmid = {29513690},
	pmcid = {PMC5841751},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Sarcopenia, Body Mass Index, Follow-Up Studies, Sex Factors, Prospective Studies, Aged, 80 and over, Age Factors, Comorbidity, Regression Analysis, CGA, Cluster Analysis, Disability Evaluation, Lower Extremity, Nonlinear Dynamics},
	pages = {e0193241},
	file = {Full Text:/Users/jcsal/Zotero/storage/GGNWQTFZ/Edmunds et al. - 2018 - Advanced quantitative methods in correlating sarco.pdf:application/pdf},
}

@article{austin107,
	title = {A {Comparison} of {Statistical} {Modeling} {Strategies} for {Analyzing} {Length} of {Stay} after {CABG} {Surgery}},
	volume = {3},
	issn = {1572-9400},
	url = {https://doi.org/10.1023/A:1024260023851},
	doi = {10.1023/A:1024260023851},
	abstract = {Investigators in clinical research are often interested in determining the association between patient characteristics and post-operative length of stay (LOS). We examined the relative performance of seven different statistical strategies for analyzing LOS in a cohort of patients undergoing CABG surgery. We compared linear regression; linear regression with log-transformed length of stay; generalized linear models with the following distributions: Poisson, negative binomial, normal, and gamma; and semi-parametric survival models.},
	language = {en},
	number = {2},
	urldate = {2023-03-19},
	journal = {Health Services and Outcomes Research Methodology},
	author = {Austin, Peter C. and Rothwell, Deanna M. and Tu, Jack V.},
	month = jun,
	year = {2002},
	keywords = {LOS, CABG surgery, generalized linear model, length of stay, predictive modeling},
	pages = {107--133},
	file = {Austin et al_2002_A Comparison of Statistical Modeling Strategies for Analyzing Length of Stay.pdf:/Users/jcsal/Zotero/storage/HSEPKGL3/Austin et al_2002_A Comparison of Statistical Modeling Strategies for Analyzing Length of Stay.pdf:application/pdf},
}

@article{takenami2686,
	title = {Impact of sarcopenia on surgical and oncologic outcomes of laparoscopic surgery for colorectal cancer},
	volume = {45},
	issn = {0219-3108},
	doi = {10.1016/j.asjsur.2021.12.075},
	abstract = {BACKGROUND: The study aimed to evaluate the impact of sarcopenia on short- and long-term outcomes for laparoscopic colorectal cancer surgery.
METHODS: Study participants were 209 patients who underwent laparoscopic surgery for any stage of colorectal cancer between 2016 and 2017. Skeletal muscle indices were calculated with preoperative computed tomography. Patients were divided into sarcopenic and non-sarcopenic groups based on index cut-off values and variables were compared.
RESULTS: The prevalence of sarcopenia was 41.1\%. Sarcopenic patients experienced shorter operative times and a lower incidence of surgical site infections; however, the incidence of severe postoperative complications and readmission were increased for this group. Although the 3-year disease-free survival rate was not statistically different between groups, sarcopenic patients had a significantly worse 3-year overall survival rate compared with than the non-sarcopenic group.
CONCLUSION: Sarcopenia has both favorable and unfavorable effects on patients who underwent laparoscopic colorectal cancer surgery.},
	language = {eng},
	number = {12},
	journal = {Asian Journal of Surgery},
	author = {Takenami, Tsutomu and Tsujinaka, Shingo and Miyakura, Yasuyuki and Kakizawa, Nao and Maemoto, Ryo and Machida, Erika and Hatsuzawa, Yuuri and Takahashi, Rei and Kimura, Yasuaki and Tamaki, Sawako and Ishikawa, Hideki and Rikiyama, Toshiki},
	month = dec,
	year = {2022},
	pmid = {35221194},
	keywords = {Humans, Muscle, Skeletal, Sarcopenia, Colorectal Neoplasms, Retrospective Studies, Prognosis, Laparoscopy, Postoperative Complications, Colorectal surgery, Readmission, Laparoscopic surgery},
	pages = {2686--2690},
	file = {Takenami et al_2022_Impact of sarcopenia on surgical and oncologic outcomes of laparoscopic surgery.pdf:/Users/jcsal/Zotero/storage/SPF5Z7AT/Takenami et al_2022_Impact of sarcopenia on surgical and oncologic outcomes of laparoscopic surgery.pdf:application/pdf},
}

@article{ouchi366,
	title = {Laparoscopic {Colorectal} {Resection} in {Patients} with {Sarcopenia}: {A} {Retrospective} {Case}-{Control} {Study}},
	volume = {26},
	issn = {1557-9034},
	shorttitle = {Laparoscopic {Colorectal} {Resection} in {Patients} with {Sarcopenia}},
	doi = {10.1089/lap.2015.0494},
	abstract = {BACKGROUND AND OBJECTIVES: Previous study has reported that sarcopenia increases the risk of postoperative complications following open colorectal resection. The aim of this retrospective case-control study was to evaluate the feasibility of laparoscopic colorectal resection in patients with sarcopenia.
METHODS: We retrospectively analyzed 60 patients who underwent laparoscopic colorectal resection for primary colorectal cancer between April 2012 and March 2015 at our institution. The patients were divided into two groups: sarcopenia group (normalized total psoas muscle area in males, {\textless}538 mm/m(2); in females, {\textless}346 mm/m(2); n = 20) and nonsarcopenia group (n = 40).
RESULTS: No significant differences in the overall rate of postoperative complications (20\% vs. 20\%) or major postoperative complications of Clavien-Dindo Grade III or more (5\% vs. 5\%) were observed between the patients in the sarcopenia and nonsarcopenia groups. Sarcopenia was not found to be a predictor of postoperative complications by univariate analysis.
CONCLUSION: Laparoscopic colorectal resection was feasible in patients with sarcopenia.},
	language = {eng},
	number = {5},
	journal = {Journal of Laparoendoscopic \& Advanced Surgical Techniques. Part A},
	author = {Ouchi, Akira and Asano, Masahiko and Aono, Keiya and Watanabe, Tetsuya and Oya, Shingo},
	month = may,
	year = {2016},
	pmid = {26982506},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Treatment Outcome, Colorectal Neoplasms, Retrospective Studies, Aged, 80 and over, Adult, Colectomy, Laparoscopy, Feasibility Studies, Laparoscopic},
	pages = {366--370},
}

@article{pedziwiatr779,
	title = {Laparoscopic colorectal cancer surgery combined with enhanced recovery after surgery protocol ({ERAS}) reduces the negative impact of sarcopenia on short-term outcomes},
	volume = {42},
	issn = {1532-2157},
	doi = {10.1016/j.ejso.2016.03.037},
	abstract = {INTRODUCTION: Progressive skeletal muscle loss (sarcopenia) is a negative prognostic factor in patients treated for colorectal cancer. Nevertheless, the clinical impact of those changes in body composition has been analyzed only in patients undergoing open resections. The aim of the study was to assess whether laparoscopy may eliminate the deleterious prognostic impact of sarcopenia and whether the combination with enhanced recovery after surgery (ERAS) protocol may improve postoperative recovery also in sarcopenic patients.
METHODS: The study included 124 (73M/51F, mean age 65.9 years) patients undergoing elective laparoscopic colorectal resection for cancer. In all of them 16-item ERAS protocol was applied. The L3 skeletal muscle area identified on a preoperative CT scan was used to calculate skeletal muscle index and assess for sarcopenia and myosteatosis. The entire study group was divided into groups regarding the presence of sarcopenia or myosteatosis. The outcome measures were: length of hospital stay, complication rate and functional recovery parameters.
RESULTS: The prevalence of sarcopenia and myosteatosis was 27.4\% and 38.7\%, respectively. There was no association between the presence of sarcopenia or myosteatosis and postoperative complications. There were also no differences in the length of stay or readmission rates. Functional recovery (time to first flatus, oral diet tolerance and mobilization) was similar regardless of the presence of muscle depletion.
CONCLUSIONS: In contrary to traditional surgical approach, laparoscopy can reduce the negative impact of sarcopenia and myosteatosis on treatment results. ERAS protocol does not affect negatively the surgical outcomes in sarcopenic patients, compared to patients without changes in body skeletal mass.},
	language = {eng},
	number = {6},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Pędziwiatr, M. and Pisarska, M. and Major, P. and Grochowska, A. and Matłok, M. and Przęczek, K. and Stefura, T. and Budzyński, A. and Kłęk, S.},
	month = jun,
	year = {2016},
	pmid = {27156809},
	keywords = {Humans, Aged, Length of Stay, Sarcopenia, Colorectal Neoplasms, Myosteatosis, Laparoscopy, Postoperative Complications, Colorectal cancer, Elective Surgical Procedures, Enhanced recovery after surgery, Fast-track surgery, Postoperative recovery},
	pages = {779--787},
	file = {Pędziwiatr et al_2016_Laparoscopic colorectal cancer surgery combined with enhanced recovery after.pdf:/Users/jcsal/Zotero/storage/H7HVHTZ2/Pędziwiatr et al_2016_Laparoscopic colorectal cancer surgery combined with enhanced recovery after.pdf:application/pdf},
}

@article{huangO256,
	title = {Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer},
	volume = {17},
	issn = {1463-1318},
	doi = {10.1111/codi.13067},
	abstract = {AIM: Recent studies have shown that sarcopenia is associated with negative postoperative outcomes. However, none of these studies analysed muscle strength or physical performance, which are also important components of sarcopenia. The present study aimed to investigate whether sarcopenia itself, as defined by low muscle mass, strength and physical performance, would predict complications after surgery for colorectal cancer.
METHOD: We conducted a prospective study of patients who underwent surgery for colorectal cancer at our department between August 2014 and February 2015. Sarcopenia was diagnosed by a combination of third lumbar vertebra muscle index (L3 MI), handgrip strength and 6-m usual gait speed. Univariate and multivariate analyses evaluating the risk factors for postoperative complications were performed. Only complications classified as Grade II or above according to the Clavien-Dindo classification were analysed in this study.
RESULTS: A total of 142 patients were included in the study, and 17 patients were diagnosed as having sarcopenia. Postoperative complications of Grade II or above occurred in 40 patients, including 10 with sarcopenia and 30 without sarcopenia. Multivariate analysis showed that sarcopenia and previous abdominal surgery were independent risk factors for postoperative complications. Patients with sarcopenia also had an obvious tendency to a higher incidence of infectious complications. By comparing two logistic regression models, sarcopenia showed a better predictive power for postoperative complications than did low muscle mass.
CONCLUSION: Sarcopenia and previous abdominal surgery are independent risk factors for complications after surgery for colorectal cancer. Including a functional aspect to the definition of sarcopenia may result in a better prediction of postoperative complications.},
	language = {eng},
	number = {11},
	journal = {Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland},
	author = {Huang, D.-D. and Wang, S.-L. and Zhuang, C.-L. and Zheng, B.-S. and Lu, J.-X. and Chen, F.-F. and Zhou, C.-J. and Shen, X. and Yu, Z.},
	month = nov,
	year = {2015},
	pmid = {26194849},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Follow-Up Studies, Risk Factors, Prospective Studies, Prognosis, Postoperative Complications, Muscle Strength, postoperative complications, risk factors, colorectal surgery, colorectal neoplasms, Physical Endurance},
	pages = {O256--264},
	file = {Huang et al_2015_Sarcopenia, as defined by low muscle mass, strength and physical performance,.pdf:/Users/jcsal/Zotero/storage/YHFDZG6L/Huang et al_2015_Sarcopenia, as defined by low muscle mass, strength and physical performance,.pdf:application/pdf},
}

@article{malietzis572,
	title = {Influence of body composition profile on outcomes following colorectal cancer surgery},
	volume = {103},
	issn = {1365-2168},
	doi = {10.1002/bjs.10075},
	abstract = {BACKGROUND: Muscle depletion is characterized by reduced muscle mass (myopenia), and increased infiltration by intermuscular and intramuscular fat (myosteatosis). This study examined the role of particular body composition profiles as prognostic markers for patients with colorectal cancer undergoing curative resection.
METHODS: Patients with colorectal cancer undergoing elective surgical resection between 2006 and 2011 were included. Lumbar skeletal muscle index (LSMI), visceral adipose tissue (VAT) surface area and mean muscle attenuation (MA) were calculated by analysis of CT images. Reduced LSMI (myopenia), increased VAT (visceral obesity) and low MA (myosteatosis) were identified using predefined sex-specific skeletal muscle index values. Univariable and multivariable Cox regression models were used to determine the role of different body composition profiles on outcomes.
RESULTS: Some 805 patients were identified, with a median follow-up of 47 (i.q.r. 24·9-65·6) months. Multivariable analysis identified myopenia as an independent prognostic factor for disease-free survival (hazard ratio (HR) 1·53, 95 per cent c.i. 1·06 to 2·39; P = 0·041) and overall survival (HR 1·70, 1·25 to 2·31; P {\textless} 0·001). The presence of myosteatosis was associated with prolonged primary hospital stay (P = 0·034), and myopenic obesity was related to higher 30-day morbidity (P = 0·019) and mortality (P {\textless} 0·001) rates.
CONCLUSION: Myopenia may have an independent prognostic effect on cancer survival for patients with colorectal cancer. Muscle depletion may represent a modifiable risk factor in patients with colorectal cancer and needs to be targeted as a relevant endpoint of health recommendations.},
	language = {eng},
	number = {5},
	journal = {The British Journal of Surgery},
	author = {Malietzis, G. and Currie, A. C. and Athanasiou, T. and Johns, N. and Anyamene, N. and Glynne-Jones, R. and Kennedy, R. H. and Fearon, K. C. H. and Jenkins, J. T.},
	month = apr,
	year = {2016},
	pmid = {26994716},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Aged, Female, Length of Stay, Male, Middle Aged, Prevalence, Sarcopenia, Treatment Outcome, Colorectal Neoplasms, Follow-Up Studies, Prognosis, Colectomy, Databases, Factual, Survival Analysis, Intra-Abdominal Fat, Postoperative Complications, Multivariate Analysis, Rectum, Elective Surgical Procedures, Obesity, Abdominal},
	pages = {572--580},
}

@article{li47,
	title = {The first step for neuroimaging data analysis: {DICOM} to {NIfTI} conversion},
	volume = {264},
	issn = {1872-678X},
	shorttitle = {The first step for neuroimaging data analysis},
	doi = {10.1016/j.jneumeth.2016.03.001},
	abstract = {BACKGROUND: Clinical imaging data are typically stored and transferred in the DICOM format, whereas the NIfTI format has been widely adopted by scientists in the neuroimaging community. Therefore, a vital initial step in processing the data is to convert images from the complicated DICOM format to the much simpler NIfTI format. While there are a number of tools that usually handle DICOM to NIfTI conversion seamlessly, some variations can disrupt this process.
NEW METHOD: We provide some insight into the challenges faced with image conversion. First, different manufacturers implement the DICOM format differently which complicates the conversion. Second, different modalities and sub-modalities may need special treatment during conversion. Lastly, the image transferring and archiving can also impact the DICOM conversion.
RESULTS: We present results in several error-prone domains, including the slice order for functional imaging, phase encoding direction for distortion correction, effect of diffusion gradient direction, and effect of gantry correction for some imaging modality.
COMPARISON WITH EXISTING METHODS: Conversion tools are often designed for a specific manufacturer or modality. The tools and insight we present here are aimed at different manufacturers or modalities.
CONCLUSIONS: The imaging conversion is complicated by the variation of images. An understanding of the conversion basics can be helpful for identifying the source of the error. Here we provide users with simple methods for detecting and correcting problems. This also serves as an overview for developers who wish to either develop their own tools or adapt the open source tools created by the authors.},
	language = {eng},
	journal = {Journal of Neuroscience Methods},
	author = {Li, Xiangrui and Morgan, Paul S. and Ashburner, John and Smith, Jolinda and Rorden, Christopher},
	month = may,
	year = {2016},
	pmid = {26945974},
	keywords = {Humans, Image Processing, Computer-Assisted, DICOM, Functional Neuroimaging, Neuroimaging, NIfTI, NiftI},
	pages = {47--56},
	file = {Li et al_2016_The first step for neuroimaging data analysis.pdf:/Users/jcsal/Zotero/storage/7AYHRSDV/Li et al_2016_The first step for neuroimaging data analysis.pdf:application/pdf},
}

@article{dun5654424,
	title = {Efficient {Johnson}-{SB} {Mixture} {Model} for {Segmentation} of {CT} {Liver} {Image}},
	volume = {2022},
	issn = {2040-2309},
	doi = {10.1155/2022/5654424},
	abstract = {To overcome the problem that the traditional Gaussian mixture model (GMM) cannot well describe the skewness distribution of the gray-level histogram of a liver CT slice, we propose a novel segmentation method for liver CT images by introducing the Johnson-SB mixture model (JSBMM). The Johnson-SB model not only has a flexible asymmetrical distribution but also covers a variety of other distributions as well. In this article, the parameter optimization formulas for JSBMM were derived by employing the expectation-maximization (EM) algorithm and maximum likelihood. The implementation process of the JSBMM-based segmentation algorithm is provided in detail. To make better use of the skewness of Johnson-SB and improve the segmentation accuracy, we devise an idea to divide the histogram into two parts and calculate the segmentation threshold for each part, respectively, which is called JSBMM-TDH. By analyzing and comparing the segmentation thresholds with different cluster numbers, it is illustrated that the segmentation threshold of JSBMM-TDH will tend to be stable with the increasing of cluster number, while that of GMM is sensitive to different cluster numbers. The proposed JSBMM-TDH is applied to segment four randomly obtained abdominal CT image sequences, and the segmentation results and robustness have been compared between JSBMM-TDH and GMM. It is verified that JSBMM-TDH has preferable segmentation results and better robustness than GMM for the segmentation of liver CT images.},
	language = {eng},
	journal = {Journal of Healthcare Engineering},
	author = {Dun, Yueqin and Kong, Yu},
	year = {2022},
	pmid = {35463693},
	pmcid = {PMC9023182},
	keywords = {Humans, Tomography, X-Ray Computed, Liver, Image Processing, Computer-Assisted, Myosteatosis, Algorithms, GMM, Normal Distribution},
	pages = {5654424},
	file = {Dun_Kong_2022_Efficient Johnson-SB Mixture Model for Segmentation of CT Liver Image.pdf:/Users/jcsal/Zotero/storage/2ZQTH2SG/Dun_Kong_2022_Efficient Johnson-SB Mixture Model for Segmentation of CT Liver Image.pdf:application/pdf},
}

@article{lee371,
	title = {Utility of {Fully} {Automated} {Body} {Composition} {Measures} on {Pretreatment} {Abdominal} {CT} for {Predicting} {Survival} in {Patients} {With} {Colorectal} {Cancer}},
	volume = {220},
	issn = {1546-3141},
	doi = {10.2214/AJR.22.28043},
	abstract = {BACKGROUND. CT examinations contain opportunistic body composition data with potential prognostic utility. Previous studies have primarily used manual or semiautomated tools to evaluate body composition in patients with colorectal cancer (CRC). OBJECTIVE. The purpose of this article is to assess the utility of fully automated body composition measures derived from pretreatment CT examinations in predicting survival in patients with CRC. METHODS. This retrospective study included 1766 patients (mean age, 63.7 ± 14.4 [SD] years; 862 men, 904 women) diagnosed with CRC between January 2001 and September 2020 who underwent pretreatment abdominal CT. A panel of fully automated artificial intelligence-based algorithms was applied to portal venous phase images to quantify skeletal muscle attenuation at the L3 lumbar level, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area at L3, and abdominal aorta Agatston score (aortic calcium). The electronic health record was reviewed to identify patients who died of any cause (n = 848). ROC analyses and logistic regression analyses were used to identify predictors of survival, with attention to highest- and lowest-risk quartiles. RESULTS. Patients who died, compared with patients who survived, had lower median muscle attenuation (19.2 vs 26.2 HU, p {\textless} .001), SAT area (168.4 cm2 vs 197.6 cm2, p {\textless} .001), and aortic calcium (620 vs 182, p {\textless} .001). Measures with highest 5-year AUCs for predicting survival in patients without (n = 1303) and with (n = 463) metastatic disease were muscle attenuation (0.666 and 0.701, respectively) and aortic calcium (0.677 and 0.689, respectively). A combination of muscle attenuation, SAT area, and aortic calcium yielded 5-year AUCs of 0.758 and 0.732 in patients without and with metastases, respectively. Risk of death was increased (p {\textless} .05) in patients in the lowest quartile for muscle attenuation (hazard ratio [HR] = 1.55) and SAT area (HR = 1.81) and in the highest quartile for aortic calcium (HR = 1.37) and decreased (p {\textless} .05) in patients in the highest quartile for VAT area (HR = 0.79) and SAT area (HR = 0.76). In 423 patients with available BMI, BMI did not significantly predict death (p = .75). CONCLUSION. Fully automated CT-based body composition measures including muscle attenuation, SAT area, and aortic calcium predict survival in patients with CRC. CLINICAL IMPACT. Routine pretreatment body composition evaluation could improve initial risk stratification of patients with CRC.},
	language = {eng},
	number = {3},
	journal = {AJR. American journal of roentgenology},
	author = {Lee, Matthew H. and Pickhardt, Silas G. and Garrett, John W. and Perez, Alberto A. and Zea, Ryan and Valle, Kevin Franco and Lubner, Meghan G. and Bates, David D. B. and Summers, Ronald M. and Pickhardt, Perry J.},
	month = mar,
	year = {2023},
	pmid = {36000663},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Colorectal Neoplasms, Retrospective Studies, body composition, colorectal cancer, CT, Artificial Intelligence, artificial intelligence, Calcium},
	pages = {371--380},
}

@inproceedings{tan3173,
	title = {An {Automated} and {Robust} {Framework} for {Quantification} of {Muscle} and {Fat} in the {Thigh}},
	doi = {10.1109/ICPR.2014.547},
	abstract = {The tissue quantification in the thigh (e.g. cross-sectional areas of adipose tissue and muscle) is important, since their quantities reflect adverse metabolic effects and muscle function. Traditional manual analysis is time-consuming and operator-dependent, especially in the case of multi-slices or 3D datasets. In clinical trials, there are a large amount of datasets acquired from magnetic resonance imaging (MRI) or X-ray computed tomography (CT) that requires automatic labeling of individual tissues. Since most segmentation algorithms are not suited for different modalities, we present an automatic and robust framework for the quantitative assessment of muscle and fat tissues on 3D MR or CT data. In our framework, a variational Bayesian Gaussian mixture model is used to cluster regions of interest in images into adipose tissues (fat and marrow), muscle, bone and background. The identification of each cluster is based on marrow detection. Furthermore, we use a combination of parametric and geodesic active contour models to distinguish different adipose tissues in 3D images. To validate our proposed framework, we have conducted preliminary experiments on five volumetric mid-thigh axial datasets of MR and CT images from clinical trials.},
	booktitle = {2014 22nd {International} {Conference} on {Pattern} {Recognition}},
	author = {Tan, Chaowei and Yan, Zhennan and Zhang, Shaoting and Belaroussi, Boubakeur and Yu, Hui Jing and Miller, Colin and Metaxas, Dimitris N.},
	month = aug,
	year = {2014},
	note = {ISSN: 1051-4651},
	keywords = {Muscles, Myosteatosis, Image segmentation, Computed tomography, MixedModel, Thigh, Bones, Magnetic resonance imaging, Three-dimensional displays},
	pages = {3173--3178},
	annote = {Mixed Models
},
	file = {IEEE Xplore Abstract Record:/Users/jcsal/Zotero/storage/24HV3ULI/6977259.html:text/html},
}

@article{goodpaster372,
	title = {Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women},
	volume = {26},
	issn = {0149-5992},
	doi = {10.2337/diacare.26.2.372},
	abstract = {OBJECTIVE: We examined whether regional adipose tissue distribution, specifically that of skeletal muscle fat and visceral abdominal fat aggregation, is characteristic of elderly individuals with hyperinsulinemia, type 2 diabetes, and impaired glucose tolerance (IGT).
RESEARCH DESIGN AND METHODS: A total of 2,964 elderly men and women (mean age 73.6 years) were recruited for cross-sectional comparisons of diabetes or glucose tolerance, generalized obesity with dual-energy X-ray absorptiometry, and regional body fat distribution with computed tomography. RESULTS-Approximately one-third of men with type 2 diabetes and less than half of women with type 2 diabetes were obese (BMI {\textgreater} or =30 kg/m(2)). Despite similar amounts of subcutaneous thigh fat, intermuscular fat was higher in subjects with type 2 diabetes and IGT than in subjects with normal glucose tolerance (NGT) (11.2 +/- 9.4, 10.3 +/- 5.8, and 9.2 +/- 5.9 cm(2) for men; 12.1 +/- 6.1, 10.9 +/- 6.5, and 9.4 +/- 5.3 cm(2) for women; both P {\textless} 0.0001). Visceral abdominal fat was also higher in men and women with type 2 diabetes and IGT than in subjects with NGT (172 +/- 79, 163 +/- 72, and 145 +/- 66 cm(2) for men; 162 +/- 66, 141 +/- 60, and 116 +/- 54 cm(2) for women; both P {\textless} 0.0001 across groups). Higher rates of intermuscular fat and visceral abdominal fat were associated with higher fasting insulin in normal-weight (BMI {\textless}25 kg/m(2)) men (r = 0.24 for intermuscular fat, r = 0.37 for visceral abdominal fat, both P {\textless} 0.0001) and women (r = 0.20 for intermuscular fat, r = 0.40 for visceral abdominal fat, both P {\textless} 0.0001). These associations were not found in obese subjects.
CONCLUSIONS: Elderly men and women with normal body weight may be at risk for metabolic abnormalities, including type 2 diabetes, if they possess an inordinate amount of muscle fat or visceral abdominal fat.},
	language = {eng},
	number = {2},
	journal = {Diabetes Care},
	author = {Goodpaster, Bret H. and Krishnaswami, Shanthi and Resnick, Helaine and Kelley, David E. and Haggerty, Catherine and Harris, Tamara B. and Schwartz, Ann V. and Kritchevsky, Steven and Newman, Anne B.},
	month = feb,
	year = {2003},
	pmid = {12547865},
	keywords = {Abdomen, Adipose Tissue, Humans, Tomography, X-Ray Computed, Aged, Female, Male, Body Mass Index, Longitudinal Studies, Absorptiometry, Photon, Cohort Studies, Myosteatosis, Insulin, Diabetes Mellitus, Type 2, Fasting, Glucose Intolerance, LAMA, Viscera},
	pages = {372--379},
}

@article{cossu1047,
	title = {Sarcopenia and {Patient}'s {Body} {Composition}: {New} {Morphometric} {Tools} to {Predict} {Clinical} {Outcome} {After} {Ivor} {Lewis} {Esophagectomy}: a {Multicenter} {Study}},
	volume = {27},
	issn = {1873-4626},
	shorttitle = {Sarcopenia and {Patient}'s {Body} {Composition}},
	doi = {10.1007/s11605-023-05611-1},
	abstract = {BACKGROUND: The impact of preoperative body composition as independent predictor of prognosis for esophageal cancer patients after esophagectomy is still unclear. The aim of the study was to explore such a relationship.
METHODS: This is a multicenter retrospective study from a prospectively maintained database. We enrolled consecutive patients who underwent Ivor-Lewis esophagectomy in four Italian high-volume centers from May 2014. Body composition parameters including total abdominal muscle area (TAMA), visceral fat area (VFA), and subcutaneous fat area (SFA) were determined based on CT images. Perioperative variables were systematically collected.
RESULTS: After exclusions, 223 patients were enrolled and 24.2\% had anastomotic leak (AL). Sixty-eight percent of patients were sarcopenic and were found to be more vulnerable in terms of postoperative 90-day mortality (p = 0.028). VFA/TAMA and VFA/SFA ratios demonstrated a linear correlation with the Clavien-Dindo classification (R = 0.311 and 0.239, respectively); patients with anastomotic leak (AL) had significantly higher VFA/TAMA (3.56 ± 1.86 vs. 2.75 ± 1.83, p = 0.003) and VFA/SFA (1.18 ± 0.68 vs. 0.87 ± 0.54, p = 0.002) ratios. No significant correlation was found between preoperative BMI and subsequent AL development (p = 0.159). Charlson comorbidity index correlated significantly with AL (p = 0.008): these patients had a significantly higher index (≥ 5).
CONCLUSION: Analytical morphometric assessment represents a useful non-invasive tool for preoperative risk stratification. The concurrent association of sarcopenia and visceral obesity seems to be the best predictor of AL, far better than simple BMI evaluation, and potentially modifiable if targeted with prehabilitation programs.},
	language = {eng},
	number = {6},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Cossu, Andrea and Palumbo, Diego and Battaglia, Silvia and Parise, Paolo and De Pascale, Stefano and Gualtierotti, Monica and Vecchiato, Massimo and Scotti, Giulia Maria and Gritti, Chiara and Bettinelli, Andrea and Puccetti, Francesco and Barbieri, Lavinia and Fabbi, Manrica and Funicelli, Luigi and Bonfitto, Giuseppe Roberto and De Martini, Paolo and Martino, Antonio and Ziccarelli, Antonio and Fapranzi, Stefano and Ravizzini, Lidia and Uzzau, Alessandro and Fumagalli Romario, Uberto and Ferrari, Giovanni and Petri, Roberto and Elmore, Ugo and De Cobelli, Francesco and Rosati, Riccardo and {SISME –Società Italiana per lo Studio delle Malattie dell’Esofago –Italian Society of disease of the esophagus}},
	month = jun,
	year = {2023},
	pmid = {36750544},
	keywords = {Body Composition, Humans, Sarcopenia, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Anastomotic Leak},
	pages = {1047--1054},
}

@article{bambae0180036,
	title = {Sarcopenia is a predictive factor for intestinal resection in admitted patients with {Crohn}'s disease},
	volume = {12},
	issn = {1932-6203},
	doi = {10.1371/journal.pone.0180036},
	abstract = {The relationship between skeletal muscle volume and the prognosis of patients with inflammatory bowel disease (IBD) remains undetermined. We conducted a retrospective study of 72 IBD patients who were admitted to the hospital due to disease exacerbation. We enrolled IBD patients who had undergone abdominal computed tomography and assessed the nutritional indices, such as the Onodera's prognostic nutritional index (O-PNI) and the controlling nutritional status (CONUT) index. The L3 skeletal muscle index (SMI), which is the ratio of the cross-sectional area of skeletal muscles at the level of the third lumbar (L3) vertebra to the height squared, was used to identify sarcopenia. Sarcopenia, defined as a low SMI, was observed in 42\% of all IBD patients (37\% with Crohn's disease (CD) and 48\% with ulcerative colitis (UC)). In UC patients, the O-PNI and CONUT values, height, and albumin levels were significantly lower than in CD patients. The SMI strongly correlated with sex, body weight, albumin level, and O-PNI in IBD patients. Multivariate analysis using the Cox regression model demonstrated that the presence of sarcopenia (P = 0.015) and disease type (CD or UC) (P = 0.007) were significant factors predicting intestinal resection. The cumulative operation-free survival rate was significantly lower for sarcopenic patients than in all IBD patients (P = 0.003) and a stratified analysis of CD patients (P = 0.001) using the Kaplan-Meier method and log-rank test. The L3 skeletal muscle area is a prognostic factor for intestinal resection in patients with CD.},
	language = {eng},
	number = {6},
	journal = {PloS One},
	author = {Bamba, Shigeki and Sasaki, Masaya and Takaoka, Azusa and Takahashi, Kenichiro and Imaeda, Hirotsugu and Nishida, Atsushi and Inatomi, Osamu and Sugimoto, Mitsushige and Andoh, Akira},
	year = {2017},
	pmid = {28644887},
	pmcid = {PMC5482469},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Hospitalization, Male, Middle Aged, Sarcopenia, Treatment Outcome, Follow-Up Studies, Kaplan-Meier Estimate, Retrospective Studies, Proportional Hazards Models, Prognosis, Organ Size, Adult, Multivariate Analysis, Lumbar Vertebrae, Albumins, Colitis, Ulcerative, Crohn Disease, IBD, Intestines},
	pages = {e0180036},
	file = {Bamba et al_2017_Sarcopenia is a predictive factor for intestinal resection in admitted patients.pdf:/Users/jcsal/Zotero/storage/5UAINCJP/Bamba et al_2017_Sarcopenia is a predictive factor for intestinal resection in admitted patients.pdf:application/pdf},
}

@article{erhayiem684,
	title = {Ratio of visceral to subcutaneous fat area is a biomarker of complicated {Crohn}'s disease},
	volume = {9},
	issn = {1542-7714},
	doi = {10.1016/j.cgh.2011.05.005},
	abstract = {BACKGROUND \& AIMS: Fat wrapping and mesenteric hypertrophy are characteristics of Crohn's disease (CD). In patients with CD, mesenteric adipose tissue releases higher levels of adiponectin, which could up-regulate production of tumor necrosis factor-α and increase the risk for aggressive disease. We investigated whether a higher ratio of visceral to subcutaneous fat was associated with complicated (fistulating or stricturing) CD.
METHODS: We identified patients with a confirmed diagnosis of CD who had computed tomography scans of their abdomens (n = 50). Areas of subcutaneous and visceral fat were measured in 1 cross-sectional scan that was taken at the level of the umbilicus. The mesenteric fat index (MFI), defined as the ratio of areas of visceral to subcutaneous fat, was compared between patients with complicated (strictures and fistulas) and inflammatory CD.
RESULTS: The mean age of the patients with complications (n = 29) was 49.3 ± 15.6 years, and in patients with inflammatory CD (n = 21) it was 37.7 ± 19.1 years. The MFI was significantly higher (P = .001) in patients with complicated disease (0.67 ± 0.29) than in those with uncomplicated disease (0.23 ± 0.10) and was the only variable that remained significantly different on multivariate analysis. The area under the receiver operating curve for the MFI was 0.95 (95\% confidence interval, 0.89-1.0), and an MFI of 0.29 identified patients with complicated CD with 93\% sensitivity and 81\% specificity.
CONCLUSIONS: A high ratio of areas of visceral to subcutaneous fat (MFI) is a marker of aggressive CD. Further studies are needed to determine the roles of adipose tissue in pathogenesis of CD.},
	language = {eng},
	number = {8},
	journal = {Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association},
	author = {Erhayiem, Bara and Dhingsa, Rajpal and Hawkey, Christopher J. and Subramanian, Venkataraman},
	month = aug,
	year = {2011},
	pmid = {21642015},
	keywords = {Humans, Tomography, X-Ray Computed, Female, Male, Middle Aged, Adult, Biomarkers, Abdominal Fat, Subcutaneous Fat, Radiography, Abdominal, VAT, Crohn Disease, IBD, Body Fat Distribution, VSR},
	pages = {684--687.e1},
}

@article{holt1255,
	title = {Visceral adiposity predicts post-operative {Crohn}'s disease recurrence},
	volume = {45},
	issn = {1365-2036},
	doi = {10.1111/apt.14018},
	abstract = {BACKGROUND: Excessive visceral adipose tissue has been associated with poorer outcomes in patients with inflammatory bowel disease.
AIM: To determine whether body composition is associated with outcome in a prospective study of post-operative Crohn's disease patients.
METHODS: The POCER study evaluated management strategies for prevention of post-operative Crohn's disease recurrence; subjects were enrolled after resection of all macroscopic Crohn's disease and were randomised to early endoscopy and possible treatment escalation, or standard care. The primary endpoint was endoscopic recurrence at 18 months. 44 subjects with cross-sectional abdominal imaging were studied, and body composition analysis performed using established techniques to measure visceral adipose tissue area, subcutaneous adipose tissue area, and skeletal muscle area.
RESULTS: The body composition parameter with the greatest variance was visceral adipose tissue. Regardless of treatment, all subjects with visceral adipose tissue/height2 {\textgreater}1.5 times the gender-specific mean experienced endoscopic recurrence at 18 months (compared to 47\%) [relative risk 2.1, 95\% CI 1.5-3.0, P = 0.012]. Waist circumference correlated strongly with visceral adipose tissue area (ρ = 0.840, P {\textless} 0.001). Low skeletal muscle was prevalent (41\% of patients), but did not predict endoscopic recurrence; however, appendicular skeletal muscle indices correlated inversely with faecal calprotectin (ρ = 0.560, P = 0.046).
CONCLUSIONS: Visceral adiposity is an independent risk factor for endoscopic recurrence of Crohn's disease after surgery. Sarcopenia correlates with inflammatory biomarkers. Measures of visceral adipose tissue may help to stratify risk in post-operative management strategies.},
	language = {eng},
	number = {9},
	journal = {Alimentary Pharmacology \& Therapeutics},
	author = {Holt, D. Q. and Moore, G. T. and Strauss, B. J. G. and Hamilton, A. L. and De Cruz, P. and Kamm, M. A.},
	month = may,
	year = {2017},
	pmid = {28244124},
	keywords = {Adiposity, Humans, Female, Male, Middle Aged, Risk Factors, Adult, Intra-Abdominal Fat, Young Adult, Recurrence, Biomarkers, Postoperative Period, Colonoscopy, VAT, Crohn Disease, IBD, Feces, Leukocyte L1 Antigen Complex, VATI},
	pages = {1255--1264},
	file = {Holt et al_2017_Visceral adiposity predicts post-operative Crohn's disease recurrence.pdf:/Users/jcsal/Zotero/storage/5CV684ZQ/Holt et al_2017_Visceral adiposity predicts post-operative Crohn's disease recurrence.pdf:application/pdf},
}

@article{baker987,
	title = {A systematic review of the nutritional consequences of esophagectomy},
	volume = {35},
	issn = {1532-1983},
	url = {https://pubmed.ncbi.nlm.nih.gov/26411750/},
	doi = {10.1016/j.clnu.2015.08.010},
	abstract = {Nutritional status is compromised in the months/years following oesophagectomy and may never return to baseline levels. The causes/consequences of weight loss/impaired nutritional intake require further investigation. The role of extended nutritional support in this population remains unclear.},
	language = {en},
	number = {5},
	urldate = {2023-05-30},
	journal = {Clinical nutrition (Edinburgh, Scotland)},
	author = {Baker, M and Halliday, V and Williams, RN and Bowery, DJ},
	month = oct,
	year = {2016},
	pmid = {26411750},
	note = {Publisher: Clin Nutr},
	pages = {987--997},
	annote = {ContentsSummaryIntroductionMaterials and methodsArticle selectionSearch strategyAssessment of quality: risk of biasData extractionResultsChanges in nutritional statusChanges in dietary intakeRelationship between nutritional factors and quality of life/symptomsSurgical approach and techniqueNutritional support (post discharge after the index admission for oesophagectomy)DiscussionReferencesFig. 1Table 1Table 2Table 3Table 4Table 5},
	file = {M et al_2016_A systematic review of the nutritional consequences of esophagectomy.pdf:/Users/jcsal/Zotero/storage/JKJ4ENN9/M et al_2016_A systematic review of the nutritional consequences of esophagectomy.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/K8Z5X4ES/26411750.html:text/html},
}

@article{wang20,
	title = {The protocol of a prospective, multicenter, randomized, controlled phase {III} study evaluating different cycles of oxaliplatin combined with {S}-1 ({SOX}) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: {RESONANCE}-{II} trial},
	volume = {21},
	issn = {1471-2407},
	shorttitle = {The protocol of a prospective, multicenter, randomized, controlled phase {III} study evaluating different cycles of oxaliplatin combined with {S}-1 ({SOX}) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer},
	doi = {10.1186/s12885-020-07764-7},
	abstract = {BACKGROUND: Curing locally advanced gastric cancer through surgery alone is difficult. Adjuvant and neoadjuvant chemotherapy bring potential benefits to more patients with gastric cancer based on several clinical trials. According to phase II studies and guidelines, SOX regimen as neoadjuvant chemotherapy is efficient. However, the optimal duration of neoadjuvant chemotherapy has not been established. In this study, we will evaluate the efficacy and safety of different cycles of SOX as neoadjuvant chemotherapy for patients with locally advanced gastric cancer.
METHODS: RESONANCE-II trial is a prospective, multicenter, randomized, controlled phase III study which will enroll 524 patients in total. Eligible patients will be registered, pre-enrolled and receive three cycles of SOX, after which tumor response evaluations will be carried out. Those who show stable disease or progressive disease will be excluded. Patients showing complete response or partial response will be enrolled and assigned into either group A for another three cycles of SOX (six cycles in total) followed by D2 surgery; or group B for D2 surgery (three cycles in total). The primary endpoint is the rate of pathological complete response and the secondary endpoints are R0 resection rate, three-year disease-free survival, five-year overall survival, and safety.
DISCUSSION: This study is the first phase III randomized trial to compare the cycles of neoadjuvant chemotherapy using SOX for resectable locally advanced cancer. Based on a total of six to eight cycles of perioperative chemotherapy usually applied in locally advanced gastric cancer, patients in group A can be considered to have completed all perioperative chemotherapy, the results of which may suggest the feasibility of using chemotherapy only before surgery in gastric cancer.
TRIAL REGISTRATION: Registered prospectively in the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) with registration number ChiCTR1900023293 on May 21st, 2019.},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Wang, Xinxin and Li, Shuo and Sun, Yihong and Li, Kai and Shen, Xian and Xue, Yingwei and Liang, Pin and Li, Guoli and Chen, Luchuan and Zhao, Qun and Li, Guoxin and Fu, Weihua and Liang, Han and Xin, Hairong and Suo, Jian and Fang, Xuedong and Zheng, Zhichao and Xu, Zekuan and Chen, Huanqiu and Zhou, Yanbing and He, Yulong and Huang, Hua and Zhu, Linghua and Yang, Kun and Ji, Jiafu and Ye, Yingjiang and Zhang, Zhongtao and Li, Fei and Wang, Xin and Tian, Yantao and Park, Sungsoo and Chen, Lin},
	month = jan,
	year = {2021},
	pmid = {33402102},
	pmcid = {PMC7786891},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Prognosis, Adult, Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Chemotherapy, Adjuvant, Young Adult, Stomach Neoplasms, Adenocarcinoma, Multicenter Studies as Topic, Research Design, Oxaliplatin, Adolescent, Drug Combinations, Oxonic Acid, Tegafur, Duration of neoadjuvant chemotherapy, Locally advanced gastric cancer, S-1},
	pages = {20},
	file = {Wang et al_2021_The protocol of a prospective, multicenter, randomized, controlled phase III.pdf:/Users/jcsal/Zotero/storage/LJ7YAPAB/Wang et al_2021_The protocol of a prospective, multicenter, randomized, controlled phase III.pdf:application/pdf},
}

@article{wouters1789,
	title = {Centralization of esophageal cancer surgery: does it improve clinical outcome?},
	volume = {16},
	issn = {1534-4681},
	shorttitle = {Centralization of esophageal cancer surgery},
	doi = {10.1245/s10434-009-0458-9},
	abstract = {BACKGROUND: The volume-outcome relationship for complex surgical procedures has been extensively studied. Most studies are based on administrative data and use in-hospital mortality as the sole outcome measure. It is still unknown if concentration of these procedures leads to improvement of clinical outcome. The aim of our study was to audit the process and effect of centralizing oesophageal resections for cancer by using detailed clinical data.
METHODS: From January 1990 until December 2004, 555 esophagectomies for cancer were performed in 11 hospitals in the region of the Comprehensive Cancer Center West (CCCW); 342 patients were operated on before and 213 patients after the introduction of a centralization project. In this project patients were referred to the hospitals which showed superior outcomes in a regional audit. In this audit patient, tumor, and operative details as well as clinical outcome were compared between hospitals. The outcome of both cohorts, patients operated on before and after the start of the project, were evaluated.
RESULTS: Despite the more severe comorbidity of the patient group, outcome improved after centralizing esophageal resections. Along with a reduction in postoperative morbidity and length of stay, mortality fell from 12\% to 4\% and survival improved significantly (P = 0.001). The hospitals with the highest procedural volume showed the biggest improvement in outcome.
CONCLUSION: Volume is an important determinant of quality of care in esophageal cancer surgery. Referral of patients with esophageal cancer to surgical units with adequate experience and superior outcomes (outcome-based referral) improves quality of care.},
	language = {eng},
	number = {7},
	journal = {Annals of Surgical Oncology},
	author = {Wouters, M. W. J. M. and Karim-Kos, H. E. and le Cessie, S. and Wijnhoven, B. P. L. and Stassen, L. P. S. and Steup, W. H. and Tilanus, H. W. and Tollenaar, R. a. E. M.},
	month = jul,
	year = {2009},
	pmid = {19370377},
	pmcid = {PMC2695873},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Aged, 80 and over, Adult, Outcome Assessment, Health Care, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Netherlands, Barrett Esophagus, Quality of Health Care},
	pages = {1789--1798},
	annote = {ContentsAbstractBackgroundMethodsResultsConclusionPatients and MethodsComprehensive Cancer Center LeidenRetrospective RegistrationInterventionProspective RegistrationControl GroupStatisticsResultsHospital VolumePatient, Tumor, and Treatment CharacteristicsOutcomeDiscussionAcknowledgementReferences},
	file = {Snapshot:/Users/jcsal/Zotero/storage/5WWUSL2X/19370377.html:text/html;Wouters et al_2009_Centralization of esophageal cancer surgery.pdf:/Users/jcsal/Zotero/storage/HT3BRJSN/Wouters et al_2009_Centralization of esophageal cancer surgery.pdf:application/pdf},
}

@misc{zotero-2290,
	title = {Use of {Preoperative} {Magnetic} {Resonance} {Imaging} to {Select} {Patients} with {Rectal} {Cancer} for {Neoadjuvant} {Chemoradiation}--{Interim} {Analysis} of the {German} {OCUM} {Trial} ({NCT01325649}) - {PubMed}},
	url = {https://pubmed.ncbi.nlm.nih.gov/26556476/},
	urldate = {2023-04-25},
	keywords = {MRI},
	file = {Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation--Interim Analysis of the German OCUM Trial (NCT01325649) - PubMed:/Users/jcsal/Zotero/storage/2S7RC92Y/26556476.html:text/html},
}

@article{cercek2363,
	title = {{PD}-1 {Blockade} in {Mismatch} {Repair}-{Deficient}, {Locally} {Advanced} {Rectal} {Cancer}},
	volume = {386},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2201445},
	abstract = {BACKGROUND: Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced rectal cancer.
METHODS: We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
RESULTS: A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100\%; 95\% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.
CONCLUSIONS: Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.).},
	language = {eng},
	number = {25},
	journal = {The New England Journal of Medicine},
	author = {Cercek, Andrea and Lumish, Melissa and Sinopoli, Jenna and Weiss, Jill and Shia, Jinru and Lamendola-Essel, Michelle and El Dika, Imane H. and Segal, Neil and Shcherba, Marina and Sugarman, Ryan and Stadler, Zsofia and Yaeger, Rona and Smith, J. Joshua and Rousseau, Benoit and Argiles, Guillem and Patel, Miteshkumar and Desai, Avni and Saltz, Leonard B. and Widmar, Maria and Iyer, Krishna and Zhang, Janie and Gianino, Nicole and Crane, Christopher and Romesser, Paul B. and Pappou, Emmanouil P. and Paty, Philip and Garcia-Aguilar, Julio and Gonen, Mithat and Gollub, Marc and Weiser, Martin R. and Schalper, Kurt A. and Diaz, Luis A.},
	month = jun,
	year = {2022},
	pmid = {35660797},
	pmcid = {PMC9492301},
	keywords = {Humans, Neoadjuvant Therapy, Treatment Outcome, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Chemoradiotherapy, Rectum, Rectal Neoplasms, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Neoplasms, Second Primary, dMMR},
	pages = {2363--2376},
	file = {Cercek et al_2022_PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.pdf:/Users/jcsal/Zotero/storage/BELXY8UM/Cercek et al_2022_PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.pdf:application/pdf},
}

@article{trejo-avila1077,
	title = {Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis},
	volume = {36},
	issn = {1432-1262},
	shorttitle = {Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer},
	doi = {10.1007/s00384-021-03839-4},
	abstract = {PURPOSE: Previous studies have shown an association of sarcopenia with adverse short- and long-term outcomes in multiple gastrointestinal cancer types. We aimed to investigate the prognostic value of sarcopenia on the postoperative outcomes and survival rates of patients with colorectal cancer (CRC).
METHODS: A systematic literature search was performed using the PubMed, Embase, Cochrane, Google Scholar, and Scopus databases. We included studies that compared postoperative outcomes or survival rates in sarcopenic and non-sarcopenic patients with CRC.
RESULTS: A total of 44 observational studies, comprising 18,891 patients, were included. The pooled prevalence of sarcopenia was 37\% (n = 7009). The pooled analysis revealed an association between sarcopenia and higher risk of total postoperative complications (23 studies, OR = 1.84; 95\% CI 1.35-2.49), postoperative severe complications (OR = 1.72; 95\% CI 1.10-2.68), postoperative mortality (OR = 3.21; 95\% CI 2.01-5.11), postoperative infections (OR = 1.40; 95\% CI 1.12-1.76), postoperative cardiopulmonary complications (OR = 2.92; 95\% CI 1.96-4.37), and prolonged length of stay (MD = 0.77; 95\% CI 0.44-1.11) after colorectal cancer surgery. However, anastomotic leakage showed comparable occurrence between sarcopenic and non-sarcopenic patients (OR = 0.99; 95\% CI 0.72 to 1.36). Regarding survival outcomes, sarcopenic patients had significantly shorter overall survival (25 studies, HR = 1.83; 95\% CI = 1.57-2.14), disease-free survival (HR = 1.55; 95\% CI = 1.29-1.88), and cancer-specific survival (HR = 1.77; 95\% CI 1.40-2.23) as compared with non-sarcopenic patients.
CONCLUSION: Among patients with colorectal cancer, sarcopenia is a strong predictor of increased postoperative complications and worse survival outcomes.},
	language = {eng},
	number = {6},
	journal = {International Journal of Colorectal Disease},
	author = {Trejo-Avila, Mario and Bozada-Gutiérrez, Katya and Valenzuela-Salazar, Carlos and Herrera-Esquivel, Jesús and Moreno-Portillo, Mucio},
	month = jun,
	year = {2021},
	pmid = {33481108},
	keywords = {Humans, Sarcopenia, Colorectal Neoplasms, Survival Rate, Prognosis, Postoperative Complications, Anastomotic Leak, Survival, Postoperative complications, Colorectal cancer, Low muscle mass},
	pages = {1077--1096},
	file = {Trejo-Avila et al_2021_Sarcopenia predicts worse postoperative outcomes and decreased survival rates.pdf:/Users/jcsal/Zotero/storage/6VADPL5W/Trejo-Avila et al_2021_Sarcopenia predicts worse postoperative outcomes and decreased survival rates.pdf:application/pdf},
}

@article{schrock348,
	title = {Total gastrectomy},
	volume = {135},
	issn = {0002-9610},
	doi = {10.1016/0002-9610(78)90064-8},
	abstract = {Total gastrectomy is indicated principally for Zollinger-Ellison syndrome and for potentially curable gastric cancer. The diagnosis of cancer should be verified by biopsy before the resection is performed, and the margins of resection should usually be examined by frozen section. Of the various reconstructions, Roux-en-Y esophagojejunostomy gave the best long-term results.},
	language = {eng},
	number = {3},
	journal = {American Journal of Surgery},
	author = {Schrock, T. R. and Way, L. W.},
	month = mar,
	year = {1978},
	pmid = {626316},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Adult, Stomach Neoplasms, Esophagus, Gastrectomy, Quality of Life, Postgastrectomy Syndromes, California, Esophagitis, Jejunum, Stomach Diseases, Zollinger-Ellison Syndrome, Total},
	pages = {348--355},
	file = {Schrock_Way_1978_Total gastrectomy.pdf:/Users/jcsal/Zotero/storage/AA6PULUL/Schrock_Way_1978_Total gastrectomy.pdf:application/pdf},
}

@article{decourtye-espiard719,
	series = {Personalizing {GI} {Cancer} {Risk} {Assessment} and {Management}: {The} {Future} is {Now}},
	title = {Hereditary {Diffuse} {Gastric} {Cancer}},
	volume = {164},
	issn = {0016-5085},
	url = {https://www.sciencedirect.com/science/article/pii/S0016508523001105},
	doi = {10.1053/j.gastro.2023.01.038},
	abstract = {Hereditary diffuse gastric cancer (HDGC) is a dominantly inherited cancer syndrome characterized by a high incidence of diffuse gastric cancer (DGC) and lobular breast cancer (LBC). HDGC is caused by germline mutations in 2 genes involved in the epithelial adherens junction complex, CDH1 and CTNNA1. We discuss the genetics of HDGC and the variability of its clinical phenotype, in particular the variable penetrance of advanced DGC and LBC, both within and between families. We review the pathology of the disease, the mechanism of tumor initiation, and its natural history. Finally, we describe current best practice for the clinical management of HDGC, including emerging genetic testing criteria for the identification of new families, methods for endoscopic surveillance, the complications associated with prophylactic surgery, postoperative quality of life, and the emerging field of HDGC chemoprevention.},
	language = {en},
	number = {5},
	urldate = {2023-07-09},
	journal = {Gastroenterology},
	author = {Decourtye-Espiard, Lyvianne and Guilford, Parry},
	month = apr,
	year = {2023},
	keywords = {Cancer Predisposition, Hereditary Diffuse Gastric Cancer},
	pages = {719--735},
	file = {ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/8J6BSMSG/S0016508523001105.html:text/html},
}

@article{lee107,
	title = {Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study},
	volume = {24},
	issn = {1474-5488},
	shorttitle = {Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer},
	doi = {10.1016/S1470-2045(22)00700-8},
	abstract = {BACKGROUND: Hereditary diffuse gastric cancer, generally caused by germline pathogenic variants in CDH1, presents with early-onset signet ring cell carcinoma. Prophylactic total gastrectomy is the definitive treatment. Endoscopic surveillance can inform the timing of prophylactic total gastrectomy through detection of microscopic signet ring cell carcinoma foci. However, evidence is scarce about the optimal endoscopic sampling technique and characterisation of signet ring cell carcinoma foci in hereditary diffuse gastric cancer. We aimed to formally assess the diagnostic yield of different sampling strategies and to identify criteria for the characterisation of endoscopic lesions.
METHODS: For this prospective longitudinal cohort study, we included individuals aged 18 years or older at the Cambridge University Hospitals National Health Service (NHS) Foundation Trust who fulfilled testing criteria for hereditary diffuse gastric cancer between June 1, 2005, and July 31, 2021. The primary outcome was detection of intramucosal signet ring cell carcinoma foci. We assessed the detection rate and anatomical location of signet ring cell carcinoma in random biopsy samples taken according to a systematic protocol compared with biopsies targeted to endoscopic findings. Endoscopic lesions were examined with white-light and narrow band imaging with magnification to assess the likelihood of cancerous foci.
FINDINGS: 145 individuals were included, of whom 68 (47\%) were male and 92 (63\%) carried the CDH1 pathogenic variant. 58 (40\%) patients were diagnosed with invasive signet ring cell carcinoma over a median follow-up time of 51 months (IQR 18-80). The first diagnosis of signet ring cell carcinoma was most commonly made from random biopsies (29 [50\%] of 58 patients), rather than targeted biopsies (15 [26\%] patients). The anatomical distribution of signet ring cell carcinoma foci detected by random biopsies more accurately reflected those identified in prophylactic total gastrectomy specimens than did targeted biopsies. Omitting random biopsies in our cohort would have led to an under-diagnosis rate of 42\%. Using a novel panel of endoscopic criteria, gastric lesions containing signet ring cell carcinoma were predicted with a sensitivity of 67·3\% and a specificity of 90·2\%.
INTERPRETATION: Random biopsies enhance the early detection of signet ring cell carcinoma and are complementary to targeted biopsies in surveillance of hereditary diffuse gastric cancer. This sampling method should be the standard of care when performing all surveillance endoscopies for individuals with hereditary diffuse gastric cancer.
FUNDING: UK Medical Research Council.},
	language = {eng},
	number = {1},
	journal = {The Lancet. Oncology},
	author = {Lee, Colin Y. C. and Olivier, Adriaan and Honing, Judith and Lydon, Anne-Marie and Richardson, Susan and O'Donovan, Maria and Tischkowitz, Marc and Fitzgerald, Rebecca C. and di Pietro, Massimiliano},
	month = jan,
	year = {2023},
	pmid = {36509094},
	keywords = {Humans, Female, Male, Prospective Studies, Longitudinal Studies, Stomach Neoplasms, Adenocarcinoma, Gastrectomy, Biopsy, Early Detection of Cancer, Carcinoma, Signet Ring Cell, Germ-Line Mutation, State Medicine},
	pages = {107--116},
	file = {1-s2.0-S1470204523000943-main.pdf:/Users/jcsal/Zotero/storage/6LPNJSSY/1-s2.0-S1470204523000943-main.pdf:application/pdf;1-s2.0-S1470204523005946-main.pdf:/Users/jcsal/Zotero/storage/FX373WE5/1-s2.0-S1470204523005946-main.pdf:application/pdf;Lee et al. - 2023 - Endoscopic surveillance with systematic random bio.pdf:/Users/jcsal/Zotero/storage/XB9C9ZVK/Lee et al. - 2023 - Endoscopic surveillance with systematic random bio.pdf:application/pdf},
}

@article{asif383,
	title = {Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study},
	volume = {24},
	issn = {1470-2045},
	shorttitle = {Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer},
	url = {https://www.sciencedirect.com/science/article/pii/S1470204523000578},
	doi = {10.1016/S1470-2045(23)00057-8},
	abstract = {Background
Loss of function variants in CDH1 are the most frequent cause of hereditary diffuse gastric cancer. Endoscopy is regarded as insufficient for early detection due to the infiltrative phenotype of diffuse-type cancers. Microscopic foci of invasive signet ring cells are pathognomonic of CDH1 and precede development of diffuse gastric cancer. We aimed to assess the safety and effectiveness of endoscopy for cancer interception in individuals with germline CDH1 variants, particularly in those who declined prophylactic total gastrectomy.
Methods
In this prospective cohort study, we included asymptomatic patients aged 2 years or older with pathogenic or likely pathogenic germline CDH1 variants who underwent endoscopic screening and surveillance at the National Institutes of Health (Bethesda, MD, USA) as part of a natural history study of hereditary gastric cancers (NCT03030404). Endoscopy was done with non-targeted biopsies and one or more targeted biopsy and assessment of focal lesions. Endoscopy findings, pathological data, personal and family cancer history, and demographics were recorded. Procedural morbidity, gastric cancer detection by endoscopy and gastrectomy, and cancer-specific events were assessed. Screening was defined as the initial endoscopy and all subsequent endoscopies were considered surveillance; follow-up endoscopy was at 6 to 12 months. The primary aim was to determine effectiveness of endoscopic surveillance for detection of gastric signet ring cell carcinoma.
Findings
Between Jan 25, 2017, and Dec 12, 2021, 270 patients (median age 46·6 years [IQR 36·5–59·8], 173 [64\%] female participants, 97 [36\%] male participants; 250 [93\%] were non-Hispanic White, eight [3\%] were multiracial, four [2\%] were non-Hispanic Black, three [1\%] were Hispanic, two [1\%] were Asian, and one [{\textless}1\%] was American Indian or Alaskan Native) with germline CDH1 variants were screened, in whom 467 endoscopies were done as of data cutoff (April 30, 2022). 213 (79\%) of 270 patients had a family history of gastric cancer, and 176 (65\%) reported a family history of breast cancer. Median follow-up was 31·1 months (IQR 17·1–42·1). 38 803 total gastric biopsy samples were obtained, of which 1163 (3\%) were positive for invasive signet ring cell carcinoma. Signet ring cell carcinoma was detected in 76 (63\%) of 120 patients who had two or more surveillance endoscopies, of whom 74 had occult cancer detected; the remaining two individuals developed focal ulcerations each corresponding to pT3N0 stage carcinoma. 98 (36\%) of 270 patients proceeded to prophylactic total gastrectomy. Among patients who had a prophylactic total gastrectomy after an endoscopy with biopsy samples negative for cancer (42 [43\%] of 98), multifocal stage IA gastric carcinoma was detected in 39 (93\%). Two (1\%) participants died during follow-up, one due to metastatic lobular breast cancer and the other due to underlying cerebrovascular disease, and no participants were diagnosed with advanced stage (III or IV) cancer during follow-up.
Interpretation
In our cohort, endoscopic cancer surveillance was an acceptable alternative to surgery in individuals with CDH1 variants who declined total gastrectomy. The low rate of incident tumours ({\textgreater}T1a) suggests that surveillance might be a rational alternative to surgery in individuals with CDH1 variants.
Funding
Intramural Research Program, National Institutes of Health.},
	language = {en},
	number = {4},
	urldate = {2023-07-09},
	journal = {The Lancet Oncology},
	author = {Asif, Bilal and Sarvestani, Amber Leila and Gamble, Lauren A and Samaranayake, Sarah G and Famiglietti, Amber L and Fasaye, Grace-Ann and Quezado, Martha and Miettinen, Markku and Korman, Louis and Koh, Christopher and Heller, Theo and Davis, Jeremy L},
	month = apr,
	year = {2023},
	pages = {383--391},
	file = {Asif et al_2023_Cancer surveillance as an alternative to prophylactic total gastrectomy in.pdf:/Users/jcsal/Zotero/storage/NFSEUBMX/Asif et al_2023_Cancer surveillance as an alternative to prophylactic total gastrectomy in.pdf:application/pdf;Asif et al_2023_Cancer surveillance as an alternative to prophylactic total gastrectomy in.pdf:/Users/jcsal/Zotero/storage/Z6ZF724B/Asif et al_2023_Cancer surveillance as an alternative to prophylactic total gastrectomy in.pdf:application/pdf;ScienceDirect Snapshot:/Users/jcsal/Zotero/storage/XW9LWMCB/S1470204523000578.html:text/html},
}

@article{blaire386,
	title = {Hereditary diffuse gastric cancer: updated clinical practice guidelines},
	volume = {21},
	issn = {1474-5488},
	shorttitle = {Hereditary diffuse gastric cancer},
	doi = {10.1016/S1470-2045(20)30219-9},
	abstract = {Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour suppressor gene CDH1, although pathogenic variants in CTNNA1 occur in a minority of families with HDGC. In this Policy Review, we present updated clinical practice guidelines for HDGC from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in gastric cancer risk between families with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients. To redress the balance between the accessibility, cost, and acceptance of genetic testing and the increased identification of pathogenic variant carriers, the HDGC genetic testing criteria have been relaxed, mainly through less restrictive age limits. Prophylactic total gastrectomy remains the recommended option for gastric cancer risk management in pathogenic CDH1 variant carriers. However, there is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely offered to patients who wish to postpone surgery, or to those whose risk of developing gastric cancer is not well defined.},
	language = {eng},
	number = {8},
	journal = {The Lancet. Oncology},
	author = {Blair, Vanessa R. and McLeod, Maybelle and Carneiro, Fátima and Coit, Daniel G. and D'Addario, Johanna L. and van Dieren, Jolanda M. and Harris, Kirsty L. and Hoogerbrugge, Nicoline and Oliveira, Carla and van der Post, Rachel S. and Arnold, Julie and Benusiglio, Patrick R. and Bisseling, Tanya M. and Boussioutas, Alex and Cats, Annemieke and Charlton, Amanda and Schreiber, Karen E. Chelcun and Davis, Jeremy L. and Pietro, Massimiliano di and Fitzgerald, Rebecca C. and Ford, James M. and Gamet, Kimberley and Gullo, Irene and Hardwick, Richard H. and Huntsman, David G. and Kaurah, Pardeep and Kupfer, Sonia S. and Latchford, Andrew and Mansfield, Paul F. and Nakajima, Takeshi and Parry, Susan and Rossaak, Jeremy and Sugimura, Haruhiko and Svrcek, Magali and Tischkowitz, Marc and Ushijima, Toshikazu and Yamada, Hidetaka and Yang, Han-Kwang and Claydon, Adrian and Figueiredo, Joana and Paringatai, Karyn and Seruca, Raquel and Bougen-Zhukov, Nicola and Brew, Tom and Busija, Simone and Carneiro, Patricia and DeGregorio, Lynn and Fisher, Helen and Gardner, Erin and Godwin, Tanis D. and Holm, Katharine N. and Humar, Bostjan and Lintott, Caroline J. and Monroe, Elizabeth C. and Muller, Mark D. and Norero, Enrique and Nouri, Yasmin and Paredes, Joana and Sanches, João M. and Schulpen, Emily and Ribeiro, Ana S. and Sporle, Andrew and Whitworth, James and Zhang, Liying and Reeve, Anthony E. and Guilford, Parry},
	month = aug,
	year = {2020},
	pmid = {32758476},
	pmcid = {PMC7116190},
	keywords = {Humans, Stomach Neoplasms, Neoplastic Syndromes, Hereditary},
	pages = {e386--e397},
	file = {Blair et al_2020_Hereditary diffuse gastric cancer.pdf:/Users/jcsal/Zotero/storage/NHDID9Z5/Blair et al_2020_Hereditary diffuse gastric cancer.pdf:application/pdf},
}

@article{passos316,
	title = {Derivation and validation of a national multicenter mortality risk stratification model – the {ExCare} model: a study protocol},
	volume = {72},
	issn = {0104-0014},
	shorttitle = {Derivation and validation of a national multicenter mortality risk stratification model – the {ExCare} model},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373516/},
	doi = {10.1016/j.bjane.2021.07.003},
	abstract = {Introduction
Surgical care is essential for proper management of various diseases. However, it can result in unfavorable outcomes. In order to identify patients at higher risk of complications, several risk stratification models have been developed. Ideally, these tools should be simple, reproducible, accurate, and externally validated. Unfortunately, none of the best-known risk stratification instruments have been validated in Brazil. In this sense, the Ex-Care model was developed by retrospective data analysis of surgical patients in a major Brazilian university hospital. It consists of four independent predictors easily collected in the preoperative evaluation, showing high accuracy in predicting death within 30 days after surgery.

Objectives
To update and validate a Brazilian national-based model of postoperative death probability within 30 days based on the Ex-Care model. Also, to develop an application for smartphones that allows preoperative risk stratification by Ex-Care model.

Methods
Ten participating centers will collect retrospective data from digital databases. Variables age, American Society of Anesthesiologists (ASA) physical status, surgical severity (major or non-major) and nature (elective or urgent) will be evaluated as predictors for in-hospital mortality within 30 postoperative days, considered the primary outcome.

Expected results
We believe that the Ex-Care model will present discriminative capacity similar to other classically used scores validated for surgical mortality prediction. Furthermore, the mobile application to be developed will provide a practical and easy-to-use tool to the professionals enrolled in perioperative care.},
	number = {3},
	urldate = {2023-07-15},
	journal = {Brazilian Journal of Anesthesiology},
	author = {Passos, Sávio Cavalcante and Stahlschmidt, Adriene and Blanco, João and Spader, Mariana Lunardi and Brandão, Rodrigo Borges and Castro, Stela Maris de Jezus and Gutierrez, Claudia de Souza and Silva Neto, Paulo Corrêa da and Stefani, Luciana Paula Cadore},
	month = jul,
	year = {2021},
	pmid = {34324938},
	pmcid = {PMC9373516},
	keywords = {Splines},
	pages = {316--321},
	file = {Passos et al_2021_Derivation and validation of a national multicenter mortality risk.pdf:/Users/jcsal/Zotero/storage/RBNB587Q/Passos et al_2021_Derivation and validation of a national multicenter mortality risk.pdf:application/pdf},
}

@article{lee973,
	title = {Frail {Patients} {Are} at {Increased} {Risk} for {Mortality} and {Prolonged} {Institutional} {Care} {After} {Cardiac} {Surgery}},
	volume = {121},
	url = {https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.108.841437},
	doi = {10.1161/CIRCULATIONAHA.108.841437},
	abstract = {Background— Frailty is an emerging concept in medicine yet to be explored as a risk factor in cardiac surgery. Where elderly patients are increasingly referred for cardiac surgery, the prevalence of a frail group among these is also on the rise. We assessed frailty as a risk factor for adverse outcomes after cardiac surgery.

Methods and Results— Functional measures of frailty and clinical data were collected prospectively for all cardiac surgery patients at a single center. Frailty was defined as any impairment in activities of daily living (Katz index), ambulation, or a documented history of dementia. Of 3826 patients, 157 (4.1\%) were frail. Frail patients were older, were more likely to be female, and had risk factors for adverse surgical outcomes. By logistic regression, frailty was an independent predictor of in-hospital mortality (odds ratio 1.8, 95\% CI 1.1 to 3.0), as well as institutional discharge (odds ratio 6.3, 95\% CI 4.2 to 9.4). Frailty was an independent predictor of reduced midterm survival (hazard ratio 1.5, 95\% CI 1.1 to 2.2).

Conclusions— Frailty is a risk for postoperative complications and an independent predictor of in-hospital mortality, institutional discharge, and reduced midterm survival. Frailty screening improves risk assessment in cardiac surgery patients and may identify a subgroup of patients who may benefit from innovative processes of care.},
	number = {8},
	urldate = {2023-07-15},
	journal = {Circulation},
	author = {Lee, Dana H. and Buth, Karen J. and Martin, Billie-Jean and Yip, Alexandra M. and Hirsch, Gregory M.},
	month = mar,
	year = {2010},
	note = {Publisher: American Heart Association},
	keywords = {Splines, cardiac surgery, frail elderly, outcomes research},
	pages = {973--978},
	file = {Lee et al_2010_Frail Patients Are at Increased Risk for Mortality and Prolonged Institutional.pdf:/Users/jcsal/Zotero/storage/7R89M457/Lee et al_2010_Frail Patients Are at Increased Risk for Mortality and Prolonged Institutional.pdf:application/pdf},
}

@article{fong1020,
	title = {Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients?},
	volume = {22},
	issn = {1477-2574},
	doi = {10.1016/j.hpb.2019.10.2437},
	abstract = {BACKGROUND: Whether the risk of venous thromboembolism (VTE) may be reduced by preoperative administration of prophylactic heparin is unknown. We hypothesized that timing of heparin administration does not significantly alter the incidence of VTE in pancreatic surgery.
METHODS: An analysis was conducted using data from Massachusetts General Hospital's National Surgical Quality Improvement Program from 2012 to 2017. All patients admitted for elective pancreatic resection were included. The primary outcome was development of VTE. Multivariable regression was performed, adjusting for patient demographics and various clinical factors.
RESULTS: In total, 1448 patients were analyzed, of whom 1062 received preoperative heparin (73.3\%). Overall, 36 (2.5\%) patients developed VTE. On unadjusted analysis, there was no statistically significant difference between patients who received preoperative heparin compared with those who did not (2.6\% vs. 1.3\%, respectively; p = 0.079). On adjusted analysis, there was an association with increased VTE rates among patients who received preoperative heparin (OR 2.93, 95\% CI 1.10-7.81; p = 0.031).
CONCLUSION: There was an association between preoperative heparin administration and increased incidence of VTE on adjusted analysis, possibly reflecting appropriate surgical judgment in patient selection for prophylaxis. These data question the inclusion of preoperative VTE pharmacologic prophylaxis as a reliable quality indicator.},
	language = {eng},
	number = {7},
	journal = {HPB: the official journal of the International Hepato Pancreato Biliary Association},
	author = {Fong, Zhi V. and Sell, Naomi M. and Fernandez-Del Castillo, Carlos and Del Carmen, Gabriel and Ferrone, Cristina R. and Chang, David C. and Warshaw, Andrew L. and Polk, Hiram C. and Lillemoe, Keith D. and Qadan, Motaz},
	month = jul,
	year = {2020},
	pmid = {31732463},
	keywords = {Humans, Risk Factors, Elective Surgical Procedures, Anticoagulants, Heparin, Venous Thromboembolism, Pancreatectomy, Splines},
	pages = {1020--1024},
	file = {Fong et al_2020_Does preoperative pharmacologic prophylaxis reduce the rate of venous.pdf:/Users/jcsal/Zotero/storage/4588SZ49/Fong et al_2020_Does preoperative pharmacologic prophylaxis reduce the rate of venous.pdf:application/pdf},
}

@article{willingham214,
	title = {Association between postoperative complications and lingering post-surgical pain: an observational cohort study},
	volume = {124},
	issn = {1471-6771},
	shorttitle = {Association between postoperative complications and lingering post-surgical pain},
	doi = {10.1016/j.bja.2019.10.012},
	abstract = {BACKGROUND: Post-surgical pain that lingers beyond the initial few-week period of tissue healing is a major predictor of pain chronification, which leads to substantial disability and new persistent opioid analgesic use. We investigated whether postoperative medical complications increase the risk of lingering post-surgical pain.
METHODS: The study population consisted of patients undergoing diverse elective surgical procedures in an academic referral centre in the USA, between September 2013 and May 2017. Multivariable logistic regression, adjusting for confounding variables and patient-specific risk factors, was used to test for an independent association between any major postoperative complication and functionally limiting lingering pain 1-3 months after surgery, as obtained from patient self-reports.
RESULTS: The cohort included 11 986 adult surgical patients; 10 562 with complete data. At least one complication (cardiovascular, respiratory, renal/gastrointestinal, wound, thrombotic, or neural) was reported by 13.3\% (95\% confidence interval: 12.7-14.0) of patients, and 19.7\% (19.0-20.5\%) reported functionally limiting lingering post-surgical pain. After adjusting for known risk factors, the patients were twice as likely (odds ratio: 2.04; 1.78-2.35) to report lingering post-surgical pain if they also self-reported a postoperative complication. Experiencing a complication was also independently predictive of lingering post-surgical pain (odds ratio: 1.95; 1.26-3.04) when complication data were extracted from the National Surgical Quality Improvement Program registry, instead of being obtained from patient self-report.
CONCLUSIONS: Medical complications were associated with a two-fold increase in functionally limiting pain 1-3 months after surgery. Understanding the mechanisms that link complications to pathological persistence of pain could help develop future approaches to prevent persistent post-surgical pain.},
	language = {eng},
	number = {2},
	journal = {British Journal of Anaesthesia},
	author = {Willingham, Mark and Rangrass, Govind and Curcuru, Caitlin and Ben Abdallah, Arbi and Wildes, Troy S. and McKinnon, Sherry and Kronzer, Alex and Sharma, Anshuman and Helsten, Dan and Hall, Bruce and Avidan, Michael S. and Haroutounian, Simon},
	month = feb,
	year = {2020},
	pmid = {31771788},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Cohort Studies, Comorbidity, Postoperative Complications, Pain, Postoperative, postoperative complications, Splines, Chronic Pain, chronic post-surgical pain, lingering post-surgical pain, medical complications, Missouri, pain},
	pages = {214--221},
}

@article{schizas120,
	title = {Sarcopenia does not affect postoperative complication rates in oesophageal cancer surgery: a systematic review and meta-analysis},
	volume = {102},
	issn = {1478-7083},
	shorttitle = {Sarcopenia does not affect postoperative complication rates in oesophageal cancer surgery},
	doi = {10.1308/rcsann.2019.0113},
	abstract = {INTRODUCTION: The high morbidity and mortality rates after oesophagectomy indicate the need for rigorous patient selection and preoperative risk assessment. Although muscle mass depletion has been proposed as a potential prognostic factor for postoperative complications and decreased survival in gastrointestinal cancer patients, available data are conflicting. The purpose of the present meta-analysis is to determine whether sarcopenia predicts postoperative outcomes in patients undergoing oesophagectomy.
METHODS: The databases MEDLINE, SCOPUS, Clinicaltrials.gov, CENTRAL and Google Scholar were searched for studies reporting on the effect of sarcopenia on postoperative outcomes following oesophageal cancer surgery. Outcomes included surgical complications, anastomotic leakage, respiratory complications, cardiovascular complications, postoperative infections, major complications and overall complications. The random effects model (DerSimonian-Laird) was used to calculate pooled effect estimates when high heterogeneity was encountered, otherwise the fixed-effects (Mantel-Haenszel) model was implemented.
FINDINGS: A total of eight studies involving 1488 patients diagnosed with oesophageal cancer and who underwent oesophagectomy were included in the meta-analysis. The presence of sarcopenia did not significantly increase the rate of surgical complications (odds ratio, OR, 0.86, 95\% confidence interval, CI, 0.40-1.85), anastomotic leakage (OR 0.75, 95\% CI 0.42-1.35), respiratory complications (OR 0.56, 95\% CI 0.21-1.48), cardiovascular complications (OR 0.94, 95\% CI 0.31-2.83), postoperative infection (OR 1.14, 95\% CI 0.52-2.50), major complications (OR 0.81, 95\% CI 0.23-2.82) or overall postoperative complications (OR 0.80, 95\% 0.32-1.99).
CONCLUSION: Sarcopenia does not seem to affect postoperative complication rates of patients undergoing oesophagectomy for oesophageal cancer. Future research should focus on determining whether prognosis differs according to muscle mass in this patient population.},
	language = {eng},
	number = {2},
	journal = {Annals of the Royal College of Surgeons of England},
	author = {Schizas, D. and Frountzas, M. and Lidoriki, I. and Spartalis, E. and Toutouzas, K. and Dimitroulis, D. and Liakakos, T. and Mylonas, K. S.},
	month = feb,
	year = {2020},
	pmid = {31508983},
	pmcid = {PMC6996429},
	keywords = {Humans, Sarcopenia, Prognosis, Meta-analysis, Esophageal Neoplasms, Esophagectomy, Oesophageal cancer, Postoperative Complications, Anastomotic Leak, Postoperative complications},
	pages = {120--132},
	file = {Schizas et al_2020_Sarcopenia does not affect postoperative complication rates in oesophageal.pdf:/Users/jcsal/Zotero/storage/XYWMIZC7/Schizas et al_2020_Sarcopenia does not affect postoperative complication rates in oesophageal.pdf:application/pdf},
}

@article{vanderwerf288,
	title = {Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy {Caucasian} population},
	volume = {72},
	issn = {1476-5640},
	doi = {10.1038/s41430-017-0034-5},
	abstract = {BACKGROUND/OBJECTIVES: Muscle mass is a key determinant of nutritional status and associated with outcomes in several patient groups. Computed tomography (CT) analysis is increasingly used to assess skeletal muscle area (SMA), skeletal muscle index (SMI) and muscle radiation attenuation (MRA). However, interpretation of these muscle parameters is difficult since values in a healthy population are lacking. The aim of this study was to provide sex specific percentiles for SMA, SMA and MRA in a healthy Caucasian population and to examine the association with age and BMI in order to define age- and BMI specific percentiles.
SUBJECTS/METHODS: In this retrospective cross-sectional study CT scans of potential kidney donors were used to assess SMA, SMI and MRA at the level of the third lumbar vertebra. Sex specific distributions were described and, based on the association between age/BMI and muscle parameters, age, and BMI specific predicted percentiles were computed. The 5th percentile was considered as cut-off.
RESULTS: CT scans of 420 Individuals were included (age range 20-82 years and BMI range 17.5-40.7 kg/m2). Sex specific cut-offs of SMA, SMI and MRA were 134.0 cm2, 41.6 cm2/m2 and 29.3 HU in men and 89.2 cm2, 32.0 cm2/m2 and 22.0 HU in women, respectively. Correlations were negative between age and all three muscle parameters, positive between BMI and SMA/SMI and negative between BMI and MRA, resulting in age- and BMI specific percentiles.
CONCLUSIONS: This study provides sex specific percentiles for SMA, SMI, and MRA. In addition, age- and BMI specific percentiles have been established.},
	language = {eng},
	number = {2},
	journal = {European Journal of Clinical Nutrition},
	author = {van der Werf, A. and Langius, J. a. E. and de van der Schueren, M. a. E. and Nurmohamed, S. A. and van der Pant, K. a. M. I. and Blauwhoff-Buskermolen, S. and Wierdsma, N. J.},
	month = feb,
	year = {2018},
	pmid = {29242526},
	pmcid = {PMC5842880},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Body Mass Index, Retrospective Studies, Sex Factors, Aged, 80 and over, Adult, Cross-Sectional Studies, Netherlands, Nutritional Status, Reference Values, Aging, White People},
	pages = {288--296},
	file = {van der Werf et al_2018_Percentiles for skeletal muscle index, area and radiation attenuation based on.pdf:/Users/jcsal/Zotero/storage/V8DB5LBQ/van der Werf et al_2018_Percentiles for skeletal muscle index, area and radiation attenuation based on.pdf:application/pdf},
}

@article{somadoy092,
	title = {Sarcopenia, the depletion of muscle mass, an independent predictor of respiratory complications after oncological esophagectomy},
	volume = {32},
	issn = {1442-2050},
	doi = {10.1093/dote/doy092},
	abstract = {Surgery for esophageal carcinoma is known to be associated with high morbidity. Recent studies have reported a correlation of nutritional and inflammatory parameters with postoperative course. This study aims to clarify the risk factors for operative morbidity after resection of esophageal carcinoma. Consecutive patients who underwent esophagectomy for esophageal squamous cell carcinoma at our institute were included (n = 102; 89 males and 13 females; mean age: 67.3 years). Clinicopathological characteristics, presence or absence of sarcopenia, and modified Glasgow prognostic score were assessed, and their correlation with postoperative complications was investigated using univariate and multivariate analyses. Sarcopenia was defined using a combination of muscle mass area and body mass index. Of the included 102 patients, 45 (44.1\%) exhibited sarcopenia (sarcopenia group), while 57 (55.9\%) did not (non-sarcopenia group). No significant difference was observed between the groups regarding surgical procedures and tumor stage; furthermore, there was no mortality. Twenty-six patients developed respiratory complications (including 20 cases of pneumonia). On univariate analysis, sarcopenia, modified Glasgow prognostic score, and American Society of Anesthesiologists physical status were found to be significantly associated with the development of postoperative respiratory complications. On multivariate analysis, sarcopenia was found to be an independent risk factor for postoperative respiratory complications after esophagectomy. We believe that identifying patients at risk and providing preoperative nutritional support as well as physical therapy aimed at strengthening of body muscles may help reduce the incidence of postoperative respiratory complications in such patients.},
	language = {eng},
	number = {3},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Soma, D. and Kawamura, Y. I. and Yamashita, S. and Wake, H. and Nohara, K. and Yamada, K. and Kokudo, N.},
	month = mar,
	year = {2019},
	pmid = {30239649},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sarcopenia, Treatment Outcome, Retrospective Studies, Risk Factors, Prognosis, sarcopenia, Esophageal Neoplasms, Esophagectomy, Esophageal Squamous Cell Carcinoma, Incidence, Postoperative Complications, Multivariate Analysis, esophagectomy, pneumonia, Respiration Disorders},
	pages = {doy092},
	file = {Soma et al_2019_Sarcopenia, the depletion of muscle mass, an independent predictor of.pdf:/Users/jcsal/Zotero/storage/PKSBIWL3/Soma et al_2019_Sarcopenia, the depletion of muscle mass, an independent predictor of.pdf:application/pdf},
}

@article{derogar551,
	title = {Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study},
	volume = {31},
	issn = {1527-7755},
	doi = {10.1200/JCO.2012.46.1517},
	abstract = {PURPOSE: The influence of hospital and surgeon volume on survival after esophageal cancer surgery deserves clarification, particularly the prognosis after the early postoperative period. The interaction between hospital and surgeon volume, and the influence of known prognostic factors need to be taken into account.
METHODS: A nationwide Swedish population-based cohort study of 1,335 patients with esophageal cancer who underwent esophageal resection in 1987 to 2005, with follow-up for survival until February 2011, was conducted. The associations between annual hospital volume, annual surgeon volume, and cumulative surgeon volume and risk of mortality were calculated with multivariable parametric survival analysis, providing hazard ratios (HRs) with 95\% CIs. HRs were mutually adjusted for the surgery volume variables and further adjusted for the prognostic factors age, sex, comorbidity, calendar period, tumor stage, tumor histology, and neoadjuvant therapy.
RESULTS: There was no independent association between annual hospital volume and overall survival, and hospital volume was not associated with short-term mortality after adjustment for hospital clustering effects. A combination of higher annual and cumulative surgeon volume reduced the mortality occurring at least 3 months after surgery (P trend {\textless} .01); the HR was 0.78 (95\% CI, 0.65 to 0.92) comparing surgeons with both annual and cumulative volume above the median with those below the median. These results remained when hospital and surgeon clustering were taken into account.
CONCLUSION: Because surgeon volume rather than hospital volume independently influences the prognosis after esophageal cancer surgery, centralization of this surgery to fewer surgeons seems warranted.},
	language = {eng},
	number = {5},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Derogar, Maryam and Sadr-Azodi, Omid and Johar, Asif and Lagergren, Pernilla and Lagergren, Jesper},
	month = feb,
	year = {2013},
	pmid = {23295792},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Risk Factors, Risk Assessment, Time Factors, Prognosis, Cohort Studies, Adult, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Comorbidity, Registries, Multivariate Analysis, Mortality, Hospitals, Odds Ratio, Sweden, Physicians},
	pages = {551--557},
	file = {Derogar et al_2013_Hospital and surgeon volume in relation to survival after esophageal cancer.pdf:/Users/jcsal/Zotero/storage/3I589WH3/Derogar et al_2013_Hospital and surgeon volume in relation to survival after esophageal cancer.pdf:application/pdf},
}

@article{dyas268,
	title = {Minimally invasive surgery is associated with decreased postoperative complications after esophagectomy},
	volume = {166},
	issn = {1097-685X},
	doi = {10.1016/j.jtcvs.2022.11.026},
	abstract = {BACKGROUND: Although some studies have compared esophagectomy outcomes by technique or approach, there is opportunity to strengthen our knowledge surrounding these outcomes. We aimed to perform a comprehensive comparison of esophagectomy postoperative complications.
METHODS: We retrospectively reviewed the American College of Surgeons National Surgical Quality Improvement Program database (2007-2018). Esophagectomies were identified using Current Procedural Terminology codes and grouped by operative technique (Ivor Lewis, transhiatal, McKeown) and surgical approach (minimally invasive vs open esophagectomy). Twelve postoperative complications were compared. Significant complications underwent risk adjustment using multivariate logistic regression.
RESULTS: Analysis was performed on 13,457 esophagectomies: 11,202 (83.2\%) open and 2255 (16.8\%) minimally invasive. There were 7611 (56.6\%) Ivor Lewis, 3348 (24.9\%) transhiatal, and 2498 (18.6\%) McKeown procedures. There were significant differences among the surgical techniques in 6 of 12 risk-adjusted complications. When comparing the outcomes of minimally invasive techniques, there were only significant differences in 2 of 12 complications: overall morbidity (minimally invasive Ivor Lewis 30.5\%, minimally invasive transhiatal 43.4\%, minimally invasive McKeown 40.3\%, P = .0009) and infections (minimally invasive Ivor Lewis 15.4\%, minimally invasive transhiatal 26.0\%, minimally invasive McKeown 25.3\%, P = .0003). Patients who underwent minimally invasive surgery were less likely to have overall morbidity (odds ratio, 0.68; 95\% confidence interval, 0.62-0.75), respiratory complications (odds ratio, 0.77; 95\% confidence interval, 0.68-0.87), urinary tract infection (odds ratio, 0.61; 95\% confidence interval, 0.43-0.88), renal complications (odds ratio, 0.52; 95\% confidence interval, 0.34-0.81), bleeding complications (odds ratio, 0.36; 95\% confidence interval, 0.30-0.43), and nonhome discharge (odds ratio, 0.54; 95\% confidence interval, 0.45-0.64), and had shorter length of stay (9.7 vs 13.2 days, P {\textless} .0001).
CONCLUSIONS: Patients undergoing minimally invasive esophagectomy have lower rates of postoperative complications regardless of esophagectomy techniques. The minimally invasive approach was associated with reduced complication variance among 3 common esophagectomy techniques.},
	language = {eng},
	number = {1},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Dyas, Adam R. and Stuart, Christina M. and Bronsert, Michael R. and Schulick, Richard D. and McCarter, Martin D. and Meguid, Robert A.},
	month = jul,
	year = {2023},
	pmid = {36577613},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, esophagectomy, Minimally Invasive Surgical Procedures, MIE, Complications, ACS-NSQIP, minimally invasive, robotic surgery},
	pages = {268--278},
}

@article{markar2130,
	title = {Implementation of {Minimally} {Invasive} {Esophagectomy} {From} a {Randomized} {Controlled} {Trial} {Setting} to {National} {Practice}},
	volume = {38},
	issn = {1527-7755},
	doi = {10.1200/JCO.19.02483},
	abstract = {PURPOSE: The aim of this study was to examine the external validity of the randomized TIME trial, when minimally invasive esophagectomy (MIE) was implemented nationally in the Netherlands, using data from the Dutch Upper GI Cancer Audit (DUCA) for transthoracic esophagectomy.
METHODS: Original patient data from the TIME trial were extracted along with data from the DUCA dataset (2011-2017). Multivariate analysis, with adjustment for patient factors, tumor factors, and year of surgery, was performed for the effect of MIE versus open esophagectomy on clinical outcomes.
RESULTS: One hundred fifteen patients from the TIME trial (59 MIE v 56 open) and 4,605 patients from the DUCA dataset (2,652 MIE v 1,953 open) were included. In the TIME trial, univariate analysis showed that MIE reduced pulmonary complications and length of hospital stay. On the contrary, in the DUCA dataset, MIE was associated with increased total and pulmonary complications and reoperations; however, benefits included increased proportion of R0 margin and lymph nodes harvested, and reduced 30-day mortality. Multivariate analysis from the TIME trial showed that MIE reduced pulmonary complications (odds ratio [OR], 0.19; 95\% CI, 0.06 to 0.61). In the DUCA dataset, MIE was associated with increased total complications (OR, 1.36; 95\% CI, 1.19 to 1.57), pulmonary complications (OR, 1.50; 95\% CI, 1.29 to 1.74), reoperations (OR, 1.74; 95\% CI, 1.42 to 2.14), and length of hospital stay. Multivariate analysis of the combined and MIE datasets showed that inclusion in the TIME trial was associated with a reduction in reoperations, Clavien-Dindo grade {\textgreater} 1 complications, and length of hospital stay.
CONCLUSION: When adopted nationally outside the TIME trial, MIE was associated with an increase in total and pulmonary complications and reoperation rate. This may reflect nonexpert surgeons outside of high-volume centers performing this minimally invasive technique in a nonstandardized fashion outside of a controlled environment.},
	language = {eng},
	number = {19},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Markar, Sheraz R. and Ni, Melody and Gisbertz, Suzanne S. and van der Werf, Leonie and Straatman, Jennifer and van der Peet, Donald and Cuesta, Miguel A. and Hanna, George B. and van Berge Henegouwen, Mark I. and {Dutch Upper GI Cancer Audit and TIME Study Group}},
	month = jul,
	year = {2020},
	pmid = {32421440},
	pmcid = {PMC7325364},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Esophagectomy, Multivariate Analysis, Minimally Invasive Surgical Procedures},
	pages = {2130--2139},
	file = {Markar et al_2020_Implementation of Minimally Invasive Esophagectomy From a Randomized Controlled.pdf:/Users/jcsal/Zotero/storage/ZN4GDNAX/Markar et al_2020_Implementation of Minimally Invasive Esophagectomy From a Randomized Controlled.pdf:application/pdf},
}

@article{bismuth1241,
	title = {Biliary strictures: classification based on the principles of surgical treatment},
	volume = {25},
	issn = {0364-2313},
	shorttitle = {Biliary strictures},
	doi = {10.1007/s00268-001-0102-8},
	abstract = {The classification of biliary strictures used at Hopital Paul Brousse is based on the lowest level at which healthy biliary mucosa is available for anastomosis. The classification is intended to help the surgeon choose the appropriate technique for the repair. Type I strictures, with a common duct stump longer than 2 cm, can be repaired without opening the left duct and without lowering the hilar plate. Type II strictures, with a stump shorter than 2 cm, require opening the left duct for a satisfactory anastomosis. Lowering the hilar plate is not always necessary but may improve the exposure. Type III lesions, in which only the ceiling of the biliary confluence is intact, require lowering the hilar plate and anastomosis on the left ductal system. There is no need to open the right duct if the communication between the ducts is wide. With type IV lesions the biliary confluence is interrupted and requires either reconstruction or two or more anastomoses. Type V lesions are strictures of the hepatic duct associated with a stricture on a separate right branch, and the branch must be included in the repair. Although this classification is intended for established strictures, it is commonly used to describe acute bile duct injuries. The surgeon must be aware, however, that the established stricture is generally one level higher than the level of the injury at the original operation.},
	language = {eng},
	number = {10},
	journal = {World Journal of Surgery},
	author = {Bismuth, H. and Majno, P. E.},
	month = oct,
	year = {2001},
	pmid = {11596882},
	keywords = {Humans, Bile Ducts, Biliary Tract Surgical Procedures, Cholestasis, Common Bile Duct, Constriction, Pathologic, Hepatic Duct, Common},
	pages = {1241--1244},
}

@article{way460,
	title = {Causes and prevention of laparoscopic bile duct injuries: analysis of 252 cases from a human factors and cognitive psychology perspective},
	volume = {237},
	issn = {0003-4932},
	shorttitle = {Causes and prevention of laparoscopic bile duct injuries},
	doi = {10.1097/01.SLA.0000060680.92690.E9},
	abstract = {OBJECTIVE: To apply human performance concepts in an attempt to understand the causes of and prevent laparoscopic bile duct injury.
SUMMARY BACKGROUND DATA: Powerful conceptual advances have been made in understanding the nature and limits of human performance. Applying these findings in high-risk activities, such as commercial aviation, has allowed the work environment to be restructured to substantially reduce human error.
METHODS: The authors analyzed 252 laparoscopic bile duct injuries according to the principles of the cognitive science of visual perception, judgment, and human error. The injury distribution was class I, 7\%; class II, 22\%; class III, 61\%; and class IV, 10\%. The data included operative radiographs, clinical records, and 22 videotapes of original operations.
RESULTS: The primary cause of error in 97\% of cases was a visual perceptual illusion. Faults in technical skill were present in only 3\% of injuries. Knowledge and judgment errors were contributory but not primary. Sixty-four injuries (25\%) were recognized at the index operation; the surgeon identified the problem early enough to limit the injury in only 15 (6\%). In class III injuries the common duct, erroneously believed to be the cystic duct, was deliberately cut. This stemmed from an illusion of object form due to a specific uncommon configuration of the structures and the heuristic nature (unconscious assumptions) of human visual perception. The videotapes showed the persuasiveness of the illusion, and many operative reports described the operation as routine. Class II injuries resulted from a dissection too close to the common hepatic duct. Fundamentally an illusion, it was contributed to in some instances by working too deep in the triangle of Calot.
CONCLUSIONS: These data show that errors leading to laparoscopic bile duct injuries stem principally from misperception, not errors of skill, knowledge, or judgment. The misperception was so compelling that in most cases the surgeon did not recognize a problem. Even when irregularities were identified, corrective feedback did not occur, which is characteristic of human thinking under firmly held assumptions. These findings illustrate the complexity of human error in surgery while simultaneously providing insights. They demonstrate that automatically attributing technical complications to behavioral factors that rely on the assumption of control is likely to be wrong. Finally, this study shows that there are only a few points within laparoscopic cholecystectomy where the complication-causing errors occur, which suggests that focused training to heighten vigilance might be able to decrease the incidence of bile duct injury.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Way, Lawrence W. and Stewart, Lygia and Gantert, Walter and Liu, Kingsway and Lee, Crystine M. and Whang, Karen and Hunter, John G.},
	month = apr,
	year = {2003},
	pmid = {12677139},
	pmcid = {PMC1514483},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Aged, 80 and over, Adult, Laparoscopy, Intraoperative Complications, Bile Ducts, Cognitive Science, Medical Errors, Video Recording},
	pages = {460--469},
	file = {Way et al_2003_Causes and prevention of laparoscopic bile duct injuries.pdf:/Users/jcsal/Zotero/storage/4NCTT5VS/Way et al_2003_Causes and prevention of laparoscopic bile duct injuries.pdf:application/pdf},
}

@article{brunt3,
	title = {Safe {Cholecystectomy} {Multi}-society {Practice} {Guideline} and {State} of the {Art} {Consensus} {Conference} on {Prevention} of {Bile} {Duct} {Injury} {During} {Cholecystectomy}},
	volume = {272},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000003791},
	abstract = {BACKGROUND: BDI is the most common serious complication of laparoscopic cholecystectomy. To address this problem, a multi-society consensus conference was held to develop evidenced-based recommendations for safe cholecystectomy and prevention of BDI.
METHODS: Literature reviews were conducted for 18 key questions across 6 broad topics around cholecystectomy directed by a steering group and subject experts from 5 surgical societies (Society of Gastrointestinal and Endoscopic Surgeons, Americas Hepato-Pancreato-Biliary Association, International Hepato-Pancreato-Biliary Association, Society for Surgery of the Alimentary Tract, and European Association for Endoscopic Surgery). Evidence-based recommendations were formulated using the grading of recommendations assessment, development, and evaluation methodology. When evidence-based recommendations could not be made, expert opinion was documented. A number of recommendations for future research were also documented. Recommendations were presented at a consensus meeting in October 2018 and were voted on by an international panel of 25 experts with greater than 80\% agreement considered consensus.
RESULTS: Consensus was reached on 17 of 18 questions by the guideline development group and expert panel with high concordance from audience participation. Most recommendations were conditional due to low certainty of evidence. Strong recommendations were made for (1) use of intraoperative biliary imaging for uncertainty of anatomy or suspicion of biliary injury; and (2) referral of patients with confirmed or suspected BDI to an experienced surgeon/multispecialty hepatobiliary team.
CONCLUSIONS: These consensus recommendations should provide guidance to surgeons, training programs, hospitals, and professional societies for strategies that have the potential to reduce BDIs and positively impact patient outcomes. Development of clinical and educational research initiatives based on these recommendations may drive further improvement in the quality of surgical care for patients undergoing cholecystectomy.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgery},
	author = {Brunt, L. Michael and Deziel, Daniel J. and Telem, Dana A. and Strasberg, Steven M. and Aggarwal, Rajesh and Asbun, Horacio and Bonjer, Jaap and McDonald, Marian and Alseidi, Adnan and Ujiki, Mike and Riall, Taylor S. and Hammill, Chet and Moulton, Carol-Anne and Pucher, Philip H. and Parks, Rowan W. and Ansari, Mohammed T. and Connor, Saxon and Dirks, Rebecca C. and Anderson, Blaire and Altieri, Maria S. and Tsamalaidze, Levan and Stefanidis, Dimitrios and {and the Prevention of Bile Duct Injury Consensus Work Group}},
	month = jul,
	year = {2020},
	pmid = {32404658},
	keywords = {Humans, Risk Factors, Intraoperative Complications, Cholecystectomy, Laparoscopic, Bile Ducts, Iatrogenic Disease},
	pages = {3--23},
	file = {Brunt et al_2020_Safe Cholecystectomy Multi-society Practice Guideline and State of the Art.pdf:/Users/jcsal/Zotero/storage/L8IZZEG9/Brunt et al_2020_Safe Cholecystectomy Multi-society Practice Guideline and State of the Art.pdf:application/pdf},
}

@article{eppsteiner635,
	title = {Surgeon volume impacts hospital mortality for pancreatic resection},
	volume = {249},
	issn = {1528-1140},
	doi = {10.1097/SLA.0b013e31819ed958},
	abstract = {OBJECTIVE: Improved outcomes after pancreatic resection (PR) by high volume (HV) surgeons have been reported in single center studies, which may be confounded with potential selection and referral bias. We attempted to determine if improved outcomes by HV surgeons are reproducible when patient demographic factors are controlled at the population level.
METHODS: Using the Nationwide Inpatient Sample, discharge records with surgeon identifiers for all nontrauma PR (n = 3581) were examined from 1998 to 2005. Surgeons were divided into 2 groups: (HV; {\textgreater} or = 5 operations/year) or low volume (LV; {\textless}5 operations/year). We created a logistic regression model to examine the relationship between surgeon type and operative mortality while accounting for patient and hospital factors. To further eliminate differences in cohorts and determine the true effect of surgeon volume on mortality, case-control groups based on patient demographics were created using propensity scores.
RESULTS: One hundred thirty-four HV and 1450 LV surgeons performed 3581 PR in 742 hospitals across 12 states that reported surgeon identifier information over the 8-year period. Patients who underwent PR by HV surgeons were more likely to be male, white raced, and a resident of a high-income zip code (P {\textless} 0.05). Significant independent factors for in-hospital mortality after PR included increasing age, male gender, Medicaid insurance, and surgery by HV surgeon. HV surgeons had a lower adjusted mortality compared with LV surgeons (2.4\% vs. 6.4\%; P {\textless} 0.0001).
CONCLUSIONS: After controlling for patient demographics and factors, pancreatic resection by a HV surgeon in this case-controlled cohort was independently associated with a 51\% reduction in in-hospital mortality.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Eppsteiner, Robert W. and Csikesz, Nicholas G. and McPhee, James T. and Tseng, Jennifer F. and Shah, Shimul A.},
	month = apr,
	year = {2009},
	pmid = {19300225},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Cause of Death, Retrospective Studies, Pancreatic Neoplasms, Survival Rate, Logistic Models, Hospital Mortality, Odds Ratio, Clinical Competence, Confidence Intervals, Pancreatectomy, Health Care Surveys, Physicians, Probability},
	pages = {635--640},
}

@article{rodgers829,
	title = {Case volume as a predictor of inpatient mortality after esophagectomy},
	volume = {142},
	issn = {0004-0010},
	doi = {10.1001/archsurg.142.9.829},
	abstract = {HYPOTHESIS: Volume criteria are poor predictors of inpatient mortality after esophagectomy. Because many factors influence mortality for complex procedures, this study was designed to quantify such factors and analyze the volume-outcome relationship for esophagectomy.
DESIGN: Retrospective review of the Nationwide Inpatient Sample database for esophagectomies. We performed multivariate analysis to identify patient and institution risk factors for death and, by using all reported volume thresholds, calculated the probability of choosing a provider with a low mortality.
PATIENTS AND SETTING: Patients undergoing esophagectomy between January 1, 1988, and December 31, 2000, included in the Nationwide Inpatient Sample database.
MAIN OUTCOME MEASURE: Inpatient mortality.
RESULTS: We identified 8075 cases of esophagectomy; 3243 had complete data sets. The national average mortality rate was 11.4\%. Independent risk factors for mortality included comorbidity, age ({\textgreater} 65 years), female sex, race, and surgeon volume. Choosing a surgeon or hospital on the basis of a particular volume threshold had a modest influence on the probability of that provider having a low mortality. A low-volume hospital (defined by the Leapfrog Group criterion as {\textless} 13 cases per year) had a probability of 61\% of having a mortality of less than 10\%, whereas a high-volume hospital had a probability of 68\%.
CONCLUSIONS: Patient factors have a greater influence on inpatient mortality than case volume does. Although there is generally an inverse relationship between case volume and mortality, there is wide scatter between individual surgeons and hospitals, with a complex volume-outcome relationship. Using volume criteria alone to choose a provider may in some instances increase the risk of mortality.},
	language = {eng},
	number = {9},
	journal = {Archives of Surgery (Chicago, Ill.: 1960)},
	author = {Rodgers, Michael and Jobe, Blair A. and O'Rourke, Robert W. and Sheppard, Brett and Diggs, Brian and Hunter, John G.},
	month = sep,
	year = {2007},
	pmid = {17875837},
	keywords = {Humans, Female, Male, Retrospective Studies, Risk Factors, Sex Factors, Risk Assessment, Predictive Value of Tests, United States, Esophagectomy, Comorbidity, Multivariate Analysis, Hospital Mortality},
	pages = {829--839},
}

@article{gottlieb-vedi1005,
	title = {Long-term {Survival} in {Esophageal} {Cancer} {After} {Minimally} {Invasive} {Compared} to {Open} {Esophagectomy}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {270},
	issn = {1528-1140},
	shorttitle = {Long-term {Survival} in {Esophageal} {Cancer} {After} {Minimally} {Invasive} {Compared} to {Open} {Esophagectomy}},
	doi = {10.1097/SLA.0000000000003252},
	abstract = {OBJECTIVE: Evaluate the existing literature comparing long-term survival after minimally invasive esophagectomy (MIE) and open esophagectomy (OE), and conduct a meta-analysis based on relevant studies.
BACKGROUND: It is unknown whether the choice between MIE and OE influences the long-term survival in esophageal cancer.
METHODS: A systematic electronic search for articles was performed in Medline, Embase, Web of Science, and Cochrane Library for studies comparing long-term survival after MIE and OE. Additionally, an extensive hand-search was conducted. The I test and χ test were used to test for statistical heterogeneity. Publication bias and small-study effects were assessed using Egger test. A random-effects meta-analysis was performed for all-cause 5-year (main outcome) and 3-year mortality, and disease-specific 5-year and 3-year mortality. Meta-regression was performed for the 5-year mortality outcomes with adjustment for the covariates age, physical status, tumor stage, and neoadjuvant or adjuvant therapy. The results were presented as hazard ratios (HRs) with 95\% confidence intervals (CIs).
RESULTS: The review identified 55 relevant studies. Among all 14,592 patients, 7358 (50.4\%) underwent MIE and 7234 (49.6\%) underwent OE. The statistical heterogeneity was limited [I = 12\%, 95\% confidence interval (CI) 0\%-41\%, and χ = 0.26] and the funnel plot was symmetrical both according to visual and statistical testing (Egger test = 0.32). Pooled analysis revealed 18\% lower 5-year all-cause mortality after MIE compared with OE (HR 0.82, 95\% CI 0.76-0.88). The meta-regression indicated no confounding.
CONCLUSIONS: The long-term survival after MIE compares well with OE and may even be better. Thus, MIE can be recommended as a standard surgical approach for esophageal cancer.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Gottlieb-Vedi, Eivind and Kauppila, Joonas H. and Malietzis, George and Nilsson, Magnus and Markar, Sheraz R. and Lagergren, Jesper},
	month = dec,
	year = {2019},
	pmid = {30817355},
	keywords = {Humans, Treatment Outcome, Survival Rate, Esophageal Neoplasms, Esophagectomy, Minimally Invasive Surgical Procedures},
	pages = {1005--1017},
}

@article{yerokun416,
	title = {Minimally {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}: {A} {Population}-{Based} {Analysis}},
	volume = {102},
	issn = {1552-6259},
	shorttitle = {Minimally {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}},
	doi = {10.1016/j.athoracsur.2016.02.078},
	abstract = {BACKGROUND: The objective of this study was to evaluate outcomes of minimally invasive approaches to esophagectomy using population-level data.
METHODS: Multivariable regression modeling was used to determine predictors associated with the use of minimally invasive approaches for patients in the National Cancer Data Base who underwent resection of middle and distal clinical T13N03M0 esophageal cancers from 2010 to 2012. Perioperative outcomes and 3-year survival were compared between propensity-matched groups of patients with esophageal cancer who underwent minimally invasive esophagectomy (MIE) or open esophagectomy (OE). A subgroup analysis was performed to evaluate the impact of using robotic-assisted operations as part of the minimally invasive approach.
RESULTS: Among 4,266 patients included, 1,308 (30.6\%) underwent MIE. It was more likely to be used in patients treated at academic (adjusted odds ratio [OR], 10.1; 95\% confidence interval [CI], 4.2-33.1) or comprehensive cancer facilities (adjusted OR, 6.4; 95\% CI, 2.6-21.1). Compared with propensity-matched patients who underwent OE, patients who underwent MIE had significantly more lymph nodes examined (15 versus 13; p = 0.016) and shorter hospital lengths of stay (10 days versus 11 days; p = 0.046) but similar resection margin positivity, readmission, and 30-day mortality (all p {\textgreater} 0.05). Survival was similar between the matched groups at 3 years for both adenocarcinoma and squamous cell carcinoma (p {\textgreater} 0.05). Compared with MIE without robotic assistance, use of a robotic approach was not associated with any significant differences in perioperative outcomes (p {\textgreater} 0.05).
CONCLUSIONS: The use of minimally invasive techniques to perform esophagectomy for esophageal cancer is associated with modestly improved perioperative outcomes without compromising survival.},
	language = {eng},
	number = {2},
	journal = {The Annals of Thoracic Surgery},
	author = {Yerokun, Babatunde A. and Sun, Zhifei and Yang, Chi-Fu Jeffrey and Gulack, Brian C. and Speicher, Paul J. and Adam, Mohamed A. and D'Amico, Thomas A. and Onaitis, Mark W. and Harpole, David H. and Berry, Mark F. and Hartwig, Matthew G.},
	month = aug,
	year = {2016},
	pmid = {27157326},
	pmcid = {PMC5142521},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Time Factors, Survival Rate, United States, Population Surveillance, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Esophagus, Thoracoscopy},
	pages = {416--423},
	file = {Yerokun et al_2016_Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer.pdf:/Users/jcsal/Zotero/storage/EQKLMBHM/Yerokun et al_2016_Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer.pdf:application/pdf},
}

@article{kitajima1036,
	title = {Combined assessment of muscle quality and quantity predicts oncological outcome in patients with esophageal cancer},
	volume = {225},
	issn = {1879-1883},
	doi = {10.1016/j.amjsurg.2022.11.032},
	abstract = {BACKGROUND: Sarcopenia consists of two dysregulation patterns of body composition, myopenia and myosteatosis. The aim of this study is to compare the preoperative status of various body composition indexes including our newly developed modified intramuscular adipose tissue content (mIMAC) to investigate these clinical values in esophageal cancer patients.
METHOD: We assessed preoperative psoas muscle mass index (PMI), IMAC, and mIMAC in 150 esophageal cancer patients.
RESULTS: Preoperative high IMAC and low mIMAC status were significantly associated with older age. Preoperative decreased mIMAC was significantly associated with advanced T classification and the presence of distant metastasis and low preoperative mIMAC was an independent prognostic factor for poor overall survival and disease-free survival in esophageal cancer patients. Combined assessment of preoperative mIMAC with PMI could help stratify risk for oncological outcomes. Finally, preoperative PMI and mIMAC were positively correlated with various nutritional factors in esophageal cancer patients.
CONCLUSION: Combined assessment between preoperative PMI and mIMAC could stratify risk for oncological outcomes, and preoperative mIMAC might be surrogate marker for aging and nutritional status in esophageal cancer patients.},
	language = {eng},
	number = {6},
	journal = {American Journal of Surgery},
	author = {Kitajima, Takahito and Okugawa, Yoshinaga and Shimura, Tadanobu and Yamashita, Shinji and Sato, Yuhki and Goel, Arul and Mizuno, Naru and Yin, Chengzeng and Uratani, Rho and Imaoka, Hiroki and Morimoto, Yuhki and Kawamura, Mikio and Mochiki, Ikuyo and Okita, Yoshiki and Yokoe, Takeshi and Ohi, Masaki and Toiyama, Yuji},
	month = jun,
	year = {2023},
	pmid = {36462959},
	keywords = {Humans, Sarcopenia, Retrospective Studies, Muscular Atrophy, Disease-Free Survival, Esophageal Neoplasms, Esophageal cancer, Nutrition, Psoas Muscles, Modified intramuscular adipose tissue content, Psoas muscle index},
	pages = {1036--1044},
	file = {Kitajima et al_2023_Combined assessment of muscle quality and quantity predicts oncological outcome.pdf:/Users/jcsal/Zotero/storage/DPZ3FVC9/Kitajima et al_2023_Combined assessment of muscle quality and quantity predicts oncological outcome.pdf:application/pdf},
}

@article{sanchez511,
	title = {Colon {Interposition} for {Esophageal} {Cancer}},
	volume = {32},
	issn = {1558-5069},
	doi = {10.1016/j.thorsurg.2022.07.006},
	abstract = {Esophagectomy and colon interposition in the adult patient, either for primary alimentary reconstruction or as a secondary replacement after initial resection/reconstruction for malignant or benign disease, remains a valuable tool in the thoracic surgeon's armamentarium. It is important for surgeons to remain versed in the complexities of the operation, including preoperative preparation and decision making, operative procedural and technical variations, and recognition and timely treatment of postoperative complications. In this article, we present technical details of the procedure, a review of selected published studies, long-term results, and indications and outcomes for revisional surgery.},
	language = {eng},
	number = {4},
	journal = {Thoracic Surgery Clinics},
	author = {Sanchez, Manuel Villa and Alicuben, Evan T. and Luketich, James D. and Sarkaria, Inderpal S.},
	month = nov,
	year = {2022},
	pmid = {36266037},
	keywords = {Humans, Adult, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Postoperative Complications, Colon, Colon interposition, Midazolam},
	pages = {511--527},
	file = {Sanchez et al_2022_Colon Interposition for Esophageal Cancer.pdf:/Users/jcsal/Zotero/storage/DYTF6CK7/Sanchez et al_2022_Colon Interposition for Esophageal Cancer.pdf:application/pdf},
}

@article{furst173,
	title = {Colon interposition for esophageal replacement: an alternative technique based on the use of the right colon},
	volume = {231},
	issn = {0003-4932},
	shorttitle = {Colon interposition for esophageal replacement},
	doi = {10.1097/00000658-200002000-00004},
	abstract = {OBJECTIVE: To describe the technique and results of an alternative colon interposition procedure in which the ascending and transverse colon is used as graft, but that still relies on the left colonic artery for blood supply.
SUMMARY BACKGROUND DATA: The standard procedure to obtain a left colon interposition graft requires ligation of the middle colic artery and mobilization of the left and right flexure. This approach carries a risk because preparation of the left flexure may damage arterial or venous collaterals located at this site that are crucial for graft perfusion.
METHODS: The authors modified the standard technique so that mobilization of the left flexure is no longer necessary. To obtain a colon interposition graft that is long enough, the ascending colon was included into the graft by ligating the middle and the right colic artery. The left colic artery remained the blood-supplying vessel. From January 1997 to June 1998, 15 patients underwent modified colon interposition with a cervical anastomosis (12 esophagectomies, 3 esophagogastrectomies).
RESULTS: In all cases, intraoperative blood supply from the left colic artery to the proximal ascending colon was sufficient. After surgery, four major complications occurred (27\%). Endoscopy demonstrated a vital graft in all patients. In one patient a leakage of the cervical anastomosis was observed. One patient died of herpes pneumonia. Postoperative artificial ventilation was required for an average of 2.8 +/- 4.6 days, the average intensive care unit stay was 6.9+/-4.5 days, and the average total hospital stay was 24.1 +/- 15.1 days.
CONCLUSION: An intact left colic artery, including its collaterals at the splenic flexure, supplies sufficient blood to the proximal ascending colon after central ligation of the middle and right colic artery. Even without mobilization of the left flexure, a sufficient graft length can be obtained. Preliminary complication rates with the use of this technique for colon interposition are in the range of those found for the standard colon interposition technique. These modifications may represent an alternative to established procedures for creating a colon interposition graft.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Fürst, H. and Hartl, W. H. and Löhe, F. and Schildberg, F. W.},
	month = feb,
	year = {2000},
	pmid = {10674607},
	pmcid = {PMC1420983},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Esophagus, Anastomosis, Surgical, Colon, Surgically-Created Structures, Transplantation, Autologous},
	pages = {173--178},
	file = {00000658-200002000-00004.pdf:/Users/jcsal/Zotero/storage/FJFZX4YA/00000658-200002000-00004.pdf:application/pdf;Fürst et al_2000_Colon interposition for esophageal replacement.pdf:/Users/jcsal/Zotero/storage/BX3WDPD4/Fürst et al_2000_Colon interposition for esophageal replacement.pdf:application/pdf},
}

@article{peters858,
	title = {Arterial anatomic considerations in colon interposition for esophageal replacement},
	volume = {130},
	issn = {0004-0010},
	doi = {10.1001/archsurg.1995.01430080060009},
	abstract = {BACKGROUND: Little has been written regarding the arterial anatomy predictive of success following esophagectomy and colon interposition.
DESIGN: Retrospective review.
SETTING: University teaching hospital.
PATIENTS: Twenty-five patients undergoing planned left colon interposition.
INTERVENTION: Colon interposition was performed via an isoperistaltic left colon graft based on the ascending branch of the left colic artery.
MAIN OUTCOME MEASURES: Five angiographic features were considered important to successful use of the left colon: (1) a patient inferior mesenteric artery, (2) a visible ascending branch of the left colic artery, (3) a well-defined anastomosis between the middle colic and left colic systems, (4) a single middle colic trunk prior to its division into right and left branches, and (5) a separate origin of the right colic artery. Venous drainage via a patent marginal vein, inferior mesenteric vein, and superior hemorrhoidal veins was preserved in all patients.
RESULTS: Left colon interposition could be performed in 21 (84\%) of 25 patients. Eighty percent of the patients (20/25) had at least four of the five criteria thought necessary for optimal graft perfusion. Three or fewer criteria were present in five patients, three of whom underwent gastric interposition. The inferior mesenteric artery was patent in all patients except one who required a right colon interposition. Ninety-two percent (23/25) demonstrated an adequate ascending left colic artery. The superior-inferior mesenteric artery anastomosis was seen in 52\% (13/25). A single-trunked middle colic artery was present 80\% (20/25) of the time. A single incidence of graft necrosis occurred secondary to venous insufficiency. Ninety-six percent of patients (24/25) were able to swallow without difficulty at the time of discharge from the hospital.
CONCLUSIONS: Replacement of the esophagus with colon can be successful in over 80\% of patients screened by angiographic criteria. Patients with an occluded or stenotic inferior mesenteric artery or variant middle colic arterial anatomy should undergo an alternate reconstruction.},
	language = {eng},
	number = {8},
	journal = {Archives of Surgery (Chicago, Ill.: 1960)},
	author = {Peters, J. H. and Kronson, J. W. and Katz, M. and DeMeester, T. R.},
	month = aug,
	year = {1995},
	pmid = {7632146},
	keywords = {Anastomosis, Surgical, Colon, Esophagectomy, Female, Humans, Male, Mass Screening, Mesenteric Arteries, Middle Aged, Patient Selection, Preoperative Care, Radiography, Retrospective Studies, Treatment Outcome},
	pages = {858--862; discussion 862--863},
	file = {Peters et al_1995_Arterial anatomic considerations in colon interposition for esophageal.pdf:/Users/jcsal/Zotero/storage/6779V8PM/Peters et al_1995_Arterial anatomic considerations in colon interposition for esophageal.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/LX3YCPPJ/7632146.html:text/html},
}

@article{j,
	title = {{MRI}-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study},
	volume = {18},
	issn = {1534-4681},
	shorttitle = {{MRI}-based indications for neoadjuvant radiochemotherapy in rectal carcinoma},
	url = {https://pubmed.ncbi.nlm.nih.gov/21509631/},
	doi = {10.1245/s10434-011-1704-5},
	abstract = {Low pCRM positivity and the high quality of mesorectal excision support use of MRI-based nRCT in rectal carcinoma. nRCT was avoidable in 45\% of patients with stage II and III disease without significant risk of undertreatment. Preoperative MRI thus allows identification of patients with high risk of …},
	language = {en},
	number = {10},
	urldate = {2023-11-21},
	journal = {Annals of surgical oncology},
	author = {J, Strassburg and R, Ruppert and H, Ptok and C, Maurer and T, Junginger and S, Merkel and P, Hermanek},
	month = oct,
	year = {2011},
	pmid = {21509631},
	note = {Publisher: Ann Surg Oncol},
	keywords = {MRI},
	file = {Snapshot:/Users/jcsal/Zotero/storage/HNLDSLDS/21509631.html:text/html},
}

@article{is,
	title = {Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer},
	volume = {249},
	issn = {1528-1140},
	url = {https://pubmed.ncbi.nlm.nih.gov/19387328/},
	doi = {10.1097/SLA.0b013e3181a38e9e},
	abstract = {A negative endoscopic biopsy is not a useful predictor of a pCR after CRT, final nodal status, or overall survival.},
	language = {en},
	number = {5},
	urldate = {2023-11-21},
	journal = {Annals of surgery},
	author = {Is, Sarkaria and Np, Rizk and Ms, Bains and Lh, Tang and Dh, Ilson and Bi, Minsky and Vw, Rusch},
	month = may,
	year = {2009},
	pmid = {19387328},
	note = {Publisher: Ann Surg},
	file = {Snapshot:/Users/jcsal/Zotero/storage/Q5DA97X3/19387328.html:text/html},
}

@article{durrleman551,
	title = {Flexible regression models with cubic splines},
	volume = {8},
	issn = {0277-6715},
	doi = {10.1002/sim.4780080504},
	abstract = {We describe the use of cubic splines in regression models to represent the relationship between the response variable and a vector of covariates. This simple method can help prevent the problems that result from inappropriate linearity assumptions. We compare restricted cubic spline regression to non-parametric procedures for characterizing the relationship between age and survival in the Stanford Heart Transplant data. We also provide an illustrative example in cancer therapeutics.},
	language = {eng},
	number = {5},
	journal = {Statistics in Medicine},
	author = {Durrleman, S. and Simon, R.},
	month = may,
	year = {1989},
	pmid = {2657958},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sex Factors, Prognosis, Adult, Age Factors, Regression Analysis, Models, Statistical, Heart Transplantation, Lymphoma, Non-Hodgkin},
	pages = {551--561},
}

@article{reisinger345,
	title = {Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery},
	volume = {261},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000000628},
	abstract = {OBJECTIVE: To determine the association of sarcopenia with postoperative morbidity and mortality after colorectal surgery.
BACKGROUND: Functional compromise in elderly colorectal surgical patients is considered as a significant factor of impaired postoperative recovery. Therefore, the predictive value of preoperative functional compromise assessment was investigated. Sarcopenia is a hallmark of functional compromise.
METHODS: A total of 310 consecutive patients who underwent oncologic colorectal surgery were included in a prospective digital database. Sarcopenia was assessed using the L3 muscle index utilizing Osirix on preoperative computed tomography. Groningen Frailty Indicator and Short Nutritional Assessment Questionnaire scores were used to assess frailty and nutritional compromise. Predictors for anastomotic leakage, sepsis, and mortality were analyzed by logistic regression analysis.
RESULTS: Age was an independent predictor of mortality [P = 0.04; odds ratio, 1.17; 95\% confidence interval (CI), 1.01-1.37]. Thirty-day/in-hospital mortality rate in sarcopenic patients was 8.8\% versus 0.7\% in nonsarcopenic patients (P = 0.001; odds ratio, 15.5; 95\% CI, 2.00-120). Sarcopenia was not predictive for anastomotic leakage or sepsis. Combination of high Short Nutritional Assessment Questionnaire score, high Groningen Frailty Indicator score, and sarcopenia strongly predicted sepsis (P = 0.001; odds ratio, 25.1; 95\% CI, 5.11-123), sensitivity, 46\%; specificity, 97\%; positive likelihood ratio, 13 (95\% CI, 4.4-38); negative likelihood ratio, 0.57 (95\% CI, 0.33-0.97).
CONCLUSIONS: Functional compromise in colorectal cancer surgery is associated with adverse postoperative outcome. Assessment of functional compromise by means of a nutritional questionnaire (Short Nutritional Assessment Questionnaire), a frailty questionnaire (Groningen Frailty Indicator), and sarcopenia measurement (L3 muscle index) can accurately predict postoperative sepsis.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Reisinger, Kostan W. and van Vugt, Jeroen L. A. and Tegels, Juul J. W. and Snijders, Claire and Hulsewé, Karel W. E. and Hoofwijk, Anton G. M. and Stoot, Jan H. and Von Meyenfeldt, Maarten F. and Beets, Geerard L. and Derikx, Joep P. M. and Poeze, Martijn},
	month = feb,
	year = {2015},
	pmid = {24651133},
	keywords = {Humans, Aged, Female, Male, Sarcopenia, Treatment Outcome, Colorectal Neoplasms, Retrospective Studies, Risk Factors, Risk Assessment, Aged, 80 and over, Age Factors, Postoperative Complications, Malnutrition, Anastomotic Leak, Hospital Mortality, Odds Ratio, Surveys and Questionnaires, Geriatric Assessment, Frail Elderly, Sepsis},
	pages = {345--352},
}

@article{argenye0202220,
	title = {Visceral fat area measured with computed tomography does not predict postoperative course in {Crohn}´s disease patients},
	volume = {13},
	issn = {1932-6203},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104989/},
	doi = {10.1371/journal.pone.0202220},
	abstract = {The role of visceral fat measured by computer tomography is yet not well defined in patients with Crohn's disease. Therefore, the present study was designed to assess the impact of visceral fat area on postoperative short-term outcome and surgical characteristics. We analyzed 95 patients, who underwent intestinal resection for symptomatic Crohn's disease at an academic tertiary referral center between 2003 and 2008. Visceral fat area was measured on preoperative computed tomography scans. Postoperative morbidity was graded according to the Clavien-Dindo classification. Visceral fat area was correlated with baseline characteristics, disease phenotype and 30-day morbidity. Body mass index and age were significantly associated with a higher visceral fat area (p = 0.001). Overall 19 (20.0\%) postoperative complications were observed, of whom 7 (7.4\%) patients required surgical re-intervention. No significant difference was found with regard to visceral fat area between patients with an uneventful and eventful postoperative course (no complications: median visceral fat area 52.0 cm2 SD 59.7, complications: 41.3 cm2 SD 42.8; p = 0.465). In contrast to current literature, we cannot support the role of visceral fat area for predicting postoperative course in Crohn's disease. In addition, no correlation of the visceral fat area and disease behavior was detected.},
	number = {8},
	urldate = {2023-07-17},
	journal = {PLoS ONE},
	author = {Argeny, Stanislaus and Tamandl, Dietmar and Scharitzer, Martina and Stift, Anton and Bergmann, Michael and Riss, Stefan},
	month = aug,
	year = {2018},
	pmid = {30133500},
	pmcid = {PMC6104989},
	pages = {e0202220},
}

@article{andreyev503,
	title = {Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?},
	volume = {34},
	issn = {0959-8049},
	doi = {10.1016/s0959-8049(97)10090-9},
	abstract = {The aim of this study was to examine whether weight loss at presentation, in patients who were to receive chemotherapy for gastrointestinal carcinomas, influences outcome and whether nutritional intervention would be worthwhile. This study was a retrospective review of prospectively gathered data. The outcomes of patients with or without weight loss and treated for locally advanced or metastatic tumours of the oesophagus, stomach, pancreas, colon or rectum were compared. In 1555 such consecutive patients treated over a 6-year period, weight loss at presentation was reported more commonly by men than women (51 versus 44\%, P = 0.01). Although patients with weight loss received lower chemotherapy doses initially, they developed more frequent and more severe dose limiting toxicity--specifically plantar-palmar syndrome (P {\textless} 0.0001) and stomatitis (P {\textless} 0.0001)--than patients without weight loss. Consequently, patients with weight loss on average received 1 month (18\%) less treatment (P {\textless} 0.0001). Weight loss correlated with shorter failure-free (P {\textless} 0.0001, hazard ratio = 1.25) and overall survival (P {\textless} 0.0001, hazard ratio = 1.63), decreased response (P = 0.006), quality of life (P {\textless} 0.0001) and performance status (P {\textless} 0.0001). Patients who stopped losing weight had better overall survival (P = 0.0004). Weight loss at presentation was an independent prognostic variable (hazard ratio = 1.43). The poorer outcome from treatment in patients with weight loss appears to occur because they receive significantly less chemotherapy and develop more toxicity rather than any specifically reduced tumour responsiveness to treatment. These findings provide a rationale for attempting randomised nutritional intervention studies in these patients.},
	language = {eng},
	number = {4},
	journal = {European Journal of Cancer (Oxford, England: 1990)},
	author = {Andreyev, H. J. and Norman, A. R. and Oates, J. and Cunningham, D.},
	month = mar,
	year = {1998},
	pmid = {9713300},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Colorectal Neoplasms, Retrospective Studies, Prospective Studies, Time Factors, Pancreatic Neoplasms, Weight Loss, Aged, 80 and over, Adult, Fluorouracil, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Treatment Failure, Quality of Life, Antimetabolites, Antineoplastic, Adolescent, WeightLoss},
	pages = {503--509},
}

@article{shichinohe1301,
	title = {Impact of {Preoperative} {Skeletal} {Muscle} {Mass} and {Nutritional} {Status} on {Short}-and {Long}-{Term} {Outcomes} {After} {Esophagectomy} for {Esophageal} {Cancer}: {A} {Retrospective} {Observational} {Study} : {Impact} of {Psoas} {Muscle} {Mass} and {Body} {Mass} on {Esophagectomy}},
	volume = {26},
	issn = {1534-4681},
	shorttitle = {Impact of {Preoperative} {Skeletal} {Muscle} {Mass} and {Nutritional} {Status} on {Short}-and {Long}-{Term} {Outcomes} {After} {Esophagectomy} for {Esophageal} {Cancer}},
	doi = {10.1245/s10434-019-07188-z},
	abstract = {BACKGROUND: Preoperative muscle volume and body mass index (BMI) are associated with postoperative outcomes. Because esophagectomy for esophageal cancer (EC) is associated with high morbidity and because EC has a poor prognosis, this study investigated the association of preoperative skeletal muscle mass and nutritional status with postoperative outcomes.
METHODS: The study analyzed 483 patients who underwent esophagectomy from 2009 to 2012. The cross-sectional area of the psoas muscle index (PMI) was measured at the third lumbar vertebral level using computed tomography. Clavien-Dindo classifications were used to analyze postoperative complications. Because skeletal muscle mass varies according to sex, all analyses were performed accordingly (390 males, 93 females).
RESULTS: For male patients, BMI was a significant multivariate factor, and PMI, a univariate factor, predicted postoperative complications and overall survival (OS). Using a preoperative nutritional and muscular (PNM) score derived from BMI and PMI results (patients were allocated 1 point if their BMI was {\textless} 18.5 kg/m2 and 1 point if their PMI was {\textless} 600 mm2/m2, for a possible maximum total of 2 points), male patients were categorized as high risk (score 2), moderate risk (score 1), or low risk (score 0). In the low-risk group, anastomotic leakage was significantly less (p = 0.01), and the 3-year OS was significantly better (p {\textless} 0.01). On the other hand, in female patients, neither BMI nor PMI was a significant factor for postoperative outcomes.
CONCLUSIONS: For male patients, the PNM score is a promising tool for predicting postoperative outcomes and identifying patients requiring preoperative nutritional intervention and rehabilitation.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgical Oncology},
	author = {Shichinohe, Toshiaki and Uemura, Shion and Hirano, Satoshi and Hosokawa, Masao},
	month = may,
	year = {2019},
	pmid = {30725311},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Follow-Up Studies, Retrospective Studies, Risk Factors, Survival Rate, Prognosis, Aged, 80 and over, Adult, Cross-Sectional Studies, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Nutritional Status, Preoperative Care, Psoas Muscles},
	pages = {1301--1310},
	file = {Shichinohe et al_2019_Impact of Preoperative Skeletal Muscle Mass and Nutritional Status on Short-and.pdf:/Users/jcsal/Zotero/storage/SCYKKC3F/Shichinohe et al_2019_Impact of Preoperative Skeletal Muscle Mass and Nutritional Status on Short-and.pdf:application/pdf},
}

@article{filip787,
	title = {Postoperative outcome after oesophagectomy for cancer: {Nutritional} status is the missing ring in the current prognostic scores},
	volume = {41},
	issn = {1532-2157},
	shorttitle = {Postoperative outcome after oesophagectomy for cancer},
	doi = {10.1016/j.ejso.2015.02.014},
	abstract = {BACKGROUND: Several prognostic scores were designed in order to estimate the risk of postoperative adverse events. None of them includes a component directly associated to the nutritional status. The aims of the study were the evaluation of performance of risk-adjusted models for early outcomes after oesophagectomy and to develop a score for severe complication prediction with special consideration regarding nutritional status.
METHODS: A comparison of POSSUM and Charlson score and their derivates, ASA, Lagarde score and nutritional index (PNI) was performed on 167 patients undergoing oesophagectomy for cancer. A logistic regression model was also estimated to obtain a new prognostic score for severe morbidity prediction.
RESULTS: Overall morbidity was 35.3\% (59 cases), severe complications (grade III-V of Clavien-Dindo classification) occurred in 20 cases. Discrimination was poor for all the scores. Multivariable analysis identified pulse, connective tissue disease, PNI and potassium as independent predictors of severe morbidity. This model showed good discrimination and calibration. Internal validation using standard bootstrapping techniques confirmed the good performance.
CONCLUSIONS: Nutrition could be an independent risk factor for major complications and a nutritional status coefficient could be included in current prognostic scores to improve risk estimation of major postoperative complications after oesophagectomy for cancer.},
	language = {eng},
	number = {6},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Filip, B. and Scarpa, M. and Cavallin, F. and Cagol, M. and Alfieri, R. and Saadeh, L. and Ancona, E. and Castoro, C.},
	month = jun,
	year = {2015},
	pmid = {25890494},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Risk Assessment, Prognosis, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Oesophageal cancer, Postoperative Complications, Logistic Models, Nutritional Status, Connective Tissue Diseases, Postoperative complications, Serum Albumin, Lymphocyte Count, Oesophagectomy, Heart Rate, Potassium, Prognostic scores},
	pages = {787--794},
	file = {Filip et al_2015_Postoperative outcome after oesophagectomy for cancer.pdf:/Users/jcsal/Zotero/storage/ZUDWTQSR/Filip et al_2015_Postoperative outcome after oesophagectomy for cancer.pdf:application/pdf},
}

@article{ding7337,
	title = {Effects of enteral nutrition support combined with enhanced recovery after surgery on the nutritional status, immune function, and prognosis of patients with esophageal cancer after {Ivor}-{Lewis} operation},
	volume = {12},
	issn = {2072-1439},
	doi = {10.21037/jtd-20-3410},
	abstract = {BACKGROUND: Esophageal cancer (EC) with a high incidence of malnutrition is a highly malignant digestive tract tumor. We investigated the effect of enteral nutrition (EN) support combined with enhanced recovery after surgery (ERAS) on the nutritional status, immune function, and prognosis of patients with EC after Ivor-Lewis operation.
METHODS: One hundred patients were randomly divided into the observation group (n=42) and the control group (n=58). The patients in observation group were treated with EN combined with ERAS intervention after Ivor-Lewis operation, and the patients in control group were treated with conventional postoperative EN intervention. The situation of operation, nutritional status, immune function recovery and prognosis between the two groups were compared.
RESULTS: There was no statistically significant difference in operation time or intraoperative blood loss between the two groups (P{\textgreater}0.05). The chest tube removal time and oral feeding time of the observation group after operation were shorter than those of the control group (P{\textless}0.05). After intervention, serum albumin (ALB), transferrin (TF), pre-albumin (PA) and hemoglobin (Hb) levels in both groups were significantly decreased. These indexes were significantly higher in the observation group than in the control group (P{\textless}0.05). There were no significant changes in the levels of immunoglobulin (Ig) A, IgG, and IgM, or the numbers of CD3+, CD4+ and CD4+/CD8+ T cells in the observation group before and after intervention (P{\textgreater}0.05); however those indexes were significantly decreased in the control group after the intervention (P{\textless}0.05). Interestingly, the levels of IgA, IgM, IgG, CD3+ T cells, CD4+ T cells and CD4+/CD8+ T cells in the observation group were significantly higher than those in the control group after intervention (P{\textless}0.05). The incidence of pulmonary infection in the observation group was significantly lower than that in the control group. The postoperative exhaust time, postoperative defecation time and postoperative hospital stay were shorter in the observation group than in the control group (P{\textless}0.05). There was no significant difference in hospitalization cost between the two groups (P{\textgreater}0.05).
CONCLUSIONS: EN combined with ERAS was more beneficial to the improvement of nutritional status and immune function recovery of patients with EC after Ivor-Lewis operation. It also shortened the length of hospital stay.},
	language = {eng},
	number = {12},
	journal = {Journal of Thoracic Disease},
	author = {Ding, Haibing and Xu, Jin and You, Jijun and Qin, Haifeng and Ma, Haitao},
	month = dec,
	year = {2020},
	pmid = {33447423},
	pmcid = {PMC7797812},
	keywords = {nutritional status, enhanced recovery after surgery (ERAS), Enteral nutrition support, esophageal cancer (EC), Ivor-Lewis operation},
	pages = {7337--7345},
	file = {Ding et al_2020_Effects of enteral nutrition support combined with enhanced recovery after.pdf:/Users/jcsal/Zotero/storage/NE8XZFZA/Ding et al_2020_Effects of enteral nutrition support combined with enhanced recovery after.pdf:application/pdf},
}

@article{wange33335,
	title = {Multidisciplinary nutritional management improves nutritional and hospitalized outcomes of patients with esophageal cancer undergoing chemoradiotherapy: {A} randomized control trial},
	volume = {102},
	issn = {1536-5964},
	shorttitle = {Multidisciplinary nutritional management improves nutritional and hospitalized outcomes of patients with esophageal cancer undergoing chemoradiotherapy},
	doi = {10.1097/MD.0000000000033335},
	abstract = {BACKGROUND: This study aimed to investigate the effects of multidisciplinary whole-course nutrition management on the nutritional status and complications during the course of treatment in patients with esophageal cancer (EC) undergoing chemoradiotherapy.
METHODS: A total of 36 EC patients undergoing chemoradiotherapy were divided into a control group (n = 18) and an intervention group (n = 18). Participants in the control group were given routine nutritional support, whereas those in the intervention group were provided whole-course nutrition management from the nutrition support team. Nutrition-related indicators, that is, serum albumin level (ALB), hemoglobin (Hb), and C reactive protein were assessed before, during, and after treatment in both groups. The incidence of complications (e.g., lymphocytopenia, radiation esophagitis, and myelosuppression), clinical outcomes, length of hospital stay, and hospital costs were also recorded. Differences between the 2 groups were tested using the Mann-Whitney U and chi-square tests.
RESULTS: The ALB and Hb levels of the patients in the control group decreased significantly [ALB: -2.6 (-5.6, 0), P = .01; Hb: -12.0 (-27.0, -2.0), P = .04] and C reactive protein increased [8.9 (2.9, 14.9), P = .02] compared to those before treatment, while the indicators of participants in the intervention group did not change (P {\textgreater} .05). The incidence of grade ≥ II lymphocytopenia was higher in the control group than that in the intervention group (33.3\% vs 61.1\%, P = .03). Moreover, compared with the control group, the average length of hospital stay decreased by 12 days [47 (40, 50) vs 35 (23, 40), P = .001], and in-patient expenses decreased by 20,504 CNY in the intervention group (P = .004).
CONCLUSION: Multidisciplinary whole-course nutrition management can maintain the nutritional status of patients with EC undergoing chemoradiotherapy. This may lower the incidence of complications, shorten hospital stays, and reduce in-patient expenses.},
	language = {eng},
	number = {12},
	journal = {Medicine},
	author = {Wang, Shu-An and Li, Fuchao and Zhu, Jiayu and Chen, Xiaotian and Ren, Wei and Gao, Bo},
	month = mar,
	year = {2023},
	pmid = {36961192},
	pmcid = {PMC10036000},
	keywords = {Humans, Esophageal Neoplasms, Chemoradiotherapy, Nutritional Status, Nutritional Support, C-Reactive Protein},
	pages = {e33335},
	file = {Wang et al_2023_Multidisciplinary nutritional management improves nutritional and hospitalized.pdf:/Users/jcsal/Zotero/storage/YYHPMIZV/Wang et al_2023_Multidisciplinary nutritional management improves nutritional and hospitalized.pdf:application/pdf},
}

@article{dong901,
	title = {Effects of {PEG} in patients with esophageal squamous cell carcinoma during concurrent chemoradiotherapy: a prospective study},
	volume = {98},
	issn = {1097-6779},
	shorttitle = {Effects of {PEG} in patients with esophageal squamous cell carcinoma during concurrent chemoradiotherapy},
	doi = {10.1016/j.gie.2023.04.2094},
	abstract = {BACKGROUND AND AIMS: This prospective study aimed to compare the changes in nutritional status and adverse events among patients with esophageal squamous cell carcinoma who received enteral nutrition through oral intake, PEG, and an enteral nasogastric tube (NGT) during concurrent chemoradiotherapy (CCRT).
METHODS: Of 141 included patients, 38, 74, and 29 patients were fed through oral intake, PEG, and NGTs, respectively. The clinical characteristics and baseline nutritional status of the 3 groups were recorded and analyzed. The Patient-Generated Subjective Global Assessment score, skeletal muscle index, and quality of life were evaluated before and after CCRT; the incidence of adverse events during feeding using PEG and NGTs was also recorded. The correlations among the different nutritional pathways and the CCRT-related adverse events (eg, radiation esophagitis and myelosuppression) were assessed.
RESULTS: At baseline, the oral intake group had a significantly better nutritional status and lower disease stage than those in the PEG and NGT groups. However, during CCRT, the oral intake group exhibited the most significant decreases in weight and skeletal muscle index. The synchronous chemotherapy completion rate was the highest in the PEG group. Multivariate analysis showed that the planning tumor volume and oral intake and NGT feeding pathways were associated with radiation esophagitis of at least grade 2.
CONCLUSIONS: We found that PEG effectively maintained the body weight and skeletal muscle index of patients with esophageal cancer during CCRT. PEG also improved the synchronous chemotherapy completion rate and reduced the occurrence of at least grade 2 radiation esophagitis. (Clinical trial registration number: NCT04199832.).},
	language = {eng},
	number = {6},
	journal = {Gastrointestinal Endoscopy},
	author = {Dong, Jie and Dai, Zhenbo and Cao, Fuliang and Zhang, Wencheng and Zhang, Tian and Chen, Xi and Chen, Yajun and Zhao, Fangdong and Li, Jiacheng and Du, Qingwu and Zhang, Kunning and Zeng, Yaqi and Li, Chunlei and Wang, Yujie and Li, Yueying and Wang, Kun and Pang, Qingsong},
	month = dec,
	year = {2023},
	pmid = {37150411},
	keywords = {Humans, Prospective Studies, Esophageal Neoplasms, Chemoradiotherapy, Esophageal Squamous Cell Carcinoma, Radiation Injuries, Quality of Life, Esophagitis},
	pages = {901--910.e3},
	file = {Dong et al_2023_Effects of PEG in patients with esophageal squamous cell carcinoma during.pdf:/Users/jcsal/Zotero/storage/7LPRKUJQ/Dong et al_2023_Effects of PEG in patients with esophageal squamous cell carcinoma during.pdf:application/pdf},
}

@article{wang2949,
	title = {Enteral nutritional support in patients undergoing chemoradiotherapy for esophageal carcinoma},
	volume = {16},
	issn = {1744-8301},
	doi = {10.2217/fon-2020-0181},
	abstract = {Esophageal cancer patients are at a high risk of malnutrition. Both the disease itself and chemoradiotherapy will lead to the deterioration of nutritional status. The development of nutritional oncology promotes the application of enteral nutrition in tumor patients. Through nutritional support, prognosis is improved and the incidence of adverse chemoradiotherapy reactions is reduced, especially in those with head and neck or esophageal cancer. This review summarizes enteral nutritional support in esophageal cancer patients undergoing chemoradiotherapy in recent years, including a selection of nutritional assessment tools, the causes and consequences of malnutrition in esophageal cancer patients, types of access and effects of enteral nutrition. More patients with esophageal cancer will benefit from the development of enteral nutrition technology in the future.},
	language = {eng},
	number = {35},
	journal = {Future Oncology (London, England)},
	author = {Wang, Bei and Jiang, Xiaowen and Tian, Dalong and Geng, Wei},
	month = dec,
	year = {2020},
	pmid = {32857598},
	keywords = {Humans, Esophageal Neoplasms, Chemoradiotherapy, Malnutrition, Stents, esophageal cancer, Enteral Nutrition, chemoradiotherapy, Intubation, Gastrointestinal, Gastrostomy, enteral nutrition, nasogastric tube, percutaneous endoscopic gastrostomy, radiation esophagitis, self-expandable metal stents},
	pages = {2949--2957},
	file = {Wang et al_2020_Enteral nutritional support in patients undergoing chemoradiotherapy for.pdf:/Users/jcsal/Zotero/storage/9QKANABQ/Wang et al_2020_Enteral nutritional support in patients undergoing chemoradiotherapy for.pdf:application/pdf},
}

@article{mine0179522,
	title = {Comparison between gastrostomy feeding and self-expandable metal stent insertion for patients with esophageal cancer and dysphagia},
	volume = {12},
	issn = {1932-6203},
	doi = {10.1371/journal.pone.0179522},
	abstract = {BACKGROUND: Self-expandable metal stent (SEMS) insertion and percutaneous gastrostomy (PG) feeding are commonly used for patients with esophageal cancer and dysphagia. This study aimed to compare outcomes between SEMS insertion and PG feeding for them.
METHODS: We retrospectively analyzed 308 patients with esophageal cancer who underwent fully covered SEMS insertion (stent group) or PG (gastrostomy group) for dysphagia due to tumor. Patients with other causes of dysphagia, such as radiation-induced or postoperative stricture, were excluded from the study. Clinical outcomes were compared between the two groups, including overall survival and need for additional intervention and postprocedural nutritional status.
RESULTS: At baseline, the stent group (n = 169) had more stage IV patients, less cervical cancers, and received radiotherapy and esophagectomy less often than the gastrostomy group (n = 64). The Kaplan-Meier curves showed higher overall survival in the gastrostomy group than in the stent group. Multivariate analysis revealed that PG was associated with better survival compared with SEMS insertion (hazard ratio 0.541, 95\% confidence interval 0.346-0.848, p = 0.007). In addition, the gastrostomy group needed additional intervention less often (3.1\% vs. 21.9\%, p {\textless} 0.001) and experienced less decrease in serum albumin levels (-0.15 ± 0.56 g/dL vs. -0.39 ± 0.58 g/dL, p = 0.011) than the stent group after procedure.
CONCLUSIONS: Our data suggested that, compared with SEMS insertion, PG is associated with better overall survival in patients with esophageal cancer and dysphagia. Stabilized nutritional status by PG may play a role in improving patient survival.},
	language = {eng},
	number = {6},
	journal = {PloS One},
	author = {Min, Yang Won and Jang, Eun Young and Jung, Ji Hey and Lee, Hyuk and Min, Byung-Hoon and Lee, Jun Haeng and Rhee, Poong-Lyul and Kim, Jae J.},
	year = {2017},
	pmid = {28632744},
	pmcid = {PMC5478133},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Proportional Hazards Models, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Deglutition Disorders, Nutrition, Cancer treatment, Dysphagia, Patients, Radiation therapy, Serum albumin, Serum Albumin, Gastrostomy, Self Expandable Metallic Stents},
	pages = {e0179522},
	file = {Min et al_2017_Comparison between gastrostomy feeding and self-expandable metal stent.pdf:/Users/jcsal/Zotero/storage/RZTPTJGV/Min et al_2017_Comparison between gastrostomy feeding and self-expandable metal stent.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/CT6QPIDD/article.html:text/html},
}

@article{lorimer1311,
	title = {Enteral {Feeding} {Access} {Has} an {Impact} on {Outcomes} for {Patients} with {Esophageal} {Cancer} {Undergoing} {Esophagectomy}: {An} {Analysis} of {SEER}-{Medicare}},
	volume = {26},
	issn = {1534-4681},
	shorttitle = {Enteral {Feeding} {Access} {Has} an {Impact} on {Outcomes} for {Patients} with {Esophageal} {Cancer} {Undergoing} {Esophagectomy}},
	doi = {10.1245/s10434-019-07230-0},
	abstract = {BACKGROUND: Optimal nutrition after esophagectomy is challenging due to alterations in eating, both from the tumor and during surgical recovery. Enteral nutrition via feeding tube is commonly used. The impact of feeding tubes on post-esophagectomy outcomes was examined in a large national data set.
METHODS: Patients with esophageal cancer (1998-2013) undergoing esophagectomy were extracted from the Surveillance Epidemiology and End Results-Medicare database. Chi-square and t tests were used to compare categorical and continuous variables. Time trend analyses were performed with Cochran-Armitage survival using log-rank and multivariable analysis with generalized linear modeling.
RESULTS: The study examined 2495 patients. The majority had enteral feeding access (71\%, n = 1794) during the perioperative period. Mortality among the patients with feeding tubes was lower at 30 days (5.4\% vs 8.4\%), 60 days (9.0\% vs 13.0\%), and 90 days (12.2\% vs 15.8\%). In the multivariable analysis, the patients with feeding tubes had improved short-term survival at 30 days (odds ratio [OR], 0.65, 95\% confidence interval [CI], 0.46-0.93), 60 days (OR, 0.64; 95\% CI, 0.49-0.85), and 90 days (OR, 0.70; 95\% CI, 0.54-0.90). The hospital stay was shorter for the patients undergoing enteral feeding tube placement (17.9 vs 19.5 days; p = 0.04). Discharge destination (home vs health care facility) showed no difference.
CONCLUSIONS: Feeding tubes in patients undergoing esophagectomy were associated with an increase in short-term survival up to 90 days after surgery. Feeding tube placement was not associated with higher rates of non-home discharges and did not prolong the hospital stay.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgical Oncology},
	author = {Lorimer, Patrick D. and Motz, Benjamin M. and Watson, Michael and Trufan, Sally J. and Prabhu, Roshan S. and Hill, Joshua S. and Salo, Jonathan C.},
	month = may,
	year = {2019},
	pmid = {30783851},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Follow-Up Studies, Survival Rate, Prognosis, Cohort Studies, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Enteral Nutrition, Nutritional Support, Intubation, Gastrointestinal, SEER Program},
	pages = {1311--1319},
	file = {Lorimer et al_2019_Enteral Feeding Access Has an Impact on Outcomes for Patients with Esophageal.pdf:/Users/jcsal/Zotero/storage/DWUAM5C3/Lorimer et al_2019_Enteral Feeding Access Has an Impact on Outcomes for Patients with Esophageal.pdf:application/pdf},
}

@article{paris3049,
	title = {Automated body composition analysis of clinically acquired computed tomography scans using neural networks},
	volume = {39},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2020.01.008},
	abstract = {BACKGROUND \& AIMS: The quantity and quality of skeletal muscle and adipose tissue is an important prognostic factor for clinical outcomes across several illnesses. Clinically acquired computed tomography (CT) scans are commonly used for quantification of body composition, but manual analysis is laborious and costly. The primary aim of this study was to develop an automated body composition analysis framework using CT scans.
METHODS: CT scans of the 3rd lumbar vertebrae from critically ill, liver cirrhosis, pancreatic cancer, and clear cell renal cell carcinoma patients, as well as renal and liver donors, were manually analyzed for body composition. Ninety percent of scans were used for developing and validating a neural network for the automated segmentation of skeletal muscle and adipose tissues. Network accuracy was evaluated with the remaining 10 percent of scans using the Dice similarity coefficient (DSC), which quantifies the overlap (0 = no overlap, 1 = perfect overlap) between human and automated segmentations.
RESULTS: Of the 893 patients, 44\% were female, with a mean (±SD) age and body mass index of 52.7 (±15.8) years old and 28.0 (±6.1) kg/m2, respectively. In the testing cohort (n = 89), DSC scores indicated excellent agreement between human and network-predicted segmentations for skeletal muscle (0.983 ± 0.013), and intermuscular (0.900 ± 0.034), visceral (0.979 ± 0.019), and subcutaneous (0.986 ± 0.016) adipose tissue. Network segmentation took {\textasciitilde}350 milliseconds/scan using modern computing hardware.
CONCLUSIONS: Our network displayed excellent ability to analyze diverse body composition phenotypes and clinical cohorts, which will create feasible opportunities to advance our capacity to predict health outcomes in clinical populations.},
	language = {eng},
	number = {10},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Paris, Michael T. and Tandon, Puneeta and Heyland, Daren K. and Furberg, Helena and Premji, Tahira and Low, Gavin and Mourtzakis, Marina},
	month = oct,
	year = {2020},
	pmid = {32007318},
	pmcid = {PMC7374050},
	keywords = {Adipose Tissue, Adiposity, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Reproducibility of Results, Adult, Predictive Value of Tests, Europe, North America, Lumbar Vertebrae, Deep Learning, Radiographic Image Interpretation, Computer-Assisted, Computed tomography, ML, Automation, Neural Networks, Computer, Automated body composition analysis, Neural network},
	pages = {3049--3055},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/5US4GG5P/Paris et al. - 2020 - Automated body composition analysis of clinically .pdf:application/pdf},
}

@article{kumar101912,
	title = {Disentangling the obesity paradox in upper gastrointestinal cancers: {Weight} loss matters more than body mass index},
	volume = {72},
	issn = {1877-783X},
	shorttitle = {Disentangling the obesity paradox in upper gastrointestinal cancers},
	doi = {10.1016/j.canep.2021.101912},
	abstract = {OBJECTIVES: The obesity paradox, whereby obesity appears to confer protection against cancer-related mortality, remains controversial. This has not yet been evaluated in upper gastrointestinal cancers.
DESIGNS: We identified esophageal, cardia, and non-cardia gastric adenocarcinomas in the Veterans Health Administration between 2006-2016. Multivariable Cox proportional hazard models evaluate the impact of BMI at- and prior to- cancer diagnosis on mortality, adjusting for demographics, clinical characteristics, weight loss, and clinical stage (early: T1B/2N0; locally advanced: ≥T2N+).
RESULTS: We identify 1308 patients: 99 \% male, median 66 years. In early disease, relative to BMI 30, BMI 18 and 20 at diagnosis had increased risk of death (HR 1.83, 95 \%CI: 1.38-2.44 and HR 1.50, 95 \%CI: 1.20-1.87, respectively, p {\textless} 0.0001). Patients with BMI {\textgreater} 30 did not. In locally advanced disease, at diagnosis BMI 18 (HR 1.58, 95 \%CI: 1.0001-1.48, p = 0.05), BMI 20 (HR 1.46, 95 \%CI: 1.01-2.09, p = 0.04), and BMI 25 (HR 1.20, 95 \%CI: 1.04-1.38, p = 0.01) had increased risk of death, but BMI {\textgreater} 30 did not. In models assessing premorbid BMI and weight loss, increasing amounts of weight loss were associated with mortality independent of BMI in early cancers. For locally advanced cancers, without weight loss, there was no association with death, regardless of BMI.
CONCLUSION: The predominant driver of mortality across clinical stages is weight loss. The obesity paradox appears to exist in early stage disease only. Future studies should investigate mechanisms for the obesity paradox, accompanying physiologic changes with weight loss preceding diagnosis, and if patients with low BMI and weight loss benefit from early nutritional support.},
	language = {eng},
	journal = {Cancer Epidemiology},
	author = {Kumar, Shria and Mahmud, Nadim and Goldberg, David S. and Datta, Jashodeep and Kaplan, David E.},
	month = jun,
	year = {2021},
	pmid = {33647837},
	pmcid = {PMC8141012},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Obesity, Body Mass Index, Retrospective Studies, Proportional Hazards Models, Weight Loss, Gastric cancer, Esophageal cancer, Cardia adenocarcinoma, Obesity paradox},
	pages = {101912},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/SGSH6EQJ/Kumar et al. - 2021 - Disentangling the obesity paradox in upper gastroi.pdf:application/pdf},
}

@article{qin11,
	title = {Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? {A} meta-analysis},
	volume = {59},
	issn = {1743-9159},
	shorttitle = {Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes?},
	doi = {10.1016/j.ijsu.2018.09.013},
	abstract = {BACKGROUND: The optimal timing of esophagectomy after neoadjuvant chemoradiation treatment (nCRT) remains unclear. Here, a meta-analysis was conducted to determine whether prolonged interval between nCRT and surgery can affect the outcomes in esophageal cancer.
MATERIALS AND METHODS: The databases PubMed, Embase, Web of Science, and Cochrane were systematically searched for studies reporting the outcomes in esophageal cancer according to the length of interval between nCRT and surgery. The primary outcome was rate of pathologic complete response (pCR), and the secondary outcomes included R0 resection rate, incidence of anastomotic leak, postoperative mortality, and two or five-year overall survival (OS). The intervals were classified into dichotomous (≤7-8 weeks and {\textgreater}7-8 weeks) for the pooled analysis, and a combined relative risk (RR) was calculated.
RESULTS: A total of 13 studies involving 15,086 patients were analyzed. The overall results indicated that an interval longer than 7-8 weeks between the end of nCRT and the surgery was significantly associated with an improved pCR rate (RR, 1.13; 95\% confidence interval [CI], 1.05-1.21; P = 0.001). However, it was related to a higher 30-day surgical mortality (RR, 1.51; 95\% CI, 1.19-1.92; P = 0.0006). The subgroup analyses only detected a significant association of the extended interval with pCR and the surgical mortality rate in adenocarcinoma patients. Moreover, an increased time interval resulted in a lower 2-year (RR, 0.94; 95\% CI, 0.90-0.98; P = 0.002) and 5-year OS (RR, 0.88; 95\% CI, 0.82-0.95; P = 0.0009). No association with R0 resection rate or anastomotic complication resulting from delayed resection was detected.
CONCLUSIONS: Although increasing the time interval from nCRT to esophagectomy was associated with significantly higher pathologic complete response rates in esophageal cancer, delaying the surgery might be disadvantageous for the long-term survival.},
	language = {eng},
	journal = {International Journal of Surgery (London, England)},
	author = {Qin, Qin and Xu, Huazhong and Liu, Jia and Zhang, Chi and Xu, Liping and Di, Xiaoke and Zhang, Xiaowen and Sun, Xinchen},
	month = nov,
	year = {2018},
	pmid = {30261331},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Time Factors, Survival Rate, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Neoadjuvant chemoradiotherapy, Esophageal cancer, Postoperative Complications, Esophagus, Surgery, Interval, Pathologic complete response, Gap},
	pages = {11--18},
}

@article{ebadi148,
	title = {Subcutaneous adiposity is an independent predictor of mortality in cancer patients},
	volume = {117},
	issn = {1532-1827},
	doi = {10.1038/bjc.2017.149},
	abstract = {BACKGROUND: Prognostic significance of adiposity, at the time of cancer diagnosis, on survival is not clear. Body mass index (kg m-2) does not provide an appropriate assessment of body composition; therefore, the concept of the 'obesity paradox' needs to be investigated based on the prognostic significance of fat and muscle. Independent prognostic significance of adipose tissue in predicting mortality, importance of visceral and subcutaneous adiposity in the presence and absence of sarcopenia on survival, was investigated.
METHODS: Adiposity markers including total adipose index (TATI), visceral adipose tissue index (VATI) and subcutaneous adipose tissue index (SATI) were estimated for 1473 gastrointestinal and respiratory cancer patients and 273 metastatic renal cell carcinoma patients using computed tomography. Univariate and multivariate analysis to determine mortality hazard ratios (HR) were conducted using cox proportional hazard models.
RESULTS: Low SATI (SATI {\textless}50.0 cm2 m-2 in males and {\textless}42.0 cm2 m-2 in females) independently associated with increased mortality (HR: 1.26; 95\% CI: 1.11-1.43; P{\textless}0.001) and shorter survival (13.1 months; 95\% CI, 11.4-14.7) compared to patients with high SATI (19.3 months; 95\% CI, 17.6-21.0; P{\textless}0.001). In the presence of sarcopenia, the longest survival was observed in patients with high subcutaneous adiposity.
CONCLUSIONS: Subcutaneous adipose tissues appear to associate with reduction in mortality risk demonstrating the prognostic importance of fat distribution. The effect of sarcopenia on survival was more pronounced in patients with low subcutaneous adiposity.},
	language = {eng},
	number = {1},
	journal = {British Journal of Cancer},
	author = {Ebadi, Maryam and Martin, Lisa and Ghosh, Sunita and Field, Catherine J. and Lehner, Richard and Baracos, Vickie E. and Mazurak, Vera C.},
	month = jun,
	year = {2017},
	pmid = {28588319},
	pmcid = {PMC5520211},
	keywords = {Adiposity, Humans, Tomography, X-Ray Computed, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Sarcopenia, Risk Factors, Proportional Hazards Models, Neoplasms, Prognosis, Intra-Abdominal Fat, Multivariate Analysis, Subcutaneous Fat, Obesity, Abdominal, Alberta, Carcinoma, Renal Cell, Kidney Neoplasms, Protective Factors, Respiratory Tract Neoplasms},
	pages = {148--155},
	file = {Ebadi et al_2017_Subcutaneous adiposity is an independent predictor of mortality in cancer.pdf:/Users/jcsal/Zotero/storage/NWPGEA42/Ebadi et al_2017_Subcutaneous adiposity is an independent predictor of mortality in cancer.pdf:application/pdf},
}

@article{jain3177,
	title = {Impact of {Clinical} {Markers} of {Nutritional} {Status} and {Feeding} {Jejunostomy} {Use} on {Outcomes} in {Esophageal} {Cancer} {Patients} {Undergoing} {Neoadjuvant} {Chemoradiotherapy}},
	volume = {12},
	issn = {2072-6643},
	doi = {10.3390/nu12103177},
	abstract = {BACKGROUND: Patients with esophageal cancer (EC) have high rates of malnutrition due to tumor location and treatment-related toxicity. Various strategies are used to improve nutritional status in patients with EC including oral and enteral support.
METHODS: We conducted a retrospective analysis to determine the impact of malnutrition and prophylactic feeding jejunostomy tube (FJT) placement on toxicity and outcomes in patients with localized EC who were treated with neoadjuvant chemoradiation therapy (nCRT) followed by esophagectomy.
RESULTS: We identified 125 patients who were treated with nCRT between 2002 and 2014. Weight loss and hypoalbuminemia occurred frequently during nCRT and were associated with multiple adverse toxicity outcomes including hematologic toxicity, nonhematologic toxicity, grade ≥3 toxicity, and hospitalizations. After adjusting for relevant covariates including the specific nCRT chemotherapy regimen received and the onset of toxicity, there were no significant associations between hypoalbuminemia, weight loss, or FJT placement and relapse-free survival (RFS) or overall survival (OS). FJT placement was associated with less weight loss during nCRT (p = 0.003) but was not associated with reduced toxicity or improved survival.
CONCLUSIONS: Weight and albumin loss during nCRT for EC are important factors relating to treatment toxicity but not RFS or OS. While pretreatment FJT placement may reduce weight loss, it may not impact treatment tolerance or survival.},
	language = {eng},
	number = {10},
	journal = {Nutrients},
	author = {Jain, Rishi and Shaikh, Talha and Yee, Jia-Llon and Au, Cherry and Denlinger, Crystal S. and Handorf, Elizabeth and Meyer, Joshua E. and Dotan, Efrat},
	month = oct,
	year = {2020},
	pmid = {33080840},
	pmcid = {PMC7602938},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Survival Rate, Prognosis, Weight Loss, Aged, 80 and over, Adult, Esophageal Neoplasms, Esophagectomy, Malnutrition, esophageal cancer, Enteral Nutrition, Nutritional Status, Jejunostomy, enteral nutrition, nutrition, Hypoalbuminemia, neoadjuvant chemoradiation},
	pages = {3177},
	file = {Jain et al_2020_Impact of Clinical Markers of Nutritional Status and Feeding Jejunostomy Use on.pdf:/Users/jcsal/Zotero/storage/93YAJT85/Jain et al_2020_Impact of Clinical Markers of Nutritional Status and Feeding Jejunostomy Use on.pdf:application/pdf},
}

@article{velotta5477,
	title = {Outcomes following interventions to sustain body weight in esophageal cancer patients starting preoperative therapy: a retrospective cohort study},
	volume = {13},
	issn = {2072-1439},
	shorttitle = {Outcomes following interventions to sustain body weight in esophageal cancer patients starting preoperative therapy},
	doi = {10.21037/jtd-20-3220},
	abstract = {BACKGROUND: To improve nutritional status and dysphagia, esophageal cancer patients starting neoadjuvant therapy in advance of curative-intent surgery may receive a jejunostomy tube (J-tube) or esophageal stent, or they may be managed without a feeding modality. We examined percent total weight loss (\%TWL), reinterventions, and progression to surgery in relation to these options.
METHODS: The retrospective cohort study included stage II-III esophageal cancer patients diagnosed during 2010-2017 who received J-tube, stent, or nutritional counseling only, without a procedure, when starting chemotherapy or combined modality chemoradiation. Data were obtained from the electronic medical record and chart review. We compared median \%TWL between intervention groups and reinterventions using Chi-square and Kruskal-Wallis tests.
RESULTS: Among the 366 patients, median \%TWL reached a nadir at 120 days, when it was 7\% for patients with no procedure (N=307), 4\% for J-tube (N=39), and 16\% for stent (N=20) (P=0.01). Individual case analysis revealed 72-80\% of the patients in the three groups started chemotherapy or chemoradiation as neoadjuvant curative-intent therapy (P difference =0.79). In J-tube patients, the reasons for intervention was anticipation of weight loss in 49\% and mitigation of actual weight loss in 15\%, whereas 95\% of stent patients received the stent for dysphagia (P{\textless}0.001). A complication of the procedure was recorded in 85\% of stent patients and 74\% of J-tube patients (P{\textless}0.001). Among those who received no procedure initially, 25\% received one later, compared with 15\% of J-tube patients and 70\% of stent patients who received a second procedure (P{\textless}0.001). Progression to surgery was observed in 65\% of patients with no procedure, 51\% of patients with J-tube, and 40\% of stent patients, P=0.28).
CONCLUSIONS: For stage II-III esophageal cancer patients starting chemotherapy, this study gives evidence that stents were associated with significant \%TWL and risk of reintervention. Although J-tube patients returned to baseline weight sooner than those with no procedure, they experienced complications from their J-tubes. For esophageal cancer patients undergoing curative-intent treatment and with acceptable levels of weight loss, no procedure at all may be superior to placing a J-tube in terms of complications, weight loss, and progression to curative-intent surgery.},
	language = {eng},
	number = {9},
	journal = {Journal of Thoracic Disease},
	author = {Velotta, Jeffrey B. and Dusendang, Jennifer R. and Kwak, Hyunjee and Huyser, Michelle and Patel, Ashish and Ashiku, Simon K. and Herrinton, Lisa J.},
	month = sep,
	year = {2021},
	pmid = {34659814},
	pmcid = {PMC8482328},
	keywords = {chemotherapy, Esophageal cancer, weight loss, care delivery, community-based studies},
	pages = {5477--5486},
	file = {Velotta et al_2021_Outcomes following interventions to sustain body weight in esophageal cancer.pdf:/Users/jcsal/Zotero/storage/98FX2G2L/Velotta et al_2021_Outcomes following interventions to sustain body weight in esophageal cancer.pdf:application/pdf},
}

@article{jenkinson299,
	title = {Laparoscopic feeding jejunostomy in esophagogastric cancer},
	volume = {21},
	issn = {1432-2218},
	doi = {10.1007/s00464-005-0727-z},
	abstract = {BACKGROUND: Patients with esophagogastric malignancies often require nutritional supplementation in the perioperative period, especially in the setting where neoadjuvant therapy may delay tumor resection. A simple technique is described here that can be performed at the time of staging laparoscopy and that has not been described before.
RESULTS: Forty-three patients treated over a 4-year period who had a laparoscopic feeding jejunostomy placed at the time of staging laparoscopy were reviewed. Of these, 35 had preoperative chemotherapy according to a modified MRC OEO2 protocol. In the period between staging and eventual resection, 32\% required immediate feeding, and in 14\% of those who were thought not to need feeding it later became necessary. More patients gained weight or had a rise in albumin in the group that had jejunal feeding (p {\textless} 0.05). The mean time to surgery was 10 weeks. There were no conversions to an open procedure, nor were there any laparotomies for tube-related complications. Dislodgement was recorded in 6 patients; blockage, in 4. In most of these cases a simple bedside replacement of the tube was all that was required. Mean time in the operating room for each procedure was 44 minutes.
CONCLUSIONS: Laparoscopic percutaneous feeding jejunostomy is a safe and simple technique that adds little to the morbidity and cost of managing patients with esophagogastric cancers. It facilitates optimization of nutrition in the perioperative period for these patients, especially in those receiving preoperative chemotherapy.},
	language = {eng},
	number = {2},
	journal = {Surgical Endoscopy},
	author = {Jenkinson, A. D. and Lim, J. and Agrawal, N. and Menzies, D.},
	month = feb,
	year = {2007},
	pmid = {17122985},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Risk Assessment, Aged, 80 and over, Adult, Chi-Square Distribution, Stomach Neoplasms, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Gastrectomy, Enteral Nutrition, Nutritional Status, Jejunostomy, Weight Gain, Probability},
	pages = {299--302},
}

@article{mellors87,
	title = {Comparison of prophylactic percutaneous endoscopic gastrostomy with reactive enteral nutrition in patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy: {A} systematic review},
	volume = {46},
	issn = {2405-4577},
	shorttitle = {Comparison of prophylactic percutaneous endoscopic gastrostomy with reactive enteral nutrition in patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy},
	doi = {10.1016/j.clnesp.2021.09.724},
	abstract = {BACKGROUND \& AIMS: Nutrition support is frequently indicated in patients with head and neck cancer (HNC). However, the optimal timing of enteral tube placement and feeding commencement is unknown. This review aims to compare the outcomes for patients with HNC undergoing curative intent radiotherapy (RT) or chemoradiotherapy (CRT) receiving either prophylactic percutaneous endoscopic gastrostomy (pPEG) tube placement/feeding or reactive enteral nutrition (rEN).
METHODS: A literature search was conducted in March 2020 across PubMed, CINAHL, Embase, Web of Science, and Scopus. Randomized controlled trials (RCTs) of patients (≥18 years) with HNC who had received either pPEG or rEN were included. Outcomes examined were weight change, nutritional status, body mass index, treatment interruptions, quality of life (QoL), disease-free survival and overall survival. Study quality and certainty of evidence were assessed using the Cochrane Risk-of-bias Tool for Randomized Trials Version 2 and the Grading of Recommendations Assessment, Development and Evaluation system, respectively.
RESULTS: Five studies (three RCTs) (n = 298) were included and definitions of pPEG and rEN were heterogenous. pPEG was associated with a clinically important reduction in short-term critical weight loss ({\textgreater}10\% weight loss), and significantly improved short-term QoL in patients with HNC. The timing of nutrition support commencement had no effect on all other outcomes. The overall certainty of evidence was 'moderate' for: nutritional status; treatment interruptions; short-term QoL; disease-free survival; and 'low' for all other outcomes.
CONCLUSIONS: Patients with HNC undergoing RT or CRT receiving pPEG tube feeding/placement were less likely to experience short-term critical weight loss and have improved short-term QoL compared to rEN. Further well-designed RCTs with consistent definitions of tube feeding protocols and the use of validated tools to evaluate nutritional status, will assist to increase the certainty of evidence and confirm the beneficial effects observed.},
	language = {eng},
	journal = {Clinical nutrition ESPEN},
	author = {Mellors, Kate and Ye, Xiaodan and Van Den Brande, Jonathan and Wai Ray Mak, Tsz and Brown, Teresa and Findlay, Merran and Bauer, Judy},
	month = dec,
	year = {2021},
	pmid = {34857252},
	keywords = {Humans, Chemoradiotherapy, Enteral Nutrition, Weight loss, Intubation, Gastrointestinal, Gastrostomy, Head and Neck Neoplasms, Head and neck cancer, Nasogastric tube, Nutritional status, Prophylactic gastrostomy},
	pages = {87--98},
}

@article{muscaritoli2898,
	title = {{ESPEN} practical guideline: {Clinical} {Nutrition} in cancer},
	volume = {40},
	issn = {1532-1983},
	shorttitle = {{ESPEN} practical guideline},
	doi = {10.1016/j.clnu.2021.02.005},
	abstract = {BACKGROUND: This practical guideline is based on the current scientific ESPEN guidelines on nutrition in cancer patients.
METHODS: ESPEN guidelines have been shortened and transformed into flow charts for easier use in clinical practice. The practical guideline is dedicated to all professionals including physicians, dieticians, nutritionists and nurses working with patients with cancer.
RESULTS: A total of 43 recommendations are presented with short commentaries for the nutritional and metabolic management of patients with neoplastic diseases. The disease-related recommendations are preceded by general recommendations on the diagnostics of nutritional status in cancer patients.
CONCLUSION: This practical guideline gives guidance to health care providers involved in the management of cancer patients to offer optimal nutritional care.},
	language = {eng},
	number = {5},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Muscaritoli, Maurizio and Arends, Jann and Bachmann, Patrick and Baracos, Vickie and Barthelemy, Nicole and Bertz, Hartmut and Bozzetti, Federico and Hütterer, Elisabeth and Isenring, Elizabeth and Kaasa, Stein and Krznaric, Zeljko and Laird, Barry and Larsson, Maria and Laviano, Alessandro and Mühlebach, Stefan and Oldervoll, Line and Ravasco, Paula and Solheim, Tora S. and Strasser, Florian and de van der Schueren, Marian and Preiser, Jean-Charles and Bischoff, Stephan C.},
	month = may,
	year = {2021},
	pmid = {33946039},
	keywords = {Humans, Cachexia, Neoplasms, Chemotherapy, Malnutrition, Radiotherapy, Nutritional Status, Europe, Anorexia, Nutritional Support, Cancer, Societies, Scientific},
	pages = {2898--2913},
	file = {Muscaritoli et al_2021_ESPEN practical guideline.pdf:/Users/jcsal/Zotero/storage/KN3M3LPX/Muscaritoli et al_2021_ESPEN practical guideline.pdf:application/pdf},
}

@article{bajaj174,
	title = {Early vs {Delayed} {Surgery} for {Esophageal} {Cancer} {During} the {COVID}-19 {Pandemic}},
	volume = {235},
	issn = {1879-1190},
	doi = {10.1097/XCS.0000000000000248},
	abstract = {BACKGROUND: During the coronavirus disease 2019 pandemic, national guidelines recommended that elective surgery for esophageal cancer be deferred by 3 months when hospital resources are limited. The impact of this delay on patient outcomes is unknown. We sought to evaluate the survival of patients with stage I and II/III esophageal cancer who undergo early vs delayed treatment.
STUDY DESIGN: Using the National Cancer Database from 2010 to 2017, multivariable Cox proportional hazards modeling and propensity score-matched analysis were employed to compare survival of patients with stage I esophageal cancer who received early (0 to 4 weeks after diagnosis) vs delayed esophagectomy (12 to 16 weeks) and of patients with stage II/III esophageal cancer who-after receiving timely chemoradiation (0 to 4 weeks after diagnosis)-underwent early (9 to 17 weeks) vs delayed esophagectomy (21 to 29 weeks).
RESULTS: For stage I esophageal cancer, 226 (41.7\%) patients underwent early esophagectomy, and 316 (58.3\%) patients underwent delayed esophagectomy. Propensity score matching created 2 groups of 134 patients with early or delayed esophagectomy, whose 5-year survival was comparable (hazard ratio [HR] 65.0\% [95\% confidence interval (CI) 55.2\% to 73.2\%] vs HR 65.1\% [95\% CI 55.6\% to 73.1\%], p = 0.50). For stage II/III esophageal cancer, 1,236 (86.1\%) patients underwent early esophagectomy, and 200 (13.9\%) underwent delayed esophagectomy. Propensity score matching created 2 groups of 130 patients; the early esophagectomy group had improved 5-year survival compared with the delayed esophagectomy group (HR 41.6\% [95\% CI 32.1\% to 50.8\%] vs HR 22.9\% [95\% CI 14.9\% to 31.8\%], p = 0.006).
CONCLUSIONS: Early esophagectomy was associated with similar survival compared with delayed esophagectomy for patients with stage I esophageal cancer. For patients with stage II/III esophageal cancer, early esophagectomy was associated with improved survival relative to delayed esophagectomy.},
	language = {eng},
	number = {2},
	journal = {Journal of the American College of Surgeons},
	author = {Bajaj, Simar S. and Shah, Kavya M. and Potter, Alexandra L. and Mayne, Nicholas R. and Sachdeva, Uma M. and Lin, Mong-Wei and Yang, Chi-Fu Jeffrey},
	month = aug,
	year = {2022},
	pmid = {35839391},
	keywords = {Humans, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Propensity Score, COVID-19, Pandemics, Gap},
	pages = {174--184},
}

@article{levinsky2555,
	title = {Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma},
	volume = {159},
	issn = {1097-685X},
	doi = {10.1016/j.jtcvs.2019.09.169},
	abstract = {BACKGROUND: Salvage and delayed esophagectomy after chemoradiation therapy (CRT) have been associated with increased morbidity and mortality, but recent series have shown similar outcomes compared to timely esophagectomy. We aim to evaluate outcomes for delayed and salvage esophagectomy for esophageal adenocarcinoma utilizing a large national database.
METHODS: The National Cancer Database for 2004 to 2014 was queried for patients with clinical stage II or III esophageal adenocarcinoma who underwent preoperative CRT and esophagectomy. Patients who underwent surgery {\textless}90 days after CRT were defined as the timely esophagectomy group (n = 7822), and those who underwent surgery ≥90 days after CRT were defined as the delayed esophagectomy group (n = 667).
RESULTS: A total of 8489 patients met our inclusion criteria. The median post-CRT interval was 49 days (range, 40-61 days) for the timely esophagectomy group and 109 days (range, 97-132 days) for the delayed esophagectomy group. The delayed group was more likely to be of black race (2.3\% vs 1.2\%; P {\textless} .01) and more likely to have Medicare (47.9\% vs 39.8\%; P {\textless} .001). There were no significant between-group differences in chemotherapy regimens (P = .17), radiation dose (P = .18), or surgical approach (P = .48). The delayed esophagectomy group had higher rates of pathological complete response (22.2\% vs 18.6\%; P = .043) and 90-day postoperative mortality (10.4\% vs 7.8\%; P {\textless} .01). On multivariate analysis, delayed esophagectomy was not independently associated with decreased overall survival.
CONCLUSIONS: In this large retrospective database study, despite increased perioperative mortality, delayed and salvage esophagectomy for adenocarcinoma appear to have similar long-term survival as timely esophagectomy. Delayed and salvage esophagectomy may be offered to patients who do not receive timely esophagectomy after CRT.},
	language = {eng},
	number = {6},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Levinsky, Nick C. and Wima, Koffi and Morris, Mackenzie C. and Ahmad, Syed A. and Shah, Shimul A. and Starnes, Sandra L. and Van Haren, Robert M. and {Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Group}},
	month = jun,
	year = {2020},
	pmid = {31767364},
	keywords = {Adenocarcinoma, Aged, chemoradiation, Chemoradiotherapy, Adjuvant, Databases, Factual, esophageal cancer, Esophageal Neoplasms, esophagectomy, Esophagectomy, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Risk Factors, Salvage, Salvage Therapy, Time Factors, Time-to-Treatment, Treatment Outcome, United States},
	pages = {2555--2566},
	file = {Full Text:/Users/jcsal/Zotero/storage/F7ZYD4LG/Levinsky et al. - 2020 - Outcome of delayed versus timely esophagectomy aft.pdf:application/pdf},
}

@article{anandavadivelan724,
	title = {Sarcopenic obesity: {A} probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients},
	volume = {35},
	issn = {1532-1983},
	shorttitle = {Sarcopenic obesity},
	doi = {10.1016/j.clnu.2015.05.011},
	abstract = {BACKGROUND \& AIMS: Profound weight loss and malnutrition subsequent to severe dysphagia and cancer cachexia are cardinal symptoms in oesophageal cancer (OC). Low muscle mass/sarcopenia has been linked to toxicity during neo-adjuvant therapy in other cancers, with worser effects in sarcopenic obesity. In this study the association between sarcopenia and/or sarcopenic obesity and dose limiting toxicity (DLT) during cycle one chemotherapy in resectable OC patients was evaluated.
METHODS: Body composition was assessed from computed tomography scans of 72 consecutively diagnosed OC patients. Lean body mass and body fat mass were estimated. Patients were grouped as sarcopenic or non-sarcopenic based on pre-defined gender-specific cut-offs for sarcopenia, and as underweight/normal (BMI {\textless} 25) or overweight/obese (BMI ≥ 25). Sarcopenic obesity was defined as sarcopenia combined with overweight and obesity. DLT was defined as temporary reduction/delay or permanent discontinuation of drugs due to adverse effects. Odds ratios for developing toxicity were ascertained using multiple logistic regression.
RESULTS: Of 72 patients, 85\% (n = 61) were males. Sarcopenia and sarcopenic obesity were present in 31 (43\%) and 10 (14\%), respectively, prior to chemotherapy. Sarcopenic patients had significantly lower adipose tissue index (p = 0.02) compared to non-sarcopenic patients. Patients with DLT (n = 24) had lower skeletal muscle mass (p = 0.04) than those without DLT. Sarcopenic patients (OR = 2.47; 95\% CI: 0.88-6.93) showed a trend towards increased DLT risk (p {\textless} 0.10). Logistic regression with BMI as an interaction term indicated higher DLT risk in sarcopenic patients with normal BMI (OR = 1.60; 95\% CI 0.30-8.40), but was non-significant. In the sarcopenic obese, risk of DLT increased significantly (OR = 5.54; 95\% CI 1.12-27.44).
CONCLUSIONS: Sarcopenic and sarcopenic obese OC patients may be at a higher risk for developing DLT during chemotherapy compared to non-sarcopenic OC patients.},
	language = {eng},
	number = {3},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Anandavadivelan, Poorna and Brismar, Torkel B. and Nilsson, Magnus and Johar, Asif M. and Martin, Lena},
	month = jun,
	year = {2016},
	pmid = {26065721},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Obesity, Pilot Projects, Sarcopenia, Body Mass Index, Neoplasm Staging, Risk Factors, Cachexia, Antineoplastic Agents, Overweight, Aged, 80 and over, Body composition, Chemotherapy, Dose-Response Relationship, Drug, Adenocarcinoma, Esophageal Neoplasms, Chemoradiotherapy, Oesophageal cancer, Carcinoma, Sweden, Academic Medical Centers, Sarcopenic obesity},
	pages = {724--730},
}

@article{ebadi1053,
	title = {Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis},
	volume = {9},
	issn = {2190-6009},
	doi = {10.1002/jcsm.12349},
	abstract = {BACKGROUND: Sarcopenia, characterized by low muscle mass, associates with mortality in patients with cirrhosis. Skeletal muscle area in a single computed tomography image at the level of the third lumbar vertebrate (L3) is a valid representative of whole body muscle mass. Controversy remains regarding applicability of psoas muscle to identify patients at greater risk of mortality. We aimed to determine psoas muscle index (PMI) association with skeletal muscle index (SMI) and to evaluate the capacity of PMI to predict liver transplant waitlist mortality.
METHODS: We evaluated listed adult patients with cirrhosis from 2012 to 2013 at four North American liver transplant centres. From L3 computed tomography images within 3 months of listing, we determined SMI and PMI expressed by cm2 /m2 . Low SMI was defined as SMI {\textless}39 cm2 /m2 in women and {\textless}50 cm2 /m2 in men as published by us earlier. Cut-offs for PMI to predict mortality were established using a receiver-operating characteristic analysis. Mortality predictors were determined using competing-risk analysis with reported results as subdistribution hazard ratios (sHRs).
RESULTS: Of 353 waitlist candidates, 68\% were men, mean age 56 ± 9 years, and Model for End-stage Liver Disease of 16 ± 8 points. Low SMI was present more frequently in men than women (51 vs. 36\%, P = 0.02). Moderately strong correlation between SMI and PMI was observed (r {\textgreater} 0.7, P {\textless} 0.001). Low PMI (males {\textless} 5.1 cm2 /m2 ; females {\textless} 4.3 cm2 /m2 ) yielded poor and moderate concordance with low SMI in men and women, respectively (Kappa coefficient 0.31 and 0.63). SMI (39 ± 9 vs. 43 ± 7 cm2 /m2 ; P = 0.009) and PMI (4.4 ± 1.3 vs. 5.2 ± 1.1 cm2 /m2 ; P = 0.001) were lower in women who died and/or were delisted (compared with non-deceased patients) whereas men who died and/or were delisted had only lower SMI (47 ± 7 vs. 51 ± 9 cm2 /m2 ; P = 0.003), but not PMI compared with non-deceased patients. In women, both SMI (sHR 0.94, P = 0.048) and PMI (sHR 0.58, P = 0.002) were predictors of mortality, while in men, SMI was significant (sHR 0.95, P = 0.001) and PMI showed a trend to be (sHR 0.85, P = 0.09) associated with mortality. Overall, 104 patients (29\%) were misclassified between SMI and PMI categories. Using PMI cut-offs, 66\% and 28\% of low SMI men and women, who have a higher risk of mortality, were incorrectly classified as low risk.
CONCLUSIONS: Skeletal muscle index is a more complete and robust measurement than PMI, especially in men with cirrhosis. Low PMI identifies an incomplete subset of patients at increased risk of mortality indicated by low SMI. Given the poor performance of PMI, SMI should not be substituted by PMI.},
	language = {eng},
	number = {6},
	journal = {Journal of Cachexia, Sarcopenia and Muscle},
	author = {Ebadi, Maryam and Wang, Connie W. and Lai, Jennifer C. and Dasarathy, Srinivasan and Kappus, Matthew R. and Dunn, Michael A. and Carey, Elizabeth J. and Montano-Loza, Aldo J. and {From the Fitness, Life Enhancement, and Exercise in Liver Transplantation (FLEXIT) Consortium}},
	month = dec,
	year = {2018},
	pmid = {30269421},
	pmcid = {PMC6240754},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Kaplan-Meier Estimate, Risk Factors, Sex Factors, Risk Assessment, Prognosis, Organ Size, Comorbidity, Biomarkers, Psoas Muscles, Computed tomography, End-stage liver disease, Liver Cirrhosis, Liver Transplantation},
	pages = {1053--1062},
	file = {Ebadi et al_2018_Poor performance of psoas muscle index for identification of patients with.pdf:/Users/jcsal/Zotero/storage/YNMFTJ78/Ebadi et al_2018_Poor performance of psoas muscle index for identification of patients with.pdf:application/pdf},
}

@article{morimoto657,
	title = {Visceral obesity is a preoperative risk factor for postoperative ileus after surgery for colorectal cancer: {Single}-institution retrospective analysis},
	volume = {3},
	issn = {2475-0328},
	shorttitle = {Visceral obesity is a preoperative risk factor for postoperative ileus after surgery for colorectal cancer},
	doi = {10.1002/ags3.12291},
	abstract = {AIM: Visceral obesity (VO) reportedly has a stronger association with complications after colorectal surgery than does body mass index. Here, we retrospectively assessed VO as a risk factor for postoperative ileus (POI) after colorectal resection in patients with colorectal cancer.
METHODS: This study included 417 consecutive patients with colorectal cancer who underwent elective surgery at our institute from January 2010 to December 2012. Visceral fat area (VFA) was calculated by image analysis software. VO was defined as VFA ≥100 cm2. We assessed 49 factors, including VO, comorbidities, surgical procedure, and postoperative complications. Data were analyzed using a propensity score-matching strategy.
RESULTS: Postoperative ileus occurred in 18 patients (4.3\%) from the entire cohort, and in 14 (5.5\%) of the 256 matched patients. Multivariate analysis (n = 417 patients) showed that significant risk factors for POI included VO (OR 7.9, 95\% confidence interval [CI] 1.9-32.1, P = .004), open surgery (OR 6.4, 95\% CI 1.6-26.7, P = .010), and pelvic/intra-abdominal abscess (OR 11.0, 95\% CI 1.1-110.2, P = .041). Propensity score matching showed two independent risk factors in the multivariate analysis: VO (OR 6.2, 95\% CI 1.3-30.4, P = .025) and open surgery (OR 9.1, 95\% CI 2.0-40.5, P = .004).
CONCLUSION: Visceral obesity may be an independent risk factor for POI in patients with colorectal cancer.},
	language = {eng},
	number = {6},
	journal = {Annals of Gastroenterological Surgery},
	author = {Morimoto, Yoshihiro and Takahashi, Hidekazu and Fujii, Makoto and Miyoshi, Norikatsu and Uemura, Mamoru and Matsuda, Chu and Yamamoto, Hirofumi and Mizushima, Tsunekazu and Mori, Masaki and Doki, Yuichiro},
	month = nov,
	year = {2019},
	pmid = {31788654},
	pmcid = {PMC6876266},
	keywords = {surgery, obesity, colorectal cancer, postoperative complication, ileus},
	pages = {657--666},
	file = {Morimoto et al_2019_Visceral obesity is a preoperative risk factor for postoperative ileus after.pdf:/Users/jcsal/Zotero/storage/SXCC4ELF/Morimoto et al_2019_Visceral obesity is a preoperative risk factor for postoperative ileus after.pdf:application/pdf},
}

@article{morsbach50a,
	title = {Body composition evaluation with computed tomography: {Contrast} media and slice thickness cause methodological errors},
	volume = {59},
	issn = {1873-1244},
	shorttitle = {Body composition evaluation with computed tomography},
	doi = {10.1016/j.nut.2018.08.001},
	abstract = {OBJECTIVE: Although computed tomography (CT) is frequently used to determine body composition, the effects of using different CT protocols is not well known. The aim of this study was to determine whether contrast media phase, radiation dose, and slice thickness in CT affect body composition segmentation.
METHODS: Clinically indicated perfusion CTs of the upper abdomen in 20 patients (seven women) between 40 and 87 y of age with high suspicion of hepatocellular carcinoma were analyzed retrospectively. Axial images from the L3 level with varying imaging delay were reconstructed after contrast media injection (18 images per patient), slice thickness (5 images, 2-10 mm), and radiation dose (4 images with one-third to four-thirds of standard dose). Muscle and fat areas were segmented semiautomatically by drawing regions of interests and using established cutoff thresholds. Skeletal muscle index (SMI), steatotic muscle area, and adipose tissue index, as well as muscle attenuation and fat attenuation, were evaluated.
RESULTS: Average SMI increased by up to 2.8\% after contrast media injection. Steatotic muscle area decreased by ≤13.8\%, and adipose tissue index decreased by ≤6.5\%. Muscle attenuation increased after contrast media injection, whereas fat attenuation decreased (all P {\textless} 0.001). SMI decreased by 1.9\% on average when increasing slice thickness from 2 to 10 mm. Steatotic muscle area increased by ≤3.3\%, and adipose tissue index increased by ≤1.5\% (all P {\textless} 0.05). Muscle attenuation did not change significantly with reconstruction thickness. Radiation dose had no effect on estimated area of spinal muscle, fatty spinal muscle, or visceral fat.
CONCLUSIONS: Contrast media have a strong effect on the evaluation of body composition, whereas the influence of slice thickness is less pronounced. Radiation dose can be reduced by ≥66\% without significantly affecting segmentation.},
	language = {eng},
	journal = {Nutrition (Burbank, Los Angeles County, Calif.)},
	author = {Morsbach, Fabian and Zhang, Yi-Hua and Martin, Lena and Lindqvist, Catarina and Brismar, Torkel},
	month = mar,
	year = {2019},
	pmid = {30419500},
	keywords = {Adipose Tissue, Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Retrospective Studies, Aged, 80 and over, Adult, Body composition, Liver Neoplasms, Radiation Dosage, Diagnostic Errors, Skeletal muscle index, Muscle, Contrast Media, Carcinoma, Hepatocellular, Computed tomography, Fat, Segmentation},
	pages = {50--55},
}

@article{porter129,
	title = {Aging of human muscle: structure, function and adaptability},
	volume = {5},
	issn = {0905-7188},
	shorttitle = {Aging of human muscle},
	doi = {10.1111/j.1600-0838.1995.tb00026.x},
	abstract = {With increasing age, human skeletal muscles gradually decrease in volume, mainly due to a reduced number of motor units and muscle fibers, and a reduced size of type 2 fibers. As a result, progressive weakening and impaired mobility occur. High-resistance strength training is beneficial, even in the very old, and could possibly reverse some of the detrimental effects of age-related weakness. The importance of exercise for older people affords an excellent opportunity for the medicine community as a major source of information and promotion of physical activity for this rapidly growing segment of the population. In this review, we summarize the current knowledge of the effects of aging on the human neuromuscular system, describe some of the major underlying mechanisms of the aging atrophy and focus on the importance of strength training to improve muscle function in older people.},
	language = {eng},
	number = {3},
	journal = {Scandinavian Journal of Medicine \& Science in Sports},
	author = {Porter, M. M. and Vandervoort, A. A. and Lexell, J.},
	month = jun,
	year = {1995},
	pmid = {7552755},
	keywords = {Humans, Muscle, Skeletal, Aged, Aging, Exercise, Muscle Contraction, Adaptation, Physiological, Electromyography, Muscle Fibers, Skeletal},
	pages = {129--142},
}

@article{sandini1231a,
	title = {A high visceral adipose tissue-to-skeletal muscle ratio as a determinant of major complications after pancreatoduodenectomy for cancer},
	volume = {32},
	issn = {1873-1244},
	doi = {10.1016/j.nut.2016.04.002},
	abstract = {OBJECTIVE: Complication rates after pancreatic resections remain high despite improvement in perioperative management. The effects of body composition and the relationship among different body compartments on surgical morbidity are not comprehensively investigated. The aim of this study was to assess whether the evaluation of different body compartments and their relationship was associated with the development of major postoperative complications after pancreatoduodenectomy (PD) for cancer.
METHODS: We retrospectively analyzed 124 patients who underwent PD and had a staging computed tomography (CT) scan at our center. CT scan was used to measure abdominal skeletal muscle area and volume, as well as visceral fat area (VFA) and volume. The total abdominal muscle area (TAMA) was then normalized for height. The severity of complications was assessed. Univariate and multivariate analyses were performed to investigate correlations between the above variables and postoperative complications. The receiver operating characteristic curve methodology was used to investigate the predictive ability of each parameter.
RESULTS: Major complications occurred in 42 patients (33.9\%). The prevalence of sarcopenia was 24.2\%. Regression analyses revealed no correlation between abdominal muscular and adipose tissue areas. Univariate analysis showed that the depletion of muscle area normalized for height was not per se predictive of complications (P = 0.318). Multivariate logistic regression showed that the VFA/TAMA was the only determinant of major complications (odds ratio, 3.20; 95\% confidence interval, 1.35-7.60; P = 0.008). The model predictive performance was 0.735 (area under the curve) with a sensitivity of 64.3\% and a specificity of 74.4\%.
CONCLUSION: Sarcopenic obesity is a strong predictor of major complications after PD for cancer.},
	language = {eng},
	number = {11-12},
	journal = {Nutrition (Burbank, Los Angeles County, Calif.)},
	author = {Sandini, Marta and Bernasconi, Davide P. and Fior, Davide and Molinelli, Matilde and Ippolito, Davide and Nespoli, Luca and Caccialanza, Riccardo and Gianotti, Luca},
	year = {2016},
	pmid = {27261062},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Obesity, Sarcopenia, Body Mass Index, Retrospective Studies, Risk Factors, Pancreatic Neoplasms, Body composition, Intra-Abdominal Fat, Postoperative Complications, Surgery, Pancreas, Morbidity, Multidetector Computed Tomography, Pancreaticoduodenectomy},
	pages = {1231--1237},
}

@article{shachar658,
	title = {Skeletal {Muscle} {Measures} as {Predictors} of {Toxicity}, {Hospitalization}, and {Survival} in {Patients} with {Metastatic} {Breast} {Cancer} {Receiving} {Taxane}-{Based} {Chemotherapy}},
	volume = {23},
	issn = {1557-3265},
	doi = {10.1158/1078-0432.CCR-16-0940},
	abstract = {PURPOSE: Severe skeletal muscle (SM) loss (sarcopenia) is associated with poor cancer outcomes, including reduced survival and increased toxicity. This study investigates SM measures in metastatic breast cancer (MBC) patients receiving first-line taxane-based chemotherapy and evaluates associations with treatment toxicity and other outcomes.
EXPERIMENTAL DESIGN: Using computerized tomography (CT) images taken for the evaluation of disease burden, skeletal muscle area (SMA), and density (SMD) were measured at the third lumbar vertebrae. Sarcopenia was defined as skeletal muscle index (SMI = SMA/height2) ≤ 41. Skeletal muscle gauge (SMG) was created by multiplying SMI × SMD. Fisher exact tests, t tests, the Kaplan-Meier method, and Cox regression modeling were used.
RESULTS: MBC patients (N = 40), median age 55 (range, 34-80), 58\% sarcopenic, median SMG 1296 AU (SD, 522). Grade 3-4 toxicity was found in 57\% of sarcopenic versus 18\% of non-sarcopenic patients (P = 0.02). Toxicity-related hospitalizations were also higher in sarcopenic patients (39\% vs. 0\%, P = 0.005) as were any adverse events-defined as any grade 3-4 toxicities, hospitalizations, dose reductions, or dose delay-(74\% vs. 35\%, P = 0.02). Low SMG was associated with grade 3-4 toxicity (P = 0.04), hospitalization (P = 0.01), and time to treatment failure (for progression or toxicity; P = 0.03). Low SMG had a borderline significant association with any adverse event (P = 0.06) and overall survival (P = 0.07).
CONCLUSIONS: SM measures are associated with toxicity outcomes and survival in MBC patients receiving first-line taxane-based chemotherapy. Further studies are needed to explore how routinely obtained CT scans can be used to individualize dosing and improve treatment planning. Clin Cancer Res; 23(3); 658-65. ©2016 AACR.},
	language = {eng},
	number = {3},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Shachar, Shlomit Strulov and Deal, Allison M. and Weinberg, Marc and Nyrop, Kirsten A. and Williams, Grant R. and Nishijima, Tomohiro F. and Benbow, Julia M. and Muss, Hyman B.},
	month = feb,
	year = {2017},
	pmid = {27489287},
	pmcid = {PMC5290138},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Hospitalization, Middle Aged, Sarcopenia, Body Mass Index, Follow-Up Studies, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols, Proportional Hazards Models, Prognosis, Organ Size, Aged, 80 and over, Adult, Body Surface Area, Adenocarcinoma, Taxoids, Breast Neoplasms, Antineoplastic Agents, Phytogenic, Specific Gravity},
	pages = {658--665},
	file = {Shachar et al_2017_Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and.pdf:/Users/jcsal/Zotero/storage/RPVYWZWK/Shachar et al_2017_Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and.pdf:application/pdf},
}

@article{cohen3865,
	title = {Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy},
	volume = {122},
	issn = {1097-0142},
	doi = {10.1002/cncr.30269},
	abstract = {BACKGROUND: Frailty has been suggested as a construct for oncologists to consider in treating older cancer patients. Therefore, the authors assessed the potential of creating a deficit-accumulation frailty index (DAFI) from a largely self-administered comprehensive geriatric assessment (CGA).
METHODS: Five hundred patients aged ≥65 years underwent a CGA before receiving chemotherapy. A DAFI was constructed, resulting in a 51-item scale, and cutoff values were examined for patients in the robust/nonfrail (cutoff value, 0.0 {\textless} 0.2), prefrail (cutoff value, 0.2 {\textless} 0.35), and frail (cutoff value, ≥ 0.35) groups.
RESULTS: Two hundred and fifty patients (50\%) were nonfrail, 197 (39\%) were prefrail, and 52 (11\%) were frail. Older patients (aged ≥ 80 years) and those who had lower education, were living alone, and had higher stage disease were associated with prefrail/frail status. Prefrail/frail patients were more likely to have grade ≥3 toxicity but not to have a dose delay or reduction, and they were more likely to discontinue drug and be hospitalized. The association with grade ≥3 toxicity was attenuated by controlling for a toxicity risk calculator, but the other outcomes were not.
CONCLUSIONS: A deficit-accumulation frailty index can be constructed from a CGA in older patients with cancer and can indicate the frailty status of the population. The frailty status so determined is associated both with outcomes likely because of chemotherapy toxicity and with those likely because of age-related physiologic and functional deficits and thus can be useful in the overall assessment of the patient. Cancer 2016;122:3865-3872. © 2016 American Cancer Society.},
	language = {eng},
	number = {24},
	journal = {Cancer},
	author = {Cohen, Harvey Jay and Smith, David and Sun, Can-Lan and Tew, William and Mohile, Supriya G. and Owusu, Cynthia and Klepin, Heidi D. and Gross, Cary P. and Lichtman, Stuart M. and Gajra, Ajeet and Filo, Julie and Katheria, Vani and Hurria, Arti and {Cancer and Aging Research Group}},
	month = dec,
	year = {2016},
	pmid = {27529755},
	pmcid = {PMC5138076},
	keywords = {Humans, Aged, Female, Male, Risk Factors, Neoplasms, Antineoplastic Agents, Aged, 80 and over, Geriatric Assessment, cancer, Aging, frailty, comprehensive geriatric assessment, deficit-accumulation index, geriatric},
	pages = {3865--3872},
	file = {Cohen et al_2016_Frailty as determined by a comprehensive geriatric assessment-derived.pdf:/Users/jcsal/Zotero/storage/KZ975U3K/Cohen et al_2016_Frailty as determined by a comprehensive geriatric assessment-derived.pdf:application/pdf},
}

@article{feng1127,
	title = {Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis},
	volume = {27},
	issn = {1437-7772},
	shorttitle = {Prognostic value of myosteatosis in patients with lung cancer},
	doi = {10.1007/s10147-022-02181-1},
	abstract = {The prognostic value of myosteatosis has been widely investigated in lung cancer, yet conclusions remain controversial. The purpose of this meta-analysis was to illuminate this issue. Medline, Embase, Cochrane Library and Web of Science Core Collection online databases were systematically searched from inception to 24 September 2021. Newcastle-Ottawa Scale tool was applied to evaluate the quality of included studies. Pooled hazard ratios (HRs) with 95\% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were used to examine prognostic value of myosteatosis. Subgroup analysis and sensitivity analysis were conducted to assess heterogeneity and stability of results. A total of 484 articles were screened from which 9 eligible studies involving 1667 patients were enrolled in this meta-analysis. Lung cancer patients with myosteatosis had significantly worse OS than patients without myosteatosis (HR 1.10, 95\% CI 1.05-1.16, P {\textless} 0.001), both in six multivariate analysis (HR 1.46, 95\% CI 1.16-1.85, P = 0.001) and in three univariate analysis (HR 1.08, 95\% CI 1.03-1.14, P = 0.003). Pooled data from five studies using multivariate survival analysis also showed that patients with myosteatosis had a statistically significant unfavorable PFS (HR = 1.27, 95\% CI 1.00-1.62, P = 0.049). Sensitivity analysis showed the result for OS was stable. But for PFS, the result was not robust. Myosteatosis might serve as an independent indicator of unfavorable survival outcomes for OS and PFS in lung cancer patients. Further studies are needed to confirm our results.},
	language = {eng},
	number = {7},
	journal = {International Journal of Clinical Oncology},
	author = {Feng, Shaofang and Mu, Huiwen and Hou, Rong and Liu, Yunxin and Zou, Jianjun and Zhao, Zheng and Zhu, Yubing},
	month = jul,
	year = {2022},
	pmid = {35604501},
	keywords = {Humans, Proportional Hazards Models, Lung Neoplasms, Prognosis, Survival Analysis, Myosteatosis, Meta-analysis, Lung cancer},
	pages = {1127--1138},
}

@article{kim4022a,
	title = {Age-related changes in muscle quality and development of diagnostic cutoff points for myosteatosis in lumbar skeletal muscles measured by {CT} scan},
	volume = {40},
	issn = {1532-1983},
	doi = {10.1016/j.clnu.2021.04.017},
	abstract = {BACKGROUND \& AIMS: We have sought to develop proper and useful indices for muscle quality measurements other than muscle attenuation (Hounsfield unit; HU) and to determine the diagnostic cutoff points for myosteatosis by using those indices measured at the L3 lumbar vertebrae level by CT scan.
METHODS: This cross-sectional analysis included 20,664 healthy adult subjects (12,697 men and 7967 women) who underwent abdominal CT scans. Total abdominal muscle area (TAMA), on the L3 vertebra was demarcated using predetermined thresholds. Intermuscular adipose tissue area (IMAT) and skeletal muscle area (SMA) were measured. SMA was divided into normal attenuation muscle area (NAMA) and low attenuation muscle area (LAMA). Their various indices were calculated. We identified the sex-specific mean values of NAMA, LAMA, IMAT, and their indices and the cutoff points equivalent to the T-scores in the young reference group.
RESULTS: The mean values of the NAMA and NAMA indices decreased with age in both sexes, LAMA, IMAT, and their indices showed an increasing tendency with age in both sexes. When using T-score {\textless} -2.0 as the cutoff for myosteatosis, the sex-specific cutoff points of NAMA, NAMA/BMI, NAMA/TAMA index, and SMA and TAMA attenuation in men and women were 103.0 and 64.5 cm2, 4.0 and 2.8, 66.4 and 65.1, 40.2 and 39.9 HU, and 34.1 and 33.5 HU, respectively. Using these cutoff points, the prevalence of myosteatosis by NAMA, NAMA/BMI, NAMA/TAMA index, or SMA or TAMA attenuation ranged from 5.9 to 8.8\% in men and from 10.2 to 20.5\% in women.
CONCLUSIONS: The NAMA/TAMA index developed in this study was useful for assessing myosteatosis. This is the first study to report the sex-specific diagnostic cutoff points for myosteatosis of trunk muscles based on T-scores measured by CT scans in healthy population. These diagnostic cutoff points may be particularly useful in the treatment and prevention of sarcopenia and myosteatosis.},
	language = {eng},
	number = {6},
	journal = {Clinical Nutrition (Edinburgh, Scotland)},
	author = {Kim, Hong-Kyu and Kim, Kyung Won and Kim, Eun Hee and Lee, Min Jung and Bae, Sung-Jin and Ko, Yousun and Park, Taeyoung and Shin, Yongbin and Kim, Ye-Jee and Choe, Jaewon},
	month = jun,
	year = {2021},
	pmid = {34144412},
	keywords = {Adipose Tissue, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Female, Male, Middle Aged, Sarcopenia, Retrospective Studies, Sex Factors, Electric Impedance, Adult, Age Factors, Cross-Sectional Studies, Myosteatosis, Muscular Diseases, Lumbar Vertebrae, Reference Values, Anthropometry, Healthy Volunteers, L3 lumbar spine level, Skeletal muscle quality, Torso},
	pages = {4022--4028},
}

@article{khorana4902,
	title = {Development and validation of a predictive model for chemotherapy-associated thrombosis},
	volume = {111},
	issn = {1528-0020},
	doi = {10.1182/blood-2007-10-116327},
	abstract = {Risk of venous thromboembolism (VTE) is elevated in cancer, but individual risk factors cannot identify a sufficiently high-risk group of outpatients for thromboprophylaxis. We developed a simple model for predicting chemotherapy-associated VTE using baseline clinical and laboratory variables. The association of VTE with multiple variables was characterized in a derivation cohort of 2701 cancer outpatients from a prospective observational study. A risk model was derived and validated in an independent cohort of 1365 patients from the same study. Five predictive variables were identified in a multivariate model: site of cancer (2 points for very high-risk site, 1 point for high-risk site), platelet count of 350 x 10(9)/L or more, hemoglobin less than 100 g/L (10 g/dL) and/or use of erythropoiesis-stimulating agents, leukocyte count more than 11 x 10(9)/L, and body mass index of 35 kg/m(2) or more (1 point each). Rates of VTE in the derivation and validation cohorts, respectively, were 0.8\% and 0.3\% in low-risk (score = 0), 1.8\% and 2\% in intermediate-risk (score = 1-2), and 7.1\% and 6.7\% in high-risk (score {\textgreater}/= 3) category over a median of 2.5 months (C-statistic = 0.7 for both cohorts). This model can identify patients with a nearly 7\% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis.},
	language = {eng},
	number = {10},
	journal = {Blood},
	author = {Khorana, Alok A. and Kuderer, Nicole M. and Culakova, Eva and Lyman, Gary H. and Francis, Charles W.},
	month = may,
	year = {2008},
	pmid = {18216292},
	pmcid = {PMC2384124},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Risk Assessment, Neoplasms, Antineoplastic Agents, Cohort Studies, Predictive Value of Tests, Logistic Models, Diagnosis, Computer-Assisted, Models, Biological, Thrombosis},
	pages = {4902--4907},
	file = {Khorana et al_2008_Development and validation of a predictive model for chemotherapy-associated.pdf:/Users/jcsal/Zotero/storage/JVG7E35H/Khorana et al_2008_Development and validation of a predictive model for chemotherapy-associated.pdf:application/pdf},
}

@article{mercier478,
	title = {The platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer},
	volume = {9},
	issn = {2078-6891},
	shorttitle = {The platelets-neutrophils to lymphocytes ratio},
	doi = {10.21037/jgo.2018.03.13},
	abstract = {BACKGROUND: The cancer micro-environment is recognized as having an increasing importance in cancer progression. Immune cells originating from the peripheral blood are important elements of this environment. Thrombocytosis, neutrophilia and lymphocytopenia have been found to be negative prognostic indicators in many cancers. This study aims to evaluate the potential of the use of a novel hematological marker, the platelet-neutrophil to lymphocyte ratio (PNLR) as a practical, reliable, and inexpensive prognostic tool in metastatic colorectal adenocarcinomas.
METHODS: Charts from 305 patients with colorectal cancer were retrospectively reviewed. Of these, 152 had metastatic disease with complete follow-up data on progression and survival. Data were extracted and stratified by a PNLR cut-off point of 2,000. Baseline parameters of the two groups were evaluated and compared with the χ2 test. Univariate and multivariate Cox proportional-hazards regression analyses were performed on variables of interest.
RESULTS: A total of 102 (67.1\%) patients had a PNLR of less than 2,000 while the index for 50 (32.9\%) patients was 2,000 or higher. Patients with a PNLR above 2,000 had a shorter median progression-free survival (PFS) [6.5 vs. 13.3 months; hazard ratio (HR), 2.05; 95\% CI, 1.32-3.19, P=0.001] than in patients with a PNLR below the threshold. Similar results were observed for median overall survival (OS) (9.6 vs. 21.8 months; HR, 2.33; 95\% CI, 1.44-3.79, P=0.001). PNLR had a higher predictive HR than Eastern Cooperative Oncology Group (ECOG) performance status (PS).
CONCLUSIONS: In this retrospective analysis of metastatic colorectal cancer patients, PNLR had prognostic value for both OS and PFS. While other variables held significance for poorer prognosis, PNLR had the highest HR and the highest significance in multivariate analysis for both PFS and OS. Thus, it represents a powerful and objective prognostic tool in the evaluation of metastatic colorectal cancer patients that is readily available and does not require any additional expenses.},
	language = {eng},
	number = {3},
	journal = {Journal of Gastrointestinal Oncology},
	author = {Mercier, Joey and Voutsadakis, Ioannis A.},
	month = jun,
	year = {2018},
	pmid = {29998013},
	pmcid = {PMC6006046},
	keywords = {Colorectal cancer, prognosis, lymphocytopenia, metastatic, neutrophilia, ratio, thrombocytosis},
	pages = {478--486},
	file = {Mercier_Voutsadakis_2018_The platelets-neutrophils to lymphocytes ratio.pdf:/Users/jcsal/Zotero/storage/XARGBREA/Mercier_Voutsadakis_2018_The platelets-neutrophils to lymphocytes ratio.pdf:application/pdf},
}

@article{fang155,
	title = {Percutaneous endoscopic gastrostomy prior to esophagectomy for esophageal cancer - a systematic review and meta-analysis},
	volume = {16},
	issn = {1747-4132},
	doi = {10.1080/17474124.2022.2027754},
	abstract = {BACKGROUND: For resectable esophageal cancer (EC), it remains controversial whether to place percutaneous endoscopic gastrostomy (PEG) before the curative surgery to provide nutritional support during the neoadjuvant therapy.
OBJECTIVE: To compare surgical outcomes for patients who received preoperative PEG and those without PEG placement (No-PEG) insertion prior to surgery in a potentially operable EC.
METHODS: A comprehensive literature search was conducted to identify randomized and non-randomized studies comparing PEG and No-PEG groups.
RESULTS: Four retrospective studies with a total number of 1,027 patients were identified and included in this meta-analysis. The differences in anastomotic leakage, anastomotic stricture, morbidity, pulmonary complications, wound infection, and hospital stay were not statistically significant between the two groups. Operation time was significantly shorter in the PEG group. There was no PEG-related gastric conduit failure and no leak from the PEG site in the PEG group.
CONCLUSION: We conclude preoperative PEG for resectable EC is a safe procedure with no adverse effect on the gastric tube construction and anastomosis, it can be selectively inserted for EC patients with marked weight loss and malnutrition or those at risk of developing malnutrition during neoadjuvant therapy.},
	language = {eng},
	number = {2},
	journal = {Expert Review of Gastroenterology \& Hepatology},
	author = {Fang, Hua-Chen and Farah, Musa Hassan and Shiue, Sheng-Jie and Cheng, Sheng-Wei and Shiue, Han-Shiang and Cheng, Chao-Ling and Chan, Tze-Sian and Liao, Ai-Ho and Wu, Ming-Shun},
	month = feb,
	year = {2022},
	pmid = {35048757},
	keywords = {Esophageal Neoplasms, Esophagectomy, esophagus cancer, Gastroscopy, Gastrostomy, Humans, neoadjuvant therapy, Nutritional Support, Operative Time, Percutaneous endoscopic gastrostomy, Postoperative Complications, systematic review and meta-analysis},
	pages = {155--162},
}

@article{minnella1081,
	title = {Effect of {Exercise} and {Nutrition} {Prehabilitation} on {Functional} {Capacity} in {Esophagogastric} {Cancer} {Surgery}: {A} {Randomized} {Clinical} {Trial}},
	volume = {153},
	issn = {2168-6262},
	shorttitle = {Effect of {Exercise} and {Nutrition} {Prehabilitation} on {Functional} {Capacity} in {Esophagogastric} {Cancer} {Surgery}},
	doi = {10.1001/jamasurg.2018.1645},
	abstract = {IMPORTANCE: Preserving functional capacity is a key element in the care continuum for patients with esophagogastric cancer. Prehabilitation, a preoperative conditioning intervention aiming to optimize physical status, has not been tested in upper gastrointestinal surgery to date.
OBJECTIVE: To investigate whether prehabilitation is effective in improving functional status in patients undergoing esophagogastric cancer resection.
DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial (available-case analysis based on completed assessments) was conducted at McGill University Health Centre (Montreal, Quebec, Canada) comparing prehabilitation with a control group. Intervention consisted of preoperative exercise and nutrition optimization. Participants were adults awaiting elective esophagogastric resection for cancer. The study dates were February 13, 2013, to February 10, 2017.
MAIN OUTCOMES AND MEASURES: The primary outcome was change in functional capacity, measured with absolute change in 6-minute walk distance (6MWD). Preoperative (end of the prehabilitation period) and postoperative (from 4 to 8 weeks after surgery) data were compared between groups.
RESULTS: Sixty-eight patients were randomized, and 51 were included in the primary analysis. The control group were a mean (SD) age, 68.0 (11.6) years and 20 (80\%) men. Patients in the prehabilitation group were a mean (SD) age, 67.3 (7.4) years and 18 (69\%) men. Compared with the control group, the prehabilitation group had improved functional capacity both before surgery (mean [SD] 6MWD change, 36.9 [51.4] vs -22.8 [52.5] m; P {\textless} .001) and after surgery (mean [SD] 6MWD change, 15.4 [65.6] vs -81.8 [87.0] m; P {\textless} .001).
CONCLUSIONS AND RELEVANCE: Prehabilitation improves perioperative functional capacity in esophagogastric surgery. Keeping patients from physical and nutritional status decline could have a significant effect on the cancer care continuum.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01666158.},
	language = {eng},
	number = {12},
	journal = {JAMA surgery},
	author = {Minnella, Enrico M. and Awasthi, Rashami and Loiselle, Sarah-Eve and Agnihotram, Ramanakumar V. and Ferri, Lorenzo E. and Carli, Francesco},
	month = dec,
	year = {2018},
	pmid = {30193337},
	pmcid = {PMC6583009},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Stomach Neoplasms, Esophageal Neoplasms, Nutritional Status, Preoperative Care, Exercise, Walking},
	pages = {1081--1089},
}

@article{inouedoz050,
	title = {Preoperative six-minute walk distance as a predictor of postoperative complication in patients with esophageal cancer},
	volume = {33},
	issn = {1442-2050},
	doi = {10.1093/dote/doz050},
	abstract = {Surgery for esophageal cancer is associated with high morbidity and mortality. Reduced pulmonary functions and exercise capacity are known as risk factors for complications after esophagectomy. The 6-minute walk distance (6MWD) measured by the 6-minute walk test (6MWT) is a simple field test that can be used to evaluate the functional exercise capacity of patients who undergo thoracic surgery. The aim of this study was to evaluate the association of the preoperative 6MWD with postoperative complications in patients with esophageal cancer. Records of a total of 111 patients who underwent thoracic surgery followed by postoperative rehabilitation from January 2013 to December 2015 were retrospectively reviewed. Data of patients who experienced Clavien-Dindo grade II or severer (grade ≥ II) complications were compared with those who experienced grade ≤I complications. The 6MWD was significantly correlated with age, serum albumin concentration, hemoglobin concentration, and hand grip strength. A total of 42 patients experienced grade ≥II. The 6MWD of patients with grade ≥ II complications was significantly shorter than that of those with grade ≤I complications. In receiver operating characteristic analysis, 6MWD ≤ 454 m was a threshold for predicting grade ≥II complications with 71.0\% sensitivity and 54.8\% specificity. The incidence of grade ≥II complications led to delayed ambulation and longer stays in hospital. In the multiple regression analysis, the preoperative risk factors for incidence of grade ≥II complications included lower levels of preoperative 6MWD and \% of the predicted value of forced expiratory volume in 1 second. Our results indicate that the 6MWT is useful to assess preoperative physical status in patients with esophageal cancer.},
	language = {eng},
	number = {2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Inoue, Takayuki and Ito, Satoru and Kanda, Mitsuro and Niwa, Yukiko and Nagaya, Motoki and Nishida, Yoshihiro and Hasegawa, Yoshinori and Koike, Masahiko and Kodera, Yasuhiro},
	month = mar,
	year = {2020},
	pmid = {31111872},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Risk Factors, Esophageal Neoplasms, Esophagectomy, Sensitivity and Specificity, Incidence, Postoperative Complications, Carcinoma, Preoperative Care, surgery, Health Status Indicators, esophageal cancer surgery, complications, Physical Fitness, rehabilitation, Walk Test},
	pages = {doz050},
}

@article{guralnikM85,
	title = {A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission},
	volume = {49},
	issn = {0022-1422},
	shorttitle = {A short physical performance battery assessing lower extremity function},
	doi = {10.1093/geronj/49.2.m85},
	abstract = {BACKGROUND: A short battery of physical performance tests was used to assess lower extremity function in more than 5,000 persons age 71 years and older in three communities.
METHODS: Balance, gait, strength, and endurance were evaluated by examining ability to stand with the feet together in the side-by-side, semi-tandem, and tandem positions, time to walk 8 feet, and time to rise from a chair and return to the seated position 5 times.
RESULTS: A wide distribution of performance was observed for each test. Each test and a summary performance scale, created by summing categorical rankings of performance on each test, were strongly associated with self-report of disability. Both self-report items and performance tests were independent predictors of short-term mortality and nursing home admission in multivariate analyses. However, evidence is presented that the performance tests provide information not available from self-report items. Of particular importance is the finding that in those at the high end of the functional spectrum, who reported almost no disability, the performance test scores distinguished a gradient of risk for mortality and nursing home admission. Additionally, within subgroups with identical self-report profiles, there were systematic differences in physical performance related to age and sex.
CONCLUSION: This study provides evidence that performance measures can validly characterize older persons across a broad spectrum of lower extremity function. Performance and self-report measures may complement each other in providing useful information about functional status.},
	language = {eng},
	number = {2},
	journal = {Journal of Gerontology},
	author = {Guralnik, J. M. and Simonsick, E. M. and Ferrucci, L. and Glynn, R. J. and Berkman, L. F. and Blazer, D. G. and Scherr, P. A. and Wallace, R. B.},
	month = mar,
	year = {1994},
	pmid = {8126356},
	keywords = {Humans, Aged, Female, Male, Risk Factors, Aged, 80 and over, Mortality, Geriatric Assessment, Nursing Homes, Activities of Daily Living, Locomotion, Patient Admission, Self Disclosure},
	pages = {M85--94},
}

@article{godin141,
	title = {A simple method to assess exercise behavior in the community},
	volume = {10},
	issn = {0700-3978},
	abstract = {The reliability and concurrent validity of a simple questionnaire to assess leisure time physical activity has been investigated on 306 self-selected healthy adults of both sexes (163 M; 143 F). Values of body fat (BF) and maximum oxygen intake (VO2 max) expressed as percentiles of appropriate age and sex categories were used as criteria of validity for the questionnaire. BF and VO2 max were predicted from the Durnin and Womersley skinfold equations, and the laboratory version of the Canadian Home Fitness Test respectively. The strongest correlation was between VO2 max (percentile) and reported strenuous exercise (r = 0.35). The optimum discriminant function for VO2 max was based on a combination of reported strenuous and light activity. This yielded a correct 2-way classification of 69\% of the subjects. A combination of sweat-inducing and moderate exercise yielded a correct 2-way classification of BF for 66\% of subjects. The reliability coefficients for the optimum discriminant functions classifying VO2 max and BF were 0.83 and 0.85 respectively. We conclude that this simple instrument has potential value for the assessment of leisure time exercise behavior, offering the possibility of examining changes in behavior following the implementation of health and physical fitness promotion programmes in the community.},
	language = {eng},
	number = {3},
	journal = {Canadian Journal of Applied Sport Sciences. Journal Canadien Des Sciences Appliquees Au Sport},
	author = {Godin, G. and Shephard, R. J.},
	month = sep,
	year = {1985},
	pmid = {4053261},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Body Weight, Adult, Adolescent, Physical Fitness, Health Promotion, Life Style, Oxygen, Physical Exertion},
	pages = {141--146},
}

@article{markar718,
	title = {Surgical and {Surgeon}-{Related} {Factors} {Related} to {Long}-{Term} {Survival} in {Esophageal} {Cancer}: {A} {Review}},
	volume = {27},
	issn = {1534-4681},
	shorttitle = {Surgical and {Surgeon}-{Related} {Factors} {Related} to {Long}-{Term} {Survival} in {Esophageal} {Cancer}},
	doi = {10.1245/s10434-019-07966-9},
	abstract = {Esophagectomy is the mainstay of curative treatment for most patients with a diagnosis of esophageal cancer. This procedure needs to be optimized to secure the best possible chance of cure for these patients. Research comparing various surgical approaches of esophagectomy generally has failed to identify any major differences in long-term prognosis. Comparisons between minimally invasive and open esophagectomy, transthoracic and transhiatal approaches, radical and moderate lymphadenectomy, and high and moderate hospital volume generally have provided only moderate alterations in long-term survival rates after adjustment for established prognostic factors. In contrast, some direct surgeon-related factors, which remain independent of known prognostic factors, seem to influence the long-term survival more strongly in esophageal cancer. Annual surgeon volume is strongly prognostic, and recent studies have suggested the existence of long surgeon proficiency gain curves for achievement of stable 5-year survival rates and possibly also a prognostic influence of surgeon age and weekday of surgery. The available literature indicates a potentially more critical role of the individual surgeon's skills than that of variations in surgical approach for optimizing the long-term survival after esophagectomy for esophageal cancer. This finding points to the value of paying more attention to how the skills of the individual esophageal cancer surgeon can best be achieved and maintained. Careful selection and evaluation of the most suitable candidates, appropriate and structured training programs, and regular peer-review assessments of experienced surgeons may be helpful in this respect.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgical Oncology},
	author = {Markar, Sheraz R. and Lagergren, Jesper},
	month = mar,
	year = {2020},
	pmid = {31691111},
	pmcid = {PMC7000496},
	keywords = {Humans, Survival Rate, Prognosis, Esophageal Neoplasms, Esophagectomy, Lymph Node Excision, Surgeons},
	pages = {718--723},
	file = {Markar_Lagergren_2020_Surgical and Surgeon-Related Factors Related to Long-Term Survival in.pdf:/Users/jcsal/Zotero/storage/VIVWZK3A/Markar_Lagergren_2020_Surgical and Surgeon-Related Factors Related to Long-Term Survival in.pdf:application/pdf},
}

@article{schlottmann423a,
	title = {Stage {III} esophageal adenocarcinoma: definitive chemoradiation vs. chemoradiation plus surgery},
	volume = {70},
	issn = {2038-3312},
	shorttitle = {Stage {III} esophageal adenocarcinoma},
	doi = {10.1007/s13304-018-0541-5},
	abstract = {The optimal management of patients with locally advanced esophageal cancer remains under debate. We aimed to compare the long-term survival outcomes between definitive chemoradiation (dCR) and chemoradiation plus surgery (CRS) in patients with stage III esophageal adenocarcinoma (EAC). Using the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program registry, adults (≥ 18 years old) with diagnosis of AJCC 6th edition stage III EAC (T3/N1, T4/N0, and T4/N1) between 2004 and 2014 were included. A multivariable Cox regression was used to assess the effect of dCR and CRS on mortality. Of the 2633 patients included, 1115 (42\%) underwent Dcr, and 1518 (58\%) underwent CRS. The 5-year survival rate was 13\% for patients undergoing dCR and 27\% for patients undergoing CRS (p {\textless} 0.0001). Our observational data suggest that patients with stage III EAC may benefit by the use of esophagectomy after chemoradiotherapy.},
	language = {eng},
	number = {4},
	journal = {Updates in Surgery},
	author = {Schlottmann, Francisco and Strassle, Paula D. and Gaber, Charles and Patti, Marco G.},
	month = dec,
	year = {2018},
	pmid = {29926306},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Survival Rate, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Surgery, Definitive chemoradiation, Esophageal adenocarcinoma},
	pages = {423--426},
}

@article{mamdani1944a,
	title = {Role of surgery following neoadjuvant chemoradiation in patients with lymph node positive locally advanced esophageal adenocarcinoma: a national cancer database analysis},
	volume = {12},
	issn = {2078-6891},
	shorttitle = {Role of surgery following neoadjuvant chemoradiation in patients with lymph node positive locally advanced esophageal adenocarcinoma},
	doi = {10.21037/jgo-21-314},
	abstract = {BACKGROUND: Concurrent chemoradiation (CRT) followed by surgery is a standard of care for locally advanced esophageal adenocarcinoma. It remains unclear if surgery following CRT offers any meaningful survival benefit compared to CRT alone in patients with clinical N3 disease who are at the highest risk of developing distant disease relapse.
METHODS: We conducted analysis of the National Cancer Database (NCDB) to compare overall survival (OS) of patients with locally advanced esophageal adenocarcinoma (cTanyN1-3M0 based on AJCC 7th staging system) who underwent CRT with or without surgery and analyzed outcomes based on the cN stage.
RESULTS: 7,520 patients were included in the analysis-74.7\% had cN1 disease, 21.1\% had cN2 disease, and 4.3\% had cN3 disease. The median OS advantage offered by CRT followed by surgery was 22, 15.8, and 9.6 months compared to CRT alone in cN1, cN2, and cN3 patients, respectively. The 5-year OS estimates in the surgical group were 36.9\%, 31.6\% and 15.9\% in cN1, cN2 and cN3 groups, respectively.
CONCLUSIONS: Surgery following CRT in patients with locally advanced esophageal adenocarcinoma leads to improvement in OS, with the largest benefit noted in patients with cN1 and cN2 disease. Surgery following CRT also confers meaningful long-term survival advantage for a subset of cN3 patients.},
	language = {eng},
	number = {5},
	journal = {Journal of Gastrointestinal Oncology},
	author = {Mamdani, Hirva and Birdas, Thomas and Jalal, Shadia I.},
	month = oct,
	year = {2021},
	pmid = {34790362},
	pmcid = {PMC8576241},
	keywords = {esophagectomy, Esophageal adenocarcinoma, lymph node staging, N3 disease, National Cancer Database (NCDB)},
	pages = {1944--1950},
	file = {Mamdani et al_2021_Role of surgery following neoadjuvant chemoradiation in patients with lymph.pdf:/Users/jcsal/Zotero/storage/IZJGBMZ5/Mamdani et al_2021_Role of surgery following neoadjuvant chemoradiation in patients with lymph.pdf:application/pdf},
}

@article{kamarajah526,
	title = {Definitive {Chemoradiotherapy} {Compared} to {Neoadjuvant} {Chemoradiotherapy} {With} {Esophagectomy} for {Locoregional} {Esophageal} {Cancer}: {National} {Population}-based {Cohort} {Study}},
	volume = {275},
	issn = {1528-1140},
	shorttitle = {Definitive {Chemoradiotherapy} {Compared} to {Neoadjuvant} {Chemoradiotherapy} {With} {Esophagectomy} for {Locoregional} {Esophageal} {Cancer}},
	doi = {10.1097/SLA.0000000000003941},
	abstract = {AIM: Ongoing randomized controlled trials seek to evaluate the potential organ-preservation strategy of definitive chemoradiotherapy as a primary treatment for esophageal cancer. This population-based cohort study aimed to assess survival following definitive chemoradiotherapy (DCR) with or without salvage esophagectomy (SALV) in the treatment of esophageal cancer.
PATIENTS AND METHODS: Data from the National Cancer Database (NCDB) from 2004 to 2015, was used to identify patients with nonmetastatic esophageal cancer receiving either DCR (n = 5977) or neoadjuvant chemoradiotherapy with planned esophagectomy (NCRS) (n = 13,555). Propensity score matching and multivariable analyses were used to account for treatment selection bias. Subset analyses compared patients receiving SALV after DCR with NCRS.
RESULTS: Comparison of baseline demographics of the unmatched cohort revealed that patients receiving NCRS were younger, had a lower burden of medical comorbidities, lower proportion of squamous cell carcinoma (SCC), and more positive lymph nodes. Following matching, NCRS was associated with significantly improved survival compared with DCR [hazard ratio (HR): 0.60, 95\% confidence Interval (CI): 0.57-0.63, P {\textless} 0.001], which persisted in subset analyses of patients with adenocarcinoma (HR: 0.60, 95\% CI: 0.56-0.63, P {\textless} 0.001) and SCC (HR: 0.58, 95\% CI: 0.53-0.63, P {\textless} 0.001). Of 829 receiving SALV after DCR, 823 patients were matched to 1643 NCRS. There was no difference in overall survival between SALV and NCRS (HR: 1.00, 95\% CI: 0.90-1.11, P = 1.0).
CONCLUSIONS: Surgery remains an integral component of the management of patients with esophageal cancer. Neoadjuvant therapy followed by planned esophagectomy appears to remain the optimum curative treatment regime in patients with locoregional esophageal cancer.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgery},
	author = {Kamarajah, Sivesh K. and Phillips, Alexander W. and Hanna, George B. and Low, Donald and Markar, Sheraz R.},
	month = mar,
	year = {2022},
	pmid = {32865948},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Retrospective Studies, Survival Rate, Cohort Studies, United States, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy},
	pages = {526--533},
	file = {Kamarajah et al_2022_Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With.pdf:/Users/jcsal/Zotero/storage/93U3R248/Kamarajah et al_2022_Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With.pdf:application/pdf},
}

@article{koeter1192,
	title = {Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the {Netherlands}: a nationwide population-based study on patterns of care and survival},
	volume = {57},
	issn = {1651-226X},
	shorttitle = {Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the {Netherlands}},
	doi = {10.1080/0284186X.2018.1450521},
	abstract = {BACKGROUND: The aim of our study was to describe treatment patterns and the impact on overall survival among elderly patients (75 years and older) with potentially curable esophageal cancer.
MATERIAL AND METHODS: Between 2003 and 2013, 13,244 patients from the nationwide population-based Netherlands Cancer Registry (NCR) were diagnosed with potentially curable esophageal cancer (cT2-3, X, any cN, cM0, X) of which 34\% were elderly patients (n = 4501).
RESULTS: Surgical treatment with or without neoadjuvant treatment remained stable among elderly patients (around the 16\% between 2003 and 2013). However, among younger patients, surgical treatment increased from 60.2 to 67.0\%. The use of definitive chemoradiation (dCRT) increased in elderly patients from 1.9 to 19.5\% and in younger patients from 5.2 to 17.2\%. Due to the increase in dCRT, treatment with curative intent doubled in the elderly from 17 to 37.1\%. Multivariable Cox regression revealed that elderly patients with an adenocarcinoma receiving surgery alone or dCRT had a significantly worse overall survival compared to those receiving surgery with neoadjuvant chemo (radio) therapy (nCRT/CT) (HR: 1.7 95\% CI 1.4-2.0 and HR: 1.9 95\% CI 1.5-2.3). However, among elderly with squamous cell carcinoma overall survival was comparable between dCRT, surgery alone and surgery with nCRT/CT.
CONCLUSIONS: Survival was comparable among elderly patients with squamous cell carcinoma who underwent surgery with nCRT/CT, surgery alone or received dCRT, while elderly patients with an adenocarcinoma who underwent surgery with nCRT/CT had a better overall survival when compared with surgery alone or dCRT. Therefore, dCRT can be considered as a reasonable alternative for surgery among potentially curable elderly patients with esophageal squamous cell carcinoma. However, in elderly patients with esophageal adenocarcinoma surgery with nCRT/CT is still preferable regarding overall survival.},
	language = {eng},
	number = {9},
	journal = {Acta Oncologica (Stockholm, Sweden)},
	author = {Koëter, M. and van Putten, M. and Verhoeven, R. H. A. and Lemmens, V. E. P. P. and Nieuwenhuijzen, G. a. P.},
	month = sep,
	year = {2018},
	pmid = {29528262},
	keywords = {Humans, Aged, Female, Male, Aged, 80 and over, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Netherlands, Practice Patterns, Physicians', Age of Onset, Choice Behavior},
	pages = {1192--1200},
	file = {Koëter et al_2018_Definitive chemoradiation or surgery in elderly patients with potentially.pdf:/Users/jcsal/Zotero/storage/2XI96TXS/Koëter et al_2018_Definitive chemoradiation or surgery in elderly patients with potentially.pdf:application/pdf},
}

@article{dicorpo989,
	title = {Treatment {Modalities} for {Esophageal} {Adenocarcinoma} in the {United} {States}: {Trends} and {Survival} {Outcomes}},
	volume = {29},
	issn = {1557-9034},
	shorttitle = {Treatment {Modalities} for {Esophageal} {Adenocarcinoma} in the {United} {States}},
	doi = {10.1089/lap.2019.0350},
	abstract = {Background: Owing to the rising incidence of esophageal adenocarcinoma (EAC), we sought to assess the national trends in the use of different treatment modalities and compare survival outcomes among them. Methods: Using Surveillance, Epidemiology, and End Results (SEER) Program registry (2004-2014), we identified adult patients diagnosed with EAC undergoing definitive chemoradiotherapy (dCRT), esophagectomy, or neoadjuvant chemoradiotherapy plus esophagectomy (nCRT/S). Linear trends in the yearly incidence of each treatment were assessed using Poisson regression. An inverse probability of treatment weighted (IPTW) Cox regression was used to estimate the effect of each treatment on mortality. IPTW was used to account for potential confounding by year of diagnosis, patient demographics, and cancer characteristics. Results: A total of 10,755 patients were included in the study. From 2004 to 2014, the use of esophagectomy alone decreased from 15\% to 5\% (P {\textless} .0001), whereas nCRT/S increased from 14\% to 20\% (P {\textless} .0001); dCRT remained relatively stable (26\% to 29\%, P = .08). The 60-month survival rate was 13.0\% for dCRT, 33.0\% for esophagectomy only, and 36.3\% for nCRT/S. After accounting for patient and cancer characteristics, both esophagectomy (hazard ratio [HR] 0.62, 95\% confidence interval [CI] 0.55-0.70, P {\textless} .0001) and nCRT/S (HR 0.45, 95\% CI 0.41-0.48, P {\textless} .0001) had significantly the highest survival rates. Conclusion: The use of esophagectomy alone has decreased, whereas nCRT/S has increased among EAC patients. Considering the better outcomes achieved with surgical resection, the use of dCRT should be discouraged in surgically fit patients.},
	language = {eng},
	number = {8},
	journal = {Journal of Laparoendoscopic \& Advanced Surgical Techniques. Part A},
	author = {Di Corpo, Marco and Schlottmann, Francisco and Strassle, Paula D. and Nurczyk, Kamil and Patti, Marco G.},
	month = aug,
	year = {2019},
	pmid = {31246532},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Kaplan-Meier Estimate, Proportional Hazards Models, Survival Rate, Adult, chemotherapy, United States, Young Adult, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, Registries, esophagectomy, esophageal adenocarcinoma, neoadjuvant therapy, Regression Analysis, SEER Program, radiotherapy, cancer, esophageal cancer survival, Poisson Distribution, SEER database},
	pages = {989--994},
}

@article{faiz986b,
	title = {Impact of {Age} and {Comorbidity} on {Choice} and {Outcome} of {Two} {Different} {Treatment} {Options} for {Patients} with {Potentially} {Curable} {Esophageal} {Cancer}},
	volume = {26},
	issn = {1534-4681},
	doi = {10.1245/s10434-019-07181-6},
	abstract = {PURPOSE: This study was designed to assess the impact of age and comorbidity on choice and outcome of definitive chemoradiotherapy (dCRT) or neoadjuvant chemoradiotherapy plus surgery.
METHODS: In this population-based study, all patients with potentially curable EC (cT1N+/cT2-3, TX, any cN, cM0) diagnosed in the South East of the Netherlands between 2004 and 2014 were included. Kaplan-Meier method with log-rank tests and multivariable Cox regression analysis were used to compare overall survival (OS).
RESULTS: A total of 702 patients was included. Age ≥ 75 years and multiple comorbidities were associated with a higher probability for dCRT (odds ratio [OR] 8.58; 95\% confidence interval [CI] 4.72-15.58; and OR 3.09; 95\% CI 1.93-4.93). The strongest associations were found for the combination of hypertension plus diabetes (OR 3.80; 95\% CI 1.97-7.32) and the combination of cardiovascular with pulmonary comorbidity (OR 3.18; 95\% CI 1.57-6.46). Patients with EC who underwent dCRT had a poorer prognosis than those who underwent nCRT plus surgery, irrespective of age, number, and type of comorbidities. In contrast, for patients with squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, OS was comparable between both groups (hazard ratio [HR] 1.52; 95\% CI 0.78-2.97; and HR 0.73; 95\% CI 0.13-4.14).
CONCLUSIONS: Histological tumor type should be acknowledged in treatment choices for patients with esophageal cancer. Neoadjuvant chemoradiotherapy plus surgery should basically be advised as treatment of choice for operable esophageal adenocarcinoma patients. For patients with esophageal squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, dCRT may be the preferred strategy.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgical Oncology},
	author = {Faiz, Z. and van Putten, M. and Verhoeven, R. H. A. and van Sandick, J. W. and Nieuwenhuijzen, G. a. P. and van der Sangen, M. J. C. and Lemmens, V. E. P. P. and Wijnhoven, B. P. L. and Plukker, J. T. M.},
	month = apr,
	year = {2019},
	pmid = {30719634},
	pmcid = {PMC6399439},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Age Factors, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, Comorbidity, Netherlands},
	pages = {986--995},
	file = {Faiz et al_2019_Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment.pdf:/Users/jcsal/Zotero/storage/ENX6YBH2/Faiz et al_2019_Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment.pdf:application/pdf},
}

@article{zhang220,
	title = {Diagnostic {Value} of {Sarcopenia} {Computed} {Tomography} {Metrics} for {Older} {Patients} with or without {Cancers} with {Gastrointestinal} {Disorders}},
	volume = {24},
	issn = {1538-9375},
	doi = {10.1016/j.jamda.2022.10.019},
	abstract = {OBJECTIVES: The diagnostic utility of poor body composition measures in sarcopenia remains unclear. We hypothesize that the skeletal muscle gauge [combination of skeletal muscle index (SMI) and skeletal muscle density (SMD); SMG = SMI × SMD] would have significant diagnostic and predictive value in certain muscle regions and populations.
DESIGN: Prospective cross-sectional study.
SETTING AND PARTICIPANTS: We examined inpatients age ≥60 years with or without cancer and with gastrointestinal disorders.
METHODS: We used computed tomography (CT) image metrics in the 12th thoracic (T12), third lumbar (L3), erector spinae muscle (ESM), and psoas muscle (PM) regions to establish correlations with the 2019 Asian Working Group for Sarcopenia Consensus and used receiver operating characteristic area under the curve (AUC) to compare differences between metrics. Associations between CT metrics and mortality were reported as relative risk after adjustments.
RESULTS: We evaluated 385 patients (median age, 69.0 years; 60.8\% men) and found consistent trends in cancer (49.6\%) and noncancer (50.4\%) cohorts. SMG had a stronger correlation with muscle mass than SMD [mean rho: 0.68 (range, 0.59‒0.73) vs 0.39 (range, 0.28‒0.48); all P {\textless} .01] in T12, L3, and PM regions and a stronger correlation with muscle function than SMI [mean rho: 0.60 (range, 0.50‒0.77) vs 0.36 (range, 0.22‒0.58); all P {\textless} .05] in T12, ESM, and L3 regions. SMG outperformed SMI in diagnostic accuracy in all regions, particularly for L3 (AUC: 0.87‒0.88 vs 0.80‒0.82; both P {\textless} .05). PMG (PM gauge) and L3SMG did not differ, whereas EMG (ESM gauge) or T12SMG and L3SMG did (AUC: 0.80‒0.82 vs 0.87‒0.88; all P {\textless} .05). L3SMI, L3SMD, T12SMG, EMG, and PMG showed no association with 1-year cancer-related mortality after adjusting for confounders; however, L3SMG [relative risk = 0.92 (0.85‒0.99); P = .023) was.
CONCLUSIONS AND IMPLICATIONS: L3SMG covers all features of sarcopenia with more diagnostic value than other metrics, allowing a complete sarcopenia assessment with CT alone and not just in populations with cancer.},
	language = {eng},
	number = {2},
	journal = {Journal of the American Medical Directors Association},
	author = {Zhang, Yunyun and Zhang, Ting and Yin, Wenjing and Zhang, Lei and Xiang, Jie},
	month = feb,
	year = {2023},
	pmid = {36463968},
	keywords = {Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Sarcopenia, Retrospective Studies, Prospective Studies, Neoplasms, Cross-Sectional Studies, Tomography, Gastrointestinal Diseases, skeletal muscle gauge, SMG, CT imaging, AWGS2019, hospitalized elderly},
	pages = {220--227.e4},
}

@article{weinberg278a,
	title = {Beyond sarcopenia: {Characterization} and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population},
	volume = {24},
	issn = {1524-4741},
	shorttitle = {Beyond sarcopenia},
	doi = {10.1111/tbj.12952},
	abstract = {Skeletal muscle loss, commonly known as sarcopenia, is highly prevalent and prognostic of adverse outcomes in oncology. However, there is limited information on adults with early breast cancer and examination of other skeletal muscle indices, despite the potential prognostic importance. This study characterizes and examines age-related changes in body composition of adults with early breast cancer and describes the creation of a novel integrated muscle measure. Female patients diagnosed with stage I-III breast cancer with abdominal computerized tomography (CT) scans within 12 weeks from diagnosis were identified from local tumor registry (N = 241). Skeletal muscle index (muscle area per height [cm2 /m2 ]), skeletal muscle density, and subcutaneous and visceral adipose tissue areas, were determined from CT L3 lumbar segments. We calculated a novel integrated skeletal measure, skeletal muscle gauge, which combines skeletal muscle index and density (SMI × SMD). 241 patients were identified with available CT imaging. Median age 52 years and range of 23-87. Skeletal muscle index and density significantly decreased with age. Using literature based cut-points, older adults (≥65 years) had significantly higher proportions of sarcopenia (63 vs 28\%) and myosteatosis (90 vs 11\%) compared to younger adults ({\textless}50 years). Body mass index was positively correlated with skeletal muscle index and negatively correlated with muscle density. Skeletal muscle gauge correlated better with increasing age (ρ = 0.52) than with either skeletal muscle index (ρ = 0.20) or density (ρ = 0.46). Wide variations and age-related changes in body composition metrics were found using routinely obtained abdominal CT imaging. Skeletal muscle index and density provide independent, complementary information, and the product of the two metrics, skeletal muscle gauge, requires further research to explore its impact on outcomes in women with curable breast cancer.},
	language = {eng},
	number = {3},
	journal = {The Breast Journal},
	author = {Weinberg, Marc S. and Shachar, Shlomit S. and Muss, Hyman B. and Deal, Allison M. and Popuri, Karteek and Yu, Hyeon and Nyrop, Kirsten A. and Alston, Shani M. and Williams, Grant R.},
	month = may,
	year = {2018},
	pmid = {29139618},
	pmcid = {PMC6414810},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Aged, Female, Middle Aged, Sarcopenia, Body Mass Index, Aged, 80 and over, Adult, sarcopenia, Breast Neoplasms, Aging, aging, skeletal muscle index, SMG, breast cancer, geriatric oncology},
	pages = {278--284},
	file = {Weinberg et al_2018_Beyond sarcopenia.pdf:/Users/jcsal/Zotero/storage/VB99WS7X/Weinberg et al_2018_Beyond sarcopenia.pdf:application/pdf},
}

@article{shachar3537,
	title = {Body {Composition} as a {Predictor} of {Toxicity} in {Patients} {Receiving} {Anthracycline} and {Taxane}-{Based} {Chemotherapy} for {Early}-{Stage} {Breast} {Cancer}},
	volume = {23},
	issn = {1557-3265},
	doi = {10.1158/1078-0432.CCR-16-2266},
	abstract = {Purpose: Poor body composition metrics (BCM) are associated with inferior cancer outcomes; however, in early breast cancer (EBC), there is a paucity of evidence regarding the impact of BCM on toxicities. This study investigates associations between BCM and treatment-related toxicity in patients with EBC receiving anthracyclines and taxane-based chemotherapy.Experimental Design: Pretreatment computerized tomographic (CT) images were evaluated for skeletal muscle area (SMA), skeletal muscle density (SMD), and fat tissue at the third lumbar vertebrae. Skeletal muscle index (SMI = SMA/height2) and skeletal muscle gauge (SMG = SMI × SMD) were also calculated. Relative risks (RR) are reported for associations between body composition measures and toxicity outcomes, after adjustment for age and body surface area (BSA).Results: BCM were calculated for 151 patients with EBC (median age, 49 years; range, 23-75 years). Fifty patients (33\%) developed grade 3/4 toxicity, which was significantly higher in those with low SMI (RR, 1.29; P = 0.002), low SMG (RR, 1.09; P = 0.01), and low lean body mass (RR, 1.48; P = 0.002). Receiver operating characteristic analysis showed the SMG measure to be the best predictor of grade 3/4 toxicity. Dividing SMG into tertiles showed toxicity rates of 46\% and 22\% for lowest versus highest tertile, respectively (P = 0.005). After adjusting for age and BSA, low SMG ({\textless}1,475 units) was significantly associated with hematologic (RR, 2.12; P = 0.02), gastrointestinal grade 3/4 toxicities (RR, 6.49; P = 0.02), and hospitalizations (RR, 1.91; P = 0.05).Conclusions: Poor BCMs are significantly associated with increased treatment-related toxicities. Further studies are needed to investigate how these metrics can be used to more precisely dose chemotherapy to reduce treatment-related toxicity while maintaining efficacy. Clin Cancer Res; 23(14); 3537-43. ©2017 AACR.},
	language = {eng},
	number = {14},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Shachar, Shlomit Strulov and Deal, Allison M. and Weinberg, Marc and Williams, Grant R. and Nyrop, Kirsten A. and Popuri, Karteek and Choi, Seul Ki and Muss, Hyman B.},
	month = jul,
	year = {2017},
	pmid = {28143874},
	pmcid = {PMC5511549},
	keywords = {Body Composition, Humans, Aged, Female, Middle Aged, Body Mass Index, Neoplasm Staging, Prognosis, Adult, Taxoids, Breast Neoplasms, SMG, Anthracyclines, Bridged-Ring Compounds},
	pages = {3537--3543},
	file = {Shachar et al_2017_Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline.pdf:/Users/jcsal/Zotero/storage/64MNZS2J/Shachar et al_2017_Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline.pdf:application/pdf},
}

@article{ahn101398,
	title = {Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: {A} new paradigm beyond sarcopenia},
	volume = {70},
	issn = {1872-9649},
	shorttitle = {Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis},
	doi = {10.1016/j.arr.2021.101398},
	abstract = {Myosteatosis, which is excessive fat infiltration in the skeletal muscle, is now considered a distinct disease from sarcopenia. Advances in imaging technique have made muscle parameters an evaluable biomarker, and many studies have proved association between myosteatosis and aging or disease process. However, the diagnosis and clinical impact of myosteatosis have not been well established. Thus, we aim to provide a systematic summary with a qualitive review of 73 eligible studies regarding these issues. First, the most widely used modality to diagnose myosteatosis is abdominal computed tomography, based on evaluation of the muscle radiodensity of the total abdominal muscle area predominantly at the L3 vertebral level. However, there was significant heterogeneity in the diagnostic methods and cutoff values used to diagnose myosteatosis (32 different cutoff values among 73 studies). Second, the clinical impact of myosteatosis on prognosis was very straightforward, and most studies have shown a negative impact of myosteatosis on overall survival and complications related to underlying diseases. However, the mechanism of the myosteatosis on mortality has not been explored well, and metabolic dysfunction (i.e. insulin resistance, systemic inflammation) would be a possible explanation. Providing systemic review of current issues can elucidate future directions for developing standardized diagnosis and management of myosteatosis.},
	language = {eng},
	journal = {Ageing Research Reviews},
	author = {Ahn, Hyemin and Kim, Dong Wook and Ko, Yousun and Ha, Jiyeon and Shin, Young Bin and Lee, Jiwoo and Sung, Yu Sub and Kim, Kyung Won},
	month = sep,
	year = {2021},
	pmid = {34214642},
	keywords = {Body Composition, Humans, Muscle, Skeletal, Tomography, X-Ray Computed, Sarcopenia, Prognosis, Myosteatosis, Muscle, Cross-sectional imaging, Standardization},
	pages = {101398},
}

@article{chimukangara2509,
	title = {A 5-item frailty index based on {NSQIP} data correlates with outcomes following paraesophageal hernia repair},
	volume = {31},
	issn = {1432-2218},
	doi = {10.1007/s00464-016-5253-7},
	abstract = {BACKGROUND: Frailty is a measure of physiologic reserve associated with increased vulnerability to adverse outcomes following surgery in older adults. The 'accumulating deficits' model of frailty has been applied to the NSQIP database, and an 11-item modified frailty index (mFI) has been validated. We developed a condensed 5-item frailty index and used this to assess the relationship between frailty and outcomes in patients undergoing paraesophageal hernia (PEH) repair.
METHODS: The NSQIP database was queried for ICD-9 and CPT codes associated with PEH repair. Subjects ≥60 years who underwent PEH repair between 2011 and 2013 were included. Five of the 11 mFI items present in the NSQIP data on the most consistent basis were selected for the condensed index. Univariate and multivariate logistic regressions were used to determine the validity of the 5-item mFI as a predictor of postoperative mortality, complications, readmission, and non-routine discharge.
RESULTS: A total of 3711 patients had data for all variables in the 5-item index, while 885 patients had complete data to calculate the 11-item mFI. After controlling for competing risk factors, including age, ASA score, wound classification, surgical approach, and procedure timing (emergent vs non-emergent), we found the 5-item mFI remained predictive of 30-day mortality and patients being discharged to a location other than home (p {\textless} 0.05). A weighted Kappa was calculated to assess agreement between the 5-item and 11-item mFI and was found to be 0.8709 (p {\textless} 0.001).
CONCLUSIONS: Frailty, as assessed by the 5-item mFI, is a reasonable alternative to the 11-item mFI in patients undergoing PEH repair. Utilization of the 5-item mFI allows for a significantly increased sample size compared to the 11-item mFI. Further study is necessary to determine whether the condensed 5-item mFI is a valid measure to assess frailty for other types of surgery.},
	language = {eng},
	number = {6},
	journal = {Surgical Endoscopy},
	author = {Chimukangara, Munyaradzi and Helm, Melissa C. and Frelich, Matthew J. and Bosler, Matthew E. and Rein, Lisa E. and Szabo, Aniko and Gould, Jon C.},
	month = jun,
	year = {2017},
	pmid = {27699515},
	pmcid = {PMC5378684},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Risk Factors, Aged, 80 and over, Outcome Assessment, Health Care, Databases, Factual, Postoperative Complications, Logistic Models, Severity of Illness Index, Outcomes, Frailty, Geriatric Assessment, Patient Discharge, Frail Elderly, Geriatric, NSQIP, Hernia, Hiatal, Herniorrhaphy, International Classification of Diseases, Paraesophageal hernia},
	pages = {2509--2519},
	file = {Chimukangara et al_2017_A 5-item frailty index based on NSQIP data correlates with outcomes following.pdf:/Users/jcsal/Zotero/storage/73A5MIQ8/Chimukangara et al_2017_A 5-item frailty index based on NSQIP data correlates with outcomes following.pdf:application/pdf},
}

@article{markar250a,
	title = {Systematic review and pooled analysis assessing the association between elderly age and outcome following surgical resection of esophageal malignancy},
	volume = {26},
	issn = {1442-2050},
	doi = {10.1111/j.1442-2050.2012.01353.x},
	abstract = {The incidence of esophageal malignancy continues to increase worldwide. At the same time, average life expectancy levels continue to climb, ensuring that more patients will present in their 70s, 80s, and 90s. The aim of this pooled analysis is to compare short- and long-term outcomes for elderly and younger patients undergoing esophagectomy for malignancy. Studies comparing the outcomes of esophagectomy for malignancy in elderly and young cohorts of patients were included. The minimum threshold age used to define the elderly cohort was 70 years. Primary outcomes were in-hospital mortality, overall and cancer-related 5-year survival. Secondary outcomes were the length of hospital stay, the incidence of anastomotic leak, conduit ischemia, cardiac and pulmonary complications, and the use of neoadjuvant therapy. Twenty-five publications comprising 9531 and 2573 operations on younger and elderly cohorts of patients respectively were analyzed. Elderly patients were less likely to receive neoadjuvant therapy (14.6\% vs. 29.47\%; pooled odds ratio [POR]= 0.48; 95\% confidence interval [C.I.]= 0.35-0.65; P {\textless} 0.05). Esophagectomy in elderly patients was associated with increased in-hospital mortality (7.83\% vs. 4.21\%; POR = 1.87; 95\% C.I. = 1.54-2.26; P {\textless} 0.05), as well as increased pulmonary (21.77\% vs. 19.49\%) and cardiac (18.7\% vs. 13.17\%) complications. Subset analysis of studies using an age threshold of 80 years showed an even more significant association between in-hospital mortality and elderly age (pooled odds ratio = 3.19; 95\% C.I. = 1.6-6.35; P {\textless} 0.05). There were no significant differences between the groups in length of hospital stay, incidence of anastomotic leak, or conduit ischemia. The elderly group showed reduced overall 5-year survival (21.23\% vs. 29.01\%; pooled odds ratio = 0.73; 95\% C.I. = 0.62-0.87; P {\textless} 0.05) and reduced cancer-free 5-year survival (34.4\% vs. 41.8\%; POR = 0.75; 95\% C.I. = 0.64-0.89; P {\textless} 0.05). Elderly patients are at increased risk of pulmonary and cardiac complications, and perioperative mortality following esophagectomy, and show reduced cancer-related 5-year survival compared with younger patients. These patients represent a high-risk cohort, who requires thorough assessment of medical comorbidity, targeted counseling, and optimized treatment pathways.},
	language = {eng},
	number = {3},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Markar, S. R. and Karthikesalingam, A. and Thrumurthy, S. and Ho, A. and Muallem, G. and Low, D. E.},
	month = apr,
	year = {2013},
	pmid = {22591068},
	keywords = {Humans, Aged, Length of Stay, Treatment Outcome, Survival Rate, Aged, 80 and over, Age Factors, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Hospital Mortality, Age},
	pages = {250--262},
	file = {Markar et al_2013_Systematic review and pooled analysis assessing the association between elderly.pdf:/Users/jcsal/Zotero/storage/936LFJ3P/Markar et al_2013_Systematic review and pooled analysis assessing the association between elderly.pdf:application/pdf},
}

@article{hodari1240a,
	title = {Assessment of morbidity and mortality after esophagectomy using a modified frailty index},
	volume = {96},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2013.05.051},
	abstract = {BACKGROUND: Esophagectomy is associated with significant morbidity and mortality. This retrospective study examined use of a modified frailty index as a potential predictor of morbidity and mortality in esophagectomy patients.
METHODS: National Surgical Quality Improvement Program Participant Use Files were reviewed for 2005 through 2010. Patients undergoing esophagectomy were selected based on CPT codes. A modified frailty index with 11 variables was used to determine correlation between frailty and postesophagectomy morbidity and mortality. Data were analyzed using χ(2) test and logistic regression.
RESULTS: A total of 2,095 patients were included in the analysis. Higher frailty scores were associated with a statistically significant increase in morbidity and mortality. A frailty score of 0, 1, 2, 3, 4, and 5 had associated morbidity rates of 17.9\% (142 of 795 patients), 25.1\% (178 of 710 patients), 31.4\% (126 of 401 patients), 34.4\% (48 of 140 patients), 44.4\% (16 of 36 patients), and 61.5\% (8 of 13 patients), respectively. A frailty score of 0, 1, 2, 3, 4, and 5 had associated mortality rates of 1.8\% (14 of 795 patients), 3.8\% (27 of 710 patients), 4\% (16 of 401 patients), 7.1\% (10 of 140 patients), 8.3\% (3 of 36 patients), and 23.1\% (3 of 13 patients), respectively. When using multivariate logistic regression for mortality comparing age, functional status, prealbumin, emergency surgery, wound class, American Society of Anesthesiologists score, and sex, only age and frailty were statistically significant. The odds ratio was 31.84 for frailty (p = 0.015) and 1.05 (p = 0.001) for age.
CONCLUSIONS: Using a large national database, a modified frailty index was shown to correlate with postesophagectomy morbidity and mortality. Such an index may be used to aid in improving risk assessment and patient selection for esophagectomy.},
	language = {eng},
	number = {4},
	journal = {The Annals of Thoracic Surgery},
	author = {Hodari, Arielle and Hammoud, Zane T. and Borgi, Jamil F. and Tsiouris, Athanasios and Rubinfeld, Ilan S.},
	month = oct,
	year = {2013},
	pmid = {23915593},
	keywords = {Humans, Aged, Retrospective Studies, Risk Factors, Esophagectomy, Severity of Illness Index, 7, Frail Elderly},
	pages = {1240--1245},
	file = {Hodari et al_2013_Assessment of morbidity and mortality after esophagectomy using a modified.pdf:/Users/jcsal/Zotero/storage/USJ7DYVZ/Hodari et al_2013_Assessment of morbidity and mortality after esophagectomy using a modified.pdf:application/pdf},
}

@article{park240a,
	title = {The impact of sarcopenia on esophagectomy for cancer: a systematic review and meta-analysis},
	volume = {23},
	issn = {1471-2482},
	shorttitle = {The impact of sarcopenia on esophagectomy for cancer},
	url = {https://doi.org/10.1186/s12893-023-02149-6},
	doi = {10.1186/s12893-023-02149-6},
	abstract = {Esophagectomy is the gold-standard treatment for locally advanced esophageal cancer but has high morbimortality rates. Sarcopenia is a common comorbidity in cancer patients. The exact burden of sarcopenia in esophagectomy outcomes remains unclear. Therefore, this systematic review and meta-analysis were performed to establish the impact of sarcopenia on postoperative outcomes of esophagectomy for cancer.},
	number = {1},
	urldate = {2024-02-16},
	journal = {BMC Surgery},
	author = {Park, Amanda and Orlandini, Marina Feliciano and Szor, Daniel José and Junior, Ulysses Ribeiro and Tustumi, Francisco},
	month = aug,
	year = {2023},
	keywords = {Sarcopenia, Meta-analysis, Esophagectomy, Esophageal neoplasms, Systematic review},
	pages = {240},
	file = {Park et al_2023_The impact of sarcopenia on esophagectomy for cancer.pdf:/Users/jcsal/Zotero/storage/YBSM7QK8/Park et al_2023_The impact of sarcopenia on esophagectomy for cancer.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/T4VA4KC4/s12893-023-02149-6.html:text/html},
}

@article{reisinger4445,
	title = {Loss of {Skeletal} {Muscle} {Mass} {During} {Neoadjuvant} {Chemoradiotherapy} {Predicts} {Postoperative} {Mortality} in {Esophageal} {Cancer} {Surgery}},
	volume = {22},
	issn = {1534-4681},
	doi = {10.1245/s10434-015-4558-4},
	abstract = {BACKGROUND: Esophageal surgery is associated with complications and mortality. It is highly important to develop tools predicting unfavorable postoperative outcome. Esophageal cancer and neoadjuvant chemoradiotherapy (CRT) induce skeletal muscle wasting, which leads to diminished physiologic reserves. The purpose of this study was to investigate whether the degree of muscle mass lost during neoadjuvant CRT predicts postoperative mortality.
METHODS: A total of 123 consecutive patients undergoing surgery for esophageal malignancy in the period 2008-2012 were included, of whom 114 received neoadjuvant CRT. Skeletal muscle mass was measured on routinely performed CT scans by assessing L3 muscle index (according to the Prado method) before and after neoadjuvant CRT, and the amount of muscle mass lost during neoadjuvant CRT (muscle loss index) was calculated. It was investigated whether this amount was associated with postoperative 30-day or in-hospital mortality and morbidity.
RESULTS: In the complete cohort, no significant association between loss of muscle mass and mortality was found. However, skeletal muscle mass was significantly lower in patients with stage III-IV tumors compared with stage I-II tumors, prior to neoadjuvant CRT. In the stage III-IV subgroup, the amount of muscle mass lost during neoadjuvant CRT was predictive of postoperative mortality: -13.5 \% (standard deviation 6.2 \%) in patients who died postoperatively compared with -5.0 \% (standard deviation 8.3 \%) in surviving patients, p = 0.02.
CONCLUSIONS: Measurement of muscle mass loss during neoadjuvant chemoradiotherapy may provide a readily available and inexpensive assessment to identify patients at risk for developing unfavorable postoperative outcome after resection of esophageal malignancies, especially in patients with stage III-IV tumors.},
	language = {eng},
	number = {13},
	journal = {Annals of Surgical Oncology},
	author = {Reisinger, Kostan W. and Bosmans, Joanna W. A. M. and Uittenbogaart, Martine and Alsoumali, Abdulaziz and Poeze, Martijn and Sosef, Meindert N. and Derikx, Joep P. M.},
	month = dec,
	year = {2015},
	pmid = {25893413},
	pmcid = {PMC4644199},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Neoadjuvant Therapy, Prevalence, Sarcopenia, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Survival Rate, Prognosis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Combined Modality Therapy, Netherlands, Postoperative Complications, Obesity, Abdominal, CRT},
	pages = {4445--4452},
	file = {Full Text:/Users/jcsal/Zotero/storage/EV6GX2HP/Reisinger et al. - 2015 - Loss of Skeletal Muscle Mass During Neoadjuvant Ch.pdf:application/pdf},
}

@article{liu6677,
	title = {Decreased {Skeletal} {Muscle} {Mass} {After} {Neoadjuvant} {Therapy} {Correlates} with {Poor} {Prognosis} in {Patients} with {Esophageal} {Cancer}},
	volume = {36},
	issn = {1791-7530},
	doi = {10.21873/anticanres.11278},
	abstract = {BACKGROUND: Loss of skeletal muscle is predictive of a poor prognosis in patients with various malignant lesions. Our aim was to determine whether changes in skeletal muscle after neo-adjuvant therapy (NAT) predict prognosis in patients with esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy.
PATIENTS AND METHODS: The cross-sectional areas of the psoas muscles were measured on computed tomographic images collected at the initial visit, preoperatively and postoperatively in 84 patients. The psoas muscle index (PMI) was calculated by normalizing the cross-sectional areas to the patients' heights.
RESULTS: Low PMI at the initial visit was not associated with a poor prognosis. The majority of patients showed decreased PMI after NAT and surgery. The group in which the post-NAT PMI decreased had poorer overall survival than group without PMI decrease (p=0.025).
CONCLUSION: Decreased PMI correlates well with a poor prognosis in patients with ESCC. Changes in PMI over a period of time may have greater sensitivity when evaluating prognosis than the PMI at any single time point.},
	language = {eng},
	number = {12},
	journal = {Anticancer Research},
	author = {Liu, Jiajia and Motoyama, Satoru and Sato, Yusuke and Wakita, Akiyuki and Kawakita, Yuta and Saito, Hajime and Minamiya, Yoshihiro},
	month = dec,
	year = {2016},
	pmid = {27920002},
	keywords = {Humans, Muscle, Skeletal, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Agents, Prognosis, Carcinoma, Squamous Cell, Esophageal Neoplasms, esophageal cancer, Skeletal muscle, prognosis, CRT, neo-adjuvant therapy},
	pages = {6677--6685},
	file = {Liu et al. - 2016 - Decreased Skeletal Muscle Mass After Neoadjuvant T.pdf:/Users/jcsal/Zotero/storage/GSDQQBSR/Liu et al. - 2016 - Decreased Skeletal Muscle Mass After Neoadjuvant T.pdf:application/pdf},
}

@article{chalabi1949,
	title = {Neoadjuvant {Immunotherapy} in {Locally} {Advanced} {Mismatch} {Repair}-{Deficient} {Colon} {Cancer}},
	volume = {390},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2400634},
	abstract = {BACKGROUND: Mismatch repair-deficient (dMMR) tumors can be found in 10 to 15\% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant immunotherapy has shown promising results, but data from studies of this approach are limited.
METHODS: We conducted a phase 2 study in which patients with nonmetastatic, locally advanced, previously untreated dMMR colon cancer were treated with neoadjuvant nivolumab plus ipilimumab. The two primary end points were safety, defined by timely surgery (i.e., ≤2-week delay of planned surgery owing to treatment-related toxic events), and 3-year disease-free survival. Secondary end points included pathological response and results of genomic analyses.
RESULTS: Of 115 enrolled patients, 113 (98\%; 97.5\% confidence interval [CI], 93 to 100) underwent timely surgery; 2 patients had surgery delayed by more than 2 weeks. Grade 3 or 4 immune-related adverse events occurred in 5 patients (4\%), and none of the patients discontinued treatment because of adverse events. Among the 111 patients included in the efficacy analysis, a pathological response was observed in 109 (98\%; 95\% CI, 94 to 100), including 105 (95\%) with a major pathological response (defined as ≤10\% residual viable tumor) and 75 (68\%) with a pathological complete response (0\% residual viable tumor). With a median follow-up of 26 months (range, 9 to 65), no patients have had recurrence of disease.
CONCLUSIONS: In patients with locally advanced dMMR colon cancer, neoadjuvant nivolumab plus ipilimumab had an acceptable safety profile and led to a pathological response in a high proportion of patients. (Funded by Bristol Myers Squibb; NICHE-2 ClinicalTrials.gov number, NCT03026140.).},
	language = {eng},
	number = {21},
	journal = {The New England Journal of Medicine},
	author = {Chalabi, Myriam and Verschoor, Yara L. and Tan, Pedro Batista and Balduzzi, Sara and Van Lent, Anja U. and Grootscholten, Cecile and Dokter, Simone and Büller, Nikè V. and Grotenhuis, Brechtje A. and Kuhlmann, Koert and Burger, Jacobus W. and Huibregtse, Inge L. and Aukema, Tjeerd S. and Hendriks, Eduard R. and Oosterling, Steven J. and Snaebjornsson, Petur and Voest, Emile E. and Wessels, Lodewyk F. and Beets-Tan, Regina G. and Van Leerdam, Monique E. and Schumacher, Ton N. and van den Berg, José G. and Beets, Geerard L. and Haanen, John B.},
	month = jun,
	year = {2024},
	pmid = {38838311},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Colonic Neoplasms, Young Adult, Disease-Free Survival, Netherlands, Antineoplastic Agents, Immunological, DNA Mismatch Repair, Time-to-Treatment, Ipilimumab, Nivolumab},
	pages = {1949--1958},
}

@article{beets1562,
	title = {A new paradigm for rectal cancer: {Organ} preservation: {Introducing} the {International} {Watch} \& {Wait} {Database} ({IWWD})},
	volume = {41},
	issn = {1532-2157},
	shorttitle = {A new paradigm for rectal cancer},
	doi = {10.1016/j.ejso.2015.09.008},
	language = {eng},
	number = {12},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Beets, G. L. and Figueiredo, N. L. and Habr-Gama, A. and van de Velde, C. J. H.},
	month = dec,
	year = {2015},
	pmid = {26493223},
	keywords = {Humans, Neoadjuvant Therapy, Colectomy, Rectal Neoplasms, Rectal, Rectal cancer, Colorectal Surgery, Decision making, EURECCA, Watch \& Wait},
	pages = {1562--1564},
}

@article{furlong107,
	title = {Targeting therapy for esophageal cancer in patients aged 70 and over},
	volume = {4},
	issn = {1879-4076},
	doi = {10.1016/j.jgo.2012.12.006},
	abstract = {BACKGROUND: While cancer is a disease of the elderly, these patients are under-represented in randomized trials. Esophageal cancer-management in the elderly is challenging because of the morbidity and mortality associated with surgery.
OBJECTIVES: We examined a strategy of neo-adjuvant chemo-radiotherapy (naCRT), followed by surgery or surveillance, in selected patients with cancer aged 70 and older.
METHODS: A prospectively-accrued database identified 56 consecutive patients over a 90-month period, who were aged 70years and over, presented with esophageal carcinoma and were treated with neo-adjuvant CRT (naCRT)±surgery.
RESULTS: Of 129 eligible patients, 66 (51\%) received palliative measures, while 63 (49\%) had curative intervention, namely 7 had surgery and 56 had naCRT±surgery. Of these 56 patients, 33 (59\%) had adenocarcinoma (AC) and 23 (41\%) had squamous cell carcinoma (SCC). Twenty-five (45\%) had a complete clinical response (cCR), of which 6 had immediate resection; 4 (67\%) had a complete pathological response (pCR); 19 patients with a cCR declined or were unfit for surgery and underwent surveillance; of these, 3 had interval esophagectomy; 16 were not offered or declined resection. Eight (50\%) have survived ≥3years. Mean overall survival was 28months for the entire cohort; 47months for cCRs; 61months for patients undergoing primary resection, 46months for cCRs who did not undergo resection and 29months for those undergoing interval resection for recurrent disease. In cCRs, surgery did not provide a survival advantage (p=0.861).
CONCLUSION: cCR yields an overall 3-year survival of 50\% without operation. As 45\% of patients have a cCR to naCRT, obligatory resection in high-risk cCR patients makes little sense. With the option for salvage esophagectomy in re-emergent disease, this selective strategy is an attractive alternative for elderly patients with cancer.},
	language = {eng},
	number = {2},
	journal = {Journal of Geriatric Oncology},
	author = {Furlong, Heidi and Bass, Gary and Breathnach, Oscar and O'Neill, Brian and Leen, Eamonn and Walsh, Thomas N.},
	month = apr,
	year = {2013},
	pmid = {24071535},
	keywords = {Humans, Aged, Female, Male, Neoadjuvant Therapy, Follow-Up Studies, Kaplan-Meier Estimate, Palliative Care, Cohort Studies, Aged, 80 and over, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Watchful Waiting, Lymphatic Metastasis},
	pages = {107--113},
}

@article{garcia-aguilar2546,
	title = {Organ {Preservation} in {Patients} {With} {Rectal} {Adenocarcinoma} {Treated} {With} {Total} {Neoadjuvant} {Therapy}},
	volume = {40},
	issn = {1527-7755},
	doi = {10.1200/JCO.22.00032},
	abstract = {PURPOSE: Prospective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated with total neoadjuvant therapy are limited.
METHODS: In this prospective, randomized phase II trial, we assessed the outcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total mesorectal excision (TME) or watch-and-wait on the basis of tumor response. Patients in both groups received 4 months of infusional fluorouracil-leucovorin-oxaliplatin or capecitabine-oxaliplatin and 5,000 to 5,600 cGy of radiation combined with either continuous infusion fluorouracil or capecitabine during radiotherapy. The trial was designed as two stand-alone studies with disease-free survival (DFS) as the primary end point for both groups, with a comparison to a null hypothesis on the basis of historical data. The secondary end point was TME-free survival.
RESULTS: Median follow-up was 3 years. Three-year DFS was 76\% (95\% CI, 69 to 84) for the INCT-CRT group and 76\% (95\% CI, 69 to 83) for the CRT-CNCT group, in line with the 3-year DFS rate (75\%) observed historically. Three-year TME-free survival was 41\% (95\% CI, 33 to 50) in the INCT-CRT group and 53\% (95\% CI, 45 to 62) in the CRT-CNCT group. No differences were found between groups in local recurrence-free survival, distant metastasis-free survival, or overall survival. Patients who underwent TME after restaging and patients who underwent TME after regrowth had similar DFS rates.
CONCLUSION: Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.},
	language = {eng},
	number = {23},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Garcia-Aguilar, Julio and Patil, Sujata and Gollub, Marc J. and Kim, Jin K. and Yuval, Jonathan B. and Thompson, Hannah M. and Verheij, Floris S. and Omer, Dana M. and Lee, Meghan and Dunne, Richard F. and Marcet, Jorge and Cataldo, Peter and Polite, Blase and Herzig, Daniel O. and Liska, David and Oommen, Samuel and Friel, Charles M. and Ternent, Charles and Coveler, Andrew L. and Hunt, Steven and Gregory, Anita and Varma, Madhulika G. and Bello, Brian L. and Carmichael, Joseph C. and Krauss, John and Gleisner, Ana and Paty, Philip B. and Weiser, Martin R. and Nash, Garrett M. and Pappou, Emmanouil and Guillem, José G. and Temple, Larissa and Wei, Iris H. and Widmar, Maria and Lin, Sabrina and Segal, Neil H. and Cercek, Andrea and Yaeger, Rona and Smith, J. Joshua and Goodman, Karyn A. and Wu, Abraham J. and Saltz, Leonard B.},
	month = aug,
	year = {2022},
	pmid = {35483010},
	pmcid = {PMC9362876},
	keywords = {Humans, Neoadjuvant Therapy, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Fluorouracil, Adenocarcinoma, Disease-Free Survival, Chemoradiotherapy, Capecitabine, Oxaliplatin, Rectal Neoplasms, Organ Preservation},
	pages = {2546--2556},
	file = {Garcia-Aguilar et al_2022_Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total.pdf:/Users/jcsal/Zotero/storage/3ESWJQP3/Garcia-Aguilar et al_2022_Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total.pdf:application/pdf},
}

@article{pipeke0237740,
	title = {The impact of properly diagnosed sarcopenia on postoperative outcomes after gastrointestinal surgery: {A} systematic review and meta-analysis},
	volume = {15},
	issn = {1932-6203},
	shorttitle = {The impact of properly diagnosed sarcopenia on postoperative outcomes after gastrointestinal surgery},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446889/},
	doi = {10.1371/journal.pone.0237740},
	abstract = {Background
Sarcopenia is defined as the loss of muscle mass combined with loss of muscle strength, with or without loss of muscle performance. The use of this parameter as a risk factor for complications after surgery is not currently used. This meta-analysis aims to assess the impact of sarcopenia defined by radiologically and clinically criteria and its relationship with complications after gastrointestinal surgeries.

Materials and methods
A review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO registration number: CRD42019132221). Articles were selected from the PUBMED and EMBASE databases that adequately assessed sarcopenia and its impact on postoperative complications in gastrointestinal surgery patients. Pooled estimates of pre-operative outcome data were calculated using the odds ratio (OR) and 95\% confidence interval (CI). Subgroup analysis were performed to assess each type of surgery.

Results
The search strategy returned 1323, with 11 studies meeting the inclusion criteria. A total of 4265 patients were analysed. The prevalence of sarcopenia between studies ranged from 6.8\% to 35.9\%. The meta-analysis showed an OR for complications after surgery of 3.01 (95\% CI 2.55–3.55) and an OR of 2.2 (95\% CI 1.44–3.36) for hospital readmission (30 days).

Conclusion
Sarcopenia, when properly diagnosed, is associated with an increase in late postoperative complications, as well as an increase in the number of postoperative hospital readmissions for various types of gastrointestinal surgery. We believe that any preoperative evaluation should include, in a patient at risk, tests for the diagnosis of sarcopenia and appropriate procedures to reduce its impact on the patient’s health.},
	number = {8},
	urldate = {2024-07-05},
	journal = {PLoS ONE},
	author = {Pipek, Leonardo Zumerkorn and Baptista, Carlos Guilherme and Nascimento, Rafaela Farias Vidigal and Taba, João Victor and Suzuki, Milena Oliveira and do Nascimento, Fernanda Sayuri and Martines, Diego Ramos and Nii, Fernanda and Iuamoto, Leandro Ryuchi and Carneiro-D’Albuquerque, Luiz Augusto and Meyer, Alberto and Andraus, Wellington},
	month = aug,
	year = {2020},
	pmid = {32822372},
	pmcid = {PMC7446889},
	pages = {e0237740},
	file = {Pipek et al_2020_The impact of properly diagnosed sarcopenia on postoperative outcomes after.pdf:/Users/jcsal/Zotero/storage/2PKE2LB5/Pipek et al_2020_The impact of properly diagnosed sarcopenia on postoperative outcomes after.pdf:application/pdf},
}

@article{kanda143,
	title = {Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis},
	volume = {19},
	issn = {1471-2482},
	doi = {10.1186/s12893-019-0617-2},
	abstract = {BACKGROUND: The global increase in elderly populations is accompanied by an increasing number of candidates for esophagectomy. Here we aimed to determine the postoperative outcomes after subtotal esophagectomy in elderly patients with esophageal cancer.
METHODS: Patients (n = 432) with who underwent curative-intent transthoracic subtotal esophagectomy with 2- or 3-field lymphadenectomies for thoracic esophageal cancer were classified as follows: non-elderly (age {\textless} 75 years, n = 373) and elderly (age ≥ 75 years, n = 59) and groups. To balance the essential variables including neoadjuvant treatment and stage of progression, we conducted propensity score analysis, and clinical characteristics, perioperative course and prognosis were compared.
RESULTS: After two-to-one propensity score matching, 100 and 50 patients were classified in the non-elderly and elderly groups. The elderly group had more comorbidities and lower preoperative cholinesterase activities and prognostic nutrition indexes. Although incidences of postoperative pneumonia, arrhythmia and delirium were slightly increased in the elderly group, no significant differences were observed in overall incidence of postoperative complications, rates of repeat surgery and death caused by surgery, and length of postoperative hospital stay between the two groups. There were no significant differences in disease-free and disease-specific survival as well as overall survival between the two groups.
CONCLUSION: Older age (≥75 years) had limited impact on morbidity, disease recurrence, and survival after subtotal esophagectomy. Therefore, age should not prevent older patients from benefitting from surgery.},
	language = {eng},
	number = {1},
	journal = {BMC surgery},
	author = {Kanda, Mitsuro and Koike, Masahiko and Tanaka, Chie and Kobayashi, Daisuke and Hayashi, Masamichi and Yamada, Suguru and Nakayama, Goro and Omae, Kenji and Kodera, Yasuhiro},
	month = oct,
	year = {2019},
	pmid = {31615499},
	pmcid = {PMC6792188},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Neoadjuvant Therapy, Prognosis, Aged, 80 and over, Adult, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Esophageal cancer, Postoperative Complications, Lymph Node Excision, Propensity Score, Feasibility Studies, Elderly, Safety, Subtotal esophagectomy},
	pages = {143},
	file = {Kanda et al_2019_Feasibility of subtotal esophagectomy with systematic lymphadenectomy in.pdf:/Users/jcsal/Zotero/storage/MYH3A4CN/Kanda et al_2019_Feasibility of subtotal esophagectomy with systematic lymphadenectomy in.pdf:application/pdf},
}

@article{paulus539,
	title = {Esophagectomy for cancer in octogenarians: should we do it?},
	volume = {402},
	issn = {1435-2451},
	shorttitle = {Esophagectomy for cancer in octogenarians},
	doi = {10.1007/s00423-017-1573-x},
	abstract = {PURPOSE: Inconsistent data exists regarding esophagectomy outcomes in octogenarians undergoing transhiatal esophagectomy for esophageal cancer.
METHODS: A retrospective review was performed for esophagectomy cancer patients between 2000 and 2012 at our tertiary referral center. Outcome data for octogenarians was compared to younger patients aged 20 to 79 years. A case-matched group of patients younger than 80 years old (n = 33) was included based on the Charlson comorbidity index with the octogenarian group (n = 33). Endpoints included operative morbidity and mortality as well as short- and long-term survival.
RESULTS: Thirty-three octogenarians met inclusion criteria. The median age was 82 years, and 79\% were male; 76\% had adenocarcinoma, 87\% had distal esophageal, and 52\% had poorly differentiated tumors. Stages 0 through III were observed in 6, 18, 27, and 48\% of octogenarians, respectively. Neoadjuvant therapy was administered to 70\% of patients, with 48\% experiencing downstaging. Transhiatal esophagectomy was performed in 82\% of patients, with R0 resection in 94\%. The mean hospital stay was 18 days, with morbidity and mortality rates 56 and 9\%, respectively, not significantly different from 13-day hospital stay, 45\% morbidity, and 9\% mortality in younger patients. Cardiac, pulmonary, and surgical site complications occurred in 24, 27, and 6\% of octogenarians, respectively. Anastomotic leak occurred in 18\% and reoperations in 3\%. The median, 3-year survival, and 5-year survival were 21 months, 55.9\%, and 37.1\%, respectively. Overall survival was worse for octogenarians (p {\textless} 0.001).
CONCLUSIONS: Postoperative mortality, morbidity, and length of stay in octogenarians are comparable to younger patients, while the overall survival is worse. With appropriate patient selection, good outcomes can be accomplished in octogenarians undergoing esophagectomy for cancer.},
	language = {eng},
	number = {3},
	journal = {Langenbeck's Archives of Surgery},
	author = {Paulus, Elizabeth and Ripat, Caroline and Koshenkov, Vadim and Prescott, Angela T. and Sethi, Kiran and Stuart, Heather and Tiesi, Gregory and Livingstone, Alan S. and Yakoub, Danny},
	month = may,
	year = {2017},
	pmid = {28303419},
	keywords = {Humans, Aged, Length of Stay, Male, Middle Aged, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Survival Rate, Aged, 80 and over, Adult, Age Factors, Young Adult, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Postoperative Complications, Carcinoma, Patient Selection, Surgery, Elderly, Octogenarian},
	pages = {539--545},
}

@article{zehetner666,
	title = {Esophagectomy for cancer in octogenarians},
	volume = {23},
	issn = {1442-2050},
	doi = {10.1111/j.1442-2050.2010.01081.x},
	abstract = {Because of changes in life expectancy, there is an increasing number of elderly patients with esophageal cancer. The aim of this study was to assess the outcome of esophagectomy for cancer in patients 80 years or older. A retrospective review was performed of the records of all patients who underwent esophagectomy for cancer from 1992 to 2007. A cardiac and pulmonary evaluation was obtained on an individual basis in the younger patients and in all octogenarians. Among 560 patients with esophagectomy for cancer, 47 patients (8\%) were octogenarians. The median age of the younger group (n= 513) was 63 years (interquartile range 56-71). Octogenarians had significantly more stage III disease (49\% vs 31\%, P= 0.02) but received less neoadjuvant therapy than younger patients (2\% vs 21\%, P= 0.0004). In octogenarians, the transhiatal resection was more common than in the younger group (79\% vs 36\%, P {\textless} 0.0001). Weight loss prior to surgery was similar in both groups, but body mass index was significantly lower in octogenarians (25 vs 28 kg/m(2) , P= 0.0002). Major complications occurred in 26\% in octogenarians and 31\% in the younger group (P= 0.51). Hospital mortality was similar (9\% for octogenarians vs 4\% in the younger group, P= 0.13). The median postoperative hospital stay was similar at 16 days (P= 0.69). There was no difference in cancer-related survival (median survival 48.9 vs 59.3 months, P= 0.31 log-rank test). Esophagectomy can be performed safely in carefully selected octogenarians with good cardiac and pulmonary function. Patients should not be denied an esophagectomy based only on their age.},
	language = {eng},
	number = {8},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Zehetner, J. and Lipham, J. C. and Ayazi, S. and Banki, F. and Oezcelik, A. and DeMeester, S. R. and Hagen, J. A. and DeMeester, T. R.},
	month = nov,
	year = {2010},
	pmid = {20545967},
	keywords = {Humans, Aged, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Body Mass Index, Neoplasm Staging, Retrospective Studies, Survival Rate, Aged, 80 and over, Age Factors, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Karnofsky Performance Status, Comparative Effectiveness Research, Heart Function Tests, Respiratory Function Tests},
	pages = {666--669},
	file = {Zehetner et al_2010_Esophagectomy for cancer in octogenarians.pdf:/Users/jcsal/Zotero/storage/4BPBYFI3/Zehetner et al_2010_Esophagectomy for cancer in octogenarians.pdf:application/pdf},
}

@article{markar1020,
	title = {Physiology, not chronology, dictates outcomes after esophagectomy for esophageal cancer: outcomes in patients 80 years and older},
	volume = {20},
	issn = {1534-4681},
	shorttitle = {Physiology, not chronology, dictates outcomes after esophagectomy for esophageal cancer},
	doi = {10.1245/s10434-012-2703-x},
	abstract = {PURPOSE: To assess short and long-term outcomes for patients aged ≥80 years undergoing esophagectomy for malignancy.
METHODS: All patients undergoing esophagectomy for cancer between 1991 and 2011 had information prospectively entered into a database; patients were divided into elderly (≥80 years) and younger ({\textless}80 years) groups.
RESULTS: Of the 500 patients included, 32 (6.4\%) were ≥80 years of age. Octogenarians had increased Charlson comorbidity index and were less likely to receive neoadjuvant chemoradiotherapy (6.3 vs. 39.7\%). Analysis of operative time, estimated blood loss, and length of intensive care unit and hospital stay revealed no significant differences between the groups. Patients ≥80 years old had increased total postoperative morbidity (68.8 vs. 44.9\%), specifically arrhythmia (31.3 vs. 16.7\%) and pneumonia (18.8 vs. 8.3\%). There were no in-hospital mortalities in patients ≥80 years (0 vs. 0.4\%), and there was no significant difference in overall survival between the groups (53.2 ± 9.1 vs. 77.6 ± 4.8 months; P = 0.58). Subset analysis demonstrated similar morbidity and length of hospital stay for patients between 70 and 79 years (n = 132) and those ≥80 years.
CONCLUSIONS: Elderly patients undergoing esophagectomy are at greater risk of postoperative complications. However, there were no significant differences in other major parameters, including length of hospital stay, mortality, and survival, indicating that selected patients ≥80 years old can and should be assessed by an experienced surgeon.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgical Oncology},
	author = {Markar, Sheraz R. and Low, Donald E.},
	month = mar,
	year = {2013},
	pmid = {23117475},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Risk Factors, Prospective Studies, Survival Rate, Prognosis, Aged, 80 and over, Age Factors, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Hospital Mortality, Morbidity},
	pages = {1020--1026},
}

@article{pipeke0237740a,
	title = {The impact of properly diagnosed sarcopenia on postoperative outcomes after gastrointestinal surgery: {A} systematic review and meta-analysis},
	volume = {15},
	issn = {1932-6203},
	shorttitle = {The impact of properly diagnosed sarcopenia on postoperative outcomes after gastrointestinal surgery},
	doi = {10.1371/journal.pone.0237740},
	abstract = {BACKGROUND: Sarcopenia is defined as the loss of muscle mass combined with loss of muscle strength, with or without loss of muscle performance. The use of this parameter as a risk factor for complications after surgery is not currently used. This meta-analysis aims to assess the impact of sarcopenia defined by radiologically and clinically criteria and its relationship with complications after gastrointestinal surgeries.
MATERIALS AND METHODS: A review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO registration number: CRD42019132221). Articles were selected from the PUBMED and EMBASE databases that adequately assessed sarcopenia and its impact on postoperative complications in gastrointestinal surgery patients. Pooled estimates of pre-operative outcome data were calculated using the odds ratio (OR) and 95\% confidence interval (CI). Subgroup analysis were performed to assess each type of surgery.
RESULTS: The search strategy returned 1323, with 11 studies meeting the inclusion criteria. A total of 4265 patients were analysed. The prevalence of sarcopenia between studies ranged from 6.8\% to 35.9\%. The meta-analysis showed an OR for complications after surgery of 3.01 (95\% CI 2.55-3.55) and an OR of 2.2 (95\% CI 1.44-3.36) for hospital readmission (30 days).
CONCLUSION: Sarcopenia, when properly diagnosed, is associated with an increase in late postoperative complications, as well as an increase in the number of postoperative hospital readmissions for various types of gastrointestinal surgery. We believe that any preoperative evaluation should include, in a patient at risk, tests for the diagnosis of sarcopenia and appropriate procedures to reduce its impact on the patient's health.},
	language = {eng},
	number = {8},
	journal = {PloS One},
	author = {Pipek, Leonardo Zumerkorn and Baptista, Carlos Guilherme and Nascimento, Rafaela Farias Vidigal and Taba, João Victor and Suzuki, Milena Oliveira and do Nascimento, Fernanda Sayuri and Martines, Diego Ramos and Nii, Fernanda and Iuamoto, Leandro Ryuchi and Carneiro-D'Albuquerque, Luiz Augusto and Meyer, Alberto and Andraus, Wellington},
	year = {2020},
	pmid = {32822372},
	pmcid = {PMC7446889},
	keywords = {Humans, Prevalence, Sarcopenia, Risk Factors, Postoperative Complications, Digestive System Surgical Procedures, Gastrointestinal Diseases, Postoperative Period},
	pages = {e0237740},
	file = {Pipek et al_2020_The impact of properly diagnosed sarcopenia on postoperative outcomes after.pdf:/Users/jcsal/Zotero/storage/BFMX2PFN/Pipek et al_2020_The impact of properly diagnosed sarcopenia on postoperative outcomes after.pdf:application/pdf},
}

@article{jogiate311,
	title = {Sarcopenia {Determined} by {Skeletal} {Muscle} {Index} {Predicts} {Overall} {Survival}, {Disease}-free {Survival}, and {Postoperative} {Complications} in {Resectable} {Esophageal} {Cancer}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {276},
	issn = {1528-1140},
	shorttitle = {Sarcopenia {Determined} by {Skeletal} {Muscle} {Index} {Predicts} {Overall} {Survival}, {Disease}-free {Survival}, and {Postoperative} {Complications} in {Resectable} {Esophageal} {Cancer}},
	doi = {10.1097/SLA.0000000000005452},
	abstract = {BACKGROUND: Sarcopenia has been identified as a prognostic factor among certain types of cancer. In esophageal cancer, patients are at increased risk of malnutrition and sarcopenia, ultimately contributing to poor outcomes. A systematic review was conducted to determine whether sarcopenia, defined by the skeletal muscle index, is predictive of overall survival, disease-free survival, and postoperative complications in resectable esophageal cancer.
MATERIALS AND METHODS: A systematic search of MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Library was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines up until January 2021. The primary outcome was overall survival; secondary outcomes included disease-free survival, pulmonary complications, and anastomotic leak.
RESULTS: Twenty-one studies (4 prospective; 17 retrospective; 3966 patients) were included. Sarcopenia was present in 1940 (48.1\%) patients and was associated with lower overall survival [hazard ratio (HR): 1.56; 95\% confidence interval (CI): 1.25-1.95; P {\textless}0.00001; I2 =71\%] and disease-free survival (HR: 1.73; 95\% CI: 1.04-2.87; P =0.03; I2 =51\%). A decrease in skeletal muscle index, independent of sarcopenia status, was associated with lower overall survival (HR: 1.81; 95\% CI: 1.20-2.73; P =0.005; I2 =92\%). Sarcopenia was associated with increased odds of pulmonary complications (odds ratio: 1.86; 95\% CI: 1.29-2.66; P =0.0008; I2 =41\%) and increased odds of anastomotic leak (odds ratio: 1.46; 95\% CI: 1.11-1.93; P =0.008; I2 =0\%).
CONCLUSIONS: Sarcopenia is a predictor of overall survival, disease-free survival, and postoperative complications in patients with resectable esophageal cancer. Studies on the modifiability of sarcopenia in the preoperative period will help determine the utility of nutritional interventions.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Jogiat, Uzair M. and Sasewich, Hannah and Turner, Simon R. and Baracos, Vickie and Eurich, Dean T. and Filafilo, Heather and Bédard, Eric L. R.},
	month = nov,
	year = {2022},
	pmid = {35794004},
	keywords = {Humans, Muscle, Skeletal, Sarcopenia, Retrospective Studies, Risk Factors, Prospective Studies, Prognosis, Disease-Free Survival, Esophageal Neoplasms, Postoperative Complications, Anastomotic Leak},
	pages = {e311--e318},
}

@article{jiange38244,
	title = {Associations between {CDH1} gene polymorphisms and the risk of gastric cancer: {A} meta-analysis based on 44 studies},
	volume = {103},
	issn = {1536-5964},
	shorttitle = {Associations between {CDH1} gene polymorphisms and the risk of gastric cancer},
	doi = {10.1097/MD.0000000000038244},
	abstract = {BACKGROUND: Numerous studies have investigated the association between CDH1 polymorphisms and gastric cancer (GC) risk. However, the results have been inconsistent and controversial. To further determine whether CDH1 polymorphisms increase the risk of GC, we conducted a meta-analysis by pooling the data.
METHODS: Relevant case-control studies were collected from PubMed, Embase, Web of Science and Cochrane databases up to January 7, 2024. Subsequently, odds ratios (ORs) with 95\% confidence intervals (CIs) were used to evaluate the strength of correlations. A sensitivity analysis was performed to evaluate the robustness and reliability of these included studies.
RESULTS: A total of 25 articles including 44 studies, were included in this meta-analysis, including 26 studies on rs16260, 6 studies on rs3743674, 7 studies on rs5030625, and 5 studies on rs1801552. The pooled results showed that rs16260 was remarkably associated with an increased GC risk of GC among Caucasians. Moreover, the rs5030625 variation dramatically enhanced GC predisposition in the Asian population. However, no evident correlations between CDH1 rs3743674 and rs1801552 polymorphisms and GC risk were observed.
CONCLUSIONS: Our findings suggested that CDH1 gene polymorphisms were significantly correlated with GC risk, especially in rs16260 and rs5030625 polymorphisms.},
	language = {eng},
	number = {23},
	journal = {Medicine},
	author = {Jiang, Qiqi and Geng, Peizhen and Zhang, Yuying and Yang, Maoquan and Zhu, Jiafeng and Zhang, Mingwei and Wang, Yamei and Feng, Yikuan and Sun, Xiaojuan},
	month = jun,
	year = {2024},
	pmid = {38847676},
	pmcid = {PMC11155553},
	keywords = {Humans, Risk Factors, Stomach Neoplasms, Case-Control Studies, White People, Antigens, CD, Asian People, Cadherins, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide},
	pages = {e38244},
	file = {Jiang et al_2024_Associations between CDH1 gene polymorphisms and the risk of gastric cancer.pdf:/Users/jcsal/Zotero/storage/77TVD7C5/Jiang et al_2024_Associations between CDH1 gene polymorphisms and the risk of gastric cancer.pdf:application/pdf},
}

@article{garcia-pelaez91,
	title = {Genotype-first approach to identify associations between {CDH1} germline variants and cancer phenotypes: a multicentre study by the {European} {Reference} {Network} on {Genetic} {Tumour} {Risk} {Syndromes}},
	volume = {24},
	issn = {1470-2045},
	shorttitle = {Genotype-first approach to identify associations between {CDH1} germline variants and cancer phenotypes},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810541/},
	doi = {10.1016/S1470-2045(22)00643-X},
	abstract = {Background
Truncating pathogenic or likely pathogenic variants of CDH1 cause hereditary diffuse gastric cancer (HDGC), a tumour risk syndrome that predisposes carrier individuals to diffuse gastric and lobular breast cancer. Rare CDH1 missense variants are often classified as variants of unknown significance. We conducted a genotype–phenotype analysis in families carrying rare CDH1 variants, comparing cancer spectrum in carriers of pathogenic or likely pathogenic variants (PV/LPV; analysed jointly) or missense variants of unknown significance, assessing the frequency of families with lobular breast cancer among PV/LPV carrier families, and testing the performance of lobular breast cancer-expanded criteria for CDH1 testing.

Methods
This genotype-first study used retrospective diagnostic and clinical data from 854 carriers of 398 rare CDH1 variants and 1021 relatives, irrespective of HDGC clinical criteria, from 29 institutions in ten member-countries of the European Reference Network on Tumour Risk Syndromes (ERN GENTURIS). Data were collected from Oct 1, 2018, to Sept 20, 2022. Variants were classified by molecular type and clinical actionability with the American College of Medical Genetics and Association for Molecular Pathology CDH1 guidelines (version 2). Families were categorised by whether they fulfilled the 2015 and 2020 HDGC clinical criteria. Genotype–phenotype associations were analysed by Student's t test, Kruskal-Wallis, χ2, and multivariable logistic regression models. Performance of HDGC clinical criteria sets were assessed with an equivalence test and Youden index, and the areas under the receiver operating characteristic curves were compared by Z test.

Findings
From 1971 phenotypes (contributed by 854 probands and 1021 relatives aged 1–93 years), 460 had gastric and breast cancer histology available. CDH1 truncating PV/LPVs occurred in 176 (21\%) of 854 families and missense variants of unknown significance in 169 (20\%) families. Multivariable logistic regression comparing phenotypes occurring in families carrying PV/LPVs or missense variants of unknown significance showed that lobular breast cancer had the greatest positive association with the presence of PV/LPVs (odds ratio 12·39 [95\% CI 2·66–57·74], p=0·0014), followed by diffuse gastric cancer (8·00 [2·18–29·39], p=0·0017) and gastric cancer (7·81 [2·03–29·96], p=0·0027). 136 (77\%) of 176 families carrying PV/LPVs fulfilled the 2015 HDGC criteria. Of the remaining 40 (23\%) families, who did not fulfil the 2015 criteria, 11 fulfilled the 2020 HDGC criteria, and 18 had lobular breast cancer only or lobular breast cancer and gastric cancer, but did not meet the 2020 criteria. No specific CDH1 variant was found to predispose individuals specifically to lobular breast cancer, although 12 (7\%) of 176 PV/LPV carrier families had lobular breast cancer only. Addition of three new lobular breast cancer-centred criteria improved testing sensitivity while retaining high specificity. The probability of finding CDH1 PV/LPVs in patients fulfilling the lobular breast cancer-expanded criteria, compared with the 2020 criteria, increased significantly (AUC 0·92 vs 0·88; Z score 3·54; p=0·0004).

Interpretation
CDH1 PV/LPVs were positively associated with HDGC-related phenotypes (lobular breast cancer, diffuse gastric cancer, and gastric cancer), and no evidence for a positive association with these phenotypes was found for CDH1 missense variants of unknown significance. CDH1 PV/LPVs occurred often in families with lobular breast cancer who did not fulfil the 2020 HDGC criteria, supporting the expansion of lobular breast cancer-centred criteria.

Funding
European Reference Network on Genetic Tumour Risk Syndromes, European Regional Development Fund, Fundação para a Ciência e a Tecnologia (Portugal), Cancer Research UK, and European Union's Horizon 2020 research and innovation programme.},
	number = {1},
	urldate = {2024-07-05},
	journal = {The Lancet. Oncology},
	author = {Garcia-Pelaez, José and Barbosa-Matos, Rita and Lobo, Silvana and Dias, Alexandre and Garrido, Luzia and Castedo, Sérgio and Sousa, Sónia and Pinheiro, Hugo and Sousa, Liliana and Monteiro, Rita and Maqueda, Joaquin J and Fernandes, Susana and Carneiro, Fátima and Pinto, Nádia and Lemos, Carolina and Pinto, Carla and Teixeira, Manuel R and Aretz, Stefan and Bajalica-Lagercrantz, Svetlana and Balmaña, Judith and Blatnik, Ana and Benusiglio, Patrick R and Blanluet, Maud and Bours, Vincent and Brems, Hilde and Brunet, Joan and Calistri, Daniele and Capellá, Gabriel and Carrera, Sergio and Colas, Chrystelle and Dahan, Karin and de Putter, Robin and Desseignés, Camille and Domínguez-Garrido, Elena and Egas, Conceição and Evans, D Gareth and Feret, Damien and Fewings, Eleanor and Fitzgerald, Rebecca C and Coulet, Florence and Garcia-Barcina, María and Genuardi, Maurizio and Golmard, Lisa and Hackmann, Karl and Hanson, Helen and Holinski-Feder, Elke and Hüneburg, Robert and Krajc, Mateja and Lagerstedt-Robinson, Kristina and Lázaro, Conxi and Ligtenberg, Marjolijn J L and Martínez-Bouzas, Cristina and Merino, Sonia and Michils, Geneviève and Novaković, Srdjan and Patiño-García, Ana and Ranzani, Guglielmina Nadia and Schröck, Evelin and Silva, Inês and Silveira, Catarina and Soto, José L and Spier, Isabel and Steinke-Lange, Verena and Tedaldi, Gianluca and Tejada, María-Isabel and Woodward, Emma R and Tischkowitz, Marc and Hoogerbrugge, Nicoline and Oliveira, Carla},
	month = jan,
	year = {2023},
	pmid = {36436516},
	pmcid = {PMC9810541},
	pages = {91--106},
	file = {Garcia-Pelaez et al_2023_Genotype-first approach to identify associations between CDH1 germline variants.pdf:/Users/jcsal/Zotero/storage/USXAIA22/Garcia-Pelaez et al_2023_Genotype-first approach to identify associations between CDH1 germline variants.pdf:application/pdf},
}

@article{ryan,
	title = {Germline {CDH1} {Variants} and {Lifetime} {Cancer} {Risk}},
	issn = {1538-3598},
	doi = {10.1001/jama.2024.10852},
	abstract = {IMPORTANCE: Approximately 1\% to 3\% of gastric cancers and 5\% of lobular breast cancers are hereditary. Loss of function CDH1 gene variants are the most common gene variants associated with hereditary diffuse gastric cancer and lobular breast cancer. Previously, the lifetime risk of gastric cancer was estimated to be approximately 25\% to 83\% and for breast cancer it was estimated to be approximately 39\% to 55\% in individuals with loss of function CDH1 gene variants.
OBJECTIVE: To describe gastric and breast cancer risk estimates for individuals with CDH1 variants.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, retrospective cohort and modeling study of 213 families from North America with a CDH1 pathogenic or likely pathogenic (P/LP) variant in 1 or more family members conducted between January 2021 and August 2022.
MAIN OUTCOMES AND MEASURES: Hazard ratios (HRs), defined as risk in variant carriers relative to noncarriers, were estimated for each cancer type and used to calculate cumulative risks and risks per decade of life up to age 80 years.
RESULTS: A total of 7323 individuals from 213 families were studied, including 883 with a CDH1 P/LP variant (median proband age, 53 years [IQR, 42-62]; 4\% Asian; 4\% Hispanic; 85\% non-Hispanic White; 50\% female). In individuals with a CDH1 P/LP variant, the prevalence of gastric cancer was 13.9\% (123/883) and the prevalence of breast cancer among female carriers was 26.3\% (144/547). The estimated HR for advanced gastric cancer was 33.5 (95\% CI, 9.8-112) at age 30 years and 3.5 (95\% CI, 0.4-30.3) at age 70 years. The lifetime cumulative risk of advanced gastric cancer in male and female carriers was 10.3\% (95\% CI, 6\%-23.6\%) and 6.5\% (95\% CI, 3.8\%-15.1\%), respectively. Gastric cancer risk estimates based on family history indicated that a carrier with 3 affected first-degree relatives had a penetrance of approximately 38\% (95\% CI, 25\%-64\%). The HR for breast cancer among female carriers was 5.7 (95\% CI, 2.5-13.2) at age 30 years and 3.9 (95\% CI, 1.1-13.7) at age 70 years. The lifetime cumulative risk of breast cancer among female carriers was 36.8\% (95\% CI, 25.7\%-62.9\%).
CONCLUSIONS AND RELEVANCE: Among families from North America with germline CDH1 P/LP variants, the cumulative risk of gastric cancer was 7\% to 10\%, which was lower than previously described, and the cumulative risk of breast cancer among female carriers was 37\%, which was similar to prior estimates. These findings inform current management of individuals with germline CDH1 variants.},
	language = {eng},
	journal = {JAMA},
	author = {Ryan, Carrie E. and Fasaye, Grace-Ann and Gallanis, Amber F. and Gamble, Lauren A. and McClelland, Paul H. and Duemler, Anna and Samaranayake, Sarah G. and Blakely, Andrew M. and Drogan, Christine M. and Kingham, Kerry and Patel, Devanshi and Rodgers-Fouche, Linda and Siegel, Ava and Kupfer, Sonia S. and Ford, James M. and Chung, Daniel C. and Dowty, James G. and Sampson, Joshua and Davis, Jeremy L.},
	month = jun,
	year = {2024},
	pmid = {38873722},
}

@article{vandieren1028,
	title = {Shifting perceptions on endoscopic surveillance and timing of prophylactic gastrectomy for hereditary diffuse gastric cancer},
	volume = {110},
	issn = {1365-2168},
	doi = {10.1093/bjs/znad192},
	language = {eng},
	number = {9},
	journal = {The British Journal of Surgery},
	author = {van Dieren, Jolanda M. and van der Post, Rachel S. and Bisseling, Tanya M.},
	month = aug,
	year = {2023},
	pmid = {37354063},
	keywords = {Humans, Stomach Neoplasms, Adenocarcinoma, Gastrectomy, Mutation, Neoplastic Syndromes, Hereditary, Germ-Line Mutation, Cadherins, Genetic Predisposition to Disease},
	pages = {1028--1029},
}

@article{hansford23,
	title = {Hereditary {Diffuse} {Gastric} {Cancer} {Syndrome}: {CDH1} {Mutations} and {Beyond}},
	volume = {1},
	issn = {2374-2445},
	shorttitle = {Hereditary {Diffuse} {Gastric} {Cancer} {Syndrome}},
	doi = {10.1001/jamaoncol.2014.168},
	abstract = {IMPORTANCE: E-cadherin (CDH1) is a cancer predisposition gene mutated in families meeting clinically defined hereditary diffuse gastric cancer (HDGC). Reliable estimates of cancer risk and spectrum in germline mutation carriers are essential for management. For families without CDH1 mutations, genetic-based risk stratification has not been possible, resulting in limited clinical options.
OBJECTIVES: To derive accurate estimates of gastric and breast cancer risks in CDH1 mutation carriers and determine if germline mutations in other genes are associated with HDGC.
DESIGN, SETTING, AND PARTICIPANTS: Testing for CDH1 germline mutations was performed on 183 index cases meeting clinical criteria for HDGC. Penetrance was derived from 75 mutation-positive families from within this and other cohorts, comprising 3858 probands (353 with gastric cancer and 89 with breast cancer). Germline DNA from 144 HDGC probands lacking CDH1 mutations was screened using multiplexed targeted sequencing for 55 cancer-associated genes.
MAIN OUTCOMES AND MEASURES: Accurate estimates of gastric and breast cancer risks in CDH1 mutation carriers and the relative contribution of other cancer predisposition genes in familial gastric cancers.
RESULTS: Thirty-one distinct pathogenic CDH1 mutations (14 novel) were identified in 34 of 183 index cases (19\%). By the age of 80 years, the cumulative incidence of gastric cancer was 70\% (95\% CI, 59\%-80\%) for males and 56\% (95\% CI, 44\%-69\%) for females, and the risk of breast cancer for females was 42\% (95\% CI, 23\%-68\%). In CDH1 mutation-negative index cases, candidate mutations were identified in 16 of 144 probands (11\%), including mutations within genes of high and moderate penetrance: CTNNA1, BRCA2, STK11, SDHB, PRSS1, ATM, MSR1, and PALB2.
CONCLUSIONS AND RELEVANCE: This is the largest reported series of CDH1 mutation carriers, providing more precise estimates of age-associated risks of gastric and breast cancer that will improve counseling of unaffected carriers. In HDGC families lacking CDH1 mutations, testing of CTNNA1 and other tumor suppressor genes should be considered. Clinically defined HDGC families can harbor mutations in genes (ie, BRCA2) with different clinical ramifications from CDH1. Therefore, we propose that HDGC syndrome may be best defined by mutations in CDH1 and closely related genes, rather than through clinical criteria that capture families with heterogeneous susceptibility profiles.},
	language = {eng},
	number = {1},
	journal = {JAMA oncology},
	author = {Hansford, Samantha and Kaurah, Pardeep and Li-Chang, Hector and Woo, Michelle and Senz, Janine and Pinheiro, Hugo and Schrader, Kasmintan A. and Schaeffer, David F. and Shumansky, Karey and Zogopoulos, George and Santos, Teresa Almeida and Claro, Isabel and Carvalho, Joana and Nielsen, Cydney and Padilla, Sarah and Lum, Amy and Talhouk, Aline and Baker-Lange, Katie and Richardson, Sue and Lewis, Ivy and Lindor, Noralane M. and Pennell, Erin and MacMillan, Andree and Fernandez, Bridget and Keller, Gisella and Lynch, Henry and Shah, Sohrab P. and Guilford, Parry and Gallinger, Steven and Corso, Giovanni and Roviello, Franco and Caldas, Carlos and Oliveira, Carla and Pharoah, Paul D. P. and Huntsman, David G.},
	month = apr,
	year = {2015},
	pmid = {26182300},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Risk Factors, Sex Factors, Risk Assessment, Aged, 80 and over, Adult, Predictive Value of Tests, Age Factors, Canada, Young Adult, Stomach Neoplasms, Incidence, Sex Distribution, Europe, Phenotype, Biomarkers, Tumor, Age Distribution, Breast Neoplasms, Germ-Line Mutation, Antigens, CD, Cadherins, Genetic Predisposition to Disease, DNA Mutational Analysis, Heredity, Pedigree, Penetrance},
	pages = {23--32},
	file = {Hansford et al_2015_Hereditary Diffuse Gastric Cancer Syndrome.pdf:/Users/jcsal/Zotero/storage/4CBQXA2X/Hansford et al_2015_Hereditary Diffuse Gastric Cancer Syndrome.pdf:application/pdf},
}

@article{roberts1325,
	title = {Comparison of {CDH1} {Penetrance} {Estimates} in {Clinically} {Ascertained} {Families} vs {Families} {Ascertained} for {Multiple} {Gastric} {Cancers}},
	volume = {5},
	issn = {2374-2445},
	doi = {10.1001/jamaoncol.2019.1208},
	abstract = {IMPORTANCE: CDH1 pathogenic variants have been estimated to confer a 40\% to 70\% and 56\% to 83\% lifetime risk for gastric cancer in men and women, respectively. These are likely to be overestimates owing to ascertainment of families with multiple cases of gastric cancer. To our knowledge, there are no penetrance estimates for CDH1 without this ascertainment bias.
OBJECTIVE: To estimate CDH1 penetrance in a patient cohort not exclusively ascertained based on strict hereditary diffuse gastric cancer (HDGC) criteria.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of 75 families found to have pathogenic variants in CDH1 through clinical ascertainment and multigene panel testing at a large commercial diagnostic laboratory from August 5, 2013, to June 30, 2018. CDH1 pathogenic variants were identified in 238 individuals from 75 families. Pedigrees from those families included cancer status for 1679 relatives. Penetrance estimates are based on 41 families for which completed pedigrees were available.
MAIN OUTCOMES AND MEASURES: Gastric cancer standardized incidence ratio estimates relative to Surveillance, Epidemiology, and End Results (SEER) Program incidence for pathogenic CDH1 variants from families ascertained without regard to HDGC criteria.
RESULTS: Among the 238 individuals with a CDH1 pathogenic variant, mean (SD) age was 49.3 (18.1) years and 63.4\% were female. Ethnicity was reported for 67 of 75 (89\%) families; of these 67 families, 51 (76\%) reported European ancestry, whereas Asian, African, Latino, and 2 or more ancestries were reported for 4 families (6\%) each. Standardized incidence ratios for gastric and breast cancer were significantly elevated above SEER incidence. Extrapolated cumulative incidence of gastric cancer at age 80 years was 42\% (95\% CI, 30\%-56\%) for men and 33\% (95\% CI, 21\%-43\%) for women with pathogenic variants in CDH1, whereas cumulative incidence of female breast cancer was estimated at 55\% (95\% CI, 39\%-68\%). International Gastric Cancer Linkage Consortium criteria were met in 25 of the 75 (33\%) families; however, dispensing with the requirement of confirmation of HDGC histologic subtype, 43 (57\%) would meet criteria.
CONCLUSIONS AND RELEVANCE: The cumulative incidence of gastric cancer for individuals with pathogenic variants in CDH1 is significantly lower than previously described. Because prophylactic gastrectomy can have bearing upon both physical and psychological health, further discussion is warranted to assess whether this surgical recommendation is appropriate for all individuals with pathogenic variants in CDH1.},
	language = {eng},
	number = {9},
	journal = {JAMA oncology},
	author = {Roberts, Maegan E. and Ranola, John Michael O. and Marshall, Megan L. and Susswein, Lisa R. and Graceffo, Sara and Bohnert, Kelsey and Tsai, Ginger and Klein, Rachel T. and Hruska, Kathleen S. and Shirts, Brian H.},
	month = sep,
	year = {2019},
	pmid = {31246251},
	pmcid = {PMC6604087},
	pages = {1325--1331},
	file = {Roberts et al_2019_Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs.pdf:/Users/jcsal/Zotero/storage/ZMW4ZKDH/Roberts et al_2019_Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs.pdf:application/pdf},
}

@article{xicola838,
	title = {Clinical features and cancer risk in families with pathogenic {CDH1} variants irrespective of clinical criteria},
	volume = {56},
	issn = {1468-6244},
	doi = {10.1136/jmedgenet-2019-105991},
	abstract = {BACKGROUND: The clinical phenotype of CDH1 pathogenic variant carriers has mostly been studied in families that fulfil criteria of hereditary diffuse gastric cancer (HDGC). We aimed at determining cancer phenotype and cancer risk estimation among families with CDH1 pathogenic variants not selected by HDGC clinical criteria.
METHODS: Patients were all consecutively identified CDH1 pathogenic variant carriers from a clinical laboratory tested with multigene panel testing and from an academic cancer genetics programme. Clinical and demographic features, cancer phenotypes and genotype-phenotype correlations were determined among CDH1 families. Age-specific cumulative cancer risks (penetrance) were calculated based on 38 families with available pedigrees.
RESULTS: Within the 113 CDH1 pathogenic variant probands and 476 relatives, 113 had gastric cancer, 177 breast cancer and 196 other cancers. Mean age at diagnosis was 47 for gastric and 54 for breast cancer. Forty-six per cent fulfilled criteria of HDGC. While 36\% of families had both gastric and breast cancers, 36\% had breast but no gastric cancers and 16\% had gastric but not breast cancers. Cumulative risk of cancer by age 80 was 37.2\% for gastric and 42.9\% for breast cancer.
CONCLUSION: In unselected CDH1 pathogenic variant carrier families, gastric cancer risks were lower and age at diagnosis higher than previously reported in families pre-selected for HDGC criteria. A substantial proportion of families did not present with any gastric cancers and their cancers were limited to breast. Thus, clinical criteria for CDH1 testing should be widened, including breast cancer families only, and a consideration for delayed prophylactic gastrectomy/surveillance should be evaluated.},
	language = {eng},
	number = {12},
	journal = {Journal of Medical Genetics},
	author = {Xicola, Rosa M. and Li, Shuwei and Rodriguez, Nicolette and Reinecke, Patrick and Karam, Rachid and Speare, Virginia and Black, Mary Helen and LaDuca, Holly and Llor, Xavier},
	month = dec,
	year = {2019},
	pmid = {31296550},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Risk Factors, Aged, 80 and over, Adult, Stomach Neoplasms, Breast Neoplasms, Germ-Line Mutation, Antigens, CD, Cadherins, Genetic Predisposition to Disease, Pedigree, Penetrance, cdh1cancer phenotypes, cdh1cumulative cancer risk, cdh1pathogenic variants, Genetic Variation, hereditary diffuse gastric cancer (hdgc)},
	pages = {838--843},
	file = {Xicola et al_2019_Clinical features and cancer risk in families with pathogenic CDH1 variants.pdf:/Users/jcsal/Zotero/storage/BL7NR3HY/Xicola et al_2019_Clinical features and cancer risk in families with pathogenic CDH1 variants.pdf:application/pdf},
}

@article{rotellini-coltvet1901,
	title = {Percutaneous {Transesophageal} {Gastrostomy}: {Procedural} {Technique} and {Outcomes}},
	volume = {34},
	issn = {1535-7732},
	shorttitle = {Percutaneous {Transesophageal} {Gastrostomy}},
	doi = {10.1016/j.jvir.2023.06.040},
	abstract = {PURPOSE: To demonstrate the safety and effectiveness of percutaneous transesophageal gastrostomy (PTEG) as a palliative option in patients with malignant bowel obstructions (MBOs), and provide a comprehensive review of PTEG indications, placement technique, and short- and long-term outcomes.
MATERIALS AND METHODS: Thirty-eight consecutive patients who underwent a PTEG procedure attempt from 2014 to 2022 were included in this analysis. Clinical indications, method of placement, technical and clinical success, adverse events, including procedure-related mortality, and effectiveness were assessed. Technical success was defined as placement of a PTEG. Clinical success was defined as improvement in clinical symptoms following PTEG placement.
RESULTS: Of the 38 patients who underwent PTEG, 19 (50\%) were men and 19 (50\%) were women (median age, 58 years; range, 21-75 years). Three (8\%) PTEG placements were performed with the patients under moderate sedation, whereas the remainder (92\%) were performed with the patients under general anesthesia. Technical success was achieved in 35 of the 38 (92\%) patients. The mean catheter duration was 61 days (median, 29 days; range, 1-562 days), with 5 of the 35 patients requiring tube exchanges after initial placement. Moreover, 7 of the 35 patients with successful PTEG placement experienced an adverse event, including 1 case of non-procedure-related mortality. All patients with successful PTEG placement experienced improvement in clinical symptoms.
CONCLUSIONS: PTEG is an effective and safe option for patients with contraindications to traditional percutaneous gastrostomy tube placement in the setting of MBO. PTEG is an effective means of providing palliation and improving the quality of life.},
	language = {eng},
	number = {11},
	journal = {Journal of vascular and interventional radiology: JVIR},
	author = {Rotellini-Coltvet, Lisa and Wallace, Alex and Saini, Gia and Naidu, Sailendra and Kriegshauser, Jefferey Scott and Patel, Indravadan and Knuttinen, Grace and Alzubaidi, Sadeer and Oklu, Rahmi},
	month = nov,
	year = {2023},
	pmid = {37419279},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Adult, Young Adult, Enteral Nutrition, Quality of Life, Intubation, Gastrointestinal, Gastrostomy, Catheters, Percutaneous transesophageal gastrostomy tube},
	pages = {1901--1907},
	file = {Rotellini-Coltvet et al. - 2023 - Percutaneous Transesophageal Gastrostomy Procedur.pdf:/Users/jcsal/Zotero/storage/Z5XR3LVZ/Rotellini-Coltvet et al. - 2023 - Percutaneous Transesophageal Gastrostomy Procedur.pdf:application/pdf},
}

@article{udomsawaengsup2314,
	title = {Percutaneous transesophageal gastrostomy ({PTEG}): a safe and effective technique for gastrointestinal decompression in malignant obstruction and massive ascites},
	volume = {22},
	issn = {1432-2218},
	shorttitle = {Percutaneous transesophageal gastrostomy ({PTEG})},
	doi = {10.1007/s00464-008-9984-y},
	abstract = {BACKGROUND: Enteral feeding and gastric decompression devices are common in critical, terminal, and chronically ill patients. Percutaneous transesophageal gastrostomy (PTEG) is a nonsurgical technique that creates an esophagostomy and allows enteral access in patients with a hostile abdomen, altered gastric anatomy, massive ascites, and carcinomatosis. We review our indications, technical experience, complications, and short- and long-term quality of life (QOL) in patients that underwent the PTEG procedure.
METHODS: Patients were terminally ill from advanced cancer requiring gastrointestinal decompression or had hostile abdomens needing long-term feeding access. The procedure is carried out by inserting a rupture-free balloon (RFB) into the cervical esophagus and utilizing transcutaneous ultrasound to puncture the balloon. A guide wire is passed through the needle into the balloon, followed by a dilator and sheath. The in-dwelling catheter is inserted through the sheath, which exits the esophagus, and resides in the stomach. Proper placement is confirmed by fluoroscopy.
RESULTS: From December 2003 to January 2006, 17 patients were treated with PTEG. Except for two patients, all of the patients had advanced metastatic cancer. Presenting symptoms were nausea, vomiting, and dysphagia. Average age was 62.8 years, with nine men. Placement was successful in 16 patients (94\%). There were no major complications and three minor complications (17.6\%). Minor complications included two esophageal leaks at the catheter site and one catheter dislodgement. Seven patients (41.2\%) died within 1 month after the procedure from their preexisting medical conditions. All patients were capable of being discharged from the hospital with adequate enteral access and gastrointestinal decompression.
CONCLUSIONS: PTEG is a safe and effective method of enteral feeding and decompression in patients that have contraindications to standard enteral access. Appropriate patient selection and timing of PTEG placement is crucial for optimum benefit.},
	language = {eng},
	number = {10},
	journal = {Surgical Endoscopy},
	author = {Udomsawaengsup, S. and Brethauer, S. and Kroh, M. and Chand, B.},
	month = oct,
	year = {2008},
	pmid = {18622539},
	keywords = {Humans, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Esophagus, Intestinal Obstruction, Gastrostomy, Decompression, Surgical, Ascites, Gastric Outlet Obstruction, Palliation, Percutaneous transesophageal gastrostomy tube},
	pages = {2314--2318},
	file = {Udomsawaengsup et al. - 2008 - Percutaneous transesophageal gastrostomy (PTEG) a.pdf:/Users/jcsal/Zotero/storage/67SBRXIT/Udomsawaengsup et al. - 2008 - Percutaneous transesophageal gastrostomy (PTEG) a.pdf:application/pdf},
}

@article{zhu262,
	title = {What to do {When} {Decompressive} {Gastrostomies} and {Jejunostomies} are not {Options}? {A} {Scoping} {Review} of {Transesophageal} {Gastrostomy} {Tubes} for {Advanced} {Malignancies}},
	volume = {29},
	issn = {1534-4681},
	shorttitle = {What to do {When} {Decompressive} {Gastrostomies} and {Jejunostomies} are not {Options}?},
	doi = {10.1245/s10434-021-10667-x},
	abstract = {BACKGROUND: In advanced malignant bowel obstruction, decompressive gastrostomy tubes (GTs) may not be feasible due to ascites, peritoneal carcinomatosis, and altered gastric anatomy. Whereas nasogastric tubes (NGTs) allow temporary decompression, percutaneous transesophageal gastrostomy tubes (PTEGs) are an alternative method for long-term palliative decompression. This study performed a scoping review to determine outcomes with PTEG in advanced malignancies.
METHODS: A systematic literature search was performed to include all studies that reported the clinical results of PTEGs for malignancy. No language, national, or publication status restrictions were used.
RESULTS: The analysis included 14 relevant studies with a total of 340 patients. In 11 studies, standard PTEGs were inserted with a rupture-free balloon's placement into the mouth or nose and esophageal puncture under fluoroscopy or ultrasound, followed by a guidewire into the stomach with placement of a single-lumen tube. Of 340 patients, 65 (19.1\%) had minor complications, and 5 (2.1\%) had significant complications, including bleeding and severe aspiration pneumonia. Of 171 patients, 169 with PTEGs (98.8\%) reported relief of nasal discomfort from NGT and alleviation of obstructive symptoms. The one randomized controlled trial reported a significantly higher quality of life with PTEGs than with NGTs.
CONCLUSIONS: When decompression for advanced malignancy is technically not feasible with a gastrostomy tube, the PTEG is a viable, safe option for palliation. The PTEG is associated with lower significant complication rates than the gastrostomy tube and significantly higher patient-derived outcomes than the NGT.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgical Oncology},
	author = {Zhu, Clara and Platoff, Rebecca and Ghobrial, Gaby and Saddemi, Jackson and Evangelisti, Taylor and Bucher, Emily and Saracco, Benjamin and Adams, Amanda and Kripalani, Simran and Atabek, Umur and Spitz, Francis R. and Hong, Young K.},
	month = jan,
	year = {2022},
	pmid = {34546480},
	keywords = {Humans, Randomized Controlled Trials as Topic, Peritoneal Neoplasms, Quality of Life, Intubation, Gastrointestinal, Jejunostomy, Gastrostomy, Abdominal malignancy, Malignant obstruction, Palliative surgery, Percutaneous transesophageal gastrostomy tube, PTEG},
	pages = {262--271},
	file = {Zhu et al_2022_What to do When Decompressive Gastrostomies and Jejunostomies are not Options.pdf:/Users/jcsal/Zotero/storage/IZZZNQ2U/Zhu et al_2022_What to do When Decompressive Gastrostomies and Jejunostomies are not Options.pdf:application/pdf},
}

@article{selby306,
	title = {Percutaneous {Transesophageal} {Gastrostomy} ({PTEG}): {A} {Safe} and {Well}-{Tolerated} {Procedure} for {Palliation} of {End}-{Stage} {Malignant} {Bowel} {Obstruction}},
	volume = {58},
	issn = {1873-6513},
	shorttitle = {Percutaneous {Transesophageal} {Gastrostomy} ({PTEG})},
	doi = {10.1016/j.jpainsymman.2019.04.031},
	abstract = {CONTEXT: Malignant bowel obstruction (MBO) is a frequent complication in patients with advanced cancer. Symptom management for patients with end-stage MBO can be challenging, especially when venting gastrostomy is contraindicated. Percutaneous transesophageal gastrostomy (PTEG) is an alternative option allowing safe and effective symptom management in palliative care patients.
OBJECTIVES: We describe our experience with an initial series of 10 patients with MBOs refractory to medical management who received PTEG for gastrointestinal decompression, with a focus on palliative outcomes and safety.
METHODS: We retrospectively reviewed the charts of 10 patients with advanced malignancy and associated gastrointestinal obstruction who received PTEG for symptom management between March 2018 and November 2018. We report on patient diagnosis, indications for PTEG, outcomes after insertion, and any associated morbidity and mortality.
RESULTS: PTEGs were successfully inserted in all 10 patients with contraindications to a venting gastrostomy. There were no acute postprocedural complications. Median time from PTEG insertion to death was 15 days. Symptoms of MBO improved in all 10 patients, and all were able to resume some degree of oral intake. Importantly, unlike with venting gastrostomies, all patients required suction to maintain resolution of MBO symptoms.
CONCLUSION: PTEG should be considered for gastrointestinal decompression in patients with MBO who are not candidates for surgical decompression or standard venting gastrostomy. This safe and effective procedure improves symptom management and quality of life for patients with MBO who are approaching end of life.},
	language = {eng},
	number = {2},
	journal = {Journal of Pain and Symptom Management},
	author = {Selby, Debbie and Nolen, Amy and Sittambalam, Cheromi and Johansen, Karen and Pugash, Robyn},
	month = aug,
	year = {2019},
	pmid = {31071424},
	keywords = {Humans, Female, Male, Middle Aged, Retrospective Studies, Palliative Care, Neoplasms, Adult, Intestinal Obstruction, Quality of Life, Gastrostomy, Percutaneous transesophageal gastrostomy tube, gastrointestinal decompression, Malignant bowel obstruction, percutaneous transesophageal gastrostomy},
	pages = {306--310},
	file = {Selby et al_2019_Percutaneous Transesophageal Gastrostomy (PTEG).pdf:/Users/jcsal/Zotero/storage/LWE26DZG/Selby et al_2019_Percutaneous Transesophageal Gastrostomy (PTEG).pdf:application/pdf},
}

@article{singal402,
	title = {Percutaneous transesophageal gastrostomy tube placement: an alternative to percutaneous endoscopic gastrostomy in patients with intra-abdominal metastasis},
	volume = {71},
	issn = {1097-6779},
	shorttitle = {Percutaneous transesophageal gastrostomy tube placement},
	doi = {10.1016/j.gie.2009.10.037},
	abstract = {BACKGROUND: PEG/jejunostomy (PEG/J) is often placed in patients with metastatic gastric cancer for palliating bowel obstruction or for feeding. However, PEG/J placement may not always be possible for many reasons.
OBJECTIVE: We wish to bring attention to the percutaneous transesophageal gastrostomy/jejunostomy (PTEG/J) as a viable alternative to nasogastric decompression in patients who are not candidates for PEG/J. PTEG/J is a largely unknown technique in the United States that designed to gain access to the stomach and proximal small bowel in these patients. We describe the use of PTEG/J in 3 patients with metastatic gastric cancer by using resources and techniques readily available in a well-stocked interventional radiology suite.
PATIENTS: In the first case, percutaneous transesophageal gastrostomy (PTEG) was placed for palliation of intractable nausea and vomiting in a 37-year-woman with diffuse gastric cancer and peritoneal carcinomatosis. In the second case, PTEG was extended into the jejunum for feeding a 60-year-old woman with metastatic gastric cancer. In the third case, PTEG extending into the jejunum was placed in a 69-year-old man for palliation of bowel obstruction caused by metastatic gastric cancer and peritoneal carcinomatosis.
METHODS: After adequate sedation is administered, a 22 x 4-mm balloon catheter is passed into the esophagus over a guidewire just below the thoracic inlet. The balloon is ruptured with a needle passed through the neck under US guidance. A guidewire is then passed through the needle into the balloon and carried into the stomach or proximal small bowel by advancing the balloon catheter. The track is then dilated over the guidewire and a pigtail 45-cm-long 14F nephrostomy tube then passed into the stomach or into the proximal small bowel over the guidewire. The catheter is secured by suturing to the skin of the neck.
RESULTS: PTEG/J was effective in achieving palliation or feeding in our patients. No complications occurred.
CONCLUSIONS: PTEG/J is a safe and effective alternative to standard percutaneous gastrostomy/jejunostomy tube placement for decompression of bowel obstruction or feeding in appropriately selected patients.},
	language = {eng},
	number = {2},
	journal = {Gastrointestinal Endoscopy},
	author = {Singal, Ashwani Kumar and Dekovich, Alexander A. and Tam, Alda L. and Wallace, Michael J.},
	month = feb,
	year = {2010},
	pmid = {20152318},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Risk Assessment, Adult, Neoplasm Invasiveness, Stomach Neoplasms, Peritoneal Neoplasms, Esophagus, Intestinal Obstruction, Enteral Nutrition, Quality of Life, Gastroscopy, Jejunostomy, Gastrostomy, Percutaneous transesophageal gastrostomy tube, Catheterization, Fluoroscopy, Sampling Studies, Ultrasonography, Doppler},
	pages = {402--406},
	file = {Singal et al_2010_Percutaneous transesophageal gastrostomy tube placement.pdf:/Users/jcsal/Zotero/storage/3HBK95UG/Singal et al_2010_Percutaneous transesophageal gastrostomy tube placement.pdf:application/pdf},
}

@article{taylor711,
	title = {Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage {I}, {II}, and {III} rectal cancer best managed by surgery alone: a prospective, multicenter, {European} study},
	volume = {253},
	issn = {1528-1140},
	shorttitle = {Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage {I}, {II}, and {III} rectal cancer best managed by surgery alone},
	doi = {10.1097/SLA.0b013e31820b8d52},
	abstract = {OBJECTIVE: To assess local recurrence, disease-free survival, and overall survival in magnetic resonance imaging (MRI)-predicted good prognosis tumors treated by surgery alone.
BACKGROUND: The MERCURY study reported that high-resolution MRI can accurately stage rectal cancer. The routine policy in most centers involved in the MERCURY study was primary surgery alone in MRI-predicted stage II or less and in MRI "good prognosis" stage III with selective avoidance of neoadjuvant therapy.
PATIENTS AND METHODS: Data were collected prospectively on all patients included in the MERCURY study who were staged as MRI-defined "good" prognosis tumors. "Good" prognosis included MRI-predicted safe circumferential resection margins, with MRI-predicted T2/T3a/T3b (less than 5 mm spread from muscularis propria), regardless of MRI N stage. None received preoperative or postoperative radiotherapy. Overall survival, disease-free survival, and local recurrence were calculated.
RESULTS: Of 374 patients followed up in the MERCURY study, 122 (33\%) were defined as "good prognosis" stage III or less on MRI. Overall and disease-free survival for all patients with MRI "good prognosis" stage I, II and III disease at 5 years was 68\% and 85\%, respectively. The local recurrence rate for this series of patients predicted to have a good prognosis tumor on MRI was 3\%.
CONCLUSIONS: The preoperative identification of good prognosis tumors using MRI will allow stratification of patients and better targeting of preoperative therapy. This study confirms the ability of MRI to select patients who are likely to have a good outcome with primary surgery alone.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Taylor, Fiona G. M. and Quirke, Philip and Heald, Richard J. and Moran, Brendan and Blomqvist, Lennart and Swift, Ian and Sebag-Montefiore, David J. and Tekkis, Paris and Brown, Gina and {MERCURY study group}},
	month = apr,
	year = {2011},
	pmid = {21475011},
	keywords = {Humans, Magnetic Resonance Imaging, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Kaplan-Meier Estimate, Neoplasm Staging, Proportional Hazards Models, Prospective Studies, Time Factors, Aged, 80 and over, Adult, Analysis of Variance, Colectomy, Neoplasm Invasiveness, Survival Analysis, Disease-Free Survival, Neoplasm Recurrence, Local, Biopsy, Needle, Immunohistochemistry, Multivariate Analysis, Preoperative Care, Rectum, Confidence Intervals, Europe, Rectal Neoplasms, Observer Variation},
	pages = {711--719},
}

@article{mellow1443,
	title = {Endoscopic laser therapy for malignancies affecting the esophagus and gastroesophageal junction. {Analysis} of technical and functional efficacy},
	volume = {145},
	issn = {0003-9926},
	abstract = {Thirty consecutive patients with far-advanced cancer affecting the esophagus and gastroesophageal junction underwent palliative endoscopic neodymium-YAG laser therapy. No patients were excluded from treatment, regardless of age, extent of disease, or performance status. Sessions were performed every other day and concluded when an endoscope could be easily passed beyond the previously obstructed area. Treatment was completed in 3.3 sessions (seven days). Luminal patency was achieved in 97\%, but did not always equate with functional success. Seventy percent (21 patients) were able to ingest all necessary calories and leave hospital for home (functional success). Reasons for discrepancy between technical success and functional success included radiation-induced pharyngeal dysphagia, anorexia, painful tumor load and debility, and treatment complications. Endoscopic laser therapy of far-advanced esophageal or gastroesophageal junction carcinoma was almost always technically feasible, with relatively low morbidity. While technical success could not always be equated with functional success, therapy was "completely" functionally successful in 70\% of patients with far-advanced disease. Poor performance status at accession correlated best with poor functional outcome.},
	language = {eng},
	number = {8},
	journal = {Archives of Internal Medicine},
	author = {Mellow, M. H. and Pinkas, H.},
	month = aug,
	year = {1985},
	pmid = {4026476},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Adult, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophagogastric Junction, Deglutition Disorders, Endoscopy, Anorexia, Melanoma, Hematemesis, Laser Therapy, Tracheoesophageal Fistula},
	pages = {1443--1446},
}

@article{nagtegaal303,
	title = {What is the role for the circumferential margin in the modern treatment of rectal cancer?},
	volume = {26},
	issn = {1527-7755},
	doi = {10.1200/JCO.2007.12.7027},
	abstract = {PURPOSE: Treatment of rectal cancer has changed dramatically over the last decade. The worldwide introduction of total mesorectal excision in combination with the increasing use of radio(chemo)-therapy has led to an improved prognosis. One of the main prognostic factors in rectal cancer is the circumferential resection margin (CRM). Since the initial description of its clinical importance in 1986, the involvement of this margin (also called lateral or radial resection margin) has been associated with a poor prognosis.
METHODS: In the current review, the evidence for the importance of the CRM in more than 17,500 patients is reviewed, and the relevance of this assessment to modern treatment is assessed.
RESULTS: We demonstrate that, after neoadjuvant therapy (both radiotherapy and radiochemotherapy), the predictive value of the CRM for local recurrence is significantly higher than when no preoperative therapy has been applied (hazard ratio [HR] = 6.3 v 2.0, respectively; P {\textless} .05). Furthermore, involvement of the CRM is a powerful predictor of both development of distant metastases (HR = 2.8; 95\% CI, 1.9 to 4.3) and survival (HR = 1.7; 95\% CI, 1.3 to 2.3). In addition to the prognostic data, this review describes different modes of margin involvement, exact definitions, and factors influencing its presence.
CONCLUSION: CRM involvement is one of the key factors in rectal cancer treatment.},
	language = {eng},
	number = {2},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Nagtegaal, Iris D. and Quirke, Phil},
	month = jan,
	year = {2008},
	pmid = {18182672},
	keywords = {Humans, Neoadjuvant Therapy, Neoplasm Staging, Neoplasm Metastasis, Survival Rate, Prognosis, Chemotherapy, Adjuvant, Neoplasm Recurrence, Local, Combined Modality Therapy, Laparoscopy, Logistic Models, Radiotherapy, Adjuvant, Neoplasm, Residual, Rectal Neoplasms},
	pages = {303--312},
}

@article{paty365,
	title = {Treatment of rectal cancer by low anterior resection with coloanal anastomosis},
	volume = {219},
	issn = {0003-4932},
	doi = {10.1097/00000658-199404000-00007},
	abstract = {OBJECTIVE: Our institution's experience with low anterior resection in combination with coloanal anastomosis (LAR/CAA) for primary rectal cancer was reviewed (1) to determine cancer treatment results, 2) to identify risk factors for pelvic recurrence, and 3) to assess the long-term success of sphincter preservation.
SUMMARY BACKGROUND DATA: Use of sphincter-preserving resection for mid-rectal and selected distal-rectal cancers continues to increase. As surgical techniques and adjuvant therapy evolve, treatment results must be carefully assessed.
METHODS: One hundred thirty-four patients treated for primary rectal cancer by LAR/CAA between 1977 and 1990 were studied retrospectively. All pathologic slides were reviewed. Median follow-up was 4 years.
RESULTS: Actuarial 5-year survival for all patients was 73\%. Among 36 patients who relapsed, distant metastatic disease had developed at the time of first clinical relapse in most (86\%). Pelvic recurrence was detected in 13 patients, an actuarial rate of 11\% at 5 years. Mesenteric implants, positive microscopic resection margin, T3 tumor, perineural invasion, blood vessel invasion, and high tumor grade were associated with increased risk for pelvic recurrence. Eleven patients ultimately required permanent colostomy, and in eight instances the cause was pelvic recurrence.
CONCLUSIONS: Low anterior resection combined with coloanal anastomosis provides good treatment for mid-rectal cancers and for some distal rectal cancers. Pelvic recurrence is not associated with short distal resection margins but is correlated with the presence of histopathologic markers of aggressive disease in the primary tumor. Long-term preservation of anal sphincter function depends primarily on control of pelvic tumor and can be achieved in more than 90\% of patients.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Paty, P. B. and Enker, W. E. and Cohen, A. M. and Lauwers, G. Y.},
	month = apr,
	year = {1994},
	pmid = {8161262},
	pmcid = {PMC1243153},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Risk Factors, Prognosis, Aged, 80 and over, Adult, Neoplasm Recurrence, Local, Combined Modality Therapy, Anastomosis, Surgical, Rectal Neoplasms, Anal Canal, Colon, Colostomy},
	pages = {365--373},
	file = {Paty et al_1994_Treatment of rectal cancer by low anterior resection with coloanal anastomosis.pdf:/Users/jcsal/Zotero/storage/9N4DZVWK/Paty et al_1994_Treatment of rectal cancer by low anterior resection with coloanal anastomosis.pdf:application/pdf},
}

@article{ruppert1519,
	title = {Oncological outcome after {MRI}-based selection for neoadjuvant chemoradiotherapy in the {OCUM} {Rectal} {Cancer} {Trial}},
	volume = {105},
	issn = {1365-2168},
	doi = {10.1002/bjs.10879},
	abstract = {BACKGROUND: It is not clear whether all patients with rectal cancer need chemoradiotherapy. A restrictive use of neoadjuvant chemoradiotherapy (nCRT) based on MRI findings for rectal cancer was investigated in this study.
METHODS: This prospective multicentre observational study included patients with stage cT2-4 rectal cancer, with any cN and cM0 status. Carcinomas in the middle and lower third that were 1 mm or less from the mesorectal fascia, all cT4 tumours, and all cT3 tumours of the lower third were classified as high risk, and these patients received nCRT followed by total mesorectal excision (TME). All other carcinomas with a minimum distance of more than 1 mm from the mesorectal fascia and those in the upper third were classified as low risk; these patients underwent TME alone (no nCRT). Patients were followed for at least 3 years. Outcomes were the rates of local recurrence, distant metastasis and survival.
RESULTS: Among 545 patients included, 428 were treated according to the study protocol: 254 (59·3 per cent) had TME alone and 174 (40·7 per cent) received nCRT and TME. Median follow-up was 60 months. The 3- and 5-year local recurrence rates were 1·3 and 2·7 per cent respectively, with no differences between the two treatment protocols. Patients with disease requiring nCRT had higher 3- and 5-year rates of distant metastasis (17·3 and 24·9 per cent respectively versus 8·9 and 14·4 per cent in patients who had TME alone; P = 0·005) and worse disease-free survival compared with that in patients who did not need nCRT (3- and 5-year rates 76·7 and 66·7 per cent, versus 84·9 and 76·0 per cent in the TME-alone group; P = 0·016).
CONCLUSION: Restriction of nCRT to high-risk patients achieved good results.},
	language = {eng},
	number = {11},
	journal = {The British Journal of Surgery},
	author = {Ruppert, R. and Junginger, T. and Ptok, H. and Strassburg, J. and Maurer, C. A. and Brosi, P. and Sauer, J. and Baral, J. and Kreis, M. and Wollschlaeger, D. and Hermanek, P. and Merkel, S. and {OCUM group}},
	month = oct,
	year = {2018},
	pmid = {29744860},
	keywords = {Humans, Magnetic Resonance Imaging, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Prospective Studies, Time Factors, Survival Rate, Aged, 80 and over, Adult, Disease-Free Survival, Neoplasm Recurrence, Local, Chemoradiotherapy, Incidence, Europe, Rectal Neoplasms},
	pages = {1519--1529},
}

@article{sarkaria764,
	title = {Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer},
	volume = {249},
	issn = {1528-1140},
	doi = {10.1097/SLA.0b013e3181a38e9e},
	abstract = {PURPOSE: Endoscopic biopsy after chemoradiation therapy (CRT) for esophageal cancer has been used to determine response to treatment. We wanted to determine if endoscopic biopsy can accurately establish evidence of local pathologic complete response (pCR) in patients undergoing CRT.
METHODS: We queried a prospectively maintained database for patients seen at Memorial Sloan-Kettering Cancer Center from 1996 to the present who underwent, (1) CRT for local-regionally advanced esophageal cancer, (2) post-CRT endoscopic biopsy, and (3) esophagectomy. Data points included pathology of post-CRT endoscopy and surgical specimens, tumor histology, and survival. Correlations were analyzed by the chi2 test and one-way analysis of variance. Survival comparisons were assessed using the Kaplan-Meier method and log-rank analysis.
RESULTS: One hundred fifty-six patients were identified. Over 80\% of patients received cisplatin-based chemotherapy and 5040 cGy of radiation. One hundred eighteen patients had no tumor identified on endoscopic biopsy. A negative biopsy at endoscopy was a poor predictor of pCR (negative predictive value: 31\%), with 69\% having local disease at esophagectomy. A positive biopsy was predictive of residual disease (positive predictive value: 95\%). Negative endoscopic biopsy better predicted a pCR for squamous cell carcinomas versus adenocarcinomas (P[r] {\textless} 0.001). Nodal status of surgical specimens was not correlated with post-treatment endoscopic findings. Survival was equivalent after surgery in patients with a negative endoscopic biopsy versus patients with positive pathology.
CONCLUSION: A negative endoscopic biopsy is not a useful predictor of a pCR after CRT, final nodal status, or overall survival.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Sarkaria, Inderpal S. and Rizk, Nabil P. and Bains, Manjit S. and Tang, Laura H. and Ilson, David H. and Minsky, Bruce I. and Rusch, Valerie W.},
	month = may,
	year = {2009},
	pmid = {19387328},
	keywords = {Humans, Female, Male, Middle Aged, Retrospective Studies, Predictive Value of Tests, Chemotherapy, Adjuvant, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Lymphatic Metastasis, Esophagus, Radiotherapy, Adjuvant, Endoscopy, Lymph Nodes},
	pages = {764--767},
}

@article{sasako4387,
	title = {Five-year outcomes of a randomized phase {III} trial comparing adjuvant chemotherapy with {S}-1 versus surgery alone in stage {II} or {III} gastric cancer},
	volume = {29},
	issn = {1527-7755},
	doi = {10.1200/JCO.2011.36.5908},
	abstract = {PURPOSE: The first planned interim analysis (median follow-up, 3 years) of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine derivative S-1 significantly improved overall survival, the primary end point. The results were therefore opened at the recommendation of an independent data and safety monitoring committee. We report 5-year follow-up data on patients enrolled onto the ACTS-GC study.
PATIENTS AND METHODS: Patients with histologically confirmed stage II or III gastric cancer who underwent gastrectomy with D2 lymphadenectomy were randomly assigned to receive S-1 after surgery or surgery only. S-1 (80 to 120 mg per day) was given for 4 weeks, followed by 2 weeks of rest. This 6-week cycle was repeated for 1 year. The primary end point was overall survival, and the secondary end points were relapse-free survival and safety.
RESULTS: The overall survival rate at 5 years was 71.7\% in the S-1 group and 61.1\% in the surgery-only group (hazard ratio [HR], 0.669; 95\% CI, 0.540 to 0.828). The relapse-free survival rate at 5 years was 65.4\% in the S-1 group and 53.1\% in the surgery-only group (HR, 0.653; 95\% CI, 0.537 to 0.793). Subgroup analyses according to principal demographic factors such as sex, age, disease stage, and histologic type showed no interaction between treatment and any characteristic.
CONCLUSION: On the basis of 5-year follow-up data, postoperative adjuvant therapy with S-1 was confirmed to improve overall survival and relapse-free survival in patients with stage II or III gastric cancer who had undergone D2 gastrectomy.},
	language = {eng},
	number = {33},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Sasako, Mitsuru and Sakuramoto, Shinichi and Katai, Hitoshi and Kinoshita, Taira and Furukawa, Hiroshi and Yamaguchi, Toshiharu and Nashimoto, Atsushi and Fujii, Masashi and Nakajima, Toshifusa and Ohashi, Yasuo},
	month = nov,
	year = {2011},
	pmid = {22010012},
	keywords = {Humans, Aged, Middle Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Stomach Neoplasms, Gastrectomy, Drug Combinations, Oxonic Acid, Tegafur},
	pages = {4387--4393},
}

@article{schrag322,
	title = {Preoperative {Treatment} of {Locally} {Advanced} {Rectal} {Cancer}},
	volume = {389},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2303269},
	abstract = {BACKGROUND: Pelvic radiation plus sensitizing chemotherapy with a fluoropyrimidine (chemoradiotherapy) before surgery is standard care for locally advanced rectal cancer in North America. Whether neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) can be used in lieu of chemoradiotherapy is uncertain.
METHODS: We conducted a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant FOLFOX (with chemoradiotherapy given only if the primary tumor decreased in size by {\textless}20\% or if FOLFOX was discontinued because of side effects) as compared with chemoradiotherapy. Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate. The primary end point was disease-free survival. Noninferiority would be claimed if the upper limit of the two-sided 90.2\% confidence interval of the hazard ratio for disease recurrence or death did not exceed 1.29. Secondary end points included overall survival, local recurrence (in a time-to-event analysis), complete pathological resection, complete response, and toxic effects.
RESULTS: From June 2012 through December 2018, a total of 1194 patients underwent randomization and 1128 started treatment; among those who started treatment, 585 were in the FOLFOX group and 543 in the chemoradiotherapy group. At a median follow-up of 58 months, FOLFOX was noninferior to chemoradiotherapy for disease-free survival (hazard ratio for disease recurrence or death, 0.92; 90.2\% confidence interval [CI], 0.74 to 1.14; P = 0.005 for noninferiority). Five-year disease-free survival was 80.8\% (95\% CI, 77.9 to 83.7) in the FOLFOX group and 78.6\% (95\% CI, 75.4 to 81.8) in the chemoradiotherapy group. The groups were similar with respect to overall survival (hazard ratio for death, 1.04; 95\% CI, 0.74 to 1.44) and local recurrence (hazard ratio, 1.18; 95\% CI, 0.44 to 3.16). In the FOLFOX group, 53 patients (9.1\%) received preoperative chemoradiotherapy and 8 (1.4\%) received postoperative chemoradiotherapy.
CONCLUSIONS: In patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery, preoperative FOLFOX was noninferior to preoperative chemoradiotherapy with respect to disease-free survival. (Funded by the National Cancer Institute; PROSPECT ClinicalTrials.gov number, NCT01515787.).},
	language = {eng},
	number = {4},
	journal = {The New England Journal of Medicine},
	author = {Schrag, Deborah and Shi, Qian and Weiser, Martin R. and Gollub, Marc J. and Saltz, Leonard B. and Musher, Benjamin L. and Goldberg, Joel and Al Baghdadi, Tareq and Goodman, Karyn A. and McWilliams, Robert R. and Farma, Jeffrey M. and George, Thomas J. and Kennecke, Hagen F. and Shergill, Ardaman and Montemurro, Michael and Nelson, Garth D. and Colgrove, Brian and Gordon, Vallerie and Venook, Alan P. and O'Reilly, Eileen M. and Meyerhardt, Jeffrey A. and Dueck, Amylou C. and Basch, Ethan and Chang, George J. and Mamon, Harvey J.},
	month = jul,
	year = {2023},
	pmid = {37272534},
	pmcid = {PMC10775881},
	keywords = {Humans, Neoadjuvant Therapy, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemotherapy, Adjuvant, Fluorouracil, Leucovorin, Disease-Free Survival, Neoplasm Recurrence, Local, Chemoradiotherapy, Organ Sparing Treatments, Oxaliplatin, Preoperative Care, Preoperative Period, Rectal Neoplasms, Anal Canal},
	pages = {322--334},
}

@article{smith657,
	title = {Watch and {Wait} in {Rectal} {Cancer} or {More} {Wait} and {See}?},
	volume = {155},
	issn = {2168-6262},
	doi = {10.1001/jamasurg.2020.0226},
	language = {eng},
	number = {7},
	journal = {JAMA surgery},
	author = {Smith, J. Joshua and Paty, Philip B. and Garcia-Aguilar, Julio},
	month = jul,
	year = {2020},
	pmid = {32347912},
	pmcid = {PMC7483390},
	keywords = {Humans, Watchful Waiting, Rectal Neoplasms},
	pages = {657--658},
	file = {Smith et al_2020_Watch and Wait in Rectal Cancer or More Wait and See.pdf:/Users/jcsal/Zotero/storage/9ADMUXNV/Smith et al_2020_Watch and Wait in Rectal Cancer or More Wait and See.pdf:application/pdf},
}

@article{smith767,
	title = {Organ {Preservation} in {Rectal} {Adenocarcinoma}: a phase {II} randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management},
	volume = {15},
	issn = {1471-2407},
	shorttitle = {Organ {Preservation} in {Rectal} {Adenocarcinoma}},
	doi = {10.1186/s12885-015-1632-z},
	abstract = {BACKGROUND: Treatment of patients with non-metastatic, locally advanced rectal cancer (LARC) includes pre-operative chemoradiation, total mesorectal excision (TME) and post-operative adjuvant chemotherapy. This trimodality treatment provides local tumor control in most patients; but almost one-third ultimately die from distant metastasis. Most survivors experience significant impairment in quality of life (QoL), due primarily to removal of the rectum. A current challenge lies in identifying patients who could safely undergo rectal preservation without sacrificing survival benefit and QoL.
METHODS/DESIGN: This multi-institutional, phase II study investigates the efficacy of total neoadjuvant therapy (TNT) and selective non-operative management (NOM) in LARC. Patients with MRI-staged Stage II or III rectal cancer amenable to TME will be randomized to receive FOLFOX/CAPEOX: a) before induction neoadjuvant chemotherapy (INCT); or b) after consolidation neoadjuvant chemotherapy (CNCT), with 5-FU or capecitabine-based chemoradiation. Patients in both arms will be re-staged after completing all neoadjuvant therapy. Those with residual tumor at the primary site will undergo TME. Patients with clinical complete response (cCR) will receive non-operative management (NOM). NOM patients will be followed every 3 months for 2 years, and every 6 months thereafter. TME patients will be followed according to NCCN guidelines. All will be followed for at least 5 years from the date of surgery or--in patients treated with NOM--the last day of treatment.
DISCUSSION: The studies published thus far on the safety of NOM in LARC have compared survival between select groups of patients with a cCR after NOM, to patients with a pathologic complete response (pCR) after TME. The current study compares 3-year disease-free survival (DFS) in an entire population of patients with LARC, including those with cCR and those with pCR. We will compare the two arms of the study with respect to organ preservation at 3 years, treatment compliance, adverse events and surgical complications. We will measure QoL in both groups. We will analyze molecular indications that may lead to more individually tailored treatments in the future. This will be the first NOM trial utilizing a regression schema for response assessment in a prospective fashion.
TRIAL REGISTRATION: NCT02008656.},
	language = {eng},
	journal = {BMC cancer},
	author = {Smith, J. Joshua and Chow, Oliver S. and Gollub, Marc J. and Nash, Garrett M. and Temple, Larissa K. and Weiser, Martin R. and Guillem, José G. and Paty, Philip B. and Avila, Karin and Garcia-Aguilar, Julio and {Rectal Cancer Consortium}},
	month = oct,
	year = {2015},
	pmid = {26497495},
	pmcid = {PMC4619249},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adult, Fluorouracil, Leucovorin, Organoplatinum Compounds, Adenocarcinoma, Disease-Free Survival, Chemoradiotherapy, Organ Sparing Treatments, Capecitabine, Oxaliplatin, Quality of Life, Induction Chemotherapy, Rectal Neoplasms, Consolidation Chemotherapy},
	pages = {767},
	file = {Smith et al_2015_Organ Preservation in Rectal Adenocarcinoma.pdf:/Users/jcsal/Zotero/storage/R8IYJMUS/Smith et al_2015_Organ Preservation in Rectal Adenocarcinoma.pdf:application/pdf},
}

@article{smithe185896,
	title = {Assessment of a {Watch}-and-{Wait} {Strategy} for {Rectal} {Cancer} in {Patients} {With} a {Complete} {Response} {After} {Neoadjuvant} {Therapy}},
	volume = {5},
	issn = {2374-2445},
	doi = {10.1001/jamaoncol.2018.5896},
	abstract = {IMPORTANCE: The watch-and-wait (WW) strategy aims to spare patients with rectal cancer unnecessary resection.
OBJECTIVE: To analyze the outcomes of WW among patients with rectal cancer who had a clinical complete response to neoadjuvant therapy.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series analysis conducted at a comprehensive cancer center in New York included patients who received a diagnosis of rectal adenocarcinoma between January 1, 2006, and January 31, 2015. The median follow-up was 43 months. Data analyses were conducted from June 1, 2016, to October 1, 2018.
EXPOSURES: Patients had a clinical complete response after completing neoadjuvant therapy and agreed to a WW strategy of active surveillance and possible salvage surgery (n = 113), or patients underwent total mesorectal excision and were found to have a pathologic complete response (pCR) at resection (n = 136).
MAIN OUTCOMES AND MEASURES: Kaplan-Meier estimates were used for analyses of local regrowth and 5-year rates of overall survival, disease-free survival, and disease-specific survival.
RESULTS: Compared with the 136 patients in the pCR group, the 113 patients in the WW group were older (median [range], 67.2 [32.1-90.9] vs 57.3 [25.0-87.9] years, P {\textless} .001) with cancers closer to the anal verge (median [range] height from anal verge, 5.5 [0.0-15.0] vs 7.0 [0.0-13.0] cm). All 22 local regrowths in the WW group were detected on routine surveillance and treated by salvage surgery (20 total mesorectal excisions plus 2 transanal excisions). Pelvic control after salvage surgery was maintained in 20 of 22 patients (91\%). No pelvic recurrences occurred in the pCR group. Rectal preservation was achieved in 93 of 113 patients (82\%) in the WW group (91 patients with no local regrowths plus 2 patients with local regrowths salvaged with transanal excision). At 5 years, overall survival was 73\% (95\% CI, 60\%-89\%) in the WW group and 94\% (95\% CI, 90\%-99\%) in the pCR group; disease-free survival was 75\% (95\% CI, 62\%-90\%) in the WW group and 92\% (95\% CI, 87\%-98\%) in the pCR group; and disease-specific survival was 90\% (95\% CI, 81\%-99\%) in the WW group and 98\% (95\% CI, 95\%-100\%) in the pCR group. A higher rate of distant metastasis was observed among patients in the WW group who had local regrowth vs those who did not have local regrowth (36\% vs 1\%, P {\textless} .001).
CONCLUSIONS AND RELEVANCE: A WW strategy for select rectal cancer patients who had a clinical complete response after neoadjuvant therapy resulted in excellent rectal preservation and pelvic tumor control; however, in the WW group, worse survival was noted along with a higher incidence of distant progression in patients with local regrowth vs those without local regrowth.},
	language = {eng},
	number = {4},
	journal = {JAMA oncology},
	author = {Smith, J. Joshua and Strombom, Paul and Chow, Oliver S. and Roxburgh, Campbell S. and Lynn, Patricio and Eaton, Anne and Widmar, Maria and Ganesh, Karuna and Yaeger, Rona and Cercek, Andrea and Weiser, Martin R. and Nash, Garrett M. and Guillem, Jose G. and Temple, Larissa K. F. and Chalasani, Sree B. and Fuqua, James L. and Petkovska, Iva and Wu, Abraham J. and Reyngold, Marsha and Vakiani, Efsevia and Shia, Jinru and Segal, Neil H. and Smith, James D. and Crane, Christopher and Gollub, Marc J. and Gonen, Mithat and Saltz, Leonard B. and Garcia-Aguilar, Julio and Paty, Philip B.},
	month = apr,
	year = {2019},
	pmid = {30629084},
	pmcid = {PMC6459120},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Retrospective Studies, Aged, 80 and over, Adult, Neoplasm Recurrence, Local, Watchful Waiting, Remission Induction, Rectal Neoplasms},
	pages = {e185896},
}

@article{strassburg2790,
	title = {{MRI}-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study},
	volume = {18},
	issn = {1534-4681},
	shorttitle = {{MRI}-based indications for neoadjuvant radiochemotherapy in rectal carcinoma},
	doi = {10.1245/s10434-011-1704-5},
	abstract = {BACKGROUND: This study evaluated use of circumferential resection margin status in preoperative MRI (mrCRM) as an indication for neoadjuvant radiochemotherapy (nRCT) in rectal carcinoma patients.
MATERIALS AND METHODS: In a multicenter prospective study, nRCT was given to patients with carcinoma of the middle rectum with positive mrCRM (≤1 mm), with cT3 low rectal carcinoma, and all patients with cT4 tumors. The short-term endpoints were pathologic pCRM (≤1 mm) as a strong predictor of local recurrence rate and the quality of total mesorectal excision according to the plane of surgery. These endpoints were compared in patients with and without nRCT.
RESULTS: Of 230 patients that met the inclusion criteria, 96 (41.7\%) received a long course of nRCT and 134 (58.3\%) were primarily operated on. The pCRM was positive in 13 of 230 (5.7\%) (primarily operated on, 2 of 134 [1.5\%]; after nRCT, 11 of 96 [11\%]). In 1 of 134 (0.7\%) case, the mrCRM was falsely negative. Patients at participating centers varied in terms of preoperative stage but not in pCRM positivity (0\%-13\%, P = .340). The plane of surgery was mesorectal (good) in 209 of 230 (90.9\%), intramesorectal (moderate) in 16 of 230 (7\%), and the muscularis propria plane (poor) in 2.2\% (5 of 230).
CONCLUSIONS: Low pCRM positivity and the high quality of mesorectal excision support use of MRI-based nRCT in rectal carcinoma. nRCT was avoidable in 45\% of patients with stage II and III disease without significant risk of undertreatment. Preoperative MRI thus allows identification of patients with high risk of local recurrence and use of selective nRCT.},
	language = {eng},
	number = {10},
	journal = {Annals of Surgical Oncology},
	author = {Strassburg, Joachim and Ruppert, Reinhard and Ptok, Henry and Maurer, Christoph and Junginger, Theodor and Merkel, Susanne and Hermanek, Paul},
	month = oct,
	year = {2011},
	pmid = {21509631},
	keywords = {Humans, Magnetic Resonance Imaging, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Survival Rate, Aged, 80 and over, Adult, Fluorouracil, Organoplatinum Compounds, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Neoplasm Recurrence, Local, Postoperative Complications, Capecitabine, Deoxycytidine, Oxaliplatin, Preoperative Care, Rectal Neoplasms},
	pages = {2790--2799},
}

@article{kalffe749,
	title = {Long-term {Survival} {After} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}: {A} {Nationwide} {Propensity}-score {Matched} {Analysis}},
	volume = {276},
	issn = {1528-1140},
	shorttitle = {Long-term {Survival} {After} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Esophageal} {Cancer}},
	doi = {10.1097/SLA.0000000000004708},
	abstract = {OBJECTIVES: This study aimed to compare long-term survival following MIE versus OE for esophageal cancer using a nationwide propensity-score matched cohort.
SUMMARY OF BACKGROUND DATA: MIE provides lower postoperative morbidity and mortality, and similar short-term oncological quality compared to OE.
METHODS: Data was acquired from the Dutch Upper Gastrointestinal Cancer Audit. Patients undergoing minimally invasive or open, transthoracic or transhiatal esophagectomy for primary esophageal cancer between 2011 and 2015 were included. A propensity-score matching analysis for MIE versus OE was performed separately for transthoracic and transhiatal esoph-agectomies.
RESULTS: A total of 1036 transthoracic MIE and OE patients, and 582 transhiatal MIE and OE patients were matched. Long-term survival was comparable for MIE and OE for both transthoracic and transhiatal procedures (5-year overall survival: transthoracic MIE 49.2\% vs OE 51.1\%, P 0.695; transhiatal MIE 48.4\% vs OE 50.7\%, P 0.832). For both procedures, MIE yielded more lymph nodes (transthoracic median 21 vs 18, P {\textless} 0.001; transhiatal 15 vs 13, P 0.007). Postoperative morbidity was comparable after transthoracic MIE and OE (60.8\% vs 64.9\%, P 0.177), with a reduced length of stay after transthoracic MIE (median 12 vs 15 days, P {\textless} 0.001). After transhiatal MIE, more postoperative complications (64.9\% vs 56.4\%, P 0.034) were observed, without subsequent difference in length of stay.
CONCLUSION: Long-term survival after MIE was equivalent to open in both propensity-score matched cohorts of patients undergoing transthoracic or transhiatal esophageal resections. Transhiatal MIE was accompanied withmore postoperative morbidity. Both transthoracic and transhiatal MIE resulted in a more extended lymphadenectomy.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Kalff, Marianne C. and Fransen, Laura F. C. and de Groot, Eline M. and Gisbertz, Suzanne S. and Nieuwenhuijzen, Grard A. P. and Ruurda, Jelle P. and Verhoeven, Rob H. A. and Luyer, Misha D. P. and van Hillegersberg, Richard and van Berge Henegouwen, Mark I. and {Dutch Upper Gastrointestinal Cancer Audit group}},
	month = dec,
	year = {2022},
	pmid = {33378310},
	keywords = {Esophageal Neoplasms, Esophagectomy, Humans, Minimally Invasive Surgical Procedures, Postoperative Complications, Propensity Score, Retrospective Studies, Treatment Outcome},
	pages = {e749--e757},
}

@article{kalff806,
	title = {Recurrent {Disease} {After} {Esophageal} {Cancer} {Surgery}: {A} {Substudy} of {The} {Dutch} {Nationwide} {Ivory} {Study}},
	volume = {276},
	issn = {1528-1140},
	shorttitle = {Recurrent {Disease} {After} {Esophageal} {Cancer} {Surgery}},
	doi = {10.1097/SLA.0000000000005638},
	abstract = {OBJECTIVE: This study investigated the patterns, predictors, and survival of recurrent disease following esophageal cancer surgery.
BACKGROUND: Survival of recurrent esophageal cancer is usually poor, with limited prospects of remission.
METHODS: This nationwide cohort study included patients with distal esophageal and gastroesophageal junction adenocarcinoma and squamous cell carcinoma after curatively intended esophagectomy in 2007 to 2016 (follow-up until January 2020). Patients with distant metastases detected during surgery were excluded. Univariable and multivariable logistic regression were used to identify predictors of recurrent disease. Multivariable Cox regression was used to determine the association of recurrence site and treatment intent with postrecurrence survival.
RESULTS: Among 4626 patients, 45.1\% developed recurrent disease a median of 11 months postoperative, of whom most had solely distant metastases (59.8\%). Disease recurrences were most frequently hepatic (26.2\%) or pulmonary (25.1\%). Factors significantly associated with disease recurrence included young age (≤65 y), male sex, adenocarcinoma, open surgery, transthoracic esophagectomy, nonradical resection, higher T-stage, and tumor positive lymph nodes. Overall, median postrecurrence survival was 4 months [95\% confidence interval (95\% CI): 3.6-4.4]. After curatively intended recurrence treatment, median survival was 20 months (95\% CI: 16.4-23.7). Survival was more favorable after locoregional compared with distant recurrence (hazard ratio: 0.74, 95\% CI: 0.65-0.84).
CONCLUSIONS: This study provides important prognostic information assisting in the surveillance and counseling of patients after curatively intended esophageal cancer surgery. Nearly half the patients developed recurrent disease, with limited prospects of survival. The risk of recurrence was higher in patients with a higher tumor stage, nonradical resection and positive lymph node harvest.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Kalff, Marianne C. and Henckens, Sofie P. G. and Voeten, Daan M. and Heineman, David J. and Hulshof, Maarten C. C. M. and van Laarhoven, Hanneke W. M. and Eshuis, Wietse J. and Baas, Peter C. and Bahadoer, Renu R. and Belt, Eric J. T. and Brattinga, Baukje and Claassen, Linda and Ćosović, Admira and Crull, David and Daams, Freek and van Dalsen, Annette D. and Dekker, Jan Willem T. and van Det, Marc J. and Drost, Manon and van Duijvendijk, Peter and van Esser, Stijn and Gaspersz, Marcia P. and Görgec, Burak and Groenendijk, Richard P. R. and Hartgrink, Henk H. and van der Harst, Erwin and Haveman, Jan W. and Heisterkamp, Joos and van Hillegersberg, Richard and Kelder, Wendy and Kingma, B. Feike and Koemans, Willem J. and Kouwenhoven, Ewout A. and Lagarde, Sjoerd M. and Lecot, Frederik and van der Linden, Philip P. and Luyer, Misha D. P. and Nieuwenhuijzen, Grard A. P. and Olthof, Pim B. and van der Peet, Donald L. and Pierie, Jean-Pierre E. N. and Pierik, E. G. J. M. Robert and Plat, Victor D. and Polat, Fatih and Rosman, Camiel and Ruurda, Jelle P. and van Sandick, Johanna W. and Scheer, Rene and Slootmans, Cettela A. M. and Sosef, Meindert N. and Sosef, Odin V. and de Steur, Wobbe O. and Stockmann, Hein B. A. C. and Stoop, Fanny J. and Vugts, Guusje and Vijgen, Guy H. E. J. and Weeda, Víola B. and Wiezer, Marinus J. and van Oijen, Martijn G. H. and van Berge Henegouwen, Mark I. and Gisbertz, Suzanne S.},
	month = nov,
	year = {2022},
	pmid = {35880759},
	keywords = {Humans, Male, Retrospective Studies, Survival Rate, Prognosis, Cohort Studies, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Lymphatic Metastasis},
	pages = {806--813},
	file = {Kalff et al_2022_Recurrent Disease After Esophageal Cancer Surgery.pdf:/Users/jcsal/Zotero/storage/Q2DRX73A/Kalff et al_2022_Recurrent Disease After Esophageal Cancer Surgery.pdf:application/pdf},
}

@article{mcgovern9,
	title = {The relationship between the modified frailty index score ({mFI}-5), malnutrition, body composition, systemic inflammation and short-term clinical outcomes in patients undergoing surgery for colorectal cancer},
	volume = {23},
	issn = {1471-2318},
	doi = {10.1186/s12877-022-03703-2},
	abstract = {BACKGROUND: While the current literature suggests an association with frailty and clinical outcomes in patients undergoing surgery for colorectal cancer (CRC), the basis of this relationship is unclear.
AIM: Examine the relationship between frailty, malnutrition, body composition, systemic inflammation and short-term clinical outcomes in patients undergoing surgery for colorectal cancer.
METHODS: Consecutive patients who underwent potentially curative resection for colorectal cancer, between April 2008 and April 2018, were identified from a prospectively maintained database. Frailty was defined using the modified five-item frailty index (mFI-5). Body composition measures included CT-derived skeletal muscle index (SMI) and density (SMD). Systemic inflammatory status was determined using Systemic Inflammatory Grade (SIG). Outcomes of interest were the incidence of post-operative complications and thirty-day mortality. Associations between categorical variables were examined using χ2 test and binary logistics regression analysis.
RESULTS: 1002 patients met the inclusion criteria. 28\% (n = 221) scored 2 or more on the mFI-5. 39\% (n = 388) of patients had a post-operative complication (Clavien-Dindo I-IV) and 1\% (n = 11) died within thirty days of surgery. On univariate analysis, mFI-5 frailty score, was significantly associated with advanced age (p {\textless} 0.001), colonic tumours (p {\textless} 0.001), reduced use of neo-adjuvant chemotherapy (p {\textless} 0.05), higher BMI (p {\textless} 0.05), low SMD (p {\textless} 0.001), elevated NLR (p {\textless} 0.05), elevated mGPS (p {\textless} 0.05), elevated SIG (p {\textless} 0.05), incidence of post-operative complications (p {\textless} 0.001) and thirty-day mortality (p {\textless} 0.05). On multivariate analysis, male sex (p {\textless} 0.05), elevated SIG (p {\textless} 0.05) and mFI-5 score (p {\textless} 0.01) remained significantly associated with the incidence of post-operative complications. mFI-5 frailty was found to remain significantly associated with the incidence post-operative complications in patients who were SIG 0 (p {\textless} 0.05).
CONCLUSION: mFI-5 frailty score was found to be significantly associated with age, systemic inflammation and post-operative outcomes in patients undergoing potentially curative resections for CRC. Incorporation of an assessment of systemic inflammatory status in future frailty screening tools may improve their prognostic value.},
	language = {eng},
	number = {1},
	journal = {BMC geriatrics},
	author = {McGovern, Josh and Grayston, Alexander and Coates, Dominic and Leadbitter, Stephen and Hounat, Adam and Horgan, Paul G. and Dolan, Ross D. and McMillan, Donald C.},
	month = jan,
	year = {2023},
	pmid = {36609242},
	pmcid = {PMC9817261},
	keywords = {Body Composition, Humans, Male, Colorectal Neoplasms, Retrospective Studies, Risk Factors, Risk Assessment, Postoperative Complications, Malnutrition, Inflammation, Frailty, mFI-5, Short-term outcomes, mFrailty5},
	pages = {9},
	file = {McGovern et al_2023_The relationship between the modified frailty index score (mFI-5),.pdf:/Users/jcsal/Zotero/storage/YP2726W4/McGovern et al_2023_The relationship between the modified frailty index score (mFI-5),.pdf:application/pdf},
}

@article{al-khamis1192,
	title = {Modified frailty index predicts early outcomes after colorectal surgery: an {ACS}-{NSQIP} study},
	volume = {21},
	issn = {1463-1318},
	shorttitle = {Modified frailty index predicts early outcomes after colorectal surgery},
	doi = {10.1111/codi.14725},
	abstract = {AIM: Frailty is defined as a decrease in physiological reserve with increased risk of morbidity following significant physiological stressors. This study examines the predictive power of the five-item modified frailty index (5-mFI) in predicting outcomes in colorectal surgery patients.
METHODS: The American College of Surgeons National Surgical Quality Improvement Program Database was queried from 2011 to 2016 to determine the predictive power of 5-mFI in patients who had colorectal surgery.
RESULTS: Of 295 490 patients, 45.8\% had a score of 0, 36.2\% had a score of 1 and 18\% had a score of ≥ 2. On univariate analysis, frailer patients had significantly greater incidences for overall morbidity, serious morbidity, mortality, prolonged length of hospital stay, discharge to a facility other than home, reoperation and unplanned readmission. These findings were consistent on multivariate analysis where the frailest patients had greater odds of postoperative overall morbidity (OR 1.39; 95\% CI 1.35-1.43), serious morbidity (OR 1.39; 95\% CI 1.33-1.45), mortality (OR 2.00; 95\% CI 1.87-2.14), prolonged length of hospital stay (OR 1.24; 95\% CI 1.20-1.27), discharge destination to a facility other than home (OR 2.80; 95\% CI 2.70-2.90), reoperation (OR 1.17; 95\% CI 1.11-1.23) and unplanned readmission (OR 1.31; 95\% CI 1.26-1.36). Weighted kappa statistics showed strong agreement between the 5-mFI and 11-mFI (kappa = 0.987, P {\textless} 0.001).
CONCLUSIONS: The 5-mFI is a valid and easy to use predictor of 30-day postoperative outcomes after colorectal surgery. This tool may guide the surgeon to proactively recognize frail patients to instigate interventions to optimize them preoperatively.},
	language = {eng},
	number = {10},
	journal = {Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland},
	author = {Al-Khamis, A. and Warner, C. and Park, J. and Marecik, S. and Davis, N. and Mellgren, A. and Nordenstam, J. and Kochar, K.},
	month = oct,
	year = {2019},
	pmid = {31162882},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Risk Factors, Risk Assessment, Prognosis, Adult, Predictive Value of Tests, Databases, Factual, Postoperative Complications, Multivariate Analysis, Reoperation, Digestive System Surgical Procedures, Rectum, Morbidity, Health Status Indicators, outcomes, Colon, Frailty, Patient Discharge, Postoperative Period, NSQIP, mFrailty5, colorectal, postoperative},
	pages = {1192--1205},
}

@article{simon1363,
	title = {Frailty in older patients undergoing emergency colorectal surgery: {USA} {National} {Surgical} {Quality} {Improvement} {Program} analysis},
	volume = {107},
	issn = {1365-2168},
	shorttitle = {Frailty in older patients undergoing emergency colorectal surgery},
	doi = {10.1002/bjs.11770},
	abstract = {BACKGROUND: Frailty is associated with advancing age and may result in adverse postoperative outcomes. A suspected growing elderly population needing emergency colorectal surgery stimulated this study of the prevalence and impact of frailty.
METHODS: Elderly patients (defined as aged at least 65 years by Medicare and the United States Census Bureau) who underwent emergency colorectal resection between 2012 and 2016 were identified from the American College of Surgeons National Surgical Quality Improvement Program population database. The five-item modified frailty index (mFI-5) score was calculated, and patients stratified into groups 0, 1 or 2 + . Main outcome measures were the prevalence of frailty, and its impact on 30-day postoperative morbidity, mortality, reoperation, duration of hospital stay (LOS), discharge destination and readmission.
RESULTS: A total of 10 025 patients were identified with a median age 75 years, of whom 41·8 per cent were men. The majority (87·7 per cent) had an ASA fitness grade of III or greater and 3129 (31·2 per cent) were frail (mFI-5 group 2+). Major morbidity occurred in one-third of patients and the postoperative mortality rate was 15·9 per cent. Some 52·0 per cent of patients had a prolonged hospital stay and 11·0 per cent were readmitted. Although most patients (88·0 per cent) lived independently before surgery, only 45·4 per cent were discharged home directly. Frailty (mFI-5 2+) predicted mortality, overall and major morbidity, reoperation, prolonged LOS, discharge to an institution and readmission, but frailty was independent of sex.
CONCLUSION: Frailty is associated with morbidity, mortality and loss of independence in elderly patients needing emergency colorectal surgery.},
	language = {eng},
	number = {10},
	journal = {The British Journal of Surgery},
	author = {Simon, H. L. and Reif de Paula, T. and Profeta da Luz, M. M. and Nemeth, S. K. and Moug, S. J. and Keller, D. S.},
	month = sep,
	year = {2020},
	pmid = {32639045},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Aged, 80 and over, Databases, Factual, United States, Postoperative Complications, Reoperation, Digestive System Surgical Procedures, Rectum, Patient Readmission, Colon, Frailty, Patient Discharge, Nursing Homes, Emergencies, Rehabilitation Centers},
	pages = {1363--1371},
	file = {Simon et al_2020_Frailty in older patients undergoing emergency colorectal surgery.pdf:/Users/jcsal/Zotero/storage/4XJLKFJR/Simon et al_2020_Frailty in older patients undergoing emergency colorectal surgery.pdf:application/pdf},
}

@article{miller504,
	title = {Frailty is a better predictor than age for outcomes in geriatric patients with rectal cancer undergoing proctectomy},
	volume = {168},
	issn = {1532-7361},
	doi = {10.1016/j.surg.2020.05.027},
	abstract = {BACKGROUND: Both frailty and older age are risk factors for adverse surgical outcomes. We hypothesized that frailty, regardless of patient age, is a predictor of poor postoperative outcome among patients with rectal cancer undergoing proctectomy.
METHODS: Patients with primary rectal cancer undergoing proctectomy between 2012 to 2015 were identified in the database of the National Quality Improvement Program. The simplified, 5-item frailty index was grouped into 0, 1, 2, and ≥3. Outcomes were morbidity and 30-day mortality.
RESULTS: This study involved 9,252 patients from the National Quality Improvement Program database. Increasingly frail patients had greater morbidity and mortality (P {\textless} .001). Logistic regression revealed that frailty was a predictor of morbidity (odds ratio = 6.7, P {\textless} .0001); in contrast, older age was not associated with morbidity when adjusting for frailty (odds ratio = 1.2, P = .14). Both older age and frailty were associated with greater mortality, with frailty (odds ratio = 20.8, P {\textless} .0001) more so than older age (odds ratio = 10.3, P {\textless} .0001).
CONCLUSION: Frailty was more strongly associated with morbidity and mortality than older age in patients undergoing proctectomy. Surgical options can be expanded to older patients with the use of simplified, 5-item frailty index as a decision-making tool.},
	language = {eng},
	number = {3},
	journal = {Surgery},
	author = {Miller, Samuel M. and Wolf, J. and Katlic, M. and D'Adamo, C. R. and Coleman, J. and Ahuja, V.},
	month = sep,
	year = {2020},
	pmid = {32665144},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Risk Factors, Risk Assessment, Aged, 80 and over, Adult, Age Factors, Young Adult, Postoperative Complications, Logistic Models, Hospital Mortality, Adolescent, Rectal Neoplasms, Feasibility Studies, Frailty, Geriatric Assessment, Frail Elderly, Clinical Decision-Making, Proctectomy},
	pages = {504--508},
}

@article{wane721,
	title = {Can the {Risk} {Analysis} {Index} for {Frailty} {Predict} {Morbidity} and {Mortality} in {Patients} {Undergoing} {High}-risk {Surgery}?},
	volume = {276},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000004626},
	abstract = {OBJECTIVE: To determine the effectiveness of the revised Risk Analysis Index (RAI-rev), administrative Risk Analysis Index (RAI-A), cancer-corrected Risk Analysis Index [RAI-rev (cancer-corrected)], and 5-variable modified Frailty Index for predicting 30-day morbidity and mortality in patients undergoing high-risk surgery.
BACKGROUND: There are several frailty composite measures, but none have been evaluated for predicting morbidity and mortality in patients undergoing high-risk surgery.
METHODS: Using the National Surgical Quality Improvement Program database, we performed a retrospective study of patients who underwentcolectomy/proctectomy, coronary artery bypass graft (CABG), pancreaticoduodenectomy, lung resection, or esophagectomy from 2006 to 2017. RAI-rev, RAI-A, RAI-rev (cancer corrected), and 5-variable modified Frailty Index scores were calculated. Pearson's chi-square tests and C-statistics were used to assess the predictive accuracy of each score's logistic regression model.
RESULTS: In the cohort of 283,545 patients, there were 178,311 (63\%) colectomy/proctectomy, 38,167 (14\%) pancreaticoduodenectomy, 40,328 (14\%) lung resection, 16,127 (6\%) CABG, and 10,602 (3\%) esophagectomy cases. The RAI-rev was a fair predictor of mortality in the total cohort (C-statistic, 0.71, 95\% CI 0.70-0.71, P {\textless} 0.001) and for patients who underwent colectomy/proctectomy (C-statistic 0.73, 95\% CI 0.72-0.74, P {\textless} 0.001) and CABG (C-statistic 0.70, 95\% CI 0.68-0.73, P {\textless} 0.001), but a poor predictor of mortality in all other operation cohorts. The RAI-A was a fair predictor of mortality for colectomy/proctectomy patients (C-statistic 0.74, 95\% CI 0.73- 0.74, P {\textless} 0.001). All indices were poor predictors of morbidity. The RAI-rev (cancer corrected) did not improve the accuracy of morbidity and mortality prediction.
CONCLUSION: The presently studied frailty indices are ineffective predictors of 30-day morbidity and mortality for patients undergoing high-risk operations.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Wan, Michelle A. and Clark, James M. and Nuño, Miriam and Cooke, David T. and Brown, Lisa M.},
	month = dec,
	year = {2022},
	pmid = {33214473},
	keywords = {Humans, Retrospective Studies, Risk Factors, Risk Assessment, Postoperative Complications, Morbidity, Frailty},
	pages = {e721--e727},
	file = {Wan et al_2022_Can the Risk Analysis Index for Frailty Predict Morbidity and Mortality in.pdf:/Users/jcsal/Zotero/storage/J28UH9NJ/Wan et al_2022_Can the Risk Analysis Index for Frailty Predict Morbidity and Mortality in.pdf:application/pdf},
}

@article{keller1396,
	title = {Evaluating the association of the new {National} {Surgical} {Quality} {Improvement} {Program} modified 5-factor frailty index with outcomes in elective colorectal surgery},
	volume = {22},
	issn = {1463-1318},
	doi = {10.1111/codi.15066},
	abstract = {BACKGROUND: The 5-factor modified frailty index (mFI-5) is a new, NSQIP-based, predictive tool for mortality and postoperative complications. The mFI-5's predictive ability has been validated within the large-scale NSQIP database but applicability in institutional databases has not been investigated. We sought to assess the association between the mFI-5 and morbidity/mortality at the institutional level.
METHODS: A divisional database was queried for 2017 elective colorectal resections and an mFI-5 calculated. The main outcome measure was the association and predictive value of the mFI-5 with major morbidity/mortality and minor complications. Univariable analyses were performed via the Cochran-Armitage Test and Cramer's V. Logistic regression evaluated the relationship between the mFI-5 and morbidity/mortality while accounting for demographics and pre-operative risk factors. Receiver operating characteristic (ROC) curves were plotted to visualize the predictive strength for outcomes.
RESULTS: Four hundred and twelve patients were analyzed. 8.7\% had major morbidity/mortality and 31.6\% minor complications. The mFI-5 categorized patients into 0 (n = 335), 1 (n = 58), and 2+ (n = 19) groups. Univariable analysis showed a higher mFI-5 was associated significantly with major morbidity/mortality (P = 0.004), but not minor (P = 0.281). Multivariable logistic regression showed a strong association between an mFI-5 score of 2+ with major complications (Major: OR = 4.616, CI [1.442-14.776], P = 0.010). ROC curves showed the mFI-5 was poor for predicting outcomes and performed better when other risk factors were added to the model.
CONCLUSION: The mFI-5 tool has an independent association with major morbidity/mortality in an institutional dataset for elective colorectal surgery, but is not predictive. Its predictive ability is enhanced when other patient-specific risk factors are incorporated.},
	language = {eng},
	number = {10},
	journal = {Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland},
	author = {Keller, D. S. and Reif de Paula, T. and Kiran, R. P. and Nemeth, S. K.},
	month = oct,
	year = {2020},
	pmid = {32291861},
	keywords = {Humans, Retrospective Studies, Risk Factors, Risk Assessment, Postoperative Complications, Elective Surgical Procedures, Colorectal Surgery, Frailty, elderly, complications, Quality Improvement, frailty index, National Surgical Quality Improvement Program (NSQIP), Surgical Outcomes},
	pages = {1396--1405},
}

@article{ida3675,
	title = {Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy},
	volume = {21},
	issn = {1534-4681},
	doi = {10.1245/s10434-014-3737-z},
	abstract = {BACKGROUND: Although a survival benefit of neoadjuvant treatment for patients with esophageal cancer has been highlighted, the influence of neoadjuvant treatment on the nutritional status of patients with esophageal cancer is not well understood.
METHODS: Changes in body composition parameters were assessed in 30 patients who underwent neoadjuvant chemotherapy (NAC) comprising docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy from August 2009 to April 2013. Body composition was evaluated before and after NAC using multifrequency bioelectrical impedance analysis (InBody 720; Biospace, Tokyo, Japan). Postoperative complications were graded according to the Clavien-Dindo classification.
RESULTS: Twenty-three postoperative events occurred in 16 patients. A decrease in body protein was observed in 13 patients (43.3 \%), while skeletal muscle (SM), body cell mass (BCM), and fat-free mass (FFM) declined in 11 patients (36.7 \%) during NAC. Changes in these four parameters during chemotherapy significantly differed between patients with postoperative complications and those without: protein, -1.6 ± 0.9 versus +4.4 ± 2.1 kg (P = 0.01); SM, -1.3 ± 1.1 versus +4.7 ± 2.4 kg (P = 0.02); BCM, -2.4 ± 1.6 versus +3.8 ± 2.2 kg (P = 0.03); and FFM, -1.4 ± 1.4 versus +4.3 ± 2.3 kg (P = 0.04).
CONCLUSIONS: Changes in body composition parameters are possible predictive markers of postoperative complications after esophagectomy after NAC. Further analysis is needed to clarify whether nutritional intervention improves such parameters and thus contributes to reduced postoperative morbidity.},
	language = {eng},
	number = {11},
	journal = {Annals of Surgical Oncology},
	author = {Ida, Satoshi and Watanabe, Masayuki and Karashima, Ryuichi and Imamura, Yu and Ishimoto, Takatsugu and Baba, Yoshifumi and Iwagami, Shiro and Sakamoto, Yasuo and Miyamoto, Yuji and Yoshida, Naoya and Baba, Hideo},
	month = oct,
	year = {2014},
	pmid = {24793436},
	keywords = {Body Composition, Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Prognosis, Fluorouracil, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Postoperative Complications, Taxoids, Docetaxel},
	pages = {3675--3679},
	file = {Ida et al. - 2014 - Changes in body composition secondary to neoadjuva.pdf:/Users/jcsal/Zotero/storage/MMQB8ZEL/Ida et al. - 2014 - Changes in body composition secondary to neoadjuva.pdf:application/pdf},
}

@article{kreis25,
	title = {Use of {Preoperative} {Magnetic} {Resonance} {Imaging} to {Select} {Patients} with {Rectal} {Cancer} for {Neoadjuvant} {Chemoradiation}--{Interim} {Analysis} of the {German} {OCUM} {Trial} ({NCT01325649})},
	volume = {20},
	issn = {1873-4626},
	doi = {10.1007/s11605-015-3011-0},
	abstract = {INTRODUCTION: Introduction of total mesorectal excision (TME) surgery for rectal cancer decreased local recurrence dramatically. Additional neoadjuvant chemoradiation (nCR) is frequently given in UICC II and III tumors based on TNM staging which is of limited accuracy. We aimed to evaluate determination of circumferential margin by magnetic resonance imaging (mrCRM) as an alternative criterium for nCR.
METHODS: Multicenter prospective cohort study which enrolled 642 patients in 13 centers with non-metastasized rectal adenocarcinoma. Patients with T4 tumors or patients with a mrCRM of 1 mm or less were treated by neoadjuvant chemoradiation. All others proceeded directly to surgery when inclusion criteria and no exclusion criteria were met. Quality of TME and accuracy of mrCRM determination were assessed during pathology workup.
RESULTS: TME was complete in 381 of 389 patients after surgery without nCR (97.9\%) and in 245 of 253 patients (96.8\%) after nCR. Negative pathology circumferential margins (pCRM) were seen in 97.4\% without nCR and in 89\% of patients after nCR. Negative pCRM was predicted by negative mrCRM in 98.3\% of rectal cancers. NCR was given to 253 of 642 patients (39.5\%). Lymph node count was 23 (range 7-79; median/range) for surgery without nCR and 19 (range 2-56) for surgery after nCR.
CONCLUSIONS: Surgical quality determined by pathology workup of specimen was very good in this study. Magnetic resonance imaging guided indication for nCR allows to achieve superb results concerning surrogate parameters for good oncological outcome. Thus, use of neoadjuvant chemoradiation with its potential detrimental side effects may be substantially reduced in selected patients.},
	language = {eng},
	number = {1},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Kreis, Martin E. and Ruppert, R. and Ptok, H. and Strassburg, J. and Brosi, P. and Lewin, A. and Schön, M. R. and Sauer, J. and Junginger, T. and Merkel, S. and Hermanek, P. and {OCUM study group}},
	month = jan,
	year = {2016},
	pmid = {26556476},
	keywords = {Humans, Magnetic Resonance Imaging, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Prospective Studies, Aged, 80 and over, Adult, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Patient Selection, Preoperative Care, Rectum, Rectal Neoplasms, Multimodal treatment, Rectal cancer, Magnetic resonance imaging, Neoadjuvant, Quality},
	pages = {25--32; discussion 32--33},
}

@article{gorgec137,
	title = {{MRI} in addition to {CT} in patients scheduled for local therapy of colorectal liver metastases ({CAMINO}): an international, multicentre, prospective, diagnostic accuracy trial},
	volume = {25},
	issn = {1474-5488},
	shorttitle = {{MRI} in addition to {CT} in patients scheduled for local therapy of colorectal liver metastases ({CAMINO})},
	doi = {10.1016/S1470-2045(23)00572-7},
	abstract = {BACKGROUND: Guidelines are inconclusive on whether contrast-enhanced MRI using gadoxetic acid and diffusion-weighted imaging should be added routinely to CT in the investigation of patients with colorectal liver metastases who are scheduled for curative liver resection or thermal ablation, or both. Although contrast-enhanced MRI is reportedly superior than contrast-enhanced CT in the detection and characterisation of colorectal liver metastases, its effect on clinical patient management is unknown. We aimed to assess the clinical effect of an additional liver contrast-enhanced MRI on local treatment plan in patients with colorectal liver metastases amenable to local treatment, based on contrast-enhanced CT.
METHODS: We did an international, multicentre, prospective, incremental diagnostic accuracy trial in 14 liver surgery centres in the Netherlands, Belgium, Norway, and Italy. Participants were aged 18 years or older with histological proof of colorectal cancer, a WHO performance status score of 0-4, and primary or recurrent colorectal liver metastases, who were scheduled for local therapy based on contrast-enhanced CT. All patients had contrast-enhanced CT and liver contrast-enhanced MRI including diffusion-weighted imaging and gadoxetic acid as a contrast agent before undergoing local therapy. The primary outcome was change in the local clinical treatment plan (decided by the individual clinics) on the basis of liver contrast-enhanced MRI findings, analysed in the intention-to-image population. The minimal clinically important difference in the proportion of patients who would have change in their local treatment plan due to an additional liver contrast-enhanced MRI was 10\%. This study is closed and registered in the Netherlands Trial Register, NL8039.
FINDINGS: Between Dec 17, 2019, and July 31, 2021, 325 patients with colorectal liver metastases were assessed for eligibility. 298 patients were enrolled and included in the intention-to-treat population, including 177 males (59\%) and 121 females (41\%) with planned local therapy based on contrast-enhanced CT. A change in the local treatment plan based on liver contrast-enhanced MRI findings was observed in 92 (31\%; 95\% CI 26-36) of 298 patients. Changes were made for 40 patients (13\%) requiring more extensive local therapy, 11 patients (4\%) requiring less extensive local therapy, and 34 patients (11\%) in whom the indication for curative-intent local therapy was revoked, including 26 patients (9\%) with too extensive disease and eight patients (3\%) with benign lesions on liver contrast-enhanced MRI (confirmed by a median follow-up of 21·0 months [IQR 17·5-24·0]).
INTERPRETATION: Liver contrast-enhanced MRI should be considered in all patients scheduled for local treatment for colorectal liver metastases on the basis of contrast-enhanced CT imaging.
FUNDING: The Dutch Cancer Society and Bayer AG - Pharmaceuticals.},
	language = {eng},
	number = {1},
	journal = {The Lancet. Oncology},
	author = {Görgec, Burak and Hansen, Ingrid S. and Kemmerich, Gunter and Syversveen, Trygve and Abu Hilal, Mohammed and Belt, Eric J. T. and Bosscha, Koop and Burgmans, Mark C. and Cappendijk, Vincent C. and D'Hondt, Mathieu and Edwin, Bjørn and van Erkel, Arian R. and Gielkens, Hugo A. J. and Grünhagen, Dirk J. and Gobardhan, Paul D. and Hartgrink, Henk H. and Horsthuis, Karin and Klompenhouwer, Elisabeth G. and Kok, Niels F. M. and Kint, Peter A. M. and Kuhlmann, Koert and Leclercq, Wouter K. G. and Lips, Daan J. and Lutin, Bart and Maas, Monique and Marsman, Hendrik A. and Meijerink, Martijn and Meyer, Yannick and Morone, Mario and Peringa, Jan and Sijberden, Jasper P. and van Delden, Otto M. and van den Bergh, Janneke E. and Vanhooymissen, Inge J. S. and Vermaas, Maarten and Willemssen, François E. J. A. and Dijkgraaf, Marcel G. W. and Bossuyt, Patrick M. and Swijnenburg, Rutger-Jan and Fretland, Åsmund A. and Verhoef, Cornelis and Besselink, Marc G. and Stoker, Jaap and {CAMINO Study Group}},
	month = jan,
	year = {2024},
	pmid = {38081200},
	keywords = {Humans, Magnetic Resonance Imaging, Tomography, X-Ray Computed, Female, Male, Colorectal Neoplasms, Prospective Studies, Liver Neoplasms, Contrast Media},
	pages = {137--146},
}

@article{vanworkum601,
	title = {Intrathoracic vs {Cervical} {Anastomosis} {After} {Totally} or {Hybrid} {Minimally} {Invasive} {Esophagectomy} for {Esophageal} {Cancer}: {A} {Randomized} {Clinical} {Trial}},
	volume = {156},
	issn = {2168-6262},
	shorttitle = {Intrathoracic vs {Cervical} {Anastomosis} {After} {Totally} or {Hybrid} {Minimally} {Invasive} {Esophagectomy} for {Esophageal} {Cancer}},
	doi = {10.1001/jamasurg.2021.1555},
	abstract = {BACKGROUND: Transthoracic minimally invasive esophagectomy (MIE) is increasingly performed as part of curative multimodality treatment. There appears to be no robust evidence on the preferred location of the anastomosis after transthoracic MIE.
OBJECTIVE: To compare an intrathoracic with a cervical anastomosis in a randomized clinical trial.
DESIGN, SETTING, AND PARTICIPANTS: This open, multicenter randomized clinical superiority trial was performed at 9 Dutch high-volume hospitals. Patients with midesophageal to distal esophageal or gastroesophageal junction cancer planned for curative resection were included. Data collection occurred from April 2016 through February 2020.
INTERVENTION: Patients were randomly assigned (1:1) to transthoracic MIE with intrathoracic or cervical anastomosis.
MAIN OUTCOMES AND MEASURES: The primary end point was anastomotic leakage requiring endoscopic, radiologic, or surgical intervention. Secondary outcomes were overall anastomotic leak rate, other postoperative complications, length of stay, mortality, and quality of life.
RESULTS: Two hundred sixty-two patients were randomized, and 245 were eligible for analysis. Anastomotic leakage necessitating reintervention occurred in 15 of 122 patients with intrathoracic anastomosis (12.3\%) and in 39 of 123 patients with cervical anastomosis (31.7\%; risk difference, -19.4\% [95\% CI, -29.5\% to -9.3\%]). Overall anastomotic leak rate was 12.3\% in the intrathoracic anastomosis group and 34.1\% in the cervical anastomosis group (risk difference, -21.9\% [95\% CI, -32.1\% to -11.6\%]). Intensive care unit length of stay, mortality rates, and overall quality of life were comparable between groups, but intrathoracic anastomosis was associated with fewer severe complications (risk difference, -11.3\% [-20.4\% to -2.2\%]), lower incidence of recurrent laryngeal nerve palsy (risk difference, -7.3\% [95\% CI, -12.1\% to -2.5\%]), and better quality of life in 3 subdomains (mean differences: dysphagia, -12.2 [95\% CI, -19.6 to -4.7]; problems of choking when swallowing, -10.3 [95\% CI, -16.4 to 4.2]; trouble with talking, -15.3 [95\% CI, -22.9 to -7.7]).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, intrathoracic anastomosis resulted in better outcome for patients treated with transthoracic MIE for midesophageal to distal esophageal or gastroesophageal junction cancer.
TRIAL REGISTRATION: Trialregister.nl Identifier: NL4183 (NTR4333).},
	language = {eng},
	number = {7},
	journal = {JAMA surgery},
	author = {van Workum, Frans and Verstegen, Moniek H. P. and Klarenbeek, Bastiaan R. and Bouwense, Stefan A. W. and van Berge Henegouwen, Mark I. and Daams, Freek and Gisbertz, Suzanne S. and Hannink, Gerjon and Haveman, Jan Willem and Heisterkamp, Joos and Jansen, Walther and Kouwenhoven, Ewout A. and van Lanschot, Jan J. B. and Nieuwenhuijzen, Grard A. P. and van der Peet, Donald L. and Polat, Fatih and Ubels, Sander and Wijnhoven, Bas P. L. and Rovers, Maroeska M. and Rosman, Camiel and {ICAN collaborative research group}},
	month = jul,
	year = {2021},
	pmid = {33978698},
	pmcid = {PMC8117060},
	keywords = {Aged, Anastomosis, Surgical, Anastomotic Leak, Carcinoma, Esophageal Neoplasms, Esophagectomy, Esophagogastric Junction, Female, Humans, Length of Stay, Male, Middle Aged, Minimally Invasive Surgical Procedures, Netherlands, Quality of Life, Treatment Outcome},
	pages = {601--610},
	file = {van Workum et al_2021_Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally.pdf:/Users/jcsal/Zotero/storage/YLBFRRBB/van Workum et al_2021_Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally.pdf:application/pdf},
}

@article{allum5062,
	title = {Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer},
	volume = {27},
	issn = {1527-7755},
	doi = {10.1200/JCO.2009.22.2083},
	abstract = {PURPOSE: OEO2 is a randomized, controlled trial of preoperative chemotherapy in patients undergoing radical surgery for esophageal cancer. Random assignment was to surgery alone (S) or to two cycles of combination cisplatin and fluorouracil before surgery (CS). Initial results reported in 2002 demonstrated an advantage for both disease-free and overall survival in the CS group. The analysis has now been updated after a median follow-up of 6 years.
PATIENTS AND METHODS: OEO2 recruited 802 patients, 400 on CS and 402 on S. The nature of the first recurrence event and cause of death are detailed. Survival has been determined from Kaplan-Meier curves and treatment comparisons made with the log-rank test. Survival by extent of resection is presented.
RESULTS: There were 655 deaths, 335 for S and 320 for CS. The survival benefit has been maintained with a hazard ratio (HR) of 0.84 (95\% CI, 0.72 to 0.98; P = .03) which in absolute terms is a 5-year survival of 23.0\% for CS compared with 17.1\% for S. The treatment effect is consistent in both adenocarcinoma and squamous cell carcinoma. The first disease-free survival event was macroscopic residual disease from incomplete resection (R2) or no resection in 26.4\% of the S group versus 14.3\% of the CS P {\textless} .001. Three-year survival by type of resection was R0 42.4\%, R1 was 18.0\%, and R2 was 8.6\%.
CONCLUSION: Long-term follow-up confirms that preoperative chemotherapy improves survival in operable esophageal cancer and should be considered as a standard of care.},
	language = {eng},
	number = {30},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Allum, William H. and Stenning, Sally P. and Bancewicz, John and Clark, Peter I. and Langley, Ruth E.},
	month = oct,
	year = {2009},
	pmid = {19770374},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Antineoplastic Combined Chemotherapy Protocols, Time Factors, Aged, 80 and over, Adult, Fluorouracil, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Chemo},
	pages = {5062--5067},
}

@article{block770,
	title = {Improvement in staging of esophageal cancer with the addition of positron emission tomography},
	volume = {64},
	issn = {0003-4975},
	doi = {10.1016/s0003-4975(97)00619-x},
	abstract = {BACKGROUND: Positron emission tomography with the glucose analogue 2-[18F]fluoro-2-deoxy-D-glucose (FDG) has been used to detect and stage a variety of malignancies. We hypothesized that FDG-positron emission tomography would improve staging of patients with esophageal cancer and thereby facilitate selection of candidates for resection.
METHODS: Fifty-eight patients (42 men and 16 women) with biopsy-proven esophageal cancer were evaluated with both FDG-positron emission tomography and computed tomography.
RESULTS: In all but 2 patients, increased FDG uptake was identified at the site of the primary tumor. Six patients were not operative candidates. Seventeen patients were not candidates for resection because of metastatic disease. Positron emission tomography identified the metastatic disease in all 17 (12 of whom underwent confirmatory biopsy), whereas computed tomography was positive for metastases in only 5. The remaining 35 patients underwent surgical exploration, were judged to have resectable disease and had esophagectomy. Pathologic examination of resected specimens identified lymph node metastases in 21 patients. These nodes were detected by positron emission tomography in 11 patients and by computed tomography in 6.
CONCLUSIONS: Positron emission tomography improved staging and facilitated selection of patients for operation by detecting distant disease not identified by computed tomography alone.},
	language = {eng},
	number = {3},
	journal = {The Annals of Thoracic Surgery},
	author = {Block, M. I. and Patterson, G. A. and Sundaresan, R. S. and Bailey, M. S. and Flanagan, F. L. and Dehdashti, F. and Siegel, B. A. and Cooper, J. D.},
	month = sep,
	year = {1997},
	pmid = {9307472},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Neoplasm Staging, Image Processing, Computer-Assisted, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Fluorodeoxyglucose F18, Radiopharmaceuticals, Lymphatic Metastasis, Patient Selection, Tomography, Emission-Computed, Fluorine Radioisotopes, Biopsy, Contrast Media, Radiographic Image Enhancement, Deoxyglucose},
	pages = {770--776; discussion 776--777},
}

@article{shapiro1090,
	title = {Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer ({CROSS}): long-term results of a randomised controlled trial},
	volume = {16},
	issn = {1474-5488},
	shorttitle = {Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer ({CROSS})},
	doi = {10.1016/S1470-2045(15)00040-6},
	abstract = {BACKGROUND: Initial results of the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) comparing neoadjuvant chemoradiotherapy plus surgery versus surgery alone in patients with squamous cell carcinoma and adenocarcinoma of the oesophagus or oesophagogastric junction showed a significant increase in 5-year overall survival in favour of the neoadjuvant chemoradiotherapy plus surgery group after a median of 45 months' follow-up. In this Article, we report the long-term results after a minimum follow-up of 5 years.
METHODS: Patients with clinically resectable, locally advanced cancer of the oesophagus or oesophagogastric junction (clinical stage T1N1M0 or T2-3N0-1M0, according to the TNM cancer staging system, sixth edition) were randomly assigned in a 1:1 ratio with permuted blocks of four or six to receive either weekly administration of five cycles of neoadjuvant chemoradiotherapy (intravenous carboplatin [AUC 2 mg/mL per min] and intravenous paclitaxel [50 mg/m(2) of body-surface area] for 23 days) with concurrent radiotherapy (41·4 Gy, given in 23 fractions of 1·8 Gy on 5 days per week) followed by surgery, or surgery alone. The primary endpoint was overall survival, analysed by intention-to-treat. No adverse event data were collected beyond those noted in the initial report of the trial. This trial is registered with the Netherlands Trial Register, number NTR487, and has been completed.
FINDINGS: Between March 30, 2004, and Dec 2, 2008, 368 patients from eight participating centres (five academic centres and three large non-academic teaching hospitals) in the Netherlands were enrolled into this study and randomly assigned to the two treatment groups: 180 to surgery plus neoadjuvant chemoradiotherapy and 188 to surgery alone. Two patients in the neoadjuvant chemoradiotherapy group withdrew consent, so a total of 366 patients were analysed (178 in the neoadjuvant chemoradiotherapy plus surgery group and 188 in the surgery alone group). Of 171 patients who received any neoadjuvant chemoradiotherapy in this group, 162 (95\%) were able to complete the entire neoadjuvant chemoradiotherapy regimen. After a median follow-up for surviving patients of 84·1 months (range 61·1-116·8, IQR 70·7-96·6), median overall survival was 48·6 months (95\% CI 32·1-65·1) in the neoadjuvant chemoradiotherapy plus surgery group and 24·0 months (14·2-33·7) in the surgery alone group (HR 0·68 [95\% CI 0·53-0·88]; log-rank p=0·003). Median overall survival for patients with squamous cell carcinomas was 81·6 months (95\% CI 47·2-116·0) in the neoadjuvant chemoradiotherapy plus surgery group and 21·1 months (15·4-26·7) in the surgery alone group (HR 0·48 [95\% CI 0·28-0·83]; log-rank p=0·008); for patients with adenocarcinomas, it was 43·2 months (24·9-61·4) in the neoadjuvant chemoradiotherapy plus surgery group and 27·1 months (13·0-41·2) in the surgery alone group (HR 0·73 [95\% CI 0·55-0·98]; log-rank p=0·038).
INTERPRETATION: Long-term follow-up confirms the overall survival benefits for neoadjuvant chemoradiotherapy when added to surgery in patients with resectable oesophageal or oesophagogastric junctional cancer. This improvement is clinically relevant for both squamous cell carcinoma and adenocarcinoma subtypes. Therefore, neoadjuvant chemoradiotherapy according to the CROSS trial followed by surgical resection should be regarded as a standard of care for patients with resectable locally advanced oesophageal or oesophagogastric junctional cancer.
FUNDING: Dutch Cancer Foundation (KWF Kankerbestrijding).},
	language = {eng},
	number = {9},
	journal = {The Lancet. Oncology},
	author = {Shapiro, Joel and van Lanschot, J. Jan B. and Hulshof, Maarten C. C. M. and van Hagen, Pieter and van Berge Henegouwen, Mark I. and Wijnhoven, Bas P. L. and van Laarhoven, Hanneke W. M. and Nieuwenhuijzen, Grard A. P. and Hospers, Geke A. P. and Bonenkamp, Johannes J. and Cuesta, Miguel A. and Blaisse, Reinoud J. B. and Busch, Olivier R. C. and Ten Kate, Fiebo J. W. and Creemers, Geert-Jan M. and Punt, Cornelis J. A. and Plukker, John Th M. and Verheul, Henk M. W. and Bilgen, Ernst J. Spillenaar and van Dekken, Herman and van der Sangen, Maurice J. C. and Rozema, Tom and Biermann, Katharina and Beukema, Jannet C. and Piet, Anna H. M. and van Rij, Caroline M. and Reinders, Janny G. and Tilanus, Hugo W. and Steyerberg, Ewout W. and van der Gaast, Ate and {CROSS study group}},
	month = sep,
	year = {2015},
	pmid = {26254683},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Disease-Free Survival, Esophageal Neoplasms, Chemoradiotherapy, Esophagogastric Junction, Paclitaxel, Carboplatin},
	pages = {1090--1098},
	file = {Shapiro et al_2015_Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal.pdf:/Users/jcsal/Zotero/storage/N4TQ87PH/Shapiro et al_2015_Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal.pdf:application/pdf},
}

@article{kelly1191,
	title = {Adjuvant {Nivolumab} in {Resected} {Esophageal} or {Gastroesophageal} {Junction} {Cancer}},
	volume = {384},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2032125},
	abstract = {BACKGROUND: No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.
METHODS: We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks for 16 weeks, followed by nivolumab at a dose of 480 mg every 4 weeks) or matching placebo. The maximum duration of the trial intervention period was 1 year. The primary end point was disease-free survival.
RESULTS: The median follow-up was 24.4 months. Among the 532 patients who received nivolumab, the median disease-free survival was 22.4 months (95\% confidence interval [CI], 16.6 to 34.0), as compared with 11.0 months (95\% CI, 8.3 to 14.3) among the 262 patients who received placebo (hazard ratio for disease recurrence or death, 0.69; 96.4\% CI, 0.56 to 0.86; P{\textless}0.001). Disease-free survival favored nivolumab across multiple prespecified subgroups. Grade 3 or 4 adverse events that were considered by the investigators to be related to the active drug or placebo occurred in 71 of 532 patients (13\%) in the nivolumab group and 15 of 260 patients (6\%) in the placebo group. The trial regimen was discontinued because of adverse events related to the active drug or placebo in 9\% of the patients in the nivolumab group and 3\% of those in the placebo group.
CONCLUSIONS: Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).},
	language = {eng},
	number = {13},
	journal = {The New England Journal of Medicine},
	author = {Kelly, Ronan J. and Ajani, Jaffer A. and Kuzdzal, Jaroslaw and Zander, Thomas and Van Cutsem, Eric and Piessen, Guillaume and Mendez, Guillermo and Feliciano, Josephine and Motoyama, Satoru and Lièvre, Astrid and Uronis, Hope and Elimova, Elena and Grootscholten, Cecile and Geboes, Karen and Zafar, Syed and Snow, Stephanie and Ko, Andrew H. and Feeney, Kynan and Schenker, Michael and Kocon, Piotr and Zhang, Jenny and Zhu, Lili and Lei, Ming and Singh, Prianka and Kondo, Kaoru and Cleary, James M. and Moehler, Markus and {CheckMate 577 Investigators}},
	month = apr,
	year = {2021},
	pmid = {33789008},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Kaplan-Meier Estimate, Aged, 80 and over, Adult, Chemotherapy, Adjuvant, Stomach Neoplasms, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Esophagogastric Junction, Intention to Treat Analysis, Double-Blind Method, Immune Checkpoint Inhibitors, Nivolumab, B7-H1 Antigen},
	pages = {1191--1203},
	file = {Kelly et al_2021_Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.pdf:/Users/jcsal/Zotero/storage/VP229UNN/Kelly et al_2021_Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.pdf:application/pdf;nejmoa2032125_appendix.pdf:/Users/jcsal/Zotero/storage/2UJYC5RB/nejmoa2032125_appendix.pdf:application/pdf;nejmoa2032125_protocol.pdf:/Users/jcsal/Zotero/storage/W8GYW4NM/nejmoa2032125_protocol.pdf:application/pdf},
}

@article{nuytens323,
	title = {Five-{Year} {Survival} {Outcomes} of {Hybrid} {Minimally} {Invasive} {Esophagectomy} in {Esophageal} {Cancer}: {Results} of the {MIRO} {Randomized} {Clinical} {Trial}},
	volume = {156},
	issn = {2168-6262},
	shorttitle = {Five-{Year} {Survival} {Outcomes} of {Hybrid} {Minimally} {Invasive} {Esophagectomy} in {Esophageal} {Cancer}},
	doi = {10.1001/jamasurg.2020.7081},
	abstract = {IMPORTANCE: Available data comparing the long-term results of hybrid minimally invasive esophagectomy (HMIE) with that of open esophagectomy are conflicting, with similar or even better results reported for the minimally invasive esophagectomy group.
OBJECTIVE: To evaluate the long-term, 5-year outcomes of HMIE vs open esophagectomy, including overall survival (OS), disease-free survival (DFS), and pattern of disease recurrence, and the potential risk factors associated with these outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial is a post hoc follow-up study that analyzes the results of the open-label Multicentre Randomized Controlled Phase III Trial, which enrolled patients from 13 different centers in France and was conducted from October 26, 2009, to April 4, 2012. Eligible patients were 18 to 75 years of age and were diagnosed with resectable cancer of the middle or lower third of the esophagus. After exclusions, patients were randomized to either the HMIE group or the open esophagectomy group. Data analysis was performed on an intention-to-treat basis from November 19, 2019, to December 4, 2020.
INTERVENTIONS: Hybrid minimally invasive esophagectomy (laparoscopic gastric mobilization with open right thoracotomy) was compared with open esophagectomy.
MAIN OUTCOMES AND MEASURES: The primary end points of this follow-up study were 5-year OS and DFS. The secondary end points were the site of disease recurrence and potential risk factors associated with DFS and OS.
RESULTS: A total of 207 patients were randomized, of whom 175 were men (85\%), and the median (range) age was 61 (23-78) years. The median follow-up duration was 58.2 (95\% CI, 56.5-63.8) months. The 5-year OS was 59\% (95\% CI, 48\%-68\%) in the HMIE group and 47\% (95\% CI, 37\%-57\%) in the open esophagectomy group (hazard ratio [HR], 0.71; 95\% CI, 0.48-1.06). The 5-year DFS was 52\% (95\% CI, 42\%-61\%) in the HMIE group vs 44\% (95\% CI, 34\%-53\%) in the open esophagectomy group (HR, 0.81; 95\% CI, 0.55-1.17). No statistically significant difference in recurrence rate or location was found between groups. In a multivariable analysis, major intraoperative and postoperative complications (HR, 2.21; 95\% CI, 1.41-3.45; P {\textless} .001) and major pulmonary complications (HR, 1.94; 95\% CI, 1.21-3.10; P = .005) were identified as risk factors associated with decreased OS. Similarly, multivariable analysis of DFS identified overall intraoperative and postoperative complications (HR, 1.93; 95\% CI, 1.28-2.90; P = .002) and major pulmonary complications (HR, 1.85; 95\% CI, 1.19-2.86; P = .006) as risk factors.
CONCLUSIONS AND RELEVANCE: This study found no difference in long-term survival between the HMIE and open esophagectomy groups. Major postoperative overall complications and pulmonary complications appeared to be independent risk factors in decreased OS and DFS, providing additional evidence that HMIE may be associated with improved oncological results compared with open esophagectomy primarily because of a reduction in postoperative complications.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00937456.},
	language = {eng},
	number = {4},
	journal = {JAMA surgery},
	author = {Nuytens, Frederiek and Dabakuyo-Yonli, Tienhan Sandrine and Meunier, Bernard and Gagnière, Johan and Collet, Denis and D'Journo, Xavier B. and Brigand, Cécile and Perniceni, Thierry and Carrère, Nicolas and Mabrut, Jean-Yves and Msika, Simon and Peschaud, Frédérique and Prudhomme, Michel and Markar, Sheraz R. and Piessen, Guillaume and {Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Groups}},
	month = apr,
	year = {2021},
	pmid = {33595631},
	pmcid = {PMC7890455},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Risk Factors, Aged, 80 and over, Adult, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Minimally Invasive Surgical Procedures},
	pages = {323--332},
	file = {Nuytens et al_2021_Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in.pdf:/Users/jcsal/Zotero/storage/UNVQ59AX/Nuytens et al_2021_Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in.pdf:application/pdf},
}

@article{mariette1023,
	title = {Health-related {Quality} of {Life} {Following} {Hybrid} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Patients} {With} {Esophageal} {Cancer}, {Analysis} of a {Multicenter}, {Open}-label, {Randomized} {Phase} {III} {Controlled} {Trial}: {The} {MIRO} {Trial}},
	volume = {271},
	issn = {1528-1140},
	shorttitle = {Health-related {Quality} of {Life} {Following} {Hybrid} {Minimally} {Invasive} {Versus} {Open} {Esophagectomy} for {Patients} {With} {Esophageal} {Cancer}, {Analysis} of a {Multicenter}, {Open}-label, {Randomized} {Phase} {III} {Controlled} {Trial}},
	doi = {10.1097/SLA.0000000000003559},
	abstract = {BACKGROUND: Hybrid minimally invasive esophagectomy (HMIE) has been shown to reduce major postoperative complications compared with open esophagectomy (OE) for esophageal cancer.
OBJECTIVES: The aim of this study was to compare short- and long-term health-related quality of life (HRQOL) following HMIE and OE within a randomized controlled trial.
METHODS: We performed a multicenter, open-label, randomized controlled trial at 13 study centers between 2009 and 2012. Patients aged 18 to 75 years with resectable cancers of the middle or lower third of the esophagus were randomized to undergo either transthoracic OE or HMIE. Patients were followed-up every 6 months for 3 years postoperatively and global health assessed with EORTC-QLQC30 and esophageal symptoms assessed with EORTC-OES18.
RESULTS: The short-term reduction in global HRQOL at 30 days specifically role functioning [-33.33 (HMIE) vs -46.3 (OE); P = 0.0407] and social functioning [-16.88 (HMIE) vs -35.74 (OE); P = 0.0003] was less substantial in the HMIE group. At 2 years, social functioning had improved following HMIE to beyond baseline (+5.37) but remained reduced in the OE group (-8.33) (P = 0.0303). At 2 years, increases in pain were similarly reduced in the HMIE compared with the OE group [+6.94 (HMIE) vs +14.05 (OE); P = 0.018]. Postoperative complications in multivariate analysis were associated with role functioning, pain, and dysphagia.
CONCLUSIONS: Esophagectomy has substantial effects upon short-term HRQOL. These effects for some specific parameters are, however, reduced with HMIE, with persistent differences up to 2 years, and maybe mediated by a reduction in postoperative complications.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Mariette, Christophe and Markar, Sheraz and Dabakuyo-Yonli, Tienhan Sandrine and Meunier, Bernard and Pezet, Denis and Collet, Denis and D'Journo, Xavier Benoit and Brigand, Cécile and Perniceni, Thierry and Carrere, Nicolas and Mabrut, Jean Yves and Msika, Simon and Peschaud, Frédérique and Prudhomme, Michel and Bonnetain, Franck and Piessen, Guillaume and {FRENCH, FREGAT}},
	month = jun,
	year = {2020},
	pmid = {31404005},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Time Factors, Prognosis, Adult, Young Adult, Esophageal Neoplasms, Esophagectomy, Quality of Life, Minimally Invasive Surgical Procedures, Adolescent, Postoperative Period},
	pages = {1023--1029},
	file = {Mariette et al_2020_Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open.pdf:/Users/jcsal/Zotero/storage/LF554P7Z/Mariette et al_2020_Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open.pdf:application/pdf},
}

@article{vandersluis621,
	title = {Robot-assisted {Minimally} {Invasive} {Thoracolaparoscopic} {Esophagectomy} {Versus} {Open} {Transthoracic} {Esophagectomy} for {Resectable} {Esophageal} {Cancer}: {A} {Randomized} {Controlled} {Trial}},
	volume = {269},
	issn = {1528-1140},
	shorttitle = {Robot-assisted {Minimally} {Invasive} {Thoracolaparoscopic} {Esophagectomy} {Versus} {Open} {Transthoracic} {Esophagectomy} for {Resectable} {Esophageal} {Cancer}},
	doi = {10.1097/SLA.0000000000003031},
	abstract = {BACKGROUND: The standard curative treatment for patients with esophageal cancer is perioperative chemotherapy or preoperative chemoradiotherapy followed by open transthoracic esophagectomy (OTE). Robot-assisted minimally invasive thoracolaparoscopic esophagectomy (RAMIE) may reduce complications.
METHODS: A single-center randomized controlled trial was conducted, assigning 112 patients with resectable intrathoracic esophageal cancer to either RAMIE or OTE. The primary endpoint was the occurrence of overall surgery-related postoperative complications (modified Clavien-Dindo classification grade 2-5).
RESULTS: Overall surgery-related postoperative complications occurred less frequently after RAMIE (59\%) compared to OTE (80\%) [risk ratio with RAMIE (RR) 0.74; 95\% confidence interval (CI), 0.57-0.96; P = 0.02]. RAMIE resulted in less median blood loss (400 vs 568 mL, P {\textless}0.001), a lower percentage of pulmonary complications (RR 0.54; 95\% CI, 0.34-0.85; P = 0.005) and cardiac complications (RR 0.47; 95\% CI, 0.27-0.83; P = 0.006) and lower mean postoperative pain (visual analog scale, 1.86 vs 2.62; P {\textless} 0.001) compared to OTE. Functional recovery at postoperative day 14 was better in the RAMIE group [RR 1.48 (95\% CI, 1.03-2.13; P = 0.038)] with better quality of life score at discharge [mean difference quality of life score 13.4 (2.0-24.7, p = 0.02)] and 6 weeks postdischarge [mean difference 11.1 quality of life score (1.0-21.1; P = 0.03)]. Short- and long-term oncological outcomes were comparable at a medium follow-up of 40 months.
CONCLUSIONS: RAMIE resulted in a lower percentage of overall surgery-related and cardiopulmonary complications with lower postoperative pain, better short-term quality of life, and a better short-term postoperative functional recovery compared to OTE. Oncological outcomes were comparable and in concordance with the highest standards nowadays.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {van der Sluis, Pieter C. and van der Horst, Sylvia and May, Anne M. and Schippers, Carlo and Brosens, Lodewijk A. A. and Joore, Hans C. A. and Kroese, Christiaan C. and Haj Mohammad, Nadia and Mook, Stella and Vleggaar, Frank P. and Borel Rinkes, Inne H. M. and Ruurda, Jelle P. and van Hillegersberg, Richard},
	month = apr,
	year = {2019},
	pmid = {30308612},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Postoperative Complications, Thoracoscopy, Robotic Surgical Procedures},
	pages = {621--630},
	file = {van der Sluis et al_2019_Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open.pdf:/Users/jcsal/Zotero/storage/MJ584ZBQ/van der Sluis et al_2019_Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open.pdf:application/pdf},
}

@article{egberts1,
	title = {Fully robotic da {Vinci} {Ivor}-{Lewis} esophagectomy in four-arm technique-problems and solutions},
	volume = {30},
	issn = {1442-2050},
	doi = {10.1093/dote/dox098},
	abstract = {The aim of this technical note is a step-by-step description of a fully robotic abdominothoracic esophagectomy with an intrathoracic esophagogastrostomy. We report on our technique and short-term results of 75 patients undergoing an Ivor-Lewis esophagectomy using a fully robotic 4-arm approach in the abdominal and thoracic phase with a hand-sewn intrathoracic anastomosis. There are several important steps and differences to consider compared to the conventional minimal invasive approach (patient's positioning, anaesthesiological set up, port placement, gastric conduit pull up, technique of esophagostrostomy). Mean operative time was 392 minutes (240-610) with a 94\% R0 resection status. Conversion to open procedure occurred in 2 (2.6\%) in the abdominal, and 14 (18.2\%) in the thoracic phase. Main reasons for conversion were problems during the lifting of the gastric conduit and difficulties in the construction of the esophagogastrostomy. The rate dropped during the last 20 patients (1/20 (10\%). Our results suggest that the reported technique is safe and feasible. It satisfies the oncological principles and provides the advantages of robotic assisted minimal invasive surgery.},
	language = {eng},
	number = {12},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Egberts, J.-H. and Stein, H. and Aselmann, H. and Hendricks, A. and Becker, T.},
	month = dec,
	year = {2017},
	pmid = {28881889},
	keywords = {Abdomen, Humans, Aged, Female, Male, Middle Aged, Aged, 80 and over, Adult, Esophagectomy, Esophagus, Stomach, Neoplasm, Residual, Intraoperative Complications, Conversion to Open Surgery, surgery, Anastomosis, Surgical, Operative Time, robotic surgery, Patient Positioning, Robotic Surgical Procedures, esophageal carcinoma, esophagus surgery, Thorax},
	pages = {1--9},
	file = {Egberts et al_2017_Fully robotic da Vinci Ivor-Lewis esophagectomy in four-arm technique-problems.pdf:/Users/jcsal/Zotero/storage/M5DSQMG5/Egberts et al_2017_Fully robotic da Vinci Ivor-Lewis esophagectomy in four-arm technique-problems.pdf:application/pdf},
}

@article{kernstine1847,
	title = {The robotic, 2-stage, 3-field esophagolymphadenectomy},
	volume = {127},
	issn = {0022-5223},
	doi = {10.1016/j.jtcvs.2004.02.014},
	language = {eng},
	number = {6},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Kernstine, Kemp H. and DeArmond, Daniel T. and Karimi, Mohsen and Van Natta, Timothy L. and Campos, Javier H. and Yoder, Mary R. and Everett, Jeffrey E.},
	month = jun,
	year = {2004},
	pmid = {15173760},
	keywords = {Humans, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Risk Assessment, Chemotherapy, Adjuvant, Adenocarcinoma, Esophageal Neoplasms, Esophagoscopy, Radiotherapy, Adjuvant, Deglutition Disorders, Preoperative Care, Minimally Invasive Surgical Procedures, Robotics},
	pages = {1847--1849},
	annote = {Not Helpful. Case report 2004
},
	file = {Kernstine et al_2004_The robotic, 2-stage, 3-field esophagolymphadenectomy.pdf:/Users/jcsal/Zotero/storage/SAFTSBST/Kernstine et al_2004_The robotic, 2-stage, 3-field esophagolymphadenectomy.pdf:application/pdf},
}

@article{stock519,
	title = {Robotic-{Assisted} {Ivor} {Lewis} {Esophagectomy}},
	volume = {33},
	issn = {1558-5042},
	doi = {10.1016/j.soc.2023.12.013},
	abstract = {Robotic-assisted surgery is a safe and effective approach to minimally invasive Ivor Lewis esophagectomy. Outcomes are optimized when surgeons are familiar with the fundamentals of minimally invasive surgery of the esophagus and after gaining sufficient experience with robotic surgical techniques.},
	language = {eng},
	number = {3},
	journal = {Surgical Oncology Clinics of North America},
	author = {Stock, Cameron and Watkins, Ammara and Moffatt-Bruce, Susan and Servais, Elliot},
	month = jul,
	year = {2024},
	pmid = {38789194},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Minimally Invasive Surgical Procedures, Robotic Surgical Procedures, Robotic surgery},
	pages = {519--527},
	file = {Stock et al_2024_Robotic-Assisted Ivor Lewis Esophagectomy.pdf:/Users/jcsal/Zotero/storage/4DEYX8B9/Stock et al_2024_Robotic-Assisted Ivor Lewis Esophagectomy.pdf:application/pdf},
}

@article{ali6329,
	title = {Robotic minimally invasive esophagectomy provides superior surgical resection},
	volume = {35},
	issn = {1432-2218},
	doi = {10.1007/s00464-020-08120-3},
	abstract = {INTRODUCTION: Robotic minimally invasive esophagectomy (RMIE) and "traditional" minimally invasive esophagectomy techniques (tMIE) have reported superior outcomes relative to open techniques. Differences in the outcomes of these two approaches have not been examined. We hypothesized that short-term outcomes of RMIE would be superior to tMIE.
METHODS AND PROCEDURES: The National Cancer Database was used to analyze outcomes of patients undergoing RMIE and tMIE from 2010 to 2016. Patients with clinical metastatic disease were excluded. Trends in the number of procedures performed with each approach were described using linear regression testing. Primary outcome of interest was 90-day mortality rate. Secondary outcomes of interest were positive surgical margin rate, number of lymph nodes (LN) removed, adequate lymphadenectomy ({\textgreater} 15 LNs), length of hospitalization (LOS), readmission rate, and conversion to open rate. Outcomes of RMIE and tMIE were compared using Wilcoxon rank sum test and chi square test as appropriate. Multivariable regression was also performed to reduce the impact of differences in the cohorts of patients receiving RMIE and tMIE.
RESULTS: 6661 minimally invasive esophagectomies were performed from 2010 to 2016 (1543/6661 (23.2\%) RMIE and 5118/6661 (76.8\%) tMIE). Over the study period, the proportion of RMIE increased from 10.4\% (64/618) in 2010 to 27.2\% (331/1216) in 2016 (p {\textless} 0.001) (Fig. 1). The primary outcome of 90-day mortality was similar between RMIE and tMIE (92/1170 (7.4\%) vs 305/4148 (7.9\%), p = 0.558) (Table 2). RMIE and tMIE also had similar readmission rate (6.3 vs 7\%, p = 0.380). There was no difference between the cohorts based on sex, age, race, insurance, and tumor size. The cohorts of patients receiving RMIE and tMIE differed in that RMIE patients had lower rates of elevated Charlson scores, were more likely to be treated at an academic institution, had a higher rate of advanced clinical T-stage and clinical nodal involvement, and had received neoadjuvant therapy. In a univariate analysis, RMIE had a lower rate of positive margin (3.9 vs 6.1\%, p = 0.001), more mean lymph nodes evaluated (16.6 ± 9.74 vs 16.1 ± 10.08 p = 0.018), lower conversion to open rate (5.4 vs 11.4\%, p {\textless} 0.001), and a shorter mean length of stay (12.1 ± 10.39 vs 12.8 ± 11.18 days, p {\textless} 0.001). In multivariable analysis, RMIE was associated with lower risk of conversion to open (OR 0.51, 95\% CI: 0.37-0.70, p {\textless} 0.001) and lower rate of positive margin (OR 0.62, 95\% CI: 0.41-0.93, p = 0.021).). Additionally, in a multivariable logistic regression, RMIE demonstrated superior adequate lymphadenectomy ({\textgreater} 15 LNs) (OR 1.18, 95\% CI 1.02-1.37, p {\textless} 0.032).
CONCLUSION: In the National Cancer Database, robotic esophagectomy is associated with superior rate of conversion to open and positive surgical margin status. We speculate enhanced dexterity and visualization of RMIE facilitates intraoperative performance leading to improvement in these outcomes.},
	language = {eng},
	number = {11},
	journal = {Surgical Endoscopy},
	author = {Ali, Ahmed M. and Bachman, Katelynn C. and Worrell, Stephanie G. and Gray, Kelsey E. and Perry, Yaron and Linden, Philip A. and Towe, Christopher W.},
	month = nov,
	year = {2021},
	pmid = {33174098},
	keywords = {Humans, Length of Stay, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Thoracic surgery, Robotic Surgical Procedures, Robotic surgery, Minimally- invasive surgery},
	pages = {6329--6334},
	file = {Ali et al_2021_Robotic minimally invasive esophagectomy provides superior surgical resection.pdf:/Users/jcsal/Zotero/storage/T6YCAPFT/Ali et al_2021_Robotic minimally invasive esophagectomy provides superior surgical resection.pdf:application/pdf},
}

@article{grimminger589,
	title = {Change from {Hybrid} to {Fully} {Minimally} {Invasive} and {Robotic} {Esophagectomy} is {Possible} without {Compromises}},
	volume = {67},
	issn = {1439-1902},
	doi = {10.1055/s-0038-1670664},
	abstract = {BACKGROUND: The incidence of esophageal carcinoma is increasing in the western world, and esophageal resection is the essential therapy. Several studies report advantages of minimally invasive esophagectomies (MIEs) versus conventional open procedures (OPs). The benefits of the use of fully MIE or robot-assisted MIE (RAMIE) compared with the hybrid approaches (laparoscopic gastric preparation and open transthoracic esophagectomy) remain unclear.
METHODS: Between July 2015 and August 2017, the data of 75 patients with esophageal carcinoma were prospectively registered. Of the 75 patients, 25 treated with a hybrid MIE (hybrid), 25 with total MIE (MIE), and 25 with RAMIE. All patients were operated by the same specialized surgeon in our center with an identical anastomotic technique (circular stapler).
RESULTS: The overall 30- and 90-day mortality rates were 0 and 1.33\% (1/75), respectively. Total hospital stay (p = 0.262), intensive care unit stay (p = 0.079), number of resected lymph nodes (p = 0.863), and R status (p = 0.132) did not differ statistically between the groups. However, pneumonia and wound infections occurred significantly and more frequently in the hybrid group compared with the minimally invasive groups (MIE and RAMIE) (p = 0.046 and p = 0.003, respectively).
CONCLUSION: Comparable results regarding morbidity and short-term outcome could be achieved in the MIE and RAMIE groups compared with the hybrid group. The data indicate that the learning curve is low in surgeons changing the technique form hybrid esophagectomy to fully MIE. Additionally, the total minimally invasive approaches seem to be associated with a low incidence of complications such as pneumonia and wound infections.},
	language = {eng},
	number = {7},
	journal = {The Thoracic and Cardiovascular Surgeon},
	author = {Grimminger, P. P. and Tagkalos, E. and Hadzijusufovic, E. and Corvinus, F. and Babic, B. and Lang, H.},
	month = oct,
	year = {2019},
	pmid = {30216947},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Treatment Outcome, Risk Factors, Time Factors, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Postoperative Complications, Learning Curve, Thoracotomy, Clinical Competence, Thoracoscopy, Robotic Surgical Procedures},
	pages = {589--596},
	annote = {Not helpful
},
	file = {Grimminger et al_2019_Change from Hybrid to Fully Minimally Invasive and Robotic Esophagectomy is.pdf:/Users/jcsal/Zotero/storage/ZC3KLINW/Grimminger et al_2019_Change from Hybrid to Fully Minimally Invasive and Robotic Esophagectomy is.pdf:application/pdf},
}

@article{pointer111,
	title = {Outcomes of 350 {Robotic}-assisted {Esophagectomies} at a {High}-volume {Cancer} {Center}: {A} {Contemporary} {Propensity}-score {Matched} {Analysis}},
	volume = {276},
	issn = {1528-1140},
	shorttitle = {Outcomes of 350 {Robotic}-assisted {Esophagectomies} at a {High}-volume {Cancer} {Center}},
	doi = {10.1097/SLA.0000000000004317},
	abstract = {OBJECTIVE: To evaluate perioperative and oncologic outcomes in our RAMIE cohort and compare outcomes with contemporary OE controls.
SUMMARY OF BACKGROUND DATA: RAMIE has emerged as an alternative to traditional open or laparoscopic approaches. Described in all esophagectomy techniques, rapid adoption has been attributed to both enhanced visualization and technical dexterity.
METHODS: We retrospectively reviewed patients who underwent RAMIE for malignancy. Patient characteristics, perioperative outcomes, and survival were evaluated. For perioperative and oncologic outcome comparison, contemporary OE controls were propensity-score matched from NSQIP and NCDB databases.
RESULTS: We identified 350 patients who underwent RAMIE between 2010 and 2019. Median body mass index was 27.4, 32\% demonstrated a Charlson Comorbidity Index {\textgreater}4. Nodal disease was identified in 50\% of patients and 74\% received neoadjuvant chemoradiotherapy. Mean operative time and blood loss were 425 minutes and 232 mL, respectively. Anastomotic leak occurred in 16\% of patients, 2\% required reoperation. Median LOS was 9 days, and 30-day mortality was 3\%. A median of 21 nodes were dissected with 96\% achieving an R0 resection. Median survival was 67.4 months. 222 RAMIE were matched 1:1 to the NSQIP OE control. RAMIE demonstrated decreased LOS (9 vs 10 days, P = 0.010) and reoperative rates (2.3 vs 12.2\%, P = 0.001), longer operative time (427 vs 311 minutes, P = 0.001), and increased rate of pulmonary embolism (5.4\% vs 0.9\%, P = 0.007) in comparison to NSQIP cohort. There was no difference in leak rate or mortality. Three hundred forty-three RAMIE were matched to OE cohort from NCDB with no difference in median overall survival (63 vs 53 months; P = 0.130).
CONCLUSION: In this largest reported institutional series, we demonstrate that RAMIE can be performed safely with excellent oncologic outcomes and decreased hospital stay when compared to the open approach.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgery},
	author = {Pointer, David T. and Saeed, Sabrina and Naffouje, Samer A. and Mehta, Rutika and Hoffe, Sarah E. and Dineen, Sean P. and Fleming, Jason B. and Fontaine, Jacques P. and Pimiento, Jose M.},
	month = jul,
	year = {2022},
	pmid = {33201093},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Anastomotic Leak, Minimally Invasive Surgical Procedures, Robotic Surgical Procedures},
	pages = {111--118},
	file = {Pointer et al_2022_Outcomes of 350 Robotic-assisted Esophagectomies at a High-volume Cancer Center.pdf:/Users/jcsal/Zotero/storage/4QWGTSWJ/Pointer et al_2022_Outcomes of 350 Robotic-assisted Esophagectomies at a High-volume Cancer Center.pdf:application/pdf},
}

@article{sarkaria920,
	title = {Early {Quality} of {Life} {Outcomes} {After} {Robotic}-{Assisted} {Minimally} {Invasive} and {Open} {Esophagectomy}},
	volume = {108},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2018.11.075},
	abstract = {BACKGROUND: Minimally invasive esophagectomy may improve some perioperative outcomes over open approaches; effects on quality of life are less clear.
METHODS: A prospective trial of robotic-assisted minimally invasive esophagectomy (RAMIE) and open esophagectomy was initiated, measuring quality of life via the Functional Assessment of Cancer Therapy-Esophageal and Brief Pain Inventory. Mixed generalized linear models assessed associations between quality of life scores over time and by surgery type.
RESULTS: In total, 106 patients underwent open esophagectomy; 64 underwent minimally invasive esophagectomy (98\% RAMIE). The groups did not differ in age, sex, comorbidities, histologic subtype, stage, or induction treatment (P = .42 to P {\textgreater} .95). Total Functional Assessment of Cancer Therapy-Esophageal scores were lower at 1 month (P {\textless} .001), returned to near baseline by 4 months, and did not differ between groups (P = .83). Brief Pain Inventory average pain severity (P = .007) and interference (P = .004) were lower for RAMIE. RAMIE had lower estimated blood loss (250 vs 350 cm3; P {\textless} .001), shorter length of stay (9 vs 11 days; P {\textless} .001), fewer intensive care unit admissions (8\% vs 20\%; P = .033), more lymph nodes harvested (25 vs 22; P = .05), and longer surgical time (6.4 vs 5.4 hours; P {\textless} .001). Major complications (39\% for RAMIE vs 52\% for open esophagectomy; P {\textgreater} .95), anastomotic leak (3\% vs 9\%; P = .41), and 90-day mortality (2\% vs 4\%; P = .85) did not differ between groups. Pulmonary (14\% vs 34\%; P = .014) and infectious (17\% vs 36\%; P = .029) complications were lower for RAMIE.
CONCLUSIONS: RAMIE is associated with lower immediate postoperative pain severity and interference and decreased pulmonary and infectious complications. Ongoing data accrual will assess mid-term and long-term outcomes in this cohort.},
	language = {eng},
	number = {3},
	journal = {The Annals of Thoracic Surgery},
	author = {Sarkaria, Inderpal S. and Rizk, Nabil P. and Goldman, Debra A. and Sima, Camelia and Tan, Kay See and Bains, Manjit S. and Adusumilli, Prasad S. and Molena, Daniela and Bott, Matthew and Atkinson, Thomas and Jones, David R. and Rusch, Valerie W.},
	month = sep,
	year = {2019},
	pmid = {31026433},
	pmcid = {PMC6774254},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Postoperative Care, Neoplasm Staging, Prospective Studies, Risk Assessment, Time Factors, Prognosis, Neoplasm Invasiveness, Survival Analysis, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Quality of Life, Preoperative Care, Thoracotomy, Pain, Postoperative, Operative Time, Robotic Surgical Procedures},
	pages = {920--928},
	file = {Sarkaria et al_2019_Early Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and.pdf:/Users/jcsal/Zotero/storage/RME24X93/Sarkaria et al_2019_Early Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and.pdf:application/pdf},
}

@article{chaodoz033,
	title = {Transition from video-assisted thoracoscopic to robotic esophagectomy: a single surgeon's experience},
	volume = {33},
	issn = {1442-2050},
	shorttitle = {Transition from video-assisted thoracoscopic to robotic esophagectomy},
	doi = {10.1093/dote/doz033},
	abstract = {Lymph node dissection (LND) along the left recurrent laryngeal nerve (RLN) is a technically challenging part of esophageal cancer surgery, especially after chemoradiotherapy (CRT). Robotic surgery holds promise to increase its safety and feasibility. The aim of this study was to describe a single thoracoscopic surgeon's experience related to the transition from video-assisted esophagectomy (VATE) to robotic esophagectomy (RE)-with a special focus on the safety of left RLN LND. Patients who underwent minimally invasive esophagectomy and RLN dissection following CRT were dichotomized according to the use of robotic surgery (robotic esophagectomy [RE] versus video-assisted thoracoscopic esophagectomy [VATE]). The following parameters were determined: (1) number of dissected nodes, (2) rates of RLN palsy, (3) rates of perioperative complications, and (4) learning curve. Learning curve analysis was performed using the 10-patient moving average (MA) for operation times and with the cumulative sum (CUSUM) method for left RLN LND (target failure rate: 15\%). The RE and VATE groups consisted of 39 and 67 patients, respectively. The intraoperative identification of the left RLN was more common in the RE group (97.4\%) than in the VATE group (68.7\%; P {\textless} 0.001). Postoperative left RLN palsy was significantly more frequent in the VATE group (26.9\%) than in the RE group (10.3\%; P = 0.042), with a higher rate of pneumonia in the former (16.4\% versus 2.6\%; P = 0.03). The MA chart revealed a downward trend followed by a flattening of the RE operation time at operation number 17 and 29, respectively. CUSUM analysis showed that the left RLN palsy rate decreased to the target rate after 12 operations. We conclude that at least 12 cases are required for a surgeon with prior experience in VATE to safely accomplish left RLN LND through a robotic approach.},
	language = {eng},
	number = {2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Chao, Yin-Kai and Wen, Yu-Wen and Chuang, Wen-Yu and Cerfolio, Robert J.},
	month = mar,
	year = {2020},
	pmid = {31022725},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Pilot Projects, Treatment Outcome, Retrospective Studies, Adult, Esophagectomy, Postoperative Complications, Lymph Node Excision, esophageal cancer, Learning Curve, Intraoperative Complications, Vocal Cord Paralysis, Thoracic Surgery, Video-Assisted, Operative Time, minimally invasive esophagectomy, robotic surgery, Robotic Surgical Procedures, Recurrent Laryngeal Nerve Injuries, recurrent laryngeal nerve lymph node},
	pages = {doz033},
	annote = {RLN dissection

},
	file = {Chao et al_2020_Transition from video-assisted thoracoscopic to robotic esophagectomy.pdf:/Users/jcsal/Zotero/storage/W8UUSI6Y/Chao et al_2020_Transition from video-assisted thoracoscopic to robotic esophagectomy.pdf:application/pdf},
}

@article{degrootdoaa079,
	title = {Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open esophagectomy: long-term follow-up of a randomized clinical trial},
	volume = {33},
	issn = {1442-2050},
	shorttitle = {Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open esophagectomy},
	doi = {10.1093/dote/doaa079},
	abstract = {Initial results of the ROBOT, which randomized between robot-assisted minimally invasive esophagectomy (RAMIE) and open transthoracic esophagectomy (OTE), showed significantly better short-term postoperative outcomes in favor of RAMIE. However, it is not yet clarified if RAMIE is equivalent to OTE regarding long-term outcomes. The aim of this study was to report the long-term oncological results of the ROBOT trial in terms of survival and disease-free survival. This study is a follow-up study of the ROBOT trial, which was a randomized controlled trial comparing RAMIE to OTE in 112 patients with intrathoracic esophageal cancer. Both the trial protocol and short-term results were previously published. The primary outcome of the current study was 5-year overall survival. Secondary outcomes were disease-free survival and recurrence patterns. Analysis was by intention to treat. During the recruitment period, 109 patients were included in the survival analysis (RAMIE n = 54, OTE n = 55). Majority of patients had clinical stage III or IV (RAMIE 63\%, OTE 55\%) and received neoadjuvant chemoradiotherapy (80\%). Median follow-up was 60 months (range 31-60). The combined 5-year overall survival rates for RAMIE and OTE were 41\% (95\% CI 27-55) and 40\% (95\% CI 26-53), respectively (log rank test P = 0.827). The 5-year disease-free survival rate was 42\% (95\% CI 28-55) in the RAMIE group and 43\% (95\% CI 29-57) in the OTE group (log rank test P = 0.749). Out of 104 patients, 57 (55\%) developed recurrent disease detected at a median of 10 months (range 0-56) after surgery. No statistically difference in recurrence rate nor recurrence pattern was observed between both groups. Overall survival and disease-free survival of RAMIE are comparable to OTE. These results continue to support the use of robotic surgery for esophageal cancer.},
	language = {eng},
	number = {Supplement\_2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {de Groot, Eline M. and van der Horst, Sylvia and Kingma, B. Feike and Goense, Lucas and van der Sluis, Pieter C. and Ruurda, Jelle P. and van Hillegersberg, Richard},
	month = nov,
	year = {2020},
	pmid = {33241302},
	keywords = {Humans, Treatment Outcome, Follow-Up Studies, Esophageal Neoplasms, Esophagectomy, Neoplasm Recurrence, Local, Postoperative Complications, esophageal cancer, Minimally Invasive Surgical Procedures, long-term survival, Robotics, RAMIE, recurrence pattern},
	pages = {doaa079},
	file = {de Groot et al_2020_Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open.pdf:/Users/jcsal/Zotero/storage/FDKZNIPU/de Groot et al_2020_Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open.pdf:application/pdf},
}

@article{gisbertz149,
	title = {The evolution of surgical approach for esophageal cancer},
	volume = {1434},
	issn = {1749-6632},
	doi = {10.1111/nyas.13957},
	abstract = {Esophageal surgery for esophageal cancer has been performed for over a century now. Minimally invasive esophagectomy (MIE) was first described in 1992, and it is now a standard approach in many countries. However, MIE is technically difficult and requires a long learning curve. It takes {\textgreater}100 cases to train for MIE with gastric tube reconstruction with an intrathoracic anastomosis. A possible option to overcome several challenges of MIE might be the use of a robotic system. A robot-assisted MIE was first described in 2005, and long-term results have shown its feasibility and safety. Over the years, different approaches for esophagectomy have been established. Our review discusses these developments and recent literature on open, minimally invasive and robotic esophageal surgery.},
	language = {eng},
	number = {1},
	journal = {Annals of the New York Academy of Sciences},
	author = {Gisbertz, Suzanne S. and Hagens, Eliza R. C. and Ruurda, Jelle P. and Schneider, Paul M. and Tan, Li Jie and Domrachev, Sergey A. and Hoeppner, Jens and van Berge Henegouwen, Mark I.},
	month = dec,
	year = {2018},
	pmid = {30191569},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Esophagus, esophageal cancer, minimally invasive esophagectomy, Robotic Surgical Procedures, esophageal resection, gastric tube reconstruction, robotic esophagectomy, transthoracic esophagectomy},
	pages = {149--155},
	annote = {Not helpful
},
}

@article{mariette545,
	title = {Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities},
	volume = {8},
	issn = {1470-2045},
	shorttitle = {Therapeutic strategies in oesophageal carcinoma},
	doi = {10.1016/S1470-2045(07)70172-9},
	abstract = {Traditionally, surgery is considered the best treatment for oesophageal cancer in terms of locoregional control and long-term survival. However, survival 5 years after surgery alone is about 25\%, and, therefore, a multidisciplinary approach that includes surgery, radiotherapy, and chemotherapy, alone or in combination, could prove necessary. The role of each of these treatments in the management of oesophageal cancer is under intensive research to define optimum therapeutic strategies. In this report we provide an update on treatment strategies for resectable oesophageal cancers on the basis of recent published work. Results of the latest randomised trials allow us to propose the following guidelines: surgery is the standard treatment, to be used alone for stages I and IIa, or possibly with neoadjuvant chemotherapy or chemoradiotherapy for stage IIb disease. For locally advanced cancers (stage III), neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is appropriate for adenocarcinomas. Chemoradiotherapy alone should only be considered in patients with squamous-cell carcinomas who show a morphological response to chemoradiotherapy, and produces a similar overall survival to chemoradiotherapy followed by surgery, but with less post-treatment morbidity. Although the addition of surgery to chemotherapy or chemoradiotherapy could result in improved local control and survival, surgery should be done in experienced hospitals where operative mortality and morbidity are low. Moreover, surgery should be kept in mind as salvage treatment in patients with no morphological response or persistent tumour after definitive chemoradiotherapy.},
	language = {eng},
	number = {6},
	journal = {The Lancet. Oncology},
	author = {Mariette, Christophe and Piessen, Guillaume and Triboulet, Jean-Pierre},
	month = jun,
	year = {2007},
	pmid = {17540306},
	keywords = {Humans, Neoadjuvant Therapy, Antineoplastic Agents, Chemotherapy, Adjuvant, Esophageal Neoplasms, Combined Modality Therapy, Radiotherapy, Adjuvant, Clinical Trials as Topic},
	pages = {545--553},
	file = {Mariette et al_2007_Therapeutic strategies in oesophageal carcinoma.pdf:/Users/jcsal/Zotero/storage/JF637ZV7/Mariette et al_2007_Therapeutic strategies in oesophageal carcinoma.pdf:application/pdf},
}

@article{young629,
	title = {Anal {Cancer}},
	volume = {100},
	issn = {1558-3171},
	doi = {10.1016/j.suc.2020.02.007},
	abstract = {Anal cancer is a rare cancer, comprising less than 5\% of gastrointestinal tract malignancies. Diagnosis of anal canal cancer can be difficult given that presenting symptoms are similar to those of benign anorectal diseases. General surgeons who encounter suspected anal canal cancer need to have a good understanding of the anatomy of the anal canal, high index of suspicion for malignancy, and low threshold to biopsy lesions when indicated. This article discusses the most commonly encountered anal canal tumors, the evaluation of these tumors, and their management. The foundation for successful therapy includes timely diagnosis, accurate staging, and routine surveillance.},
	language = {eng},
	number = {3},
	journal = {The Surgical Clinics of North America},
	author = {Young, Anne N. and Jacob, Elizabeth and Willauer, Patrick and Smucker, Levi and Monzon, Raul and Oceguera, Luis},
	month = jun,
	year = {2020},
	pmid = {32402305},
	keywords = {Follow-Up Studies, Neoplasm Staging, Prognosis, Adenocarcinoma, Carcinoma, Squamous Cell, Chemoradiotherapy, Lymphatic Metastasis, Anal Canal, Melanoma, Anus Neoplasms, Anal canal, Anal cancer, Carcinoma, Basal Cell, Diagnosis, Differential, Proctoscopy, Squamous cell carcinoma},
	pages = {629--634},
	file = {Young et al_2020_Anal Cancer.pdf:/Users/jcsal/Zotero/storage/NLIED257/Young et al_2020_Anal Cancer.pdf:application/pdf},
}

@article{schmidt814,
	title = {Defining {Benchmarks} for {Transthoracic} {Esophagectomy}: {A} {Multicenter} {Analysis} of {Total} {Minimally} {Invasive} {Esophagectomy} in {Low} {Risk} {Patients}},
	volume = {266},
	issn = {1528-1140},
	shorttitle = {Defining {Benchmarks} for {Transthoracic} {Esophagectomy}},
	doi = {10.1097/SLA.0000000000002445},
	abstract = {OBJECTIVE: To define "best possible" outcomes in total minimally invasive transthoracic esophagectomy (ttMIE).
BACKGROUND: TtMIE, performed by experts in patients with low comorbidity, may serve as a benchmark procedure for esophagectomy.
PATIENTS AND METHODS: From a cohort of 1057 ttMIE, performed over a 5-year period in 13 high-volume centers for esophageal surgery, we selected a study group of 334 patients (31.6\%) that fulfilled criteria of low comorbidity (American Society of Anesthesiologists score ≤2, WHO/ECOG score ≤1, age ≤65 years, body mass index 19-29 kg/m). Endpoints included postoperative morbidity measured by the Clavien-Dindo classification and the comprehensive complication index. Benchmark values were defined as the 75th percentile of the median outcome parameters of the participating centers to represent best achievable results.
RESULTS: Benchmark patients were predominantly male (82.9\%) with a median age of 58 years (53-62). High intrathoracic (Ivor Lewis) and cervical esophagogastrostomy (McKeown) were performed in 188 (56.3\%) and 146 (43.7\%) patients, respectively. Median (IQR) ICU and hospital stay was 0 (0-2) and 12 (9-18) days, respectively. 56.0\% of patients developed at least 1 complication, and 26.9\% experienced major morbidity (≥grade III), mostly related to pulmonary complications (25.7\%), anastomotic leakage (15.9\%), and cardiac events (13.5\%). Benchmark values at 30 days after hospital discharge were ≤55.7\% and ≤30.8\% for overall and major complications, ≤18.0\% for readmission, ≤3.1\% for positive resection margins, and ≥23 for lymph node yield. Benchmarks at 30 and 90 days were ≤1.0\% and ≤4.6\% for mortality, and ≤40.8 and ≤42.8 for the comprehensive complication index, respectively.
CONCLUSION: This outcome analysis of patients with low comorbidity undergoing ttMIE may serve as a reference to evaluate surgical performance in major esophageal resection.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgery},
	author = {Schmidt, Henner M. and Gisbertz, Susanne S. and Moons, Johnny and Rouvelas, Ioannis and Kauppi, Juha and Brown, Andrew and Asti, Emanuele and Luyer, Misha and Lagarde, Sjoerd M. and Berlth, Felix and Philippron, Annouck and Bruns, Christiane and Hölscher, Arnulf and Schneider, Paul M. and Raptis, Dimitri A. and van Berge Henegouwen, Mark I. and Nafteux, Philippe and Nilsson, Magnus and Räsanen, Jari and Palazzo, Francesco and Rosato, Ernest and Mercer, Stuart and Bonavina, Luigi and Nieuwenhuijzen, Grard and Wijnhoven, Bas P. L. and Schröder, Wolfgang and Pattyn, Piet and Grimminger, Peter P. and Gutschow, Christian A.},
	month = nov,
	year = {2017},
	pmid = {28796646},
	keywords = {Adult, Aged, Benchmarking, Databases, Factual, Esophagectomy, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Laparoscopy, Male, Middle Aged, Outcome Assessment, Health Care, Postoperative Complications, Retrospective Studies, Thoracoscopy},
	pages = {814--821},
}

@article{lewis18,
	title = {The surgical treatment of carcinoma of the oesophagus; with special reference to a new operation for growths of the middle third},
	volume = {34},
	issn = {0007-1323},
	doi = {10.1002/bjs.18003413304},
	language = {eng},
	journal = {The British Journal of Surgery},
	author = {Lewis, I.},
	month = jul,
	year = {1946},
	pmid = {20994128},
	keywords = {Humans, Esophagus, Carcinoma, ESOPHAGUS/surgery},
	pages = {18--31},
}

@article{ketele246556,
	title = {Nationwide {Association} of {Surgical} {Performance} of {Minimally} {Invasive} {Esophagectomy} {With} {Patient} {Outcomes}},
	volume = {7},
	issn = {2574-3805},
	doi = {10.1001/jamanetworkopen.2024.6556},
	abstract = {IMPORTANCE: Suboptimal surgical performance is hypothesized to be associated with less favorable patient outcomes in minimally invasive esophagectomy (MIE). Establishing this association may lead to programs that promote better surgical performance of MIE and improve patient outcomes.
OBJECTIVE: To investigate associations between surgical performance and postoperative outcomes after MIE.
DESIGN, SETTING, AND PARTICIPANTS: In this nationwide cohort study of 15 Dutch hospitals that perform more than 20 MIEs per year, 7 masked expert MIE surgeons assessed surgical performance using videos and a previously developed and validated competency assessment tool (CAT). Each hospital submitted 2 representative videos of MIEs performed between November 4, 2021, and September 13, 2022. Patients registered in the Dutch Upper Gastrointestinal Cancer Audit between January 1, 2020, and December 31, 2021, were included to examine patient outcomes.
EXPOSURE: Hospitals were divided into quartiles based on their MIE-CAT performance score. Outcomes were compared between highest (top 25\%) and lowest (bottom 25\%) performing quartiles. Transthoracic MIE with gastric tube reconstruction.
MAIN OUTCOME AND MEASURE: The primary outcome was severe postoperative complications (Clavien-Dindo ≥3) within 30 days after surgery. Multilevel logistic regression, with clustering of patients within hospitals, was used to analyze associations between performance and outcomes.
RESULTS: In total, 30 videos and 970 patients (mean [SD] age, 66.6 [9.1] years; 719 men [74.1\%]) were included. The mean (SD) MIE-CAT score was 113.6 (5.5) in the highest performance quartile vs 94.1 (5.9) in the lowest. Severe postoperative complications occurred in 18.7\% (41 of 219) of patients in the highest performance quartile vs 39.2\% (40 of 102) in the lowest (risk ratio [RR], 0.50; 95\% CI, 0.24-0.99). The highest vs the lowest performance quartile showed lower rates of conversions (1.8\% vs 8.9\%; RR, 0.21; 95\% CI, 0.21-0.21), intraoperative complications (2.7\% vs 7.8\%; RR, 0.21; 95\% CI, 0.04-0.94), and overall postoperative complications (46.1\% vs 65.7\%; RR, 0.54; 95\% CI, 0.24-0.96). The R0 resection rate (96.8\% vs 94.2\%; RR, 1.03; 95\% CI, 0.97-1.05) and lymph node yield (mean [SD], 38.9 [14.7] vs 26.2 [9.0]; RR, 3.20; 95\% CI, 0.27-3.21) increased with oncologic-specific performance (eg, hiatus dissection, lymph node dissection). In addition, a high anastomotic phase score was associated with a lower anastomotic leakage rate (4.6\% vs 17.7\%; RR, 0.14; 95\% CI, 0.06-0.31).
CONCLUSIONS AND RELEVANCE: These findings suggest that better surgical performance is associated with fewer perioperative complications for patients with esophageal cancer on a national level. If surgical performance of MIE can be improved with MIE-CAT implementation, substantially better patient outcomes may be achievable.},
	language = {eng},
	number = {4},
	journal = {JAMA network open},
	author = {Ketel, Mirte H. M. and Klarenbeek, Bastiaan R. and Abma, Inger and Belgers, Eric H. J. and Coene, Peter-Paul L. O. and Dekker, Jan Willem T. and van Duijvendijk, Peter and Emous, Marloes and Gisbertz, Suzanne S. and Haveman, Jan Willem and Heisterkamp, Joos and Nieuwenhuijzen, Grard A. P. and Ruurda, Jelle P. and van Sandick, Johanna W. and van der Sluis, Pieter C. and van Det, Marc J. and van Esser, Stijn and Law, Simon and de Steur, Wobbe O. and Sosef, Meindert N. and Wijnhoven, Bas and Hannink, Gerjon and Rosman, Camiel and van Workum, Frans and {MIE-CAT Netherlands Collaborative Group}},
	month = apr,
	year = {2024},
	pmid = {38639938},
	pmcid = {PMC11031683},
	keywords = {Aged, Cohort Studies, Esophageal Neoplasms, Esophagectomy, Humans, Male, Minimally Invasive Surgical Procedures, Postoperative Complications, Treatment Outcome},
	pages = {e246556},
	file = {Ketel et al_2024_Nationwide Association of Surgical Performance of Minimally Invasive.pdf:/Users/jcsal/Zotero/storage/YY7TUAG3/Ketel et al_2024_Nationwide Association of Surgical Performance of Minimally Invasive.pdf:application/pdf},
}

@article{eyck1995,
	title = {Ten-{Year} {Outcome} of {Neoadjuvant} {Chemoradiotherapy} {Plus} {Surgery} for {Esophageal} {Cancer}: {The} {Randomized} {Controlled} {CROSS} {Trial}},
	volume = {39},
	issn = {1527-7755},
	shorttitle = {Ten-{Year} {Outcome} of {Neoadjuvant} {Chemoradiotherapy} {Plus} {Surgery} for {Esophageal} {Cancer}},
	doi = {10.1200/JCO.20.03614},
	abstract = {PURPOSE: Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer. We aimed to assess long-term outcome of this regimen.
METHODS: From 2004 through 2008, we randomly assigned 366 patients to either five weekly cycles of carboplatin and paclitaxel with concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week) followed by surgery, or surgery alone. Follow-up data were collected through 2018. Cox regression analyses were performed to compare overall survival, cause-specific survival, and risks of locoregional and distant relapse. The effect of neoadjuvant chemoradiotherapy beyond 5 years of follow-up was tested with time-dependent Cox regression and landmark analyses.
RESULTS: The median follow-up was 147 months (interquartile range, 134-157). Patients receiving neoadjuvant chemoradiotherapy had better overall survival (hazard ratio [HR], 0.70; 95\% CI, 0.55 to 0.89). The effect of neoadjuvant chemoradiotherapy on overall survival was not time-dependent (P value for interaction, P = .73), and landmark analyses suggested a stable effect on overall survival up to 10 years of follow-up. The absolute 10-year overall survival benefit was 13\% (38\% v 25\%). Neoadjuvant chemoradiotherapy reduced risk of death from esophageal cancer (HR, 0.60; 95\% CI, 0.46 to 0.80). Death from other causes was similar between study arms (HR, 1.17; 95\% CI, 0.68 to 1.99). Although a clear effect on isolated locoregional (HR, 0.40; 95\% CI, 0.21 to 0.72) and synchronous locoregional plus distant relapse (HR, 0.43; 95\% CI, 0.26 to 0.72) persisted, isolated distant relapse was comparable (HR, 0.76; 95\% CI, 0.52 to 1.13).
CONCLUSION: The overall survival benefit of patients with locally advanced resectable esophageal or junctional cancer who receive preoperative chemoradiotherapy according to CROSS persists for at least 10 years.},
	language = {eng},
	number = {18},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Eyck, Ben M. and van Lanschot, J. Jan B. and Hulshof, Maarten C. C. M. and van der Wilk, Berend J. and Shapiro, Joel and van Hagen, Pieter and van Berge Henegouwen, Mark I. and Wijnhoven, Bas P. L. and van Laarhoven, Hanneke W. M. and Nieuwenhuijzen, Grard A. P. and Hospers, Geke A. P. and Bonenkamp, Johannes J. and Cuesta, Miguel A. and Blaisse, Reinoud J. B. and Busch, Olivier R. and Creemers, Geert-Jan M. and Punt, Cornelis J. A. and Plukker, John Th M. and Verheul, Henk M. W. and Spillenaar Bilgen, Ernst J. and van der Sangen, Maurice J. C. and Rozema, Tom and Ten Kate, Fiebo J. W. and Beukema, Jannet C. and Piet, Anna H. M. and van Rij, Caroline M. and Reinders, Janny G. and Tilanus, Hugo W. and Steyerberg, Ewout W. and van der Gaast, Ate and {CROSS Study Group}},
	month = jun,
	year = {2021},
	pmid = {33891478},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagectomy, Netherlands, Paclitaxel, Lymph Node Excision, Carboplatin},
	pages = {1995--2004},
	file = {Eyck et al_2021_Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal.pdf:/Users/jcsal/Zotero/storage/V2UW4NFC/Eyck et al_2021_Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal.pdf:application/pdf},
}

@article{im477,
	title = {Surgery in patients with portal hypertension: a preoperative checklist and strategies for attenuating risk},
	volume = {18},
	issn = {1557-8224},
	shorttitle = {Surgery in patients with portal hypertension},
	doi = {10.1016/j.cld.2014.01.006},
	abstract = {Patients with liver disease and portal hypertension are at increased risk of complications from surgery. Recent advances have allowed better optimization of patients with cirrhosis before surgery and a reduction in postoperative complications. Despite this progress, the estimation of surgical risk in a patient with cirrhosis is challenging. The MELD score has shown promise in predicting postoperative mortality compared with the Child-Turcotte-Pugh score. This article addresses current concepts in the perioperative evaluation of patients with liver disease and portal tension, including a preoperative liver assessment (POLA) checklist that may be useful towards mitigating perioperative complications.},
	language = {eng},
	number = {2},
	journal = {Clinics in Liver Disease},
	author = {Im, Gene Y. and Lubezky, Nir and Facciuto, Marcelo E. and Schiano, Thomas D.},
	month = may,
	year = {2014},
	pmid = {24679507},
	keywords = {Humans, Postoperative Complications, Severity of Illness Index, Surgery, Preoperative Care, Elective Surgical Procedures, Ascites, Checklist, Child-Turcotte-Pugh, Cirrhosis, Contraindications, Hypertension, Portal, MELD, Portal hypertension, Risk Reduction Behavior, TIPS, Variceal bleeding},
	pages = {477--505},
}

@article{teh1261,
	title = {Risk factors for mortality after surgery in patients with cirrhosis},
	volume = {132},
	issn = {0016-5085},
	doi = {10.1053/j.gastro.2007.01.040},
	abstract = {BACKGROUND \& AIMS: Current methods of predicting risk of postoperative mortality in patients with cirrhosis are suboptimal. The utility of the Model for End-stage Liver Disease (MELD) in predicting mortality after surgery other than liver transplantation is unknown. The aim of this study was to determine the risk factors for postoperative mortality in patients with cirrhosis.
METHODS: Patients with cirrhosis (N = 772) who underwent major digestive (n = 586), orthopedic (n = 107), or cardiovascular (n = 79) surgery were studied. Control groups of patients with cirrhosis included 303 undergoing minor surgical procedures and 562 ambulatory patients. Univariate and multivariable proportional hazards analyses were used to determine the relationship between risk factors and mortality.
RESULTS: Patients undergoing major surgery were at increased risk for mortality up to 90 days postoperatively. By multivariable analysis, only MELD score, American Society of Anesthesiologists class, and age predicted mortality at 30 and 90 days, 1 year, and long-term, independently of type or year of surgery. Emergency surgery was the only independent predictor of duration of hospitalization postoperatively. Thirty-day mortality ranged from 5.7\% (MELD score, {\textless}8) to more than 50\% (MELD score, {\textgreater}20). The relationship between MELD score and mortality persisted throughout the 20-year postoperative period.
CONCLUSIONS: MELD score, age, and American Society of Anesthesiologists class can quantify the risk of mortality postoperatively in patients with cirrhosis, independently of the procedure performed. These factors can be used in determining operative mortality risk and whether elective surgical procedures can be delayed until after liver transplantation.},
	language = {eng},
	number = {4},
	journal = {Gastroenterology},
	author = {Teh, Swee H. and Nagorney, David M. and Stevens, Susanna R. and Offord, Kenneth P. and Therneau, Terry M. and Plevak, David J. and Talwalkar, Jayant A. and Kim, W. Ray and Kamath, Patrick S.},
	month = apr,
	year = {2007},
	pmid = {17408652},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Retrospective Studies, Risk Factors, Time Factors, Survival Rate, Prognosis, Postoperative Complications, Digestive System Surgical Procedures, Cardiovascular Surgical Procedures, Orthopedic Procedures, Liver Cirrhosis, Minnesota},
	pages = {1261--1269},
}

@article{childerse176233,
	title = {Understanding {Costs} of {Care} in the {Operating} {Room}},
	volume = {153},
	issn = {2168-6262},
	doi = {10.1001/jamasurg.2017.6233},
	abstract = {IMPORTANCE: Increasing value requires improving quality or decreasing costs. In surgery, estimates for the cost of 1 minute of operating room (OR) time vary widely. No benchmark exists for the cost of OR time, nor has there been a comprehensive assessment of what contributes to OR cost.
OBJECTIVES: To calculate the cost of 1 minute of OR time, assess cost by setting and facility characteristics, and ascertain the proportion of costs that are direct and indirect.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional and longitudinal analysis examined annual financial disclosure documents from all comparable short-term general and specialty care hospitals in California from fiscal year (FY) 2005 to FY2014 (N = 3044; FY2014, n = 302). The analysis focused on 2 revenue centers: (1) surgery and recovery and (2) ambulatory surgery.
MAIN OUTCOMES AND MEASURES: Mean cost of 1 minute of OR time, stratified by setting (inpatient vs ambulatory), teaching status, and hospital ownership. The proportion of cost attributable to indirect and direct expenses was identified; direct expenses were further divided into salary, benefits, supplies, and other direct expenses.
RESULTS: In FY2014, a total of 175 of 302 facilities (57.9\%) were not for profit, 78 (25.8\%) were for profit, and 49 (16.2\%) were government owned. Thirty facilities (9.9\%) were teaching hospitals. The mean (SD) cost for 1 minute of OR time across California hospitals was \$37.45 (\$16.04) in the inpatient setting and \$36.14 (\$19.53) in the ambulatory setting (P = .65). There were no differences in mean expenditures when stratifying by ownership or teaching status except that teaching hospitals had lower mean (SD) expenditures than nonteaching hospitals in the inpatient setting (\$29.88 [\$9.06] vs \$38.29 [\$16.43]; P = .006). Direct expenses accounted for 54.6\% of total expenses (\$20.40 of \$37.37) in the inpatient setting and 59.1\% of total expenses (\$20.90 of \$35.39) in the ambulatory setting. Wages and benefits accounted for approximately two-thirds of direct expenses (inpatient, \$14.00 of \$20.40; ambulatory, \$14.35 of \$20.90), with nonbillable supplies accounting for less than 10\% of total expenses (inpatient, \$2.55 of \$37.37; ambulatory, \$3.33 of \$35.39). From FY2005 to FY2014, expenses in the OR have increased faster than the consumer price index and medical consumer price index. Teaching hospitals had slower growth in costs than nonteaching hospitals. Over time, the proportion of expenses dedicated to indirect costs has increased, while the proportion attributable to salary and supplies has decreased.
CONCLUSIONS AND RELEVANCE: The mean cost of OR time is \$36 to \$37 per minute, using financial data from California's short-term general and specialty hospitals in FY2014. These statewide data provide a generalizable benchmark for the value of OR time. Furthermore, understanding the composition of costs will allow those interested in value improvement to identify high-yield targets.},
	language = {eng},
	number = {4},
	journal = {JAMA surgery},
	author = {Childers, Christopher P. and Maggard-Gibbons, Melinda},
	month = apr,
	year = {2018},
	pmid = {29490366},
	pmcid = {PMC5875376},
	keywords = {Humans, Time Factors, Longitudinal Studies, Cross-Sectional Studies, California, Direct Service Costs, Equipment and Supplies, Hospital, Hospital Costs, Hospitals, Proprietary, Hospitals, Public, Hospitals, Teaching, Hospitals, Voluntary, Operating Rooms, Salaries and Fringe Benefits, Surgicenters},
	pages = {e176233},
	file = {Childers_Maggard-Gibbons_2018_Understanding Costs of Care in the Operating Room.pdf:/Users/jcsal/Zotero/storage/PVRULBNS/Childers_Maggard-Gibbons_2018_Understanding Costs of Care in the Operating Room.pdf:application/pdf},
}

@article{hampson277,
	title = {Variation and {Predictors} of {Surgical} {Case} {Costs} among {Urologists}},
	volume = {4},
	issn = {2352-0779},
	doi = {10.1016/j.urpr.2016.07.005},
	abstract = {INTRODUCTION: Shifts in the health care delivery system have emphasized providing cost-efficient care. The operating room comprises a significant proportion of hospital costs. Analysis of practice variation in operating room supply use can provide insight into opportunities for cost reduction and improved efficiency without compromising outcomes.
METHODS: A retrospective review was conducted of urological procedures performed at the University of California San Francisco Medical Center from September 2012 through December 2015. Supply costs for individual cases were itemized and aggregated using the institution negotiated rate. Operative time was monetized. Supply cost was analyzed with multivariate mixed effects models evaluating surgeon experience and surgeon volume.
RESULTS: The majority of common urological procedures demonstrate significant variation among surgeons in supply, time and overall cost. Surgeon annual procedure specific volume was a significant predictor of lower cost in multivariate analysis of supply cost (p = 0.016) and correlated with a lower likelihood of the case supply cost being in the top quintile (p {\textless}0.001). Surgeon experience was not a significant predictor of absolute supply cost or being in the top quintile of supply cost.
CONCLUSIONS: Significant variation exists among supply costs of high volume procedures. Higher surgeon procedure specific volume predicts lower operating room supply costs. Targeting procedures with variation for cost optimization via standardization could have a substantial impact on operating room costs and efficiency. The experience of high volume surgeons may be useful to guide optimal supply use given their comparatively lower costs.},
	language = {eng},
	number = {4},
	journal = {Urology Practice},
	author = {Hampson, Lindsay A. and Odisho, Anobel Y. and Meng, Maxwell V. and Carroll, Peter R.},
	month = jul,
	year = {2017},
	pmid = {30906821},
	pmcid = {PMC6425944},
	keywords = {cost control, cost-benefit analysis, health care costs, operating rooms, urology},
	pages = {277--284},
	file = {Hampson et al_2017_Variation and Predictors of Surgical Case Costs among Urologists.pdf:/Users/jcsal/Zotero/storage/M27W88UM/Hampson et al_2017_Variation and Predictors of Surgical Case Costs among Urologists.pdf:application/pdf},
}

@article{reynolds401,
	title = {{ICORG} 10-14: {NEOadjuvant} trial in {Adenocarcinoma} of the {oEsophagus} and {oesophagoGastric} junction {International} {Study} ({Neo}-{AEGIS})},
	volume = {17},
	issn = {1471-2407},
	shorttitle = {{ICORG} 10-14},
	doi = {10.1186/s12885-017-3386-2},
	abstract = {BACKGROUND: Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemotherapy and neoadjuvant chemoradiation. The Neo-AEGIS trial, uniquely powered on AEG, and including comprehensive modern staging, compares both these regimens.
METHODS: This open label, multicentre, phase III RCT randomises patients (cT2-3, N0-3, M0) in a 1:1 fashion to receive CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks). The power calculation is a 10\% difference in favour of CROSS, powered at 80\%, two-sided alpha level of 0.05, requiring 540 patients to be evaluable, 594 to be recruited if a 10\% dropout is included (297 in each group). The primary endpoint is overall survival, with a minimum 3-year follow up. Secondary endpoints include: disease free survival, recurrence rates, clinical and pathological response rates, toxicities of induction regimens, post-operative pathology and tumour regression grade, operative in-hospital complications, and health-related quality of life. The trial also affords opportunities for establishing a bio-resource of pre-treatment and resected tumour, and translational research.
DISCUSSION: This RCT directly compares two established treatment regimens, and addresses whether radiation therapy positively impacts on overall survival compared with a standard perioperative chemotherapy regimen Sponsor: Irish Clinical Research Group (ICORG).
TRIAL REGISTRATION: NCT01726452 . Protocol 10-14. Date of registration 06/11/2012.},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Reynolds, J. V. and Preston, S. R. and O'Neill, B. and Baeksgaard, L. and Griffin, S. M. and Mariette, C. and Cuffe, S. and Cunningham, M. and Crosby, T. and Parker, I. and Hofland, K. and Hanna, G. and Svendsen, L. B. and Donohoe, C. L. and Muldoon, C. and O'Toole, D. and Johnson, C. and Ravi, N. and Jones, G. and Corkhill, A. K. and Illsley, M. and Mellor, J. and Lee, K. and Dib, M. and Marchesin, V. and Cunnane, M. and Scott, K. and Lawner, P. and Warren, S. and O'Reilly, S. and O'Dowd, G. and Leonard, G. and Hennessy, B. and Dermott, R. Mc},
	month = jun,
	year = {2017},
	pmid = {28578652},
	pmcid = {PMC5457631},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Adult, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophagogastric Junction, Paclitaxel, Quality of Life, Carboplatin, Neoadjuvant chemotherapy, Oesophageal, Neoadjuvant chemoradiation therapy, Oesophagogastric junction},
	pages = {401},
	file = {Reynolds et al_2017_ICORG 10-14.pdf:/Users/jcsal/Zotero/storage/RWTWHAS2/Reynolds et al_2017_ICORG 10-14.pdf:application/pdf},
}

@article{childers835,
	title = {Estimation of the {Acquisition} and {Operating} {Costs} for {Robotic} {Surgery}},
	volume = {320},
	issn = {1538-3598},
	doi = {10.1001/jama.2018.9219},
	abstract = {This study used 1999-2017 financial statements from INTUITIVE, the company that supplies most robotic technology, to establish a hospital cost benchmark to inform future cost-effectiveness evaluations.},
	language = {eng},
	number = {8},
	journal = {JAMA},
	author = {Childers, Christopher P. and Maggard-Gibbons, Melinda},
	month = aug,
	year = {2018},
	pmid = {30167686},
	pmcid = {PMC6142989},
	keywords = {Humans, United States, Cost-Benefit Analysis, Robotic Surgical Procedures, Hospital Costs, Surgical Instruments},
	pages = {835--836},
}

@article{kalata1303,
	title = {Comparative {Safety} of {Robotic}-{Assisted} vs {Laparoscopic} {Cholecystectomy}},
	volume = {158},
	issn = {2168-6254},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512167/},
	doi = {10.1001/jamasurg.2023.4389},
	abstract = {This cohort study compares the rates and safety outcomes of robotic-assisted cholecystectomy with laparoscopic cholecystectomy in a nationally representative population of older adults.},
	number = {12},
	urldate = {2024-08-09},
	journal = {JAMA Surgery},
	author = {Kalata, Stanley and Thumma, Jyothi R. and Norton, Edward C. and Dimick, Justin B. and Sheetz, Kyle H.},
	month = dec,
	year = {2023},
	pmid = {37728932},
	pmcid = {PMC10512167},
	pages = {1303--1310},
	file = {Kalata et al_2023_Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy.pdf:/Users/jcsal/Zotero/storage/S3Y85LZ9/Kalata et al_2023_Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy.pdf:application/pdf},
}

@article{strosberg1436,
	title = {A retrospective comparison of robotic cholecystectomy versus laparoscopic cholecystectomy: operative outcomes and cost analysis},
	volume = {31},
	issn = {1432-2218},
	shorttitle = {A retrospective comparison of robotic cholecystectomy versus laparoscopic cholecystectomy},
	doi = {10.1007/s00464-016-5134-0},
	abstract = {INTRODUCTION: Robotic-assisted surgery is gaining popularity in general surgery. Our objective was to evaluate and compare operative outcomes and total costs for robotic cholecystectomy (RC) and laparoscopic cholecystectomy (LC).
METHODS AND PROCEDURES: A retrospective review was performed for all patients who underwent single-procedure RC and LC from January 2011 to July 2015 by a single surgeon at a large academic medical center. Demographics, diagnosis, perioperative variables, postoperative complications, 30-day readmissions, and operative and hospital costs were collected and analyzed between those patient groups.
RESULTS: A total of 237 patients underwent RC or LC, and comprised the study population. Ninety-seven patients (40.9 \%) underwent LC, and 140 patients (50.1 \%) underwent RC. Patients who underwent RC had a higher body mass index (p = 0.03), lower rates of coronary artery disease (p {\textless} 0.01), and higher rates of chronic cholecystitis (p {\textless} 0.01). There were lower rates of intraoperative cholangiography (p {\textless} 0.01) and conversion to an open procedure (p {\textless} 0.01), however longer operative times (p {\textless} 0.01) for patients in the RC group. There were no bile duct injuries in either group, no difference in bile leak rates (p = 0.65), or need for reoperation (p = 1.000). Cost analysis of outpatient-only procedures, excluding cases with conversion to open or use of intraoperative cholangiography, demonstrated higher total charges (p {\textless} 0.01) and cost (p {\textless} 0.01) and lower revenue (p {\textless} 0.01) for RC compared to LC, with no difference in total payments (p = 0.34).
CONCLUSIONS: Robotic cholecystectomy appears to be safe although costlier in comparison with laparoscopic cholecystectomy. Further studies are needed to understand the long-term implications of robotic technology, the cost to the health care system, and its role in minimally invasive surgery.},
	language = {eng},
	number = {3},
	journal = {Surgical Endoscopy},
	author = {Strosberg, David S. and Nguyen, Michelle C. and Muscarella, Peter and Narula, Vimal K.},
	month = mar,
	year = {2017},
	pmid = {27495346},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Aged, 80 and over, Adult, Young Adult, Postoperative Complications, Conversion to Open Surgery, Adolescent, Operative Time, Cholecystectomy, Laparoscopic, Costs and Cost Analysis, Chronic Disease, Laparoscopic surgery, Robotic Surgical Procedures, Robotic surgery, Bile Duct Diseases, Cholangiography, Cholangitis, Cholecystectomy, Cholecystitis, Choledocholithiasis, Cholelithiasis, Cost analysis, Gallbladder Diseases},
	pages = {1436--1441},
}

@article{olavarriam2457,
	title = {Robotic versus laparoscopic ventral hernia repair: multicenter, blinded randomized controlled trial},
	volume = {370},
	issn = {1756-1833},
	shorttitle = {Robotic versus laparoscopic ventral hernia repair},
	doi = {10.1136/bmj.m2457},
	abstract = {OBJECTIVE: To determine whether robotic ventral hernia repair is associated with fewer days in the hospital 90 days after surgery compared with laparoscopic repair.
DESIGN: Pragmatic, blinded randomized controlled trial.
SETTING: Multidisciplinary hernia clinics in Houston, USA.
PARTICIPANTS: 124 patients, deemed appropriate candidates for elective minimally invasive ventral hernia repair, consecutively presenting from April 2018 to February 2019.
INTERVENTIONS: Robotic ventral hernia repair (n=65) versus laparoscopic ventral hernia repair (n=59).
MAIN OUTCOME MEASURES: The primary outcome was number of days in hospital within 90 days after surgery. Secondary outcomes included emergency department visits, operating room time, wound complications, hernia recurrence, reoperation, abdominal wall quality of life, and costs from the healthcare system perspective. Outcomes were pre-specified before data collection began and analyzed as intention to treat.
RESULTS: Patients from both groups were similar at baseline. Ninety day follow-up was completed in 123 (99\%) patients. No evidence was seen of a difference in days in hospital between the two groups (median 0 v 0 days; relative rate 0.90, 95\% confidence interval 0.37 to 2.19; P=0.82). For secondary outcomes, no differences were noted in emergency department visits, wound complications, hernia recurrence, or reoperation. However, robotic repair had longer operative duration (141 v 77 min; mean difference 62.89, 45.75 to 80.01; P≤0.001) and increased healthcare costs (\$15 865 (£12 746; €14 125) v \$12 955; cost ratio 1.21, 1.07 to 1.38; adjusted absolute cost difference \$2767, \$910 to \$4626; P=0.004). Among patients with robotic ventral hernia repair, two had an enterotomy compared none with laparoscopic repair. The median one month postoperative improvement in abdominal wall quality of life was 3 with robotic ventral hernia repair compared with 15 following laparoscopic repair.
CONCLUSION: This study found no evidence of a difference in 90 day postoperative hospital days between robotic and laparoscopic ventral hernia repair. However, robotic repair increased operative duration and healthcare costs.
TRIAL REGISTRATION: Clinicaltrials.gov NCT03490266.},
	language = {eng},
	journal = {BMJ (Clinical research ed.)},
	author = {Olavarria, Oscar A. and Bernardi, Karla and Shah, Shinil K. and Wilson, Todd D. and Wei, Shuyan and Pedroza, Claudia and Avritscher, Elenir B. and Loor, Michele M. and Ko, Tien C. and Kao, Lillian S. and Liang, Mike K.},
	month = jul,
	year = {2020},
	pmid = {32665218},
	pmcid = {PMC7359869},
	keywords = {Humans, Length of Stay, Laparoscopy, Postoperative Complications, Reoperation, Recurrence, Quality of Life, Operative Time, Robotic Surgical Procedures, Herniorrhaphy, Hospital Costs, Emergency Service, Hospital, Hernia, Ventral},
	pages = {m2457},
	file = {Olavarria et al_2020_Robotic versus laparoscopic ventral hernia repair.pdf:/Users/jcsal/Zotero/storage/TXJ3RYQL/Olavarria et al_2020_Robotic versus laparoscopic ventral hernia repair.pdf:application/pdf},
}

@article{lee28,
	title = {Improving {Operating} {Room} {Efficiency}},
	volume = {20},
	issn = {1534-6285},
	doi = {10.1007/s11934-019-0895-3},
	abstract = {PURPOSE OF REVIEW: Operating rooms are critical financial centers for hospital systems, with surgical care representing about a third of all health care spending. However, not all of the costs are appropriate or necessary, as there are sometimes significant inefficiencies in how operating rooms are utilized.
RECENT FINDINGS: Recent innovations utilizing patient-centered data, systems principles from manufacturing industries, and enhanced communication processes have made significant improvements in improving operating room efficiency. By focusing on improving communication, standardizing processes, and embracing a learning health system with innovations, significant improvements in operating room efficiency can be seen to improve outcomes and costs for the health system and patient.},
	language = {eng},
	number = {6},
	journal = {Current Urology Reports},
	author = {Lee, Daniel J. and Ding, James and Guzzo, Thomas J.},
	month = apr,
	year = {2019},
	pmid = {30989344},
	keywords = {Humans, Quality Improvement, Operating Rooms, Cost efficiency, Efficiency, Organizational, Lean, Operating room costs, Operating room efficiency, Six sigma},
	pages = {28},
	file = {Lee et al_2019_Improving Operating Room Efficiency.pdf:/Users/jcsal/Zotero/storage/FRFKMXZG/Lee et al_2019_Improving Operating Room Efficiency.pdf:application/pdf},
}

@article{bellini20,
	title = {Artificial {Intelligence}: {A} {New} {Tool} in {Operating} {Room} {Management}. {Role} of {Machine} {Learning} {Models} in {Operating} {Room} {Optimization}},
	volume = {44},
	issn = {1573-689X},
	shorttitle = {Artificial {Intelligence}},
	doi = {10.1007/s10916-019-1512-1},
	abstract = {We conducted a systematic review of literature to better understand the role of new technologies in the perioperative period; in particular we focus on the administrative and managerial Operating Room (OR) perspective. Studies conducted on adult (≥ 18 years) patients between 2015 and February 2019 were deemed eligible. A total of 19 papers were included. Our review suggests that the use of Machine Learning (ML) in the field of OR organization has many potentials. Predictions of the surgical case duration were obtain with a good performance; their use could therefore allow a more precise scheduling, limiting waste of resources. ML is able to support even more complex models, which can coordinate multiple spaces simultaneously, as in the case of the post-anesthesia care unit and operating rooms. Types of Artificial Intelligence could also be used to limit another organizational problem, which has important economic repercussions: cancellation. Random Forest has proven effective in identifing surgeries with high risks of cancellation, allowing to plan preventive measures to reduce the cancellation rate accordingly. In conclusion, although data in literature are still limited, we believe that ML has great potential in the field of OR organization; however, further studies are needed to assess the effective role of these new technologies in the perioperative medicine.},
	language = {eng},
	number = {1},
	journal = {Journal of Medical Systems},
	author = {Bellini, Valentina and Guzzon, Marco and Bigliardi, Barbara and Mordonini, Monica and Filippelli, Serena and Bignami, Elena},
	month = dec,
	year = {2019},
	pmid = {31823034},
	keywords = {Humans, Machine Learning, Machine learning, Artificial intelligence, Artificial Intelligence, Perioperative, Operating Rooms, Efficiency, Organizational, Operating room efficiency, Anesthesia, Appointments and Schedules, Big data, Block time, Hospital administration, Models, Organizational, Operating room, Recovery room, Robotic assisted surgery, Scheduling},
	pages = {20},
	file = {Bellini et al_2019_Artificial Intelligence.pdf:/Users/jcsal/Zotero/storage/I8937I7F/Bellini et al_2019_Artificial Intelligence.pdf:application/pdf},
}

@article{sahni348,
	title = {Artificial {Intelligence} in {U}.{S}. {Health} {Care} {Delivery}},
	volume = {389},
	issn = {1533-4406},
	doi = {10.1056/NEJMra2204673},
	language = {eng},
	number = {4},
	journal = {The New England Journal of Medicine},
	author = {Sahni, Nikhil R. and Carrus, Brandon},
	month = jul,
	year = {2023},
	pmid = {37494486},
	keywords = {Humans, United States, Artificial Intelligence, Delivery of Health Care},
	pages = {348--358},
	file = {Sahni_Carrus_2023_Artificial Intelligence in U.pdf:/Users/jcsal/Zotero/storage/6LUQGTXR/Sahni_Carrus_2023_Artificial Intelligence in U.pdf:application/pdf},
}

@article{schouten19,
	title = {Operating {Room} {Performance} {Optimization} {Metrics}: a {Systematic} {Review}},
	volume = {47},
	issn = {1573-689X},
	shorttitle = {Operating {Room} {Performance} {Optimization} {Metrics}},
	doi = {10.1007/s10916-023-01912-9},
	abstract = {Literature proposes numerous initiatives for optimization of the Operating Room (OR). Despite multiple suggested strategies for the optimization of workflow on the OR, its patients and (medical) staff, no uniform description of 'optimization' has been adopted. This makes it difficult to evaluate the proposed optimization strategies. In particular, the metrics used to quantify OR performance are diverse so that assessing the impact of suggested approaches is complex or even impossible. To secure a higher implementation success rate of optimisation strategies in practice we believe OR optimisation and its quantification should be further investigated. We aim to provide an inventory of the metrics and methods used to optimise the OR by the means of a structured literature study. We observe that several aspects of OR performance are unaddressed in literature, and no studies account for possible interactions between metrics of quality and efficiency. We conclude that a systems approach is needed to align metrics across different elements of OR performance, and that the wellbeing of healthcare professionals is underrepresented in current optimisation approaches.},
	language = {eng},
	number = {1},
	journal = {Journal of Medical Systems},
	author = {Schouten, Anne M. and Flipse, Steven M. and van Nieuwenhuizen, Kim E. and Jansen, Frank Willem and van der Eijk, Anne C. and van den Dobbelsteen, John J.},
	month = feb,
	year = {2023},
	pmid = {36738376},
	pmcid = {PMC9899172},
	keywords = {Humans, Benchmarking, Workflow, Operating Rooms, Efficiency, Organizational, Operation Room, Optimization, Performance Metrics},
	pages = {19},
	file = {Schouten et al_2023_Operating Room Performance Optimization Metrics.pdf:/Users/jcsal/Zotero/storage/7EZZC2C4/Schouten et al_2023_Operating Room Performance Optimization Metrics.pdf:application/pdf},
}

@article{balch252,
	title = {Methods and evaluation metrics for reducing material waste in the operating room: a scoping review},
	volume = {174},
	issn = {1532-7361},
	shorttitle = {Methods and evaluation metrics for reducing material waste in the operating room},
	doi = {10.1016/j.surg.2023.04.051},
	abstract = {BACKGROUND: Operating rooms contribute up to 70\% of total hospital waste. Although multiple studies have demonstrated reduced waste through targeted interventions, few examine processes. This scoping review highlights methods of study design, outcome assessment, and sustainability practices of operating room waste reduction strategies employed by surgeons.
METHODS: Embase, PubMed, and Web of Science were screened for operating room-specific waste-reduction interventions. Waste was defined as hazardous and non-hazardous disposable material and energy consumption. Study-specific elements were tabulated by study design, evaluation metrics, strengths, limitations, and barriers to implementation in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines.
RESULTS: A total of 38 articles were analyzed. Among them, 74\% of studies had pre- versus postintervention designs, and 21\% used quality improvement instruments. No studies used an implementation framework. The vast majority (92\%) of studies measured cost as an outcome, whereas others included disposable waste by weight, hospital energy consumption, and stakeholder perspectives. The most common intervention was instrument tray optimization. Common barriers to implementation included lack of stakeholder buy-in, knowledge gaps, data capture, additional staff time, need for hospital or federal policies, and funding. Intervention sustainability was discussed in few studies (23\%) and included regular waste audits, hospital policy change, and educational initiatives. Common methodologic limitations included limited outcome evaluation, narrow scope of intervention, and inability to capture indirect costs.
CONCLUSION: Appraisal of quality improvement and implementation methods are critical for developing sustainable interventions for reducing operating room waste. Universal evaluation metrics and methodologies may aid in both quantifying the impact of waste reduction initiatives and understanding their implementation in clinical practice.},
	language = {eng},
	number = {2},
	journal = {Surgery},
	author = {Balch, Jeremy A. and Krebs, Jonathan R. and Filiberto, Amanda C. and Montgomery, William G. and Berkow, Lauren C. and Upchurch, Gilbert R. and Loftus, Tyler J.},
	month = aug,
	year = {2023},
	pmid = {37277308},
	keywords = {Humans, Benchmarking, Operating Rooms},
	pages = {252--258},
	file = {Balch et al_2023_Methods and evaluation metrics for reducing material waste in the operating room.pdf:/Users/jcsal/Zotero/storage/L88AIB7Q/Balch et al_2023_Methods and evaluation metrics for reducing material waste in the operating room.pdf:application/pdf},
}

@article{tagge1040,
	title = {Improving operating room efficiency in academic children's hospital using {Lean} {Six} {Sigma} methodology},
	volume = {52},
	issn = {1531-5037},
	doi = {10.1016/j.jpedsurg.2017.03.035},
	abstract = {BACKGROUND/PURPOSE: Lean Six Sigma (LSS) is a process improvement methodology that utilizes a collaborative team effort to improve performance by systematically identifying root causes of problems. Our objective was to determine whether application of LSS could improve efficiency when applied simultaneously to all services of an academic children's hospital.
METHODS: In our tertiary academic medical center, a multidisciplinary committee was formed, and the entire perioperative process was mapped, using fishbone diagrams, Pareto analysis, and other process improvement tools. Results for Children's Hospital scheduled main operating room (OR) cases were analyzed, where the surgical attending followed themselves.
RESULTS: Six hundred twelve cases were included in the seven Children's Hospital operating rooms (OR) over a 6-month period. Turnover Time (interval between patient OR departure and arrival of the subsequent patient) decreased from a median 41min in the baseline period to 32min in the intervention period (p{\textless}0.0001). Turnaround Time (interval between surgical dressing application and subsequent surgical incision) decreased from a median 81.5min in the baseline period to 71min in the intervention period (p{\textless}0.0001).
CONCLUSION: These results demonstrate that a coordinated multidisciplinary process improvement redesign can significantly improve efficiency in an academic Children's Hospital without preselecting specific services, removing surgical residents, or incorporating new personnel or technology.
STUDY TYPE: Prospective comparative study, Level II.},
	language = {eng},
	number = {6},
	journal = {Journal of Pediatric Surgery},
	author = {Tagge, Edward P. and Thirumoorthi, Arul S. and Lenart, John and Garberoglio, Carlos and Mitchell, Kenneth W.},
	month = jun,
	year = {2017},
	pmid = {28389078},
	keywords = {Humans, Prospective Studies, Time Factors, Perioperative Care, Academic Medical Centers, California, Quality Improvement, Child, Operating Rooms, Efficiency, Organizational, Operating room, Efficiency, Hospitals, Pediatric, Lean Six Sigma, Process Assessment, Health Care, Process mapping, Total quality improvement, Total Quality Management},
	pages = {1040--1044},
}

@article{cima83,
	title = {Use of lean and six sigma methodology to improve operating room efficiency in a high-volume tertiary-care academic medical center},
	volume = {213},
	issn = {1879-1190},
	doi = {10.1016/j.jamcollsurg.2011.02.009},
	abstract = {BACKGROUND: Operating rooms (ORs) are resource-intense and costly hospital units. Maximizing OR efficiency is essential to maintaining an economically viable institution. OR efficiency projects often focus on a limited number of ORs or cases. Efforts across an entire OR suite have not been reported. Lean and Six Sigma methodologies were developed in the manufacturing industry to increase efficiency by eliminating non-value-added steps. We applied Lean and Six Sigma methodologies across an entire surgical suite to improve efficiency.
STUDY DESIGN: A multidisciplinary surgical process improvement team constructed a value stream map of the entire surgical process from the decision for surgery to discharge. Each process step was analyzed in 3 domains, ie, personnel, information processed, and time. Multidisciplinary teams addressed 5 work streams to increase value at each step: minimizing volume variation; streamlining the preoperative process; reducing nonoperative time; eliminating redundant information; and promoting employee engagement. Process improvements were implemented sequentially in surgical specialties. Key performance metrics were collected before and after implementation.
RESULTS: Across 3 surgical specialties, process redesign resulted in substantial improvements in on-time starts and reduction in number of cases past 5 pm. Substantial gains were achieved in nonoperative time, staff overtime, and ORs saved. These changes resulted in substantial increases in margin/OR/day.
CONCLUSIONS: Use of Lean and Six Sigma methodologies increased OR efficiency and financial performance across an entire operating suite. Process mapping, leadership support, staff engagement, and sharing performance metrics are keys to enhancing OR efficiency. The performance gains were substantial, sustainable, positive financially, and transferrable to other specialties.},
	language = {eng},
	number = {1},
	journal = {Journal of the American College of Surgeons},
	author = {Cima, Robert R. and Brown, Michael J. and Hebl, James R. and Moore, Robin and Rogers, James C. and Kollengode, Anantha and Amstutz, Gwendolyn J. and Weisbrod, Cheryl A. and Narr, Bradly J. and Deschamps, Claude and {Surgical Process Improvement Team, Mayo Clinic, Rochester}},
	month = jul,
	year = {2011},
	pmid = {21420879},
	keywords = {Humans, Perioperative Care, Academic Medical Centers, Quality Improvement, Specialties, Surgical, Operating Rooms, Efficiency, Organizational, Process Assessment, Health Care, Total Quality Management},
	pages = {83--92; discussion 93--94},
}

@misc{zotero-3379,
	title = {Internet of {Things} and {New} {Technologies} for {Tracking} {Perioperative} {Patients} {With} an {Innovative} {Model} for {Operating} {Room} {Scheduling}: {Protocol} for a {Development} and {Feasibility} {Study} - {PubMed}},
	url = {https://pubmed.ncbi.nlm.nih.gov/37405821/},
	urldate = {2024-08-09},
}

@article{jansson1513,
	title = {Artificial intelligence-enhanced care pathway planning and scheduling system: content validity assessment of required functionalities},
	volume = {22},
	issn = {1472-6963},
	shorttitle = {Artificial intelligence-enhanced care pathway planning and scheduling system},
	doi = {10.1186/s12913-022-08780-y},
	abstract = {BACKGROUND: Artificial intelligence (AI) and machine learning are transforming the optimization of clinical and patient workflows in healthcare. There is a need for research to specify clinical requirements for AI-enhanced care pathway planning and scheduling systems to improve human-AI interaction in machine learning applications. The aim of this study was to assess content validity and prioritize the most relevant functionalities of an AI-enhanced care pathway planning and scheduling system.
METHODS: A prospective content validity assessment was conducted in five university hospitals in three different countries using an electronic survey. The content of the survey was formed from clinical requirements, which were formulated into generic statements of required AI functionalities. The relevancy of each statement was evaluated using a content validity index. In addition, weighted ranking points were calculated to prioritize the most relevant functionalities of an AI-enhanced care pathway planning and scheduling system.
RESULTS: A total of 50 responses were received from clinical professionals from three European countries. An item-level content validity index ranged from 0.42 to 0.96. 45\% of the generic statements were considered good. The highest ranked functionalities for an AI-enhanced care pathway planning and scheduling system were related to risk assessment, patient profiling, and resources. The highest ranked functionalities for the user interface were related to the explainability of machine learning models.
CONCLUSION: This study provided a comprehensive list of functionalities that can be used to design future AI-enhanced solutions and evaluate the designed solutions against requirements. The relevance of statements concerning the AI functionalities were considered somewhat relevant, which might be due to the low level or organizational readiness for AI in healthcare.},
	language = {eng},
	number = {1},
	journal = {BMC health services research},
	author = {Jansson, Miia and Ohtonen, Pasi and Alalääkkölä, Timo and Heikkinen, Juuso and Mäkiniemi, Minna and Lahtinen, Sanna and Lahtela, Riikka and Ahonen, Merja and Jämsä, Sirpa and Liisantti, Janne},
	month = dec,
	year = {2022},
	pmid = {36510176},
	pmcid = {PMC9746075},
	keywords = {Humans, Prospective Studies, Machine Learning, Machine learning, Artificial Intelligence, AI, Care pathway, Critical Pathways, Drugs, Generic, Health Facilities, human-AI interaction, Human-in-loop},
	pages = {1513},
	file = {Full Text:/Users/jcsal/Zotero/storage/HY5C2LV4/Jansson et al. - 2022 - Artificial intelligence-enhanced care pathway planning and scheduling system content validity asses.pdf:application/pdf},
}

@article{saxton1223,
	title = {Preoperative frailty and quality of life as predictors of postoperative complications},
	volume = {253},
	issn = {1528-1140},
	doi = {10.1097/SLA.0b013e318214bce7},
	abstract = {BACKGROUND: Prediction of postoperative complications has been based on assessing comorbidities. However, the evaluation of these comorbidities has not consistently identified those at higher risk of complications, primarily due to the inability to assess how these comorbidities affect functional status. We hypothesized that preoperative functional measures of patients' health status can predict postoperative complications.
METHODS: A sample of patients undergoing general surgical operations were reviewed for age, gender, diagnosis (for severity), operations (for complexity), number of comorbidities, preoperative frailty (as determined by the Canadian Study of Health and Ageing Frailty Index), preoperative quality of life (as determined by the SF-36), occurrence of postoperative complications, number of postoperative complications, and severity of complications. Data were analyzed by linear and multiple logistic regression analyses, and the Mann-Whitney U test.
RESULTS: Two hundred and twenty-six patients were evaluated, average age 61 ± 13 years, 47\% male patients. Frailty Index (FI) correlated with number of comorbidities (r = 0.61, P {\textless} 0.001), and all of the domains of the SF-36. Patients who had postoperative complications had higher median preoperative FI than those would did not [0.075 (IQR 0.046-0.118) vs. 0.059 (IQR 0.045-0.089), P = 0.007]. Multiple logistic regression analysis demonstrated that operation complexity, FI, and the role-emotional domain were associated with and increased risk of postoperative complications, whereas the bodily pain domain was associated with a lower risk of postoperative complications.
CONCLUSIONS: This study demonstrates that preoperative functional status as measured by FI and SF-36 may help identify patients at higher risk of postoperative complications. In our ageing population, use of such measures may help in better patient selection.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Saxton, Adrienne and Velanovich, Vic},
	month = jun,
	year = {2011},
	pmid = {21412145},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Health Status, Comorbidity, Postoperative Complications, Logistic Models, Quality of Life, Preoperative Period},
	pages = {1223--1229},
}

@article{bihorac652,
	title = {{MySurgeryRisk}: {Development} and {Validation} of a {Machine}-learning {Risk} {Algorithm} for {Major} {Complications} and {Death} {After} {Surgery}},
	volume = {269},
	issn = {1528-1140},
	shorttitle = {{MySurgeryRisk}},
	doi = {10.1097/SLA.0000000000002706},
	abstract = {OBJECTIVE: To accurately calculate the risk for postoperative complications and death after surgery in the preoperative period using machine-learning modeling of clinical data.
BACKGROUND: Postoperative complications cause a 2-fold increase in the 30-day mortality and cost, and are associated with long-term consequences. The ability to precisely forecast the risk for major complications before surgery is limited.
METHODS: In a single-center cohort of 51,457 surgical patients undergoing major inpatient surgery, we have developed and validated an automated analytics framework for a preoperative risk algorithm (MySurgeryRisk) that uses existing clinical data in electronic health records to forecast patient-level probabilistic risk scores for 8 major postoperative complications (acute kidney injury, sepsis, venous thromboembolism, intensive care unit admission {\textgreater}48 hours, mechanical ventilation {\textgreater}48 hours, wound, neurologic, and cardiovascular complications) and death up to 24 months after surgery. We used the area under the receiver characteristic curve (AUC) and predictiveness curves to evaluate model performance.
RESULTS: MySurgeryRisk calculates probabilistic risk scores for 8 postoperative complications with AUC values ranging between 0.82 and 0.94 [99\% confidence intervals (CIs) 0.81-0.94]. The model predicts the risk for death at 1, 3, 6, 12, and 24 months with AUC values ranging between 0.77 and 0.83 (99\% CI 0.76-0.85).
CONCLUSIONS: We constructed an automated predictive analytics framework for machine-learning algorithm with high discriminatory ability for assessing the risk of surgical complications and death using readily available preoperative electronic health records data. The feasibility of this novel algorithm implemented in real time clinical workflow requires further testing.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Bihorac, Azra and Ozrazgat-Baslanti, Tezcan and Ebadi, Ashkan and Motaei, Amir and Madkour, Mohcine and Pardalos, Panagote M. and Lipori, Gloria and Hogan, William R. and Efron, Philip A. and Moore, Frederick and Moldawer, Lyle L. and Wang, Daisy Zhe and Hobson, Charles E. and Rashidi, Parisa and Li, Xiaolin and Momcilovic, Petar},
	month = apr,
	year = {2019},
	pmid = {29489489},
	pmcid = {PMC6110979},
	keywords = {Humans, Risk Assessment, Postoperative Complications, Preoperative Period, Machine Learning, Algorithms},
	pages = {652--662},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/9DPHUXT5/Bihorac et al. - 2019 - MySurgeryRisk Development and Validation of a Machine-learning Risk Algorithm for Major Complicatio.pdf:application/pdf},
}

@article{fairley756,
	title = {Improving the efficiency of the operating room environment with an optimization and machine learning model},
	volume = {22},
	issn = {1572-9389},
	doi = {10.1007/s10729-018-9457-3},
	abstract = {The operating room is a major cost and revenue center for most hospitals. Thus, more effective operating room management and scheduling can provide significant benefits. In many hospitals, the post-anesthesia care unit (PACU), where patients recover after their surgical procedures, is a bottleneck. If the PACU reaches capacity, patients must wait in the operating room until the PACU has available space, leading to delays and possible cancellations for subsequent operating room procedures. We develop a generalizable optimization and machine learning approach to sequence operating room procedures to minimize delays caused by PACU unavailability. Specifically, we use machine learning to estimate the required PACU time for each type of surgical procedure, we develop and solve two integer programming models to schedule procedures in the operating rooms to minimize maximum PACU occupancy, and we use discrete event simulation to compare our optimized schedule to the existing schedule. Using data from Lucile Packard Children's Hospital Stanford, we show that the scheduling system can significantly reduce operating room delays caused by PACU congestion while still keeping operating room utilization high: simulation of the second half of 2016 shows that our model could have reduced total PACU holds by 76\% without decreasing operating room utilization. We are currently working on implementing the scheduling system at the hospital.},
	language = {eng},
	number = {4},
	journal = {Health Care Management Science},
	author = {Fairley, Michael and Scheinker, David and Brandeau, Margaret L.},
	month = dec,
	year = {2019},
	pmid = {30387040},
	keywords = {Humans, Computer Simulation, California, Machine Learning, Machine learning, Program Evaluation, Operating Rooms, Efficiency, Organizational, Optimization, Hospitals, Pediatric, Discrete event simulation, Integer programming, Operating room scheduling, Operations research, Personnel Staffing and Scheduling, Post anesthesia care unit, Recovery Room},
	pages = {756--767},
	file = {PDF:/Users/jcsal/Zotero/storage/NCUUJ5QD/Fairley et al. - 2019 - Improving the efficiency of the operating room environment with an optimization and machine learning.pdf:application/pdf},
}

@article{kalata1303a,
	title = {Comparative {Safety} of {Robotic}-{Assisted} vs {Laparoscopic} {Cholecystectomy}},
	volume = {158},
	issn = {2168-6262},
	doi = {10.1001/jamasurg.2023.4389},
	abstract = {IMPORTANCE: Robotic-assisted cholecystectomy is rapidly being adopted into practice, partly based on the belief that it offers specific technical and safety advantages over traditional laparoscopic surgery. Whether robotic-assisted cholecystectomy is safer than laparoscopic cholecystectomy remains unclear.
OBJECTIVE: To determine the uptake of robotic-assisted cholecystectomy and to analyze its comparative safety vs laparoscopic cholecystectomy.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used Medicare administrative claims data for nonfederal acute care hospitals from January 1, 2010, to December 31, 2019. Participants included 1 026 088 fee-for-service Medicare beneficiaries 66 to 99 years of age who underwent cholecystectomy with continuous Medicare coverage for 3 months before and 12 months after surgery. Data were analyzed August 17, 2022, to June 1, 2023.
EXPOSURE: Surgical technique used to perform cholecystectomy: robotic-assisted vs laparoscopic approaches.
MAIN OUTCOMES AND MEASURES: The primary outcome was rate of bile duct injury requiring definitive surgical reconstruction within 1 year after cholecystectomy. Secondary outcomes were composite outcome of bile duct injury requiring less-invasive postoperative surgical or endoscopic biliary interventions, and overall incidence of 30-day complications. Multivariable logistic analysis was performed adjusting for patient factors and clustered within hospital referral regions. An instrumental variable analysis was performed, leveraging regional variation in the adoption of robotic-assisted cholecystectomy within hospital referral regions over time, to account for potential confounding from unmeasured differences between treatment groups.
RESULTS: A total of 1 026 088 patients (mean [SD] age, 72 [12.0] years; 53.3\% women) were included in the study. The use of robotic-assisted cholecystectomy increased 37-fold from 211 of 147 341 patients (0.1\%) in 2010 to 6507 of 125 211 patients (5.2\%) in 2019. Compared with laparoscopic cholecystectomy, robotic-assisted cholecystectomy was associated with a higher rate of bile duct injury necessitating a definitive operative repair within 1 year (0.7\% vs 0.2\%; relative risk [RR], 3.16 [95\% CI, 2.57-3.75]). Robotic-assisted cholecystectomy was also associated with a higher rate of postoperative biliary interventions, such as endoscopic stenting (7.4\% vs 6.0\%; RR, 1.25 [95\% CI, 1.16-1.33]). There was no significant difference in overall 30-day complication rates between the 2 procedures. The instrumental variable analysis, which was designed to account for potential unmeasured differences in treatment groups, also showed that robotic-assisted cholecystectomy was associated with a higher rate of bile duct injury (0.4\% vs 0.2\%; RR, 1.88 [95\% CI, 1.14-2.63]).
CONCLUSIONS AND RELEVANCE: This cohort study's finding of significantly higher rates of bile duct injury with robotic-assisted cholecystectomy compared with laparoscopic cholecystectomy suggests that the utility of robotic-assisted cholecystectomy should be reconsidered, given the existence of an already minimally invasive, predictably safe laparoscopic approach.},
	language = {eng},
	number = {12},
	journal = {JAMA surgery},
	author = {Kalata, Stanley and Thumma, Jyothi R. and Norton, Edward C. and Dimick, Justin B. and Sheetz, Kyle H.},
	month = dec,
	year = {2023},
	pmid = {37728932},
	pmcid = {PMC10512167},
	keywords = {Humans, Aged, Female, Male, Retrospective Studies, Cohort Studies, United States, Medicare, Cholecystectomy, Laparoscopic, Infant, Bile Ducts, Robotic Surgical Procedures},
	pages = {1303--1310},
	file = {Full Text:/Users/jcsal/Zotero/storage/3L23G7HT/Kalata et al. - 2023 - Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy.pdf:application/pdf},
}

@article{schaefer1,
	title = {The {GIST} of {Advances} in {Treatment} of {Advanced} {Gastrointestinal} {Stromal} {Tumor}},
	volume = {42},
	issn = {1548-8756},
	doi = {10.1200/EDBK_351231},
	abstract = {Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin and a compelling clinical and biologic model for the rational development of molecularly targeted agents. This is because the majority of GISTs are driven by gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinases. Specific GIST mutations circumscribe well-defined molecular subgroups that must be determined during the diagnostic work-up to guide clinical management, including therapeutic decisions. Surgery is the cornerstone treatment in localized disease and can also be clinically relevant in the metastatic setting. The correct combination and sequence of targeted agents and surgical procedures improves outcomes for patients with GIST and should be discussed individually within multidisciplinary expert teams. All currently approved agents for the treatment of GIST are based on orally available tyrosine kinase inhibitors targeting KIT and PDGFRA oncogenic activation. Although first-line imatinib achieves remarkable prolonged disease control, the benefit of subsequent lines of treatment is more modest. Novel therapeutic strategies focus on overcoming the heterogeneity of KIT or PDGFRA secondary mutations and providing more potent inhibition of specific challenging mutations. This article reviews the current understanding and treatment of GIST, with an emphasis on recent advances.},
	language = {eng},
	journal = {American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting},
	author = {Schaefer, Inga-Marie and DeMatteo, Ronald P. and Serrano, César},
	month = apr,
	year = {2022},
	pmid = {35522913},
	pmcid = {PMC9113521},
	keywords = {Humans, Gastrointestinal Neoplasms, Antineoplastic Agents, Gastrointestinal Stromal Tumors, Mutation, Drug Resistance, Neoplasm, Imatinib Mesylate, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-kit},
	pages = {1--15},
	file = {Full Text:/Users/jcsal/Zotero/storage/ZI8HQ9K4/Schaefer et al. - 2022 - The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.pdf:application/pdf},
}

@article{faron114,
	title = {Linear {Relationship} of {Peritoneal} {Cancer} {Index} and {Survival} in {Patients} with {Peritoneal} {Metastases} from {Colorectal} {Cancer}},
	volume = {23},
	issn = {1534-4681},
	doi = {10.1245/s10434-015-4627-8},
	abstract = {BACKGROUND: The peritoneal cancer index (PCI) is the main prognostic factor for establishing potentially resectable peritoneal metastases from colorectal cancer. Attempts have been made to set a PCI cutoff on which to base indications of complete cytoreductive surgery (CCRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), but none have reached consensus. The aim of this study was to investigate the relation between the PCI and overall survival (OS).
METHODS: We included all consecutive patients homogeneously treated with CCRS and HIPEC between 2003 and 2012. The PCI was calculated at the end of the surgical procedure. The correlation between the PCI and OS was studied using statistical modeling from the simplest to the most complex methods (including linear, quadratic, cubic, and spline cubic). These models were compared by Akaike's information criteria (AIC).
RESULTS: For the 173 treated patients, 5-year OS reached 41 \%. The mean PCI was 10.2 (±6.8). The linear model was the most appropriate to relate the PCI to OS as confirmed with the AIC scoring system. In multivariate analysis, the PCI was confirmed as being the most important prognostic factor (hazard ratio = 1.1 for each supplementary point, p {\textless} 0.0001).
CONCLUSIONS: There is a perfect linear correlation between the PCI and OS, which precludes setting a unique PCI cutoff for CCRS + HIPEC. Overall, CCRS + HIPEC is generally indicated for PCI {\textless} 12 and contraindicated for PCI {\textgreater} 17. Between 12 and 17, other parameters have to be taken into account, such as the presence of extraperitoneal metastases, general performance status, and chemosensitivity.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgical Oncology},
	author = {Faron, Matthieu and Macovei, Raluca and Goéré, Diane and Honoré, Charles and Benhaim, Léonor and Elias, Dominique},
	month = jan,
	year = {2016},
	pmid = {26014158},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Survival Rate, Prognosis, Adult, Young Adult, Peritoneal Neoplasms, Neoplasm Recurrence, Local, Combined Modality Therapy, Chemotherapy, Cancer, Regional Perfusion, Hyperthermia, Induced, HIPEC},
	pages = {114--119},
}

@article{quenet256,
	title = {Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases ({PRODIGE} 7): a multicentre, randomised, open-label, phase 3 trial},
	volume = {22},
	issn = {1474-5488},
	shorttitle = {Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases ({PRODIGE} 7)},
	doi = {10.1016/S1470-2045(20)30599-4},
	abstract = {BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery has been associated with encouraging survival results in some patients with colorectal peritoneal metastases who were eligible for complete macroscopic resection. We aimed to assess the specific benefit of adding HIPEC to cytoreductive surgery compared with receiving cytoreductive surgery alone.
METHODS: We did a randomised, open-label, phase 3 trial at 17 cancer centres in France. Eligible patients were aged 18-70 years and had histologically proven colorectal cancer with peritoneal metastases, WHO performance status of 0 or 1, a Peritoneal Cancer Index of 25 or less, and were eligible to receive systemic chemotherapy for 6 months (ie, they had adequate organ function and life expectancy of at least 12 weeks). Patients in whom complete macroscopic resection or surgical resection with less than 1 mm residual tumour tissue was completed were randomly assigned (1:1) to cytoreductive surgery with or without oxaliplatin-based HIPEC. Randomisation was done centrally using minimisation, and stratified by centre, completeness of cytoreduction, number of previous systemic chemotherapy lines, and timing of protocol-mandated systemic chemotherapy. Oxaliplatin HIPEC was administered by the closed (360 mg/m2) or open (460 mg/m2) abdomen techniques, and systemic chemotherapy (400 mg/m2 fluorouracil and 20 mg/m2 folinic acid) was delivered intravenously 20 min before HIPEC. All individuals received systemic chemotherapy (of investigators' choosing) with or without targeted therapy before or after surgery, or both. The primary endpoint was overall survival, which was analysed in the intention-to-treat population. Safety was assessed in all patients who received surgery. This trial is registed with ClinicalTrials.gov, NCT00769405, and is now completed.
FINDINGS: Between Feb 11, 2008, and Jan 6, 2014, 265 patients were included and randomly assigned, 133 to the cytoreductive surgery plus HIPEC group and 132 to the cytoreductive surgery alone group. After median follow-up of 63·8 months (IQR 53·0-77·1), median overall survival was 41·7 months (95\% CI 36·2-53·8) in the cytoreductive surgery plus HIPEC group and 41·2 months (35·1-49·7) in the cytoreductive surgery group (hazard ratio 1·00 [95·37\% CI 0·63-1·58]; stratified log-rank p=0·99). At 30 days, two (2\%) treatment-related deaths had occurred in each group.. Grade 3 or worse adverse events at 30 days were similar in frequency between groups (56 [42\%] of 133 patients in the cytoreductive surgery plus HIPEC group vs 42 [32\%] of 132 patients in the cytoreductive surgery group; p=0·083); however, at 60 days, grade 3 or worse adverse events were more common in the cytoreductive surgery plus HIPEC group (34 [26\%] of 131 vs 20 [15\%] of 130; p=0·035).
INTERPRETATION: Considering the absence of an overall survival benefit after adding HIPEC to cytoreductive surgery and more frequent postoperative late complications with this combination, our data suggest that cytoreductive surgery alone should be the cornerstone of therapeutic strategies with curative intent for colorectal peritoneal metastases.
FUNDING: Institut National du Cancer, Programme Hospitalier de Recherche Clinique du Cancer, Ligue Contre le Cancer.},
	language = {eng},
	number = {2},
	journal = {The Lancet. Oncology},
	author = {Quénet, François and Elias, Dominique and Roca, Lise and Goéré, Diane and Ghouti, Laurent and Pocard, Marc and Facy, Olivier and Arvieux, Catherine and Lorimier, Gérard and Pezet, Denis and Marchal, Frédéric and Loi, Valeria and Meeus, Pierre and Juzyna, Beata and de Forges, Hélène and Paineau, Jacques and Glehen, Olivier and {UNICANCER-GI Group and BIG Renape Group}},
	month = feb,
	year = {2021},
	pmid = {33476595},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, France, Peritoneal Neoplasms, Disease-Free Survival, Combined Modality Therapy, Oxaliplatin, HIPEC, Cytoreduction Surgical Procedures, Hyperthermic Intraperitoneal Chemotherapy},
	pages = {256--266},
	file = {Full Text:/Users/jcsal/Zotero/storage/BDVJWMB7/Quénet et al. - 2021 - Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery al.pdf:application/pdf},
}

@article{sugarbakerS129,
	title = {The {PRODIGE} 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other {HIPEC} regimens},
	volume = {12},
	issn = {2078-6891},
	doi = {10.21037/jgo-2020-15},
	language = {eng},
	number = {Suppl 1},
	journal = {Journal of Gastrointestinal Oncology},
	author = {Sugarbaker, Paul H. and Van der Speeten, Kurt},
	month = apr,
	year = {2021},
	pmid = {33970156},
	pmcid = {PMC8100721},
	keywords = {HIPEC},
	pages = {S129--S130},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/2LHYYSPW/Sugarbaker and Van der Speeten - 2021 - The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to di.pdf:application/pdf},
}

@article{cashinS120,
	title = {Hyperthermic intraperitoneal chemotherapy ({HIPEC}) for colorectal and appendiceal peritoneal metastases: lessons learned from {PRODIGE} 7},
	volume = {12},
	issn = {2078-6891},
	shorttitle = {Hyperthermic intraperitoneal chemotherapy ({HIPEC}) for colorectal and appendiceal peritoneal metastases},
	doi = {10.21037/jgo-2020-05},
	abstract = {The treatment for peritoneal metastases from appendiceal, colon and rectal cancer (MO1) has relied on cytoreductive surgery (CRS) to remove all visible evidence of disease plus a perioperative chemotherapy for the entire abdomen to eliminate microscopic residual disease. Using the results obtained from the PRODIGE 7 randomized controlled trial, methodological issues were discussed and possible improvements to the hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin were sought. Possible methodological and pharmacologic flaws were identified. Several methodological flaws included the sample size, cross-over option, neoadjuvant chemotherapy use and timing of the peritoneal disease evaluation. The sample size issue raised the question of what the minimal clinically relevant benefit we want in future trials. Neoadjuvant FOLFOX may have induced acquired drug resistance to oxaliplatin. Several pharmacological issues were identified including limited 5-fluorouracil exposure as well as limited oxaliplatin peritoneal exposure time. Insufficient 5-fluorouracil accompanied the oxaliplatin as only a bolus dose was used and continuous 5-FU infusion has previously been an integral part of oxaliplatin treatment. Finally, only approximately one-half of the oxaliplatin entered body tissues or tumor. Three suggestions from the lessons learned from a critique of PRODIGE 7 were offered as adjustments to the HIPEC protocol. The Efficacy of HIPEC, a perioperative FOLFOX or a return to HIPEC with mitomycin C were described.},
	language = {eng},
	number = {Suppl 1},
	journal = {Journal of Gastrointestinal Oncology},
	author = {Cashin, Peter and Sugarbaker, Paul H.},
	month = apr,
	year = {2021},
	pmid = {33968432},
	pmcid = {PMC8100699},
	keywords = {irinotecan, HIPEC, 5-fluorouracil, cytoreductive surgery (CRS), early postoperative intraperitoneal chemotherapy (EPIC), hyperthermia, Intraperitoneal chemotherapy},
	pages = {S120--S128},
	file = {Full Text:/Users/jcsal/Zotero/storage/435G94ZP/Cashin and Sugarbaker - 2021 - Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastas.pdf:application/pdf},
}

@article{rovers710,
	title = {Perioperative {Systemic} {Therapy} vs {Cytoreductive} {Surgery} and {Hyperthermic} {Intraperitoneal} {Chemotherapy} {Alone} for {Resectable} {Colorectal} {Peritoneal} {Metastases}: {A} {Phase} 2 {Randomized} {Clinical} {Trial}},
	volume = {156},
	issn = {2168-6262},
	shorttitle = {Perioperative {Systemic} {Therapy} vs {Cytoreductive} {Surgery} and {Hyperthermic} {Intraperitoneal} {Chemotherapy} {Alone} for {Resectable} {Colorectal} {Peritoneal} {Metastases}},
	doi = {10.1001/jamasurg.2021.1642},
	abstract = {IMPORTANCE: To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM).
OBJECTIVE: To assess the feasibility and safety of perioperative systemic therapy in patients with resectable CPM and the response of CPM to neoadjuvant treatment.
DESIGN, SETTING, AND PARTICIPANTS: An open-label, parallel-group phase 2 randomized clinical trial in all 9 Dutch tertiary centers for the surgical treatment of CPM enrolled participants between June 15, 2017, and January 9, 2019. Participants were patients with pathologically proven isolated resectable CPM who did not receive systemic therapy within 6 months before enrollment.
INTERVENTIONS: Randomization to perioperative systemic therapy or CRS-HIPEC alone. Perioperative systemic therapy comprised either four 3-week neoadjuvant and adjuvant cycles of CAPOX (capecitabine and oxaliplatin), six 2-week neoadjuvant and adjuvant cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin), or six 2-week neoadjuvant cycles of FOLFIRI (fluorouracil, leucovorin, and irinotecan) and either four 3-week adjuvant cycles of capecitabine or six 2-week adjuvant cycles of fluorouracil with leucovorin. Bevacizumab was added to the first 3 (CAPOX) or 4 (FOLFOX/FOLFIRI) neoadjuvant cycles.
MAIN OUTCOMES AND MEASURES: Proportions of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative morbidity. Key secondary outcomes were centrally assessed rates of objective radiologic and major pathologic response of CPM to neoadjuvant treatment. Analyses were done modified intention-to-treat in patients starting neoadjuvant treatment (experimental arm) or undergoing upfront surgery (control arm).
RESULTS: In 79 patients included in the analysis (43 [54\%] men; mean [SD] age, 62 [10] years), experimental (n = 37) and control (n = 42) arms did not differ significantly regarding the proportions of macroscopic complete CRS-HIPEC (33 of 37 [89\%] vs 36 of 42 [86\%] patients; risk ratio, 1.04; 95\% CI, 0.88-1.23; P = .74) and Clavien-Dindo grade 3 or higher postoperative morbidity (8 of 37 [22\%] vs 14 of 42 [33\%] patients; risk ratio, 0.65; 95\% CI, 0.31-1.37; P = .25). No treatment-related deaths occurred. Objective radiologic and major pathologic response rates of CPM to neoadjuvant treatment were 28\% (9 of 32 evaluable patients) and 38\% (13 of 34 evaluable patients), respectively.
CONCLUSIONS AND RELEVANCE: In this randomized phase 2 trial in patients diagnosed with resectable CPM, perioperative systemic therapy seemed feasible, safe, and able to induce response of CPM, justifying a phase 3 trial.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02758951.},
	language = {eng},
	number = {8},
	journal = {JAMA surgery},
	author = {Rovers, Koen P. and Bakkers, Checca and Nienhuijs, Simon W. and Burger, Jacobus W. A. and Creemers, Geert-Jan M. and Thijs, Anna M. J. and Brandt-Kerkhof, Alexandra R. M. and Madsen, Eva V. E. and van Meerten, Esther and Tuynman, Jurriaan B. and Kusters, Miranda and Versteeg, Kathelijn S. and Aalbers, Arend G. J. and Kok, Niels F. M. and Buffart, Tineke E. and Wiezer, Marinus J. and Boerma, Djamila and Los, Maartje and de Reuver, Philip R. and Bremers, Andreas J. A. and Verheul, Henk M. W. and Kruijff, Schelto and de Groot, Derk Jan A. and Witkamp, Arjen J. and van Grevenstein, Wilhelmina M. U. and Koopman, Miriam and Nederend, Joost and Lahaye, Max J. and Kranenburg, Onno and Fijneman, Remond J. A. and van 't Erve, Iris and Snaebjornsson, Petur and Hemmer, Patrick H. J. and Dijkgraaf, Marcel G. W. and Punt, Cornelis J. A. and Tanis, Pieter J. and de Hingh, Ignace H. J. T. and {Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group}},
	month = aug,
	year = {2021},
	pmid = {34009291},
	pmcid = {PMC8135056},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Fluorouracil, Leucovorin, Organoplatinum Compounds, Camptothecin, Adenocarcinoma, Peritoneal Neoplasms, Capecitabine, Oxaliplatin, Perioperative Period, Feasibility Studies, Bevacizumab, Mitomycin, HIPEC, Cytoreduction Surgical Procedures, Hyperthermic Intraperitoneal Chemotherapy, Response Evaluation Criteria in Solid Tumors},
	pages = {710--720},
	file = {Full Text:/Users/jcsal/Zotero/storage/U8NV79W5/Rovers et al. - 2021 - Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherap.pdf:application/pdf},
}

@article{klaver761,
	title = {Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer ({COLOPEC}): a multicentre, open-label, randomised trial},
	volume = {4},
	issn = {2468-1253},
	shorttitle = {Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer ({COLOPEC})},
	doi = {10.1016/S2468-1253(19)30239-0},
	abstract = {BACKGROUND: Nearly a quarter of patients with locally advanced (T4 stage) or perforated colon cancer are at risk of developing peritoneal metastases, often without curative treatment options. We aimed to determine the efficacy of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally advanced colon cancer.
METHODS: This multicentre, open-label trial was done in nine hospitals that specialised in HIPEC in the Netherlands. Patients with clinical or pathological T4N0-2M0-stage tumours or perforated colon cancer were randomly assigned (1:1), with a web-based randomisation application, before resection of the primary tumour, to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy (experimental group) or to adjuvant systemic chemotherapy alone (control group). Patients were stratified by tumour characteristic (T4 or perforation), age ({\textless}65 years or ≥65 years), and surgical approach of the primary tumour resection (laparoscopic or open). Key eligibility criteria included age between 18 and 75 years, adequate clinical condition for HIPEC, and intention to start adjuvant systemic chemotherapy. Patients with metastatic disease were ineligible. Adjuvant HIPEC consisted of fluorouracil (400 mg/m2) and leucovorin (20 mg/m2) delivered intravenously followed by intraperitoneal delivery of oxaliplatin (460 mg/m2) for 30 min at 42°C, delivered simultaneously or within 5-8 weeks after primary tumour resection. In all patients without evidence of recurrent disease at 18 months, a diagnostic laparoscopy was done. The primary endpoint was peritoneal metastasis free-survival at 18 months, measured in the intention-to-treat population, with the Kaplan-Meier method. Adverse events were assessed in all patients who received assigned treatment. This study is registered with ClinicalTrials.gov, number NCT02231086.
FINDINGS: Between April 1, 2015, and Feb 20, 2017, 204 patients were randomly assigned to treatment (102 in each group). In the HIPEC group, two patients withdrew consent after randomisation. In this group, 19 (19\%) of 100 patients were diagnosed with peritoneal metastases: nine (47\%) during surgical exploration preceding intentional adjuvant HIPEC, eight (42\%) during routine follow-up, and two (11\%) during diagnostic laparoscopy at 18-months. In the control group, 23 (23\%) of 102 patients were diagnosed with peritoneal metastases, of whom seven (30\%) were diagnosed by laparoscopy at 18-months and 16 during regular follow-up (therefore making them ineligible for diagnostic laparoscopy). In the intention-to-treat analysis (n=202), there was no difference in peritoneal-free survival at 18-months (80·9\% [95\% CI 73·3-88·5] for the experimental group vs 76·2\% [68·0-84·4] for the control group, log-rank one-sided p=0·28). 12 (14\%) of 87 patients who received adjuvant HIPEC developed postoperative complications and one (1\%) encapsulating peritoneal sclerosis.
INTERPRETATION: In patients with T4 or perforated colon cancer, treatment with adjuvant HIPEC with oxaliplatin did not improve peritoneal metastasis-free survival at 18 months. Routine use of adjuvant HIPEC is not advocated on the basis of this trial.
FUNDING: Organization for Health Research and Development and the Dutch Cancer Society.},
	language = {eng},
	number = {10},
	journal = {The Lancet. Gastroenterology \& Hepatology},
	author = {Klaver, Charlotte E. L. and Wisselink, Daniel D. and Punt, Cornelis J. A. and Snaebjornsson, Petur and Crezee, Johannes and Aalbers, Arend G. J. and Brandt, Alexandra and Bremers, Andre J. A. and Burger, Jacobus W. A. and Fabry, Hans F. J. and Ferenschild, Floris and Festen, Sebastiaan and van Grevenstein, Wilhelmina M. U. and Hemmer, Patrick H. J. and de Hingh, Ignace H. J. T. and Kok, Niels F. M. and Musters, Gijsbert D. and Schoonderwoerd, Lotte and Tuynman, Jurriaan B. and van de Ven, Anthony W. H. and van Westreenen, Henderik L. and Wiezer, Marinus J. and Zimmerman, David D. E. and van Zweeden, Annette A. and Dijkgraaf, Marcel G. W. and Tanis, Pieter J. and {COLOPEC collaborators group}},
	month = oct,
	year = {2019},
	pmid = {31371228},
	keywords = {Humans, Aged, Female, Length of Stay, Male, Middle Aged, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Colectomy, Colonic Neoplasms, Adenocarcinoma, Peritoneal Neoplasms, Postoperative Complications, Oxaliplatin, Intraoperative Complications, Hyperthermia, Induced, HIPEC},
	pages = {761--770},
	file = {Full Text:/Users/jcsal/Zotero/storage/X2HAHVHL/Klaver et al. - 2019 - Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (C.pdf:application/pdf},
}

@article{rubenstein1020,
	title = {{AGA} {Clinical} {Practice} {Guideline} on {Endoscopic} {Eradication} {Therapy} of {Barrett}'s {Esophagus} and {Related} {Neoplasia}},
	volume = {166},
	issn = {1528-0012},
	doi = {10.1053/j.gastro.2024.03.019},
	abstract = {BACKGROUND \& AIMS: Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Endoscopic eradication therapy (EET) can be effective in eradicating BE and related neoplasia and has greater risk of harms and resource use than surveillance endoscopy. This clinical practice guideline aims to inform clinicians and patients by providing evidence-based practice recommendations for the use of EET in BE and related neoplasia.
METHODS: The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients, conducted an evidence review, and used the Evidence-to-Decision Framework to develop recommendations regarding the use of EET in patients with BE under the following scenarios: presence of (1) high-grade dysplasia, (2) low-grade dysplasia, (3) no dysplasia, and (4) choice of stepwise endoscopic mucosal resection (EMR) or focal EMR plus ablation, and (5) endoscopic submucosal dissection vs EMR. Clinical recommendations were based on the balance between desirable and undesirable effects, patient values, costs, and health equity considerations.
RESULTS: The panel agreed on 5 recommendations for the use of EET in BE and related neoplasia. Based on the available evidence, the panel made a strong recommendation in favor of EET in patients with BE high-grade dysplasia and conditional recommendation against EET in BE without dysplasia. The panel made a conditional recommendation in favor of EET in BE low-grade dysplasia; patients with BE low-grade dysplasia who place a higher value on the potential harms and lower value on the benefits (which are uncertain) regarding reduction of esophageal cancer mortality could reasonably select surveillance endoscopy. In patients with visible lesions, a conditional recommendation was made in favor of focal EMR plus ablation over stepwise EMR. In patients with visible neoplastic lesions undergoing resection, the use of either endoscopic mucosal resection or endoscopic submucosal dissection was suggested based on lesion characteristics.
CONCLUSIONS: This document provides a comprehensive outline of the indications for EET in the management of BE and related neoplasia. Guidance is also provided regarding the considerations surrounding implementation of EET. Providers should engage in shared decision making based on patient preferences. Limitations and gaps in the evidence are highlighted to guide future research opportunities.},
	language = {eng},
	number = {6},
	journal = {Gastroenterology},
	author = {Rubenstein, Joel H. and Sawas, Tarek and Wani, Sachin and Eluri, Swathi and Singh, Shailendra and Chandar, Apoorva K. and Perumpail, Ryan B. and Inadomi, John M. and Thrift, Aaron P. and Piscoya, Alejandro and Sultan, Shahnaz and Singh, Siddharth and Katzka, David and Davitkov, Perica},
	month = jun,
	year = {2024},
	pmid = {38763697},
	pmcid = {PMC11345740},
	keywords = {Humans, Treatment Outcome, Adenocarcinoma, Esophageal Neoplasms, Esophagoscopy, Barrett Esophagus, Endoscopic Mucosal Resection, Barrett’s Esophagus, Evidence-Based Medicine, Clinical Decision-Making, Ablation Techniques, Cryosurgery, Gastroenterology, Radiofrequency Ablation},
	pages = {1020--1055},
	file = {nihms-2015307:/Users/jcsal/Downloads/nihms-2015307.pdf:application/pdf},
}

@article{rastogi394,
	title = {Incidence of esophageal adenocarcinoma in patients with {Barrett}'s esophagus and high-grade dysplasia: a meta-analysis},
	volume = {67},
	issn = {0016-5107},
	shorttitle = {Incidence of esophageal adenocarcinoma in patients with {Barrett}'s esophagus and high-grade dysplasia},
	doi = {10.1016/j.gie.2007.07.019},
	abstract = {BACKGROUND: Patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) are at a high risk for developing esophageal adenocarcinoma. However, the reported rate of cancer development in patients with HGD who were undergoing surveillance has varied among published studies.
OBJECTIVE: To determine an overall precise estimate of cancer incidence in patients with HGD who were undergoing surveillance endoscopy.
DESIGN: Systematic review and meta-analysis.
METHODS: We conducted a systematic search of the published literature and selected original articles that examined patients with histologically proven BE and HGD, patients who had not undergone endoscopic ablation or surgical therapy, patients with 6 months' follow-up, no esophageal cancer at the time of enrollment or within 6 months, and studies in which follow-up was reported in person-time. Two investigators independently conducted the search and abstraction.
MAIN OUTCOME MEASUREMENT: The weighted mean event rate was calculated and expressed as the weighted incidence rate, and its CIs were calculated.
RESULTS: The search yielded 4 articles that met the inclusion criteria, and these were analyzed. A total of 236 patients with HGD were followed for 1241 patient-years, and esophageal adenocarcinoma was reported in 69 patients, providing a crude incidence rate of 5.57 per 100 patient-years. The weighted incidence rate was 6.58 per 100 patient-years (95\% CI, 4.97-8.19).
LIMITATIONS: A small number of studies that met inclusion criteria.
CONCLUSIONS: In patients with BE and with HGD who were undergoing surveillance, esophageal adenocarcinoma develops in approximately 6 per 100 patient-years during the first few years of follow-up. These data may better inform physicians and patients in management decisions.},
	language = {eng},
	number = {3},
	journal = {Gastrointestinal Endoscopy},
	author = {Rastogi, Amit and Puli, Srinivas and El-Serag, Hashem B. and Bansal, Ajay and Wani, Sachin and Sharma, Prateek},
	month = mar,
	year = {2008},
	pmid = {18045592},
	keywords = {Humans, Adenocarcinoma, Esophageal Neoplasms, Incidence, Barrett Esophagus, Endoscopy},
	pages = {394--398},
}

@article{al-batran835,
	title = {The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the {Arbeitsgemeinschaft} {Internistische} {Onkologie} ({FLOT65}+)},
	volume = {49},
	issn = {1879-0852},
	shorttitle = {The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer},
	doi = {10.1016/j.ejca.2012.09.025},
	abstract = {BACKGROUND: We evaluated the feasibility and tolerability of triple- versus double-drug chemotherapy in elderly patients with oesophagogastric cancer.
METHODS: Patients aged 65 years or older with locally advanced or metastatic oesophagogastric cancer were stratified and randomised to infusional 5-FU, leucovorin and oxaliplatin without (FLO) or with docetaxel 50 mg/m(2) (FLOT) every 2 weeks. The study is registered at ClinicalTrials.gov, identifier NCT00737373.
FINDINGS: One hundred and forty three (FLO, 71; FLOT, 72) patients with a median age of 70 years were enrolled. The triple combination was associated with more treatment-related National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3/4 adverse events (FLOT, 81.9\%; FLO, 38.6\%; P{\textless}.001) and more patients experiencing a ≥10-points deterioration of European Organization for Research and Treatment of Cancer Quality of Life (EORTC QoL) global health status scores (FLOT, 47.5\%; FLO 20.5\%; p=.011). The triple combination was associated with more alopecia (P{\textless}.001), neutropenia (P{\textless}.001), leukopenia (P{\textless}.001), diarrhoea (P=.006) and nausea (P=.029).). No differences were observed in treatment duration and discontinuation due to toxicity, cumulative doses or toxic deaths between arms. The triple combination improved response rates and progression-free survival in the locally advanced subgroup and in the subgroup of patients aged between 65 and 70 years but not in the metastatic group or in patients aged 70 years and older.
INTERPRETATION: The triple-drug chemotherapy was feasible in elderly patients with oesophagogastric cancer. However, toxicity was significantly increased and QoL deteriorated in a relevant proportion of patients.
FUNDING: The study was partially funded by Sanofi-Aventis.},
	language = {eng},
	number = {4},
	journal = {European Journal of Cancer (Oxford, England: 1990)},
	author = {Al-Batran, Salah-Eddin and Pauligk, Claudia and Homann, Nils and Hartmann, Jörg T. and Moehler, Markus and Probst, Stephan and Rethwisch, Volker and Stoehlmacher-Williams, Jan and Prasnikar, Nicole and Hollerbach, Stephan and Bokemeyer, Carsten and Mahlberg, Rolf and Hofheinz, Ralf D. and Luley, Kim and Kullmann, Frank and Jäger, Elke},
	month = mar,
	year = {2013},
	pmid = {23063354},
	keywords = {Humans, Aged, Female, Male, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Survival Rate, Prognosis, Leucovorin, Organoplatinum Compounds, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Oxaliplatin, Taxoids, Quality of Life, Docetaxel, Feasibility Studies, FLOT},
	pages = {835--842},
}

@article{radlinski5850,
	title = {Use of endoscopic ultrasound in pre-treatment staging of esophageal cancer did not alter management plan},
	volume = {12},
	issn = {2072-1439},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656415/},
	doi = {10.21037/jtd-20-1299},
	abstract = {Background
Initial staging of esophageal cancer relies on EUS in addition to FDG-PET/CT. It is our hypothesis that with the advancement of FDG-PET/CT staging, endoscopic ultrasound may not be required for initial staging in all cases. The purpose of this study is to analyze whether EUS affects initial treatment stratification in patients diagnosed with esophageal cancer.

Methods
A retrospective database at the University of Virginia was queried for patients diagnosed with esophageal squamous cell carcinoma and adenocarcinoma who underwent EGD with EUS and FDG-PET/CT at their initial evaluation from 10/2013 to 5/2017. Two thoracic surgeons were asked to determine appropriate management for each case. Options included surgical resection, neoadjuvant chemoradiotherapy followed by resection, definitive chemoradiotherapy, or chemotherapy with or without palliative radiation. Both surgeons received the FDG-PET/CT report along with the EGD report. For each case, one or both surgeons were randomly allocated to review EUS results in addition to the clinical information. The treatment decisions of each thoracic surgeon were compared to determine if EUS reports impacted clinical management. Simple and weighted correlation coefficients (kappa) were calculated to compare agreement of treatment choices between the two surgeons using McNemars test. Conditional logistic regression was used to assess the influence of EUS on the treatment recommendations.

Results
A total of 50 patients (44 male and 6 female) were enrolled and data was collected. The thoracic surgeons agreed on treatment decisions in 39 cases and disagreed on 11 cases. Agreement between surgeons was good despite lack of EUS information for one surgeon on each case (weighted Kappa =0.73, 95\% CI: 0.57–0.89). Using conditional logistic regression, EUS did not have a statistically independent association with agreement on treatment plan (P for model =0.17).

Conclusions
EUS did not have a statistically independent association with agreement on treatment plan for newly diagnosed esophageal cancer (P for model =0.17). Our findings suggest that EUS may not be necessary in the algorithm for the initial staging of every case of esophageal cancer. Selective, rather than mandatory use of EUS seems warranted.},
	number = {10},
	urldate = {2024-10-04},
	journal = {Journal of Thoracic Disease},
	author = {Radlinski, Mark and Martin, Linda W. and Walters, Dustin M. and Northup, Patrick and Wang, Andrew Y. and Rodee, Terri and Sauer, Bryan G. and Shami, Vanessa M.},
	month = oct,
	year = {2020},
	pmid = {33209417},
	pmcid = {PMC7656415},
	pages = {5850--5856},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/ETKE6Y6S/Radlinski et al. - 2020 - Use of endoscopic ultrasound in pre-treatment staging of esophageal cancer did not alter management.pdf:application/pdf},
}

@article{findlay1488,
	title = {Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, {PET} and laparoscopy},
	volume = {102},
	issn = {1365-2168},
	doi = {10.1002/bjs.9905},
	abstract = {BACKGROUND: Following CT, guidelines for staging oesophageal and gastro-oesophageal junction (GOJ) cancer recommend endoscopic ultrasonography (EUS), PET-CT and laparoscopy for T3-T4 GOJ tumours. These recommendations are based on generic utilities, but it is unclear whether the test risk outweighs the potential benefit for some patients. This study sought to quantify investigation risks, benefits and utilities, in order to develop pragmatic, personalized staging recommendations.
METHODS: All patients with a histological diagnosis of oesophageal or GOJ cancer staged between May 2006 and July 2013 comprised a development set; those staged from July 2013 to July 2014 formed the prospective validation set. Probability thresholds of altering management were calculated and predictive factors identified. Algorithms and models (decision tree analysis, logistic regression, artificial neural networks) were validated internally and independently.
RESULTS: Some 953 patients were staged following CT, by [(18) F]fluorodeoxyglucose PET-CT (918), EUS (798) and laparoscopy (458). Of these patients, 829 comprised the development set (800 PET-CT, 698 EUS, 397 laparoscopy) and 124 the validation set (118 PET-CT, 100 EUS, 61 laparoscopy). EUS utility in the 71.8 per cent of patients with T2-T4a disease on CT was minimal (0.4 per cent), its risk exceeding benefit. EUS was moderately accurate for pT1 N0 disease. A number of factors predicted metastases on PET-CT and laparoscopy, although none could inform an algorithm. PET-CT altered management in 23.0 per cent, and laparoscopy in 7.1 per cent, including those with T2 and distal oesophageal tumours.
CONCLUSION: Although EUS provided additional information on T and N category, its risk outweighed potential benefit in patients with T2-T4a disease on CT. Laparoscopy seemed justified for distal oesophageal tumours of T2 or greater.},
	language = {eng},
	number = {12},
	journal = {The British Journal of Surgery},
	author = {Findlay, J. M. and Bradley, K. M. and Maile, E. J. and Braden, B. and Maw, J. and Phillips-Hughes, J. and Gillies, R. S. and Maynard, N. D. and Middleton, M. R.},
	month = nov,
	year = {2015},
	pmid = {26458070},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Prospective Studies, Aged, 80 and over, Reproducibility of Results, Adult, Esophageal Neoplasms, Fluorodeoxyglucose F18, Radiopharmaceuticals, Esophagogastric Junction, Laparoscopy, Positron-Emission Tomography, Endosonography, Multidetector Computed Tomography, Decision Theory},
	pages = {1488--1499},
}

@article{mansfield3227,
	title = {Routine staging with endoscopic ultrasound in patients with obstructing esophageal cancer and dysphagia rarely impacts treatment decisions},
	volume = {31},
	issn = {1432-2218},
	doi = {10.1007/s00464-016-5351-6},
	abstract = {BACKGROUND: Endoscopic ultrasound (EUS) has been routinely utilized for the locoregional staging of esophageal cancer. One important aspect of clinical staging has been to stratify patients to treatment with neoadjuvant chemoradiation or primary surgical therapy. We hypothesized that EUS may have a limited impact on clinical decision making in patients with dysphagia and obstructing esophageal masses.
METHODS: This retrospective cohort study included all patients with esophageal adenocarcinoma undergoing esophageal EUS between July 2008 and September 2013. Dysplastic Barrett's esophagus without invasive adenocarcinoma or incomplete staging was excluded. Patient demographics, endoscopic tumor characteristics, the presence of dysphagia, sonographic staging, and post-EUS therapy were recorded. Pathologic staging for patients who underwent primary surgical therapy was also recorded. Locally advanced disease was defined as at least T3 or N1, as these patients are typically treated with neoadjuvant therapy.
RESULTS: Two hundred sixteen patients underwent EUS for esophageal adenocarcinoma, with 147 (68.1\%) patients having symptoms of dysphagia on initial presentation. Patients with dysphagia were significantly more likely to have locally advanced disease on EUS than patients without dysphagia (p {\textless} 0.0001). Additionally, 145 (67.1\%) patients had a partially or completely obstructing mass on initial endoscopy, of which 136 (93.8\%) were locally advanced (p {\textless} 0.0001 vs. non-obstructing lesions).
CONCLUSIONS: An overwhelming majority of patients presenting with dysphagia and/or the presence of at least partially obstructing esophageal mass at the time of esophageal cancer diagnosis had an EUS that demonstrated at least locally advanced disease. The present study supports the hypothesis that EUS may be of limited benefit for management of esophageal cancer in patients with an obstructing mass and dysphagia.},
	language = {eng},
	number = {8},
	journal = {Surgical Endoscopy},
	author = {Mansfield, Sara A. and El-Dika, Samer and Krishna, Somashekar G. and Perry, Kyle A. and Walker, Jon P.},
	month = aug,
	year = {2017},
	pmid = {27864719},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Cohort Studies, Adult, Predictive Value of Tests, Adenocarcinoma, Esophageal Neoplasms, Esophageal cancer, Severity of Illness Index, Decision Support Techniques, Endosonography, Dysphagia, Endoscopic ultrasound, Staging},
	pages = {3227--3233},
}

@article{faigel2257,
	title = {Biopsy-negative malignant esophageal stricture: diagnosis by endoscopic ultrasound},
	volume = {93},
	issn = {0002-9270},
	shorttitle = {Biopsy-negative malignant esophageal stricture},
	doi = {10.1111/j.1572-0241.1998.00629.x},
	abstract = {Endoscopic ultrasound (EUS) of the esophagus has been used primarily in staging biopsy-proven cancers. Its use as a primary diagnostic modality for esophageal malignancy has not been previously described. We report our recent experience in four patients with dysphagia and endoscopic biopsies negative for malignancy, including one patient with clinical and manometric features suggestive of achalasia. In all cases, EUS revealed a large infiltrating tumor invading through the esophageal wall into the surrounding tissues, and in one case into the aorta. Computed tomography suggested the possibility of a tumor in only one of the cases. Two patients underwent esophagectomy and were found to have adenocarcinoma. Two patients underwent repeat biopsy with alternative aggressive biopsy techniques and were found to have squamous cell carcinoma. We conclude that EUS is useful in the diagnosis of esophageal cancer and should be performed in selected patients with esophageal strictures whose biopsies are negative for malignancy; i.e., those with suspicious endoscopic or radiographic appearance, atypical presentation (e.g., profound weight loss, short duration of symptoms, or advanced age), and failure to respond to treatment.},
	language = {eng},
	number = {11},
	journal = {The American Journal of Gastroenterology},
	author = {Faigel, D. O. and Deveney, C. and Phillips, D. and Fennerty, M. B.},
	month = nov,
	year = {1998},
	pmid = {9820410},
	keywords = {Humans, Aged, Male, Middle Aged, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Endosonography, Biopsy, Esophageal Stenosis},
	pages = {2257--2260},
}

@article{markar711,
	title = {Emergency {Presentation} of {Esophagogastric} {Cancer}: {Predictors} and {Long}-term {Prognosis}},
	volume = {267},
	issn = {1528-1140},
	shorttitle = {Emergency {Presentation} of {Esophagogastric} {Cancer}},
	doi = {10.1097/SLA.0000000000002224},
	abstract = {OBJECTIVE: To identify patient factors that are associated with emergency presentation of esophageal and gastric cancer, and further to evaluate long-term prognosis in this cohort.
BACKGROUND: The incidence of emergency presentation is variable, with the prognosis of patients stabilized and discharged to return for elective surgery unknown.
METHODS: The primary admission of patients with esophageal or gastric cancer within the Hospital Episode Statistics database (1997-2012) was used to classify as emergency or elective diagnosis. Multivariate regression analyses were used to identify patient factors associated with emergency diagnosis and prognosis.
RESULTS: A total of 35,807 (29.4\%) and 45,866 (39.6\%) patients with esophageal and gastric cancer presented as an emergency over the study period. Age ≥70, female sex, non-white ethnicity, Charlson comorbidity index score ≥3 and more deprived Townsend index were independent predictors of emergency cancer diagnosis. Emergency diagnosis was an independent predictor of increased 5-year mortality for all patients with esophageal cancer [hazard ratio (HR) = 1.63, 95\% confidence interval (CI) 1.61-1.65] and gastric cancer (HR = 1.20, 95\% CI 1.16-1.23). Specifically patients receiving surgery on an elective follow-up admission with an initial emergency diagnosis had a poorer prognosis (esophageal cancer: HR = 1.35, 95\% CI 1.27-1.44, gastric cancer: HR = 1.13. 95\% CI 1.04-1.22), with a significant increase in liver recurrence (esophageal cancer: 7.1\% vs 4.9\%; P {\textless} 0.001, gastric cancer: 7.0\% vs 4.8\%; P {\textless} 0.001) compared to patients referred electively.
CONCLUSIONS: Emergency presentation of esophageal and gastric cancer is associated with a poor prognosis, due to the increased incidence of metastatic disease at diagnosis and a higher recurrence rate after surgery.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Markar, Sheraz R. and Mackenzie, Hugh and Jemal, Sara and Faiz, Omar and Cunningham, David and Hanna, George B.},
	month = apr,
	year = {2018},
	pmid = {28323674},
	keywords = {Humans, Aged, Female, Hospitalization, Male, Neoplasm Metastasis, Proportional Hazards Models, Prognosis, Stomach Neoplasms, Esophageal Neoplasms, Recurrence, Emergencies},
	pages = {711--715},
}

@article{abu-daff34,
	title = {Esophagectomy in esophageal perforations: an analysis},
	volume = {29},
	issn = {1442-2050},
	shorttitle = {Esophagectomy in esophageal perforations},
	doi = {10.1111/dote.12294},
	abstract = {This study aimed to study the factors that are associated with urgent esophagectomy for the treatment of esophageal perforations and the impact of this therapy. A retrospective review of all esophageal perforations treated at a tertiary care hospital from January 1984 to January 2012 was performed. Compiling demographics, cause and site of perforations, time to presentation, comorbidities, radiological tests, the length of perforation, the hemodynamic status of the patient, type of treatment required, and outcomes were performed. Univariate, multivariate, and Cox regression analyses were conducted. Of 127 cases of esophageal perforation, it was spontaneous in 44 (35\%), iatrogenic in 53 (44\%), foreign body ingestion in 22 (17\%), and traumatic perforation in 7 (6\%) cases. Overall, 85 of the 127 (67\%) patients were managed operatively, 35 (27.6\%) patients were treated conservatively, and 7 (6.3\%) patients were treated by endoscopic stent placement. Of the 85 patients who were managed operatively, 21 (16.5\%) required esophagectomies, 13 (15.3\%) had esophagectomy with immediate reconstruction, 5 (5.9\%) patients had esophagectomy followed by delayed reconstruction, and 3 (3.5\%) patients failed primary repair and required an esophagectomy as a secondary definitive procedure. Multivariate analysis revealed that esophagectomy in esophageal perforations was associated with the presence of benign or malignant esophageal stricture (P = 0.001) and a perforation {\textgreater}5 cm (P = 0.001). Mortality was mainly associated with the presence of a benign or malignant esophageal stricture (P = 0.04). The presence of pre-existing benign or malignant stricture or large perforation ({\textgreater}5 cm) is associated with the need for an urgent esophagectomy with or without immediate reconstruction. Performing esophagectomy was not found to be a significant prognosticator for mortality.},
	language = {eng},
	number = {1},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Abu-Daff, S. and Shamji, F. and Ivanovic, J. and Villeneuve, P. J. and Gilbert, S. and Maziak, D. E. and Sundaresan, R. S. and Seely, A. J. E.},
	month = jan,
	year = {2016},
	pmid = {25327568},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Radiography, Aged, 80 and over, Adult, Esophagectomy, Esophagus, Stents, Severity of Illness Index, esophagectomy, Esophageal Stenosis, mortality, Time-to-Treatment, esophageal perforation, Esophageal Perforation, Saudi Arabia},
	pages = {34--40},
}

@article{gillen3065,
	title = {Palliative cardia resection with gastroesophageal reconstruction for perforated carcinoma of the gastroesophageal junction},
	volume = {15},
	issn = {1007-9327},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702118/},
	doi = {10.3748/wjg.15.3065},
	abstract = {Iatrogenic perforation of esophageal cancer or cancer of the gastroesophageal (GE) junction is a serious complication that, in addition to short term morbidity and mortality, significantly compromises the success of any subsequent oncological therapy. Here, we present an 82-year-old man with iatrogenic perforation of adenocarcinoma of the GE junction. Immediate surgical intervention included palliative resection and GE reconstruction. In the case of iatrogenic tumor perforation, the primary goal should be adequate palliative (and not oncological) therapy. The different approaches for iatrogenic perforation, i.e. surgical versus endoscopic therapy are discussed.},
	number = {24},
	urldate = {2024-10-09},
	journal = {World Journal of Gastroenterology : WJG},
	author = {Gillen, Sonja and Friess, Helmut and Kleeff, Jörg},
	month = jun,
	year = {2009},
	pmid = {19554663},
	pmcid = {PMC2702118},
	pages = {3065--3067},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/92MBEC6L/Gillen et al. - 2009 - Palliative cardia resection with gastroesophageal reconstruction for perforated carcinoma of the gas.pdf:application/pdf},
}

@article{suarez-poveda505,
	title = {Diagnostic performance of {CT} esophagography in patients with suspected esophageal rupture},
	volume = {21},
	issn = {1438-1435},
	doi = {10.1007/s10140-014-1222-4},
	abstract = {Esophageal rupture is a surgical catastrophe. The gold standard for diagnosing is iodine, water-soluble contrast medium esophagography. CT esophagography has shown promising results. This study aimed to assess the diagnostic performance of CT esophagography in patients with a suspicion of esophageal rupture. This prospective study assessed the performance of a diagnostic test and was approved by local IRB committee. Patients who presented with a clinical suspicion of esophageal rupture were included. CT esophagography findings were described by the emergency radiologist. Clinical outcomes (presence or absence of esophageal rupture) were reported by surgeons. The operative characteristics were calculated. A final predictive scale for rupture was built. A total of 64 patients were recruited (age 26.5 years, 90 \% male, 82 \% trauma). Sensitivity, specificity, and positive and negative likelihood ratios (LRs) were 77.7 \% (95 \% confidence interval (CI) 45-100), 94.3 \% (87.2-100), 14 (9.81-19.9), and 0.24 (0.05-1.22), respectively. The final model for predicting rupture included five variables: age (odds ratio (OR) 1.03; 95 \% CI, 0.95-1.11; p=0.04), leakage of contrast media into the mediastinum or pleural space (OR 10.0; 95 \% CI, 0.64-156.9; p=0.10), extraluminal air or fluid collections (OR 43.1; 95 \% CI, 1.52-1217.3; p=0.027), esophageal wall thickening (OR 10.1; 95 \% CI, 0.50-202.8; p=0.12), and left pneumothorax or pleural effusion (OR 6.5; 95 \% CI, 0.31-132.7; p=0.2). The overall agreement was 0.40 (95 \% CI, 0.09-0.72) for the predictive model. The model sensitivity was 50.0 \%, and the specificity was 98.4 \%. CT esophagography shows a good diagnostic performance in patients with a suspected esophageal rupture.},
	language = {eng},
	number = {5},
	journal = {Emergency Radiology},
	author = {Suarez-Poveda, Tatiana and Morales-Uribe, Carlos H. and Sanabria, Alvaro and Llano-Sánchez, Adriana and Valencia-Delgado, Andrés Mauricio and Rivera-Velázquez, Luis Fernando and Bedoya-Ospina, John Fernando},
	month = oct,
	year = {2014},
	pmid = {24748526},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Prospective Studies, Adult, Young Adult, Sensitivity and Specificity, Esophagus, Adolescent, Rupture},
	pages = {505--510},
}

@article{madsen2984,
	title = {Esophagram should be performed to diagnose esophageal perforation before inter-hospital transfer},
	volume = {15},
	issn = {2072-1439},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323583/},
	doi = {10.21037/jtd-22-1798},
	abstract = {Background
Early recognition of esophageal perforation may prevent morbidity and mortality, and accurate diagnostic imaging facilitates triage. Stable patients with suspected perforation may be transferred to higher levels of care before appropriate work-up and diagnosis confirmation. We reviewed patients transferred for esophageal perforation to critically analyze the diagnostic workflow.

Methods
We performed a retrospective review of patients transferred to our tertiary care institution from 2015–2021 for suspected esophageal perforation. Demographics, referring site characteristics, diagnostic studies, and management were analyzed. Bivariate comparisons were performed using Wilcoxon-Mann-Whitney tests for continuous variables and chi-squared or Fisher’s exact tests for categorical variables.

Results
Sixty-five patients were included. Etiology of suspected perforation was spontaneous in 53.8\% and iatrogenic in 33.8\%. Most patients were transferred within 24 hours from time of suspected perforation (66.2\%). Transferring sites included seven states and were 101–300 miles (32.3\%) or {\textgreater}300 miles (26.2\%) away. CT imaging was obtained in 96.9\% before transfer, most commonly demonstrating pneumomediastinum (46.2\%). Only 21.5\% of patients had an esophagram before transfer. Following transfer, 36.9\% (n=24) were ultimately not found to have esophageal perforation, demonstrated by negative arrival esophagram in 79.1\%. In patients with confirmed perforation (n=41), 58.5\% had surgery, 26.8\% endoscopic intervention, and 14.6\% supportive care.

Conclusions
After transfer a proportion of patients were ultimately found to not have esophageal perforation, typically demonstrated by negative esophagram upon arrival. We conclude that a recommendation of performing esophagram at the presenting site, when possible, may prevent unnecessary transfers, and will likely reduce costs, conserve resources, and decrease management delays.},
	number = {6},
	urldate = {2024-10-09},
	journal = {Journal of Thoracic Disease},
	author = {Madsen, Helen J. and Stuart, Christina M. and Wojcik, Brandon M. and Dyas, Adam R. and Hunt, Amanda and Helmkamp, Laura J. and Gergen, Anna K. and Weyant, Michael J. and Randhawa, Simran K. and Mitchell, John D. and Meguid, Robert A.},
	month = jun,
	year = {2023},
	pmid = {37426131},
	pmcid = {PMC10323583},
	pages = {2984--2996},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/DXXBNSUR/Madsen et al. - 2023 - Esophagram should be performed to diagnose esophageal perforation before inter-hospital transfer.pdf:application/pdf},
}

@article{chen2594,
	title = {A prospective study of total gastrectomy for {CDH1}-positive hereditary diffuse gastric cancer},
	volume = {18},
	issn = {1534-4681},
	doi = {10.1245/s10434-011-1648-9},
	abstract = {BACKGROUND: Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome. Up to 30\% of families with HDGC have mutations in the E-cadherin gene, CDH1. The role of prophylactic versus therapeutic gastrectomy for HDGC was studied prospectively.
METHODS: Eighteen consecutive patients with CDH1 mutations and positive family history were studied prospectively, including 13 without and 5 with symptoms. Proportions were compared by Fisher's exact test, and survival by the Breslow modification of the Wilcoxon rank-sum test.
RESULTS: Each patient underwent total gastrectomy (TG), and 17 (94\%) were found to have signet ring cell adenocarcinoma. Twelve of 13 asymptomatic patients had T1, N0 cancer, and only 2/12 (16\%) had it diagnosed preoperatively despite state-of-the-art screening methods. Each asymptomatic patient did well postoperatively, and no patient has recurred. For five symptomatic patients, each (100\%) was found to have signet ring cell adenocarcinoma (P = 0.002 versus asymptomatic) by preoperative endoscopy; three (60\%) had lymph node involvement and two (40\%) had distant metastases at time of operation. Two-year survival was 100\% for asymptomatic and 40\% for symptomatic patients (P {\textless} 0.01).
CONCLUSION: The data show that asymptomatic patients with family history of HDGC and CDH1 mutation have high probability of having signet ring cell adenocarcinoma of the stomach that is not able to be diagnosed on endoscopy; when symptoms arise, the diagnosis can be made by endoscopy, but they have metastases and decreased survival. Surveillance endoscopy is of limited value, and prophylactic gastrectomy (PG) is recommended for patients with family history of HDGC and CDH1 mutations.},
	language = {eng},
	number = {9},
	journal = {Annals of Surgical Oncology},
	author = {Chen, Yijun and Kingham, Kerry and Ford, James M. and Rosing, James and Van Dam, Jacques and Jeffrey, R. Brooke and Longacre, Teri A. and Chun, Nicki and Kurian, Allison and Norton, Jeffrey A.},
	month = sep,
	year = {2011},
	pmid = {21424370},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Prospective Studies, Survival Rate, Prognosis, Adult, Young Adult, Stomach Neoplasms, Gastrectomy, Adolescent, Mutation, Carcinoma, Signet Ring Cell, Antigens, CD, Cadherins, Genetic Predisposition to Disease, Pedigree},
	pages = {2594--2598},
}

@article{vanderpost361,
	title = {Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline {CDH1} mutation carriers},
	volume = {52},
	issn = {1468-6244},
	shorttitle = {Hereditary diffuse gastric cancer},
	doi = {10.1136/jmedgenet-2015-103094},
	abstract = {Germline CDH1 mutations confer a high lifetime risk of developing diffuse gastric (DGC) and lobular breast cancer (LBC). A multidisciplinary workshop was organised to discuss genetic testing, surgery, surveillance strategies, pathology reporting and the patient's perspective on multiple aspects, including diet post gastrectomy. The updated guidelines include revised CDH1 testing criteria (taking into account first-degree and second-degree relatives): (1) families with two or more patients with gastric cancer at any age, one confirmed DGC; (2) individuals with DGC before the age of 40 and (3) families with diagnoses of both DGC and LBC (one diagnosis before the age of 50). Additionally, CDH1 testing could be considered in patients with bilateral or familial LBC before the age of 50, patients with DGC and cleft lip/palate, and those with precursor lesions for signet ring cell carcinoma. Given the high mortality associated with invasive disease, prophylactic total gastrectomy at a centre of expertise is advised for individuals with pathogenic CDH1 mutations. Breast cancer surveillance with annual breast MRI starting at age 30 for women with a CDH1 mutation is recommended. Standardised endoscopic surveillance in experienced centres is recommended for those opting not to have gastrectomy at the current time, those with CDH1 variants of uncertain significance and those that fulfil hereditary DGC criteria without germline CDH1 mutations. Expert histopathological confirmation of (early) signet ring cell carcinoma is recommended. The impact of gastrectomy and mastectomy should not be underestimated; these can have severe consequences on a psychological, physiological and metabolic level. Nutritional problems should be carefully monitored.},
	language = {eng},
	number = {6},
	journal = {Journal of Medical Genetics},
	author = {van der Post, Rachel S. and Vogelaar, Ingrid P. and Carneiro, Fátima and Guilford, Parry and Huntsman, David and Hoogerbrugge, Nicoline and Caldas, Carlos and Schreiber, Karen E. Chelcun and Hardwick, Richard H. and Ausems, Margreet G. E. M. and Bardram, Linda and Benusiglio, Patrick R. and Bisseling, Tanya M. and Blair, Vanessa and Bleiker, Eveline and Boussioutas, Alex and Cats, Annemieke and Coit, Daniel and DeGregorio, Lynn and Figueiredo, Joana and Ford, James M. and Heijkoop, Esther and Hermens, Rosella and Humar, Bostjan and Kaurah, Pardeep and Keller, Gisella and Lai, Jennifer and Ligtenberg, Marjolijn J. L. and O'Donovan, Maria and Oliveira, Carla and Pinheiro, Hugo and Ragunath, Krish and Rasenberg, Esther and Richardson, Susan and Roviello, Franco and Schackert, Hans and Seruca, Raquel and Taylor, Amy and Ter Huurne, Anouk and Tischkowitz, Marc and Joe, Sheena Tjon A. and van Dijck, Benjamin and van Grieken, Nicole C. T. and van Hillegersberg, Richard and van Sandick, Johanna W. and Vehof, Rianne and van Krieken, J. Han and Fitzgerald, Rebecca C.},
	month = jun,
	year = {2015},
	pmid = {25979631},
	pmcid = {PMC4453626},
	keywords = {Humans, Female, Colorectal Neoplasms, Population Surveillance, Stomach Neoplasms, Breast Neoplasms, Practice Guidelines as Topic, Early Detection of Cancer, Germ-Line Mutation, Antigens, CD, Cadherins, DNA Mutational Analysis, Cancer: breast, Cancer: gastric, Clinical genetics, Diagnostics, Genetic Counseling, Genetic Testing, Heterozygote, Pregnancy, Stomach and duodenum},
	pages = {361--374},
	file = {Full Text:/Users/jcsal/Zotero/storage/HWSR4Z65/van der Post et al. - 2015 - Hereditary diffuse gastric cancer updated clinical guidelines with an emphasis on germline CDH1 mut.pdf:application/pdf},
}

@article{pilonis263,
	title = {Hereditary {Diffuse} {Gastric} {Cancer}: {Approaches} to {Screening}, {Surveillance}, and {Treatment}},
	volume = {72},
	issn = {1545-326X},
	shorttitle = {Hereditary {Diffuse} {Gastric} {Cancer}},
	url = {https://pubmed.ncbi.nlm.nih.gov/33217247/},
	doi = {10.1146/annurev-med-051019-103216},
	abstract = {Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome associated with a significant lifetime risk of diffuse gastric cancer (DGC), a malignancy characterized by late clinical presentation and poor prognosis, as well as lobular breast cancer. HDGC is linked to germline pathogenic variants in …},
	language = {en},
	urldate = {2024-10-09},
	journal = {Annual review of medicine},
	author = {Pilonis, ND and M, Tischkowitz and Rc, Fitzgerald and M, di Pietro},
	month = jan,
	year = {2021},
	pmid = {33217247},
	note = {Publisher: Annu Rev Med},
	pages = {263--280},
	file = {Full Text:/Users/jcsal/Zotero/storage/ZDCZNFNZ/Nd et al. - 2021 - Hereditary Diffuse Gastric Cancer Approaches to Screening, Surveillance, and Treatment.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/UGYPNRKY/33217247.html:text/html},
}

@article{allo1064,
	title = {Efficacy of endoscopic therapy and long-term outcomes of upper gastrointestinal tumor bleeding in patients with esophageal cancer},
	volume = {58},
	issn = {1502-7708},
	doi = {10.1080/00365521.2023.2199439},
	abstract = {BACKGROUND: Upper gastrointestinal bleeding (UGIB) from malignancies is associated with a poor outcome. Only a small number of studies on gastrointestinal tumor bleeding have been published so far, focusing mainly on bleeding from gastric cancer. Since the information on patients with UGIB from esophageal cancer appears insufficient, this study aimed to present clinical and endoscopic findings, treatment options as well as clinical outcomes such as rebleeding and survival of those patients.
METHODS: This retrospective analysis included all patients admitted with UGIB from esophageal cancer at our university hospital during a 10-year period.
RESULTS: 45 patients were analyzed of whom 26 (57.8\%) already had cancer stage IV at index bleeding. 22 (48.9\%) patients presented with hemodynamic instability and 30 (66.7\%) patients received blood transfusions. Active bleeding was present in 24 (53.3\%) patients, of whom 20 (83.3\%) received endoscopic therapy. Successful hemostasis was achieved in 18 (90\%) of 20 patients with Argon plasma coagulation used most frequently (52.4\%). Early and delayed rebleeding occurred in 5 (12.5\%) and 11 (27.5\%) of all inoperable patients, respectively. Intake of anticoagulation or anti-platelet drugs were risk factors for delayed rebleeding and the median overall survival after index bleeding was 1.2 months.
CONCLUSION: UGIB from esophageal cancer occurred most frequently in advanced tumor stages and was associated with significant blood loss. Even though initial endoscopic therapy was effective, rebleeding occurred in a significant number of patients. Those taking anticoagulants or anti-platelet drugs should be closely monitored for rebleeding. The overall survival after index bleeding was poor.},
	language = {eng},
	number = {9},
	journal = {Scandinavian Journal of Gastroenterology},
	author = {Allo, Gabriel and Bürger, Martin and Chon, Seung-Hun and Gülcicegi, Dilan and Krämer, Laurenz and Goeser, Tobias and Kütting, Fabian},
	year = {2023},
	pmid = {37029631},
	keywords = {Humans, Gastrointestinal Neoplasms, Retrospective Studies, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophageal cancer, Gastrointestinal Hemorrhage, endoscopic therapy, Hemostasis, Endoscopic, upper gastrointestinal bleeding},
	pages = {1064--1070},
}

@article{carter26,
	title = {Aortoesophageal fistula},
	volume = {136},
	issn = {0002-9610},
	doi = {10.1016/0002-9610(78)90195-2},
	abstract = {With the advent of cardiovascular and bypass procedures, aortoesophageal fistula has progressed from the stage of a pathologic curiosity to a treatable lesion. Although the causes of aortoesophageal fistula are varied, a remarkably consistent clinical picture emerges from study of this condition. Chiari's triad of midthoracic pain, sentinel hemorrhage, and a symptom-free interval followed by fatal exsanguination remains the most important clinical finding today. Although contrast esophagography, esophagoscopy, and aortography are important diagnositc aids, immediate left thoracotomy may be the only means of making the diagnosis and saving the patient when hemorrhage is profuse. In most cases (80 per cent of the present series) there is a symptom-free period varying from hours to days from the original sentinel hemorrhage to the final exsanguination. This permits the informed surgeon trained in cardiovascular technics an opportunity to salvage some of these patients. The various methods of aortic and esophageal repair are discussed.},
	language = {eng},
	number = {1},
	journal = {American Journal of Surgery},
	author = {Carter, R. and Mulder, G. A. and Snyder, E. N. and Brewer, L. A.},
	month = jul,
	year = {1978},
	pmid = {677387},
	keywords = {Humans, Lung Neoplasms, Esophageal Neoplasms, Esophagus, Esophageal Perforation, Aorta, Aorta, Thoracic, Aortic Aneurysm, Aortic Diseases, Esophageal Fistula, Fistula, Foreign Bodies},
	pages = {26--30},
}

@article{siersema416,
	title = {Massive hemorrhage caused by a perforating {Gianturco}-{Z} stent resulting in an aortoesophageal fistula},
	volume = {29},
	issn = {0013-726X},
	doi = {10.1055/s-2007-1004227},
	abstract = {Endoscopic placement of self-expanding metal stents is regarded as a safe and effective method of palliating obstructive esophageal malignancies. We report here the case of a 49-year-old woman with an inoperable squamous-cell carcinoma located in the mid-esophagus. After two courses of chemotherapy, a silicone-covered Gianturco-Z stent was placed because of progressive tumor growth. Eighteen days after the stent placement, the patient presented with hematemesis, and died 24 hours after admission. At autopsy, the proximal end of the stent was found to have perforated through the normal esophageal mucosa into the aorta, resulting in an aortoesophageal fistula. This complication should be considered in patients who present with massive hemorrhage after undergoing radiotherapy or chemotherapy, or both, before stent placement in the mid-esophagus.},
	language = {eng},
	number = {5},
	journal = {Endoscopy},
	author = {Siersema, P. D. and Tan, T. G. and Sutorius, F. F. and Dees, J. and van Blankenstein, M.},
	month = jun,
	year = {1997},
	pmid = {9270927},
	keywords = {Humans, Female, Middle Aged, Palliative Care, Esophageal Neoplasms, Stents, Esophageal Stenosis, Hemorrhage, Aortic Diseases, Esophageal Fistula, Fistula, Fatal Outcome},
	pages = {416--420},
}

@article{chen8374,
	title = {The {Long}-{Term} {Clinical} {Impact} of {Thoracic} {Endovascular} {Aortic} {Repair} ({TEVAR}) for {Advanced} {Esophageal} {Cancer} {Invading} {Aorta}},
	volume = {28},
	issn = {1534-4681},
	doi = {10.1245/s10434-021-10081-3},
	abstract = {BACKGROUND: Advanced esophageal cancer invading the aorta is considered unsuitable for surgery with definitive chemotherapy or chemoradiation as the treatments of choice. In the current study, we evaluated the long-term clinical impact of combining thoracic endovascular aortic repair (TEVAR) with multimodality treatment in caring for such patients.
METHODS: We evaluated 48 patients who had advanced esophageal cancer with aortic invasion. The oncological outcome, including overall survival (OS) and progression-free survival (PFS), after multimodality treatment with or without TEVAR is evaluated for these patients.
RESULTS: Overall, 25/48 patients (52.1\%) received a TEVAR procedure. There was no significant difference in OS (p = 0.223) between patients who did or did not receive TEVAR; however, patients who received TEVAR had significantly less local tumor recurrence (p = 0.020) and longer PFS (p = 0.019). This impact was most evident in patients who received both TEVAR and esophagectomy, with an incremental increase in hazard ratio (HR) for disease progression of 2.89 (95\% confidence interval [CI] 0.86-9.96) and 4.37 (95\% CI 1.33-14.33) observed under multivariable analysis, respectively, in comparison with patients who underwent only one or neither of these procedures (p = 0.005 for trend test).
CONCLUSION: TEVAR is a feasible procedure for esophageal cancers invading the aorta and can be used for curative-intent resection to improve local tumor control and PFS.},
	language = {eng},
	number = {13},
	journal = {Annals of Surgical Oncology},
	author = {Chen, Ke-Cheng and Wu, I.-Hui and Chang, Chih-Yang and Huang, Pei-Ming and Lin, Mong-Wei and Lee, Jang-Ming},
	month = dec,
	year = {2021},
	pmid = {34085143},
	pmcid = {PMC8591004},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Risk Factors, Esophageal Neoplasms, Esophagectomy, Aorta, Aorta, Thoracic, Blood Vessel Prosthesis Implantation, Endovascular Procedures},
	pages = {8374--8384},
	file = {Full Text:/Users/jcsal/Zotero/storage/5N6N7Y93/Chen et al. - 2021 - The Long-Term Clinical Impact of Thoracic Endovascular Aortic Repair (TEVAR) for Advanced Esophageal.pdf:application/pdf},
}

@article{canaud248,
	title = {Thoracic endovascular aortic repair in management of aortoesophageal fistulas},
	volume = {59},
	issn = {1097-6809},
	doi = {10.1016/j.jvs.2013.07.117},
	abstract = {OBJECTIVE: To provide a systematic review of the outcomes of thoracic endovascular aortic repair (TEVAR) for aortoesophageal fistula (AEF) and to identify prognostic factors associated with poor outcomes.
METHODS: Literature searches of the Embase, Medline, and Cochrane databases identified relevant articles reporting results of TEVAR for AEF. The main outcome measure was the composite of aortic mortality, recurrence of the AEF, and stent graft explantation. The secondary outcome measure was aortic-related mortality.
RESULTS: Fifty-five articles were integrated after a literature search identified 72 patients treated by TEVAR for AEFs. The technical success rate of TEVAR was 87.3\%. The overall 30-day mortality was 19.4\%. Prolonged antibiotics ({\textgreater}4 weeks) were administered in 80\% of patients. Concomitant or staged resection or repair of the esophagus was performed in 44.4\% of patients. Stent graft explantation was performed within the first month after TEVAR as a planned treatment in 11.1\%. After a mean follow-up of 7.4 months (range, 1-33 months), the all-cause mortality was 40.2\%, and the aortic-related mortality was 33.3. Prolonged antibiotic treatment (P = .001) and repair of AEFs due to a foreign body (P = .038) were associated with a significant lower aortic mortality. On univariate analysis, TEVAR and concomitant or staged adjunctive procedures (resection, repair of the esophagus, or a planned stent graft explantation) were associated with a significantly lower incidence of aortic-related mortality (P = .0121). When entered into a binary logistic regression analysis, prolonged antibiotic treatment was the only factor associated with a significant lower incidence of the endpoint (P = .003).
CONCLUSIONS: Late infection or recurrence of the AEF and associated mortality rates are high when TEVAR is used as a sole therapeutic strategy. Prolonged antibiotic treatment has a strong negative association with mortality. A strategy of a temporizing endovascular procedure to stabilize the patient in extremis, and upon recovery, an open surgical esophageal repair with or without stent graft explantation is advocated.},
	language = {eng},
	number = {1},
	journal = {Journal of Vascular Surgery},
	author = {Canaud, Ludovic and Ozdemir, Baris Ata and Bee, William Wynter and Bahia, Sandeep and Holt, Peter and Thompson, Matt},
	month = jan,
	year = {2014},
	pmid = {24199764},
	keywords = {Humans, Female, Male, Middle Aged, Treatment Outcome, Risk Factors, Time Factors, Chi-Square Distribution, Logistic Models, Reoperation, Recurrence, Odds Ratio, Device Removal, Aorta, Thoracic, Aortic Diseases, Esophageal Fistula, Blood Vessel Prosthesis Implantation, Endovascular Procedures, Anti-Bacterial Agents, Blood Vessel Prosthesis, Prosthesis-Related Infections, Vascular Fistula},
	pages = {248--254},
}

@article{sakai95,
	title = {Efficacy of thoracic endovascular aortic repair for aorto-esophageal fistula due to esophageal cancer: a systematic review and meta-analysis},
	volume = {21},
	issn = {1612-9067},
	shorttitle = {Efficacy of thoracic endovascular aortic repair for aorto-esophageal fistula due to esophageal cancer},
	doi = {10.1007/s10388-024-01042-2},
	abstract = {Aorto-esophageal fistula (AEF) due to esophageal cancer (EC) is a life-threatening condition characterized by sudden hemorrhage, which often causes sudden death. To evaluate the efficacy and safety of thoracic endovascular aortic repair (TEVAR) for AEF due to EC, we performed a systematic review and meta-analysis. We searched the MEDLINE (PubMed) databases, the Cochrane Library databases, Ichushi-Web (the databases of the Japan Medical Abstract Society), and CiNii (Academic information search service of the National Institute of Information from Japan) from January 2000 to November 2023 for articles about TEVAR for an emergent aortic hemorrhage (salvage TEVAR [S-TEVAR]), and the prophylactic procedure (P-TEVAR). Six studies (140 cases) were eligible for meta-analysis. The 90-day mortality of S-TEVAR and P-TEVAR was 40\% (95\% CI 23-60, I2 = 36\%) and 8\% (95\% CI 3-17, I2 = 0\%), respectively. Post-S-TEVAR hemorrhagic and infectious complications were 17\% (95\% CI 3-57, I2 = 71\%) and 20\% (95\% CI 5-57, I2 = 66\%), respectively. Post-P-TEVAR hemorrhagic and infectious complications were 2\% (95\% CI 0-10, I2 = 0\%) and 3\% (95\% CI 1-12, I2 = 0\%), respectively. TEVAR for AEF due to EC may be a useful therapeutic option to manage or prevent hemorrhagic oncological emergencies.},
	language = {eng},
	number = {2},
	journal = {Esophagus: Official Journal of the Japan Esophageal Society},
	author = {Sakai, Makoto and Sohda, Makoto and Uchida, Shintaro and Yamaguchi, Arisa and Watanabe, Takayoshi and Saito, Hideyuki and Nakazawa, Nobuhiro and Kuriyama, Kengo and Sano, Akihiko and Ogawa, Hiroomi and Yokobori, Takehiko and Nagai, Kazue and Shirabe, Ken and Saeki, Hiroshi},
	month = apr,
	year = {2024},
	pmid = {38302854},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Risk, Esophageal Neoplasms, Esophageal cancer, Postoperative Complications, Aorta, Thoracic, Aortic Diseases, Esophageal Fistula, Vascular Fistula, Aorto-esophageal fistula, Endovascular Aneurysm Repair, Thoracic endovascular aortic repair},
	pages = {95--101},
}

@article{kondoh37,
	title = {Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study},
	volume = {14},
	issn = {1472-684X},
	shorttitle = {Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer},
	doi = {10.1186/s12904-015-0034-y},
	abstract = {BACKGROUND: Bleeding negatively impacts quality of life in patients with unresectable advanced gastric cancer and has the potential to be lethal. When blood transfusion and endoscopic hemostasis are unsuccessful to stop bleeding, radiation to stomach is selected in patients with unsuitable condition for surgery. We performed a retrospective cohort study to clarify the utility of radiotherapy in treating gastric bleeding, particularly for patients with limited life expectancy.
METHODS: We evaluated the efficacy and safety of palliative radiotherapy in patients with advanced gastric cancer between January 2007 and December 2012 in Aichi Cancer Center Hospital. All patients had gastric bleeding requiring blood transfusion. We defined hemostasis as an increase in hemoglobin level to more than 7.0 g/dL together with the cessation of melena or hematemesis for at least 1 week.
RESULTS: During the study period, 313 advanced gastric cancer patients treated in our institution. Of these 17 patients received gastric radiotherapy to stop bleeding. Two patients were excluded from analysis due to combined treatment of intravascular embolization. Eleven out of 15 patients (73 \%) had undergone two or more previous chemotherapy regimens. Ten patients (67 \%) had an Eastern Cooperative Oncology Group performance status of 3 and 14 patients (93 \%) were in palliative prognostic index group B or C. The median total planned radiation dose was 30 Gy in 10 fractions. At a median interval of 2 days after initiation of radiotherapy, 11 patients (73 \%) achieved hemostasis; rebleeding was observed in four patients (36 \%). The median hemoglobin level before radiotherapy was significantly increased from 6.0 to 9.0 g/dL (p {\textless} 0.0001). The median volume of red blood cell transfusion was significantly decreased from 1120 to 280 mL (p = 0.007). The median rebleeding-free survival interval was 27 days, with a median overall survival of 63 days. The cause of death was bleeding in 1 patient (7 \%) and cancer progression without bleeding in 12 patients (80 \%). There were no severe adverse events attributable to radiotherapy.
CONCLUSIONS: Palliative radiotherapy for gastric bleeding achieves hemostasis within a short time frame. This appears to be a useful treatment option, especially for patients with end-stage, unresectable advanced gastric cancer.},
	language = {eng},
	journal = {BMC palliative care},
	author = {Kondoh, Chihiro and Shitara, Kohei and Nomura, Motoo and Takahari, Daisuke and Ura, Takashi and Tachibana, Hiroyuki and Tomita, Natsuo and Kodaira, Takeshi and Muro, Kei},
	month = aug,
	year = {2015},
	pmid = {26238344},
	pmcid = {PMC4524128},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Palliative Care, Aged, 80 and over, Adult, Stomach Neoplasms, Radiotherapy Dosage, Severity of Illness Index, Quality of Life, Hemoglobins, Gastrointestinal Hemorrhage},
	pages = {37},
	file = {Full Text:/Users/jcsal/Zotero/storage/TLJFX427/Kondoh et al. - 2015 - Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gast.pdf:application/pdf},
}

@article{kawabata177,
	title = {Experience of {Low}-{Dose}, {Short}-{Course} {Palliative} {Radiotherapy} for {Bleeding} from {Unresectable} {Gastric} {Cancer}},
	volume = {20},
	issn = {1557-7740},
	doi = {10.1089/jpm.2016.0141},
	abstract = {BACKGROUND/AIMS: The optimal regimen of radiotherapy (RT) for bleeding from gastric cancer (GC) has not yet been established. The aim of this study was to evaluate the usefulness of low-dose, short-course palliative RT (LSP-RT) for bleeding from GC.
MATERIAL AND METHODS: We reviewed the clinical data of 18 patients (26 courses) who received palliative RT for bleeding from GC between 2004 and 2014. The radiation dose was 6 Gy in three fractions. The total courses of RT for each patient were 1-4 (median, 1).
RESULTS: The treatment success rate of the first and the additional RT at two weeks after RT was 55\% and 75\%, respectively. Regarding first RT, there was a statistically significant increase in the mean hemoglobin level for one month (p = 0.009) and a significant decrease in the mean number of transfused red blood cell units for one month (p = 0.012). Toxicities were observed in two patients: one patient who received chemotherapy developed grade 3 afebrile leukocytopenia and another who had a malignant stricture suffered from a gastric obstruction. The performance status was improved in 3 of the 12 evaluable patients (25\%) and dietary intake became possible one month after RT in three of the four patients who had not been able to eat before RT.
CONCLUSION: LSP-RT is expected to be not only an effective and safe treatment option for bleeding from GC, but also repeatable in cases of rebleeding. Furthermore, this treatment modality may be able to improve the patient's quality of life.},
	language = {eng},
	number = {2},
	journal = {Journal of Palliative Medicine},
	author = {Kawabata, Hideaki and Uno, Koji and Yasuda, Kenjiro and Yamashita, Masato},
	month = feb,
	year = {2017},
	pmid = {27672720},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Palliative Care, Aged, 80 and over, Stomach Neoplasms, gastric cancer, Radiation Dosage, Quality of Life, Gastrointestinal Hemorrhage, Medical Audit, quality of life, bleeding, hemostasis, Hemostasis, palliative radiotherapy},
	pages = {177--180},
}

@article{sugita420,
	title = {Verification of the {Utility} of {Palliative} {Radiotherapy} for {Hemostasis} of {Gastric} {Cancer} {Bleeding}: a {Case} {Control} {Study}},
	volume = {53},
	issn = {1941-6636},
	shorttitle = {Verification of the {Utility} of {Palliative} {Radiotherapy} for {Hemostasis} of {Gastric} {Cancer} {Bleeding}},
	doi = {10.1007/s12029-021-00632-y},
	abstract = {PURPOSE: Bleeding from unresectable gastric cancer is a localized condition that adversely affects quality of life. Radiotherapy can be used to treat gastric cancer bleeding when surgery, endoscopic treatment, and intravascular embolization are ineffective. This study evaluated the utility of radiotherapy for unresectable hemorrhagic gastric cancer.
METHODS: We retrospectively analyzed data from 33 patients with gastric cancer bleeding who underwent palliative radiotherapy in our hospital between April 2013 and May 2020. In this study, successful hemostasis was defined as {\textgreater} 1 month after starting radiotherapy with the patient alive and showing no need for blood transfusion, no drop in hemoglobin, and no evidence of melena or hematemesis.
RESULTS: Patients comprised 26 men (79\%) and 7 women (21\%), with a median age of 71 years (range, 41-78 years). Hemostasis was achieved in 24 patients (73\%). Thirty-two patients (94\%) have been discharged home or transferred to the hospice. Patients with successful hemostasis from radiotherapy showed significantly longer overall survival than patients with unsuccessful hemostasis (p = 0.0026). No toxicities of grade 2 or more were encountered.
CONCLUSIONS: This retrospective study found that palliative radiotherapy for gastric cancer bleeding was useful and safe and can improve remaining quality of life in patients with poor prognosis.},
	language = {eng},
	number = {2},
	journal = {Journal of Gastrointestinal Cancer},
	author = {Sugita, Hirofumi and Sakuramoto, Shinichi and Mihara, Yoshiaki and Matsui, Kazuaki and Nishibeppu, Keiji and Ebara, Gen and Fuijta, Shohei and Fujihata, Shiro and Oya, Shuichiro and Miyawaki, Yutaka and Sato, Hiroshi and Horita, Yosuke and Hamaguchi, Tetsuya and Noda, Shin-Ei and Kato, Shingo and Hirano, Yasumitsu and Okamoto, Kojun and Koyama, Isamu},
	month = jun,
	year = {2022},
	pmid = {33754255},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Adult, Stomach Neoplasms, Case-Control Studies, Gastric cancer, Quality of Life, Gastrointestinal Hemorrhage, Hemostasis, Bleeding, Palliative radiotherapy},
	pages = {420--426},
}

@article{white715,
	title = {Expandable stents for iatrogenic perforation of esophageal malignancies},
	volume = {7},
	issn = {1091-255X},
	doi = {10.1016/s1091-255x(03)00064-7},
	abstract = {The management of patients with iatrogenic perforation of esophageal cancers is controversial. We reviewed the management of perforated esophageal malignancies at a single institution with a large volume of patients with esophageal cancer. Cases of iatrogenic perforation of the esophagus occurring during a 3-year period were identified from the hospital endoscopy database. Inpatient and outpatient records were reviewed, and subjects were visited to obtain follow-up information. Perforation was suspected after 10 of 492 endoscopic dilatation procedures done in patients with obstructing esophageal malignancies. All patients were diagnosed immediately. One patient with pneumomediastinum and pneumoperitoneum died 7 days after laparotomy. Nine patients with pneumomediastinum were managed endoscopically with delayed (n=1) or immediate (n=8) placement of a self-expanding metal stent. Patients were treated in the hospital for an average of 5.4 days. No patients developed clinical signs of sepsis, and all were discharged tolerating a soft diet. Follow-up data were obtained for seven of nine discharged patients (range 152 to 263 days). None developed signs or symptoms of infection or recurrent dysphagia. Immediate placement of a coated self-expanding metal stent is an effective treatment for iatrogenic perforation of an obstructing esophageal malignancy.},
	language = {eng},
	number = {6},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {White, Russell E. and Mungatana, Caesar and Topazian, Mark},
	year = {2003},
	pmid = {13129545},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Aged, 80 and over, Adult, Esophageal Neoplasms, Stents, Endoscopy, Dilatation, Iatrogenic Disease, Esophageal Perforation},
	pages = {715--719; discussion 719--720},
}

@article{kobayashie361,
	title = {Successful {Stenting} {Followed} by {Surgery} for {Perforated} {Esophageal} {Cancer} {Due} to {Chemotherapy}},
	volume = {108},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2019.04.022},
	abstract = {Perforation of esophageal cancer solely due to preoperative chemotherapy is extremely rare, but can be associated with pyothorax and can be difficult to treat. Here, we report the case of a successfully treated patient with thoracic esophageal cancer who had esophageal perforation during docetaxel, cisplatin, and 5-fluorouracil chemotherapy. A 73-year-old patient had esophageal perforation on the fourth day of the first docetaxel, cisplatin, 5-fluorouracil cycle. The second docetaxel, cisplatin, 5-fluorouracil cycle was administered after insertion of esophageal stenting and subtotal esophagectomy. Early drainage and stent placement were crucial for achieving infection control and allowing for a subsequent complete resection.},
	language = {eng},
	number = {6},
	journal = {The Annals of Thoracic Surgery},
	author = {Kobayashi, Teruyuki and Makino, Tomoki and Yamasaki, Makoto and Tanaka, Koji and Mori, Masaki and Doki, Yuichiro},
	month = dec,
	year = {2019},
	pmid = {31102633},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Male, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Antineoplastic Combined Chemotherapy Protocols, Risk Assessment, Dose-Response Relationship, Drug, Drug Administration Schedule, Fluorouracil, Carcinoma, Squamous Cell, Cisplatin, Esophageal Neoplasms, Esophagectomy, Combined Modality Therapy, Deglutition Disorders, Stents, Docetaxel, Esophageal Stenosis, Contrast Media, Esophageal Perforation},
	pages = {e361--e363},
}

@article{abbas749,
	title = {Contemporaneous management of esophageal perforation},
	volume = {146},
	issn = {1532-7361},
	doi = {10.1016/j.surg.2009.06.058},
	abstract = {BACKGROUND: Esophageal perforation is an important therapeutic challenge. We hypothesized that patients with minimal mediastinal contamination at the time of diagnosis could be managed successfully with nonoperative treatment modalities.
METHODS: We performed a retrospective review of 119 consecutive patients with esophageal perforation from 1998 to 2008. Demographics, cause of perforation, clinical presentation, diagnostic methods, and management results were evaluated. The decision to operate was based on the extent of mediastinal contamination and systemic sepsis rather than cause of perforation.
RESULTS: Median time to diagnosis among all patients was 12 hours (range, 1-120). Spontaneous (Boerhaave's) perforation occurred in 44 (37\%) patients. Iatrogenic perforations constituted the remaining patients (n = 75). After instrumental perforation, 9 patients (13\%) required esophagectomy, 48 patients were managed with repair and drainage, and the remaining 18 were managed nonoperatively. All 34 patients undergoing operative therapy for spontaneous perforations were treated with esophageal repair. Overall mortality was 14\%, with intrathoracic perforations having 18\% mortality, cervical 8\%, and gastroesophageal junction 3\%. Patients undergoing nonoperative therapy had a shorter hospitalizations (13 vs 24 days), fewer complications (36\% vs 62\%), and less mortality (4\% vs 15\%) compared with those undergoing operative intervention.
CONCLUSION: An approach to esophageal perforation based on injury severity and the degree of mediastinal and pleural contamination is of paramount importance. Although operative management remains the standard in the majority of patients with esophageal perforation, nonoperative management may be successfully implemented in selected patients with a low morbidity and mortality if favorable radiographic and clinical characteristics are present.},
	language = {eng},
	number = {4},
	journal = {Surgery},
	author = {Abbas, Ghulam and Schuchert, Matthew J. and Pettiford, Brian L. and Pennathur, Arjun and Landreneau, James and Landreneau, Joshua and Luketich, James D. and Landreneau, Rodney J.},
	month = oct,
	year = {2009},
	pmid = {19789035},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Survival Rate, Stents, Esophageal Perforation},
	pages = {749--755; discussion 755--756},
}

@article{schweigert1002,
	title = {Spotlight on esophageal perforation: {A} multinational study using the {Pittsburgh} esophageal perforation severity scoring system},
	volume = {151},
	issn = {1097-685X},
	shorttitle = {Spotlight on esophageal perforation},
	doi = {10.1016/j.jtcvs.2015.11.055},
	abstract = {OBJECTIVE: The Pittsburgh group has suggested a perforation severity score (PSS) for better decision making in the management of esophageal perforation. Our study aim was to determine whether the PSS can be used to stratify patients with esophageal perforation into distinct subgroups with differential outcomes in an independent study population.
METHODS: In a retrospective study cases of esophageal perforation were collected (study-period, 1990-2014). The PSS was analyzed using logistic regression as a continuous variable and stratified into low, intermediate, and high score groups.
RESULTS: Data for 288 patients (mean age, 59.9 years) presenting with esophageal perforation (during the period 1990-2014) were abstracted. Etiology was spontaneous (Boerhaave; n = 119), iatrogenic (instrumentation; n = 85), and traumatic perforation (n = 84). Forty-three patients had coexisting esophageal cancer. The mean PSS was 5.82, and was significantly higher in patients with fatal outcome (n = 57; 19.8\%; mean PSS, 9.79 vs 4.84; P {\textless} .001). Mean PSS was also significantly higher in patients receiving operative management (n = 200; 69\%; mean PSS, 6.44 vs 4.40; P {\textless} .001). Using the Pittsburgh strata, patients were assigned to low PSS (≤2; n = 63), intermediate PSS (3-5; n = 86), and high PSS ({\textgreater}5; n = 120) groups. Perforation-related morbidity, length of stay, frequency of operative treatment, and mortality increased with increasing PSS strata. Patients with high PSS were 3.37 times more likely to have operative management compared with low PSS.
CONCLUSIONS: The Pittsburgh PSS reliably reflects the seriousness of esophageal perforation and stratifies patients into low-, intermediate-, and high-risk groups with differential morbidity and mortality outcomes.},
	language = {eng},
	number = {4},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Schweigert, Michael and Sousa, Hugo Santos and Solymosi, Norbert and Yankulov, Aleksandar and Fernández, Marta Jiménez and Beattie, Rory and Dubecz, Attila and Rabl, Charlotte and Law, Simon and Tong, Daniel and Petrov, Danail and Schäbitz, Annemaria and Stadlhuber, Rudolf J. and Gumpp, Julia and Ofner, Dietmar and McGuigan, Jim and Costa-Maia, José and Witzigmann, Helmut and Stein, Hubert J.},
	month = apr,
	year = {2016},
	pmid = {26897241},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Risk Factors, Aged, 80 and over, Adult, Predictive Value of Tests, Logistic Models, Decision Trees, Decision Support Techniques, Odds Ratio, Europe, Critical Pathways, esophageal perforation, Esophageal Perforation, esophagus, foregut surgery, Hong Kong, Injury Severity Score, sepsis},
	pages = {1002--1009},
	file = {Full Text:/Users/jcsal/Zotero/storage/WRU5ZWKK/Schweigert et al. - 2016 - Spotlight on esophageal perforation A multinational study using the Pittsburgh esophageal perforati.pdf:application/pdf},
}

@article{merkow3268,
	title = {Effect of histologic subtype on treatment and outcomes for esophageal cancer in the {United} {States}},
	volume = {118},
	issn = {1097-0142},
	doi = {10.1002/cncr.26608},
	abstract = {BACKGROUND: Esophageal adenocarcinoma (AC) and squamous cell carcinoma (SCC) have distinct clinico-pathologic characteristics; however, it is unclear whether treatment patterns differ by histologic subtype. The objective of this study was to examine differences in treatment use and outcomes by histologic subtype for esophageal cancer in the United States.
METHODS: From the National Cancer Data Base, patients with esophageal cancer were identified. Regression models were formulated to assess the influence of histologic subtype on treatment use and overall survival.
RESULTS: From 1998 to 2007, 80,961 patients were identified with esophageal cancer in the United States. A higher percentage of patients with nonmetastatic AC underwent surgical resection compared with patients with nonmetastatic SCC (AC, 65.7\%; SCC, 36.0\%; P{\textless}.001), who were more often treated with chemoradiotherapy alone (AC, 25.7\%; SCC, 54.1\%; P{\textless}.001). High-volume academic centers used surgery more frequently for both AC and SCC than did other centers, yet even at high-volume academic centers, surgery was used much less often to treat SCC than AC (AC, 79.3\%; SCC, 53.7\%; P{\textless}.001). The likelihood of operative treatment for nonmetastatic disease was significantly lower in patients with SCC compared with patients with AC (P{\textless}.001). Overall survival was lower for patients with stage II/III disease of either histologic subtype treated with chemoradiotherapy alone compared with surgery plus chemoradiotherapy (P{\textless}.001).
CONCLUSION: A large proportion of patients with esophageal cancer are being treated nonoperatively, and treatment use varies according to tumor histology, particularly by center type.},
	language = {eng},
	number = {13},
	journal = {Cancer},
	author = {Merkow, Ryan P. and Bilimoria, Karl Y. and McCarter, Martin D. and Chow, Warren B. and Gordon, Howard S. and Stewart, Andrew K. and Ko, Clifford Y. and Bentrem, David J.},
	month = jul,
	year = {2012},
	pmid = {22006369},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Prognosis, United States, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Chemoradiotherapy},
	pages = {3268--3276},
}

@article{dimick1046,
	title = {Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions},
	volume = {32},
	issn = {2694-233X},
	doi = {10.1377/hlthaff.2011.1365},
	abstract = {Research has shown that black patients more frequently undergo surgery at low-quality hospitals than do white patients. We assessed the extent to which living in racially segregated areas and living in geographic proximity to low-quality hospitals contribute to this disparity. Using national Medicare data for all patients who underwent one of three high-risk surgical procedures in 2005-08, we found that black patients actually tended to live closer to higher-quality hospitals than white patients did but were 25-58 percent more likely than whites to receive surgery at low-quality hospitals. Racial segregation was also a factor, with black patients in the most segregrated areas 41-96 percent more likely than white patients to undergo surgery at low-quality hospitals. To address these disparities, care navigators and public reporting of comparative quality could steer patients and their referring physicians to higher-quality hospitals, while quality improvement efforts could focus on improving outcomes for high-risk surgery at hospitals that disproportionately serve black patients. Unfortunately, existing policies such as pay-for-performance, bundled payments, and nonpayment for adverse events may divert resources and exacerbate these disparities.},
	language = {eng},
	number = {6},
	journal = {Health Affairs (Project Hope)},
	author = {Dimick, Justin and Ruhter, Joel and Sarrazin, Mary Vaughan and Birkmeyer, John D.},
	month = jun,
	year = {2013},
	pmid = {23733978},
	pmcid = {PMC4789147},
	keywords = {Humans, Aged, Risk Assessment, Lung Neoplasms, Aged, 80 and over, Outcome Assessment, Health Care, United States, Logistic Models, Hospitals, Medicare, Surgical Procedures, Operative, Disparities, Healthcare Disparities, Aortic Aneurysm, Abdominal, Black or African American, White People, Quality Indicators, Health Care, Access To Care, Coronary Artery Bypass, Minority Health, Quality Of Care, Racism},
	pages = {1046--1053},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/FATQ6XBE/Dimick et al. - 2013 - Black patients more likely than whites to undergo surgery at low-quality hospitals in segregated reg.pdf:application/pdf},
}

@article{bonner961,
	title = {Hospital-{Level} {Racial} and {Ethnic} {Segregation} {Among} {Medicare} {Beneficiaries} {Undergoing} {Common} {Surgical} {Procedures}},
	volume = {157},
	issn = {2168-6262},
	doi = {10.1001/jamasurg.2022.3135},
	language = {eng},
	number = {10},
	journal = {JAMA surgery},
	author = {Bonner, Sidra N. and Kunnath, Nicholas and Dimick, Justin B. and Ibrahim, Andrew M.},
	month = oct,
	year = {2022},
	pmid = {35921121},
	pmcid = {PMC9350841},
	keywords = {Humans, Aged, United States, Hospitals, Medicare, Racial Groups, Ethnicity, Fee-for-Service Plans},
	pages = {961--964},
	file = {PDF:/Users/jcsal/Zotero/storage/ZI3PWNYB/Bonner et al. - 2022 - Hospital-Level Racial and Ethnic Segregation Among Medicare Beneficiaries Undergoing Common Surgical.pdf:application/pdf},
}

@article{alvaradodoad025,
	title = {Disparities and access to thoracic surgeons among esophagectomy patients in the {United} {States}},
	volume = {36},
	issn = {1442-2050},
	doi = {10.1093/dote/doad025},
	abstract = {Esophagectomy is a complex operation with significant morbidity and mortality. Previous studies have shown that sub-specialization is associated with improved esophagectomy outcomes. We hypothesized that disparities would exist among esophagectomy patients regarding access to thoracic surgeons based on demographic, geographic, and hospital factors. The Premier Healthcare Database was used to identify adult inpatients receiving esophagectomy for esophageal and gastric cardia cancer, Barrett's esophagus, and achalasia from 2015 to 2019 using ICD-10 codes. Patients were categorized as receiving their esophagectomy from a thoracic versus non-thoracic provider. Survey methodology was used to correct for sampling error. Backwards selection from bivariable analysis was used in a survey-weighted multivariable logistic regression to determine predictors of esophagectomy provider specialization. During the study period, 960 patients met inclusion criteria representing an estimated population size of 3894 patients. Among them, 1696 (43.5\%) were performed by a thoracic surgeon and 2199 (56.5\%) were performed by non-thoracic providers. On multivariable analysis, factors associated with decreased likelihood of receiving care from a thoracic provider included Black (OR 0.41, p {\textless} 0.001), Other (OR 0.21, p {\textless} 0.001), and Unknown race (OR 0.22, p = 0.04), and uninsured patients (OR 0.53, p = 0.03). Urban hospital setting was associated with an increased likelihood of care by a thoracic provider (OR 4.43, p = 0.001). In this nationally representative study, Nonwhite race, rural hospital setting, and lower socioeconomic status were factors associated with decreased likelihood of esophagectomy patients receiving care from a thoracic surgeon. Efforts to address these disparities and provide appropriate access to thoracic surgeons is warranted.},
	language = {eng},
	number = {11},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Alvarado, Christine E. and Worrell, Stephanie G. and Sarode, Anuja L. and Bassiri, Aria and Jiang, Boxiang and Linden, Philip A. and Towe, Christopher W.},
	month = oct,
	year = {2023},
	pmid = {37163475},
	keywords = {Humans, Retrospective Studies, Adult, United States, Esophageal Neoplasms, Esophagectomy, Barrett Esophagus, Thoracic surgery, Disparities, Surgeons, Access to care, General thoracic surgery},
	pages = {doad025},
}

@article{liu1973,
	title = {Disparities in the utilization of high-volume hospitals for complex surgery},
	volume = {296},
	issn = {1538-3598},
	doi = {10.1001/jama.296.16.1973},
	abstract = {CONTEXT: Referral to high-volume hospitals has been recommended for operations with a demonstrated volume-outcome relationship. The characteristics of patients who receive care at low-volume hospitals may be different from those of patients who receive care at high-volume hospitals. These differences may limit their ability to access or receive care at a high-volume hospital.
OBJECTIVE: To identify patient characteristics associated with the use of high-volume hospitals, using California's Office of Statewide Health Planning and Development patient discharge database.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of Californians receiving the following inpatient operations from 2000 through 2004: elective abdominal aortic aneurysm repair, coronary artery bypass grafting, carotid endarterectomy, esophageal cancer resection, hip fracture repair, lung cancer resection, cardiac valve replacement, coronary angioplasty, pancreatic cancer resection, and total knee replacement.
MAIN OUTCOME MEASURES: Patient race/ethnicity and insurance status in high-volume (highest 20\% of patients by mean annual volume) and in low-volume (lowest 20\%) hospitals.
RESULTS: A total of 719,608 patients received 1 of the 10 operations. Overall, nonwhites, Medicaid patients, and uninsured patients were less likely to receive care at high-volume hospitals and more likely to receive care at low-volume hospitals when controlling for other patient-level characteristics. Blacks were significantly (P{\textless}.05) less likely than whites to receive care at high-volume hospitals for 6 of the 10 operations (relative risk [RR] range, 0.40-0.72), while Asians and Hispanics were significantly less likely to receive care at high-volume hospitals for 5 (RR range, 0.60-0.91) and 9 (RR range, 0.46-0.88), respectively. Medicaid patients were significantly less likely than Medicare patients to receive care at high-volume hospitals for 7 of the operations (RR range, 0.22-0.66), while uninsured patients were less likely to be treated at high-volume hospitals for 9 (RR range, 0.20-0.81).
CONCLUSIONS: There are substantial disparities in the characteristics of patients receiving care at high-volume hospitals. The interest in selective referral to high-volume hospitals should include explicit efforts to identify the patient and system factors required to reduce current inequities regarding their use.},
	language = {eng},
	number = {16},
	journal = {JAMA},
	author = {Liu, Jerome H. and Zingmond, David S. and McGory, Marcia L. and SooHoo, Nelson F. and Ettner, Susan L. and Brook, Robert H. and Ko, Clifford Y.},
	month = oct,
	year = {2006},
	pmid = {17062860},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Aged, 80 and over, Adult, United States, Hospitals, Medicare, Surgical Procedures, Operative, Databases as Topic, Outcome and Process Assessment, Health Care, Health Services Accessibility, Socioeconomic Factors, California, Ethnicity, Medically Uninsured, Medicaid, Minority Groups, State Health Planning and Development Agencies, Utilization Review},
	pages = {1973--1980},
	file = {jed60065:/Users/jcsal/Zotero/storage/GYMFSAUD/jed60065.pdf:application/pdf;joc60139:/Users/jcsal/Zotero/storage/HB364XSZ/joc60139.pdf:application/pdf;PDF:/Users/jcsal/Zotero/storage/Y9DQ6TIG/Liu et al. - 2006 - Disparities in the utilization of high-volume hospitals for complex surgery.pdf:application/pdf},
}

@article{wasif1116,
	title = {Racial and {Socioeconomic} {Differences} in the {Use} of {High}-{Volume} {Commission} on {Cancer}-{Accredited} {Hospitals} for {Cancer} {Surgery} in the {United} {States}},
	volume = {25},
	issn = {1534-4681},
	doi = {10.1245/s10434-018-6374-0},
	abstract = {BACKGROUND: Although major cancer surgery at a high-volume hospital is associated with lower postoperative mortality, the use of such hospitals may not be equally distributed.
OBJECTIVE: Our aim was to study socioeconomic and racial differences in cancer surgery at Commission on Cancer (CoC)-accredited high-volume hospitals.
METHODS: The National Cancer Database (NCDB) was used to identify patients undergoing surgery for colon, esophageal, liver, and pancreatic cancer from 2003 to 2012. Annual hospital volume for each cancer was categorized using quartiles of patient volume. Patient-level predictors of surgery at a high-volume hospital, trends in the use of a high-volume hospital, and adjusted likelihood of surgery at a high-volume hospital in 2012 versus 2003 were analyzed.
RESULTS: African American patients were less likely to undergo surgery at a high-volume hospital for esophageal (odds ratio [OR] 0.59, 95\% confidence interval [CI] 0.49-0.73) and pancreatic cancer (OR 0.83, 95\% CI 0.74-0.92), while uninsured patients and those residing in low educational attainment zip codes were less likely to undergo surgery at a high-volume hospital for esophageal, liver, and pancreatic cancer. In 2012, African Americans, uninsured patients, and those from low educational attainment zip codes were no more likely to undergo surgery at a high-volume hospital than in 2003 for any cancer type. These differences were not seen in colon cancer patients, for whom significant regionalization was not seen.
CONCLUSIONS: Differences in the use of CoC-accredited high-volume hospitals for major cancer surgery were seen nationwide and persisted over the duration of the study. Strategies to increase referrals and/or access to high-volume hospitals for African American and socioeconomically disadvantaged patients should be explored.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgical Oncology},
	author = {Wasif, Nabil and Etzioni, David and Habermann, Elizabeth B. and Mathur, Amit and Pockaj, Barbara A. and Gray, Richard J. and Chang, Yu-Hui},
	month = may,
	year = {2018},
	pmid = {29450752},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasms, Pancreatic Neoplasms, Aged, 80 and over, Colonic Neoplasms, Databases, Factual, United States, Liver Neoplasms, Esophageal Neoplasms, Hospitals, High-Volume, Health Services Accessibility, Educational Status, Income, Medically Uninsured, Black or African American, White People, Accreditation, Rural Population, Urban Population},
	pages = {1116--1125},
}

@article{epstein179,
	title = {Racial and ethnic differences in the use of high-volume hospitals and surgeons},
	volume = {145},
	issn = {1538-3644},
	doi = {10.1001/archsurg.2009.268},
	abstract = {OBJECTIVE: To examine racial/ethnic differences in the use of high-volume hospitals and surgeons for 10 surgical procedures with documented associations between volume and mortality.
DESIGN: Cross-sectional regression analysis.
SETTING: New York City area hospital discharge data, 2001-2004.
PATIENTS: Adults from 4 racial/ethnic categories (white, black, Asian, and Hispanic) who underwent surgery for cancer (breast, colorectal, gastric, lung, or pancreatic resection), cardiovascular disease (coronary artery bypass graft, coronary angioplasty, abdominal aortic aneurysm repair, or carotid endarterectomy), or orthopedic conditions (total hip replacement).
MAIN OUTCOME MEASURE: Treatment by a high-volume surgeon at a high-volume hospital.
RESULTS: There were 133 821 patients who underwent 1 of the 10 procedures. For 9 of the 10 procedures, black patients were significantly (P {\textless} .05) less likely (after adjustment for sociodemographic characteristics, insurance type, proximity to high-volume providers, and comorbidities) to be operated on by a high-volume surgeon at a high-volume hospital and more likely to be operated on by a low-volume surgeon at a low-volume hospital. Asian and Hispanic patients, respectively, were significantly less likely to use high-volume surgeons at high-volume hospitals for 5 and 4 of the 10 procedures and more likely to use low-volume surgeons at low-volume hospitals for 3 and 5 of the 10 procedures.
CONCLUSIONS: Minority patients in New York City are doubly disadvantaged in their surgical care; they are substantially less likely to use both high-volume hospitals and surgeons for procedures with an established volume-mortality association. Better information is needed about which providers minority patients have access to and how they select them.},
	language = {eng},
	number = {2},
	journal = {Archives of Surgery (Chicago, Ill.: 1960)},
	author = {Epstein, Andrew J. and Gray, Bradford H. and Schlesinger, Mark},
	month = feb,
	year = {2010},
	pmid = {20157087},
	keywords = {Humans, Aged, Middle Aged, Adult, Cross-Sectional Studies, Surgical Procedures, Operative, Health Services Accessibility, Healthcare Disparities, Socioeconomic Factors, Ethnicity, White People, Minority Groups, Hospitals, Urban, New York City},
	pages = {179--186},
	file = {PDF:/Users/jcsal/Zotero/storage/AM5HZHE9/Epstein et al. - 2010 - Racial and ethnic differences in the use of high-volume hospitals and surgeons.pdf:application/pdf},
}

@article{chen1014,
	title = {Socioeconomic factors in timing of esophagectomy and association with outcomes},
	volume = {124},
	issn = {1096-9098},
	doi = {10.1002/jso.26606},
	abstract = {BACKGROUND AND OBJECTIVES: Disparities in esophageal cancer are well-established. The standard treatment for locally advanced esophageal cancer is chemoradiation followed by surgery. We sought to evaluate the association between socioeconomic factors, time to surgery, and patient outcomes.
METHODS: All patients ≥18 years old diagnosed with T2/3/4 or node-positive esophageal cancer between 2004 and 2016 and who underwent chemoradiation and esophagectomy in the National Cancer Database were included. Multivariable regression was used to assess the association between socioeconomic variables and time to surgery (grouped into {\textless}56, 56-84, and 85-112 days).
RESULTS: A total of 12 157 patients were included. Five-year overall survival was 39\%, 35\%, and 35\% for the three groups examined. Postoperative 30- and 90-day mortality was increased in both the 56-84 days to surgery group (odds ratio [OR]: 1.30 and 1.20, respectively) and the 85-112 days group (OR: 1.37 and 1.56, respectively) when compared to {\textless}56 days. Patients of a minority race, public insurance, or lower income were more likely to have a longer time to surgery.
CONCLUSION: Longer time to surgery is associated with increased postoperative mortality and is more common in patients with lower socioeconomic status. Further research exploring reasons for delays to esophagectomy among disadvantaged patients could help target interventions to reduce disparities.},
	language = {eng},
	number = {7},
	journal = {Journal of Surgical Oncology},
	author = {Chen, Kevin A. and Strassle, Paula D. and Meyers, Michael O.},
	month = dec,
	year = {2021},
	pmid = {34254329},
	pmcid = {PMC10151060},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, United States, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, esophagectomy, Medicare, Healthcare Disparities, North Carolina, Income, postoperative complications, Time-to-Treatment, healthcare disparities, Medicaid, combined modality therapy, Race Factors},
	pages = {1014--1021},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/V7B9VYGD/Chen et al. - 2021 - Socioeconomic factors in timing of esophagectomy and association with outcomes.pdf:application/pdf;nihms-1890126:/Users/jcsal/Zotero/storage/GJ7ZIJLK/nihms-1890126.pdf:application/pdf},
}

@article{delman3801,
	title = {A narrative review of socioeconomic disparities in the treatment of esophageal cancer},
	volume = {13},
	issn = {2072-1439},
	doi = {10.21037/jtd-20-3095},
	abstract = {The persistent challenges of disparities in healthcare have led to significantly distinct outcomes among patients from different racial, ethnic, and underserved populations. Esophageal Cancer, not unlike other surgical diseases, has seen significant disparities in care. Esophageal cancer is currently the 6th leading cause of death from cancer and the 8th most common cancer in the world. Surgical disparities in the care of patients with Esophageal Cancer have been described in the literature, with a prevailing theme associating minority status with worse outcomes. The goal of this review is to provide an updated account of the literature on disparities in Esophageal Cancer presentation and treatment. We will approach this task through a conceptual framework that highlights the five main themes of surgical disparities: patient-level factors, provider-level factors, system and access issues, clinical care and quality, and postoperative outcomes, care and rehabilitation. All five categories play a complex role in the delivery of high-quality, equitable care for patients with Esophageal Cancer. While describing disparities in care is the first step to correcting them, moving forward, we should focus on developing effective interventions to mitigate disparities, policies linking disparities to quality-of-care metrics, and delivery system change to enable minority patients to more easily access high volume centers.},
	language = {eng},
	number = {6},
	journal = {Journal of Thoracic Disease},
	author = {Delman, Aaron M. and Ammann, Allison M. and Turner, Kevin M. and Vaysburg, Dennis M. and Van Haren, Robert M.},
	month = jun,
	year = {2021},
	pmid = {34277070},
	pmcid = {PMC8264668},
	keywords = {Esophageal cancer, surgery, disparities},
	pages = {3801--3808},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/LDXAVVF4/Delman et al. - 2021 - A narrative review of socioeconomic disparities in the treatment of esophageal cancer.pdf:application/pdf;jtd-13-06-3801:/Users/jcsal/Zotero/storage/NUARRBGT/jtd-13-06-3801.pdf:application/pdf},
}

@article{bonner595,
	title = {The {Impact} of {Racial} {Disparities} and the {Social} {Determinants} of {Health} on {Esophageal} and {Gastric} {Cancer} {Outcomes}},
	volume = {33},
	issn = {1558-5042},
	doi = {10.1016/j.soc.2023.12.015},
	abstract = {Reducing long-standing inequities in gastric and esophageal cancers is a priority of patients, providers, and policy makers. Many social determinants of health influence risk factors for disease development, incidence, treatment, and outcomes of gastric and esophageal cancers.},
	language = {eng},
	number = {3},
	journal = {Surgical Oncology Clinics of North America},
	author = {Bonner, Sidra N. and Edwards, Melanie A.},
	month = jul,
	year = {2024},
	pmid = {38789201},
	keywords = {Humans, Risk Factors, Stomach Neoplasms, Gastric cancer, Esophageal Neoplasms, Esophageal cancer, Healthcare Disparities, Health Status Disparities, Social Determinants of Health, Racial disparities, Social determinants of health},
	pages = {595--604},
	annote = {Review

},
	file = {PDF:/Users/jcsal/Zotero/storage/LAIHTARB/Bonner and Edwards - 2024 - The Impact of Racial Disparities and the Social Determinants of Health on Esophageal and Gastric Can.pdf:application/pdf},
}

@article{bakkilae225664,
	title = {Evaluation of {Racial} {Disparities} in {Quality} of {Care} for {Patients} {With} {Gastrointestinal} {Tract} {Cancer} {Treated} {With} {Surgery}},
	volume = {5},
	issn = {2574-3805},
	doi = {10.1001/jamanetworkopen.2022.5664},
	abstract = {IMPORTANCE: Racial disparities have been demonstrated in many facets of health care, but a comprehensive understanding of who is most at risk for substandard surgical care of gastrointestinal tract cancers is lacking.
OBJECTIVE: To examine racial disparities in quality of care of patients with gastrointestinal tract cancers.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of patients with gastrointestinal tract cancer included the US population as captured in the National Cancer Database with a diagnosis from January 1, 2004, to December 31, 2017. Participants included 565 124 adults who underwent surgical resection of gastrointestinal tract cancers. Data were analyzed from June 21 to December 23, 2021.
EXPOSURES: Race and site of cancer.
MAIN OUTCOMES AND MEASURES: Oncologic standard of care, as defined by negative resection margin, adequate lymphadenectomy, and receipt of indicated adjuvant chemotherapy and/or radiotherapy.
RESULTS: Among 565 124 adult patients who underwent surgical resection of a gastrointestinal tract cancer, 10.9\% were Black patients, 83.5\% were White patients, 54.7\% were men, and 50.7\% had Medicare coverage. The most common age range at diagnosis was 60 to 69 years (28.5\%). Longer median survival was associated with negative resection margins (87.3 [IQR, 28.5-161.9] months vs 22.9 [IQR, 8.8-69.2] months; P {\textless} .001) and adequate lymphadenectomies (80.7 [IQR, 25.6 to not reached] months vs 57.6 [IQR, 17.7-153.8] months; P {\textless} .001). After adjustment for covariates, Black patients were less likely than White patients to have negative surgical margins overall (odds ratio [OR], 0.96 [95\% CI, 0.93-0.98]) and after esophagectomy (OR, 0.71 [95\% CI, 0.58-0.87]), proctectomy (OR, 0.71 [95\% CI, 0.66-0.76]), and biliary resection (OR, 0.75 [95\% CI, 0.61-0.91]). Black patients were also less likely to have adequate lymphadenectomy overall (OR, 0.89 [95\% CI, 0.87-0.91]) and after colectomy (OR, 0.89 [95\% CI, 0.87-0.92]), esophagectomy (OR, 0.72 [95\% CI, 0.63-0.83]), pancreatectomy (OR, 0.90 [95\% CI, 0.85-0.96]), proctectomy (OR, 0.93 [95\% CI, 0.88-0.98]), proctocolectomy (OR, 0.90 [95\% CI, 0.81-1.00]), and enterectomy (OR, 0.71 [95\% CI, 0.65-0.79]). Black patients were more likely than White patients not to be recommended for chemotherapy (OR, 1.15 [95\% CI, 1.10-1.21]) and radiotherapy (OR, 1.49 [95\% CI, 1.35-1.64]) because of comorbidities and more likely not to receive recommended chemotherapy (OR, 1.68 [95\% CI, 1.55-1.82]) and radiotherapy (OR, 2.18 [95\% CI, 1.97-2.41]) for unknown reasons.
CONCLUSIONS AND RELEVANCE: These findings suggest that there are significant racial disparities in surgical care of gastrointestinal tract cancers. Black patients are less likely than White patients to receive standard of care with respect to negative surgical margins, adequate lymphadenectomies, and use of adjuvant therapies. Both system- and physician-level reforms are needed to eradicate these disparities in health care.},
	language = {eng},
	number = {4},
	journal = {JAMA network open},
	author = {Bakkila, Baylee F. and Kerekes, Daniel and Nunez-Smith, Marcella and Billingsley, Kevin G. and Ahuja, Nita and Wang, Karen and Oladele, Carol and Johnson, Caroline H. and Khan, Sajid A.},
	month = apr,
	year = {2022},
	pmid = {35377425},
	pmcid = {PMC8980937},
	keywords = {Humans, Aged, Gastrointestinal Neoplasms, Male, Middle Aged, Retrospective Studies, Adult, United States, Medicare, Healthcare Disparities, White People},
	pages = {e225664},
	file = {assari_2022_ic_220048_1648138445.50153:/Users/jcsal/Zotero/storage/65H4XW3Y/assari_2022_ic_220048_1648138445.50153.pdf:application/pdf;bakkila_2022_oi_220185_1648138431.44053:/Users/jcsal/Zotero/storage/PDVFFYQ2/bakkila_2022_oi_220185_1648138431.44053.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/Y3H4Q6RV/Bakkila et al. - 2022 - Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer.pdf:application/pdf},
}

@article{bliton529,
	title = {Understanding {Racial} {Disparities} in {Gastrointestinal} {Cancer} {Outcomes}: {Lack} of {Surgery} {Contributes} to {Lower} {Survival} in {African} {American} {Patients}},
	volume = {30},
	issn = {1538-7755},
	shorttitle = {Understanding {Racial} {Disparities} in {Gastrointestinal} {Cancer} {Outcomes}},
	doi = {10.1158/1055-9965.EPI-20-0950},
	abstract = {BACKGROUND: Race/ethnicity-related differences in rates of cancer surgery and cancer mortality have been observed for gastrointestinal (GI) cancers. This study aims to estimate the extent to which differences in receipt of surgery explain racial/ethnic disparities in cancer survival.
METHODS: The National Cancer Database was used to obtain data for patients diagnosed with stage I-III mid-esophageal, distal esophagus/gastric cardia (DEGC), noncardia gastric, pancreatic, and colorectal cancer in years 2004-2015. Mediation analysis was used to identify variables influencing the relationship between race/ethnicity and mortality, including surgery.
RESULTS: A total of 600,063 patients were included in the study: 3.5\% mid-esophageal, 12.4\% DEGC, 4.9\% noncardia gastric, 17.0\% pancreatic, 40.1\% colon, and 22.0\% rectal cancers. The operative rates for Black patients were low relative to White patients, with absolute differences of 21.0\%, 19.9\%, 2.3\%, 8.3\%, 1.6\%, and 7.7\%. Adjustment for age, stage, and comorbidities revealed even lower odds of receiving surgery for Black patients compared with White patients. The observed HRs for Black patients compared with White patients ranged from 1.01 to 1.42. Mediation analysis showed that receipt of surgery and socioeconomic factors had greatest influence on the survival disparity.
CONCLUSIONS: The results of this study indicate that Black patients appear to be undertreated compared with White patients for GI cancers. The disproportionately low operative rates contribute to the known survival disparity between Black and White patients.
IMPACT: Interventions to reduce barriers to surgery for Black patients should be promoted to reduce disparities in GI cancer outcomes.See related commentary by Hébert, p. 438.},
	language = {eng},
	number = {3},
	journal = {Cancer Epidemiology, Biomarkers \& Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology},
	author = {Bliton, John N. and Parides, Michael and Muscarella, Peter and Papalezova, Katia T. and In, Haejin},
	month = mar,
	year = {2021},
	pmid = {33303644},
	pmcid = {PMC8049948},
	keywords = {Humans, Gastrointestinal Neoplasms, Socioeconomic Factors, Ethnicity, Black or African American, White People},
	pages = {529--538},
	file = {529:/Users/jcsal/Zotero/storage/YBVJE7BV/529.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/9DSD6SAT/Bliton et al. - 2021 - Understanding Racial Disparities in Gastrointestinal Cancer Outcomes Lack of Surgery Contributes to.pdf:application/pdf},
}

@article{torain408,
	title = {Surgical {Disparities}: {A} {Comprehensive} {Review} and {New} {Conceptual} {Framework}},
	volume = {223},
	issn = {1879-1190},
	shorttitle = {Surgical {Disparities}},
	doi = {10.1016/j.jamcollsurg.2016.04.047},
	language = {eng},
	number = {2},
	journal = {Journal of the American College of Surgeons},
	author = {Torain, Maya J. and Maragh-Bass, Allysha C. and Dankwa-Mullen, Irene and Hisam, Butool and Kodadek, Lisa M. and Lilley, Elizabeth J. and Najjar, Peter and Changoor, Navin R. and Rose, John A. and Zogg, Cheryl K. and Maddox, Yvonne T. and Britt, L. D. and Haider, Adil H.},
	month = aug,
	year = {2016},
	pmid = {27296524},
	keywords = {Humans, Surgical Procedures, Operative, Health Services Accessibility, Healthcare Disparities},
	pages = {408--418},
	file = {PDF:/Users/jcsal/Zotero/storage/YVUHKAUX/Torain et al. - 2016 - Surgical Disparities A Comprehensive Review and New Conceptual Framework.pdf:application/pdf},
}

@article{sune003921,
	title = {Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system},
	volume = {4},
	issn = {2044-6055},
	shorttitle = {Disparities in selective referral for cancer surgeries},
	doi = {10.1136/bmjopen-2013-003921},
	abstract = {OBJECTIVES: Among considerable efforts to improve quality of surgical care, expedited measures such as a selective referral to high-volume institutions have been advocated. Our objective was to examine whether racial, insurance and/or socioeconomic disparities exist in the use of high-volume hospitals for complex surgical oncological procedures within the USA.
DESIGN, SETTING AND PARTICIPANTS: Patients undergoing colectomy, cystectomy, oesophagectomy, gastrectomy, hysterectomy, lung resection, pancreatectomy or prostatectomy were identified retrospectively, using the Nationwide Inpatient Sample, between years 1999 and 2009. This resulted in a weighted estimate of 2 508 916 patients.
PRIMARY OUTCOME MEASURES: Distribution of patients according to race, insurance and income characteristics was examined according to low-volume and high-volume hospitals (highest 20\% of patients according to the procedure-specific mean annual volume). Generalised linear regression models for prediction of access to high-volume hospitals were performed.
RESULTS: Insurance providers and county income levels varied differently according to patients' race. Most Caucasians resided in wealthier counties, regardless of insurance types (private/Medicare), while most African Americans resided in less wealthy counties (≤\$24 999), despite being privately insured. In general, Caucasians, privately insured, and those residing in wealthier counties (≥\$45 000) were more likely to receive surgery at high-volume hospitals, even after adjustment for all other patient-specific characteristics. Depending on the procedure, some disparities were more prominent, but the overall trend suggests a collinear effect for race, insurance type and county income levels.
CONCLUSIONS: Prevailing disparities exist according to several patient and sociodemographic characteristics for utilisation of high-volume hospitals. Efforts should be made to directly reduce such disparities and ensure equal healthcare delivery.},
	language = {eng},
	number = {3},
	journal = {BMJ open},
	author = {Sun, Maxine and Karakiewicz, Pierre I. and Sammon, Jesse D. and Sukumar, Shyam and Gervais, Mai-Kim and Nguyen, Paul L. and Choueiri, Toni K. and Menon, Mani and Trinh, Quoc-Dien},
	month = mar,
	year = {2014},
	pmid = {24657917},
	pmcid = {PMC3963094},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasms, United States, Hospitals, Racial Groups, Healthcare Disparities, Social Class, Income, Black or African American, White People, Insurance, Health, Health Equity, Health Services Administration \& Management, Referral and Consultation},
	pages = {e003921},
	file = {e003921.full:/Users/jcsal/Zotero/storage/RQWYF47T/e003921.full.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/HBFXL45N/Sun et al. - 2014 - Disparities in selective referral for cancer surgeries implications for the current healthcare deli.pdf:application/pdf},
}

@article{stitzenberg2824,
	title = {Trends in centralization of cancer surgery},
	volume = {17},
	issn = {1534-4681},
	doi = {10.1245/s10434-010-1159-0},
	abstract = {BACKGROUND: The association between procedure volume and clinical outcomes has led many to advocate centralization of cancer procedures at high-volume centers (HVCs). Regional studies show practice patterns changing with increasing centralization of esophageal and pancreatic procedures at HVCs but little change for colorectal procedures. We hypothesize that similar trends are occurring nationwide.
METHODS: Secondary data analysis was performed by means of the National Inpatient Sample. We examined trends in hospital procedure volume from 1999 to 2007 for all extirpative esophageal, pancreatic, and colorectal cancer procedures. Survey-weighted multivariate logistic regressions were used to examine the likelihood of surgery at a low-volume center (LVC) over time as well as to determine sociodemographic factors associated with surgery at LVCs.
RESULTS: A total of 351,164 cases met the inclusion criteria (6,345 esophagus, 17,658 pancreas, 255,753 colon, 71,408 rectum). The likelihood of surgery at a LVC in 2007 compared to 1999 was as follows: esophagus odds ratio [OR] 0.42 (95\% confidence interval [95\% CI], 0.34, 0.53), pancreas OR 0.40 (95\% CI, 0.35, 0.46), colon OR 0.88 (95\% CI, 0.85, 0.91), rectum OR 0.83 (95\% CI, 0.78, 0.89). Admission through an emergency department was associated with a higher likelihood of surgery at a LVC, even after adjusting for clinical and sociodemographic factors. Volume was also associated with race and payer; black patients and the uninsured were particularly likely to remain at LVCs.
CONCLUSIONS: Practice patterns have changed substantially to follow national recommendations for centralization of complex cancer surgery. Despite this, disparities remain with regard to access to HVCs.},
	language = {eng},
	number = {11},
	journal = {Annals of Surgical Oncology},
	author = {Stitzenberg, Karyn B. and Meropol, Neal J.},
	month = nov,
	year = {2010},
	pmid = {20559740},
	keywords = {Humans, Female, Male, Retrospective Studies, Adult, United States, Hospitals, Digestive System Neoplasms, Healthcare Disparities},
	pages = {2824--2831},
	file = {PDF:/Users/jcsal/Zotero/storage/YHPH9393/Stitzenberg and Meropol - 2010 - Trends in centralization of cancer surgery.pdf:application/pdf},
}

@article{luchtenborg3141,
	title = {High procedure volume is strongly associated with improved survival after lung cancer surgery},
	volume = {31},
	issn = {1527-7755},
	doi = {10.1200/JCO.2013.49.0219},
	abstract = {PURPOSE: Studies have reported an association between hospital volume and survival for non-small-cell lung cancer (NSCLC). We explored this association in England, accounting for case mix and propensity to resect.
METHODS: We analyzed data on 134,293 patients with NSCLC diagnosed in England between 2004 and 2008, of whom 12,862 (9.6\%) underwent surgical resection. Hospital volume was defined according to number of patients with resected lung cancer in each hospital in each year of diagnosis. We calculated hazard ratios (HRs) for death in three predefined periods according to hospital volume, sex, age, socioeconomic deprivation, comorbidity, and propensity to resect.
RESULTS: There was increased survival in hospitals performing {\textgreater} 150 surgical resections compared with those carrying out {\textless} 70 (HR, 0.78; 95\% CI, 0.67 to 0.90; Ptrend {\textless} .01). The association between hospital volume and survival was present in all three periods of follow-up, but the magnitude of association was greatest in the early postoperative period.
CONCLUSION: High-volume hospitals have higher resection rates and perform surgery among patients who are older, have lower socioeconomic status, and have more comorbidities; despite this, they achieve better survival, most notably in the early postoperative period.},
	language = {eng},
	number = {25},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Lüchtenborg, Margreet and Riaz, Sharma P. and Coupland, Victoria H. and Lim, Eric and Jakobsen, Erik and Krasnik, Mark and Page, Richard and Lind, Michael J. and Peake, Michael D. and Møller, Henrik},
	month = sep,
	year = {2013},
	pmid = {23897962},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Aged, 80 and over, Adult, Hospitals, High-Volume, Adolescent, Child, Infant, Infant, Newborn, Referral and Consultation, Child, Preschool},
	pages = {3141--3146},
	file = {Full Text:/Users/jcsal/Zotero/storage/M2X2BJQC/Lüchtenborg et al. - 2013 - High procedure volume is strongly associated with improved survival after lung cancer surgery.pdf:application/pdf},
}

@article{steyerberg510,
	title = {Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients},
	volume = {23},
	issn = {0732-183X},
	shorttitle = {Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer},
	doi = {10.1200/JCO.2005.05.169},
	abstract = {PURPOSE: We investigated racial disparities in access to surgical evaluation, receipt of surgery, and survival among elderly patients with locoregional esophageal cancer.
METHODS: We selected 2,946 white patients and 367 black patients who were older than 65 years and had clinically locoregional esophageal cancer in the Surveillance, Epidemiology, and End Results (SEER) registry (1991 to 1999). Treatment and outcome data were obtained from the linked SEER-Medicare databases. We used logistic regression analysis to estimate odds ratios (ORs) for being seen by a surgeon and for undergoing surgery. Cox proportional hazards analyses were performed to estimate hazard ratios (HRs) for survival adjusted for medical, nonmedical, and treatment characteristics.
RESULTS: The rate of surgery for black patients was half that of white patients (25\% v 46\%; OR, 0.38; P {\textless} .001), which was caused by both a lower rate of seeing a surgeon (70\% v 78\%; OR, 0.66; P {\textless} .001) and a lower rate of surgery once seen (35\% v 59\%; OR, 0.38; P {\textless} .001). These racial disparities were only partly explained by differences in patient and cancer characteristics, and not by nonmedical factors, such as socioeconomic status. The 2-year survival rate was lower for black patients (18\% v 25\%; HR, 1.18; P = .004), but this racial difference disappeared when corrected for treatment received (adjusted HR, 1.02; P = .80).
CONCLUSION: Underuse of potentially curative surgery is an important potential explanation for the poorer survival of black patients with locoregional esophageal cancer. Barriers to surgical evaluation and treatment need to be reduced, whether related to patient or healthcare system factors.},
	language = {eng},
	number = {3},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Steyerberg, Ewout W. and Earle, Craig C. and Neville, Bridget A. and Weeks, Jane C.},
	month = jan,
	year = {2005},
	pmid = {15659496},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Aged, 80 and over, Age Factors, Survival Analysis, United States, Esophageal Neoplasms, Surgical Procedures, Operative, Odds Ratio, Regression Analysis, Health Services Accessibility, Social Class, SEER Program, Black or African American, White People, Black People},
	pages = {510--517},
	file = {PDF:/Users/jcsal/Zotero/storage/WDCDCDHL/Steyerberg et al. - 2005 - Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer.pdf:application/pdf},
}

@article{paulson1198,
	title = {Underuse of esophagectomy as treatment for resectable esophageal cancer},
	volume = {143},
	issn = {1538-3644},
	doi = {10.1001/archsurg.143.12.1198},
	abstract = {HYPOTHESIS: Esophagectomy is underused as treatment for resectable stage I, II, and III esophageal cancers.
DESIGN AND SETTING: Retrospective cohort study using the Surveillance, Epidemiology, and End Results-Medicare linked database.
PATIENTS: We used the Surveillance, Epidemiology, and End Results database to identify persons 65 years or older who were not enrolled in a health maintenance organization and who were diagnosed as having stage I, II, or III esophageal cancer between January 1, 1997, and December 31, 2002 (N = 2386).
MAIN OUTCOME MEASURES: The rate of surgical intervention was compared across varying patient characteristics, including age, race, comorbidity score, sex, tumor stage, and socioeconomic region. Survival was compared between patients who received surgery and those who did not using Kaplan-Meier curves, the log-rank test, and Cox proportional hazards regression. Statistical analysis was performed using the chi2 test and multiple logistic regression.
RESULTS: The overall rate of surgical intervention in this cohort was 34.1\%. In all, 36.8\% of white patients underwent surgical treatment of their disease, whereas only 19.2\% of nonwhite patients did. Patients residing in areas with high poverty rates were 27\% less likely to have surgery. Older age and higher comorbidity scores were also associated with lower rates of surgery. Patients who received surgical treatment for their disease experienced significantly longer survival than did patients who did not undergo surgical resection.
CONCLUSIONS: There seems to be significant underuse of esophagectomy as treatment for potentially resectable stage I, II, and III esophageal cancers across all patient groups. In nonwhite and low socioeconomic patient cohorts, the underuse is even more pronounced.},
	language = {eng},
	number = {12},
	journal = {Archives of Surgery (Chicago, Ill.: 1960)},
	author = {Paulson, E. Carter and Ra, Jin and Armstrong, Katrina and Wirtalla, Christopher and Spitz, Francis and Kelz, Rachel Rapaport},
	month = dec,
	year = {2008},
	pmid = {19075172},
	keywords = {Humans, Aged, Female, Male, Retrospective Studies, Cohort Studies, Aged, 80 and over, Survival Analysis, United States, Esophageal Neoplasms, Esophagectomy, SEER Program},
	pages = {1198--1203; discussion 1203},
	file = {PDF:/Users/jcsal/Zotero/storage/TCM5BHJ8/Paulson et al. - 2008 - Underuse of esophagectomy as treatment for resectable esophageal cancer.pdf:application/pdf},
}

@article{okusanya179,
	title = {Robotic assisted minimally invasive esophagectomy ({RAMIE}): the {University} of {Pittsburgh} {Medical} {Center} initial experience},
	volume = {6},
	issn = {2225-319X},
	shorttitle = {Robotic assisted minimally invasive esophagectomy ({RAMIE})},
	doi = {10.21037/acs.2017.03.12},
	language = {eng},
	number = {2},
	journal = {Annals of Cardiothoracic Surgery},
	author = {Okusanya, Olugbenga T. and Sarkaria, Inderpal S. and Hess, Nicholas R. and Nason, Katie S. and Sanchez, Manuel Villa and Levy, Ryan M. and Pennathur, Arjun and Luketich, James D.},
	month = mar,
	year = {2017},
	pmid = {28447008},
	pmcid = {PMC5387149},
	pages = {179--185},
	file = {Full Text:/Users/jcsal/Zotero/storage/SQEAICCE/Okusanya et al. - 2017 - Robotic assisted minimally invasive esophagectomy (RAMIE) the University of Pittsburgh Medical Cent.pdf:application/pdf},
}

@article{okusanya116,
	title = {Technique of robotic assisted minimally invasive esophagectomy ({RAMIE})},
	volume = {3},
	issn = {2221-2965},
	doi = {10.21037/jovs.2017.06.09},
	abstract = {Minimally invasive esophagectomy (MIE) has gained popularity over the last two decades as an oncologically sound alternative to open esophagectomy. Robotic assisted minimally invasive esophagectomy (RAMIE) has been developed at few highly-specialized centers, and overall experience with this technique remains limited. Herein, we describe our overall approach to this operation and specific technical issues.},
	language = {eng},
	journal = {Journal of Visualized Surgery},
	author = {Okusanya, Olugbenga T. and Hess, Nicholas R. and Luketich, James D. and Sarkaria, Inderpal S.},
	year = {2017},
	pmid = {29078676},
	pmcid = {PMC5639003},
	keywords = {Esophagectomy, esophageal cancer, minimally invasive, robotic},
	pages = {116},
	file = {Full Text:/Users/jcsal/Zotero/storage/Z8DRPGEY/Okusanya et al. - 2017 - Technique of robotic assisted minimally invasive esophagectomy (RAMIE).pdf:application/pdf},
}

@article{batirel844796,
	title = {Uniportal {VATS} {Approach} in {Esophageal} {Cancer} – {How} to {Do} {It} {Update}},
	volume = {9},
	url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC8990028/},
	doi = {10.3389/fsurg.2022.844796},
	abstract = {The adoption of minimally invasive esophagectomy has been used for over a decade, and the chest part is evolving into a uniportal video-assisted thoracoscopic surgery (VATS) approach. Uniportal esophageal mobilization and anastomosis have many ...},
	language = {en},
	urldate = {2024-10-25},
	journal = {Frontiers in Surgery},
	author = {Batirel, Hasan},
	month = mar,
	year = {2022},
	pmid = {35402499},
	pages = {844796},
	annote = {Triangular stapled anastomosis - 30\% stricture rate
},
}

@article{egberts1485,
	title = {Robot-{Assisted} {Oesophagectomy}: {Recommendations} {Towards} a {Standardised} {Ivor} {Lewis} {Procedure}},
	volume = {23},
	issn = {1873-4626},
	shorttitle = {Robot-{Assisted} {Oesophagectomy}},
	doi = {10.1007/s11605-019-04207-y},
	abstract = {A considerable number of reports have been published on the feasibility, techniques, and early postoperative results of robotic-assisted oesophageal surgery. However, these are mostly smaller case series, suggesting that the robot-assisted Ivor Lewis procedure is still in the implementation phase and far from being standardised. Oesophageal surgeons from seven robotic university centres in Germany, experienced in both minimally invasive and robot-assisted minimally invasive surgery, took part in a workshop on robot-assisted surgery. An intensive exchange of opinions and experiences, followed by a step-by-step re-enactment of the operation in a cadaver lab, enabled us to develop a standardised robot-assisted Ivor Lewis surgical workflow, which is presented here. Systematic and objective comparison of experiences and results using a robot-assisted Ivor Lewis procedure has made it possible to develop a standardised surgical workflow that is now clinically applied in our centres. It is hoped that standardisation of this procedure will help to maintain patient safety, prevent medical errors, and facilitate the learning curve, while introducing robotic surgery into a centre.},
	language = {eng},
	number = {7},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Egberts, Jan-Hendrik and Biebl, M. and Perez, D. R. and Mees, S. T. and Grimminger, P. P. and Müller-Stich, B. P. and Stein, H. and Fuchs, H. and Bruns, C. J. and Hackert, T. and Lang, H. and Pratschke, J. and Izbicki, J. and Weitz, J. and Becker, T.},
	month = jul,
	year = {2019},
	pmid = {30937716},
	keywords = {Humans, Cadaver, Esophagectomy, Esophagus, Minimally Invasive Surgical Procedures, Anastomosis, Surgical, Oesophagectomy, Robotic Surgical Procedures, RAMIE, Focus Groups, Ivor Lewis procedure, Robotic oesophagectomy},
	pages = {1485--1492},
	file = {PDF:/Users/jcsal/Zotero/storage/SFJXKURZ/Egberts et al. - 2019 - Robot-Assisted Oesophagectomy Recommendations Towards a Standardised Ivor Lewis Procedure.pdf:application/pdf},
}

@article{potscher469,
	title = {Robot-assisted esophageal surgery using the da {Vinci}® {Xi} system: operative technique and initial experiences},
	volume = {13},
	issn = {1863-2491},
	shorttitle = {Robot-assisted esophageal surgery using the da {Vinci}® {Xi} system},
	doi = {10.1007/s11701-018-0872-8},
	abstract = {In this review, we would like to illustrate our experience with the da Vinci® Xi system in case of esophageal surgery. Since the da Vinci® Xi system was installed in our department, it has resulted in a great improvement in cases of minimally invasive surgery. After the successful establishment in the field of colorectal surgery, the next step was surgery of the upper gastrointestinal tract. Due to the features of the robotic system, we can definitely observe the advantages and a positive effect in case of minimal invasive esophagectomy (MIE). We have also tried to develop an adequate surgical standard of the robotic-assisted minimal invasive esophagectomy with the da Vinci® Xi.},
	language = {eng},
	number = {3},
	journal = {Journal of Robotic Surgery},
	author = {Pötscher, A. and Bittermann, C. and Längle, F.},
	month = jun,
	year = {2019},
	pmid = {30209678},
	keywords = {Humans, Esophagectomy, Esophageal cancer, Postoperative Complications, Esophagus, Robotic Surgical Procedures, Robotic surgery, da Vinci® Xi, Robot-assisted minimal invasive esophagectomy},
	pages = {469--474},
	file = {PDF:/Users/jcsal/Zotero/storage/77QBFU6W/Pötscher et al. - 2019 - Robot-assisted esophageal surgery using the da Vinci® Xi system operative technique and initial exp.pdf:application/pdf},
}

@article{vandersluis1,
	title = {Robot-{Assisted} {Minimally} {Invasive} {Esophagectomy} with {Intrathoracic} {Anastomosis} ({Ivor} {Lewis}): {Promising} {Results} in 100 {Consecutive} {Patients} (the {European} {Experience})},
	volume = {25},
	issn = {1873-4626},
	shorttitle = {Robot-{Assisted} {Minimally} {Invasive} {Esophagectomy} with {Intrathoracic} {Anastomosis} ({Ivor} {Lewis})},
	doi = {10.1007/s11605-019-04510-8},
	abstract = {BACKGROUND: Robot-assisted minimally invasive esophagectomy (RAMIE) with intrathoracic anastomosis is gaining popularity as a treatment for esophageal cancer. The aim of this study was to describe postoperative complications and short-term oncologic outcomes for RAMIE procedures using the da Vinci Xi robotic system 4-arm technique.
METHODS: Data of 100 consecutive patients with esophageal or gastro-esophageal junction carcinoma undergoing modified Ivor Lewis esophagectomy were prospectively collected. All operations were performed by the same surgeon using an identical intrathoracic anastomotic reconstruction technique with the same perioperative management. Intraoperative and postoperative complications were graded according to Esophagectomy Complications Consensus Group (ECCG) definitions.
RESULTS: Mean duration was 416 min (±80); 70\% of patients had an uncomplicated postoperative recovery. Pulmonary complications were observed in 17\% of patients. Anastomotic leakage was observed in 8\% of patients. Median ICU stay was 1 day and median overall postoperative hospital stay was 11 days. The 30-day mortality was 1\%; 90-day mortality was 3\%. A R0 resection was reached in 92\% of patients with a median number of 29 dissected lymph nodes. All patients had at least 7 months of follow-up with a median follow-up of 17 months. Median overall survival was not reached yet.
CONCLUSION: RAMIE with intrathoracic anastomosis (Ivor Lewis) for esophageal or gastro-esophageal junction cancer was technically feasible and safe. Postoperative complications and short-term oncologic results were comparable to the highest international standards nowadays.},
	language = {eng},
	number = {1},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {van der Sluis, Pieter Christiaan and Tagkalos, Evangelos and Hadzijusufovic, Edin and Babic, Benjamin and Uzun, Eren and van Hillegersberg, Richard and Lang, Hauke and Grimminger, Peter Philipp},
	month = jan,
	year = {2021},
	pmid = {32072382},
	pmcid = {PMC7850999},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Laparoscopy, Postoperative Complications, Minimally Invasive Surgical Procedures, Anastomosis, Surgical, MIE, Robotics, RAMIE, Ivor Lewis, Minimally invasive},
	pages = {1--8},
	file = {Full Text:/Users/jcsal/Zotero/storage/MEITDMWZ/van der Sluis et al. - 2021 - Robot-Assisted Minimally Invasive Esophagectomy with Intrathoracic Anastomosis (Ivor Lewis) Promisi.pdf:application/pdf},
}

@article{nakauchi85,
	title = {Robot-assisted mediastinoscopic esophagectomy for esophageal cancer: the first clinical series},
	volume = {16},
	issn = {1612-9067},
	shorttitle = {Robot-assisted mediastinoscopic esophagectomy for esophageal cancer},
	doi = {10.1007/s10388-018-0634-8},
	abstract = {BACKGROUND: Radical esophagectomy for esophageal cancer is associated with high morbidity, especially with pulmonary complications. Mediastinoscopic esophagectomy via a small left neck incision combined with the esophageal hiatus, without using transthoracic approach, has been reported to reduce pulmonary complication; however, from technical point of view, this approach using non-articulating, straight, long forceps is extremely challenging, especially in the middle mediastinal area. Its technical difficulties may be attenuated using da Vinci Surgical System. The aim of this study was to evaluate the feasibility and safety of robot-assisted mediastinoscopic esophagectomy.
METHODS: Robot-assisted mediastinoscopic esophagectomy was performed in six patients between October 2016 and May 2017. Robotic esophageal mobilization with upper and middle mediastinal lymphadenectomy was performed via the three da Vinci Xi (Intuitive Surgical, Inc. Sunnyvale, CA) trocars placed on the 5-cm left cervical incision. Thereafter, the remaining part of radical esophagectomy was completed via a transhiatal approach.
RESULTS: Upper and middle mediastinal lymphadenectomy was robotically completed via the transcervical approach in all cases without conversion to transthoracic approach. No postoperative complications (Clavien-Dindo classification grade ≥ III) were observed.
CONCLUSIONS: Robot-assisted mediastinoscopic esophagectomy was technically feasible and safe. Use of da Vinci Surgical System may help attenuate technical difficulties in transcervical middle mediastinal lymph node dissection.},
	language = {eng},
	number = {1},
	journal = {Esophagus: Official Journal of the Japan Esophageal Society},
	author = {Nakauchi, Masaya and Uyama, Ichiro and Suda, Koichi and Shibasaki, Susumu and Kikuchi, Kenji and Kadoya, Shinichi and Ishida, Yoshinori and Inaba, Kazuki},
	month = jan,
	year = {2019},
	pmid = {30074105},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Lymphatic Metastasis, Lymph Node Excision, Feasibility Studies, Robotic Surgical Procedures, Mediastinoscopy, Robotic},
	pages = {85--92},
	file = {PDF:/Users/jcsal/Zotero/storage/F8FSHN53/Nakauchi et al. - 2019 - Robot-assisted mediastinoscopic esophagectomy for esophageal cancer the first clinical series.pdf:application/pdf},
}

@article{grimminger404,
	title = {Robotic-{Assisted} {Ivor} {Lewis} {Esophagectomy} ({RAMIE}) with a {Standardized} {Intrathoracic} {Circular} {End}-to-side {Stapled} {Anastomosis} and a {Team} of {Two} ({Surgeon} and {Assistant} {Only})},
	volume = {66},
	issn = {1439-1902},
	doi = {10.1055/s-0037-1606198},
	abstract = {Robotic-assisted surgery is rapidly increasing, especially in general surgery. It has been shown for years that the minimal invasive esophagectomy (MIE) is possible using a robotic system, for example, da Vinci Xi, Intuitive Surgical. In the past, most robotic esophageal resections have been performed thoracoscopically, and the anastomosis was mostly sutured at the neck. Due to the increase of usable instruments and technical progress, it is possible to perform the total abdominothoracic esophagectomy with an intrathoracic sutured anastomosis robotically. In this article, we would like to present the standardized operation technique and tricks for the robotic-assisted (da Vinci Xi) Ivor Lewis MIE (RAMIE), especially the robotic technique in combination with a standardized intrathoracic circular end-to-side stapled esophagogastric anastomosis.},
	language = {eng},
	number = {5},
	journal = {The Thoracic and Cardiovascular Surgeon},
	author = {Grimminger, Peter P. and Hadzijusufovic, Edin and Lang, Hauke},
	month = aug,
	year = {2018},
	pmid = {28869991},
	keywords = {Humans, Treatment Outcome, Esophagectomy, Laparoscopy, Esophagus, Stomach, Gastrostomy, Surgical Stapling, Patient Positioning, Surgeons, Robotic Surgical Procedures, Esophagostomy, Physician Assistants, Plastic Surgery Procedures},
	pages = {404--406},
}

@article{huscher1034,
	title = {Intrathoracic {Robotic}-{Sewn} {Anastomosis} {During} {Ivor} {Lewis} {Esophagectomy} for {Cancer}: {Back} to {Basics}?},
	volume = {27},
	issn = {1873-4626},
	shorttitle = {Intrathoracic {Robotic}-{Sewn} {Anastomosis} {During} {Ivor} {Lewis} {Esophagectomy} for {Cancer}},
	doi = {10.1007/s11605-023-05616-w},
	abstract = {BACKGROUND: To assess the feasibility, clinical utility, and safety of intrathoracic robotic-sewn esophageal anastomosis (IrEA) during Ivor Lewis esophagectomy for adenocarcinoma of the lower third of the esophagus, or cancer at the gastro-esophageal junction type I (Siewert classification).
METHODS: A protocol for completely robotic Ivor Lewis esophagectomy (CrIE) and intrathoracic robotic-sewn anastomosis (IrEA) was established at the authors' institutions from January 2015 through December 2019. Overall surgery-related postoperative complications were analyzed. Overall survival and disease-free survival analysis were performed using standard methods.
RESULTS: The study population consisted of 40 patients. Median operative time was 320 min (sd 62, range 235-500 min), and conversion to open rate was 0\%. Anastomotic leak rate was 10\%. The mean number of examined lymph nodes (ELN) was 19 (IQR 11-29), and the mean number of positive lymph nodes (PLN) was 3 (IQR 0-5). Short- and long-term surgical and oncological outcomes were comparable at a medium follow-up of 37 months. The median overall survival was 48 months while the mean disease-free survival was 29 months.
CONCLUSION: This pilot series, in which an intrathoracic robotic-sewn anastomosis (IrEA) was performed during CrIE, demonstrated the safety and feasibility of this approach. Compared to the current standard of care at a high-volume center, IrEA was associated with better postoperative surgical outcomes and similar oncological outcomes to those reported worldwide today. These results call for further validation in a prospective and controlled setting to be fully incorporated into clinical practice.},
	language = {eng},
	number = {5},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Huscher, C. G. S. and Cobellis, F. and Lazzarin, G.},
	month = may,
	year = {2023},
	pmid = {36732403},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Adult, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Postoperative Complications, Anastomosis, Surgical, Feasibility Studies, Robotic Surgical Procedures, Robotics, Robotic esophagectomy, Robotic-sewn anastomosis},
	pages = {1034--1041},
	file = {PDF:/Users/jcsal/Zotero/storage/SR9NFUY9/Huscher et al. - 2023 - Intrathoracic Robotic-Sewn Anastomosis During Ivor Lewis Esophagectomy for Cancer Back to Basics.pdf:application/pdf},
}

@article{baca139,
	title = {Totally robotic ivor-{Lewis} esophagectomy with intrathoracic robot-sewn anastomosis for cardio-esophageal cancer with the da {VINCI} {XI}},
	volume = {30},
	issn = {1879-3320},
	doi = {10.1016/j.suronc.2019.07.010},
	language = {eng},
	journal = {Surgical Oncology},
	author = {Baca, Bilgi and Benlice, Cigdem and Hamzaoglu, Ismail and Karahasanoglu, Tayfun},
	month = sep,
	year = {2019},
	pmid = {31500778},
	keywords = {Humans, Aged, Male, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Anastomosis, Surgical, Video Recording, Robotic Surgical Procedures, Robotic surgery, Heart Neoplasms, Ivor-Lewis esophagectomy},
	pages = {139--140},
	annote = {Not helpful. Video not available
},
}

@article{pla99,
	title = {Absence of thoracotomy by intrathoracic manual suture and transabdominal removal of surgical specimen during {Ivor} {Lewis} robotic esophagectomy},
	volume = {102},
	issn = {2173-5077},
	doi = {10.1016/j.cireng.2023.11.015},
	abstract = {In the surgical treatment of esophageal cancer, robotic surgery allows performing an intrathoracic handsewn anastomosis in a simpler, faster and more comfortable way for the surgeon than open surgery and traditional minimally invasive surgery. With this, we avoid the use of self-suture instruments, some of which require a small thoracotomy for their introduction. However, the retrieval of the specimen requires the practice of this thoracotomy, of variable size, that can be associated with intense chest pain. We describe a technical modification of the classic robotic Ivor Lewis that allows removal of the surgical piece through a minimal abdominal incision, thus avoiding controlled rib fracture, as well as the possible sequelae of making an incision in the chest wall.},
	language = {eng},
	number = {2},
	journal = {Cirugia Espanola},
	author = {Plá, Ana Conesa and Martín, David Ruiz de Angulo and Ruiz, Vicente Munítiz and de Haro, Luisa Fernanda Martínez},
	month = feb,
	year = {2024},
	pmid = {38219823},
	keywords = {Humans, Esophagectomy, Thoracotomy, Anastomosis, Surgical, Robotic Surgical Procedures, Robotic esophagectomy, Anastomosis manual, Esofaguectomía de Ivor Lewis, Esofaguectomía robótica, Extracción transabdominal del especimen, Hand-Sewn anastomosis, Ivor Lewis esophagectomy, Sofaguectomía transtorácica, Sutures, Transabdominal specimen extraction, Transthoracic esophagectomy},
	pages = {99--102},
	file = {PDF:/Users/jcsal/Zotero/storage/Y45L5K26/Plá et al. - 2024 - Absence of thoracotomy by intrathoracic manual suture and transabdominal removal of surgical specime.pdf:application/pdf},
}

@article{marano941,
	title = {Robot-assisted esophagectomy with robot-sewn intrathoracic anastomosis ({Ivor} {Lewis}): surgical technique and early results},
	volume = {75},
	issn = {2038-3312},
	shorttitle = {Robot-assisted esophagectomy with robot-sewn intrathoracic anastomosis ({Ivor} {Lewis})},
	doi = {10.1007/s13304-022-01439-7},
	abstract = {Esophagectomy is the selected treatment for nonmetastatic esophageal and esophagogastric junction cancer, although high perioperative morbidity and mortality incur. Robot-assisted minimally invasive esophagectomy (RAMIE) effectively reduces cardiopulmonary complications compared to open esophagectomy and offers a technical advantage, especially for lymph node dissection and intrathoracic anastomosis. This article aims at describing our initial experience of Ivor Lewis RAMIE, focusing on the technique's main steps and robotic-sewn esophagogastrostomy. Prospectively collected data from all consecutive patients who underwent Ivor Lewis RAMIE for cancer was reviewed. Reconstruction was performed with a gastric conduit pull-up and a robotic-sewn intrathoracic anastomosis. Intraoperative and postoperative complications were recorded as prescribed by the Esophagectomy Complications Consensus Group (ECCG). Thirty patients underwent Ivor Lewis RAMIE with complete mediastinal lymph node dissection and robot-sewn anastomosis. No intraoperative complications nor conversion occurred. Pulmonary complications totaled 26.7\%. Anastomotic leakage (ECCG, type III) and conduit necrosis (ECCG, type III) both occurred in one patient (3.3\%). Chylothorax appeared in 2 patients (6.7\%) (ECCG, Type IIA). Anastomotic stricture, successfully treated with endoscopic dilatations, occurred in 8 cases (26.7\%). Median overall postoperative stay was 11 days (range, 6-51 days). 30 day and 90 day mortality was 0\%. R0 resection was performed in 96.7\% of patients with a median number of 47 retrieved lymph nodes. RAMIE with robot-sewn intrathoracic anastomosis appears to be feasible, safe and effective, with favorable perioperative results. Nevertheless, further high-quality studies are needed to define the best anastomotic technique for Ivor Lewis RAMIE.},
	language = {eng},
	number = {4},
	journal = {Updates in Surgery},
	author = {Marano, Alessandra and Salomone, Sara and Pellegrino, Luca and Geretto, Paolo and Robella, Manuela and Borghi, Felice},
	month = jun,
	year = {2023},
	pmid = {36510101},
	pmcid = {PMC9744375},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Postoperative Complications, Anastomosis, Surgical, Robotic Surgical Procedures, Robotics, RAMIE, Robotic, Intrathoracic anastomosis, Ivor-Lewis},
	pages = {941--952},
	file = {Full Text:/Users/jcsal/Zotero/storage/86XNQVRN/Marano et al. - 2023 - Robot-assisted esophagectomy with robot-sewn intrathoracic anastomosis (Ivor Lewis) surgical techni.pdf:application/pdf;s13304-022-01439-7:/Users/jcsal/Zotero/storage/FLHMK3SQ/s13304-022-01439-7.pdf:application/pdf},
}

@article{wang811835,
	title = {Double-{Docking} {Technique}, an {Optimized} {Process} for {Intrathoracic} {Esophagogastrostomy} in {Robot}-{Assisted} {Ivor} {Lewis} {Esophagectomy}},
	volume = {9},
	issn = {2296-875X},
	doi = {10.3389/fsurg.2022.811835},
	abstract = {BACKGROUND: Though robotic Ivor Lewis esophagectomy has been increasingly applied, intrathoracic esophagogastrostomy is still a technical barrier. In this retrospective study, we introduced a double-docking technique for intrathoracic esophagogastrostomy to optimize surgical exposure and facilitate intrathoracic anastomosis. Moreover, we compared the clinical outcomes between the double-docking technique and anastomosis with a single-docking procedure in robotic Ivor Lewis esophagectomy.
METHODS: From March 2017 to September 2020, the clinical data of 68 patients who underwent robotic Ivor Lewis esophagectomy were reviewed, including 23 patients who underwent the double-docking technique (double-docking group) and 45 patients who underwent single-docking robotic esophagectomy (single-docking group). All patients were diagnosed with esophageal cancer or gastro-esophageal junction by biopsy before surgery. The technical details of the double-docking technique are described in this article.
RESULTS: There was no difference in the patient demographics data between the two groups. The median surgical time in the double-docking group was slightly shorter than in the classic group without statistical difference (380 vs. 395 min, p = 0.368). In the double-docking group, the median blood loss was 90 mL, the median number of lymph nodes harvested was 17, and the R0 resection rates were 100\% (23/23). There were no differences in the surgical outcomes between the two groups.
CONCLUSIONS: Based on our experience, the double-docking technique provides good surgical exposure when fashioning anastomosis, and such a technique does not increase the surgical time. Therefore, we believe that the double-docking technique is a safe and effective method for intrathoracic esophagogastrostomy while providing good exposure and ensuring the convenience and reliability of intrathoracic anastomosis.},
	language = {eng},
	journal = {Frontiers in Surgery},
	author = {Wang, Fuqiang and Zhang, Hanlu and Qiu, Guanghao and Wang, Zihao and Li, Zhiyang and Wang, Yun},
	year = {2022},
	pmid = {35388362},
	pmcid = {PMC8978993},
	keywords = {robotic surgery, esophageal carcinoma, esophagus surgery, Ivor Lewis esophagectomy, anastomosis},
	pages = {811835},
	file = {fsurg-09-811835:/Users/jcsal/Zotero/storage/E8HG74XQ/fsurg-09-811835.pdf:application/pdf;Full Text:/Users/jcsal/Zotero/storage/L5SJ98HR/Wang et al. - 2022 - Double-Docking Technique, an Optimized Process for Intrathoracic Esophagogastrostomy in Robot-Assist.pdf:application/pdf},
}

@article{sarkaria211,
	title = {Robotic-assisted minimally invasive esophagectomy: the {Ivor} {Lewis} approach},
	volume = {24},
	issn = {1558-5069},
	shorttitle = {Robotic-assisted minimally invasive esophagectomy},
	doi = {10.1016/j.thorsurg.2014.02.010},
	abstract = {Robotic-assisted minimally invasive esophagectomy (RAMIE) is emerging as a potential alternative approach to standard minimally invasive esophagectomy (MIE). However, early reports vary widely in operative approach, method, and reporting of outcomes, including operative complications. A formal, prospective academic program to evaluate RAMIE was initiated at the authors' institution, with the primary goal of maximizing patient safety during the introduction of new technology into the operating room. The standardized RAMIE Ivor Lewis approach developed through this program is described in detail. The available literature is reviewed, with early reports suggesting outcomes similar to those of MIE and standard open esophagectomy.},
	language = {eng},
	number = {2},
	journal = {Thoracic Surgery Clinics},
	author = {Sarkaria, Inderpal S. and Rizk, Nabil P.},
	month = may,
	year = {2014},
	pmid = {24780426},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Esophageal Diseases, Minimally Invasive Surgical Procedures, Minimally invasive esophagectomy, Robotics, Robotic surgery},
	pages = {211--222, vii},
	file = {PDF:/Users/jcsal/Zotero/storage/FEYUWXQU/Sarkaria and Rizk - 2014 - Robotic-assisted minimally invasive esophagectomy the Ivor Lewis approach.pdf:application/pdf},
}

@article{mcclelland523,
	title = {The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the {United} {States}, part 1: {African}-{American} patients},
	volume = {2},
	issn = {2452-1094},
	shorttitle = {The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the {United} {States}, part 1},
	doi = {10.1016/j.adro.2017.07.002},
	abstract = {INTRODUCTION: African Americans experience the highest burden of cancer incidence and mortality in the United States and have been persistently less likely to receive interventional care, even when such care has been proven superior to conservative management by randomized controlled trials. The presence of disparities in access to radiation therapy (RT) for African American cancer patients has rarely been examined in an expansive fashion.
METHODS AND MATERIALS: An extensive literature search was performed using the PubMed database to examine studies investigating disparities in RT access for African Americans.
RESULTS: A total of 55 studies were found, spanning 11 organ systems. Disparities in access to RT for African Americans were most prominently study in cancers of the breast (23 studies), prostate (7 studies), gynecologic system (5 studies), and hematologic system (5 studies). Disparities in RT access for African Americans were prevalent regardless of organ system studied and often occurred independently of socioeconomic status. Fifty of 55 studies (91\%) involved analysis of a population-based database such as Surveillance, Epidemiology and End Result (SEER; 26 studies), SEER-Medicare (5 studies), National Cancer Database (3 studies), or a state tumor registry (13 studies).
CONCLUSIONS: African Americans in the United States have diminished access to RT compared with Caucasian patients, independent of but often in concert with low socioeconomic status. These findings underscore the importance of finding systemic and systematic solutions to address these inequalities to reduce the barriers that patient race provides in receipt of optimal cancer care.},
	language = {eng},
	number = {4},
	journal = {Advances in Radiation Oncology},
	author = {McClelland, Shearwood and Page, Brandi R. and Jaboin, Jerry J. and Chapman, Christina H. and Deville, Curtiland and Thomas, Charles R.},
	year = {2017},
	pmid = {29204518},
	pmcid = {PMC5707425},
	pages = {523--531},
	file = {Full Text:/Users/jcsal/Zotero/storage/ESG8AFXI/McClelland et al. - 2017 - The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the Unite.pdf:application/pdf},
}

@article{merkow357,
	title = {Use of multimodality neoadjuvant therapy for esophageal cancer in the {United} {States}: assessment of 987 hospitals},
	volume = {19},
	issn = {1534-4681},
	shorttitle = {Use of multimodality neoadjuvant therapy for esophageal cancer in the {United} {States}},
	doi = {10.1245/s10434-011-1945-3},
	abstract = {BACKGROUND: Consensus guidelines recommend neoadjuvant therapy in locally advanced esophageal cancer; however, whether this recommendation has been widely adopted is unknown. Therefore, we evaluated the utilization of neoadjuvant therapy in esophageal cancer and its association with outcomes in the United States.
METHODS: From the National Cancer Data Base all patients with middle and lower third clinical stage I-III esophageal cancers who underwent surgical resection were identified (1998-2007). Multivariable regression models were developed to identify predictors of neoadjuvant therapy use and associated outcomes.
RESULTS: We identified 8562 patients who underwent surgical resection for esophageal cancer. In nonmetastatic locally advanced tumors, neoadjuvant therapy use increased (stage II 47.9\% to 72.5\%; stage III 51.0\% to 90.1\%; P {\textless} 0.001). On multivariable analysis, factors associated with the decreased use of neoadjuvant therapy for stage II and III disease were age ≥75 years, Medicare insurance coverage, Charlson score ≥2, stage II (vs. III) disease, and geographic region. Patients with stage II and III disease who underwent neoadjuvant therapy had a lower risk of positive lymph nodes (odds ratio [OR] 0.45, 95\% confidence interval [CI] 0.35-0.55) and positive surgical margins (OR 0.51, 95\% CI 0.38-0.69). Thirty-day postoperative mortality rates were not significantly affected by neoadjuvant therapy (OR 0.90, 95\% CI 0.66-1.24). A pathologic complete response was observed in 10.8\% of patients. The only factor that was predictive of pathologic complete response was squamous cell tumor histology (OR 2.14, 95\% CI 1.52-3.02).
CONCLUSIONS: In surgically treated patients, the use of neoadjuvant trimodal therapy has increased in the past decade; however, opportunities exist to improve adherence to national guidelines.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Merkow, Ryan P. and Bilimoria, Karl Y. and McCarter, Martin D. and Chow, Warren B. and Ko, Clifford Y. and Bentrem, David J.},
	month = feb,
	year = {2012},
	pmid = {21769460},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Neoplasm Staging, Survival Rate, United States, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy},
	pages = {357--364},
}

@article{greenstein881,
	title = {Racial disparities in esophageal cancer treatment and outcomes},
	volume = {15},
	issn = {1534-4681},
	doi = {10.1245/s10434-007-9664-5},
	abstract = {PURPOSE: Blacks have a higher mortality rate than whites from esophageal cancer, but the reasons underlying this disparity remain unclear. In this study, we used a national sample of patients with resectable esophageal cancer to assess the extent to which racial inequalities in care can explain outcome disparities.
METHODS: We identified all non-Hispanic white and black patients diagnosed with T0-T2, node-negative esophageal cancer between 1988 and 2003 from the Surveillance, Epidemiology, and End Results registry. Racial differences in esophageal-specific survival were assessed using the Kaplan-Meier method. We performed Cox regression to test for racial differences in survival after adjusting for potential confounders and to assess the extent to which disparities can be explained by later diagnosis or treatment inequalities.
RESULTS: A total of 1522 patients were included in the study. Blacks had worse esophageal-specific survival rates than whites (37\% vs 60\% 5-year survival; P {\textless} .0001). Blacks were more likely to be diagnosed at a more advanced stage and to have squamous cell tumors, but were less likely to undergo surgery. In multivariate regression controlling for age, sex, marital status, histology, and tumor location, black race was associated with worse survival. When tumor status, surgery, and radiotherapy were added to the model, race was no longer significantly associated with survival.
CONCLUSION: These data suggest that blacks are at greater risk of death from esophageal cancer. While the disparity is due in part to differences in tumor histology, diagnosis at an earlier stage and higher rates of surgery among blacks could reduce this survival disparity.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgical Oncology},
	author = {Greenstein, Alexander J. and Litle, Virginia R. and Swanson, Scott J. and Divino, Celia M. and Packer, Stuart and McGinn, Thomas G. and Wisnivesky, Juan P.},
	month = mar,
	year = {2008},
	pmid = {17987341},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Survival Analysis, United States, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Healthcare Disparities, SEER Program, Black or African American, White People},
	pages = {881--888},
}

@article{dong657,
	title = {Underuse of {Surgery} {Accounts} for {Racial} {Disparities} in {Esophageal} {Cancer} {Survival} {Times}: {A} {Matched} {Cohort} {Study}},
	volume = {17},
	issn = {1542-7714},
	shorttitle = {Underuse of {Surgery} {Accounts} for {Racial} {Disparities} in {Esophageal} {Cancer} {Survival} {Times}},
	doi = {10.1016/j.cgh.2018.07.018},
	abstract = {BACKGROUND \& AIMS: There are racial disparities in survival times of patients with esophageal cancer. We examined the sequential effects of characteristics, diagnosis, and treatment-related factors on the disparity in survival times of black vs white patients with esophageal cancer.
METHODS: We identified 1900 black and 15,523 non-Hispanic white (NHW) patients, 65 years or older, diagnosed with esophageal squamous cell carcinoma or esophageal adenocarcinoma from 1994 through 2011 in the Surveillance Epidemiology and End Results (SEER)-Medicare database. Patients were followed up until death or December 31, 2012. Three sets of 1900 NHW patients were matched sequentially to the same set of 1900 black patients, based on demographics (age, sex, year of diagnosis, and SEER site), presentation (demographics plus cancer stage, grade, and comorbidity), and treatment (presentation variables plus surgery, chemotherapy, or radiation therapy).
RESULTS: The absolute difference in 5-year survival between black patients (13.3\%) and NHW patients (18.4\%) was 5.1\% (95\% CI, 2.3\%-7.7\%; P = .001) in the demographics match. After we matched for presentation, the difference in 5-year survival was reduced to 2.3\% (95\% CI, 0.3\%-4.8\%), but remained statistically significant (P = .04). Additional matching of patients on treatment-related factors eliminated the racial difference in 5-year survival (P = .59). Among patients matched for disease presentation, only 10.8\% of black patients underwent surgery, compared with 22.8\% of NHW patients (P {\textless} .001). Histology, tumor location, socioeconomic status, chemotherapy, and radiation therapy each were associated with the receipt of surgery. None of these factors, however, could explain the racial difference in the receipt of surgery.
CONCLUSIONS: In the SEER-Medicare database, underuse of surgical treatment can account for the disparities in survival times between black and NHW patients with esophageal cancer.},
	language = {eng},
	number = {4},
	journal = {Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association},
	author = {Dong, Jing and Gu, Xiangjun and El-Serag, Hashem B. and Thrift, Aaron P.},
	month = mar,
	year = {2019},
	pmid = {30036643},
	keywords = {Humans, Aged, Female, Male, Follow-Up Studies, Cohort Studies, Aged, 80 and over, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, EAC, Mortality, Surgical Procedures, Operative, Healthcare Disparities, Procedures and Techniques Utilization, White People, Black People, Race Factors, Diagnostic Tests, Routine, ESCC, Matched Sampling, Minority Populations},
	pages = {657--665.e13},
}

@article{al-refaie81,
	title = {Who receives their complex cancer surgery at low-volume hospitals?},
	volume = {214},
	issn = {1879-1190},
	doi = {10.1016/j.jamcollsurg.2011.10.003},
	abstract = {BACKGROUND: Previous literature has consistently shown worse operative outcomes at low-volume hospitals (LVH) after complex cancer surgery. Whether patient-related factors impact this association remains unknown. We hypothesize that patient-related factors contribute to receipt of complex cancer surgery at LVH.
STUDY DESIGN: Using the 2003-2008 National Inpatient Sample, we identified 59,841 patients who underwent cancer operations for lung, esophagus, and pancreas tumors. Logistic regression models were used to examine the impact of sociodemographic factors on receipt of complex cancer surgery at LVH.
RESULTS: Overall, 38.4\% received their cancer surgery at LVH. A higher proportion of esophagectomies were performed at LVH (70.3\%), followed by pancreatectomy (38.2\%) and lung resection (33.8\%). Patients who were non-white, with non-private insurance, and had more comorbidities were all more likely to receive their cancer surgery at LVH (for all, p {\textless} 0.05). Multivariate analyses continued to demonstrate that non-white race, insurance status, increased comorbidities, region, and nonelective admission predicted receipt of cancer surgery at LVH across all 3 procedures.
CONCLUSIONS: In this large national study, non-white race and increased comorbidities contributed to receipt of cancer surgery at LVH. Patient selection and access to high-volume hospitals are likely reasons worthy of additional investigation. This study provides additional insight into the volume-outcomes relationship. Given the demonstrated outcomes disparity between high-volume hospitals and LVH, future policy and research should encourage mechanisms for referral of patients with cancer to high-volume hospitals for their surgical care.},
	language = {eng},
	number = {1},
	journal = {Journal of the American College of Surgeons},
	author = {Al-Refaie, Waddah B. and Muluneh, Binyam and Zhong, Wei and Parsons, Helen M. and Tuttle, Todd M. and Vickers, Selwyn M. and Habermann, Elizabeth B.},
	month = jan,
	year = {2012},
	pmid = {22112418},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Lung Neoplasms, Pancreatic Neoplasms, Aged, 80 and over, Outcome Assessment, Health Care, Esophageal Neoplasms, Esophagectomy, Pancreatectomy, Pneumonectomy, Health Facility Size},
	pages = {81--87},
}

@article{azad494,
	title = {Circulating {Tumor} {DNA} {Analysis} for {Detection} of {Minimal} {Residual} {Disease} {After} {Chemoradiotherapy} for {Localized} {Esophageal} {Cancer}},
	volume = {158},
	issn = {1528-0012},
	doi = {10.1053/j.gastro.2019.10.039},
	abstract = {BACKGROUND \& AIMS: Biomarkers are needed to risk stratify after chemoradiotherapy for localized esophageal cancer. These could improve identification of patients at risk for cancer progression and selection of additional therapy.
METHODS: We performed deep sequencing (CAncer Personalized Profiling by deep Sequencing, [CAPP-Seq]) analyses of plasma cell-free DNA collected from 45 patients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes and fixed esophageal tumor biopsy samples collected during esophagogastroduodenoscopy. Patients were treated from May 2010 through October 2015; 23 patients subsequently underwent esophagectomy, and 22 did not undergo surgery. We also sequenced DNA from blood samples from 40 healthy control individuals. We analyzed 802 regions of 607 genes for single-nucleotide variants previously associated with esophageal adenocarcinoma or squamous cell carcinoma. Patients underwent imaging analyses 6-8 weeks after chemoradiotherapy and were followed for 5 years. Our primary aim was to determine whether detection of circulating tumor DNA (ctDNA) after chemoradiotherapy is associated with risk of tumor progression (growth of local, regional, or distant tumors, detected by imaging or biopsy).
RESULTS: The median proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07\%, indicating that ultrasensitive assays are needed for quantification and analysis of ctDNA from localized esophageal tumors. Detection of ctDNA after chemoradiotherapy was associated with tumor progression (hazard ratio, 18.7; P {\textless} .0001), formation of distant metastases (hazard ratio, 32.1; P {\textless} .0001), and shorter disease-specific survival times (hazard ratio, 23.1; P {\textless} .0001). A higher proportion of patients with tumor progression had new mutations detected in plasma samples collected after chemoradiotherapy than patients without progression (P = .03). Detection of ctDNA after chemoradiotherapy preceded radiographic evidence of tumor progression by an average of 2.8 months. Among patients who received chemoradiotherapy without surgery, combined ctDNA and metabolic imaging analysis predicted progression in 100\% of patients with tumor progression, compared with 71\% for only ctDNA detection and 57\% for only metabolic imaging analysis (P {\textless} .001 for comparison of either technique to combined analysis).
CONCLUSIONS: In an analysis of cell-free DNA in blood samples from patients who underwent chemoradiotherapy for esophageal cancer, detection of ctDNA was associated with tumor progression, metastasis, and disease-specific survival. Analysis of ctDNA might be used to identify patients at highest risk for tumor progression.},
	language = {eng},
	number = {3},
	journal = {Gastroenterology},
	author = {Azad, Tej D. and Chaudhuri, Aadel A. and Fang, Penny and Qiao, Yawei and Esfahani, Mohammad S. and Chabon, Jacob J. and Hamilton, Emily G. and Yang, Yi D. and Lovejoy, Alex and Newman, Aaron M. and Kurtz, David M. and Jin, Michael and Schroers-Martin, Joseph and Stehr, Henning and Liu, Chih Long and Hui, Angela Bik-Yu and Patel, Viren and Maru, Dipen and Lin, Steven H. and Alizadeh, Ash A. and Diehn, Maximilian},
	month = feb,
	year = {2020},
	pmid = {31711920},
	pmcid = {PMC7010551},
	keywords = {Humans, Tomography, X-Ray Computed, Aged, Female, Male, Middle Aged, Kaplan-Meier Estimate, Retrospective Studies, Disease Progression, Prospective Studies, Risk Assessment, Progression-Free Survival, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Chemoradiotherapy, Esophagus, Neoplasm, Residual, Biopsy, Feasibility Studies, Biomarkers, Tumor, Healthy Volunteers, Circulating Tumor DNA, Genetics, High-Throughput Nucleotide Sequencing, Polymorphism, SNP},
	pages = {494--505.e6},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/A62D7MY2/Azad et al. - 2020 - Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for.pdf:application/pdf},
}

@article{shah390,
	title = {Improving outcomes in patients with oesophageal cancer},
	volume = {20},
	issn = {1759-4782},
	doi = {10.1038/s41571-023-00757-y},
	abstract = {The care of patients with oesophageal cancer or of individuals who have an elevated risk of oesophageal cancer has changed dramatically. The epidemiology of squamous cell and adenocarcinoma of the oesophagus has diverged over the past several decades, with a marked increase in incidence only for oesophageal adenocarcinoma. Only in the past decade, however, have molecular features that distinguish these two forms of the disease been identified. This advance has the potential to improve screening for oesophageal cancers through the development of novel minimally invasive diagnostic technologies predicated on cancer-specific genomic or epigenetic alterations. Surgical techniques have also evolved towards less invasive approaches associated with less morbidity, without compromising oncological outcomes. With improvements in multidisciplinary care, advances in radiotherapy and new tools to detect minimal residual disease, certain patients may no longer even require surgical tumour resection. However, perhaps the most anticipated advance in the treatment of patients with oesophageal cancer is the advent of immune-checkpoint inhibitors, which harness and enhance the host immune response against cancer. In this Review, we discuss all these advances in the management of oesophageal cancer, representing only the beginning of a transformation in our quest to improve patient outcomes.},
	language = {eng},
	number = {6},
	journal = {Nature Reviews. Clinical Oncology},
	author = {Shah, Manish A. and Altorki, Nasser and Patel, Pretish and Harrison, Sebron and Bass, Adam and Abrams, Julian A.},
	month = jun,
	year = {2023},
	pmid = {37085570},
	keywords = {Humans, Adenocarcinoma, Esophageal Neoplasms},
	pages = {390--407},
	file = {PDF:/Users/jcsal/Zotero/storage/GQEGUSQM/Shah et al. - 2023 - Improving outcomes in patients with oesophageal cancer.pdf:application/pdf},
}

@article{svrceke452,
	title = {Improving individualised therapies in localised gastro-oesophageal adenocarcinoma},
	volume = {25},
	issn = {1474-5488},
	doi = {10.1016/S1470-2045(24)00180-3},
	abstract = {Despite our increased understanding of the biological and molecular aspects of gastro-oesophageal tumourigenesis, the identification of prognostic or predictive factors remains challenging. Patients with resectable gastric and oesophageal adenocarcinoma are often treated similarly after surgical resection, regardless of their tumour biology, clinical characteristics, and histological treatment response. Substantial progress has been made in the past 5 years in managing patients with gastric or oesophageal adenocarcinoma, including the use of immune checkpoint inhibitors and new targeted therapies, leading to substantial improvements in clinical outcomes. These advancements have primarily been established in advanced and metastatic disease, while the management framework for local and locoregional disease is just beginning to shift. We provide an overview of existing data on biomarkers and tumour-related and host-related factors that are relevant to stratify patients into low-risk and high-risk recurrence groups, both before and after surgery, paving the way for more personalised treatment approaches.},
	language = {eng},
	number = {9},
	journal = {The Lancet. Oncology},
	author = {Svrcek, Magali and Voron, Thibault and André, Thierry and Smyth, Elizabeth C. and de la Fouchardière, Christelle},
	month = sep,
	year = {2024},
	pmid = {39214116},
	keywords = {Humans, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Biomarkers, Tumor, Molecular Targeted Therapy, Precision Medicine},
	pages = {e452--e463},
	file = {PDF:/Users/jcsal/Zotero/storage/J6ZLFJYN/Svrcek et al. - 2024 - Improving individualised therapies in localised gastro-oesophageal adenocarcinoma.pdf:application/pdf},
}

@article{siddharthan257,
	title = {Anal intraepithelial neoplasia: diagnosis, screening, and treatment},
	volume = {32},
	issn = {1108-7471},
	shorttitle = {Anal intraepithelial neoplasia},
	doi = {10.20524/aog.2019.0364},
	abstract = {Anal intraepithelial neoplasia (AIN) is a premalignant lesion for anal cancer. It is more commonly found in high-risk patients (e.g., human papilloma virus (HPV)/human immunodeficiency virus infections, post-organ transplantation patients, and men who have sex with men) and development is driven by HPV infection. The incidence of AIN is difficult to estimate, but is heavily skewed by preexisting conditions, particularly in high-risk populations. The diagnosis is made from cytology or biopsy during routine examinations, and can be performed at a primary care provider's office. A pathologist can then review and classify cells, based on nucleus-to-cytoplasm ratios. The classification of low or high grade can better predict progression from AIN to anal cancer. There is little debate that AIN can develop into anal cancer, and the main rationale for treatment is to delay the progression. Significant controversy remains regarding screening, surveillance, and treatment for AIN. Management options are separated into surveillance (watchful waiting) and interventional strategies. Emerging data suggest that close patient follow up with a combination of ablative and topical treatments may offer the greatest benefit. HPV vaccination offers a unique treatment prior to HPV infection and the subsequent development of AIN, but its use after the development of AIN is limited. Ablative treatment includes excision, fulguration, and laser therapy.},
	language = {eng},
	number = {3},
	journal = {Annals of Gastroenterology},
	author = {Siddharthan, Ragavan V. and Lanciault, Christian and Tsikitis, Vassiliki Liana},
	year = {2019},
	pmid = {31040622},
	pmcid = {PMC6479653},
	keywords = {Anal intraepithelial neoplasia, HPV-related squamous epithelial dysplasia, human papilloma virus (HPV)},
	pages = {257--263},
	file = {Full Text:/Users/jcsal/Zotero/storage/4QZC4X9V/Siddharthan et al. - 2019 - Anal intraepithelial neoplasia diagnosis, screening, and treatment.pdf:application/pdf},
}

@article{wei1496,
	title = {Impact of {Human} {Papillomavirus} {Vaccine} {Against} {Anal} {Human} {Papillomavirus} {Infection}, {Anal} {Intraepithelial} {Neoplasia}, and {Recurrence} of {Anal} {Intraepithelial} {Neoplasia}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {228},
	issn = {1537-6613},
	shorttitle = {Impact of {Human} {Papillomavirus} {Vaccine} {Against} {Anal} {Human} {Papillomavirus} {Infection}, {Anal} {Intraepithelial} {Neoplasia}, and {Recurrence} of {Anal} {Intraepithelial} {Neoplasia}},
	doi = {10.1093/infdis/jiad183},
	abstract = {BACKGROUND: We sought to summarize human papillomavirus (HPV) vaccine efficacy/effectiveness (VE) against anal HPV infection and anal intraepithelial neoplasia (AIN).
METHODS: We performed literature review and meta-analysis to estimate VE, stratified by age and analytic population (per-protocol efficacy [PPE] or intention-to-treat [ITT] population in clinical trials, or all participants in real-world studies).
RESULTS: We identified 6 clinical trials and 8 real-world studies. In participants vaccinated at age ≤26 years (mainly human immunodeficiency virus [HIV]-negative individuals), significant VE against incident/prevalent anal HPV infection was reported in clinical trials, with a higher estimate in PPE (2 studies with 2390 participants; VE, 84\% [95\% confidence interval (CI), 77\%-90\%]; I2 = 0\%) than ITT (2 studies with 4885 participants; 55\%, 39\%-67\%; I2 = 46\%) populations or in real-world studies (4 studies with 2375 participants; 77\%, 40\%-91\%; I2 = 81\%). HPV vaccination at age ≤26 years was associated with significant VE in preventing persistent anal HPV infection and AIN. No significant VE against anal HPV infection or AIN was found in persons vaccinated at age {\textgreater}26 years (mainly people living with HIV).
CONCLUSIONS: There is strong evidence for high VE against anal HPV infection and AIN in HIV-negative individuals vaccinated at age ≤26 years. However, the lower impact in ITT than in PPE populations and the lack of significant effect in people living with HIV aged {\textgreater}26 years indicates that vaccines have the higher impact in populations with less sexual exposure to anal HPV.},
	language = {eng},
	number = {11},
	journal = {The Journal of Infectious Diseases},
	author = {Wei, Feixue and Alberts, Catharina J. and Albuquerque, Andreia and Clifford, Gary M.},
	month = nov,
	year = {2023},
	pmid = {37257044},
	keywords = {Humans, Adult, Carcinoma in Situ, Anus Neoplasms, anus, clinical trials, HIV Infections, human papillomavirus, Human Papillomavirus Viruses, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, real-world studies, vaccine},
	pages = {1496--1504},
	file = {PDF:/Users/jcsal/Zotero/storage/WCSE54VX/Wei et al. - 2023 - Impact of Human Papillomavirus Vaccine Against Anal Human Papillomavirus Infection, Anal Intraepithe.pdf:application/pdf},
}

@article{hoeppnerLBA1,
	title = {Prospective randomized multicenter phase {III} trial comparing perioperative chemotherapy ({FLOT} protocol) to neoadjuvant chemoradiation ({CROSS} protocol) in patients with adenocarcinoma of the esophagus ({ESOPEC} trial).},
	volume = {42},
	issn = {0732-183X},
	url = {https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA1},
	doi = {10.1200/JCO.2024.42.17_suppl.LBA1},
	abstract = {LBA1
Background: The most effective multimodal approach for treatment of resectable locally advanced esophageal adenocarcinoma (EAC) is under debate. A prior ranking question is if neoadjuvant chemoradiation therapy or perioperative chemotherapy is superior. ESOPEC (NCT02509286) is a multicenter prospective randomized trial comparing neoadjuvant CROSS (41.4Gy plus carboplatin/paclitaxel) followed by surgery versus perioperative FLOT (5-FU/ leucovorin/oxaliplatin/docetaxel) and surgery for the curative treatment of EAC. Methods: Patients with cT1 cN+ cM0 or cT2-4a cNany cM0 resectable EAC were eligible. The primary endpoint is overall survival (OS; 90\% power; hazard ratio [HR] 0.645, 218 events needed; one sided significance level of 2.5\%). Analysis is by intention-to-treat in all randomized patients. The effect of treatment on OS is estimated using Cox regression stratified by study site, and including N stage (N0, N+), and age as covariates. Results: Between Feb 2016 and Apr 2020, 438 patients from 25 sites in Germany were randomly assigned to two treatment groups (221 FLOT; 217 CROSS). Baseline characteristics (male sex 89.3\%, median age 63 [range 30-86], cT3/4 80.5\%; cN+ 79.7\%) were well balanced between both arms. Neoadjuvant treatment was started in 403 patients (207 FLOT; 196 CROSS). Surgery was done in 371 patients (191 FLOT; 180 CROSS). R0 resection was achieved in 351 patients (180 FLOT; 171 CROSS). 90 days postsurgical mortality was 4.3\% (3.2\% FLOT; 5.6\% CROSS). After a median follow up of 55 months, 218 patients had died (97 FLOT; 121 CROSS). Median OS was 66 (95\% CI 36 – not estimable) months in the FLOT arm, and 37 (95\% CI 28 – 43) months in the CROSS arm. The 3-year OS rates were 57.4\% (95\% CI 50.1 – 64.0\%) for FLOT and 50.7\% (95\% CI 43.5 – 57.5\%) for CROSS (HR 0.70, 95\% CI 0.53-0.92, p=0.012). In 359 patients with available tumor regression status, pathological complete response was achieved in 35 (19.3\%, 95\%-CI 13.9 – 25.9\%) in FLOT and in 24 (13.5\%, 95\%-CI 8.8 – 19.4\%) in CROSS. Conclusions: Perioperative FLOT improves survival in resectable EAC compared to neoadjuvant CROSS. Funding: The trial was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project number 264590883. Clinical trial information: NCT02509286.},
	number = {17\_suppl},
	urldate = {2024-11-06},
	journal = {Journal of Clinical Oncology},
	author = {Hoeppner, Jens and Brunner, Thomas and Lordick, Florian and Schmoor, Claudia and Kulemann, Birte and Neumann, Ulf Peter and Folprecht, Gunnar and Keck, Tobias and Benedix, Frank and Schmeding, Maximilan and Reitsamer, Ernst and Bruns, Christiane J. and Lock, Johan F. and Reichert, Benedikt and Ghadimi, Michael and Wille, Kai and Gockel, Ines and Izbicki, Jakob R. and Utzolino, Stefan and Grimminger, Peter Philipp},
	month = jun,
	year = {2024},
	note = {Publisher: Wolters Kluwer},
	pages = {LBA1--LBA1},
}

@article{lagergren159a,
	title = {Patient {Age} and {Survival} {After} {Surgery} for {Esophageal} {Cancer}},
	volume = {28},
	issn = {1534-4681},
	doi = {10.1245/s10434-020-08653-w},
	abstract = {BACKGROUND: Esophagectomy for esophageal cancer is associated with a substantial risk of life-threatening complications and a limited long-term survival. This study aimed to clarify the controversial questions of how age influences short-term and long-term survival.
METHODS: This population-based cohort study included almost all patients who underwent curatively intended esophagectomy for esophageal cancer in Sweden in 1987-2010, with follow-up through 2016. The exposure was age, analyzed both as a continuous and categorical variable. The probability of mortality was computed using a novel flexible parametric model approach. The reported probabilities are proper measures of the risk of dying, and the related odds ratios (OR) are therefore more suitable measures of association than hazard ratios. The outcomes were 90-day all-cause mortality, 5-year all-cause mortality, and 5-year disease-specific mortality. A novel flexible parametric model was used to derive the instantaneous probability of dying and the related OR along with 95\% confidence intervals (CIs), adjusted for sex, education, comorbidity, tumor histology, pathological tumor stage, and resection margin status.
RESULTS: Among 1737 included patients, the median age was 65.6 years. When analyzed as a continuous variable, older age was associated with slightly higher odds of 90-day all-cause mortality (OR 1.05, 95\% CI 1.02-1.07), 5-year all-cause mortality (OR 1.02, 95\% CI 1.01-1.03), and 5-year disease-specific mortality (OR 1.01, 95\% CI 1.01-1.02). Compared with patients aged {\textless} 70 years, those aged 70-74 years had no increased risk of any mortality outcome, while patients aged ≥ 75 years had higher odds of 90-day mortality (OR 2.85, 95\% CI 1.68-4.84), 5-year all-cause mortality (OR 1.56, 95\% CI 1.27-1.92), and 5-year disease-specific mortality (OR 1.38, 95\% CI 1.09-1.76).
CONCLUSIONS: Patient age 75 years or older at esophagectomy for esophageal cancer appears to be an independent risk factor for higher short-term mortality and lower long-term survival.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgical Oncology},
	author = {Lagergren, Jesper and Bottai, Matteo and Santoni, Giola},
	month = jan,
	year = {2021},
	pmid = {32468352},
	pmcid = {PMC7752878},
	keywords = {Humans, Aged, Female, Male, Treatment Outcome, Prognosis, Cohort Studies, Age Factors, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Sweden},
	pages = {159--166},
	file = {Full Text:/Users/jcsal/Zotero/storage/D9W4NKB7/Lagergren et al. - 2021 - Patient Age and Survival After Surgery for Esophageal Cancer.pdf:application/pdf},
}

@article{han897,
	title = {Clinical outcomes of oesophagectomy in elderly versus relatively younger patients: a meta-analysis},
	volume = {29},
	issn = {1569-9285},
	shorttitle = {Clinical outcomes of oesophagectomy in elderly versus relatively younger patients},
	doi = {10.1093/icvts/ivz208},
	abstract = {OBJECTIVES: The surgical efficacy of oesophagectomy for elderly patients ({\textgreater}80 years old) is still unclear. The aim of this meta-analysis was to compare the clinical outcomes of oesophagectomy between elderly and relatively younger patients.
METHODS: PubMed, EMBASE and the Cochrane Library were searched for relevant studies comparing the clinical outcomes of oesophagectomy for elderly and relatively younger patients. Odds ratios were extracted to obtain pooled estimates of the perioperative effect, and hazard ratios were extracted to compare survival outcomes between the 2 cohorts.
RESULTS: Nine studies involving 4946 patients were included in this meta-analysis. For patients older than 80 years of age, in-hospital mortality [odds ratio (OR) 2.00, 95\% confidence interval (CI) 1.28-3.13; P = 0.002] and the incidence rates of cardiac (OR 1.55, 95\% CI 1.10-2.20; P = 0.01) and pulmonary (OR 1.57, 95\% CI 1.11-2.22; P = 0.01) complications were higher than those of relatively younger patients. The overall postoperative complication rate (OR 1.40, 95\% CI 0.82-2.40; P = 0.22) and the incidence of anastomotic leak (OR 0.92, 95\% CI 0.58-1.47; P = 0.73) were not significantly different between the 2 groups. Elderly patients had a worse overall 5-year survival rate (HR 2.66, 95\% CI 1.65-4.28; P {\textless} 0.001) than that of relatively younger patients. The cancer-related 5-year survival rate of elderly patients was also lower than that of relatively younger patients (HR 3.37, 95\% CI 2.36-4.82; P {\textless} 0.001).
CONCLUSIONS: Compared with relatively younger patients, elderly patients with oesophageal cancer undergoing oesophagectomy are at higher risk of in-hospital mortality and have lower survival rates. However, there is no conclusive evidence that the overall rate of complications is elevated in elderly patients.},
	language = {eng},
	number = {6},
	journal = {Interactive Cardiovascular and Thoracic Surgery},
	author = {Han, Yu and Liu, Shengjun and Guo, Wei and Zhang, Yajie and Li, Hecheng},
	month = dec,
	year = {2019},
	pmid = {31765482},
	keywords = {Humans, Aged, Risk Factors, Survival Rate, Aged, 80 and over, Age Factors, Meta-analysis, Esophageal Neoplasms, Esophagectomy, Oesophageal cancer, Anastomotic Leak, Hospital Mortality, Surgery, Global Health},
	pages = {897--905},
	file = {Full Text:/Users/jcsal/Zotero/storage/ELVDCJ7L/Han et al. - 2019 - Clinical outcomes of oesophagectomy in elderly versus relatively younger patients a meta-analysis.pdf:application/pdf},
}

@article{kamarajah1828,
	title = {Elderly patients have increased perioperative morbidity and mortality from oesophagectomy for oesophageal cancer: {A} systematic review and meta-analysis},
	volume = {47},
	issn = {1532-2157},
	shorttitle = {Elderly patients have increased perioperative morbidity and mortality from oesophagectomy for oesophageal cancer},
	doi = {10.1016/j.ejso.2021.02.030},
	abstract = {BACKGROUND: Although oesophagectomy remains technically challenging and associated with high morbidity and mortality, it is now increasingly performed in an ever-ageing population with improvement in perioperative care. However, the risks in the elderly population are poorly quantified. The study aims to review the current evidence to quantify further the postoperative risk of oesophagectomy for cancer in the elderly population compared to younger patients.
METHOD: A systematic literature search of PubMed, EMBASE and the Cochrane Library databases was conducted including studies reporting oesophagectomy for cancer in the elderly population. A meta-analysis was reported in accordance with the recommendations of the Cochrane Library and PRISMA guidelines. Primary outcome was overall complications and secondary outcomes were pulmonary and cardiac complications, anastomotic leaks, overall and disease-free survival.
RESULTS: This review identified 37 studies incorporating 30,836 patients. Increasing age was significantly associated with increased rates of overall complications (OR 1.67, CI95\%: 1.42-1.96), pulmonary complications (OR 1.87, CI95\%: 1.48-2.35), and cardiac complications (OR: 2.22, CI95\%: 1.95-2.53). However, there was no increased risk of anastomotic leak (OR: 0.98, CI95\%: 0.85-1.18). Elderly patients were significantly more likely to have lower rates of 5-year overall survival (OR: 1.36, CI95\%: 1.11-1.66) and 5-year disease-free survival (OR: 1.72, CI95\%: 1.51-1.96).
CONCLUSION: Elderly patients undergoing oesophagectomy for cancer are at increased risk of overall, pulmonary and cardiac complications, irrespective of age subgroups, albeit no difference in anastomotic leaks. Therefore, they represent high-risk patients warranting implementation of preoperative pathways such as prehabilitation to improve cardiopulmonary fitness prior to surgery, although benefit of prehabilitation is yet to be proven. This information will also aid future pre-operative counselling and informed consent.},
	language = {eng},
	number = {8},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Kamarajah, Sivesh K. and Gujjuri, Rohan R. and Elhadi, Muhammed and Umar, Hamza and Bundred, James R. and Subramanya, Manjunath S. and Evans, Richard Pt and Powell, Susan L. and Griffiths, Ewen A.},
	month = aug,
	year = {2021},
	pmid = {33814241},
	keywords = {Humans, Aged, Middle Aged, Aged, 80 and over, Age Factors, Adenocarcinoma, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Esophageal Squamous Cell Carcinoma, Postoperative Complications, Heart Diseases, Anastomotic Leak, Mortality, Survival, Cancer, Outcomes, Elderly, Lung Diseases, Oesophagectomy, Leaks},
	pages = {1828--1835},
}

@article{wang1553,
	title = {Prognostic {Factors} and {Outcomes} in {Elderly} {Esophagectomy} {Patients} with {Esophageal} {Cancer}},
	volume = {31},
	issn = {1534-4681},
	doi = {10.1245/s10434-023-14634-6},
	abstract = {BACKGROUND: Choosing the appropriate treatment for elderly patients with esophageal cancer remains a contentious issue. While surgery is still a valid option, we aimed to identify predictors and outcomes in elderly esophagectomy patients with esophageal cancer.
PATIENTS AND METHODS: We analyzed characteristics, surgical outcomes, survival rates, cause-specific mortality, and recurrence in 120 patients with stage I-IV esophageal cancer. Univariate and multivariate analyses were used to identify risk factors for event-free survival (EFS) and overall survival (OS).
RESULTS: The median follow-up period was 31 months, with 5-year overall survival (OS) and event-free survival (EFS) rates standing at 45.2\% and 41.5\%, respectively. Notably, lower body mass index (BMI ≤ 22 kg/m2) and reduced preoperative albumin levels (pre-ALB {\textless} 40 g/L) led to a significant decrease in OS rates. Postoperative pulmonary complications resulted in higher in-hospital and 90-day mortality rates. After about 31 months post-surgery, the rate of cancer-specific deaths stabilized. The most common sites for distant metastasis were the lungs, supraclavicular lymph nodes, liver, and bone. The study identified lower BMI, lower pre-ALB levels, and postoperative pulmonary complications as independent risk factors for poorer EFS and OS outcomes.
CONCLUSIONS: Esophagectomy remains a safe and feasible treatment for elderly patients, though the prevention of postoperative pulmonary infection is crucial. Factors such as lower BMI, lower pre-ALB levels, advanced tumor stage, postoperative pulmonary complications, and certain treatment modalities significantly influence the outcomes in elderly esophagectomy patients. These findings provide critical insights into the characteristics and outcomes of this patient population.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgical Oncology},
	author = {Wang, Peiyuan and Lei, Mengxia and Chen, Yujie and He, Hao and Lin, Junpeng and Lin, Hui and Wei, Wenwei and Chen, Peng and Zhang, Derong and Chen, Weijie and Zhou, Hang and Gao, Pengqiang and Liu, Shuoyan and Wang, Feng},
	month = mar,
	year = {2024},
	pmid = {37996639},
	keywords = {Humans, Aged, Neoplasm Staging, Retrospective Studies, Survival Rate, Prognosis, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Lymph Nodes},
	pages = {1553--1561},
}

@article{skorus341,
	title = {Outcome of esophageal cancer in the elderly - systematic review of the literature},
	volume = {12},
	issn = {1895-4588},
	doi = {10.5114/wiitm.2017.72318},
	abstract = {INTRODUCTION: As the population ages, the number of elderly patients with esophageal cancer increases. Esophageal cancer has a poor prognosis and is associated with decreased life quality.
AIM: To review the literature about the outcome of esophageal cancer in patients over 65.
MATERIAL AND METHODS: Articles published between January 2006 and November 2016 in the PubMed/Medline and ResearchGate databases were reviewed. Nineteen retrospective studies were included.
RESULTS: Six thousand seven hundred and twenty-nine patients over 65 were analyzed. Thirty-day mortality ranges from 3.2\% to 8.1\%. Overall 5-year survival rates range from 0\% to 49.2\%, and the median survival rate ranges from 9.6 to 108.2 months. The incidence of complications in the surgery group ranges from 27\% to 69\%. Chemoradiotherapy grade ≥ 3 toxicity was observed in 22-36\% of patients.
CONCLUSIONS: Chronological age seems to have little influence on outcome of esophageal cancer. Open esophagectomy seems to be the mainstay of treatment for patients with esophageal cancer, regardless of age. There is still high mortality and morbidity involved in this procedure. To reduce them, some less invasive methods are being trialed.},
	language = {eng},
	number = {4},
	journal = {Wideochirurgia I Inne Techniki Maloinwazyjne = Videosurgery and Other Miniinvasive Techniques},
	author = {Skorus, Urszula A. and Kenig, Jakub},
	month = dec,
	year = {2017},
	pmid = {29362648},
	pmcid = {PMC5776485},
	keywords = {chemotherapy, esophageal cancer, esophagectomy, outcomes, elderly, minimally invasive surgery},
	pages = {341--349},
	file = {Full Text:/Users/jcsal/Zotero/storage/FT6S6BV3/Skorus and Kenig - 2017 - Outcome of esophageal cancer in the elderly - systematic review of the literature.pdf:application/pdf},
}

@article{schlottmann9,
	title = {Postoperative outcomes of esophagectomy for cancer in elderly patients},
	volume = {229},
	issn = {1095-8673},
	doi = {10.1016/j.jss.2018.03.050},
	abstract = {BACKGROUND: The number of elderly patients with esophageal cancer is expected to increase. We aimed to determine the postoperative outcomes of esophagectomy for esophageal cancer in elderly patients.
MATERIAL AND METHODS: A retrospective, population-based analysis was performed using the National inpatient sample for the period 2000-2014. Adult patients ≥18 years old (yo) diagnosed with esophageal cancer who underwent esophagectomy during their inpatient hospitalization were included. Patients were categorized into {\textless}70 yo and ≥70 yo. Multivariable linear and logistic regressions were used to assess the potential effect of age on postoperative complications, inpatient mortality, and hospital charges.
RESULTS: Overall, 5243 patients were included, with 3699 (70.6\%) {\textless}70 yo and 1544 (29.5\%) ≥70 yo. The yearly rate of esophagectomies among patients ≥70 yo did not significantly changed during the study period (28.4\% in 2000 and 26.3\% in 2014, P = 0.76). Elderly patients were significantly more likely to have postoperative cardiac failure (odds ratio 1.59, 95\% confidence interval [CI] 1.21, 2.09, P = 0.0009) and inpatient mortality (odds ratio 1.84, 95\% CI 1.39, 2.45, P {\textless} 0.0001). Among the elderly patients, hospital charges were, on average, \$16,320 greater (95\% CI \$3110, \$29,530) than patients {\textless}70 yo (P = 0.02). The predicted probability of mortality increased consistently across age (1.5\% in 40 yo, 2.5\% in 50 yo, 3.6\% in 60 yo, 5.4\% in 70 yo, and 7.0\% in 80 yo).
CONCLUSIONS: Elderly patients undergoing esophagectomy for cancer have a significantly higher risk of postoperative mortality and pose a higher financial burden on the health care system. Elderly patients with esophageal cancer should be carefully selected for surgery.},
	language = {eng},
	journal = {The Journal of Surgical Research},
	author = {Schlottmann, Francisco and Strassle, Paula D. and Nayyar, Apoorve and Herbella, Fernando A. M. and Cairns, Bruce A. and Patti, Marco G.},
	month = sep,
	year = {2018},
	pmid = {29937021},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Retrospective Studies, Age Factors, Databases, Factual, United States, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Hospital Mortality, Patient Selection, Mortality, Elective Surgical Procedures, Elderly, Postoperative Period, Hospital Charges},
	pages = {9--14},
}

@article{yamashita632,
	title = {The impact of the {Charlson} comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent},
	volume = {48},
	issn = {1436-2813},
	doi = {10.1007/s00595-018-1630-2},
	abstract = {PURPOSE: The aim of this study was to clarify the influence of Charlson comorbidity index (CCI) on treatment options, and on short- and mid-term outcomes in esophageal cancer patients who underwent esophagectomy.
METHODS: Patients who underwent curative-intent esophagectomy from 2009 to 2014 were classified by CCI. A CCI of ≥ 2 was defined as high, while a CCI of 0 or 1 was classified as low. Clinicopathological parameters, including overall survival (OS) and disease-specific survival (DSS), were compared between the groups.
RESULTS: Among 548 patients, the most frequent comorbidity was chronic obstructive pulmonary disease (n = 142, 25.9\%), followed by solid tumor (n = 79, 14.4\%). A high CCI was significantly correlated with older age (P {\textless} 0.001), surgery alone (P = 0.020), a lower number of dissected lymph nodes (P {\textless} 0.001), lower rate of R0 resection (P = 0.048), and prolonged hospital stay (P {\textless} 0.001). In the low group, OS after surgery was favorable in comparison to the the high group. Although DSS was comparable between the groups, the CCI was significantly associated with a poor prognosis in patients with stage ≥ II disease.
CONCLUSIONS: The CCI was significantly correlated with the prognosis of esophageal cancer patients who underwent curative-intent esophagectomy.},
	language = {eng},
	number = {6},
	journal = {Surgery Today},
	author = {Yamashita, Kotaro and Watanabe, Masayuki and Mine, Shinji and Fukudome, Ian and Okamura, Akihiko and Yuda, Masami and Hayami, Masaru and Imamura, Yu},
	month = jun,
	year = {2018},
	pmid = {29383595},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Survival Rate, Prognosis, Aged, 80 and over, Adult, Age Factors, Esophageal Neoplasms, Esophagectomy, Comorbidity, Overall survival, Comorbidity burden, Disease-specific survival, Pulmonary Disease, Chronic Obstructive},
	pages = {632--639},
}

@article{backemar1097,
	title = {Impact of co-morbidity on mortality after oesophageal cancer surgery},
	volume = {102},
	issn = {1365-2168},
	doi = {10.1002/bjs.9854},
	abstract = {BACKGROUND: There is limited knowledge of how co-morbidities influence survival after surgery for oesophageal cancer. This population-based cohort study investigated how Charlson co-morbidity index and specific co-morbidities influenced all-cause and disease-specific mortality.
METHODS: Data from all patients who underwent oesophageal cancer surgery in Sweden in 1987-2010, with follow-up until 2012, came from histopathology records, operation charts and nationwide registers. Associations between co-morbidities (Charlson co-morbidity index) and mortality were analysed using Cox proportional hazard regression with adjustment for potential confounding, and presented as hazard ratio (HR) with 95 per cent c.i.
RESULTS: Among 1822 patients there were 1474 deaths (80.9 per cent), of which 1139 (77.3 per cent) occurred between 91 days and 5 years after surgery. Overall all-cause mortality was increased in patients with a Charlson score of 2 or more (HR 1.24, 95 per cent c.i. 1.08 to 1.42), and those with a history of myocardial infarction (HR 1.23, 1.01 to 1.49) or congestive heart failure (HR 1.31, 1.04 to 1.67). Patients with squamous cell carcinoma had increased overall all-cause mortality if they had been diagnosed with cerebrovascular disease (HR 1.35, 1.00 to 1.83) or other cancers (HR 1.36, 1.09 to 1.71), whereas those with adenocarcinoma did not. A Charlson score of 1 or exposure to the co-morbidity groups peripheral vascular disease, chronic pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes and liver disease did not increase mortality. The disease-specific results were generally similar to the all-cause mortality data.
CONCLUSION: Co-morbidity with a Charlson score of 2 or more, previous myocardial infarction and congestive heart failure were associated with increased mortality after oesophageal cancer surgery undertaken with curative intent.},
	language = {eng},
	number = {9},
	journal = {The British Journal of Surgery},
	author = {Backemar, L. and Lagergren, P. and Johar, A. and Lagergren, J.},
	month = aug,
	year = {2015},
	pmid = {26059747},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Follow-Up Studies, Retrospective Studies, Proportional Hazards Models, Aged, 80 and over, Adult, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Comorbidity, Registries, Sweden},
	pages = {1097--1105},
}

@article{vanderwilk467,
	title = {Chemoradiotherapy {Followed} by {Active} {Surveillance} {Versus} {Standard} {Esophagectomy} for {Esophageal} {Cancer}: {A} {Systematic} {Review} and {Individual} {Patient} {Data} {Meta}-analysis},
	volume = {275},
	issn = {1528-1140},
	shorttitle = {Chemoradiotherapy {Followed} by {Active} {Surveillance} {Versus} {Standard} {Esophagectomy} for {Esophageal} {Cancer}},
	doi = {10.1097/SLA.0000000000004930},
	abstract = {OBJECTIVE: To compare overall survival of patients with a cCR undergoing active surveillance versus standard esophagectomy.
SUMMARY OF BACKGROUND DATA: One-third of patients with esophageal cancer have a pathologically complete response in the resection specimen after neoadjuvant chemoradiotherapy. Active surveillance may be of benefit in patients with cCR, determined with diagnostics during response evaluations after chemoradiotherapy.
METHODS: A systematic review and meta-analysis was performed comparing overall survival between patients with cCR after chemoradiotherapy undergoing active surveillance versus standard esophagectomy. Authors were contacted to supply individual patient data. Overall and progression-free survival were compared using random effects meta-analysis of randomized or propensity score matched data. Locoregional recurrence rate was assessed. The study-protocol was registered (PROSPERO: CRD42020167070).
RESULTS: Seven studies were identified comprising 788 patients, of which after randomization or propensity score matching yielded 196 active surveillance and 257 standard esophagectomy patients. All authors provided individual patient data. The risk of all-cause mortality for active surveillance was 1.08 [95\% confidence interval (CI): 0.62-1.87, P = 0.75] after intention-to-treat analysis and 0.93 (95\% CI: 0.56-1.54, P = 0.75) after per-protocol analysis. The risk of progression or all-cause mortality for active surveillance was 1.14 (95\% CI: 0.83-1.58, P = 0.36). Five-year locoregional recurrence rate during active surveillance was 40\% (95\% CI: 26\%-59\%). 95\% of active surveillance patients undergoing postponed esophagectomy for locoregional recurrence had radical resection.
CONCLUSIONS: Overall survival was comparable in patients with cCR after chemoradiotherapy undergoing active surveillance or standard esophagectomy. Diagnostic follow-up is mandatory in active surveillance and postponed esophagectomy should be offered to operable patients in case of locoregional recurrence.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgery},
	author = {van der Wilk, Berend J. and Eyck, Ben M. and Hofstetter, Wayne L. and Ajani, Jaffer A. and Piessen, Guillaume and Castoro, Carlo and Alfieri, Rita and Kim, Jong H. and Kim, Sung-Bae and Furlong, Heidi and Walsh, Thomas N. and Nieboer, Daan and Wijnhoven, Bas P. L. and Lagarde, Sjoerd M. and Lanschot, J. Jan B. van},
	month = mar,
	year = {2022},
	pmid = {34191461},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Watchful Waiting, Patient Generated Health Data},
	pages = {467--476},
}

@article{leong1810,
	title = {Preoperative {Chemoradiotherapy} for {Resectable} {Gastric} {Cancer}},
	volume = {391},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2405195},
	abstract = {BACKGROUND: In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone.
METHODS: We conducted an international, phase 3 trial in which patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone (control). In both groups, patients received either epirubicin, cisplatin, and fluorouracil or fluorouracil, leucovorin, oxaliplatin, and docetaxel both before and after surgery; the preoperative-chemoradiotherapy group also received chemoradiotherapy (45 Gy in 25 fractions of radiation, plus fluorouracil infusion). The primary end point was overall survival, and secondary end points included progression-free survival, pathological complete response, toxic effects, and quality of life.
RESULTS: A total of 574 patients underwent randomization at 70 sites in Australasia, Canada, and Europe: 286 to the preoperative-chemoradiotherapy group and 288 to the perioperative-chemotherapy group. A higher percentage of patients in the preoperative-chemoradiotherapy group than in the perioperative-chemotherapy group had a pathological complete response (17\% vs. 8\%) and greater tumor downstaging after resection. At a median follow-up of 67 months, no significant between-group differences in overall survival or progression-free survival were noted. The median overall survival was 46 months with preoperative chemoradiotherapy and 49 months with perioperative chemotherapy (hazard ratio for death, 1.05; 95\% confidence interval, 0.83 to 1.31), and the median progression-free survival was 31 months and 32 months, respectively. Treatment-related toxic effects were similar in the two groups.
CONCLUSIONS: The addition of preoperative chemoradiotherapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone among patients with resectable gastric and gastroesophageal junction adenocarcinoma. (Funded by the National Health and Medical Research Council and others; TOPGEAR ClinicalTrials.gov number, NCT01924819.).},
	language = {eng},
	number = {19},
	journal = {The New England Journal of Medicine},
	author = {Leong, Trevor and Smithers, B. Mark and Michael, Michael and Haustermans, Karin and Wong, Rebecca and Gebski, Val and O'Connell, Rachel L. and Zalcberg, John and Boussioutas, Alex and Findlay, Michael and Willis, David and Moore, Alisha and Murray, William K. and Lordick, Florian and O'Callaghan, Chris and Swallow, Carol and Darling, Gail and Miller, Danielle and Strickland, Andrew and Liberman, Moishe and Mineur, Laurent and Simes, John and {Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group}},
	month = nov,
	year = {2024},
	pmid = {39282905},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols, Progression-Free Survival, Fluorouracil, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Cisplatin, Dose Fractionation, Radiation, Esophagogastric Junction, Quality of Life, Epirubicin},
	pages = {1810--1821},
	file = {PDF:/Users/jcsal/Zotero/storage/4LEV4PKC/Leong et al. - 2024 - Preoperative Chemoradiotherapy for Resectable Gastric Cancer.pdf:application/pdf},
}

@article{cats616,
	title = {Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer ({CRITICS}): an international, open-label, randomised phase 3 trial},
	volume = {19},
	issn = {1474-5488},
	shorttitle = {Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer ({CRITICS})},
	doi = {10.1016/S1470-2045(18)30132-3},
	abstract = {BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies have not been investigated in a head to head comparison. We aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma.
METHODS: In this investigator-initiated, open-label, randomised phase 3 trial, we enrolled patients aged 18 years or older who had stage IB- IVA resectable gastric or gastro-oesophageal adenocarcinoma (as defined by the American Joint Committee on Cancer, sixth edition), with a WHO performance status of 0 or 1, and adequate cardiac, bone marrow, liver, and kidney function. Patients were enrolled from 56 hospitals in the Netherlands, Sweden, and Denmark, and were randomly assigned (1:1) with a computerised minimisation programme with a random element to either perioperative chemotherapy (chemotherapy group) or preoperative chemotherapy with postoperative chemoradiotherapy (chemoradiotherapy group). Randomisation was done before patients were given any preoperative chemotherapy treatment and was stratified by histological subtype, tumour localisation, and hospital. Patients and investigators were not masked to treatment allocation. Surgery consisted of a radical resection of the primary tumour and at least a D1+ lymph node dissection. Postoperative treatment started within 4-12 weeks after surgery. Chemotherapy consisted of three preoperative 21-day cycles and three postoperative cycles of intravenous epirubicin (50 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) or oxaliplatin (130 mg/m2 on day 1), and capecitabine (1000 mg/m2 orally as tablets twice daily for 14 days in combination with epirubicin and cisplatin, or 625 mg/m2 orally as tablets twice daily for 21 days in combination with epirubicin and oxaliplatin), received once every three weeks. Chemoradiotherapy consisted of 45 Gy in 25 fractions of 1·8 Gy, for 5 weeks, five daily fractions per week, combined with capecitabine (575 mg/m2 orally twice daily on radiotherapy days) and cisplatin (20 mg/m2 intravenously on day 1 of each 5 weeks of radiation treatment). The primary endpoint was overall survival, analysed by intention-to-treat. The CRITICS trial is registered at ClinicalTrials.gov, number NCT00407186; EudraCT, number 2006-004130-32; and CKTO, 2006-02.
FINDINGS: Between Jan 11, 2007, and April 17, 2015, 788 patients were enrolled and randomly assigned to chemotherapy (n=393) or chemoradiotherapy (n=395). After preoperative chemotherapy, 372 (95\%) of 393 patients in the chemotherapy group and 369 (93\%) of 395 patients in the chemoradiotherapy group proceeded to surgery, with a potentially curative resection done in 310 (79\%) of 393 patients in the chemotherapy group and 326 (83\%) of 395 in the chemoradiotherapy group. Postoperatively, 233 (59\%) of 393 patients started chemotherapy and 245 (62\%) of 395 started chemoradiotherapy. At a median follow-up of 61·4 months (IQR 43·3-82·8), median overall survival was 43 months (95\% CI 31-57) in the chemotherapy group and 37 months (30-48) in the chemoradiotherapy group (hazard ratio from stratified analysis 1·01 (95\% CI 0·84-1·22; p=0·90). After preoperative chemotherapy, in the total safety population of 781 patients (assessed together), there were 368 (47\%) grade 3 adverse events; 130 (17\%) grade 4 adverse events, and 13 (2\%) deaths. Causes of death during preoperative treatment were diarrhoea (n=2), dihydropyrimidine deficiency (n=1), sudden death (n=1), cardiovascular events (n=8), and functional bowel obstruction (n=1). During postoperative treatment, grade 3 and 4 adverse events occurred in 113 (48\%) and 22 (9\%) of 233 patients in the chemotherapy group, respectively, and in 101 (41\%) and ten (4\%) of 245 patients in the chemoradiotherapy group, respectively. Non-febrile neutropenia occurred more frequently during postoperative chemotherapy (79 [34\%] of 233) than during postoperative chemoradiotherapy (11 [4\%] of 245). No deaths were observed during postoperative treatment.
INTERPRETATION: Postoperative chemoradiotherapy did not improve overall survival compared with postoperative chemotherapy in patients with resectable gastric cancer treated with adequate preoperative chemotherapy and surgery. In view of the poor postoperative patient compliance in both treatment groups, future studies should focus on optimising preoperative treatment strategies.
FUNDING: Dutch Cancer Society, Dutch Colorectal Cancer Group, and Hoffmann-La Roche.},
	language = {eng},
	number = {5},
	journal = {The Lancet. Oncology},
	author = {Cats, Annemieke and Jansen, Edwin P. M. and van Grieken, Nicole C. T. and Sikorska, Karolina and Lind, Pehr and Nordsmark, Marianne and Meershoek-Klein Kranenbarg, Elma and Boot, Henk and Trip, Anouk K. and Swellengrebel, H. A. Maurits and van Laarhoven, Hanneke W. M. and Putter, Hein and van Sandick, Johanna W. and van Berge Henegouwen, Mark I. and Hartgrink, Henk H. and van Tinteren, Harm and van de Velde, Cornelis J. H. and Verheij, Marcel and {CRITICS investigators}},
	month = may,
	year = {2018},
	pmid = {29650363},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Time Factors, Progression-Free Survival, Chemotherapy, Adjuvant, Stomach Neoplasms, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Dose Fractionation, Radiation, Gastrectomy, Lymph Node Excision, Quality of Life, Europe, Medication Adherence},
	pages = {616--628},
}

@article{patel813,
	title = {Neoadjuvant-{Adjuvant} or {Adjuvant}-{Only} {Pembrolizumab} in {Advanced} {Melanoma}},
	volume = {388},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2211437},
	abstract = {BACKGROUND: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown.
METHODS: In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses) for approximately 1 year or until disease recurred or unacceptable toxic effects developed (adjuvant-only group). The primary end point was event-free survival in the intention-to-treat population. Events were defined as disease progression or toxic effects that precluded surgery; the inability to resect all gross disease; disease progression, surgical complications, or toxic effects of treatment that precluded the initiation of adjuvant therapy within 84 days after surgery; recurrence of melanoma after surgery; or death from any cause. Safety was also evaluated.
RESULTS: At a median follow-up of 14.7 months, the neoadjuvant-adjuvant group (154 patients) had significantly longer event-free survival than the adjuvant-only group (159 patients) (P = 0.004 by the log-rank test). In a landmark analysis, event-free survival at 2 years was 72\% (95\% confidence interval [CI], 64 to 80) in the neoadjuvant-adjuvant group and 49\% (95\% CI, 41 to 59) in the adjuvant-only group. The percentage of patients with treatment-related adverse events of grades 3 or higher during therapy was 12\% in the neoadjuvant-adjuvant group and 14\% in the adjuvant-only group.
CONCLUSIONS: Among patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified. (Funded by the National Cancer Institute and Merck Sharp and Dohme; S1801 ClinicalTrials.gov number, NCT03698019.).},
	language = {eng},
	number = {9},
	journal = {The New England Journal of Medicine},
	author = {Patel, Sapna P. and Othus, Megan and Chen, Yuanbin and Wright, G. Paul and Yost, Kathleen J. and Hyngstrom, John R. and Hu-Lieskovan, Siwen and Lao, Christopher D. and Fecher, Leslie A. and Truong, Thach-Giao and Eisenstein, Jennifer L. and Chandra, Sunandana and Sosman, Jeffrey A. and Kendra, Kari L. and Wu, Richard C. and Devoe, Craig E. and Deutsch, Gary B. and Hegde, Aparna and Khalil, Maya and Mangla, Ankit and Reese, Amy M. and Ross, Merrick I. and Poklepovic, Andrew S. and Phan, Giao Q. and Onitilo, Adedayo A. and Yasar, Demet G. and Powers, Benjamin C. and Doolittle, Gary C. and In, Gino K. and Kokot, Niels and Gibney, Geoffrey T. and Atkins, Michael B. and Shaheen, Montaser and Warneke, James A. and Ikeguchi, Alexandra and Najera, Jose E. and Chmielowski, Bartosz and Crompton, Joseph G. and Floyd, Justin D. and Hsueh, Eddy and Margolin, Kim A. and Chow, Warren A. and Grossmann, Kenneth F. and Dietrich, Eliana and Prieto, Victor G. and Lowe, Michael C. and Buchbinder, Elizabeth I. and Kirkwood, John M. and Korde, Larissa and Moon, James and Sharon, Elad and Sondak, Vernon K. and Ribas, Antoni},
	month = mar,
	year = {2023},
	pmid = {36856617},
	pmcid = {PMC10410527},
	keywords = {Humans, Neoadjuvant Therapy, Disease Progression, Chemotherapy, Adjuvant, Antineoplastic Agents, Immunological, Melanoma, Adjuvants, Immunologic, Skin Neoplasms},
	pages = {813--823},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/IJECMMQ4/Patel et al. - 2023 - Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.pdf:application/pdf},
}

@article{hiekene390614,
	title = {Neoadjuvant {Immunotherapy} in {Melanoma}: {The} {Paradigm} {Shift}},
	volume = {43},
	issn = {1548-8756},
	shorttitle = {Neoadjuvant {Immunotherapy} in {Melanoma}},
	doi = {10.1200/EDBK_390614},
	abstract = {Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with or without in-transit metastases, represents approximately 15\% of new melanoma diagnoses every year with additional cases presenting as recurrent nodal disease following previous treatment of a primary melanoma. The standard of care for patients with resectable clinical stage III melanoma is surgical resection, consisting of therapeutic lymph node dissection and/or resection of in-transit disease and consideration of adjuvant systemic therapy and occasionally adjuvant radiation. These patients have high rates of regional recurrence and progression to metastatic disease postsurgery, highlighting the need for better treatment options. With the success of immune checkpoint inhibitors in both the adjuvant and metastatic settings, the use of these agents in the neoadjuvant setting has been an emerging area of research interest. In this chapter, we will discuss the rationale for neoadjuvant immunotherapy; review impactful clinical trials; and define response monitoring, surgical considerations, emerging therapies, and unanswered questions for neoadjuvant therapy as a recent paradigm shift in the management of clinical stage III melanoma.},
	language = {eng},
	journal = {American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting},
	author = {Hieken, Tina J. and Kreidieh, Firas and Aedo-Lopez, Veronica and Block, Matthew S. and McArthur, Grant A. and Amaria, Rodabe N.},
	month = jan,
	year = {2023},
	pmid = {37116111},
	keywords = {Humans, Neoadjuvant Therapy, Immunotherapy, Melanoma, Skin Neoplasms, Melanoma, Cutaneous Malignant},
	pages = {e390614},
	file = {Full Text:/Users/jcsal/Zotero/storage/3LSLXKXL/Hieken et al. - 2023 - Neoadjuvant Immunotherapy in Melanoma The Paradigm Shift.pdf:application/pdf},
}

@article{huffmane2200420,
	title = {Analysis of {Circulating} {Tumor} {DNA} to {Predict} {Risk} of {Recurrence} in {Patients} {With} {Esophageal} and {Gastric} {Cancers}},
	volume = {6},
	issn = {2473-4284},
	doi = {10.1200/PO.22.00420},
	abstract = {PURPOSE: Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in esophagogastric cancers (EGC) is less characterized and could identify high-risk patients who have been treated with curative intent.
METHODS: In this retrospective analysis of real-world data, ctDNA levels were analyzed in the preoperative, postoperative, and surveillance settings in patients with EGC using a personalized multiplex polymerase chain reaction-based next-generation sequencing assay. Plasma samples (n = 943) from 295 patients at {\textgreater} 70 institutions were collected before surgery, postoperatively, and/or serially during routine clinical follow-up from September 19, 2019, to February 21, 2022. ctDNA detection was annotated to clinicopathologic features and recurrence-free survival.
RESULTS: A total of 295 patients with EGC were analyzed, and 212 patients with stages I-III disease were further explored. Pretreatment ctDNA was detected in 96\% (23/24) of patients with preoperative time points. Postoperative ctDNA was detected in 23.5\% (16/68) of patients with stage I-III EGC within 16 weeks (molecular residual disease window) after surgery without receiving systemic therapy. ctDNA detection at any time point after surgery (hazard ratio [HR], 23.6; 95\% CI, 10.2 to 66.0; P {\textless} .0001), within the molecular residual disease window (HR, 10.7; 95\% CI, 4.3 to 29.3; P {\textless} .0001), and during the surveillance period (HR, 17.7; 95\% CI, 7.3 to 50.7; P {\textless} .0001) was associated with shorter recurrence-free survival. In multivariable analysis, ctDNA status and clinical stage of disease were independently associated with outcomes.
CONCLUSION: Using real-world data, we demonstrate that postoperative tumor-informed ctDNA detection in EGC is feasible and allows for enhanced patient risk stratification and prognostication during curative-intent therapy.},
	language = {eng},
	journal = {JCO precision oncology},
	author = {Huffman, Brandon M. and Aushev, Vasily N. and Budde, Griffin L. and Chao, Joseph and Dayyani, Farshid and Hanna, Diana and Botta, Gregory P. and Catenacci, Daniel V. T. and Maron, Steven B. and Krinshpun, Shifra and Sharma, Shruti and George, Giby V. and Malhotra, Meenakshi and Jurdi, Adham and Moshkevich, Solomon and Aleshin, Alexey and Kasi, Pashtoon M. and Klempner, Samuel J.},
	month = dec,
	year = {2022},
	pmid = {36480779},
	pmcid = {PMC10530958},
	keywords = {Humans, Retrospective Studies, Stomach Neoplasms, Esophageal Neoplasms, Circulating Tumor DNA},
	pages = {e2200420},
	file = {Full Text:/Users/jcsal/Zotero/storage/BL7LH5KR/Huffman et al. - 2022 - Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gast.pdf:application/pdf},
}

@article{eyck35,
	title = {Detection of circulating tumour {DNA} after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer},
	volume = {259},
	issn = {1096-9896},
	doi = {10.1002/path.6016},
	abstract = {Active surveillance instead of standard surgery after neoadjuvant chemoradiotherapy (nCRT) has been proposed for patients with oesophageal cancer. Circulating tumour DNA (ctDNA) may be used to facilitate selection of patients for surgery. We show that detection of ctDNA after nCRT seems highly suggestive of major residual disease. Tumour biopsies and blood samples were taken before, and 6 and 12 weeks after, nCRT. Biopsies were analysed with regular targeted next-generation sequencing (NGS). Circulating cell-free DNA (cfDNA) was analysed using targeted NGS with unique molecular identifiers and digital polymerase chain reaction. cfDNA mutations matching pre-treatment biopsy mutations confirmed the presence of ctDNA. In total, 31 patients were included, of whom 24 had a biopsy mutation that was potentially detectable in cfDNA (77\%). Pre-treatment ctDNA was detected in nine of 24 patients (38\%), four of whom had incurable disease progression before surgery. Pre-treatment ctDNA detection had a sensitivity of 47\% (95\% CI 24-71) (8/17), specificity of 85\% (95\% CI 42-99) (6/7), positive predictive value (PPV) of 89\% (95\% CI 51-99) (8/9), and negative predictive value (NPV) of 40\% (95\% CI 17-67) (6/15) for detecting major residual disease ({\textgreater}10\% residue in the resection specimen or progression before surgery). After nCRT, ctDNA was detected in three patients, two of whom had disease progression. Post-nCRT ctDNA detection had a sensitivity of 21\% (95\% CI 6-51) (3/14), specificity of 100\% (95\% CI 56-100) (7/7), PPV of 100\% (95\% CI 31-100) (3/3), and NPV of 39\% (95\% CI 18-64) (7/18) for detecting major residual disease. The addition of ctDNA to the current set of diagnostics did not lead to more patients being clinically identified with residual disease. These results indicate that pre-treatment and post-nCRT ctDNA detection may be useful in identifying patients at high risk of disease progression. The addition of ctDNA analysis to the current set of diagnostic modalities may not improve detection of residual disease after nCRT. © 2022 The Authors. The Journal of Pathology published by John Wiley \& Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.},
	language = {eng},
	number = {1},
	journal = {The Journal of Pathology},
	author = {Eyck, Ben M. and Jansen, Maurice Phm and Noordman, Bo Jan and Atmodimedjo, Peggy N. and van der Wilk, Berend J. and Martens, John Wm and Helmijr, Jean A. and Beaufort, Corine M. and Mostert, Bianca and Doukas, Michail and Wijnhoven, Bas Pl and Lagarde, Sjoerd M. and van Lanschot, J. Jan B. and Dinjens, Winand Nm},
	month = jan,
	year = {2023},
	pmid = {36196486},
	pmcid = {PMC10092085},
	keywords = {Humans, Neoadjuvant Therapy, Disease Progression, Esophageal Neoplasms, Chemoradiotherapy, Neoplasm, Residual, neoadjuvant therapy, oesophageal cancer, Biomarkers, Tumor, Mutation, Circulating Tumor DNA, active surveillance, circulating tumour DNA, high-throughput nucleotide sequencing, oesophagectomy, polymerase chain reaction, residual neoplasm},
	pages = {35--45},
	file = {Full Text:/Users/jcsal/Zotero/storage/9DMDHKGM/Eyck et al. - 2023 - Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally adv.pdf:application/pdf},
}

@article{zhang129,
	title = {An update of clinical value of circulating tumor {DNA} in esophageal cancer: a systematic review and meta-analysis},
	volume = {24},
	issn = {1471-2407},
	shorttitle = {An update of clinical value of circulating tumor {DNA} in esophageal cancer},
	doi = {10.1186/s12885-024-11879-6},
	abstract = {BACKGROUND: Esophageal cancer (EC) is a deadly disease with limited therapeutic options. Although circulating tumor DNA (ctDNA) could be a promising tool in this regard, the availiable evidence is limited. We performed a systematic review and meta-analysis to summarize the clinical applicability of the next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) technology on the ctDNA detection of the EC and listed the current challenges.
METHODS: We systematically searched MEDLINE (via PubMed), Embase (via OVID), ISI Web of Science database and Cochrane Library from January, 2000 to April, 2023. Progression-free survival (PFS) and overall survival (OS) were set as primary outcome endpoints. Pathologic response was evaluated by tumor regression grade (TRG), according to the eighth edition of the American Joint Committee on Cancer (AJCC). Major pathologic regression (MPR) was defined as TRG 1 and 2. The MPR was set as secondary endpoint. Hazard rate (HR) and associated 95\% CI were used as the effect indicators the association between ctDNA and prognosis of EC. MPR rates were also calculated. Fixed-effect model (Inverse Variance) or random-effect model (Mantel-Haenszel method) was performed depending on the statistically heterogeneity.
RESULTS: Twenty-two studies, containing 1144 patients with EC, were included in this meta-analysis. The results showed that OS (HR = 3.87; 95\% CI, 2.86-5.23) and PFS (HR = 4.28; 95\% CI, 3.34-5.48) were shorter in ctDNA-positive patients. In the neoadjuvant therapy, the sensitivity analysis showed the clarified HR of ctDNA-positive was 1.13(95\% CI, 1.01-1.28). We also found that TP53, NOTCH1, CCND1 and CNKN2A are the most frequent mutation genes.
CONCLUSIONS: Positive ctDNA is associated with poor prognosis, which demonstrated clinical value of ctDNA. Longitudinal ctDNA monitoring showed potential prognostic value in the neoadjuvant therapy. In an era of precision medicine, ctDNA could be a promising tool to individualize treatment planning and to improve outcomes in EC.
PROSPERO REGISTRATION NUMBER: CRD42023412465.},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Zhang, Yaozhong and Du, Huazhen and Wang, Na and Wang, Lei and Huang, Yajie},
	month = jan,
	year = {2024},
	pmid = {38267901},
	pmcid = {PMC10809487},
	keywords = {Circulating Tumor DNA, Circulating tumor DNA (ctDNA), Databases, Factual, Droplet digital polymerase chain reaction (ddPCR), Esophageal cancer (EC), Esophageal Neoplasms, Gene Library, Genes, cdc, Humans, Meta-analysis, Next-generation sequencing (NGS)},
	pages = {129},
	file = {Full Text:/Users/jcsal/Zotero/storage/U7YFV24M/Zhang et al. - 2024 - An update of clinical value of circulating tumor DNA in esophageal cancer a systematic review and m.pdf:application/pdf},
}

@article{gogenur8666,
	title = {{ctDNA} for {Risk} of {Recurrence} {Assessment} in {Patients} {Treated} with {Neoadjuvant} {Treatment}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {29},
	issn = {1534-4681},
	shorttitle = {{ctDNA} for {Risk} of {Recurrence} {Assessment} in {Patients} {Treated} with {Neoadjuvant} {Treatment}},
	doi = {10.1245/s10434-022-12366-7},
	abstract = {BACKGROUND: We wanted to investigate the association between circulating tumor DNA (ctDNA) detection at baseline, during and after neoadjuvant treatment, after surgery, and recurrence, in patients with nonmetastatic cancer.
PATIENTS AND METHODS: In this systematic review and meta-analysis, we included studies that investigated patients undergoing neoadjuvant treatment for nonmetastatic cancer and provided recurrence indices stratified for ctDNA status at the following timepoints: baseline, during treatment, posttreatment, and postsurgery. Study quality was reported with the Newcastle-Ottawa scale, REMARK checklist, and GRADE approach. PubMed, Embase, Cochrane Library, and Web of Science were our data sources (inception to 3 June 2021). The main outcome was risk of recurrence.
RESULTS: We identified ten studies including 727 patients with rectal, breast, gastric, and bladder cancer. All studies reported posttreatment ctDNA analysis, while seven, four, and six reported baseline, during treatment, and postsurgery ctDNA analysis, respectively. ctDNA detection was associated to recurrence across all timepoints [baseline: risk ratio (RR) 2.86, 95\% confidence interval (CI) 1.33-6.14, during treatment: RR 3.81, 95\% CI 2.09-6.92, posttreatment: RR 4.29, 95\% CI 2.79-6.60, postsurgery: RR 8.03, 95\% CI 3.16-20.43]. Heterogeneity was low to moderate.
CONCLUSIONS: This meta-analysis of observational studies found that ctDNA detection in patients undergoing neoadjuvant treatment for nonmetastatic cancer was associated with recurrence. A stronger association was evident in posttreatment and postsurgery timepoints. However, some studies reported low negative predictive value (NPV) of pathological complete response, showing that ctDNA-detection-guided escalation and de-escalation studies following neoadjuvant treatment regimens are needed before its role as a treatment guidance can be affirmed.},
	language = {eng},
	number = {13},
	journal = {Annals of Surgical Oncology},
	author = {Gögenur, Mikail and Hadi, Noor Al-Huda and Qvortrup, Camilla and Andersen, Claus Lindbjerg and Gögenur, Ismail},
	month = dec,
	year = {2022},
	pmid = {35933546},
	keywords = {Humans, Neoadjuvant Therapy, Neoplasms, Observational Studies as Topic, Circulating Tumor DNA},
	pages = {8666--8674},
	file = {PDF:/Users/jcsal/Zotero/storage/8U4SW98U/Gögenur et al. - 2022 - ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment A Systematic.pdf:application/pdf},
}

@article{kato6248,
	title = {Analysis of {Circulating} {Tumor} {DNA} and {Clinical} {Correlates} in {Patients} with {Esophageal}, {Gastroesophageal} {Junction}, and {Gastric} {Adenocarcinoma}},
	volume = {24},
	issn = {1557-3265},
	doi = {10.1158/1078-0432.CCR-18-1128},
	abstract = {PURPOSE: Esophageal, gastroesophageal junction, and gastric adenocarcinoma (herein gastroesophageal adenocarcinomas) are associated with poor prognosis and limited systemic treatment options. To further understand the genomic landscape of gastroesophageal cancers and its clinical correlations, circulating tumor DNA (ctDNA) from patients' plasma was evaluated using next-generation sequencing (NGS).
EXPERIMENTAL DESIGN: We analyzed genomic alterations of 55 patients (mostly advanced disease; 9, surgically resectable) with gastroesophageal adenocarcinomas using clinical-grade NGS performed on plasma-derived ctDNA (54-73 gene panel). The test detects single-nucleotide variants, as well as copy number amplifications, fusions, and indels in selected genes.
RESULTS: Seventy-six percent of patients (42/55) had ≥1 genomic alteration [including variants of unknown significance (VUS)] and 69.1\% (38/55) had ≥1 characterized alteration (excluding VUSs). The median number of alterations per patient was 2 (range, 0-15). TP53 (50.9\%, 28/55), PIK3CA (16.4\%, 9/55), ERBB2 (14.5\%, 8/55), and KRAS (14.5\%, 8/55) genes were most frequently affected characterized alterations. Thirty-one patients also had tissue NGS. Concordance between tissue and ctDNA ranged from 61.3\% (TP53 alterations) to 87.1\% (KRAS alterations). ERBB2 alterations were significantly associated with poor overall survival (HR, 14.06; 95\% confidence interval, 2.44-81.03; P = 0.003 multivariate analysis). Among patients with ≥1 alteration, no 2 patients had identical molecular portfolios. All patients with ≥1 characterized alteration had theoretically targetable alterations by an FDA-approved agent (on- or off-label). Illustrative case treated with cognate agent is presented.
CONCLUSIONS: Evaluation of ctDNA by NGS among patients with gastroesophageal adenocarcinoma is feasible. Patients harbored heterogeneous patterns of genomics, with most having alterations that are potentially pharmacologically tractable.},
	language = {eng},
	number = {24},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Kato, Shumei and Okamura, Ryosuke and Baumgartner, Joel M. and Patel, Hitendra and Leichman, Lawrence and Kelly, Kaitlyn and Sicklick, Jason K. and Fanta, Paul T. and Lippman, Scott M. and Kurzrock, Razelle},
	month = dec,
	year = {2018},
	pmid = {30348637},
	pmcid = {PMC6384095},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Neoplasm Staging, Prognosis, Aged, 80 and over, Adult, Young Adult, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Neoplasm Grading, Biomarkers, Tumor, Genetic Testing, Circulating Tumor DNA, High-Throughput Nucleotide Sequencing, Gene Expression Profiling},
	pages = {6248--6256},
	file = {Full Text:/Users/jcsal/Zotero/storage/N8U8UIYI/Kato et al. - 2018 - Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophag.pdf:application/pdf},
}

@article{myles2263,
	title = {Restrictive versus {Liberal} {Fluid} {Therapy} for {Major} {Abdominal} {Surgery}},
	volume = {378},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa1801601},
	abstract = {BACKGROUND: Guidelines to promote the early recovery of patients undergoing major surgery recommend a restrictive intravenous-fluid strategy for abdominal surgery. However, the supporting evidence is limited, and there is concern about impaired organ perfusion.
METHODS: In a pragmatic, international trial, we randomly assigned 3000 patients who had an increased risk of complications while undergoing major abdominal surgery to receive a restrictive or liberal intravenous-fluid regimen during and up to 24 hours after surgery. The primary outcome was disability-free survival at 1 year. Key secondary outcomes were acute kidney injury at 30 days, renal-replacement therapy at 90 days, and a composite of septic complications, surgical-site infection, or death.
RESULTS: During and up to 24 hours after surgery, 1490 patients in the restrictive fluid group had a median intravenous-fluid intake of 3.7 liters (interquartile range, 2.9 to 4.9), as compared with 6.1 liters (interquartile range, 5.0 to 7.4) in 1493 patients in the liberal fluid group (P{\textless}0.001). The rate of disability-free survival at 1 year was 81.9\% in the restrictive fluid group and 82.3\% in the liberal fluid group (hazard ratio for death or disability, 1.05; 95\% confidence interval, 0.88 to 1.24; P=0.61). The rate of acute kidney injury was 8.6\% in the restrictive fluid group and 5.0\% in the liberal fluid group (P{\textless}0.001). The rate of septic complications or death was 21.8\% in the restrictive fluid group and 19.8\% in the liberal fluid group (P=0.19); rates of surgical-site infection (16.5\% vs. 13.6\%, P=0.02) and renal-replacement therapy (0.9\% vs. 0.3\%, P=0.048) were higher in the restrictive fluid group, but the between-group difference was not significant after adjustment for multiple testing.
CONCLUSIONS: Among patients at increased risk for complications during major abdominal surgery, a restrictive fluid regimen was not associated with a higher rate of disability-free survival than a liberal fluid regimen and was associated with a higher rate of acute kidney injury. (Funded by the Australian National Health and Medical Research Council and others; RELIEF ClinicalTrials.gov number, NCT01424150 .).},
	language = {eng},
	number = {24},
	journal = {The New England Journal of Medicine},
	author = {Myles, Paul S. and Bellomo, Rinaldo and Corcoran, Tomas and Forbes, Andrew and Peyton, Philip and Story, David and Christophi, Chris and Leslie, Kate and McGuinness, Shay and Parke, Rachael and Serpell, Jonathan and Chan, Matthew T. V. and Painter, Thomas and McCluskey, Stuart and Minto, Gary and Wallace, Sophie and {Australian and New Zealand College of Anaesthetists Clinical Trials Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group}},
	month = jun,
	year = {2018},
	pmid = {29742967},
	keywords = {Abdomen, Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Risk Factors, Postoperative Complications, Digestive System Surgical Procedures, Fluid Therapy, Blood Loss, Surgical, Acute Kidney Injury, Hypotonic Solutions, Rehydration Solutions},
	pages = {2263--2274},
	file = {Full Text:/Users/jcsal/Zotero/storage/QTVQSA6V/Myles et al. - 2018 - Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery.pdf:application/pdf},
}

@article{paradis558,
	title = {Predictive {Factors} for {Successful} {Same}-{Day} {Discharge} {After} {Minimally} {Invasive} {Colectomy} and {Stoma} {Reversal}},
	volume = {67},
	issn = {1530-0358},
	doi = {10.1097/DCR.0000000000003149},
	abstract = {BACKGROUND: Same-day discharge after minimally invasive colorectal surgery is a safe, effective practice in specific patients that can enhance the efficiency of enhanced recovery pathways.
OBJECTIVE: To identify predictive factors associated with success or failure of same-day discharge.
DESIGN: Prospective cohort study from January 2020 to March 2023.
SETTINGS: Tertiary colorectal center.
PATIENTS: Adult patients eligible for same-day discharge with remote postdischarge follow-up included those with minimal comorbidities, residing near the hospital, having sufficient home support, and owning a mobile device.
INTERVENTIONS: Patients were discharged on the day of surgery upon meeting specific criteria, including adequate pain control, tolerance of oral intake, independent mobility, urination, and the absence of complications. Successful same-day discharge was defined as discharge on the day of surgery without unplanned visits in the first 72 hours.
MAIN OUTCOME MEASURES: Factors associated with successful or failed same-day discharge after minimally invasive colorectal surgery.
RESULTS: A total of 175 patients (85.3\%) were discharged on the day of surgery, with 14 patients (8\%) having an unplanned visit within 72 hours. Overall, 161 patients (78.5\%) were categorized as same-day discharge success and 44 patients (21.5\%) as same-day discharge failure. The same-day discharge failure group had a higher Charlson Comorbidity Index (3.7 vs 2.8, p = 0.03). Mean length of stay (0.8 vs 3.0, p = 0.00), 30-day complications (10\% vs 48\%, p = 0.00), and readmissions (8\% vs 27\%, p = 0.00) were higher in the same-day discharge failure group. Regression analysis showed that failed same-day discharge was associated with higher comorbidities (OR 0.79; 95\% CI, 0.66-0.95) and prolonged postanesthesia care unit time (OR 0.99; 95\% CI, 0.99-0.99). Individuals who received a regional nerve block (OR 4.1; 95\% CI, 1.2-14) and those who did not consume postoperative opioids (OR 4.6; 95\% CI, 1-21) were more likely to have successful same-day discharge.
LIMITATIONS: Single-center study.
CONCLUSIONS: Our findings indicate that comorbidities and prolonged postanesthesia care unit stays were associated with same-day discharge failure, whereas regional nerve blocks and minimal postoperative opioids were related to success. These factors may inform future research aiming to enhance colorectal surgery recovery protocols. See Video Abstract .
FACTORES PREDICTIVOS PARA UN ALTA EXITOSA EL MISMO DA DESPUS DE UNA COLECTOMA MNIMAMENTE INVASIVA Y REVERSIN DEL ESTOMA: ANTECEDENTES:El alta el mismo día después de una cirugía colorrectal mínimamente invasiva es una práctica segura y eficaz en pacientes específicos que puede mejorar la eficiencia de las vías de recuperación mejoradas.OBJETIVO:Identificar factores predictivos asociados con el éxito o fracaso del alta el mismo día.DISEÑO:Estudio de cohorte prospectivo del 01/2020 al 03/2023.AJUSTES:Centro colorrectal terciario.PACIENTES:Los pacientes adultos elegibles para el alta el mismo día con seguimiento remoto posterior al alta incluyeron aquellos con comorbilidades mínimas, que residían cerca del hospital, tenían suficiente apoyo en el hogar y poseían un dispositivo móvil.INTERVENCIONES:Los pacientes fueron dados de alta el día de la cirugía al cumplir con criterios específicos, incluido un control adecuado del dolor, tolerancia a la ingesta oral, movilidad independiente, micción y ausencia de complicaciones. El alta exitosa el mismo día se definió como el alta el día de la cirugía sin visitas no planificadas en las primeras 72 horas.PRINCIPALES MEDIDAS DE RESULTADO:Factores asociados con el alta exitosa o fallida el mismo día después de una cirugía colorrectal mínimamente invasiva.RESULTADOS:Un total de 175 (85,3\%) pacientes fueron dados de alta el día de la cirugía y 14 (8\%) pacientes tuvieron una visita no planificada dentro de las 72 horas. En total, 161 (78,5\%) pacientes se clasificaron como éxito del alta el mismo día y 44 (21,5\%) pacientes como fracaso del alta el mismo día. El grupo de fracaso del alta el mismo día tuvo un índice de comorbilidad de Charlson más alto (3,7, 2,8, p = 0,03). La duración media de la estancia hospitalaria (0,8, 3,0, p = 0,00), las complicaciones a los 30 días (10\%, 48\%, p = 0,00) y los reingresos (8\%, 27\%, p = 0,00) fueron mayores en el mismo día grupo de fallo de descarga. El análisis de regresión mostró que el alta fallida el mismo día se asoció con mayores comorbilidades (OR 0,79; IC del 95 \%: 0,66; 0,95) y tiempo prolongado en la unidad de cuidados postanestésicos (OR 0,99; IC del 95 \%: 0,99; 0,99). Las personas que recibieron un bloqueo nervioso regional (OR 4,1; IC del 95 \%: 1,2, 14) y aquellos que no consumieron opioides posoperatorios (OR 4,6, IC del 95 \%: 1-21) tuvieron más probabilidades de tener éxito en el mismo día -descarga.LIMITACIONES:Estudio unicéntrico.CONCLUSIONES:Nuestros hallazgos indican que las comorbilidades y las estancias prolongadas en la unidad de cuidados postanestésicos se asociaron con el fracaso del alta el mismo día, mientras que los bloqueos nerviosos regionales y los opioides postoperatorios mínimos se relacionaron con el éxito. Estos factores pueden informar investigaciones futuras destinadas a mejorar los protocolos de recuperación de la cirugía colorrectal. (Traducción-Yesenia Rojas-Khalil ).},
	language = {eng},
	number = {4},
	journal = {Diseases of the Colon and Rectum},
	author = {Paradis, Tiffany and Robitaille, Stephan and Wang, Anna and Gervais, Camille and Liberman, A. Sender and Charlebois, Patrick and Stein, Barry L. and Fiore, Julio F. and Feldman, Liane S. and Lee, Lawrence},
	month = apr,
	year = {2024},
	pmid = {38127647},
	keywords = {Humans, Length of Stay, Prospective Studies, Adult, Colectomy, ERAS, Patient Discharge},
	pages = {558--565},
}

@article{irani5,
	title = {Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the {American} {Society} of {Colon} and {Rectal} {Surgeons} and the {Society} of {American} {Gastrointestinal} and {Endoscopic} {Surgeons}},
	volume = {37},
	issn = {1432-2218},
	doi = {10.1007/s00464-022-09758-x},
	abstract = {The American Society of Colon and Rectal Surgeons (ASCRS) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) are dedicated to ensuring high-quality innovative patient care for surgical patients by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus as well as minimally invasive surgery. The ASCRS and SAGES society members involved in the creation of these guidelines were chosen because they have demonstrated expertise in the specialty of colon and rectal surgery and enhanced recovery. This consensus document was created to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus and develop clinical practice guidelines based on the best available evidence. While not proscriptive, these guidelines provide information on which decisions can be made and do not dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, healthcare workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. These guidelines should not be deemed inclusive of all proper methods of care nor exclusive of methods of care reasonably directed toward obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all the circumstances presented by the individual patient. This clinical practice guideline represents a collaborative effort between the American Society of Colon and Rectal Surgeons (ASCRS) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and was approved by both societies.},
	language = {eng},
	number = {1},
	journal = {Surgical Endoscopy},
	author = {Irani, Jennifer L. and Hedrick, Traci L. and Miller, Timothy E. and Lee, Lawrence and Steinhagen, Emily and Shogan, Benjamin D. and Goldberg, Joel E. and Feingold, Daniel L. and Lightner, Amy L. and Paquette, Ian M.},
	month = jan,
	year = {2023},
	pmid = {36515747},
	pmcid = {PMC9839829},
	keywords = {Humans, United States, Endoscopy, Digestive System Surgical Procedures, Rectum, Colon, ERAS, Colorectal surgery, Surgeons, Enhanced recovery},
	pages = {5--30},
	file = {Full Text:/Users/jcsal/Zotero/storage/BUPPS9A7/Irani et al. - 2023 - Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American.pdf:application/pdf},
}

@article{gounder898,
	title = {Nirogacestat, a γ-{Secretase} {Inhibitor} for {Desmoid} {Tumors}},
	volume = {388},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2210140},
	abstract = {BACKGROUND: Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments.
METHODS: We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat (150 mg) or placebo twice daily. The primary end point was progression-free survival.
RESULTS: From May 2019 through August 2020, a total of 70 patients were assigned to receive nirogacestat and 72 to receive placebo. Nirogacestat had a significant progression-free survival benefit over placebo (hazard ratio for disease progression or death, 0.29; 95\% confidence interval, 0.15 to 0.55; P{\textless}0.001); the likelihood of being event-free at 2 years was 76\% with nirogacestat and 44\% with placebo. Between-group differences in progression-free survival were consistent across prespecified subgroups. The percentage of patients who had an objective response was significantly higher with nirogacestat than with placebo (41\% vs. 8\%; P{\textless}0.001), with a median time to response of 5.6 months and 11.1 months, respectively; the percentage of patients with a complete response was 7\% and 0\%, respectively. Significant between-group differences in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life, were observed (P≤0.01). Frequent adverse events with nirogacestat included diarrhea (in 84\% of the patients), nausea (in 54\%), fatigue (in 51\%), hypophosphatemia (in 42\%), and maculopapular rash (in 32\%); 95\% of adverse events were of grade 1 or 2. Among women of childbearing potential receiving nirogacestat, 27 of 36 (75\%) had adverse events consistent with ovarian dysfunction, which resolved in 20 women (74\%).
CONCLUSIONS: Nirogacestat was associated with significant benefits with respect to progression-free survival, objective response, pain, symptom burden, physical functioning, role functioning, and health-related quality of life in adults with progressing desmoid tumors. Adverse events with nirogacestat were frequent but mostly low grade. (Funded by SpringWorks Therapeutics; DeFi ClinicalTrials.gov number, NCT03785964.).},
	language = {eng},
	number = {10},
	journal = {The New England Journal of Medicine},
	author = {Gounder, Mrinal and Ratan, Ravin and Alcindor, Thierry and Schöffski, Patrick and van der Graaf, Winette T. and Wilky, Breelyn A. and Riedel, Richard F. and Lim, Allison and Smith, L. Mary and Moody, Stephanie and Attia, Steven and Chawla, Sant and D'Amato, Gina and Federman, Noah and Merriam, Priscilla and Van Tine, Brian A. and Vincenzi, Bruno and Benson, Charlotte and Bui, Nam Quoc and Chugh, Rashmi and Tinoco, Gabriel and Charlson, John and Dileo, Palma and Hartner, Lee and Lapeire, Lore and Mazzeo, Filomena and Palmerini, Emanuela and Reichardt, Peter and Stacchiotti, Silvia and Bailey, Howard H. and Burgess, Melissa A. and Cote, Gregory M. and Davis, Lara E. and Deshpande, Hari and Gelderblom, Hans and Grignani, Giovanni and Loggers, Elizabeth and Philip, Tony and Pressey, Joseph G. and Kummar, Shivaani and Kasper, Bernd},
	month = mar,
	year = {2023},
	pmid = {36884323},
	pmcid = {PMC11225596},
	keywords = {Humans, Female, Antineoplastic Agents, Adult, Progression-Free Survival, Quality of Life, Double-Blind Method, Amyloid Precursor Protein Secretases, Fibromatosis, Aggressive, Gamma Secretase Inhibitors and Modulators, Tetrahydronaphthalenes, Valine},
	pages = {898--912},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/3QZG5HRY/Gounder et al. - 2023 - Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.pdf:application/pdf},
}

@article{valletti245,
	title = {Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology},
	volume = {19},
	issn = {1477-7819},
	shorttitle = {Gastric cancer with positive peritoneal cytology},
	doi = {10.1186/s12957-021-02351-x},
	abstract = {BACKGROUND: The optimal treatment in patients with gastric cancer and peritoneal disease remains controversial. Some guidelines indicate palliative treatment only, while others consider surgical treatment in case of positive lavage cytology (CY+) or limited peritoneal disease. Here, we analyzed the role of peritoneal disease in patients with gastric cancer, and the prognostic relevance of response to neoadjuvant therapy.
METHODS: In this retrospective cohort analysis, we analyzed patients with adenocarcinoma of the stomach or esophago-gastric junction from a single center operated between 2011 and 2019. According to histology and lavage cytology, patients were classified into four risk groups: (A) no peritoneal disease, (B) CY+ who converted to negative lavage cytology (CY-) after neoadjuvant chemotherapy, (C) CY+ without conversion after chemotherapy, and (D) patients with visible peritoneal metastasis.
RESULTS: Overall, n = 172 patients were included. At initial presentation, n = 125 (73\%) had no peritoneal disease, and about a third of patients (n = 47, 27\%) had microscopic or macroscopic peritoneal disease. Among them, n = 14 (8\%) were CY+ without visible peritoneal metastasis, n = 9 converted to CY- after chemotherapy, and in n = 5 no conversion was observed. Median overall survival was not reached in patients who had initially no peritoneal disease and in patients who converted after chemotherapy, resulting in 3-year survival rates of 65\% and 53\%. In contrast, median overall survival was reduced to 13 months (95\% CI 8.7-16.7) in patients without conversion and was 16 months (95\% CI 12-20.5) in patients with peritoneal metastasis without difference between the two groups (p = .364). The conversion rate from CY+ to CY- was significantly higher after neoadjuvant treatment with FLOT (5-fluorouracil plus leucovorin, oxaliplatin, and docetaxel) compared to ECF (epirubicin, cisplatin, and 5-fluorouracil) (p = 0.027).
CONCLUSION: Conversion of CY+ to CY- after neoadjuvant chemotherapy with FLOT is a significant prognostic factor for a better overall survival. Surgical treatment in well-selected patients should therefore be considered. However, peritoneal recurrence remains frequent despite conversion, urging for a better local control.},
	language = {eng},
	number = {1},
	journal = {World Journal of Surgical Oncology},
	author = {Valletti, Massimiliano and Eshmuminov, Dilmurodjon and Gnecco, Nicola and Gutschow, Christian Alexander and Schneider, Paul Magnus and Lehmann, Kuno},
	month = aug,
	year = {2021},
	pmid = {34404403},
	pmcid = {PMC8371873},
	keywords = {Humans, Retrospective Studies, Prognosis, Stomach Neoplasms, Gastric cancer, Neoplasm Recurrence, Local, Induction Chemotherapy, Peritoneal Lavage, Peritoneal lavage cytology, Peritoneal metastasis, Neoadjuvant chemotherapy},
	pages = {245},
	file = {Full Text:/Users/jcsal/Zotero/storage/LWMRXXAJ/Valletti et al. - 2021 - Gastric cancer with positive peritoneal cytology survival benefit after induction chemotherapy and.pdf:application/pdf},
}

@article{mezhir16,
	title = {Positive {Peritoneal} {Cytology} in {Patients} with {Gastric} {Cancer}: {Natural} {History} and {Outcome} of 291 {Patients}},
	volume = {2},
	issn = {0975-7651},
	shorttitle = {Positive {Peritoneal} {Cytology} in {Patients} with {Gastric} {Cancer}},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373003/},
	doi = {10.1007/s13193-011-0074-6},
	abstract = {Background.
          
Positive peritoneal cytology is a predictor of poor survival in patients with gastric cancer. Our aim is to more clearly define the natural history of this cohort.


            Methods.
          
Review of a prospectively maintained gastric cancer database of patients who had diagnostic laparoscopy with peritoneal washings. Clinicopathologic and treatmentrelated variables were obtained. Univariate and multivariate analyses were performed for factors associated with disease-specific survival (DSS).


            Results.
          
From January 1993 to April 2009, a total of 1241 patients with gastric cancer underwent laparoscopy with peritoneal washings; 291 (23\%) had positive cytology. There were 198 patients (68\%) who had visible metastases discovered at laparoscopy (M1), and 93 patients (32\%) were without gross evidence of advanced disease (M1 Cyt+). The median DSS for the entire cohort was 1 year; for M1, DSS was 0.8 years, and for M1 Cyt+, DSS was 1.3 years. At baseline, independent predictors of worse DSS were poor performance status, M1 disease, and diffuse tumors. Among the subset of patients with M1 Cyt + disease, performance status was the strongest independent predictor of DSS. A total of 48 of the 291 Cyt + patients had repeat staging laparoscopy after chemotherapy. Compared with patients who had persistently positive cytology (n = 21), those who converted to negative cytology (n = 27) had a significant improvement in DSS (2.5 years vs. 1.4 years, P = 0.0003).


            Conclusions.
          
Patients with positive cytology as the only evidence of advanced disease exhibit a poor outcome; however, clearing of Cyt + disease by chemotherapy is associated with a statistically significant improvement in DSS. The role for gastrectomy in patients with positive peritoneal cytology remains uncertain.},
	number = {1},
	urldate = {2024-11-26},
	journal = {Indian Journal of Surgical Oncology},
	author = {Mezhir, James J. and Shah, Manish A. and Jacks, Lindsay M. and Brennan, Murray F. and Coit, Daniel G. and Strong, Vivian E.},
	month = mar,
	year = {2011},
	pmid = {22696066},
	pmcid = {PMC3373003},
	pages = {16--23},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/L4XFSMVH/Mezhir et al. - 2011 - Positive Peritoneal Cytology in Patients with Gastric Cancer Natural History and Outcome of 291 Pat.pdf:application/pdf},
}

@article{massy-westropp127,
	title = {Hand {Grip} {Strength}: age and gender stratified normative data in a population-based study},
	volume = {4},
	issn = {1756-0500},
	shorttitle = {Hand {Grip} {Strength}},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101655/},
	doi = {10.1186/1756-0500-4-127},
	abstract = {Background
The North West Adelaide Health Study is a representative longitudinal cohort study of people originally aged 18 years and over. The aim of this study was to describe normative data for hand grip strength in a community-based Australian population. Secondary aims were to investigate the relationship between body mass index (BMI) and hand grip strength, and to compare Australian data with international hand grip strength norms.

Methods
The sample was randomly selected and recruited by telephone interview. Overall, 3 206 (81\% of those recruited) participants returned to the clinic during the second stage (2004-2006) which specifically focused on the collection of information relating to musculoskeletal conditions.

Results
Following the exclusion of 435 participants who had hand pain and/or arthritis, 1366 men and 1312 women participants provided hand grip strength measurement. The study population was relatively young, with 41.5\% under 40 years; and their mean BMI was 28.1 kg/m2 (SD 5.5). Higher hand grip strength was weakly related to higher BMI in adults under the age of 30 and over the age of 70, but inversely related to higher BMI between these ages. Australian norms from this sample had amongst the lowest of the hand grip strength of the internationally published norms, except those from underweight populations.

Conclusions
This population demonstrated higher BMI and lower grip strength in younger participants than much of the international published, population data. A complete exploration of the relationship between BMI and hand grip strength was not fully explored as there were very few participants with BMI in the underweight range. The age and gender grip strength values are lower in younger adults than those reported in international literature.},
	urldate = {2024-11-27},
	journal = {BMC Research Notes},
	author = {Massy-Westropp, Nicola M and Gill, Tiffany K and Taylor, Anne W and Bohannon, Richard W and Hill, Catherine L},
	month = apr,
	year = {2011},
	pmid = {21492469},
	pmcid = {PMC3101655},
	pages = {127},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/4Q6PD767/Massy-Westropp et al. - 2011 - Hand Grip Strength age and gender stratified normative data in a population-based study.pdf:application/pdf},
}

@article{mathiowetz69,
	title = {Grip and pinch strength: normative data for adults},
	volume = {66},
	issn = {0003-9993},
	shorttitle = {Grip and pinch strength},
	abstract = {The primary purpose of this study was to establish clinical norms for adults aged 20 to 75+ years on four tests of hand strength. A dynamometer was used to measure grip strength and a pinch gauge to measure tip, key, and palmar pinch. A sample of 310 male and 328 female adults, ages 20 to 94, from the seven-county Milwaukee area were tested using standardized positioning and instructions. Right hand and left hand data were stratified into 12 age groups for both sexes. This stratification provides a means of comparing the score of individual patients to that of normal subjects of the same age and sex. The highest grip strength scores occurred in the 25 to 39 age groups. For tip, key, and palmar pinch the average scores were relatively stable from 20 to 59 years, with a gradual decline from 60 to 79 years. A high correlation was seen between grip strength and age, but a low to moderate correlation between pinch strength and age. The newer pinch gauge used in this study appears to read higher than that used in a previous normative study. Comparison of the average hand strength of right-handed and left-handed subjects showed only minimal differences.},
	language = {eng},
	number = {2},
	journal = {Archives of Physical Medicine and Rehabilitation},
	author = {Mathiowetz, V. and Kashman, N. and Volland, G. and Weber, K. and Dowe, M. and Rogers, S.},
	month = feb,
	year = {1985},
	pmid = {3970660},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Sex Factors, Adult, Age Factors, Reference Values, Physical Exertion, Functional Laterality, Hand, Wrist},
	pages = {69--74},
}

@article{blackham1203,
	title = {Is {Linitis} {Plastica} a {Contraindication} for {Surgical} {Resection}: {A} {Multi}-{Institution} {Study} of the {U}.{S}. {Gastric} {Cancer} {Collaborative}},
	volume = {23},
	issn = {1534-4681},
	shorttitle = {Is {Linitis} {Plastica} a {Contraindication} for {Surgical} {Resection}},
	doi = {10.1245/s10434-015-4947-8},
	abstract = {BACKGROUND: Current staging and treatment guidelines for gastric adenocarcinoma do not differentiate between linitis plastic (LP) and non-LP cancers. Significant controversy exists regarding the surgical management of LP patients.
METHODS: Using the multi-institutional U.S. Gastric Cancer Collaborative database, 869 gastric cancer patients who underwent resection between 2000 and 2012 were identified. Clinicopathologic and outcomes data of 58 LP patients were compared to 811 non-LP patients.
RESULTS: Stage III/IV disease was more common at presentation in LP patients compared with non-LP patients (90 vs. 44 \%, p {\textless} 0.01). Despite the fact that most LP patients underwent total gastrectomy (88 vs. 39 \%, p {\textless} 0.01), final positive margins were more common in LP patients (33 vs. 7 \%, p {\textless} 0.01). The use of frozen section allowed 15 intraoperative positive margins in 38 patients to be converted to negative final margins. Median overall survival (OS) was significantly worse in patients with LP (11.6 vs. 37.8 months, p {\textless} 0.01). There was no difference in median OS of LP patients based on stage (I/II, 17.3 mo; III, 10.6 mo; IV, 12.0 mo; p = 0.46). LP and non-LP patients who underwent optimal resection (negative margin and D2/3 lymphadenectomy) had better survival compared with those with nonoptimal resections. The median OS for optimally resected stage III LP (n = 22) and stage III non-LP (n = 185) patients was nearly identical (26.7 vs. 25.3 mo; p = 0.69).
CONCLUSIONS: Future staging systems and treatment guidelines should differentiate between LP and non-LP gastric cancers. Long-term survival in select LP patients who undergo optimal resections is comparable to optimally resected non-LP patients.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgical Oncology},
	author = {Blackham, Aaron U. and Swords, Doug S. and Levine, Edward A. and Fino, Nora F. and Squires, Malcolm H. and Poultsides, George and Fields, Ryan C. and Bloomston, Mark and Weber, Sharon M. and Pawlik, Timothy M. and Jin, Linda X. and Spolverato, Gaya and Schmidt, Carl and Worhunsky, David and Cho, Clifford S. and Maithel, Shishir K. and Votanopoulos, Konstantinos I.},
	month = apr,
	year = {2016},
	pmid = {26530447},
	pmcid = {PMC4980579},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Staging, Retrospective Studies, Risk Factors, Survival Rate, Prognosis, Stomach Neoplasms, Adenocarcinoma, Gastrectomy, Lymph Node Excision, Neoplasm Grading, Contraindications, Linitis Plastica},
	pages = {1203--1211},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/MZZ9XKTG/Blackham et al. - 2016 - Is Linitis Plastica a Contraindication for Surgical Resection A Multi-Institution Study of the U.S..pdf:application/pdf},
}

@article{wang241,
	title = {The effect of socioeconomic status on health-care delay and treatment of esophageal cancer},
	volume = {13},
	issn = {1479-5876},
	doi = {10.1186/s12967-015-0579-9},
	abstract = {BACKGROUND: Socioeconomic status (SES) has been focused on as a key determinant of the incidence of cancer, cancer stage at diagnosis as well as treatment choices in western countries. However, to the authors' knowledge, little work has been done concerning the relationship of SES and esophageal cancer in China.
METHODS: Patients diagnosed with primary esophageal cancer from January to December 2007 in Qilu hospital were included. Socioeconomic status was determined by a questionnaire including religion, years of schooling and high education, place of residence, occupation, annual household income, and insurance.
RESULTS: A total of 238 cases were collected in this study. Linear-by-linear association testing revealed that health-care delay was significantly associated with SES (P = 0.009). Multivariable logistic regression analysis revealed that increased health-care delay ({\textgreater}2 months) was more frequently observed in patients with lower SES (OR 2.271; 95\% CI 1.069-4.853). Patients diagnosed at TNM I and II were more frequently in higher SES groups (P = 0.017). The association test was statistically significant for undergoing surgical resection only (P = 0.015) and chemotherapy (P = 0.015). Multivariable logistic regression analysis revealed that surgical resection only was less performed in higher SES group compared with lower SES group (OR 0.372; 95\% CI 0.188-0.734). For chemotherapy, higher SES patients had a three-fold higher likelihood compared with lower SES group (OR 3.042; 95\% CI 1.335-6.928).
CONCLUSION: Socioeconomic status was found to be associated with health-care delay, tumor stage and treatment modalities in esophageal cancer.},
	language = {eng},
	journal = {Journal of Translational Medicine},
	author = {Wang, Nana and Cao, Fangli and Liu, Fang and Jia, Yibin and Wang, Jianbo and Bao, Cihang and Wang, Xintong and Song, Qingxu and Tan, Bingxu and Cheng, Yufeng},
	month = jul,
	year = {2015},
	pmid = {26205792},
	pmcid = {PMC4511992},
	keywords = {Humans, Female, Male, Middle Aged, Neoplasm Staging, Esophageal Neoplasms, Social Class, Delivery of Health Care},
	pages = {241},
	file = {Full Text:/Users/jcsal/Zotero/storage/32UDM8H5/Wang et al. - 2015 - The effect of socioeconomic status on health-care delay and treatment of esophageal cancer.pdf:application/pdf},
}

@article{lineback416,
	title = {Barriers to {Accessing} {Optimal} {Esophageal} {Cancer} {Care} for {Socioeconomically} {Disadvantaged} {Patients}},
	volume = {103},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2016.08.085},
	abstract = {BACKGROUND: The 5-year survival of patients with low socioeconomic status (SES) and esophageal cancer is significantly lower than that in patients with high SES. It is poorly understood what causes these worse outcomes. We hypothesized that a qualitative approach could elucidate the underlying causes of these differences.
METHODS: Patients with a diagnosis of esophageal cancer were recruited through flyers in regional cancer centers as well as through Facebook advertisements in cancer support groups and newspapers; they participated in a 1-hour semistructured interview or completed an online survey. Patients were stratified into low- and high-SES groups and were surveyed about their health history and access to cancer care. Data were coded into common themes based on participant responses.
RESULTS: Eighty patients completed the interviews or surveys, with 38 in the high-SES group and 42 in the low-SES group. There were no clinically significant differences between the groups in comorbidities and cancer staging. Patients with low SES were offered operative treatment at significantly lower rates (19 of 42 [44.7\%] versus 29 of 38 [76.3\%]; p = 0.0048), had a decreased rate of second opinions (10 of 42 [23.8\%] versus 25 of 38 [65.8\%]; p = 0.00016), and were more likely to lose their jobs (14 of 42 [33.3\%] versus 1 of 38 [2.6\%]; p = 0.00044) than their high-SES counterparts. Thematic analysis found that communication difficulties, lack of understanding of treatment, and financial troubles were consistently reported more prominently in the lower-SES groups. Having a facilitator (eg, social worker) improved care by helping patients navigate complex treatments and financial concerns.
CONCLUSIONS: Financial and communication barriers exist, which may lead to disparities in cancer outcomes for patients with low SES. There is a critical need for medical advocates to assist patients with limited resources.},
	language = {eng},
	number = {2},
	journal = {The Annals of Thoracic Surgery},
	author = {Lineback, Christina M. and Mervak, Colin M. and Revels, Sha'shonda L. and Kemp, Micheal T. and Reddy, Rishindra M.},
	month = feb,
	year = {2017},
	pmid = {27825692},
	keywords = {Humans, Female, Male, Middle Aged, Neoplasm Staging, Esophageal Neoplasms, Michigan, Surveys and Questionnaires, Health Services Accessibility, Socioeconomic Factors, Vulnerable Populations},
	pages = {416--421},
}

@article{zhangzrac035,
	title = {Effect of sex on survival after resection of oesophageal cancer: nationwide cohort study},
	volume = {6},
	issn = {2474-9842},
	shorttitle = {Effect of sex on survival after resection of oesophageal cancer},
	doi = {10.1093/bjsopen/zrac035},
	abstract = {BACKGROUND: Accumulating evidence suggests a survival benefit after curative oesophageal cancer surgery in women compared with men. The aim of this study was to explore sex disparities in survival after surgery with curative intent in patients with oesophageal cancer.
METHODS: This was a population-based cohort study, including all patients with oesophageal or gastric cancer who underwent surgery with a curative intent between 2006 and 2017 in Sweden. Female versus male mortality rate ratio (MRR) and excess mortality rate ratio (EMRR) were used as measures of survival. Two different parametric models were designed to account for potential confounders. Patients with gastric cancer were used as a comparison group as no differences in survival between sexes were expected among these patients.
RESULTS: A total of 1301 patients underwent resection for oesophageal adenocarcinoma and 305 patients for oesophageal squamous cell carcinoma. Women had a lower EMRR (0.76, 95 per cent c.i. 0.58 to 1.01, P = 0.056; 0.52, 95 per cent c.i. 0.32 to 0.84, P = 0.007 respectively) in both histological subtypes. The effect was more profound in early clinical stages, in patients receiving neoadjuvant treatment, and without postoperative complications. No sex-related difference was observed in survival of patients with gastric cancer.
CONCLUSIONS: Women undergoing resection for oesophageal carcinoma have better survival compared with men.},
	language = {eng},
	number = {3},
	journal = {BJS open},
	author = {Zhang, Ji and Bellocco, Rino and Ye, Weimin and Johansson, Jan and Nilsson, Magnus and Lindblad, Mats},
	month = may,
	year = {2022},
	pmid = {35639945},
	pmcid = {PMC9154327},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Cohort Studies, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Sex},
	pages = {zrac035},
	file = {Full Text:/Users/jcsal/Zotero/storage/XCG5P8EJ/Zhang et al. - 2022 - Effect of sex on survival after resection of oesophageal cancer nationwide cohort study.pdf:application/pdf},
}

@article{rohatgi152,
	title = {Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome},
	volume = {19},
	issn = {1120-8694},
	shorttitle = {Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation},
	doi = {10.1111/j.1442-2050.2006.00557.x},
	abstract = {The purpose of this study was to identify gender-dependent differences in presentation at baseline and therapy outcome in esophageal carcinoma patients treated with preoperative chemoradiotherapy (CTRT). We stratified patients according to gender and statistically compared pretreatment clinical stage, post-CTRT effect on carcinoma in the resected specimen, overall survival (OS), and patterns of failure. Of the 235 patients who underwent preoperative CTRT, 203 were men and 32 were women. Carcinomas in women correlated significantly with clinical stage II classification (78\%vs. 55\%) while cancers in men correlated significantly with clinical stage III classification (39\%vs. 16\%; P = 0.02). Carcinomas in women also correlated significantly with lower clinical N classification; more women had cN0 (52\%) compared to men (28\%; P = 0.01). Similarly, in the surgical specimens, more women had pN0 (78\%) compared to men (64\%; P = 0.06). At a median follow-up of 37 months, 10\% more women than men remain alive (63\%vs. 53\%; P = 0.3). Distant metastases-free survival time was longer for women than men. Our results suggest that localized esophageal carcinoma is diagnosed in more advanced stages in men than in women. The reasons for these differences remain unclear and further expansion of these observations and study of biologic differences that might exist are warranted.},
	language = {eng},
	number = {3},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Rohatgi, P. R. and Correa, A. M. and Swisher, S. G. and Wu, T. T. and Liao, Z. and Komaki, R. and Walsh, G. L. and Vaporciyan, A. A. and Lee, J. H. and Rice, D. C. and Roth, J. A. and Ajani, J. A.},
	year = {2006},
	pmid = {16722991},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Treatment Outcome, Neoplasm Staging, Retrospective Studies, Sex Factors, Disease Progression, Prognosis, Chemotherapy, Adjuvant, Disease-Free Survival, Esophageal Neoplasms, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Sex},
	pages = {152--157},
}

@article{rowse1147,
	title = {Sex {Disparities} {After} {Induction} {Chemoradiotherapy} and {Esophagogastrectomy} for {Esophageal} {Cancer}},
	volume = {104},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2017.05.030},
	abstract = {BACKGROUND: The impact of sex on the outcomes of treatment for locally advanced esophageal carcinoma is unclear. This study analyzed the impact of sex on response to neoadjuvant chemoradiotherapy (nCRT), tumor recurrence, and survival.
METHODS: From January 1990 through December 2013, female patients who received nCRT followed by esophagogastrectomy at 3 affiliated centers were compared with control male patients based on age, pretreatment clinical stage, histologic type, and surgical era. Only patients staged preoperatively with computed tomographic scans and endoscopic ultrasonography (EUS) were included.
RESULTS: There were 366 patients (145 women and 221 men). The median female age was 64 years (range, 22-81 years), whereas male patients were 61 years (range, 33-82 years). The histologic type was adenocarcinoma in 105 (72\%) women and 192 (87\%) men, and it was squamous cell carcinoma in 40 (28\%) women and 29 (13\%) men (p = 0.005). Women were more likely to attain either a complete pathologic (CP) response or a nearly complete pathologic (NCP) response to induction therapy (84 [58\%]) compared with men (103 [47\%]; p = 0.034). Men had an 80\% increased risk of recurrence (hazard ratio [HR], 1.80; 95\% CI, 1.15-2.68; p = 0.008). There was no sex association with risk of death (p = 0.538). Irrespective of sex, a partial responder (relative to a complete or nearly complete responder) was 3 times more likely to have recurrence (HR, 2.96; 95\% CI, 1.98-4.43; p {\textless} 0.001) and 2.5 times more likely to die (HR, 2.56; 95\% CI, 1.88-3.48; p {\textless} 0.001).
CONCLUSIONS: Female sex correlated with improved rates of achieving either a CP response or an NCP response after neoadjuvant chemotherapy and a smaller likelihood of experiencing tumor recurrence. Future efforts should be directed at understanding determinants of this sex disparity.},
	language = {eng},
	number = {4},
	journal = {The Annals of Thoracic Surgery},
	author = {Rowse, Phillip G. and Jaroszewski, Dawn E. and Thomas, Mathew and Harold, Kristi and Harmsen, William S. and Shen, K. Robert},
	month = oct,
	year = {2017},
	pmid = {28842111},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Cause of Death, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Sex Factors, Proportional Hazards Models, Risk Assessment, Prognosis, Adult, Databases, Factual, Neoplasm Invasiveness, Survival Analysis, United States, Adenocarcinoma, Case-Control Studies, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Logistic Models, Gastrectomy, Remission Induction, Multivariate Analysis},
	pages = {1147--1152},
}

@article{luo74,
	title = {Impact of sex on the prognosis of patients with esophageal squamous cell cancer underwent definitive radiotherapy: a propensity score-matched analysis},
	volume = {14},
	issn = {1748-717X},
	shorttitle = {Impact of sex on the prognosis of patients with esophageal squamous cell cancer underwent definitive radiotherapy},
	doi = {10.1186/s13014-019-1278-0},
	abstract = {BACKGROUND: The impact of sex on prognosis of patients with esophageal squamous cell cancer (ESCC) who underwent definitive radiotherapy remained unclear. The present study aimed to determine the impact of sex on the prognosis of patients with ESCC underwent definitive radiotherapy.
METHODS: Between January 2009 and December 2015, patients with ESCC underwent definitive radiotherapy in Shantou Central Hospital were included in this study. The Progression-free survival (PFS) and overall survival (OS) rates were estimated using the Kaplan-Meier method. The PFS and OS were compared between female and male patients. The Cox regression model was used to identify prognostic factors. Propensity score-matched analysis was performed to balance baseline characteristics between female and male patients.
RESULTS: A total of 683 ESCC patients treated with definitive radiotherapy were included, with 497 male and 186 female patients. In the whole cohort, female patients had a significantly longer median PFS (14.0 months vs 10.6 months, P = 0.0001, HR = 0.688, 95\% CI, 0.567-0.836) and OS (20.8 months vs 15.9 months, P = 0.0005, HR = 0.702, 95\% CI, 0.575-0.857). In the matched cohort, female patients still had a significantly longer median PFS (13.5 months vs 11.6 months) and OS (19.6 months vs 16.1 months). Multivariate analysis showed that sex was an independent prognostic factor for PFS (HR = 0.746, 95\% CI, 0.611-0.910, P = 0.004) and OS (HR = 0.755, 95\% CI, 0.615-0.926, P = 0.007).
CONCLUSIONS: This present study indicated that sex was an independent prognostic factor in Chinese patients with ESCC underwent definitive radiotherapy, with better survival outcome for women than men. Efforts should be made to investigate the underlying biological mechanism.},
	language = {eng},
	number = {1},
	journal = {Radiation Oncology (London, England)},
	author = {Luo, He-San and Xu, Hong-Yao and Du, Ze-Sen and Li, Xu-Yuan and Wu, Sheng-Xi and Huang, He-Cheng and Lin, Lian-Xing},
	month = may,
	year = {2019},
	pmid = {31046792},
	pmcid = {PMC6498616},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Sex Factors, Prognosis, Aged, 80 and over, Adult, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Radiotherapy, Adjuvant, Radiotherapy Dosage, Propensity Score, Radiotherapy, Conformal, Sex, Definitive radiotherapy, Esophageal squamous cell cancer, Propensity score-matched},
	pages = {74},
	file = {Full Text:/Users/jcsal/Zotero/storage/2T6YY975/Luo et al. - 2019 - Impact of sex on the prognosis of patients with esophageal squamous cell cancer underwent definitive.pdf:application/pdf},
}

@article{rowse1147a,
	title = {Sex {Disparities} {After} {Induction} {Chemoradiotherapy} and {Esophagogastrectomy} for {Esophageal} {Cancer}},
	volume = {104},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2017.05.030},
	abstract = {BACKGROUND: The impact of sex on the outcomes of treatment for locally advanced esophageal carcinoma is unclear. This study analyzed the impact of sex on response to neoadjuvant chemoradiotherapy (nCRT), tumor recurrence, and survival.
METHODS: From January 1990 through December 2013, female patients who received nCRT followed by esophagogastrectomy at 3 affiliated centers were compared with control male patients based on age, pretreatment clinical stage, histologic type, and surgical era. Only patients staged preoperatively with computed tomographic scans and endoscopic ultrasonography (EUS) were included.
RESULTS: There were 366 patients (145 women and 221 men). The median female age was 64 years (range, 22-81 years), whereas male patients were 61 years (range, 33-82 years). The histologic type was adenocarcinoma in 105 (72\%) women and 192 (87\%) men, and it was squamous cell carcinoma in 40 (28\%) women and 29 (13\%) men (p = 0.005). Women were more likely to attain either a complete pathologic (CP) response or a nearly complete pathologic (NCP) response to induction therapy (84 [58\%]) compared with men (103 [47\%]; p = 0.034). Men had an 80\% increased risk of recurrence (hazard ratio [HR], 1.80; 95\% CI, 1.15-2.68; p = 0.008). There was no sex association with risk of death (p = 0.538). Irrespective of sex, a partial responder (relative to a complete or nearly complete responder) was 3 times more likely to have recurrence (HR, 2.96; 95\% CI, 1.98-4.43; p {\textless} 0.001) and 2.5 times more likely to die (HR, 2.56; 95\% CI, 1.88-3.48; p {\textless} 0.001).
CONCLUSIONS: Female sex correlated with improved rates of achieving either a CP response or an NCP response after neoadjuvant chemotherapy and a smaller likelihood of experiencing tumor recurrence. Future efforts should be directed at understanding determinants of this sex disparity.},
	language = {eng},
	number = {4},
	journal = {The Annals of Thoracic Surgery},
	author = {Rowse, Phillip G. and Jaroszewski, Dawn E. and Thomas, Mathew and Harold, Kristi and Harmsen, William S. and Shen, K. Robert},
	month = oct,
	year = {2017},
	pmid = {28842111},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Cause of Death, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Sex Factors, Proportional Hazards Models, Risk Assessment, Prognosis, Adult, Databases, Factual, Neoplasm Invasiveness, Survival Analysis, United States, Adenocarcinoma, Case-Control Studies, Carcinoma, Squamous Cell, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Logistic Models, Gastrectomy, Remission Induction, Multivariate Analysis},
	pages = {1147--1152},
}

@article{haddad130,
	title = {Does {Vertical} {Integration} {Improve} {Access} to {Surgical} {Care} for {Medicaid} {Beneficiaries}?},
	volume = {230},
	issn = {1879-1190},
	doi = {10.1016/j.jamcollsurg.2019.09.016},
	abstract = {BACKGROUND: Vertical integration is increasingly common among surgical specialties in the US; however, the effect of vertical integration on access to care for low-income populations remains poorly understood. We explored the characteristics of surgical practices associated with vertical integration and the effect of integration on surgical access for Medicaid populations.
STUDY DESIGN: Using a survey of US office-based physician practices, we examined characteristics of 15 surgical subspecialties from 2007 to 2017, including provider sex and specialty, practice payer mix, surgical volume, and county socioeconomic status. Using multivariable logistic regression and time-series analysis, we evaluated practice and provider characteristics associated with vertical integration-our primary outcome-and practice Medicaid acceptance rates-our secondary outcome.
RESULTS: Our analysis included 84,795 unique surgical practices (303,903 practice-years). The rate of vertical integration during the 10-year period was 18.0\%, with 72.1\% of surgical practices never integrating. Practices that integrated were more likely to accept Medicaid patients than practices that did not (81.0\% vs 60.8\%, p {\textless} 0.001). Accepting Medicaid increased the likelihood of vertical integration relative to practices that did not (odds ratio [OR] 4.20, 95\% CI 3.93 to 4.49). Practices that integrated were more likely to accept Medicaid in the future (OR 2.61, 95\% CI 2.40 to 2.83), even after adjusting for previous Medicaid acceptance and hospital and time fixed effects.
CONCLUSIONS: Surgical practices caring for the underinsured are more likely to join larger health care systems, driven by market characteristics. Vertical integration is associated with future increased rates of Medicaid acceptance among practices, allowing for increased access to surgical care for vulnerable, low-income patients. The potential benefit of increased surgical access for low-income beneficiaries from vertical integration must be balanced with the potential for increased prices.},
	language = {eng},
	number = {1},
	journal = {Journal of the American College of Surgeons},
	author = {Haddad, Diane N. and Resnick, Matthew J. and Nikpay, Sayeh S.},
	month = jan,
	year = {2020},
	pmid = {31672671},
	pmcid = {PMC9109457},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Adult, United States, Young Adult, Surgical Procedures, Operative, Adolescent, Health Services Accessibility, Health Care Surveys, Specialties, Surgical, Medicaid},
	pages = {130--135.e4},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/4NNZ2R7L/Haddad et al. - 2020 - Does Vertical Integration Improve Access to Surgical Care for Medicaid Beneficiaries.pdf:application/pdf},
}

@article{khalil1477,
	title = {Association {Between} {Historical} {Redlining} and {Access} to {High}-{Volume} {Hospitals} {Among} {Patients} {Undergoing} {Complex} {Cancer} {Surgery} in {California}},
	volume = {31},
	issn = {1534-4681},
	doi = {10.1245/s10434-023-14679-7},
	abstract = {BACKGROUND: We sought to determine the impact of historical redlining on travel patterns and utilization of high-volume hospitals (HVHs) among patients undergoing complex cancer operations.
METHODS: The California Department of Health Care Access and Information database was utilized to identify patients who underwent esophagectomy (ES), pneumonectomy (PN), pancreatectomy (PA), or proctectomy (PR) for cancer between 2010 and 2020. Patient ZIP codes were assigned Home Owners' Loan Corporation grades (A: 'Best'; B: 'Still Desirable'; C: 'Definitely Declining'; and D: 'Hazardous/Redlined'). A clustered multivariable regression was used to assess the likelihood of patients undergoing surgery at an HVH, bypassing the nearest HVH, and total real driving time and travel distance.
RESULTS: Among 14,944 patients undergoing high-risk cancer surgery (ES: 4.7\%, n = 1216; PN: 57.8\%, n = 8643; PD: 14.4\%, n = 2154; PR: 23.1\%, n = 3452), 782 (5.2\%) individuals resided in the 'Best', whereas 3393 (22.7\%) individuals resided in redlined areas. Median travel distance was 7.8 miles (interquartile range [IQR] 4.1-14.4) and travel time was 16.1 min (IQR 10.7-25.8). Overall, 10,763 (ES: 17.4\%; PN: 76.0\%; PA: 63.5\%; PR: 78.4\%) patients underwent surgery at an HVH. On multivariable regression, patients residing in redlined areas were less likely to undergo surgery at an HVH (odds ratio [OR] 0.67, 95\% confidence interval [CI] 0.54-0.82) and were more likely to bypass the nearest hospital (OR 1.80, 95\% CI 1.44-2.46). Notably, Medicaid insurance, minority status, limited English-language proficiency, and educational level mediated the disparities in access to HVH.
CONCLUSION: Surgical disparities in access to HVH among patients from historically redlined areas are largely mediated by social determinants such as insurance and minority status.},
	language = {eng},
	number = {3},
	journal = {Annals of Surgical Oncology},
	author = {Khalil, Mujtaba and Munir, Muhammad Musaab and Woldesenbet, Selamawit and Katayama, Erryk and Diaz, Adrian and Chen, J. C. and Obeng-Gyasi, Samilia and Pawlik, Timothy M.},
	month = mar,
	year = {2024},
	pmid = {38082168},
	keywords = {Humans, Neoplasms, United States, Hospitals, High-Volume, Disparities, Health Services Accessibility, California, Social determinants of health, Minority Groups, Cancer outcomes, Redlining, Structural racism},
	pages = {1477--1487},
}

@article{diaz617,
	title = {Association of {Neighborhood} {Characteristics} with {Utilization} of {High}-{Volume} {Hospitals} {Among} {Patients} {Undergoing} {High}-{Risk} {Cancer} {Surgery}},
	volume = {28},
	issn = {1534-4681},
	doi = {10.1245/s10434-020-08860-5},
	abstract = {INTRODUCTION: As high-risk cancer surgery continues to become more centralized, it is important to understand the association of neighborhood characteristics relative to access to surgical care. We sought to determine the neighborhood level characteristics that may be associated with travel patterns and utilization of high-volume hospitals.
METHODS: The California Office of Statewide Health Planning database was used to identify patients who underwent pancreatectomy (PD), esophagectomy (ES), proctectomy (PR), or pneumonectomy (PN) for cancer between 2014 and 2016. Total minutes (m) traveled as well as whether a patient bypassed the nearest hospital that performed the operation to get to a higher-volume center was assessed. Data were merged with the Centers for Disease control social vulnerability index (SVI).
RESULTS: Overall, 26,937 individuals (ES: 4.7\%; PN: 53.5\% PD: 13.9\% PR: 27.9\%) underwent a complex oncologic operation. Median travel time was 16 m (interquartile range [IQR] 8.3-30.24) [ES: 21.8 m (IQR 10.6-46.9); PN: 14 m (IQR 7.8-27.0); PD: 21.2 m (IQR 10.6-42.6); PR: 15 m (IQR 8.1-28.4)]. Nearly three-quarter of patients (ES: 34\%; PN: 73\%; PD: 72\%; LR: 81\%) underwent an operation at a high-volume hospital. For all four operations, patients who resided in a county with a high overall SVI were less likely to have surgery at a high-volume hospital (ES: odds ratio [OR] 0.39, 95\% confidence interval [CI] 0.24-0.65; PN: OR: 0.67, 95\% CI 0.51-0.88; PD: OR 0.61, 95\% CI 0.44-0.84; PR: OR 0.76, 95\% CI 0.58-0.98).
CONCLUSIONS: Patients residing in communities of high social vulnerability were less likely to undergo high-risk cancer surgery at a high-volume hospital. The identification of society-based contextual disparities in access to complex surgical care should serve to inform targeted strategies to direct additional resources toward these vulnerable communities.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Diaz, Adrian and Chavarin, Daniel and Paredes, Anghela Z. and Tsilimigras, Diamantis I. and Pawlik, Timothy M.},
	month = feb,
	year = {2021},
	pmid = {32699923},
	keywords = {Humans, Neoplasms, United States, Esophagectomy, Hospitals, High-Volume, Health Services Accessibility, Residence Characteristics, Pancreatectomy},
	pages = {617--631},
}

@article{mishra1785,
	title = {{ACA} {Medicaid} expansion reduced disparities in use of high-volume hospitals for pancreatic surgery},
	volume = {170},
	issn = {1532-7361},
	doi = {10.1016/j.surg.2021.05.033},
	abstract = {BACKGROUND: Early evaluation of the Affordable Care Act's Medicaid expansion demonstrated persistent disparities among Medicaid beneficiaries in use of high-volume hospitals for pancreatic surgery. Longer-term effects of expansion remain unknown. This study evaluated the impact of expansion on the use of high-volume hospitals for pancreatic surgery among Medicaid and uninsured patients.
METHODS: State inpatient databases (2012-2017), the American Hospital Association Annual Survey Database, and the Area Resource File from the Health Resources and Services Administration, were used to examine 8,264 non-elderly adults who underwent pancreatic surgery in nine expansion and two non-expansion states. High-volume hospitals were defined as performing 20 or more resections/year. Linear probability triple differences models measured pre- and post-Affordable Care Act utilization rates of pancreatic surgery at high-volume hospitals among Medicaid and uninsured patients versus privately insured patients in expansion versus non-expansion states.
RESULTS: The Affordable Care Act's expansion was associated with increased rates of utilization of high-volume hospitals for pancreatic surgery by Medicaid and uninsured patients (48\% vs 55.4\%, P = .047) relative to privately insured patients in expansion states (triple difference estimate +11.7\%, P = .022). A pre-Affordable Care Act gap in use of high-volume hospitals among Medicaid and uninsured patients in expansion states versus non-expansion states (48\% vs 77\%, P {\textless} .0001) was reduced by 15.1\% (P = .001) post Affordable Care Act. A pre Affordable Care Act gap between expansion versus non-expansion states was larger for Medicaid and uninsured patients relative to privately insured patients by 24.9\% (P {\textless} .0001) and was reduced by 11.7\% (P = .022) post Affordable Care Act. Rates among privately insured patients remained unchanged.
CONCLUSION: Medicaid expansion was associated with greater utilization of high-volume hospitals for pancreatic surgery among Medicaid and uninsured patients. These findings are informative to non-expansion states considering expansion. Future studies should target understanding referral mechanism post-expansion.},
	language = {eng},
	number = {6},
	journal = {Surgery},
	author = {Mishra, Ankit and DeLia, Derek and Zeymo, Alexander and Aminpour, Nathan and McDermott, James and Desale, Sameer and Al-Refaie, Waddah B.},
	month = dec,
	year = {2021},
	pmid = {34303545},
	keywords = {Humans, Female, Male, Middle Aged, Pancreatic Neoplasms, Adult, United States, Hospitals, High-Volume, Health Services Accessibility, Healthcare Disparities, Pancreatectomy, Medicaid, Referral and Consultation, Patient Protection and Affordable Care Act},
	pages = {1785--1793},
}

@article{herb304,
	title = {A {Comparison} of {Area}-{Level} {Socioeconomic} {Status} {Indices} in {Colorectal} {Cancer} {Care}},
	volume = {280},
	issn = {1095-8673},
	doi = {10.1016/j.jss.2022.07.036},
	abstract = {INTRODUCTION: There are multiple measures of area socioeconomic status (SES) and there is little evidence on the comparative performance of these measures. We hypothesized adding area SES measures improves model ability to predict guideline concordant care and overall survival compared to models with standard clinical and demographic data alone.
MATERIALS AND METHODS: We included patients with colorectal cancer from 2006 to 2015 from the North Carolina Cancer Registry merged with insurance claims data. The primary area SES study variables were the Social Deprivation Index, Distressed Communities Index, Area Deprivation Index, and Social Vulnerability Index. We used multivariable logistic modeling and Cox proportional hazards modeling to assess the adjusted association of each indicator, with guideline concordant care and overall survival, respectively. Model performance of the SES measures was compared to a base model using likelihood ratio testing and area under the curve (AUC) assessments to compare SES indicator models with each other.
RESULTS: We found that the Area Deprivation Index, Social Vulnerability Index and Social Deprivation Index, but not Distressed Communities Index, were significantly associated with receiving guideline concordant care and significantly improved model fit over the base model on likelihood ratio testing. All models had similar AUCs. With respect to overall survival, we found that all indices were independently and significantly associated with survival and had significantly improved model fit over the base model on likelihood ratio testing. AUC analysis again showed all area SES measures had comparable performance for overall survival at 5 y.
CONCLUSIONS: This analysis demonstrates the importance of including these measures in risk adjustment models. However, of the commonly available measures, no one measure stood out as superior to others.},
	language = {eng},
	journal = {The Journal of Surgical Research},
	author = {Herb, Joshua and Dunham, Lisette and Stitzenberg, Karyn},
	month = dec,
	year = {2022},
	pmid = {36030606},
	keywords = {Humans, Colorectal Neoplasms, Registries, Colorectal cancer, Socioeconomic Factors, Social Class, Socioeconomic status, Neighborhood deprivation, Risk Adjustment},
	pages = {304--311},
	file = {PDF:/Users/jcsal/Zotero/storage/Z5IX2YWK/Herb et al. - 2022 - A Comparison of Area-Level Socioeconomic Status Indices in Colorectal Cancer Care.pdf:application/pdf},
}

@article{bakillah176,
	title = {Barriers and facilitators to surgical access in underinsured and immigrant populations},
	volume = {226},
	issn = {1879-1883},
	doi = {10.1016/j.amjsurg.2023.04.003},
	abstract = {BACKGROUND: Marginalized communities are at risk of receiving inequitable access to surgical care. We aimed to examine the barriers and facilitators to access to surgery in underinsured and immigrant populations.
METHODS: A systematic review of disparities in access to surgical care was performed between January 1, 2000-March 2, 2022. Methodological quality was assessed with the Mixed Methods Appraisal Tool. A convergent integrated approach was used to code common themes between studies.
RESULTS: Of 1315 publications, a total of 66 studies were included for systematic review. Eight studies specifically discussed immigrant patient populations. Barriers and facilitators to surgical access were categorized by patient and health systems related factors.
CONCLUSIONS: Established facilitators to improve surgical access are centered on patient-level factors while interventions to address systems-related barriers are limited and may be an area for further investigation. Research focused on access to surgery in immigrant populations remains sparse.},
	language = {eng},
	number = {2},
	journal = {American Journal of Surgery},
	author = {Bakillah, Emna and Brown, Danielle and Syvyk, Solomiya and Wirtalla, Christopher and Kelz, Rachel R.},
	month = aug,
	year = {2023},
	pmid = {37156680},
	keywords = {Humans, Medically Uninsured, Health disparities, Emigrants and Immigrants, Immigrant, Qualitative Research, Surgical access, Uninsured},
	pages = {176--185},
}

@article{chan1,
	title = {Narrative review of worldwide data on outcomes of robotic esophagectomy},
	volume = {6},
	journal = {Annals of Esophagus},
	author = {Chan, EG and Villa Sanchez, Manuel},
	month = jun,
	year = {2023},
	pages = {1},
	file = {PDF:/Users/jcsal/Zotero/storage/76K4J6J7/Chan and Villa Sanchez - 2023 - Narrative review of worldwide data on outcomes of robotic esophagectomy.pdf:application/pdf},
}

@article{weaver1301,
	title = {Can {MDM2} analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?},
	volume = {23},
	issn = {1530-0285},
	doi = {10.1038/modpathol.2010.106},
	abstract = {Well-differentiated liposarcoma/atypical lipomatous tumor can be difficult to differentiate from benign lipomatous tumors, especially on limited biopsy material. Adjunctive tests for MDM2 (murine double minute 2) have proven useful in whole-tissue sections; however, their utility has not been determined within the increasingly popular core needle biopsy. Herein, we compare the ability of MDM2 immunohistochemistry and MDM2 fluorescence in situ hybridization (FISH) to discriminate benign lipomatous tumors from well-differentiated liposarcoma on core needle biopsies. Well-differentiated liposarcoma (n=17) and an assortment of benign lipomatous tumors (n=37), which had concurrent or previous core needle biopsies, and resection specimens were subjected to both MDM2 immunohistochemistry and MDM2 FISH on both whole-tissue sections and corresponding core needle biopsy sections. Percentage tumor cells positive for MDM2 by immunohistochemistry and an MDM2:CEP12 FISH ratio was calculated in each biopsy and resection specimen pair and the results were compared. MDM2 FISH had a higher sensitivity (100\%) and specificity (100\%) compared with MDM2 immunohistochemistry (65 and 89\%) in core needle biopsies, respectively. In addition, MDM2 immunohistochemistry had a false-positive rate of 11\%, compared to 0\% with FISH. The average MDM2:CEP12 ratio was similar in the biopsy material compared with the whole-tissue sections in both well-differentiated liposarcoma and the benign lipomatous tumor group of neoplasms. Detection of MDM2 amplification by FISH is a more sensitive and specific adjunctive test than MDM2 immunohistochemistry to differentiate well-differentiated liposarcoma from various benign lipomatous tumors, especially on limited tissue samples.},
	language = {eng},
	number = {10},
	journal = {Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc},
	author = {Weaver, Joshua and Rao, Priya and Goldblum, John R. and Joyce, Michael J. and Turner, Sondra L. and Lazar, Alexander J. F. and López-Terada, Dolores and Tubbs, Raymond R. and Rubin, Brian P.},
	month = oct,
	year = {2010},
	pmid = {20495536},
	keywords = {Humans, Sensitivity and Specificity, Biopsy, Needle, Immunohistochemistry, Biomarkers, Tumor, Diagnosis, Differential, In Situ Hybridization, Fluorescence, Lipoma, Liposarcoma, Proto-Oncogene Proteins c-mdm2},
	pages = {1301--1306},
}

@article{modlin61,
	title = {Gastroenteropancreatic neuroendocrine tumours},
	volume = {9},
	issn = {1474-5488},
	doi = {10.1016/S1470-2045(07)70410-2},
	abstract = {Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms that present many clinical challenges. They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mass effects. Investigation and management should be highly individualised for a patient, taking into consideration the likely natural history of the tumour and general health of the patient. Management strategies include surgery for cure (which is achieved rarely) or for cytoreduction, radiological intervention (by chemoembolisation and radiofrequency ablation), chemotherapy, and somatostatin analogues to control symptoms that result from release of peptides and neuroamines. New biological agents and somatostatin-tagged radionuclides are under investigation. The complexity, heterogeneity, and rarity of GEP NETs have contributed to a paucity of relevant randomised trials and little or no survival increase over the past 30 years. To improve outcome from GEP NETs, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling. More-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed. Comparison between treatments is currently very difficult. Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics.},
	language = {eng},
	number = {1},
	journal = {The Lancet. Oncology},
	author = {Modlin, Irvin M. and Oberg, Kjell and Chung, Daniel C. and Jensen, Robert T. and de Herder, Wouter W. and Thakker, Rajesh V. and Caplin, Martyn and Delle Fave, Gianfranco and Kaltsas, Greg A. and Krenning, Eric P. and Moss, Steven F. and Nilsson, Ola and Rindi, Guido and Salazar, Ramon and Ruszniewski, Philippe and Sundin, Anders},
	month = jan,
	year = {2008},
	pmid = {18177818},
	keywords = {Humans, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Animals, Biomarkers, Tumor, Carcinoma, Neuroendocrine, Molecular Biology, Protein-Tyrosine Kinases, Somatostatin},
	pages = {61--72},
	file = {1-s2.0-S1470204507704102-main:C\:\\Users\\jsalo01\\Downloads\\1-s2.0-S1470204507704102-main.pdf:application/pdf},
}

@article{basuroy1071,
	title = {Review article: the investigation and management of gastric neuroendocrine tumours},
	volume = {39},
	issn = {1365-2036},
	shorttitle = {Review article},
	doi = {10.1111/apt.12698},
	abstract = {BACKGROUND: Gastric carcinoids (GCs) or neuroendocrine tumours (NETs) are increasingly identified at endoscopy, and account for 0.6-2\% of all gastric polyps identified. The SEER database in the US has demonstrated a rising incidence of gastric NETs amongst all NETs; from 2.2\% between 1950 and 1969 to 6.0\% between 2000 and 2007.
AIM: To review the literature and assist clinicians in managing patients with GCs.
METHODS: A literature search was conducted through MEDLINE using search terms: gastric, carcinoid, neuroendocrine tumour, therapy, endoscopy, mucosal resection, submucosal dissection. Relevant articles were identified through manual review. The reference lists of these articles were reviewed to include further appropriate articles.
RESULTS: There are three types of GCs with important epidemiological, pathophysiological, histological and endoscopic differences that affect prognosis and management. Type 1 and 2 GCs develop in the context of hypergastrinaemia that originates from achlorhydria in atrophic gastritis and a gastrinoma, respectively. Type 3 GCs occur sporadically and independent of gastrin. The histological type, grade and Ki67 index are used to determine prognosis and direct clinical management. Type 1 GCs {\textgreater}1 cm in size and type 2 GCs should be assessed for invasion beyond the submucosa with EUS prior to endoscopic resection with EMR or ESD. Type 3 GCs should be managed as per recommendations for gastric adenocarcinoma. The treatment of advanced disease is multimodal.
CONCLUSIONS: Patients with gastric carcinoids should be discussed in a specialist neuroendocrine tumour multidisciplinary meeting to ensure all treatment options are explored in localised and advanced disease. Areas of controversy exist that need further research.},
	language = {eng},
	number = {10},
	journal = {Alimentary Pharmacology \& Therapeutics},
	author = {Basuroy, R. and Srirajaskanthan, R. and Prachalias, A. and Quaglia, A. and Ramage, J. K.},
	month = may,
	year = {2014},
	pmid = {24628514},
	keywords = {Humans, Prognosis, Stomach Neoplasms, Endoscopy, Dissection, Polyps, Gastrins, Gastritis, Atrophic, Neuroendocrine Tumors},
	pages = {1071--1084},
}

@article{fraenkel691,
	title = {Epidemiology of gastroenteropancreatic neuroendocrine tumours},
	volume = {26},
	issn = {1532-1916},
	doi = {10.1016/j.bpg.2013.01.006},
	abstract = {Gastroenteropancreatic neuroendocrine tumours are a heterogeneous group of tumours arising from diffuse endocrine cells, causing unique clinical syndromes. These tumours, formerly named carcinoid, can involve any part of the gastrointestinal tract and the endocrine pancreas and have a wide range of malignant potential: from benign to poorly differentiated tumours. In this review we will summarize the data available on the epidemiology of gastroenteropancreatic tumours as it is reported from around the world. This includes annual incidence rates at the various anatomic sites, and trends in incidence rates with time. In addition age and stage at presentation, gender and racial differences and finally prognosis and survival were collected when reported.},
	language = {eng},
	number = {6},
	journal = {Best Practice \& Research. Clinical Gastroenterology},
	author = {Fraenkel, M. and Kim, M. K. and Faggiano, A. and Valk, G. D.},
	month = dec,
	year = {2012},
	pmid = {23582913},
	keywords = {Humans, Pancreatic Neoplasms, United States, Stomach Neoplasms, Incidence, Registries, Europe, Global Health, Neuroendocrine Tumors, Intestinal Neoplasms},
	pages = {691--703},
	file = {Full Text:/Users/jcsal/Zotero/storage/52W8IVNZ/Fraenkel et al. - 2012 - Epidemiology of gastroenteropancreatic neuroendocrine tumours.pdf:application/pdf},
}

@article{ychou1715a,
	title = {Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an {FNCLCC} and {FFCD} multicenter phase {III} trial},
	volume = {29},
	issn = {1527-7755},
	shorttitle = {Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma},
	doi = {10.1200/JCO.2010.33.0597},
	abstract = {PURPOSE: After curative resection, the prognosis of gastroesophageal adenocarcinoma is poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of perioperative fluorouracil plus cisplatin in resectable gastroesophageal adenocarcinoma.
PATIENTS AND METHODS: Overall, 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction (GEJ), or stomach were randomly assigned to either perioperative chemotherapy and surgery (CS group; n = 113) or surgery alone (S group; n = 111). Chemotherapy consisted of two or three preoperative cycles of intravenous cisplatin (100 mg/m(2)) on day 1, and a continuous intravenous infusion of fluorouracil (800 mg/m(2)/d) for 5 consecutive days (days 1 to 5) every 28 days and three or four postoperative cycles of the same regimen. The primary end point was OS.
RESULTS: Compared with the S group, the CS group had a better OS (5-year rate 38\% v 24\%; hazard ratio [HR] for death: 0.69; 95\% CI, 0.50 to 0.95; P = .02); and a better disease-free survival (5-year rate: 34\% v 19\%; HR, 0.65; 95\% CI, 0.48 to 0.89; P = .003). In the multivariable analysis, the favorable prognostic factors for survival were perioperative chemotherapy (P = .01) and stomach tumor localization (P {\textless} .01). Perioperative chemotherapy significantly improved the curative resection rate (84\% v 73\%; P = .04). Grade 3 to 4 toxicity occurred in 38\% of CS patients (mainly neutropenia) but postoperative morbidity was similar in the two groups.
CONCLUSION: In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.},
	language = {eng},
	number = {13},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Ychou, Marc and Boige, Valérie and Pignon, Jean-Pierre and Conroy, Thierry and Bouché, Olivier and Lebreton, Gilles and Ducourtieux, Muriel and Bedenne, Laurent and Fabre, Jean-Michel and Saint-Aubert, Bernard and Genève, Jean and Lasser, Philippe and Rougier, Philippe},
	month = may,
	year = {2011},
	pmid = {21444866},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Adult, Chemotherapy, Adjuvant, Drug Administration Schedule, Fluorouracil, Stomach Neoplasms, Cisplatin, Disease-Free Survival, Esophageal Neoplasms, Combined Modality Therapy, Esophagogastric Junction, Perioperative Period},
	pages = {1715--1721},
}

@article{hoeppner323,
	title = {Perioperative {Chemotherapy} or {Preoperative} {Chemoradiotherapy} in {Esophageal} {Cancer}},
	volume = {392},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2409408},
	abstract = {BACKGROUND: The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative chemoradiotherapy.
METHODS: In this phase 3, multicenter, randomized trial, we assigned in a 1:1 ratio patients with resectable esophageal adenocarcinoma to receive perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery. Eligibility criteria included a primary tumor with a clinical stage of cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease, in which T indicates the size and extent of the tumor (higher numbers indicate a more advanced tumor), and N indicates the presence (N+) or absence (N0) of cancer spread to the lymph nodes, without evidence of metastatic spread. The primary end point was overall survival.
RESULTS: From February 2016 through April 2020, we assigned 221 patients to the FLOT group and 217 patients to the preoperative-chemoradiotherapy group. With a median follow-up of 55 months, overall survival at 3 years was 57.4\% (95\% confidence interval [CI], 50.1 to 64.0) in the FLOT group and 50.7\% (95\% CI, 43.5 to 57.5) in the preoperative-chemoradiotherapy group (hazard ratio for death, 0.70; 95\% CI, 0.53 to 0.92; P = 0.01). Progression-free survival at 3 years was 51.6\% (95\% CI, 44.3 to 58.4) in the FLOT group and 35.0\% (95\% CI, 28.4 to 41.7) in the preoperative-chemoradiotherapy group (hazard ratio for disease progression or death, 0.66; 95\% CI, 0.51 to 0.85). Among the patients who started the assigned treatment, grade 3 or higher adverse events were observed in 120 of 207 patients (58.0\%) in the FLOT group and in 98 of 196 patients (50.0\%) in the preoperative-chemoradiotherapy group. Serious adverse events were observed in 98 of 207 patients (47.3\%) in the FLOT group and in 82 of 196 patients (41.8\%) in the preoperative-chemoradiotherapy group. Mortality at 90 days after surgery was 3.1\% in the FLOT group and 5.6\% in the preoperative-chemoradiotherapy group.
CONCLUSIONS: Perioperative chemotherapy with FLOT led to improved survival among patients with resectable esophageal adenocarcinoma as compared with preoperative chemoradiotherapy. (Funded by the German Research Foundation; ESOPEC ClinicalTrials.gov number, NCT02509286.).},
	language = {eng},
	number = {4},
	journal = {The New England Journal of Medicine},
	author = {Hoeppner, Jens and Brunner, Thomas and Schmoor, Claudia and Bronsert, Peter and Kulemann, Birte and Claus, Rainer and Utzolino, Stefan and Izbicki, Jakob Robert and Gockel, Ines and Gerdes, Berthold and Ghadimi, Michael and Reichert, Benedikt and Lock, Johan F. and Bruns, Christiane and Reitsamer, Ernst and Schmeding, Maximillian and Benedix, Frank and Keck, Tobias and Folprecht, Gunnar and Thuss-Patience, Peter and Neumann, Ulf Peter and Pascher, Andreas and Imhof, Detlef and Daum, Severin and Strieder, Tanja and Krautz, Christian and Zimmermann, Simone and Werner, Jens and Mahlberg, Rolf and Illerhaus, Gerald and Grimminger, Peter and Lordick, Florian},
	month = jan,
	year = {2025},
	pmid = {39842010},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Kaplan-Meier Estimate, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Leucovorin, Survival Analysis, Adenocarcinoma, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Paclitaxel, Oxaliplatin, Docetaxel, Preoperative Care, Carboplatin, Perioperative Care},
	pages = {323--335},
	file = {PDF:/Users/jcsal/Zotero/storage/K6NBWF7V/Hoeppner et al. - 2025 - Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.pdf:application/pdf},
}

@article{furst173a,
	title = {Colon interposition for esophageal replacement: an alternative technique based on the use of the right colon},
	volume = {231},
	issn = {0003-4932},
	shorttitle = {Colon interposition for esophageal replacement},
	doi = {10.1097/00000658-200002000-00004},
	abstract = {OBJECTIVE: To describe the technique and results of an alternative colon interposition procedure in which the ascending and transverse colon is used as graft, but that still relies on the left colonic artery for blood supply.
SUMMARY BACKGROUND DATA: The standard procedure to obtain a left colon interposition graft requires ligation of the middle colic artery and mobilization of the left and right flexure. This approach carries a risk because preparation of the left flexure may damage arterial or venous collaterals located at this site that are crucial for graft perfusion.
METHODS: The authors modified the standard technique so that mobilization of the left flexure is no longer necessary. To obtain a colon interposition graft that is long enough, the ascending colon was included into the graft by ligating the middle and the right colic artery. The left colic artery remained the blood-supplying vessel. From January 1997 to June 1998, 15 patients underwent modified colon interposition with a cervical anastomosis (12 esophagectomies, 3 esophagogastrectomies).
RESULTS: In all cases, intraoperative blood supply from the left colic artery to the proximal ascending colon was sufficient. After surgery, four major complications occurred (27\%). Endoscopy demonstrated a vital graft in all patients. In one patient a leakage of the cervical anastomosis was observed. One patient died of herpes pneumonia. Postoperative artificial ventilation was required for an average of 2.8 +/- 4.6 days, the average intensive care unit stay was 6.9+/-4.5 days, and the average total hospital stay was 24.1 +/- 15.1 days.
CONCLUSION: An intact left colic artery, including its collaterals at the splenic flexure, supplies sufficient blood to the proximal ascending colon after central ligation of the middle and right colic artery. Even without mobilization of the left flexure, a sufficient graft length can be obtained. Preliminary complication rates with the use of this technique for colon interposition are in the range of those found for the standard colon interposition technique. These modifications may represent an alternative to established procedures for creating a colon interposition graft.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Fürst, H. and Hartl, W. H. and Löhe, F. and Schildberg, F. W.},
	month = feb,
	year = {2000},
	pmid = {10674607},
	pmcid = {PMC1420983},
	keywords = {Anastomosis, Surgical, Colon, Colon Interposition, Esophageal Neoplasms, Esophagectomy, Esophagus, Humans, Surgically-Created Structures, Transplantation, Autologous},
	pages = {173--178},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/KYH7XENU/Fürst et al. - 2000 - Colon interposition for esophageal replacement an alternative technique based on the use of the rig.pdf:application/pdf},
}

@article{orringer47,
	title = {Reversing esophageal discontinuity},
	volume = {19},
	issn = {1043-0679},
	doi = {10.1053/j.semtcvs.2006.11.004},
	abstract = {Catastrophic esophageal or gastric disruption drive the decision to "disconnect" the esophagus to prevent ongoing mediastinal soilage. The operations used to establish esophageal discontinuity are not standardized and vary widely, the surgeon often focusing on saving the patient's life, not on how alimentary continuity will ultimately be restored. Patients who survive the initial disastrous infectious complications are typically desperate to have further surgery to allow them to eat again. Relatively little is written about the decisions involved in reversing esophageal discontinuity--the timing of the operation, preoperative assessment and preparation, planning and conduct of the operation, and outcome. The nuances of reestablishing alimentary continuity in this disparate patient population are the focus of this article.},
	language = {eng},
	number = {1},
	journal = {Seminars in Thoracic and Cardiovascular Surgery},
	author = {Orringer, Mark B.},
	year = {2007},
	pmid = {17403458},
	keywords = {Anastomosis, Surgical, Colon, Colon Interposition, Critical Care, Decision Making, Digestive System Surgical Procedures, Esophageal Diseases, Esophagectomy, Esophagostomy, Esophagus, Humans, Mediastinitis, Perioperative Care, Postoperative Complications, Stomach, Treatment Outcome},
	pages = {47--55},
	file = {PDF:/Users/jcsal/Zotero/storage/I5AN5TZT/Orringer - 2007 - Reversing esophageal discontinuity.pdf:application/pdf},
}

@article{cheng151,
	title = {Colon interposition},
	volume = {155},
	issn = {0080-0015},
	doi = {10.1007/978-3-642-59600-1_16},
	abstract = {In the anatomy of the colon vasculature, the ascending branch of the left colic artery is the primary supplying vessel (96.91\%). Isoperistaltic transposition of the transverse colon is preferred (83.58\%). Riolan's vascular arcade is not a major vessel of the colon. It can only be found in less than 10\% of patients, and whether or not this arcade is complete cannot be used as criterion to judge colon blood supply. Animal experiments and clinical studies have confirmed the superiority of one-layer over two-layer anastomosis. The former is simpler, safer, and more reliable, with a lower incidence of anastomotic leak or stricture. Based on a comprehensive evaluation of the disease type, patient age, heart and lung functions, nutritional status, and accompanying diseases, three colon transposition routes are available (anterosternal subcutaneous tunnel, retrosternal tunnel, and esophageal bed passage). The advantages and disadvantages of each route are analyzed, and the left-middle-left retrosternal route is described. The indications for esophageal reconstruction with colon operation (ERC) were collected and verified, increasing the number of indications to seven categories of diseases. The main complications of ERC, i.e., colon segment necrosis, anastomotic leak, recurrent laryngeal nerve injury, and intestinal obstruction were systematically studied, and their causes and prevention are detailed. The number of patients is the highest in a single unit among all the published reports. The incidence of complications and deaths are the lowest.},
	language = {eng},
	journal = {Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer},
	author = {Cheng, B. and Chen, K. and Gao, S. and Tu, Z.},
	year = {2000},
	pmid = {10693249},
	keywords = {Adolescent, Adult, Aged, Anastomosis, Surgical, Child, Child, Preschool, Colon, Colon Interposition, Esophageal Diseases, Female, Humans, Male, Middle Aged, Postoperative Complications},
	pages = {151--160},
}

@article{sanchez511,
	title = {Colon {Interposition} for {Esophageal} {Cancer}},
	volume = {32},
	issn = {1558-5069},
	doi = {10.1016/j.thorsurg.2022.07.006},
	abstract = {Esophagectomy and colon interposition in the adult patient, either for primary alimentary reconstruction or as a secondary replacement after initial resection/reconstruction for malignant or benign disease, remains a valuable tool in the thoracic surgeon's armamentarium. It is important for surgeons to remain versed in the complexities of the operation, including preoperative preparation and decision making, operative procedural and technical variations, and recognition and timely treatment of postoperative complications. In this article, we present technical details of the procedure, a review of selected published studies, long-term results, and indications and outcomes for revisional surgery.},
	language = {eng},
	number = {4},
	journal = {Thoracic Surgery Clinics},
	author = {Sanchez, Manuel Villa and Alicuben, Evan T. and Luketich, James D. and Sarkaria, Inderpal S.},
	month = nov,
	year = {2022},
	pmid = {36266037},
	keywords = {Adult, Colon, Colon interposition, Colon Interposition, Esophageal cancer, Esophageal Neoplasms, Esophagectomy, Humans, Midazolam, Postoperative Complications},
	pages = {511--527},
	file = {PDF:/Users/jcsal/Zotero/storage/K96EDN6J/Sanchez et al. - 2022 - Colon Interposition for Esophageal Cancer.pdf:application/pdf},
}

@article{demeester460,
	title = {Indications, surgical technique, and long-term functional results of colon interposition or bypass},
	volume = {208},
	issn = {0003-4932},
	doi = {10.1097/00000658-198810000-00008},
	abstract = {Over a 17-year period, 92 patients with esophageal disease underwent colon interposition or bypass, with each operation performed by the same surgeon. The indication was cure of cancer in 20 patients, relief of dysphagia in 55 (cancer in 17 patients and benign in 38), loss of gastrointestinal (G.I.) continuity in ten, and tracheoesophageal fistula in seven patients (malignant in five, benign in 2). The thirty-day operative mortality rate was 5\%, and the hospital mortality rate was 9\%. Graft necrosis occurred in seven of 92 patients, four of whom later underwent a successful second reconstruction. Thirteen patients required subsequent revisional surgery. In 85 patients, the left colon based on the inferior mesenteric artery was used, and in seven, the right colon was used. Technical insights were gained to help preserve the blood supply to the graft and improve its function in transporting food. Thirty-four patients were available for interview 2-17 years after operation (median of 5 years) 28 of whom had benign disease, and six of whom had malignant disease); 82\% of the patients felt they were cured of their preoperative symptoms, 18\% improved, and none worsened. Eighty-eight per cent of the patients were able to receive an unrestricted diet. All patients except one were satisfied with the results of surgery, and, asked what they would do if they had to make the choice again, all responded that they would have the operation. Twenty-six of the interviewed patients had their eating ability evaluated with a test meal and the transit time of a liquid and solid barium bolus measured. Compared to controls, patients with colon interpositions consumed a smaller capacity meal over a longer period of time and were not dependent on liquids to flush the food through the colon graft. A colon interposition provides good quality of deglutition, is very durable, and is the organ of choice for patients who require an esophageal substitute and are potential candidates for long survival.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {DeMeester, T. R. and Johansson, K. E. and Franze, I. and Eypasch, E. and Lu, C. T. and McGill, J. E. and Zaninotto, G.},
	month = oct,
	year = {1988},
	pmid = {3178334},
	pmcid = {PMC1493741},
	keywords = {Adult, Aged, Aged, 80 and over, Colon, Colon Interposition, Eating, Esophageal Diseases, Esophageal Neoplasms, Esophagoplasty, Esophagus, Female, Humans, Male, Middle Aged, Postoperative Complications, Radiography, Reoperation},
	pages = {460--474},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/Y9X33L7S/DeMeester et al. - 1988 - Indications, surgical technique, and long-term functional results of colon interposition or bypass.pdf:application/pdf},
}

@article{furst173,
	title = {Colon interposition for esophageal replacement: an alternative technique based on the use of the right colon},
	volume = {231},
	issn = {0003-4932},
	shorttitle = {Colon interposition for esophageal replacement},
	doi = {10.1097/00000658-200002000-00004},
	abstract = {OBJECTIVE: To describe the technique and results of an alternative colon interposition procedure in which the ascending and transverse colon is used as graft, but that still relies on the left colonic artery for blood supply.
SUMMARY BACKGROUND DATA: The standard procedure to obtain a left colon interposition graft requires ligation of the middle colic artery and mobilization of the left and right flexure. This approach carries a risk because preparation of the left flexure may damage arterial or venous collaterals located at this site that are crucial for graft perfusion.
METHODS: The authors modified the standard technique so that mobilization of the left flexure is no longer necessary. To obtain a colon interposition graft that is long enough, the ascending colon was included into the graft by ligating the middle and the right colic artery. The left colic artery remained the blood-supplying vessel. From January 1997 to June 1998, 15 patients underwent modified colon interposition with a cervical anastomosis (12 esophagectomies, 3 esophagogastrectomies).
RESULTS: In all cases, intraoperative blood supply from the left colic artery to the proximal ascending colon was sufficient. After surgery, four major complications occurred (27\%). Endoscopy demonstrated a vital graft in all patients. In one patient a leakage of the cervical anastomosis was observed. One patient died of herpes pneumonia. Postoperative artificial ventilation was required for an average of 2.8 +/- 4.6 days, the average intensive care unit stay was 6.9+/-4.5 days, and the average total hospital stay was 24.1 +/- 15.1 days.
CONCLUSION: An intact left colic artery, including its collaterals at the splenic flexure, supplies sufficient blood to the proximal ascending colon after central ligation of the middle and right colic artery. Even without mobilization of the left flexure, a sufficient graft length can be obtained. Preliminary complication rates with the use of this technique for colon interposition are in the range of those found for the standard colon interposition technique. These modifications may represent an alternative to established procedures for creating a colon interposition graft.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Fürst, H. and Hartl, W. H. and Löhe, F. and Schildberg, F. W.},
	month = feb,
	year = {2000},
	pmid = {10674607},
	pmcid = {PMC1420983},
	keywords = {Anastomosis, Surgical, Colon, Colon Interposition, Esophageal Neoplasms, Esophagectomy, Esophagus, Humans, Surgically-Created Structures, Transplantation, Autologous},
	pages = {173--178},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/URSVIM2Y/Fürst et al. - 2000 - Colon interposition for esophageal replacement an alternative technique based on the use of the rig.pdf:application/pdf},
}

@article{leong2252,
	title = {{TOPGEAR}: {A} {Randomized}, {Phase} {III} {Trial} of {Perioperative} {ECF} {Chemotherapy} with or {Without} {Preoperative} {Chemoradiation} for {Resectable} {Gastric} {Cancer}: {Interim} {Results} from an {International}, {Intergroup} {Trial} of the {AGITG}, {TROG}, {EORTC} and {CCTG}},
	volume = {24},
	issn = {1534-4681},
	shorttitle = {{TOPGEAR}},
	doi = {10.1245/s10434-017-5830-6},
	abstract = {BACKGROUND: Postoperative chemoradiation and perioperative chemotherapy using epirubicin/cisplatin/5-fluorouracil (ECF) represent two standards of care for resectable gastric cancer. In the TOPGEAR (Trial Of Preoperative therapy for Gastric and Esophagogastric junction AdenocaRcinoma) trial, we hypothesized that adding preoperative chemoradiation to perioperative ECF will improve survival; however, the safety and feasibility of preoperative chemoradiation have yet to be determined.
METHODS: TOPGEAR is an international phase III trial in which patients with adenocarcinoma of the stomach were randomized to perioperative ECF alone or with preoperative chemoradiation. The ECF-alone group received three preoperative cycles of ECF, while the chemoradiation group received two cycles of preoperative ECF followed by chemoradiation. Both groups received three postoperative cycles of ECF. A planned interim analysis of the first 120 patients was conducted, and was reviewed by the Independent Data Safety Monitoring Committee to assess treatment compliance, toxicity/safety, and response rates.
RESULTS: The proportion of patients who received all cycles of preoperative chemotherapy was 93\% (ECF group) and 98\% (chemoradiation group), while 65 and 53\%, respectively, received all cycles of postoperative chemotherapy. Overall, 92\% of patients allocated to preoperative chemoradiation received this treatment. The proportion of patients proceeding to surgery was 90\% (ECF group) and 85\% (chemoradiation group). Grade 3 or higher surgical complications occurred in 22\% of patients in both groups. Furthermore, grade 3 or higher gastrointestinal toxicity occurred in 32\% (ECF group) and 30\% (chemoradiation group) of patients, while hematologic toxicity occurred in 50 and 52\% of patients.
CONCLUSIONS: These results demonstrate that preoperative chemoradiation can be safely delivered to the vast majority of patients without a significant increase in treatment toxicity or surgical morbidity.},
	language = {eng},
	number = {8},
	journal = {Annals of Surgical Oncology},
	author = {Leong, Trevor and Smithers, B. Mark and Haustermans, Karin and Michael, Michael and Gebski, Val and Miller, Danielle and Zalcberg, John and Boussioutas, Alex and Findlay, Michael and O'Connell, Rachel L. and Verghis, Jaclyn and Willis, David and Kron, Tomas and Crain, Melissa and Murray, William K. and Lordick, Florian and Swallow, Carol and Darling, Gail and Simes, John and Wong, Rebecca},
	month = aug,
	year = {2017},
	pmid = {28337660},
	keywords = {Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Chemotherapy, Adjuvant, Cisplatin, Combined Modality Therapy, Epirubicin, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Perioperative Care, Preoperative Care, Prognosis, Stomach Neoplasms, Survival Rate},
	pages = {2252--2258},
	file = {PDF:/Users/jcsal/Zotero/storage/NPCXCEMQ/Leong et al. - 2017 - TOPGEAR A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperativ.pdf:application/pdf},
}

@article{leong1810,
	title = {Preoperative {Chemoradiotherapy} for {Resectable} {Gastric} {Cancer}},
	volume = {391},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2405195},
	abstract = {BACKGROUND: In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone.
METHODS: We conducted an international, phase 3 trial in which patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone (control). In both groups, patients received either epirubicin, cisplatin, and fluorouracil or fluorouracil, leucovorin, oxaliplatin, and docetaxel both before and after surgery; the preoperative-chemoradiotherapy group also received chemoradiotherapy (45 Gy in 25 fractions of radiation, plus fluorouracil infusion). The primary end point was overall survival, and secondary end points included progression-free survival, pathological complete response, toxic effects, and quality of life.
RESULTS: A total of 574 patients underwent randomization at 70 sites in Australasia, Canada, and Europe: 286 to the preoperative-chemoradiotherapy group and 288 to the perioperative-chemotherapy group. A higher percentage of patients in the preoperative-chemoradiotherapy group than in the perioperative-chemotherapy group had a pathological complete response (17\% vs. 8\%) and greater tumor downstaging after resection. At a median follow-up of 67 months, no significant between-group differences in overall survival or progression-free survival were noted. The median overall survival was 46 months with preoperative chemoradiotherapy and 49 months with perioperative chemotherapy (hazard ratio for death, 1.05; 95\% confidence interval, 0.83 to 1.31), and the median progression-free survival was 31 months and 32 months, respectively. Treatment-related toxic effects were similar in the two groups.
CONCLUSIONS: The addition of preoperative chemoradiotherapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone among patients with resectable gastric and gastroesophageal junction adenocarcinoma. (Funded by the National Health and Medical Research Council and others; TOPGEAR ClinicalTrials.gov number, NCT01924819.).},
	language = {eng},
	number = {19},
	journal = {The New England Journal of Medicine},
	author = {Leong, Trevor and Smithers, B. Mark and Michael, Michael and Haustermans, Karin and Wong, Rebecca and Gebski, Val and O'Connell, Rachel L. and Zalcberg, John and Boussioutas, Alex and Findlay, Michael and Willis, David and Moore, Alisha and Murray, William K. and Lordick, Florian and O'Callaghan, Chris and Swallow, Carol and Darling, Gail and Miller, Danielle and Strickland, Andrew and Liberman, Moishe and Mineur, Laurent and Simes, John and {Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group}},
	month = nov,
	year = {2024},
	pmid = {39282905},
	keywords = {Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Adjuvant, Cisplatin, Dose Fractionation, Radiation, Epirubicin, Esophagogastric Junction, Female, Fluorouracil, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoadjuvant Therapy, Progression-Free Survival, Quality of Life, Stomach Neoplasms, Survival Analysis},
	pages = {1810--1821},
}

@article{frisco260,
	title = {Medullary thyroid cancer with {RET} {V804M} mutation: more indolent than expected?},
	volume = {173},
	issn = {1532-7361},
	shorttitle = {Medullary thyroid cancer with {RET} {V804M} mutation},
	doi = {10.1016/j.surg.2022.05.005},
	abstract = {BACKGROUND: Significant genotype-phenotype variability among multiple endocrine neoplasia type 2A patients with a RET V804M mutation has been reported.
METHODS: Patients with a RET V804M mutation treated at a single center were identified (January 1996-December 2020). The baseline characteristics, operative details, pathology, biochemical, and long-term data were analyzed.
RESULTS: There were 79 patients; none developed pheochromocytoma or hyperparathyroidism or died in the study period. The mean age was 41.5 years (range = 1.0-81.0 years); 46.8\% were men. Of 68 surgical patients, 53 (77.9\%) underwent total thyroidectomy and 15 (22.1\%) underwent total thyroidectomy with central neck dissection with or without lateral neck dissection. Twenty-four patients had elevated preoperative calcitonin, of whom 12 underwent total thyroidectomy (median = 7.5; range = 5.0-237.0 pg/mL), 10 underwent total thyroidectomy + central neck dissection (median = 27.6; range = 5.1-147.0 pg/mL), and 2 underwent total thyroidectomy + central neck dissection + lateral neck dissection (median = 3182.0; range = 361.0-6003.0 pg/mL). Pathology was benign (27.9\%), papillary thyroid cancer alone (1.5\%), C-cell hyperplasia (23.5\%), and medullary thyroid cancer (47.1\%; median tumor size = 3.0 mm). Three patients had elevated calcitonin postoperatively (median follow-up time = 60.0 months). In adjusted modeling, a preoperative calcitonin {\textgreater}5 pg/mL was associated with having medullary thyroid cancer on final pathology (odds ratio = 13.3; 95\% confidence interval, 3.2-56.3; P {\textless} .001).
CONCLUSION: In this large United States cohort of surgical patients with a RET V804M mutation, most had indolent disease and were without classic multiple endocrine neoplasia type 2A features. Calcitonin {\textgreater}5 pg/mL may serve as a meaningful value to guide surveillance and timing of surgery.},
	language = {eng},
	number = {1},
	journal = {Surgery},
	author = {Frisco, Nicholas A. and Gunn, Alexander H. and Thomas, Samantha M. and Stang, Michael T. and Scheri, Randall P. and Kazaure, Hadiza S.},
	month = jan,
	year = {2023},
	pmid = {36150924},
	keywords = {Humans, Mutation, Adrenal Gland Neoplasms, Calcitonin, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Proto-Oncogene Mas, Proto-Oncogene Proteins c-ret, Thyroid Neoplasms, Thyroidectomy},
	pages = {260--267},
	file = {PDF:/Users/jcsal/Zotero/storage/B3SAYYH5/Frisco et al. - 2023 - Medullary thyroid cancer with RET V804M mutation more indolent than expected.pdf:application/pdf},
}

@article{loveday4275,
	title = {p.{Val804Met}, the {Most} {Frequent} {Pathogenic} {Mutation} in {RET}, {Confers} a {Very} {Low} {Lifetime} {Risk} of {Medullary} {Thyroid} {Cancer}},
	volume = {103},
	issn = {1945-7197},
	doi = {10.1210/jc.2017-02529},
	abstract = {CONTEXT: To date, penetrance figures for medullary thyroid cancer (MTC) for variants in rearranged during transfection (RET) have been estimated from families ascertained because of the presence of MTC.
OBJECTIVE: To gain estimates of penetrance, unbiased by ascertainment, we analyzed 61 RET mutations assigned as disease causing by the American Thyroid Association (ATA) in population whole-exome sequencing data.
DESIGN: For the 61 RET mutations, we used analyses of the observed allele frequencies in ∼51,000 individuals from the Exome Aggregation Consortium (ExAC) database that were not contributed via The Cancer Genome Atlas (TCGA; non-TCGA ExAC), assuming lifetime penetrance for MTC of 90\%, 50\%, and unbounded.
SETTING: Population-based.
RESULTS: Ten of 61 ATA disease-causing RET mutations were present in the non-TCGA ExAC population with observed frequency consistent with penetrance for MTC of {\textgreater}90\%. For p.Val804Met, the lifetime penetrance for MTC, estimated from the allele frequency observed, was 4\% [95\% confidence interval (CI), 0.9\% to 8\%].
CONCLUSIONS: Based on penetrance analysis in carrier relatives of p.Val804Met-positive cases of MTC, p.Val804Met is currently understood to have high-lifetime penetrance for MTC (87\% by age 70), albeit of later onset of MTC than other RET mutations. Given our unbiased estimate of penetrance for RET p.Val804Met of 4\% (95\% CI, 0.9\% to 8\%), the current recommendation by the ATA of prophylactic thyroidectomy as standard for all RET mutation carriers is likely inappropriate.},
	language = {eng},
	number = {11},
	journal = {The Journal of Clinical Endocrinology and Metabolism},
	author = {Loveday, Chey and Josephs, Katherine and Chubb, Daniel and Gunning, Adam and Izatt, Louise and Tischkowitz, Marc and Ellard, Sian and Turnbull, Clare},
	month = nov,
	year = {2018},
	pmid = {29590403},
	pmcid = {PMC6194854},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Risk Assessment, Adult, United States, Datasets as Topic, Practice Guidelines as Topic, Societies, Medical, Polymorphism, Single Nucleotide, Penetrance, Carcinoma, Neuroendocrine, Multiple Endocrine Neoplasia Type 2a, Proto-Oncogene Proteins c-ret, Thyroid Neoplasms, Thyroidectomy, Databases, Genetic, Endocrinology, Exome Sequencing, Gene Frequency, Prophylactic Surgical Procedures, V804M},
	pages = {4275--4282},
	file = {Full Text:/Users/jcsal/Zotero/storage/2H2BG38A/Loveday et al. - 2018 - p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medul.pdf:application/pdf},
}

@article{machens3516,
	title = {Letter to the {Editor}: "p.{Val804Met}, the {Most} {Frequent} {Pathogenic} {Mutation} in {RET}, {Confers} a {Very} {Low} {Lifetime} {Risk} of {Medullary} {Thyroid} {Cancer}"},
	volume = {103},
	issn = {1945-7197},
	shorttitle = {Letter to the {Editor}},
	doi = {10.1210/jc.2018-00906},
	language = {eng},
	number = {9},
	journal = {The Journal of Clinical Endocrinology and Metabolism},
	author = {Machens, Andreas and Dralle, Henning},
	month = sep,
	year = {2018},
	pmid = {29947771},
	keywords = {Humans, Mutation, Proto-Oncogene Proteins c-ret, Thyroid Neoplasms, V804M},
	pages = {3516--3517},
	file = {Full Text:/Users/jcsal/Zotero/storage/CDEQ56BL/Machens and Dralle - 2018 - Letter to the Editor p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low.pdf:application/pdf},
}

@article{turnbull3518,
	title = {Response to {Letter} to the {Editor}: "p.{Val804Met}, the {Most} {Frequent} {Pathogenic} {Mutation} in {RET}, {Confers} a {Very} {Low} {Lifetime} {Risk} of {Medullary} {Thyroid} {Cancer}"},
	volume = {103},
	issn = {1945-7197},
	shorttitle = {Response to {Letter} to the {Editor}},
	doi = {10.1210/jc.2018-01094},
	language = {eng},
	number = {9},
	journal = {The Journal of Clinical Endocrinology and Metabolism},
	author = {Turnbull, Clare and Loveday, Chey and Izatt, Louise and Ellard, Sian},
	month = sep,
	year = {2018},
	pmid = {30032180},
	keywords = {Humans, Mutation, Proto-Oncogene Proteins c-ret, Thyroid Neoplasms, V804M},
	pages = {3518--3519},
	file = {Full Text:/Users/jcsal/Zotero/storage/GT5LYPWU/Turnbull et al. - 2018 - Response to Letter to the Editor p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confer.pdf:application/pdf},
}

@article{feldman93,
	title = {Variable expressivity of familial medullary thyroid carcinoma ({FMTC}) due to a {RET} {V804M} ({GTG}--{\textgreater}{ATG}) mutation},
	volume = {128},
	issn = {0039-6060},
	doi = {10.1067/msy.2000.107103},
	abstract = {BACKGROUND: Multiple endocrine neoplasia type 2 (MEN 2) and familial medullary thyroid carcinoma (FMTC) are autosomal dominantly inherited cancer syndromes that predispose to C-cell hyperplasia and MTC. MEN 2A and FMTC are caused by mutations in the RET proto-oncogene.
METHODS: We used a multiplex polymerase chain reaction-based assay to screen exons 10, 11, 13, and 14 of RET for mutations in 2 families with FMTC. We correlated mutation status with calcitonin and pathologic studies to determine genotype-phenotype correlations.
RESULTS: We identified a mutation in codon 804 in exon 14 (GTG--{\textgreater}ATG; V804M) in both families. An 86-year-old person who was a gene carrier and other individuals over age 70 who were suspected by pedigree analysis to be gene carriers had no overt clinical evidence of MTC. Four of 21 patients who underwent a thyroidectomy also had papillary thyroid cancer. One individual in each family had metastatic MTC at age 30 and 32 years, and all 26 people having thyroidectomies had either MTC or C-cell hyperplasia, leading us to continue to recommend prophylactic thyroidectomy for all identified patients who were gene carriers.
CONCLUSIONS: Because of active MTC in younger members of these families, including metastases, we have continued to advocate thyroid surgery in mutation-positive individuals. While DNA diagnosis of gene carriers and subsequent genetic counseling was relatively straightforward, the acceptance of surgical recommendations was more difficult for some individuals. These families demonstrate that the search for RET mutations should include exons 13, 14, 15, and 16 in patients whose studies in exons 10 and 11 are negative.},
	language = {eng},
	number = {1},
	journal = {Surgery},
	author = {Feldman, G. L. and Edmonds, M. W. and Ainsworth, P. J. and Schuffenecker, I. and Lenoir, G. M. and Saxe, A. W. and Talpos, G. B. and Roberson, J. and Petrucelli, N. and Jackson, C. E.},
	month = jul,
	year = {2000},
	pmid = {10876191},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Aged, 80 and over, Adult, Phenotype, Age of Onset, Pedigree, Carcinoma, Medullary, Proto-Oncogene Mas, Proto-Oncogene Proteins c-ret, Thyroid Neoplasms, Thyroidectomy, V804M, Drosophila Proteins, Exons, Family Health, Point Mutation, Proto-Oncogene Proteins, Receptor Protein-Tyrosine Kinases},
	pages = {93--98},
}

@article{chen138,
	title = {The {Impact} of {COVID}-19 {Pandemic} on the {Diagnosis}, {Treatment}, and {Outcomes} of {Colorectal} {Cancer} in {Singapore}},
	volume = {61},
	issn = {1648-9144},
	doi = {10.3390/medicina61010138},
	abstract = {Background and Objectives: During the COVID-19 pandemic, many countries implemented lockdowns and social distancing measures, which may delay the early diagnosis of colorectal cancer (CRC). This study aims to review the impact of the pandemic on the diagnosis and treatment outcomes of CRC. Materials and Methods: Patients who underwent colonoscopy or surgery for CRC were included. The study was divided into the pre-COVID-19 (January 2019-January 2020), early COVID-19 (February-May 2020), recovery (June-December 2020), and heightened alert (January-December 2021) periods. Cox regression was used to model the waiting time to colonoscopy. Multivariable logistic regression identified associations between time periods and incidence of CRC diagnosed. The characteristics and outcomes of the surgical procedures that were performed were compared across the time periods. Results: A total of 18,662 colonoscopies and 1462 surgical procedures were performed in the study period. Compared to the pre-COVID-19 period, there was a longer time to colonoscopy during the recovery (HR: 0.91; 95\% CI: 0.87, 0.94) and heightened alert periods (HR: 0.88; 95\% CI 0.85, 0.91). The early COVID-19 (OR: 1.36; 95\% CI: 1.04, 1.77) and recovery (OR: 1.20; 95\% CI: 1.01, 1.43) periods were associated with higher odds of diagnosing CRC. Compared to the pre-COVID-19 period, there was a higher proportion of ASA 4 patients (4.3\% vs. 1.3\%; p {\textless} 0.001) and stage 4 CRC patients (22.2\% vs. 16.9\%; p = 0.001) that required surgery during the heightened alert period. Similarly, there was a higher proportion of emergency surgeries (22\% vs. 13.3\%; p = 0.002); diverting stomas (13.5\% vs. 10.5\%; p = 0.005), and Hartmann's procedures (4.4\% vs. 0.4\%; p = 0.001) performed during the heightened alert period. Conclusions: The pandemic was associated with a higher proportion of metastatic CRC patients requiring surgery. Healthcare policies should facilitate early cancer screening, diagnosis, and treatment to reduce cancer-related morbidity for future pandemics.},
	language = {eng},
	number = {1},
	journal = {Medicina (Kaunas, Lithuania)},
	author = {Chen, Hui Lionel Raphael and Lee, Piea Peng and Zhao, Yun and Ng, Wei Hao Caleb and Zhao, Jiashen and Tan, Yu En Christopher and Loh, Bo Jie Sean and Chow, Kah-Hoe Pierce and Tan, Hiang Khoon and Tan, Kwong-Wei Emile},
	month = jan,
	year = {2025},
	pmid = {39859120},
	pmcid = {PMC11766542},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Colorectal Neoplasms, Retrospective Studies, Adult, surgery, colorectal cancer, outcomes, COVID-19, Early Detection of Cancer, Time-to-Treatment, Colonoscopy, Pandemics, colonoscopy, COVID-19 pandemic, SARS-CoV-2, Singapore},
	pages = {138},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/2RKNPTKM/Chen et al. - 2025 - The Impact of COVID-19 Pandemic on the Diagnosis, Treatment, and Outcomes of Colorectal Cancer in Si.pdf:application/pdf},
}

@article{taulean129,
	title = {Influence of {SARS}-{CoV2} {Pandemic} on {Colorectal} {Cancer} {Diagnosis}, {Presentation}, and {Surgical} {Management} in a {Tertiary} {Center}: {A} {Retrospective} {Study}},
	volume = {15},
	issn = {2075-4418},
	shorttitle = {Influence of {SARS}-{CoV2} {Pandemic} on {Colorectal} {Cancer} {Diagnosis}, {Presentation}, and {Surgical} {Management} in a {Tertiary} {Center}},
	doi = {10.3390/diagnostics15020129},
	abstract = {Background: Oncological surgery during the COVID-19 pandemic was performed only in carefully selected cases, due to variation in the allocation of resources. The purpose of this study was to highlight the impact of the pandemic lockdown on the presentation, diagnosis, and surgical management of colorectal cancers as well as the post-pandemic changes in this area. Material and methods: This single center, retrospective comparative study contained 1687 patients, divided into three groups with equal time frames of two years, consisting of a pre-pandemic, pandemic, and post-pandemic period, in which preoperative and perioperative as well as postoperative parameters were compared. Results: Statistically significant differences regarding environment, type of admission, and ASA score, as well as a more advanced tumoral stage, increased number of important postoperative complications, and a lower minimally invasive surgical approach, were highlighted within the pandemic group. Statistically significant differences regarding emergency diagnosis as well as late diagnosis were highlighted. There were no significant differences regarding the tumor location, postoperative 30-day mortality, or hospitalization duration. Conclusions: COVID-19 significantly impacted the surgical timing in colorectal cancer, as well as addressability for the rural population, with a marked decrease in elective cases as well as an increased number of cases diagnosed in an emergency setting, with locally advanced tumors. However, no significant changes in postoperative mortality or hospitalization duration were highlighted. In addition, most of the changes highlighted were reverted in the post-pandemic period. Further studies are required to observe the long-term effects in terms of morbidity and mortality, regarding the delay of diagnosis and oncological treatment.},
	language = {eng},
	number = {2},
	journal = {Diagnostics (Basel, Switzerland)},
	author = {Taulean, Roman and Zaharie, Roxana and Valean, Dan and Usatiuc, Lia and Dib, Mohammad and Moiș, Emil and Popa, Calin and Ciocan, Andra and Fetti, Alin and Al-Hajjar, Nadim and Zaharie, Florin},
	month = jan,
	year = {2025},
	pmid = {39857012},
	pmcid = {PMC11763504},
	keywords = {diagnosis, prognosis, colorectal surgery, COVID-19 pandemic, morbidity and mortality},
	pages = {129},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/5XBDCELI/Taulean et al. - 2025 - Influence of SARS-CoV2 Pandemic on Colorectal Cancer Diagnosis, Presentation, and Surgical Managemen.pdf:application/pdf},
}

@article{mattiuzzi,
	title = {Mortality trends for colorectal cancer during the {COVID}-19 pandemic in the {US}},
	issn = {1863-4362},
	doi = {10.1007/s11845-025-03883-x},
	language = {eng},
	journal = {Irish Journal of Medical Science},
	author = {Mattiuzzi, Camilla and Lippi, Giuseppe},
	month = jan,
	year = {2025},
	pmid = {39853534},
}

@article{szkudlarek134,
	title = {Impact of the {COVID}-19 {Pandemic} on {Histopathological} {Cancer} {Diagnostics} in {Lower} {Silesia}: {A} {Comparative} {Analysis} of {Prostate}, {Breast}, and {Colorectal} {Cancer} from 2018 to 2022},
	volume = {17},
	issn = {2072-6694},
	shorttitle = {Impact of the {COVID}-19 {Pandemic} on {Histopathological} {Cancer} {Diagnostics} in {Lower} {Silesia}},
	doi = {10.3390/cancers17010134},
	abstract = {BACKGROUND/OBJECTIVE: The COVID-19 pandemic significantly disrupted healthcare systems worldwide including cancer diagnostics. This study aimed to assess the impact of the pandemic on histopathological cancer diagnostics in Lower Silesia, Poland, specifically focusing on prostate, breast, and colorectal cancer cases from 2018 to 2022. The objective was to evaluate diagnostic volumes and trends before, during, and after the pandemic and to understand the effect of healthcare disruptions on cancer detection.
METHODS: Histopathological and cytological data were collected from multiple laboratories across Lower Silesia. Samples were categorized into three periods: pre-pandemic (January 2018-February 2020), pandemic (March 2020-May 2022), and post-pandemic (June-December 2022). Statistical analyses included comparisons of diagnostic volumes and positive diagnoses across these periods.
RESULTS: A significant reduction in the number of histopathological examinations occurred during the pandemic, particularly during its early phase. This decline was accompanied by a higher frequency of positive cancer diagnoses, suggesting the prioritization of high-risk cases. Post-pandemic, diagnostic activity showed partial recovery, though it remained below the pre-pandemic levels, with notable differences across cancer types.
CONCLUSIONS: The COVID-19 pandemic significantly disrupted cancer diagnostics in Lower Silesia, delaying detection and highlighting healthcare system vulnerabilities. These findings underscore the importance of resilient healthcare systems that can ensure the continuity of essential diagnostic services and address inequalities in access to care during crises.},
	language = {eng},
	number = {1},
	journal = {Cancers},
	author = {Szkudlarek, Danuta and Kalinowska, Katarzyna and Wiatrak, Benita},
	month = jan,
	year = {2025},
	pmid = {39796761},
	pmcid = {PMC11720222},
	keywords = {colorectal cancer, COVID-19, breast cancer, prostate cancer},
	pages = {134},
}

@article{kumare0317057,
	title = {Effect of the {COVID}-19 pandemic on colorectal cancer screening in two university-affiliated health care systems},
	volume = {20},
	issn = {1932-6203},
	doi = {10.1371/journal.pone.0317057},
	abstract = {OBJECTIVES: In two large university affiliated healthcare systems, we examined trends in colorectal cancer (CRC) screening both prior to and during the COVID-19 pandemic to compare the trends in non-invasive screening tests and colonoscopy.
MATERIALS AND METHODS: In this retrospective time-trend analysis, we obtained the numbers of colonoscopies and non-invasive tests performed monthly during the pandemic and the year prior to it. We obtained colonoscopy data from five endoscopy units with the indication determined by dual independent review. Monthly numbers of completed fecal immunochemical (FIT) and FIT-DNA tests were obtained from the electronic medical records of both health systems. Trends in testing, numbers, and stage of incident CRCs diagnosed during the 30-month interval were examined using Poisson regression and logistic regression, respectively.
RESULTS: From January 2019 to June 2021, we identified 16,939 FIT tests, 2,942 FIT-DNA tests, and 38,332 colonoscopies from the two health systems, and 368 colorectal cancers (105 early stage, 263 advanced stage) from the private hospital system. Overall colonoscopy volume declined by 18.7\% (from 16,483 to 13,393) in 2020 compared to 2019 in both health systems, returning to baseline in 2021. Non-invasive tests declined by 21.9\% in 2020, but increased in 2021 due to greater use of FIT/DNA. Compared to 2019, incident CRCs declined in 2020 but rebounded in 2021, with no difference in early versus late-stage cancers.
CONCLUSIONS: These trends in CRC screening tests may be useful for modeling the effects of the pandemic on the longer-term outcomes of CRC incidence and mortality.},
	language = {eng},
	number = {1},
	journal = {PloS One},
	author = {Kumar, Vinod and Golzarri-Arroyo, Lilian and Roth, Sarah and Imperiale, Thomas F.},
	year = {2025},
	pmid = {39761313},
	pmcid = {PMC11703052},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Retrospective Studies, COVID-19, Early Detection of Cancer, Colonoscopy, Occult Blood, Pandemics, SARS-CoV-2},
	pages = {e0317057},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/9JZIJYVA/Kumar et al. - 2025 - Effect of the COVID-19 pandemic on colorectal cancer screening in two university-affiliated health c.pdf:application/pdf},
}

@article{langevin,
	title = {Rebound in {Fecal} {Testing}, {Colonoscopy} {Utilization}, and {Colorectal} {Neoplasia} {Detection} {During} the {COVID}-19 {Pandemic}},
	issn = {1572-0241},
	doi = {10.14309/ajg.0000000000003293},
	abstract = {INTRODUCTION: The COVID-19 pandemic reduced colorectal cancer (CRC) screening, but the rebound in testing and outcomes after the pandemic has not been widely reported. We evaluated CRC test utilization and colorectal neoplasia detection among screening eligible patients in a large health system in 2020 and 2021, compared with 2019 (prepandemic).
METHODS: Using a retrospective cohort study design, fecal immunochemical test (FIT) and colonoscopy utilization, FIT positivity, and neoplasia detection were evaluated annually in 2019-2021 among Kaiser Permanente Northern California patients aged 50-75 years overall and by sex, age, race and ethnicity, and spoken language preference.
RESULTS: Compared with 2019, reductions in FIT, colonoscopy, FIT positivity, and neoplasia detection in 2020 were followed by a strong rebound in 2021 and no subgroups by age and sex or minority subgroups by race and ethnicity or spoken language preference demonstrably lagged in their recovery in 2021. Among White persons and those with an English language preference, there was a small lag in recovery to baseline levels. The overall decline in CRC testing by colonoscopy in 2020 was offset by a lesser decrease in FIT utilization in 2020, and a strong rebound in FIT utilization in 2021 helped to offset the small lag in the rebound in colonoscopies completed in 2021.
DISCUSSION: Findings may help guide organizations looking to improve CRC screening and minimize health care disparities related to national emergencies such as pandemics. Long-term studies are needed to evaluate how pandemic-related changes in CRC screening practices will affect future CRC outcomes.},
	language = {eng},
	journal = {The American Journal of Gastroenterology},
	author = {Langevin, Michael J. and Jensen, Christopher D. and Marks, Amy R. and Merchant, Sophie A. and Badalov, Jessica and Lee, Jeffrey K. and Lam, Angela Y. and Halm, Ethan A. and Levin, Theodore R.},
	month = jan,
	year = {2025},
	pmid = {39760381},
}

@article{janssens445,
	title = {Decreased incidence and shift in stage distribution for colorectal cancers in {Belgium} during the {COVID}-19 pandemic},
	volume = {87},
	issn = {1784-3227},
	doi = {10.51821/87.4.13081},
	abstract = {BACKGROUND AND STUDY AIMS: The COVID-19 pandemic substantially impacted the healthcare system and society in 2020. This study assessed its possible impact on occurrence and stage of colorectal cancer diagnoses in Belgium.
METHODS: Population-based data from the Belgian Cancer Registry were used to extrapolate 2017-2019 trends in incidence and stage distribution to expected counts for 2020 that were subsequently compared to the observed values. Stage-specific predictions were corrected to account for the overall decline in diagnoses.
RESULTS: In 2020, 705 fewer than expected invasive and 255 fewer in situ colorectal cancers were diagnosed. For colon cancer, significant declines were observed in all genders and regions, mainly in the screening age group and in age 75+. For rectal cancers, there was only a significant decline in the latter two groups. Colon cancer pStage distribution did not change significantly. In situ rectal tumors showed a relative decline in Flanders and in the screening age group. In the latter group, more than expected cStage III rectal cancers were observed in women.
CONCLUSIONS: The excess decline in in situ rectal cancers is likely attributable to the temporary suspension of the colorectal screening program during the first pandemic wave. The overall decline in colon and rectal cancer incidence in Belgium in 2020 was not accompanied by a stage shift. Longer-term effects or impact on clinically relevant outcomes cannot be excluded.},
	language = {eng},
	number = {4},
	journal = {Acta Gastro-Enterologica Belgica},
	author = {Janssens, S. and Van Herck, K. and Peacock, H. M. and Giusti, F. and Silversmit, G. and Van Damme, N. and Van Eycken, L.},
	year = {2024},
	pmid = {39745031},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Neoplasm Staging, Aged, 80 and over, Adult, colon cancer, Incidence, Registries, colorectal cancer, COVID-19, Early Detection of Cancer, rectal cancer, COVID-19 pandemic, SARS-CoV-2, Belgium, population-based data, stage shift},
	pages = {445--455},
}

@article{zheng3983,
	title = {The {Association} of the {COVID}-19 {Pandemic} with the {Uptake} of {Colorectal} {Cancer} {Screening} {Varies} by {Socioeconomic} {Status} in {Flanders}, {Belgium}},
	volume = {16},
	issn = {2072-6694},
	doi = {10.3390/cancers16233983},
	abstract = {OBJECTIVES: To assess the association of the COVID-19 pandemic with an uptake rate and screening interval between two screening rounds in colorectal cancer screening program (CRCSP) and identify the disproportionate correlation of socioeconomic status (SES) factors.
METHODS: An analysis was performed on aggregated screening and SES data at the area level in Flanders, Belgium, during 2018-2022. The screening uptake rate was the percentage of people returning self-test results within 40 days after invitation, and the screening interval was the number of days between current and previous screening. Differences in uptake rate and screening interval before and during COVID-19 were categorized into 10 quantiles, and determinants were evaluated using quantile regression models.
RESULTS: Significant change was seen from March to August 2020. The areas with the greatest decrease in uptake rate and screening interval had low population density, and areas with the greatest increase in screening interval had the highest income and percentage of home ownership. In regression analysis, more people living alone (β = -0.09), lower income (β = 0.10), and a higher percentage of home ownership (β = -0.06) were associated with a greater decrease in uptake rate. Areas with lower population density (β = -0.75), fewer people of Belgian nationality (β = -0.11), and higher income (β = 0.42) showed greater increases in screening interval.
CONCLUSIONS: During the COVID-19 pandemic, people in areas with low SES were less likely to participate in screening, whereas people in areas with high SES were more likely to delay participation. A tailored invitation highlighting benefits of CRCSP is needed for people with low SES to improve uptake. Timely warnings could help people who delay participation adhere to screening intervals.},
	language = {eng},
	number = {23},
	journal = {Cancers},
	author = {Zheng, Senshuang and Ding, Lilu and Greuter, Marcel J. W. and Tran, Thuy Ngan and Sidorenkov, Grigory and Hoeck, Sarah and Goossens, Mathieu and Van Hal, Guido and de Bock, Geertruida H.},
	month = nov,
	year = {2024},
	pmid = {39682170},
	pmcid = {PMC11640482},
	keywords = {colorectal cancer, COVID-19, Belgium, cancer screening, guideline uptake, socioeconomic status},
	pages = {3983},
	file = {Full Text:/Users/jcsal/Zotero/storage/PSI4B3VE/Zheng et al. - 2024 - The Association of the COVID-19 Pandemic with the Uptake of Colorectal Cancer Screening Varies by So.pdf:application/pdf},
}

@article{khalaf177,
	title = {Prevalence and {Outcomes} of {Emergency} {Presentations} of {Colorectal} {Cancer} in {Veterans} {Affairs} {Health} {Care} {System}},
	volume = {70},
	issn = {1573-2568},
	doi = {10.1007/s10620-024-08762-6},
	abstract = {BACKGROUND: Colorectal cancer (CRC) diagnoses are frequently made through emergency presentations (EPs), a new cancer diagnosis following an emergency care episode or unplanned inpatient admission. The extent and implications of EPs are not well known in the Veterans Affairs (VA) health system, where robust CRC screening protocols exist. The impact of the COVID-19 pandemic on the route of CRC diagnosis also remains unclear.
METHODS: We conducted a retrospective cohort study of all incident CRC cases diagnosed nationally in the VA health care system from 2017 to 2021. We applied a previously validated algorithm to identify CRC EPs and used multivariable logistic regression and Cox proportional hazards models to examine the associations between EPs and CRC stage, treatment, and mortality.
RESULTS: We identified 9,096 patients with CRC, 28.1\% of whom had EPs, with the proportion of EPs increasing over the study period from 26.4\% in 2017-2019 to 31.4\% in 2020-2021. Patients with EPs were more likely to have advanced stage disease (adjusted OR 1.70; 95\% CI 1.53-1.88) and less likely to receive cancer treatment (adjusted OR 0.65; 95\% CI 0.56-0.75) than patients without EPs. Patients with EPs also had significantly higher mortality risk (adjusted HR 1.70; 95\% CI 1.56-1.84).
CONCLUSION: In a large cohort of patients diagnosed with CRC, we found EPs to be common and independently associated with worse cancer outcomes. EPs also increased during the COVID-19 pandemic. Interventions are needed to reduce potentially avoidable EPs and improve outcomes of patients with CRC diagnosis.},
	language = {eng},
	number = {1},
	journal = {Digestive Diseases and Sciences},
	author = {Khalaf, Natalia and Ali, Basim and Zimolzak, Andrew J. and Liu, Yan and Kramer, Jennifer R. and El-Serag, Hashem B. and Kanwal, Fasiha and Singh, Hardeep},
	month = jan,
	year = {2025},
	pmid = {39661278},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prevalence, Colorectal Neoplasms, Retrospective Studies, United States, Survival, Colorectal cancer, COVID-19, Epidemiology, Veterans, Emergency Service, Hospital, SARS-CoV-2, Emergency cancer diagnosis, Emergency presentation, Health services, United States Department of Veterans Affairs},
	pages = {177--190},
}

@article{yoon,
	title = {The impact of the {COVID}-19 pandemic on clinical practices related to colorectal cancer and colonoscopy in {South} {Korea}: a nationwide population-based study},
	issn = {1598-9100},
	shorttitle = {The impact of the {COVID}-19 pandemic on clinical practices related to colorectal cancer and colonoscopy in {South} {Korea}},
	doi = {10.5217/ir.2024.00066},
	abstract = {BACKGROUND/AIMS: Despite of the coronavirus disease 2019 (COVID-19) pandemic, there is little data regarding its impact on colorectal cancer (CRC)-related clinical practice. This study aimed to assess the changes in its impact during the COVID-19 pandemic.
METHODS: This was a retrospective national population-based study using the Health Insurance Review and Assessment database from January 2019 to December 2021. The number of patients in 2020 and 2021 was compared with those in 2019 for the diagnostic and therapeutic colonoscopy, CRC-related operation, and any treatment for CRC.
RESULTS: The annual number of patients undergoing diagnostic colonoscopies decreased by 6.9\% in 2020 but increased 8.1\% in 2021, compared to those in 2019; number of patients undergoing therapeutic colonoscopies increased by 6.0\% and 37.7\% in 2020 and 2021, respectively; number of patients operated for CRC decreased by 4.2\% in 2020 and increased by 2.3\% in 2021. The number of patients treated for CRC decreased by 2.8\% in 2020 and increased by 4.4\% in 2021. Diagnostic and therapeutic colonoscopies and any CRC-related treatment decreased by 43.8\%, 37.5\%, and 11.3\% in March 2020, during the first surge of COVID-19, but increased by 26.0\%, 58.1\%, and 9.5\% in June 2021, respectively. CRC-related operations decreased by 24.1\% in April 2020 and increased by 12.6\% in August 2021.
CONCLUSIONS: Negative impact of the COVID-19 pandemic on clinical practices related to CRC completely recovered within second year. It could be considered for the development of an optimal strategy on CRC management in response to the pandemic-driven crisis.},
	language = {eng},
	journal = {Intestinal Research},
	author = {Yoon, Jin Young and Lee, Moon Hyung and Kwak, Min Seob and Cha, Jae Myung},
	month = nov,
	year = {2024},
	pmid = {39610265},
	keywords = {Colorectal neoplasms, COVID-19, Colonoscopy, Mass screening, Surgical procedures},
}

@article{siddique,
	title = {Disparities in {Colorectal} {Cancer} {Screening} {Before} and {After} the {Onset} of the {COVID} {Pandemic}},
	issn = {1525-1497},
	doi = {10.1007/s11606-024-09153-3},
	abstract = {BACKGROUND: Colorectal cancer (CRC) screening is underutilized among those with lower socioeconomic status and in racial and ethnic minoritized populations who have been disproportionately impacted by COVID.
OBJECTIVE: To compare disparities in CRC screening before and after the onset of the COVID pandemic among privately insured individuals.
DESIGN: Retrospective cohort study using deidentified claims data from the USA between January 1, 2017, and December 31, 2022.
PARTICIPANTS: Blue Cross Blue Shield beneficiaries aged 50-75 years with average risk of CRC.
MAIN MEASURE(S): Mean screening use was compared by demographic and area-level socioeconomic factors between the periods preceding (January 1, 2017 to February 28, 2020) and following (July 1, 2020 to December 31, 2022) the onset of the COVID pandemic. Difference-in-differences analysis was used to evaluate changes in screening differences.
RESULTS: Our study included 21,724,223 beneficiaries. Compared to males, females had higher screening in both periods (p {\textless} 0.05), and this sex difference in screening increased 1.63\% (95\% confidence interval [CI]: 1.32\%, 1.94\%) following the onset of the pandemic. Compared to residents in areas with high socioeconomic status (SES), low SES area residents had lower screening (p {\textless} 0.001) during both periods. Furthermore, this difference grew 4.32\% (95\% CI, 3.76\%, 4.88\%) during the post-onset period. Metropolitan area residents had higher screening than non-metropolitan area residents during both periods (p {\textless} 0.001); however, this difference decreased 0.77\% (95\% CI, 0.34\%, 1.20\%) during the post-onset period. Among beneficiaries with high risk of CRC, the difference in screening based on social deprivation index and metropolitan area status increased 6.99\% (95\% CI, 5.77\%, 8.20\%) and 1.82\% (95\% CI, 0.88\%, 2.74\%), respectively.
CONCLUSIONS: Among privately insured individuals, CRC screening after the COVID pandemic recovered unevenly based on sex, area-level socioeconomic measures, and metropolitan area status, with pre-pandemic disparities persisting and even worsening for some of the factors.},
	language = {eng},
	journal = {Journal of General Internal Medicine},
	author = {Siddique, Sunny and Wang, Rong and Gaddy, Jacquelyne J. and Stempel, Jessica M. and Warren, Joshua L. and Gross, Cary P. and Ma, Xiaomei},
	month = nov,
	year = {2024},
	pmid = {39495455},
	keywords = {disparity, colorectal cancer screening, COVID},
	file = {PDF:/Users/jcsal/Zotero/storage/BTTMTP2H/Siddique et al. - 2024 - Disparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic.pdf:application/pdf},
}

@article{munigala18201,
	title = {Disparities in the use of colorectal cancer screening in a universally insured population during the {COVID}-19 pandemic},
	volume = {12},
	issn = {2045-7634},
	doi = {10.1002/cam4.6400},
	abstract = {BACKGROUND: Despite the known efficacy of colorectal cancer (CRC) screening, the rates of individuals undergoing such testing have remained lower than target thresholds, even prior to the healthcare disruptions associated with the COVID-19 pandemic. We evaluated the impact of the COVID-19 pandemic on CRC screening within a nationally representative US population and assessed disparities in screening across racial/ethnic groups and socioeconomic (SES) strata.
METHODS: We performed a retrospective cross-sectional study using all eligible TRICARE beneficiaries aged 45-64 years between FY 2018 and 2021. High-risk individuals, those with a previous or current CRC diagnosis, and/or a personal/family history of colonic polyps, were excluded. The pre-COVID-19 period (September 1, 2018-March 31, 2020) was compared to the COVID-19 period (April 1, 2020-September 30, 2021). Secondary analyses were performed, evaluating the interaction between the COVID-19 time period, race, and our proxy for socioeconomic status.
RESULTS: During the study period, we identified 1,749,688 eligible individuals. Following the onset of the COVID-19 pandemic, CRC screening overall decreased from 34\% in the pre-pandemic period to 30\% following the onset of the pandemic (p {\textless} 0.001). This finding persisted even after adjusting for confounders in multivariable analysis (odds ratio [OR] for the pandemic timeframe: 0.79; 95\% CI: 0.27, 0.31; p {\textless} 0.001). In the setting of SES, in the pandemic period, the odds of individuals from both Senior Enlisted (OR: 0.55; 95\% CI: 0.54, 0.56) and Junior Enlisted sponsor ranks (OR: 0.27; 95\% CI: 0.25, 0.30) were diminished as compared to Senior Officers.
CONCLUSIONS AND RELEVANCE: We found a 21\% reduction in the odds of CRC screening in the context of the COVID-19 pandemic. Reductions in colonoscopies and other types of screening tests were not offset by changes in the use of at-home tests such as Cologuard.},
	language = {eng},
	number = {17},
	journal = {Cancer Medicine},
	author = {Munigala, Satish and Schoenfeld, Andrew J. and Mani, Vivitha and Banaag, Amanda and Umoh, Ada and Coles, Christian L. and Koehlmoos, Tracey Perez},
	month = sep,
	year = {2023},
	pmid = {37644735},
	pmcid = {PMC10524012},
	keywords = {colorectal cancer, screening, cancer prevention, epidemiology and prevention},
	pages = {18201--18210},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/69EQXDLI/Munigala et al. - 2023 - Disparities in the use of colorectal cancer screening in a universally insured population during the.pdf:application/pdf},
}

@article{girardi130,
	title = {Disparities in access to breast, colorectal, and cervical cancer screening programmes have intensified during the pandemic period. {Findings} of a health equity audit conducted by the {Pavia} {Healthcare} {Protection} {Agency} ({Lombardy} {Region}, {Northern} {Italy})},
	volume = {48},
	issn = {1120-9763},
	doi = {10.19191/EP24.2.A672.040},
	abstract = {OBJECTIVES: to evaluate the disparities in access to cancer screening programmes in the Province of Pavia (Lombardy Region, Northern Italy), along with identifying the factors influencing these disparities; to assess the impact of the pandemic emergency on invitation and screening coverage in the three organized screening programmes, which are provided free of charge to the target population.
DESIGN: observational retrospective study covering both the pre-pandemic and the pandemic periods.
SETTING AND PARTICIPANTS: for breast cancer screening, the eligible population comprises women aged 45 to 74; colorectal cancer screening is offered to men and women aged 50 to 74; cervical cancer screening is tailored based on women age. The management of all three screening programmes is overseen by the Health Protection Agency of Pavia, which proactively invites the eligible population through invitation letters.
MAIN OUTCOMES MEASURES: for each screening programme, the examination coverage (the number of screened individuals out of the total eligible population) was analysed considering its influencing factors, with a specific emphasis on equity-related factors such as demographics (sex, age), geographic factors (country and continent of birth, residential district), comorbidities.
RESULTS: the SARS-CoV-2 pandemic has led to a reorganization of healthcare services and to a reduction of the offer, resulting in an overall reduction in test coverage for all three programmes (-16.3\% for breast and colorectal cancer screening, -8.5\% for cervical cancer screening). The disparities in coverage among various population groups, reflecting inequalities in access, further escalated from the pre-pandemic to the pandemic period. Noteworthy, equity-related predictors of reduced screening access were non-Italian nationality and residency in rural or mountainous districts.
CONCLUSIONS: during periods of healthcare system strain, such as the pandemic, disparities in access can become more pronounced. It is crucial to implement measures for enhancing access to screening in a more equitable manner.},
	language = {eng},
	number = {2},
	journal = {Epidemiologia E Prevenzione},
	author = {Girardi, Daniela and Vecchio, Riccardo and Tanious, Marina and Cacitti, Stefano and Ancarani, Cinzia and Dalle Carbonare, Simona and Perotti, Pietro and Bonafede, Chiara and Cavallo, Roberta and Gentile, Leandro and Parrini, Andrea and Lucente, Erika Maria and Carlesso, Alessandro and Cadum, Ennio and Cecconami, Lorella and Odone, Anna and Deandrea, Silvia},
	year = {2024},
	pmid = {38770730},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Retrospective Studies, Health Services Accessibility, Healthcare Disparities, Breast Neoplasms, Mass Screening, COVID-19, Early Detection of Cancer, Italy, Pandemics, Health Equity, SARS-CoV-2, Mass screening, Equity, Health equity audit (HEA), Prevention, Uterine Cervical Neoplasms},
	pages = {130--139},
}

@article{zhao1580,
	title = {Colorectal {Cancer} {Screening} {Rates} at {Federally} {Qualified} {Health} {Centers} {From} 2014 to 2022: {Incomplete} {Recovery} {From} {COVID}-19 and {Worsening} {Disparities}},
	volume = {119},
	issn = {1572-0241},
	shorttitle = {Colorectal {Cancer} {Screening} {Rates} at {Federally} {Qualified} {Health} {Centers} {From} 2014 to 2022},
	doi = {10.14309/ajg.0000000000002706},
	abstract = {INTRODUCTION: Federally Qualified Health Centers (FQHC) provide preventive health services such as colorectal cancer (CRC) screening to low-income and underinsured individuals. Overall CRC screening participation in the United States declined during the COVID-19 pandemic and recovered by 2021; however, trends in underresourced settings are unknown.
METHODS: Using Uniform Data System data from 2014 to 2022, we assessed trends in FQHC CRC screening rates nationally, in California, and in Los Angeles County and determined clinic-level factors associated with recent screening rate changes. For each FQHC, we calculated the screening rate change from 2019 to 2020, 2020 to 2021, and 2020 to 2022. We used mixed-effects linear regression to determine clinic-level characteristics associated with each screening rate change.
RESULTS: Across all FQHC (n = 1,281), 7,016,181 patients were eligible for CRC screening in 2022. Across the United States and in California, median screening rates increased from 2014 to 2019, severely declined in 2020, and failed to return to prepandemic levels by 2022. Both nationally and in California, CRC screening declined most dramatically from 2019 to 2020 in FQHC serving majority Hispanic/Latino patients or a high proportion of patients experiencing homelessness. From 2020 to 2022, screening rates did not recover completely in US FQHC, with disproportionate recovery among FQHC serving majority non-Hispanic Black patients.
DISCUSSION: CRC screening rates at FQHC did not return to prepandemic levels by 2022, and recovery varied by FQHC patient characteristics. Tailored interventions addressing low and decreasing CRC screening rates in FQHC are urgently needed to mitigate worsening CRC disparities.},
	language = {eng},
	number = {8},
	journal = {The American Journal of Gastroenterology},
	author = {Zhao, Matthew Y. and Lei, Yvonne Y. and Aaronson, Megan R. M. and De Silva, Sadie R. and Badiee, Jayraan and May, Folasade P.},
	month = aug,
	year = {2024},
	pmid = {38529856},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, United States, Healthcare Disparities, California, Safety-net Providers, COVID-19, Early Detection of Cancer, SARS-CoV-2},
	pages = {1580--1589},
	file = {PDF:/Users/jcsal/Zotero/storage/636IJMLE/Zhao et al. - 2024 - Colorectal Cancer Screening Rates at Federally Qualified Health Centers From 2014 to 2022 Incomplet.pdf:application/pdf},
}

@article{khan3222,
	title = {Association of {COVID}-19 {Pandemic} with {Colorectal} {Cancer} {Screening}: {Impact} of {Race}/{Ethnicity} and {Social} {Vulnerability}},
	volume = {31},
	issn = {1534-4681},
	shorttitle = {Association of {COVID}-19 {Pandemic} with {Colorectal} {Cancer} {Screening}},
	doi = {10.1245/s10434-024-15029-x},
	abstract = {BACKGROUND: The COVID-19 pandemic disrupted health care delivery, including cancer screening practices. This study sought to determine the impact of the COVID-19 pandemic lockdown on colorectal cancer (CRC) screening relative to social vulnerability.
METHODS: Using the Medicare Standard Analytic File, individuals 65 years old or older who were eligible for guideline-concordant CRC screening between 2019 and 2021 were identified. These data were merged with the Center for Disease Control Social Vulnerability Index (SVI) dataset. Changes in county-level monthly screening volumes relative to the start of the COVID-19 pandemic (March 2020) and easing of restrictions (March 2021) were assessed relative to SVI.
RESULTS: Among 10,503,180 individuals continuously enrolled in Medicare with no prior diagnosis of CRC, 1,362,457 (12.97\%) underwent CRC screening between 2019 and 2021. With the COVID-19 pandemic, CRC screening decreased markedly across the United States (median monthly screening: pre-pandemic [n = 76,444] vs pandemic era [n = 60,826]; median Δn = 15,618; p {\textless} 0.001). The 1-year post-pandemic overall CRC screening utilization generally rebounded to pre-COVID-19 levels (monthly median screening volumes: pandemic era [n = 60,826] vs post-pandemic [n = 74,170]; median Δn = 13,344; p {\textless} 0.001). Individuals residing in counties with the highest SVI experienced a larger decline in CRC screening odds than individuals residing in low-SVI counties (reference, low SVI: pre-pandemic high SVI [OR, 0.85] vs pandemic high SVI [OR, 0.81] vs post-pandemic high SVI [OR, 0.85]; all p {\textless} 0.001).
CONCLUSIONS: The COVID-19 pandemic was associated with a decrease in CRC screening volumes. Patients who resided in high social vulnerability areas experienced the greatest pandemic-related decline.},
	language = {eng},
	number = {5},
	journal = {Annals of Surgical Oncology},
	author = {Khan, Muhammad Muntazir Mehdi and Munir, Muhammad Musaab and Woldesenbet, Selamawit and Endo, Yutaka and Khalil, Mujtaba and Tsilimigras, Diamantis and Harzman, Alan and Huang, Emily and Kalady, Matthew and Pawlik, Timothy M.},
	month = may,
	year = {2024},
	pmid = {38361094},
	pmcid = {PMC10997707},
	keywords = {Humans, Aged, Neoplasms, United States, Medicare, Colorectal cancer, Ethnicity, COVID-19, Cancer screening, Early Detection of Cancer, Pandemics, COVID-19 pandemic, Communicable Disease Control, Social Vulnerability},
	pages = {3222--3232},
	file = {Full Text:/Users/jcsal/Zotero/storage/IR9HPLGQ/Khan et al. - 2024 - Association of COVID-19 Pandemic with Colorectal Cancer Screening Impact of RaceEthnicity and Soci.pdf:application/pdf},
}

@article{boyle486,
	title = {Inequalities in the recovery of colorectal cancer services during the {COVID}-19 pandemic: a national population-based study},
	volume = {26},
	issn = {1463-1318},
	shorttitle = {Inequalities in the recovery of colorectal cancer services during the {COVID}-19 pandemic},
	doi = {10.1111/codi.16887},
	abstract = {AIM: Evidence is lacking on whether there were inequalities in the recovery of colorectal cancer (CRC) services within the English National Health Service (NHS) following the COVID-19 pandemic. The aim of this study was to evaluate recovery according to patient age and socioeconomic status.
METHOD: Using routinely collected data, CRC patients diagnosed and treated in the English NHS were identified for two timeframes: the 'initial pandemic period' (April-June 2020) and the 'pandemic period' (April 2020-March 2022). Poisson models evaluated changes in numbers of diagnoses, major resections, adjuvant chemotherapy and neoadjuvant radiotherapy use for each timeframe, relative to the equivalent pre-pandemic timeframe (April-June 2019 and April 2018-March 2020, respectively), stratified by age and socioeconomic status. Tumour stage at presentation was evaluated over time.
RESULTS: Substantial deficits in diagnoses, major resections and adjuvant chemotherapy were identified in the initial pandemic period, whilst the use of neoadjuvant radiotherapy increased. Overall, these deficits recovered. Patients outside screening age, and in the most deprived group, had greater deficits in diagnoses and major resections. There was no evidence of stage migration by June 2021.
CONCLUSIONS: CRC services showed recovery to baseline during the pandemic. However, evident inequalities must be addressed in ongoing recovery efforts. Long-term outcomes will fully establish the impact of the pandemic on CRC patients.},
	language = {eng},
	number = {3},
	journal = {Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland},
	author = {Boyle, Jemma M. and Kuryba, Angela and Blake, Helen A. and van der Meulen, Jan and Fearnhead, Nicola S. and Braun, Michael S. and Walker, Kate},
	month = mar,
	year = {2024},
	pmid = {38302858},
	keywords = {Humans, Colorectal Neoplasms, Chemotherapy, Adjuvant, colorectal cancer, COVID-19, State Medicine, Pandemics, COVID‐19, deprivation, health services research},
	pages = {486--496},
	file = {PDF:/Users/jcsal/Zotero/storage/D4FK3V83/Boyle et al. - 2024 - Inequalities in the recovery of colorectal cancer services during the COVID-19 pandemic a national.pdf:application/pdf},
}

@article{chung1013,
	title = {Disparate impact of the {COVID}-19 pandemic on delays in colorectal cancer treatment: {A} {National} {Cancer} {Database} study},
	volume = {175},
	issn = {1532-7361},
	shorttitle = {Disparate impact of the {COVID}-19 pandemic on delays in colorectal cancer treatment},
	doi = {10.1016/j.surg.2023.12.016},
	abstract = {BACKGROUND: Timely treatment for patients with colorectal cancer may have been disrupted by the COVID-19 pandemic. We evaluated the impact of the pandemic on delays to treatment with surgery or systemic therapy for patients with colorectal cancer and delineated factors predictive of delayed treatment.
METHODS: Using the National Cancer Database, patients diagnosed with colorectal cancer were categorized by year of diagnosis as COVID-19 era (2020) versus pre-COVID-19 (2018-2019). Categorical variables were compared by χ2 analysis. Multivariate logistic regression was used to assess odds ratios for delayed time to surgery or chemoimmunotherapy, defined as {\textgreater}60 days.
RESULTS: In total, 50,689 patients colorectal cancer were diagnosed patients who were pre-COVID-19 vs 21,331 within the COVID-19-era. Patients diagnosed with COVID-19 had a higher stage at diagnosis. There were no differences in the proportion of delayed time to surgery for patients diagnosed in 2020, but patients who were tested for COVID-19 had increased proportions of delayed time to surgery (P {\textless} .0001). In multivariate analysis, Black race (P = .0026) and uninsured/underinsured status (P = .0017) were associated with delayed time to surgery. Diagnosis during COVID-19 did not increase delayed time to chemoimmunotherapy, regardless of COVID-19 testing or positivity; however, delays were seen for Black (P {\textless} .0001), Hispanic (P {\textless} .0001), and uninsured/underinsured patients (P {\textless} .0001).
CONCLUSION: Although the pandemic did not delay treatment for colorectal cancer overall, vulnerable and underserved populations were disproportionately affected by delays to all forms of therapy. The difference in colorectal cancer outcomes in the coming years as a result of delays in treatment may be significant for these patients.},
	language = {eng},
	number = {4},
	journal = {Surgery},
	author = {Chung, Sophie H. and Rasic, Gordana and Romatoski, Kelsey S. and Kenzik, Kelly and Tseng, Jennifer F. and Sachs, Teviah E.},
	month = apr,
	year = {2024},
	pmid = {38245445},
	keywords = {Humans, Colorectal Neoplasms, Immunotherapy, COVID-19, Pandemics, COVID-19 Testing},
	pages = {1013--1020},
}

@article{levi85,
	title = {Racial/ethnic and socioeconomic disparities in colorectal cancer screening in a large organization with universal insurance before and during the coronavirus disease 2019 pandemic},
	volume = {31},
	issn = {1475-5793},
	doi = {10.1177/09691413231214186},
	abstract = {OBJECTIVES: Israel is regarded as a country with a developed economy and a moderate income inequality index. In this population-based study, we aimed to measure the inequalities in colorectal cancer screening within Clalit Health, an organization with universal insurance, before and during the coronavirus disease 2019 pandemic.
SETTING: Retrospective analysis within Clalit Health Services, Israel.
METHODS: We evaluated the rate of being up to date with screening (having a colonoscopy within 10 years or a fecal occult blood test within 1 year) and the colonoscopy completion rate (having a colonoscopy within 6 months of a positive fecal occult blood test) among subjects aged 50-75 in 2019-2021.
RESULTS: In 2019, out of 918,135 subjects, 61.3\% were up to date with screening; high socioeconomic status: 65.9\% (referent), medium-socioeconomic status: 60.1\% (odds ratio 0.81, 95\% confidence interval 0.80-0.82), low-socioeconomic status: 59.0\% (odds ratio 0.75, 95\% confidence interval 0.74-0.75); Jews: 61.9\% (referent), Arabs: 59.7\% (odds ratio 0.91, 95\% confidence interval 0.90-0.92), Ultraorthodox-Jews: 51.7\% (odds ratio 0.77, 95\% confidence interval 0.75-0.78). Out of 21,308 with a positive fecal occult blood test, the colonoscopy completion rate was 51.8\%; high-socioeconomic status: 59.8\% (referent), medium-socioeconomic status: 54.1\% (odds ratio 0.79, 95\% confidence interval 0.73-0.86), low-socioeconomic status: 45.5\% (odds ratio 0.60, 95\% confidence interval 0.56-0.65); Jews: 54.7\% (referent), Ultraorthodox-Jews: 51.4\% (odds ratio 0.91, 95\% confidence interval 0.90-0.92), Arabs: 44.7\% (odds ratio 0.77, 95\% confidence interval 0.75-0.78). In 2020-2021, there was a slight drop in the rate of being up to date with screening, while most of the discrepancies were kept or slightly increased with time.
CONCLUSIONS: We report significant inequalities in colorectal cancer screening before and during the coronavirus disease 2019 pandemic in Israel, despite a declared policy of equality and universal insurance.},
	language = {eng},
	number = {2},
	journal = {Journal of Medical Screening},
	author = {Levi, Zohar and Abu-Frecha, Naim and Comanesther, Doron and Backenstein, Tania and Cohen, Arnon D. and Eizenstein, Sapir and Flugelman, Anath and Weinstein, Orly},
	month = jun,
	year = {2024},
	pmid = {37964557},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Colorectal Neoplasms, Retrospective Studies, colorectal cancer, Healthcare Disparities, Socioeconomic Factors, Social Class, Ethnicity, screening, COVID-19, Early Detection of Cancer, Israel, Colonoscopy, Occult Blood, Pandemics, disparities, SARS-CoV-2, Arabs, coronavirus disease 2019, ethnic, insurance, Jews, Racial, socioeconomic, Socioeconomic Disparities in Health, Universal Health Insurance},
	pages = {85--90},
}

@article{kang500,
	title = {The elderly population are more vulnerable for the management of colorectal cancer during the {COVID}-19 pandemic: a nationwide, population-based study},
	volume = {21},
	issn = {1598-9100},
	shorttitle = {The elderly population are more vulnerable for the management of colorectal cancer during the {COVID}-19 pandemic},
	doi = {10.5217/ir.2023.00004},
	abstract = {BACKGROUND/AIMS: The impact of coronavirus disease 2019 (COVID-19) on the management of colorectal cancer (CRC) may worse in elderly population, as almost all COVID-19 deaths occurred in the elderly patients. This study aimed to evaluate the impact of COVID-19 on CRC management in the elderly population.
METHODS: The numbers of patients who underwent colonoscopy, who visited hospitals or operated for CRC in 2020 and 2021 (COVID-19 era) were compared with those in 2019, according to 3 age groups (≥70 years, 50-69 years, and ≤49 years), based on the nationwide, population-based database (2019-2021) in South Korea.
RESULTS: The annual volumes of colonoscopy and hospital visits for CRC in 2020 were more significantly declined in the old age group than in the young age group (both P{\textless}0.001). In addition, the annual volume of patients operated for CRC numerically more declined in old age group than in young age group. During the first surge of COVID-19 (March and April 2020), old age patients showed statistically significant declines for the monthly number of colonoscopies (-46.5\% vs. -39.3\%, P{\textless}0.001), hospital visits (-15.4\% vs. -7.9\%, P{\textless}0.001), CRC operations (-33.8\% vs. -0.7\%, P{\textless}0.05), and colonoscopic polypectomies (-41.8\% vs. -38.0\%, P{\textless}0.001) than young age patients, compared with those of same months in 2019.
CONCLUSIONS: Elderly population are more vulnerable for the management of CRC during the COVID-19 pandemic. Therefore, the elderly population are more carefully cared for in the management of CRC during the next pandemic.},
	language = {eng},
	number = {4},
	journal = {Intestinal Research},
	author = {Kang, Hong Sun and Jeon, Seung Hoon and Park, Su Bee and Youn, Jin Young and Kwak, Min Seob and Cha, Jae Myung},
	month = oct,
	year = {2023},
	pmid = {37640379},
	pmcid = {PMC10626012},
	keywords = {Colorectal neoplasms, COVID-19, Colonoscopy, Mass screening, Age groups},
	pages = {500--509},
	file = {Full Text:/Users/jcsal/Zotero/storage/7JUYW2Y2/Kang et al. - 2023 - The elderly population are more vulnerable for the management of colorectal cancer during the COVID-.pdf:application/pdf},
}

@article{overtoom,
	title = {Prolonged {Time} to {Surgery} in {Patients} with {Residual} {Disease} {After} {Neoadjuvant} {Chemoradiotherapy} for {Esophageal} {Cancer}},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000006488},
	abstract = {OBJECTIVE: To investigate whether prolonged time to surgery negatively affects survival, pathological outcome or postoperative complications in patients with histologically proven residual disease after neoadjuvant chemoradiotherapy for locally advanced esophageal cancer.
SUMMARY BACKGROUND DATA: Historically, the standard time to surgery (TTS) has been six to eight weeks after completion of nCRT. The effect of prolonged TTS is gaining interest, with contradicting results on survival and surgical morbidity. It can be hypothesized that, in patients with residual disease six weeks after completion of nCRT, prolonged TTS might be associated with worse survival and higher morbidity.
METHODS: Patients with locally advanced esophageal cancer who had biopsy-proven residual disease six weeks after nCRT and underwent surgery, were categorized according to interval to surgery (TTS{\textgreater}12w vs. TTS≤12w). Primary outcome of this study was overall survival. Secondary outcomes were disease-free survival, surgical outcomes, pathological outcomes, and postoperative complications. Multivariable Cox regression was used for comparing survival and logistic regression for other outcomes, adjusted for the confounders age, cT, cN, Charlson comorbidity index, weight loss during nCRT, and WHO performance score after completion of nCRT.
RESULTS: Forty patients were included for TTS{\textgreater}12w and 127 for TTS≤12w. TTS{\textgreater}12w was associated with better overall survival (adjusted hazard ratio (aHR) 0.46, 95\%CI 0.24-0.90), and disease-free survival (aHR 0.48, 95\%CI 0.24-0.94), but also with more postoperative respiratory complications (aOR 3.66, 95\%CI 1.52-9.59). Other outcomes were comparable between both groups.
CONCLUSION: Prolonged TTS in patients with histologically proven residual disease after completion of nCRT for esophageal cancer did not have a negative effect on overall and disease-free survival, but patients did have a higher risk for postoperative respiratory complications.},
	language = {eng},
	journal = {Annals of Surgery},
	author = {Overtoom, Hidde C. G. and Eyck, Ben M. and van der Wilk, Berend J. and Noordman, Bo J. and van der Sluis, Pieter C. and Wijnhoven, Bas P. L. and van Lanschot, J. Jan B. and Lagarde, Sjoerd M. and {SANO study group*}},
	month = aug,
	year = {2024},
	pmid = {39140597},
}

@article{vanderwilk,
	title = {{NEOADJUVANT} {CHEMORADIOTHERAPY} {FOLLOWED} {BY} {ACTIVE} {SURVEILLANCE} {VERSUS} {STANDARD} {SURGERY} {FOR} {OESOPHAGEAL} {CANCER} ({SANO}-{TRIAL}): {A} {MULTICENTRE} {STEPPED}-{WEDGE} {CLUSTER}-{RANDOMISED} {NONINFERIORITY} {TRIAL}},
	volume = {37},
	url = {https://academic.oup.com/dote/article/37/Supplement_1/doae057.392/7746911},
	abstract = {Background
One of the standard treatments for patients with locally advanced oesophageal cancer is neoadjuvant chemoradiotherapy followed by oesophagectomy. Of these patients, 29\% have a pathologically complete response. Active surveillance may be an alternative for patients with clinically complete response (i.e. no residual tumour detected using clinical response evaluations).
Methods
A multicentre stepped-wedge cluster-randomised noninferiority trial was performed in twelve Dutch hospitals. Patients with a clinically complete response were included, determined with endoscopic biopsies, endoscopic ultrasound with fine-needle aspiration and PET-CT. Afterwards, patients underwent active surveillance or standard surgery. Primary endpoint was overall survival, which was analysed according to modified intention-to-treat (allowing cross-over at time of clinically complete response), traditional intention-to-treat and according to histology. Noninferiority was defined as two-year survival rate for active surveillance 15\% below standard surgery.
Results
Between November 8, 2017 and January 17, 2021, 1115 patient were screened of whom 309 patients were included, 198 underwent active surveillance and 111 standard surgery. Two-year overall survival for active surveillance was noninferior to standard surgery (3\% higher, 95\% upper boundary 7\% lower). There were no significant differences in overall survival according to modified intention-to-treat analysis (HR:1.14, 95\%CI:0.74–1.78, p=0.55), traditional intention-to-treat analysis (HR:0.83, 95\%CI:0.53–1.31, p=0.42) or in the analysis according to histology. Eighty-three patients from the active surveillance group underwent postponed surgery with postoperative complications and radicality comparable to standard surgery. Sixty-nine patients had persistent CCR and 22 patients developed distant metastases within six months, prior to surgery. Median disease-free survival for active surveillance was 35 (95\%CI 28–NR) versus 49 months (95\%CI 31–NR) for standard surgery (HR1.25, 95\%CI:0.83–1.89,p=0.29). Health-related quality of life was better at six and nine months for active surveillance.
Conclusion
Overall survival following active surveillance for oesophageal cancer is noninferior compared to standard surgery after two years. Postponed oesophagectomy for locoregional regrowth appeared safe. Of 198 patients who underwent active surveillance, 91 patients (46\%) had been spared oesophagectomy, resulting in improved HRQOL. For the long-term efficacy of active surveillance, extended follow-up is required.},
	number = {Supplement\_1},
	journal = {Diseases of the Esophagus},
	author = {van der Wilk, Berend and Eyck, Ben M and Wijnhoven, Bas P. L.},
	month = sep,
	year = {2024},
	keywords = {Salvage, SANO},
}

@article{ko516,
	title = {Can {Proximal} {Gastrectomy} with {Double}-{Tract} {Reconstruction} {Replace} {Total} {Gastrectomy}? {A} {Propensity} {Score} {Matching} {Analysis}},
	volume = {24},
	issn = {1873-4626},
	shorttitle = {Can {Proximal} {Gastrectomy} with {Double}-{Tract} {Reconstruction} {Replace} {Total} {Gastrectomy}?},
	doi = {10.1007/s11605-019-04195-z},
	abstract = {BACKGROUND: This retrospective cohort study compared proximal gastrectomy (PG) with double-tract reconstruction (DTR) versus total gastrectomy (TG) with Roux-en-Y reconstruction in terms of clinical outcomes.
METHODS: All consecutive patients with upper early gastric cancer (EGC) who underwent PG-DTR or TG in 2008-2016 were selected. TG patients who matched PG-DTR patients in age, sex, body mass index, clinical stage, and ASA score were selected by propensity score matching. Groups were compared in terms of clinicopathological characteristics, clinical outcomes, early (≤ 30 days), late ({\textgreater} 30 days), and severe (Clavien-Dindo grade ≥ III) postoperative complications, 1-year reflux morbidity, recurrence, and mortality.
RESULTS: Of 322 patients, 52 underwent PG-DTR. A matching TG group of 52 patients was selected. The PG-DTR group had smaller tumors (p = 0.02), smaller proximal and distal resection margins (p = 0.01, p {\textless} 0.01), and fewer retrieved lymph nodes (p {\textless} 0.01). PG-DTR associated with shorter times to diet and hospital stay (both p = 0.02). Groups did not differ in early (11.3 vs. 19.2\%, p = 0.19), late (1.9 vs. 5.7\%, p = 0.31), or severe complication rates (7.7 vs. 13.5\%, p = 0.34). At 1 year, the groups did not differ in reflux symptoms (Visick score) or endoscopic esophagitis (Los Angeles Classification). There were no recurrences. Five-year overall survival rates were 100 and 81.6\% (p = 0.02), respectively.
CONCLUSION: PG-DTR associated with better clinical outcomes and survival. Complication and reflux rates were similar. PG-DTR may be suitable for upper EGC.},
	language = {eng},
	number = {3},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Ko, Hyo Jung and Kim, Ki Hyun and Lee, Si-Hak and Choi, Cheol Woong and Kim, Su Jin and In Choi, Chang and Kim, Dae-Hwan and Kim, Dong-Heon and Hwang, Sun-Hwi},
	month = mar,
	year = {2020},
	pmid = {30937710},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Stomach Neoplasms, Neoplasm Recurrence, Local, Laparoscopy, Postoperative Complications, Gastrectomy, Propensity Score, Double-tract reconstruction, Propensity score matching, Proximal gastrectomy, Total gastrectomy, Upper gastric cancer, Dual Tract},
	pages = {516--524},
}

@article{aikou114,
	title = {Antrum preserving double tract method for reconstruction following proximal gastrectomy},
	volume = {18},
	issn = {0047-1909},
	doi = {10.1007/BF02470857},
	abstract = {The antrum preserving double tract method was originally designed in order to gain the smooth transfer of larger foods through the duodenal route. Surgical improvement was then made at a few points when carrying out the anastomosis between the residual stomach and the jejunum. In the clinical field, this method is characterized by a better transfer of large foods into the duodenum than the conventional double tract method. The clinical investigation revealed that gastrin release remained after the operation due to both the good passage and the presence of food in the residual stomach. The antrum preserving double tract method is a reasonable and simple method which can maintain physiological pancreaticocibal synchronism.},
	language = {eng},
	number = {1},
	journal = {The Japanese Journal of Surgery},
	author = {Aikou, T. and Natsugoe, S. and Shimazu, H. and Nishi, M.},
	month = jan,
	year = {1988},
	pmid = {3386066},
	keywords = {Anastomosis, Surgical, Gastrectomy, Gastric Emptying, Humans, Jejunostomy, Postgastrectomy Syndromes, Pyloric Antrum},
	pages = {114--115},
	file = {PDF:/Users/jcsal/Zotero/storage/EL22LQAS/Aikou et al. - 1988 - Antrum preserving double tract method for reconstruction following proximal gastrectomy.pdf:application/pdf},
}

@article{cherri17588359221099347,
	title = {Microsatellite instability and chemosensitivity in solid tumours},
	volume = {14},
	issn = {1758-8340},
	doi = {10.1177/17588359221099347},
	abstract = {The use of biomarkers that influence a targeted choice in cancer treatments is the future of medical oncology. Within this scenario, in recent years, an important role has been played by knowledge of microsatellite instability (MSI), a molecular fingerprint that identifies defects in the mismatch repair system. This knowledge has changed clinical practice in the adjuvant setting of colon cancer, and its role in the neoadjuvant setting in gastric tumours is becoming increasingly interesting, as well as in endometrial cancers in both early and advanced diseases. Furthermore, it has undoubtedly conditioned the first lines of treatment in the metastatic setting in different types of cancers. The incidence of MSI is different in different cancer types, as well as in early cancers versus metastatic disease. Knowing the incidence of MSI in the various histologies can provide insight into the potential use of this biomarker considering its prognostic value, especially in the early stages, and its predictive role with respect to treatment response. In particular, MSI can guide the choice of chemotherapy treatments in the adjuvant setting of colon and perioperative setting in gastric tumours, which could lead to immunotherapy treatments in these patients in both the early stages of the disease and the metastatic setting where the response to immunotherapy drugs in diseases with MSI is now well established. In this review, we focus on colon, gastric and endometrial cancers, and we briefly discuss other cancer types where MSI could have a potential role in oncological treatment decisions.},
	language = {eng},
	journal = {Therapeutic Advances in Medical Oncology},
	author = {Cherri, Sara and Oneda, Ester and Noventa, Silvia and Melocchi, Laura and Zaniboni, Alberto},
	year = {2022},
	pmid = {35620236},
	pmcid = {PMC9127927},
	keywords = {chemotherapy, colon cancer, gastric cancer, cancer, microsatellite instability, endometrial cancer},
	pages = {17588359221099347},
	file = {Full Text:/Users/jcsal/Zotero/storage/LSU2GC39/Cherri et al. - 2022 - Microsatellite instability and chemosensitivity in solid tumours.pdf:application/pdf},
}

@article{rinninella960,
	title = {Body {Composition} {Changes} in {Gastric} {Cancer} {Patients} during {Preoperative} {FLOT} {Therapy}: {Preliminary} {Results} of an {Italian} {Cohort} {Study}},
	volume = {13},
	issn = {2072-6643},
	shorttitle = {Body {Composition} {Changes} in {Gastric} {Cancer} {Patients} during {Preoperative} {FLOT} {Therapy}},
	doi = {10.3390/nu13030960},
	abstract = {BACKGROUND: The impact of the new chemotherapy, fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) on body composition in gastric cancer (GC) patients remains unknown. We assessed body composition changes of GC patients receiving the FLOT regimen and their impact on treatment outcomes.
METHODS: Preoperative pre- and post-FLOT computed tomography (CT) scans of advanced GC patients were studied. Lumbar skeletal muscle index (SMI) and adipose indices were calculated before and after FLOT.
RESULTS: A total of 26 patients were identified between April 2019 and January 2020. Nineteen patients were sarcopenic at diagnosis. The mean BMI decreased (from 24.4 ± 3.7 to 22.6 ± 3.1; p {\textless} 0.0001) as well as the SMI (from 48.74 ± 9.76 to 46.52 ± 9.98; p = 0.009) and visceral adipose index (VAI) (from 49.04 ± 31.06 to 41.99 ± 23.91; p = 0.004) during preoperative FLOT therapy. BMI, SMI, and VAI variations were not associated with toxicity, Response Evaluation Criteria in Solid Tumors (RECIST), response, delay and completion of perioperative FLOT chemotherapy, and the execution of gastrectomy; a decrease of SMI ≥ 5\% was associated with a higher Mandard tumor regression grade (p = 0.01).
CONCLUSIONS: Almost three-quarters (73.1\%) of GC patients were sarcopenic at diagnosis. Preoperative FLOT was associated with a further reduction in SMI, BMI, and VAI. These changes were not associated with short-term outcomes.},
	language = {eng},
	number = {3},
	journal = {Nutrients},
	author = {Rinninella, Emanuele and Strippoli, Antonia and Cintoni, Marco and Raoul, Pauline and Vivolo, Raffaella and Di Salvatore, Mariantonietta and Genco, Enza and Manfredi, Riccardo and Bria, Emilio and Tortora, Giampaolo and Gasbarrini, Antonio and Pozzo, Carmelo and Mele, Maria Cristina},
	month = mar,
	year = {2021},
	pmid = {33809587},
	pmcid = {PMC7999770},
	keywords = {Body Composition, Humans, Tomography, X-Ray Computed, Female, Male, Middle Aged, Neoadjuvant Therapy, Sarcopenia, Body Mass Index, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, sarcopenia, body composition, Fluorouracil, Leucovorin, Stomach Neoplasms, gastric cancer, Combined Modality Therapy, Oxaliplatin, Docetaxel, adipose tissue, muscle mass, SMI, Italy, toxicity, neoadjuvant chemotherapy, FLOT, personalized medicine},
	pages = {960},
	file = {Full Text:/Users/jcsal/Zotero/storage/TD48Y7SC/Rinninella et al. - 2021 - Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy Preliminary Re.pdf:application/pdf},
}

@article{juez2408,
	title = {Impact of {Neoadjuvant} {Treatment} on {Body} {Composition} in {Patients} with {Locally} {Advanced} {Gastric} {Cancer}},
	volume = {16},
	issn = {2072-6694},
	doi = {10.3390/cancers16132408},
	abstract = {Neoadjuvant chemotherapy (NT) followed by radical surgery is the standard treatment for locally advanced gastric cancer (GC). The incidence of sarcopenia in upper gastrointestinal tract malignancies is very high, and it may be increased after NT. This study aimed to evaluate the impact of NT on body composition. A retrospective study of patients with locally advanced GC undergoing gastrectomy who had received NT in a tertiary hospital between 2012 and 2019 was conducted. CT measured the skeletal muscle index, total psoas area, and visceral and subcutaneous adipose tissue before and after NT. Of the 180 gastrectomies for GC, 61 patients received NT. During NT, changes in body composition were observed with a decrease in the skeletal muscle mass index (SMMI -2.5\%; p {\textless} 0.001), and these changes were significantly greater in men (SMMI -10.55\%). Before surgery, patients who received NT presented 15\% more sarcopenia than those without NT (p = 0.048). In conclusion, patients with locally advanced gastric cancer who receive NT have significant changes in body composition during chemotherapy. These changes, which are at the expense of a loss of muscle mass, lead to an increased incidence of pre-surgical sarcopenia.},
	language = {eng},
	number = {13},
	journal = {Cancers},
	author = {Juez, Luz Divina and Priego, Pablo and Cuadrado, Marta and Blázquez, Luis A. and Sánchez-Picot, Silvia and Gil, Pablo and Longo, Federico and Galindo, Julio and Fernández-Cebrián, José María and Botella-Carretero, José I.},
	month = jun,
	year = {2024},
	pmid = {39001470},
	pmcid = {PMC11240361},
	keywords = {sarcopenia, gastric, cancer, gastrectomy, neoadjuvant},
	pages = {2408},
	file = {Full Text:/Users/jcsal/Zotero/storage/D869FX3W/Juez et al. - 2024 - Impact of Neoadjuvant Treatment on Body Composition in Patients with Locally Advanced Gastric Cancer.pdf:application/pdf},
}

@article{huemer3051,
	title = {Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the {FLOT} protocol},
	volume = {149},
	issn = {1432-1335},
	doi = {10.1007/s00432-022-04096-w},
	abstract = {PURPOSE: Perioperative chemotherapy with FLOT constitutes a standard of care approach for locally advanced, resectable gastric or gastro-esophageal junction (GEJ) cancer. We aimed at investigating anthropometric, CT-based and FDG-PET-based body composition parameters and dynamics during this multidisciplinary approach and the impact on clinical outcomes.
METHODS: This retrospective, single-center study was based on medical records and (FDG-PET)-CT images among gastric/GEJ cancer patients undergoing perioperative FLOT chemotherapy.
RESULTS: Between 2016 and 2021, 46 gastric/GEJ cancer patients started perioperative FLOT at our tertiary cancer center (Salzburg, Austria). At a median follow-up of 32 months median PFS was 47.4 months and median OS was not reached. The skeletal muscle index (SMI, cm2/m2) turned out to be the only body composition parameter with a statistically significant decrease during pre-operative FLOT (51.3 versus 48.8 cm2/m2, p = 0.02). Neither pre-FLOT body mass index (BMI), nor SMI had an impact on the duration of pre-operative FLOT, the time interval from pre-operative FLOT initiation to surgery, the necessity of pre-operative or post-operative FLOT de-escalation or the likelihood of the start of postoperative chemotherapy. Pre-FLOT BMI (overweight versus normal, HR: 0.11, 95\% CI: 0.02-0.65, p = 0.02) and pre-FLOT SMI (sarcopenia versus no sarcopenia, HR: 5.08, 95\% CI: 1.27-20.31, p = 0.02) were statistically significantly associated with PFS in the multivariable analysis.
CONCLUSION: The statistically significant SMI loss during pre-operative FLOT and the meaningful impact of baseline SMI and BMI on PFS argue for the implementation of a nutritional screening and support program prior to the initiation of pre-operative FLOT in clinical routine.},
	language = {eng},
	number = {7},
	journal = {Journal of Cancer Research and Clinical Oncology},
	author = {Huemer, Florian and Hecht, Stefan and Scharinger, Bernhard and Schlintl, Verena and Rinnerthaler, Gabriel and Schlick, Konstantin and Heregger, Ronald and Melchardt, Thomas and Wimmer, Angela and Mühlbacher, Iris and Koch, Oliver Owen and Neureiter, Daniel and Klieser, Eckhard and Seyedinia, Sara and Beheshti, Mohsen and Greil, Richard and Weiss, Lukas},
	month = jul,
	year = {2023},
	pmid = {35864270},
	pmcid = {PMC10314876},
	keywords = {Body Composition, Humans, Sarcopenia, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols, Nutrition Assessment, Stomach Neoplasms, Adenocarcinoma, Gastric cancer, Fluorodeoxyglucose F18, Esophagogastric Junction, Nutritional Status, Perioperative chemotherapy, Skeletal muscle index, Body mass index},
	pages = {3051--3064},
	file = {Full Text:/Users/jcsal/Zotero/storage/93X2ZDCP/Huemer et al. - 2023 - Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction c.pdf:application/pdf},
}

@article{tolonen3398,
	title = {Association between {Computed} {Tomography}-{Determined} {Loss} of {Muscle} {Mass} and {Impaired} {Three}-{Month} {Survival} in {Frail} {Older} {Adults} with {Cancer}},
	volume = {15},
	issn = {2072-6694},
	doi = {10.3390/cancers15133398},
	abstract = {As patients with solid (non-hematological) cancers and a life expectancy of {\textless}3 months rarely benefit from oncological treatment, we examined whether the CT-determined loss of muscle mass is associated with an impaired 3-month overall survival (OS) in frail ≥75-year-old patients with cancer. Frailty was assessed with G8-screening and comprehensive geriatric assessment in older adults at risk of frailty. The L3-level skeletal (SMI) and psoas (PMI) muscle indexes were determined from routine CT scans. Established and optimized SMI and PMI cut-offs were used. In the non-curative treatment group (n = 58), 3-month OS rates for normal and low SMI were 95\% and 64\% (HR 9.28; 95\% CI 1.2-71) and for PMI 88\%, and 60\%, respectively (HR 4.10; 1.3-13). A Cox multivariable 3-month OS model showed an HR of 10.7 (1.0-110) for low SMI, 2.34 (0.6-9.8) for ECOG performance status 3-4, 2.11 (0.5-8.6) for clinical frailty scale 5-9, and 0.57 (0.1-2.8) for males. The 24-month OS rates in the curative intent group (n = 21) were 91\% and 38\% for the normal and low SMI groups, respectively. In conclusion, CT-determined low muscle mass is independently associated with an impaired 3-month OS and, alongside geriatric assessment, could aid in oncological versus best supportive care decision-making in frail patients with non-curable cancers.},
	language = {eng},
	number = {13},
	journal = {Cancers},
	author = {Tolonen, Antti and Kerminen, Hanna and Lehtomäki, Kaisa and Huhtala, Heini and Bärlund, Maarit and Österlund, Pia and Arponen, Otso},
	month = jun,
	year = {2023},
	pmid = {37444508},
	pmcid = {PMC10340736},
	keywords = {sarcopenia, computed tomography, cancer, frailty, loss of muscle mass, older adults},
	pages = {3398},
	file = {Full Text:/Users/jcsal/Zotero/storage/5P9F79RT/Tolonen et al. - 2023 - Association between Computed Tomography-Determined Loss of Muscle Mass and Impaired Three-Month Surv.pdf:application/pdf},
}

@article{asgestandardsofpracticecommittee271,
	title = {American {Society} for {Gastrointestinal} {Endoscopy} guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations},
	volume = {98},
	issn = {1097-6779},
	shorttitle = {American {Society} for {Gastrointestinal} {Endoscopy} guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers},
	doi = {10.1016/j.gie.2023.03.015},
	abstract = {This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based summary and recommendations regarding the role of endoscopic submucosal dissection (ESD) in the management of early esophageal and gastric cancers. It is accompanied by the document subtitled "Methodology and Review of Evidence," which provides a detailed account of the methodology used for the evidence review. This guideline was developed using the Grading of Recommendations, Assessment, Development and Evaluation framework and specifically addresses the role of ESD versus EMR and/or surgery, where applicable, for the management of early esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), and gastric adenocarcinoma (GAC) and their corresponding precursor lesions. For ESCC, the ASGE suggests ESD over EMR for patients with early-stage, well-differentiated, nonulcerated cancer {\textgreater}15 mm, whereas in patients with similar lesions ≤15 mm, the ASGE suggests either ESD or EMR. The ASGE suggests against surgery for such patients with ESCC, whenever possible. For EAC, the ASGE suggests ESD over EMR for patients with early-stage, well-differentiated, nonulcerated cancer {\textgreater}20 mm, whereas in patients with similar lesions measuring ≤20 mm, the ASGE suggests either ESD or EMR. For GAC, the ASGE suggests ESD over EMR for patients with early-stage, well- or moderately differentiated, nonulcerated intestinal type cancer measuring 20 to 30 mm, whereas for patients with similar lesions {\textless}20 mm, the ASGE suggests either ESD or EMR. The ASGE suggests against surgery for patients with such lesions measuring ≤30 mm, whereas for lesions that are poorly differentiated, regardless of size, we suggest surgical evaluation over endoscopic approaches.},
	language = {eng},
	number = {3},
	journal = {Gastrointestinal Endoscopy},
	author = {{ASGE standards of practice committee} and Forbes, Nauzer and Elhanafi, Sherif E. and Al-Haddad, Mohammad A. and Thosani, Nirav C. and Draganov, Peter V. and Othman, Mohamed O. and Ceppa, Eugene P. and Kaul, Vivek and Feely, Michael M. and Sahin, Ilyas and Buxbaum, James L. and Calderwood, Audrey H. and Chalhoub, Jean M. and Coelho-Prabhu, Nayantara and Desai, Madhav and Fujii-Lau, Larissa L. and Kohli, Divyanshoo R. and Kwon, Richard S. and Machicado, Jorge D. and Marya, Neil B. and Pawa, Swati and Ruan, Wenly and Sheth, Sunil G. and Storm, Andrew C. and Thiruvengadam, Nikhil R. and Qumseya, Bashar J. and {(ASGE Standards of Practice Committee Chair)}},
	month = sep,
	year = {2023},
	pmid = {37498266},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Endoscopy, Gastrointestinal, Endoscopic Mucosal Resection},
	pages = {271--284},
}

@article{asgestandardsofpracticecommittee335,
	title = {{ASGE} guideline on screening and surveillance of {Barrett}'s esophagus},
	volume = {90},
	issn = {1097-6779},
	doi = {10.1016/j.gie.2019.05.012},
	language = {eng},
	number = {3},
	journal = {Gastrointestinal Endoscopy},
	author = {{ASGE STANDARDS OF PRACTICE COMMITTEE} and Qumseya, Bashar and Sultan, Shahnaz and Bain, Paul and Jamil, Laith and Jacobson, Brian and Anandasabapathy, Sharmila and Agrawal, Deepak and Buxbaum, James L. and Fishman, Douglas S. and Gurudu, Suryakanth R. and Jue, Terry L. and Kripalani, Sapna and Lee, Jeffrey K. and Khashab, Mouen A. and Naveed, Mariam and Thosani, Nirav C. and Yang, Julie and DeWitt, John and Wani, Sachin and {ASGE Standards of Practice Committee Chair}},
	month = sep,
	year = {2019},
	pmid = {31439127},
	keywords = {Humans, Neoplasm Staging, Adenocarcinoma, Esophageal Neoplasms, Watchful Waiting, Esophagoscopy, Barrett Esophagus, Endosonography, Mass Screening, Early Detection of Cancer, Microscopy, Confocal},
	pages = {335--359.e2},
}

@article{standardsofpracticecommittee907,
	title = {Endoscopic eradication therapy for patients with {Barrett}'s esophagus-associated dysplasia and intramucosal cancer},
	volume = {87},
	issn = {1097-6779},
	doi = {10.1016/j.gie.2017.10.011},
	language = {eng},
	number = {4},
	journal = {Gastrointestinal Endoscopy},
	author = {{Standards of Practice Committee} and Wani, Sachin and Qumseya, Bashar and Sultan, Shahnaz and Agrawal, Deepak and Chandrasekhara, Vinay and Harnke, Ben and Kothari, Shivangi and McCarter, Martin and Shaukat, Aasma and Wang, Amy and Yang, Julie and Dewitt, John},
	month = apr,
	year = {2018},
	pmid = {29397943},
	keywords = {Humans, Population Surveillance, Esophageal Neoplasms, Esophagectomy, Watchful Waiting, Esophagoscopy, Barrett Esophagus, Endoscopic Mucosal Resection},
	pages = {907--931.e9},
}

@misc{zotero-3904,
	title = {Citrix {Workspace}},
	url = {https://goremote.carolinas.org/Citrix/GoRemoteWeb/},
	urldate = {2025-03-04},
	file = {Citrix Workspace:/Users/jcsal/Zotero/storage/RGLBK3AR/GoRemoteWeb.html:text/html},
}

@article{andre255,
	title = {Neoadjuvant {Nivolumab} {Plus} {Ipilimumab} and {Adjuvant} {Nivolumab} in {Localized} {Deficient} {Mismatch} {Repair}/{Microsatellite} {Instability}-{High} {Gastric} or {Esophagogastric} {Junction} {Adenocarcinoma}: {The} {GERCOR} {NEONIPIGA} {Phase} {II} {Study}},
	volume = {41},
	issn = {1527-7755},
	shorttitle = {Neoadjuvant {Nivolumab} {Plus} {Ipilimumab} and {Adjuvant} {Nivolumab} in {Localized} {Deficient} {Mismatch} {Repair}/{Microsatellite} {Instability}-{High} {Gastric} or {Esophagogastric} {Junction} {Adenocarcinoma}},
	doi = {10.1200/JCO.22.00686},
	abstract = {PURPOSE: In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy remains debatable for gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H).
PATIENTS AND METHODS: NEONIPIGA (ClinicalTrials.gov identifier: NCT04006262) phase II study evaluated neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by surgery and adjuvant nivolumab 480 mg once every four weeks (nine injections) in patients with locally advanced resectable dMMR/MSI-H, clinical (c) tumor (T)2-T4 node (N)x metastasis (M)0 gastric/GEJ adenocarcinoma. The primary end point was a pathological complete response (pCR) rate.
RESULTS: Between October 2019 and June 2021, 32 patients with dMMR/MSI-H gastric/GEJ adenocarcinoma were enrolled. The median age was 65.5 years (range, 40-80). Clinical stages were cT2-T3N0 (n = 9), cT2-T3N1 (n = 22), and cT3N1M1 (n = 1, wrongly included). With a median follow-up of 14.9 months (95\% CI, 10.6 to 17.6), 32 patients received neoadjuvant immunotherapy (27 patients completed all cycles). Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19\%). Twenty-nine patients underwent surgery; three did not have surgery and had complete endoscopic response with tumor-free biopsies and a normal computed tomography scan (two refused surgery and one had metastasis at inclusion). The rate of surgical morbidity (Clavien-Dindo classification) was 55\% (one postoperative death occurred). All 29 patients had an R0 resection, and 17 (58.6\%; 90\% CI, 41.8 to 74.1) had pCR (pathological T0N0). Becker tumor regression grades 1a, 1b, 2, and 3 were observed in 17 patients, three (including two pathological T0N1), two, and seven patients, respectively. Of the 29 patients with surgery, 23 received adjuvant nivolumab. At database lock, no patient had relapse and one died without relapse.
CONCLUSION: Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.},
	language = {eng},
	number = {2},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {André, Thierry and Tougeron, David and Piessen, Guillaume and de la Fouchardière, Christelle and Louvet, Christophe and Adenis, Antoine and Jary, Marine and Tournigand, Christophe and Aparicio, Thomas and Desrame, Jérôme and Lièvre, Astrid and Garcia-Larnicol, Marie-Line and Pudlarz, Thomas and Cohen, Romain and Memmi, Salomé and Vernerey, Dewi and Henriques, Julie and Lefevre, Jérémie H. and Svrcek, Magali},
	month = jan,
	year = {2023},
	pmid = {35969830},
	pmcid = {PMC9839243},
	keywords = {Humans, Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Stomach Neoplasms, Adenocarcinoma, Neoplasm Recurrence, Local, Esophagogastric Junction, Microsatellite Instability, DNA Mismatch Repair, ICI, Ipilimumab, Nivolumab},
	pages = {255--265},
	file = {Full Text:/Users/jcsal/Zotero/storage/JS22RH4H/André et al. - 2023 - Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair.pdf:application/pdf},
}

@article{iv226a,
	title = {The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation},
	volume = {35},
	issn = {1108-7471},
	shorttitle = {The evolution of rectal cancer treatment},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062836/},
	doi = {10.20524/aog.2022.0712},
	abstract = {There has been a staggering increase in the incidence of rectal cancer, drawing our attention to early detection and optimization of its medical and surgical treatment. With this review we highlight all the major trials that revolutionized rectal cancer management and improved oncologic outcomes. We present the origins of the trimodal therapy and the studies that supported the sequence of treatment. We describe the evolution in surgical management with total mesorectal excision as the standard of care, and we review the most impactful short- vs. long-course long-course radiation therapy trials. Today, the current standard of care for non-metastatic locally advanced rectal cancer includes preoperative chemoradiation with either induction or consolidation chemotherapy, total mesorectal excision and adjuvant therapy. We discuss the advent of the “watch and wait” strategy for patients who have a complete clinical response after total neoadjuvant treatment, as well as possible future directions in the treatment of locoregional disease.},
	number = {3},
	urldate = {2025-03-16},
	journal = {Annals of Gastroenterology},
	author = {IV, Arthur Affleck and Koprowski, Marina Affi and Nabavizadeh, Nima and Tsikitis, Vassiliki Liana},
	year = {2022},
	pmid = {35599927},
	pmcid = {PMC9062836},
	keywords = {Rectal},
	pages = {226--233},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/565BI3L5/IV et al. - 2022 - The evolution of rectal cancer treatment the journey to total neoadjuvant therapy and organ preserv.pdf:application/pdf},
}

@article{bahadoer29a,
	title = {Short-course radiotherapy followed by chemotherapy before total mesorectal excision ({TME}) versus preoperative chemoradiotherapy, {TME}, and optional adjuvant chemotherapy in locally advanced rectal cancer ({RAPIDO}): a randomised, open-label, phase 3 trial},
	volume = {22},
	issn = {1474-5488},
	shorttitle = {Short-course radiotherapy followed by chemotherapy before total mesorectal excision ({TME}) versus preoperative chemoradiotherapy, {TME}, and optional adjuvant chemotherapy in locally advanced rectal cancer ({RAPIDO})},
	doi = {10.1016/S1470-2045(20)30555-6},
	abstract = {BACKGROUND: Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation (RAPIDO) trial aimed to reduce distant metastases without compromising locoregional control.
METHODS: In this multicentre, open-label, randomised, controlled, phase 3 trial, participants were recruited from 54 centres in the Netherlands, Sweden, Spain, Slovenia, Denmark, Norway, and the USA. Patients were eligible if they were aged 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, had a biopsy-proven, newly diagnosed, primary, locally advanced rectal adenocarcinoma, which was classified as high risk on pelvic MRI (with at least one of the following criteria: clinical tumour [cT] stage cT4a or cT4b, extramural vascular invasion, clinical nodal [cN] stage cN2, involved mesorectal fascia, or enlarged lateral lymph nodes), were mentally and physically fit for chemotherapy, and could be assessed for staging within 5 weeks before randomisation. Eligible participants were randomly assigned (1:1), using a management system with a randomly varying block design (each block size randomly chosen to contain two to four allocations), stratified by centre, ECOG performance status, cT stage, and cN stage, to either the experimental or standard of care group. All investigators remained masked for the primary endpoint until a prespecified number of events was reached. Patients allocated to the experimental treatment group received short-course radiotherapy (5 × 5 Gy over a maximum of 8 days) followed by six cycles of CAPOX chemotherapy (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, and a chemotherapy-free interval between days 15-21) or nine cycles of FOLFOX4 (oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin [folinic acid] 200 mg/m2 intravenously on days 1 and 2, followed by bolus fluorouracil 400 mg/m2 intravenously and fluorouracil 600 mg/m2 intravenously for 22 h on days 1 and 2, and a chemotherapy-free interval between days 3-14) followed by total mesorectal excision. Choice of CAPOX or FOLFOX4 was per physician discretion or hospital policy. Patients allocated to the standard of care group received 28 daily fractions of 1·8 Gy up to 50·4 Gy or 25 fractions of 2·0 Gy up to 50·0 Gy (per physician discretion or hospital policy), with concomitant twice-daily oral capecitabine 825 mg/m2 followed by total mesorectal excision and, if stipulated by hospital policy, adjuvant chemotherapy with eight cycles of CAPOX or 12 cycles of FOLFOX4. The primary endpoint was 3-year disease-related treatment failure, defined as the first occurrence of locoregional failure, distant metastasis, new primary colorectal tumour, or treatment-related death, assessed in the intention-to-treat population. Safety was assessed by intention to treat. This study is registered with the EudraCT, 2010-023957-12, and ClinicalTrials.gov, NCT01558921, and is now complete.
FINDINGS: Between June 21, 2011, and June 2, 2016, 920 patients were enrolled and randomly assigned to a treatment, of whom 912 were eligible (462 in the experimental group; 450 in the standard of care group). Median follow-up was 4·6 years (IQR 3·5-5·5). At 3 years after randomisation, the cumulative probability of disease-related treatment failure was 23·7\% (95\% CI 19·8-27·6) in the experimental group versus 30·4\% (26·1-34·6) in the standard of care group (hazard ratio 0·75, 95\% CI 0·60-0·95; p=0·019). The most common grade 3 or higher adverse event during preoperative therapy in both groups was diarrhoea (81 [18\%] of 460 patients in the experimental group and 41 [9\%] of 441 in the standard of care group) and neurological toxicity during adjuvant chemotherapy in the standard of care group (16 [9\%] of 187 patients). Serious adverse events occurred in 177 (38\%) of 460 participants in the experimental group and, in the standard of care group, in 87 (34\%) of 254 patients without adjuvant chemotherapy and in 64 (34\%) of 187 with adjuvant chemotherapy. Treatment-related deaths occurred in four participants in the experimental group (one cardiac arrest, one pulmonary embolism, two infectious complications) and in four participants in the standard of care group (one pulmonary embolism, one neutropenic sepsis, one aspiration, one suicide due to severe depression).
INTERPRETATION: The observed decreased probability of disease-related treatment failure in the experimental group is probably indicative of the increased efficacy of preoperative chemotherapy as opposed to adjuvant chemotherapy in this setting. Therefore, the experimental treatment can be considered as a new standard of care in high-risk locally advanced rectal cancer.
FUNDING: Dutch Cancer Foundation, Swedish Cancer Society, Spanish Ministry of Economy and Competitiveness, and Spanish Clinical Research Network.},
	language = {eng},
	number = {1},
	journal = {The Lancet. Oncology},
	author = {Bahadoer, Renu R. and Dijkstra, Esmée A. and van Etten, Boudewijn and Marijnen, Corrie A. M. and Putter, Hein and Kranenbarg, Elma Meershoek-Klein and Roodvoets, Annet G. H. and Nagtegaal, Iris D. and Beets-Tan, Regina G. H. and Blomqvist, Lennart K. and Fokstuen, Tone and Ten Tije, Albert J. and Capdevila, Jaume and Hendriks, Mathijs P. and Edhemovic, Ibrahim and Cervantes, Andrés and Nilsson, Per J. and Glimelius, Bengt and van de Velde, Cornelis J. H. and Hospers, Geke A. P. and {RAPIDO collaborative investigators}},
	month = jan,
	year = {2021},
	pmid = {33301740},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Time Factors, United States, Adenocarcinoma, Chemoradiotherapy, Adjuvant, Dose Fractionation, Radiation, Neoplasm Recurrence, Local, Treatment Failure, Digestive System Surgical Procedures, Europe, Rectal Neoplasms, Rectal},
	pages = {29--42},
	file = {Full Text:/Users/jcsal/Zotero/storage/69L7LSV5/Bahadoer et al. - 2021 - Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus pre.pdf:application/pdf},
}

@article{conroy702,
	title = {Neoadjuvant chemotherapy with {FOLFIRINOX} and preoperative chemoradiotherapy for patients with locally advanced rectal cancer ({UNICANCER}-{PRODIGE} 23): a multicentre, randomised, open-label, phase 3 trial},
	volume = {22},
	issn = {1474-5488},
	shorttitle = {Neoadjuvant chemotherapy with {FOLFIRINOX} and preoperative chemoradiotherapy for patients with locally advanced rectal cancer ({UNICANCER}-{PRODIGE} 23)},
	doi = {10.1016/S1470-2045(21)00079-6},
	abstract = {BACKGROUND: Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain common. We aimed to assess whether administering neoadjuvant chemotherapy before preoperative chemoradiotherapy could reduce the risk of distant recurrences.
METHODS: We did a phase 3, open-label, multicentre, randomised trial at 35 hospitals in France. Eligible patients were adults aged 18-75 years and had newly diagnosed, biopsy-proven, rectal adenocarcinoma staged cT3 or cT4 M0, with a WHO performance status of 0-1. Patients were randomly assigned (1:1) to either the neoadjuvant chemotherapy group or standard-of-care group, using an independent web-based system by minimisation method stratified by centre, extramural extension of the tumour into perirectal fat according to MRI, tumour location, and stage. Investigators and participants were not masked to treatment allocation. The neoadjuvant chemotherapy group received neoadjuvant chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles), chemoradiotherapy (50 Gy during 5 weeks and 800 mg/m2 concurrent oral capecitabine twice daily for 5 days per week), total mesorectal excision, and adjuvant chemotherapy (3 months of modified FOLFOX6 [intravenous oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2, followed by intravenous 400 mg/m2 fluorouracil bolus and then continuous infusion at a dose of 2400 mg/m2 over 46 h every 14 days for six cycles] or capecitabine [1250 mg/m2 orally twice daily on days 1-14 every 21 days]). The standard-of-care group received chemoradiotherapy, total mesorectal excision, and adjuvant chemotherapy (for 6 months). The primary endpoint was disease-free survival assessed in the intention-to-treat population at 3 years. Safety analyses were done on treated patients. This trial was registered with EudraCT (2011-004406-25) and ClinicalTrials.gov (NCT01804790) and is now complete.
FINDINGS: Between June 5, 2012, and June 26, 2017, 461 patients were randomly assigned to either the neoadjuvant chemotherapy group (n=231) or the standard-of-care group (n=230). At a median follow-up of 46·5 months (IQR 35·4-61·6), 3-year disease-free survival rates were 76\% (95\% CI 69-81) in the neoadjuvant chemotherapy group and 69\% (62-74) in the standard-of-care group (stratified hazard ratio 0·69, 95\% CI 0·49-0·97; p=0·034). During neoadjuvant chemotherapy, the most common grade 3-4 adverse events were neutropenia (38 [17\%] of 225 patients) and diarrhoea (25 [11\%] of 226). During chemoradiotherapy, the most common grade 3-4 adverse event was lymphopenia (59 [28\%] of 212 in the neoadjuvant chemotherapy group vs 67 [30\%] of 226 patients in the standard-of-care group). During adjuvant chemotherapy, the most common grade 3-4 adverse events were lymphopenia (18 [11\%] of 161 in the neoadjuvant chemotherapy group vs 42 [27\%] of 155 in the standard-of-care group), neutropenia (nine [6\%] of 161 vs 28 [18\%] of 155), and peripheral sensory neuropathy (19 [12\%] of 162 vs 32 [21\%] of 155). Serious adverse events occurred in 63 (27\%) of 231 participants in the neoadjuvant chemotherapy group and 50 (22\%) of 230 patients in the standard-of-care group (p=0·167), during the whole treatment period. During adjuvant therapy, serious adverse events occurred in 18 (11\%) of 163 participants in the neoadjuvant chemotherapy group and 36 (23\%) of 158 patients in the standard-of-care group (p=0·0049). Treatment-related deaths occurred in one ({\textless}1\%) of 226 patients in the neoadjuvant chemotherapy group (sudden death) and two (1\%) of 227 patients in the standard-of-care group (one sudden death and one myocardial infarction).
INTERPRETATION: Intensification of chemotherapy using FOLFIRINOX before preoperative chemoradiotherapy significantly improved outcomes compared with preoperative chemoradiotherapy in patients with cT3 or cT4 M0 rectal cancer. The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is more efficient and better tolerated than adjuvant chemotherapy. Therefore, the PRODIGE 23 results might change clinical practice.
FUNDING: Institut National du Cancer, Ligue Nationale Contre le Cancer, and R\&D Unicancer.},
	language = {eng},
	number = {5},
	journal = {The Lancet. Oncology},
	author = {Conroy, Thierry and Bosset, Jean-François and Etienne, Pierre-Luc and Rio, Emmanuel and François, Éric and Mesgouez-Nebout, Nathalie and Vendrely, Véronique and Artignan, Xavier and Bouché, Olivier and Gargot, Dany and Boige, Valérie and Bonichon-Lamichhane, Nathalie and Louvet, Christophe and Morand, Clotilde and de la Fouchardière, Christelle and Lamfichekh, Najib and Juzyna, Béata and Jouffroy-Zeller, Claire and Rullier, Eric and Marchal, Frédéric and Gourgou, Sophie and Castan, Florence and Borg, Christophe and {Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group}},
	month = may,
	year = {2021},
	pmid = {33862000},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Adult, Fluorouracil, Leucovorin, Irinotecan, Chemoradiotherapy, Oxaliplatin, Quality of Life, Rectal Neoplasms, Rectal},
	pages = {702--715},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/M8CZX4HQ/Conroy et al. - 2021 - Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locall.pdf:application/pdf},
}

@article{fokase215445,
	title = {Chemoradiotherapy {Plus} {Induction} or {Consolidation} {Chemotherapy} as {Total} {Neoadjuvant} {Therapy} for {Patients} {With} {Locally} {Advanced} {Rectal} {Cancer}: {Long}-term {Results} of the {CAO}/{ARO}/{AIO}-12 {Randomized} {Clinical} {Trial}},
	volume = {8},
	issn = {2374-2445},
	shorttitle = {Chemoradiotherapy {Plus} {Induction} or {Consolidation} {Chemotherapy} as {Total} {Neoadjuvant} {Therapy} for {Patients} {With} {Locally} {Advanced} {Rectal} {Cancer}},
	doi = {10.1001/jamaoncol.2021.5445},
	abstract = {IMPORTANCE: Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established.
OBJECTIVE: To report the long-term results of the secondary end points prespecified in the Randomized Phase 2 Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy (CAO/ARO/AIO-12 trial) for Locally Advanced Rectal Cancer.
DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial included 311 patients who were recruited from the accrued CAO/ARO/AIO-12 trial population from June 15, 2015, to January 31, 2018, from 18 centers in Germany. Patients with cT3-4 and/or node-positive rectal adenocarcinoma were included in the analysis. Data were analyzed from June 15, 2015, to January 31, 2018. The follow-up analysis was conducted between January 31, 2018, and November 30, 2020.
INTERVENTIONS: Patients were randomly assigned to group A for 3 cycles of fluorouracil, leucovorin, and oxaliplatin before fluorouracil/oxaliplatin CRT (50.4 Gy), or to group B for CRT before chemotherapy. Total mesorectal excision was scheduled on day 123 after the start of total neoadjuvant therapy in both groups.
MAIN OUTCOMES AND MEASURES: The end points assessed in this secondary analysis included long-term oncologic outcomes, chronic toxicity, patient-reported outcome measures for global health status (GHS) and quality of life (QoL), and the Wexner stool incontinence score.
RESULTS: Of the 311 patients enrolled, 306 were evaluable, including 156 in group A (mean [SD] age, 60 [11] years; 106 men [68\%]) and 150 in group B (mean [SD] age, 62 [10] years; 100 men [67\%]). After a median follow-up of 43 months (range, 35-60 months), the 3-year disease-free survival was 73\% in both groups (hazard ratio, 0.95; 95\% CI, 0.63-1.45, P = .82); the 3-year cumulative incidence of locoregional recurrence (6\% vs 5\%, P = .67) and distant metastases (18\% vs 16\%, P = .52) were not significantly different. Chronic toxicity grade 3 to 4 occurred in 10 of 85 patients (11.8\%) in group A and 8 of 66 patients (9.9\%) in group B at 3 years. The GHS/QoL score decreased after total mesorectal excision but returned to pretreatment levels 1 year after randomization with no difference between the groups. Stool incontinence deteriorated 1 year after randomization in both groups and only improved slightly at 3 years, but never reached baseline levels.
CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL, or stool incontinence and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02363374.},
	language = {eng},
	number = {1},
	journal = {JAMA oncology},
	author = {Fokas, Emmanouil and Schlenska-Lange, Anke and Polat, Bülent and Klautke, Gunther and Grabenbauer, Gerhard G. and Fietkau, Rainer and Kuhnt, Thomas and Staib, Ludger and Brunner, Thomas and Grosu, Anca-Ligia and Kirste, Simon and Jacobasch, Lutz and Allgäuer, Michael and Flentje, Michael and Germer, Christoph-Thomas and Grützmann, Robert and Hildebrandt, Guido and Schwarzbach, Matthias and Bechstein, Wolf O. and Sülberg, Heiko and Friede, Tim and Gaedcke, Jochen and Ghadimi, Michael and Hofheinz, Ralf-Dieter and Rödel, Claus and {German Rectal Cancer Study Group}},
	month = jan,
	year = {2022},
	pmid = {34792531},
	pmcid = {PMC8603234},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Neoplasm Recurrence, Local, Chemoradiotherapy, Quality of Life, Rectal Neoplasms, Rectal, Consolidation Chemotherapy},
	pages = {e215445},
}

@article{couwenberge389558,
	title = {New {Opportunities} for {Minimizing} {Toxicity} in {Rectal} {Cancer} {Management}},
	volume = {43},
	issn = {1548-8748},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450577/},
	doi = {10.1200/EDBK_389558},
	abstract = {Advances in multimodal management of locally advanced rectal cancer (LARC), consisting of preoperative chemotherapy and/or radiotherapy followed by surgery with or without adjuvant chemotherapy, have improved local disease control and patient survival but are associated with significant risk for acute and long-term morbidity. Recently published trials, evaluating treatment dose intensification via the addition of preoperative induction or consolidation chemotherapy (total neoadjuvant therapy [TNT]), have demonstrated improved tumor response rates while maintaining acceptable toxicity. In addition, TNT has led to an increased number of patients achieving a clinical complete response and thus eligible to pursue a nonoperative, organ preserving, watch and wait approach, thereby avoiding toxicities associated with surgery, such as bowel dysfunction and stoma-related complications. Ongoing trials using immune checkpoint inhibitors in patients with mismatch repair-deficient tumors suggest that this subgroup of patients with LARC could potentially be treated with immunotherapy alone, sparing them the toxicity associated with preoperative treatment and surgery. However, the majority of rectal cancers are mismatch repair-proficient and less responsive to immune checkpoint inhibitors and require multimodal management. The synergy noted in preclinical studies between immunotherapy and radiotherapy on immunogenic tumor cell death has led to the design of ongoing clinical trials that explore the benefit of combining radiotherapy, chemotherapy, and immunotherapy (mainly of immune checkpoint inhibitors) and aim to increase the number of patients eligible for organ preservation.},
	urldate = {2025-03-16},
	journal = {American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting},
	author = {Couwenberg, Alice M. and Varvoglis, Dimitrios N. and Grieb, Brian C. and Marijnen, Corrie A.M. and Ciombor, Kristen K. and Guillem, Jose G.},
	month = jun,
	year = {2023},
	pmid = {37307515},
	pmcid = {PMC10450577},
	keywords = {Rectal},
	pages = {e389558},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/8VNJK326/Couwenberg et al. - 2023 - New Opportunities for Minimizing Toxicity in Rectal Cancer Management.pdf:application/pdf},
}

@article{liscu912,
	title = {Therapeutic {Management} of {Locally} {Advanced} {Rectal} {Cancer}: {Existing} and {Prospective} {Approaches}},
	volume = {14},
	issn = {2077-0383},
	shorttitle = {Therapeutic {Management} of {Locally} {Advanced} {Rectal} {Cancer}},
	doi = {10.3390/jcm14030912},
	abstract = {Rectal cancer (RC) presents significant challenges in diagnosis and treatment, with increasing incidence among younger populations. Treatment approaches, particularly for locally advanced rectal cancer (LARC), have evolved, notably with the introduction of total neoadjuvant therapy (TNT). TNT combines neoadjuvant chemotherapy and chemoradiotherapy before surgery, improving overall survival and reducing both metastasis and local recurrence rates compared to traditional methods, while enabling more patients to complete the full oncological treatment. Clinical trials, such as RAPIDO, OPRA, and PRODIGE 23, have demonstrated the effectiveness of TNT in tumor downstaging and complete pathological responses, offering better outcomes for patients; however, debates persist regarding the role of neoadjuvant radiotherapy, with novel strategies exploring its omission in specific cases to reduce toxicity and enhance quality of life. In addition, organ preservation strategies, such as the watch-and-wait (WW) approach, have emerged as viable options for patients with a complete response to neoadjuvant therapy. Future directions point towards personalized treatment plans incorporating radiogenomics and the integration of artificial intelligence into diagnostics to optimize patient outcomes. This review aims to synthesize current treatment strategies and ongoing advancements in rectal cancer management, providing insights into potential future innovations.},
	language = {eng},
	number = {3},
	journal = {Journal of Clinical Medicine},
	author = {Lișcu, Horia-Dan and Verga, Nicolae and Atasiei, Dimitrie-Ionuț and Ilie, Andreea-Teodora and Vrabie, Maria and Roșu, Laura and Poștaru, Alexandra and Glăvan, Stefania and Lucaș, Adriana and Dinulescu, Maria and Delea, Andreea and Ionescu, Andreea-Iuliana},
	month = jan,
	year = {2025},
	pmid = {39941583},
	pmcid = {PMC11818342},
	keywords = {neoadjuvant therapy, TNT, locally advanced rectal cancer, long-course radiotherapy, short-course radiotherapy, treatment, Rectal Review},
	pages = {912},
}

@article{edwardsS1550,
	title = {American {Society} for {Metabolic} and {Bariatric} {Surgery}: postoperative care pathway guidelines for {Roux}-en-{Y} gastric bypass},
	issn = {1878-7533},
	shorttitle = {American {Society} for {Metabolic} and {Bariatric} {Surgery}},
	doi = {10.1016/j.soard.2025.01.005},
	abstract = {BACKGROUND: Clinical care pathways and guidelines help guide and provide structure to clinicians and providers to improve healthcare delivery and quality. The Quality Improvement and Patient Safety (QIPS) Committee of the American Society for Metabolic and Bariatric Surgery (ASMBS) has previously published care pathways for the performance of laparoscopic sleeve gastrectomy (LSG), preoperative care of patients undergoing Roux-en-Y gastric bypass (RYGB), and most recently, intraoperative care of patients undergoing RYGB.
OBJECTIVES: This current RYGB care pathway guideline was created to address postoperative care guidance.
SETTING: Academic Health Center.
METHODS: For this systematic review, PubMed queries were performed from January 1979 to December 2019. Follow-up queries were performed from January 2020 to July 2024. Peer-reviewed publications were reviewed according to the level of evidence (LoE) regarding specific key questions developed by the QIPS Committee and working group for this pathway.
RESULTS: Evidence-based recommendations are made for the postoperative care of patients undergoing RYGB, including recommendations for early postoperative care, postoperative medication management, and long-term postoperative surveillance.
CONCLUSIONS: This document may provide a structure to providers based on current evidence for the postoperative care of patients with overweight or obesity undergoing RYGB.},
	language = {eng},
	journal = {Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery},
	author = {Edwards, Michael A. and Powers, Kinga and Vosburg, R. Wesley and Zhou, Randal and Stroud, Andrea and Obeid, Nabeel R. and Pilcher, John and Levy, Shauna and McArthur, Karina and Basishvili, Givi and Rosenbluth, Amy and Petrick, Anthony and Lin, Henry and Kindel, Tammy},
	month = jan,
	year = {2025},
	pmid = {39965985},
	keywords = {Guidelines, Care pathway, ASMBS, Postoperative, Quality Improvement and Patient Safety Committee, Roux-en-Y gastric bypass},
	pages = {S1550--7289(25)00059--0},
}

@article{kang1003,
	title = {A comparison of 30-day versus 90-day proton pump inhibitor therapy in prevention of marginal ulcers after laparoscopic {Roux}-en-{Y} gastric bypass},
	volume = {12},
	issn = {1878-7533},
	doi = {10.1016/j.soard.2015.11.010},
	abstract = {BACKGROUND: Marginal ulceration is one of the most common complications after laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery. Proton pump inhibitors (PPIs) are commonly administered to decrease the incidence of marginal ulcer development.
OBJECTIVE: We examine the differential impact of employing a 30-day versus 90-day postoperative PPI regimen on the development of marginal ulceration after LRYGB.
SETTING: University hospital.
METHODS: A retrospective cohort design was used to study all patients undergoing LRYGB at a single, high-volume bariatric center in Hamilton, Ontario, Canada. Three years previously, the duration of postoperative PPI administration was increased at our center from 30 to 90 days. Diagnosis of marginal ulceration was confirmed by upper endoscopy in patients presenting with epigastric pain and a clinical history suggestive of marginal ulceration. A χ(2) test of independence was performed to examine incidence of marginal ulceration and PPI duration.
RESULTS: A total of 1016 patients underwent LRYGB at our center between January 2009 and January 2013. No differences in baseline characteristics were observed between groups. Of the 1016 patients followed, 614 received 30 days of PPI therapy and 402 received 90 days of PPI therapy. The incidence of marginal ulceration after LRYGB decreased significantly (P{\textless}.05) among patients receiving daily PPI for 90 days (n = 26, 6.5\%) compared with those receiving PPI for 30 days (n = 76, 12.4\%).
CONCLUSION: This study suggests a significant benefit to longer duration prophylactic PPI administration after gastric bypass surgery to minimize the risk of symptomatic marginal ulceration.},
	language = {eng},
	number = {5},
	journal = {Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery},
	author = {Kang, Xian and Zurita-Macias, Luis and Hong, Dennis and Cadeddu, Margherita and Anvari, Mehran and Gmora, Scott},
	month = jun,
	year = {2016},
	pmid = {26948448},
	keywords = {Humans, Female, Male, Postoperative Care, Retrospective Studies, Risk Factors, Adult, Drug Administration Schedule, Laparoscopy, Postoperative Complications, Gastroscopy, Proton Pump Inhibitors, Bariatric surgery, Gastric Bypass, LRYGB, Marginal ulceration, Peptic Ulcer, PPI, Proton pump inhibitors},
	pages = {1003--1007},
}

@article{mortensen1209,
	title = {Consensus guidelines for enhanced recovery after gastrectomy: {Enhanced} {Recovery} {After} {Surgery} ({ERAS}®) {Society} recommendations},
	volume = {101},
	issn = {1365-2168},
	shorttitle = {Consensus guidelines for enhanced recovery after gastrectomy},
	doi = {10.1002/bjs.9582},
	abstract = {BACKGROUND: Application of evidence-based perioperative care protocols reduces complication rates, accelerates recovery and shortens hospital stay. Presently, there are no comprehensive guidelines for perioperative care for gastrectomy.
METHODS: An international working group within the Enhanced Recovery After Surgery (ERAS®) Society assembled an evidence-based comprehensive framework for optimal perioperative care for patients undergoing gastrectomy. Data were retrieved from standard databases and personal archives. Evidence and recommendations were classified according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system and were discussed until consensus was reached within the group. The quality of evidence was rated 'high', 'moderate', 'low' or 'very low'. Recommendations were graded as 'strong' or 'weak'.
RESULTS: The available evidence has been summarized and recommendations are given for 25 items, eight of which contain procedure-specific evidence. The quality of evidence varies substantially and further research is needed for many issues to improve the strength of evidence and grade of recommendations.
CONCLUSION: The present evidence-based framework provides comprehensive advice on optimal perioperative care for the patient undergoing gastrectomy and facilitates multi-institutional prospective cohort registries and adequately powered randomized trials for further research.},
	language = {eng},
	number = {10},
	journal = {The British Journal of Surgery},
	author = {Mortensen, K. and Nilsson, M. and Slim, K. and Schäfer, M. and Mariette, C. and Braga, M. and Carli, F. and Demartines, N. and Griffin, S. M. and Lassen, K. and {Enhanced Recovery After Surgery (ERAS®) Group}},
	month = sep,
	year = {2014},
	pmid = {25047143},
	keywords = {Humans, Postoperative Care, Postoperative Complications, Gastrectomy, Preoperative Care, Dietary Supplements, Nutritional Support, Nerve Block, Decompression, Surgical, Analgesia, Epidural, Counseling, Anticoagulants, Drainage, Evidence-Based Medicine, Alcohol Drinking, Antibiotic Prophylaxis, Bed Rest, Cathartics, Glucose Metabolism Disorders, Hypothermia, Postoperative Nausea and Vomiting, Smoking Prevention, Water-Electrolyte Imbalance},
	pages = {1209--1229},
}

@article{zingg1175,
	title = {Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery: a prospective, randomized trial},
	volume = {23},
	issn = {0179-1958},
	shorttitle = {Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery},
	doi = {10.1007/s00384-008-0536-7},
	abstract = {BACKGROUND: Postoperative ileus is a common condition after abdominal surgery. Many prokinetic drugs have been evaluated including osmotic laxatives. The data on colon-stimulating laxatives are scarce. This prospective, randomized, double-blind trial investigates the effect of the colon-stimulating laxative bisacodyl on postoperative ileus in elective colorectal resections.
MATERIALS AND METHODS: Between November 2004 and February 2007, 200 consecutive patients were randomly assigned to receive either bisacodyl or placebo. Primary endpoint was time to gastrointestinal recovery (mean time to first flatus passed, first defecation, and first solid food tolerated; GI-3). Secondary endpoints were incidence and duration of nasogastric tube reinsertion, incidence of vomiting, length of hospital stay, and visual analogue scores for pain, cramps, and nausea.
RESULTS: One hundred sixty-nine patients were analyzed, and 31 patients discontinued the study. Groups were comparable in baseline demographics. Time to GI-3 was significantly shorter in the bisacodyl group (3.0 versus 3.7 days, P = 0.007). Of the single parameters defining GI-3, there was a 1-day difference in time to defecation in favor to the bisacodyl group (3.0 versus 4.0 days, P = 0.001), whereas no significant difference in time to first flatus or tolerance of solid food was seen. No significant difference in the secondary endpoints was seen. Morbidity and mortality did not differ between groups.
CONCLUSION: Bisacodyl accelerated gastrointestinal recovery and might be considered as part of multimodal recovery programs after colorectal surgery.},
	language = {eng},
	number = {12},
	journal = {International Journal of Colorectal Disease},
	author = {Zingg, U. and Miskovic, D. and Pasternak, I. and Meyer, P. and Hamel, C. T. and Metzger, U.},
	month = dec,
	year = {2008},
	pmid = {18665373},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Aged, 80 and over, Adult, Postoperative Complications, Rectum, Adolescent, Elective Surgical Procedures, Double-Blind Method, Colon, ERAS, Postoperative Period, Cathartics, Bisacodyl, Gastrointestinal Motility, Ileus},
	pages = {1175--1183},
}

@article{holmebakk419,
	title = {Relationship between {R1} resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour},
	volume = {106},
	issn = {1365-2168},
	doi = {10.1002/bjs.11027},
	abstract = {BACKGROUND: According to guidelines, adjuvant treatment or re-excision should be considered after R1 resection of gastrointestinal stromal tumours (GISTs). However, the prognostic significance of R1 resection is uncertain and tumour rupture confounds its assessment. Here, the impact of positive margins was examined and related to rupture in a population-based cohort.
METHODS: Patients undergoing surgery for non-metastatic GIST since 2000 were identified in the sarcoma database of Oslo University Hospital. Margins were coded according to the residual tumour (R) classification and tumour rupture defined according to the Oslo criteria.
RESULTS: Among 410 patients, there were 47 who underwent R1 resection and 52 had tumour rupture. The relative risk of R1 resection with rupture was 3·55 (95 per cent c.i. 2·09 to 6·03; P {\textless} 0·001). In patients without rupture, there was no difference in estimated 5-year recurrence-free survival after R0 versus R1 resection (87·6 versus 93 per cent; hazard ratio (HR) 0·71, 95 per cent c.i. 0·17 to 2·98; P = 0·638); nor was there any difference among patients with rupture (37 versus 31 per cent; HR 1·31, 0·68 to 2·54; P = 0·420). In multivariable analysis, tumour rupture but not R1 resection was independently associated with recurrence. Twenty-four patients at very low, low or intermediate risk did not receive adjuvant imatinib after R1 resection and remained recurrence-free.
CONCLUSION: Positive resection margins are strongly associated with tumour rupture. R1 resection does not independently influence prognosis. Adjuvant imatinib may not be justified after R1 resection in the absence of tumour rupture or other high-risk features.},
	language = {eng},
	number = {4},
	journal = {The British Journal of Surgery},
	author = {Hølmebakk, T. and Bjerkehagen, B. and Hompland, I. and Stoldt, S. and Boye, K.},
	month = mar,
	year = {2019},
	pmid = {30507040},
	keywords = {Humans, Aged, Female, Gastrointestinal Neoplasms, Male, Middle Aged, Treatment Outcome, Kaplan-Meier Estimate, Retrospective Studies, Proportional Hazards Models, Risk Assessment, Prognosis, Adult, Databases, Factual, Survival Analysis, Disease-Free Survival, Neoplasm Recurrence, Local, Margins of Excision, Digestive System Surgical Procedures, Gastrointestinal Stromal Tumors, Hospitals, University, Imatinib Mesylate, Rupture, Norway},
	pages = {419--426},
}

@article{melis114a,
	title = {Correlations between neoadjuvant treatment, anemia, and perioperative complications in patients undergoing esophagectomy for cancer},
	volume = {153},
	issn = {1095-8673},
	doi = {10.1016/j.jss.2008.06.005},
	abstract = {INTRODUCTION: The influence of preoperative hemoglobin levels on outcomes of patients undergoing esophagectomy for cancer is not clearly defined. The goal of this article was to explore the association between combined modality therapy, preoperative anemia status, and perioperative blood transfusion and risk of postoperative complications among patients undergoing esophageal resection.
METHODS: From a retrospective esophageal database, 413 patients were identified. Anemia was defined according to the World Health Organization classification of {\textless}13 g/dL or {\textless}12 g/dL for men or women, respectively. Statistical analysis was performed with analysis of variance, Pearson's chi(2), or Fisher exact test as appropriate. The independent association of anemia, blood transfusion, and combined modality treatment on risk of postoperative complications were examined using multiple logistic regression.
RESULTS: Information on combined modality treatment, preoperative hemoglobin levels, and blood transfusion was available for 413 patients, of whom 57\% received combined modality treatment. Overall 197 (47.6\%) patients were preoperatively found to be anemic, and those who had received combined modality treatment were more likely to be anemic (60.6\% versus 30.7\%, P {\textless} 0.001). Anemic patients required more blood transfusions than nonanemic patients (46.7\% versus 29.6\%, P {\textless} 0.001). Seventy-five percent of patients who required transfusion during the hospital stay had received combined modality treatment (P = 0.01). Combined modality treatment and anemia were not associated with increased risk of complications. Patients with any perioperative complication and surgical site infections were more likely to have received blood transfusion compared to patients without complications (OR = 1.73; 95\% CI 1.04-2.87 and OR = 2.98; 95\% CI 1.04-8.55; respectively).
CONCLUSIONS: Overall, we determined that administration of neoadjuvant treatment to esophageal cancer patients was not associated with an increased rate of perioperative complications. Preoperative anemia did not predict worsened short-term outcomes, but increased the chances of red blood cell transfusion, which were significantly associated with higher overall complications and increased risk of surgical site infections. These data confirm previous studies that allogenic red blood cell transfusions are independent risk factors for increased morbidity and mortality and should be minimized during surgery for esophageal cancer.},
	language = {eng},
	number = {1},
	journal = {The Journal of Surgical Research},
	author = {Melis, Marcovalerio and McLoughlin, James M. and Dean, E. Michelle and Siegel, Erin M. and Weber, Jill M. and Shah, Nilay and Kelley, Scott T. and Karl, Richard C.},
	month = may,
	year = {2009},
	pmid = {19201421},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Anemia, Hemoglobins, Transfusion Reaction},
	pages = {114--120},
}

@article{songun439,
	title = {Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide {Dutch} {D1D2} trial},
	volume = {11},
	issn = {1474-5488},
	shorttitle = {Surgical treatment of gastric cancer},
	doi = {10.1016/S1470-2045(10)70070-X},
	abstract = {BACKGROUND: Historical data and recent studies show that standardised extended (D2) lymphadenectomy leads to better results than standardised limited (D1) lymphadenectomy. Based on these findings, the Dutch D1D2 trial, a nationwide prospectively randomised clinical trial, was undertaken to compare D2 with D1 lymphadenectomy in patients with resectable primary adenocarcinoma of the stomach. The aim of the study was to assess the effect of D2 compared with D1 surgery on disease recurrence and survival in patients treated with curative intent.
METHODS: Between August, 1989, and July, 1993, patients were entered and randomised at 80 participating hospitals by means of a telephone call to the central data centre of the trial. The sequence of randomisation was in blocks of six with stratification for the participating centre. Eligibility criteria were a histologically proven adenocarcinoma of the stomach without evidence of distance metastasis, age younger than 85 years, and adequate physical condition for D1 or D2 lymphadenectomy. Patients were excluded if they had previous or coexisting cancer or had undergone gastrectomy for benign tumours. Strict quality control measures for pathological assessment were implemented and monitored. Analyses were by intention to treat. This study is registered with the NCI trial register, as DUT-KWF-CKVO-8905, EU-90003.
FINDINGS: A total of 1078 patients were entered in the study, of whom 996 were eligible. 711 patients underwent the randomly assigned treatment with curative intent (380 in the D1 group and 331 in the D2 group) and 285 had palliative treatment. Data were collected prospectively and all patients were followed up for a median time of 15.2 years (range 6.9-17.9 years). Analyses were done for the 711 patients treated with curative intent and were according to the allocated treatment group. Of the 711 patients, 174 (25\%) were alive, all but one without recurrence. Overall 15-year survival was 21\% (82 patients) for the D1 group and 29\% (92 patients) for the D2 group (p=0.34). Gastric-cancer-related death rate was significantly higher in the D1 group (48\%, 182 patients) compared with the D2 group (37\%, 123 patients), whereas death due to other diseases was similar in both groups. Local recurrence was 22\% (82 patients) in the D1 group versus 12\% (40 patients) in D2, and regional recurrence was 19\% (73 patients) in D1 versus 13\% (43 patients) in D2. Patients who had the D2 procedure had a significantly higher operative mortality rate than those who had D1 (n=32 [10\%] vs n=15 [4\%]; 95\% CI for the difference 2-9; p=0.004), higher complication rate (n=142 [43\%] vs n=94 [25\%]; 11-25; p{\textless}0.0001), and higher reoperation rate (n=59 [18\%] vs n=30 [8\%]; 5-15; p=0.00016).
INTERPRETATION: After a median follow-up of 15 years, D2 lymphadenectomy is associated with lower locoregional recurrence and gastric-cancer-related death rates than D1 surgery. The D2 procedure was also associated with significantly higher postoperative mortality, morbidity, and reoperation rates. Because a safer, spleen-preserving D2 resection technique is currently available in high-volume centres, D2 lymphadenectomy is the recommended surgical approach for patients with resectable (curable) gastric cancer.
FUNDING: Dutch Health Insurance Funds Council and The Netherlands Cancer Foundation.},
	language = {eng},
	number = {5},
	journal = {The Lancet. Oncology},
	author = {Songun, Ilfet and Putter, Hein and Kranenbarg, Elma Meershoek-Klein and Sasako, Mitsuru and van de Velde, Cornelis J. H.},
	month = may,
	year = {2010},
	pmid = {20409751},
	keywords = {Humans, Aged, Female, Male, Follow-Up Studies, Prospective Studies, Survival Analysis, Stomach Neoplasms, Adenocarcinoma, Gastrectomy, Lymph Node Excision},
	pages = {439--449},
	file = {PDF:/Users/jcsal/Zotero/storage/6UV2YNL6/Songun et al. - 2010 - Surgical treatment of gastric cancer 15-year follow-up results of the randomised nationwide Dutch D.pdf:application/pdf},
}

@misc{zotero-3945,
	title = {Patient survival after {D1} and {D2} resections for gastric cancer: long-term results of the {MRC} randomized surgical trial. {Surgical} {Co}-operative {Group} - {PubMed}},
	url = {https://pubmed.ncbi.nlm.nih.gov/10188901/},
	urldate = {2025-03-22},
	file = {Patient survival after D1 and D2 resections for gastric cancer\: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group - PubMed:/Users/jcsal/Zotero/storage/V27FHBDU/10188901.html:text/html},
}

@article{gastrointestinaltumorstudygroup1465,
	title = {Prolongation of the disease-free interval in surgically treated rectal carcinoma},
	volume = {312},
	issn = {0028-4793},
	doi = {10.1056/NEJM198506063122301},
	abstract = {To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients). Five years after the entry of the last patient and with a median follow-up of all survivors for 80 months, the recurrence rate was highest among the control patients (55 per cent) and lowest among the patients receiving a combination of adjuvant radiation and chemotherapy (33 per cent). Time to tumor recurrence differed significantly among the four treatment groups (P less than 0.04); it was significantly prolonged by combined radiation and chemotherapy as compared with resection alone (P less than 0.009). Overall survival did not differ significantly among the treatment groups. The superiority of the combined-modality regimen appeared to be attributable to the effects of radiation therapy and chemotherapy in controlling local and distant recurrences, respectively. We conclude that this study provides evidence supporting the use of postoperative radiation therapy in conjunction with chemotherapy in patients who have had "curative" resection of rectal cancer with involvement of perirectal fat or regional nodes or both (Stages B2 and C).},
	language = {eng},
	number = {23},
	journal = {The New England Journal of Medicine},
	author = {{Gastrointestinal Tumor Study Group}},
	month = jun,
	year = {1985},
	pmid = {2859523},
	keywords = {Humans, Female, Male, Middle Aged, Follow-Up Studies, Neoplasm Metastasis, Prospective Studies, Fluorouracil, Adenocarcinoma, Neoplasm Recurrence, Local, Combined Modality Therapy, Rectal Neoplasms, Drug Therapy, Combination, Random Allocation, Semustine},
	pages = {1465--1472},
}

@article{sauer1731,
	title = {Preoperative versus postoperative chemoradiotherapy for rectal cancer},
	volume = {351},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa040694},
	abstract = {BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer.
METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival.
RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01).
CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.},
	language = {eng},
	number = {17},
	journal = {The New England Journal of Medicine},
	author = {Sauer, Rolf and Becker, Heinz and Hohenberger, Werner and Rödel, Claus and Wittekind, Christian and Fietkau, Rainer and Martus, Peter and Tschmelitsch, Jörg and Hager, Eva and Hess, Clemens F. and Karstens, Johann-H. and Liersch, Torsten and Schmidberger, Heinz and Raab, Rudolf and {German Rectal Cancer Study Group}},
	month = oct,
	year = {2004},
	pmid = {15496622},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Postoperative Care, Follow-Up Studies, Neoplasm Staging, Proportional Hazards Models, Antineoplastic Agents, Adult, Fluorouracil, Survival Analysis, Neoplasm Recurrence, Local, Combined Modality Therapy, Incidence, Postoperative Complications, Radiotherapy, Preoperative Care, Rectal Neoplasms, Quality Control},
	pages = {1731--1740},
	file = {Full Text:/Users/jcsal/Zotero/storage/K4F8L2GS/Sauer et al. - 2004 - Preoperative versus postoperative chemoradiotherapy for rectal cancer.pdf:application/pdf},
}

@article{cohen787,
	title = {An {Examination} of {American} {College} of {Surgeons} {NSQIP} {Surgical} {Risk} {Calculator} {Accuracy}},
	volume = {224},
	issn = {1879-1190},
	doi = {10.1016/j.jamcollsurg.2016.12.057},
	abstract = {BACKGROUND: The American College of Surgeons NSQIP offers a Surgical Risk Calculator (SRC) that provides detailed, patient-level, risk assessments for many adverse outcomes to surgeons, patients, and the general public. The SRC calculator was designed to help guide discussion and decisions by providing generally applicable (not hospital-specific) information about surgical risk using easily understood and broadly available preoperative variables. Although large, internal evaluations have shown that the SRC has good accuracy (model discrimination and calibration), external validations have been inconsistent and tend to favor a conclusion of inadequate performance.
STUDY DESIGN: External studies, attempting to validate the SRC, were examined with respect to 3 design features: sample size (small samples reduce reliability), case-mix homogeneity (homogeneity reduces discrimination); and number of institutions providing data (few institutions reduces generalizability). The impact of each feature was then examined in several sets of simulation studies.
RESULTS: Each of the 3 design features has the potential to act as an artifactual cause for apparent SRC predictive failure. In addition, demonstrations that SRC estimates are inferior to those from models that use additional (sometimes operation-specific) predictor variables were seen as not relevant with respect to the SRC's intended scope.
CONCLUSIONS: The SRC predictive failures, reported by studies with the described design limitations, should not be misunderstood as disqualifying the SRC as an accurate and appropriate tool for its intended purpose of providing a general purpose risk calculator, applicable across many surgical domains, using easily understood and generally available predictive information.},
	language = {eng},
	number = {5},
	journal = {Journal of the American College of Surgeons},
	author = {Cohen, Mark E. and Liu, Yaoming and Ko, Clifford Y. and Hall, Bruce L.},
	month = may,
	year = {2017},
	pmid = {28389191},
	keywords = {Humans, Risk Assessment, Reproducibility of Results, United States, Postoperative Complications, Quality Improvement},
	pages = {787--795e1},
}

@article{bilimoria833,
	title = {Development and evaluation of the universal {ACS} {NSQIP} surgical risk calculator: a decision aid and informed consent tool for patients and surgeons},
	volume = {217},
	issn = {1879-1190},
	shorttitle = {Development and evaluation of the universal {ACS} {NSQIP} surgical risk calculator},
	doi = {10.1016/j.jamcollsurg.2013.07.385},
	abstract = {BACKGROUND: Accurately estimating surgical risks is critical for shared decision making and informed consent. The Centers for Medicare and Medicaid Services may soon put forth a measure requiring surgeons to provide patients with patient-specific, empirically derived estimates of postoperative complications. Our objectives were to develop a universal surgical risk estimation tool, to compare performance of the universal vs previous procedure-specific surgical risk calculators, and to allow surgeons to empirically adjust the estimates of risk.
STUDY DESIGN: Using standardized clinical data from 393 ACS NSQIP hospitals, a web-based tool was developed to allow surgeons to easily enter 21 preoperative factors (demographics, comorbidities, procedure). Regression models were developed to predict 8 outcomes based on the preoperative risk factors. The universal model was compared with procedure-specific models. To incorporate surgeon input, a subjective surgeon adjustment score, allowing risk estimates to vary within the estimate's confidence interval, was introduced and tested with 80 surgeons using 10 case scenarios.
RESULTS: Based on 1,414,006 patients encompassing 1,557 unique CPT codes, a universal surgical risk calculator model was developed that had excellent performance for mortality (c-statistic = 0.944; Brier score = 0.011 [where scores approaching 0 are better]), morbidity (c-statistic = 0.816, Brier score = 0.069), and 6 additional complications (c-statistics {\textgreater} 0.8). Predictions were similarly robust for the universal calculator vs procedure-specific calculators (eg, colorectal). Surgeons demonstrated considerable agreement on the case scenario scoring (80\% to 100\% agreement), suggesting reliable score assignment between surgeons.
CONCLUSIONS: The ACS NSQIP surgical risk calculator is a decision-support tool based on reliable multi-institutional clinical data, which can be used to estimate the risks of most operations. The ACS NSQIP surgical risk calculator will allow clinicians and patients to make decisions using empirically derived, patient-specific postoperative risks.},
	language = {eng},
	number = {5},
	journal = {Journal of the American College of Surgeons},
	author = {Bilimoria, Karl Y. and Liu, Yaoming and Paruch, Jennifer L. and Zhou, Lynn and Kmiecik, Thomas E. and Ko, Clifford Y. and Cohen, Mark E.},
	month = nov,
	year = {2013},
	pmid = {24055383},
	pmcid = {PMC3805776},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Risk Assessment, Aged, 80 and over, United States, Postoperative Complications, Decision Support Techniques, General Surgery, Societies, Medical, Informed Consent, NSQIP, Risk Adjustment, Patient Education as Topic},
	pages = {833--842.e1--3},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/FLVYAJK3/Bilimoria et al. - 2013 - Development and evaluation of the universal ACS NSQIP surgical risk calculator a decision aid and i.pdf:application/pdf;nihms-506521:/Users/jcsal/Zotero/storage/74FCT38R/nihms-506521.pdf:application/pdf},
}

@article{reijers1178,
	title = {Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage {III} melanoma: the {PRADO} trial},
	volume = {28},
	issn = {1546-170X},
	shorttitle = {Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage {III} melanoma},
	doi = {10.1038/s41591-022-01851-x},
	abstract = {Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly associated with prolonged relapse-free survival (RFS). The PRADO extension cohort of the OpACIN-neo trial ( NCT02977052 ) addressed the feasibility and effect on clinical outcome of using pathologic response after neoadjuvant ipilimumab and nivolumab as a criterion for further treatment personalization. In total, 99 patients with clinical stage IIIb-d nodal melanoma were included and treated with 6 weeks of neoadjuvant ipilimumab 1 mg kg-1 and nivolumab 3 mg kg-1. In patients achieving major pathologic response (MPR, ≤10\% viable tumor) in their index lymph node (ILN, the largest lymph node metastasis at baseline), therapeutic lymph node dissection (TLND) and adjuvant therapy were omitted. Patients with pathologic partial response (pPR; {\textgreater}10 to ≤50\% viable tumor) underwent TLND only, whereas patients with pathologic non-response (pNR; {\textgreater}50\% viable tumor) underwent TLND and adjuvant systemic therapy ± synchronous radiotherapy. Primary objectives were confirmation of pRR (ILN, at week 6) of the winner neoadjuvant combination scheme identified in OpACIN-neo; to investigate whether TLND can be safely omitted in patients achieving MPR; and to investigate whether RFS at 24 months can be improved for patients achieving pNR. ILN resection and ILN-response-tailored treatment were feasible. The pRR was 72\%, including 61\% MPR. Grade 3-4 toxicity within the first 12 weeks was observed in 22 (22\%) patients. TLND was omitted in 59 of 60 patients with MPR, resulting in significantly lower surgical morbidity and better quality of life. The 24-month relapse-free survival and distant metastasis-free survival rates were 93\% and 98\% in patients with MPR, 64\% and 64\% in patients with pPR, and 71\% and 76\% in patients with pNR, respectively. These findings provide a strong rationale for randomized clinical trials testing response-directed treatment personalization after neoadjuvant ipilimumab and nivolumab.},
	language = {eng},
	number = {6},
	journal = {Nature Medicine},
	author = {Reijers, Irene L. M. and Menzies, Alexander M. and van Akkooi, Alexander C. J. and Versluis, Judith M. and van den Heuvel, Noëlle M. J. and Saw, Robyn P. M. and Pennington, Thomas E. and Kapiteijn, Ellen and van der Veldt, Astrid A. M. and Suijkerbuijk, Karijn P. M. and Hospers, Geke A. P. and Rozeman, Elisa A. and Klop, Willem M. C. and van Houdt, Winan J. and Sikorska, Karolina and van der Hage, Jos A. and Grünhagen, Dirk J. and Wouters, Michel W. and Witkamp, Arjen J. and Zuur, Charlotte L. and Lijnsvelt, Judith M. and Torres Acosta, Alejandro and Grijpink-Ongering, Lindsay G. and Gonzalez, Maria and Jóźwiak, Katarzyna and Bierman, Carolien and Shannon, Kerwin F. and Ch'ng, Sydney and Colebatch, Andrew J. and Spillane, Andrew J. and Haanen, John B. A. G. and Rawson, Robert V. and van de Wiel, Bart A. and van de Poll-Franse, Lonneke V. and Scolyer, Richard A. and Boekhout, Annelies H. and Long, Georgina V. and Blank, Christian U.},
	month = jun,
	year = {2022},
	pmid = {35661157},
	keywords = {Humans, Neoadjuvant Therapy, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local, Quality of Life, Melanoma, Ipilimumab, Nivolumab, Skin Neoplasms, Melanoma, Cutaneous Malignant},
	pages = {1178--1188},
	file = {Full Text:/Users/jcsal/Zotero/storage/5QSQPB44/Reijers et al. - 2022 - Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolum.pdf:application/pdf},
}

@article{allen925,
	title = {Optimal {Timing} of {Urinary} {Catheter} {Removal} {After} {Thoracic} {Operations}: {A} {Randomized} {Controlled} {Study}},
	volume = {102},
	issn = {1552-6259},
	shorttitle = {Optimal {Timing} of {Urinary} {Catheter} {Removal} {After} {Thoracic} {Operations}},
	doi = {10.1016/j.athoracsur.2016.03.115},
	abstract = {BACKGROUND: There are very few randomized trials confirming the belief that prolonged urinary catheterization increases urinary tract infections, and none of these have included a comparative analysis of patients with an epidural catheter in place. The aim of this prospective randomized trial was to determine if removal of the urinary catheter within 48 hours after a thoracic operation, as required by the Surgical Care Improvement Project (SCIP) Measure 9, leads to increases in urinary tract reintervention and lower rates of urinary tract infections.
METHODS: From February 2012 to August 2014, patients undergoing a general thoracic surgical procedure in whom an epidural catheter was placed for analgesia were eligible for inclusion in the trial. Patients were randomized to urinary catheter removal within 48 hours of the operation completion or 6 hours after epidural catheter removal.
RESULTS: The study enrolled 374 patients, 217 men (58\%) and 157 women (42\%). The 247 eligible and evaluated patients, 141 (57.1\%) men and 106 (42.9\%) women, were a median age of 61.5 years (range, 21 to 87 years). There were no statistically significant differences in any of the preoperative or operative categories between the two groups. Median length of stay was 5 days (range, 2 to 42 days) for all patients, and there was no difference between the two groups. Postoperatively, 19 patients (7.7\%) required urinary catheter reinsertion after it was removed. A significantly greater number of patients in the early removal group required reinsertion of the urinary catheter (15 [12.4\%] vs 4 [3.2\%]); p = 0.0065). Patients whose urinary catheter was removed within 48 hours of the operation had a much higher rate of bladder scans postoperatively (59.5\% [n = 72]) and required more in-and-out catheterization than those whose urinary catheter was removed 6 hours after the epidural analgesia was discontinued (31.0\% [n = 39]; p {\textless} 0.0001). The only documented urinary tract infection in the entire cohort occurred in a patient whose urinary catheter was removed within 48 hours after the operation. No urinary tract infections developed in the 126 patients whose urinary catheter remained in place until the epidural catheter was removed.
CONCLUSIONS: In a randomized control trial, patients with an epidural catheter in place after a general thoracic surgical operation have a higher rate of urinary problems when the urinary catheter is removed early, while the epidural catheter is still in place, compared with patients whose urinary catheter is removed after the epidural analgesia is discontinued.},
	language = {eng},
	number = {3},
	journal = {The Annals of Thoracic Surgery},
	author = {Allen, Mark S. and Blackmon, Shanda H. and Nichols, Francis C. and Cassivi, Stephen D. and Harmsen, William S. and Lechtenberg, Bettie and Pierson, Karlyn and Wigle, Dennis A. and Shen, K. Robert},
	month = sep,
	year = {2016},
	pmid = {27283107},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Time Factors, Aged, 80 and over, Adult, Thoracic Surgical Procedures, Device Removal, Urinary Catheters, Epidural},
	pages = {925--930},
}

@article{hu1302,
	title = {Early removal of urinary catheter after surgery requiring thoracic epidural: a prospective trial},
	volume = {28},
	issn = {1532-8422},
	shorttitle = {Early removal of urinary catheter after surgery requiring thoracic epidural},
	doi = {10.1053/j.jvca.2014.05.009},
	abstract = {OBJECTIVES: To prevent urinary retention, urinary catheters commonly are removed only after thoracic epidural discontinuation after thoracotomy. However, prolonged catheterization increases the risk of infection. The purpose of this study was to determine the rates of urinary retention and catheter-associated infection after early catheter removal.
DESIGN: This study described a prospective trial instituting an early urinary catheter removal protocol compared with a historic control group of patients.
SETTING: The protocol was instituted at a single, academic thoracic surgery unit.
PARTICIPANTS: The study group was comprised of patients undergoing surgery requiring thoracotomy who received an intraoperative epidural for postoperative pain control.
INTERVENTIONS: An early urinary catheter removal protocol was instituted prospectively, with all catheters removed on or before postoperative day 2. Urinary retention was determined by bladder ultrasound and treated with recatheterization.
MEASUREMENTS AND MAIN RESULTS: The primary outcomes were urinary retention rate, defined as bladder volume{\textgreater}400 mL, and urinary tract infection rate. Results were compared with a retrospective cohort of 210 consecutive patients who underwent surgery before protocol initiation. Among the 101 prospectively enrolled patients, urinary retention rate was higher (26.7\% v 12.4\%, p = 0.003), while urinary tract infection rate improved moderately (1\% v 3.8\%, p = 0.280).
CONCLUSIONS: Early removal of urinary catheters with thoracic epidurals in place is associated with a high incidence of urinary retention. However, an early catheter removal protocol may play a role in a multifaceted approach to reducing the incidence of catheter-associated urinary tract infections.},
	language = {eng},
	number = {5},
	journal = {Journal of Cardiothoracic and Vascular Anesthesia},
	author = {Hu, Yinin and Craig, Sarah J. and Rowlingson, John C. and Morton, Steve P. and Thomas, Christopher J. and Persinger, Matthew B. and Isbell, James and Lau, Christine L. and Kozower, Benjamin D.},
	month = oct,
	year = {2014},
	pmid = {25281046},
	pmcid = {PMC4185405},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Retrospective Studies, Prospective Studies, Time Factors, Cohort Studies, Thoracotomy, Analgesia, Epidural, Device Removal, Urinary Catheters, epidural anesthesia, thoracic epidural anesthesia, thoracic surgical procedures, urinary catheter removal, urinary catheterization, urinary retention, urinary tract infections},
	pages = {1302--1306},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/IUJS8NTW/Hu et al. - 2014 - Early removal of urinary catheter after surgery requiring thoracic epidural a prospective trial.pdf:application/pdf},
}

@article{cabalage120,
	title = {Potential {Clinical} {Utility} of a {Targeted} {Circulating} {Tumor} {DNA} {Assay} in {Esophageal} {Adenocarcinoma}},
	volume = {276},
	issn = {1528-1140},
	doi = {10.1097/SLA.0000000000005177},
	abstract = {OBJECTIVE: To explore the clinical utility of circulating tumor DNA (ctDNA) in esophageal adenocarcinoma (EAC) by developing a cost-effective and rapid technique utilising targeted amplicon sequencing.
SUMMARY OF BACKGROUND DATA: Emerging evidence suggests that levels of ctDNA in the blood can be used to monitor treatment response and in the detection of disease recurrence in various cancer types. Current staging modalities for EAC such as computerised tomography of the chest/abdomen/pelvis (CT) and positron emission tomography (PET) do not reliably detect occult micro-metastatic disease, the presence of which signifies a poor prognosis. After curative-intent treatment, some patients are still at high risk of recurrent disease, and there is no widely accepted optimal surveillance tool for patients with EAC.
METHODS: Sixty-two patients with EAC were investigated for the presence of ctDNA using a tumor-informed approach. We designed a custom targeted amplicon sequencing panel of target specific primers covering mutational foci in 9 of the most commonly mutated genes in EAC. Serial blood samples were taken before and after neoadjuvant treatment (NAT), and during surveillance.
RESULTS: Somatic mutations were detected in pre-treatment biopsy samples of 55 out of 62 (89\%) EAC patients. Mutations in TP53 (80\%) were the most common. Out of these 55 patients, 20 (36\%) had detectable ctDNA at baseline. The majority (90\%) of patients with detectable ctDNA had either locally advanced tumors, nodal involvement or metastatic disease. In patients with locally advanced tumors, disease free survival (DFS) was more accurately stratified using pre-treatment ctDNA status [HR 4.34 (95\% CI 0.93-20.21); P = 0.05] compared to nodal status on PET-CT. In an exploratory subgroup analysis, patients who are node negative but ctDNA positive have inferior DFS [HR 11.71 (95\% CI 1.16-118.80) P = 0.04]. In blood samples taken before and following NAT, clearance of ctDNA after NAT was associated with a favourable response to treatment. Furthermore, patients who are ctDNA positive during post-treatment surveillance are at high risk of relapse.
CONCLUSIONS: Our study shows that ctDNA has potential to provide additional prognostication over conventional staging investigation such as CT and PET. It may also have clinical utility in the assessment of response to NAT and as a biomarker for the surveillance of recurrent disease.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Cabalag, Carlos S. and Yates, Michael and Corrales, Mariana Benitez and Yeh, Paul and Wong, Stephen Q. and Zhang, Bonnie Z. and Fujihara, Kenji M. and Chong, Lynn and Hii, Michael W. and Dawson, Sarah-Jane and Phillips, Wayne A. and Duong, Cuong P. and Clemons, Nicholas J.},
	month = aug,
	year = {2022},
	pmid = {35737908},
	pmcid = {PMC9259043},
	keywords = {Humans, Prognosis, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Positron Emission Tomography Computed Tomography, Biomarkers, Tumor, Mutation, Circulating Tumor DNA},
	pages = {e120--e126},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/L7BLGWBA/Cabalag et al. - 2022 - Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.pdf:application/pdf},
}

@article{iden83,
	title = {Circulating tumor {DNA} predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer},
	volume = {28},
	issn = {1436-3305},
	doi = {10.1007/s10120-024-01556-9},
	abstract = {BACKGROUND: Gastric and gastroesophageal junction (GEJ) cancer represents a significant global health challenge, with high recurrence rates and poor survival outcomes. This study investigates circulating tumor DNA (ctDNA) as a biomarker for assessing recurrence risk in patients with resectable gastric and GEJ adenocarcinomas (AC).
METHODS: Patients with resectable gastric and GEJ AC, undergoing perioperative chemotherapy and surgery, were prospectively enrolled. Serial plasma samples were collected at baseline, after one cycle of chemotherapy, after preoperative chemotherapy, and after surgery. ctDNA was assessed by a ddPCR test (TriMeth), which targets the gastrointestinal cancer-specific methylation patterns of the genes C9orf50, KCNQ5, and CLIP4.
RESULTS: ctDNA analysis was performed on 229 plasma samples from 86 patients. At baseline, ctDNA was detected in 56\% of patients, which decreased to 37\% following one cycle of chemotherapy, 25\% after preoperative chemotherapy and 15\% after surgical resection. The presence of ctDNA after one cycle of chemotherapy was associated with reduced recurrence-free survival (RFS) (HR = 2.54, 95\% confidence interval (CI) 1.33-4.85, p = 0.005) and overall survival (OS) (HR = 2.23, 95\% CI 1.07-4.62, p = 0.032). Similarly, ctDNA after surgery was associated with significantly shorter RFS (HR = 6.22, 95\% CI 2.39-16.2, p {\textless} 0.001) and OS (HR = 6.37, 95\% CI 2.10-19.3, p = 0.001). Multivariable regression analysis confirmed ctDNA after surgery as an independent prognostic factor (p {\textless} 0.001).
CONCLUSION: ctDNA analysis has the potential to identify patients at elevated risk of recurrence, thus providing personalized treatment strategies for patients with resectable gastric and GEJ cancer. Further validation in larger cohorts and ctDNA-guided interventions are needed for future clinical use.},
	language = {eng},
	number = {1},
	journal = {Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association},
	author = {Iden, Cecilie Riis and Mustafa, Salah Mohammad and Øgaard, Nadia and Henriksen, Tenna and Jensen, Sarah Østrup and Ahlborn, Lise Barlebo and Egebjerg, Kristian and Baeksgaard, Lene and Garbyal, Rajendra Singh and Nedergaard, Mette Kjølhede and Achiam, Michael Patrick and Andersen, Claus Lindbjerg and Mau-Sørensen, Morten},
	month = jan,
	year = {2025},
	pmid = {39369091},
	pmcid = {PMC11706848},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Survival Rate, Prognosis, Aged, 80 and over, Adult, Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophagogastric Junction, Biomarkers, Tumor, Circulating Tumor DNA, Circulating tumor DNA, Curative treatment, DNA methylation, Gastroesophageal cancer, Tumor biomarkers},
	pages = {83--95},
	file = {PDF:/Users/jcsal/Zotero/storage/YV5ZTHBE/Iden et al. - 2025 - Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastr.pdf:application/pdf},
}

@article{vandenende286,
	title = {Genome-wide and panel-based cell-free {DNA} characterization of patients with resectable esophageal adenocarcinoma},
	volume = {261},
	issn = {1096-9896},
	doi = {10.1002/path.6175},
	abstract = {Circulating tumor DNA (ctDNA) holds promise in resectable esophageal adenocarcinoma (EAC) to predict patient outcome but is not yet sensitive enough to be clinically applicable. Our aim was to combine ctDNA mutation data with shallow whole-genome sequencing (sWGS)-derived copy number tumor fraction estimates (ichorCNA) to improve pathological response and survival prediction in EAC. In total, 111 stage II/III EAC patients with baseline (n = 111), post-neoadjuvant chemoradiotherapy (nCRT) (n = 68), and pre-surgery (n = 92) plasma samples were used for ctDNA characterization. sWGS ({\textless}5× coverage) was performed on all time-point samples, and copy number aberrations were estimated using ichorCNA. Baseline and pre-surgery samples were sequenced using a custom amplicon panel for mutation detection. Detection of baseline ctDNA was successful in 44.3\% of patients by amplicon sequencing and 10.5\% by ichorCNA. Combining both, ctDNA could be detected in 50.5\% of patients. Baseline ctDNA positivity was related to higher T stage (cT3, 4) (p = 0.017). There was no relationship between pathological response and baseline ctDNA positivity. However, baseline ctDNA metrics (variant allele frequency {\textgreater} 1\% or ichorCNA {\textgreater} 3\%) were associated with a high risk of disease progression [HR = 2.23 (95\% CI 1.22-4.07), p = 0.007]. The non-clearance of a baseline variant or ichorCNA {\textgreater} 3\% in pre-surgery samples was related to early progression [HR = 4.58 (95\% CI 2.22-9.46), p {\textless} 0.001]. Multi-signal analysis improves detection of ctDNA and can be used for prognostication of resectable EAC patients. Future studies should explore the potential of multi-modality sequencing for risk stratification and treatment adaptation based on ctDNA results. © 2023 The Authors. The Journal of Pathology published by John Wiley \& Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.},
	language = {eng},
	number = {3},
	journal = {The Journal of Pathology},
	author = {van den Ende, Tom and van der Pol, Ymke and Creemers, Aafke and Moldovan, Norbert and Boers, Dries and van Berge Henegouwen, Mark I. and Hulshof, Maarten Ccm and Cillessen, Saskia Agm and van Grieken, Nicole Ct and Pegtel, D. Michiel and Derks, Sarah and Bijlsma, Maarten F. and Mouliere, Florent and van Laarhoven, Hanneke Wm},
	month = nov,
	year = {2023},
	pmid = {37615198},
	keywords = {Humans, Adenocarcinoma, Esophageal Neoplasms, neoadjuvant therapy, esophageal neoplasms, Biomarkers, Tumor, Mutation, immunotherapy, Circulating Tumor DNA, cell-free nucleic acids, Cell-Free Nucleic Acids},
	pages = {286--297},
	file = {PDF:/Users/jcsal/Zotero/storage/8Y3RRE8T/van den Ende et al. - 2023 - Genome-wide and panel-based cell-free DNA characterization of patients with resectable esophageal ad.pdf:application/pdf},
}

@article{egyud343,
	title = {Detection of {Circulating} {Tumor} {DNA} in {Plasma}: {A} {Potential} {Biomarker} for {Esophageal} {Adenocarcinoma}},
	volume = {108},
	issn = {1552-6259},
	shorttitle = {Detection of {Circulating} {Tumor} {DNA} in {Plasma}},
	doi = {10.1016/j.athoracsur.2019.04.004},
	abstract = {BACKGROUND: Recent literature has demonstrated the potential of "liquid biopsy" and detection of circulating tumor (ct)DNA as a cancer biomarker. However, to date there is a lack of data specific to esophageal adenocarcinoma (EAC). This study was conducted to determine how detection and quantification of ctDNA changes with disease burden in patients with EAC and evaluate its potential as a biomarker in this population.
METHODS: Blood samples were obtained from patients with stage I to IV EAC. Longitudinal blood samples were collected from a subset of patients. Imaging studies and pathology reports were reviewed to determine disease course. Tumor samples were sequenced to identify mutations. Mutations in plasma DNA were detected using custom, barcoded, patient-specific sequencing libraries. Mutations in plasma were quantified, and associations with disease stage and response to therapy were explored.
RESULTS: Plasma samples from a final cohort of 38 patients were evaluated. Baseline plasma samples were ctDNA positive for 18 patients (47\%) overall, with tumor allele frequencies ranging from 0.05\% to 5.30\%. Detection frequency of ctDNA and quantity of ctDNA increased with stage. Data from longitudinal samples indicate that ctDNA levels correlate with and precede evidence of response to therapy or recurrence.
CONCLUSIONS: ctDNA can be detected in plasma of EAC patients and correlates with disease burden. Detection of ctDNA in early-stage EAC is challenging and may limit diagnostic applications. However, our data demonstrate the potential of ctDNA as a dynamic biomarker to monitor treatment response and disease recurrence in patients with EAC.},
	language = {eng},
	number = {2},
	journal = {The Annals of Thoracic Surgery},
	author = {Egyud, Matthew and Tejani, Mohamedtaki and Pennathur, Arjun and Luketich, James and Sridhar, Praveen and Yamada, Emiko and Ståhlberg, Anders and Filges, Stefan and Krzyzanowski, Paul and Jackson, Jennifer and Kalatskaya, Irina and Jiao, Wei and Nielsen, Gradon and Zhou, Zhongren and Litle, Virginia and Stein, Lincoln and Godfrey, Tony},
	month = aug,
	year = {2019},
	pmid = {31059681},
	pmcid = {PMC6676214},
	keywords = {Humans, Female, Male, Neoplasm Staging, Disease Progression, Adenocarcinoma, Esophageal Neoplasms, Biomarkers, Tumor, Mutation, Circulating Tumor DNA, DNA, Neoplasm, Liquid Biopsy},
	pages = {343--349},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/2R7VD42H/Egyud et al. - 2019 - Detection of Circulating Tumor DNA in Plasma A Potential Biomarker for Esophageal Adenocarcinoma.pdf:application/pdf},
}

@article{koldby108,
	title = {Tumor-specific genetic aberrations in cell-free {DNA} of gastroesophageal cancer patients},
	volume = {54},
	issn = {1435-5922},
	doi = {10.1007/s00535-018-1508-5},
	abstract = {The applicability of liquid biopsies is studied intensively in all types of cancer and analysis of circulating tumor DNA (ctDNA) has recently been implemented clinically for mutation detection in lung cancer. ctDNA may provide information about tumor quantity and mutations present in the tumor, and as such have many potential applications in diagnosis and treatment of cancer. It has been suggested that ctDNA analysis may overcome the issue of intra-tumor heterogeneity faced by tissue biopsies and serve as an additional diagnostic tool. Furthermore, liquid biopsies are potentially helpful for monitoring of treatment response as well as detection of minimal residual disease and relapse. Gastroesophageal cancers (GEC) have high mortality rates and the majority of patients present with advanced stage at diagnosis or succumb due to disease recurrence even after radical resection of the primary tumor. Biomarkers that can help optimize treatment strategy are thus highly desirable. The present study is a review of published data on ctDNA in GEC patients. We identified 25 studies in which tumor-specific genetic aberrations were investigated in plasma or serum and discuss these in relation to the methods applied for ctDNA analysis. The methods used for ctDNA detection greatly influence the sensitivity of the analysis and, therefore, the potential clinical applications. We found that studies of ctDNA in GEC, although limited in number, are promising for several applications such as genetic profiling of tumors and monitoring of disease progression. However, more studies are needed to establish if and how this analysis can be clinically implemented.},
	language = {eng},
	number = {2},
	journal = {Journal of Gastroenterology},
	author = {Koldby, Kristina Magaard and Mortensen, Michael Bau and Detlefsen, Sönke and Pfeiffer, Per and Thomassen, Mads and Kruse, Torben A.},
	month = feb,
	year = {2019},
	pmid = {30242476},
	keywords = {Humans, Stomach Neoplasms, Gastric cancer, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophageal cancer, Neoplasm, Residual, Biomarkers, Tumor, Polymorphism, Single Nucleotide, DNA Mutational Analysis, Circulating Tumor DNA, Circulating tumor DNA, Liquid Biopsy, Biomarker, Cell-free DNA, DNA Copy Number Variations},
	pages = {108--121},
	file = {PDF:/Users/jcsal/Zotero/storage/HN6THGCI/Koldby et al. - 2019 - Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.pdf:application/pdf},
}

@article{salati4607,
	title = {{ctDNA} analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality},
	volume = {17},
	issn = {1744-8301},
	shorttitle = {{ctDNA} analysis in the personalized clinical management of gastroesophageal adenocarcinoma},
	doi = {10.2217/fon-2021-0228},
	abstract = {Gastroesophageal adenocarcinoma (GEA) is a global health issue with a high fatality-to-case ratio and a 5-year overall survival that has only slightly improved. High-throughput molecular profiling has uncovered a profound complexity and heterogeneity in GEA biology, which limits considerably the treatment advances. Liquid biopsy with circulating tumor (ct)DNA analysis could elucidate GEA molecular heterogeneity and provide diagnostic, prognostic and predictive information to guide clinical decision-making. However, only a handful of studies have shown positive results for the application of ctDNA analysis in GEA clinical management. As a result, no comprehensive information is available to date on this continuously evolving topic. Here, we discuss the current state of knowledge, along with promises and challenges related to ctDNA analysis in GEA.},
	language = {eng},
	number = {33},
	journal = {Future Oncology (London, England)},
	author = {Salati, Massimiliano and Venetis, Konstantinos and Fassan, Matteo and Malapelle, Umberto and Pagni, Fabio and Sajjadi, Elham and Fusco, Nicola and Ghidini, Michele},
	month = nov,
	year = {2021},
	pmid = {34406032},
	keywords = {Humans, Risk Assessment, Antineoplastic Agents, Prognosis, Stomach Neoplasms, Adenocarcinoma, gastric cancer, Esophageal Neoplasms, Esophagogastric Junction, Biomarkers, Tumor, Mutation, prognosis, Clinical Decision-Making, biomarker, Molecular Targeted Therapy, DNA Mutational Analysis, Circulating Tumor DNA, High-Throughput Nucleotide Sequencing, Precision Medicine, Liquid Biopsy, circulating tumor DNA, ctDNA, efficacy prediction, gastroesophageal adenocarcinoma, liquid biopsy, minimal residual disease, precision medicine},
	pages = {4607--4618},
}

@article{triantafyllou352,
	title = {Multidisciplinary treatment of esophageal cancer: {The} role of active surveillance after neoadjuvant chemoradiation},
	volume = {4},
	issn = {2475-0328},
	shorttitle = {Multidisciplinary treatment of esophageal cancer},
	doi = {10.1002/ags3.12350},
	abstract = {The optimal treatment of esophageal cancer is still controversial. Neoadjuvant chemoradiotherapy followed by radical esophagectomy is a standard treatment. Morbidity after esophagectomy however is still considerable and has an impact on patients' quality of life. Given a pathologic complete response rate of approximately 30\% in patients after neoadjuvant chemoradiation followed by surgery, active surveillance has been introduced as a new alternative approach. Active surveillance involves regular clinical response evaluations in patients after neoadjuvant therapy to detect residual or recurrent disease. As long as there is no suspicion of disease activity, surgery is withheld. Esophagectomy is reserved for patients presenting with an incomplete response or resectable recurrent disease. Active surveillance after neoadjuvant treatment has been previously applied in other types of malignancy with encouraging results. This paper discusses its role in esophageal cancer.},
	language = {eng},
	number = {4},
	journal = {Annals of Gastroenterological Surgery},
	author = {Triantafyllou, Tania and Wijnhoven, Bas},
	month = jul,
	year = {2020},
	pmid = {32724878},
	pmcid = {PMC7382442},
	keywords = {esophageal cancer, neoadjuvant chemoradiation, active surveillance, salvage surgery},
	pages = {352--359},
	file = {Full Text:/Users/jcsal/Zotero/storage/I283YT96/Triantafyllou and Wijnhoven - 2020 - Multidisciplinary treatment of esophageal cancer The role of active surveillance after neoadjuvant.pdf:application/pdf},
}

@article{yuan3,
	title = {Liquid biopsy for esophageal cancer: {Is} detection of circulating cell-free {DNA} as a biomarker feasible?},
	volume = {41},
	issn = {2523-3548},
	shorttitle = {Liquid biopsy for esophageal cancer},
	doi = {10.1002/cac2.12118},
	abstract = {Esophageal cancer (EC) is a common cancer and is histopathologically classified into esophageal squamous cell carcinoma and esophageal adenocarcinoma. EC is a worldwide public health issue because of late diagnosis and lack of effective therapy. In contrast to standard tumor biopsies, liquid biopsies are emerging as a tool which is minimally invasive that can complement or even substitute more classical approaches. Specifically, cell-free DNA (cfDNA) has shown promise in cancer-related clinical applications. Indeed, cfDNA has been shown to be an effective circulating biomarker for non-invasive cancer diagnosis and monitoring of cancer patients. Although the clinical application of cfDNA has been reported on other cancers, few studies have evaluated its use in EC. Here, we review this relevant literature and discuss limitations and advantages of its application in the diagnosis and monitoring of EC.},
	language = {eng},
	number = {1},
	journal = {Cancer Communications (London, England)},
	author = {Yuan, Zuyang and Wang, Xinfeng and Geng, Xiao and Li, Yin and Mu, Juwei and Tan, Fengwei and Xue, Qi and Gao, Shugeng and He, Jie},
	month = jan,
	year = {2021},
	pmid = {33264481},
	pmcid = {PMC7819547},
	keywords = {Humans, Adenocarcinoma, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Biomarkers, Tumor, Cell-Free Nucleic Acids, Liquid Biopsy},
	pages = {3--15},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/LG95F4GD/Yuan et al. - 2021 - Liquid biopsy for esophageal cancer Is detection of circulating cell-free DNA as a biomarker feasib.pdf:application/pdf},
}

@article{mine934106,
	title = {A {Review} of {Circulating} {Tumor} {DNA} in the {Diagnosis} and {Monitoring} of {Esophageal} {Cancer}},
	volume = {28},
	issn = {1643-3750},
	doi = {10.12659/MSM.934106},
	abstract = {Circulating tumor DNA (ctDNA) is a type of cell-free DNA released by tumor cells after necrosis and apoptosis, and it can be actively secreted by tumor cells. Since ctDNA is derived from various tumor sites, it can provide far more comprehensive genomic and epigenomic information than a single-site biopsy. Therefore, ctDNA can overcome tumor heterogeneity, which is the major limitation of a traditional tissue biopsy approach. Noninvasive ctDNA assays allow continuous real-time monitoring of the molecular status of cancers. Recently, ctDNA assays have been widely used in clinical practice, including cancer diagnosis, evaluation of therapeutic efficacy and prognosis, and monitoring of relapse and metastasis. Although ctDNA shows a high diagnostic performance in advanced esophageal cancer, it is far from satisfactory for early diagnosis of esophageal cancer. Monitoring the dynamic changes of ctDNA is beneficial for the evaluation of therapeutic efficacy and prediction of early recurrence in esophageal cancer. It is necessary to establish standards for individualized ctDNA detection in the evaluation of treatment response and surveillance of esophageal cancer and to develop clinical practice guideline for the systemic treatment of patients with "ctDNA recurrence." This review aims to provide an update on the role of ctDNA in the diagnosis and monitoring of esophageal cancer.},
	language = {eng},
	journal = {Medical Science Monitor: International Medical Journal of Experimental and Clinical Research},
	author = {Min, Jiang and Zhou, Huilin and Jiang, Su and Yu, Hong},
	month = feb,
	year = {2022},
	pmid = {35210388},
	pmcid = {PMC8886734},
	keywords = {Humans, Prognosis, Esophageal Neoplasms, Biomarkers, Tumor, Mutation, DNA Mutational Analysis, Circulating Tumor DNA, Cell-Free Nucleic Acids},
	pages = {e934106},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/G4CJ324P/Min et al. - 2022 - A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer.pdf:application/pdf},
}

@article{chakrabartie2200710,
	title = {Circulating {Tumor} {DNA}-{Guided} {Recurrence} {Risk} {Assessment} in {Esophageal} and {Gastric} {Cancer}: {Assay} {Holds} the {Key}},
	volume = {7},
	issn = {2473-4284},
	shorttitle = {Circulating {Tumor} {DNA}-{Guided} {Recurrence} {Risk} {Assessment} in {Esophageal} and {Gastric} {Cancer}},
	doi = {10.1200/PO.22.00710},
	language = {eng},
	journal = {JCO precision oncology},
	author = {Chakrabarti, Sakti and Mahipal, Amit},
	month = mar,
	year = {2023},
	pmid = {36952644},
	keywords = {Humans, Risk Assessment, Stomach Neoplasms, Esophageal Neoplasms, Circulating Tumor DNA},
	pages = {e2200710},
	file = {Full Text:/Users/jcsal/Zotero/storage/PULJ6M54/Chakrabarti and Mahipal - 2023 - Circulating Tumor DNA-Guided Recurrence Risk Assessment in Esophageal and Gastric Cancer Assay Hold.pdf:application/pdf},
}

@article{li13,
	title = {Clinical applications and perspectives of circulating tumor {DNA} in gastric cancer},
	volume = {24},
	issn = {1475-2867},
	doi = {10.1186/s12935-024-03209-4},
	abstract = {Gastric cancer remains a leading cause of cancer-related death worldwide, largely due to inadequate screening methods, late diagnosis, and limited treatment options. Liquid biopsy has emerged as a promising non-invasive approach for cancer screening and prognosis by detecting circulating tumor components like circulating tumor DNA (ctDNA) in the blood. Numerous gastric cancer-specific ctDNA biomarkers have now been identified. CtDNA analysis provides insight into genetic and epigenetic alterations in tumors, holding promise for predicting treatment response and prognosis in gastric cancer patients. This review summarizes current research on ctDNA biology and detection technologies, while highlighting clinical applications of ctDNA for gastric cancer diagnosis, prognosis, and guiding treatment decisions. Current challenges and future perspectives for ctDNA analysis are also discussed.},
	language = {eng},
	number = {1},
	journal = {Cancer Cell International},
	author = {Li, Jing-Han and Zhang, Dan-Ying and Zhu, Ji-Min and Dong, Ling},
	month = jan,
	year = {2024},
	pmid = {38184573},
	pmcid = {PMC10770949},
	keywords = {Gastric cancer, Circulating tumor DNA, Biomarker, Liquid biopsy},
	pages = {13},
	file = {Full Text:/Users/jcsal/Zotero/storage/BRXT9RW7/Li et al. - 2024 - Clinical applications and perspectives of circulating tumor DNA in gastric cancer.pdf:application/pdf},
}

@article{hofste4417,
	title = {Circulating {Tumor} {DNA}-{Based} {Disease} {Monitoring} of {Patients} with {Locally} {Advanced} {Esophageal} {Cancer}},
	volume = {14},
	issn = {2072-6694},
	doi = {10.3390/cancers14184417},
	abstract = {Patients diagnosed with locally advanced esophageal cancer are often treated with neoadjuvant chemoradiotherapy followed by surgery. This study explored whether detection of circulating tumor DNA (ctDNA) in plasma can be used to predict residual disease during treatment. Diagnostic tissue biopsies from patients with esophageal cancer receiving neoadjuvant chemoradiotherapy and surgery were analyzed for tumor-specific mutations. These tumor-informed mutations were used to measure the presence of ctDNA in serially collected plasma samples using hybrid capture-based sequencing. Plasma samples were obtained before chemoradiotherapy, and prior to surgery. The association between ctDNA detection and progression-free and overall survival was measured. Before chemoradiotherapy, ctDNA was detected in 56\% (44/78) of patients and detection was associated with tumor stage and volume (p = 0.05, Fisher exact and p = 0.02, Mann-Whitney, respectively). After chemoradiotherapy, ctDNA was detected in 10\% (8/78) of patients. This preoperative detection of ctDNA was independently associated with recurrent disease (hazard ratio 2.8, 95\% confidence interval 1.1-6.8, p = 0.03, multivariable Cox-regression) and worse overall survival (hazard ratio 2.9, 95\% confidence interval 1.2-7.1, p = 0.02, multivariable Cox-regression).Ultradeep sequencing-based detection of ctDNA in preoperative plasma of patients with locally advanced esophageal cancer may help to assess which patients have a high risk of recurrence after neoadjuvant chemoradiotherapy and surgery.},
	language = {eng},
	number = {18},
	journal = {Cancers},
	author = {Hofste, Lisa S. M. and Geerlings, Maartje J. and von Rhein, Daniel and Tolmeijer, Sofie H. and Weiss, Marjan M. and Gilissen, Christian and Hofste, Tom and Garms, Linda M. and Janssen, Marcel J. R. and Rütten, Heidi and Rosman, Camiel and van der Post, Rachel S. and Klarenbeek, Bastiaan R. and Ligtenberg, Marjolijn J. L.},
	month = sep,
	year = {2022},
	pmid = {36139577},
	pmcid = {PMC9497103},
	keywords = {esophageal cancer, circulating tumor DNA, liquid biopsies, neoadjuvant treatment, next-generation sequencing},
	pages = {4417},
	file = {Full Text:/Users/jcsal/Zotero/storage/E25F827B/Hofste et al. - 2022 - Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer.pdf:application/pdf},
}

@article{vanderwilkS1470,
	title = {Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer ({SANO} trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial},
	issn = {1474-5488},
	shorttitle = {Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer ({SANO} trial)},
	doi = {10.1016/S1470-2045(25)00027-0},
	abstract = {BACKGROUND: A substantial proportion of individuals with oesophageal cancer have a pathological complete response after neoadjuvant chemoradiotherapy and oesophagectomy. We aimed to investigate whether active surveillance could be an alternative for individuals with a clinical complete response after neoadjuvant chemoradiotherapy.
METHODS: We performed a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial in 12 Dutch hospitals. Individuals with locally advanced oesophageal cancer and a clinical complete response after neoadjuvant chemoradiotherapy (ie, no tumour detected with endoscopic biopsies, ultrasound, and PET-CT) underwent active surveillance or standard surgery (ie, oesophagectomy within 2 weeks after reaching clinical complete response). There were no inclusion restrictions regarding comorbidities or performance status, but participants had carcinoma, were age 18 years or older, and were treated with curative intent. Randomisation of hospitals was performed using computer-generated sequences without stratification methods, after an initial phase of all hospitals performing standard surgery. The primary endpoint was overall survival, analysed according to a modified intention-to-treat principle (allowing crossover at time of clinical complete response) and an intention-to-treat principle. Non-inferiority was defined as 2-year survival rate for active surveillance of 15\% or less below that for standard surgery. The trial was registered within the Netherlands Trial Register, NTR-6803, and the inclusion phase has been completed.
FINDINGS: Between Nov 8, 2017, and Jan 17, 2021, 1115 individuals were screened, of whom 309 were included. 198 underwent active surveillance and 111 underwent standard surgery. 242 (78\%) participants were male and 67 (22\%) were female. Median follow-up was 38 months (IQR 32-48). 2-year overall survival for active surveillance (74\% [95\% CI 69-78]) was non-inferior to standard surgery (71\% [62-78]) after modified intention-to-treat analysis (one-sided 95\% boundary: 7\% lower). It remained non-inferior in the intention-to-treat analysis (75\% [68-80] vs 70\% [63-77], one-sided 95\% boundary: 6\% lower). There were no significant differences in overall survival according to modified intention-to-treat analysis (hazard ratio 1·14, two-sided 95\% CI 0·74-1·78) or intention-to-treat analysis (0·83, 0·53-1·31). The frequency of postoperative complications and postoperative mortality after standard surgery or postponed surgery after active surveillance was similar between groups.
INTERPRETATION: Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended follow-up is required. The results of the present trial could be used for patient counselling and shared decision making.
FUNDING: Dutch Cancer Society (KWF) and Netherlands Organisation for Health Research and Development (ZonMw).},
	language = {eng},
	journal = {The Lancet. Oncology},
	author = {van der Wilk, Berend J. and Eyck, Ben M. and Wijnhoven, Bas P. L. and Lagarde, Sjoerd M. and Rosman, Camiel and Noordman, Bo J. and Valkema, Maria J. and Bisseling, Tanya M. and Coene, Peter-Paul L. O. and van Det, Marc J. and Dekker, Jan Willem T. and van Dieren, Jolanda M. and Doukas, Michail and van Esser, Stijn and Fiets, W. Edward and Hartgrink, Henk H. and Heisterkamp, Joos and Holster, I. Lisanne and Klarenbeek, Bastiaan and van Klaveren, David and Kouw, Eva and Kouwenhoven, Ewout A. and Luyer, Misha D. and Mostert, Bianca and Nieuwenhuijzen, Grard A. P. and Oostenbrug, Liekele E. and Pierie, Jean-Pierre and van Sandick, Johanna W. and Sosef, Meindert N. and Spaander, Manon C. W. and Valkema, Roelf and van der Zaag, Edwin S. and Steyerberg, Ewout W. and van Lanschot, J. Jan B. and {SANO Study Group}},
	month = mar,
	year = {2025},
	pmid = {40112851},
	pages = {S1470--2045(25)00027--0},
	file = {1-s2.0-S1470204525000270-mmc1:/Users/jcsal/Zotero/storage/7LS47HSJ/1-s2.0-S1470204525000270-mmc1.pdf:application/pdf;1-s2.0-S1470204525000725-main:/Users/jcsal/Zotero/storage/478TXMXF/1-s2.0-S1470204525000725-main.pdf:application/pdf;PDF:/Users/jcsal/Zotero/storage/YZAWR4AZ/van der Wilk et al. - 2025 - Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophagea.pdf:application/pdf},
}

@article{mantziari7,
	title = {{18F}- {FDG} {PET}/{CT}-derived parameters predict clinical stage and prognosis of esophageal cancer},
	volume = {20},
	issn = {1471-2342},
	doi = {10.1186/s12880-019-0401-x},
	abstract = {BACKGROUND: Although 18F- FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18F- FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis.
METHODS: All patients (n = 86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005 and 2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor's maximal Standardized Uptake Value (SUVmax), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.
RESULTS: High baseline SUVmax was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUVmax {\textgreater} 8.25 g/mL (p {\textless} 0.001), TLG {\textgreater} 41.7 (p {\textless} 0.001) and MTV {\textgreater} 10.70 cm3 (p {\textless} 0.01) whereas a SUVmax {\textgreater} 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p = 0.030), particularly in squamous cell cancer.
CONCLUSIONS: Baseline 18F- FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUVmax, TLG and MTV can predict a locally advanced tumor with high accuracy. A SUVmax {\textgreater} 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.},
	language = {eng},
	number = {1},
	journal = {BMC medical imaging},
	author = {Mantziari, Styliani and Pomoni, Anastasia and Prior, John O. and Winiker, Michael and Allemann, Pierre and Demartines, Nicolas and Schäfer, Markus},
	month = jan,
	year = {2020},
	pmid = {31969127},
	pmcid = {PMC6977262},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Prognosis, Aged, 80 and over, Adult, Survival Analysis, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms, Positron Emission Tomography Computed Tomography, Esophageal cancer, Fluorodeoxyglucose F18, Radiopharmaceuticals, Sensitivity and Specificity, Radiographic Image Interpretation, Computer-Assisted, TNM stage, 18FDG PET/CT, Glycolysis, Metabolic imaging, Nuclear imaging},
	pages = {7},
	file = {Full Text:/Users/jcsal/Zotero/storage/KGW42JN6/Mantziari et al. - 2020 - 18F- FDG PETCT-derived parameters predict clinical stage and prognosis of esophageal cancer.pdf:application/pdf},
}

@article{janmahasatian1051,
	title = {Quantification of lean bodyweight},
	volume = {44},
	issn = {0312-5963},
	doi = {10.2165/00003088-200544100-00004},
	abstract = {BACKGROUND: Lean bodyweight (LBW) has been recommended for scaling drug doses. However, the current methods for predicting LBW are inconsistent at extremes of size and could be misleading with respect to interpreting weight-based regimens.
OBJECTIVE: The objective of the present study was to develop a semi-mechanistic model to predict fat-free mass (FFM) from subject characteristics in a population that includes extremes of size. FFM is considered to closely approximate LBW. There are several reference methods for assessing FFM, whereas there are no reference standards for LBW.
PATIENTS AND METHODS: A total of 373 patients (168 male, 205 female) were included in the study. These data arose from two populations. Population A (index dataset) contained anthropometric characteristics, FFM estimated by dual-energy x-ray absorptiometry (DXA - a reference method) and bioelectrical impedance analysis (BIA) data. Population B (test dataset) contained the same anthropometric measures and FFM data as population A, but excluded BIA data. The patients in population A had a wide range of age (18-82 years), bodyweight (40.7-216.5 kg) and BMI values (17.1-69.9 kg/m2). Patients in population B had BMI values of 18.7-38.4 kg/m2. A two-stage semi-mechanistic model to predict FFM was developed from the demographics from population A. For stage 1 a model was developed to predict impedance and for stage 2 a model that incorporated predicted impedance was used to predict FFM. These two models were combined to provide an overall model to predict FFM from patient characteristics. The developed model for FFM was externally evaluated by predicting into population B.
RESULTS: The semi-mechanistic model to predict impedance incorporated sex, height and bodyweight. The developed model provides a good predictor of impedance for both males and females (r2 = 0.78, mean error [ME] = 2.30 x 10(-3), root mean square error [RMSE] = 51.56 [approximately 10\% of mean]). The final model for FFM incorporated sex, height and bodyweight. The developed model for FFM provided good predictive performance for both males and females (r2 = 0.93, ME = -0.77, RMSE = 3.33 [approximately 6\% of mean]). In addition, the model accurately predicted the FFM of subjects in population B (r2 = 0.85, ME = -0.04, RMSE = 4.39 [approximately 7\% of mean]).
CONCLUSIONS: A semi-mechanistic model has been developed to predict FFM (and therefore LBW) from easily accessible patient characteristics. This model has been prospectively evaluated and shown to have good predictive performance.},
	language = {eng},
	number = {10},
	journal = {Clinical Pharmacokinetics},
	author = {Janmahasatian, Sarayut and Duffull, Stephen B. and Ash, Susan and Ward, Leigh C. and Byrne, Nuala M. and Green, Bruce},
	year = {2005},
	pmid = {16176118},
	keywords = {Adiposity, Body Composition, Humans, Aged, Female, Male, Middle Aged, Body Mass Index, Sex Factors, Body Weight, Absorptiometry, Photon, Electric Impedance, Aged, 80 and over, Reproducibility of Results, Adult, Adolescent, Body Height, Models, Biological},
	pages = {1051--1065},
}

@article{vanderzijden7759,
	title = {Interval {Metastases} {After} {Neoadjuvant} {Chemoradiotherapy} for {Patients} with {Locally} {Advanced} {Esophageal} {Cancer}: {A} {Multicenter} {Observational} {Cohort} {Study}},
	volume = {31},
	issn = {1534-4681},
	shorttitle = {Interval {Metastases} {After} {Neoadjuvant} {Chemoradiotherapy} for {Patients} with {Locally} {Advanced} {Esophageal} {Cancer}},
	doi = {10.1245/s10434-024-15890-w},
	abstract = {BACKGROUND: Despite trimodality treatment, 10\% to 20\% of patients with esophageal cancer experience interval metastases after surgery. Restaging may identify patients who should not proceed to surgery, as well as a subgroup with limited metastases for whom long-term disease-control can be obtained. This study aimed to determine the proportion of patients with interval metastases after neoadjuvant chemoradiotherapy (nCRT) and to evaluate treatment and survival.
METHODS: Patients who had cT2-4aN0-3M0 esophageal cancer treated with nCRT were identified from a trial database. Metastases detected up to 14 weeks after nCRT on 18F-FDG-PET/CT or during surgery were categorized as oligometastases (≤3 lesions located in one single organ or one extra-regional lymph node station) or as non-oligometastases. The primary outcome was the proportion of patients with metastases after nCRT. The secondary outcomes were overall survival (OS) and the site and treatment of metastases.
RESULTS: Between 2013 and 2021, 973 patients received nCRT, and 10.3\% had interval metastases. Of 100 patients, 30 (30\%) had oligometastases, located mostly in non-regional lymph nodes (33.3\%) or bones (26.7\%). The median OS of this group was 13.8 months (95\% confidence interval [CI] 9.2-27.1 months). Of 30 patients, 12 (40\%) with oligometastases underwent potentially curative treatment, with a median OS of 22.8 months (95\% CI 10.4-NA). The patients with non-oligometastases underwent mostly systemic therapy or BSC and had a median OS of 9 months (95\% CI 7.4-10.9 months).
CONCLUSIONS: Interval metastases were detected in about 10\% of patients after nCRT, underscoring the importance of re-staging with 18F-FDG-PET/CT for those who proceed to surgery. A favorable survival might be accomplished for a subgroup of patients with oligometastases.},
	language = {eng},
	number = {12},
	journal = {Annals of Surgical Oncology},
	author = {van der Zijden, Charlène J. and van der Sluis, Pieter C. and Mostert, Bianca and Nuyttens, Joost J. M. E. and van Lanschot, J. Jan B. and Spaander, Manon C. W. and Valkema, Roelf and Coene, Peter Paul L. O. and Dekker, Jan Willem T. and Fiets, Willem E. and Hartgrink, Hendrik H. and Hazen, Wouter L. and Kouwenhoven, Ewout A. and Nieuwenhuijzen, Grard A. P. and Rosman, Camiel and van Sandick, Johanna W. and Sosef, Meindert N. and van der Zaag, Edwin S. and Lagarde, Sjoerd M. and Wijnhoven, Bas P. L.},
	month = nov,
	year = {2024},
	pmid = {39068317},
	pmcid = {PMC11467105},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Retrospective Studies, Survival Rate, Prognosis, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant, Esophageal Neoplasms, Esophagectomy, Chemoradiotherapy, Positron Emission Tomography Computed Tomography, Esophageal cancer, Fluorodeoxyglucose F18, Lymphatic Metastasis, Esophagogastric junction cancer, Interval metastases, Palliative therapy},
	pages = {7759--7766},
	file = {Full Text:/Users/jcsal/Zotero/storage/DGRHVCSU/van der Zijden et al. - 2024 - Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophagea.pdf:application/pdf},
}

@article{lambdin4573,
	title = {A {Randomized} {Phase} {III} {Study} of {Neoadjuvant} {Chemotherapy} {Followed} by {Surgery} {Versus} {Surgery} {Alone} for {Patients} with {High}-{Risk} {Retroperitoneal} {Sarcoma} ({STRASS2})},
	volume = {30},
	issn = {1068-9265},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687743/},
	doi = {10.1245/s10434-023-13500-9},
	number = {8},
	urldate = {2025-04-08},
	journal = {Annals of surgical oncology},
	author = {Lambdin, Jacob and Ryan, Carrie and Gregory, Stephanie and Cardona, Kenneth and Hernandez, Jonathan M. and van Houdt, Winan J. and Gronchi, Alessandro},
	month = aug,
	year = {2023},
	pmid = {37170037},
	pmcid = {PMC10687743},
	pages = {4573--4575},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/CN2E6E5Z/Lambdin et al. - 2023 - A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone fo.pdf:application/pdf},
}

@article{slagter877,
	title = {{CRITICS}-{II}: a multicentre randomised phase {II} trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer},
	volume = {18},
	issn = {1471-2407},
	shorttitle = {{CRITICS}-{II}},
	doi = {10.1186/s12885-018-4770-2},
	abstract = {BACKGROUND: Although radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor. Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy, postoperative chemoradiotherapy and postoperative chemotherapy. However, these regimens suffer from poor patient compliance, particularly in the postoperative phase of treatment. The CRITICS-II trial aims to optimize preoperative treatment by comparing three treatment regimens: (1) chemotherapy, (2) chemotherapy followed by chemoradiotherapy and (3) chemoradiotherapy.
METHODS: In this multicentre phase II non-comparative study, patients with clinical stage IB-IIIC (TNM 8th edition) resectable gastric adenocarcinoma are randomised between: (1) 4 cycles of docetaxel+oxaliplatin+capecitabine (DOC), (2) 2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin) or (3) chemoradiotherapy. Primary endpoint is event-free survival, 1 year after randomisation (events are local and/or regional recurrence or progression, distant recurrence, or death from any cause). Secondary endpoints include: toxicity, surgical outcomes, percentage radical (R0) resections, pathological tumour response, disease recurrence, overall survival, and health related quality of life. Exploratory endpoints include translational studies on predictive and prognostic biomarkers.
DISCUSSION: The aim of this study is to select the most promising among three preoperative treatment arms in patients with resectable gastric adenocarcinoma. This treatment regimen will subsequently be compared with the standard therapy in a phase III trial.
TRIAL REGISTRATION: clinicaltrials.gov NCT02931890 ; registered 13 October 2016. Date of first enrolment: 21 December 2017.},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Slagter, Astrid E. and Jansen, Edwin P. M. and van Laarhoven, Hanneke W. M. and van Sandick, Johanna W. and van Grieken, Nicole C. T. and Sikorska, Karolina and Cats, Annemieke and Muller-Timmermans, Pietje and Hulshof, Maarten C. C. M. and Boot, Henk and Los, Maartje and Beerepoot, Laurens V. and Peters, Frank P. J. and Hospers, Geke A. P. and van Etten, Boudewijn and Hartgrink, Henk H. and van Berge Henegouwen, Mark I. and Nieuwenhuijzen, Grard A. P. and van Hillegersberg, Richard and van der Peet, Donald L. and Grabsch, Heike I. and Verheij, Marcel},
	month = sep,
	year = {2018},
	pmid = {30200910},
	pmcid = {PMC6131797},
	keywords = {Humans, Female, Male, Neoadjuvant Therapy, Treatment Outcome, Follow-Up Studies, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Chemotherapy, Chemotherapy, Adjuvant, Stomach Neoplasms, Gastric cancer, Chemoradiotherapy, Adjuvant, Chemoradiotherapy, Combined Modality Therapy, Gastrectomy, Neoplasm Grading, Quality of Life, Surgery, Preoperative treatment, Resectable},
	pages = {877},
	file = {Full Text:/Users/jcsal/Zotero/storage/GREQ8EEB/Slagter et al. - 2018 - CRITICS-II a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery.pdf:application/pdf},
}

@article{filiberto152,
	title = {Resource use for cholecystectomy with versus without cholangiography: {A} multicenter, propensity-matched analysis},
	volume = {174},
	issn = {1532-7361},
	shorttitle = {Resource use for cholecystectomy with versus without cholangiography},
	doi = {10.1016/j.surg.2023.04.027},
	abstract = {BACKGROUND: Intraoperative cholangiography may allow for earlier identification of common bile duct injury and choledocholithiasis. The role of intraoperative cholangiography in decreasing resource use related to biliary pathology remains unclear. This study tests the null hypothesis that there is no difference in resource use for patients undergoing laparoscopic cholecystectomy with versus without intraoperative cholangiography.
METHODS: This retrospective, longitudinal cohort study included 3,151 patients who underwent laparoscopic cholecystectomy at 3 university hospitals. To minimize differences in baseline characteristics while maintaining adequate statistical power, propensity scores were used to match 830 patients who underwent intraoperative cholangiography at surgeon discretion and 795 patients who underwent cholecystectomy without intraoperative cholangiography. Primary outcomes were the incidence of postoperative endoscopic retrograde cholangiography, the interval between surgery and endoscopic retrograde cholangiography, and total direct costs.
RESULTS: In the propensity-matched analysis, the intraoperative cholangiography and no intraoperative cholangiography cohorts had similar age, comorbidities, American Society of Anesthesiologists Sequential Organ Failure Assessment scores, and total/direct bilirubin ratios. The intraoperative cholangiography cohort had a lower postoperative endoscopic retrograde cholangiography (2.4\% vs 4.3\%; P = .04), a shorter interval between cholecystectomy and endoscopic retrograde cholangiography (2.5 [1.0-17.8] vs 4.5 [2.0-9.5] days; P = .04), and shorter length of stay (0.3 [0.2-1.5] vs 1.4 [0.3-3.2] days; P {\textless} .001). Patients undergoing intraoperative cholangiography had lower total direct costs (\$4.0K [3.6K-5.4K] vs \$8.1K [4.9K-13.0K]; P {\textless} .001). There were no differences in 30-day or 1-year mortality among the cohorts.
CONCLUSION: Compared with laparoscopic cholecystectomy without intraoperative cholangiography, cholecystectomy with intraoperative cholangiography was associated with decreased resource use, which was primarily attributable to decreased incidence and the earlier timing of postoperative endoscopic retrograde cholangiography.},
	language = {eng},
	number = {2},
	journal = {Surgery},
	author = {Filiberto, Amanda C. and Nyren, Molly Q. and Underwood, Patrick W. and Balch, Jeremy A. and Abbott, Kenneth L. and Efron, Philip A. and Sarosi, George A. and Bihorac, Azra and Upchurch, Gilbert R. and Loftus, Tyler J.},
	month = aug,
	year = {2023},
	pmid = {37188579},
	keywords = {Humans, Retrospective Studies, Longitudinal Studies, Cholecystectomy, Laparoscopic, Cholangiography, Choledocholithiasis},
	pages = {152--158},
}

@article{kim719,
	title = {The {Society} of {Thoracic} {Surgeons} {Expert} {Consensus} {Statements} on a {Framework} for a {Standardized} {National} {Robotic} {Curriculum} for {Thoracic} {Surgery} {Trainees}},
	volume = {119},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2024.12.003},
	abstract = {OBJECTIVE: With robotic technology's rapid growth and integration, an urgent need to bridge the educational gap in thoracic surgical training has emerged. This document, a result of consensus among a group of experts in the practice and training of robotic surgery from The Society of Thoracic Surgeons, aims to provide a framework for a standardized national robotic curriculum for thoracic surgery trainees.
METHODS: The Society of Thoracic Surgeons Task Force on Robotic Thoracic Surgery and Workforce on E-learning and Educational Innovation assembled an expert group with the input of the Thoracic Surgery Director's Association. A focused literature review was performed, and expert consensus statements were developed using a modified Delphi process to address 3 major themes: (1) program expectations, (2) components of training, and (3) assessment and feedback.
RESULTS: A consensus was reached on 12 recommendations. These consensus statements reflect updated insights on developing a standardized robotics curriculum based on the latest literature and current educational experience, focusing on program expectations and educational guidelines to develop an optimal training curriculum.
CONCLUSIONS: The expert panel provides several key recommendations to provide a framework for developing a standardized national robotic thoracic curriculum, which would improve resident education and abridge any educational disparity that may exist among programs.},
	language = {eng},
	number = {4},
	journal = {The Annals of Thoracic Surgery},
	author = {Kim, Samuel S. and Schumacher, Lana and Cooke, David T. and Servais, Elliot and Rice, David and Sarkaria, Inderpal and Yang, Stephen and Abbas, Abbas and Sanchetti, Manu and Long, Jason and Kotova, Svetlana and Park, Bernard J. and D'Souza, Desmond and Shah-Jadeja, Mansi and Ajouz, Hana and Godoy, Luis and Bahatyrevich, Nataliya and Hayanga, Jeremiah and Lazar, John},
	month = apr,
	year = {2025},
	pmid = {39706508},
	keywords = {Humans, United States, Clinical Competence, Thoracic Surgical Procedures, Thoracic Surgery, Societies, Medical, Consensus, Robotic Surgical Procedures, Curriculum, Education, Medical, Graduate, Internship and Residency},
	pages = {719--732},
}

@article{kooij892,
	title = {{ASO} {Visual} {Abstract}: {The} {Current} {State} of {Robot}-{Assisted} {Minimally} {Invasive} {Esophagectomy} ({RAMIE})-{Outcomes} from the {Upper} {GI} {International} {Robotic} {Association} ({UGIRA}) {Esophageal} {Registry}},
	volume = {32},
	issn = {1534-4681},
	shorttitle = {{ASO} {Visual} {Abstract}},
	doi = {10.1245/s10434-024-16450-y},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Kooij, Cezanne D. and de Jongh, Cas and Kingma, B. Feike and van Berge Henegouwen, Mark I. and Gisbertz, Suzanne S. and Chao, Yin-Kai and Chiu, Philip W. and Rouanet, Philippe and Mourregot, Anne and Immanuel, Arul and Mala, Tom and van Boxel, Gijs I. and Carter, Nicholas C. and Li, Hecheng and Fuchs, Hans F. and Bruns, Christiane J. and Giacopuzzi, Simone and Kalff, Jörg C. and Hölzen, Jens-Peter and Juratli, Mazen A. and Benedix, Frank and Lorenz, Eric and Egberts, Jan-Hendrik and Haveman, Jan W. and van Etten, Boudewijn and Müller, Beat P. and Grimminger, Peter P. and Berlth, Felix and Piessen, Guillaume and van den Berg, Jan W. and Milone, Marco and Luketich, James D. and Sarkaria, Inderpal S. and Sallum, Rubens A. A. and van Det, Marc J. and Kouwenhoven, Ewout A. and Brüwer, Matthias and Harustiak, Tomas and Kinoshita, Takahiro and Fujita, Takeo and Daiko, Hiroyuki and Li, Zhigang and Ruurda, Jelle P. and van Hillegersberg, Richard and {and UGIRA Study Group}},
	month = feb,
	year = {2025},
	pmid = {39616293},
	pages = {892--893},
}

@article{jung4466,
	title = {Hybrid laparoscopic versus fully robot-assisted minimally invasive esophagectomy: an international propensity-score matched analysis of perioperative outcome},
	volume = {37},
	issn = {1432-2218},
	shorttitle = {Hybrid laparoscopic versus fully robot-assisted minimally invasive esophagectomy},
	doi = {10.1007/s00464-023-09911-0},
	abstract = {BACKGROUND: Currently, little is known regarding the optimal technique for the abdominal phase of RAMIE. The aim of this study was to investigate the outcome of robot-assisted minimally invasive esophagectomy (RAMIE) in both the abdominal and thoracic phase (full RAMIE) compared to laparoscopy during the abdominal phase (hybrid laparoscopic RAMIE).
METHODS: This retrospective propensity-score matched analysis of the International Upper Gastrointestinal International Robotic Association (UGIRA) database included 807 RAMIE procedures with intrathoracic anastomosis between 2017 and 2021 from 23 centers.
RESULTS: After propensity-score matching, 296 hybrid laparoscopic RAMIE patients were compared to 296 full RAMIE patients. Both groups were equal regarding intraoperative blood loss (median 200 ml versus 197 ml, p = 0.6967), operational time (mean 430.3 min versus 417.7 min, p = 0.1032), conversion rate during abdominal phase (2.4\% versus 1.7\%, p = 0.560), radical resection (R0) rate (95.6\% versus 96.3\%, p = 0.8526) and total lymph node yield (mean 30.4 versus 29.5, p = 0.3834). The hybrid laparoscopic RAMIE group showed higher rates of anastomotic leakage (28.0\% versus 16.6\%, p = 0.001) and Clavien Dindo grade 3a or higher (45.3\% versus 26.0\%, p {\textless} 0.001). The length of stay on intensive care unit (median 3 days versus 2 days, p = 0.0005) and in-hospital (median 15 days versus 12 days, p {\textless} 0.0001) were longer for the hybrid laparoscopic RAMIE group.
CONCLUSIONS: Hybrid laparoscopic RAMIE and full RAMIE were oncologically equivalent with a potential decrease of postoperative complications and shorter (intensive care) stay after full RAMIE.},
	language = {eng},
	number = {6},
	journal = {Surgical Endoscopy},
	author = {Jung, Jin-On and de Groot, Eline M. and Kingma, B. Feike and Babic, Benjamin and Ruurda, Jelle P. and Grimminger, Peter P. and Hölzen, Jens P. and Chao, Yin-Kai and Haveman, Jan W. and van Det, Marc J. and Rouanet, Philippe and Benedix, Frank and Li, Hecheng and Sarkaria, Inderpal and van Berge Henegouwen, Mark I. and van Boxel, Gijs I. and Chiu, Philip and Egberts, Jan-Hendrik and Sallum, Rubens and Immanuel, Arul and Turner, Paul and Low, Donald E. and Hubka, Michal and Perez, Daniel and Strignano, Paolo and Biebl, Matthias and Chaudry, M. Asif and Bruns, Christiane J. and van Hillegersberg, Richard and Fuchs, Hans F. and {UGIRA Study Group}},
	month = jun,
	year = {2023},
	pmid = {36808472},
	pmcid = {PMC10234920},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Postoperative Complications, Minimally Invasive Surgical Procedures, Complications, Robotic Surgical Procedures, Robotics, RAMIE, Hybrid laparoscopic approach, Perioperative outcome, Propensity-score matching, Robot-assisted minimally invasive esophagectomy},
	pages = {4466--4477},
	file = {Full Text:/Users/jcsal/Zotero/storage/TGA5JG48/Jung et al. - 2023 - Hybrid laparoscopic versus fully robot-assisted minimally invasive esophagectomy an international p.pdf:application/pdf},
}

@article{ekeke374,
	title = {Comparison of robotic-assisted minimally invasive esophagectomy versus minimally invasive esophagectomy: {A} propensity-matched study from a single high-volume institution},
	volume = {166},
	issn = {1097-685X},
	shorttitle = {Comparison of robotic-assisted minimally invasive esophagectomy versus minimally invasive esophagectomy},
	doi = {10.1016/j.jtcvs.2022.11.027},
	abstract = {OBJECTIVE: Robotic-assisted minimally invasive esophagectomy accounts for a growing proportion of esophagectomies, potentially due to improved technical capabilities simplifying the challenging aspects of standard minimally invasive esophagectomy. However, there is limited evidence directly comparing both operations. The objective is to evaluate the short-term and long-term outcomes of robotic-assisted minimally invasive esophagectomy in comparison with the minimally invasive esophagectomy approach for patients with esophageal cancer over a 7-year period at a high-volume center. The primary end points of this study were overall survival and disease-free survival. Secondary end points included operation-specific morbidity, lymph node yield, readmission status, and in-hospital, 30-day, and 90-day mortality.
METHODS: Patients who underwent robotic-assisted minimally invasive esophagectomy or standard minimally invasive esophagectomy over a 7-year period were identified from a prospectively maintained database. Inclusion criteria were patients with stage I to III disease, operations performed past the learning curve, and no evidence of scleroderma or cirrhosis. A 1:3 propensity match (robotic-assisted minimally invasive esophagectomy:minimally invasive esophagectomy) for multiple clinical covariates was performed to identify the final study cohort. Perioperative outcomes were compared between the 2 operations.
RESULTS: A total of 734 patients undergoing minimally invasive esophagectomy (n = 630) or robotic-assisted minimally invasive esophagectomy (n = 104) for esophageal cancer were identified. After exclusions and matching, a total cohort of 246 patients undergoing robotic-assisted minimally invasive esophagectomy (n = 65) or minimally invasive esophagectomy (n = 181) were identified. There was no difference in overall survival (P = .69) or disease-free survival (P = .70). There were no significant differences in rates of major morbidity: pneumonia (17\% vs 17\%, P = .34), chylothorax (8\% vs 9\%, P = .95), recurrent laryngeal nerve injury (0\% vs 1.5\%, P = 1), anastomotic leak (5\% vs 4\%, P = .49), intraoperative complications (9\% vs 8\%, P = .73), or complete resection rates (99\% vs 96\%, P = .68). There was no difference in in-hospital (P = .89), 30-day (P = .66) or 90-day mortality (P = .73) between both cohorts. The robotic-assisted minimally invasive esophagectomy cohort yielded a higher median lymph node harvest in comparison with the minimally invasive esophagectomy cohort (32 vs 29, P = .02).
CONCLUSIONS: Robotic-assisted minimally invasive esophagectomy may improve lymphadenectomy in patients undergoing esophagectomy for cancer. Minimally invasive esophagectomy and robotic-assisted minimally invasive esophagectomy are otherwise associated with similar mortality, morbidity, and perioperative outcomes. Further prospective study is required to investigate whether improved lymph node resection may translate to improved oncologic outcomes.},
	language = {eng},
	number = {2},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Ekeke, Chigozirim N. and Kuiper, Gino M. and Luketich, James D. and Ruppert, Kristine M. and Copelli, Susan J. and Baker, Nicholas and Levy, Ryan M. and Awais, Omar and Christie, Neil A. and Dhupar, Rajeev and Pennathur, Arjun and Sarkaria, Inderpal S.},
	month = aug,
	year = {2023},
	pmid = {36732144},
	pmcid = {PMC11232031},
	keywords = {Humans, Treatment Outcome, Retrospective Studies, Esophageal Neoplasms, Esophagectomy, Postoperative Complications, Minimally Invasive Surgical Procedures, minimally invasive esophagectomy, Robotic Surgical Procedures, esophageal malignancy, lymphadenectomy, Robotic-Assisted Minimally Invasive Esophagectomy},
	pages = {374--382.e1},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/XJRMTPW9/Ekeke et al. - 2023 - Comparison of robotic-assisted minimally invasive esophagectomy versus minimally invasive esophagect.pdf:application/pdf},
}

@article{witek6195,
	title = {Technique of robotic esophagectomy},
	volume = {13},
	issn = {2072-1439},
	doi = {10.21037/jtd.2020.02.43},
	abstract = {Robotic surgery continues to grow in thoracic surgery, and currently plays an evolving role in esophagectomy. Robotic assisted minimally invasive esophagectomy (RAMIE) has continued to expand, with many institutions adapting the technique. As the overall experience continues to grow, new data is emerging in its support. We present our approach to this operation.},
	language = {eng},
	number = {10},
	journal = {Journal of Thoracic Disease},
	author = {Witek, Tadeusz D. and Brady, John J. and Sarkaria, Inderpal S.},
	month = oct,
	year = {2021},
	pmid = {34795971},
	pmcid = {PMC8575817},
	keywords = {Esophagectomy, esophageal cancer, minimally invasive, robotic},
	pages = {6195--6204},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/NXY2ZVAX/Witek et al. - 2021 - Technique of robotic esophagectomy.pdf:application/pdf},
}

@article{luketich705,
	title = {Commentary: {Minimally} invasive esophagectomy ({MIE}) and robotic-assisted esophagectomy ({RAMIE}): {We} need high-volume surgeons, more science, and more robots!},
	volume = {162},
	issn = {1097-685X},
	shorttitle = {Commentary},
	doi = {10.1016/j.jtcvs.2021.05.011},
	language = {eng},
	number = {3},
	journal = {The Journal of Thoracic and Cardiovascular Surgery},
	author = {Luketich, James D. and Pennathur, Arjun and Sarkaria, Inderpal},
	month = sep,
	year = {2021},
	pmid = {34127279},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Minimally Invasive Surgical Procedures, Surgeons, Robotic Surgical Procedures, Robotics, Boehmeria},
	pages = {705--706},
}

@article{abbasdoaa109,
	title = {Specific complications and limitations of robotic esophagectomy},
	volume = {33},
	issn = {1442-2050},
	doi = {10.1093/dote/doaa109},
	abstract = {Regardless of the approach to esophagectomy, it is an operation that may be associated with significant risk to the patient. Robotic-assisted minimally invasive esophagectomy (RAMIE) has the same potential for short- and long-term complications as does open and minimally invasive esophagectomy. These complications include among others, the risk for anastomotic leak, gastric tip necrosis, vocal cord palsy, and chylothorax. Moreover, there are additional risks that are unique to the robotic platform such as hardware or software malfunction. These risks are heavily influenced by numerous factors including the patient's comorbidities, whether neoadjuvant therapy was administered, and the extent of the surgical team's experience. The limitations of RAMIE are therefore based on the careful assessment of the patient for operability, the tumor for resectability and the team for surgical ability. This article will tackle the topic of complications and limitations of RAMIE by examining each of these issues. It will also describe the recommended terminology for reporting post-esophagectomy complications.},
	language = {eng},
	number = {Supplement\_2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Abbas, Abbas E. and Sarkaria, Inderpal S.},
	month = nov,
	year = {2020},
	pmid = {33241309},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, esophagectomy, Vocal Cord Paralysis, Minimally Invasive Surgical Procedures, complications, Robotic Surgical Procedures, RAMIE},
	pages = {doaa109},
	file = {Full Text:/Users/jcsal/Zotero/storage/AEI3K3SV/Abbas and Sarkaria - 2020 - Specific complications and limitations of robotic esophagectomy.pdf:application/pdf},
}

@article{witek269,
	title = {Open, {Minimally} {Invasive}, and {Robotic} {Approaches} for {Esophagectomy}: {What} {Is} the {Approach} {Algorithm}?},
	volume = {30},
	issn = {1558-5069},
	shorttitle = {Open, {Minimally} {Invasive}, and {Robotic} {Approaches} for {Esophagectomy}},
	doi = {10.1016/j.thorsurg.2020.04.010},
	abstract = {Esophageal cancer requires a multimodality treatment approach, with surgical resection a key component in many cases. When it comes to esophagectomy, several approaches and techniques exist, including transhiatal versus transthoracic and open versus minimally invasive. Each approach has its associated risks and advantages. When determining the optimal approach and technique, several variables need to be considered. The key variables include patient and tumor characteristics, as well as surgeon comfort and experience with each approach. Regardless of the approach, the goal should remain the same, that is, performing a safe operation without compromise of oncologic principles.},
	language = {eng},
	number = {3},
	journal = {Thoracic Surgery Clinics},
	author = {Witek, Tadeusz D. and Melvin, Thomas J. and Luketich, James D. and Sarkaria, Inderpal S.},
	month = aug,
	year = {2020},
	pmid = {32593360},
	keywords = {Humans, Esophageal Neoplasms, Esophagectomy, Esophageal cancer, Laparoscopy, Esophageal Diseases, Barrett Esophagus, Minimally Invasive Surgical Procedures, Algorithms, Minimally invasive esophagectomy, Robotic Surgical Procedures, Robotic assisted esophagectomy},
	pages = {269--277},
}

@article{kidane935,
	title = {Neoadjuvant {Therapy} {Vs} {Upfront} {Surgery} for {Clinical} {T2N0} {Esophageal} {Cancer}: {A} {Systematic} {Review}},
	volume = {108},
	issn = {1552-6259},
	shorttitle = {Neoadjuvant {Therapy} {Vs} {Upfront} {Surgery} for {Clinical} {T2N0} {Esophageal} {Cancer}},
	doi = {10.1016/j.athoracsur.2019.04.008},
	abstract = {BACKGROUND: The optimal approach to clinical T2N0 (cT2N0) esophageal cancer is unclear. Our objective is to perform a systematic review investigating whether neoadjuvant therapy results in better outcomes compared with upfront surgery in cT2N0 esophageal cancer.
METHODS: We performed a systematic review and meta-analysis of randomized and nonrandomized studies (1995 to 2017) comparing use of neoadjuvant therapy with upfront surgery in the treatment of cT2N0 esophageal cancer. Independent and duplicate assessment was used. All meta-analytical techniques were performed in RevMan 5.3.
RESULTS: Nine cohort studies, including 5433 patients, were included for meta-analysis. Use of neoadjuvant therapy was associated with significantly higher complete resection rates compared with upfront surgery (risk ratio, 0.67; 95\% confidence interval, 0.55 to 0.81; P {\textless} .001). There was no difference in 5-year overall or recurrence-free survival. There were no significant differences in perioperative mortality as well as perioperative complications, although meta-analysis results are limited by inconsistent reporting of such complications. Lymphovascular invasion and larger tumor size were significant predictors of upstaging. Four of the studies were at high risk of bias. The remaining 5 studies were larger and more robust but were assessed as being of uncertain risk of bias.
CONCLUSIONS: Use of neoadjuvant therapy was associated with significantly higher complete resection rates compared with upfront surgery although this did not translate to differences in survival outcomes. No differences in perioperative morbidity or mortality were identified. Based on qualitative systematic review, lymphovascular invasion and larger tumor size are potential factors for helping to select those patients who may benefit from neoadjuvant therapy.},
	language = {eng},
	number = {3},
	journal = {The Annals of Thoracic Surgery},
	author = {Kidane, Biniam and Korst, Robert J. and Weksler, Benny and Farrell, Ashley and Darling, Gail E. and Martin, Linda W. and Reddy, Rishindra and Sarkaria, Inderpal S.},
	month = sep,
	year = {2019},
	pmid = {31077657},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Risk Assessment, Prognosis, Outcome Assessment, Health Care, Randomized Controlled Trials as Topic, Neoplasm Invasiveness, Survival Analysis, United States, Disease-Free Survival, Esophageal Neoplasms, Esophagectomy},
	pages = {935--944},
}

@article{sarkaria268,
	title = {Attaining {Proficiency} in {Robotic}-{Assisted} {Minimally} {Invasive} {Esophagectomy} {While} {Maximizing} {Safety} {During} {Procedure} {Development}},
	volume = {11},
	issn = {1559-0879},
	doi = {10.1097/IMI.0000000000000297},
	abstract = {OBJECTIVE: Robotic-assisted minimally invasive esophagectomy (RAMIE) is an emerging complex operation with limited reports detailing morbidity, mortality, and requirements for attaining proficiency. Our objective was to develop a standardized RAMIE technique, evaluate procedure safety, and assess outcomes using a dedicated operative team and 2-surgeon approach.
METHODS: We conducted a study of sequential patients undergoing RAMIE from January 25, 2011, to May 5, 2014. Intermedian demographics and perioperative data were compared between sequential halves of the experience using the Wilcoxon rank sum test and the Fischer exact test. Median operative time was tracked over successive 15-patient cohorts.
RESULTS: One hundred of 313 esophageal resections performed at our institution underwent RAMIE during the study period. A dedicated team including 2 attending surgeons and uniform anesthesia and OR staff was established. There were no significant differences in age, sex, histology, stage, induction therapy, or risk class between the 2 halves of the study. Estimated blood loss, conversions, operative times, and overall complications significantly decreased. The median resected lymph nodes increased but was not statistically significant. Median operative time decreased to approximately 370 minutes between the 30th and the 45th cases. There were no emergent intraoperative complications, and the anastomotic leak rate was 6\% (6/100). The 30-day mortality was 0\% (0/100), and the 90-day mortality was 1\% (1/100).
CONCLUSIONS: Excellent perioperative and short-term patient outcomes with minimal mortality can be achieved using a standardized RAMIE procedure and a dedicated team approach. The structured process described may serve as a model to maximize patients' safety during development and assessment of complex novel procedures.},
	language = {eng},
	number = {4},
	journal = {Innovations (Philadelphia, Pa.)},
	author = {Sarkaria, Inderpal S. and Rizk, Nabil P. and Grosser, Rachel and Goldman, Debra and Finley, David J. and Ghanie, Amanda and Sima, Camelia S. and Bains, Manjit S. and Adusumilli, Prasad S. and Rusch, Valerie W. and Jones, David R.},
	year = {2016},
	pmid = {27662372},
	pmcid = {PMC5427663},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Treatment Outcome, Aged, 80 and over, Adult, Survival Analysis, Esophageal Neoplasms, Esophagectomy, Minimally Invasive Surgical Procedures, Clinical Competence, Perioperative Care, Operative Time, Robotic Surgical Procedures},
	pages = {268--273},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/AKWMBV7R/Sarkaria et al. - 2016 - Attaining Proficiency in Robotic-Assisted Minimally Invasive Esophagectomy While Maximizing Safety D.pdf:application/pdf},
}

@article{ripley226,
	title = {Pretreatment {Dysphagia} in {Esophageal} {Cancer} {Patients} {May} {Eliminate} the {Need} for {Staging} by {Endoscopic} {Ultrasonography}},
	volume = {101},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2015.06.062},
	abstract = {BACKGROUND: Neoadjuvant therapy is commonly administered to patients with localized disease who have T3-4 esophageal disease as staged by endoscopic ultrasound (EUS). Previously, we noted that patients who present with dysphagia have a higher EUS T stage. We hypothesized that the presence of dysphagia is predictive of EUS T3-4 disease and that staging EUS could be forgone for esophageal cancer patients with dysphagia.
METHODS: We performed a prospective, intent-to-treat, single-cohort study in which patients with potentially resectable esophageal cancer completed a standardized four-tier dysphagia score survey. EUS was performed as part of our standard evaluation. To determine whether the presence of dysphagia predicted EUS T3-4 disease, the dysphagia score was compared with EUS T stage.
RESULTS: The study enrolled 114 consecutive patients between August 2012 and February 2014: 77\% (88 of 114) received neoadjuvant therapy, 18\% (20 of 114) did not, and 5\% (6 of 114) pursued treatment elsewhere. In total, 70\% (80 of 114) underwent esophagectomy; of these, 54\% (61 of 114) had dysphagia and 46\% (53 of 114) did not. Dysphagia scores were 66\% (40 of 61) grade 1, 25\% (15 of 61) grade 2, and 10\% (6 of 61) grade 3 to 4. Among patients with dysphagia, 89\% (54 of 61) had T3-4 disease by EUS; among those without dysphagia, only 53\% (28 of 53) had T3-4 disease by EUS (p {\textless} 0.001).
CONCLUSIONS: The presence of dysphagia in patients with esophageal cancer was highly predictive of T3-4 disease by EUS. On the basis of this finding, approximately 50\% of patients currently undergoing staging EUS at our institution could potentially forgo EUS before neoadjuvant therapy. Patients without dysphagia, however, should still undergo EUS.},
	language = {eng},
	number = {1},
	journal = {The Annals of Thoracic Surgery},
	author = {Ripley, R. Taylor and Sarkaria, Inderpal S. and Grosser, Rachel and Sima, Camelia S. and Bains, Manjit S. and Jones, David R. and Adusumilli, Prasad S. and Huang, James and Finley, David J. and Rusch, Valerie W. and Rizk, Nabil P.},
	month = jan,
	year = {2016},
	pmid = {26603024},
	pmcid = {PMC4765728},
	keywords = {Humans, Female, Male, Middle Aged, Neoadjuvant Therapy, Follow-Up Studies, Neoplasm Staging, Prospective Studies, Esophageal Neoplasms, Endosonography, Dysphonia, Unnecessary Procedures},
	pages = {226--230},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/PIUGNUN5/Ripley et al. - 2016 - Pretreatment Dysphagia in Esophageal Cancer Patients May Eliminate the Need for Staging by Endoscopi.pdf:application/pdf},
}

@article{sarkariae107,
	title = {Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a four-arm platform: experience, technique and cautions during early procedure development},
	volume = {43},
	issn = {1873-734X},
	shorttitle = {Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a four-arm platform},
	doi = {10.1093/ejcts/ezt013},
	abstract = {OBJECTIVES: This study reports an early, single-institution experience of combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy (RAMIE) using a four-arm robotic platform, with special attention given to the pitfalls and complications during procedure development.
METHODS: We conducted a prospective, single-cohort, observational study of patients undergoing RAMIE at a single institution.
RESULTS: A total of 21 patients (median age, 62 years [range, 37-83 years]) underwent RAMIE with a four-arm robotic platform (17 by Ivor Lewis and 4 by McKeown). Of the patients, 17 (81\%) had a complete (R0) resection, and 16 (76\%) received induction treatment, the majority (14/21 [67\%]) with combined chemoradiation. The median operative time was 556 min (range, 395-807 min), which decreased to 414 min (range, 405-543 min) for the last 5 cases in the series. The median estimated blood loss was 307 cm(3) (range, 200-500 cm(3)), and the median length of hospital stay was 10 days (range, 7-70 days). The median number of lymph nodes resected was 20 (range, 10-49). Five (24\%) patients were converted to open procedures. Five patients (24\%) had major complications. One (5\%) died of complications on postoperative Day 70, and 3 (14\%) had clinically significant anastomotic leaks (Grade II or greater, by Common Terminology Criteria for Adverse Events version 3.0). Three patients (14\%) in this early experience developed airway fistulas.
CONCLUSIONS: While four-arm RAMIE may offer advantages over standard minimally invasive esophagectomy approaches, its adoption in a structured program, with critical evaluation of adverse events and subsequent adjustment of technique, is paramount to maximize patient safety, minimize complications and improve the conduct of operation early in the learning curve. Particular technical consideration should be given to prevention of airway complications.},
	language = {eng},
	number = {5},
	journal = {European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery},
	author = {Sarkaria, Inderpal S. and Rizk, Nabil P. and Finley, David J. and Bains, Manjit S. and Adusumilli, Prasad S. and Huang, James and Rusch, Valerie W.},
	month = may,
	year = {2013},
	pmid = {23371971},
	keywords = {Humans, Aged, Female, Male, Middle Aged, Prospective Studies, Cohort Studies, Aged, 80 and over, Adult, Esophageal Neoplasms, Esophagectomy, Laparoscopy, Perioperative Period, Anastomosis, Surgical, Thoracoscopy, Robotics},
	pages = {e107--115},
	file = {Full Text:/Users/jcsal/Zotero/storage/S2RHR7C2/Sarkaria et al. - 2013 - Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a fo.pdf:application/pdf},
}

@article{wanbahrume794,
	title = {Oral water-soluble contrast for malignant bowel obstruction: open label pilot study},
	volume = {13},
	issn = {2045-4368},
	shorttitle = {Oral water-soluble contrast for malignant bowel obstruction},
	doi = {10.1136/bmjspcare-2021-003444},
	abstract = {OBJECTIVES: Malignant bowel obstruction (MBO) is a common, challenging condition in advanced cancer. Oral water-soluble contrast medium (Gastrografin) has been used in the management of MBO without quality studies of its effectiveness and safety. The purpose of this study was to evaluate the feasibility, effectiveness and adverse effects of Gastrografin in patients with MBO and to assess feasibility of the study protocol.
METHODS: A prospective, interventional, single-arm, open label study of Gastrografin across two centres. Patients with unresolved inoperable MBO after 24 hours of conservative medical management were given a single dose of 100 mL of oral Gastrografin.
RESULTS: Over 33 months, 69 individual patients were screened. Of the 20 recruited, 17 completed study assessments (85\%). MBO resolved in 10 of 17 patients (59\%). Gastrografin passed through to the rectum in 14 patients (78\%). The most common adverse effects were diarrhoea, vomiting, nausea and abdominal pain.
CONCLUSIONS: Patient recruitment took longer than anticipated, but the study protocol is feasible. Gastrografin was found to be a relatively effective option for the treatment of MBO. An adeqautely powered randomised controlled trial is needed to formally assess the efficacy and safety of Gastrografin© in MBO.},
	language = {eng},
	number = {e3},
	journal = {BMJ supportive \& palliative care},
	author = {Wan Bahrum, Wan Fadzrul Izuan Bin and Hardy, Janet and Foster, Karyn and Good, Phillip},
	month = jan,
	year = {2024},
	pmid = {35045980},
	keywords = {Humans, Pilot Projects, Prospective Studies, Intestinal Obstruction, Contrast Media, Diatrizoate Meglumine, supportive care, intestinal obstruction, other cancer, symptoms and symptom management, Water},
	pages = {e794--e797},
}

@misc{zotero-3614,
	title = {Citrix {Workspace}},
	url = {https://goremote.carolinas.org/Citrix/GoRemoteWeb/},
	urldate = {2025-05-16},
}

@article{visser2687,
	title = {Outcomes of {Salvage} {Surgery} for {Esophageal} {Carcinoma}: {A} {Nationwide} {Cohort} {Study} from the {Dutch} {Upper} {GI} {Cancer} {Audit}},
	volume = {32},
	issn = {1534-4681},
	shorttitle = {Outcomes of {Salvage} {Surgery} for {Esophageal} {Carcinoma}},
	doi = {10.1245/s10434-024-16490-4},
	abstract = {BACKGROUND: Salvage esophagectomy is more complex and associated with higher postoperative morbidity and mortality than standard resection. This study aimed to investigate short-term outcomes and the influence of hospital volume on these outcomes of salvage surgery for esophageal cancer.
METHODS: The study enrolled all patients undergoing esophagectomy for esophageal cancer registered in the Dutch Upper Gastrointestinal Cancer Audit (DUCA) between 2012 and 2022. The patients were classified as salvage or non-salvage by registering surgeons. Salvage surgery is defined in the DUCA as surgery after definitive chemoradiotherapy. Postoperative mortality (30-day/in-hospital) and morbidity were compared between the salvage and non-salvage patients using multilevel logistic regression analyses. Hospital variation in the use of salvage esophagectomy was investigated using funnel plots. The influence of hospital volume (≤ 40 to {\textgreater} 40 cases) and salvage volume ({\textless} 6 to ≥ 6 cases) on outcomes for salvage patients were investigated. Using backward elimination, relevant baseline characteristics influencing salvage outcomes were identified.
RESULTS: Between 2012 and 2022, 7749 patients underwent esophagectomy, 251 (3\%) of whom underwent salvage resection, varying from 0 to 8\% between centers. Severe complications (43\% vs 28\%; odds ratio [OR], 1.81; 95 \% confidence interval [CI], 1.40-2.34) and 30-day/in-hospital mortality (11\% vs 3\%; OR, 3.65; 95\% CI, 2.38-5.61) were higher after salvage surgery than after non-salvage surgery. Salvage patients treated in high-volume centers had a lower risk of 30-day/in-hospital mortality than those treated in low-volume centers (9\% vs 19\%; OR, 0.42; 95\% CI, 0.18-0.99), with no relation between salvage volume and outcome. Male sex, older age ({\textgreater} 75 years), and squamous cell carcinoma were associated with worse short-term outcomes of salvage surgery.
CONCLUSIONS: Salvage surgery is associated with worse short-term outcomes than non-salvage esophagectomy. Outcomes after salvage surgery were favorable in high-volume esophagectomy centers.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgical Oncology},
	author = {Visser, Maurits R. and Voeten, Daan M. and Gisbertz, Suzanne S. and Ruurda, Jelle P. and van Hillegersberg, Richard and van Berge Henegouwen, Mark I. and {Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group}},
	month = apr,
	year = {2025},
	pmid = {39627639},
	keywords = {Aged, Cohort Studies, Complications, Esophageal carcinoma, Esophageal Neoplasms, Esophagectomy, Female, Follow-Up Studies, Hospital Mortality, Hospitals, High-Volume, Hospitals, Low-Volume, Humans, Male, Middle Aged, Netherlands, Postoperative Complications, Prognosis, Salvage esophagectomy, Salvage Therapy, Surgery, Survival Rate},
	pages = {2687--2697},
}

@article{zotero-3612,
	title = {Ivor {Lewis} {Esophagectomy} {Procedure} {Guide}},
}

@article{burt140,
	title = {Robotic {Ivor}-{Lewis} esophagectomy in 15 steps},
	volume = {19},
	issn = {2666-2507},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267876/},
	doi = {10.1016/j.xjtc.2023.03.007},
	urldate = {2025-05-19},
	journal = {JTCVS Techniques},
	author = {Burt, Bryan M. and Onaitis, Mark},
	month = mar,
	year = {2023},
	pmid = {37324348},
	pmcid = {PMC10267876},
	pages = {140--141},
	file = {PubMed Central Full Text PDF:/Users/jcsal/Zotero/storage/JUBKDKA8/Burt and Onaitis - 2023 - Robotic Ivor-Lewis esophagectomy in 15 steps.pdf:application/pdf},
}

@article{faiz779,
	title = {Elective colonic surgery for cancer in the elderly: an investigation into postoperative mortality in {English} {NHS} hospitals between 1996 and 2007},
	volume = {13},
	issn = {1463-1318},
	shorttitle = {Elective colonic surgery for cancer in the elderly},
	doi = {10.1111/j.1463-1318.2010.02290.x},
	abstract = {BACKGROUND: This study was primarily aimed to quantify perioperative mortality risk in elderly patients undergoing elective colonic resectional surgery. In addition, the safety of minimally invasive colonic surgery in this patient group was evaluated.
METHODS: All patients aged {\textgreater} 75 undergoing elective colonic resection for colorectal malignancy between 1996 and 2007 in English NHS hospitals were included from the Hospital Episode Statistics (HES) dataset.
RESULTS: Between the study dates, 28,746 patients {\textgreater} 75 years underwent elective colonic resection. The national annual number of colonic excisions carried out amongst elderly patients increased from 2188 patients in 1996/7 to 3240 patients in 2006/7. Following adjustment for gender, comorbidity and surgical approach, advancing age was an independent predictor for 30-day mortality (OR 2.47 for patients aged 85-89 vs 75-79, P {\textless} 0.001). Use of laparoscopy was a significant predictor of reduced perioperative mortality (OR 0.56, P = 0.003) once adjusted for advancing age, gender and comorbidity. Comparison of 30-day and 1-year postoperative mortality following elective colonic resection in patients aged 90 revealed a large excess of patients dying outside of the immediate perioperative period (10.1\% and 26.2\% for proximal cancers, respectively; 12.9\% and 36.1\% for distal colonic resections, respectively).
CONCLUSIONS: Advancing age is an independent risk factor for postoperative death in elderly patients undergoing elective colonic resection for cancer. The risk of death in the elderly is extremely high and surgical decision-making should incorporate the mortality risk that occurs outside the immediate perioperative period. In this national series, patients selected for a laparoscopic procedure were at lower risk of perioperative death than those undergoing the conventional approach.},
	language = {eng},
	number = {7},
	journal = {Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland},
	author = {Faiz, O. and Haji, A. and Bottle, A. and Clark, S. K. and Darzi, A. W. and Aylin, P.},
	month = jul,
	year = {2011},
	pmid = {20412094},
	keywords = {Age Factors, Aged, Aged, 80 and over, Colectomy, Colonic Neoplasms, Elective Surgical Procedures, Female, Hospital Mortality, Hospitals, Public, Humans, Laparoscopy, Male, National Health Programs, United Kingdom},
	pages = {779--785},
}

@article{faries2211,
	title = {Completion {Dissection} or {Observation} for {Sentinel}-{Node} {Metastasis} in {Melanoma}},
	volume = {376},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa1613210},
	abstract = {BACKGROUND: Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., survival until death from melanoma) among patients with node-positive intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for patients with sentinel-node metastases is not clear.
METHODS: In an international trial, we randomly assigned patients with sentinel-node metastases detected by means of standard pathological assessment or a multimarker molecular assay to immediate completion lymph-node dissection (dissection group) or nodal observation with ultrasonography (observation group). The primary end point was melanoma-specific survival. Secondary end points included disease-free survival and the cumulative rate of nonsentinel-node metastasis.
RESULTS: Immediate completion lymph-node dissection was not associated with increased melanoma-specific survival among 1934 patients with data that could be evaluated in an intention-to-treat analysis or among 1755 patients in the per-protocol analysis. In the per-protocol analysis, the mean (±SE) 3-year rate of melanoma-specific survival was similar in the dissection group and the observation group (86±1.3\% and 86±1.2\%, respectively; P=0.42 by the log-rank test) at a median follow-up of 43 months. The rate of disease-free survival was slightly higher in the dissection group than in the observation group (68±1.7\% and 63±1.7\%, respectively; P=0.05 by the log-rank test) at 3 years, based on an increased rate of disease control in the regional nodes at 3 years (92±1.0\% vs. 77±1.5\%; P{\textless}0.001 by the log-rank test); these results must be interpreted with caution. Nonsentinel-node metastases, identified in 11.5\% of the patients in the dissection group, were a strong, independent prognostic factor for recurrence (hazard ratio, 1.78; P=0.005). Lymphedema was observed in 24.1\% of the patients in the dissection group and in 6.3\% of those in the observation group.
CONCLUSIONS: Immediate completion lymph-node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma-specific survival among patients with melanoma and sentinel-node metastases. (Funded by the National Cancer Institute and others; MSLT-II ClinicalTrials.gov number, NCT00297895 .).},
	language = {eng},
	number = {23},
	journal = {The New England Journal of Medicine},
	author = {Faries, Mark B. and Thompson, John F. and Cochran, Alistair J. and Andtbacka, Robert H. and Mozzillo, Nicola and Zager, Jonathan S. and Jahkola, Tiina and Bowles, Tawnya L. and Testori, Alessandro and Beitsch, Peter D. and Hoekstra, Harald J. and Moncrieff, Marc and Ingvar, Christian and Wouters, Michel W. J. M. and Sabel, Michael S. and Levine, Edward A. and Agnese, Doreen and Henderson, Michael and Dummer, Reinhard and Rossi, Carlo R. and Neves, Rogerio I. and Trocha, Steven D. and Wright, Frances and Byrd, David R. and Matter, Maurice and Hsueh, Eddy and MacKenzie-Ross, Alastair and Johnson, Douglas B. and Terheyden, Patrick and Berger, Adam C. and Huston, Tara L. and Wayne, Jeffrey D. and Smithers, B. Mark and Neuman, Heather B. and Schneebaum, Schlomo and Gershenwald, Jeffrey E. and Ariyan, Charlotte E. and Desai, Darius C. and Jacobs, Lisa and McMasters, Kelly M. and Gesierich, Anja and Hersey, Peter and Bines, Steven D. and Kane, John M. and Barth, Richard J. and McKinnon, Gregory and Farma, Jeffrey M. and Schultz, Erwin and Vidal-Sicart, Sergi and Hoefer, Richard A. and Lewis, James M. and Scheri, Randall and Kelley, Mark C. and Nieweg, Omgo E. and Noyes, R. Dirk and Hoon, Dave S. B. and Wang, He-Jing and Elashoff, David A. and Elashoff, Robert M.},
	month = jun,
	year = {2017},
	pmid = {28591523},
	pmcid = {PMC5548388},
	keywords = {Adult, Aged, Disease-Free Survival, Female, Humans, Intention to Treat Analysis, Lymph Node Excision, Lymph Nodes, Lymphatic Metastasis, Lymphedema, Male, Melanoma, Middle Aged, Neoplasm Staging, Postoperative Complications, Prognosis, Proportional Hazards Models, Sentinel Lymph Node, Sentinel Lymph Node Biopsy, Survival Analysis, Ultrasonography, Watchful Waiting, Young Adult},
	pages = {2211--2222},
	file = {Full Text:/Users/jcsal/Zotero/storage/NGLTGIID/Faries et al. - 2017 - Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.pdf:application/pdf},
}

@article{morton599,
	title = {Final trial report of sentinel-node biopsy versus nodal observation in melanoma},
	volume = {370},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa1310460},
	abstract = {BACKGROUND: Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial.
METHODS: We evaluated outcomes in 2001 patients with primary cutaneous melanomas randomly assigned to undergo wide excision and nodal observation, with lymphadenectomy for nodal relapse (observation group), or wide excision and sentinel-node biopsy, with immediate lymphadenectomy for nodal metastases detected on biopsy (biopsy group). Results No significant treatment-related difference in the 10-year melanoma-specific survival rate was seen in the overall study population (20.8\% with and 79.2\% without nodal metastases). Mean (± SE) 10-year disease-free survival rates were significantly improved in the biopsy group, as compared with the observation group, among patients with intermediate-thickness melanomas, defined as 1.20 to 3.50 mm (71.3 ± 1.8\% vs. 64.7 ± 2.3\%; hazard ratio for recurrence or metastasis, 0.76; P=0.01), and those with thick melanomas, defined as {\textgreater}3.50 mm (50.7 ± 4.0\% vs. 40.5 ± 4.7\%; hazard ratio, 0.70; P=0.03). Among patients with intermediate-thickness melanomas, the 10-year melanoma-specific survival rate was 62.1 ± 4.8\% among those with metastasis versus 85.1 ± 1.5\% for those without metastasis (hazard ratio for death from melanoma, 3.09; P{\textless}0.001); among patients with thick melanomas, the respective rates were 48.0 ± 7.0\% and 64.6 ± 4.9\% (hazard ratio, 1.75; P=0.03). Biopsy-based management improved the 10-year rate of distant disease-free survival (hazard ratio for distant metastasis, 0.62; P=0.02) and the 10-year rate of melanoma-specific survival (hazard ratio for death from melanoma, 0.56; P=0.006) for patients with intermediate-thickness melanomas and nodal metastases. Accelerated-failure-time latent-subgroup analysis was performed to account for the fact that nodal status was initially known only in the biopsy group, and a significant treatment benefit persisted.
CONCLUSIONS: Biopsy-based staging of intermediate-thickness or thick primary melanomas provides important prognostic information and identifies patients with nodal metastases who may benefit from immediate complete lymphadenectomy. Biopsy-based management prolongs disease-free survival for all patients and prolongs distant disease-free survival and melanoma-specific survival for patients with nodal metastases from intermediate-thickness melanomas. (Funded by the National Cancer Institute, National Institutes of Health, and the Australia and New Zealand Melanoma Trials Group; ClinicalTrials.gov number, NCT00275496.).},
	language = {eng},
	number = {7},
	journal = {The New England Journal of Medicine},
	author = {Morton, Donald L. and Thompson, John F. and Cochran, Alistair J. and Mozzillo, Nicola and Nieweg, Omgo E. and Roses, Daniel F. and Hoekstra, Harold J. and Karakousis, Constantine P. and Puleo, Christopher A. and Coventry, Brendon J. and Kashani-Sabet, Mohammed and Smithers, B. Mark and Paul, Eberhard and Kraybill, William G. and McKinnon, J. Gregory and Wang, He-Jing and Elashoff, Robert and Faries, Mark B. and {MSLT Group}},
	month = feb,
	year = {2014},
	pmid = {24521106},
	pmcid = {PMC4058881},
	keywords = {Adult, Aged, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Observation, Sentinel Lymph Node Biopsy, Skin Neoplasms, Survival Rate},
	pages = {599--609},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/3G88L529/Morton et al. - 2014 - Final trial report of sentinel-node biopsy versus nodal observation in melanoma.pdf:application/pdf},
}

@article{habr-gama711,
	title = {Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results},
	volume = {240},
	issn = {0003-4932},
	shorttitle = {Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy},
	doi = {10.1097/01.sla.0000141194.27992.32},
	abstract = {OBJECTIVE: Report overall long-term results of stage 0 rectal cancer following neoadjuvant chemoradiation and compare long-term results between operative and nonoperative treatment.
METHODS: Two-hundred sixty-five patients with distal rectal adenocarcinoma considered resectable were treated by neoadjuvant chemoradiation (CRT) with 5-FU, Leucovorin and 5040 cGy. Patients with incomplete clinical response were referred to radical surgical resection. Patients with incomplete clinical response treated by surgery resulting in stage p0 were compared to patients with complete clinical response treated by nonoperative treatment. Statistical analysis was performed using chi2, Student t test and Kaplan-Meier curves.
RESULTS: Overall and disease-free 10-year survival rates were 97.7\% and 84\%. In 71 patients (26.8\%) complete clinical response was observed following CRT (Observation group). Twenty-two patients (8.3\%) showed incomplete clinical response and pT0N0M0 resected specimens (Resection group). There were no differences between patient's demographics and tumor's characteristics between groups. In the Resection group, 9 definitive colostomies and 7 diverting temporary ileostomies were performed. Mean follow-up was 57.3 months in Observation Group and 48 months in Resection Group. There were 3 systemic recurrences in each group and 2 endorectal recurrences in Observation Group. Two patients in the Resection group died of the disease. Five-year overall and disease-free survival rates were 88\% and 83\%, respectively, in Resection Group and 100\% and 92\% in Observation Group.
CONCLUSIONS: Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy. Surgical resection may not lead to improved outcome in this situation and may be associated with high rates of temporary or definitive stoma construction and unnecessary morbidity and mortality rates.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Habr-Gama, Angelita and Perez, Rodrigo Oliva and Nadalin, Wladimir and Sabbaga, Jorge and Ribeiro, Ulysses and Silva e Sousa, Afonso Henrique and Campos, Fábio Guilherme and Kiss, Desidério Roberto and Gama-Rodrigues, Joaquim},
	month = oct,
	year = {2004},
	pmid = {15383798},
	pmcid = {PMC1356472},
	keywords = {Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Antineoplastic Agents, Colostomy, Disease-Free Survival, Female, Fluorouracil, Follow-Up Studies, Humans, Ileostomy, Leucovorin, Longitudinal Studies, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Neoplasm Staging, Radiotherapy Dosage, Rectal Neoplasms, Remission Induction, Survival Rate, Treatment Outcome},
	pages = {711--717; discussion 717--718},
}

@article{capovilladoab088,
	title = {End to side circular stapled anastomosis during robotic-assisted {Ivor} {Lewis} minimally invasive esophagectomy ({RAMIE})},
	volume = {35},
	issn = {1442-2050},
	doi = {10.1093/dote/doab088},
	abstract = {Robotic-assisted minimally invasive esophagectomy (RAMIE) represents an established approach for the treatment of esophageal cancer. Aim of this study is to evaluate the feasibility and safety of our technique for performing the intrathoracic anastomosis during RAMIE.All the procedures were performed by the same surgeon using the same technique for performing the intrathoracic anastomosis. Intraoperative and postoperative outcomes were recorded. Postoperative complications were classified according to the Esophagectomy Complications Consensus Group (ECCG); the primary outcome was the evaluation of the feasibility and safety of our technique. From 2016 to 2021, 204 patients underwent Ivor Lewis RAMIE at our Center. Two patients (0.9\%) were converted during the thoracic phase. The anastomosis was completed in all the other patients forming complete anastomotic rings. The median duration for the robotic-assisted thoracoscopic phase was 224 minutes. Twenty-two of the RAMIE-Ivor Lewis patients had an anastomotic leakage (10.3\%). The overall 90-day postoperative mortality was 1.9\%. The procedure resulted to be feasible and safe in our cohort of patients.},
	language = {eng},
	number = {8},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Capovilla, Giovanni and Hadzijusufovic, Edin and Tagkalos, Evangelos and Froiio, Caterina and Berlth, Felix and Mann, Carolina and Staubitz, Julia and Uzun, Eren and Lang, Hauke and Grimminger, Peter P.},
	month = aug,
	year = {2022},
	pmid = {34979549},
	keywords = {Anastomosis, Surgical, Boehmeria, esophageal cancer, Esophageal Neoplasms, esophagectomy, Esophagectomy, Humans, Ivor Lewis, Minimally Invasive Surgical Procedures, RAMIE, Retrospective Studies, robotic surgery, Robotic Surgical Procedures},
	pages = {doab088},
	file = {PDF:/Users/jcsal/Zotero/storage/QI32NANB/Capovilla et al. - 2022 - End to side circular stapled anastomosis during robotic-assisted Ivor Lewis minimally invasive esoph.pdf:application/pdf},
}

@article{kitagami107,
	title = {A standardized protocol for robot-assisted minimally invasive esophagectomy: improving efficiency and reducing costs},
	volume = {19},
	issn = {1863-2491},
	shorttitle = {A standardized protocol for robot-assisted minimally invasive esophagectomy},
	doi = {10.1007/s11701-025-02269-6},
	abstract = {Robot-assisted minimally invasive esophagectomy (RAMIE) has shown potential benefits over conventional procedures for esophageal cancer. However, uniform surgical protocols are lacking, leading to variability in outcomes and increased costs. This retrospective study included 180 patients with esophageal cancer who underwent RAMIE between May 2018 and September 2024. A standardized approach, termed counterclockwise partitioned mediastinal dissection (CPMD), was introduced in 114 of these cases. Perioperative parameters including operative time, blood loss, complications, and cost of disposable instruments, were compared between patients treated before and after protocol standardization. Among the 114 patients who received the standardized RAMIE protocol, the median thoracic console time significantly decreased to 148 min, with overall blood loss reduced to 62 ml. No conversions to open surgery were required in either cohort. Compared to the pre-standardization group, postoperative complications-including recurrent laryngeal nerve paralysis-were lower and only one patient needed reoperation. Importantly, reusing robotic instruments from the thoracic phase in the abdominal phase reduced disposable instrument costs, resulting in a savings of approximately 168,000 Japanese Yen (USD 1050) per case. Implementing a standardized RAMIE protocol enhances procedural efficiency, reduces blood loss, and lowers costs without compromising surgical or oncological outcomes. This approach may facilitate broader adoption of RAMIE as a safe and cost-effective strategy for esophageal cancer surgery.},
	language = {eng},
	number = {1},
	journal = {Journal of Robotic Surgery},
	author = {Kitagami, Hidehiko and Poudel, Saseem and Kitayama, Yosuke and Koinuma, Junkichi and Ebihara, Yuma and Hirano, Satoshi},
	month = mar,
	year = {2025},
	pmid = {40063141},
	keywords = {Aged, Blood Loss, Surgical, Cost-Benefit Analysis, Cost-effectiveness, Esophageal cancer, Esophageal Neoplasms, Esophagectomy, Female, Humans, Male, Mediastinal dissection, Middle Aged, Minimally Invasive Surgical Procedures, Operative Time, Postoperative Complications, Retrospective Studies, Robot-assisted minimally invasive esophagectomy (RAMIE), Robotic Surgical Procedures, Standardization, Surgical technique},
	pages = {107},
}

@article{ngdoaf019,
	title = {Robotic- assisted minimally invasive {Ivor}-{Lewis} handsewn anastomosis technique and outcomes from a large-volume {European} centre},
	volume = {38},
	issn = {1442-2050},
	doi = {10.1093/dote/doaf019},
	abstract = {In minimally invasive transthoracic esophagectomy, intrathoracic anastomoses are usually performed with stapling devices to avoid a technically challenging handsewn technique in the upper mediastinum. Few have published about handsewn anastomotic techniques due to the technically demanding requirements for suturing with rigid instruments in the thoracic cavity. With robot-assisted minimally invasive esophagectomy (RAMIE), the robot provides increased dexterity, enabling construction of a hand-sewn intrathoracic anastomosis. This study aimed to evaluate the outcomes of our technique for hand-sewn intrathoracic anastomosis in RAMIE, following the initial learning phase between 2016 and 2018 in UMC Utrecht. Patients who underwent RAMIE with a robot-assisted hand-sewn intrathoracic anastomosis were included in this retrospective study. Data were extracted from a prospectively maintained institutional database. Key technique steps included esophageal stay-sutures, use of barbed sutures for the anastomosis, placement of tension-releasing stitches, and covering of the anastomosis with omentum. The primary outcome was anastomotic leakage; secondary outcomes included anastomotic stricture rate and duration of anastomosis construction. Between 1 November 2019 and 30 May 2023, 89 consecutive patients were included. Anastomotic leakage (defined by the Esophageal Complications Consensus Group) occurred in 11 patients (12.4\%), which involved a grade I leak in four patients (4.5\%), grade II leak in one patient (1.1\%), and grade III leakage in six patients (6.7\%). The median duration of anastomosis creation was 33 minutes (range, 23-55 minutes). Stricture rate was 32.6\% (29 patients) at 1 year post-operatively for which dilation was needed for all patients. This study shows that a robot-assisted hand-sewn intrathoracic anastomosis in RAMIE is feasible, safe, and reliable.},
	language = {eng},
	number = {2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Ng, Annalisa Y. L. and Goense, Lucas and Van De Horst, Sylvia and Van Den Berg, Jan Willem and Ruurda, Jelle P. and Van Hillegersberg, Richard},
	month = mar,
	year = {2025},
	pmid = {40100150},
	pmcid = {PMC11915846},
	keywords = {Adult, Aged, Anastomosis, Surgical, Anastomotic Leak, Esophageal Neoplasms, Esophagectomy, Esophagus, Female, handsewn anastomosis, Humans, intrathoracic anastomosis, Male, Middle Aged, Minimally Invasive Surgical Procedures, Postoperative Complications, Retrospective Studies, robot-assisted minimally invasive esophagectomy (RAMIE), Robotic Surgical Procedures, Suture Techniques, technique, Treatment Outcome},
	pages = {doaf019},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/FQLVIDDQ/Ng et al. - 2025 - Robotic- assisted minimally invasive Ivor-Lewis handsewn anastomosis technique and outcomes from a l.pdf:application/pdf},
}

@article{weijsS675,
	title = {New insights into the surgical anatomy of the esophagus},
	volume = {9},
	issn = {2072-1439},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538986/},
	doi = {10.21037/jtd.2017.03.172},
	abstract = {Implementation of (robot assisted) minimally invasive esophagectomy and increased knowledge of the relation between the autonomic nervous system and the immune response have led to new insights regarding the surgical anatomy of the esophagus. First, two layers of connective tissue were identified; the aorto-esophageal and aorto-pleural ligaments that separate the peri-esophageal compartment, containing vagus nerves, carinal lymph nodes and trachea, from the para-aortic compartment; containing thoracic duct and azygos vein. Second the surgical anatomy of the pulmonary vagus nerve branches has been described in detail. Based on the hypothesis that sparing the vagal nerve branches may be important a method to spare the pulmonary branches of the vagus nerve during thoracoscopic esophagectomy was validated in a cadaver study. Further studies will now investigate the impact of these new insights in the surgical anatomy of the esophagus in clinical practice.},
	number = {Suppl 8},
	urldate = {2025-05-23},
	journal = {Journal of Thoracic Disease},
	author = {Weijs, Teun J. and Ruurda, Jelle P. and Luyer, Michael D. P. and Cuesta, Miguel A. and van Hillegersberg, Richard and Bleys, Ronaldus L. A. W.},
	month = jul,
	year = {2017},
	pmid = {28815062},
	pmcid = {PMC5538986},
	pages = {S675--S680},
	file = {Full Text:/Users/jcsal/Zotero/storage/6R52ZZMQ/Weijs et al. - 2017 - New insights into the surgical anatomy of the esophagus.pdf:application/pdf},
}

@article{nilsson1015,
	title = {Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled {NeoRes} {II} trial},
	volume = {34},
	issn = {1569-8041},
	doi = {10.1016/j.annonc.2023.08.010},
	abstract = {BACKGROUND: The optimal time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer is unknown and has traditionally been 4-6 weeks in clinical practice. Observational studies have suggested better outcomes, especially in terms of histological response, after prolonged delay of up to 3 months after nCRT. The NeoRes II trial is the first randomised trial to compare standard to prolonged TTS after nCRT for oesophageal cancer.
PATIENTS AND METHODS: Patients with resectable, locally advanced oesophageal cancer were randomly assigned to standard delay of surgery of 4-6 weeks or prolonged delay of 10-12 weeks after nCRT. The primary endpoint was complete histological response of the primary tumour in patients with adenocarcinoma (AC). Secondary endpoints included histological tumour response, resection margins, overall and progression-free survival in all patients and stratified by histologic type.
RESULTS: Between February 2015 and March 2019, 249 patients from 10 participating centres in Sweden, Norway and Germany were randomised: 125 to standard and 124 to prolonged TTS. There was no significant difference in complete histological response between AC patients allocated to standard (21\%) compared to prolonged (26\%) TTS (P = 0.429). Tumour regression, resection margins and number of resected lymph nodes, total and metastatic, did not differ between the allocated interventions. The first quartile overall survival in patients allocated to standard TTS was 26.5 months compared to 14.2 months after prolonged TTS (P = 0.003) and the overall risk of death during follow-up was 35\% higher after prolonged delay (hazard ratio 1.35, 95\% confidence interval 0.94-1.95, P = 0.107).
CONCLUSION: Prolonged TTS did not improve histological complete response or other pathological endpoints, while there was a strong trend towards worse survival, suggesting caution in routinely delaying surgery for {\textgreater}6 weeks after nCRT.},
	language = {eng},
	number = {11},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Nilsson, K. and Klevebro, F. and Sunde, B. and Rouvelas, I. and Lindblad, M. and Szabo, E. and Halldestam, I. and Smedh, U. and Wallner, B. and Johansson, J. and Johnsen, G. and Aahlin, E. K. and Johannessen, H.-O. and Alexandersson von Döbeln, G. and Hjortland, G. O. and Wang, N. and Shang, Y. and Borg, D. and Quaas, A. and Bartella, I. and Bruns, C. and Schröder, W. and Nilsson, M.},
	month = nov,
	year = {2023},
	pmid = {37657554},
	keywords = {Adenocarcinoma, Chemoradiotherapy, Esophageal Neoplasms, Humans, Margins of Excision, neoadjuvant chemoradiotherapy, Neoadjuvant Therapy, oesophageal adenocarcinoma, oesophageal squamous cell carcinoma, Progression-Free Survival, prolonged time, standard time, surgery, Time-to-Treatment},
	pages = {1015--1024},
	file = {Full Text:/Users/jcsal/Zotero/storage/NIZBITUM/Nilsson et al. - 2023 - Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherap.pdf:application/pdf},
}

@article{weijs3816,
	title = {Preserving the pulmonary vagus nerve branches during thoracoscopic esophagectomy},
	volume = {30},
	issn = {1432-2218},
	doi = {10.1007/s00464-015-4683-y},
	abstract = {BACKGROUND: Pulmonary vagus branches are transected as part of a transthoracic esophagectomy and lymphadenectomy for cancer. This may contribute to the development of postoperative pulmonary complications. Studies in which sparing of the pulmonary vagus nerve branches during thoracoscopic esophagectomy is investigated are lacking. Therefore, this study aimed to determine the feasibility and pitfalls of sparing pulmonary vagus nerve branches during thoracoscopic esophagectomy.
METHODS: In 10 human cadavers, a thoracoscopic esophagectomy was performed while sparing the pulmonary vagus nerve branches. The number of intact nerve branches, their distribution over the lung lobes and the number and location of the remaining lymph nodes in the relevant esophageal lymph node stations (7, 10R and 10L) were recorded during microscopic dissection.
RESULTS: A median of 9 (range 5-16) right pulmonary vagus nerve branches were spared, of which 4 (0-12) coursed to the right middle/inferior lung lobe. On the left side, 10 (3-12) vagus nerve branches were spared, of which 4 (2-10) coursed to the inferior lobe. In 8 cases, lymph nodes were left behind, at stations 10R and 10L while sparing the vagus nerve branches. Lymph nodes at station 7 were always removed.
CONCLUSIONS: Sparing of pulmonary vagus nerve branches during thoracoscopic esophagectomy is feasible. Extra care should be given to the dissection of peribronchial lymph nodes, station 10R and 10L.},
	language = {eng},
	number = {9},
	journal = {Surgical Endoscopy},
	author = {Weijs, Teus J. and Ruurda, Jelle P. and Luyer, Misha D. P. and Nieuwenhuijzen, Grard A. P. and van der Horst, Sylvia and Bleys, Ronald L. A. W. and van Hillegersberg, Richard},
	month = sep,
	year = {2016},
	pmid = {26659242},
	keywords = {Cadaver, Dissection, Esophageal Neoplasms, Esophagectomy, Feasibility Studies, Humans, Lung, Lymph Node Excision, Lymph Nodes, Mediastinal lymphadenectomy, Organ Sparing Treatments, Postoperative Complications, Pulmonary complications, Pulmonary nerves, Thoracoscopic esophagectomy, Vagus Nerve},
	pages = {3816--3822},
	file = {PDF:/Users/jcsal/Zotero/storage/SBF6W857/Weijs et al. - 2016 - Preserving the pulmonary vagus nerve branches during thoracoscopic esophagectomy.pdf:application/pdf},
}

@article{cuesta2576,
	title = {A new concept of the anatomy of the thoracic oesophagus: the meso-oesophagus. {Observational} study during thoracoscopic esophagectomy},
	volume = {29},
	issn = {1432-2218},
	shorttitle = {A new concept of the anatomy of the thoracic oesophagus},
	doi = {10.1007/s00464-014-3972-1},
	abstract = {BACKGROUND: During thoracoscopic oesophageal surgery, we observed not previously described fascia-like structures. Description of similar structures in rectal cancer surgery was of paramount importance in improving the quality of resection. Therefore, we aimed to describe a new comprehensive concept of the surgical anatomy of the thoracic oesophagus with definition of the meso-oesophagus.
METHODS: We retrospectively evaluated 35 consecutive unedited videos of thoracoscopic oesophageal resections for cancer, to determine the surgical anatomy of the oesophageal fascia's vessels and lymphatic drainage. The resulting concept was validated in a prospective study, including 20 patients at three different centres. Additional confirmation was sought by a histologic study of a cadaver's thorax.
RESULTS: A thin layer of connective tissue around the infracarinal oesophagus, involving the lymph nodes at the level of the carina, was observed during thoracoscopic esophagectomy in 32 of the 35 patients included in the retrospective study and in 19 of the 20 patients included in the prospective study. A thick fascia-like structure from the upper thoracic aperture to the lower thoracic aperture was visualized in all patients. This fascia is encountered between the descending aorta and left aspect of the infracarinal oesophagus. Above the carina it expands on both sides of the oesophagus to lateral mediastinal structures. This fascia contains oesophageal vessels, lymph vessels and nodes and nerves. The histologic study confirmed these findings.
CONCLUSIONS: Here we described the concept of the "meso-oesophagus". Applying the description of the meso-oesophagus will create a better understanding of the oesophageal anatomy, leading to more adequate and reproducible surgery.},
	language = {eng},
	number = {9},
	journal = {Surgical Endoscopy},
	author = {Cuesta, Miguel A. and Weijs, Teus J. and Bleys, Ronald L. A. W. and van Hillegersberg, Richard and van Berge Henegouwen, Mark I. and Gisbertz, Suzanne S. and Ruurda, Jelle P. and Straatman, Jennifer and Osugi, Harushi and van der Peet, Donald L.},
	month = sep,
	year = {2015},
	pmid = {25480608},
	keywords = {Adenocarcinoma, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Esophagus, Female, Humans, Lymphatic Vessels, Male, Middle Aged, Prospective Studies, Retrospective Studies, Thoracoscopy, Video Recording},
	pages = {2576--2582},
	file = {PDF:/Users/jcsal/Zotero/storage/2IAY3RNQ/Cuesta et al. - 2015 - A new concept of the anatomy of the thoracic oesophagus the meso-oesophagus. Observational study du.pdf:application/pdf},
}

@article{cuesta1863,
	title = {Surgical anatomy of the supracarinal esophagus based on a minimally invasive approach: vascular and nervous anatomy and technical steps to resection and lymphadenectomy},
	volume = {31},
	issn = {1432-2218},
	shorttitle = {Surgical anatomy of the supracarinal esophagus based on a minimally invasive approach},
	doi = {10.1007/s00464-016-5186-1},
	abstract = {BACKGROUND: During esophageal dissection and lymphadenectomy of the upper mediastinum by thoracoscopy in prone position, we observed a complex anatomy in which we had to resect the esophagus, dissect vessels and nerves, and take down some of these in order to perform a complete lymphadenectomy. In order to improve the quality of the dissection and standardization of the procedure, we describe the surgical anatomy and steps involved in this procedure.
METHODS: We retrospectively evaluated twenty consecutive and unedited videos of thoracoscopic esophageal resections. We recorded the vascular anatomy of the supracarinal esophagus, lymph node stations and the steps taken in this procedure. The resulting concept was validated in a prospective study including five patients.
RESULTS: Seventy percent of patients in the retrospective study had one right bronchial artery (RBA) and two left bronchial arteries (LBA). The RBA was divided at both sides of the esophagus in 18 patients, with preservation of one LBA or at least one esophageal branch in all cases. Both recurrent laryngeal nerves were identified in 18 patients. All patients in the prospective study had one RBA and two LBA, and in four patients the RBA was divided at both sides of the esophagus and preserved one of the LBA. Lymphadenectomy was performed of stations 4R, 4L, 2R and 2L, with a median of 11 resected lymph nodes. Both recurrent laryngeal nerves were identified in four patients. In three patients, only the left recurrent nerve could be identified. Two patients showed palsy of the left recurrent laryngeal nerve, and one showed neuropraxia of the left vocal cord.
CONCLUSIONS: Knowledge of the surgical anatomy of the upper mediastinum and its anatomical variations is important for standardization of an adequate esophageal resection and paratracheal lymphadenectomy with preservation of any vascularization of the trachea, bronchi and the recurrent laryngeal nerves.},
	language = {eng},
	number = {4},
	journal = {Surgical Endoscopy},
	author = {Cuesta, Miguel A. and van der Wielen, Nicole and Weijs, Teus J. and Bleys, Ronald L. A. W. and Gisbertz, Suzanne S. and van Duijvendijk, Peter and van Hillegersberg, Richard and Ruurda, Jelle P. and van Berge Henegouwen, Mark I. and Straatman, Jennifer and Osugi, Harushi and van der Peet, Donald L.},
	month = apr,
	year = {2017},
	pmid = {27553798},
	pmcid = {PMC5346129},
	keywords = {Adenocarcinoma, Bronchial arteries, Carcinoma, Squamous Cell, Dissection, Esophageal Neoplasms, Esophagectomy, Esophagus, Humans, Lymph Node Excision, Lymphadenectomy, Mediastinum, Prospective Studies, Recurrent laryngeal nerve, Retrospective Studies, Thoracoscopy, Treatment Outcome, Upper mediastinum, Video Recording},
	pages = {1863--1870},
	file = {Full Text:/Users/jcsal/Zotero/storage/SXUGA5GT/Cuesta et al. - 2017 - Surgical anatomy of the supracarinal esophagus based on a minimally invasive approach vascular and.pdf:application/pdf},
}

@article{weijs431,
	title = {Topography and extent of pulmonary vagus nerve supply with respect to transthoracic oesophagectomy},
	volume = {227},
	issn = {1469-7580},
	doi = {10.1111/joa.12366},
	abstract = {Pulmonary complications are frequently observed after transthoracic oesophagectomy. These complications may be reduced by sparing the vagus nerve branches to the lung. However, current descriptions of the regional anatomy are insufficient. Therefore, we aimed to provide a highly detailed description of the course of the pulmonary vagus nerve branches. In six fixed adult human cadavers, bilateral microscopic dissection of the vagus nerve branches to the lungs was performed. The level of branching and the number, calibre and distribution of nerve branches were described. Nerve fibres were identified using neurofilament immunohistochemistry, and the nerve calibre was measured using computerized image analysis. Both lungs were supplied by a predominant posterior and a smaller anterior nerve plexus. The right lung was supplied by 13 (10-18) posterior and 3 (2-3) anterior branches containing 77\% (62-100\%) and 23\% (0-38\%) of the lung nerve supply, respectively. The left lung was supplied by a median of 12 (8-13) posterior and 3 (2-4) anterior branches containing 74\% (60-84\%) and 26\% (16-40\%) of the left lung nerve supply, respectively. During transthoracic oesophagectomy with en bloc lymphadenectomy and transection of the vagus nerves at the level of the azygos vein, 68-100\% of the right lung nerve supply and 86-100\% of the inferior left lung lobe nerve supply were severed. When vagotomy was performed distally to the last large pulmonary branch, 0-8\% and 0-13\% of the nerve branches to the right middle/inferior lobes and left inferior lobe, respectively, were lost. In conclusion, this study provides a detailed description of the extensive pulmonary nerve supply provided by the vagus nerves. During oesophagectomy, extensive mediastinal lymphadenectomy denervates the lung to a great extent; however, this can be prevented by performing the vagotomy distal to the caudalmost large pulmonary branch. Further research is required to determine the feasibility of sparing the pulmonary vagus nerve branches without compromising the completeness of lymphadenectomy.},
	language = {eng},
	number = {4},
	journal = {Journal of Anatomy},
	author = {Weijs, Teus J. and Ruurda, Jelle P. and Luyer, Misha D. P. and Nieuwenhuijzen, Grard A. P. and van Hillegersberg, Richard and Bleys, Ronald L. A. W.},
	month = oct,
	year = {2015},
	pmid = {26352410},
	pmcid = {PMC4580102},
	keywords = {Adult, Anatomic Landmarks, autonomic nervous system, Cadaver, Esophagectomy, Female, Humans, Immunohistochemistry, lung, Lung, Male, Nerve Fibers, oesophageal surgery, pulmonary nerves, Vagus Nerve, Vagus Nerve Injuries},
	pages = {431--439},
	file = {PDF:/Users/jcsal/Zotero/storage/RX5RFVUH/Weijs et al. - 2015 - Topography and extent of pulmonary vagus nerve supply with respect to transthoracic oesophagectomy.pdf:application/pdf},
}

@article{fujita31,
	title = {Mediastinal lymphnode dissection procedure during esophageal cancer operation--carefully considered for preserving respiratory function},
	volume = {18},
	issn = {0047-1909},
	doi = {10.1007/BF02470843},
	abstract = {In 22 patients with esophageal cancer, mediastinal lymphnode dissection procedure, with preservation of the right bronchial artery and pulmonary branches of the right vagus nerve, was performed during radical esophagectomy. In patients who underwent this procedure, respiratory function was sufficiently maintained against severe complications and the operative and hospital death rate was less than that of other esophagectomized patients.},
	language = {eng},
	number = {1},
	journal = {The Japanese Journal of Surgery},
	author = {Fujita, H. and Hawahara, H. and Yamana, H. and Shirohazu, G. and Yoshimura, Y. and Minami, T. and Negoto, Y. and Irie, H. and Shima, I. and Machi, J.},
	month = jan,
	year = {1988},
	pmid = {3386070},
	keywords = {Bronchial Arteries, Esophageal Neoplasms, Humans, Lymph Nodes, Mediastinum, Neck, Postoperative Complications, Respiratory Insufficiency, Vagotomy, Vagus Nerve},
	pages = {31--34},
	file = {PDF:/Users/jcsal/Zotero/storage/RW3PVVIR/Fujita et al. - 1988 - Mediastinal lymphnode dissection procedure during esophageal cancer operation--carefully considered.pdf:application/pdf},
}

@article{vanderhorstS834,
	title = {Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum},
	volume = {9},
	issn = {2072-1439},
	doi = {10.21037/jtd.2017.03.151},
	abstract = {BACKGROUND: Patients with upper third esophageal cancer or esophageal cancer with upper mediastinal paratracheal lymph node metastases are often precluded from surgery because of technical difficulties. With the aid of robotic surgery, an excellent overview and reach of the thoracic inlet can be accomplished. In this way, patients with upper mediastinal esophageal cancer are eligible for esophageal resection with curative intent. The aim of this study was to review the results of a consecutive series of patients who underwent robot-assisted minimally invasive esophagectomy (RAMIE) for tumors of the upper 1/3 of the esophagus or positive lymph nodes in the upper mediastinum.
METHODS: Between 2007-2016, 31 patients who underwent RAMIE in the UMC Utrecht for proximal esophageal cancer or proximal thoracic lymphadenopathy were identified from a prospective surgical database. Perioperative characteristics and oncologic outcomes were collected.
RESULTS: The majority of patients had a squamous cell carcinoma. Clinical tumor stage was cT3 or higher in 25 (81\%) of patients. Clinically positive lymph nodes (cN1-3) were observed in 29 (94\%) patients. Neoadjuvant treatment was administered in 27 (87\%) patients. Median duration of the surgical procedure was 435 min (range 299-874 min). Pulmonary complications were most frequent and occurred in 13 (42\%) patients. Median intensive care (ICU stay) was 1 day (range 1-65 days) and median overall postoperative hospital stay was 15 days (range 10-118 days). In hospital mortality was 10\%. Causes of mortality were tracheo-neo-esophageal fistula, sepsis after abdominal wall drainage due to leakage of the jejunal fistula resulting in respiratory and kidney failure, after which refraining further treatment resulting in death, and irreversible ARDS in a patient with COPD Gold III needing extracorporeal life support. Radical resection was achieved in 30 (97\%) of the patients. Median number of retrieved lymph nodes was 22 (range 9-57). Median time of follow up was 18 months (range 3-81 months). Median disease-free survival was 13 months (range 0-81 months) and median overall survival was 16 months (range 0-81 months). Tumor recurrence occurred in 15 patients (48\%) and was locoregional only in 3 patients, systemic only in 5 patients and combined locoregional and systemic in 7 patients.
CONCLUSIONS: Robot assisted thoraco-laparoscopic esophagectomy with curative intent in patients with upper mediastinal esophageal cancer is feasible, but associated with increased in hospital mortality. Short-term oncologic results are encouraging.},
	language = {eng},
	number = {Suppl 8},
	journal = {Journal of Thoracic Disease},
	author = {van der Horst, Sylvia and Weijs, Teun Johannes and Ruurda, Jelle Pieter and Haj Mohammad, Nadia and Mook, Stella and Brosens, Lodewijk Adriaan Anton and van Hillegersberg, Richard},
	month = jul,
	year = {2017},
	pmid = {28815081},
	pmcid = {PMC5538971},
	keywords = {Esophageal cancer, esophagectomy, minimally invasive surgery, robotic surgical procedures},
	pages = {S834--S842},
	file = {Full Text:/Users/jcsal/Zotero/storage/VV76FWIA/van der Horst et al. - 2017 - Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the up.pdf:application/pdf},
}

@article{vanderhorst218,
	title = {Extended thoracic lymph node dissection in robotic-assisted minimal invasive esophagectomy ({RAMIE}) for patients with superior mediastinal lymph node metastasis},
	volume = {8},
	issn = {2225-319X},
	doi = {10.21037/acs.2019.01.04},
	abstract = {BACKGROUND: Robot-assisted surgery may have a role in improving oncological outcomes in esophagectomy. Especially in the anatomical areas in the chest that are more difficult to reach in open surgery (including the superior mediastinum). The dexterity of the robotic instruments aid in performing a more extensive nodal dissection and the precision and detailed vision of the robotic system potentially improves staging, oncological outcomes and reduces complications (i.e., recurrent nerve palsy). In this article, we describe our experience and clinical outcomes in patients treated by robot assisted minimal invasive esophagectomy (RAMIE) in cN+ esophageal cancer patients with positive nodes localized in the superior mediastinum.
METHODS: From May 2007-2018, all patients who had involved nodes by either fluor-18-deoxyglucose positron-emission-tomography-computed tomography (FDG-PET-CT) or endoscopic ultrasound (EUS) + fine needle aspiration (FNA) localized in the superior mediastinum (above level Th4/sternal angle) were identified. Patient characteristics, perioperative data, postoperative clinical outcomes/complications and overall survival were prospectively recorded and retrospectively evaluated.
RESULTS: Forty patients (48\% adenocarcinoma) met our inclusion criteria. All patients underwent a three-stage procedure with cervical anastomosis and 90\% of the patients underwent neoadjuvant chemoradiotherapy. Mortality occurred in three patients (7.5\%), of which two were caused by severe acute respiratory distress syndrome (ARDS). The most frequent complications were pneumonia (25\%), chylothorax (20\%), anastomotic leakage (17.5\%) and vocal cord paralysis (17.5\%) which was grade 1 in 72\% of the patients. Radicality rate (R0 resection) was 98\% and the average lymph node yield was 24 (range, 9-57). Median overall and disease-free survival was 26 and 17 months, respectively.
CONCLUSIONS: RAMIE for esophageal cancer patients with node positive disease in the superior mediastinum is associated with increased mortality/morbidity. Oncological outcome showed excellent lymph node yield, R0 rate and survival was equal compared to patients with lower mediastinal node positive disease.},
	language = {eng},
	number = {2},
	journal = {Annals of Cardiothoracic Surgery},
	author = {van der Horst, Sylvia and de Maat, Michiel F. G. and van der Sluis, Pieter C. and Ruurda, Jelle P. and van Hillegersberg, Richard},
	month = mar,
	year = {2019},
	pmid = {31032205},
	pmcid = {PMC6462563},
	keywords = {Lymph node dissection, mediastinal lymph nodes, metastasis, minimally invasive esophagectomy (MIE), robotic},
	pages = {218--225},
	file = {Full Text:/Users/jcsal/Zotero/storage/QQUMJSQX/van der Horst et al. - 2019 - Extended thoracic lymph node dissection in robotic-assisted minimal invasive esophagectomy (RAMIE) f.pdf:application/pdf},
}

@article{degroot1357,
	title = {Implementation of the robotic abdominal phase during robot-assisted minimally invasive esophagectomy ({RAMIE}): results from a high-volume center},
	volume = {37},
	issn = {1432-2218},
	shorttitle = {Implementation of the robotic abdominal phase during robot-assisted minimally invasive esophagectomy ({RAMIE})},
	doi = {10.1007/s00464-022-09681-1},
	abstract = {BACKGROUND: Evidence on the added value of robotic-assistance in the abdominal phase during esophagectomy is scarce. In 2003, our center implemented the robotic thoracic phase for esophagectomy. In November 2018 the robot was also implemented in the abdominal phase. The aim of this study was to evaluate the implementation of the abdominal phase during robot-assisted minimally invasive esophagectomy (RAMIE).
METHODS: Consecutive patients who underwent full RAMIE with intrathoracic anastomosis for esophageal cancer were included. Patients were extracted from a prospectively maintained institutional database. A cumulative sum (CUSUM) analysis was performed for abdominal operation time and abdominal lymph node yield. Intraoperative, postoperative and oncological outcomes including collected lymph nodes per abdominal lymph node station were reported.
RESULTS: Between 2018 and 2021, 70 consecutive patients were included. The majority of the patients had an adenocarcinoma (n = 55, 77\%) and underwent neoadjuvant chemo(radio)therapy (n = 65, 95\%). The median operative time for the abdominal phase was 180 min (range 110-233). The CUSUM analysis for abdominal operation time showed a plateau at case 22. There were no intraoperative complications or conversions during the abdominal phase. The most common postoperative complications were pneumonia (n = 18, 26\%) and anastomotic leakage (n = 14, 20\%). Radical resection margins were achieved in 69 (99\%) patients. The median total lymph node yield was 42 (range 23-83) and the median abdominal lymph node yield was 16 (range 2-43). The CUSUM analysis for abdominal lymph node yield showed a plateau at case 21. Most abdominal lymph nodes were collected from the left gastric artery (median 4, range 0-20).
CONCLUSIONS: This study shows that a robotic abdominal phase was safely implemented for RAMIE without compromising intraoperative, postoperative and oncological outcomes. The learning curve is estimated to be 22 cases in a high-volume center with experienced upper GI robotic surgeons.},
	language = {eng},
	number = {2},
	journal = {Surgical Endoscopy},
	author = {de Groot, E. M. and Goense, L. and Kingma, B. F. and van den Berg, J. W. and Ruurda, J. P. and van Hillegersberg, R.},
	month = feb,
	year = {2023},
	pmid = {36203109},
	pmcid = {PMC9945034},
	keywords = {Abdominal phase, Boehmeria, Esophageal Neoplasms, Esophagectomy, Humans, Learning curve, Lymph Node Excision, Minimally Invasive Surgical Procedures, Postoperative Complications, RAMIE, Robot, Robotic Surgical Procedures, Robotics, Treatment Outcome},
	pages = {1357--1365},
	file = {Full Text:/Users/jcsal/Zotero/storage/5X43A9VJ/de Groot et al. - 2023 - Implementation of the robotic abdominal phase during robot-assisted minimally invasive esophagectomy.pdf:application/pdf},
}

@article{low286,
	title = {International {Consensus} on {Standardization} of {Data} {Collection} for {Complications} {Associated} {With} {Esophagectomy}: {Esophagectomy} {Complications} {Consensus} {Group} ({ECCG})},
	volume = {262},
	issn = {1528-1140},
	shorttitle = {International {Consensus} on {Standardization} of {Data} {Collection} for {Complications} {Associated} {With} {Esophagectomy}},
	doi = {10.1097/SLA.0000000000001098},
	abstract = {INTRODUCTION: Perioperative complications influence long- and short-term outcomes after esophagectomy. The absence of a standardized system for defining and recording complications and quality measures after esophageal resection has meant that there is wide variation in evaluating their impact on these outcomes.
METHODS: The Esophageal Complications Consensus Group comprised 21 high-volume esophageal surgeons from 14 countries, supported by all the major thoracic and upper gastrointestinal professional societies. Delphi surveys and group meetings were used to achieve a consensus on standardized methods for defining complications and quality measures that could be collected in institutional databases and national audits.
RESULTS: A standardized list of complications was created to provide a template for recording individual complications associated with esophagectomy. Where possible, these were linked to preexisting international definitions. A Delphi survey facilitated production of specific definitions for anastomotic leak, conduit necrosis, chyle leak, and recurrent nerve palsy. An additional Delphi survey documented consensus regarding critical quality parameters recommended for routine inclusion in databases. These quality parameters were documentation on mortality, comorbidities, completeness of data collection, blood transfusion, grading of complication severity, changes in level of care, discharge location, and readmission rates.
CONCLUSIONS: The proposed system for defining and recording perioperative complications associated with esophagectomy provides an infrastructure to standardize international data collection and facilitate future comparative studies and quality improvement projects.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {Low, Donald E. and Alderson, Derek and Cecconello, Ivan and Chang, Andrew C. and Darling, Gail E. and DʼJourno, Xavier Benoit and Griffin, S. Michael and Hölscher, Arnulf H. and Hofstetter, Wayne L. and Jobe, Blair A. and Kitagawa, Yuko and Kucharczuk, John C. and Law, Simon Ying Kit and Lerut, Toni E. and Maynard, Nick and Pera, Manuel and Peters, Jeffrey H. and Pramesh, C. S. and Reynolds, John V. and Smithers, B. Mark and van Lanschot, J. Jan B.},
	month = aug,
	year = {2015},
	pmid = {25607756},
	keywords = {Consensus, Data Collection, Databases, Factual, Delphi Technique, Esophageal Neoplasms, Esophagectomy, Humans, International Cooperation, Quality Indicators, Health Care},
	pages = {286--294},
	file = {PDF:/Users/jcsal/Zotero/storage/UPWC6CRN/Low et al. - 2015 - International Consensus on Standardization of Data Collection for Complications Associated With Esop.pdf:application/pdf},
}

@article{oesophago-gastricanastomosisstudygrouponbehalfofthewestmidlandsresearchcollaborativee382,
	title = {Rates of {Anastomotic} {Complications} and {Their} {Management} {Following} {Esophagectomy}: {Results} of the {Oesophago}-{Gastric} {Anastomosis} {Audit} ({OGAA})},
	volume = {275},
	issn = {1528-1140},
	shorttitle = {Rates of {Anastomotic} {Complications} and {Their} {Management} {Following} {Esophagectomy}},
	doi = {10.1097/SLA.0000000000004649},
	abstract = {OBJECTIVE: This study aimed to characterize rates and management of anastomotic leak (AL) and conduit necrosis (CN) after esophagectomy in an international cohort.
BACKGROUND: Outcomes in patients with anastomotic complications of esophagectomy are currently uncertain. Optimum strategies to manage AL/CN are unknown, and have not been assessed in an international cohort.
METHODS: This prospective multicenter cohort study included patients undergoing esophagectomy for esophageal cancer between April 2018 and December 2018 (with 90 days of follow-up). The primary outcomes were AL and CN, as defined by the Esophageal Complications Consensus Group. The secondary outcomes included 90-day mortality and successful AL/CN management, defined as patients being alive at 90 day postoperatively, and requiring no further AL/CN treatment.
RESULTS: This study included 2247 esophagectomies across 137 hospitals in 41 countries. The AL rate was 14.2\% (n = 319) and CN rate was 2.7\% (n = 60). The overall 90-day mortality rate for patients with AL was 11.3\%, and increased significantly with severity of AL (Type 1: 3.2\% vs. Type 2: 13.2\% vs. Type 3: 24.7\%, P {\textless} 0.001); a similar trend was observed for CN. Of the 329 patients with AL/CN, primary management was successful in 69.6\% of cases. Subsequent rounds of management lead to an increase in the rate of successful treatment, with cumulative success rates of 85.4\% and 88.1\% after secondary and tertiary management, respectively.
CONCLUSION: Patient outcomes worsen significantly with increasing AL and CN severity. Reintervention after failed primary anastomotic complication management can be successful, hence surgeons should not be deterred from trying alternative management strategies.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgery},
	author = {{Oesophago-Gastric Anastomosis Study Group on behalf of the West Midlands Research Collaborative}},
	month = feb,
	year = {2022},
	pmid = {33630459},
	keywords = {Aged, Anastomosis, Surgical, Anastomotic Leak, Clinical Audit, Esophagectomy, Esophagus, Female, Humans, Male, Middle Aged, Necrosis, Prospective Studies, Stomach},
	pages = {e382--e391},
}

@article{evansdoz007,
	title = {Study protocol for a multicenter prospective cohort study on esophagogastric anastomoses and anastomotic leak (the {Oesophago}-{Gastric} {Anastomosis} {Audit}/{OGAA})},
	volume = {33},
	issn = {1442-2050},
	doi = {10.1093/dote/doz007},
	abstract = {Esophagectomy is a mainstay in curative treatment for esophageal cancer; however, the reported techniques and outcomes can vary greatly. Thirty-day mortality of patients with an intact anastomosis is 2-3\% as compared to 17-35\% in patients who have an anastomotic leak. The subsequent management of leaks postesophagectomy has great global variability with little consensus on a gold standard of practice. The aim of this multicentre prospective audit is to analyze current techniques of esophagogastric anastomosis to determine the effect on the anastomotic leak rate. Leak rates and leak management will be assessed to determine their impact on patient outcomes. A 12-month international multicentre prospective audit started in April 2018 and is coordinated by a team from the West Midlands Research Collaborative. This will include patients undergoing esophagectomy over 9 months and encompassing a 90-day follow-up period. A pilot data collection period occurred at four UK centers in 2017 to trial the data collection form. The audit standards will include anastomotic leak and the conduit necrosis rate should be less than 13\% and major postoperative morbidity (Clavien-Dindo Grade III or more) should be less than 35\%. The 30-day mortality rate should be less than 5\% and the 90-day mortality rate should be less than 8\%. This will be a trainee-led international audit of esophagectomy practice. Key support will be given by consultant colleagues and anesthetists. Individualized unit data will be distributed to the respective contributing sites. An overall anonymized report will be made available to contributing units. Results of the audit will be published in peer-reviewed journals with all collaborators fully acknowledged. The key information and results from the audit will be disseminated at relevant scientific meetings.},
	language = {eng},
	number = {1},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Evans, R. P. T. and Singh, P. and Nepogodiev, D. and Bundred, J. and Kamarajah, S. and Jefferies, B. and Siaw-Acheampong, K. and Wanigasooriya, K. and McKay, S. and Mohamed, I. and Whitehouse, T. and Alderson, D. and Gossage, J. and van Hillegersberg, R. and Vohra, R. S. and Griffiths, E. A.},
	month = jan,
	year = {2020},
	pmid = {30888419},
	keywords = {Adult, Aged, Anastomosis, Surgical, anastomotic leak, Anastomotic Leak, Esophageal Neoplasms, esophagectomy, Esophagectomy, Esophagus, Female, Humans, Male, Medical Audit, Middle Aged, outcome assessment (health care), Pilot Projects, Practice Patterns, Physicians', Prospective Studies, prospective study, Research Design, Stomach, United Kingdom},
	pages = {doz007},
	file = {PDF:/Users/jcsal/Zotero/storage/UQYIFIQ3/Evans et al. - 2020 - Study protocol for a multicenter prospective cohort study on esophagogastric anastomoses and anastom.pdf:application/pdf},
}

@article{weijs6509,
	title = {Strategies to reduce pulmonary complications after esophagectomy},
	volume = {19},
	issn = {2219-2840},
	doi = {10.3748/wjg.v19.i39.6509},
	abstract = {Esophagectomy, the surgical removal of all or part of the esophagus, is a surgical procedure that is associated with high morbidity and mortality. Pulmonary complications are an especially important postoperative problem. Therefore, many perioperative strategies to prevent pulmonary complications after esophagectomy have been investigated and introduced in daily clinical practice. Here, we review these strategies, including improvement of patient performance and technical advances such as minimally invasive surgery that have been implemented in recent years. Furthermore, interventions such as methylprednisolone, neutrophil elastase inhibitor and epidural analgesia, which have been shown to reduce pulmonary complications, are discussed. Benefits of the commonly applied routine nasogastric decompression, delay of oral intake and prophylactic mechanical ventilation are unclear, and many of these strategies are also evaluated here. Finally, we will discuss recent insights and new developments aimed to improve pulmonary outcomes after esophagectomy.},
	language = {eng},
	number = {39},
	journal = {World Journal of Gastroenterology},
	author = {Weijs, Teus J. and Ruurda, Jelle P. and Nieuwenhuijzen, Grard A. P. and van Hillegersberg, Richard and Luyer, Misha D. P.},
	month = oct,
	year = {2013},
	pmid = {24151374},
	pmcid = {PMC3801361},
	keywords = {Acute lung injury, Acute respiratory distress syndrome, Complications, Esophagectomy, Health Status, Humans, Lung Diseases, Pneumonia, Postoperative Care, Preoperative Care, Treatment Outcome},
	pages = {6509--6514},
	file = {Full Text:/Users/jcsal/Zotero/storage/4C2B2QE2/Weijs et al. - 2013 - Strategies to reduce pulmonary complications after esophagectomy.pdf:application/pdf},
}

@article{nozoe396,
	title = {Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma},
	volume = {28},
	issn = {0748-7983},
	doi = {10.1053/ejso.2002.1257},
	abstract = {AIMS: The relationship between the pre-operative nutritional condition and the outcome of the surgical treatment in patients with oesophageal carcinoma has been discussed diversely. The aim of the current study was to demonstrate the relationship between pre-operative nutritional condition and post-operative complications and prognosis following surgical treatment for oesophageal carcinoma.
METHODS: Two hundred and fifty-eight patients with oesophageal carcinoma treated with oesophageal resection and reconstruction were selected. The correlation of pre-operative values of prognostic nutritional index (PNI) with the incidence of post-operative complications and prognosis of the patients was investigated.
RESULTS: The mean pre-operative value of PNI in patients with post-operative complications (41.8+/-5.4) was significantly lower than that in patients without post-operative complications (46.5+/-5.3; P{\textless}0.0001). The survival in patients with higher PNI value was significantly more favourable than that in patients with lower PNI value (P=0.0001).
CONCLUSIONS: Pre-operative assessment of the nutritional condition could provide predictive information for post-operative complications in patients with oesophageal carcinoma.},
	language = {eng},
	number = {4},
	journal = {European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
	author = {Nozoe, T. and Kimura, Y. and Ishida, M. and Saeki, H. and Korenaga, D. and Sugimachi, K.},
	month = jun,
	year = {2002},
	pmid = {12099649},
	keywords = {Aged, Carcinoma, Esophageal Neoplasms, Esophagectomy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Nutritional Status, Plastic Surgery Procedures, Postoperative Complications, Postoperative Period, Preoperative Care, Probability, Proportional Hazards Models, Retrospective Studies, Statistics, Nonparametric, Survival Analysis, Treatment Outcome},
	pages = {396--400},
}

@article{hulzebos1851,
	title = {Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing {CABG} surgery: a randomized clinical trial},
	volume = {296},
	issn = {1538-3598},
	shorttitle = {Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing {CABG} surgery},
	doi = {10.1001/jama.296.15.1851},
	abstract = {CONTEXT: Postoperative pulmonary complications (PPCs) after coronary artery bypass graft (CABG) surgery are a major source of morbidity and mortality, and increase length of hospital stay and resource utilization. The prehospitalization period before CABG surgery may be used to improve a patient's pulmonary condition. The efficacy of preoperative inspiratory muscle training (IMT) in reducing the incidence of PPCs in high-risk patients undergoing CABG surgery has not yet been determined.
OBJECTIVE: To evaluate the prophylactic efficacy of preoperative IMT on the incidence of PPCs in high-risk patients scheduled for elective CABG surgery.
DESIGN, SETTING, AND PATIENTS: A single-blind, randomized clinical trial conducted at the University Medical Center Utrecht, Utrecht, the Netherlands, with enrollment between July 2002 and August 2005. Of 655 patients referred for elective CABG surgery, 299 (45.6\%) met criteria for high risk of developing PPCs, of whom 279 were enrolled and followed up until discharge from hospital.
INTERVENTION: Patients were randomly assigned to receive either preoperative IMT (n = 140) or usual care (n = 139). Both groups received the same postoperative physical therapy.
MAIN OUTCOME MEASURES: Incidence of PPCs, especially pneumonia, and duration of postoperative hospitalization.
RESULTS: Both groups were comparable at baseline. After CABG surgery, PPCs were present in 25 (18.0\%) of 139 patients in the IMT group and 48 (35.0\%) of 137 patients in the usual care group (odds ratio [OR], 0.52; 95\% confidence interval [CI], 0.30-0.92). Pneumonia occurred in 9 (6.5\%) of 139 patients in the IMT group and in 22 (16.1\%) of 137 patients in the usual care group (OR, 0.40; 95\% CI, 0.19-0.84). Median duration of postoperative hospitalization was 7 days (range, 5-41 days) in the IMT group vs 8 days (range, 6-70 days) in the usual care group by Mann-Whitney U statistic (z = -2.42; P = .02).
CONCLUSION: Preoperative IMT reduced the incidence of PPCs and duration of postoperative hospitalization in patients at high risk of developing a pulmonary complication undergoing CABG surgery.
TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN17691887.},
	language = {eng},
	number = {15},
	journal = {JAMA},
	author = {Hulzebos, Erik H. J. and Helders, Paul J. M. and Favié, Nine J. and De Bie, Rob A. and Brutel de la Riviere, Aart and Van Meeteren, Nico L. U.},
	month = oct,
	year = {2006},
	pmid = {17047215},
	keywords = {Aged, Breathing Exercises, Coronary Artery Bypass, Cough, Female, Humans, Length of Stay, Male, Pleural Effusion, Pneumonia, Pneumothorax, Postoperative Complications, Preoperative Care, Respiratory Function Tests, Respiratory Tract Diseases, Risk Assessment, Single-Blind Method},
	pages = {1851--1857},
}

@article{valkenet502,
	title = {Multicentre randomized clinical trial of inspiratory muscle training versus usual care before surgery for oesophageal cancer},
	volume = {105},
	issn = {0007-1323},
	url = {https://doi.org/10.1002/bjs.10803},
	doi = {10.1002/bjs.10803},
	abstract = {Up to 40 per cent of patients undergoing oesophagectomy develop pneumonia. The aim of this study was to assess whether preoperative inspiratory muscle training (IMT) reduces the rate of pneumonia after oesophagectomy.Patients with oesophageal cancer were randomized to a home-based IMT programme before surgery or usual care. IMT included the use of a flow-resistive inspiratory loading device, and patients were instructed to train twice a day at high intensity (more than 60 per cent of maximum inspiratory muscle strength) for 2 weeks or longer until surgery. The primary outcome was postoperative pneumonia; secondary outcomes were inspiratory muscle function, lung function, postoperative complications, duration of mechanical ventilation, length of hospital stay and physical functioning.Postoperative pneumonia was diagnosed in 47 (39·2 per cent) of 120 patients in the IMT group and in 43 (35·5 per cent) of 121 patients in the control group (relative risk 1·10, 95 per cent c.i. 0·79 to 1·53; P = 0·561). There was no statistically significant difference in postoperative outcomes between the groups. Mean(s.d.) maximal inspiratory muscle strength increased from 76·2(26·4) to 89·0(29·4) cmH2O (P \&lt; 0·001) in the intervention group and from 74·0(30·2) to 80·0(30·1) cmH2O in the control group (P \&lt; 0·001). Preoperative inspiratory muscle endurance increased from 4 min 14 s to 7 min 17 s in the intervention group (P \&lt; 0·001) and from 4 min 20 s to 5 min 5 s in the control group (P = 0·007). The increases were highest in the intervention group (P \&lt; 0·050).Despite an increase in preoperative inspiratory muscle function, home-based preoperative IMT did not lead to a decreased rate of pneumonia after oesophagectomy. Registration number: NCT01893008 (https://www.clinicaltrials.gov).},
	number = {5},
	urldate = {2025-05-24},
	journal = {British Journal of Surgery},
	author = {Valkenet, K and Trappenburg, J C A and Ruurda, J P and Guinan, E M and Reynolds, J V and Nafteux, P and Fontaine, M and Rodrigo, H E and van der Peet, D L and Hania, S W and Sosef, M N and Willms, J and Rosman, C and Pieters, H and Scheepers, J J G and Faber, T and Kouwenhoven, E A and Tinselboer, M and Räsänen, J and Ryynänen, H and Gosselink, R and van Hillegersberg, R and Backx, F J G},
	month = apr,
	year = {2018},
	pages = {502--511},
	file = {Snapshot:/Users/jcsal/Zotero/storage/2RYI6VCF/6123118.html:text/html},
}

@article{mizusawa9352,
	title = {Inspiratory {Muscle} {Training} {Before} {Esophagectomy} {Increases} {Diaphragmatic} {Excursion}: {A} {Randomized} {Controlled} {Trial}},
	volume = {31},
	issn = {1534-4681},
	shorttitle = {Inspiratory {Muscle} {Training} {Before} {Esophagectomy} {Increases} {Diaphragmatic} {Excursion}},
	url = {https://doi.org/10.1245/s10434-024-16180-1},
	doi = {10.1245/s10434-024-16180-1},
	abstract = {Inspiratory muscle training (IMT) has preventive effects against postoperative pulmonary complications (PPCs) after upper abdominal surgery. However, its impact on diaphragmatic function has not been evaluated. This study investigated the effect of preoperative IMT on diaphragmatic excursion (DE) and prevention of PPCs for patients with esophageal cancer.},
	language = {en},
	number = {13},
	urldate = {2025-05-24},
	journal = {Annals of Surgical Oncology},
	author = {Mizusawa, Hiroki and Higashimoto, Yuji and Shiraishi, Osamu and Shiraishi, Masashi and Sugiya, Ryuji and Noguchi, Masaya and Fujita, Shuhei and Kimura, Tamotsu and Ishikawa, Akira and Yasuda, Takushi},
	month = dec,
	year = {2024},
	keywords = {Cancer Prevention, Chemoprevention, Diaphragmatic excursion, Esophagectomy, Inspiratory muscle training, Oesophageal cancer, Oncology, Postoperative pulmonary complications, Surgery, Thoracic Surgery, Ultrasonography},
	pages = {9352--9361},
}

@article{kooij823,
	title = {The {Current} {State} of {Robot}-{Assisted} {Minimally} {Invasive} {Esophagectomy} ({RAMIE}): {Outcomes} from the {Upper} {GI} {International} {Robotic} {Association} ({UGIRA}) {Esophageal} {Registry}},
	volume = {32},
	issn = {1534-4681},
	shorttitle = {The {Current} {State} of {Robot}-{Assisted} {Minimally} {Invasive} {Esophagectomy} ({RAMIE})},
	doi = {10.1245/s10434-024-16364-9},
	abstract = {BACKGROUND: Robot-assisted minimally invasive esophagectomy (RAMIE) is increasingly adopted in centers worldwide, with ongoing refinements to enhance results. This study aims to assess the current state of RAMIE worldwide and to identify potential areas for improvement.
METHODS: This descriptive study analyzed prospective data from esophageal cancer patients who underwent transthoracic RAMIE in Upper GI International Robotic Association (UGIRA) centers. Main endpoints included textbook outcome rate, surgical techniques, and perioperative outcomes. Analyses were performed separately for intrathoracic (Ivor-Lewis) and cervical anastomosis (McKeown), divided into three time cohorts (2016-2018, 2019-2020, 2021-2023). A sensitivity analysis was conducted with cases after the learning curve ({\textgreater} 70 cases).
RESULTS: Across 28 UGIRA centers, 2012 Ivor-Lewis and 1180 McKeown procedures were performed. Over the time cohorts, textbook outcome rates were 39\%, 48\%, and 49\% for Ivor-Lewis, and 49\%, 63\%, and 61\% for McKeown procedures, respectively. Fully robotic procedures accounted for 66\%, 51\%, and 60\% of Ivor-Lewis procedures, and 53\%, 81\%, and 66\% of McKeown procedures. Lymph node yield showed 27, 30, and 30 nodes in Ivor-Lewis procedures, and 26, 26, and 34 nodes in McKeown procedures. Furthermore, high mediastinal lymphadenectomy was performed in 65\%, 43\%, and 37\%, and 70\%, 48\%, and 64\% of Ivor-Lewis and McKeown procedures, respectively. Anastomotic leakage rates were 22\%, 22\%, and 16\% in Ivor-Lewis cases, and 14\%, 12\%, and 11\% in McKeown cases. Hospital stay was 13, 14, and 13 days for Ivor-Lewis procedures, and 12, 9, and 11 days for McKeown procedures. In Ivor-Lewis and McKeown, respectively, the sensitivity analysis revealed textbook outcome rates of 43\%, 54\%, and 51\%, and 47\%, 64\%, and 64\%; anastomotic leakage rates of 28\%, 18\%, and 15\%, and 13\%, 11\%, and 10\%; and hospital stay of 11, 12, and 12 days, and 10, 9, and 9 days.
CONCLUSIONS: This study demonstrates favorable outcomes over time in achieving textbook outcome after RAMIE. Areas for improvement include a reduction of anastomotic leakage and shortening of hospital stay.},
	language = {eng},
	number = {2},
	journal = {Annals of Surgical Oncology},
	author = {Kooij, Cezanne D. and de Jongh, Cas and Kingma, B. Feike and van Berge Henegouwen, Mark I. and Gisbertz, Suzanne S. and Chao, Yin-Kai and Chiu, Philip W. and Rouanet, Philippe and Mourregot, Anne and Immanuel, Arul and Mala, Tom and van Boxel, Gijs I. and Carter, Nicholas C. and Li, Hecheng and Fuchs, Hans F. and Bruns, Christiane J. and Giacopuzzi, Simone and Kalff, Jörg C. and Hölzen, Jens-Peter and Juratli, Mazen A. and Benedix, Frank and Lorenz, Eric and Egberts, Jan-Hendrik and Haveman, Jan W. and van Etten, Boudewijn and Müller, Beat P. and Grimminger, Peter P. and Berlth, Felix and Piessen, Guillaume and van den Berg, Jan W. and Milone, Marco and Luketich, James D. and Sarkaria, Inderpal S. and Sallum, Rubens A. A. and van Det, Marc J. and Kouwenhoven, Ewout A. and Brüwer, Matthias and Harustiak, Tomas and Kinoshita, Takahiro and Fujita, Takeo and Daiko, Hiroyuki and Li, Zhigang and Ruurda, Jelle P. and van Hillegersberg, Richard and {UGIRA Study Group}},
	month = feb,
	year = {2025},
	pmid = {39496901},
	pmcid = {PMC11698755},
	keywords = {Aged, Esophageal cancer, Esophageal Neoplasms, Esophagectomy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Minimally invasive esophagectomy, Minimally Invasive Surgical Procedures, Postoperative Complications, Prognosis, Prospective Studies, Registries, Robot-assisted esophagectomy, Robotic Surgical Procedures},
	pages = {823--833},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/BQBCHH7K/Kooij et al. - 2025 - The Current State of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) Outcomes from the Uppe.pdf:application/pdf},
}

@article{feenstra,
	title = {Paravertebral versus {EPidural} {Analgesia} in {Minimally} {Invasive} {Esophageal} {ResectioN} ({PEPMEN}): {A} {Randomized} {Controlled} {Multicenter} {Trial}},
	issn = {1528-1140},
	shorttitle = {Paravertebral versus {EPidural} {Analgesia} in {Minimally} {Invasive} {Esophageal} {ResectioN} ({PEPMEN})},
	doi = {10.1097/SLA.0000000000006551},
	abstract = {OBJECTIVE: To compare quality of recovery in patients receiving epidural or paravertebral analgesia for minimally invasive esophagectomy (MIE).
SUMMARY BACKGROUND DATA: Paravertebral analgesia may be a promising alternative to epidural analgesia, avoiding potential side effects and improving postoperative recovery.
METHODS: This randomized controlled superiority trial was conducted across four Dutch centers with esophageal cancer patients scheduled for transthoracic MIE with intrathoracic anastomosis, randomizing patients to receive either epidural or paravertebral analgesia. The primary outcome was Quality of Recovery (QoR-40) on the third postoperative day (POD). Secondary outcomes included quality of life, postoperative pain, opioid consumption, inotropic/vasopressor medication use, hospital stay, complications, readmission, and mortality.
RESULTS: From December 2019 to February 2023, 192 patients were included: 94 received epidural and 98 paravertebral analgesia. QoR-40 score on POD3 was not different between groups (mean difference 3.7, 95\%CI -2.3 to 9.7; P=0.268). Epidural patients had significant higher QoR-40 scores on POD1 and 2 (mean difference 7.7, 95\%CI 2.3-13.1; P=0.018 and mean difference 7.3, 95\%CI 1.9-12.7; P=0.020) and lower pain scores (median 1 versus 2; P={\textless}0.001 and median 1 versus 2; P=0.033). More epidural patients required vasopressor medication on POD1 (38.3\% versus 13.3\%; P{\textless}0.001). Urinary catheters were removed earlier in the paravertebral group (median POD3 versus 4; P={\textless}0.001). No significant differences were found in postoperative complications or hospital/Intensive Care Unit stay.
CONCLUSIONS: This randomized controlled trial did not demonstrate superiority of paravertebral over epidural analgesia regarding quality of recovery on POD3 after MIE. Both techniques are effective and can be offered in clinical practice.},
	language = {eng},
	journal = {Annals of Surgery},
	author = {Feenstra, Minke L. and Kooij, Cezanne D. and Eshuis, Wietse J. and de Groot, Eline M. and Hermanides, Jeroen and Kingma, B. Feike and Gisbertz, Suzanne S. and Ruurda, Jelle P. and Daams, Freek and Marsman, Marije and van den Bosch, Oscar F. C. and Ten Hoope, Werner and Goense, Lucas and Luyer, Misha D. P. and Nieuwenhuijzen, Grard A. P. and Scholten, Harm J. and Buise, Marc and van Det, Marc J. and Kouwenhoven, Ewout A. and van der Meer, Franciscus and Frederix, Geert W. J. and Hollmann, Markus W. and Cheong, Edward and van Berge Henegouwen, Mark I. and van Hillegersberg, Richard},
	month = oct,
	year = {2024},
	pmid = {39360422},
}

@article{overbeek290,
	title = {The {Association} {Between} {Preoperative} {Inspiratory} {Muscle} {Training} {Variables} and {Postoperative} {Pulmonary} {Complications} in {Subjects} {With} {Esophageal} {Cancer}},
	volume = {69},
	issn = {1943-3654},
	doi = {10.4187/respcare.11199},
	abstract = {BACKGROUND: Preoperative inspiratory muscle training (IMT) is frequently used in patients waiting for major surgery to improve respiratory muscle function and to reduce the risk of postoperative pulmonary complications (PPCs). Currently, the mechanism of action of IMT in reducing PPCs is still unclear. Therefore, we investigated the associations between preoperative IMT variables and the occurrence of PPCs in patients with esophageal cancer.
METHODS: A multi-center cohort study was conducted in subjects scheduled for esophagectomy, who followed IMT as part of a prehabilitation program. IMT variables included maximum inspiratory pressure (PImax) before and after IMT and IMT intensity variables including training load, frequency, and duration. Associations between PImax and IMT intensity variables and PPCs were analyzed using independent samples t tests and logistic regression analyses, corrected for age and pulmonary comorbidities and stratified for the occurrence of anastomotic leakages.
RESULTS: Eighty-seven subjects were included (69 males; mean age 66.7 ± 7.3 y). A higher PImax (odds ratio 1.016, P = .07) or increase in PImax during IMT (odds ratio 1.020, P = .066) was not associated with a reduced risk of PPCs after esophagectomy. Intensity variables of IMT were also not associated (P ranging from .16 to .95) with PPCs after esophagectomy. Analyses stratified for the occurrence of anastomotic leakages showed no associations between IMT variables and PPCs.
CONCLUSIONS: This study shows that an improvement in preoperative inspiratory muscle strength during IMT and training intensity of IMT were not associated with a reduced risk on PPCs after esophagectomy. Further research is needed to investigate other possible factors explaining the mechanism of action of preoperative IMT in patients undergoing major surgery, such as the awareness of patients related to respiratory muscle function and a diaphragmatic breathing pattern.},
	language = {eng},
	number = {3},
	journal = {Respiratory Care},
	author = {Overbeek, Meike C. and Reijneveld, Elja Ae and Valkenet, Karin and van Adrichem, Edwin J. and Dronkers, Jaap J. and Ruurda, Jelle P. and Veenhof, Cindy},
	month = feb,
	year = {2024},
	pmid = {37935528},
	pmcid = {PMC10984600},
	keywords = {Aged, Anastomotic Leak, Breathing Exercises, cancer, Cohort Studies, Diaphragm, Esophageal Neoplasms, Humans, inspiratory muscle training, Male, Middle Aged, Muscle Strength, physiotherapy, Postoperative Complications, postoperative pulmonary complications, respiratory muscles, Respiratory Muscles, surgery},
	pages = {290--297},
}

@article{cuesta6895,
	title = {A novel anatomical description of the esophagus: the supracarinal mesoesophagus},
	volume = {37},
	issn = {1432-2218},
	shorttitle = {A novel anatomical description of the esophagus},
	doi = {10.1007/s00464-023-10109-7},
	abstract = {BACKGROUND: During thoracoscopic esophageal resection, while performing the supracarinal lymphadenectomy along the left recurrent laryngeal nerve (LRLN) from the aortic arch to the thoracic apex, we observed a not previously described bilayered fascia-like structure, serving as prolongation of the already known mesoesophagus.
METHODS: We retrospectively evaluated 70 consecutively unedited videos of thoracoscopic interventions on esophageal resections for cancer, in order to determine the validity of this finding and to describe its utility for performing a systematic and more accurate dissection of the LRLN and its adequate lymphadenectomy.
RESULTS: After mobilization of the upper esophagus from the trachea and tilting the esophagus by means of two ribbons, a bilayered fascia was observed between the esophagus and the left subclavian artery in 63 of the 70 patients included in this study. By opening the right layer, the left recurrent nerve became visualized and could be dissected free in its whole trajectory. Vessels and branches of the LRLN were divided between miniclips. Mobilizing the esophagus to the right, the base of this fascia could be found at the left subclavian artery. After dissecting and clipping the thoracic duct, complete lymphadenectomy of 2 and 4L stations could be performed. Mobilizing the esophagus in distal direction, the fascia continued at the level of the aortic arch, where it had to be divided in order to mobilize the esophagus from the left bronchus. Here, a lymphadenectomy of the aorta-pulmonary window lymph nodes (station 8) can be performed. It seems that from there the fascia continued without interruption with the previously described mesoesophagus between the thoracic aorta and the esophagus.
CONCLUSIONS: Here we described the concept of the supracarinal mesoesophagus on the left side. Applying the description of the mesoesophagus will create a better understanding of the supracarinal anatomy, leading to a more adequate and reproducible surgery.},
	language = {eng},
	number = {9},
	journal = {Surgical Endoscopy},
	author = {Cuesta, Miguel A. and van Jaarsveld, Romy C. and Mingol, Fernando and Bleys, Ronald L. A. W. and van Hillegersberg, Richard and Padules, Carmen and Bruna, Marcos and Ruurda, Jelle P.},
	month = sep,
	year = {2023},
	pmid = {37314483},
	pmcid = {PMC10462511},
	keywords = {Esophageal Neoplasms, Esophagectomy, Humans, Left recurrent laryngeal nerve, Lymph Node Excision, Mesoesophagus, Prone position, Retrospective Studies, Thoracoscopy},
	pages = {6895--6900},
	file = {Full Text:/Users/jcsal/Zotero/storage/BK8DIBXX/Cuesta et al. - 2023 - A novel anatomical description of the esophagus the supracarinal mesoesophagus.pdf:application/pdf},
}

@article{filzvonreiterdankdoac072,
	title = {The surgical anatomy of a (robot-assisted) minimally invasive transcervical esophagectomy},
	volume = {36},
	issn = {1442-2050},
	doi = {10.1093/dote/doac072},
	abstract = {BACKGROUND: Transcervical esophagectomy allows for esophagectomy through transcervical access and bypasses the thoracic cavity, thereby eliminating single lung ventilation. A challenging surgical approach demands thorough understanding of the encountered anatomy. This study aims to provide a comprehensive overview of surgical anatomy encountered during the (robot-assisted) minimally invasive transcervical esophagectomy (RACE and MICE).
METHODS: To assess the surgical anatomy of the lower neck and mediastinum, MR images were made of a body donor after, which it was sliced at 24-μm intervals with a cryomacrotome. Images were made every 3 slices resulting in 3.200 images of which a digital 3D multiplanar reconstruction was made. For macroscopic verification, microscopic slices were made and stained every 5 mm (Mallory-Cason). Schematic drawings were made of the 3D reconstruction to demonstrate the course of essential anatomical structures in the operation field and identify anatomical landmarks.
RESULTS: Surgical anatomy 'boxes' of three levels (superior thoracic aperture, upper mediastinum, subcarinal) were created. Four landmarks were identified: (i) the course of the thoracic duct in the mediastinum; (ii) the course of the left recurrent laryngeal nerve; (iii) the crossing of the azygos vein right and dorsal of the esophagus; and (iv) the position of the aortic arch, the pulmonary arteries, and veins.
CONCLUSIONS: The presented 3D reconstruction of unmanipulated human anatomy and schematic 3D 'boxes' provide a comprehensive overview of the surgical anatomy during the RACE or MICE. Our findings provide a useful tool to aid surgeons in learning the complex anatomy of the mediastinum and the exploration of new surgical approaches such as the RACE or MICE.},
	language = {eng},
	number = {4},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Filz von Reiterdank, I. C. L. J. and Defize, I. L. and de Groot, E. M. and Wedel, T. and Grimminger, P. P. and Egberts, J. H. and Stein, H. and Ruurda, J. P. and van Hillegersberg, R. and Bleys, R. L. a. W.},
	month = mar,
	year = {2023},
	pmid = {36222066},
	keywords = {Esophageal Neoplasms, Esophagectomy, esophagus, Humans, Lymph Node Excision, mediastinum, MICE, minimally invasive, oncology, RACE, robot-assisted, Robotics},
	pages = {doac072},
	file = {PDF:/Users/jcsal/Zotero/storage/DVXL7PHM/Filz von Reiterdank et al. - 2023 - The surgical anatomy of a (robot-assisted) minimally invasive transcervical esophagectomy.pdf:application/pdf},
}

@article{bretelere21705,
	title = {Wireless {Remote} {Home} {Monitoring} of {Vital} {Signs} in {Patients} {Discharged} {Early} {After} {Esophagectomy}: {Observational} {Feasibility} {Study}},
	volume = {3},
	issn = {2561-9128},
	shorttitle = {Wireless {Remote} {Home} {Monitoring} of {Vital} {Signs} in {Patients} {Discharged} {Early} {After} {Esophagectomy}},
	doi = {10.2196/21705},
	abstract = {BACKGROUND: Hospital stays after major surgery are shorter than ever before. Although enhanced recovery and early discharge have many benefits, some complications will now first manifest themselves in home settings. Remote patient monitoring with wearable sensors in the first days after hospital discharge may capture clinical deterioration earlier but is largely uncharted territory.
OBJECTIVE: This study aimed to assess the technical feasibility of patients, discharged after esophagectomy, being remotely monitored at home with a wireless patch sensor and the experiences of these patients. In addition, we determined whether observing vital signs with a wireless patch sensor influences clinical decision making.
METHODS: In an observational feasibility study, vital signs of patients were monitored with a wearable patch sensor (VitalPatch, VitalConnect Inc) during the first 7 days at home after esophagectomy and discharge from hospital. Vital signs trends were shared with the surgical team once a day, and they were asked to check the patient's condition by phone each morning. Patient experiences were evaluated with a questionnaire, and technical feasibility was analyzed on a daily basis as the percentage of data loss and gap durations. In addition, the number of patients for whom a change in clinical decision was made based on the results of remote vital signs monitoring at home was assessed.
RESULTS: Patients (N=20) completed 7 days each of home monitoring with the wearable patch sensor. Each of the patients had good recovery at home, and remotely observed vital signs trends did not alter clinical decision making. Patients appreciated that surgeons checked their vital signs daily (mean 4.4/5) and were happy to be called by the surgical team each day (mean 4.5/5). Wearability of the patch was high (mean 4.4/5), and no reports of skin irritation were mentioned. Overall data loss of vital signs measurements at home was 25\%; both data loss and gap duration varied considerably among patients.
CONCLUSIONS: Remote monitoring of vital signs combined with telephone support from the surgical team was feasible and well perceived by all patients. Future studies need to evaluate the impact of home monitoring on patient outcome as well as the cost-effectiveness of this new approach.},
	language = {eng},
	number = {2},
	journal = {JMIR perioperative medicine},
	author = {Breteler, Martine J. M. and Numan, Lieke and Ruurda, Jelle P. and van Hillegersberg, Richard and van der Horst, Sylvia and Dohmen, Daan A. J. and van Rossum, Mathilde C. and Kalkman, Cor J.},
	month = dec,
	year = {2020},
	pmid = {33393923},
	pmcid = {PMC7728408},
	keywords = {remote monitoring, telemonitoring, vital signs monitoring, wearables, wireless monitoring},
	pages = {e21705},
	file = {Full Text:/Users/jcsal/Zotero/storage/3LGNBGHP/Breteler et al. - 2020 - Wireless Remote Home Monitoring of Vital Signs in Patients Discharged Early After Esophagectomy Obs.pdf:application/pdf},
}

@article{vanderhorstdoaa071,
	title = {Robot-assisted minimally invasive esophagectomy ({RAMIE}): tips and tricks from the bedside assistant view-expert experiences},
	volume = {33},
	issn = {1442-2050},
	shorttitle = {Robot-assisted minimally invasive esophagectomy ({RAMIE})},
	doi = {10.1093/dote/doaa071},
	abstract = {The role of bedside assistants in robot-assisted minimally invasive esophagectomy is important. It includes knowledge of the procedure, knowledge of the da Vinci Surgical System, skills in laparoscopy, and good communicative skills. An experienced bedside assistant will likely improve efficiency and safety of robot-assisted minimally invasive esophagectomy.},
	language = {eng},
	number = {Supplement\_2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {van der Horst, S. and Voli, C. and Polanco, I. A. and van Hillegersberg, R. and Ruurda, J. P. and Park, B. and Molena, D.},
	month = nov,
	year = {2020},
	pmid = {s},
	pmcid = {PMC8325014},
	keywords = {bedside assistant, Boehmeria, esophageal cancer, Esophageal Neoplasms, Esophagectomy, Humans, minimally invasive surgery, Minimally Invasive Surgical Procedures, robotic surgery, Robotic Surgical Procedures, Robotics, Treatment Outcome},
	pages = {doaa071},
	file = {PDF:/Users/jcsal/Zotero/storage/B8CNQV9G/van der Horst et al. - 2020 - Robot-assisted minimally invasive esophagectomy (RAMIE) tips and tricks from the bedside assistant.pdf:application/pdf},
}

@article{degrootdoaa055,
	title = {Technical details of the hand-sewn and circular-stapled anastomosis in robot-assisted minimally invasive esophagectomy},
	volume = {33},
	issn = {1442-2050},
	doi = {10.1093/dote/doaa055},
	abstract = {The circular mechanical and hand-sewn intrathoracic anastomosis are most often used in robot-assisted minimally invasive esophagectomy (RAMIE). The aim of this study was to describe the technical details of both techniques that were pioneered in two high volume centers for RAMIE. A prospectively maintained database was used to identify patients with esophageal cancer who underwent RAMIE with intrathoracic anastomosis. The primary outcome was anastomotic leakage, which was analyzed using a moving average curve. For the hand-sewn anastomosis, video recordings were reviewed to evaluate number of sutures and distances between the anastomosis and the longitudinal staple line or gastric conduit tip. Between 2016 and 2019, a total of 68 patients with a hand-sewn anastomosis and 60 patients with a circular-stapled anastomosis were included in the study. For the hand-sewn anastomosis, the moving average curve for anastomotic leakage (including grade 1-3) started at a rate of 40\% (cases 1-10) and ended at 10\% (cases 59-68). For the circular-stapled anastomosis, the moving average started at 10\% (cases 1-10) and ended at 20\% (cases 51-60). This study showed the technical details and refinements that were applied in developing two different anastomotic techniques for RAMIE. Results markedly improved during the period of development with specific changes in technique for the hand-sewn anastomosis. The circular-stapled anastomosis showed a more stable rate of performance.},
	language = {eng},
	number = {Supplement\_2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {de Groot, Eline M. and Möller, Thorben and Kingma, B. Feike and Grimminger, Peter P. and Becker, Thomas and van Hillegersberg, Richard and Egberts, Jan-Hendrik and Ruurda, Jelle P.},
	month = nov,
	year = {2020},
	pmid = {33241304},
	keywords = {Anastomosis, Surgical, Anastomotic Leak, Esophageal Neoplasms, Esophagectomy, Humans, intrathoracic anastomosis, RAMIE, Robotics, Surgical Stapling, Suture Techniques, technique, Treatment Outcome},
	pages = {doaa055},
	file = {PDF:/Users/jcsal/Zotero/storage/D8E9KKA5/de Groot et al. - 2020 - Technical details of the hand-sewn and circular-stapled anastomosis in robot-assisted minimally inva.pdf:application/pdf},
}

@article{chiudoaa052,
	title = {Robot-assisted cervical esophagectomy: first clinical experiences and review of the literature},
	volume = {33},
	issn = {1442-2050},
	shorttitle = {Robot-assisted cervical esophagectomy},
	doi = {10.1093/dote/doaa052},
	abstract = {Pulmonary complications, and especially pneumonia, remain one of the most common complications after esophagectomy for esophageal cancer. These complications are reduced by minimally invasive techniques or by avoiding thoracic access through a transhiatal approach. However, a transhiatal approach does not allow for a full mediastinal lymphadenectomy. A transcervical mediastinal esophagectomy avoids thoracic access, which may contribute to a decrease in pulmonary complications after esophagectomy. In addition, this technique allows for a full mediastinal lymphadenectomy. A number of pioneering studies have been published on this topic. Here, the initial experience is presented as well as a review of the current literature concerning transcervical esophagectomy, with a focus on the robot-assisted cervical esophagectomy procedure.},
	language = {eng},
	number = {Supplement\_2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Chiu, Philip Wai-Yan and de Groot, Eline Marieke and Yip, Hon-Chi and Egberts, Jan-Hendrik and Grimminger, Peter and Seto, Yasuyuki and Uyama, Ichiro and van der Sluis, Pieter Christiaan and Stein, Hubert and Sallum, Rubens and Ruurda, Jelle P. and van Hillegersberg, Richard},
	month = nov,
	year = {2020},
	pmid = {33241301},
	keywords = {Da Vinci, Esophageal Neoplasms, esophagectomy, Esophagectomy, Humans, Lymph Node Excision, MIE, minimally invasive esophagectomy, RAMIE, Robotic Surgical Procedures, robotics, Robotics, transcervical},
	pages = {doaa052},
	file = {Full Text:/Users/jcsal/Zotero/storage/I2Z5TP5M/Chiu et al. - 2020 - Robot-assisted cervical esophagectomy first clinical experiences and review of the literature.pdf:application/pdf},
}

@article{kingmadoaa047,
	title = {A structured training pathway to implement robot-assisted minimally invasive esophagectomy: the learning curve results from a high-volume center},
	volume = {33},
	issn = {1442-2050},
	shorttitle = {A structured training pathway to implement robot-assisted minimally invasive esophagectomy},
	doi = {10.1093/dote/doaa047},
	abstract = {To ensure safe implementation of robot-assisted minimally invasive esophagectomy (RAMIE), the learning process should be optimized. This study aimed to report the results of a surgeon who implemented RAMIE in a German high-volume center by following a tailored and structured training pathway that involved proctoring. Consecutive patients who underwent RAMIE during the course of the program were included from a prospective database. A single surgeon, who had prior experience in conventional MIE, performed all RAMIE procedures. Cumulative sum (CUSUM) learning curves were plotted for the thoracic operating time and intraoperative blood loss. Perioperative outcomes were compared between patients who underwent surgery before and after a learning curve plateau occurred. Between 2017 and 2018, the adopting center adhered to the structured training pathway, and a total of 70 patients were included in the analysis. The CUSUM learning curves showed plateaus after 22 cases. In consecutive cases 23 to 70, the operating time was shorter for both the thoracic phase (median 215 vs. 249 minutes, P = 0.001) and overall procedure (median 394 vs. 440 minutes, P = 0.005), intraoperative blood loss was less (median 210 vs. 400 milliliters, P = 0.029), and lymph node yield was higher (median 32 vs. 23 nodes, P = 0.001) when compared to cases 1 to 22. No significant differences were found in terms of conversion rates, postoperative complications, length of stay, completeness of resection, or mortality. In conclusion, the structured training pathway resulted in a short and safe learning curve for RAMIE in this single center's experience. As the pathway seems effective in implementing RAMIE without compromising the early oncological outcomes and complication rates, it is advised for surgeons who are wanting to adopt this technique.},
	language = {eng},
	number = {Supplement\_2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Kingma, B. Feike and Hadzijusufovic, Edin and Van der Sluis, Pieter C. and Bano, Erida and Lang, Hauke and Ruurda, Jelle P. and Hillegersberg van, Richard and Grimminger, Peter P.},
	month = nov,
	year = {2020},
	pmid = {33241300},
	keywords = {esophageal cancer, Esophageal Neoplasms, esophageal surgery, Esophagectomy, Humans, Learning Curve, minimally invasive surgery, Minimally Invasive Surgical Procedures, robotic surgery, Robotic Surgical Procedures, robotics, Robotics, Treatment Outcome},
	pages = {doaa047},
	file = {Full Text:/Users/jcsal/Zotero/storage/G9XEQ5KQ/Kingma et al. - 2020 - A structured training pathway to implement robot-assisted minimally invasive esophagectomy the lear.pdf:application/pdf},
}

@article{schurink170,
	title = {Metastatic incidence of ({PET}){CT} positive lung hilar and retroperitoneal lymph nodes in esophageal cancer patients},
	volume = {33},
	issn = {1879-3320},
	doi = {10.1016/j.suronc.2020.02.012},
	abstract = {BACKGROUND: Extra-regional lymph node metastases strongly determine treatment options in patients with esophageal cancer. Staging modalities such as (FDG-PET) CT scanning frequently show activity in retroperitoneal and lung hilar lymph nodes. This study evaluated the incidence of histologically confirmed metastases, treatment approach and recurrence patterns in patients with (FDG-PET) CT positivity in these regions.
METHODS: All patients with (FDG-PET-) CT positive hilar and/or retroperitoneal lymph nodes at primary staging or restaging discussed at a multidisciplinary tumor board meeting for staging of esophageal cancer between January 2012-December 2017 were included. Biopsies and follow-up were evaluated to determine the presence of metastases and progression rates.
RESULTS: From 2012 to 2017, 65 of 857 patients (7.6\%) were selected with positive retroperitoneal and/or hilar lymph nodes. A total of 47/65 (72.3\%) patients had positive retroperitoneal lymph nodes, which contained metastases in 19 (29.2\%). When no biopsy was performed and curative treatment was given (n = 14), 9 patients had progression or locoregional and distant recurrence. Positive hilar lymph nodes were identified in 21 (32.3\%) patients; 4 were biopsied and none contained metastases. In these patients no recurrence of disease was seen during follow-up.
CONCLUSIONS: The majority of biopsied (PET)CT-positive retroperitoneal lymph nodes at staging contained metastases, while biopsied (PET)CT-positive hilar nodes did not. Histological evaluation of (PET)CT -positive retroperitoneal lymph nodes at staging imaging is recommended, while based on this small series, (PET)CT-positive hilar lymph nodes most likely represent reactive lymphadenopathy.},
	language = {eng},
	journal = {Surgical Oncology},
	author = {Schurink, B. and Mazza, E. and Ruurda, J. P. and Roeling, T. a. P. and Bleys, R. L. a. W. and van Hillegersberg, R.},
	month = jun,
	year = {2020},
	pmid = {32561084},
	keywords = {Adenocarcinoma, Aged, Chemoradiotherapy, Esophageal cancer, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Esophagectomy, Female, Humans, Lung, Lymph nodes, Lymph Nodes, Lymphatic Metastasis, Male, Metastases, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Retroperitoneal Space, Staging},
	pages = {170--176},
}

@article{defizeS288,
	title = {Restaging after chemoradiotherapy for locally advanced esophageal cancer},
	volume = {7},
	issn = {2305-5839},
	doi = {10.21037/atm.2019.11.57},
	language = {eng},
	number = {Suppl 8},
	journal = {Annals of Translational Medicine},
	author = {Defize, Ingmar L. and van Hillegersberg, Richard and Mook, Stella and Meijer, Gert J. and Lin, Steven H. and Ruurda, Jelle P. and van Rossum, Peter S. N.},
	month = dec,
	year = {2019},
	pmid = {32016007},
	pmcid = {PMC6976470},
	pages = {S288},
	file = {Full Text:/Users/jcsal/Zotero/storage/6FAWZG78/Defize et al. - 2019 - Restaging after chemoradiotherapy for locally advanced esophageal cancer.pdf:application/pdf},
}

@article{goense111,
	title = {Impact of postoperative complications on outcomes after oesophagectomy for cancer},
	volume = {106},
	issn = {1365-2168},
	doi = {10.1002/bjs.11000},
	abstract = {BACKGROUND: To allocate healthcare resources optimally, complication-related quality initiatives should target complications that have the greatest overall impact on outcomes after surgery. The aim of this study was to identify the most clinically relevant complications after oesophagectomy for cancer in a nationwide cohort study.
METHODS: Consecutive patients who underwent oesophagectomy for cancer between January 2011 and December 2016 were identified from the Dutch Upper Gastrointestinal Cancer Audit. The adjusted population attributable fraction (PAF) was used to estimate the impact of specific postoperative complications on the clinical outcomes postoperative mortality, reoperation, prolonged hospital stay and readmission to hospital in the study population. The PAF represents the percentage reduction in the frequency of a given outcome (such as death) that would occur in a theoretical scenario where a specific complication (for example anastomotic leakage) was able to be prevented completely in the study population.
RESULTS: Some 4096 patients were analysed. Pulmonary complications and anastomotic leakage had the greatest overall impact on postoperative mortality (risk-adjusted PAF 44·1 and 30·4 per cent respectively), prolonged hospital stay (risk-adjusted PAF 31·4 and 30·9 per cent) and readmission to hospital (risk-adjusted PAF 7·3 and 14·7 per cent). Anastomotic leakage had the greatest impact on reoperation (risk-adjusted PAF 47·1 per cent). In contrast, the impact of other complications on these outcomes was relatively small.
CONCLUSION: Reducing the incidence of pulmonary complications and anastomotic leakage may have the greatest clinical impact on outcomes after oesophagectomy.},
	language = {eng},
	number = {1},
	journal = {The British Journal of Surgery},
	author = {Goense, L. and Meziani, J. and Ruurda, J. P. and van Hillegersberg, R.},
	month = jan,
	year = {2019},
	pmid = {30370938},
	keywords = {Adenocarcinoma, Aged, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Female, Humans, Length of Stay, Male, Patient Readmission, Postoperative Complications, Prospective Studies, Reoperation, Risk Factors, Treatment Outcome},
	pages = {111--119},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/UHDCL7RV/Goense et al. - 2019 - Impact of postoperative complications on outcomes after oesophagectomy for cancer.pdf:application/pdf},
}

@article{leers781,
	title = {The {CARDIA}-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction ({GEJ}) type {II}},
	volume = {20},
	issn = {1471-2407},
	shorttitle = {The {CARDIA}-trial protocol},
	doi = {10.1186/s12885-020-07152-1},
	abstract = {BACKGROUND: Adenocarcinoma of the gastroesophageal junction (GEJ) Siewert type II can be resected by transthoracic esophagectomy or transhiatal extended gastrectomy. Both allow for a complete tumor resection, yet there is an ongoing controversy about which surgical approach is superior with regards to quality of life, oncological outcomes and survival. While some studies suggest a better oncological outcome after transthoracic esophagectomy, others favor transhiatal extended gastrectomy for a better postoperative quality of life. To date, only retrospective studies are available, showing ambiguous results.
METHODS: This study is a multinational, multicenter, randomized, clinical superiority trial. Patients (n = 262) with a GEJ type II tumor resectable by both transthoracic esophagectomy and transhiatal extended gastrectomy will be enrolled in the trial. Type II tumors are defined as tumors with their midpoint between ≤1 cm proximal and ≤ 2 cm distal of the top of gastric folds on preoperative endoscopy. Patients will be included in one of the participating European sites and are randomized to either transthoracic esophagectomy or transhiatal extended gastrectomy. The trial is powered to show superiority for esophagectomy with regards to the primary efficacy endpoint overall survival. Key secondary endpoints are complete resection (R0), number and localization of tumor infiltrated lymph nodes at dissection, post-operative complications, disease-free survival, quality of life and cost-effectiveness. Postoperative survival and quality of life will be followed-up for 24 months after discharge. Further survival follow-up will be conducted as quarterly phone calls up to 60 months.
DISCUSSION: To date, as level 1 evidence is lacking, there is no consensus on which surgery is superior and both surgeries are used to treat GEJ type II carcinoma worldwide. The CARDIA trial is the first randomized trial to compare transthoracic esophagectomy versus transhiatal extended gastrectomy in patients with GEJ type II tumors. Several quality control measures were implemented in the protocol to ensure data reliability and increase the trial's significance. It is hypothesized that esophagectomy allows for a higher rate of radical resections and a more complete mediastinal lymph node dissection, resulting in a longer overall survival, while still providing an acceptable quality of life and cost-effectiveness.
TRIAL REGISTRATION: The trial was registered on August 2nd 2019 at the German Clinical Trials Register under the trial-ID DRKS00016923 .},
	language = {eng},
	number = {1},
	journal = {BMC cancer},
	author = {Leers, Jessica M. and Knepper, Laura and van der Veen, Arjen and Schröder, Wolfgang and Fuchs, Hans and Schiller, Petra and Hellmich, Martin and Zettelmeyer, Ulrike and Brosens, Lodewijk A. A. and Quaas, Alexander and Ruurda, Jelle P. and van Hillegersberg, Richard and Bruns, Christiane J.},
	month = aug,
	year = {2020},
	pmid = {32819399},
	pmcid = {PMC7439687},
	keywords = {Adult, Cardia, cardia carcinoma, Cost-Benefit Analysis, Disease-Free Survival, Equivalence Trials as Topic, esophageal adenocarcinoma, Esophageal Neoplasms, esophagectomy, Esophagectomy, Esophagogastric Junction, Esophagus, Europe, Female, Follow-Up Studies, gastrectomy, Gastrectomy, gastroesophageal junction, Humans, Lymph Node Excision, Male, Margins of Excision, Multicenter Studies as Topic, Postoperative Complications, Prospective Studies, Quality of Life, Randomized Controlled Trials as Topic, Siewert type II, Stomach Neoplasms},
	pages = {781},
	file = {Full Text:/Users/jcsal/Zotero/storage/AE99TPJU/Leers et al. - 2020 - The CARDIA-trial protocol a multinational, prospective, randomized, clinical trial comparing transt.pdf:application/pdf},
}

@article{hoshi196,
	title = {Liquid {Biopsy} and {Multidisciplinary} {Treatment} for {Esophageal} {Cancer}},
	volume = {17},
	issn = {2072-6694},
	doi = {10.3390/cancers17020196},
	abstract = {Esophageal cancer (EC) is one of the leading causes of cancer-related deaths globally. Surgery is the standard treatment for resectable EC after preoperative chemoradiotherapy or chemotherapy, followed by postoperative adjuvant chemotherapy in certain cases. Upper gastrointestinal endoscopy and computed tomography (CT) are predominantly performed to evaluate the efficacy of these treatments, but their sensitivity and accuracy for evaluating minimal residual disease remain unsatisfactory, thereby requiring the development of alternative methods. In recent years, interest has been increasing in using liquid biopsy to assess treatment responses. Liquid biopsy is a noninvasive technology for detecting cell components in the blood and other body fluids. It involves collecting a small sample of body fluid, which is then analyzed for the presence of components, including circulating tumor DNA (ctDNA), microRNA (miRNA), or circulating tumor cells (CTCs). Further, ctDNA and miRNA are analyzed with various techniques, including digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS). CTCs are isolated by determining surface antigens using immunomagnetic techniques or by filtering the blood according to cell size and rigidity. Several studies indicate that investigating these materials helps predict EC prognosis and recurrence and possibly stratifies high-risk groups. Liquid biopsy may also apply to the selection of cases that have achieved a complete response through preoperative treatment to prevent surgery and preserve the esophagus, as well as identifying the suitability of postoperative chemotherapy and the timing of conversion surgery for unresectable EC. The potential of liquid biopsy to enhance treatment decisions will further advance EC treatment.},
	language = {eng},
	number = {2},
	journal = {Cancers},
	author = {Hoshi, Yuki and Matsuda, Satoru and Takeuchi, Masashi and Kawakubo, Hirofumi and Kitagawa, Yuko},
	month = jan,
	year = {2025},
	pmid = {39857978},
	pmcid = {PMC11763614},
	keywords = {circulating tumor cells, ctDNA, esophageal cancer, liquid biopsy, miRNA},
	pages = {196},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/LHSSRNZP/Hoshi et al. - 2025 - Liquid Biopsy and Multidisciplinary Treatment for Esophageal Cancer.pdf:application/pdf},
}

@article{takei,
	title = {Circulating {Tumor} {DNA} {Assessment} to {Predict} {Risk} of {Recurrence} after {Surgery} in {Patients} with {Locally} {Advanced} {Esophageal} {Squamous} {Cell} {Carcinoma}: {A} {Prospective} {Observational} {Study}},
	issn = {1528-1140},
	shorttitle = {Circulating {Tumor} {DNA} {Assessment} to {Predict} {Risk} of {Recurrence} after {Surgery} in {Patients} with {Locally} {Advanced} {Esophageal} {Squamous} {Cell} {Carcinoma}},
	doi = {10.1097/SLA.0000000000006699},
	abstract = {OBJECTIVE: To investigate the association between perioperative ctDNA status and prognosis in patients with esophageal squamous cell carcinoma (ESCC).
BACKGROUND: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for assessing molecular residual disease (MRD) in various malignancies. However, there are limited studies evaluating the utility of ctDNA for predicting recurrence risk in patients with ESCC.
METHODS: We prospectively enrolled patients with locally advanced ESCC who were scheduled to receive neoadjuvant chemotherapy (NAC) followed by surgery. This report retrospectively analyzed ctDNA with a personalized, tumor-informed 16-plex mPCR-NGS assay at multiple time points: pre-NAC, post-NAC but before surgery, postoperatively, and longitudinally during follow-up.
RESULTS: A total of 28 patients who underwent curative surgery, and had successful whole-exome sequencing analysis of tumor tissue samples were included in this report. At the pre-NAC time point, ctDNA was detected in 50\% of patients with stage I and 100\% of those with stages II, III, and IV. Post-NAC but before surgery, ctDNA was detected in 33.3\% of patients. The recurrence rate was 77.8\% in ctDNA-positive patients compared to 27.8\% in ctDNA-negative patients, with significantly worse recurrence-free survival (RFS) for ctDNA-positive patients vs. ctDNA-negative patients (HR: 4.56, P =0.01). In patients analyzed during the MRD window (2-16 weeks post-surgery), the recurrence rate was 100\% in ctDNA-positive patients compared to 30.4\% in ctDNA-negative patients, with significantly worse RFS (HR: 30.99, P {\textless}0.0001). Similarly, during surveillance ({\textgreater}16 weeks post-surgery), detectable ctDNA was significantly associated with poor RFS (HR: 27.34, P =0.003).
CONCLUSION: This study suggests that ctDNA-based MRD assessment may be valuable for evaluating patients with ESCC, particularly in post-NAC and postsurgical settings.},
	language = {eng},
	journal = {Annals of Surgery},
	author = {Takei, Shogo and Kotani, Daisuke and Laliotis, George and Sato, Kazuma and Fujiwara, Naoto and Kawazoe, Akihito and Hashimoto, Tadayoshi and Mishima, Saori and Nakayama, Izuma and Nakamura, Yoshiaki and Bando, Hideaki and Kuboki, Yasutoshi and Sakashita, Shingo and Spickard, Erik and George, Giby V. and Dutta, Punashi and Sharma, Shruti and Malhotra, Meenakshi and Sethi, Himanshu and Jurdi, Adham and Liu, Minetta C. and Yoshino, Takayuki and Shitara, Kohei and Kojima, Takashi and Fujita, Takeo},
	month = mar,
	year = {2025},
	pmid = {40115982},
}

@article{iden83a,
	title = {Circulating tumor {DNA} predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer},
	volume = {28},
	issn = {1436-3305},
	doi = {10.1007/s10120-024-01556-9},
	abstract = {BACKGROUND: Gastric and gastroesophageal junction (GEJ) cancer represents a significant global health challenge, with high recurrence rates and poor survival outcomes. This study investigates circulating tumor DNA (ctDNA) as a biomarker for assessing recurrence risk in patients with resectable gastric and GEJ adenocarcinomas (AC).
METHODS: Patients with resectable gastric and GEJ AC, undergoing perioperative chemotherapy and surgery, were prospectively enrolled. Serial plasma samples were collected at baseline, after one cycle of chemotherapy, after preoperative chemotherapy, and after surgery. ctDNA was assessed by a ddPCR test (TriMeth), which targets the gastrointestinal cancer-specific methylation patterns of the genes C9orf50, KCNQ5, and CLIP4.
RESULTS: ctDNA analysis was performed on 229 plasma samples from 86 patients. At baseline, ctDNA was detected in 56\% of patients, which decreased to 37\% following one cycle of chemotherapy, 25\% after preoperative chemotherapy and 15\% after surgical resection. The presence of ctDNA after one cycle of chemotherapy was associated with reduced recurrence-free survival (RFS) (HR = 2.54, 95\% confidence interval (CI) 1.33-4.85, p = 0.005) and overall survival (OS) (HR = 2.23, 95\% CI 1.07-4.62, p = 0.032). Similarly, ctDNA after surgery was associated with significantly shorter RFS (HR = 6.22, 95\% CI 2.39-16.2, p {\textless} 0.001) and OS (HR = 6.37, 95\% CI 2.10-19.3, p = 0.001). Multivariable regression analysis confirmed ctDNA after surgery as an independent prognostic factor (p {\textless} 0.001).
CONCLUSION: ctDNA analysis has the potential to identify patients at elevated risk of recurrence, thus providing personalized treatment strategies for patients with resectable gastric and GEJ cancer. Further validation in larger cohorts and ctDNA-guided interventions are needed for future clinical use.},
	language = {eng},
	number = {1},
	journal = {Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association},
	author = {Iden, Cecilie Riis and Mustafa, Salah Mohammad and Øgaard, Nadia and Henriksen, Tenna and Jensen, Sarah Østrup and Ahlborn, Lise Barlebo and Egebjerg, Kristian and Baeksgaard, Lene and Garbyal, Rajendra Singh and Nedergaard, Mette Kjølhede and Achiam, Michael Patrick and Andersen, Claus Lindbjerg and Mau-Sørensen, Morten},
	month = jan,
	year = {2025},
	pmid = {39369091},
	pmcid = {PMC11706848},
	keywords = {Adenocarcinoma, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Circulating tumor DNA, Circulating Tumor DNA, Curative treatment, DNA methylation, Esophageal Neoplasms, Esophagogastric Junction, Female, Gastroesophageal cancer, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Prospective Studies, Stomach Neoplasms, Survival Rate, Tumor biomarkers},
	pages = {83--95},
}

@article{landere2400288,
	title = {Circulating {Tumor} {DNA} as a {Prognostic} {Biomarker} for {Recurrence} in {Patients} {With} {Locoregional} {Esophagogastric} {Cancers} {With} a {Pathologic} {Complete} {Response}},
	volume = {8},
	issn = {2473-4284},
	doi = {10.1200/PO.24.00288},
	abstract = {PURPOSE: After neoadjuvant therapy (NAT) and surgery, up to one third and one half of patients with esophagogastric adenocarcinoma with a pathologic complete response (pCR; tumor regression grade 0 [TRG-0]) and near-pCR (TRG-1) will recur, respectively. Our study aims to evaluate postoperative circulating tumor DNA (ctDNA) as a predictor of recurrence in patients with pCR or near-pCR after curative-intent neoadjuvant chemotherapy or neoadjuvant chemoradiation and surgery.
METHODS: We retrospectively identified patients from 11 institutions with stages I-IV esophagogastric cancers (EGCs) who completed NAT and had TRG-0/1 scores at the time of curative-intent surgery. Postoperative plasma samples were collected for ctDNA analysis within a 16-week molecular residual disease (MRD) window after definitive surgery, and during surveillance from January 7, 2020, to November 9, 2023, at the provider's discretion. ctDNA was assessed using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc). The primary outcome was recurrence-free survival (RFS).
RESULTS: We obtained 309 blood samples from 42 patients with esophagogastric adenocarcinoma with a pCR after neoadjuvant treatment over a median follow-up time of 28.5 months (range, 0.2-81.7). Detectable ctDNA in the 16-week MRD window (N = 23) correlated with higher rates of recurrence (67\%; 2/3) compared with undetectable ctDNA (15\%; 3/20). Detectable ctDNA within the MRD window was associated with a significantly shorter RFS (hazard ratio [HR], 6.2; P = .049). Among 32 patients who had ctDNA analyzed in the surveillance setting, the recurrence rate was 100\% (5/5) in the ctDNA-positive cohort compared with 7.4\% (2/27) in ctDNA-negative patients and was associated with shorter RFS (HR, 37.6; P {\textless} .001).
CONCLUSION: Within the subgroup of patients with EGC and favorable pathologic responses (TRG 0-1) after NAT, the presence of postoperative ctDNA identified patients with elevated recurrence risk.},
	language = {eng},
	journal = {JCO precision oncology},
	author = {Lander, Eric Michael and Aushev, Vasily N. and Huffman, Brandon M. and Hanna, Diana and Dutta, Punashi and Ferguson, Jenifer and Sharma, Shruti and Jurdi, Adham and Liu, Minetta C. and Eng, Cathy and Klempner, Samuel J. and Gibson, Michael K.},
	month = dec,
	year = {2024},
	pmid = {39642325},
	pmcid = {PMC11634147},
	keywords = {Adenocarcinoma, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Circulating Tumor DNA, Esophageal Neoplasms, Esophagogastric Junction, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Pathologic Complete Response, Prognosis, Retrospective Studies, Stomach Neoplasms},
	pages = {e2400288},
}

@article{ruurda313,
	title = {Robot-assisted endoscopic surgery: a four-year single-center experience},
	volume = {22},
	issn = {0253-4886},
	shorttitle = {Robot-assisted endoscopic surgery},
	doi = {10.1159/000088628},
	abstract = {BACKGROUND: Robotic systems were introduced in the late 1990s with the objective to overcome the technical limitations of endoscopic surgery. In this prospective cohort study the potential safety, feasibility, pitfalls and challenges of robotic systems in gastrointestinal endoscopic surgery are assessed and our vision on future perspectives is presented.
METHODS: Between August 2000 and December 2004, 208 procedures were performed with support of the Intuitive Surgical da Vincitrade mark robotic system. We started with cholecystectomies (40) and Nissen fundoplications (41) to gain experience with robot-assisted surgery. In the following years more complex procedures were carried out, i.e. colorectal procedures (7), type III/IV paraesophageal hernia repair (32), redo Nissen fundoplications (9), Heller myotomies (24), esophageal resections (22), rectopexies (16) and aortobifemoral bypasses (3).
RESULTS: The median robotic set-up time was 13 min, and 7 min in the last 50 procedures. The median operating time for the total of procedures was 120 min (45-420) and the median blood loss was 30 ml (0-800). Fourteen procedures were converted to open surgery (6.7\%). Equipment-related problems, such as start-up failures and positioning difficulties of the robotic arms, were encountered in 11 cases (5.3\%). Postoperative complications were seen in 11 patients (11/176, 6.3\%) after robot-assisted laparoscopic procedures. Pulmonary complications occurred in 11 patients, cardiac in 3, anastomic leakage in 3, chylous leakage in 3 and vocal cord paralysis in 3 after thoracoscopic esophagolymphadenectomy for esophageal cancer. One patient died 12 days after esophageal resection (0.5\%).
CONCLUSION: During the implementation of this robotic system, we experienced an obvious learning curve, particularly with regard to the positioning of the robot cart and communication between the surgeon and operating team. After 4 years, we have experienced that the merits of the current generation of this technology probably is preserved to complex endoscopic procedures with delicate dissection and suturing. In the nearby future we will focus on the treatment of motility disorders and malignancies of the esophagus and stomach. The position of the robot in the endoscopic operating room will have to be clarified by the outcome of prospective research. Furthermore, priorities have to be acclaimed on technical sophistication and cost reduction of these systems.},
	language = {eng},
	number = {5},
	journal = {Digestive Surgery},
	author = {Ruurda, Jelle P. and Draaisma, Werner A. and van Hillegersberg, Richard and Borel Rinkes, Inne H. M. and Gooszen, Hein G. and Janssen, Lucas W. M. and Simmermacher, Rogier K. J. and Broeders, Ivo A. M. J.},
	year = {2005},
	pmid = {16192731},
	keywords = {Adolescent, Adult, Aged, Aged, 80 and over, Clinical Competence, Endoscopy, Gastrointestinal, Feasibility Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Robotics, Treatment Outcome, Utrecht},
	pages = {313--320},
	file = {PDF:/Users/jcsal/Zotero/storage/2PDM7MUH/Ruurda et al. - 2005 - Robot-assisted endoscopic surgery a four-year single-center experience.pdf:application/pdf},
}

@article{vandersluis264,
	title = {Learning {Curve} for {Robot}-{Assisted} {Minimally} {Invasive} {Thoracoscopic} {Esophagectomy}: {Results} {From} 312 {Cases}},
	volume = {106},
	issn = {1552-6259},
	shorttitle = {Learning {Curve} for {Robot}-{Assisted} {Minimally} {Invasive} {Thoracoscopic} {Esophagectomy}},
	doi = {10.1016/j.athoracsur.2018.01.038},
	abstract = {BACKGROUND: Thoracic laparoscopic robot-assisted minimally invasive esophagectomy (RAMIE) was developed in 2003. RAMIE was shown to be safe and oncologically effective. The aim of this study was to assess the learning curve and the proctoring program for a newly introduced surgeon (surgeon 2).
METHODS: The "learning curve" was defined as the number of operations that must be performed by a surgeon to achieve a steady level of performance. Measures of proficiency to describe the learning curve of the proctor and the newly introduced surgeon 2 included operating time, blood loss, and conversion rates and were analyzed using the cumulative sum method. Results of the newly introduced surgeon were compared with the proctor in the same period of time.
RESULTS: The proctor performed 232 of 312 procedures (74\%) and surgeon 2 performed 80 of 312 procedures (26\%). The proctor reached proficiency after 70 procedures in 55 months. The structured proctoring program for surgeon 2 started with 20 procedures as assisting table surgeon, followed by 5 observational and 15 supervised cases. Surgeon 2 performed at the same level as the proctor concerning operating time, blood loss, conversion rates, radicality, and complications. For surgeon 2, the learning phase of thoracic laparoscopic RAMIE was completed within 24 cases (15 supervised and 9 independent cases) in 13 months; a reduction of 66\% in the number of operations and a reduction of 76\% in time, compared with the proctor.
CONCLUSIONS: The learning phase of thoracic laparoscopic RAMIE consisted of 70 procedures in 55 months. A structured proctoring for RAMIE substantially reduced the number of procedures and time required to achieve proficiency.},
	language = {eng},
	number = {1},
	journal = {The Annals of Thoracic Surgery},
	author = {van der Sluis, Pieter C. and Ruurda, Jelle P. and van der Horst, Sylvia and Goense, Lucas and van Hillegersberg, Richard},
	month = jul,
	year = {2018},
	pmid = {29454718},
	keywords = {Adult, Aged, Clinical Competence, Cohort Studies, Disease-Free Survival, Esophagectomy, Female, Follow-Up Studies, Humans, Learning Curve, Male, Middle Aged, Minimally Invasive Surgical Procedures, Netherlands, Retrospective Studies, Risk Assessment, Robotic Surgical Procedures, Statistics, Nonparametric, Survival Analysis, Thoracoscopy, Treatment Outcome, Utrecht},
	pages = {264--271},
	file = {PDF:/Users/jcsal/Zotero/storage/CFMZK3RC/van der Sluis et al. - 2018 - Learning Curve for Robot-Assisted Minimally Invasive Thoracoscopic Esophagectomy Results From 312 C.pdf:application/pdf},
}

@article{vanworkum88,
	title = {Learning {Curve} and {Associated} {Morbidity} of {Minimally} {Invasive} {Esophagectomy}: {A} {Retrospective} {Multicenter} {Study}},
	volume = {269},
	issn = {1528-1140},
	shorttitle = {Learning {Curve} and {Associated} {Morbidity} of {Minimally} {Invasive} {Esophagectomy}},
	doi = {10.1097/SLA.0000000000002469},
	abstract = {OBJECTIVE: To investigate the morbidity that is associated with the learning curve of minimally invasive esophagectomy.
BACKGROUND: Although learning curves have been described, it is currently unknown how much extra morbidity is associated with the learning curve of technically challenging surgical procedures.
METHODS: Prospectively collected data were retrospectively analyzed of all consecutive patients undergoing minimally invasive Ivor Lewis esophagectomy in 4 European expert centers. The primary outcome parameter was anastomotic leakage. Secondary outcome parameters were operative time and textbook outcome ("optimal outcome"). Learning curves were plotted using weighted moving average and CUSUM analysis was used to determine after how many cases the plateau was reached. Learning associated morbidity was calculated with area under the curve analysis.
RESULTS: This study included 646 patients. Three of the 4 hospitals reached the plateau of 8\% anastomotic leakage. The length of the learning curve was 119 cases. The mean incidence of anastomotic leakage decreased from 18.8\% during the learning phase to 4.5\% after the plateau had been reached (P {\textless} 0.001). Thirty-six extra patients (10.1\% of all patients operated on during the learning curve) experienced learning associated anastomotic leakage, that could have been avoided if patients were operated by surgeons who had completed the learning curve. The incidence of textbook outcome increased from 28\% to 53\% and the mean operative time decreased from 344 minutes to 270 minutes.
CONCLUSIONS: A considerable number of 36 extra patients (10.1\%) experienced learning associated anastomotic leakage. More research is urgently needed to investigate how learning associated morbidity can be reduced to increase patient safety during learning curves.},
	language = {eng},
	number = {1},
	journal = {Annals of Surgery},
	author = {van Workum, Frans and Stenstra, Marianne H. B. C. and Berkelmans, Gijs H. K. and Slaman, Annelijn E. and van Berge Henegouwen, Mark I. and Gisbertz, Suzanne S. and van den Wildenberg, Frits J. H. and Polat, Fatih and Irino, Tomoyuki and Nilsson, Magnus and Nieuwenhuijzen, Grard A. P. and Luyer, Misha D. and Adang, Eddy M. and Hannink, Gerjon and Rovers, Maroeska M. and Rosman, Camiel},
	month = jan,
	year = {2019},
	pmid = {28857809},
	keywords = {Aged, Clinical Competence, Education, Medical, Graduate, Esophageal Neoplasms, Esophagectomy, Female, Humans, Learning Curve, Male, Middle Aged, Minimally Invasive Surgical Procedures, Morbidity, Netherlands, Operative Time, Postoperative Complications, Retrospective Studies, Surgeons, Survival Rate},
	pages = {88--94},
	file = {PDF:/Users/jcsal/Zotero/storage/ETGC4RFB/van Workum et al. - 2019 - Learning Curve and Associated Morbidity of Minimally Invasive Esophagectomy A Retrospective Multice.pdf:application/pdf},
}

@article{vanhillegersberg1435,
	title = {First experience with robot-assisted thoracoscopic esophagolymphadenectomy for esophageal cancer},
	volume = {20},
	issn = {1432-2218},
	doi = {10.1007/s00464-005-0674-8},
	abstract = {BACKGROUND: Transthoracic esophagectomy with extended lymph node dissection is associated with higher morbidity rates than transhiatal esophagectomy. This morbidity rate could be reduced by the use of minimally invasive techniques. The feasibility of robot-assisted thoracoscopic esophagectomy (RTE) with mediastinal lymphadenectomy was assessed prospectively.
METHODS: This study investigated 21 consecutive patients with esophageal cancer who underwent RTE using the Da Vinci robotic system. Continuity was restored with a gastric conduit and a cervical anastomosis.
RESULTS: A total of 18 (86\%) procedures were completed thoracoscopically. The operating time for the thoracoscopic phase was 180 min (range, 120-240 min), and the median blood loss was 400 ml (range, 150-700 ml). A median of 20 (range, 9-30) lymph nodes were retrieved. The median intensive care unit stay was 4 days (range, 1-129 days), and the hospital stay was 18 days (range, 11-182 days). Pulmonary complications occurred in 10 patients (48\%), and one patient (5\%) died of a tracheoneoesophageal fistula.
CONCLUSIONS: In this initial experience, robot-assisted thoracoscopic esophagectomy was found to be feasible, providing an effective lymphadenectomy with low blood loss. Standardization of the technique and increased experience should reduce the complication rate, which is in the range of the rate for open transthoracic dissection.},
	language = {eng},
	number = {9},
	journal = {Surgical Endoscopy},
	author = {van Hillegersberg, R. and Boone, J. and Draaisma, W. A. and Broeders, I. a. M. J. and Giezeman, M. J. M. M. and Borel Rinkes, I. H. M.},
	month = sep,
	year = {2006},
	pmid = {16703427},
	keywords = {Adenocarcinoma, Aged, Blood Loss, Surgical, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Feasibility Studies, Female, Humans, Intensive Care Units, Length of Stay, Lung Diseases, Lymph Node Excision, Male, Middle Aged, Minimally Invasive Surgical Procedures, Prospective Studies, Robotics, Thoracoscopy, Tracheoesophageal Fistula},
	pages = {1435--1439},
	file = {PDF:/Users/jcsal/Zotero/storage/8FYFAQ7R/van Hillegersberg et al. - 2006 - First experience with robot-assisted thoracoscopic esophagolymphadenectomy for esophageal cancer.pdf:application/pdf},
}

@article{froiiodoac044,
	title = {Semiprone thoracoscopic approach during totally minimally invasive {Ivor}-{Lewis} esophagectomy seems to be beneficial},
	volume = {36},
	issn = {1442-2050},
	doi = {10.1093/dote/doac044},
	abstract = {Minimally invasive Ivor-Lewis Esophagectomy (MIE) is widely accepted as a surgical treatment of resectable esophageal cancer. Aim of this paper is to describe the surgical details of our standardized MIE technique and its safety. We also evaluate the esophageal mobilization in semiprone compared to the left lateral position. A retrospective analysis of 141 consecutive patients who underwent Ivor-Lewis esophagectomy for cancer, from February 2016 to September 2021, was conducted. All the procedures were performed by totally thoraco-laparoscopic with an intrathoracic end-to-side circular stapled anastomosis. Thoracic phase was performed in left lateral position (LLP-group, n=47) followed by a semiprone position (SP-group, n=94). The intraoperative and postoperative outcomes were prospectively collected and analyzed. The procedure was completed without intraoperative complication in 94.68\% of cases in SP-group and in 93.62\% of cases in LLP-group (P=0.99). The total operative time and thoracic operative time were significantly shorter in SP-group (P=0.0096; P=0.009). No statistically significant differences were detected in postoperative outcomes between the groups, except for anastomotic strictures (higher in LLP-group, P=0.02) and intensive care unit stay (longer in LLP-group, P=00.1). No reoperation was needed in any cases. Surgical radicality was comparable; the median of harvested lymph nodes was significantly higher in SP-group (P{\textless}0.0001). The present semiprone technique of thoraco-laparoscopic Ivor-Lewis esophagectomy is safe and feasible but may also provide some advantages in terms of lymph nodes harvested and total operation time.},
	language = {eng},
	number = {2},
	journal = {Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus},
	author = {Froiio, Caterina and Uzun, Eren and Hadzijusufovic, Edin and Capovilla, Giovanni and Berlth, Felix and Lang, Hauke and Grimminger, Peter P.},
	month = jan,
	year = {2023},
	pmid = {35780319},
	keywords = {Anastomosis, Surgical, esophageal cancer, Esophageal Neoplasms, Esophagectomy, Humans, Ivor-Lewis, Laparoscopy, MIE, minimal invasive esophagectomy, Minimally Invasive Surgical Procedures, Postoperative Complications, Retrospective Studies, semiprone position, Treatment Outcome},
	pages = {doac044},
	file = {PDF:/Users/jcsal/Zotero/storage/IL5EPRAG/Froiio et al. - 2023 - Semiprone thoracoscopic approach during totally minimally invasive Ivor-Lewis esophagectomy seems to.pdf:application/pdf},
}

@article{tagkalos2242,
	title = {The {Circular} {Stapled} {Esophagogastric} {Anastomosis} in {Esophagectomy}: {No} {Differences} in {Anastomotic} {Insufficiency} and {Stricture} {Rates} {Between} the 25 mm and 28 mm {Circular} {Stapler}},
	volume = {25},
	issn = {1873-4626},
	shorttitle = {The {Circular} {Stapled} {Esophagogastric} {Anastomosis} in {Esophagectomy}},
	doi = {10.1007/s11605-020-04895-x},
	abstract = {BACKGROUND: For patients undergoing an Ivor Lewis esophagectomy with a circular stapled anastomosis, the optimal diameter of the used circular stapler to restore continuity is unknown. The aim of this study was to compare the 25 mm stapled versus the 28 mm stapled esophagogastric anastomosis after Ivor Lewis esophagectomy, focusing on anastomotic insufficiency and postoperative anastomotic strictures.
METHODS: Between February 2008 and June 2019, 349 consecutive patients underwent Ivor Lewis esophagectomy with gastric conduit reconstruction and circular stapled anastomosis. Patient characteristics and postoperative results, such as anastomotic insufficiency rates, postoperative anastomotic stricture rates, time to anastomotic stricture rate, and the number of dilatations, were recorded in a prospective database and analyzed.
RESULTS: In 222 patients (64\%), the 25 mm circular stapler was used and in 127 patients (36\%) the 28 mm circular stapler was used. There were no differences in baseline characteristics. Anastomotic insufficiency rates were comparable between the 25 mm (12\%) and the 28 mm groups (11\%) (p = 0.751). There were no differences between postoperative anastomotic strictures in the 25 mm (14\%) and the 28 mm groups (14\%) (p = 0.863). Within patients with postoperative anastomotic strictures, a median number of 2 dilatations were observed in each group (p = 0.573) without differences in the time to first diagnosis (p = 0.412).
CONCLUSION: There were no differences in anastomotic insufficiency and postoperative anastomotic stricture rates between the 25 mm and the 28 mm circular stapled esophagogastric anastomosis after Ivor Lewis esophagectomy. Both the 25 mm and 28 mm stapler can be safely used to create a circular stapled esophagogastric anastomosis to restore continuity after esophagectomy.},
	language = {eng},
	number = {9},
	journal = {Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract},
	author = {Tagkalos, E. and van der Sluis, P. C. and Uzun, E. and Berlth, F. and Staubitz, J. and Gockel, I. and van Hillegersberg, R. and Lang, H. and Grimminger, Peter P.},
	month = sep,
	year = {2021},
	pmid = {33506342},
	pmcid = {PMC8484169},
	keywords = {Anastomosis, Surgical, Anastomotic Leak, Circular stapled anastomosis, Constriction, Pathologic, Esophageal Neoplasms, Esophagectomy, Esophago-gastric anastomosis, Humans, Ivor-Lewis Esophagectomy, Postoperative Complications, Treatment Outcome},
	pages = {2242--2249},
	file = {Full Text:/Users/jcsal/Zotero/storage/CF57VZ43/Tagkalos et al. - 2021 - The Circular Stapled Esophagogastric Anastomosis in Esophagectomy No Differences in Anastomotic Ins.pdf:application/pdf},
}

@article{goense247,
	title = {Aortic {Calcification} {Increases} the {Risk} of {Anastomotic} {Leakage} {After} {Ivor}-{Lewis} {Esophagectomy}},
	volume = {102},
	issn = {1552-6259},
	doi = {10.1016/j.athoracsur.2016.01.093},
	abstract = {BACKGROUND: Anastomotic leakage is associated with increased morbidity and mortality after esophagectomy. Calcification of the arteries supplying the gastric tube has been identified as a risk factor for leakage of the cervical anastomosis, but its potential contribution to the risk of intrathoracic anastomotic leakage has not been elucidated. This study evaluated the relationship between calcification and the occurrence of leakage of the intrathoracic anastomosis after Ivor-Lewis esophagectomy.
METHODS: Consecutive patients who underwent minimally invasive esophagectomy for cancer at 2 institutions were analyzed. Diagnostic computed tomography images were used to detect calcification of the arteries supplying the gastric tube (eg, aorta, celiac axis). Multivariable logistic regression analysis was used to determine the relationship between vascular calcification and anastomotic leakage.
RESULTS: Of 167 included patients, anastomotic leakage occurred in 40 (24\%). In univariable analysis, leakage was most frequently observed in patients with calcification of the aorta (major calcification: 37\% leakage [16 of 43]; minor calcification: 32\% [18 of 56]; no calcification: 9\% [6 of 70], p {\textless} 0.001). Calcification of other studied arteries was not significantly associated with leakage. A significant association with leakage remained for minor (odds ratio, 5.4; 95\% confidence interval, 1.7 to 16.5) and major (odds ratio, 7.0; 95\% confidence interval, 1.9 to 26.4) aortic calcifications in multivariable analysis.
CONCLUSIONS: Atherosclerotic calcification of the aorta is an independent risk factor for leakage of the intrathoracic anastomosis after Ivor-Lewis esophagectomy for cancer. The calcification scoring system may aid in patient selection and lead to earlier diagnosis of this potentially fatal complication.},
	language = {eng},
	number = {1},
	journal = {The Annals of Thoracic Surgery},
	author = {Goense, Lucas and van Rossum, Peter S. N. and Weijs, Teus J. and van Det, Marc J. and Nieuwenhuijzen, Grard A. and Luyer, Misha D. and van Leeuwen, Maarten S. and van Hillegersberg, Richard and Ruurda, Jelle P. and Kouwenhoven, Ewout A.},
	month = jul,
	year = {2016},
	pmid = {27112648},
	keywords = {Aged, 80 and over, Anastomotic Leak, Aortic Diseases, Calcinosis, Carcinoma, Squamous Cell, Esophageal Neoplasms, Esophagectomy, Female, Humans, Incidence, Male, Minimally Invasive Surgical Procedures, Netherlands, Prognosis, Retrospective Studies, Risk Factors, Tomography, X-Ray Computed},
	pages = {247--252},
}

@article{irino315,
	title = {Thoracoscopic side-to-side esophagogastrostomy by use of linear stapler-a simplified technique facilitating a minimally invasive {Ivor}-{Lewis} operation},
	volume = {401},
	issn = {1435-2451},
	doi = {10.1007/s00423-016-1396-1},
	abstract = {PURPOSE: Minimally invasive esophagectomy (MIE) has been met with increased interest for the surgical treatment of esophageal cancer. One critical obstacle for the implementation of MIE has been the intrathoracic anastomosis. In this study, we describe a technique of thoracoscopic intrathoracic anastomosis using a linear stapler in prone position and present the short-term outcomes of this procedure.
METHODS: This prospective pilot study included 46 consecutive patients with a cancer either of the gastroesophageal junction (GEJ) or the distal esophagus who underwent either total MIE or thoracoscopic-assisted esophagectomy followed by intrathoracic stapled side-to-side anastomosis. The short-term outcomes including postoperative complications were recorded and analyzed.
RESULTS: This pilot study included 41 males (89 \%) and 5 females (11 \%) with a mean age of 65.7 years. The majority had adenocarcinoma (93 \%). Before surgery, 4 patients (8.7 \%) had an incomplete endoscopic submucosal resection, 5 patients (11 \%) received chemotherapy alone, and 33 patients (71 \%) had chemoradiotherapy. Mean operation time was 408 minutes. Postoperative complications classified as Clavien-Dindo Grade IIIa or more severe occurred in 7 patients (15 \%), of whom 4 patients (8.7 \%) developed anastomotic leakages without any need for intensive care. Another 2 patients (4.3 \%) required intensive care due to aspiration pneumonia and acute renal failure. No in-hospital mortality was registered. Only one patient (2.2 \%) with anastomotic leakage developed postoperative anastomotic stenosis requiring balloon dilatation.
CONCLUSIONS: The intrathoracic stapled side-to-side anastomosis technique seems to be feasible, safe, and easy to perform, associated with a limited postsurgical complication rate and a good functional outcome.},
	language = {eng},
	number = {3},
	journal = {Langenbeck's Archives of Surgery},
	author = {Irino, Tomoyuki and Tsai, Jon A. and Ericson, Jessica and Nilsson, Magnus and Lundell, Lars and Rouvelas, Ioannis},
	month = may,
	year = {2016},
	pmid = {26960591},
	keywords = {Aged, Anastomosis, Surgical, Esophageal Neoplasms, Esophagectomy, Esophagus, Female, Humans, Intrathoracic anastomosis, Male, Middle Aged, Minimally invasive esophagectomy, Operative Time, Pilot Projects, Postoperative complication, Prospective Studies, Side-to-side stapled anastomosis, Stomach, Surgical Stapling, Thoracoscopy},
	pages = {315--322},
	file = {PDF:/Users/jcsal/Zotero/storage/3DFCDW6C/Irino et al. - 2016 - Thoracoscopic side-to-side esophagogastrostomy by use of linear stapler-a simplified technique facil.pdf:application/pdf},
}

@article{kukar1729,
	title = {Minimally {Invasive} {Ivor} {Lewis} {Esophagectomy} with {Linear} {Stapled} {Anastomosis} {Associated} with {Low} {Leak} and {Stricture} {Rates}},
	volume = {24},
	issn = {1873-4626},
	url = {https://doi.org/10.1007/s11605-019-04320-y},
	doi = {10.1007/s11605-019-04320-y},
	abstract = {Minimally invasive foregut surgery is increasingly performed for both benign and malignant diseases. We present a retrospective series of patients who underwent minimally invasive Ivor Lewis esophagectomy (MIE) with linear stapled anastomosis performed at two centers in the USA, with a focus on evaluating leak and stricture rates.},
	language = {en},
	number = {8},
	urldate = {2025-05-27},
	journal = {Journal of Gastrointestinal Surgery},
	author = {Kukar, Moshim and Ben-David, Kfir and Peng, June S. and Attwood, Kristopher and Thomas, Ryan M. and Hennon, Mark and Nwogu, Chukwumere and Hochwald, Steven N.},
	month = aug,
	year = {2020},
	keywords = {Abdominal Surgery, Esophageal cancer, Intrathoracic anastomosis, Ivor Lewis esophagectomy, Microendoscopy, Minimally invasive esophagectomy, Minimally Invasive Surgery, Oesophagogastroscopy, Surgery, Urological Surgery},
	pages = {1729--1735},
	file = {PDF:/Users/jcsal/Zotero/storage/77F9JVEY/Kukar et al. - 2020 - Minimally Invasive Ivor Lewis Esophagectomy with Linear Stapled Anastomosis Associated with Low Leak.pdf:application/pdf},
}

@article{fabbi2681,
	title = {End-to-side circular stapled versus side-to-side linear stapled intrathoracic esophagogastric anastomosis following minimally invasive {Ivor}-{Lewis} esophagectomy: comparison of short-term outcomes},
	volume = {407},
	issn = {1435-2451},
	shorttitle = {End-to-side circular stapled versus side-to-side linear stapled intrathoracic esophagogastric anastomosis following minimally invasive {Ivor}-{Lewis} esophagectomy},
	doi = {10.1007/s00423-022-02567-9},
	abstract = {PURPOSE: The search for the optimal procedure for creation of a safe gastroesophageal intrathoracic anastomosis with a lower risk of leakage in totally minimally invasive Ivor-Lewis esophagectomy (TMIIL) is ongoing. In the present study, we compared the outcomes of end-to-side (with circular stapler [CS]) and side-to-side (with linear stapler [LS]) techniques for intrathoracic anastomosis during TMIIL performed in 2 European high-volume centers for upper gastrointestinal surgery. A propensity score method was used to compare the CS and LS groups.
METHODS: We retrospectively evaluated patients with lower esophageal cancer or Siewert type 1 or 2 esophagogastric junction carcinoma who underwent a planned TMIIL esophagectomy, performed from January 2017 to September 2020. The anastomosis was created by a semi-mechanical technique using a LS in one center and by a mechanical technique using a CS in the other center. General features, operative techniques, pathology data, and short-term outcomes were analyzed. Statistical evaluations were performed on the whole cohort, stratifying the analyses by risk strata factors identified with the propensity scores, and on a subgroup of patients matched by propensity score. The primary endpoint of the study was the rate of anastomotic leakage in the two groups. Secondary endpoints included rates of anastomotic stricture and overall postoperative complications.
RESULTS: Considering the whole population, 256 patients were included; of those, 220 received the anastomosis with a circular stapler (CS group), and 36 received the anastomosis with a linear stapler (LS group). No significant differences by group in terms of sex, age, American Society of Anesthesiologists physical status classification, and type of neoplasm were showed. The rate of anastomotic leakage did not differ in the two groups (9.6\% CS vs. 5.6\% LS, p = 0.438), as well as the rate of anastomotic stricture in the 3-month follow-up (0.9\% CS vs. 2.8\% LS, p = 0.367). The rate of chyle leakage and of pulmonary, cardiac, and infective complications was not significantly different in the groups. After propensity score matching, 72 patients were included in the analysis. The 2 obtained propensity score matched groups did not differ for any of the clinical and pathologic variables considered for the analysis, resulting in well-balanced cohorts. The results obtained on the whole population were confirmed in the matched groups.
CONCLUSIONS: The results of our study suggest that both techniques for esophagogastric anastomosis during TMIIL are feasible, safe, and effective, with comparable rates of postoperative anastomotic leakage and stricture.},
	language = {eng},
	number = {7},
	journal = {Langenbeck's Archives of Surgery},
	author = {Fabbi, Manrica and van Berge Henegouwen, Mark I. and Fumagalli Romario, Uberto and Gandini, Sara and Feenstra, Minke and De Pascale, Stefano and Gisbertz, Suzanne S.},
	month = nov,
	year = {2022},
	pmid = {35639136},
	keywords = {Anastomosis, Surgical, Anastomotic Leak, Anastomotic leakage, Anastomotic stricture, Constriction, Pathologic, End-to-side intrathoracic anastomosis, Esophageal Neoplasms, Esophagectomy, Humans, Minimally invasive Ivor–Lewis esophagectomy, Postoperative Complications, Retrospective Studies, Side-to-side intrathoracic anastomosis, Surgical Stapling, Treatment Outcome},
	pages = {2681--2692},
}

@article{raute184060,
	title = {Efficacy and {Tolerability} of 5-{Year} {Adjuvant} {Imatinib} {Treatment} for {Patients} {With} {Resected} {Intermediate}- or {High}-{Risk} {Primary} {Gastrointestinal} {Stromal} {Tumor}},
	volume = {4},
	issn = {2374-2437},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440723/},
	doi = {10.1001/jamaoncol.2018.4060},
	abstract = {This phase 2, multi-institutional clinical trial assesses whether patients with resected primary gastrointestinal stromal tumor receiving 5 years of adjuvant imatinib mesylate therapy have improved recurrence-free survival and overall survival compared with patients receiving a shorter duration of therapy in previous studies.},
	number = {12},
	urldate = {2025-06-10},
	journal = {JAMA Oncology},
	author = {Raut, Chandrajit P. and Espat, N. Joseph and Maki, Robert G. and Araujo, Dejka M. and Trent, Jonathan and Williams, Toni Faith and Purkayastha, D. Das and DeMatteo, Ronald P.},
	month = dec,
	year = {2018},
	pmid = {30383140},
	pmcid = {PMC6440723},
	pages = {e184060},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/2UVNJMUX/Raut et al. - 2018 - Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermedi.pdf:application/pdf},
}

@article{joensuu1265,
	title = {One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial},
	volume = {307},
	issn = {1538-3598},
	shorttitle = {One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor},
	doi = {10.1001/jama.2012.347},
	abstract = {CONTEXT: Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo.
OBJECTIVE: To investigate the role of imatinib administration duration as adjuvant treatment of patients who have a high estimated risk for GIST recurrence after surgery.
DESIGN, SETTING, AND PATIENTS: Patients with KIT-positive GIST removed at surgery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Sweden. The risk of GIST recurrence was estimated using the modified National Institutes of Health Consensus Criteria.
INTERVENTION: Imatinib, 400 mg per day, orally for either 12 months or 36 months, started within 12 weeks of surgery.
MAIN OUTCOME MEASURES: The primary end point was RFS; the secondary end points included overall survival and treatment safety.
RESULTS: Two hundred patients were allocated to each group. The median follow-up time after randomization was 54 months in December 2010. Diagnosis of GIST was confirmed in 382 of 397 patients (96\%) in the intention-to-treat population at a central pathology review. KIT or PDGFRA mutation was detected in 333 of 366 tumors (91\%) available for testing. Patients assigned for 36 months of imatinib had longer RFS compared with those assigned for 12 months (hazard ratio [HR], 0.46; 95\% CI, 0.32-0.65; P {\textless} .001; 5-year RFS, 65.6\% vs 47.9\%, respectively) and longer overall survival (HR, 0.45; 95\% CI, 0.22-0.89; P = .02; 5-year survival, 92.0\% vs 81.7\%). Imatinib was generally well tolerated, but 12.6\% and 25.8\% of patients assigned to the 12- and 36-month groups, respectively, discontinued imatinib for a reason other than GIST recurrence.
CONCLUSION: Compared with 12 months of adjuvant imatinib, 36 months of imatinib improved RFS and overall survival of GIST patients with a high risk of GIST recurrence.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116935.},
	language = {eng},
	number = {12},
	journal = {JAMA},
	author = {Joensuu, Heikki and Eriksson, Mikael and Sundby Hall, Kirsten and Hartmann, Jörg T. and Pink, Daniel and Schütte, Jochen and Ramadori, Giuliano and Hohenberger, Peter and Duyster, Justus and Al-Batran, Salah-Eddin and Schlemmer, Marcus and Bauer, Sebastian and Wardelmann, Eva and Sarlomo-Rikala, Maarit and Nilsson, Bengt and Sihto, Harri and Monge, Odd R. and Bono, Petri and Kallio, Raija and Vehtari, Aki and Leinonen, Mika and Alvegård, Thor and Reichardt, Peter},
	month = mar,
	year = {2012},
	pmid = {22453568},
	keywords = {Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Chemotherapy, Adjuvant, Drug Administration Schedule, Female, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors, Humans, Imatinib Mesylate, Male, Middle Aged, Neoplasm Recurrence, Local, Piperazines, Proto-Oncogene Proteins c-kit, Pyrimidines, Receptor, Platelet-Derived Growth Factor alpha, Survival Analysis, Treatment Outcome, Young Adult},
	pages = {1265--1272},
}

@article{blay1157,
	title = {A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized {GIST} at high risk of relapse},
	volume = {35},
	issn = {1569-8041},
	doi = {10.1016/j.annonc.2024.08.2343},
	abstract = {BACKGROUND: The administration of adjuvant imatinib during 3 years is indicated after resection of primary localized GIST at high risk of recurrence, but many patients relapse afterwards.
METHODS: IMADGIST (NCT02260505) was a multicenter, open-label, randomized phase III study evaluating the maintenance of imatinib for 3 more years (6-year arm) compared with interruption (3-year arm) from the day of randomization, conducted in the French Sarcoma Group. The primary endpoint was intent-to-treat disease-free survival. Secondary endpoints included overall survival, time to imatinib resistance, response after imatinib reintroduction at relapse, and safety.
RESULTS: From 24 December 2014 to 4 April 2023, 136 patients aged ≥18 years, Eastern Cooperative Oncology Group performance status ≤2, with a localized gastrointestinal stromal tumor with an R0 or R1 surgery, and a risk of tumor recurrence ≥35\% according to National Comprehensive Cancer Network (NCCN) risk classification were randomized in 14 centers. Sixty-five patients were randomized to the 3-year arm versus 71 to the 6-year arm. There were 68 males and females. Primary sites were gastric and small bowel in 60 (44\%) and 64 (47\%) patients, respectively. Respectively, 52 (38\%) and 71 (52\%) patients had a risk of relapse of 35\%-70\% and {\textgreater}70\%. With a median follow-up of 55 months (interquartile range 46-59 months) after randomization, disease-free survival was significantly superior in the 6-year arm [hazard ratio: 0.40 (0.20-0.69), P = 0.0008]. Time to imatinib resistance, survival, adverse events, and quality of life were not different in the two arms.
CONCLUSIONS: Three additional years of adjuvant imatinib reduces the risk of relapse in patients who have received 3 years of adjuvant imatinib with an acceptable tolerance.},
	language = {eng},
	number = {12},
	journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
	author = {Blay, J.-Y. and Schiffler, C. and Bouché, O. and Brahmi, M. and Duffaud, F. and Toulmonde, M. and Landi, B. and Lahlou, W. and Pannier, D. and Bompas, E. and Bertucci, F. and Chaigneau, L. and Collard, O. and Pracht, M. and Henon, C. and Ray-Coquard, I. and Armoun, K. and Salas, S. and Spalato-Ceruso, M. and Adenis, A. and Verret, B. and Penel, N. and Moreau-Bachelard, C. and Italiano, A. and Dufresne, A. and Metzger, S. and Chabaud, S. and Perol, D. and Le Cesne, A.},
	month = dec,
	year = {2024},
	pmid = {39241959},
	keywords = {adjuvant therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Gastrointestinal Neoplasms, gastrointestinal stromal tumors, Gastrointestinal Stromal Tumors, Humans, imatinib mesylate, Imatinib Mesylate, Male, Middle Aged, Neoplasm Recurrence, Local, randomized clinical trial},
	pages = {1157--1168},
}

@article{gd,
	title = {{NCCN} {Task} {Force} report: update on the management of patients with gastrointestinal stromal tumors},
	volume = {8 Suppl 2},
	issn = {1540-1405},
	shorttitle = {{NCCN} {Task} {Force} report},
	url = {https://pubmed.ncbi.nlm.nih.gov/20457867/},
	doi = {10.6004/jnccn.2010.0116},
	abstract = {The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecu …},
	language = {en},
	number = {2},
	urldate = {2025-07-26},
	journal = {Journal of the National Comprehensive Cancer Network : JNCCN},
	author = {Demetri, George and von Mehren, Margaret and Antonescu, Christina and Rp, DeMatteo and Kn, Ganjoo and Rg, Maki and Pw, Pisters and Cp, Raut and Rf, Riedel and S, Schuetze and Hm, Sundar and Jc, Trent and Jd, Wayne},
	month = apr,
	year = {2010},
	pmid = {20457867},
	note = {Publisher: J Natl Compr Canc Netw},
	pages = {S1--S41},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/DU9NDGMS/Gd et al. - 2010 - NCCN Task Force report update on the management of patients with gastrointestinal stromal tumors.pdf:application/pdf;Snapshot:/Users/jcsal/Zotero/storage/SDHZZQ4D/20457867.html:text/html},
}

@article{weber3058,
	title = {Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging},
	volume = {19},
	issn = {0732-183X},
	doi = {10.1200/JCO.2001.19.12.3058},
	abstract = {PURPOSE: Preoperative chemotherapy in patients with gastroesophageal cancer is hampered by the lack of reliable predictors of tumor response. This study evaluates whether positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may predict response early in the course of therapy.
PATIENTS AND METHODS: Forty consecutive patients with locally advanced adenocarcinomas of the esophagogastric junction were studied by FDG-PET at baseline and 14 days after initiation of cisplatin-based polychemotherapy. Clinical response (reduction of tumor length and wall thickness by {\textgreater} 50\%) was evaluated after 3 months of therapy using endoscopy and standard imaging techniques. Patients with potentially resectable tumors underwent surgery, and tumor regression was assessed histopathologically.
RESULTS: The reduction of tumor FDG uptake (mean +/- 1 SD) after 14 days of therapy was significantly different between responding (-54\% +/- 17\%) and nonresponding tumors (-15\% +/- 21\%). Optimal differentiation was achieved by a cutoff value of 35\% reduction of initial FDG uptake. Applying this cutoff value as a criterion for a metabolic response predicted clinical response with a sensitivity and specificity of 93\% (14 of 15 patients) and 95\% (21 of 22), respectively. Histopathologically complete or subtotal tumor regression was achieved in 53\% (eight of 15) of the patients with a metabolic response but only in 5\% (one of 22) of the patients without a metabolic response. Patients without a metabolic response were also characterized by significantly shorter time to progression/recurrence (P =.01) and shorter overall survival (P =.04).
CONCLUSION: PET imaging may differentiate responding and nonresponding tumors early in the course of therapy. By avoiding ineffective and potentially harmful treatment, this may markedly facilitate the use of preoperative therapy, especially in patients with potentially resectable tumors.},
	language = {eng},
	number = {12},
	journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	author = {Weber, W. A. and Ott, K. and Becker, K. and Dittler, H. J. and Helmberger, H. and Avril, N. E. and Meisetschläger, G. and Busch, R. and Siewert, J. R. and Schwaiger, M. and Fink, U.},
	month = jun,
	year = {2001},
	pmid = {11408502},
	keywords = {Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Disease-Free Survival, Drug Monitoring, Esophageal Neoplasms, Esophagogastric Junction, Female, Fluorodeoxyglucose F18, Humans, Leucovorin, Male, Middle Aged, Patient Selection, Preoperative Care, Prognosis, Prospective Studies, Radiopharmaceuticals, Sensitivity and Specificity, Statistics, Nonparametric, Survival Rate, Tomography, Emission-Computed},
	pages = {3058--3065},
}

@article{schneider902,
	title = {Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer},
	volume = {248},
	issn = {1528-1140},
	doi = {10.1097/SLA.0b013e31818f3afb},
	abstract = {OBJECTIVE: To prospectively assess the sensitivity (sens), specificity (spec), positive predictive value (ppv), negative predictive value (npv), and accuracy (acc) for clinical response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound (EUS) to determine histomorphologic regression UICC T-category downstaging after neoadjuvant chemoradiation for esophageal cancer.
BACKGROUND: Histomorphologic regression is meanwhile established as objective parameter for response and prognosis after neoadjuvant chemoradiation for esophageal cancer.
PATIENTS AND METHODS: Within a prospective observation trial, 80 patients with localized esophageal cancers (cT2-4,Nx,M0) received standardized neoadjuvant chemoradiation (cisplatin, 5-fluorouracil, 36 Gy) and were resected by transthoracic en bloc esophagectomy and two-field lymphadenectomy. Tumor regression was based on the percentage of vital residual tumor cells and classified in 4 categories as reported previously. Evaluation by endoscopy and EUS was performed based on WHO/UICC criteria before starting chemoradiation and before resection and rebiopsies were taken at the time of re-endoscopy.
RESULTS: Histomorphologic response was of significant (log rank) prognostic importance (P {\textless} 0.001), whereas clinical response evaluation by endoscopy (P = 0.1), rebiopsy (P = 0.34), and EUS (P = 0.35) was not. The results of the 3 diagnostic modalities to assess histomorphologic regression by endoscopy and rebiopsy UICC ypT-category downstaging for EUS are summarized: Endoscopy: sens 60\%, spec 34\%, ppv 49\%, npv 44\%, acc 47\%. Rebiopsy: sens 36\%, spec 100\%, ppv 100\%, npv 24\%, acc 47\%. EUS: sens 7\%, spec 79\%, ppv 18\%, npv 57\%, acc 50\%.
CONCLUSIONS: Histomorphologic regression is an objective response parameter of significant prognostic importance. The diagnostic accuracy of endoscopy, rebiopsy, and EUS is inadequate for objective response evaluation after neoadjuvant chemoradiation and can be omitted for this purpose in the clinical practice.},
	language = {eng},
	number = {6},
	journal = {Annals of Surgery},
	author = {Schneider, Paul M. and Metzger, Ralf and Schaefer, Hartmut and Baumgarten, Frank and Vallbohmer, Daniel and Brabender, Jan and Wolfgarten, Eva and Bollschweiler, Elfriede and Baldus, Stephan E. and Dienes, Hans P. and Hoelscher, Arnulf H.},
	month = dec,
	year = {2008},
	pmid = {19092334},
	keywords = {Adult, Aged, Biopsy, Carcinoma, Squamous Cell, Chemotherapy, Adjuvant, Endosonography, Esophageal Neoplasms, Esophagectomy, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Prognosis, Radiotherapy Dosage, Radiotherapy, Adjuvant, Risk Assessment, Sensitivity and Specificity, Young Adult},
	pages = {902--908},
}

@article{levine472,
	title = {Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography ({18F}-{FDG}-{PET}) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer},
	volume = {243},
	issn = {0003-4932},
	doi = {10.1097/01.sla.0000208430.07050.61},
	abstract = {OBJECTIVE: To evaluate the utility of F-FDG-PET in predicting response to concomitant chemoradiation in locally-advanced esophageal cancer.
SUMMARY BACKGROUND DATA: Approximately 25\% of esophageal cancer patients experience a pathologic complete response (pCR) to preoperative chemoradiation therapy. Computed tomography, endoscopy, and endoscopic ultrasound are unable to identify patients experiencing a pCR. Growing evidence supports the use of F-FDG-PET in the staging of esophageal cancer in its ability to detect occult metastatic and lymph nodal disease. The identification of patients with a pCR to chemoradiation could potentially spare those patients the morbidity associated with a resection.
METHODS: Eligibility criteria included T3-T4N0M0 or T1-T4N1M0 esophageal cancer. Patients underwent an initial F-FDG-PET before treatment and then repeated 4 to 6 weeks after chemoradiation, prior to the esophagectomy. Chemoradiation consisted of: cisplatinum, 5-fluorouracil, and radiation to a median dose of 50.4 Gy. Pathologic response was determined from a systematic review of the esophagectomy specimens.
RESULTS: Sixty-four patients have completed therapy to date. Response was as follows: pCR 27\%, pathologic residual microscopic (pCRmicro) 14.5\%, partial response 19\%, and stable or progressive disease 39.5\%. A pretreatment standardized uptake value (SUVmax1hour) {\textgreater} or = 15 was associated with an observed 77.8\% significant response (pCR + pCRmicro) compared with 24.2\% for patients with a pretreatment SUVmax1hour {\textless} 15 (P = 0.005). Significant response was observed in 71.4\% of patients with a decrease in SUVmax1hour {\textgreater} or = 10 compared with 33.3\% when the SUVmax1hour decreased {\textless}10 (P = 0.004).
CONCLUSIONS: Pretreatment and posttreatment F-FDG-PET can be useful for predicting significant response to chemoradiation in esophageal cancer. These data should be considered in evaluation of patients for esophagectomy after chemoradiation.},
	language = {eng},
	number = {4},
	journal = {Annals of Surgery},
	author = {Levine, Edward A. and Farmer, Michael R. and Clark, Paige and Mishra, Girish and Ho, Coty and Geisinger, Kim R. and Melin, Susan A. and Lovato, James and Oaks, Tim and Blackstock, A. William},
	month = apr,
	year = {2006},
	pmid = {16552197},
	pmcid = {PMC1448953},
	keywords = {Adenocarcinoma, Adult, Aged, 80 and over, Carcinoma, Squamous Cell, Combined Modality Therapy, Esophageal Neoplasms, Esophagectomy, Female, Fluorodeoxyglucose F18, Humans, Male, Neoadjuvant Therapy, Positron-Emission Tomography, Predictive Value of Tests, Prospective Studies, Radiopharmaceuticals, Radiotherapy Dosage},
	pages = {472--478},
}

@article{kukar555,
	title = {Role of {Repeat} {18F}-{Fluorodeoxyglucose} {Positron} {Emission} {Tomography} {Examination} in {Predicting} {Pathologic} {Response} {Following} {Neoadjuvant} {Chemoradiotherapy} for {Esophageal} {Adenocarcinoma}},
	volume = {150},
	issn = {2168-6262},
	doi = {10.1001/jamasurg.2014.3867},
	abstract = {IMPORTANCE: Predicting complete pathologic response (CPR) preoperatively can significantly affect surgical decision making. There are conflicting data regarding positron emission tomography computed tomography (PET CT) characteristics and the ability of PET CT to predict pathologic response following neoadjuvant chemoradiotherapy in esophageal adenocarcinoma because most existing studies that include squamous histology have limited numbers and use nonstandardized PET CT imaging.
OBJECTIVE: To determine if PET CT characteristics are associated with CPR in patients undergoing trimodality treatment for esophageal adenocarcinoma.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective medical record review was conducted at a large tertiary cancer center from a prospectively maintained database from January 1, 2005, to December 31, 2012. Inclusion criteria were patients undergoing esophagectomy for locally advanced esophageal adenocarcinoma post-neoadjuvant chemoradiotherapy with 2 standardized PET CT studies done at our institution (pre-neoadjuvant chemoradiotherapy and post-neoadjuvant chemoradiotherapy) for review. Data collected included clinical, pathologic, imaging, and treatment characteristics.
MAIN OUTCOME AND MEASURE: The primary study outcome was the association of PET CT characteristics with histologic confirmed pathologic response.
RESULTS: Of the total participants, 77 patients met the inclusion criteria. Twenty-two patients (28.6\%) had CPR vs 55 patients (71.4\%) who had incomplete pathologic response. The 2 groups were similar in age, sex, race/ethnicity, comorbid conditions, Eastern Cooperative Oncology Group status, tumor grade, chemotherapy, and radiation regimen and days between the 2 PET CTs. The mean prestandardized uptake variable (SUV; 14.5 vs 11.2; P = .05), δ SUV (10.3 vs 5.4; P = .02), and relative δ SUV (0.6 vs 0.4; P = .02) were significantly higher in those with CPR vs incomplete pathologic response. Using the Youden Index, a δ SUV value less than 45\% was predictive of residual disease with a positive predictive value of 91.7\% (95\% CI, 73-99; P {\textless} .05).
CONCLUSIONS AND RELEVANCE: To our knowledge, this is the largest study examining the role of PET CT characteristics in esophageal adenocarcinoma for patients undergoing neoadjuvant chemoradiotherapy that demonstrates that δ SUV of less than 45\% is associated with patients with residual disease but not CPR. Based on the findings from our study, the current recommendation is still surgical resection regardless of the posttherapy PET SUV in the primary tumor. However, our study highlights the ability to detect patients with residual disease and the need to critically evaluate these patients for consideration of additional therapies.},
	language = {eng},
	number = {6},
	journal = {JAMA surgery},
	author = {Kukar, Moshim and Alnaji, Raed M. and Jabi, Feraas and Platz, Timothy A. and Attwood, Kristopher and Nava, Hector and Ben-David, Kfir and Mattson, David and Salerno, Kilian and Malhotra, Usha and Kanehira, Kazunori and Gannon, James and Hochwald, Steven N.},
	month = jun,
	year = {2015},
	pmid = {25902198},
	keywords = {Adenocarcinoma, Aged, Aged, 80 and over, Chemoradiotherapy, Esophageal Neoplasms, Female, Fluorodeoxyglucose F18, Humans, Male, Middle Aged, Neoadjuvant Therapy, Positron-Emission Tomography, Radiopharmaceuticals, Tomography, X-Ray Computed},
	pages = {555--562},
}

@article{maron7098,
	title = {Circulating {Tumor} {DNA} {Sequencing} {Analysis} of {Gastroesophageal} {Adenocarcinoma}},
	volume = {25},
	issn = {1557-3265},
	doi = {10.1158/1078-0432.CCR-19-1704},
	abstract = {PURPOSE: Gastroesophageal adenocarcinoma (GEA) has a poor prognosis and few therapeutic options. Utilizing a 73-gene plasma-based next-generation sequencing (NGS) cell-free circulating tumor DNA (ctDNA-NGS) test, we sought to evaluate the role of ctDNA-NGS in guiding clinical decision-making in GEA.
EXPERIMENTAL DESIGN: We evaluated a large cohort (n = 2,140 tests; 1,630 patients) of ctDNA-NGS results (including 369 clinically annotated patients). Patients were assessed for genomic alteration (GA) distribution and correlation with clinicopathologic characteristics and outcomes.
RESULTS: Treatment history, tumor site, and disease burden dictated tumor-DNA shedding and consequent ctDNA-NGS maximum somatic variant allele frequency. Patients with locally advanced disease having detectable ctDNA postoperatively experienced inferior median disease-free survival (P = 0.03). The genomic landscape was similar but not identical to tissue-NGS, reflecting temporospatial molecular heterogeneity, with some targetable GAs identified at higher frequency via ctDNA-NGS compared with previous primary tumor-NGS cohorts. Patients with known microsatellite instability-high (MSI-High) tumors were robustly detected with ctDNA-NGS. Predictive biomarker assessment was optimized by incorporating tissue-NGS and ctDNA-NGS assessment in a complementary manner. HER2 inhibition demonstrated a profound survival benefit in HER2-amplified patients by ctDNA-NGS and/or tissue-NGS (median overall survival, 26.3 vs. 7.4 months; P = 0.002), as did EGFR inhibition in EGFR-amplified patients (median overall survival, 21.1 vs. 14.4 months; P = 0.01).
CONCLUSIONS: ctDNA-NGS characterized GEA molecular heterogeneity and rendered important prognostic and predictive information, complementary to tissue-NGS.See related commentary by Frankell and Smyth, p. 6893.},
	language = {eng},
	number = {23},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Maron, Steven B. and Chase, Leah M. and Lomnicki, Samantha and Kochanny, Sara and Moore, Kelly L. and Joshi, Smita S. and Landron, Stacie and Johnson, Julie and Kiedrowski, Lesli A. and Nagy, Rebecca J. and Lanman, Richard B. and Kim, Seung Tae and Lee, Jeeyun and Catenacci, Daniel V. T.},
	month = dec,
	year = {2019},
	pmid = {31427281},
	pmcid = {PMC6891164},
	keywords = {Adenocarcinoma, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Circulating Tumor DNA, Cohort Studies, Combined Modality Therapy, Esophageal Neoplasms, Esophagogastric Junction, Female, Genome, Human, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Prognosis, Stomach Neoplasms, Survival Rate, Young Adult},
	pages = {7098--7112},
	file = {Full Text:/Users/jcsal/Zotero/storage/KILCIKJZ/Maron et al. - 2019 - Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.pdf:application/pdf},
}

@article{wang436,
	title = {Evaluation of a plasma cell-free {DNA} methylation test for colorectal cancer diagnosis: a multicenter clinical study},
	volume = {22},
	issn = {1741-7015},
	shorttitle = {Evaluation of a plasma cell-free {DNA} methylation test for colorectal cancer diagnosis},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462859/},
	doi = {10.1186/s12916-024-03662-y},
	abstract = {Background
A blood-based diagnostic test is a promising strategy for colorectal cancer (CRC). The MethyDT test (IColohunter), which detects methylation levels of NTMT1 and MAP3K14-AS1, exhibited potential in discriminating CRC, but its clinical performance needs to be validated in large-scale populations.

Methods
A multicenter, double-blinded, cross-sectional study that enrolled 1194 participants was performed. Plasma samples were collected to detect methylation levels of NTMT1 and MAP3K14-AS1 using quantitative methylation-specific PCR with the MethyDT test, and the accuracy was further evaluated by Sanger sequencing.

Results
The sensitivities of the MethyDT test for detecting CRC, early stages of CRC (I and II), advanced adenoma (AA), and high-grade intraepithelial neoplasia (HGIN) were 91.2\% (95\% confidence interval [CI], 88.4–94.0), 87.4\% (95\% CI, 82.5–92.2), 43.5\% (95\% CI, 35.7–51.4), and 72.7\% (95\% CI, 57.5–87.9), respectively. The specificities for participants with non-AA, interfering diseases (ID), and no evidence of disease (NED) were 85.0\% (95\% CI, 78.8–91.3), 93.7\% (95\% CI, 91.4–95.9) and 97.3\% (95\% CI, 90.5–99.7), respectively, and its overall specificity for all-controls was 92.4\% (95\% CI, 90.3–94.4). The consistency of the MethyDT test with pathology for CRC was high with a kappa value of 0.830 (95\% CI, 0.795–0.865). Additionally, the MethyDT test was comparable to Sanger sequencing for detecting methylation with kappa values {\textgreater} 0.97.

Conclusions
The MethyDT test demonstrates excellent sensitivity and specificity for CRC and high consistency with Sanger sequencing for methylation, suggesting it may serve as a potential noninvasive diagnostic tool for the detection of CRC.

Trial registration
This clinical trial has been registered in ClinicalTrials.gov (NCT05508503).

Supplementary Information
The online version contains supplementary material available at 10.1186/s12916-024-03662-y.},
	urldate = {2025-08-01},
	journal = {BMC Medicine},
	author = {Wang, Zhijie and He, Zixuan and Lin, Rong and Feng, Zhijie and Li, Xiuling and Sui, Xiangyu and Gu, Lun and Xia, Tian and Zhou, Dihan and Zhao, Bali and Li, Yanqing and Li, Zhaoshen and Bai, Yu},
	month = oct,
	year = {2024},
	pmid = {39379942},
	pmcid = {PMC11462859},
	pages = {436},
	file = {Full Text PDF:/Users/jcsal/Zotero/storage/HXTG4QC5/Wang et al. - 2024 - Evaluation of a plasma cell-free DNA methylation test for colorectal cancer diagnosis a multicenter.pdf:application/pdf},
}

@article{petere2400582,
	title = {Assessment of {Circulating} {Tumor} {DNA} {Burden} in {Patients} {With} {Metastatic} {Gastric} {Cancer} {Using} {Real}-{World} {Data}},
	volume = {9},
	issn = {2473-4284},
	doi = {10.1200/PO-24-00582},
	abstract = {PURPOSE: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker with prognostic and potentially predictive value for several tumor types, including gastric cancer (GC). This study uses real-world data (RWD) to investigate the association of pretreatment ctDNA burden with clinical outcomes among patients with first-line (1L)-treated metastatic gastric cancer (mGC) in the United States.
METHODS: Patients were identified from the GuardantINFORM real-world clinical-genomic database. Adult patients with mGC who underwent testing with the Guardant360 assay from June 2014 to March 2022 and within 60 days before 1L treatment were included. The median of the maximum variant allele fraction (MVAF) was used to classify patients into high or low ctDNA burden groups, with undetectable ctDNA burden included in the low group. Associations with real-world outcome variables derived from claims, including time to treatment discontinuation (rwTTD), time to next treatment (rwTTNT), and overall survival (rwOS), were assessed using log-rank tests and multivariable Cox models.
RESULTS: A cohort of 824 patients with mGC was identified. Median MVAF was 2.9\%, with 91\% having detectable ctDNA. Among patients receiving chemo-based treatment (n = 537), rwTTDs were similar in low and high ctDNA burden groups, while those with high ctDNA burden showed significantly shorter rwTTNT and rwOS (median rwTTNT = 4.8 months v 7.4 months, P {\textless} .001; median rwOS = 13.2 months v 19.1 months, P {\textless} .001). Multivariable Cox analyses showed similar results. ctDNA burden in immunotherapy (n = 100) and trastuzumab-based (n = 99) treatment groups did not have significant associations with outcomes.
CONCLUSION: We used RWD to demonstrate that high pretreatment ctDNA burden was associated with worse clinical outcomes in a mGC population receiving 1L chemotherapy-based treatments. Our analysis suggests ctDNA burden could be used as a prognostic biomarker for mGC.},
	language = {eng},
	journal = {JCO precision oncology},
	author = {Peter, Senaka A. and Cristescu, Razvan and Peña, Carol and Watkins, Angela and Espenschied, Carin R. and Zhang, Nicole and Liao, Jiemin},
	month = may,
	year = {2025},
	pmid = {40324115},
	keywords = {Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Circulating Tumor DNA, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Stomach Neoplasms},
	pages = {e2400582},
}

@article{odegaard3539,
	title = {Validation of a {Plasma}-{Based} {Comprehensive} {Cancer} {Genotyping} {Assay} {Utilizing} {Orthogonal} {Tissue}- and {Plasma}-{Based} {Methodologies}},
	volume = {24},
	issn = {1557-3265},
	doi = {10.1158/1078-0432.CCR-17-3831},
	abstract = {Purpose: To analytically and clinically validate a circulating cell-free tumor DNA sequencing test for comprehensive tumor genotyping and demonstrate its clinical feasibility.Experimental Design: Analytic validation was conducted according to established principles and guidelines. Blood-to-blood clinical validation comprised blinded external comparison with clinical droplet digital PCR across 222 consecutive biomarker-positive clinical samples. Blood-to-tissue clinical validation comprised comparison of digital sequencing calls to those documented in the medical record of 543 consecutive lung cancer patients. Clinical experience was reported from 10,593 consecutive clinical samples.Results: Digital sequencing technology enabled variant detection down to 0.02\% to 0.04\% allelic fraction/2.12 copies with ≤0.3\%/2.24-2.76 copies 95\% limits of detection while maintaining high specificity [prevalence-adjusted positive predictive values (PPV) {\textgreater}98\%]. Clinical validation using orthogonal plasma- and tissue-based clinical genotyping across {\textgreater}750 patients demonstrated high accuracy and specificity [positive percent agreement (PPAs) and negative percent agreement (NPAs) {\textgreater}99\% and PPVs 92\%-100\%]. Clinical use in 10,593 advanced adult solid tumor patients demonstrated high feasibility ({\textgreater}99.6\% technical success rate) and clinical sensitivity (85.9\%), with high potential actionability (16.7\% with FDA-approved on-label treatment options; 72.0\% with treatment or trial recommendations), particularly in non-small cell lung cancer, where 34.5\% of patient samples comprised a directly targetable standard-of-care biomarker.Conclusions: High concordance with orthogonal clinical plasma- and tissue-based genotyping methods supports the clinical accuracy of digital sequencing across all four types of targetable genomic alterations. Digital sequencing's clinical applicability is further supported by high rates of technical success and biomarker target discovery. Clin Cancer Res; 24(15); 3539-49. ©2018 AACR.},
	language = {eng},
	number = {15},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Odegaard, Justin I. and Vincent, John J. and Mortimer, Stefanie and Vowles, James V. and Ulrich, Bryan C. and Banks, Kimberly C. and Fairclough, Stephen R. and Zill, Oliver A. and Sikora, Marcin and Mokhtari, Reza and Abdueva, Diana and Nagy, Rebecca J. and Lee, Christine E. and Kiedrowski, Lesli A. and Paweletz, Cloud P. and Eltoukhy, Helmy and Lanman, Richard B. and Chudova, Darya I. and Talasaz, AmirAli},
	month = aug,
	year = {2018},
	pmid = {29691297},
	keywords = {Humans, Female, Male, Neoplasms, Biomarkers, Tumor, Mutation, Circulating Tumor DNA, High-Throughput Nucleotide Sequencing, Cell-Free Nucleic Acids, Genomics, Genotype, Genotyping Techniques, G360},
	pages = {3539--3549},
	file = {PDF:/Users/jcsal/Zotero/storage/NEHIDYWA/Odegaard et al. - 2018 - Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and.pdf:application/pdf},
}

@article{azad494,
	title = {Circulating {Tumor} {DNA} {Analysis} for {Detection} of {Minimal} {Residual} {Disease} {After} {Chemoradiotherapy} for {Localized} {Esophageal} {Cancer}},
	volume = {158},
	issn = {1528-0012},
	doi = {10.1053/j.gastro.2019.10.039},
	abstract = {BACKGROUND \& AIMS: Biomarkers are needed to risk stratify after chemoradiotherapy for localized esophageal cancer. These could improve identification of patients at risk for cancer progression and selection of additional therapy.
METHODS: We performed deep sequencing (CAncer Personalized Profiling by deep Sequencing, [CAPP-Seq]) analyses of plasma cell-free DNA collected from 45 patients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes and fixed esophageal tumor biopsy samples collected during esophagogastroduodenoscopy. Patients were treated from May 2010 through October 2015; 23 patients subsequently underwent esophagectomy, and 22 did not undergo surgery. We also sequenced DNA from blood samples from 40 healthy control individuals. We analyzed 802 regions of 607 genes for single-nucleotide variants previously associated with esophageal adenocarcinoma or squamous cell carcinoma. Patients underwent imaging analyses 6-8 weeks after chemoradiotherapy and were followed for 5 years. Our primary aim was to determine whether detection of circulating tumor DNA (ctDNA) after chemoradiotherapy is associated with risk of tumor progression (growth of local, regional, or distant tumors, detected by imaging or biopsy).
RESULTS: The median proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07\%, indicating that ultrasensitive assays are needed for quantification and analysis of ctDNA from localized esophageal tumors. Detection of ctDNA after chemoradiotherapy was associated with tumor progression (hazard ratio, 18.7; P {\textless} .0001), formation of distant metastases (hazard ratio, 32.1; P {\textless} .0001), and shorter disease-specific survival times (hazard ratio, 23.1; P {\textless} .0001). A higher proportion of patients with tumor progression had new mutations detected in plasma samples collected after chemoradiotherapy than patients without progression (P = .03). Detection of ctDNA after chemoradiotherapy preceded radiographic evidence of tumor progression by an average of 2.8 months. Among patients who received chemoradiotherapy without surgery, combined ctDNA and metabolic imaging analysis predicted progression in 100\% of patients with tumor progression, compared with 71\% for only ctDNA detection and 57\% for only metabolic imaging analysis (P {\textless} .001 for comparison of either technique to combined analysis).
CONCLUSIONS: In an analysis of cell-free DNA in blood samples from patients who underwent chemoradiotherapy for esophageal cancer, detection of ctDNA was associated with tumor progression, metastasis, and disease-specific survival. Analysis of ctDNA might be used to identify patients at highest risk for tumor progression.},
	language = {eng},
	number = {3},
	journal = {Gastroenterology},
	author = {Azad, Tej D. and Chaudhuri, Aadel A. and Fang, Penny and Qiao, Yawei and Esfahani, Mohammad S. and Chabon, Jacob J. and Hamilton, Emily G. and Yang, Yi D. and Lovejoy, Alex and Newman, Aaron M. and Kurtz, David M. and Jin, Michael and Schroers-Martin, Joseph and Stehr, Henning and Liu, Chih Long and Hui, Angela Bik-Yu and Patel, Viren and Maru, Dipen and Lin, Steven H. and Alizadeh, Ash A. and Diehn, Maximilian},
	month = feb,
	year = {2020},
	pmid = {31711920},
	pmcid = {PMC7010551},
	keywords = {Adenocarcinoma, Aged, Biomarkers, Tumor, Biopsy, Carcinoma, Squamous Cell, Chemoradiotherapy, Circulating Tumor DNA, Disease Progression, Esophageal Neoplasms, Esophagus, Feasibility Studies, Female, Genetics, Healthy Volunteers, High-Throughput Nucleotide Sequencing, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm, Residual, Polymorphism, Progression-Free Survival, Prospective Studies, Retrospective Studies, Risk Assessment, SNP, Tomography, X-Ray Computed},
	pages = {494--505.e6},
	file = {Accepted Version:/Users/jcsal/Zotero/storage/LRGVG576/Azad et al. - 2020 - Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for.pdf:application/pdf},
}

@article{chin311,
	title = {Detection of {Solid} {Tumor} {Molecular} {Residual} {Disease} ({MRD}) {Using} {Circulating} {Tumor} {DNA} ({ctDNA})},
	volume = {23},
	issn = {1179-2000},
	doi = {10.1007/s40291-019-00390-5},
	abstract = {Circulating tumor DNA (ctDNA) is a component of cell-free DNA that is shed by malignant tumors into the bloodstream and other bodily fluids. Levels of ctDNA are typically low, particularly in patients with localized disease, requiring highly sophisticated methods for detection and quantification. Multiple liquid biopsy methods have been developed for ctDNA analysis in solid tumor malignancies and are now enabling detection and assessment of earlier stages of disease, post-treatment molecular residual disease (MRD), resistance to targeted systemic therapy, and tumor mutational burden. Understanding ctDNA biology, mechanisms of release, and clearance and size characteristics, in conjunction with the application of molecular barcoding and targeted error correction, have increased the sensitivity and specificity of ctDNA detection techniques. Combinatorial approaches including integration of ctDNA data with circulating protein biomarkers may further improve assay sensitivity and broaden the scope of ctDNA applications. Circulating viral DNA may be utilized to monitor disease in some virally induced malignancies. In spite of increasingly accurate methods of ctDNA detection, results need to be interpreted with caution given that somatic mosaicisms such as clonal hematopoiesis of indeterminate potential (CHIP) may give rise to genetic variants in the bloodstream unrelated to solid tumors, and the limited concordance observed between different commercial platforms. Overall, highly precise ctDNA detection and quantification methods have the potential to transform clinical practice via non-invasive monitoring of solid tumor malignancies, residual disease detection at earlier timepoints than standard clinical and/or imaging surveillance, and treatment personalization based on real-time assessment of the tumor genomic landscape.},
	language = {eng},
	number = {3},
	journal = {Molecular Diagnosis \& Therapy},
	author = {Chin, Re-I. and Chen, Kevin and Usmani, Abul and Chua, Chanelle and Harris, Peter K. and Binkley, Michael S. and Azad, Tej D. and Dudley, Jonathan C. and Chaudhuri, Aadel A.},
	month = jun,
	year = {2019},
	pmid = {30941670},
	pmcid = {PMC6561896},
	keywords = {Biomarkers, Tumor, Circulating Tumor DNA, Genomics, High-Throughput Nucleotide Sequencing, Humans, Liquid Biopsy, Molecular Diagnostic Techniques, Neoplasm, Residual, Neoplasms},
	pages = {311--331},
}

@article{janjigian217,
	title = {Perioperative {Durvalumab} in {Gastric} and {Gastroesophageal} {Junction} {Cancer}},
	volume = {393},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2503701},
	abstract = {BACKGROUND: Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain high. Immunotherapy plus chemotherapy may improve outcomes.
METHODS: In a phase 3, multinational, double-blind, randomized trial, we assigned participants with resectable gastric or gastroesophageal junction adenocarcinoma, in a 1:1 ratio, to receive durvalumab at a dose of 1500 mg or placebo every 4 weeks plus FLOT for 4 cycles (2 cycles each of neoadjuvant and adjuvant therapy), followed by durvalumab or placebo every 4 weeks for 10 cycles. The primary end point was event-free survival; secondary end points included overall survival and pathological complete response.
RESULTS: A total of 474 participants were randomly assigned to the durvalumab group, and 474 to the placebo group (median follow-up, 31.5 months; interquartile range, 26.7 to 36.6). Two-year event-free survival (Kaplan-Meier estimate) was 67.4\% among the participants in the durvalumab group and 58.5\% among those in the placebo group (hazard ratio for event or death, 0.71; 95\% confidence interval [CI], 0.58 to 0.86; P{\textless}0.001). Two-year overall survival was 75.7\% in the durvalumab group and 70.4\% in the placebo group (piecewise hazard ratio for death during months 0 to 12, 0.99 [95\% CI, 0.70 to 1.39], and during the period from month 12 onward, 0.67 [95\% CI, 0.50 to 0.90]; P = 0.03 by a stratified log-rank test [exceeding the significance threshold of P{\textless}0.0001]). The percentage of participants with a pathological complete response was 19.2\% in the durvalumab group and 7.2\% in the placebo group (relative risk, 2.69 [95\% CI, 1.86 to 3.90]). Adverse events with a maximum grade of 3 or 4 were reported in 340 participants (71.6\%) in the durvalumab group and in 334 (71.2\%) in the placebo group. The percentage of participants with delayed surgery was 10.1\% and 10.8\%, respectively, and the percentage with delayed initiation of adjuvant treatment was 2.3\% and 4.6\%.
CONCLUSIONS: Perioperative durvalumab plus FLOT led to significantly better event-free survival outcomes than FLOT alone among participants with resectable gastric or gastroesophageal junction adenocarcinoma. (Funded by AstraZeneca; MATTERHORN ClinicalTrials.gov number, NCT04592913.).},
	language = {eng},
	number = {3},
	journal = {The New England Journal of Medicine},
	author = {Janjigian, Yelena Y. and Al-Batran, Salah-Eddin and Wainberg, Zev A. and Muro, Kei and Molena, Daniela and Van Cutsem, Eric and Hyung, Woo Jin and Wyrwicz, Lucjan and Oh, Do-Youn and Omori, Takeshi and Moehler, Markus and Garrido, Marcelo and Oliveira, Sulene C. S. and Liberman, Moishe and Oliden, Victor Castro and Smyth, Elizabeth C. and Stein, Alexander and Bilici, Mehmet and Alvarenga, Maria Lorena and Kozlov, Vadim and Rivera, Fernando and Kawazoe, Akihito and Serrano, Olivier and Heilbron, Eric and Negro, Alejandra and Kurland, John F. and Tabernero, Josep and {MATTERHORN Investigators}},
	month = jul,
	year = {2025},
	pmid = {40454643},
	keywords = {Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Docetaxel, Double-Blind Method, Esophageal Neoplasms, Esophagogastric Junction, Female, Fluorouracil, Humans, Kaplan-Meier Estimate, Leucovorin, Male, Middle Aged, Neoadjuvant Therapy, Oxaliplatin, Perioperative Care, Stomach Neoplasms, Treatment Outcome},
	pages = {217--230},
	file = {PDF:/Users/jcsal/Zotero/storage/2VPDGZDL/Janjigian et al. - 2025 - Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.pdf:application/pdf},
}

@article{kasper1121,
	title = {Current {Management} of {Desmoid} {Tumors}: {A} {Review}},
	volume = {10},
	issn = {2374-2445},
	shorttitle = {Current {Management} of {Desmoid} {Tumors}},
	doi = {10.1001/jamaoncol.2024.1805},
	abstract = {IMPORTANCE: Desmoid tumor (DT) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been made. To update the 2020 global evidence-based consensus guideline on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus meeting in Milan, Italy, on June 30, 2023, under the auspices of the European Reference Network on Rare Adult Solid Cancers and Sarcoma Patient Advocacy Global Network, the Desmoid Foundation Italy, and the Desmoid Tumor Research Foundation. The meeting brought together over 90 adult and pediatric sarcoma experts from different disciplines as well as patients and patient advocates from around the world.
OBSERVATIONS: The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors. Literature searches of MEDLINE and Embase databases were performed for English-language randomized clinical trials (RCTs) of systemic therapies to obtain data to support the consensus recommendations. Of the 18 full-text articles retrieved, only 4 articles met the inclusion criteria. The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery; and the γ-secretase inhibitor nirogacestat, the first representative of the newest class of medical agents and first approved drug for DT. Management of DT is complex and should be carried out exclusively in designated DT referral centers equipped with a multidisciplinary tumor board. Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.
CONCLUSIONS AND RELEVANCE: The therapeutic armamentarium of DT therapy is continually expanding. It is imperative to carefully select the management strategy for each patient with DT to optimize tumor control and enhance quality of life.},
	language = {eng},
	number = {8},
	journal = {JAMA oncology},
	author = {Kasper, Bernd and Baldini, Elizabeth H. and Bonvalot, Sylvie and Callegaro, Dario and Cardona, Kenneth and Colombo, Chiara and Corradini, Nadège and Crago, Aimee M. and Dei Tos, Angelo P. and Dileo, Palma and Elnekave, Eldad and Erinjeri, Joseph P. and Navid, Fariba and Farma, Jeffrey M. and Ferrari, Andrea and Fiore, Marco and Gladdy, Rebecca A. and Gounder, Mrinal and Haas, Rick L. and Husson, Olga and Kurtz, Jean-Emmanuel and Lazar, Alex J. and Orbach, Daniel and Penel, Nicolas and Ratan, Ravi and Raut, Chandrajit P. and Roland, Christina L. and Schut, Ann-Rose W. and Sparber-Sauer, Monika and Strauss, Dirk C. and Van der Graaf, Winette T. A. and Vitellaro, Marco and Weiss, Aaron R. and Gronchi, Alessandro and {Desmoid Tumor Working Group}},
	month = aug,
	year = {2024},
	pmid = {38900421},
	keywords = {Humans, Desmoid Tumors},
	pages = {1121--1128},
}

@article{hardacker3739a,
	title = {Treatment of clinical {T2N0M0} esophageal cancer},
	volume = {21},
	issn = {1534-4681},
	doi = {10.1245/s10434-014-3929-6},
	abstract = {BACKGROUND: Management of clinical T2N0M0 (cT2N0M0) esophageal cancer remains controversial. We reviewed our institutional experience over 21 years (1990-2011) to determine clinical staging accuracy, optimal treatment approaches, and factors predictive of survival in this patient population.
METHODS: Patients with cT2N0M0 esophageal cancer determined by endoscopic ultrasound (EUS) were identified through a prospectively collected database. Demographics, perioperative data, and outcomes were examined. Cox regression model and Kaplan-Meier plots were used for statistical survival analysis.
RESULTS: A total of 731 patients underwent esophagectomy, of whom 68 cT2N0M0 patients (9 \%) were identified. Fifty-seven patients (84 \%) had adenocarcinoma. Thirty-three patients (48.5 \%) were treated with neoadjuvant chemoradiation followed by surgery, and 35 underwent surgical resection alone. All resections except one included a transthoracic approach with two-field lymph node dissection. Thirty-day operative mortality was 2.9 \%. Only 3 patients (8.5 \%) who underwent surgery alone had T2N0M0 disease identified by pathology: the disease of 15 (42.8 \%) was found to be overstaged and 17 (48.5 \%) understaged after surgery. Understaging was more common in poorly differentiated tumors (p = 0.03). Nine patients (27.2 \%) had complete pathologic response after chemoradiotherapy. Absence of lymph node metastases (pN0) was significantly more frequent in the neoadjuvant group (29 of 33 vs. 21 of 35, p = 0.01). Median follow-up was 44.2 months. Overall 5-year survival was 50.8 \%. On multivariate analysis, adenocarcinoma (p = 0.001) and pN0 after resection (p = 0.01) were significant predictors of survival.
CONCLUSIONS: EUS was inaccurate in staging cT2N0M0 esophageal cancer in this study. Poorly differentiated tumors were more frequently understaged. Adenocarcinoma and absence of lymph node metastases (pN0) were independently predictive of long-term survival. pN0 status was significantly more common in patients undergoing neoadjuvant therapy, but long-term survival was not affected by neoadjuvant therapy. A strategy of neoadjuvant therapy followed by resection may be optimal in this group, especially in patients with disease likely to be understaged.},
	language = {eng},
	number = {12},
	journal = {Annals of Surgical Oncology},
	author = {Hardacker, Thomas J. and Ceppa, DuyKhanh and Okereke, Ikenna and Rieger, Karen M. and Jalal, Shadia I. and LeBlanc, Julia K. and DeWitt, John M. and Kesler, Kenneth A. and Birdas, Thomas J.},
	month = nov,
	year = {2014},
	pmid = {25047477},
	keywords = {Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Combined Modality Therapy, Endosonography, Esophageal Neoplasms, Esophagectomy, Female, Follow-Up Studies, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Prognosis, Prospective Studies, Radiotherapy, Survival Rate},
	pages = {3739--3743},
}

@article{hoeppner323a,
	title = {Perioperative {Chemotherapy} or {Preoperative} {Chemoradiotherapy} in {Esophageal} {Cancer}},
	volume = {392},
	issn = {1533-4406},
	doi = {10.1056/NEJMoa2409408},
	abstract = {BACKGROUND: The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative chemoradiotherapy.
METHODS: In this phase 3, multicenter, randomized trial, we assigned in a 1:1 ratio patients with resectable esophageal adenocarcinoma to receive perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery or preoperative chemoradiotherapy (radiotherapy at a dose of 41.4 Gy and carboplatin and paclitaxel) plus surgery. Eligibility criteria included a primary tumor with a clinical stage of cT1 cN+, cT2-4a cN+, or cT2-4a cN0 disease, in which T indicates the size and extent of the tumor (higher numbers indicate a more advanced tumor), and N indicates the presence (N+) or absence (N0) of cancer spread to the lymph nodes, without evidence of metastatic spread. The primary end point was overall survival.
RESULTS: From February 2016 through April 2020, we assigned 221 patients to the FLOT group and 217 patients to the preoperative-chemoradiotherapy group. With a median follow-up of 55 months, overall survival at 3 years was 57.4\% (95\% confidence interval [CI], 50.1 to 64.0) in the FLOT group and 50.7\% (95\% CI, 43.5 to 57.5) in the preoperative-chemoradiotherapy group (hazard ratio for death, 0.70; 95\% CI, 0.53 to 0.92; P = 0.01). Progression-free survival at 3 years was 51.6\% (95\% CI, 44.3 to 58.4) in the FLOT group and 35.0\% (95\% CI, 28.4 to 41.7) in the preoperative-chemoradiotherapy group (hazard ratio for disease progression or death, 0.66; 95\% CI, 0.51 to 0.85). Among the patients who started the assigned treatment, grade 3 or higher adverse events were observed in 120 of 207 patients (58.0\%) in the FLOT group and in 98 of 196 patients (50.0\%) in the preoperative-chemoradiotherapy group. Serious adverse events were observed in 98 of 207 patients (47.3\%) in the FLOT group and in 82 of 196 patients (41.8\%) in the preoperative-chemoradiotherapy group. Mortality at 90 days after surgery was 3.1\% in the FLOT group and 5.6\% in the preoperative-chemoradiotherapy group.
CONCLUSIONS: Perioperative chemotherapy with FLOT led to improved survival among patients with resectable esophageal adenocarcinoma as compared with preoperative chemoradiotherapy. (Funded by the German Research Foundation; ESOPEC ClinicalTrials.gov number, NCT02509286.).},
	language = {eng},
	number = {4},
	journal = {The New England Journal of Medicine},
	author = {Hoeppner, Jens and Brunner, Thomas and Schmoor, Claudia and Bronsert, Peter and Kulemann, Birte and Claus, Rainer and Utzolino, Stefan and Izbicki, Jakob Robert and Gockel, Ines and Gerdes, Berthold and Ghadimi, Michael and Reichert, Benedikt and Lock, Johan F. and Bruns, Christiane and Reitsamer, Ernst and Schmeding, Maximillian and Benedix, Frank and Keck, Tobias and Folprecht, Gunnar and Thuss-Patience, Peter and Neumann, Ulf Peter and Pascher, Andreas and Imhof, Detlef and Daum, Severin and Strieder, Tanja and Krautz, Christian and Zimmermann, Simone and Werner, Jens and Mahlberg, Rolf and Illerhaus, Gerald and Grimminger, Peter and Lordick, Florian},
	month = jan,
	year = {2025},
	pmid = {39842010},
	keywords = {Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Chemoradiotherapy, Chemotherapy, Adjuvant, Docetaxel, Esophageal Neoplasms, Esophagectomy, Female, Fluorouracil, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Leucovorin, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Oxaliplatin, Paclitaxel, Perioperative Care, Radiotherapy Dosage, Treatment Outcome},
	pages = {323--335},
}

@article{fuchs433,
	title = {Intraoperative {Endoscopic} {Botox} {Injection} {During} {Total} {Esophagectomy} {Prevents} the {Need} for {Pyloromyotomy} or {Dilatation}},
	volume = {26},
	issn = {1557-9034},
	doi = {10.1089/lap.2015.0575},
	abstract = {BACKGROUND: Esophagectomy may lead to impairment in gastric emptying unless pyloric drainage is performed. Pyloric drainage may be technically challenging during minimally invasive esophagectomy and can add morbidity. We sought to determine the effectiveness of intraoperative endoscopic injection of botulinum toxin into the pylorus during robotic-assisted esophagectomy as an alternative to surgical pyloric drainage.
MATERIALS AND METHODS: We performed a retrospective analysis of patients with adenocarcinoma and squamous cell carcinoma of the distal esophagus or gastroesophageal junction who underwent robotic-assisted transhiatal esophagectomy (RATE) without any surgical pyloric drainage. Patients with and without intraoperative endoscopic injection of 200 units of botulinum toxin in 10 cc of saline (BOTOX group) were compared to those that did not receive any pyloric drainage (noBOTOX group). Main outcome measure was the incidence of postoperative pyloric stenosis; secondary outcomes included operative and oncologic parameters, length of stay (LOS), morbidity, and mortality.
RESULTS: From November 2006 to August 2014, 41 patients (6 females) with a mean age of 65 years underwent RATE without surgical drainage of the pylorus. There were 14 patients in the BOTOX group and 27 patients in the noBOTOX group. Mean operative time was not different between the comparison groups. There was one conversion to open surgery in the BOTOX group. No pyloric dysfunction occurred in the BOTOX group postoperatively, and eight stenoses in the noBOTOX group (30\%) required endoscopic therapy (P {\textless} .05). There were no differences in incidence of anastomotic strictures or anastomotic leaks. One patient in group noBOTOX required pyloroplasty 3 months after esophagectomy. There was one death in the noBOTOX group postoperatively (30-day mortality 2.4\%). Mean LOS was 9.6 days, and BOTOX patients were discharged earlier (7.4 versus 10.7, P {\textless} .05).
CONCLUSION: Intraoperative endoscopic injection of botulinum toxin into the pylorus during RATE is feasible, safe, and effective and can prevent the need for pyloromyotomy.},
	language = {eng},
	number = {6},
	journal = {Journal of Laparoendoscopic \& Advanced Surgical Techniques. Part A},
	author = {Fuchs, Hans F. and Broderick, Ryan C. and Harnsberger, Cristina R. and Divo, Francisco Alvarez and Coker, Alisa M. and Jacobsen, Garth R. and Sandler, Bryan J. and Bouvet, Michael and Horgan, Santiago},
	month = jun,
	year = {2016},
	pmid = {27043862},
	keywords = {Adenocarcinoma, Adult, Aged, Aged, 80 and over, Botulinum Toxins, Type A, Carcinoma, Squamous Cell, Dilatation, Drainage, Endoscopy, Esophageal Neoplasms, Esophagectomy, Female, Follow-Up Studies, Humans, Incidence, Injections, Intraoperative Care, Male, Middle Aged, Neuromuscular Agents, Postoperative Complications, Pyloric Stenosis, pylorus, Pylorus, Retrospective Studies, Robotic Surgical Procedures, Treatment Outcome},
	pages = {433--438},
}

@article{saeed6046,
	title = {Intra-operative pyloric {BOTOX} injection versus pyloric surgery for prevention of delayed gastric emptying after esophagectomy},
	volume = {38},
	issn = {1432-2218},
	doi = {10.1007/s00464-024-11151-9},
	abstract = {BACKGROUND: Delayed gastric emptying (DGE) is a common complication after esophagectomy. BOTOX injections and pyloric surgeries (PS), including pyloroplasty (PP) and pyloromyotomy (PM), are performed intraoperatively as prophylaxis against DGE. This study compares the effects of pyloric BOTOX injection and PS for preventing DGE post-esophagectomy.
METHODS: We retrospectively reviewed Moffitt's IRB-approved database of 1364 esophagectomies, identifying 475 patients receiving BOTOX or PS during esophageal resection. PS was further divided into PP and PM. Demographics, clinical characteristics, and postoperative outcomes were compared using Chi-Square, Fisher's exact test, Wilcoxon rank-sum, and ANOVA. Propensity-score matching was performed between BOTOX and PP cohorts.
RESULTS: 238 patients received BOTOX, 108 received PP, and 129 received PM. Most BOTOX patients underwent fully minimally invasive robotic Ivor-Lewis esophagectomy (81.1\% vs 1.7\%) while most PS patients underwent hybrid open/Robotic Ivor-Lewis esophagectomy (95.7\% vs 13.0\%). Anastomotic leak (p = 0.57) and pneumonia (p = 0.75) were comparable between groups. However, PS experienced lower DGE rates (15.9\% vs 9.3\%; p = 0.04) while BOTOX patients had less postoperative weight loss (9.7 vs 11.45 kg; p = 0.02). After separating PP from PM, leak (p = 0.72) and pneumonia (p = 0.07) rates remained similar. However, PP patients had the lowest DGE incidence (1.9\% vs 15.7\% vs 15.9\%; p =  {\textless} 0.001) and the highest bile reflux rates (2.8\% vs 0\% vs 0.4\%; p = 0.04). Between matched cohorts of 91 patients, PP had lower DGE rates (18.7\% vs 1.1\%; p =  {\textless} 0.001) and less weight loss (9.8 vs 11.4 kg; p =  {\textless} 0.001). Other complications were comparable (all p {\textgreater} 0.05). BOTOX was consistently associated with shorter LOS compared to PS (all p =  {\textless} 0.001).
CONCLUSION: PP demonstrates lower rates of DGE in unmatched and matched analyses. Compared to BOTOX, PS is linked to reduced DGE rates. While BOTOX is associated with more favorable LOS, this may be attributable to difference in operative approach. PP improves DGE rates after esophagectomy without improving other postoperative complications.},
	language = {eng},
	number = {10},
	journal = {Surgical Endoscopy},
	author = {Saeed, Samir H. and Sinnamon, Andrew J. and Fontaine, Jacques P. and Mehta, Rutika J. and Pena, Luis R. and Mok, Shaffer R. S. and Baldonado, Jobelle J. R. and Pimiento, Jose M.},
	month = oct,
	year = {2024},
	pmid = {39134721},
	keywords = {Aged, Anastomotic Leak, Botulinum Toxins, Type A, Delayed gastric emptying, Esophageal cancer, Esophagectomy, Female, Gastric Emptying, Gastroparesis, Humans, Injections, Intraoperative Care, Male, Middle Aged, Postoperative Complications, Propensity Score, Propensity score matching, Pyloric BOTOX injection, Pyloromyotomy, Pyloroplasty, Pylorus, Retrospective Studies},
	pages = {6046--6052},
}

@article{mann221,
	title = {Prophylactic endoscopic pylorus dilatation prior to esophagectomy for esophageal cancer to prevent delayed gastric emptying, study protocol for a placebo-controlled randomized trial ({PROPPER} trial)},
	volume = {26},
	issn = {1745-6215},
	doi = {10.1186/s13063-025-08912-9},
	abstract = {INTRODUCTION: Delayed gastric emptying (DGE) due to pyloric dysfunction remains a common postoperative complication after esophagectomy for cancer and can lead to severe secondary complications. As shown in a retrospective study, prophylactic EPBD performed 1 day before surgery can reduce the rate of postoperative DGE by reducing pyloric resistance. The objective of this study is to analyze the effect of prophylactic EPBD on postoperative DGE rates in patients receiving minimally invasive esophagectomy for cancer by gastric pull-up.
METHODS: This study is designed as a multicenter randomized controlled trial (RCT) including patients with esophageal cancer or cancer of the gastroesophageal junction (adenocarcinoma and squamous cell carcinoma, with or without neoadjuvant treatment) scheduled for minimally invasive esophagectomy with gastric pull-up. After randomization, patients will either receive preoperative EPBD or a sham intervention in the routine preoperative endoscopy performed 1 day before surgery. The primary endpoint of this study will be rates of DGE, particularly those resulting from pyloric dysfunction, requiring intervention. Secondary outcomes will be major and minor postoperative complication rates, in-hospital mortality, adverse events during gastroscopy, length of ICU and hospital stay as well as postoperative pain and quality of life. In order to detect a difference between both groups at a two-sided 5\% significance level, to achieve a power of 0.8 with a calculated dropout rate of approximately 20\%, a sample size of 118 patients with 59 patients in every study arm will be needed.
DISCUSSION: The presented PROPPER trial is the first multicenter RCT that will provide evidence regarding the efficacy of preoperative EPBD in reducing DGE after minimally invasive esophagectomy for cancer.
TRIAL REGISTRATION: This trial was registered in the German Clinical Trials Register (DRKS), under the identifier DRKS00034360. Registered on May 29, 2024. The WHO trial registration data set can be found here: http://drks.de/search/en/trial/DRKS00034360 .},
	language = {eng},
	number = {1},
	journal = {Trials},
	author = {Mann, C. and Berlth, F. and Lozanovski, V. J. and Passalacqua, M. and Hadzijusufovic, E. and Uzun, E. and Capovilla, G. and Valmasoni, M. and Lang, H. and Grimminger, P. P.},
	month = jun,
	year = {2025},
	pmid = {40551220},
	pmcid = {PMC12183813},
	keywords = {Dilatation, Esophageal Neoplasms, Esophagectomy, Female, Gastric emptying, Gastric Emptying, Gastric pull-up, Gastroparesis, Humans, Ivor–Lewis esophagectomy, Male, Minimally invasive esophagectomy, Multicenter Studies as Topic, Pneumatic dilatation, Postoperative Complications, Pylorus, Quality of Life, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome},
	pages = {221},
}
